<SEC-DOCUMENT>0000950170-23-006264.txt : 20230306
<SEC-HEADER>0000950170-23-006264.hdr.sgml : 20230306
<ACCEPTANCE-DATETIME>20230306163143
ACCESSION NUMBER:		0000950170-23-006264
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230306
DATE AS OF CHANGE:		20230306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rallybio Corp
		CENTRAL INDEX KEY:			0001739410
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851083789
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40693
		FILM NUMBER:		23709350

	BUSINESS ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203- 859-3820

	MAIL ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rallybio Holdings, LLC
		DATE OF NAME CHANGE:	20180502
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rlyb-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-06T16:22:51.7411+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:rlyb="http://rallybio.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_47aa72fa-e49a-471b-b726-9f400a561be4" name="dei:EntityCentralIndexKey" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68">0001739410</ix:nonNumeric><ix:nonNumeric id="F_84dd8f7d-ddeb-46c7-9071-71361a486b29" name="dei:AmendmentFlag" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68">false</ix:nonNumeric><ix:nonFraction id="F_a8b218a9-357a-4bed-96d6-b4ed1c8b213d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_75ef69ec-1699-43a1-8661-5fb4744a1488" name="dei:DocumentFiscalPeriodFocus" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68">FY</ix:nonNumeric><ix:nonFraction id="F_c061875b-de88-45aa-8ea1-324496d0e556" name="us-gaap:CommitmentsAndContingencies" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_898355c9-91b8-4668-b906-0ac3fdb3ad20" name="dei:CurrentFiscalYearEndDate" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68">--12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rlyb-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_283e6bfc-26b6-4abc-bae8-943016a346b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c1e2b90-2c05-4121-b927-020165db9017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f72d314-6340-48e4-a0cb-90c92493675d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa0c8ed8-7c96-41b2-acbc-bd397cca2e41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonStockAllocatedToIncentiveUnitsHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72dc7c73-c37f-40b1-ac29-eb5aba9c919a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e29c70d6-5177-4a18-b728-136ccc6f1118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rlyb:ReVenturesILlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9608e295-9fc8-4f1c-8325-defd050a4e3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0a66521-307e-45f2-b9e4-4aaa00c5d3cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12986d42-bc40-4315-b656-9d19b413c96d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d937f0f8-a8e7-46a1-90c2-541038ce8510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91e37f8e-3f15-4cf1-a0ed-4b07ba1acb40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rlyb:ReVenturesILlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_548746fb-814e-4818-9836-b487dff1ca83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eed08da7-0a3b-4480-a783-cde12cc17f8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a26e436-c6db-4d63-858b-564767b5ca18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rlyb:StockOptionsAndUnvestedRestrictedShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18a5ceed-0060-4aa3-9c6c-c98a4ad6ca26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_effcd34e-4aab-4920-ac25-05c20a2a8e59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46cd10da-534a-45a6-8e92-23bccca412b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58bb02df-6ead-4192-bfb4-4babb5d12fd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f129d90-d234-416a-9fec-871604aa4382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1df02247-1abd-4b9e-b9a2-5286622dd357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b5ba2a5-21d0-491d-a212-155407944f28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6740c4f-f839-42cf-8933-5c00be44fad6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c135ce81-16f6-4644-8431-2f49154ea889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82d6c3cd-26a6-4fbe-bd6e-fb539f862b2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b6ed73d-3d7a-4d4e-ad0c-6cf1487dd354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77017543-72b8-463e-b4d8-4744e243dddf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65531b3d-72ed-4e61-b9c1-459069ccf882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed90055c-50cc-4284-9412-3619d9ee515a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:OverAllotmentOnInitialPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_023380b6-8582-4311-9388-b97a86a5ebc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35605b6e-be30-43c7-8f50-20c9ee13c798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e04c4b7c-8231-4981-815c-01cc0725ee41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rlyb:ReVenturesILlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ef707b6-6cf6-44ea-a226-c236562f6196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9a8b852-841f-4a26-95af-c55e17becf4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_049edda4-c91f-4ae4-ac5b-361c6c909078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonStockAllocatedToCommonUnitHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_739866d4-323a-4be2-8ffe-a4e8744c785c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d08dcb07-924b-4a3a-9c4a-4828ff956a08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb11c8d1-4dd0-4a80-b4f9-1d7bcbb74fd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rlyb:CapitalizedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83726cf3-dbf7-458d-b892-83b3f6200320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a09cca07-b477-48a1-96b3-6e73343c9cfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70c6b661-e569-4779-8379-10ef41316fc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c8eb427-a9b9-4fd2-8278-278c9bafa4ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1e1819d-7e08-4d58-9f61-b60962efde73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_428be2be-619b-438c-84e3-581e1bff5f22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5134fef2-9d7d-4ee4-a874-8036c0bffab9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7a1f81b-226a-425e-9556-8238ac7cd556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfa92b31-04bb-40fe-917d-31a1f4c22c5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rlyb:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1789f82-5498-493f-9c96-de21198bf03e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25fa2078-2908-479e-9ea7-121c863893fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb2bd404-8085-4064-9e41-d047d221dbff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rlyb:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f078dfa-939c-4606-85c9-ea74c47eccf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbbe5259-ca6b-485d-bfa6-99647ffab256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_027b9ced-d4c4-4cc7-bebc-9fecdde23fc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rlyb:StockOptionsAndUnvestedRestrictedShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86e82aa6-b04b-4ef2-95b4-8a74005d949f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e81591b1-65b4-4ea6-b99c-cc189388ddfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4381cd1-83ec-453c-b2da-602cb3171ce9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b380165-d0ba-48ca-8553-1fc3c5916d47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86c28a70-242c-4117-a116-d03b63d2edf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a304c311-7529-4e1e-a84f-c3b32740f27f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90ca1d69-a91f-474d-9d24-d97bc3609482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de3e32cc-aea0-4d0f-927a-9048039d7772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ef647fa-f912-4e8a-ab8e-43e6ba78d2c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7770416e-82d7-4b9d-9294-67c572a1763b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f34bb779-7894-494b-b952-272e8729ec8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96ab8a98-bc35-4ad3-930b-5cede1b585c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rlyb:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d27a7c8-536f-4ccb-8034-2a8478fce538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rlyb:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97b56dc7-df26-44a2-b55c-c37821ed5567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbf9eec7-f7b0-4d37-8259-cb61089f9136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17a4f0c1-9607-4df6-8818-c739af03c27b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b90c853-7aaa-440f-a295-28aae572ec3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rlyb:LicenseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlyb:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlyb:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f58e8139-a6dd-456f-af79-4387faed9da6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e76e6912-e263-4b3a-800f-e5564ea50f5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rlyb:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b92e8ce1-fdcf-4c2d-a2d7-c1581bdfc31f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_896be549-e10a-4adb-b5c3-195576990921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae3fd3df-ccaf-4d78-a4b5-c90ef740f58a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6767ad15-fcb8-4673-8113-97780ad364b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e52f2ef-b76e-43c9-a29f-eee88975b5b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_291895eb-b1c2-4869-bbc2-c46ab5500661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8de022cc-ebdd-40ce-9a3d-5efc20768011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_115c7363-4207-4550-8e08-adb9ff8a9635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c0b1833-e4eb-4b6b-a37a-11f4af7b61ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46b5d7b6-c58d-45f0-9c8d-0874f28c30ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34ce8dda-3f7a-4174-a6cc-40dc210ea8ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:PerformanceBasedIncentiveCommonUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae8060f7-9d9e-4228-a650-4909d1ec8e45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rlyb:CapitalizedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6d9b87b-c787-4fdd-889d-759840ee3096"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rlyb:LicenseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlyb:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlyb:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae469bc2-9800-4dc5-bcf4-0fdac12554b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13887808-dda9-4f62-b93c-5568ce0ac531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05f50029-fc68-47b8-9fa9-e99bbdb4f94a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:SeriesBRedeemableConvertiblePreferredUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd12daa8-050e-4026-94a2-6adc935a3816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45070b2f-cf01-42c1-887f-e78f1a625a2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e57589c1-5d53-466f-b251-aaba3c58effd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ec8e39c-7a88-422a-a74f-d98b410d67ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_239aad29-ce03-4108-838f-d640e267ee47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rlyb:CapitalizedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e128323-fbea-4fe5-84d7-e5c466f1a588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec08abe0-0fe7-4c99-8d7a-a6994ffdb9c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52dabac6-294d-46ca-a017-e4ded6aceebe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4c85d43-b21c-4db7-af84-cec208374d89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rlyb:ReVenturesILlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38646d43-f81a-4024-b133-4680c40d4fef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d89fc97-b610-46e8-adf8-5e121995a4ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4c6a782-6462-4fbb-ab36-0733d6a1beb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3145b273-e2d9-4683-a591-82fa75386376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:IncentiveUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a27f538-6112-4043-acae-7f43c3d21b17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlyb:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlyb:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59253fec-c553-4ded-aad6-b2d0ecef61ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9e6864c-0599-4c62-be7b-906252ee6393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0419c87f-3e9a-4f46-8744-7ba8ebb85189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlyb:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlyb:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_420228b8-f02f-4ea0-8120-8161b9596926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14f240d5-c0ae-4980-979c-1550d7d172d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6215fc9c-66e2-43ef-b652-b9895d59b307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:SeriesA1AndA2RedeemableConvertiblePreferredUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28193283-a9f2-41e6-9349-c6552278982f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96275cfa-74c5-412d-adca-3d72d0a97037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:OverAllotmentOnFollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a256dcbc-4261-4079-a35a-af552e6fd37e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_6be49bc8-7261-44a8-9cb4-3c22017b8dfb" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_08ffe394-9bb7-4114-b678-1681fc3209ab" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a67428a7-0123-4178-93ee-63f2659705b8" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, </span><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_0b159ddc-d0f6-47c5-a31b-097380a68563" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e84f35fc-2f62-4c95-a031-48582c18d2b7" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_af67fafe-1d9c-4042-80e2-bb57029e2ef8" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">001-40693</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img114804231_0.jpg" alt="img114804231_0.jpg" style="width:126px;height:35px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_5baa59e0-c2ab-4f5a-a94c-223f475f4e8a" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RALLYBIO CORPORATION</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4ddbb509-20d9-40e0-9021-3553aed44029" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4627e352-7fdd-42db-afda-60db180938fe" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">85-1083789</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_b67df06e-336e-46f8-ab31-db0969755bce" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">234 Church Street</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_49f07723-c55d-456c-a6f3-1d382a5524a7" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Suite 1020</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4baf4474-e3f8-42ec-b9bc-c6ecbcbf634f" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">New Haven</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_c353d93a-855f-475d-8b97-ecae8497c7d5" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CT</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e863fed7-ecae-454a-a7cb-52ac3b9397e1" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">06510</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_69610e1c-804f-49fa-92bf-132149098034" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">203</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_01302eef-1d3e-4043-9d38-ad34a65b33a8" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">859-3820</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_cacf6c3a-3eb7-4a97-bd35-aa5e160683ab" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_38d1a776-7c67-4a80-b024-2bb5a8d718ee" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f78b77fa-62da-40b4-b24c-1053d09d0f20" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">NASDAQ</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;Global Select Market</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES &#9744;     </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_52633e53-3fb0-41f2-9cc4-080c93a060a1" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  YES &#9744;     </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4d3a32b2-ce5d-40c3-9b99-437d6f0aa233" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_0c6d82cf-9f4a-4799-9c19-89e88ef2ea31" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#9746;     NO &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_3ae36845-1776-4afb-87cf-88561b1c2511" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#9746;     NO &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.12%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:55.657%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.324%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.898%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_119c2f55-52fb-44e2-b928-3bd149d8fe1f" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_1062ff33-aa92-4c7c-adc2-fc521a58e79c" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_bd4b7756-d157-4128-9bef-f997c9819bac" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_8931c161-8ee5-4eaa-888a-f8fcc48a7443" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_bbb760ab-9f3d-40e8-a1a4-dea9af27cad7" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by checkmark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  &#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b)  &#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES &#9744;     NO </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_436810b6-6229-4e6f-b585-bd9e480e1a23" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The aggregate market value of the registrant's voting common stock held by non-affiliates as of June 30, 2022 was approximately $</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_48b0a523-b5c0-404e-9684-633812d1cb57" contextRef="C_90ca1d69-a91f-474d-9d24-d97bc3609482" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">120.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, based on the closing price of the registrant&#x2019;s common stock as reported by Nasdaq on that date.<br />The number of shares of Registrant&#x2019;s Common Stock outstandin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">g as of March 1, 2023 was </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1a1bdcf8-cd16-444a-a863-0eca6b5ed63c" contextRef="C_28193283-a9f2-41e6-9349-c6552278982f" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,075,024</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <div style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_babeb532-e01b-45b9-9be3-9c6ac75f3628" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Portions of the registrant&#x2019;s Definitive Proxy Statement for its 2023 Annual Meeting of Stockholders scheduled to be held on May 17, 2023, which Definitive Proxy will be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year end of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> are incorporated by reference into Part II and Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements that are based on management&#x2019;s beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;could,&#x201d; &#x201c;intend,&#x201d; &#x201c;target,&#x201d; &#x201c;project,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the initiation, timing, progress, results, and cost of our research and development programs, and our current and future preclinical and clinical studies, including statements regarding the timing of initiation and completion of our clinical trials for RLYB212, RLYB116 and RLYB331, and the natural history study for our fetal and neonatal alloimmune thrombocytopenia (&#34;FNAIT&#34;) prevention program, and related preparatory work, and the period during which the results of the trials will become available; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the success, cost and timing of our clinical development of our product candidates, including RLYB212, RLYB116, RLYB114 and RLYB331; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to initiate, recruit and enroll patients in and conduct our clinical trials at the pace that we project; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations or warnings in the label of any of our product candidates, if approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to compete with companies currently marketing or engaged in the development of treatments for diseases that our product candidates are designed to target, including paroxysmal nocturnal hemoglobinuria  (&#34;PNH&#34;) and generalized myasthenia gravis (&#34;gMG&#34;); </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our reliance on third parties to conduct our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our reliance on third parties to manufacture drug substance for use in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the size and growth potential of the markets for RLYB212, RLYB116, RLYB114, RLYB331 and any of our current product candidates or other product candidates we may identify and pursue, and our ability to serve those markets; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to expand our pipeline through collaborations, partnerships and other transactions with third parties; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to identify and advance through clinical development any additional product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the commercialization of our current product candidates and any other product candidates we may identify and pursue, if approved, including our ability to successfully build commercial infrastructure or enter into collaborations with third parties to market our current product candidates and any other product candidates we may identify and pursue; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to retain and recruit key personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to obtain and maintain adequate intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our expectations regarding government and third-party payor coverage and reimbursement; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our estimates of our expenses, ongoing losses, capital requirements and our needs for or ability to obtain additional financing; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our expected uses of the net proceeds from our initial public offering and any subsequent offerings; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the potential benefits of strategic collaboration agreements, including our agreements with Exscientia Limited (&#34;Exscientia&#34;) and AbCellera, our ability to enter into strategic collaborations or arrangements, including potential business development opportunities and potential licensing partnerships, and our ability to attract collaborators with development, regulatory and commercialization expertise; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our financial performance; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">developments and projections relating to our competitors or our industry; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">other risks and uncertainties, including those listed under the section titled &#x201c;Risk Factors.&#x201d;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Annual Report on Form 10-K entitled &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as guarantees of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Trademarks</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We use Rallybio as a trademark in the United States and/or in other countries. This Annual Report on Form 10-K contains references to our trademark and to those belonging to other entities, including Affibody</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and Albumod</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#x2019; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risk Factor Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our business is subject to a number of risks that are discussed more fully in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K. These risks include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the foreseeable future. We have not commercialized any products and have never generated revenue from the commercialization of any product. We are not currently profitable, and we may never achieve or sustain profitability; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We will require significant additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of RLYB212, RLYB116, or any additional product candidates we may develop; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are heavily dependent on the success of RLYB212 and RLYB116, which are in early-stage clinical development. If we are not able to develop, obtain regulatory approval for, or successfully commercialize our product candidates, or if we experience significant delays in doing so, our business will be materially harmed; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preclinical studies and clinical trials are expensive, time consuming, and difficult to design and implement, and involve uncertain outcomes. Any product candidates that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including our focus on rare diseases;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Results of preclinical studies, clinical trials, or analyses that we may announce or publish from time to time, may not be indicative of results obtained in later trials, and any interim results we may publish could be different than final results; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any product candidates that we develop or the administration thereof, may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The regulatory approval processes of the U.S. Food and Drug Administration (the &#34;FDA&#34;), the European Medicines Agency (the &#34;EMA&#34;), and comparable foreign regulatory authorities,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">including the Medicines and Healthcare products Regulatory Agency in the United Kingdom (the &#x201c;MHRA&#x201d;), are lengthy, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for RLYB212, RLYB116 or any of our other product candidates, our business will be substantially harmed;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our product candidates target rare diseases and conditions, and the market opportunities for RLYB212, RLYB116 and any of our other product candidates, if approved, may be smaller than we anticipate. As a result, our commercial opportunity may be limited and because the target populations of our product candidates are for rare diseases, we must be able to successfully identify patients and capture a significant market share to achieve profitability and growth;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA, EMA or other comparable foreign regulatory authorities could require the clearance or approval of an in vitro diagnostic or companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests, including RLYB212. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our drug development strategy and we may not realize the commercial potential of any such product candidate; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We face significant competition from biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We intend to continue to acquire or in-license rights to additional product candidates or collaborate with third parties for the development and commercialization of our product candidates. We may not succeed in identifying and acquiring businesses or assets, in-licensing intellectual property rights or establishing and maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all, and these transactions could disrupt our business, cause dilution to our stockholders or reduce our financial resources; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The foregoing is only a summary of some of our risks. For a more detailed discussion of these and other risks you should consider before making an investment in our common stock, see &#x201c;Risk Factors.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">iii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.0%;"></td>
    <td style="width:83.917%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART I.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">45</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item3legalproceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Mine Safety Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART II.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_mda"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_qaq"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_sas_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART III.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">115</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">iv</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1. Bus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">iness.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since our launch in January 2018, we have built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of maternal fetal blood disorders, complement dysregulation, hematology, and metabolic disorders. We have assembled a team of experienced biopharma industry leaders with extensive research, development, and rare disease expertise to deliver on our mission of becoming a leader in the development of therapies for patients with rare diseases. We are drawing on our decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible &#x2013; and change the odds for rare disease patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Approach</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At Rallybio Corporation (the &#34;Company&#34;), we do not accept that millions of patients suffering from devastating rare diseases should have to live without transformative treatments. There are an estimated 25 to 30 million people affected by as many as 7,000 rare diseases in the United States alone, with a significantly greater number of affected people globally. We are building a diversified pipeline of product candidates that we believe have the potential to transform the lives of patients in need. Our goal is to deliver therapeutics that provide meaningful clinical benefits to patients so they can become unbound and undefined by the diseases from which they suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe the success of the Company is built on three key strengths:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our extensive knowledge of rare diseases and our scientific expertise positions us to identify therapies with the potential for transformative impact.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> We seek to acquire and develop product candidates that possess a clear mechanism of action and that aim to address diseases with a well-understood pathophysiology for which there is a significant unmet medical need. We believe that a product candidate&#x2019;s mechanism of action should target the causal biology of the disease to provide the highest probability of dramatically improving the lives of patients. We believe that our team&#x2019;s extensive experience in rare diseases and our scientific expertise position us to identify opportunities where these links can be made, which may go unnoticed by others.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our ability to source, identify and evaluate potential high-quality product candidates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. We apply decades of experience across drug discovery, research, development, regulatory strategy and manufacturing to source, identify and evaluate therapeutic targets and product candidates that we believe have a high probability of success. Our ability to source these product candidates is facilitated by our extensive network of relationships with leaders in industry and in academic centers worldwide. We view ourselves as partners of choice given our team&#x2019;s track record of success in developing and delivering new therapies to patients.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our team&#x2019;s proven execution capability to drive product candidates through clinical development to regulatory approvals. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have assembled a team with a proven history of successfully advancing product candidates from discovery to clinical development and through regulatory approval. Members of our team have played critical roles in the approval of more than 30 drugs, including seven approvals for rare disease therapeutics since 2013, and secured approvals from regulatory authorities in the Americas, Europe, Australia and Asia. In doing so, our employees previously developed and implemented novel clinical trial designs and successfully conducted clinical trials in never-before treated patient populations. We believe this collective prior experience positions us to efficiently and expertly execute at each step in the research and development process and enhances the value we can bring to product candidates and patients. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Team</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our founders, Martin W. Mackay, Ph.D., Stephen Uden, M.D., and Jeffrey M. Fryer, CPA, were previously executives at Alexion Pharmaceuticals, Inc.(&#34;Alexion&#34;), and worked together to successfully build, develop, and launch transformative therapies for patients with rare diseases. Several members of our team were integral in the successful development and/or approval of therapies such as Strensiq (asfotase alfa) for patients with perinatal-, infantile-, and juvenile-onset hypophosphatasia (&#34;HPP&#34;), Kanuma (sebelipase alfa) for patients with lysosomal acid lipase deficiency (&#34;LAL-D&#34;), Nulibry (fosdenopterin) for patients with molybdenum cofactor deficiency (&#34;MoCD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Type A&#34;), Soliris (eculizumab) for patients with refractory generalized myasthenia gravis (&#34;gMG&#34;), Soliris for patients with relapsing neuromyelitis optica spectrum disorder (&#34;NMOSD&#34;), Ultomiris (ravulizumab-cwvz), for patients with paroxysmal nocturnal hemoglobinuria (&#34;PNH&#34;) and Ultomiris for patients with atypical hemolytic uremic syndrome (&#34;aHUS&#34;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In January 2023, Rallybio announced the appointment of Jonathan I. Lieber as Chief Financial Officer (&#34;CFO&#34;), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio&#x2019;s Co-Founder and former CFO.  The Company announced Mr. Fryer&#x2019;s retirement in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer departed the Company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment banker.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe our team&#x2019;s prior contributions have made a significant positive impact on the lives of thousands of patients around the world. As a strong and experienced team, we believe we can transform the lives of thousands more.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our pipeline is illustrated in the chart below:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img114804231_1.jpg" alt="img114804231_1.jpg" style="width:672px;height:274px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FNAIT: Fetal and neonatal alloimmune thrombocytopenia; HPA-1a: Human platelet antigen-1a; C5: Complement component 5; ABD: Albumin-binding domain; HPP: Hypophosphatasia; ENPP1: Ectonucleotide pyrophosphatase/phosphodiesterase 1</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">*Disease areas under consideration: hematology, including disorders such as PNH, neurology, including disorders such as gMG and severe dermatologic indications</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br />Prevention of FNAIT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our product candidate is targeting the prevention of fetal and neonatal alloimmune thrombocytopenia (&#34;FNAIT&#34;) a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. FNAIT can arise during pregnancy due to an immune incompatibility between an expectant mother and her fetus in a specific platelet antigen called human platelet antigen 1 (&#34;HPA-1&#34;). This incompatibility can cause an expectant mother to develop antibodies that attack the platelets of her fetus. The destruction of platelets in the fetus can result in severely low platelet counts, or thrombocytopenia, potentially leading to devastating consequences including miscarriage, stillbirth, death of the newborn, or severe lifelong neurological disability in those babies who survive. There is currently no approved therapy for the prevention or treatment of FNAIT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We estimate that there are over 22,000 pregnancies at high risk of developing FNAIT each year in the United States, Canada, United Kingdom, other major European countries and Australia. Because there are no approved therapies to prevent FNAIT, expectant mothers are not currently screened for FNAIT risk. As a result, the vast majority of pregnancies at risk for FNAIT go unidentified and untreated. In those pregnancies that are identified as at-risk, typically due to the delivery of a prior FNAIT affected child, expectant mothers may be treated with weekly intravenously-administered high doses of immunoglobulin G, (&#34;IVIG&#34;), along with the oral steroid immunosuppressant prednisone. However, IVIG administration does not prevent the immune response, called alloimmunization, and is costly, time-intensive, difficult to tolerate and associated with significant treatment-related complications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In 2019, we acquired all rights to RLYB211 and RLYB212, two anti-HPA-1a antibody candidates, from Prophylix AS (&#34;Prophylix&#34;). We believe that targeting HPA-1a with an anti-HPA-1a antibody has the potential to drive rapid elimination of HPA-1a positive platelets from the circulation of expectant mothers and prevent alloimmunization and thereby, the occurrence of FNAIT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB211 is an intravenously administered polyclonal anti-HPA-1a antibody derived from the plasma of women who have developed antibodies to HPA-1a from a prior HPA-1 incompatible pregnancy. We believe data from our Phase 1/2 clinical trial for RLYB211, initially presented in July 2021 at the International Society on Thrombosis and Haemostasis (&#x201c;ISTH&#x201d;) Congress and subsequently published in the Journal of Thrombosis and Hemostasis (Geisen et al., 2022, In Press), demonstrate that RLYB211 rapidly and completely eliminates HPA-1a-positive platelets in HPA-1a negative subjects, establishing proof-of-mechanism for the ability of an anti-HPA-1a antibody to cause rapid platelet elimination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody that has the same mechanism of action as RLYB211, with favorable attributes supporting its potential as a first-in-class candidate for the prevention of HPA-1a maternal alloimmunization and the occurrence of FNAIT, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the potential for low volume subcutaneous prophylactic administration, which is the preferred route of administration based on primary market research with OB/GYNs and Maternal-Fetal Medicine specialists in the United States and Europe;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a pharmacokinetic (&#34;PK&#34;) profile that has the potential to maintain circulating concentrations of anti-HPA-1a antibody at levels that are very close to peak exposure levels through the entire treatment period, thus maximizing the capacity of RLYB212 to neutralize fetal antigen; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the ability to produce using standard monoclonal antibody manufacturing methods. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have received approval for two clinical trial applications (&#34;CTAs&#34;) for RLYB212 in Germany; the first for a Phase 1 first-in-human trial and the second for a Phase 1b proof of concept trial. In January 2022, we announced that the first subjects were dosed in the Phase 1 study. This ongoing single-blind, placebo-controlled Phase 1 study is designed to evaluate the safety and PK of single and repeat subcutaneous doses of RLYB212 in HPA-1a negative healthy subjects. In the second quarter of 2022, we initiated the Phase 1b proof-of-concept study to evaluate the ability of subcutaneous RLYB212 to rapidly eliminate transfused HPA-1a positive platelets from the circulation of HPA-1a negative healthy subjects. In the third quarter of 2022, we announced preliminary results from the proof-of-concept study, demonstrating RLYB212 rapidly and completely eliminates HPA-1a positive platelets with a greater than 90% reduction of the mean platelet elimination half-life compared to placebo, consistent with proof-of-concept criteria.  We also announced that dosing had commenced under an amended protocol that expanded the dose range of RLYB212, with a goal of providing a broader range of PK and pharmacodynamics (&#x201c;PD&#x201d;) data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the first quarter of 2023, we announced proof-of-concept in the Phase 1b study for RLYB212.  Results showed that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects with additional findings from the study that show a reduction in mean platelet elimination half-life was greater than 90% in both RLYB212 dose groups compared to placebo and was dose related. RLYB212 was also observed to be well-tolerated with no serious adverse events reported. The broad range of PK and PD data in the Phase 1b study will allow for substantive modeling to inform dose selection for a future registrational study. The Company expects to report the complete dataset from the Phase 1b clinical study of RLYB212 at a scientific conference in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the first quarter of 2023 we also initiated the multi-dose cohort of its single-center Phase 1 trial in Europe. This portion of the Phase 1 study will evaluate safety and PK of RLYB212 based on repeat dosing over 12 weeks in healthy male and female participants. We expect results from this cohort of subjects in the fourth quarter of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Given the favorable development profile of RLYB212 to date, the data generated to date for RLYB212, and  manufacturing and supply efficiencies, we have discontinued the development of RLYB211.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, we are conducting a FNAIT natural history alloimmunization study. This prospective, non-interventional, multinational natural history study is designed to screen up to 30,000 expectant mothers presenting at Gestation Week 10 to 14 prenatal visit to determine the frequency of women at higher FNAIT risk among expectant mothers of different racial and ethnic characteristics, as well as the frequency of HPA-1a alloimmunization and pregnancy outcomes among these women. Subject to discussion with regulatory authorities, we expect that data from this study will contribute to a control dataset for a future single-arm Phase 2/3 registration trial for RLYB212. An additional objective of the FNAIT natural history study is to operationalize de</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">novo the laboratory test paradigm for FNAIT risk and generate FNAIT laboratory test performance data that we plan to use for future regulatory discussions. Screening of expectant mothers is ongoing.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Treatment of Disorders Due to Complement Dysregulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The complement system plays a central role in innate immunity, as well as, shaping adaptive immune response. Dysregulation of the complement pathway has been implicated in the pathogenesis of a growing number of diseases, making it an attractive target for therapeutic intervention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Antibody inhibitors of complement component 5 (&#34;C5&#34;) have been successfully developed to treat diseases caused by complement pathway dysregulation, including PNH, aHUS, refractory gMG and relapsing NMOSD. Despite the approval of antibody-based C5 inhibitors for patients with these diseases, we believe there remains significant need in the market for safe, effective, patient-friendly and accessible therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our team has a track record of success and significant expertise in designing, developing and securing approval for complement inhibitors, including Soliris and Ultomiris, for patients around the world with severe and rare complement-mediated diseases. We believe this knowledge and expertise positions us to successfully advance our programs and deliver transformative benefits to patients in need of an improved or alternative therapeutic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our most advanced product candidate in this therapeutic area is RLYB116, an inhibitor of complement factor C5, which is a central component of the complement pathway. RLYB116 is an Affibody molecule attached to an albumin binding domain that has the potential to drive the rapid, complete and sustained inhibition of C5 with a subcutaneous injection. We received approval in the fourth quarter of 2021 for a Human Research Ethics Committee (&#34;HREC&#34;) submission to support a Phase 1 trial of RLYB116 in healthy participants and in the first quarter of 2022, we initiated the Phase 1 trial in Australia. The single-blind, placebo-controlled dose escalation study is designed to evaluate the safety, PK, and PD of single dose and multiple dose RLYB116 in healthy participants. In November 2022, we announced preliminary results from our Phase 1 single ascending dose study of RLYB116. The preliminary data showed that all study participants that were administered a single 1 mL subcutaneous injection of 100 mg of RLYB116 (n=6) demonstrated a reduction in free C5 greater than 99% within 24 hours of dosing. The terminal elimination half-life of RLYB116 was greater than 300 hours. Subcutaneously administered RLYB116 was observed to be generally well-tolerated at the 100 mg dose, with some mild adverse events but no drug-related serious adverse events reported. In the fourth quarter of 2022, we initiated the multiple ascending dose Phase 1 study of RLYB116. The single-blind, dose escalation, placebo-controlled study is designed to evaluate the safety, PK, and PD of RLYB116 in healthy participants. Initial data from the ongoing multiple ascending dose study are expected in the fourth quarter of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disease areas under consideration for RLYB116 include PNH, gMG and severe and rare dermatologic diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. We continue to advance the development of RLYB114, formulated for intravitreal injection, for the treatment of ophthalmic disorders with a goal to partner this program with a company that specializes in ophthalmology drug development.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Hematological Disorders</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In May 2022, we obtained worldwide exclusive rights to RLYB331, a preclinical antibody. We believe RLYB331 has the potential to address a significant unmet need for patients with severe anemias with ineffective erythropoiesis and iron overload, including beta thalassemia and a subset of lower risk myelodysplastic syndromes. Currently these patients are underserved by the existing standard of care. RLYB331 is a monoclonal antibody that is designed to inhibit Matriptase-2 (&#34;MTP-2&#34;). The inhibition of MTP-2 significantly increases levels of hepcidin, decreases iron load and treats ineffective erythropoiesis. We continue to conduct investigational new drug (&#34;IND&#34;)-enabling activities for RLYB331, to support the transition of this asset into clinical development.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Artificial Intelligence Drug Discovery Collaboration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have established a partnership with Exscientia Limited (&#34;Exscientia&#34;), an Oxford, UK-based artificial intelligence (&#34;AI&#34;) and machine learning drug discovery company with a proprietary chemical design platform, to rapidly and efficiently discover novel small molecule drug candidates. Our partnership consists of a joint venture, focused on the discovery and development of small molecule therapeutics for the treatment of patients with rare metabolic diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The joint venture is focused on targeting an Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (&#34;ENPP1&#34;) inhibitor for the treatment of HPP. HPP is a rare, genetic disease characterized by mutations in the ALPL gene. The ALPL gene provides instructions for making an enzyme called tissue-nonspecific alkaline phosphatase, which plays an important role in the growth and development of bones and teeth. The incidence of HPP has been reported to be 1 in 100,000 to 1 in 300,000 (United States and Canada) for severe disease and 1 in 6,370 (European Union) for less severe forms. These mutations lead to diminished activity of the alkaline phosphatase enzyme and the accumulation of inorganic pyrophosphate (&#x201c;PPi&#x201d;), which inhibits bone mineralization causing multiple skeletal pathologies. We believe that a small molecule inhibitor of ENPP1 has the potential to bring meaningful benefit to HPP patients by reducing excess levels of pyrophosphate, thereby removing an inhibitor of calcium mineralization and bone formation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In vivo efficacy data are expected in the second half of 2023. Following those results, the companies expect to commence IND-enabling studies</span><span style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br />AbCellera Collaboration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2022, we entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera&#x2019;s antibody discovery engine with Rallybio&#x2019;s clinical and commercial expertise in rare diseases to identify optimal clinical candidates with a goal of delivering therapies to patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the terms of the agreement, AbCellera and Rallybio will co-develop up to five rare disease therapeutic targets, which will be chosen together by both companies. The collaboration will allow Rallybio to add product candidates to our existing pipeline with the option for AbCellera to conduct process development and clinical manufacturing activities. The partnership&#x2019;s first program will focus on addressing the significant unmet therapeutic needs of patients with rare metabolic diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our mission is aligned with our expertise: to identify and accelerate the development of life-transforming therapies for patients with severe and rare disorders. To achieve this mission, our strategy includes the following key components:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Establish a leading rare disease company through a team that delivers transformative medicines to patients.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> We believe our team&#x2019;s expertise and knowledge are fundamental to our long-term success. Our research and development team is led by experienced drug development executives who were integral in the approvals of more than 30 drugs from leading companies, including Alexion, Astellas Pharma Inc., Wyeth, LLC and Pfizer Inc. We plan to continue to leverage our team&#x2019;s expertise to enable focused clinical development of multiple product candidates in parallel, resulting in a diversified portfolio that we believe will provide multiple opportunities to create value by significantly improving the lives of patients.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Advance RLYB212 through clinical development for the prevention of FNAIT.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> In the first quarter of 2023 we announced proof-of-concept for RLYB212 in a Phase 1b study. The results showed that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects with additional findings from the study that show a reduction in mean platelet elimination half-life was greater than 90% in both RLYB212 dose groups compared to placebo and was dose related.  In the first quarter of 2023 we also initiated the multi-dose cohort of a single-center Phase 1 trial in Europe. This portion of the Phase 1 study will evaluate safety and PK of RLYB212 based on repeat dosing over 12 weeks in healthy male and female participants. We expect to report results from this cohort of subjects in the fourth quarter of 2023.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Advance RLYB116 into and through clinical development for the treatment of diseases of complement dysregulation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We received approval in the fourth quarter of 2021 for a HREC submission to support the initiation of a RLYB116 Phase 1 trial in healthy participants. In 2022, we announced positive topline results from this Phase 1 single ascending dose study of RLYB116. The preliminary data showed that all study participants that were administered a single 1 mL subcutaneous injection of 100 mg of RLYB116 (n=6) demonstrated a reduction in free C5 greater than 99% within 24 hours of dosing. The terminal elimination half-life of RLYB116 was greater than 300 hours. Subcutaneously administered RLYB116 was observed to be generally well-tolerated at the 100 mg dose, with mild adverse events and no drug-related serious adverse events reported. In the fourth quarter of 2022, we initiated the multiple ascending dose Phase 1 study of RLYB116. The single-blind, </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">dose escalation, placebo-controlled study is designed to evaluate the safety, PK, and PD of RLYB116 in healthy participants. Initial data from this study are expected in the fourth quarter of 2023.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Advance our preclinical candidates, RLYB114 and RLYB331 through preclinical development.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that both RLYB114 and RLYB331 have significant potential to meet the unmet needs of patients and are currently working on activities to support the preclinical development of both of these product candidates. In the case of RLYB331 we intend to continue advancement of IND-enabling activities to support transition of the asset into clinical development. In the case of RLYB114, we intend to seek a collaboration with another company that specializes in ophthalmology drug development. However, we intend to conduct preclinical development activities for RLYB331 with the intent to move this program into clinical development.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Maximize the value of our collaborations with Exscientia and AbCellera.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  We have ongoing collaborations with Exscientia for the discovery and development of small molecule therapeutics and AbCellera for novel antibody-based therapeutics. Both collaborations focus on the development of new treatments for patients with rare metabolic diseases. Specifically, our initial work with Exscientia targets ENPP1 and we expect to report in vivo efficacy data in the second half of 2023 prior to the commencement of IND-enabling studies. Our collaboration with AbCellera is currently in the discovery stage. We intend to support both of these collaborations with a goal of moving multiple additional programs into clinical development over the next several years.  </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expand our pipeline through partnering, acquiring or in-licensing additional product candidates that target validated biology. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are focused on developing drugs that directly impact known disease pathways which we believe will allow us to increase the probability of clinical, regulatory and commercial success. We continue to accelerate our business development activities and actively pursue the acquisition or in-licensing of additional product candidates as well as partnerships and collaborations. Our team has strong relationships with key academic and industry leaders in the rare disease field built from our past success in developing and commercializing therapies for rare diseases. We plan to continue to leverage our existing collaborations and relationships to further our business development opportunities and thereby expand our pipeline.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Maximize the value of pipeline product candidates through commercial independence in key markets and select partnerships. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We plan to build a fully integrated and focused commercial organization to launch our rare therapeutics, if approved, in key markets. We believe our commercial organization can be efficiently targeted at groups of specialists who typically treat patients with the diseases to be addressed by our product candidates. For certain other markets, we plan to explore strategic partnerships to efficiently deliver our therapeutics to patients, with the goal of transforming patient care in our focus areas around the globe. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We were founded in January 2018 by Drs. Mackay and Uden and Mr. Fryer to identify and accelerate the development of life-transforming therapies for patients with severe and rare disorders. At Alexion, Dr. Mackay was Global Head of Research &amp; Development, Dr. Uden served as Head of Research, and Mr. Fryer was Chief Tax Officer. Many of our employees have worked together extensively during their careers across different companies. During these years of collaboration, several members of our team were integral in the successful development and/or approval of transformative therapies for thousands of patients with rare diseases. As a focused, cohesive and experienced Rallybio team, we hope to transform the lives of many thousands more.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In August 2021, we completed our initial public offering (&#x201c;IPO&#x201d;), pursuant to which we issued and sold 7,130,000 shares of our common stock, inclusive of 930,000 shares sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $13.00 per share. The gross proceeds from the IPO, including the exercise of the underwriter's option to purchase additional shares were $92.7 million and the net proceeds were approximately $83.0 million, after deducting underwriting discounts and commissions and other offering costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In November 2022, we completed a follow-on offering of approximately $54.8 million pursuant to which we issued 5,803,655 shares of common stock, inclusive of 803,654 shares of common stock sold pursuant to the partial exercise of the underwriters' option to purchase additional shares at a price of $6.00 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares of common stock at a price of $5.9999, which represents the per share public offering price for the shares less $0.0001 per share. The net proceeds from the November 2022 follow-on offering were approximately $50.8 million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB212 for the prevention of FNAIT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are developing RLYB212, an anti-HPA-1a antibody product candidate for the prevention of FNAIT, a maternal fetal blood disorder that can cause potentially devastating outcomes including miscarriage, neonatal death and severe life-long neurological disability of the newborn. RLYB212 is a monoclonal anti-HPA-1a antibody that we believe has the potential to prevent maternal alloimmunization and thereby the occurrence of FNAIT. We have received approval for two CTAs for RLYB212 in Germany. The first was for a Phase 1 first-in-human trial and the second is for a Phase 1b proof of concept trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are also conducting an ongoing FNAIT natural history alloimmunization study. This prospective, non-interventional, multinational study is designed to determine the frequency of women at higher FNAIT risk among expectant mothers of different racial and ethnic characteristics, as well as the frequency of HPA-1a alloimmunization and pregnancy outcomes among these women. We expect that data from this study will be used to support future registration of RLYB212, by providing historical controlled data to support a single-arm Phase 2/3 registration trial design. An additional objective of the FNAIT natural history study is to operationalize de novo the laboratory test paradigm for FNAIT risk and generate FNAIT laboratory test performance data for future regulatory discussions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Maternal fetal blood disorders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FNAIT is one of several devastating disorders that is caused by an immune incompatibility of a mother and fetus during pregnancy. One of the best-characterized prenatal immune incompatibility disorders is Rh disease. This condition arises when the mother is RhD negative and her fetus is RhD positive. RhD incompatibility may lead to destruction of red blood cells in the fetus and can result in severe outcomes including miscarriage or loss of a newborn. Rh disease is treated by giving at-risk expectant mothers low doses of antibodies to RhD. These antibodies remove fetal red blood cells that have crossed into the mother&#x2019;s circulation, thereby preventing her from developing an immune response that could destroy the red blood cells in the fetus. Since the approval of the first Rho (D) Immune Globulin in 1968, known as RhoGAM, expectant mothers in many countries, including in North America and Europe, are routinely screened for their RhD status, and Rh disease is largely prevented in at-risk expectant mothers. We are pursuing a similar approach to preventing FNAIT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">FNAIT disease background</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Like Rh disease, FNAIT is a disorder that occurs during pregnancy when an expectant mother&#x2019;s immune system attacks a specific antigen on the platelets of her fetus, leading to their destruction. This results in an increased risk of bleeding in the fetus and newborn. In the majority of cases, the effects of FNAIT are mild; however, up to 20% of FNAIT cases experience intracranial hemorrhage (&#34;ICH&#34;), which can lead to devastating outcomes such as miscarriage, stillbirth, loss of the newborn and severe lifelong neurological disabilities in those babies that survive.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FNAIT is caused by a mismatch in the type of HPA-1 that is expressed by the expectant mother and the fetus. There are two predominant forms of HPA-1, known as HPA-1a and HPA-1b, which are expressed on the surface of platelets. These two alleles differ by a single amino acid. Individuals who are homozygous for HPA-1b, meaning that they have two copies of the HPA-1b allele and no copies of the HPA-1a allele, are also known as HPA-1a negative. Upon exposure to HPA-1a, these individuals can develop antibodies to that antigen in a process known as alloimmunization. In expectant mothers, alloimmunization can occur upon mixing of fetal blood with maternal blood. When alloimmunization occurs in an expectant mother, the anti-HPA-1a antibodies that develop in the mother can cross the placenta and destroy platelets in the fetus.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pathophysiology of FNAIT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img114804231_2.jpg" alt="img114804231_2.jpg" style="width:672px;height:384px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> There are no approved therapies to treat or prevent FNAIT and, therefore, expectant mothers are not currently screened for FNAIT risk. Today, expectant mothers at risk of FNAIT are typically only identified following the delivery of an FNAIT affected child. These mothers may be treated during subsequent pregnancies with weekly administration of IVIG, along with the oral steroid immunosuppressant prednisone. While IVIG administration can potentially mitigate the detrimental effects of anti-HPA-1a antibodies, it does not prevent alloimmunization, is costly, time-intensive, difficult to tolerate and associated with significant treatment-related complications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Babies with FNAIT are typically diagnosed at the time of delivery by the presence of low platelet counts identified during routine analysis, the presence of petechiae on the skin or due to the manifestations of severe complications such as ICH or gastrointestinal bleeding. Upon diagnosis, babies with FNAIT may receive platelet transfusions and may be admitted to the neonatal intensive care unit. In severe cases, babies may suffer life-long neurological disability or may not survive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We project that there may be over 22,000 pregnancies annually that are at high risk of FNAIT in the United States, Canada, United Kingdom, other major European countries and Australia. These pregnancies represent expectant mothers who are HPA-1a negative, who are at high risk of alloimmunization and who are carrying an HPA-1a positive fetus.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">While the frequency of HPA-1a negative status in non-Caucasian populations is not established, studies show that approximately 2% of the Caucasian population is HPA-1a negative. Based on this frequency and live birth rates of Caucasian women from 2018, we estimate that there are approximately 110,000 HPA-1a negative expectant mothers in the aforementioned countries each year. From this population of expectant mothers, a subset is at higher risk of FNAIT due to the presence of a specific HLA allele, known as DRB3*01:01. Genetic studies have found that expectant mothers who have this specific HLA allele are approximately 25 times more likely to develop antibodies to HPA-1a than those without this allele. This higher-risk group represents approximately 27% of HPA-1a negative expectant mothers, or approximately 30,000 individuals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">From this population, an estimated 89% of women would not already have antibodies to HPA-1a and, of these, an estimated 86% would be expected to be carrying an HPA-1a positive fetus. As illustrated below, based on these estimates, we project there may be over 22,000 pregnancies annually that are at high risk of FNAIT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pregnancies At Risk of FNAIT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><img src="img114804231_3.jpg" alt="img114804231_3.jpg" style="width:282px;height:262px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">*Source: NCHS National Vital Statistics Report Volume 68, Number 13, November 30, 2019, Births: Final Data for 2018; World Bank Population Data (2018); Kjeldsen-Kragh, et al Blood 2007; Hardy-Weinberg estimate; Kjeldsen-Kragh et al Blood 110, 833-839 (2007)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Given the well-established prevalence of HPA-1a negativity in the Caucasian population, our current estimates of the FNAIT at-risk population are derived from the estimated proportion of Caucasian births from approximately eight million live births per year in the above-mentioned countries. We are committed, however, to ensuring that all expectant mothers of any race or ethnicity who are at high risk of FNAIT are identified and eligible for treatment. To this end, we are conducting a FNAIT natural history study, in part to obtain better prevalence estimates of the FNAIT at-risk population in racial and ethnic groups that may have been underrepresented in previously published studies. We believe that data from this study will better inform the size of the total FNAIT at-risk population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that screening for FNAIT risk can be performed routinely and cost effectively as part of standard prenatal testing provided to expectant mothers during pregnancy. Testing for maternal HPA-1 type and presence of the HLA-DRB3*01:01 allele could occur during the first trimester, at the same time as other routine blood work and risk screening, and we don&#x2019;t expect that an additional blood draw would be required. Importantly, U.S. and EU physicians have advised that our approach and timing for FNAIT screening would fit well within the established first trimester prenatal testing paradigm and could slot in at the same time as routine blood typing and Rh testing. Based on our global market research with maternal-fetal medicine specialists, obstetricians-gynecologists and payers, we believe there is not only high awareness of the catastrophic impact of FNAIT, but also a strong desire to both screen and provide preventive therapy to at-risk expectant mothers, if there were an approved product to prevent FNAIT and affordable screening tests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe screening and preventive treatment can have a significant impact on this potentially devastating disease. For example, screening and treatment in Rh disease have been highly effective in reducing the number of affected births. In developed countries with access to prenatal testing and treatment, the prevalence of Rh disease is 2.5 per 100,000 compared to 276 per 100,000 worldwide. We believe that applying a similar approach to the prevention of FNAIT could lead to a significant reduction in the number of babies at risk for FNAIT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are working with a third party to include screening tests for maternal HPA-1 type, maternal HLA-DRB3*D1:01 status, maternal HPA-1a antibodies and fetal HPA-1 genotype in our FNAIT natural history trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our solution: RLYB212</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are developing RLYB212, a monoclonal anti-HPA-1a antibody developed from transformed memory B-cells isolated from a mother who previously experienced severe FNAIT affected pregnancies. In the first quarter of 2023, we announced proof-of-concept in a Phase 1b study for RLYB212.  Results showed that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects. In the Phase 1b study, RLYB212 was observed to be well-tolerated with no serious adverse events reported. We believe that the broad range of PK and PD data in the Phase 1b study will allow for substantive modeling to inform dose selection for a future registrational study. Also, in the first quarter of 2023 we initiated the multi-dose cohort of our single-center Phase 1 trial in Europe. This portion of the Phase 1</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">study will evaluate safety and PK of RLYB212 based on repeat dosing over 12 weeks in healthy male and female participants. We expect to report the results from this cohort of subjects in the fourth quarter of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> We believe RLYB212 is a potential first-in-class product candidate for prevention of FNAIT based on:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Dose administration.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> RLYB212 is dosed subcutaneously which simplifies the treatment regimen for at-risk expectant mothers and is highly preferred by physicians in both the United States and EU, based on primary market research.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PK profile.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Our PK modeling suggests that subcutaneous administration of RLYB212 could maximize the capacity of RLYB212 to neutralize fetal antigen over the course of treatment.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Standard manufacturing and stable supply</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Commercial quantities of RLYB212 are expected to be produced by standard monoclonal antibody production methods. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br />RLYB211: Established Proof-of-Mechanism for an Anti-HPA-1a Antibody to Cause Rapid Platelet Elimination</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB211 is an intravenously administered polyclonal anti-HPA-1a antibody derived from the plasma of women who have developed antibodies to HPA-1a from a prior HPA-1 incompatible pregnancy. Data from our Phase 1/2 clinical trial for RLYB211, initially presented in July 2021 at the International Society on Thrombosis and Haemostasis (&#x201c;ISTH&#x201d;) Congress and subsequently published in the Journal of Thrombosis and Hemostasis (Geisen et al., 2022, In Press), demonstrate that RLYB211 rapidly and completely eliminates HPA-1a-positive platelets in HPA-1a negative subjects, establishing proof-of-mechanism for the ability of an anti-HPA-1a antibody to cause rapid platelet elimination. Our product candidate RLYB212 has the same mechanism of action as RLYB211 with the relative of benefits that RLYB212 has as a monoclonal antibody.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB211 Led to Rapid Clearance of Transfused HPA-1a Positive (i.e., HPA-1ab) Platelets from Healthy Participants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img114804231_4.jpg" alt="img114804231_4.jpg" style="width:480px;height:338px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">RLYB212 preclinical data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A mouse model of FNAIT has been created in which the amino acids comprising the HPA-1a antigen are reconstituted in the mouse gene. These transgenic mice (referred to as APLDQ mice based on the amino acid changes) recapitulate multiple aspects of FNAIT. Administration of anti-HPA-1a antibodies to APLDQ mice leads to destruction of APLDQ platelets and severe thrombocytopenia. Injection of platelets from APLDQ mice into wild-type mice can induce an HPA-1a specific immune response. Finally, wild-type female mice pre-immunized with APLDQ platelets, when bred with APLDQ male mice, give birth to severely thrombocytopenic pups, many of which exhibit an accompanying bleeding phenotype. Treatment of these pregnant female mice with IVIG resulted in lowering the level of anti-APLDQ antibodies in the fetus and a reduction in thrombocytopenia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In a prophylactic treatment model, a single large bolus intravenous injection of 1 x 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> APLDQ platelets (equivalent to about one-sixth of the total blood volume in the host) was administered to wild-type mice. At a dose of 0.4 &#xb5;g (yielding a peak concentration of approximately 0.2 &#xb5;g/ml), RLYB212 was able to drive rapid and complete elimination of APLDQ platelets, as shown in the first graph below, and prevent a host antibody response, as shown in the second graph below. As shown in third graph below, this dose correlates to a concentration of RLYB212 projected to bind approximately 10% of the HPA-1a antigen present on the transfused APLDQ platelets. Thus, the approximately 10% receptor binding is sufficient to clear platelets and prevent alloimmunization in the mouse model.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB212 Induced Rapid Elimination of APLDQ Platelets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img114804231_5.jpg" alt="img114804231_5.jpg" style="width:429px;height:324px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB212 Prevented the Development of Antibodies to APLDQ Platelets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img114804231_6.jpg" alt="img114804231_6.jpg" style="width:402px;height:251px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Clinical development of RLYB212</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A Phase 1 single and multiple dose study of RLYB212 in HPA-1a negative healthy participants was initiated in the fourth quarter of 2021. This ongoing single-blind, placebo-controlled study is designed to evaluate the safety and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PK of single and repeat doses of subcutaneously administered RLYB212. An overview of the study's design is illustrated below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Design of the Ongoing Phase 1 PK and Safety Study of RLYB212 in HPA-1a Negative Healthy Participants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><img src="img114804231_7.jpg" alt="img114804231_7.jpg" style="width:672px;height:177px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The ongoing Phase 1b proof of concept study that was initiated in the second quarter of 2022 is designed to assess the ability of subcutaneously administered RLYB212 to rapidly eliminate transfused HPA-1a positive platelets from the circulation of HPA-1a negative healthy male participants. In the third quarter of 2022, we announced preliminary results from this study, demonstrating that one week after a single subcutaneous dose, RLYB212 rapidly and completely eliminated HPA-1a positive platelets with a greater than 90% reduction of the mean platelet elimination half-life compared to placebo in a challenge model of a catastrophic fetal maternal hemorrhage, consistent with our proof-of-concept criteria.  We also announced that dosing had commenced under an amended protocol that expanded the dose range of RLYB212, thereby providing a broader range of PK and PD data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Design of the Phase 1b Trial of RLYB212 in Healthy Male Participants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img114804231_8.jpg" alt="img114804231_8.jpg" style="width:672px;height:152px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the first quarter of 2023, we announced proof-of-concept in the Phase 1b study for RLYB212.  Results showed that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects with additional findings from the study that show a reduction in mean platelet elimination half-life was greater than 90% in both RLYB212 dose groups compared to placebo and was dose related. We believe that the broad range of PK and PD data in the Phase 1b study will allow for substantive modeling to inform dose selection for a future registrational study. The Company expects to report the complete dataset from the Phase 1b study of RLYB212 at a scientific conference in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the first quarter of 2023 we initiated the multi-dose cohort of our single-center Phase 1 trial in Europe. This portion of that study will evaluate safety and PK of RLYB212 based on repeat dosing over 12 weeks in healthy male and female participants. We expect to report results from this cohort of subjects in the fourth quarter of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subject to future successful discussions with regulatory authorities, we plan to conduct a registrational enabling Phase 2/3 trial of RLYB212 in expectant mothers at higher FNAIT risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Prospective FNAIT Natural History Alloimmunization Study</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have a prospective, non-interventional, multinational natural history study ongoing. The primary objective of this ongoing study is to determine the frequency of women who are HPA-1a antibody negative and have the HLA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">allele DRB3*01:01, and are therefore at higher FNAIT risk among pregnant women of different racial and ethnic characteristics who present for prenatal care at gestation weeks 10 to 14. A secondary objective will be to identify the frequency of HPA-1a alloimmunization and pregnancy outcomes among women identified to be at higher FNAIT risk. We expect that the data from this study will contribute to a control dataset for a future, single-armed registration trial for RLYB212.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB116 for the treatment of disorders due to complement dysregulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB116 is an inhibitor of complement component C5, a component of the complement pathway which plays a central role in innate immunity as well as shaping adaptive immune response. Dysregulation of the complement pathway has been implicated in the pathogenesis of a growing number of diseases, making it an attractive target for therapeutic intervention. Antibody inhibitors of C5 have been successfully developed to treat diseases caused by immune dysfunction, including PNH, aHUS, refractory gMG and relapsing NMOSD. Despite approved products for these indications, we believe there remains an unmet need in patients with these diseases for therapies that are more patient-friendly and accessible. RLYB116 is an Affibody molecule, which is an antibody mimetic protein that has a much smaller molecular weight than a traditional antibody and may also be easier and less costly to produce. In contrast to C5-targeted antibody therapeutics that are administered intravenously, RLYB116 has the potential to be administered as a small volume subcutaneous injection. RLYB116 also includes an albumin binding domain, which may extend the half-life of the Affibody domain. In addition, amino acid changes have been made to RLYB116 that are intended to enhance its stability. We view RLYB116 as a potential pipeline-in-a-product with disease areas under consideration including PNH, gMG and severe dermatologic indications. However, we plan to evaluate the development of RLYB116 for the treatment of additional rare complement-mediated diseases. We believe RLYB116 could potentially enable more patients suffering from PNH and gMG to be treated globally and could also provide a meaningful therapeutic impact for patients suffering from a broad number of other diseases of complement dysregulation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on our team&#x2019;s experience studying and developing therapies targeting the complement system, we believe there are four important attributes that could support clinical and commercial success in the treatment of patients suffering from complement-mediated diseases. These include a mechanism of action targeting terminal complement, the ability to produce rapid, complete and sustained inhibition of C5, a safety profile consistent with C5 antibodies currently approved for therapeutic use and pricing flexibility to treat a broad range of complement-mediated diseases. We believe RLYB116 has the potential to demonstrate these attributes, and if so, could have a life-transforming impact on patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The complement system</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The complement system includes over 30 proteins in plasma and on cell surfaces that support the body&#x2019;s adaptive or antibody-based immune system in the destruction of pathogenic bacteria. Complement proteins circulate in the blood in an inactive form prior to activation in response to infection. Activation occurs through a pathway of proteolytic cleavage events initiated by pathogen recognition and resulting in pathogen destruction. Three complement pathways that converge on C5 are known and are referred to as the classical, lectin and alternative pathways that converge on C5. In the classical pathway, antibodies bind to antigens, which in turn trigger a protease cascade that activates complement protein C3 and then complement protein C5. Activation of C5 convertase generates C5b which can initiate formation of membrane pores and subsequent lysis of cells. The binding of C5b to host cells is normally prevented by the presence of specific glycoproteins on the cell surface.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">PNH disease background</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PNH is a rare, potentially life-threatening hematologic disease characterized by complement-mediated destruction of red blood cells, or hemolysis. In patients with PNH, blood precursor cells acquire a mutation in a gene encoding a protein that anchors a specific set of proteins on the cell surface. When these proteins, known as glycoproteins, are in place on the blood precursor cells, then the cells are protected from immune attack. However, in patients with PNH, these mutations cause the absence of these glycoproteins and renders red blood cells susceptible to destruction by the complement pathway. Once the cells are destroyed, by a mechanism known as lysis, the hemoglobin from these cells is then removed from circulation by the kidneys and excreted in the urine. Excess hemoglobin and additional proteins from lysed red blood cells cause the kidney damage seen in most patients with PNH. The observed increase in the rate of thrombosis in PNH patients is believed to be related to altered platelet function as well as to other activities associated with the C5a protein, such as vasoconstriction and increases in inflammation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Early signs of PNH include hemoglobinuria, or dark colored urine, resulting from excretion of hemoglobin from lysed red blood cells, which is more prominent in the morning and decreases during the day. More serious symptoms of PNH include anemia, excessive weakness, fatigue, severe abdominal pain, severe headaches and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recurrent infections. PNH leads to over a 60-fold increase in the risk of venous thromboembolism compared to the general population and these thrombotic events lead to between 40% and 67% of deaths in PNH patients. Approximately two thirds of patients with PNH develop chronic kidney disease  (&#34;CKD&#34;), and kidney failure is the cause of death in 8% to 18% of patients with PNH. In the absence of disease-modifying treatment, PNH results in the death of approximately 35% of affected individuals within five years of diagnosis. The prevalence of PNH has been estimated to be approximately 12-13 people per million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br /><br />Current treatments for PNH and their limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The only curative treatment currently available for PNH is a stem cell transplant from a related donor. However, this procedure is associated with significant risk and is typically used only in those patients with severe disease, such as life-threatening thrombosis or dangerously low blood counts. Various supportive therapies include anticoagulants, red blood cell transfusions and supplements of iron and folate. These therapies provide some relief from symptoms but do not address the underlying cause of the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There are two approved disease-modifying drugs for PNH: eculizumab, marketed by AstraZeneca as Soliris; and ravulizumab, marketed by AstraZeneca as Ultomiris. Both of these products are antibodies that bind to complement C5 and prevent its cleavage by C5 convertase to C5a and C5b, thus blocking a central step in the complement pathway. Both products are roughly equivalent in their ability to block C5 cleavage, prevent hemolysis, minimize the need for transfusions and stabilize hemoglobin.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Eculizumab and ravulizumab are each administered intravenously by healthcare professionals: eculizumab at biweekly intervals and ravulizumab at eight-week intervals. Ravulizumab can also be delivered subcutaneously. Despite the requirement for intravenous administration and limitations on access, wide adoption of these drugs has led to worldwide sales of eculizumab and ravulizumab which in 2022 exceeded $5 billion. We believe that a product that works through a similar mechanism but with a low-volume, more convenient route of administration and improved patient access has the opportunity to further transform PNH therapy for patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Potential benefits of our approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are pursuing PNH as part of our initial development strategy for three reasons. First, PNH has a well-understood disease pathophysiology driven by complement, providing a sound biological rationale for a C5-targeted intervention. Second, PNH offers the opportunity for early clinical validation using objective endpoints, including impact on lactate dehydrogenase, a component of red blood cells that is increased in circulation as a result of hemolysis. And third &#x2013; and most importantly &#x2013; we believe that with a patient-friendly and accessible therapy, RLYB116 could potentially provide transformative therapeutic impact for unserved and underserved patients with PNH globally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">gMG disease background</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">gMG is a potentially life-threatening, rare autoimmune neuromuscular disorder. Patients with gMG develop antibodies that attack critical signaling proteins at the junction between nerve and muscle cells, thereby inhibiting the ability of nerves to communicate properly with muscles. This inhibition leads to muscle weakness, which can occur in ocular muscles leading to droopy eyelids as well as blurred or double vision due to partial paralysis of eye movements and in the muscles in the face, neck, throat and jaw, causing problems in chewing and swallowing. gMG can also cause respiratory problems, speech difficulties and weakness in skeletal muscles leading to problems in limb function. The symptoms of the disease can be transient and can remit spontaneously in the early stages of the disease. However, as the disease progresses, symptom-free periods become less frequent and disease exacerbations can last for months. Up to 20% of gMG patients experience respiratory crisis at least once in their lives. During such a crisis, a decline in respiratory function can become life-threatening and often requires intubation and mechanical ventilation, and hospital stays for patients in crisis last a median of seventeen days. According to a comprehensive epidemiological study of gMG in western Denmark form 1975-89, from the time of diagnosis, the overall survival rates at 3, 5, 10 and 20 years are estimated to be 85%, 81%, 69% and 63%, respectively. In addition, patients with gMG suffer from poor quality of life due to the impact of their disease on physical function as well as the burden of treatment-related adverse events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The most common proteins that have been targeted by these autoimmune antibodies are AchR, which are within the neuromuscular junction and bind to the acetylcholine neurotransmitter released by the nerve; and muscle-specific kinase (&#34;MuSK&#34;) a tyrosine kinase involved in propagating neuronal signals. The presence of these autoimmune antibodies blocks the signaling from neurons to muscles which results in outward signs of muscle weakness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The pathology in gMG arises not only from interrupting signal transduction, but from physical destruction of the post-synaptic membrane through activation of the complement pathway. Over 80% of patients with gMG have antibodies to AchR and these antibodies can lead to complement-driven lysis of the post-synaptic membrane. Eculizumab is approved for the treatment of AchR antibody-positive gMG based on its ability to lead to significant improvements in the Myasthenia Gravis-Specific Activities of Daily Living scale and the Quantitative Myasthenia Gravis score which measures muscle weakness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The prevalence of gMG has been estimated to be at least 100 people per million. As with many autoimmune diseases, there are no known genetic alterations that specifically cause gMG. In most patients, the disorder arises spontaneously. Approximately 3% of patients have a primary relative with gMG, suggesting that there are genetic factors that may predispose development of the disease, but these genes have yet to be identified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Current treatments for gMG and their limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the first-line setting, patients presenting with symptomatic gMG are commonly treated with acetylcholinesterase inhibitors such as pyridostigmine in order to improve neuromuscular transmission. As the disease progresses, patients may receive immunosuppressive therapies such as azathioprine, glucocorticoids, mycophenolate and cyclosporine. These therapies are used off-label for patients with gMG and unfortunately, each of these can be associated with substantive treatment burden and in some cases, can lead to a worsening of the disease. Soliris (eculizumab) has been approved in the United States, EU, Japan and other markets for the treatment of patients with refractory gMG who are anti-AChR positive. Substantive symptom improvements have been noted with eculizimab treatment at the first assessment at one week after first dose administration. Rituximab may also be used off-label and is believed to have more benefit in patients with gMG with anti-MuSK antibodies compared to those with anti-AChR antibodies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For patients with severe gMG or recurrent exacerbation and crisis, there are a number of methods utilized to reduce circulating IgG antibodies, as published studies have shown that decreases in circulating IgG antibody levels are correlated with increased relief of symptoms and decreases in the length of hospital stays. These procedures include: plasma exchange, a process whereby blood is taken from a patient and IgG antibodies are physically removed from the plasma before it is returned to the patient; and administration of IVIG, which provides therapeutic benefit through multiple hypothesized mechanisms, including the saturation of the FcRn receptor, which may lead to increased degradation of the endogenous autoimmune antibodies. Both procedures are burdensome for patients and repeat administration is usually required to obtain significant reduction in symptoms. In addition, the large volumes of intravenous fluid associated with the administration of IVIG can lead to pulmonary edema and kidney complications in elderly patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Potential benefits of our approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are pursuing gMG as part of our initial development strategy for two reasons. First, complement overactivity is known to contribute to the disease pathophysiology of gMG, again providing a sound biological rationale for a C5-targeted intervention. Second &#x2013; and most importantly &#x2013; we believe there is significant unmet need that we can address. We believe the convenience of subcutaneous self-administration may enable treatment of a broad population of gMG patients at both earlier and late stages of disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our solution: RLYB116</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB116 is an engineered protein that includes an Affibody molecule and an albumin binding domain. We acquired rights to RLYB116 from Swedish Orphan Biovitrum AB (Publ) (&#34;Sobi&#34;). RLYB116 has been designed to be optimized for C5 binding, stability, and long half-life in serum. Potential benefits of RLYB116 include:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subcutaneous administration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. The low molecular weight allows for a higher concentration of active molecules than antibodies in an equivalent volume. This increases the probability of being able to deliver RLYB116 in a volume suitable for subcutaneous administration.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Efficiency of manufacturing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. RLYB116 is expressed in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">E coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, providing for a more streamlined manufacturing process compared to antibodies or other biologics expressed in mammalian cell culture, which typically require larger scale and longer manufacturing times.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less frequent dosing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Linkage of the Affibody domain to an albumin binding domain may lengthen the dosing interval of RLYB116 by extending the biological half-life.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Broader indication opportunity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Linkage to an albumin binding domain may also improve distribution to tissues throughout the body creating the potential for additional tissue targets and indications.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Potentially lower risk of treatment conversion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Due to 1:1 binding to C5, there is an expected lack of risk for drug-target-drug complex formation when switching from treatment with an antibody.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Favorable stability.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> The Affibody platform provides the possibility of delivering highly stable and soluble therapeutic agents that allow for high-concentration low-volume products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Affibody Scaffold and RLYB116 Structure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><img src="img114804231_9.jpg" alt="img114804231_9.jpg" style="width:300px;height:262px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">PD properties of RLYB116</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An ex vivo hemolytic inhibition assay suggests that RLYB116 may inhibit C5-mediated red blood cell destruction at a dose that could be clinically useful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Clinical development of RLYB116</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We received approval in the fourth quarter of 2021 for a HREC submission to support the initiation of a RLYB116 Phase 1 trial in healthy participants and in the first quarter of 2022 we initiated the Phase 1 trial in Australia. This trial is designed to evaluate the safety, tolerability and PK of RLYB116 following subcutaneous administration of a single dose and multiple doses. We also plan to incorporate a measure of PD activity into the single and multiple ascending dose segments of the trial. There are 40 participants in the single ascending dose segment with evaluations at 5 dose levels. We plan to enroll up to 84 participants with up to 7 dosing strategies in the multiple ascending dose segment of the trial.  We are also planning to conduct a future trial in patients with PNH to assess the effect of RLYB116 on measures of PK and PD activity as well as safety and tolerability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Design of the Initial Phase 1 Single Ascending Dose Trial of RLYB116 in Healthy Participants <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img114804231_10.jpg" alt="img114804231_10.jpg" style="width:667px;height:173px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br />In November 2022, we announced positive topline results from our Phase 1 single ascending dose study of RLYB116. These preliminary data showed that all study participants that were administered a single 1 mL subcutaneous injection of 100 mg of RLYB116 (n=6) demonstrated a reduction in free C5 greater than 99% within 24 hours of dosing. The terminal elimination half-life of RLYB116 was greater than 300 hours. Subcutaneously administered RLYB116 was observed to be generally well-tolerated at the 100 mg dose, with mild adverse events and no drug-related serious adverse events reported.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The single ascending dose phase of the study included 2, 10, 30, 100, and 300 mg subcutaneous doses, which enabled an evaluation of a maximum tolerated dose.  Mild to moderate adverse events were observed with no serious adverse events or severe adverse events.  Concentrations of RLYB116 were consistent with the increase in dose. Free C5 concentration reductions greater than 99% within 24 hours were demonstrated with both 100 mg and 300 mg doses. Based on the data from the 100mg dose and the volume of administration of the 300 mg</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">dose, the Company intends to move forward with the 100mg dose as a starting point for the evaluation of multiple dose administration of RLYB116.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the fourth quarter of 2022, we initiated dosing in the first multiple ascending dose cohort of a Phase 1 study of  RLYB116. The single-blind, dose escalation, placebo-controlled study is designed to evaluate the safety, PK, and PD of RLYB116 in healthy participants. We expect to report initial data in the fourth quarter of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We anticipate conducting subsequent trials in patients with PNH and gMG, which are both indications in which C5 inhibition has been clinically validated. Beyond these initial indications, we plan to evaluate the development of RLYB116 for the treatment of additional rare complement-mediated diseases, including severe dermatologic indications, given the growing numbers of diseases understood to be mediated by complement dysregulation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB114 for the treatment of ophthalmic disorders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB114 is a C5-targeted Affibody molecule conjugated to polyethylene glycol (&#34;PEG&#34;). The addition of PEG to protein therapeutics is a well-established method of extending the half-life and reducing the immunogenicity of  molecules in the body. Given the role of the complement system in retinal and ocular pathology, we are exploring a range of ophthalmic diseases, including inflammatory and degenerative disorders, for the development of RLYB114.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Potential role of complement in ocular diseases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Dysregulation of the complement system may drive ocular inflammation and contribute to vision loss in multiple diseases such as age-related macular degeneration (&#34;AMD&#34;). A number of genetic studies have shown links between alterations in genes encoding various complement factors and the risk of development of AMD. Several clinical trials of inhibitors of the complement pathway including C5 inhibitors have been conducted, with reports of modest efficacy. Reasons for this limited efficacy are unknown but could include the disease stage, level of intervention in the complement pathway, drug delivery mechanism and the ability of the therapeutic to cross Bruch&#x2019;s membrane and the retinal pigment epithelium.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preclinical studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on a non-clinical intravitreal PK study, RLYB114 may have a half-life comparable to Eylea. RLYB114 was also well tolerated in this study with no major signs of ocular toxicities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our solution: RLYB114</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We continue to advance the preclinical development of RLYB114, formulated for intravitreal injection, for the treatment of ophthalmic disorders with a goal to partner this program with a company that specializes in ophthalmology drug development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB331 for the treatment of severe anemia with ineffective erythropoiesis and iron overload</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In May 2022, we obtained worldwide exclusive rights to RLYB331, a preclinical antibody. We believe RLYB331 has the potential to address a significant unmet need for patients with severe anemias with ineffective erythropoiesis and iron overload, including beta thalassemia and a subset of lower risk myelodysplastic syndromes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Currently these patients are underserved by the existing standard of care. RLYB331 is a  monoclonal antibody that is designed to inhibit MTP-2. The inhibition of MTP-2 significantly increases levels of hepcidin, decreases iron load and treats ineffective erythropoiesis. We continue to conduct investigational new drug (IND)-enabling activities for RLYB331, to support the transition of this asset into clinical development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AI drug discovery collaboration with Exscientia</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We established a partnership with Exscientia, an AI and machine learning drug discovery company. Exscientia has built dedicated AI systems that learn from a wide range of data and apply enhanced knowledge through iterations of design. Our partnership currently consists of a joint venture that focuses on the discovery and development of small molecules for the treatment of patients with rare metabolic diseases. We are initially targeting ENPP1, an enzyme involved in regulating extracellular levels of pyrophosphate, a natural inhibitor of calcium mineralization in bone formation, for the treatment of patients with HPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">RE Ventures I, LLC : ENPP1 inhibitor program for the treatment of patients with HPP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are developing an ENPP1 inhibitor for the treatment of patients with HPP, a rare, potentially life-threatening genetic disease characterized by mutations in the ALPL gene. These mutations lead to diminished activity of the tissue non-specific alkaline phosphatase (&#34;TNSALP&#34;) enzyme and the accumulation of PPi, which inhibits bone mineralization causing multiple skeletal pathologies. ENPP1 is a Type II transmembrane glycoprotein that cleaves</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ATP, producing PPi, and is a major source of PPi production in cells. We believe that controlling inhibition of ENPP1 may reduce PPi levels and restore balance within the bone mineralization process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">HPP disease overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">HPP is an inherited disorder that affects the development of bones and teeth. More than 300 mutations in the ALPL gene associated with HPP have been identified. These mutations are associated with a wide range of disease severity. The most severe forms of the disorder tend to occur before birth and in early infancy. Infants afflicted with the disorder have short limbs, an abnormally shaped chest, soft skull bones, poor feeding, failure to gain weight, respiratory complications and high levels of calcium in the blood, or hypercalcemia, which can lead to life-threatening complications. In other cases, the disease is not recognized until later in childhood where it manifests as rickets, pain, decreased mobility, deficits of growth and fractures. Children with less severe HPP can experience early loss of primary teeth and may have short stature with bowed legs or knock knees, enlarged wrist and ankle joints and an abnormal skull shape. Findings in adults include a softening of the bones, known as osteomalacia, and recurrent fractures in the foot and thigh bones that can lead to chronic pain. The incidence of HPP has been reported to be 1 in 100,000 (United States and Canada) to 1 in 300,000 (EU) for severe disease and 1 in 6,370 (EU) for less severe forms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The various manifestations of HPP are caused by the combination of a lack of phosphate and an excess of PPi due to a deficiency of TNSALP, the enzyme that converts PPi to phosphate. This deficiency negatively impacts bone formation by reducing the hydrolysis of PPi to phosphate required for normal bone formation, resulting in a build-up of PPi, a potent inhibitor of mineralization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Strensiq, an enzyme replacement therapy marketed by AstraZeneca, is the only approved therapy to treat patients with perinatal-, infantile- and juvenile-onset HPP. The therapy has been shown to lead to significant improvements in morbidity and mortality in patients with perinatal- and infantile-onset HPP, and improvements in morbidity for patients with juvenile-onset HPP. However, Strensiq has limitations, including its dosing regimen and patient access. Strensiq is administered by subcutaneous injection either three or six times per week using a weight-based dosing scale, which can be both onerous and painful for patients. Furthermore, a population of adult patients may have difficulty accessing the therapy given reimbursement dynamics in countries around the world as a result of weight-based dosing that drives high costs for heavier patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our solution: an ENPP1 small molecule inhibitor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are developing an orally available, small molecule ENPP1 inhibitor designed to reduce PPi levels through the controlled inhibition of ENPP1, which we hypothesize may restore the balance of PPi and phosphate needed to promote bone mineralization. This program is in its early stages and preclinical and clinical development is required. If an ENPP1 inhibitor is successfully advanced through clinical development and obtains marketing approval, we believe that an oral small molecule ENPP1 inhibitor, administered as a stand-alone therapy or in combination with Strensiq, could have significant benefit in managing HPP and improving the lives of patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lead molecules demonstrated encouraging activity in functional assays. In vivo efficacy data in our ENPP1 program is expected in the second half of 2023. Following those results, we and Exscientia expect to commence IND-enabling studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Scientific Rational: ENPP1 Inhibition for the Treatment of Hypophosphatasia</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.845%;"></td>
    <td style="width:54.155%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><img src="img114804231_11.jpg" alt="img114804231_11.jpg" style="width:305px;height:171px;" />&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.65pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under normal conditions, the level of PPi and Pi is kept in balance by activity of TNSALP, ENPP1 and ANKH.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.845%;"></td>
    <td style="width:54.155%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img114804231_12.jpg" alt="img114804231_12.jpg" style="width:305px;height:171px;" />&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.65pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In patients with HPP, the reduction of PPi hydrolysis by TNSALP results in a relative increase in PPi, leading to an inhibition of mineralization, and inhibited hydroxyapatite formation.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img114804231_13.jpg" alt="img114804231_13.jpg" style="width:305px;height:171px;" />&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.65pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Through controlled inhibition of ENPP1, we aim to reduce PPi and improve mineralization, restoring hydroxyapatite formation.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AbCellera Collaboration<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera&#x2019;s antibody discovery engine with Rallybio&#x2019;s clinical and commercial expertise in rare diseases to identify optimal clinical candidates with a goal of delivering therapies to patients. Under the terms of the agreement, AbCellera and Rallybio will co-develop up to five rare disease therapeutic targets, which will be chosen together by both companies.  The partnership&#x2019;s first program will focus on addressing the significant unmet therapeutic needs of patients with rare metabolic diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. There are many public and private biopharmaceutical companies, universities, government agencies and other research organizations actively engaged in the research and development of products that may be like our product candidates or address similar markets. In addition, the number of companies seeking to develop and commercialize products and therapies competing with our product candidates is likely to increase. However, we seek to build our portfolio with key differentiating attributes to provide a competitive advantage in the markets we target. The success of our product candidates, if approved, is likely to be a result of their efficacy, safety, convenience, price, the level of biosimilar or generic competition and/or the availability of reimbursement from government and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">FNAIT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. There are currently no approved therapies for the prevention or treatment of FNAIT. In one frequently used approach to manage pregnancies where the mother is known to have a history of FNAIT, physicians administer high levels of IVIG. Companies that currently market IVIG include ADMA Biologics, Bio Products Laboratory, CSL Behring, Grifols, Kedrion Biopharma, Leadiant Biosciences, Octapharma and Takeda Pharmaceutical Company Limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">PNH</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. The only curative treatment currently available for PNH is a stem cell transplant from a related donor. However, this procedure is associated with significant risk and is used only in those patients with severe disease, such as life-threatening thrombosis or dangerously low blood counts. Various supportive therapies include anticoagulants, red blood cell transfusions and iron and folate supplements. These therapies provide some relief from symptoms but do not address the underlying cause of the disease. There are three approved drugs for PNH: eculizumab, marketed by AstraZeneca as Soliris; ravulizumab, marketed by AstraZeneca as Ultomiris, and pegcetacoplan, marketed by Apellis Pharmaceuticals as Empaveli. Eculizumab and ravulizumab are antibodies that bind complement C5 and pegcetacoplan is a pegylated pentadecapeptide that targets complement C3. There</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">are several companies in mid- to late-stage clinical trials developing treatments for PNH. These include Akari Therapeutics, Alnylam Pharmaceuticals, Novartis, Regeneron Pharmaceuticals and Roche.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">MG</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Very early-stage MG is symptomatically treated by the use of acetylcholinesterase inhibitors such as pyridostigmine bromide, marketed as Mestinon by Bausch Health. Eculizumab is also approved for the treatment of generalized MG in patients who are positive for anti-AChR antibodies. Efgartigimod, marketed as Vyvgart by Argenx SE, is a neonatal Fc receptor blocker also approved for the treatment of patients with generalized MG who are positive for anti-AChR antibodies. There are several other companies developing assets in mid- to late-stage clinical development for the treatment of MG using a variety of approaches and modalities. These companies include AstraZeneca, Catalyst Pharmaceuticals, CureVac, Horizon Therapeutics, Immunovant, Inc. and UCB Biopharma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">HPP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. There is one approved treatment for HPP, asfotase alfa, marketed by AstraZeneca as Strensiq, which is an alkaline phosphotase enzyme replacement therapy, and the only approved therapy for the treatment of perinatal-, infantile- and juvenile-onset HPP. AstraZeneca is developing a second generation enzyme replacement therapy, ALXN-1850 which is currently in clinical development, and Aruvant is developing ARU-2801, an AAV gene therapy currently in preclinical development. There are several companies pursuing ENPP1 small molecule inhibitors for the treatment of cancer, including Angarus Therapeutics, Avammune Therapeutics, Tcino Bioscience, Zenshine Pharmaceuticals and Stingray Therapeutics with all these companies in discovery or preclinical development. We are not aware of other small molecule inhibitors in development for the treatment of patients with HPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many of our competitors may have significantly greater name recognition and financial, manufacturing, marketing, product development, technical, commercial infrastructure, and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our success depends, in part, on our ability to obtain, maintain, defend, and enforce patent rights and other intellectual property rights that protect our business, preserve the confidentiality of our trade secrets, and operate without infringing the valid and enforceable intellectual property rights of others. In addition to our efforts to protect our product candidates and methods of using them, we also seek to secure or acquire patent rights regarding other products and methods that are important to the general development of commercial products. We utilize a multi-layered approach that includes acquiring intellectual property rights through purchase or exclusive license, filing and prosecuting U.S. and foreign patent applications directed to our own innovations, and developing and protecting proprietary know-how to maintain our competitive position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our ongoing efforts to secure patent rights that protect our business constitute a key component of our business strategy. We also strive to protect as trade secrets or confidential know-how, certain aspects of our programs and technological innovations that are commercially valuable but are not amenable to or appropriate for patent protection. We achieve this, in part, through the use of confidentiality agreements with our employees, consultants, scientific advisors, collaborators, licensors, and contractors, and by striving to maintain physical security of our premises and digital security of our electronic information and technology systems.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notwithstanding our commitment to protecting our intellectual property rights, we, like other pharmaceutical and biopharmaceutical companies, are subject to several sources of uncertainty that can affect those rights. For example, we cannot be certain that any patents that we currently own or in-license, or that we may own or in-license in the future, will not be challenged, held to be invalid and/or unenforceable, have the scope of their claims narrowed, or be circumvented by others. Nor can we be certain that such patents will successfully protect our products or our business from competition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Similarly, with respect to patent applications that are currently pending, or that may be pending in the future, we cannot be certain that such patent applications will result in the issuance of granted patents, or of patent claims with the desired claim scope. In order to secure an issued patent, an invention claimed in a patent application must meet certain legal requirements for patentability, which differ between countries based on each country&#x2019;s particular patent laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, because of the significant amount of time required for clinical development and regulatory review of product candidates, we cannot be certain that any of our product candidates will be commercialized while there is significant patent term remaining on patents relating to those products. The term of a patent depends upon the legal requirements for determination of patent term in the country in which that patent is granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a non-provisional patent application. In the United States, a patent&#x2019;s term may, in certain cases, be lengthened by patent term adjustment (&#34;PTA&#34;) which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office (&#34;USPTO&#34;) in examining and granting the patent. Likewise, a patent&#x2019;s term may be shortened if it is terminally disclaimed over an earlier-expiring patent with a common owner or inventor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The term of a U.S. patent relating to an approved drug product may also be extended to compensate the patentee for delays due to the regulatory approval process. Such a patent term extension (&#34;PTE&#34;) cannot exceed five years, and cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Furthermore, the term can be extended for only one patent applicable to each regulatory review period and only those claims covering the approved product, or a method for using it or manufacturing it, may be extended. In the future, if any of our product candidates receive approval by the U.S. Food and Drug Administration (the &#34;FDA&#34;) we expect to apply for PTE on any issued patents covering those products, depending upon the length of the clinical studies for each product and other factors. There can be no assurance that we will benefit from any PTE or favorable adjustments to the terms of any patents we currently own or in-license or that we may own or in-license in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to and separate from patent exclusivity, the FDA may also grant marketing exclusivity of varying lengths in connection with the approval of a New Chemical Entity (5 years), Biologic (12 years), or Orphan Drug indication (7 years). Marketing exclusivity may also be granted for new clinical studies (3 years) and pediatric studies (6 months) on approved drugs. Depending on the length of the regulatory approval process and the ability to make use of the procedures for obtaining PTE, any FDA exclusivity period may in part or in whole overlap with any patent exclusivity to which we are entitled. We intend to pursue relevant marketing exclusivities in the US and in foreign countries in which any candidate product is approved. However, we cannot be certain that any such exclusivities will be granted or, if granted, will insulate our commercial product(s) from competition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With respect to trade secrets, while we have confidence in the protective measures that we employ, such measures can be breached, and we may not have adequate remedies for any such breach. We also cannot be certain that any of our activities will not be subject to the intellectual property rights of others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of March 1, 2023, we owned two patent families that were acquired from Prophylix and relate to the current product candidates in our FNAIT prevention program, RLYB211 and RLYB212. The acquired patent family covering RLYB212 and its use in treating and preventing FNAIT includes patents issued in Australia, Europe, Mexico, Russia and the United States. Patent applications in this family are pending in Brazil, Canada, Israel, New Zealand and the United States. The granted patents in this family will expire in 2035, excluding any PTA or PTE that may be awarded. The acquired patent family covering administration of RLYB211 for the prophylactic treatment of FNAIT includes patents issued in the United States, Europe and Canada. The foreign patents and one of the U.S. patents will expire at the end of 2026, while the other U.S. patent expires in November 2030 due to a PTA granted by the USPTO. In addition, we filed and own three pending International (PCT) patent applications directed to dosing and administration of RLYB211 and RLYB212, one pending International (PCT) patent application directed to assays for quantifying anti-HPA1a antibodies, and one pending United States provisional patent application directed to the formulation of RLYB212. We also exclusively in-license certain rights to technology from Versiti Blood Research Institute Foundation, Inc. pertaining to a mouse model of FNAIT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of March 1, 2023, we owned two patent families relating to the current product candidates in our complement program, RLYB114 and RLYB116, and certain aspects of their use that were acquired from Sobi. These two patent families currently include three granted U.S. patents and one pending U.S. patent application, with granted patents and/or pending patent applications in more than 25 additional countries worldwide, including granted patents in Australia, Canada, Europe (all European Patent Convention contracting states) and Japan. In the United States, Australia, the European Patent Convention contracting states and Japan, applications in both patent families have been granted and are scheduled to expire between 2033 and 2034, excluding any PTA or PTE. In Canada, currently one patent family has been granted and is scheduled to expire in 2033. The second family patents are pending in Canada. In addition, we filed and own a pending International (PCT) patent application directed to dosing and administration of RLYB116. We have also non-exclusively in-licensed certain patent rights relating to our current product candidates from Affibody, including patent rights relating to the Affibody molecule technology and Albumod albumin binding molecule technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of March 1, 2023, we exclusively in-licensed from Kymab Limited certain patent rights to the current product candidate in our iron overload program, RLYB331, as well as back-up compounds. Under the exclusive license, we are managing prosecution of a patent family relating to RLYB331 and the back-up compounds. The patent family currently includes pending patent applications in the United States and in more than 20 other countries/regions, including Australia, Brazil, Canada, China, Eurasia, Europe, India, Japan, Mexico, and Saudi Arabia. In addition, we have non-exclusively in-licensed from Kymab Limited certain patent rights relating to the development, manufacture, and use of RLYB331 and the back-up compounds.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">License Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Product License Agreement with Affibody AB</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2019, our subsidiary IPC Research, LLC (&#34;IPC Research&#34;) and Sobi entered into a Contract Assignment Agreement pursuant to which Sobi assigned to, and IPC Research assumed, all obligations in a certain Product License Agreement (&#34;PLA&#34;) as amended, between Sobi and Affibody AB (&#34;Affibody&#34;), dated March 9, 2012, as amended on January 1, 2018 and December 22, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the PLA, we obtained a license to the Affibody platform technology and a particular albumin binding domain (&#34;ABD&#34;), in order to further develop and commercialize certain Affibody ligands, which we are now developing as RLYB116 and RLYB114.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the PLA, Affibody grants us (a) a non-exclusive right under certain patents to use the Affibody ligands alone or as a fusion protein and (b) an exclusive right to use the Affibody ligands alone or as a fusion protein, in each case, for human therapeutic use. Affibody also grants us (a) a non-exclusive right under certain patents to use the ABD in combination with the Affibody ligands as a fusion protein and (b) an exclusive right to use the ABD solely in combination with the Affibody ligands as a fusion protein, in each case, for human therapeutic use. Affibody grants us a non-exclusive license under applicable know-how needed to practice the rights and licenses granted under the PLA. All licenses to us are sublicensable, provided that each sublicense is consistent with the terms and conditions of the PLA. Under the PLA, Affibody has an exclusive right under any product patents, which are a category of certain patents that we own, to use the specific Affibody ligands outside of human therapeutics and a non-exclusive right under know-how needed to practice the Affibody ligands outside of human therapeutics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the PLA, Affibody is the exclusive owner of, and controls prosecution, maintenance, and defense of intellectual property covering, platform technology. We are the exclusive owner of, and control prosecution, maintenance, and defense of intellectual property covering, product technology. Affibody agrees to disclose to us any improvement to the Affibody technology that it deems commercially reasonable for us to practice and grants us an option to license any such improvement. We have the first right to enforce product patents against a third-party infringer and Affibody retains the first right to enforce any other licensed patent. We agree to not provide or make available any Affibody Ligand to a third-party on a standalone basis except for research purposes or to commercialize a licensed product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We agree to use commercially reasonable efforts to develop and commercialize a licensed product. We also will pay Affibody certain regulatory milestones up to an aggregate amount of &#x20ac;7.5 million and (a) a mid-single-digit royalty on annual net sales of products if such products are covered by a valid claim of a product patent or a platform patent or (b) low-single-digit royalties on annual net sales of products that are not covered by any such valid claim. Our obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of (a) the expiration of the last-to-expire valid claim of a patent covering a licensed product or (b) the 10th anniversary following first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The PLA will terminate when we are no longer obligated to pay royalties to Affibody. Either party may terminate the PLA upon material breach of the PLA by the other, subject to a cure period, or immediately in the case of the other party&#x2019;s insolvency, bankruptcy or a similar event. Affibody may terminate the PLA immediately if we or any of our affiliates or third party transferees commences any proceeding challenging the validity of the licensed patents or any of Affibody&#x2019;s other patents or challenging the confidentiality or substance of the licensed know-how or licensed technology. We may terminate the PLA for convenience upon 90 days prior written notice and upon payment of any amounts due to Affibody through the effective date of such termination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If Affibody terminates the PLA or if we terminate the PLA for convenience, (a) all rights and licenses granted under the PLA will terminate, (b) at Affibody&#x2019;s request, we must transfer all rights to the product technology free of charge to Affibody and (c) we must return or destroy all of Affibody&#x2019;s confidential information. Furthermore, if we terminate for convenience, we must grant Affibody an exclusive, royalty free perpetual right to use all regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">filings, approvals and data provided to regulatory authorities in support of such filings or approvals that relate to the licensed product. However, if we terminate the PLA as a result of Affibody&#x2019;s material breach of the PLA or its insolvency or bankruptcy, we will retain our license and rights under the PLA, provided that we will remain bound by certain obligations under the PLA with respect milestone payments, royalties (subject to a reduction in rate, in the case of material breach), audits and indemnity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Product License Agreement with Sanofi</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In May, 2022, through our subsidiary, Rallybio IPE, LLC (&#34;Rallybio IPE&#34;), we entered into a License Agreement with Kymab Limited (Sanofi) (the &#34;Sanofi License Agreement&#34;). Under the Sanofi License Agreement, Sanofi provides Rallybio IPE with worldwide exclusive rights to Sanofi&#x2019;s KY1066, which is now referred to as RLYB331. Under the terms of the Sanofi License Agreement, Rallybio has an exclusive license to certain Sanofi patents to develop, manufacture and commercialize RLYB331 and Rallybio agrees to use commercially reasonable efforts to develop and commercialize a licensed product in at least one indication in the field in each of several major markets, as described in the Sanofi License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We paid Sanofi an upfront cash payment of $3.0 million. In addition, Rallybio has agreed to pay Sanofi up to an aggregate of $43.0 million in development and regulatory milestones and up to an aggregate of $150.0 million in commercial milestones for a product in its first indication, plus tiered low-to-mid double digit percentages of such milestone amounts for up to three additional indications, and mid to high single digit royalties on net sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Sanofi License Agreement contains other customary license terms including sublicensing, development, regulatory, manufacturing, commercialization, milestones, royalties, intellectual property, and termination. The Sanofi License Agreement will expire on a product-by-product and country-by-country basis at the end of the applicable royalty term. Either party may terminate the Sanofi License Agreement upon material breach of the Sanofi License Agreement by the other, subject to a cure period. Rallybio may terminate the Sanofi License Agreement for convenience upon 90 days prior written notice to Sanofi. Sanofi may terminate the Sanofi License Agreement immediately in the case of Rallybio&#x2019;s insolvency, bankruptcy or a similar event, or if Rallybio or its affiliates participates in any proceeding challenging the validity of the licensed patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the Sanofi License Agreement is terminated in its entirety, among other things (a) all rights and licenses granted by Sanofi under the License Agreement (including any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shall negotiate an arrangement to provide Sanofi rights to the patents, know-how, materials and other properties controlled by Rallybio applicable to any of the licensed product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Purchase Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Asset Transfer Agreement with Swedish Orphan Biovitrum AB (Publ)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2019, through IPC Research, we entered into an agreement with Sobi, pursuant to which we acquired the right, title and interest in assets related to certain C5 inhibitor compounds. We are currently developing the assets acquired from Sobi as RLYB116 and RLYB114.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We paid Sobi an upfront purchase price of $5.0 million and we are obligated to pay Sobi an aggregate amount of up to $51.0 million upon achievement of certain development milestones and an aggregate amount of up to $65.0 million upon achievement of certain sales milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also will pay Sobi tiered, low single-digit royalties on annual net sales to third parties for products containing any compound transferred under the agreement as an active ingredient. Our obligation to pay royalties expires, on a country-by-country and product-by-product basis, on the later of (a) the 10th anniversary following first commercial sale of such product in such country and (b) the expiration date in such country of the last to expire of any issued patent included in the patent rights acquired from Sobi that includes at least one valid claim covering the sale of such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are obligated to use commercially reasonable efforts to research, develop and exploit at least one product that contains a compound transferred under the agreement as an active ingredient in each of the United States, EU and Japan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If, prior to the commercial launch in the United States of the first product containing the compounds, we decide to divest our rights in the assets acquired from Sobi or to terminate all research, development and commercialization activities in respect of the acquired compounds, we must notify Sobi and negotiate in good faith with Sobi a possible business transaction relating to the assets. This right of negotiation will not apply to a transaction to sell</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">all or substantially all of the assets of IPC Research or an affiliate of IPC Research, a pledge of the assets as collateral or a sale or transfer of the assets to an affiliate of IPC Research that agrees to be bound by the right of negotiation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Asset Purchase Agreement with Prophylix</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2019, though our subsidiary Rallybio IPA, LLC (&#34;Rallybio IPA&#34;), we entered into an agreement with Prophylix to acquire all of Prophylix&#x2019;s rights, title and interest in, to and under all assets, properties and rights related to Prophylix&#x2019;s plasma-derived anti-HPA-1a immunoglobulin, and Prophylix&#x2019;s monoclonal antibody, which we are developing as RLYB212.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We paid Prophylix an upfront purchase price of approximately $1.2 million and reimbursed Prophylix approximately $1.8 million for certain manufacturing costs incurred by Prophylix. We are obligated to pay Prophylix an aggregate of up to $19.0 million upon achievement of certain development milestones and an aggregate of up to $20.0 million upon achievement of certain sales milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also will pay Prophylix tiered, mid-single-digit royalties on annual net sales of products containing the monoclonal antibody and tiered mid-to-high-single and low-double-digit royalties on annual net sales of products containing plasma-derived anti-HPA-1a immunoglobulin, subject to certain offsets for royalties payable under certain third-party licenses. Furthermore, the then-applicable royalty rate will be reduced by a mid-double digit percentage for the remaining royalty term on a country-by-country basis if it becomes reasonably likely that the Prophylix patents may no longer be enforceable in such country due to a challenge of the enforceability of the patents or the enforceability of the royalty payments following the expiration of all valid claims of the patents in such country. Our obligation to pay royalties terminates on a country-by-country and product-by-product basis on the later of (a) the expiration of the last-to-expire valid claim of a Prophylix patent covering a product, (b) expiration of regulatory exclusivity for the product in such country or (c) the 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> year anniversary following first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event the FDA grants a priority review voucher for one of our product candidates developed using the technology acquired from Prophylix, we will pay Prophylix either: (a) if we sell such priority review voucher to a third-party within 12 months of its receipt, a mid-double digit percentage of the proceeds we receive from the sale, net of taxes, or (b) if we do not sell the priority review voucher to a third-party within 12 months of receipt, a mid-double digit percentage of the fair market value of the priority review voucher as determined in accordance with the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are obligated to use commercially reasonable efforts to develop and commercialize products containing plasma-derived anti-HPA-1a immunoglobulin in the United States and in at least one major European market. The agreement provides that if we provide notice to Prophylix that we determined that commercialization of products containing plasma-derived anti-HPA-1a immunoglobulin is not feasible due to an insufficient plasma supply following our continued and diligent efforts to obtain a sufficient plasma supply, then our obligation to develop products containing plasma-derived anti-HPA-1a immunoglobulin will cease, and we will be obligated to use commercially reasonable efforts to develop and commercialize products containing the monoclonal antibody in the United States and in at least one major European market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If, after using commercially reasonable efforts to develop and commercialize products containing plasma-derived anti-HPA-1a immunoglobulin and the monoclonal antibody in the United States and in at least one major European market, we decide not to pursue any further development or commercialization activities for such products, then Prophylix will have the right to repurchase the remaining assets acquired under the agreement for approximately $1.2 million. Prophylix also will have the right to repurchase the remaining assets acquired under the agreement for approximately $1.2 million if we elect to transfer all or substantially all of the assets acquired under the agreement to a third-party who does not agree to assume our obligations to develop and commercialize the products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Joint Venture Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2019, we entered into a partnership with Exscientia and created RE Ventures I, LLC (&#34;RE Ventures&#34;), which is jointly owned by Exscientia and one of our wholly-owned subsidiaries, each a Member and collectively the Members. The joint venture was formed to initiate early-stage drug discovery of orally available small molecules targeting ENPP1 for the treatment of HPP, and thereafter for the future research, development, manufacture, sale and exploitation of any company-owned technology and compounds, including any resulting compound identified by the steering committee of the joint venture.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the RE Ventures operating agreement, we received a 50% interest in the joint venture in exchange for an initial contribution of &#163;0.5 million ($0.6 million, based on the exchange rate at the time). RE Ventures used this initial capital to fund stage 1 of the ENPP1 program, and we committed to fund additional amounts if costs of stage 1 exceeded the initial funding. In June 2020, RE Ventures determined that the stage 1 objective of discovering compounds for ENPP1 with a certain potency had been achieved. In 2020, we contributed &#163;1.1 million ($1.3 million, based on the exchange rate at the time) in support of Stage 2 development of the ENPP1 program. During 2021, we contributed approximately &#163;1.4 million ($2.0 million, based on the exchange rate at the time) to RE Ventures in support of ongoing Stage 2 development of the ENPP1 program. During 2022,we contributed  &#163;0.2 million ($0.3 million, based on the exchange rate at the time) to RE Ventures in support of ongoing development of the ENPP1 program. The board of managers of RE Ventures may determine from time to time that additional capital is necessary or appropriate to enable RE Ventures to conduct its activities, and may seek (but not require) additional capital contributions from the Members.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event that either Member does not fund a portion of committed additional amounts, the other Member may contribute the unfunded amount and the respective membership interests in RE Ventures will be adjusted accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A steering committee is responsible for oversight of RE Ventures&#x2019; research and deployment plans as well as intellectual property and regulatory matters. A two-person board of managers manages the business and affairs of RE Ventures and is responsible for all management and other responsibilities not specifically reserved to the steering committee or to the Members. Each Member designates one member to the board.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Each Member is subject to customary restrictions on its transfer of interests in RE Ventures, including a right of first refusal, co-sale right and drag-along provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AbCellera Collaboration Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2022, the Company entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera&#x2019;s antibody discovery engine with Rallybio&#x2019;s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and ultimately deliver therapies to patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the terms of the agreement, AbCellera and Rallybio will co-develop up to five rare disease therapeutic targets, which will be chosen together by both companies. The collaboration will allow Rallybio to add product candidates to its existing pipeline and also provides the option for AbCellera to conduct process development and clinical manufacturing activities. The partnership&#x2019;s first program will focus on addressing the significant unmet therapeutic needs of patients with rare metabolic diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Manufacturing and Supply</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We do not own or operate, and currently have no plans to establish, any internal manufacturing facilities. We currently rely and expect to continue to rely on third-party contract manufacturer organizations (&#34;CMOs&#34;) for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial production of any product candidates that are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We currently rely on multiple CMOs for all of our preclinical and clinical supply requirements, including drug substances and drug products, and label and packaging for our preclinical research and clinical trials. We believe that we will be able to contract with other CMOs to manufacture drug substances if our existing sources of drug substances were no longer available to us or with sufficient capacity, but there is no assurance that the drug substance capacity would be available from other CMOs on acceptable terms, on the timeframe that our business would require, or at all. We do not currently have supply commitments or other arrangements in place with our existing CMOs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We do not have any current contractual relationships for the manufacture of commercial supplies of any of our product candidates if they are approved by the regulatory authorities, and we intend to enter into agreements with a CMO and one or more back-up manufacturers for the commercial production of our product candidates as they near phase 3 clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any products to be used in clinical trials and any approved product that we may commercialize will need to be manufactured in facilities, and by processes, that comply with the FDA&#x2019;s current Good Manufacturing Practice (&#34;cGMP&#34;) requirements and comparable requirements of the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal resources to manage our CMOs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that RLYB212, RLYB116, RLYB114, and RLYB331 can be manufactured in reliable and reproducible biologic and chemical processes from readily available starting materials. We believe that our manufacturing processes are amenable to scale-up and will not require unusual or expensive equipment. We expect to continue to develop, on our own or with our collaborators, product candidates that can be produced cost-effectively at contract manufacturing facilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect to rely on third parties for the manufacture of any in vitro diagnostic device, companion diagnostics or companion drug delivery systems we develop. For example, we have engaged a third-party to assist in developing laboratory screening tests and in our evaluation of potential companion diagnostics in conjunction with our development of RLYB212. Depending on the regulatory pathway and technology solutions we choose, we may engage third parties to continue the development and manufacturing of any device developed to support our therapeutic products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The research, development, testing, manufacture, quality control, packaging, labeling, storage, record-keeping, distribution, import, export, promotion, advertising, marketing, sale, pricing and reimbursement of drug and biologic products are extensively regulated by governmental authorities in the United States and other countries. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory requirements, both pre-approval and post-approval, require the expenditure of substantial time and financial resources. The regulatory requirements applicable to drug and biological product development, approval and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted by the agencies in ways that may have a significant impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. Government Regulation of Drug and Biological Products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, (the &#34;FDCA&#34;), and in the case of biologics, also under the Public Health Service Act (the &#34;PHSA&#34;), and their implementing regulations. Failure to comply with the applicable U.S. requirements may result in FDA refusal to approve pending New Drug Applications (&#34;NDAs&#34;) or Biologics License Applications (&#34;BLAs&#34;) or delays in development and may subject an applicant to administrative or judicial sanctions, such as issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or civil or criminal prosecution brought by the FDA and the U.S. Department of Justice or other governmental entities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA must approve our product candidates for therapeutic indications before they may be marketed in the United States. For drug products, the FDA must approve an NDA, and for biologic products, the FDA must approve a BLA. An applicant seeking approval to market and distribute a new drug or biologic in the United States generally must satisfactorily complete each of the following steps:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">completion of preclinical laboratory tests and animal studies according to Good Laboratory Practice (&#34;GLP&#34;) regulations or other applicable regulations;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">manufacture and testing of the therapeutic or biologic moiety and its respective product formulation according to cGMP regulations or other applicable regulations;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin and must be updated annually and amended when certain changes are made;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">approval by an independent institutional review board (&#34;IRB&#34;) or ethics committee representing each clinical trial site before each clinical trial may be initiated;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practices (&#34;GCPs&#34;) and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">preparation and submission to the FDA of an NDA or BLA requesting marketing approval for one or more proposed indications, including payment of application user fees;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">review of the NDA or BLA by an FDA advisory committee, where applicable;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug or biologic and its respective finished product is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&#x2019;s identity, strength, quality and purity;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data submitted in support of the NDA or BLA; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FDA review and approval of the NDA or BLA, which may be subject to additional post- approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#34;REMS&#34;) and any other potential post- approval studies required by the FDA. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preclinical Studies and IND</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Before testing any drug or biological product candidate in humans, the product candidate must undergo rigorous preclinical testing. The preclinical developmental stage generally involves laboratory evaluations of drug chemistry/biology, formulation, and stability, as well as in vitro and animal studies to assess safety and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety and toxicology studies. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Imposition of a clinical hold could cause significant delays or difficulties in initiating and/or completing planned clinical trials in a timely manner. Certain long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may initiate or continue after an IND for an investigational product candidate is submitted to the FDA and human clinical trials have been initiated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Human Clinical Trials in Support of an NDA or BLA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Clinical trials involve the administration of an investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing the objectives of the study, inclusion and exclusion criteria, dosing procedures and the parameters to be used in monitoring the safety and effectiveness criteria to be evaluated. Each protocol, as well as any subsequent amendments, must be submitted to the FDA as part of the IND.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An IRB representing each institution that is participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must thereafter conduct a continuing review of the trial. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors and the safety of human subjects. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to clinical trial subjects or their legal representatives and must operate in compliance with FDA regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Clinical trials must also comply with extensive GCP standards intended to ensure protection of human subjects and the quality and integrity of the study data, including requirements for obtaining subjects&#x2019; informed consent. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group may recommend continuation of the trial as planned, changes in trial conduct or cessation of the trial at designated checkpoints based on access to certain data from the study. The FDA may at any time while clinical trials are ongoing impose a partial or complete clinical hold based on concerns for patient safety and/or noncompliance with regulatory requirements. This order issued by the FDA would cause suspension of an ongoing trial until all outstanding concerns have been adequately addressed, and the FDA has notified the company that investigations may proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Human clinical trials to evaluate therapeutic indications to support NDAs and BLAs for marketing approval are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Phase 1: The product candidate is initially introduced into human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, and excretion, and if possible, to gain early evidence for effectiveness. Phase 1 trials may be conducted in healthy volunteers or, in the case of some products for severe or life-threatening diseases, including many rare diseases, the initial human testing is often conducted in patients with the target disease or condition.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Phase 2: Clinical trials are conducted in a limited patient population with a specified disease or condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Phase 3: Clinical trials are undertaken with an expanded patient population to further evaluate dosage, and to provide substantial evidence of clinical efficacy and safety in an expanded patient population, often at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, to document a clinical benefit in the case of drugs or biologics approved under FDA&#x2019;s accelerated approval regulations and to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol, GCP or other IRB requirements or if the drug has been associated with unexpected serious harm to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Information about certain clinical trials, including details of the protocol and eventually study results, also must be submitted within specific time frames to the National Institutes of Health for public dissemination on the ClinicalTrials.gov data registry. Similar requirements for posting clinical trial information in clinical trial registries exist in the EU and in other countries outside the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the development of a new drug or biological product, sponsors have the opportunity to meet with the FDA at certain points, including prior to submission of an IND, at the end of phase 2 and before submission of an NDA or BLA. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional nonclinical studies and must also develop additional information about the physical characteristics of the drug or biological product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, potency and purity of the final drug or biological product. For biological products in particular, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined in order to help ensure safety, purity and potency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketing Application Submission and FDA Review</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#x2019;s chemistry, manufacturing, controls (&#34;CMC&#34;) and proposed labeling, are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#x2019;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. The fee required for the submission of an NDA or BLA under the Prescription Drug User Fee Act (&#34;PDUFA&#34;) is substantial (for example, for fiscal year 2022 this application fee is approximately $3.1 million), and the sponsor of an approved NDA or BLA is also subject to an annual program fee, currently more than $350,000 per program. These fees are typically adjusted annually, but exemptions and waivers may be available under certain circumstances. No user fee is required for orphan drug product applications, except when an application also includes an indication for a non-rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA conducts a preliminary review of all NDAs and BLAs within 60 days of receipt and informs the sponsor by the 74th day after the FDA&#x2019;s receipt of the submission whether an application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">After the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant and six months from the filing date for an application with &#x201c;priority review.&#x201d; The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, it is not uncommon for FDA review of an NDA or BLA to extend beyond the PDUFA goal date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Before approving an NDA or BLA, the FDA will typically conduct a pre-approval inspection of the manufacturing facilities for the therapeutic/biologic to determine whether the manufacturing processes and facilities comply with GMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with GCP requirements and the integrity of the clinical data submitted to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, the FDA may refer any NDA or BLA, including applications for novel product candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. The FDA also may require submission of a REMS, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug or biological product. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS and the FDA will not approve the NDA or BLA without a REMS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the Pediatric Research Equity Act of 2003 (&#34;PREA&#34;), an NDA or BLA or certain supplements thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless this requirement is waived, deferred or inapplicable. Sponsors must submit a pediatric study plan to FDA outlining the proposed pediatric study or studies they plan to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The FDA must then review the information submitted, consult with the sponsor and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. In general, PREA requirements do not apply to drugs or biologics for indications granted orphan drug designation by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA reviews an NDA or BLA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#x2019;s identity, strength, quality and purity. The approval process is lengthy and often difficult, and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA may issue either an approval letter or a Complete Response Letter (&#34;CRL&#34;). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time- consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA or BLA addressing all of the deficiencies identified in the letter or withdraw the application. If and when those deficiencies have been addressed to the FDA&#x2019;s satisfaction in a resubmission of the NDA or BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If a product receives regulatory approval from the FDA, the approval is limited to the conditions of use (e.g., patient population, indication) described in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Regulation of Combination Products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certain products may be comprised of components, such as drug or biologic components and device components that would normally be regulated under different types of regulations, and frequently by different centers at the FDA. These products are known as combination products. We expect to rely on a delivery system, such as pre-filled syringes, pen-injectors and/or autoinjectors to deliver certain of our product candidates. Although we have not yet selected the delivery system to use for administration of such product candidates, including RLYB212 and RLYB116, we expect that, if approved, any such product candidate would be regulated as a combination product, because it is composed of both a drug or biological product and a delivery system &#x201c;device.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA center for combination products, although the lead center may consult with other centers within the FDA. The determination of which center will be the lead center is based on the &#x201c;primary mode of action&#x201d; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible for review of the drug product would have primary jurisdiction for the combination product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A combination product involving a novel drug or biological product and delivery system generally would have a drug or biologic primary mode of action. A combination product with a drug or biologic primary mode of action would be reviewed and approved pursuant to the drug or biologic approval processes. In reviewing the NDA or BLA for such a product, however, the FDA review division reviewing the application could consult with their counterparts in the device center to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. Approval may require the performance of certain clinical studies, such as clinical usability or human factors studies to demonstrate the safety and/or effectiveness of the device component of the combination product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Similar considerations apply to regulation of drugs combined with delivery systems outside the United States, including in the EU.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expedited Programs for Serious Conditions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation, priority review designation and accelerated approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA also may review sections of the NDA or BLA for a fast track product on a rolling basis before the complete application is submitted if the sponsor and the FDA agree on a schedule for the submission of the application sections and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA. Fast track designation may be rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, a new drug or biological product may be eligible for Breakthrough Therapy designation if it is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient development program beginning as early as Phase 1 and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. Breakthrough designation may be rescinded by the FDA if the designation is no longer supported.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA may designate a product for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug or biologic qualifies for priority review. Significant improvement over available therapies may be illustrated, for example, by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications and to shorten the FDA&#x2019;s goal for taking action on a marketing application from ten months to six months for an original BLA or NDA from the date of filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Finally, the FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#34;IMM&#34;) and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. For drugs granted accelerated approval, FDA generally requires sponsors to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#x2019;s clinical benefit. Failure to conduct required post-approval studies with due diligence, failure to confirm a clinical benefit during the post-approval studies, or dissemination of false or misleading promotional materials would allow the FDA to withdraw the product approval on an expedited basis. All promotional materials for product candidates approved under accelerated approval are subject to prior review by the FDA unless FDA informs the applicant otherwise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Post-approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, governing, among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product and product problems to the FDA, product sampling and distribution, manufacturing and promotion and advertising. Although physicians may prescribe legally available products for unapproved uses or patient populations (i.e., &#x201c;off-label uses&#x201d;), manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or an NDA/BLA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials. The FDA may also place other conditions on approvals including the requirement for a REMS to assure the safe use of the product, which may require substantial commitment of resources post-approval to ensure compliance. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FDA regulations require that drug and biological products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and satisfy the FDA or comparable foreign regulatory authorities&#x2019; satisfaction before any product is approved and our commercial products can be manufactured. In addition, for any of our product candidates that include a device delivery system, the device component will be subject to aspects of the Quality System Regulations (&#34;QSRs&#34;) applicable to medical devices. Manufacturers of drug-device combination products may either opt to comply with all quality regulations governing each component of the product separately, or may take a &#x201c;streamlined approach&#x201d; to cGMP that allows the manufacturer to demonstrate compliance with the drug cGMPs along with compliance with several specific provisions from the device QSR&#x2014;namely, management responsibility, design controls, purchasing controls, corrective and preventive action, installation, and servicing, as applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations, including requirements for quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our CMOs that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMPs, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA or BLA, including voluntary recall and regulatory sanctions as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Once an approval of a drug/biologic product is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information, imposition of post-market clinical trials requirement to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about a product;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">mandated modification of promotional materials and labeling and issuance of corrective information;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">fines, warning letters, untitled letters or other enforcement-related letters or clinical holds on post-approval clinical trials;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">refusal of the FDA to approve pending NDAs/BLAs or supplements to approved NDAs/BLAs, or suspension or revocation of product approvals;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#34;PDMA&#34;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Additionally, the Drug Supply Chain Security Act (&#34;DSCSA&#34;) imposes requirements related to identifying and tracing certain prescription drugs distributed in the United States, including most biological products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. Patent Term Restoration and Hatch-Waxman Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval for our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch Waxman Amendments permit restoration of the patent term up to five years as compensation for patent term lost during the FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date, and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA plus the time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Regulatory exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&#34;ANDA&#34;) or a 505(b)(2) NDA submitted by another company for another version of such drug. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDCA also provides three years of exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent for other conditions of use. Three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, both drugs and biologics can obtain pediatric exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Biosimilars and Reference Product Exclusivity for Biological Products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2010, the Patient Protection and Affordable Care Act was enacted in the United States and included the Biologics Price Competition and Innovation Act of 2009 (the &#34;BPCIA&#34;). The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, the FDA has approved a number of biosimilars. No interchangeable biosimilars, however, have been approved. The FDA has also issued several guidance documents outlining its approach to reviewing and approving biosimilars and interchangeable biosimilars.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the BPCIA, a manufacturer may submit an application that is &#x201c;biosimilar to&#x201d; or &#x201c;interchangeable with&#x201d; a previously approved biological product or &#x201c;reference product.&#x201d; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product, although to date no such products have been approved for marketing in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The biosimilar applicant must demonstrate that the product is biosimilar based on data from analytical studies showing that the biosimilar product is highly similar to the reference product, data from animal studies (including</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">toxicity) and data from one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity, and potency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. The FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The BPCIA is complex and only beginning to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for the treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available for the disease or condition will be recovered from sales of the product in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Orphan drug designation qualifies a company for certain tax credits. In addition, if a product candidate that has orphan drug designation subsequently receives the first FDA approval for that drug for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years following product approval unless the subsequent product candidate is demonstrated to be clinically superior. Absent a showing of clinical superiority, the FDA cannot approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete orphan disease designation application. To qualify for orphan exclusivity, however, the drug must be clinically superior to the previously approved product that is the same drug for the same condition. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB211 and RLYB212 have each been granted orphan drug designation by the FDA for the prevention of FNAIT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rare Pediatric Disease Designation and Priority Review Vouchers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act requiring the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of &#x201c;rare pediatric diseases&#x201d; by, upon initial approval of an application meeting certain specified criteria, providing companies with a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may sell or otherwise transfer the voucher to another company. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted an application relying on the priority review voucher. The FDA may also revoke any rare pediatric disease priority review voucher if the rare pediatric disease product for which the voucher was awarded is not marketed in the United States within one year following the date of approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to receive a rare pediatric disease priority review voucher upon BLA or NDA approval, the product must receive designation from the FDA as a drug for a rare pediatric disease prior to submission of the marketing application. A &#x201c;rare pediatric disease&#x201d; is a disease that is serious or life-threatening, in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and affects fewer than 200,000 people in the United States, or affects more than 200,000 people in the United States but there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug. In addition to receiving rare pediatric disease designation, in order to receive a rare pediatric disease priority review voucher, the NDA or BLA must be given priority review, rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population, not seek approval for a different adult indication in the original rare pediatric disease product application and be for a drug that does not include a previously approved active ingredient. In addition, under current statutory sunset provisions, even if a marketing application meets all of these requirements, FDA may only award a voucher prior to September 30, 2026 and only if the approved product received rare pediatric disease drug product designation prior to September 30, 2024.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB211 and RLYB212 have each been granted rare pediatric disease designation by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FDA Approval or Clearance of Companion Diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the FDCA, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance via 510(k) notification or approval via Premarket Approval (&#x201c;PMA&#x201d;) application from the FDA prior to commercial distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">companion diagnostics. According to the guidance, for novel drugs and biologics, a companion diagnostic device and its corresponding</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#x2019;s labeling. Approval or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the therapeutic products</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">companion diagnostic devices on issues related to co-development of the products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA previously has required </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">companion diagnostics intended to select the patients who will respond to a product candidate to obtain PMA simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. PMA applications are subject to an application fee, which for fiscal year 2022 is $374,858.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A clinical trial is typically required for a PMA application and, in some cases, the FDA may require a clinical study in support of a 510(k) submission. A manufacturer that wishes to conduct a clinical study involving the device is subject to the FDA&#x2019;s investigational device exemption (&#34;IDE&#34;) regulation. The IDE regulations distinguish between significant and non-significant risk device studies and the procedures for obtaining approval to begin the study differ accordingly. Also, some types of studies are exempt from the IDE regulations. A significant risk device presents a potential for serious risk to the health, safety, or welfare of a subject. Significant risk devices are devices that are substantially important in diagnosing, curing, mitigating, or treating disease or in preventing impairment to human health. Studies of devices that pose a significant risk require both FDA and an IRB approval prior to initiation of a clinical study. Many companion diagnostics are considered significant risk devices due to their role in diagnosing a disease or condition. Non-significant risk devices are devices that do not pose a significant risk to the human subjects. A non-significant risk device study requires only IRB approval prior to initiation of a clinical study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. In the United States, device manufacturers are also subject to FDA&#x2019;s medical device reporting regulations, which require that a manufacturer report to the FDA if</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, and FDA&#x2019;s correction and removal reporting regulations, which require that manufacturers report to the FDA corrections or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health. A medical device manufacturer&#x2019;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which covers the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Regulation Outside of the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the 27-EU member states, before we may commence clinical trials or market products in those countries or areas.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Following the United Kingdom&#x2019;s (the &#x201c;UK&#x201d;) vote to leave the EU, in Great Britain (being England, Wales and Scotland), all medicinal products with a centralized EU marketing authorization were automatically converted to Great Britain marketing authorizations unless marketing authorization holders opted out of this process.</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> According to Article 5(4) of Annex 2 to the Northern Ireland Protocol contained in the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the EU and the European Atomic Energy Community, c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">entralized marketing authorizations continue to apply in Northern Ireland. For three years from January 1, 2021, the Medicines and Healthcare products Regulatory Agency (&#34;MHRA&#34;), the UK medicines regulator, may rely on a European Commission marketing authorization approval in the centralized procedure in order to expedite an application for a Great Britain marketing authorization. A separate application is still required, and marketing authorizations are granted by the Medicines and Healthcare products Regulatory Agency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The EU and the UK have concluded a trade and cooperation agreement (&#x201c;TCA&#x201d;), which was provisionally applicable from January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of the outcomes of good manufacturing practice (&#x201c;GMP&#x201d;) inspections and applicants and marketing authorization holders may submit GMP certificates issued by the MHRA for sites located outside the EU/European Economic Area (&#x201c;EEA&#x201d;) as supporting information for EU regulatory submissions. However, the TCA does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. Great Britain has also implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland, which is the subject of ongoing negotiation between the UK Government and the European Commission). The regulatory regime in Great Britain currently broadly aligns with EU regulations. However it is possible that these regimes may diverge in future. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the UK in the long-term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With the exception of the EU EEA applying the harmonized regulatory rules for medicinal products, the approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">European Union Drug Development, Review and Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the EU, our product candidates will also be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization is granted by a competent regulatory agency. Similar to the United States, the various phases of preclinical and clinical research in the EU are subject to significant regulatory controls.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The EU clinical trials regulatory framework is currently in the process of transitioning to an updated regime. Although the old regime, the EU Clinical Trials Directive 2001/20/EC(the &#x201c;CTD&#x201d;), sought to harmonize the EU clinical trials regulatory framework, the EU Member States applied the provisions of the CTD differently. This led to significant variations in the Member State regimes. Under the current regime, before a clinical trial can be initiated it must be authorized in each of the EU Member States where the trial is to be conducted by the National Competent Authority (&#x201c;NCA&#x201d;), and an Ethics Committee, in each EU Member State where the trial is to be conducted must have issued a favorable opinion on the trial. Under the old regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and Ethics Committees of the EU Member State where they occurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of January 31, 2022, Regulation (EU) No 536/2014 on clinical trials (the &#x201c;CTR&#x201d;), came into effect, and with it, the launch of the Clinical Trials Information System (&#x201c;CTIS&#x201d;), the centralized EU portal and database for clinical trials. The CTR is directly applicable in all EU Member States (and so does not require national implementing legislation in each EU Member State to give effect to the EU law instrument). The CTR has simplified the approval process for clinical trials to be carried out in the EU. Rather than applying for a clinical trial authorization in each EU Member State where the trial will be conducted, the CTR provides that one application be submitted centrally, via CTIS, which will then be reviewed by the designated NCA. If successful, the resulting decision arising from the evaluation process would cover all EU Member States concerned by the application.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">From January 31, 2023 all submissions of initial CTA applications for a new clinical trial must be made via CTIS. By January 31, 2025, all ongoing trials approved under the CTD must comply with the CTR and information relating to such clinical trials must be recorded in CTIS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For any of our product candidates that incorporate a medical device to administer the medicinal product and are intended to be commercialized as a single integral product intended exclusively for use in the given combination and not usable separately, then the combination product is regulated by Directive 2001/83/EC or Regulation (EC) 726/2004 as a medicinal product. However, the medical device used for administration must satisfy the requirements for its general safety and performance under EU law governing general medical devices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The EU regulatory regime currently provided under Directive 93/42/EEC (the &#34;Medical Devices Directive&#34;) will be replaced by Regulation (EU) 2017/745 on medical devices (the &#34;Medical Devices Regulation&#34;). The Medical Devices Regulation came into application on May 26, 2021, subject to the transitional provisions for certain medical devices to remain on the EU market if they were certified under the Medical Devices Directive for a limited period. There are significant changes to the EU regulatory system governing medical devices under the Medical Devices Regulation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the Medical Devices Regulation, data relating to the general safety and performance of the medical device must be contained in an application for marketing authorization for the combination product. Such information must be provided by the manufacturer of the medical device in its EU declaration of conformity or the relevant certificate issued by a notified body allowing the medical device manufacturer to affix a European Conformity (&#x201c;CE&#x201d;) mark to the medical device. If the dossier submitted to support the marketing authorization does not include the results of the conformity assessment and where for the conformity assessment of the device, if used separately, the involvement of a notified body is required in accordance with the Medical Devices Regulation, the medicinal products authority such as the EMA responsible for assessing applications for marketing authorization via the centralized procedure can require the applicant for a marketing authorization to provide an opinion on the conformity of the device part with the relevant general safety and performance requirements issued by a designated notified body.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By May 26, 2024, all manufacturers must comply with the Medical Devices Regulation. However, the EU legislature has proposed extending this transitional period. This proposal is currently being considered through the co-decision legislative procedure for the draft legislation to be adopted by the European Parliament and the European Council.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the EU regulatory regime, a company may submit marketing authorization applications under a centralized, decentralized or mutual recognition procedure. Where the product is intended to be marketed in one EU member state, a national application for a marketing authorization is filed. The centralized procedure is compulsory for medicinal products produced by biotechnology, designated orphan medicines, advanced-therapy medicines such as gene-therapies, and those medicinal products containing new active substances for specific indications such as the treatment of HIV, AIDS and immune dysfunctions, cancer, neurodegenerative diseases, diabetes, and viral diseases, and is optional for other medicines, which are highly innovative.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Centralized Procedure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the centralized procedure, a single marketing authorization application is submitted to the EMA where it will be evaluated by its advisory committee, the Committee for Medicinal Products for Human Use (the &#x201c;CHMP&#x201d;). A favorable CHMP opinion results in a single marketing authorization granted by the European Commission in an implementing decision, known as a centralized marketing authorization. A centralized marketing authorization is valid for all EU member states and, by extension (after taking the corresponding national implementing measures), in Norway, Iceland and Liechtenstein. In general, the initial marketing authorization is valid for five years, but once renewed is usually valid for an unlimited period. Under the centralized procedure, the maximum timeframe for the evaluation of a marketing authorization application by the EMA is 210 days, excluding clock stops. Clock-stops allow the applicant the necessary time to provide additional information in response to questions raised by the CHMP. The clock-stops considerably extend the time taken by the CHMP to complete the evaluation of a marketing authorization application. Ordinarily, within 67 days of receipt of the positive scientific opinion provided by the EMA, the European Commission will issue a binding decision on the marketing authorization application.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Decentralized Procedure</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The decentralized procedure allows marketing authorization applications to be submitted simultaneously in two or more EU member states, whereas the mutual recognition procedure must be used if the product has been authorized in at least one EU member state on a national basis, and the applicant seeks approval progressively of the same medicinal product in one or more EU member state(s). Both the decentralized and mutual recognition procedures provide for approval by one or more &#x201c;concerned&#x201d; member state(s) based on an assessment of an application performed by one &#x201c;reference&#x201d; member state. Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to the reference member state and concerned member state(s). The reference member state prepares a draft assessment and drafts of the related materials within 120 days of the receipt of a valid application. Within 90 days of receiving the reference member state&#x2019;s positive assessment report, each concerned member state must approve the assessment report and related materials, unless they identify a potential serious risk to public health.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Mutual Recognition Procedure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the mutual recognition procedure, the concerned member state(s) have the same 90-day period to recognize the marketing authorization in the reference member state. The decentralized procedure contemplates a single clock-stop at day 105, which may extend the process for completing the assessment procedure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In either case, if there is a disagreement between member states during the assessment of the submitted data based on concerns about serious risks to public health, the Coordination Group for Mutual Recognition and Decentralized Procedures will consider the matter and seek to reach a conclusion within 60 days. If this is not possible, the reference member state can escalate the issue to the EMA for arbitration. The purely national procedure results in a marketing authorization in a single EU member state.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Conditional Marketing Authorization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In specific circumstances, E.U. legislation (Article 14&#x2013;a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use)) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the product candidate is intended for the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases; (2) the drug candidate is intended to meet unmet medical needs of patients; (3) a marketing authorization may be granted prior to submission of comprehensive clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4) the risk-benefit balance of the product candidate is positive, and (5) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and can be renewed annually, if the risk-benefit balance remains positive, and after a satisfactory assessment of benefit: risk balance and progress in fulfilling the specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pediatric Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the EEA, companies developing a new medicinal product must agree upon a pediatric investigation plan (&#x201c;PIP&#x201d;), with the EMA&#x2019;s Pediatric Committee (&#x201c;PDCO&#x201d;) and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which a marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults or other age groups not covered by the agreed PIP. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO in circumstances where the medicinal product or the product class is likely to be ineffective or unsafe in part or all of the pediatric population; or the disease or condition occurs only in adult populations, or the specific medicinal product does not represent a significant therapeutic benefit over existing treatments in pediatric patients. Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP (even where such results are negative) are eligible for six months&#x2019; supplementary protection certificate extension. In the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. This pediatric reward is subject to the condition that the results are provided in respect of all studies in compliance with the agreed PIP and is not automatically available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">European Union Regulatory Data Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the EU, new products, which are considered referenced medicinal products, authorized for marketing qualify for eight years of data exclusivity and an additional two years of market exclusivity upon grants of a marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">European Union Orphan Designation and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life- threatening or chronically debilitating condition, (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. The term &#x2018;significant benefit&#x2019; is defined in Regulation (EC) 847/2000 to mean a clinically relevant advantage or a major contribution to patient care.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten year market exclusivity period, the EMA or the competent authorities of the Member States of the EEA, cannot accept an application for a marketing authorization for a similar medicinal product for the same indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The ten-year market exclusivity in the EU may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the applicant consents to a second orphan medicinal product application; or</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the applicant cannot supply enough orphan medicinal product. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A &#x201c;similar medicinal product&#x201d; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An equivalent regime is reflected in domestic law in the UK. Under the UK regime, however, orphan designations are not granted and instead a decision is made at the point of marketing authorization grant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB211 and RLYB212 have each been granted orphan drug designation by the EMA for the prevention of FNAIT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Priority Medicines Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The EMA grants access to the Priority Medicines (&#34;PRIME&#34;) program to investigational medicines for which it determines there to be preliminary data available showing the potential to address an unmet medical need and bring a major therapeutic advantage to patients. As part of the program, EMA provides early and enhanced dialogue and support to optimize the development of eligible medicines and speed up their evaluation, aiming to bring promising treatments to patients sooner. Rallybio anticipates that it will request PRIME designation for certain of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Periods of Authorization and Renewals</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is generally valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rest of the World Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Coverage, Pricing and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sales of any biopharmaceutical products, if and when approved by the FDA or analogous authorities outside the United States, will depend in significant part on the availability of third-party coverage and reimbursement for the products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, third-party payors include government healthcare programs such as Medicare and Medicaid, private health insurers, managed care plans and other organizations. These third-party payors are increasingly</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">challenging the price and examining the cost-effectiveness of medical products and services, including biopharmaceutical products. Significant uncertainty exists regarding coverage and reimbursement for newly approved healthcare products. Coverage does not ensure adequate reimbursement. It is time consuming and expensive to seek coverage and reimbursement from third-party payors. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA regulatory approvals. Third-party payors may take into account clinical practice guidelines in determining coverage and there may be significant delays before our products are addressed by such guidelines and we cannot predict what position such guidelines would take with respect to our products if and when addressed. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication, or utilize other mechanisms to manage utilization (such as requiring prior authorization for coverage for a product for use in a particular patient). Limits on coverage may impact demand for our products. Even if coverage is obtained, third-party reimbursement may not be adequate to allow us to sell our products on a competitive and profitable basis. As result, we may not be able to maintain price levels high enough to realize an appropriate return on investment in product development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of our product candidate to currently available therapies (so called health technology assessment (&#34;HTA&#34;) in order to obtain reimbursement or pricing approval). For example, subject to the requirements set out in Directive 89/105/EEC relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems, EU Member States have the legal competence to set national measures of an economic nature on the marketing of medicinal products in order to control public health expenditure on such products. Accordingly, EU Member States can restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Other EU Member States allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the United States and generally tend to be significantly lower.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel import or distribution (arbitrage between low-priced and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other U.S. Health Care Laws and Regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, biopharmaceutical manufacturers and their products are subject to extensive regulation at the federal and state level, such as laws intended to prevent fraud and abuse in the healthcare industry. These laws, some of which will apply only if and when we have an approved product, include:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (&#34;HIPAA&#34;) which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products prior to approval or for off-label use and regulates the distribution of samples;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">federal Open Payments (or federal &#x201c;sunshine&#x201d; law), which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers to the Centers for Medicare &amp; Medicaid Services within the U.S. Department of Health and Human Services (&#34;CMS&#34;) for re-disclosure to the public, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">analogous state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or report information related to payments to health care providers, marketing expenditures or drug prices; and state laws governing privacy, security and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">laws and regulations prohibiting bribery and corruption, such as the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#34;FCPA&#34;) which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Ensuring compliance is time consuming and costly. Violations of the laws may be subject to criminal and/or civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, which could adversely affect our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Similar healthcare laws and regulations exist in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Health Care Reform in the United States and Potential Changes to Health Care Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Health care reform has been a significant trend in the U.S. health care industry and elsewhere. In particular, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services. Under the Trump administration, there were efforts to repeal or modify prior health care reform legislation and regulation and to implement new health care reform measures, including measures related to payment for drugs under government health care programs. The Biden administration has also focused on health care reform, specifically reforms that would address the high cost of drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There has been heightened governmental scrutiny in recent years over the manner in which manufacturers set prices for their marketed products, which has resulted in proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing and reform government program reimbursement methodologies for pharmaceutical and biologic products. At the state level, individual states are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional federal and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">state health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For a more detailed discussion of health care reform in the U.S., see &#x201c;Risk Factors&#x2014;Risks Related to Healthcare Laws and Other Legal Compliance Matters.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Data Privacy Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">U.S. Privacy Law</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information, including laws requiring the safeguarding of personal information and laws requiring notification to governmental authorities and data subjects as well as remediation in the event of a data breach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There have been several developments in recent years with respect to U.S. state data privacy laws. In 2018, California passed into law the California Consumer Privacy Act (the &#34;CCPA&#34;), which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#x2019;s requirements are similar to those found in the General Data Protection Regulation (the &#34;GDPR&#34;), including requiring businesses to provide notice to data subjects regarding the personal information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#x201c;sales&#x201d; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. It also provides California residents a private right of action, including the ability to seek statutory damages, in the event of a breach involving their personal information. Compliance with the CCPA is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. On November 3, 2020, California voters passed a ballot initiative for the California Privacy Rights Act (the &#34;CPRA&#34;), which significantly expands the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also expands personal information rights of California residents, including creating a right to opt out of sharing of personal information with third parties for advertising, expanding the lookback period for the right to know about personal information held by businesses, and expanding the right to erasure for information held by third parties. Most CPRA provisions took effect on January 1, 2023, though the obligations apply to any personal information collected after January 1, 2022, with enforcement scheduled to begin on July 1, 2023. Similar laws have been proposed or passed at the U.S. federal and state level, including the Virginia Consumer Data Protection Act, which took effect on January 1, 2023, the Colorado Consumer Protection Act, which will take effect on July 1, 2023, the Connecticut Data Privacy Act, which will take effect on July 1, 2023,and the Utah Consumer Privacy Act, which will take effect on December 31, 2023. New data privacy laws have been proposed in more than half of the states in the United States and in the U.S. Congress, reflecting a trend toward more stringent privacy legislation in the United States, which trend may accelerate under the current U.S. presidential administration. Compliance with evolving U.S. privacy and security laws, requirements and regulations may result in cost increases due to necessary systems changes, new limitations or constraints on our business models and the development of new administrative processes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">GDPR</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many countries outside of the United States maintain rigorous laws governing the privacy and security of personal information. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is subject to the GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, and it imposes heightened requirements on companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before processing such data. Examples of obligations imposed by the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, appointing a data protection officer, providing notification of data breaches and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#x20ac;20 million, or 4% of annual global revenues, whichever is greater. The GDPR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. In July 2020, the Court of Justice of the European Union (the &#34;CJEU&#34;), invalidated the EU-U.S. Privacy Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. On June 4, 2021, the European Commission released two revised sets of standard contractual clauses, which have been designed in part to assist organizations in meeting the requirement of the CJEU&#x2019;s judgment. However, it is unclear how the use of these clauses will be scrutinized and enforced by supervisory authorities and privacy interest groups, and the process of entering into agreements with new standard contractual clauses, and updating our existing agreements that contain the previous clauses, may lead to additional costs and increase our overall risk exposure. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by GDPR.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employees and Human Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our employees are driven by our mission to identify and accelerate the development of transformative therapies for patients with rare disorders. We believe that our deep commitment to high ethical and professional standards is fundamental to our mission, and we are determined to build a culture that values diversity, inclusiveness and equity, and empowers a skilled and experienced workforce to perform at the highest levels. We commit our resources and make investments, including through recruiting, training and collaboration, to promote the culture that we desire, and we expect our employees to embrace the Company&#x2019;s values and culture in all that we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we employed 41 full-time employees. Of our full-time employees, 23 employees are engaged in new product sourcing through business development, research, manufacturing, product development and clinical development, and 18 are engaged in executive, finance, human resources, legal and other administrative functions. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants while ensuring fair and equitable systems and incentives to our employee base. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based incentive awards, in order to increase stockholder value and the success of the Company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We offer a benefits program that provides resources to help employees manage their health, finances and life outside of work. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Corporate Information and Reorganization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Holdings, LLC (&#34;Rallybio Holdings&#34;) was formed in Delaware in March 2018 and Rallybio IPD, LLC was formed in Delaware in May 2020. On June 30, 2021, Rallybio IPD, LLC was converted into a Delaware corporation and changed its name to Rallybio Corporation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our principal executive offices are located at 234 Church Street, Suite 1020, New Haven, CT 06510 and our telephone number is (203) 859-3820. Our corporate website address is https://www.rallybio.com. Information contained on or accessible through our website is not incorporated by reference into this report and you should not consider information contained on or accessible through our website to be part of this report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to the IPO and the Reorganization, the Company was a 100% owned subsidiary of Rallybio Holdings and Rallybio Holdings held 100% of the outstanding membership units in five wholly-owned subsidiaries; Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, Rallybio IPD, LLC, and IPC Research, LLC. On June 30, 2021, Rallybio Holdings completed a series of transactions pursuant to which (i) Rallybio IPD, LLC, a direct subsidiary of Rallybio Holdings, was converted from a Delaware limited liability company to a Delaware corporation and changed its name to Rallybio Corporation, and (ii) four direct subsidiaries of Rallybio Corporation, each a Delaware limited liability company (collectively the &#34;Merger Subs&#34;), each consummated a separate merger with one of Rallybio Holdings direct subsidiaries, other than Rallybio IPD, LLC (collectively the &#34;Asset Subsidiaries&#34;), with the Asset Subsidiaries surviving the mergers and Rallybio Holdings receiving common stock of the Company in exchange for its interest in each Asset Subsidiary, which resulted in the Asset Subsidiaries becoming</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">subsidiaries of the Company and the Company becoming the only direct subsidiary of Rallybio Holdings. On July 28, 2021, immediately prior to the completion of the IPO, Rallybio Holdings liquidated and distributed 100% of the capital stock of the Company, consisting solely of common stock, to the unitholders of Rallybio Holdings. The liquidation of Rallybio Holdings and distribution of the capital stock of Rallybio Corporation to the unitholders of Rallybio Holdings is referred to as the &#x201c;Liquidation&#x201d; and these other transactions are collectively referred to as the &#x201c;Reorganization.&#x201d; As a result of the liquidation, the unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Internet address is www.rallybio.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report on Form 10-K.  Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the &#34;Exchange Act&#x201d;) are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (&#34;SEC&#34;). In addition, our filings with the SEC may be accessed through the SEC&#x2019;s Interactive Data Electronic Applications system at http://www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1A. Ri</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">sk Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes appearing in this Annual Report on Form 10-K and the section of this Annual Report on Form 10-K titled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d;. Negative consequences from these risks could harm our business, prospects, operating results and financial condition or cause the trading price of our common stock to decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. See &#x201c;Cautionary Note Regarding Forward-Looking Statements.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the foreseeable future. We have not commercialized any products and have never generated revenue from the commercialization of any product. We are not currently profitable, and we may never achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are a clinical-stage biotechnology company with a limited operating history. As a result, we are not profitable and have incurred significant losses since our formation. We had net losses of $66.7 million and $47.0 million for the years ended December 31, 2022 and 2021, respectively.  As of December 31, 2022, we had an accumulated deficit of $160.7 million. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to gain regulatory approval and become commercially viable. Since inception, we have devoted substantially all of our resources to raising capital, organizing and staffing the Company, business planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio, developing and progressing our product candidates and preparing for clinical trials and establishing arrangements with third parties for the manufacture of our product candidates and component materials, including activities relating to our preclinical development and manufacturing activities for each of our programs and our Phase 1 clinical trials for RLYB212 and RLYB116. We do not have any product candidates approved for sale and have not generated any revenue from product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect to incur significant additional operating losses in the foreseeable future as we advance our programs through preclinical and clinical development, expand our research and development activities, acquire and develop new product candidates, complete preclinical studies and clinical trials, finance our business development strategy, seek regulatory approval for the commercialization of our product candidates and commercialize our products, if approved. The costs of advancing product candidates through each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance any product candidate to marketing approval in even a single jurisdiction are substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any product candidates or achieve or maintain profitability. Our expenses will increase substantially if and as we:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance Phase 1 and Phase1b clinical trials for RLYB212, our lead product candidate for our FNAIT program;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance Phase 1 and Phase1b clinical trials for RLYB116, and file an IND or a CTA for other product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance our natural history alloimmunization study of FNAIT (&#34;FNAIT Natural History Alloimmunization Study&#34;), and other studies to support our development program and related regulatory submissions for RLYB212;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">seek regulatory approvals for RLYB212, RLYB116 and any other product candidates, as well as for any related companion diagnostic, if required;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continue our discovery and development activities with Exscientia;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continue to discover and develop additional product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">hire additional clinical, scientific, and commercial personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">add operational, financial, and management personnel, including personnel to support our product development and planned future commercialization efforts and to support our transition to a public company;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">acquire or in-license other product candidates or technologies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">maintain, expand, and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any product candidate for which we obtain regulatory approval; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establish a sales, marketing, and distribution infrastructure to commercialize our programs, if approved, and for any other product candidates for which we may obtain marketing approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We do not know when or whether we will become profitable. Our ability to generate revenue and become profitable depends upon our ability to successfully complete the development of our product candidates and to obtain the necessary regulatory approvals for their commercialization, which is subject to substantial additional risks and uncertainties, as described under &#x201c;&#x2014; Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval.&#x201d; Each of our product candidates will require additional preclinical and/or clinical development, regulatory approval in multiple jurisdictions, the securing of manufacturing supply, capacity, distribution channels and expertise, the use of external vendors, the building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. As a result, we expect to continue to incur net losses and negative cash flows in the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through current or future collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we successfully commercialize RLYB212, RLYB116 or any of our other product candidates, we may continue to incur substantial research and development and other expenses to identify and develop other product candidates. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis or meet outside expectations for our profitability. Our failure to become and remain profitable would decrease the value of the Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business, execute our business plan or continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We will require significant additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of RLYB212, RLYB116 or any additional product candidates we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect to spend significant amounts of capital to complete the development of, seek regulatory approvals for and, if approved, commercialize RLYB212 and RLYB116. These expenditures will include costs related to our ongoing Phase 1 and Phase 1b clinical trials for RLYB212 and RLYB116. We expect similar expenditures as we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance our FNAIT Natural History Alloimmunization Study and development of RLYB331. In addition, we are obligated to make certain milestone and royalty payments in connection with achievement of certain development and commercial milestones as well as the sale of resulting products under our agreements with Prophylix, Swedish Orphan Biovitrum AB (Publ) Sobi, Affibody, and Sanofi. We may also spend significant capital to develop laboratory tests, and if required by the FDA or other healthcare agencies, one or more companion diagnostics, to identify patients for inclusion in our clinical trials or who are likely to respond to our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities as of December 31, 2022, will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2025. This estimate and our expectation to advance the preclinical and clinical development of RLYB212, RLYB116 and any other product candidates are based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect, or our clinical trials may be more expensive, time consuming or difficult to design or implement than we currently anticipate. Changing circumstances, including any unanticipated expenses, could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because of the numerous risks and uncertainties, the length of time and scope of activities associated with development of RLYB212, RLYB116 or any product candidate we may develop is highly uncertain, we are unable to estimate the actual amount of funds we will require for development, approval and any approved marketing and commercialization activities. Our future capital requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including our ongoing Phase 1 and Phase 1b clinical trials for RLYB212 and RLYB116, and the development of any other product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the identification, assessment, acquisition and/or development of additional research programs and additional product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA, and other comparable foreign regulatory authorities, including any additional clinical trials required by the FDA, EMA or other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the willingness of the FDA, EMA and other comparable foreign regulatory authorities to accept our clinical trial designs, as well as data from our completed and planned preclinical studies and clinical trials, as the basis for review and approval of RLYB212, RLYB116 and any other product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the progress, timing and costs of the development by us or third parties of companion diagnostics, if required, for RLYB212 or any other product candidates, including design, manufacturing and regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of filing, prosecuting, and enforcing our patent claims and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs associated with potential clinical trial liability or product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to develop and commercialize products that are considered medically and/or financially differentiated to competitive products by physicians, patients and payers;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost and timing of completion of commercial-scale manufacturing activities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of making royalty, milestone or other payments under any future in-license agreements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to maintain our collaborations with Exscientia and AbCellera on favorable terms and establish new collaborations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the extent to which we in-license or acquire additional product candidates or technologies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the severity, duration and impact of the COVID-19 pandemic, which may adversely impact our business;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the initiation, progress and timing of our commercialization of RLYB212 and RLYB116, if approved, or any other product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the availability of third-party coverage and reimbursement for and pricing of any approved products; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We will require significant additional capital to advance the development and potential commercialization of our product candidates, which we may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Depending on our business performance, the economic climate and market conditions, we may be unable to raise additional funds when needed on acceptable terms, or at all. Moreover, the effects of the COVID-19 pandemic continue and uncertain geopolitical events, such as the war in Ukraine, have impacted the global economy, and a severe or prolonged economic downturn could result in a variety of challenges for our business, including disruptions in the financial markets, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may need to significantly delay, scale back or discontinue the development of one or more of our product candidates or the commercialization of any product that may be approved for marketing, and we could be forced to discontinue operations. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our product candidate development efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Until such time, if ever, as we generate significant revenue from product sales, we expect to finance our operations through the sale of equity, debt financings, marketing and distribution arrangements and collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent that we raise additional capital through the future sale of equity or convertible debt securities, including sales of our common stock pursuant to our Sales Agreement with Cowen and Company LLC (&#34;Cowen&#34;), dated August 8, 2022 (the &#34;Sales Agreement&#34;), each shareholder's ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect their rights as a common stockholder. In addition, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and we may need to dedicate a substantial additional portion of any operating cash flows to the payment of principal and interest on such indebtedness. Any future indebtedness, combined with our other financial obligations, could increase our vulnerability to adverse changes in general economic, industry and market conditions, limit our flexibility in planning for, or reacting to, changes in our business and the industry and impose a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us.  If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio was founded in January 2018 and our operations to date have been limited to financing and staffing the Company, identifying, evaluating and acquiring or in-licensing product candidates and technologies, conducting preclinical studies and our clinical trials for RLYB211, RLYB212 and RLYB116, and preclinical studies for RLYB211, RLYB212, RLYB116, RLYB114, and RLYB331, and developing a pipeline of other preclinical and research programs. We have not yet demonstrated the ability to complete successfully a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial-scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a longer operating history or a history of successfully developing, obtaining marketing approval for and commercializing pharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. We will eventually need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our quarterly and annual financial results may fluctuate, which makes our results difficult to predict and may cause our results to fall short of expectations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our financial condition and operating results have varied in the past and will continue to fluctuate from quarter-to-quarter and year-to-year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this Annual Report on Form 10-K:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">variations in the level of expense related to the ongoing development of our product candidates or research pipeline;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">delays or failures in advancement of existing or future product candidates into the clinic or in clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the feasibility of developing, manufacturing and commercializing our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our relationships, and any associated exclusivity terms, with strategic collaborators;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements, or the termination or modification of any such existing or future arrangements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our operation in a net loss position in the foreseeable future;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability, ourselves or with collaborators, to develop a companion diagnostic, if required, and obtain marketing approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to consistently manufacture our product candidates, including in sufficient quantities for clinical or commercial purposes;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our dependence on, and the need to attract and retain, key management and other personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">developments or disputes concerning patents or other proprietary rights, litigation matters and our ability to obtain and maintain patent protection for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">business interruptions such as power outages, strikes, civil unrest, wars, acts of terrorism or natural disasters;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">potential advantages that our competitors and potential competitors may have in developing and commercializing competing technologies or products, securing funding for or obtaining the rights to critical intellectual property;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulatory developments affecting our product candidates or those of our competitors; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to use our net operating loss (&#34;NOL&#34;) and income tax credit carryforwards to offset income tax. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Due to these and other factors, the results of any of our prior quarterly or annual periods should not be relied upon as indications of our future operating performance, and a period-to-period comparison of our results of operations may not be a meaningful indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss and income tax credit carryforwards to offset future income tax liabilities may be subject to certain limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have incurred substantial NOLs during our history. To the extent that we continue to generate taxable losses, unused losses will carry forward and can be used to offset future taxable income, if any, until such unused losses expire. NOLs generated in taxable years beginning after December 31, 2017 are not subject to expiration. Federal NOLs generated in taxable years beginning after December 31, 2017 generally may not be carried back to prior taxable years except that, under the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;), federal NOLs generated in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the taxable year in which the loss arises. Additionally, the deduction for NOLs arising in taxable years beginning after December 31, 2017 is generally limited to 80% of current year taxable income, however, as a result of the CARES Act, for taxable years beginning before January 1, 2021, the deductibility of federal NOLs generated in taxable years beginning after December 31, 2017 is not so limited. We also have substantial federal and state research and development and other tax credit carryforwards. These tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, in general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, (the &#x201c;Code&#x201d;), a corporation that undergoes an &#x201c;ownership change&#x201d; is subject to limitations on its ability to use its pre-change NOLs and tax credit carryforwards to offset future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#x2019;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Some of our historical NOLs may be subject to annual limitations on our ability to use them due to prior ownership changes. Additionally, we may experience such ownership changes in the future as a result of future transactions in our stock, some of which may be outside our control. If we undergo an ownership change, our ability to use our NOLs and income tax credit carryforwards could be further limited. For these reasons, we may not be able to use a material portion of our NOLs or tax credit carryforwards, even if we attain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are heavily dependent on the success of RLYB212 and RLYB116, which are in early-stage clinical development. If we are not able to develop, obtain regulatory approval for, or successfully commercialize our product candidates, or if we experience significant delays in doing so, our business will be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our lead programs are in early-stage clinical development and we do not currently have any commercial products that generate revenues or any other sources of revenue. To date, we have invested a significant portion of our efforts and financial resources in the development of RLYB212 for the prevention of FNAIT and the development of RLYB116. Our future success is substantially dependent on our ability to successfully complete preclinical and clinical development for, obtain regulatory approval for, and successfully commercialize, our product candidates, which may never occur. We currently have no products that are approved for commercial sale and may never be able to develop a marketable product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, we have received approval for two CTAs in for RLYB212.  In the first quarter of 2023, we announced proof-of-concept in the Phase 1b study for RLYB212.  Any delays in the advancement of our clinical trials for RLYB212 could impact our product development timelines, result in increased costs, affect our ability to obtain marketing approval for RLYB212 according to our plans, and delay commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate the safety and efficacy of our investigational product candidates for use in each target indication through lengthy, complex and expensive preclinical studies and clinical trials. Failure can occur at any time during the preclinical study and clinical trial processes, and, because our product candidates are in an early stage of development, there is a high risk of failure, and we may never succeed in developing marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our ability to generate product revenue will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. Ongoing and future preclinical studies and clinical trials of our product candidates may not show sufficient safety or efficacy or be of sufficient quality to obtain or maintain regulatory approvals. There can be no assurance that any of our product candidates, even if approved, will prove to be commercially viable therapeutics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB212 and RLYB116 are designed for subcutaneous self-administration. The formulation or physical properties of RLYB212 and RLYB116 may ultimately be determined to be inadequate to support this route of administration. If subcutaneous administration is not feasible, then we may need to identify additional formulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">or routes of administration, which could delay initiation of our clinical trials or commercialization and result in significant additional costs. Further, alternative formulations and routes of administration may be required to differentiate our product candidates from competitors and/or secure access to support successful commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Commercialization of product candidates we may develop will require additional preclinical and clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the EMA; obtaining manufacturing supply, capacity and expertise; building of a commercial organization; and significant marketing efforts. The success of our most advanced product candidates and other product candidates will depend on several factors, including the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">successful and timely initiation of preclinical studies, and successful and timely initiation of, enrollment in, and completion of our clinical trials with results that support a finding of safety and effectiveness and an acceptable risk-benefit profile of our product candidates in the intended populations within the timeframes we have projected;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulatory grants of authorization to proceed under INDs or CTAs such that we can commence planned or future clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">receipt of regulatory approvals from applicable regulatory authorities for our product candidates, and if required, in vitro diagnostic devices including companion diagnostics;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to successfully utilize certain delivery systems, such as pre-filled syringes (&#34;PFSs&#34;) pen-injectors and/or autoinjectors, for certain of our product candidates and to obtain regulatory approval of any such drug/device combination product;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the outcome, timing, and cost of meeting regulatory requirements, including any post-marketing commitments, established by the FDA, EMA and other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establishing commercially viable arrangements with third-party manufacturers for clinical supply and commercial manufacturing;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establishing sales, marketing and distribution capabilities, whether alone or through a collaboration, to support commercialization of our product candidates, if and when approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">effectively differentiating and competing with other therapies approved and/or used for the same indications as our product candidates, particularly RLYB116;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establishing appropriate prices for any product candidates that receive regulatory approval that reflect the value that the product candidates offer in the indications for which they are approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">obtaining and maintaining third-party coverage and reimbursement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">enforcing and defending intellectual property rights and claims; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">maintaining an acceptable safety profile of the product candidates following approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product candidates successfully, which would materially harm our business. Due to the uncertain and time-consuming clinical development and regulatory approval process, we may not successfully develop any of our product candidates and may choose to discontinue the development of any of our product candidates. If we discontinue development of a product candidate, we will not receive anticipated revenues from that product candidate and we may not receive any return on our investment in that product candidate. We may discontinue a product candidate for clinical reasons if it does not prove to be safe and effective for its targeted indications. During clinical development, companies in our field often need to discontinue the development of product candidates if such product candidates do not achieve the necessary efficacy at tolerated doses required for patient benefit. In addition, there may be important facts about the safety, efficacy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and risk versus benefit of our product candidates that are not known to us at this time. Any unexpected safety events or our failure to generate sufficient data in our clinical trials to demonstrate efficacy may cause a product candidate to fail clinical development. Furthermore, even if that product candidate meets its safety and efficacy endpoints, we may discontinue its development for various reasons, such as changes in the competitive environment or the standard of care and the prioritization of our resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The COVID-19 pandemic in the United States and other countries has resulted in and may further result in disruptions to our preclinical studies, clinical trials, manufacturing and other business operations, which could adversely affect our business and the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The global COVID-19 pandemic continues to impact worldwide economic activity, particularly economic activity in the United States, and poses a continued risk that we or our employees, contractors, suppliers, or other partners may be prevented from or delayed in conducting business activities for an indefinite period of time, including due to shutdowns, quarantines and other public health measures that may be requested or mandated by governmental authorities. The continued prevalence of COVID-19 and the measures taken by the governments of countries affected could disrupt the supply chain and the manufacture or shipment of both drug substance and finished drug product for our product candidates for preclinical testing or clinical trials, cause diversion of healthcare resources away from the conduct of preclinical and clinical trial matters to focus on pandemic concerns, limit travel in a manner that interrupts key trial activities, such as trial site initiations and monitoring, delay regulatory filings with regulatory agencies in affected areas or adversely affect our ability to obtain or timing to obtain regulatory approvals. These actions have in the past, continue to and could in the future negatively affect our preclinical studies, clinical trials, manufacturing and other business operations, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preclinical studies and clinical trials:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> The continued impact of COVID-19 may cause delays and disruptions to some of our preclinical studies and clinical trials, which could include a slow down in enrollment and more difficult or intermittent collection of data for patients enrolled in trials as a result of healthcare provider response to COVID-19. In addition, some participants and clinical investigators may be unable or unwilling to comply with clinical trial protocols. We initiated a global natural history study for FNAIT in September 2021 that requires screening a large number of potential participants, as well as clinical trials for RLYB212 and RLYB116, and we could experience delays in screening due to COVID-19. Significant delays or disruptions to our preclinical studies or clinical trials could adversely affect our ability to timely initiate studies, conduct successful studies, generate scientifically robust clinical data, obtain regulatory approvals or commercialize our product candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Manufacturing and supply:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> We have encountered only limited disruptions to our manufacturing and supply chain as a result of COVID-19 to date, which have not had a material adverse impact on our business, but significant or prolonged disruptions could materially impact our business, operations or financial results. Even if our manufacturing operations are not materially disrupted, pandemic-related disruptions in other businesses, such as shipping and logistics companies, could affect the availability of our product candidates for our preclinical studies and clinical trials.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operations: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In accordance with direction from state and local government authorities to protect the health of our employees, their families, and our communities, we made several changes to our operations in response to COVID-19. This response included performing office-based work outside of the office. Our increased reliance on personnel working from home may negatively impact productivity or disrupt, delay or otherwise adversely impact our business. In addition, remote working could increase our cyber security risk. Government authorities could impose further restrictions, including mandated shutdown of businesses, which may negatively affect our operations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock Price:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> The extent and duration of the impact of the COVID-19 pandemic on our stock price is uncertain. The COVID-19 pandemic may cause our stock price to be more volatile, and our ability to raise capital could be impaired. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We continue to monitor the potential impact of the COVID-19 pandemic on our business and financial statements. To date, we have not incurred impairment losses in the carrying values of our assets as a result of the pandemic and we are not aware of any specific related event or circumstance that would require us to revise our estimates reflected in our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and prospects. The extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">financial condition and liquidity, including planned and future clinical trials and research and development costs, will depend on future developments that are highly uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An important component of our strategy is expanding our pipeline through partnering, acquiring or in-licensing additional product candidates that target validated biology. We also seek to identify and develop product candidates under our joint venture with Exscientia and our strategic alliance with AbCellera. If we fail to identify additional potential product candidates, or fail to partner, acquire or in-license additional product candidates, our business could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research programs to develop additional product candidates require substantial technical, financial, and human resources whether or not they are ultimately successful. Our efforts may initially show promise in identifying potential indications or product candidates, yet fail to yield results for clinical development for several reasons, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the research methodology used may not be successful in identifying potential indications or product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">potential product candidates may, after further study, be shown to have harmful or unexpected adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">it may take greater human and financial resources than we possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through research programs, thereby limiting our ability to develop, diversify, and expand our product portfolio. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Because we have limited financial and human resources, we intend to focus initially on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that could have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preclinical studies and clinical trials are expensive, time consuming and difficult to design and implement, and involve uncertain outcomes. Any product candidates that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Before obtaining marketing approval from the FDA, EMA or other comparable regulatory authorities for the sale of our product candidates, we must complete preclinical studies and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. To initiate clinical trials for any future product candidates, we must submit the results of preclinical studies to the FDA, EMA or other comparable foreign regulatory authorities, along with other information, including information about CMC and our proposed clinical trial protocol, as part of an IND or similar regulatory filing that must be accepted by the FDA, EMA or other applicable regulatory authorities before we may proceed with clinical development. In the event that regulators require us to complete additional preclinical studies or we are required to satisfy other regulator requests, such as obtaining alignment on the device regulatory pathway for our FNAIT prevention program, the start of our clinical trials may be delayed or prevented. Even after we receive and incorporate guidance from these regulatory authorities, the FDA, EMA or other regulatory authorities could (i) disagree that we have satisfied their requirements to commence our clinical trial, (ii) change their position on the acceptability of our data, trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or (iii) impose stricter requirements for approval than we currently expect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned preclinical studies or clinical trials, will begin on time, need to be redesigned, enroll an adequate number of patients on time, or be completed on schedule, or at all. We may experience numerous unforeseen events that could delay or prevent our ability to complete current clinical trials or initiate and complete</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">new trials, any of which may delay or prevent us from receiving marketing approval or commercializing our product candidates. These events include, but are not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities requiring us to submit additional data or imposing other requirements before permitting us to commence a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">delays in receiving or denial by regulatory agencies of permission to proceed with our planned clinical trials or any other clinical trials we may initiate, or placement of a clinical trial on hold;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">negative results from our non-clinical trials or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">challenges, delays and cost involved in identifying, recruiting and retaining suitable patients and clinical trial sites in sufficient numbers to participate in clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">delays in reaching an agreement on acceptable terms with prospective contract research organizations (&#34;CROs&#34;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">delays in obtaining IRB approval at each site within the United States, or Independent Ethics Committee (&#34;IEC&#34;) approval at sites outside the United States;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">delays or problems in analyzing data, or the need for additional analysis or data or the need to enroll additional patients;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">failure by us, our CROs, trial sites or investigators to adhere to clinical trial, regulatory, legal or contractual requirements and perform trials in accordance with the FDA&#x2019;s GCP requirements and trial protocol;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">inadequate quantity or quality of product candidate or other materials necessary to conduct clinical trials, for example as a result of delays in defining and implementing the manufacturing process for materials used in clinical trials or for the manufacture of larger quantities or other delays or issues arising in the manufacturing of sufficient supply of finished drug product;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">problems with designing and readiness of in vitro diagnostic devices, including companion diagnostic testing, if required, and our inability, or that of our collaborators, to develop any required laboratory diagnostic tests or companion diagnostics for RLYB212 or any other product candidate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">lack of adequate funding to continue a clinical trial, including as a result of unanticipated costs or increases in costs of clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">occurrence of serious adverse events including unexpected serious adverse events, associated with the product candidate or reports from non-clinical or clinical testing of our own or competing therapies that raise safety or efficacy concerns, or delays or failures in addressing patient safety concerns that arise during the course of a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">changes in regulatory requirements and guidance that require changes to planned or ongoing preclinical and clinical studies, or the conduct of additional studies; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">difficulties recruiting and retaining employees, consultants or contractors with the required level of expertise. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, we could encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the FDA, EMA or other regulatory authorities, or recommended for termination by a Data and Safety Monitoring Board (&#34;DSMB&#34;) for such trial. Such authorities may impose a suspension or termination or recommend an alteration to clinical trials due to several factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, the identification of safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions. Furthermore, we rely and will rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in the section titled &#x201c;&#x2014; Risks Related to Our Dependence on Third Parties.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our lead product candidates, RLYB212 and RLYB116, are still in early clinical development and will require the successful completion of one or more registrational clinical trials before we are prepared to submit a BLA for regulatory approval by the FDA. We cannot predict with any certainty if or when we might complete the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">development of RLYB212 or RLYB116, submit a BLA for regulatory approval or whether any such BLA will be approved by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Principal investigators for our clinical trials could serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of a clinical trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed or prevented. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including our focus on rare diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timely completion of clinical trials in accordance with their protocols depends, among other things, on the speed at which we can recruit eligible patients to participate in testing our product candidates and our ability to enroll a sufficient number of patients who remain in the study until its conclusion. Clinical trial recruitment delays often result in increased costs, delays in advancing product development, delays in testing the effectiveness of technologies, delays in obtaining regulatory approval or termination of clinical trials. We may be unable to enroll a sufficient number of patients to complete any of our clinical trials, including our natural history study for our FNAIT program, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Patient enrollment and retention in clinical trials depends on many factors, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the design of the clinical trial, including the patient eligibility criteria defined in the protocol;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the size and nature of the patient population required for analysis of the trial&#x2019;s primary endpoints;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the existing body of safety and efficacy data with respect to the product candidate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the proximity of patients to clinical sites;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or medical devices that may be approved for the indications we are investigating;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">competing clinical trials being conducted by other companies or institutions, particularly for RLYB116;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to obtain and maintain patient consents;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">other factors we may not be able to control, such as the COVID-19 pandemic that may limit patients, principal investigators or staff, or clinical site availability. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, we may have difficulty identifying and enrolling patients for our planned clinical trials because the conditions for which we plan to evaluate our current product candidates are rare diseases and we anticipate that there will be limited patient pools from which to draw for clinical trials. Further, because screening for many of these diseases is not widely adopted, and because it can be difficult to diagnose these diseases in the absence of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">screening, we may have difficulty finding patients who are eligible to participate in our studies or trials. For example, participants in clinical trials for RLYB212 have the rare HPA-1b/b genotype and we may have difficulty identifying participants for these clinical trials. In addition, our clinical trials for RLYB116 will compete with other clinical trials for product candidates that are currently being tested in clinical trials for PNH and gMG and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Furthermore, any negative results we may report in clinical trials of any of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same or a similar product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outside of the United States, our ability to initiate, enroll and complete a clinical trial successfully is subject to numerous additional risks, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">difficulty in establishing or managing relationships with CROs and physicians;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">different standards for the conduct of clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our inability to locate qualified local consultants, physicians and partners; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may not be able to initiate or continue clinical trials required by the FDA, the EMA or other regulatory authorities if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials. If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials. Delays or failures in planned patient enrollment or retention may result in increased costs or program delays, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Results of preclinical studies, clinical trials or analyses that we may announce or publish from time to time, may not be indicative of results obtained in later trials, and any interim results we may publish could be different than final results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The results of preclinical studies, clinical trials or analyses of the results from such trials, may not be predictive of the results of later clinical trials. Product candidates in later clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and prior clinical trials or having shown promising results based on analyses of data from earlier trials. Late-stage clinical trials may include a larger number of patients and could differ in other significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, patient population, efficacy endpoints, dosing regimen and statistical design. Our Phase 1b clinical trial for RLYB212 is single blinded, making it difficult to predict how rapid platelet clearance will lead to prevention of alloimmunization in pregnant women at higher risk for FNAIT and whether the results that we have observed and may observe in such trial will be repeated in larger and more advanced clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding earlier promising results. In addition, conclusions based on promising data from analyses of clinical results, such as the prospective and post hoc analysis of results may be shown to be incorrect in subsequent clinical trials that have pre-specified end points or may not be considered adequate by regulatory authorities. We believe data from our Phase 1/2 clinical trial of RLYB211 has demonstrated proof-of-concept of our proposed mechanism of action and supported advancing RLYB212 into clinical trials, however, we cannot guarantee that clinical trial results will be similar for RLYB212. Even if we complete later clinical trials as planned, we cannot be certain that their results will support the safety and efficacy requirements sufficient to obtain regulatory approval, and, as a result, our clinical development plans may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, interim, &#x201c;top-line&#x201d; and preliminary data from our clinical trials that we announce or publish may change as more patient data become available or as additional analyses are conducted. The data obtained in such clinical trials are subject to additional audit and verification procedures and following such procedures, such interim data could be materially different from the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Any product candidates that we develop or the administration thereof, may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adverse events or undesirable side effects caused by any product candidates we develop could cause us or regulatory authorities or IRBs, IECs or DSMBs, where applicable, to interrupt, delay, or halt clinical trials and, if</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we seek approval of any such product candidate, could result in a more restrictive label, imposition of a REMS program by the FDA or the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities. Additionally, the administration process or related procedures associated with our product candidates also may cause adverse side effects. Even if we determine that serious adverse events are unrelated to study treatment, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects. For example, complement inhibitors have, by design, immunosuppressive effects and, in some cases, may be administered to patients with significantly compromised health. As a result, administration of RLYB116 could make patients more susceptible to infection. The chronic dosing of patients with RLYB116 could lead to an immune response that causes adverse reactions or impairs the activity and/or efficacy. Patients may develop an allergic reaction to the drug and/or develop antibodies directed at RLYB116, or may require immunization with a meningococcal vaccine and prophylactic antibiotics. An immune response that causes adverse reactions or impairs the activity of RLYB116 could cause a delay in or termination of our development plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Some potential therapeutics that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. In addition, side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential clinical trial or product liability claims. Inadequate training or failures by clinical trial personnel in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Furthermore, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors may only be uncovered when a significantly larger number of patients have been exposed to the drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we or others later identify undesirable side effects caused by any product candidate that we develop after the product is approved, several negative consequences could result, which could materially harm our business, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label, limit the approved use of such product candidate, or otherwise restrict distribution or marketing such as through requiring adoption of a REMS program;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may be required to conduct additional clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical trials. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities, including the Medicines and Healthcare products Regulatory Agency in the United Kingdom,  are lengthy, time- consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for RLYB212, RLYB116 or any of our other product candidates, our business will be substantially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, we are not permitted to market a product candidate until we receive approval of a BLA or a NDA from the FDA. The process of obtaining BLA and NDA approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. Approval policies or regulations may change, and the FDA and other regulatory authorities have substantial discretion in the approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. In addition, the FDA may require post-approval clinical trials or studies as a condition of approval, which also may be costly. The FDA approval for a limited indication or approval with required warning language, such as a boxed warning, could significantly impact our ability to successfully market our product candidates. The FDA also may require adoption of a REMS requiring prescriber training, post-market registries, or otherwise restricting the marketing and dissemination of these products. The FDA may inform us that an approved device, including a companion diagnostic, is required to obtain marketing approval of RLYB212. Companion diagnostics are subject to regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">as medical devices and must be separately approved for marketing by the FDA. Certain of our product candidates will rely on delivery systems, such as PFSs, pen-injectors and/or autoinjectors, and may ultimately be regulated as a drug/device combination product. Although the FDA and similar foreign regulatory agencies have systems in place for the review and approval of combination products, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the product development and approval process. Despite the time and expense invested in the clinical development of product candidates, regulatory approval is never guaranteed for our product candidates or a companion diagnostic, if required. Assuming successful clinical development, we intend to seek product approvals in countries outside the United States, including in Europe. As a result, we would be subject to regulation by the EMA, as well as the other regulatory agencies in these countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates and we may be forced to abandon our development efforts for our product candidate, which would significantly harm our business, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The time required to obtain approval by the FDA, EMA and other comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for any product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate to the satisfaction of the FDA, EMA or other comparable foreign regulatory authority, that such product candidates are safe and effective for their intended uses. Data obtained from preclinical studies and clinical trials are susceptible to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials, or marketing approval. Even if we believe the preclinical or clinical data for our product candidates are sufficient to support approval, such data may not be considered sufficient to support approval by the FDA, EMA and other comparable regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For example, we have proposed to use real-world data from our FNAIT Natural History Alloimmunization Study to support our development program and related regulatory submissions for RLYB212. Specifically, the natural history study data would assist us in assessing the frequency of women at higher risk of FNAIT among women of different racial and ethnic characteristics and the occurrence of HPA-1a alloimmunization in these women. The natural history studies and other real-world evidence we may submit to support applications for marketing approval may not be accepted by the FDA, EMA, or other comparable foreign regulatory authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA, EMA or other comparable foreign regulatory authority can delay, limit, or deny approval of RLYB212, RLYB116 or any of our other product candidates that we develop or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities that our product candidate is safe and effective for its proposed indication;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing an active ingredient in our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA, EMA or other comparable foreign regulatory authorities for approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety and efficacy in the full population for which we seek approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States or the applicable foreign jurisdiction;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may be unable to demonstrate that our product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of a BLA or NDA or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA&#x2019;s or the applicable foreign regulatory authority&#x2019;s disagreement regarding the formulation, the labeling, and/or the specifications of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA, EMA, or other comparable foreign regulatory authorities may require us to obtain clearance or approval of a companion diagnostic test;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">additional time may be required to obtain regulatory approval for our product candidates because they are combination products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any BLAs or NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our product candidates. If the FDA does not accept or approve our BLAs or NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any BLA or NDA that we submit may be delayed or prevented, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our BLA or NDA. Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our product candidates target rare diseases and conditions, and the market opportunities for RLYB212, RLYB116 or any of our other product candidates, if approved, may be smaller than we anticipate. As a result, our commercial opportunity may be limited and because the target populations of our product candidates are for rare diseases, we must be able to successfully identify patients and capture a significant market share to achieve profitability and growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our product candidates target rare diseases and conditions. We are developing RLYB212 for the potential prevention of FNAIT, and we estimate that each year greater than 22,000 pregnancies are at high risk for FNAIT in the United States, Canada, United Kingdom, other major European countries and Australia, based on the presence of HLA DRB3*01:01 positive and HPA-1a negative antibody in mothers and HPA-1a positive in the fetus. With respect to RLYB116, we estimate that there are approximately 4,700 patients with PNH and up to 60,000 patients with gMG in the United States. Our projections of the number of eligible patients are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, population statistics and market research, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of eligible patients, and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to. For example, even if we obtain FDA approval for RLYB212 or RLYB116, the drug may be approved for a target population that is more limited than what we currently anticipate. Furthermore, even if we obtain significant market share for any product candidate, if approved, the potential target populations for our product candidates are for rare diseases, and we may never achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Further, in many cases there are either no or limited screening or diagnostic tests for the indications our product candidates are being developed to potentially treat. For example, the successful prevention of FNAIT in mothers at risk for developing this rare disorder will require identifying expectant mothers who are HPA-1 negative and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">HLA DRB3*01:01 positive and HPA-1a positive in the fetus. In collaboration with partners, we may develop screening and diagnostics tests to help us to identify individuals at risk, and the FDA, EMA or other comparable foreign regulatory authorities may require us to do so. The lack of screening and diagnostic tests, coupled with the fact that there is frequently limited awareness among certain health care providers concerning the rare diseases we may seek to treat, often means that a proper diagnosis can, and frequently does, take years to identify (or an appropriate diagnosis may never be made for certain patients). As a result, even if one of our product candidates is approved for commercial sale, we may not be able to grow our revenues due to difficulty in identifying eligible patients. There can be no guarantee that any of our programs will be effective at identifying patients that will benefit from our product candidates, and even if we can identify patients that our product candidates can help, the number of patients that our product candidates may ultimately treat may turn out to be lower than we expect, they may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify, all of which may adversely affect our ability to grow and generate revenue and adversely affect our results of operations and our business. In addition, even in instances where we are able to expand the number of patients being treated, the number may be offset by the number of patients that discontinue use of the applicable product in a given period resulting in a net loss of patients and potentially decreased revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The FDA, EMA or other comparable foreign regulatory authorities could require the clearance or approval of an in vitro diagnostic or companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our drug development strategy and we may not realize the commercial potential of any such product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If safe and effective use of RLYB212 or any of our other product candidates depends on an in vitro diagnostic, then the FDA generally will require approval or clearance of that test, known as a companion diagnostic, at the same time that the FDA approves our product candidates. The process of development and approval of such diagnostic is time consuming and costly. Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA, EMA and other comparable foreign regulatory authorities as medical devices and require separate regulatory approval from therapeutic approval prior to commercialization. The FDA previously has required in vitro diagnostic tests intended to select the patients who will respond to a product candidate to obtain a PMA simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of preclinical and clinical data and the submission and review by the FDA, can take several years or longer. It involves a rigorous pre-market review during which the applicant must prepare and provide FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Given our limited experience in developing and commercializing in vitro diagnostic devices, including companion diagnostic tests, we do not plan to develop such tests internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for these in vitro diagnostic tests. We may not be able to enter into arrangements with a provider to develop screening and/or diagnostic tests for use in connection with a registrational trial for RLYB212 or for commercialization of RLYB212, or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of RLYB212. We and our future collaborators may encounter difficulties in developing and obtaining approval for such tests, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval of in vitro diagnostic tests could delay or prevent approval of RLYB212 or any of our other product candidates. In addition, we, our collaborators or third parties may encounter production difficulties that could constrain the supply of such tests, and both they and we may have difficulties gaining acceptance of the use of such tests by physicians. We believe that adoption of screening and treatment into clinical practice guidelines is important for market access, third-party payer reimbursement, utilization in medical practice and commercial success. Both our collaborators and we may have difficulty gaining acceptance of such screening and/or diagnostic tests into clinical practice guidelines. If such tests fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales, if any, of RLYB212 if it is approved for commercial sale, or any other approved products that require an in vitro diagnostic test. In addition, any collaborator or third-party with whom we contract may decide not to commercialize or to discontinue selling or manufacturing the test that we anticipate using in connection with development and commercialization of our product candidates, or our relationship with such collaborator or third-party may otherwise terminate. We may not be able to enter into arrangements with another provider to obtain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">supplies of an alternative in vitro diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We face significant competition from biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If a product candidate we develop is approved, we will face intense competition. There are many public and private biopharmaceutical companies, universities, government agencies and other research organizations actively engaged in the research and development of products that may be like our product candidates or address similar markets. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, the number of companies seeking to develop and commercialize products and therapies competing with our product candidates is likely to increase. However, we seek to build our portfolio with key differentiating attributes to provide a competitive advantage in the markets we target. We believe RLYB212 could be a first-in-class antibody for the prevention of FNAIT, and no direct mechanistic based clinical competition currently exists. Our second product candidate, RLYB116 faces competition from a number of companies for the treatment of patients with PNH and gMG, including Soliris and Ultomiris marketed by AstraZeneca. If we successfully develop and, if approved, commercialize RLYB116, this therapy may compete, or potentially be used in conjunction, with currently marketed treatments, including Soliris and Ultomiris, and any new therapies that may become available in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Competition could render any product candidate we develop obsolete, less competitive, or uneconomical. In addition, product candidates developed by our competitors may prove to be more safe or more effective than our product candidates. Our competitors may, among other things:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">have significantly greater name recognition and financial, manufacturing, marketing, product development, technical, commercial infrastructure, and human resources than we do;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">more effectively recruit and retain qualified scientific and management personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">more effectively establish clinical trial sites and patient registration;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe side effects;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">obtain quicker regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">better protect their patents and intellectual property or acquire technologies that are complementary to, or necessary for, our programs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">implement more effective approaches to sales, marketing, pricing, coverage, market access, and reimbursement; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">form more advantageous strategic alliances or collaborations. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we are not able to effectively compete for any of the foregoing reasons, our business will be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Disruptions in the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes and other events that may otherwise affect the FDA&#x2019;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. In April 2021, the FDA released additional guidance on its handling of inspections during the COVID-19 pandemic, addressing situations where the FDA may request to conduct a remote interactive evaluation. While participation in a remote interactive evaluation is voluntary, declining the FDA&#x2019;s guidance could impede the FDA&#x2019;s ability to make a timely regulatory decision (e.g., regarding adequacy of a clinical trial used in support of a pending application or adequacy of a drug manufacturing operation described in the application). Additionally, in July 2021, the FDA transitioned to the &#x201c;base-case scenario&#x201d; in its &#x201c;Resiliency Roadmap for FDA Inspectional Oversight,&#x201d; where the FDA will move to standard operational levels for domestic surveillance inspections, though there was another pause in domestic inspectional activities in early 2022 as a result of the COVID-19 Omicron variant, which was lifted on February 7, 2022. Regulatory authorities outside the United States may also impose similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval for a product candidate in the United States, we or our current or future collaborators may never obtain approval for or commercialize the product candidate in any other jurisdiction, which would limit our ability to realize its full market potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to market any product in a particular jurisdiction, we or our current or future collaborators must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy on a country-by-country basis. Approval by the FDA in the United States does not ensure approval by comparable regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our or our collaborators&#x2019; ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time- consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and we will be unable to realize the full market potential of any product we develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval for any of our product candidates, we will still face extensive and ongoing regulatory requirements and obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval preclinical and clinical testing, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of the FDA and other regulatory authorities. These requirements include submissions of safety and other post- marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements regarding the distribution of samples to physicians and recordkeeping and GLP and GCP requirements for non-clinical studies and any clinical trials that we conduct post-approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA may also require costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. Additionally, the FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in a manner that is consistent with the provisions of the approved labeling. If we market our products for uses beyond their approved indications or otherwise inconsistent with the FDA-approved labeling, we may be subject to enforcement action for off-label marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice. Violation of the FDCA and other statutes, including the False Claims Act, and equivalent legislation in other countries relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state and other countries&#x2019; health care fraud and abuse laws and state consumer protection laws. Even if it is later determined we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions and have to divert significant management resources from other matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restrictions on manufacturing such products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restrictions in the labeling or on the marketing of products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restrictions on product distribution or use;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">requirements to conduct post-marketing studies or additional post-marketing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">issuance of warning letters or untitled letters;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit, or delays in such approvals;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recalls or market withdrawals of products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">fines, restitution, or disgorgement of profits or revenues;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">suspension or termination of ongoing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">product seizure; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">injunctions, consent decrees, or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we obtain FDA approval for RLYB212 or RLYB116, safety risks not identified in our prior clinical trials may first appear after we obtain approval and commercialize these product candidates. Any new post-marketing adverse events may significantly impact our ability to market the drugs and may require that we recall and discontinue commercialization of the products. Furthermore, if any confirmatory post-marketing trial fails to confirm the clinical profile or clinical benefits of RLYB212 or RLYB116, the FDA may withdraw its approval, which would materially harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Further, the FDA&#x2019;s, EMA&#x2019;s and other comparable regulatory authorities&#x2019; policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate or increase the costs and regulatory burden of commercialization. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition, and results of operations. Furthermore, non-compliance by us or any collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, may also result in significant financial penalties, which would adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may seek Fast Track designation, Breakthrough Therapy designation, or PRIME designation for our product candidates, but we might not receive any such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If a drug is intended for the treatment of a serious or life-threatening condition, and non-clinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product candidate may qualify for FDA Fast Track designation, for which sponsors must apply. Sponsors of fast-track products may have more frequent interactions with the FDA, and, in some circumstances, the FDA may initiate review of sections of a fast track product&#x2019;s application before the application is complete. We may submit an application for Fast Track designation for RLYB212 and RLYB116. The FDA has broad discretion whether to grant this designation, and we may not receive it. Moreover, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#x2019;s priority review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also may seek a Breakthrough Therapy designation for RLYB212 or other product candidates if future results support such designation. A Breakthrough Therapy is defined as a drug (including biologic) that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Sponsors of products that have been designated as breakthrough therapies are eligible to receive more intensive FDA guidance on establishing an efficient drug development program, an organization commitment involving senior managers, and may be eligible for rolling review. Drugs designated as breakthrough therapies by the FDA may also be eligible for other expedited review programs, including accelerated approval and priority review, if supported by clinical data at the time the BLA or NDA is submitted to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that RLYB212 meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if RLYB212 qualifies as a Breakthrough Therapy, the FDA may later decide that RLYB212 no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the EU we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#x2019;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the EU or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the EU and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that can substantiate the claims. The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#x2019;s grant of a marketing authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may be unsuccessful in obtaining or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">RLYB212 and RLYB116 or any of our other product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States and the EU may designate drugs for relatively small patient populations as orphan drugs. Under the U.S. Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of more than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#x2019;s Committee for Orphan Medicinal Products evaluates, and the European Commission grants, an orphan drug designation principally to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. In addition, the product under consideration is indicated for a condition where there exists no satisfactory method of diagnosis, prevention or treatment authorized in the EU or, if such method exists, that the medicinal product will be of significant benefit to those affected by that condition. Each of the FDA and the European Commission has granted orphan drug designation for RLYB211 and RLYB212 for the treatment of FNAIT. We may seek orphan drug designation in the United States and the EU for our other product candidates but may be unsuccessful in doing so. There can be no assurance that the FDA or the EMA&#x2019;s Committee for Orphan Medicinal Products will consider orphan designation for any indication for which we apply or re-apply, or that we will be able to maintain such designation. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug or biologic for the same orphan designation for that time period, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. In the United States, the exclusivity period is seven years. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years in Europe if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Similarly, in the EU, the market exclusivity can be broken if the holder of the marketing authorization for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product. In addition, in both the United States and EU, if a different drug is subsequently approved for marketing for the same or a similar indication as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity, which only protects against approval of the &#x201c;same&#x201d; drug for the same indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may seek accelerated approval by the FDA for one or more of our product candidates. Accelerated approval by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA requires that a sponsor of a product receiving accelerated approval perform a post-marketing confirmatory clinical trial or trials. In addition, the FDA currently requires as a condition for accelerated approval the pre-submission of promotional materials to FDA for review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if we decide to submit an application for accelerated approval there can be no assurance that such submission or application will be accepted or that the FDA will determine that the product candidate is eligible for or grant accelerated approval. A</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">failure to obtain any planned accelerated approval for our product candidates would result in a longer time period to commercialization of our product candidates, if approved, could increase the cost of development of our product candidates and could harm our competitive position in the marketplace. If we receive accelerated approval for any of our product candidates, the FDA may withdraw accelerated approval if, among other things, a confirmatory trial required to verify the predicted clinical benefit of the product fails to verify such benefit or if such trial is not conducted with due diligence. Withdrawal of any accelerated approval could substantially harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Although RLYB212 has received FDA designation as rare pediatric disease drug products, any marketing application we submit for RLYB212 may not qualify for issuance of a rare pediatric disease priority review voucher.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, RLYB211 and RLYB212 have received designation from the FDA as rare pediatric disease drug products. Receipt of rare pediatric disease designation is a prerequisite to qualifying for receipt of a rare pediatric disease priority review voucher upon approval of a marketing application for the rare pediatric disease drug product. The priority review voucher may be used to obtain priority review of a future marketing application that would not otherwise qualify to receive priority review. Priority review shortens the FDA&#x2019;s goal for taking action on a marketing application from ten months to six months for an original BLA or NDA from the date of filing. As an alternative to using the priority review voucher to obtain priority review of one of its own marketing applications, the sponsor of a rare pediatric disease drug product receiving a priority review voucher may also sell or otherwise transfer the voucher to another company. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted an application relying on the priority review voucher. The FDA may also revoke any rare pediatric disease priority review voucher if the rare pediatric disease product for which the voucher was awarded is not marketed in the United States within one year following the date of approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There is no guarantee that, if we ever submit and obtain approval for RLYB212 or any other product candidate for which we may obtain rare pediatric disease designation in the future, we will receive a rare pediatric disease priority review voucher. In addition to receiving rare pediatric disease designation, in order to receive a rare pediatric disease priority review voucher, the NDA or BLA must be granted priority review, rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population, not seek approval for a different adult indication in the original rare pediatric disease product application and be for a drug that does not include a previously approved active ingredient. Under current statutory sunset provisions, even if a marketing application meets all of these requirements, the FDA may only award a voucher prior to September 30, 2026 and only if the approved product received rare pediatric disease drug product designation prior to September 30, 2024. We cannot be certain that we will receive approval for any of our rare pediatric disease designated products prior to the statutory sunset date, if ever. Moreover, even if we believe that our marketing application meets the other requirements to be eligible to receive a priority review voucher upon approval, the FDA may disagree.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The successful commercialization of any product candidate we develop will depend in part on the extent to which regulatory authorities and private health insurers establish coverage and reimbursement. Failure to obtain or maintain coverage and reimbursement for our product candidates, if approved, could limit our or our collaborators&#x2019; ability to market those products and decrease our or our collaborators&#x2019; ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If any product candidate is approved for marketing, our ability to obtain coverage and reimbursement for any such product by governmental healthcare programs, such as Medicare and Medicaid, private health insurers, and other third-party payors is essential for most patients to be able to afford prescription medications. Our ability to achieve acceptable levels of coverage and reimbursement for products or procedures using our products by regulatory authorities, private health insurers and other third-party payors will therefore have an effect on our ability to successfully commercialize any product candidates we develop. We cannot be sure that coverage and reimbursement will be available for our product candidates, if and when such candidates obtain marketing approval, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause third-party payors to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any product we commercialize. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care and additional legislative, administrative, or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense and new products face increasing challenges in entering</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the market successfully. Third-party payors are increasingly challenging the price and examining the cost-effectiveness of new products in addition to their safety and efficacy. To obtain or maintain coverage and reimbursement for any current or future product, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our product. These studies will be in addition to the studies required to obtain regulatory approvals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may also need to provide discounts to purchasers to encourage purchasing of any approved product and rebates to third party payors to increase the possibility of favorable coverage and adequate cost sharing thresholds for patients. We may be required to provide discounts or rebates on any approved product under government healthcare programs or to certain government and private purchasers in order to obtain coverage under federal health care programs such as Medicaid. Participation in such programs would require us to track and report certain drug prices. We may be subject to fines and other penalties if we fail to report such prices accurately.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor, and one third-party payor&#x2019;s decision to cover a particular product does not ensure that other payors will also provide similar coverage. Additionally, the process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the price of such product or establishing the reimbursement rate that the payor will pay for the product once coverage is approved. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and reimbursement will be obtained or will be consistent across payors. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We or our collaborators may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we or our collaborators are able to charge for products we or our collaborators commercialize. Accordingly, in markets outside of the United States, the reimbursement for products we or our collaborators commercialize may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Even if a product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors and the medical community. Commercial success also will depend, in large part, on the coverage and reimbursement of our product candidates and associated screening and/or diagnostic tests by third-party payors, including private insurance providers and government payors. Various factors will influence whether our product candidates are accepted in the market if approved for commercial sale, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the efficacy, safety and tolerability of our products, and potential advantages compared to alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the clinical indications for which the product is approved, and product labeling or product insert requirements of the FDA, EMA or other comparable foreign regulatory authorities, including any limitations or warnings contained in a product&#x2019;s approved labeling;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the effectiveness of sales and marketing efforts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of treatment in relation to alternative treatments, including any similar treatments;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to offer our products for sale at competitive prices;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the availability and access to screening and/or diagnostic tests;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the strength of marketing and distribution support;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the availability of third-party coverage and reimbursement for any of our products that are approved and any screening and/or diagnostic testing, as appropriate; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any restrictions on the use of our product together with other medications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Market acceptance of our product candidates is heavily dependent on patients&#x2019; and physicians&#x2019; perceptions that our product candidates are safe and effective treatments for their targeted indications and willingness to use screening and/or diagnostic tests to identify at-risk target populations for our therapeutics. The perceptions of any product are also influenced by perceptions of competitors&#x2019; products that are in the same class or that have a similar mechanism of action. Because we expect sales of our product candidates, if approved, to generate substantially all our revenues in the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If approved, our product candidates that are regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The BPCIA was enacted as part of the Patient Protection and Affordable Care Act (the &#34;ACA&#34;) to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#x201c;interchangeable&#x201d; based on its similarity to an approved biologic. Under the BPCIA, reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as their BLA does not rely on the reference product, sponsor&#x2019;s data or submit the application as a biosimilar application. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty, and any new policies or processes adopted by the FDA could have a material adverse effect on the future commercial prospects for our biological products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. The approval of a biosimilar of our product candidates could have a material adverse impact on our business due to increased competition and pricing pressure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If the FDA, EMA or other comparable foreign regulatory authorities approve generic versions of any of our small molecule investigational products that receive marketing approval, or such authorities do not grant our products appropriate periods of exclusivity before approving generic versions of those products, the sales of our products, if approved, could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Once an NDA is approved, the product covered thereby becomes a &#x201c;reference listed drug&#x201d; in the FDA&#x2019;s publication, &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; commonly known as the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of ANDAs in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials to assess safety and efficacy. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labelling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference listed drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Generic drug manufacturers may seek to launch generic products following the expiration of any applicable exclusivity period we obtain if our products are approved, even if we still have patent protection for such products. Competition that our products could face from generic versions of our products could materially and adversely affect our future revenue, profitability, and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidates we develop, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to market and successfully commercialize any product candidates we develop, if approved, we must build our sales and marketing capabilities or enter into collaborations with third parties for these services. We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. If we commercialize any of our product candidates that may be approved ourselves, we will need to develop an in-house marketing organization and sales force across rare disease therapeutic areas, which will require significant expenditures, management resources, and time. There are significant expenses and risks involved with establishing our own sales and marketing capabilities, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales leads and provide our sales and marketing team with adequate access to physicians who may prescribe our products, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train, and retrain marketing and sales personnel. Any failure or delay in the development of a product candidate that affects the expected timing of commercialization of the product candidate or results in the failure of the product candidate to be commercialized could result in us having prematurely or unnecessarily incurred costly commercialization expenses. Our investment would be lost if we are unable to retain or reposition our sales and marketing personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may also enter into collaborations for the sales and marketing of our product candidates, if approved. To the extent that we depend on collaborators for sales and marketing activities, any revenues we receive will depend upon the success of those collaborators&#x2019; sales and marketing teams and the collaborators&#x2019; prioritization of our products and compliance with applicable regulatory requirements, and there can be no assurance that the collaborators&#x2019; efforts will be successful. If we are unable to build our own sales and marketing team or enter into a collaboration for the commercialization of product candidates we develop, if approved, we may be forced to delay the commercialization of our product candidates or reduce the scope of our sales or marketing activities, which would have an adverse effect on our business, operating results and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We intend to continue to acquire or in-license rights to additional product candidates or collaborate with third parties for the development and commercialization of our product candidates. We may not succeed in identifying and acquiring businesses or assets, in-licensing intellectual property rights or establishing and maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all, and these transactions could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We acquired all rights to RLYB211 and RLYB212 from Prophylix in 2019 and rights to RLYB116 and RLYB114 from Sobi in 2019. We also obtained worldwide exclusive rights to Sanofi&#x2019;s KY1066, now referred to as RLYB331, and have entered into a joint venture with Exscientia for the development of small molecule therapeutics for rare diseases, as well as a discovery and collaboration agreement with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. An important component of our approach to product development is to acquire or in-license rights to product candidates, products or technologies, acquire other businesses or enter into collaborations with third parties. We may not be able to enter into such transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">on favorable terms, or at all. Any such acquisitions, in-licenses or collaborations may not strengthen our competitive position, and these transactions may be viewed negatively by analysts, investors, customers, or other third parties with whom we have relationships. We may decide to incur debt in connection with an acquisition, or in-license or issue our common stock or other equity securities as consideration for the acquisition, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may not be able to successfully integrate the acquired personnel, technologies, and operations into our existing business in an effective, timely, and non-disruptive manner. Such transactions may also divert management attention from day-to-day responsibilities, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or in-licenses or the effect that any such transactions might have on our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may not realize the anticipated benefits of any current or future collaboration, each of which involves or will involve numerous risks, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale, or downsizing;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator may seek to renegotiate or terminate its relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator may cease development in therapeutic areas that are the subject of our collaboration;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator may not devote sufficient capital or resources towards our product candidates, or may fail to comply with applicable regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator may change the success criteria for a product candidate, thereby delaying or ceasing development of such candidate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a significant delay in initiation of certain development activities by a collaborator will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator could develop a product that competes, either directly or indirectly, with our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator with commercialization obligations may not commit sufficient financial resources or personnel to the marketing, distribution, or sale of a product;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to meet demand requirements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator may terminate a strategic alliance;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a dispute may arise between us and a collaborator concerning the research, development, or commercialization of a product candidate resulting in a delay in milestones or royalty payments or termination of the relationship and possibly resulting in costly litigation or arbitration, which may divert management&#x2019;s attention and resources; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator may use our products or technology in such a way as to invite litigation from a third-party. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborations on acceptable terms or to successfully transition away from terminated collaborations, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense, or find alternative sources of capital, which would have a material adverse impact on our clinical development plans and business. If we fail to establish and maintain collaborations related to our product candidates, we could bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise for which we have not budgeted. This could negatively affect the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may face significant competition in identifying and acquiring businesses or assets, in-licensing intellectual property rights and seeking appropriate collaboration partners for our product candidates, and the negotiation process may be time-consuming and complex. In order for us to successfully partner our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other products or product candidates available for licensing from or in connection with collaborations with other companies. Our success in acquiring business or assets or in partnering with collaborators may depend on our history or perceived capability of successful product development. Even if we are successful in our efforts to acquire businesses or assets, in-license intellectual property rights or establish collaborations, we may not be successful in developing such products candidates or technologies or able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our reliance on a central team consisting of a limited number of employees and third parties who provide various administrative, research and development, and other services across our organization presents operational challenges that may adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we had 41 full-time employees, upon whom we rely for various administrative, research and development, business development and other support services shared among our subsidiaries and the Exscientia joint venture. The size of our centralized team may limit our ability to devote adequate personnel, time, and resources to support the operations of all of our subsidiaries and the Exscientia joint venture, including their research and development activities, the management of financial, accounting, and reporting matters, and the oversight of our third-party vendors and partners. If our centralized team or our third-party vendors and partners performing such functions fail to provide adequate administrative, research and development, or other services across our entire organization, our business, financial condition, and results of operations could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA, and other similar regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) data privacy, security, fraud and abuse and other healthcare laws and regulations; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these or other laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government agency could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us or them and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We currently rely and will rely on third parties for the manufacture of drug substance for our preclinical studies and clinical trials and expect to continue to do so for commercialization of any product candidates that we may develop that are approved for marketing. We also rely and will rely on third parties for the design and manufacture of companion diagnostics related to RLYB212 and any other product candidates that may require a companion diagnostic. Our reliance on third parties may increase the risk that we will not have sufficient quantities of such drug substance, product candidates, or any</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">products that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing RLYB212 and RLYB116 or any other product candidate. Instead, we rely on and expect to continue to rely on contract manufacturers for the supply of cGMP-drug substance and drug product of RLYB212 and RLYB116 and any other product candidates we develop and, in the future, for commercial supply. Reliance on third parties may expose us to more risk than if we were to manufacture our product candidates ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may be unable to establish necessary supply agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the possible breach of the manufacturing agreement by the third-party;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for us;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">reliance on the third-party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the possible inability of third-party suppliers to supply and/or transport materials, components and products to us in a timely manner as a result of disruptions to the global supply chain, including in connection with the COVID-19 pandemic.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Third-party manufacturers may fail to comply with cGMP regulations or similar regulatory requirements outside the United States. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our product candidates for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Moreover, our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">While we provide oversight of manufacturing activities, we have limited ability to control the execution of manufacturing activities by, and are or will be dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates by our CMOs. As a result, we are subject to the risk that our product candidates may have manufacturing defects or fail to comply with regulatory requirements, which we have limited ability to prevent. CMOs may also have competing obligations that prevent them from manufacturing our product candidates in a timely manner. If a CMO cannot successfully manufacture drug substance that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance, and qualified personnel, and we were not involved in developing our CMOs&#x2019; policies and procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The facilities and processes used to manufacture our product candidates are subject to inspection by the FDA, EMA and other comparable foreign authorities. If the FDA, EMA or other comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities or conduct additional studies, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. Finding new CMOs or third-party suppliers involves additional cost and requires our management&#x2019;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates. If we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We have limited ability to control the process or timing of the acquisition of these raw materials by our CMOs. The COVID-19 pandemic may also have an impact on the ability of our CMOs to acquire raw materials. Moreover, we currently do not have any agreements for the production of these raw materials. Supplies of raw materials could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable time frame, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of the manufacture of our product candidates. Moreover, our product candidates utilize drug substances that are produced on a small scale, which could limit our ability to reach agreements with alternative suppliers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the intellectual property and proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes, misappropriates or otherwise violates the intellectual property or the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved. Further, the extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, given our limited experience in developing and commercializing companion diagnostics, we do not plan to develop companion diagnostics internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for companion diagnostics if required. Reliance on these third-party collaborators exposes us to risks due to our limited control of their activities, including compliance by them with cGMP regulations or similar foreign requirements and inspection of their manufacturing facilities by the FDA or comparable foreign regulatory authorities and their obtaining, maintaining and protecting their intellectual property rights necessary to develop and manufacture companion diagnostics while not infringing on the intellectual property rights of others. We or our third-party collaborators also will need to source raw materials for any companion diagnostics, including obtaining amounts sufficient for widespread adoption of testing and a potential commercial launch of RLYB212, if approved, and we may be dependent on our collaborators to identify and obtain reliable sources of raw materials. Our collaborators also may breach their agreements with us or otherwise fail to perform to our satisfaction, which could impact the development timeline of our product candidates, and we may incur additional costs and delays if we need to transition to a new third-party companion diagnostic partner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We rely, and will continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If we fail to effectively oversee and manage these third parties, if they do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We rely, and will continue to rely, on CROs, CRO-contracted vendors, and clinical trial sites to ensure the proper and timely conduct of our clinical trials. Our reliance on CROs for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We and our CROs will be required to comply with the GLP requirements for our preclinical studies and GCP requirements for our clinical trials. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we, or our CROs, fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements and may require a large number of patients. Our failure or any failure by our CROs, investigators, CMOs or other third</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">parties to comply with regulatory requirements or to recruit enough patients may delay ongoing or planned clinical trials or require us to repeat clinical trials, which would delay the regulatory approval process. Failure by us or by third parties we engage to comply with regulatory requirements can also result in fines, adverse publicity, and civil and criminal sanctions. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our CROs, vendors and clinical trial investigators are not our employees, and we do not control whether they devote sufficient time and resources to our clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs and other third parties involved in our preclinical studies and clinical trials, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs and other third parties involved in our trials do not successfully carry out their contractual duties or obligations, or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidates that we develop. As a result, our financial results and the commercial prospects for any product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If our relationship with any CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#x2019;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes, and additional proposed changes, to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of health care. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. The ACA expanded health care coverage through a Medicaid expansion and the implementation of the individual mandate for health insurance coverage. The ACA also imposed an annual fee payable on manufacturers of branded prescription drugs and biologic agents (other than those designated as orphan drugs) and included changes to the coverage and reimbursement of drug products under government healthcare programs. Such changes included an expansion in the Medicaid drug rebate program and an increase in the statutory minimum rebates a manufacturer must pay under the program as well as a new Medicare Part D coverage gap discount program requiring manufacturers to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period in exchange for coverage of the drugs under Medicare Part D. Under the Trump administration, there were ongoing efforts to modify or repeal all or certain provisions of the Healthcare Reform Act. For example, tax reform legislation was enacted at the end of 2017 that eliminated the tax penalty established under the ACA for individuals who do not maintain the mandated health insurance coverage beginning in 2019. The ACA has also been subject to judicial challenge. In June 2021, the Supreme Court rejected the most recent challenge to the constitutionality of the ACA on the grounds that the states and individuals that brought the challenge did not have standing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Beyond the ACA, there have been ongoing health care reform efforts. Drug pricing and payment reform was a focus of the Trump Administration and has been a focus of the Biden Administration.  For example, federal legislation enacted in 2021 eliminates a statutory cap on Medicaid drug rebate program rebates effective January 1, 2024. As another example, in 2022, the Inflation Reduction Act (&#x201c;IRA&#x201d;) of 2022 contains various drug pricing and payment provisions. Among other provisions, the IRA imposes a yearly cap ($2,000 in 2025) on out-of-pocket</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">prescription drug costs in Medicare Part D, implements a new Medicare Part D manufacturer discount drug program in 2025; requires manufacturers to pay a rebate to the federal government if prices for single-source drugs and biologicals covered under Medicare Part B and nearly all covered drugs under Part D increase faster than the rate of inflation and, starting in 2026, creates a drug price negotiation program under which the prices for certain high Medicare spend drugs and biologicals without generic or biosimilar competition will be limited by a cap that is defined by reference to, among other things, a specified non-federal average manufacturer price. Such legislative changes or other changes could affect the market conditions for our products. As another example, in February 2023, in response to an executive order from President Biden to consider new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for Medicare and Medicaid patients, CMS recently selected for testing three new payment models for drugs. One model would adjust Part B payments for drugs approved by FDA under the accelerated approval pathway to encourage timely confirmatory trial completion  We expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Some of the health care reform changes have been and may continue to be subject to legal challenge. For example, revisions to regulations under the federal anti-kickback statute would remove protection for traditional Medicare Part D discounts offered by pharmaceutical manufacturers to pharmacy benefit managers and health plans. Pursuant to court order, the removal was delayed, and the IRA further delayed implementation of the rule until January 1, 2032.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There have also been efforts by federal and state government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation. Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, at the federal level, there have been administration initiatives, Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for drugs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adoption of new legislation at the federal or state level could affect demand for, or pricing of, any future products if approved for sale. We cannot, however, predict the ultimate content, timing or effect of any changes to the ACA or other federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General legislative cost control measures may also affect reimbursement for our product candidates. The Budget Control Act, as amended, resulted in the imposition of reductions in Medicare (but not Medicaid) payments to providers in 2013 and will remain in effect through 2031 (except May 1, 2020 to March 31, 2022) unless additional Congressional action is taken. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we, or any third parties we may engage, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our business operations and current and future arrangements with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">market, sell, and distribute our product candidates, if approved. Such laws, some of which may apply only after our products are approved for marketing, include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. federal HIPAA which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products prior to approval or for off-label use and regulates the distribution of samples;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. federal Open Payments (or federal &#x201c;sunshine&#x201d; law), which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers to CMS for re-disclosure to the public, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or report information related to payments to health care providers, marketing expenditures or drug prices; and state laws governing privacy, security, and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. laws and regulations prohibiting bribery and corruption, such as the FCPA, which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information, such as, where applicable, the GDPR which imposes obligations and restrictions on the collection, use, and disclosure of personal data relating to individuals located in the EU and the EEA (including health data). See &#x201c;&#x2014;Our business operations may subject us to data protection laws, including the GDPR, the United Kingdom GDPR, the CCPA and other similar laws.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare and other laws and regulations will involve substantial costs. Given the breadth of the laws and regulations and narrowness of any exceptions, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, regulatory authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations, including our consulting agreements and other relationships with healthcare providers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to actions including the imposition of civil, criminal, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Further, defending against any such actions can be costly, time consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our business operations may subject us to data protection laws, including the GDPR, the United Kingdom GDPR, the CCPA and other similar laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The GDPR applies to companies established in the EEA, as well as to companies that are not established in the EEA and which collect and use personal data in relation to (i) offering goods or services to, or (ii) monitoring the behavior of, individuals located in the EEA. If we conduct clinical trial programs in the EEA (whether the trials are conducted directly by us or through a clinical vendor or collaborator) or enter into research collaborations involving the monitoring of individuals in the EEA, or market our products to individuals in the EEA, we will be subject to the GDPR. The GDPR puts in place stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data (or reliance on another appropriate legal basis), the provision of robust and detailed disclosures to individuals about how personal data is collected and processed (in a concise, intelligible and easily accessible form), an individual data rights regime (including access, erasure, objection, restriction, rectification and portability), maintaining a record of data processing, data export restrictions governing transfers of data from the EEA, short timelines for data breach notifications to be given to data protection regulators or supervisory authorities (and in certain cases, affected individuals) of significant data breaches, and limitations on retention of information. The GDPR also puts in place increased requirements pertaining to health data and other special categories of personal data, as well as a definition of pseudonymized (i.e., key-coded) data. Further, the GDPR provides that EEA member states may establish their own laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use, and share such data and/or could cause our costs to increase. In addition, there are certain obligations if we contract third-party processors in connection with the processing of personal data. If our or our collaborators&#x2019; or service providers&#x2019; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data, or fines of up to 20 million Euros or up to 4% of our total worldwide annual revenue of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, including class-action type litigation, negative publicity, reputational harm and a potential loss of business and goodwill.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may also have to comply with the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law following &#34;Brexit.&#34; The UK GDPR mirrors the fines under the GDPR with fines up to the greater of &#x20ac;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term. On June 28, 2021 the European Commission issued an adequacy decision in respect of the UK&#x2019;s data protection framework, enabling data transfers from EU member states to the UK to continue without requiring organizations to put in place contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally revoke the adequacy decision at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the EEA and the United Kingdom to the United States. Most recently, on July 16, 2020, the CJEU invalidated the EU-US Privacy Shield Framework (the &#34;Privacy Shield&#34;) under which personal data could be transferred from the EEA to US entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. The CJEU went on to state that if a competent supervisory authority believes that the standard contractual clauses cannot be complied with in the destination country and the required level of protection cannot be secured by other means, such supervisory authority is under an obligation to suspend or prohibit that transfer. On June 4, 2021, the European Commission released two revised sets of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">standard contractual clauses, which have been designed in part to assist organizations in meeting the requirement of the CJEU&#x2019;s judgment. However, it is unclear how the use of these clauses will be scrutinized and enforced by supervisory authorities and privacy interest groups, and the process of entering into agreements with new standard contractual clauses and updating our existing agreements that contain the previous clauses, may lead to additional costs and increase our overall risk exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These recent developments may require us to review and amend the legal mechanisms by which we make and/ or receive personal data transfers to/ in the United States. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. While we do not believe that we are directly subject to HIPAA as either a &#x201c;covered entity&#x201d; or &#x201c;business associate,&#x201d; U.S. sites at which we conduct clinical trials are likely to be covered entities and thus must ensure that they obtain adequate patient authorization or establish another basis under HIPAA to disclose a clinical trial subject&#x2019;s individually identifiable health information to us and other entities participating in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, the CCPA came into effect in January 2020 and, among other things, requires new disclosures to California individuals and affords such individuals new abilities to opt out of certain sales of personal information, and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Because we have not yet generated revenue and do not meet the CCPA&#x2019;s other jurisdictional tests, we do not yet meet the applicable threshold for the CCPA to apply to our business. If our business becomes subject to CCPA in the future, it could increase our compliance costs and potential liability. Further, the California Privacy Rights Act was approved by California voters in 2020 and imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions went into effect on January 1, 2023, though the obligations for covered businesses will apply to any personal information collected after January 1, 2022. Similar laws have been proposed or passed at the U.S. federal and state level, including the Virginia Consumer Data Protection Act, which went into effect on January 1, 2023, the Colorado Consumer Protection Act, which will take effect on July 1, 2023, the Connecticut Data Privacy Act, which will take effect on July 1, 2023, and the Utah Consumer Privacy Act, which will take effect on December 31, 2023.  We expect to be subject to additional privacy laws at both the U.S. state level and abroad, as many jurisdictions worldwide in addition to those examples described above have either recently passed data privacy legislation or are considering enacting such legislation. As such, we will need to review periodically our operations in comparison to developments in such laws. Achieving and sustaining compliance with applicable international, federal and state privacy, security, fraud and reporting laws may prove time-consuming and costly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and select other countries related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. If we are unable to obtain or maintain patent protection in jurisdictions important to our business with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In some circumstances involving technology that we license from third parties, we do not have the sole right to control the preparation, filing and prosecution of patent applications or to maintain, enforce and defend the in-licensed patents. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The patent rights of pharmaceutical and biotechnology companies generally are highly uncertain, involve complex legal and factual questions and have been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged in the United States or in numerous foreign jurisdictions. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patent eligibility of certain inventions or discoveries relating to biotechnology. These decisions conclude, among other things, that abstract ideas, natural phenomena and laws of nature are not themselves patent eligible subject matter. Precisely what constitutes a law of nature or abstract idea is uncertain, and certain aspects of our technology could be considered ineligible for patenting under applicable law. In addition, the scope of patent protection outside the United States is uncertain, and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law precludes the patentability of methods of treatment of the human body. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents that protect our technology and product candidates, in whole or in part, in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Changes in either the patent laws or interpretation of the patent laws in the United States or other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, affect the value or narrow the scope of our patent rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Further, third parties may have intellectual property rights relating to our product candidates of which we are unaware. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases are not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and in-licensed patent rights are uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We, or our licensors, may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">interference proceedings challenging our patent rights or the patent rights of others in the United States and/or foreign countries. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. For these reasons, our owned and in- licensed patent portfolio may not provide us with sufficient rights to exclude others from using or commercializing technology and products similar or identical to any of our technology and product candidates for any period of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Patent terms may not protect our competitive position for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are approved for use or commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours during periods when commercial exclusivity would be valuable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, which if granted could extend the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, the term of a patent that covers an FDA-approved drug may be eligible for limited PTE which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a PTE of up to five years beyond the expiration date of the patent. The length of the PTE is related to the length of time the drug is under regulatory review. A PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. In addition, the patent term of only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for PTEs on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted and, even if granted, the length of such extensions. We may not be granted PTE either in the United States or in any foreign country, even where that patent is eligible for PTE, if, for example, we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the regulatory authority could be less than we request. If we obtain such an extension, it may be for a shorter period than we had sought. If we are unable to obtain any PTE or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furthermore, for any future licensed patents, we may not have the right to control prosecution, including filing with the USPTO or any foreign agency, of a petition for PTE under the Hatch-Waxman Act or analogous foreign provisions. Thus, for example, if one of our licensed patent applications, if granted, is eligible for PTE under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a PTE is filed or obtained from the USPTO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Changes in either the patent laws or interpretation of patent laws in the United States or other jurisdictions, including patent reform legislation such as the U.S. Leahy-Smith America Invents Act (the &#34;Leahy-Smith Act&#34;) could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include provisions that switched the United States from a first- to-invent system to a first-inventor-to-file system, affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents and enable third-party submission of prior art to the USPTO during patent prosecution, and provide additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, under the Leahy-Smith Act and pursuant to foreign laws outside of the United States, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. Such laws could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has increased uncertainty with respect to the validity and enforceability of patents once obtained. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Competitors and other third parties may infringe, misappropriate or otherwise violate patents or other intellectual property that we or our licensors may own, obtain or acquire. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property claims, which can be expensive and time-consuming. Any claims we assert against others could provoke them to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. In a patent infringement proceeding, the perceived infringers could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are common. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings in the European Patent Office. The outcomes of allegations of invalidity or unenforceability are unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An adverse result in any such proceeding could put one or more of our current or future owned or in- licensed patents at risk of being invalidated or interpreted narrowly and could put any of our owned or in- licensed patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third-party from using the technology at issue in a proceeding, for example, on the basis that our owned or in-licensed patents do not cover that technology. Furthermore, if the breadth or strength of protection provided by our current or future patents and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products, diagnostic tests, or services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during litigation. Any of the foregoing could allow third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Third parties may allege that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, inter partes review and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates may be subject to claims that they infringe the patent rights of third parties. Our competitors and others may have significantly larger and more mature patent portfolios than we have. In addition, future litigation may be initiated by patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. Competitors may also assert that our product candidates infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources and management attention to defend. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Because patent applications can take many years to issue, pending patent applications may result in issued patents that our product candidates infringe. For example, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use or manufacture of our product candidates or technologies. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe the intellectual property rights of third parties. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third-party&#x2019;s intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A court could hold that third-party patents are valid, enforceable and infringed. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one that requires us to present clear and convincing evidence as to the invalidity of the claims of any such U.S. patent, there is no assurance that a court would invalidate the claims of any such U.S. patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief. For example, if any third-party patents were held to cover the manufacturing process of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidates. In the event of a successful claim of infringement against us, we may also have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, indemnify customers, collaborators or other third parties, seek new regulatory approvals, and redesign our infringing products, which may not be possible or practical. If we are found to infringe, misappropriate or otherwise violate a third-party&#x2019;s intellectual property rights, we may be required to obtain a license from such third-party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities, which would impair our ability to pursue our business. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our adversaries may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application and prosecution process. In certain circumstances, we may rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms, and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to office actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the current and future patents and patent applications covering our product candidates, our competitors might be able to enter the market with similar or identical products or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we are unable to obtain licenses from third parties on commercially reasonable terms, our business could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to our existing licensing agreements, it may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, if approved, in which case we would be required to obtain a license from these third parties. The in-licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">may be unwilling to assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, such as substantial licensing or royalty payments, our business could be materially harmed. If we are unable to obtain a necessary license, the third parties owning such intellectual property rights could seek an injunction prohibiting our sales or we may be unable to otherwise develop or commercialize the affected product candidates, which could materially harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations, and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in our intellectual property licenses with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are party to license agreements that impose, and we may enter into additional licensing and funding arrangements with third parties that may impose, among other things, diligence, development, and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. Under our existing licensing agreements, including our license agreement with Affibody, we are obligated to pay milestones and royalties on net product sales of product candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements, or our counterparties may require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects, or impede, delay or prohibit the further development or commercialization of, one or more product candidates that rely on such agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disputes may arise regarding intellectual property that is or becomes subject to a licensing agreement, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the scope of rights granted under the license agreement and other matters of contract interpretation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">whether and the extent to which our technology and processes infringe the intellectual property rights of the licensor that are not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">whether our licensor or its licensor had the right to grant the license agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property rights without their authorization;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our involvement in the prosecution of licensed patents and our licensors&#x2019; overall patent enforcement strategy;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the amounts of royalties, milestones or other payments due under the license agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the sublicensing of patent and other rights under collaborative development relationships;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Despite our efforts, our licensors or future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors could seek regulatory approval for and market products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Third parties may attempt to develop and commercialize competitive products in foreign countries where we do not have any patent protection and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, adequate judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling our inventions in such countries or importing products made using our inventions into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect, to the same extent as the United States or at all, inventions that constitute new methods of treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many countries, including India, China and certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition, results of operations, and prospects may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor, co-inventor, owner or co-owner. For example, we or our licensors or collaborators may have inventorship or ownership disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#x2019; or collaborators&#x2019; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors or collaborators fail in defending any such claims, we may be required to pay monetary damages and we may also lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of such third parties, or that they have wrongfully used or disclosed alleged trade secrets of their current or former employers, or that we have misappropriated their intellectual property, or that they own what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many of our employees, consultants and contractors were previously employed at or engaged by universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Many of them executed proprietary rights, non-disclosure and/or non-competition agreements in connection with such previous employment or engagement. Although we try to ensure that the individuals who work for us do not use the intellectual property rights, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or they have, inadvertently or otherwise, used, infringed, misappropriated or otherwise violated the intellectual property rights, or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties. We may also be subject to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. Any litigation or the threat of litigation may adversely affect our ability to hire employees or engage consultants and contractors. A loss of key personnel or their work product could hamper or prevent us from developing and commercializing products and product candidates, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in obtaining such an agreement from each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we fail in prosecuting or defending any such claims, we may be required to pay monetary damages, and we may also lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive position and prospects. Such intellectual property rights could be awarded to a third-party, and we could be required to obtain a license from such third-party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furthermore, we expect that, over time, our trade secrets, know-how and proprietary information may be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel to and from academic and industry scientific positions. Consequently, without costly efforts to protect our proprietary technology, we may be unable to prevent others from exploiting that technology, which could affect our ability to expand in domestic and international markets. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be materially and adversely harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. These security measures may be breached, and we may not have adequate remedies for any breach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these trademarks or trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trademarks or trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark or trade name infringement claims brought by owners of other registered trademarks or trade names that incorporate variations of our trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks and trade names may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain a competitive advantage. For example:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we or our license partners or current or future collaborators might not have been the first to file patent applications covering our or their inventions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">it is possible that our owned and in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we cannot ensure that any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the patents of others may harm our business; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may choose not to seek patent protection in order to maintain certain trade secrets or know-how, and a third-party may subsequently file a patent covering such intellectual property.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Employees, Managing Our Growth and Our Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are highly dependent on the expertise of the principal members of our management, scientific, and clinical teams. Our scientific and clinical development personnel have extensive experience developing and implementing novel clinical trial designs and successfully conducting clinical trials in never-before treated patient populations. If we lose one or more of our executive officers or key employees, our ability to execute our programs and implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We may also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many of our employees were previously employed by Alexion (now part of AstraZeneca), a potential competitor. To the extent we employ or engage personnel from competitors, we may be subject to allegations that such individuals have been improperly solicited or have divulged proprietary or other confidential information, or that their former employers own their research output.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or lease or acquire new facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our business and operations would suffer in the event of system failures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Despite the implementation of security measures, our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural and manmade disasters (including hurricanes), terrorism, war, and telecommunication and electrical failures. While we do not believe that we have experienced any such system failure or accident to date, if such an event were to occur and cause interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs. For example, the loss of preclinical or clinical trial data from completed,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ongoing, or planned trials, or the loss of other proprietary data, could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we currently rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability, and the development of our product candidates could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our proprietary or confidential information may be lost, or we may suffer security breaches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals. In the ordinary course of our business, we and third parties with which we have relationships will continue to collect and store sensitive data, including clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our and our collaborators&#x2019; security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to employee error, technical vulnerabilities, malfeasance, or other disruptions. Several proposed and enacted federal, state and international laws and regulations obligate companies to notify individuals of security breaches involving personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors, or other organizations with which we have formed strategic relationships. Although, to our knowledge, neither we nor any such third parties have experienced any material security breach, and even though we may have contractual protections with such third parties, any such breach could compromise our or their networks and the information stored therein could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and significant costs, including regulatory penalties, fines, and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation, and cause a loss of confidence in us and our or such third parties&#x2019; ability to conduct clinical trials, which could adversely affect our reputation and delay the clinical development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">An active trading market for our common stock may not be sustained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If a market for our common stock is not sustained, it may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations may be below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The market price of our common stock may be volatile, which could result in substantial losses for investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares of our common stock were offered in our IPO in July 2021 at a price of $13.00 per share and between the date of our IPO and March 1, 2023, the closing price per share of our common stock has ranged from as low as $4.67 to as high as $23.40. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the success of existing or new competitive product candidates or technologies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the timing and results of preclinical studies for any product candidates that we may develop;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">failure or discontinuation of any of our product development and research programs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the success of the development of companion diagnostics, if required, for use with our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">commencement or termination of collaborations for our product development and research programs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulatory or legal developments in the United States and other countries;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the level of expenses related to any of our research programs or product candidates that we may develop;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the results of our efforts to develop additional product candidates or products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">announcement or expectation of additional financing efforts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">sales of our common stock by us, our insiders or other stockholders;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">expiration of market stand-off or lock-up agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">effects of public health crises, pandemics and epidemics, such as COVID-19;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">general economic, industry, and market conditions; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the other factors described in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Annual Report on Form 10-K. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#x2019;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If securities analysts stop publishing research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The trading market for our common stock is influenced in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">A significant portion of our total outstanding shares may be sold into the market, which could cause the market price of our common stock to decline significantly, even if our business is doing well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. As of March 1, 2023, we have 38,075,024 shares of common stock outstanding.  All of these shares may be resold in the public market immediately, unless held by our affiliates who are subject to volume limitations under Rule 144. As of March 1, 2023, we also have pre-funded warrants to purchase up to an aggregate of 3,333,388 shares of common stock outstanding. We may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#x2019;s election upon 61 days&#x2019; notice to us subject to the terms of such pre-funded warrants, provided that such percentage may in no event exceed 19.99%.  Moreover, as of December 31, 2022, certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. In addition, we have entered into the Sales Agreement with Cowen to offer and sell shares of our common stock having an aggregate offering price of up to $100,000,000, from time to time, through an at-the-market offering program. We also registered an aggregate of 7,659,526 shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Insiders have substantial influence over us, which could limit your ability to affect the outcome of key transactions, including a change of control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our directors and executive officers and their affiliates beneficially own shares representing approximately 35% of our outstanding common stock as of March 1, 2023. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. The interests of these holders may not always coincide with our corporate interests or the interests of other stockholders, and they may act in a manner with which you may not agree or that may not be in the best interests of our other stockholders. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#x2019;s attention and resources from our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, of our common stock will be your sole source of gain on an investment in our common stock in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act and we may remain an emerging growth company until December 31, 2026. For so long as we remain an emerging growth company, we are permitted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (&#34;SOX Section 404&#34;), not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to other public companies.  We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#x201c;opt out&#x201d; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#x201c;opt out&#x201d; of such extended transition period, or (ii) no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our financial statements may not be directly comparable to those of other public companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Our amended and restated certificate of incorporation and bylaws include provisions that:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">authorize &#x201c;blank check&#x201d; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">create a classified board of directors whose members serve staggered three-year terms;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">specify that special meetings of our stockholders can be called only by our board of directors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">prohibit stockholder action by written consent;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">provide that our directors may be removed only for cause;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">specify that no stockholder is permitted to cumulate votes at any election of directors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated bylaws. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware (the &#34;DGCL&#34;) which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation designates the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state or federal courts (as appropriate) within the State of Delaware are exclusive forums for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, (4) action against us or any of our directors or officers involving a claim or defense arising pursuant to the Exchange Act or the Securities Act, or (5) any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This exclusive forum provision does not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision does not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#x201c;facially valid&#x201d; under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum provision. If the federal forum provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The federal forum provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">A variety of risks associated with operating internationally could materially adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our business strategy includes potentially expanding internationally. Doing business internationally involves several risks, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">multiple, conflicting, and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, economic sanctions laws and regulations, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">additional potentially relevant third-party patent rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">difficulties in staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">limits in our ability to penetrate international markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">certain expenses, including, among others, expenses for travel, translation, and insurance; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the FCPA its books and records provisions, or its anti-bribery provisions, as well as other applicable laws and regulations prohibiting bribery and corruption. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">U.S. federal income tax reform could adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review through the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, the Tax Cuts and Jobs Act, (the &#34;TCJA&#34;), was enacted in 2017 and significantly reformed the Code. The TCJA, among other things, contains significant changes to corporate and individual taxation, some of which could adversely impact an investment in our common stock. On March 27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 pandemic, including temporary beneficial changes to the treatment of NOLs, interest deductibility limitations and payroll tax matters. There also may be technical corrections legislation or other legislative changes proposed with respect to the TCJA and CARES Act, the effects of which cannot be predicted and may be adverse to us or our stockholders. Additionally, the Inflation Reduction Act of 2022 the IRA was enacted in August 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Among other things, the IRA implemented a one percent (1%) excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic corporations, and a corporate alternative minimum tax of fifteen percent (15%) on book income of certain large corporations.  Future changes in tax laws could have a material adverse effect on our business, cash flows, financial condition or results of operations. In particular, proposed tax legislation could result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government policy directly affecting our business or indirectly affecting us because of impacts on our customers and suppliers. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Potential clinical trial or product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The use of any product candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of clinical trial and product liability claims. Clinical trial or product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, clinical trial or product liability claims may result in:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">impairment of our business reputation and significant negative media attention;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">withdrawal of participants from our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">significant costs to defend the litigation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">distraction of management&#x2019;s attention from our primary business;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">substantial monetary awards to patients or other claimants;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">inability to commercialize a product candidate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">decreased market demand for any product; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">loss of revenue. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The clinical trial and product liability insurance we currently carry, and any additional clinical trial and product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidate, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful clinical trial or product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operation and business, including preventing or limiting the commercialization of any product candidates we develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions and geopolitical instability could adversely affect our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn, period of sustained increased inflation, or additional global financial crises, could result in a variety of risks to our business, including weakened demand for our product candidates, if approved, or our ability to raise additional capital when needed on acceptable terms, if at all. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. Further, geopolitical instability outside the United States may also impact our operations or affect global markets, such as the recent invasion of Ukraine by Russia.  While we do not currently conduct clinical trials in the Ukraine or Russia, we cannot be certain what the overall impact of these events will be on our business or on the business of any of our third-party partners, including our contract research organizations, contract manufacturers or other partners. The impact of these events could also expand into other markets where we do business. Similarly, the volatility associated with the COVID-19 pandemic has caused significant instability and disruptions in the capital and credit markets. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which current geopolitical tensions, the economic climate and the financial market conditions could adversely impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have incurred, and will incur increased costs as a result of operating as a public company, and our management will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a public company, we have incurred, and particularly after we are no longer an &#x201c;emerging growth company,&#x201d; we will incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to Section 404 of SOX Section 404, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form 10-K with the SEC after we become a public company. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by SOX Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1B. Unr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">esolved Staff Comments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">operties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our corporate headquarters is located at 234 Church Street, Suite 1020, New Haven, CT 06510, where we lease and occupy 9,000 square feet of office space. The current terms of our leases in New Haven expire September 30, 2025. We also lease 117 square feet of office space at 400 Farmington Avenue, Suite R2846, Farmington, CT 06032. The current term of our Farmington lease expires January 31, 2024. We believe that this office space is sufficient to meet our current needs. If required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item3legalproceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 3. Legal Proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources, negative publicity and reputational harm and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 4. Mine Sa</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">fety Disclosures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Not Applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RT II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 5. Market for Registr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our common stock began trade on the Nasdaq Global Select Market under the symbol &#x201c;RLYB.&#x201d;  Trading of our common stock commenced on July 29, 2021 in connection with our IPO. Prior to that time, there was no established public trading market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stockholders</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, there were 37 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have never declared or paid any dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors our board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. Our ability to pay cash dividends on our capital stock in the future may also be limited by the terms of any preferred securities we may issue or agreements governing any indebtedness we may incur.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information provided in the following table is as of December 31, 2022:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.736%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:19.108%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.094%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.968999999999998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:19.095%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Plan category</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number of securities to be issued upon exercise of outstanding options, warrants and rights and outstanding nonvested restricted stock units<br />&#160;&#160;&#160;(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-average exercise price of outstanding options, warrants and rights   <br />&#160;&#160;&#160;&#160;(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number of securities remaining available for future issuance under equity compensation plans <br />&#160;&#160;&#160;(3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity compensation plans approved by security holders</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,737,914</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.01</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,631,945</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity compensation plans not approved by security holders</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(1) Reflects 2,609,314 shares of common stock to be issued upon exercise of outstanding options under our 2021 Equity Incentive Plan and 128,600 outstanding restricted stock units that were issued under the 2021 Equity Incentive Plan. This figure does not include 1,006,368 outstanding restricted stock awards that were issued under the 2021 Equity Incentive Plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(2) The weighted-average exercise price is calculated based on the exercise prices of outstanding options and does not include outstanding restricted stock units (which have no exercise price).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(3) Includes 2,058,157 shares available for future issuance under the 2021 Equity Incentive Plan and 573,788 shares available for future issuance under the 2021 Employee Stock Purchase Plan. The number of shares of our common stock delivered in satisfaction of awards under the 2021 Equity Incentive Plan will not be reduced by (i) any shares withheld by us in payment of the exercise price or purchase price of an award or in satisfaction of tax withholding requirements or (ii) any shares underlying any portion of an award that is settled in cash or that expires, becomes unexercisable, terminates or is forfeited to or repurchased by us without the delivery (or retention, in the case of restricted or unrestricted stock) of shares of our common stock. The number of shares available for delivery under the 2021 Equity Incentive Plan will not be increased by any shares that have been delivered under the 2021 Equity Incentive Plan and are subsequently repurchased using proceeds directly attributable to stock option exercises. In addition, the number of shares reserved for issuance under the 2021 Equity Incentive Plan automatically increases on January 1 of each year through 2031 by the lesser of (i) five percent of the number of shares of our common stock outstanding as of such date and (ii) the number of shares of our common stock determined by our board of directors on or prior to such date. The number of shares reserved for issuance under the 2021 Employee Stock Purchase Plan automatically increases on January 1 of each year through 2031 by the least of (i) one percent of the number of shares of our common stock outstanding as of such date, (ii) 582,648 shares of our common stock and (iii) the number of shares of our common stock determined by our board of directors on or prior to such date (up to a maximum of 6,117,804 shares in the aggregate).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Use of Proceeds from Registered Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In August, 2021, we completed the IPO of our common stock pursuant to which we issued and sold 7,130,000 shares of our common stock, inclusive of 930,000 shares sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $13.00 per share. The aggregate offering price of our IPO was $92.7 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The offer and sale of all of the shares of our common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-257655), which was declared effective by the SEC on July 28, 2021 and a registration statement on Form S-1MEF (File No. 333-258244), which was automatically effective upon filing with the SEC on July 28, 2021. Following the sale of all of the shares offered in connection with the closing of our IPO, the offering terminated. Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C. acted as co-managers for the offering.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We received aggregate gross proceeds from our IPO of $92.7 million, or aggregate net proceeds of $83.0 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering costs were incurred or paid, directly or indirectly, to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we had not used any of the net proceeds from our IPO. There has been no material change in our planned use of the net proceeds from our IPO as described in the IPO Prospectus, other than that a portion of the net proceeds may be used for preclinical development of RLYB331.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">m 6. </span><span id="item_6_selected_financial_data"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Reserved</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_mda"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 7. Manageme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nt&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled &#x201c;Risk Factors&#34; in Part I, Item 1A of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. See &#x201c;Cautionary Note Regarding Forward-Looking Statements.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since our launch in January 2018, we have built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of maternal fetal blood disorders, complement dysregulation, hematology, and metabolic disorders. We have assembled a team of experienced biopharma industry leaders with extensive research, development, and rare disease expertise to deliver on our mission of becoming a leader in the development of therapies for patients with rare diseases. We are drawing on our decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible &#x2013; and change the odds for rare disease patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Maternal Fetal Blood Disorders</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br />RLYB212 is a monoclonal anti-HPA-1a antibody for the prevention of FNAIT, a potentially life-threatening rare hematological disease that impacts fetuses and newborns. We are currently conducting multiple clinical trials as part of the development program for RLYB212.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have received approval for two CTAs for RLYB212 in Germany; the first for a Phase 1 first-in-human trial and the second for a Phase 1b proof of concept trial. In January 2022, we announced that the first subjects were dosed in the Phase 1 study. This ongoing single-blind, placebo-controlled Phase 1 study is designed to evaluate the safety and PK of single and repeat subcutaneous doses of RLYB212 in HPA-1a negative healthy subjects. In the second quarter of 2022, we initiated the Phase 1b proof-of-concept study to evaluate the ability of subcutaneous RLYB212 to rapidly eliminate transfused HPA-1a positive platelets from the circulation of HPA-1a negative healthy subjects. In the third quarter of 2022 we announced preliminary results from the proof-of-concept study, demonstrating RLYB212 rapidly and completely eliminates HPA-1a positive platelets with a greater than 90% reduction of the mean platelet elimination half-life compared to placebo, consistent with proof-of-concept criteria.  We also announced that dosing had commenced under an amended protocol that expanded the dose range of RLYB212, thereby providing a broader range of PK and PD data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the first quarter of 2023, we announced proof-of-concept in a Phase 1b study for RLYB212.  Results showed that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects with additional findings from the study that show a reduction in mean platelet elimination half-life was greater than 90% in both RLYB212 dose groups compared to placebo and was dose related. We believe that the broad range of PK and PD data in the Phase 1b study will allow for substantive modeling to inform dose selection for a future registrational study.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the first quarter of 2023, we also initiated the multi-dose cohort of its single-center Phase 1 trial in Europe. This portion of the Phase 1 study will evaluate safety and PK of RLYB212 based on repeat dosing over 12 weeks in healthy male and female participants. The Company expects results from this cohort of subjects in the fourth quarter of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, we are conducting a FNAIT natural history alloimmunization study. This prospective, non-interventional, multinational natural history study is designed to screen up to 30,000 expectant mothers presenting at Gestation Week 10 to 14 prenatal visit to determine the frequency of women at higher FNAIT risk among expectant mothers of different racial and ethnic characteristics, as well as the frequency of HPA-1a alloimmunization and pregnancy outcomes among these women. Subject to discussion with regulatory authorities, we expect that data from this study will contribute to a control dataset for a future single-arm Phase</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2/3 registration trial for RLYB212. The FNAIT natural history study will operationalize de novo the laboratory test paradigm for FNAIT risk and generate FNAIT laboratory test performance data that we plan to use for future regulatory discussions. Screening of expectant mothers is ongoing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Given the favorable development profile of RLYB212 to date, the data generated to date for RLYB212, and the expected manufacturing and supply efficiencies for RLYB212, RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, will not be advanced further in clinical development.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Complement Dysregulation<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are also focused on developing therapies that address diseases of complement dysregulation, including PNH, gMG, severe dermatologic indications, and ophthalmic disorders. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of C5 in development for the treatment of patients with PNH and gMG. We received approval in the fourth quarter of 2021 for a HREC submission to support the Phase 1 trial of RLYB116 in healthy participants and in the first quarter of 2022, we initiated the Phase 1 trial in Australia. The single-blind, placebo-controlled dose escalation study is designed to evaluate the safety, PK, and PD of single dose RLYB116 in healthy volunteers. In November 2022, we announced positive topline results from our Phase 1 single ascending dose study of RLYB116. These data showed that all study participants that were administered a single 1 mL subcutaneous injection of 100 mg of RLYB116 (n=6) demonstrated a reduction in free C5 greater than 99% within 24 hours of dosing. The terminal elimination half-life of RLYB116 was greater than 300 hours. Subcutaneously administered RLYB116 was observed to be well-tolerated at the 100 mg dose, with mild adverse events and no drug-related serious adverse events reported. In the fourth quarter of 2022 we initiated dosing in the first multiple ascending dose cohort of a Phase 1 study of RLYB116 and initial data are expected in the fourth quarter of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB114 is a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated. We  continue to advance development of RLYB114, formulated for intravitreal injection, for the treatment of ophthalmic disorders.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Hematological Disorders<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In May 2022, we obtained worldwide exclusive rights to Sanofi&#x2019;s KY1066, now referred to as RLYB331, a preclinical antibody. We believe RLYB331 has the potential to address a significant unmet need for patients with severe anemias with ineffective erythropoiesis and iron overload, including beta thalassemia and a subset of lower risk myelodysplastic syndromes. Currently these patients are underserved by the existing standard of care. RLYB331 is a preclinical therapeutic monoclonal antibody that inhibits MTP-2. The inhibition of MTP-2 significantly increases levels of hepcidin, decreases iron load and treats ineffective erythropoiesis. We are continuing to conduct IND-enabling activities for RLYB331 to support transition of the asset into clinical development. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Metabolic Disorders<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, in collaboration with Exscientia, we continue to work toward the selection of a small molecule development candidate to advance into the clinic targeting ENPP1 for the treatment of patients with HPP. Significant progress has been made to identify a lead compound and generate mouse in vivo biomarker evidence to support modulation of on-target activity. Through our collaboration with a leading global HPP expert, in vivo efficacy data is expected in the second half of 2023. Following those results, both companies expect to commence IND-enabling studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2022, the Company entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera&#x2019;s antibody discovery engine with Rallybio&#x2019;s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and ultimately deliver therapies to patients. The partnership&#x2019;s first program will focus on addressing the significant unmet therapeutic needs of patients with rare metabolic diseases.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Recent Updates <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In January 2023, Rallybio announced the appointment of Jonathan I. Lieber as CFO, effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio&#x2019;s Co-Founder and former CFO. The Company announced Mr. Fryer&#x2019;s retirement in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer departed the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment banker. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since inception, we have devoted substantially all of our resources to raising capital, organizing and staffing the Company, business planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio, developing and progressing our product candidates, preparing for clinical trials and establishing arrangements with third parties for the manufacture of our product candidates and component materials, including activities relating to our preclinical development and manufacturing activities for each of our programs. We do not have any product candidates approved for sale and have not generated any revenue from product sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since our inception, we have funded our operations primarily through equity financings. From our inception and prior to our initial public offering IPO, we received proceeds of approximately $182.5 million from equity financing. In August 2021, we closed our IPO and issued and sold 7,130,000 shares of common stock, inclusive of 930,000 shares sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $13.00 per share. We received net proceeds of approximately $83.0 million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In November 2022, we completed a follow-on offering of approximately $54.8 million pursuant to which we issued 5,803,655 shares of common stock, inclusive of 803,654 shares of common stock sold pursuant to the partial exercise of the underwriters' option to purchase additional shares at a price of $6.00 per share and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares of common stock at a price of $5.9999, which represents the per share public offering price for the shares less the $0.0001 per share exercise price for each pre-funded warrant. The net proceeds from the November 2022 follow-on offering were approximately $50.8 million, after deducting underwriting discounts and commissions and other offering costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents and marketable securities of $169.0 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2025. This estimate and our expectation to advance the preclinical and clinical development of RLYB212, RLYB116, and any other product candidates are based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect, or our clinical trials may be more expensive, time consuming or difficult to design or implement than we currently anticipate. See &#x201c;&#x2014;Liquidity and Capital Resources.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have incurred significant operating losses since inception, including net losses of $66.7 million and $47.0 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $160.7 million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We have not commercialized any products and have never generated revenue from the commercialization of any product. We expect to incur significant additional operating losses in the foreseeable future as we advance our programs through preclinical and clinical development, expand our research and development activities, acquire and develop new product candidates, complete preclinical studies and clinical trials, finance our business development strategy, seek regulatory approval for the commercialization of our product candidates and commercialize our products, if approved. Our expenses will increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance our Phase 1 clinical trial for RLYB212, our product candidate for our FNAIT prevention program;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance our clinical trial for RLYB116, and file an IND or a CTA for other product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance our natural history alloimmunization study of FNAIT and other studies to support our development program and related regulatory submissions for RLYB212;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">seek regulatory approvals for RLYB212, RLYB116 and any other product candidates, as well as for any related companion diagnostic, if required;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continue our discovery and development joint venture with Exscientia;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continue our discovery and development collaboration with AbCellera;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continue to discover and develop additional product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">hire additional clinical, scientific, and commercial personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">add operational, financial, and management personnel, including personnel to support our product development and planned future commercialization efforts and to support our operations as a public company;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">acquire or in-license other product candidates or technologies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">maintain, expand, and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any product candidate for which we obtain regulatory approval; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize our programs, if approved, and for any other product candidates for which we may obtain marketing approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Our inability to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Reorganization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to the IPO and the Reorganization, the Company was a 100% owned subsidiary of Rallybio Holdings, a Delaware limited liability company which was incorporated in Delaware on March 22, 2018 and Rallybio Holdings held 100% of the outstanding membership units in five wholly-owned subsidiaries; Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, Rallybio IPD, LLC, and IPC Research, LLC. On June 30, 2021, Rallybio Holdings completed a series of transactions pursuant to which (i) Rallybio IPD, LLC, a direct subsidiary of Rallybio Holdings that was formed in Delaware in May 2020, was converted from a Delaware limited liability company to a Delaware corporation and changed its name to Rallybio Corporation, and (ii) four direct subsidiaries of Rallybio Corporation, each a Delaware limited liability company (collectively the &#34;Merger Subs&#34;), each consummated a separate merger with one of Rallybio Holdings direct subsidiaries, other than Rallybio IPD, LLC (collectively the &#34;Asset Subsidiaries&#34;), with the Asset Subsidiaries surviving the mergers and Rallybio Holdings receiving common stock of the Company in exchange for its interest in each Asset Subsidiary, which resulted in the Asset Subsidiaries becoming subsidiaries of the Company and the Company becoming the only direct subsidiary of Rallybio Holdings. On July 28, 2021, immediately prior to the completion of the IPO, Rallybio Holdings liquidated and distributed 100% of the capital stock of the Company, consisting solely of common stock, to the unitholders of Rallybio Holdings. The liquidation of Rallybio Holdings and distribution of the capital stock of Rallybio Corporation to the unitholders of Rallybio Holdings is referred to as the &#x201c;Liquidation&#x201d; and these other transactions are collectively referred to as the &#x201c;Reorganization.&#x201d; As a result of the Reorganization and subsequent Liquidation, the unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation, and the Company's consolidated financial statements are subsequently reported from Rallybio Corporation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Impact of COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We continue to monitor the potential impact of the COVID-19 pandemic on our business and financial statements. To date, we have not incurred impairment losses in the carrying values of our assets as a result of the COVID-19 pandemic and we are not aware of any specific related event or circumstance that would require us to revise our estimates reflected in our financial statements. We are following, and plan to continue to follow, recommendations from federal, state and local governments regarding workplace policies, practices and procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and prospects in the future. The extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, financial condition and liquidity, including our ability to obtain financing and planned and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, including the availability, administration rates and duration of efficacy of vaccines and their effectiveness against the current or new variants of the virus, and the duration and intensity of the related effects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br />Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development expenses consist of costs incurred in connection with our research and development activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">external research and development expenses incurred under agreements with third parties, such as CROs as well as investigative sites and consultants that conduct our clinical trials and other scientific development services;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">costs related to manufacturing material for our clinical trials, including fees paid to CMOs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">manufacturing scale-up expenses and the cost of acquiring and manufacturing clinical trial materials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">employee-related expenses, including salaries, bonuses, benefits, share-based compensation and other related costs for those employees involved in research and development efforts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">costs of outside consultants, including their fees, and related travel expenses;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">expenses to acquire technologies, such as intellectual property, to be used in research and development including in-process research and development (&#34;IPR&amp;D&#34;) that has no alternative future use at the time of asset acquisitions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">costs related to compliance with regulatory requirements; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">facilities, depreciation and other indirect costs allocated to employees and activities supporting our research and development efforts. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Costs for certain activities are recognized based on an evaluation of the progress to completion of each specific contract using information and data provided to us by our vendors and analyzing the progress of our research studies or other services performed. Significant judgments and estimates are made in determining the expenses incurred balances at the end of any reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our direct, external research and development expenses consist primarily of fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our process development, manufacturing and clinical development activities. Our direct external research and development expenses also include fees incurred under license and intellectual property purchase agreements. We track these external research and development costs on a program-by-program basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We do not allocate employee costs, costs associated with our facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources and third-party consultants primarily to conduct our research and development activities as well as for managing our process development, manufacturing and clinical development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research and development expenses in the foreseeable future as we continue the development of our product candidates and manufacturing processes and conduct discovery and research activities for our clinical programs. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#x2019;s commercial potential. We will need to raise substantial additional capital in the future. Our clinical development costs are expected to increase significantly with our ongoing clinical trials. We anticipate that our expenses will increase substantially and may fluctuate from quarter to quarter, particularly due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the scope, rate of progress and expenses of our ongoing research activities and clinical trials and other research and development activities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">successful enrollment in and completion of clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">whether our product candidates show safety and efficacy in our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continued acceptable safety profile of the products following any regulatory approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any changes in the outcome of any of these variables with respect to the development of our product candidates in clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. For example, if the FDA, the EMA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative expenses consist primarily of salaries, benefits and share-based compensation for our personnel in executive, legal, business development, finance and accounting, and other administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, tax and consulting services, insurance costs, travel expenses and direct and allocated facility costs not otherwise included in research and development expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Total Other Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total other income, net, includes interest income earned on cash, cash equivalents and marketable securities, interest expense and other income and expense items.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Loss on Investment in Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company recognizes its pro-rata share of losses in the joint venture with Exscientia on its consolidated statements of operations and comprehensive loss within the loss on investment in joint venture line item, with a corresponding change to the joint venture investment asset on the consolidated balance sheets for equity method investments for which it does not have a controlling interest in.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comparison of the years ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes our results of operations:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.11%;"></td>
    <td style="width:1.399%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.811%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.39%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.949%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.39%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.949%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CHANGE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">40,689</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26,909</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13,780</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">27,195</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,739</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,456</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">67,884</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">45,648</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,236</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(67,884</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(45,648</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(22,236</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,305</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">140</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,165</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss from continuing operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(65,579</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(45,508</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(20,071</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss on investment in joint venture</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,075</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,505</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(430</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(66,654</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(47,013</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(19,641</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes our research and development costs for each of the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.324%;"></td>
    <td style="width:1.648%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.052999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.648%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.339%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.648%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.339%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CHANGE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Direct research and development by program</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB211</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">379</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,554</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(1,175</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB212</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13,151</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,936</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,215</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB116</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,269</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,236</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,033</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB114</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,116</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,092</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RLYB331</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">967</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">967</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other program candidates</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">55</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(55</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset acquisition IPR&amp;D expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,073</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,073</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Other unallocated research and development costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Personnel expenses (including share-based compensation)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13,079</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,604</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,475</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">655</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">432</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">223</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">40,689</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26,909</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13,780</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development expenses were $40.7 million for the year ended December 31, 2022, compared to $26.9 million for the year ended December 31, 2021. The increase of $13.8 million was primarily due to:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a $3.1 million increase in asset acquisition IPR&amp;D expense related to the second quarter 2022 acquisition of the worldwide exclusive rights to Sanofi's KY1066, now referred to as RLYB331;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a $2.2 million increase in costs related to the development of RLYB212, primarily attributable to an increase in clinical development costs;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a $2.0 million increase in costs related to the development of RLYB116, primarily attributable to an increase in clinical development costs and clinical manufacturing costs;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a $1.0 million increase in costs related to the development of RLYB331, primarily attributable to an increase in preclinical research and development costs after the asset acquisition in the second quarter of 2022; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a $6.5 million increase in personnel expenses, including an increase of $2.4 million in non-cash share-based compensation expense, primarily due to an increase in research and development related headcount in 2022.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These increases were partially offset by:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a $1.2 million decrease related to the development of RLYB211 as we prioritized development of RLYB212, and subsequently made the decision to not continue the development of RLYB211.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We anticipate that our research and development expenses will continue to increase as we continue to advance our current research programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative expenses were $27.2 million for the year ended December 31, 2022, compared to $18.7 million for the year ended December 31, 2021. The increase of $8.5 million is primarily related to an increase in payroll and personnel-related costs due to an increase in general and administrative related headcount, including an increase of $3.5 million in non-cash share-based compensation expense and an increase in costs associated with operating as a public company for a full year in 2022 as compared to 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We anticipate that our general and administrative expenses related to providing administrative support to our research and development activities will continue to increase as we continue to support our growing research and development activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Total Other Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total other income, net, for the year ended December 31, 2022 was $2.3 million compared to $0.1 million for the year ended December 31, 2021. The increase in total other income of $2.2 million is primarily attributable to an increase in interest income from marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Loss On Investment In Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss on investment in joint venture for the year ended December 31, 2022 was $1.1 million compared to $1.5 million for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since our inception, we have funded our operations primarily through equity financings. From our inception and prior to our IPO, we received proceeds of approximately $182.5 million from equity financings. In August 2021, we closed our IPO and issued and sold 7,130,000 shares of common stock, inclusive of 930,000 shares sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $13.00 per share.  We received net proceeds of approximately $83.0 million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In August 2022, we filed a Registration Statement on Form S-3 (the &#x201c;Shelf&#x201d;) with the SEC in relation to the registration and potential future issuance of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $300.0 million. The Shelf was declared effective on August 15, 2022. The Company also simultaneously entered into a Sales Agreement with Cowen. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $100.0 million from time to time at prices through Cowen acting as our agent. Pursuant to the Sales Agreement, sales of our common stock, if any, will be made in sales deemed to be &#x201c;at the market offerings&#x201d; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#34;Securities Act&#34;). Under the Sales Agreement, Cowen will be entitled to compensation equal to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. As of December 31, 2022, the Company has not sold any shares of common stock pursuant to the Sales Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In November 2022, we completed a follow-on offering of approximately $54.8 million consisting of 5,803,655 shares of common stock, inclusive of 803,654 shares of common stock sold pursuant to the partial exercise of the underwriters' option to purchase additional shares at the price of $6.00 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares of common stock at a price of $5.9999, which represents the per share public offering price for the shares less the $0.0001 per share exercise price for each pre-funded warrant. The net proceeds from the November 2022 follow-on offering were approximately $50.8 million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we had $169.0 million of cash, cash equivalents and marketable securities.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Uses of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We currently have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years. See &#34;Contractual Obligations&#34;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br />Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2025. These initiatives do not impact the future clinical development plans for RLYB212 or RLYB116. This estimate and our expectation to advance the preclinical and clinical development of RLYB212, RLYB116, and any other product candidates are based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect, or our clinical trials may be more expensive, time consuming or difficult to design or implement than we currently anticipate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has implemented cash preservation initiatives including reviewing certain discretionary expenses and managing the timing of certain future preclinical development activities. However, we expect to incur significant expenses and operating losses in the foreseeable future as we advance our product candidates through clinical development, seek regulatory approval and pursue commercialization of any approved product candidates. Furthermore, we expect to incur additional costs associated with operating as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Because of the numerous risks and uncertainties, length of time and scope of activities associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the actual</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">amount of funds we will require for development, approval and any approved marketing and commercialization activities. Our future capital requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including our Phase 1 and Phase 1b clinical trials for RLYB212, the clinical trial for RLYB116 and the development of any other product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the identification, assessment, acquisition and/or development of additional research programs and additional product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other comparable foreign regulatory authorities, including any additional clinical trials required by the FDA, EMA or other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the willingness of the FDA, EMA and other comparable foreign regulatory authorities to accept our clinical trial designs, as well as data from our completed and planned preclinical studies and clinical trials, as the basis for review and approval of RLYB212, RLYB116 and any other product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost and timing of the manufacture and supply of non-clinical and clinical trial material for RLYB212, RLYB116 and our other product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the progress, timing and costs of the development by us or third parties of companion diagnostics, if required, for RLYB212 or any other product candidates, including design, manufacturing and regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of filing, prosecuting and enforcing our patent claims and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs associated with potential clinical trial liability or product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to develop and commercialize products that are considered medically and/or financially differentiated to competitive products by physicians, patients and payers;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost and timing of completion of commercial-scale manufacturing activities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of making royalty, milestone or other payments under our current or any future in-license agreements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to maintain our collaboration with Exscientia on favorable terms and establish new collaborations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the extent to which we in-license or acquire additional product candidates or technologies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the severity, duration and impact of the COVID-19 pandemic, which may adversely impact our business;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the initiation, progress and timing of our commercialization of RLYB212 and RLYB116, if approved, or any other product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the availability of third-party coverage and reimbursement for and pricing of any approved products; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A change in the outcome of any of these, or other variables with respect to the development of any of our product candidates, could significantly change the costs and timing associated with the development of that product candidate. We will need to continue to rely on additional financing to achieve our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to the variables described above, if and when any of our product candidates successfully complete development, we will incur substantial additional costs associated with regulatory filings, marketing approval,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">post-marketing requirements, maintaining our intellectual property rights and regulatory protection, in addition to other commercial costs. We cannot reasonably estimate these costs at this time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Until such time, if ever, as we generate significant revenue from product sales, we expect to finance our operations through the sale of equity, debt financings, marketing and distribution arrangements and collaborations, strategic alliances and licensing arrangements or other sources. We currently have no credit facility or committed sources of capital. If we raise additional funds through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and we may need to dedicate a substantial additional portion of any operating cash flows to the payment of principal and interest on such indebtedness. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes our cash flows for each of the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.565%;"></td>
    <td style="width:1.616%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.036999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.606%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.174999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(57,284</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(45,533</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(112,170</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(2,333</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">51,078</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">82,967</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(118,376</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35,101</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022, net cash used in operating activities was $57.3 million as compared to $45.5 million for the year ended December 31, 2021. The increase in cash used in operating activities was primarily due to an increase in both research and development and general and administrative expenses. Our research and development expenses increased as a result of IPR&amp;D expenses associated with the acquisition of worldwide exclusive rights to Sanofi&#x2019;s KY1066, now referred to as RLYB331, in addition to an increase in research in development expenses related to efforts to advance the development of our product candidates and an increase in research and development headcount related expenses, as compared to the year ended December 31, 2021. General and administrative expenses increased due to increases in our general and administrative supporting functions and the costs of operating as a public company, as compared to the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash used in investing activities was $112.2 million for the year ended December 31, 2022 as compared to $2.3 million for the year ended December 31, 2021. The increase in net cash used in investing activities was primarily related to the purchases of highly rated debt securities as compared to the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash provided by financing activities was $51.1 million for the year ended December 31, 2022, primarily representing the net proceeds from our November 2022 follow-on offering, after deducting underwriting discounts and commissions and payments of other offering costs. Net cash provided by financing activities was $83.0 million for the year ended December 31, 2021, representing the net proceeds from the IPO after deducting underwriting discounts and commissions and payments of other offering costs. </span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Contractual Obligations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes our contractual obligations as of December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.423%;"></td>
    <td style="width:1.109%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.576999999999998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.109%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.576999999999998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.12%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.588000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.12%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.588000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.12%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.668000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PAYMENTS DUE BY PERIOD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">TOTAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LESS THAN<br />1 YEAR</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1-3 YEARS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3-5 YEARS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">MORE THAN<br />5 YEARS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating lease obligations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">586</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">586</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The contractual obligation amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions and the approximate timing of the actions under the contracts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Purchase and Other Obligations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We enter contracts in the normal course of business with CROs and other third-party vendors for clinical trials and testing and manufacturing services. Aside from those included in the table above, most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments that may be due upon cancellation consist of payments for services provided or expenses incurred. These payments are not included in the table above as the amount and timing of such payments are not known.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may incur contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable under agreements we have entered into with various third-party entities pursuant to which we have acquired or in-licensed intellectual property. Due to the uncertainty of the achievement and timing of the events that require payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time and have not been included in the table above. See &#x201c;Business&#x2014;License Agreement&#x201d; and &#x201c;Business&#x2014;Asset Purchase Agreements&#x201d; included elsewhere in this Annual Report on Form 10-K for a description of these agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#34;U.S. GAAP&#34;). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 &#x201c;Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation&#x201d; to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our research and development expenses that are incurred as of each reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and with vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Share-Based Compensation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for share-based compensation in accordance with ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Compensation&#x2014;Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Generally, share-based compensation is measured at the grant date for all equity-based awards made to employees based on the fair value of the awards and is recognized over the requisite service period, which is generally the vesting period. Share-based compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition is probable. The Company has elected to recognize the actual forfeitures by reducing the share-based compensation in the same period as the forfeitures occur. The Company classifies share-based compensation in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipients&#x2019; payroll costs are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Black-Scholes option-pricing model uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our common stock options, the risk-free interest rate for a period that approximates the expected term of our common stock options, and our expected dividend yield. See Note 2 &#x201c;Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation&#x201d; of our consolidated financial statements for additional information on the assumptions utilized in the Black-Scholes option-pricing model.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Incentive Units</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certain common shares of Rallybio Corporation were issued during the Liquidation of Rallybio Holdings to previous unit holders of Rallybio Holdings in respect of profit interest incentive units. See Note 2 &#x201c;Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation&#x201d; of our consolidated financial statements for additional information on the Reorganization. Prior to our IPO, we periodically granted incentive units to employees which vest over a four-year period. These incentive units were issued in the form of profits interests providing the employee with compensation equal to the increase in the value of the unit over a participation threshold per unit, as determined at the time of grant. The holder, therefore, had the right to participate in distributions of profits only in excess of such participation threshold. The participation threshold was based on the valuation of a single common unit on or around the grant date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to our IPO, we measured equity-based compensation based on the grant date fair value of the unit-based awards and recognized equity-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period of the respective award. Unit-based compensation expense is classified in our consolidated statements of operations and comprehensive loss based on the function to which the related services are provided or in the same manner in which the grantee&#x2019;s payroll costs are classified. Forfeitures are accounted for as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As there had been no public market for our common units, prior to the IPO, the estimated fair value of our common units had been determined by the Rallybio Holdings board of managers after considering valuation reports provided by an independent third-party valuation firm. In accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, a third-party valuation firm prepared valuations of our common units using an option pricing method (&#34;OPM&#34;) which uses market approaches, and a Black-Scholes option pricing model to estimate our enterprise value or a hybrid method, combining the OPM with the probability weighted expected return method (&#x201c;PWERM&#x201d;). The OPM treats common units and preferred units as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#x2019;s securities changes to value the common units of the company. The PWERM values each class of equity based on an analysis of the range of potential future enterprise values of the company and the manner in which those values would accrue to the owners of the different classes of equity. The PWERM involves estimating the overall value of the subject company under various liquidity event scenarios and allocating the value to the various share classes based on their respective claim on the proceeds as of the date of each event. A discount for lack of marketability of the common units is then applied to arrive at an indication of value for the common units as of the valuation date. The OPM methodology was utilized for incentive unit grants during the first quarter 2021 while a hybrid method that incorporated both the OPM and the PWERM methodology was used for grants of incentive units in the second quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There are significant judgments related to volatility and time to liquidity as well as estimates inherent in these valuations. These judgments and estimates include assumptions regarding our future operating performance, the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">stage of development of our product candidates, the timing of a potential IPO or other liquidity events and the determination of the appropriate valuation methodology at each valuation date. The assumptions underlying these valuations represent management&#x2019;s best estimates, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our equity-based compensation expense could be materially different. Subsequent to the IPO, the fair value of our common stock was determined based on the quoted market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the Liquidation, holders of common and incentive units of Rallybio Holdings received shares of common stock and restricted stock of Rallybio Corporation, based upon a conversion price determined by the board of managers of Rallybio Holdings immediately prior to the Liquidation. Holders of incentive units of Rallybio Holdings that were vested as of the consummation of the Reorganization received shares of common stock of the Corporation with respect to such units. Holders of incentive units of Rallybio Holdings that were unvested as of the consummation of the Reorganization received shares of restricted stock of the Corporation with respect to such units. The shares of restricted common stock are subject to the same vesting conditions as the incentive units for which such shares were exchanged.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As an emerging growth company (an &#x201c;EGC&#x201d;) under the JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act, for EGCs include presentation of only two years of audited financial statements in a registration statement for an initial public offering, an exemption from the requirement to provide an auditor&#x2019;s report on internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. Additionally, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#x201c;opt out&#x201d; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualify as an EGC. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company&#x201d; meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue was less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue was less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an EGC, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022 and 2021, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 &#x201c;Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation&#x201d; to our consolidated financial statements for the year ended December 31, 2022 appearing elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_quantitative_qualitative_disclosu">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_controls_procedures">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_qaq"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 7A. Q</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">uantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information under this item.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_sas_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 8. Fina</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ncial Statements and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The financial information required by Item 8 is located beginning on page F-1 of this Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9. Changes in and Disagr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">eements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9A. Control</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">s and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our management, with the participation of our chief executive officer and chief financial officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including, our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Management's Annual Report on Internal Control over Financial Reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our management, under the supervision and with the participation of our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the criteria in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based on the results of its evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Internal control over financial reporting includes policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and disposition of assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with the authorization of its management and directors; and (3) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on its financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There has been no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9B. Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9C. Disclosure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Not Applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">T III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 10. Directors, Executive </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Officers and Corporate Governance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the Securities Exchange Commission with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 11. Execu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">tive Compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the Securities Exchange Commission with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br />Item 12. Security O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">wnership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 12 will be included in our Definitive Proxy Statement to be filed with the Securities Exchange Commission with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 13. Certain Relationships a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the Securities Exchange Commission with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 14. Principal Accounting Fees and Services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the Securities Exchange Commission with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 15. Exhib</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">its, Financial Statement Schedules.</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibits: </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.034%;"></td>
    <td style="width:2.002%;"></td>
    <td style="width:88.964%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.36pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex21.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Plan of Liquidation and Dissolution (incorporated by reference to Exhibit 2.1 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.1</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521233263/d211041dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of Rallybio Corporation (incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Current Report on Form 8-K (File No. 001-40693), filed with the SEC on August 2, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521233263/d211041dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amended and Restated Bylaws of Rallybio Corporation (incorporated by reference to Exhibit 3.2 to the Company&#x2019;s Current Report on Form 8-K (File No. 001-40693), filed with the SEC on August 2, 2021).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.034%;"></td>
    <td style="width:2.002%;"></td>
    <td style="width:88.964%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Specimen stock certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Registration Rights Agreement, dated July 28, 2021, among the Registrant and certain of its stockholders (incorporated by reference to Exhibit 4.1 to the Company&#x2019;s Current Report on Form 8-K (File No. 001-40693), filed with the SEC on August 2, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312522284569/d407423dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 001-40693), filed with the SEC on November 14, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.4*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rlyb-ex4_4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Description of Registrant&#x2019;s Securities.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.1+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Purchase Agreement, by and between Rallybio IPA, LLC and Prophylix AS, dated June 28, 2019 (incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), filed with the SEC on July 2, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.2+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Transfer Agreement, by and between Swedish Orphan Biovitrum AB (PUBL) and IPC Research, LLC, dated March 15, 2019 (incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), filed with the SEC on July 2, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.3+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Product License Agreement, by and between Affibody AB and Swedish Orphan Biovitrum AB (PUBL), dated March 9, 2012, and assigned to IPC Research, LLC on March 15, 2019 (incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), filed with the SEC on July 2, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.4+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amendment No. 1 to Product License Agreement, by and between Affibody AB and Swedish Orphan Biovitrum AB (PUBL), dated January 1, 2018, and assigned to IPC Research, LLC on March 15, 2019 (incorporated by reference to Exhibit 10.4 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), filed with the SEC on July 2, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.5+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amendment No. 2 to Product License Agreement, by and between Affibody AB and IPC Research, LLC, dated December 22, 2020 (incorporated by reference to Exhibit 10.5 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), filed with the SEC on July 2, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.6+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000095017022015571/rlyb-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">License Agreement, by and between Rallybio IPE, LLC and Kymab Limited, dated as of May 5, 2022 (incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Quarterly Report on Form 10-Q (File No. 001-40693), filed with the SEC on August 8, 2022).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.7+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating Agreement of RE Ventures I, LLC, by and between Rallybio IPB, LLC and Exscientia Limited, dated July 19, 2019 (incorporated by reference to Exhibit 10.6 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), filed with the SEC on July 2, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.8#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Indemnification Agreement, between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.9 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.9#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Holdings, LLC 2018 Share Plan, as amended (incorporated by reference to Exhibit 10.10 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), filed with the SEC on July 2, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.10#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Restricted Share Agreement (Capital Interests) under the Rallybio Holdings, LLC 2018 Share Plan (incorporated by reference to Exhibit 10.9 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.11#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Restricted Share Agreement (Profits Interests) under the Rallybio Holdings, LLC 2018 Share Plan (incorporated by reference to Exhibit 10.10 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.12#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Contribution and Restricted Share Agreement (incorporated by reference to Exhibit 10.11 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.13#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.14#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Non-Qualified Stock Option Award Agreement under the Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.13 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.15#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.14 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.034%;"></td>
    <td style="width:2.002%;"></td>
    <td style="width:88.964%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.16#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1015.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Incentive Stock Option Award Agreement under the Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.15 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.17#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Restricted Stock Unit Award Agreement under the Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.16 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.18#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1017.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Restricted Stock Unit Award Agreement for Non-Employee Directors under the Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.17 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.19#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Corporation 2021 Cash Incentive Plan (incorporated by reference to Exhibit 10.18 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.20#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1019.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Corporation 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.19 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.21#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1020.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amended and Restated Employment Agreement between Rallybio, LLC and Martin Mackay (incorporated by reference to Exhibit 10.20 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.22#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1021.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amended and Restated Employment Agreement between Rallybio, LLC and Stephen Uden (incorporated by reference to Exhibit 10.21 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.23#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1022.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amended and Restated Employment Agreement between Rallybio, LLC and Jeffrey M. Fryer (incorporated by reference to Exhibit 10.22 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.24#*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rlyb-ex10_24.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employment Agreement between Rallybio Corporation and Jonathan I. Lieber, dated as of February 1, 2023</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.25#*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rlyb-ex10_25.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Confidential Release and Separation Agreement between Rallybio Corporation and Jeffrey M. Fryer, dated as of February 15, 2023</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.26#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1023.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Equity Adjusted Notice (incorporated by reference to Exhibit 10.23 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-257655), as amended, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rlyb-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subsidiaries of Registrant.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rlyb-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consent of Deloitte &amp; Touche LLP, independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rlyb-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rlyb-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rlyb-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rlyb-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">*	Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">#      Indicates management contract or compensatory plan</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">+      Portions of this exhibit (indicated by asterisks) have been redacted because they are both not material and the registrant customarily and actually treats such information as private or confidential.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 16. F</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">orm 10-K Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.387%;"></td>
    <td style="width:2.698%;"></td>
    <td style="width:5.536%;"></td>
    <td style="width:46.379%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RALLYBIO CORPORATION</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date: March 6, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Martin W. Mackay</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Martin W. Mackay, Ph.D</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Chief Executive Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:48.323%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:21.677%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TITLE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DATE</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Martin W. Mackay</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;Chief Executive Officer and Director (Principal Executive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Martin W. Mackay, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Jonathan I. Lieber</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Chief Financial Officer and Treasurer (Principal</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;March 6, 2023</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Jonathan I. Lieber</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Accounting and Financial Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Helen M. Boudreau</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Helen M. Boudreau</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Wendy K. Chung</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Wendy K Chung, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Rob Hopfner</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rob Hopfner, R.Ph., Ph.D., MBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Ronald M. Hunt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Ronald M. Hunt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Lucian Iancovici</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lucian Iancovici, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Hui Liu</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;March 6, 2023</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Hui Liu, Ph.D</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Christine A. Nash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Christine A. Nash, MBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Kush M. Parmar</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;March 6, 2023</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Kush M. Parmar, M.D., Ph.D</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">/s/ Paula Soteropoulos</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Paula Soteropoulos</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.738%;"></td>
    <td style="width:7.262%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;(PCAOB ID No. </span><span style="font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_623447f0-9c2b-4d5c-a7b1-adaa9fc75e3c" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">34</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_statements_change"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated Statements of Changes in Stockholders' Equit</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">y</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:12.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#cash_flow"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_condensed_consolidated_financia"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent_registered"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the stockholders and the Board of Directors of Rallybio Corporation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Rallybio Corporation and subsidiaries (the &#34;Company&#34;) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#x2019; equity, and cash flows, for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#34;financial statements&#34;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_dd25e305-b6e4-4b3f-a6a2-6c5884d8b9e6" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_76007439-a328-443b-8360-2493ceb8d0fb" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Hartford, Connecticut  </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 6, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have served as the Company's auditor since 2018.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RALLYBIO CORPORATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ed Balance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.615%;"></td>
    <td style="width:1.752%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.447%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.74%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.447%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br />2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br />2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d1f6fafb-bb4c-40d5-b9d7-bac7be71a5d5" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4ccb2c4b-5617-4d2e-b093-26805e9524ea" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_debc5f8c-8bf5-400e-bb88-707009082b8a" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b8533377-a725-44d9-b65d-27d3cafaa86d" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_50168457-1880-4b7f-90fe-80568625a937" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,502</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3185d271-13cb-4f59-9232-d4e91ae3508d" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0faeed35-df74-491c-b259-2800712fc34c" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179,496</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d334b39d-7032-4009-bd1f-7a7adfd608bf" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180,869</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b835f877-0598-4c6d-bf53-7970e935bec1" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">385</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f0edc15a-5b00-4860-9966-432214500398" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a0d894e0-bf5b-418e-9f54-8583790a20ea" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">524</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_41298e9a-7b05-4a84-8daa-6438c07f8e73" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Investment in joint venture</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c16bda1a-d736-4d34-94b4-2569812da560" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ff877fcc-ce2a-45c4-bc0d-4d7bf70927b4" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">805</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fbd57c65-4240-4ff7-a324-894e5fbfd242" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_10126d67-31ae-4067-81a1-e1028ef70fce" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">182,185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3a0f3875-aecd-4aa1-95ce-cc8097913332" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,114</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4b0bcc2a-8ccc-409b-9a86-28358d734d0b" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">603</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e63e5fed-ea1e-41c6-8ca2-7a503fe44427" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,449</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9317c292-808f-4479-929b-b25a4bb5e101" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,948</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3d969406-1a71-4752-a9c7-9c3605686c8b" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f1128fbc-2adf-476b-a57f-2f149550ec88" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_26117cdd-9a3f-4043-afd3-82d8e5d7e5c9" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,744</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6625a7ec-db4a-4ca6-9434-e457b9f9105a" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,551</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_63e7fcee-3fa7-4036-9dbe-705b294fe926" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_de743be1-53fb-4634-9f6f-88c86c4ae5ba" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities, noncurrent</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c334a01a-8595-4e32-b4a5-cf4126a761d9" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4d0fbe14-ae6d-4510-97b7-c1ca028bde29" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_75b75d33-3033-4a6a-8deb-dbb3a0a10c01" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_76153cda-5415-48a9-a10b-89325fbaaf7a" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,583</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_c061875b-de88-45aa-8ea1-324496d0e556;"><span style="-sec-ix-hidden:F_a8b218a9-357a-4bed-96d6-b4ed1c8b213d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Commitments and contingencies (Note 10)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_232c6faa-b4f9-4999-ac99-6b581e043acc" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_7b72da09-8620-4915-88ab-37996b56d904" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;par value per share; </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2b4a86bc-e673-4f81-9ef6-35cdeae8b456" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f99945b7-7e4f-40ef-a513-75210f7b57d1" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;shares <br />&#160;&#160;&#160;authorized as of December 31, 2022 and 2021, respectively; <br />&#160;&#160;&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_169959d9-1b34-4c29-ad54-caf57cbef8ad" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_9e1c8508-f82e-4e66-918b-504bd38c0418" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,837,369</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_77d69187-bfc2-4931-87a0-cf286f95f04f" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_3a9e68d8-3cc1-4da6-9e57-8c78ac041166" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,129,970</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;shares issued and outstanding <br />&#160;&#160;&#160;as of December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_21f5a16d-f72c-4468-967b-03d00606a9fe" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5375908b-0cfe-478e-8746-b6a5e06333c1" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d4edb4dd-4da5-41a2-97ef-2ce6e2fcb3dc" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_e3001728-8b55-43cb-9166-e18401fcba25" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;par value per share; </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_91b18dd3-2cba-491a-b5d4-19271e0ae889" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ffcfc074-95d5-4504-82bc-7425a94ea773" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;shares <br />&#160;&#160;&#160;authorized as of December 31, 2022 and 2021, respectively; <br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a5a1aca6-684a-40b8-a5a1-45a2996a561e" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_789fd225-4e5f-41d0-943d-b2b5bda0e81a" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d6a6f1c8-cdbb-400c-b5c9-f9980c1f3588" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1a2e68dd-8899-450a-94d0-810463e19655" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;shares issued or outstanding as of December 31, 2022 and <br />&#160;&#160;&#160;2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ce8451b8-e363-491e-a63c-fde6ce8ff831" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_37a5c09e-ae9b-4f32-8d61-e46015e1b6bf" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8a0875e-c3ec-41cc-8505-a82a0b43b3ee" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">330,208</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_330b9f74-6a33-474c-9a39-2c92e32eb66c" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">269,626</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ed3f5a2d-6ff6-403c-83be-9c168bca7dd7" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c31b3882-1b88-4930-b09f-2dd727aebc70" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_38f444a4-0e0e-481c-a9df-78e76c9bf839" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">160,681</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ce4a49d4-7aa6-4e19-8f47-3c7af17d6c40" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">94,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e410dd53-6f3d-428f-8dc3-78b02ddb85ab" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6e29f6ac-c5de-49e5-8d90-3193a4d4eecf" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,602</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3c27778c-aa8a-41dd-a70a-bb89ffcddaff" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dc9a5c45-5f9b-4a12-829a-3447f5dcbdb0" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">182,185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">See accompanying notes of the consolidated financial statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RALLYBIO CORPORATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_statements_operat"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Operations and Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.311%;"></td>
    <td style="width:1.729%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:21.194%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.433%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:21.332%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_193cf31c-db93-498a-82e8-b5ace982fba6" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,689</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_af125654-3a90-40b2-a92c-96b13290c97b" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b989eaab-8763-40da-b439-d18134bbee95" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,195</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f6a81bda-438c-45b3-bcac-2f3bcefc1761" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,739</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a9ebf353-8f9d-4e90-a0a1-e6fbe89e5b20" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,884</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c7ca376d-a0f5-4c78-a694-638a39547aed" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,648</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_96aa7b4f-118a-4576-aa78-fe82234a46aa" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">67,884</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c0d7d315-3da4-4382-8c2d-2fa6b52318aa" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,648</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other income (expenses):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_66635418-2ccc-46f5-99ab-8768544cef71" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,963</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6061a1e6-fe82-42da-90d5-e2e7c3c7b70e" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_721aa855-0509-4ef9-a8e0-c3ac92874c66" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2551e0c4-f93e-4af4-a8ce-42bff4d113ba" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_018d693d-743b-46c1-8257-33aeba9cdafc" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">342</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6a0f0b12-bb2c-4651-b3c0-94bb76f97b2a" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d00462c2-3b55-4e3a-8172-19b734e2da07" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,305</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4caf4f16-e53b-4d08-b848-789c9b76537a" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss from continuing operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_56f230e6-e803-4c28-84bd-88734e58561a" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">65,579</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ae5cacd9-fe9e-4bf5-90a4-3d1dc2c1259e" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss on investment in joint venture</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aacfb863-544d-4fbf-bc5c-c375135e907b" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_17c69429-25f4-4d3f-bcdf-37f9a7a4648b" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,505</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a423bed1-deb2-4c8d-bcbd-69dde24a5c51" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,654</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_071c0bbb-0be5-430b-babb-01ea4c09aa57" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,013</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7c6452e5-5e34-4874-b060-328f8352f685" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_32aa08c9-9507-47f0-9a24-44bd150a810b" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.09</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_778d6191-a33b-4294-8205-06d999022c6f" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_1f843658-0ca8-43f5-b2f9-ccc1560e96a1" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.84</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_55fd906f-29b2-4e85-bb04-1a4572c7bc95" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_d7bb24b0-936a-4f07-b705-26ca2fdef305" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,821,311</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_752f137b-a011-4fd3-91b4-9a54b3041d74" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_309f88e7-f2f3-4910-af9d-fd67bae5415a" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,519,114</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_58688980-6fed-4089-9f89-bbfc52abf1b5" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_49085c58-b586-457b-aca9-ba27ac7ed19b" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3b8bd350-fcd5-468c-840f-2d48cfb49a3c" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_68174710-227b-45e2-bafc-63408141c065" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ca333fe0-5c1f-4530-b786-ffe4b7dca5f0" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,868</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f9dea46b-78f3-4578-88d7-6f36b3d88f3b" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,013</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">See accompanying notes of the consolidated financial statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RALLYBIO CORPORATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_statements_change"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated Statements of Changes in S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">tockholders' Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.172%;"></td>
    <td style="width:0.989%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.448%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.989%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.715%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.661999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.661999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.315%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.049999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">COMMON</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ADDITIONAL <br />PAID-IN</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ACCUMULATED</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ACCUMULATED OTHER COMPREHENSIVE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">STOCKHOLDERS'</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands, except share amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SHARES</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AMOUNT</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CAPITAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DEFICIT</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LOSS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">EQUITY</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e6c54a0e-b53f-4958-b1da-35b3a78235e1" contextRef="C_18a5ceed-0060-4aa3-9c6c-c98a4ad6ca26" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">23,410,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e1d3a9b2-8852-43e9-b3f6-4ee6faf71057" contextRef="C_18a5ceed-0060-4aa3-9c6c-c98a4ad6ca26" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9e812cd8-f2c1-4ac0-8685-3d17ff80ede3" contextRef="C_13887808-dda9-4f62-b93c-5568ce0ac531" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183,015</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_53b76de2-ad8e-483c-a4ad-d19c4aed1fa4" contextRef="C_cbbe5259-ca6b-485d-bfa6-99647ffab256" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_159809a8-8e69-4878-8080-9d2423fa6902" contextRef="C_7ec8e39c-7a88-422a-a74f-d98b410d67ed" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">136,003</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions and offering costs of $</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_284f9ab9-2064-4f71-aef5-902662cd696c" contextRef="C_6e128323-fbea-4fe5-84d7-e5c466f1a588" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,721</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ada15448-b502-4062-b63e-15aca79ae5d2" contextRef="C_a9e6864c-0599-4c62-be7b-906252ee6393" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,130,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_349c3b90-cc53-48c3-ba99-863034253c3b" contextRef="C_a9e6864c-0599-4c62-be7b-906252ee6393" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_45a2104c-12e5-4428-8b65-9464c891f0e4" contextRef="C_ae469bc2-9800-4dc5-bcf4-0fdac12554b2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,966</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3ef24a1c-649b-4880-8158-0a0eabcaaee8" contextRef="C_6e128323-fbea-4fe5-84d7-e5c466f1a588" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_367e228c-90b3-4c89-b82f-e05ca46cf49c" contextRef="C_7770416e-82d7-4b9d-9294-67c572a1763b" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,589,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c8442630-cabb-4f89-b13c-f033cdb55ae7" contextRef="C_6b6ed73d-3d7a-4d4e-ad0c-6cf1487dd354" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_08af3b31-acd4-4cb1-ad50-c28aa63e37dd" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_51958e02-d2f8-4160-a7ff-a38e41ec7b18" contextRef="C_46cd10da-534a-45a6-8e92-23bccca412b7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,013</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3e095d91-43ee-4452-89b1-45221f6c34bb" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,013</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance, December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9637d7b1-243f-4b68-aaf9-f1b5bdee5b09" contextRef="C_83726cf3-dbf7-458d-b892-83b3f6200320" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,129,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c7a18699-bed7-4345-a123-c9e7de42b62f" contextRef="C_83726cf3-dbf7-458d-b892-83b3f6200320" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c2adcda2-f137-40b7-868f-a39c4e9d8950" contextRef="C_46b5d7b6-c58d-45f0-9c8d-0874f28c30ef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">269,626</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_429dac8f-5b23-4782-b316-722e097cb708" contextRef="C_59253fec-c553-4ded-aad6-b2d0ecef61ec" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">94,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_597a428a-987c-44d2-b667-39191e82798f" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,602</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock and pre-funded warrants upon completion of the follow-on offering, net of underwriting discounts and commissions and offering costs of $</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ace88c0c-cf8e-4ba0-a277-39dc15bba420" contextRef="C_e81591b1-65b4-4ea6-b99c-cc189388ddfa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,976</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_992a46a5-3089-4488-95bf-9aa5656a2a71" contextRef="C_f58e8139-a6dd-456f-af79-4387faed9da6" name="rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,803,655</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_07e2c769-881d-4ed6-9513-a3f685cab24c" contextRef="C_f58e8139-a6dd-456f-af79-4387faed9da6" name="rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b55e08ee-025c-4c33-b564-2c148137a25d" contextRef="C_ae3fd3df-ccaf-4d78-a4b5-c90ef740f58a" name="rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,845</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4e943cdb-c07d-477c-9fdf-cd2b7b942b32" contextRef="C_e81591b1-65b4-4ea6-b99c-cc189388ddfa" name="rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock from the stock purchase plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d6a4dd79-ddb7-4bf3-ad5c-919149a696f6" contextRef="C_a09cca07-b477-48a1-96b3-6e73343c9cfc" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,845</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_87fce7fa-d2ac-400d-8e87-3ab7728a8956" contextRef="C_7c0b1833-e4eb-4b6b-a37a-11f4af7b61ab" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bf514d28-974a-4cd4-8742-3c448dee5fa5" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock from the stock award plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ae659d3f-fb1e-4199-a8f4-f270f8f65eb9" contextRef="C_a09cca07-b477-48a1-96b3-6e73343c9cfc" name="rlyb:StockIssuedDuringPeriodSharesVested" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9f7cd3cd-3067-4c43-a160-d92dc546d201" contextRef="C_a09cca07-b477-48a1-96b3-6e73343c9cfc" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aafe9bdf-af7e-40da-b936-d80ceb7bad4d" contextRef="C_7c0b1833-e4eb-4b6b-a37a-11f4af7b61ab" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b544bb1c-b033-468b-a112-27cc2fa0e27c" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeiture of restricted common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_19ea3342-6810-4495-bf3b-2bf5a0b9462f" contextRef="C_a09cca07-b477-48a1-96b3-6e73343c9cfc" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">139,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aed77a97-4a5d-4c15-a32e-1b01f840c820" contextRef="C_7c0b1833-e4eb-4b6b-a37a-11f4af7b61ab" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,499</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8306edf3-133e-4692-9012-04d0e7d466b2" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,499</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f4b4e499-dfee-4ec1-8b43-5f9bd5c9b472" contextRef="C_420228b8-f02f-4ea0-8120-8161b9596926" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,654</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5729bced-f2c1-4bc2-a460-4f68efa97172" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,654</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6f7e8b86-f349-4701-a2db-3ef742104265" contextRef="C_f0a66521-307e-45f2-b9e4-4aaa00c5d3cd" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d27aa9f2-0d5f-4a86-aba3-ec31780a3475" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3f0e17e4-57ea-4b03-8ac8-09960cbd7130" contextRef="C_548746fb-814e-4818-9836-b487dff1ca83" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,837,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4dde25bd-0016-45f3-82d7-281383f0dabc" contextRef="C_548746fb-814e-4818-9836-b487dff1ca83" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ab67f8fc-398b-492a-a966-bc8d9a6d8a37" contextRef="C_8de022cc-ebdd-40ce-9a3d-5efc20768011" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">330,208</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bd41e661-dc8c-4df2-a211-406214f992de" contextRef="C_38646d43-f81a-4024-b133-4680c40d4fef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">160,681</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0a5fa738-a102-43b2-827c-04e0addf3756" contextRef="C_f34bb779-7894-494b-b952-272e8729ec8a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5dc8a32d-e770-41fc-a324-b30d51f0260a" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">See accompanying notes of the consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RALLYBIO CORPORATION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="cash_flow"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">S</span><span id="condensed_consolidated_statements_cash_f"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">tatements of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.844%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.873%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.045%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED <br />&#160;&#160;&#160;DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash Flows used in Operating Activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_becb830e-3670-4ec0-a064-7ee02175e0af" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,654</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2c3dfc40-bff2-4508-9d04-5a0867f2246c" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,013</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_339d6ed5-3dfa-48f3-aab3-7ef339924e65" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bd1879c5-e65a-4210-955c-d1a8adfa47ba" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net accretion of discounts/premiums on debt securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3e032a83-414d-467b-b221-6c69c0df7f5e" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5dc679e9-0bdd-4d94-8af9-b972f2309b63" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a5b8105d-0a92-4e6d-b882-ad5310b1f807" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,499</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_26a092fa-67dd-4676-9da0-7c1648be10ae" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss on investment in joint venture</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1fc86c7a-35eb-4ed5-8489-6c2cf32165e9" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5ae21fe1-5dff-4346-b659-4a8d31dceb7b" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,505</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prepaid expenses, right-of-use assets and other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_98f5ae5a-895f-482d-9979-1c117e6bb901" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0fdcabb1-0a3d-4315-9966-a64314c6c466" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_494a691b-ad15-42db-92f8-06bf6e69f3c1" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_56f0a6bb-c23b-4bdf-acf6-aaa23ae6228e" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">976</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses and operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_328017a4-1043-44cd-8c05-0c57b595de69" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,222</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_81259ea6-9009-4f5d-9f81-7504a22a9e58" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bfa83ca2-fc75-4aa2-87b1-f624b796de0e" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,284</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9ff9772e-dcdd-4c73-9df0-d337a0fe1aff" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash Flows used in Investing Activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3fe4e0a4-41a3-46d1-b570-e52ee4341005" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_49931a66-8b97-47d1-a853-63183b5a5885" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eed6f1ec-cc38-468d-a01c-f9bc4a89b0a7" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_151e7f55-94b6-4af4-a3a1-ceb5f6bbe056" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9b3e1717-70bb-49b3-b967-68b05a72085a" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a5af9333-7791-484f-b708-a97be71e8383" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">333</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Investment in joint venture</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a2178a4e-2c7c-47f4-9b10-2597ce4f5593" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:PaymentsToAcquireInterestInJointVenture" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dd9b68fe-6b6e-4f0b-b9f0-1684b38f7718" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:PaymentsToAcquireInterestInJointVenture" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b5bf4e74-bee1-4936-b285-322034bae269" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">112,170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_37c2b7a4-7598-4ded-866e-1289c4ad8472" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,333</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash Flows from Financing Activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from the issuance of common stock and pre-funded warrants upon the completion of the follow-on offering, net of underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fe7fd682-183a-498d-96fa-7a9cf4caa008" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:FollowOnOfferingDiscountsAndCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,289</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_67a2e726-870c-4267-b9e4-d4bea4a381cd" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2473fc2d-eb50-4529-96c6-b057cebd6a57" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="rlyb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from the issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6587058c-8df5-4a02-8f67-3a95b5d51eb1" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="rlyb:UnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,488</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_38c4848a-67c2-4774-8683-795dc88c1d3f" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2093b93e-06e7-4447-bcfe-5e8eb16c5a61" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from the issuance of common stock from the stock purchase plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c4d4034e-63a8-4c83-9824-457eaab4fc6b" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ab4787f0-b166-4531-a57c-b18136c2c4f4" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from the issuance of common stock from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5fc0b3e1-784c-479c-9adf-9fde3fb95cbb" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_87972ec6-c6c5-4bd1-9386-6cbb7cbb3cf9" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Payments of offering costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_86a310f2-ed93-4e3f-85b9-962e9b707a4d" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9f6eb2cd-f592-4a0d-a516-f6bcbfa13be4" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,233</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c5903c59-9da3-4a41-9023-9f76cd6aec0a" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,078</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ec143e9a-351f-4c1d-8338-87ab10773353" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_45a88792-315d-4e22-8239-a38fff8f0349" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">118,376</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b7072223-0cd5-4748-bd81-9f78f1b83768" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,101</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents&#x2014;beginning of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f173d3a6-6c4c-45ad-b155-6581ed446a87" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5041cb17-d380-402f-9938-7d5c3a2aaa79" contextRef="C_7ec8e39c-7a88-422a-a74f-d98b410d67ed" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">140,233</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents&#x2014;end of year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3176d56a-b68e-4eb8-8043-a487260bc81b" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d5323f93-f4aa-4e35-b17d-d9c034eafd04" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Supplemental Disclosures of Noncash Investing and Financing Activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Offering costs in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c0ffb44b-1814-4157-878d-aafc3f67d210" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:OfferingCostsInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">139</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7f0365ce-b04c-4927-bbb2-33e73cd07350" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="rlyb:OfferingCostsInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6dbba0e8-bad6-4648-b276-a692c79ddc35" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3c7492f6-bef5-484c-9ce8-934ae1ac9878" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">See accompanying notes of the consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RALLYBIO CORPORATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_condensed_consolidated_financia"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notes to Consolid</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4215e2da-a694-4c27-bc55-b715e388df29" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1. BUSINESS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Corporation and subsidiaries (the &#34;Company&#34;, &#34;we&#34;, &#34;our&#34;, or &#34;us&#34;) is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since our launch in January 2018, we have built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of maternal fetal blood disorders, complement dysregulation, hematology, and metabolic disorders. We have assembled a team of experienced biopharma industry leaders with extensive research, development, and rare disease expertise to deliver on our mission of becoming a leader in the development of therapies for patients with rare diseases. We are drawing on our decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible &#x2013; and change the odds for rare disease patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In August 2021, the Company completed its initial public offering (&#34;IPO&#34;), pursuant to which it issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d582d7a5-d03a-4fb5-8682-0ba6802a5140" contextRef="C_896be549-e10a-4adb-b5c3-195576990921" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,130,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock, inclusive of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c282481d-c666-4bfd-93a6-8dffb5fa658e" contextRef="C_ed90055c-50cc-4284-9412-3619d9ee515a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">930,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_530dcd12-bd18-4bb7-bbaf-d0364a18631f" contextRef="C_291895eb-b1c2-4869-bbc2-c46ab5500661" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share. The gross proceeds from the IPO, including the exercise of the underwriter's option to purchase additional shares were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_59057fbb-89fb-48a7-8bd8-28ea92fbcd06" contextRef="C_896be549-e10a-4adb-b5c3-195576990921" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">92.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and the net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d5a755e3-0cea-47df-b15e-d95d5dd8f8e4" contextRef="C_896be549-e10a-4adb-b5c3-195576990921" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">83.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In November 2022, the Company completed a follow-on offering of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3fb31b3b-05b2-4aef-bd12-6b6300b54df3" contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">54.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million consisting of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cf42ca05-053a-4c73-b633-58576c191248" contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,803,655</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock, inclusive of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4d3483d6-bf88-432d-9634-a3d061f6bd1d" contextRef="C_96275cfa-74c5-412d-adca-3d72d0a97037" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">803,654</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock sold pursuant to the partial exercise of the underwriters' option to purchase additional shares at the price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2e3815a1-b189-4a81-a1cc-846ff751d411" contextRef="C_115c7363-4207-4550-8e08-adb9ff8a9635" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f69f03cc-ff7c-449b-a548-1d8151216fa5" contextRef="C_115c7363-4207-4550-8e08-adb9ff8a9635" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,333,388</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_684e794f-53bc-426b-9111-e32167a2652d" contextRef="C_cb2bd404-8085-4064-9e41-d047d221dbff" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">5.9999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which represents the per share public offering price for the shares less the $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_677125e8-ea48-43f1-bf44-6423851a7780" contextRef="C_cb2bd404-8085-4064-9e41-d047d221dbff" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share exercise price for each pre-funded warrant</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. The net proceeds from the November 2022 follow-on offering were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c9f0ecd8-2f0d-43d2-b84c-9c69be4f5aa7" contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Prior to the IPO and Reorganization, the Company was a 100% owned subsidiary of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Holdings, LLC (&#34;Rallybio Holdings&#34;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">, a Delaware limited liability company which</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was incorporated in Delaware on March 22, 2018 and Rallybio Holdings held 100% of the outstanding membership units in five wholly-owned subsidiaries; Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, Rallybio IPD, LLC, and IPC Research, LLC. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">On June 30, 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Holdings</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> completed a series of transactions pursuant to which (i) Rallybio IPD, LLC, a direct subsidiary of Rallybio Holdings that was formed in Delaware in May 2020, was converted from a Delaware limited liability company to a Delaware corporation and changed its name to Rallybio Corporation, and (ii) four direct subsidiaries of Rallybio Corporation, each a Delaware limited liability company (collectively the &#34;Merger Subs&#34;), each consummated a separate merger with one of Rallybio Holdings direct subsidiaries, other than Rallybio IPD, LLC (collectively the &#34;Asset Subsidiaries&#34;), with the Asset Subsidiaries surviving the mergers and Rallybio Holdings receiving common stock of the Company in exchange for its interest in each Asset Subsidiary, which resulted in the Asset Subsidiaries becoming subsidiaries of the Company and the Company becoming the only direct subsidiary of Rallybio Holdings. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On July 28, 2021, immediately prior</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> to the completion of the IPO, Rallybio Holdings liquidated and distributed 100% of the capital stock of the Company, consisting solely of common stock, to the unitholders of Rallybio Holdings. The liquidation of Rallybio Holdings and distribution of the capital stock of Rallybio Corporation to the unitholders of Rallybio Holdings is referred to as the &#x201c;Liquidation&#x201d; and these other transactions are collectively referred to as the &#x201c;Reorganization.&#x201d; As a result of the Reorganization and subsequent Liquidation, the unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation, and the Company's consolidated financial statements are subsequently reported from Rallybio Corporation. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Note 2, &#34;Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation&#34; for the basis of presentation of these financial statements after the Reorganization and Liquidation discussed herein.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_7af4ea22-3a42-4680-b63d-54d62bfacf30" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span><ix:nonNumeric id="F_f5f4fccd-8174-4c81-91af-79301aeac1ef" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:IpoAndReorganizationPolicyPolicyTextBlock" escape="true" continuedAt="F_f5f4fccd-8174-4c81-91af-79301aeac1ef_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">IPO and Reorganization </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014; As discussed in Note 1, &#34;Business,&#34; in connection with the Reorganization, all of Rallybio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Holdings' direct subsidiaries, other than Rallybio Corporation, became direct subsidiaries of the Company prior to the Liquidation of Rallybio Holdings. Prior to the completion of the Company's IPO, Rallybio Holdings liquidated and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation. Subsequent to the Reorganization and the Liquidation of Rallybio Holdings </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">the consolidated financial statements are reported from Rallybio Corporation. </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_f5f4fccd-8174-4c81-91af-79301aeac1ef_1" continuedAt="F_f5f4fccd-8174-4c81-91af-79301aeac1ef_2"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The capital structure of Rallybio Holdings prior to the Liquidation consisted of four classes of membership units: common units; Series A-1 preferred units; Series A-2 preferred units; Series B preferred units; and incentive common units (&#34;incentive units&#34;). The number of shares of common stock that the holders of each class of units received in the Liquidation was based on the value of Rallybio Holdings prior to the Liquidation, determined by reference to the initial public offering price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_de5d3a98-fd94-4837-9bcf-fd3d22894af8" contextRef="C_291895eb-b1c2-4869-bbc2-c46ab5500661" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. The common stock of the Company was allocated to the holders of existing units in Rallybio Holdings as follows:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a644caea-f81c-4939-b4c9-4893d377a96b" contextRef="C_6215fc9c-66e2-43ef-b652-b9895d59b307" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">33,478,255</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Series A-1 preferred units and Series A-2 preferred units of Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6583ad2c-69d5-4cc9-be2f-5bd8bc727d41" contextRef="C_d08dcb07-924b-4a3a-9c4a-4828ff956a08" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,257,590</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company; </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ca7fd9b6-c9b1-4be5-8207-35e5b68751fe" contextRef="C_05f50029-fc68-47b8-9fa9-e99bbdb4f94a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">104,442,965</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Series B preferred units of Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a4ca5c59-1787-47ec-8f99-9245d3aba253" contextRef="C_2f72d314-6340-48e4-a0cb-90c92493675d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,402,235</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f29bf6ad-4ee9-42ad-a56d-96008e11235a" contextRef="C_a256dcbc-4261-4079-a35a-af552e6fd37e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> common units and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2156c277-21c0-4b47-a9c8-8d617d19fd93" contextRef="C_34ce8dda-3f7a-4174-a6cc-40dc210ea8ca" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> of performance based incentive common units of Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0bd7d0e9-6922-4026-811b-19754c9470ba" contextRef="C_049edda4-c91f-4ae4-ac5b-361c6c909078" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">706,701</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f07004fe-9540-4ec1-b138-1b796557958c" contextRef="C_5134fef2-9d7d-4ee4-a874-8036c0bffab9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">188,454</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, respectively, in shares of common stock of the Company. Shares of common stock issued in respect of unvested common units and performance based incentive common units as of the Liquidation are shares of restricted common stock and subject to vesting in accordance with the vesting schedule applicable to such units; and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b4663b2c-8ae2-42ce-942f-2aa5c32f0af2" contextRef="C_3145b273-e2d9-4683-a591-82fa75386376" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,869,704</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> incentive units in Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fb88986f-d181-46ac-b75e-46b853519b3c" contextRef="C_fa0c8ed8-7c96-41b2-acbc-bd397cca2e41" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,444,990</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company. Shares of common stock issued in respect of unvested incentive units as of the Liquidation are shares of restricted common stock and continue to be subject to vesting in accordance with the vesting schedule applicable to such incentive units. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a result of the Liquidation, the holders of units in Rallybio Holdings collectively were issued an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b09de4c4-a801-4249-b7a0-0ae079a0917d" contextRef="C_77017543-72b8-463e-b4d8-4744e243dddf" name="rlyb:LiquidationCommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">24,999,970</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company prior to the completion of the IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Reorganization and subsequent Liquidation resulted in a change in reporting entity as described in ASC 250. In accordance with the guidance applicable to these circumstances, the equity structure has been adjusted in all comparative periods up to the Liquidation to reflect the number of shares of the Company&#x2019;s common stock, issued to Rallybio Holdings unitholders in connection with the Liquidation. As such, historical Rallybio Holdings convertible redeemable preferred units, common units, and incentive units have been retroactively adjusted in these financial statements to shares and earnings per share in accordance with the ratio of common shares received by each membership unit class. Rallybio Holdings' convertible redeemable preferred units previously classified as mezzanine equity, including the Series B Preferred Unit Agreement executed during the year 2020 with a total aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f7a29c4e-cc38-4fea-98fa-50610ed8a51f" contextRef="C_72dc7c73-c37f-40b1-ac29-eb5aba9c919a" name="rlyb:AggregatePurchasePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">145.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, have been retroactively adjusted in these financial statements, converted into common stock, and reclassified to permanent as a result of the retrospective application of the Liquidation and change in reporting entity.</span></p></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_f5f4fccd-8174-4c81-91af-79301aeac1ef_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span></ix:continuation></span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_6a8e6505-bd16-437c-b687-1a6e042b64ff" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basis of Presentation&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;), and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#34;SEC&#34;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_87c8a05b-a2e9-4107-be1b-593ba24134f3" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Principles of Consolidation&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_ea374159-1cb7-4ec0-81af-deb0f8c44bd0" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:UseOfEstimates" escape="true"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Use of Estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the fair value of its common un</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">its and incentive units awarded to employees prior to the Company's IPO, for purposes of recording stock-based incentive compensation, the fair value of stock options, as well as contracted research and development expenses incurred.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_8fd7e9ad-6eeb-418a-b500-32b267d00a27" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liquidity and Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued. Since its inception, the Company has incurred net losses and negative cash flows from operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company incurred a net loss of $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_efd94498-e2bc-4753-a29e-9049ee6aac65" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">66.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0cba8663-0b5d-40cb-bb0c-387491307ace" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">47.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million, respectively. In addition, as of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fb0b8660-5d2b-430a-af80-eb3f0ac1e957" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">160.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million. The Company expects to continue to generate operating losses and negative cash flows in the foreseeable future.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">The Company currently expects that cash, cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e577d2c7-5c53-451f-8434-5d8980faba14" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">169.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million at December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the consolidated financial statements are issued. However, w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">e do not anticipate that the current cash, cash equivalents and marketable securities as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> will be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates, if approved. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e77238fc-48ae-453c-aa64-f7c0dfc9f84c" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:CollaborativeArrangementAccountingPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">The Company considers the nature and contractual terms of an arrangement to assess whether an arrangement involves a joint operating activity that expose two or more parties to significant risks and rewards dependent on the commercial success of the activity. If the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts for such arrangement as a collaborative arrangement under ASC 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">(&#34;ASC 808&#34;). ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition matters subjected to other authoritative guidance, in certain cases by analogy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">For arrangements determined to be within the scope of ASC 808 for certain research and development activities where a collaborative partner is not a customer following the guidance of ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Recognition </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">(&#34;ASC 606&#34;), the Company accounts for payments due to a collaboration partner as research and development expense and for payments owed to us from our collaboration partner for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. The Company classifies payments owed or receivables recorded as other current liabilities and other current assets, respectively, in the Company&#x2019;s consolidated balance sheets. See Note 3, &#x201c;License and Collaboration Agreements&#x201d; for additional details.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_40126778-ab72-4e4f-8fc3-7f5633a041eb" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:AssetAcquisitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Acquisitions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this screen criteria is met, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire in-process research and development (&#34;IPR&amp;D&#34;) with no alternative future use is charged to research and development expense at the acquisition date. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Note 3, &#x201c;License and Collaboration Agreements&#x201d; for additional details.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_be167d73-99d9-41bd-8870-22d7e996625f" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ConsolidationVariableInterestEntityPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Variable Interest Entity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company evaluates its ownership, contractual, and other interests in entities to determine if it has any variable interest in a variable interest entity (&#x201c;VIE&#x201d;). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. If the Company determines that an entity in which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company&#x2019;s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The Company evaluated its investment in RE Ventures I, LLC, a limited liability company (&#x201c;REV-I&#x201d;), defined in Note 9, and concluded that it represented a VIE and was not deemed the primary beneficiary. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Note 9, &#x201c;Investment in Joint Venture&#x201d; for additional details.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_3b3be1f1-ffe1-48c6-9072-f46f9074dad8" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EquityMethodInvestmentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity Method Investments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Investments &#x2013; Equity Method and Joint Ventures </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(&#34;ASC </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">323&#34;). The Company recognizes its pro-rata share of income and losses in &#x201c;loss on investment in joint venture&#x201d; on the consolidated statements of operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">comprehensive loss, with a corresponding change to the investment in joint venture asset on the consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_89f4be34-583d-44f5-84dc-399ed3cf7dc0" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company&#x2019;s principal financial instruments are comprised of cash, cash equivalents, available for sale marketable securities, accounts payable and accrued liabilities. The carrying value of all financial instruments approximates fair value.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_5d5ac865-a1fe-42d4-bbd2-3d996734fb7d" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Concentrations of Credit Risk&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company invests its excess cash in money market funds and marketable securities in government insured financial institutions that are subject to minimal credit and market risk. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_c68b0449-952c-4836-90bc-1004f9f06604" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and Cash Equivalents&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company classifies amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market funds, with original maturities of three months or less at the time of purchase as cash and cash equivale</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nts. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_9b01a260-1fad-4639-856e-78e6f5909e33" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable Securities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#x2014; We invest our excess cash balances in highly rated United States (&#34;U.S.&#34;) government-backed debt securities and treasuries.  We classify our marketable securities as available-for-sale and accordingly, record such securities at fair value. Debt securities with original maturities of greater than 90 days are classified as available-for-sale marketable securities and debt securities with original maturities of less than 90 days from the date of purchase are classified as cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unrealized gains and losses on our marketable debt securities that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. If any adjustment to fair value reflects a significant decline in the value of the security, we evaluate the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to our consolidated statements of operations and comprehensive loss. Credit losses are identified when we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_ee87beff-9cd5-49ea-86b6-f03640ba91e1" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and Equipment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;Property and equipment are recorded at cost and consists of computer and other equipment, capitalized software, furniture and fixtures and leasehold improvements. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, or for leasehold improvements, over the remaining term of the lease, if shorter. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4660d55e-aaf6-4555-b6eb-4cd69e5c6b19" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:PropertyAndEquipmentUsefulLivesTableTextBlock" escape="true" continuedAt="F_4660d55e-aaf6-4555-b6eb-4cd69e5c6b19_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The estimated useful life for each major asset classification are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_4660d55e-aaf6-4555-b6eb-4cd69e5c6b19_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.519%;"></td>
          <td style="width:2.398%;"></td>
          <td style="width:38.083%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Classification</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer and other equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_732f61a3-3788-487c-9a69-a227fb7c69be" contextRef="C_52dabac6-294d-46ca-a017-e4ded6aceebe" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized software</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_32a449e8-1038-454e-a83f-13f8fd7c8570" contextRef="C_239aad29-ce03-4108-838f-d640e267ee47" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_c4b0b84e-763a-42e7-9c96-ebce65d8c5be" contextRef="C_3f129d90-d234-416a-9fec-871604aa4382" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">lesser of lease life or useful life</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_dac7788a-e29f-4ace-8e75-3c105f80ec49" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c0f566f6-65c3-4ed9-a9b5-2155b23d262e" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ce244a9a-2c0a-45c9-9ff5-4d47ec94df93" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> such impairments were recorded during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_26db5623-1536-46f9-9771-b929ae25e07e" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leases </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;At the inception of an arrangement, we determine if an arrangement is, or contains, a lease based on the facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease we (i) identify lease and non-lease components, (ii) determine the consideration in the contract, (iii) determine whether the lease is an operating or financing lease; and iv)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recognize lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of fixed, or in substance fixed, lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable we use our incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have elected to combine lease components with non-lease components on our office real estate asset class. Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed, or in substance fixed, are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our consolidated statements of operations and comprehensive loss. Some leases include options to extend or terminate the lease and the Company includes these options in the recognition of the Company&#x2019;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise such options.  We have elected the short-term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with an original term of 12 months or less.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_d1668185-d925-4578-9d49-e4a4ad02e2e2" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company uses the asset and liability method of accounting for income taxes, as set forth in ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Accounting for Income Taxes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(&#34;ASC 740&#34;). Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company evaluates whether deferred tax assets are more likely than not of being realized in determining whether a valuation allowance is necessary. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company determined that it is more likely than not that deferred taxes will not be realized and as a result recorded a valuation allowance against its deferred tax assets. Following the Reorganization, the Company files a consolidated U.S. federal income tax return and has elected to include all subsidiaries owned more than </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1c3dd352-232c-4290-a3c9-db083ede9fd3" contextRef="C_65531b3d-72ed-4e61-b9c1-459069ccf882" name="rlyb:ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%. Prior to the Reorganization, the LLCs owned </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2bdd2466-c6ea-4a52-9563-9c229e3ef648" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="rlyb:ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% by the Company have each elected to be treated as and taxed as a corporation and each filed a separate U.S. federal income tax return.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_38586a8b-9d2a-471a-b662-52b66f303cca" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and Development Expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;Research and development expenses are comprised of costs incurred in performing research and development activities including personnel salaries, benefits, and equity-based compensation; external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; the cost of developing and manufacturing clinical study materials, program regulatory costs, expenses associated with obligations under asset acquisitions, license agreements and other direct and indirect costs. Costs incurred in connection with research and development activities are expensed as incurred. Costs are considered incurred based on an evaluation of the progress to completion of each contract using information and data provided by the respective vendors, including the Company&#x2019;s clinical sites. Depending upon the timing of invoicing by the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These prepaid expenses or accrued expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f1871ac0-63e2-41e9-aeed-4a5b63eb8540" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred Offering Costs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014; The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such equity financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders' equity as a reduction of additional paid-in-capital generated as a result of the offering. Should the planned equity financing no longer be considered probable of being consummated, the offering costs are expensed immediately as a charge to operating expense. Deferred offering costs are included in prepaid expenses and other assets on the consolidated balance sheets.  Deferred offering costs as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f2a58fb5-54dc-45c9-8264-7b6ec8988987" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. There were </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_266b5919-b246-4389-8267-4f4c862af832" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> deferred offering costs as of December 31, 2021.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_07cdcff9-d4c0-4cac-9334-e5e325a8f8c5" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:StockWarrantsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock Warrants </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for stock warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance included in ASC 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(&#34;ASC 480&#34;) and ASC 815,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (&#34;ASC </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">815&#34;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">that </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">meet all of the criteria for equity classification are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and remeasured each balance sheet date thereafter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e1136fbd-9d85-4bab-a545-7e116273f8aa" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-Based Compensation&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for share-based compensation in accordance with ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Compensation&#x2014;Stock Compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(&#34;ASC 718&#34;). Generally, share-based compensation is measured at the grant date for all equity-based awards made to employees based on the fair value of the awards and is recognized over the requisite service period, which is generally the vesting period. Share-based compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition is probable. The Company has elected to recognize the actual forfeitures by reducing the share-based compensation in the same period as the forfeitures occur. The Company classifies share-based compensation in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipients&#x2019; payroll costs are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#34;Black-Scholes&#34;) for stock option grants. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Black-Scholes requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company. The historical volatility is calculated based on a period of time corresponding with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted where the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date corresponding with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_3c34d672-125c-42e0-b47b-77856497c34b" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair Value Measurements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liabilities and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3&#x2014;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e8d5f92b-8b71-42ea-a561-68c20172c1bb" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Segment Information</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;Operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">segments are defined as components of an enterprise for which discrete financial information is regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The Company manages its operations as a single segment for the purposes of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">allocating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">resources, assessing performance, and making operating decisions. All tangible assets of the Company are held in the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_0d5b9015-5ff5-4602-b2df-9d1157d76492" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic and Diluted Net Loss Per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Basic shares outstanding includes the weighted-average effect of the Company's pre-funded warrants to purchase shares of our common stock requiring little consideration upon exercise. Unvested restricted common shares as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> are not considered participating securities and as such are excluded from the weighted-average number of shares used for calculating basic and diluted net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially dilutive securities include restricted common shares and stock options. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e7106077-6178-406f-bff3-63ec35bef387" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;In February 2016, FASB issued ASU 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(ASU 2016-02&#34;), that requires lessees to recognize leases on-balance sheet and to make certain disclosures associated with their leasing arrangements. The new standard establishes a right-of-use (&#34;ROU&#34;) model that requires a lessee to recognize an ROU asset and lease liability on the consolidated balance sheets for all leases with a term longer than twelve months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss. The Company adopted ASU 2016-02 Leases on January 1, 2022 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative periods consolidated financial statements and recognize a cumulative-effect adjustment to the consolidated balance sheets on the date of adoption. The Company elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and initial direct costs. At adoption we recognized approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_854f809b-c49a-4fca-8776-24e4229dcc1b" contextRef="C_35605b6e-be30-43c7-8f50-20c9ee13c798" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_abd60e8e-e10e-4561-bcc8-10300ace49d1" contextRef="C_35605b6e-be30-43c7-8f50-20c9ee13c798" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of ROU assets and corresponding lease liabilities. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Note 5, &#x201c;Leases&#x201d; for additional details.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /><br />In June 2016, the FASB issued ASC 2016-13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">, Financial Instruments - Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (&#34;ASC 2016-13&#34;),</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. We adopted the new standard on January 1, 2022 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments. Our significant financial assets that are within the scope of the new standard consist of available for sale debt securities. There was no impact to our consolidated statements of operations and comprehensive loss or consolidated balance sheets upon adoption. See Note 4 for discussion of unrealized losses on our available for sale marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_07cb7548-9a26-4801-8152-6ac51b9640b3" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company qualifies as an emerging growth company (&#34;EGC&#34;) as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_fa16da91-9040-436d-b669-345fc7c30c44" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:LicenseAndCollaborationAgreementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LICENSE AND COLLABORATION AGREEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Asset Acquisition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In May 2022, we obtained worldwide exclusive rights to RLYB331, with Kymab Limited (&#34;Sanofi&#34;) a preclinical antibody. We believe RLYB331 has the potential to address a significant unmet need for patients with severe anemias with ineffective erythropoiesis and iron overload, including beta thalassemia and a subset of lower risk myelodysplastic syndromes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the terms of the license agreement, we made an upfront payment to Sanofi of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6cd27037-951f-4376-b629-3931408003ab" contextRef="C_0419c87f-3e9a-4f46-8744-7ba8ebb85189" name="rlyb:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in the second quarter of 2022 for the exclusive license to KY1066. We could also be required to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> pay up to an aggreg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_878f7171-b237-4723-8fff-683da37b5c34" contextRef="C_1a27f538-6112-4043-acae-7f43c3d21b17" name="rlyb:AggregateDevelopmentAndRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.0</ix:nonFraction></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">in development and regulatory milestones and up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b1065631-93dc-401b-a28f-d7373642e92f" contextRef="C_1a27f538-6112-4043-acae-7f43c3d21b17" name="rlyb:ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">150.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in commercial milestones for a product in its first indication, plus tiered low-to-mid double digit percentages of such milestone amounts </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">for up to three additional indications, and mid to high single digit royalties on net sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The license was accounted for as an asset acquisition as substantially all of the fair value of the asset acquired was concentrated in a single asset and thus the acquisition was deemed not to be a business combination. The acquired license rights represent an IPR&amp;D asset that was determined to have no alternative future use. Accordingly, the Company recorded an IPR&amp;D charge of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6d073e44-84bf-4e7a-949a-4409f0b84b42" contextRef="C_d6d9b87b-c787-4fdd-889d-759840ee3096" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million to research and development expense, including transaction costs associated with this asset acquisition of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_835a5813-b3d6-4d19-8c4b-6fa7ff0e90f1" contextRef="C_3b90c853-7aaa-440f-a295-28aae572ec3c" name="rlyb:AssetAcquisitionTransactionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, in the accompanying consolidated statements of operations and comprehensive loss for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">AbCellera Collaboration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2022, the Company entered into a multi-year, multi-target collaboration with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Under the terms of the agreement, AbCellera and Rallybio will co-develop and share the development costs of up to five rare disease therapeutic targets, which will be chosen together by both companies. At the point one party in the collaboration opts-out of future co-development cost sharing, that party will be entitled to a share of future profit sharing from commercialization of the collaboration target, dependent on the proportion of their co-development contributions compared to the total development costs of a target as defined within the agreement. The agreement also has defined profit sharing floors that correspond to the stage of development at the time a collaboration party opts-out of co-developing a target.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company concluded that the agreement with AbCellera will be accounted under the scope of ASC 808 as both parties will actively participate in joint operating activities and are exposed to significant risks and rewards that depend on the commercial success of those activities. Under ASC 808, certain transactions between collaborative arrangement participants should follow the accounting for revenue under ASC 606 when the collaborative arrangement participant is a customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company determined that co-d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">evelopment arrangement as defined in our agreement with AbCellera does not meet  the definition of a customer as defined by ASC 606. As a result, these activities will be accounted for as research and development costs. Payments due because of the co-development will be recorded as research and development expense in the period such expenses are incurred and for payments owed to us from our collaboration partner for the reimbursement of research and development costs will be recorded as a contra-research and development expense in the period such expenses are incurred. Costs related to the AbCellera collaboration were not material for the year ended December 31, 2022.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4ddbdd58-3b38-446f-aad9-69e4b5c355ca" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4. MARKETABLE SECURITIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_581eb9df-4962-4dd4-913e-4ec201aaafa0" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of our marketable securities by type of security as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.675%;"></td>
        <td style="width:2.053%;"></td>
        <td style="width:11.199%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.404%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.41%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.564%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.671%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair Value Hierarchy Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross Unrealized Holding Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross Unrealized Holding Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3765e758-663a-4a97-9b5d-bfabd362d215" contextRef="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,647</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bd59f00f-d51e-49a0-a706-8802aae8d084" contextRef="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_047ab01e-b6b2-470d-a43d-9ccc77c395d4" contextRef="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_77bbc26b-ca16-4f14-b3e4-91f7e7d99505" contextRef="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,647</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e6b072fc-7661-4c5f-b3c9-880f2255f1fa" contextRef="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0c6fca46-1827-4db0-bdf0-afb84be8e751" contextRef="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_142d2c3f-6b38-4f65-a46e-5690f57af095" contextRef="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d403f73a-c50d-4e70-b8b3-7f86178ea91f" contextRef="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,203</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_198c4641-5a21-425a-be64-5db8eaf0e5f0" contextRef="C_f9a8b852-841f-4a26-95af-c55e17becf4f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,860</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f8366da2-ebed-49ab-8371-53ddf72f83c2" contextRef="C_f9a8b852-841f-4a26-95af-c55e17becf4f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_63f6a48a-a914-4161-9650-47a351a8a430" contextRef="C_f9a8b852-841f-4a26-95af-c55e17becf4f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_70fef430-4b71-4804-9fe3-181f4d7df277" contextRef="C_f9a8b852-841f-4a26-95af-c55e17becf4f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,815</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bc8d9ba2-ab7d-4dd6-817c-457dddf69a22" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,879</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a81c6c75-772e-493b-bef1-36c23dfbf05c" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_57a1c39d-a26d-45eb-8b14-aeae44b40ddb" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_97acc497-9103-4f17-901d-7413b6440c5e" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_5d82f845-8b0d-4876-b0a3-6c91e60ad434" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The fair values of marketable securities by classification in the consolidated balance sheets was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.107%;"></td>
        <td style="width:2.332%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.561%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e416a5cb-89d7-4157-8c75-2693e0a62e98" contextRef="C_739866d4-323a-4be2-8ffe-a4e8744c785c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,629</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7d2ab123-4fb5-42b4-a595-5f99d0b4120c" contextRef="C_1d27a7c8-536f-4ccb-8034-2a8478fce538" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_94be3d26-b311-4ac7-97ac-9e81621b23f5" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_9cef2594-f8e7-4ca2-87ae-92967d9d97db" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The fair values of available-for-sale debt securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, by contractual maturity, are summarized as follows:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.107%;"></td>
        <td style="width:2.332%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.561%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b5c5eb0c-0ec7-487c-a85a-96c14d4db986" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Due after one year through two years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_293f688e-df37-4d1c-a546-19abf386e4ef" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">998</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d5bd9cb6-6405-41bc-b76e-373358ffc4e9" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br />The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_efcb23be-b220-4fca-a7e9-fa4640ee0cc1" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">70.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. We did </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7115181d-e0ef-4996-9a64-8ca790a38a21" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">t have any investments in a continuous unrealized loss position for more than twelve months as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, we believe that the cost basis of our available-for-sale debt securities is recoverable. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_069379e7-92ff-4912-a331-326fb17bebad" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> allowance for credit losses was recorded as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2021, the Company held money market funds that were classified as cash and cash equivalents on the Company's consolidated balance sheets of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7a5a11f0-aa17-41b1-a1d8-fadb7888c22e" contextRef="C_ec08abe0-0fe7-4c99-8d7a-a6994ffdb9c1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. These money market funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_e8e85bc5-34d3-418b-88a0-dbddb7a6dd1e" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5. LEASES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_907f0f31-e4e0-44e8-a421-280c772b6f6b" contextRef="C_a4381cd1-83ec-453c-b2da-602cb3171ce9" name="us-gaap:LessorOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have operating leases for approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0ad019b7-fb0b-449f-b205-b87df95e2135" contextRef="C_de3e32cc-aea0-4d0f-927a-9048039d7772" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt-sec:numwordsen">nine thousand</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet of corporate office space. The weighted-average remaining lease term is </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_10147747-d1aa-4219-866c-8bdfc707cb12" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The weighted-average discount rate utilized on our operating lease liabilities as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ba0afd44-eb47-4383-996b-f080f9af1bee" contextRef="C_de3e32cc-aea0-4d0f-927a-9048039d7772" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">4.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating leases are included in operating lease ROU assets, operating lease liabilities, and operating lease liabilities, noncurrent in our consolidated balance sheets as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4cd40d3c-d744-49a3-8afc-5449d33dc79f" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes the presentation of the Company's operating lease as presented on the consolidated balance sheets:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.024%;"></td>
        <td style="width:1.937%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.039%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7fde4a6f-4e03-4d7e-9534-9845a932abc0" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">524</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f5270af1-b83a-4e4d-b3e9-a7e53267fe28" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_055f6b54-af6a-4bd1-9655-27e99ad6dc4b" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">374</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f79b62bf-5c9d-4b41-8d75-6c61d9d4cbc6" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_07546d94-65ef-4f29-a8c7-e8dd3a1b3f4b" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_07546d94-65ef-4f29-a8c7-e8dd3a1b3f4b_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Future minimum lease payments from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 until the expiration of the operating lease are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.272%;"></td>
        <td style="width:2.912%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:24.816000000000003%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_49604e88-1a0f-4a26-a529-803d36c86613" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">200</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fff07461-ffe2-4220-aba8-59cb8199d7a6" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">230</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_15c73110-92ef-41bf-b0ae-e6c02808e14c" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e6984a8b-dd61-46d8-86b1-807272f23059" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="rlyb:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1e226369-8649-4006-8dd3-af3ee3b1c65a" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less: imputed discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_af766f97-368c-43af-a170-508187be0088" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Carrying value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4a34dd2a-d78c-45f9-b691-6d9d90f8a53c" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aabeb5e9-2652-4f8f-9a8b-d325c9611b95" contextRef="C_a4381cd1-83ec-453c-b2da-602cb3171ce9" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b097c8e7-d9ab-47f1-a45f-a994ad159af6" contextRef="C_58bb02df-6ead-4192-bfb4-4babb5d12fd7" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in operating lease rent expense for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, respectively.  Lease payments made were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f902924b-5197-456d-95b6-13fab47debd0" contextRef="C_a4381cd1-83ec-453c-b2da-602cb3171ce9" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8633e8c4-4c0b-4c43-ad30-0a1e526a4784" contextRef="C_58bb02df-6ead-4192-bfb4-4babb5d12fd7" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, with such amounts reflected in the consolidated statements of cash flows in operating activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As the result of adopting ASU 2016-02 using the modified retrospective transition method, we did not restate periods prior to the adoption date of January 1, 2022. These periods continue to be presented in accordance with ASC 840. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_07546d94-65ef-4f29-a8c7-e8dd3a1b3f4b_1" continuedAt="F_07546d94-65ef-4f29-a8c7-e8dd3a1b3f4b_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2021, the future undiscounted minimum lease payments on our operating leases were as follows:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span></ix:continuation></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_07546d94-65ef-4f29-a8c7-e8dd3a1b3f4b_2">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.272%;"></td>
        <td style="width:2.912%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:24.816000000000003%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">YEAR ENDING DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_37eb3ed4-864f-4d8c-a0c6-9089610a592f" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_759cbf73-c31a-4237-9012-f89f823b8136" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">195</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4d6c5e00-6eb7-44d0-80cd-5a73fe2f9586" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">230</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1e050bd3-33e6-463e-97e5-d24f19140cc9" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">176</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5d0e09ed-ded9-4971-82ec-c11de9aff417" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="rlyb:OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c0594f80-7567-4c27-a72a-9b39ef0372d4" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="rlyb:OperatingLeasesFutureMinimumPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e225ae59-4cc5-4c74-b252-ab5db952992c" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6. BALANCE SHEET COMPONENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and Equipment&#x2014;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_b054e016-8481-433d-915b-ad47644fba18" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.523%;"></td>
        <td style="width:1.602%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.122%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.612%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.142%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br />2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer and other equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_81157749-7681-40c7-bce3-34a23ae79b96" contextRef="C_8e52f2ef-b76e-43c9-a29f-eee88975b5b8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ea27ba9d-6222-47dc-8758-f8c1805ee6e1" contextRef="C_9ef707b6-6cf6-44ea-a226-c236562f6196" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bed40e38-c872-4121-aca6-86922a9b6aaa" contextRef="C_ae8060f7-9d9e-4228-a650-4909d1ec8e45" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e91d3240-2c53-4040-a174-25d22ea680ec" contextRef="C_bb11c8d1-4dd0-4a80-b4f9-1d7bcbb74fd2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2b5449ef-d961-4466-8ab3-515f5b1d31c4" contextRef="C_82d6c3cd-26a6-4fbe-bd6e-fb539f862b2d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1f6dd207-6450-4d9c-8020-2e3e481a6fd2" contextRef="C_4ef647fa-f912-4e8a-ab8e-43e6ba78d2c3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_802b0317-d912-4faa-b65e-afba72c59730" contextRef="C_e1e1819d-7e08-4d58-9f61-b60962efde73" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">338</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_43ad0f22-e209-4839-82a0-632f86a0d4ca" contextRef="C_7f078dfa-939c-4606-85c9-ea74c47eccf4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">315</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_47259e6d-26e0-4034-a1a8-807eb6269e45" contextRef="C_2d89fc97-b610-46e8-adf8-5e121995a4ef" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b973e122-01a9-45e9-8442-225c0af6464d" contextRef="C_86e82aa6-b04b-4ef2-95b4-8a74005d949f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e45eaea8-3963-4512-beb6-55dff73634a0" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_deae7597-f13e-4b71-b051-f20da2b85afd" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment&#x2014;net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5fe94ee3-4b27-4cc7-aa4b-c115f40b8116" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5c200454-3e5c-4dd9-a2e2-5829f7ccd750" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation expense totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_18af30c5-0f42-450f-839e-88a6c3904056" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">million</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a1424356-782a-48aa-a8dc-20964b3a8bcf" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prepaid Expenses and Other Assets&#x2014;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_82ed632b-b809-4d44-a9ad-db9b57efeba5" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prepaid expenses and other assets consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.641%;"></td>
        <td style="width:2.66%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.505%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.69%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.505%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br />2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d09e87a6-b5f4-4cee-a186-ffe742218829" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="rlyb:PrepaidResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,904</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6cf0e4d8-02ec-427f-b71e-4e7562b7de0e" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="rlyb:PrepaidResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,303</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d4085c3e-f2c8-402c-86cf-01d6b1aeec95" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">933</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4a20b2de-b5ad-4697-9512-b438830e3262" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,467</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other prepaids</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0e884a80-2980-49f4-bf20-e45e888f002a" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">615</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e200655a-e7b0-4655-95eb-859eb1563607" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">370</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f2512657-6823-45a4-8b9e-8fb96da9e9b5" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,050</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6ce39510-f922-47cd-a1e4-483bac63a810" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">395</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_274134fd-b5aa-4138-b92a-855c4fcdfcdf" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7815f89f-6532-4f06-80dc-d44f450a351f" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued Expenses&#x2014;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_53f931d9-2e28-458f-9cce-65e3f4042db4" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.523%;"></td>
        <td style="width:1.602%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.122%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.612%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.142%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br />2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1225503e-1049-4001-ae67-7a043bbb4420" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="rlyb:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,582</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5b4b1446-4257-4464-b74b-0820fda19ec0" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="rlyb:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Compensation and related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_51177cc3-0b60-41aa-82aa-eb939eeafd9b" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,703</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b2fd7490-3aa3-4e79-9337-ca09f7d1fa8f" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,955</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b2b32f80-1afa-4c66-a85a-048f521a1c50" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">510</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_47a02380-3e18-478c-baaf-5f652d18be0c" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">539</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_44406a6f-9212-4a5b-b319-dc43e34490a8" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9aad53a7-222f-4992-a2f0-bac18c0c257f" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">517</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dd7668f4-5834-4b80-8641-764a9b98f659" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,449</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_38db96fa-2992-4698-b5dc-a84b8331d8c2" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_e3af9a01-8980-41b9-ba43-db6358be4b08" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7. STOCKHOLDERS' EQUITY</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Common Stock<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In August 2021, the Company completed its IPO, pursuant to which it issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_66df7464-2376-4f32-9f37-f726a9fac594" contextRef="C_896be549-e10a-4adb-b5c3-195576990921" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,130,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock, inclusive of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5150f54c-2f2d-4750-9f98-e6a71d7c7274" contextRef="C_ed90055c-50cc-4284-9412-3619d9ee515a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">930,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6adf870f-9ffc-4dab-a55d-8bc47a5a71a7" contextRef="C_291895eb-b1c2-4869-bbc2-c46ab5500661" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">share. The gross proceeds from the IPO, including the exercise</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the underwriter's option to purchase additional shares were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_32b05afc-8c7e-4c26-9062-f119898c2bb5" contextRef="C_896be549-e10a-4adb-b5c3-195576990921" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">92.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and the net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9487ce89-f8f2-4d62-9804-7f2e6b60bbce" contextRef="C_896be549-e10a-4adb-b5c3-195576990921" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">83.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In November 2022, the Company completed a follow-on offering of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_660f02d1-f9ad-4245-91a4-c73ad4ae4433" contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">54.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million consisting of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8bf4fff-9b7b-4ecb-a6f4-425a03829fff" contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,803,655</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock, inclusive of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_94165224-201d-4702-b6dd-fa5fabbf4329" contextRef="C_96275cfa-74c5-412d-adca-3d72d0a97037" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">803,654</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock sold pursuant to the partial exercise of the underwriters' option to purchase additional shares at the price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_38938d41-03b5-4c71-8577-88548f3aa2c3" contextRef="C_115c7363-4207-4550-8e08-adb9ff8a9635" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0707b6b7-c41e-4d56-b9fb-090d064ebbf7" contextRef="C_115c7363-4207-4550-8e08-adb9ff8a9635" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,333,388</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ec5c80c1-5eef-4361-b94e-06c081774c8e" contextRef="C_e76e6912-e263-4b3a-800f-e5564ea50f5f" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">5.9999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which represents the per share public offering price for the shares less the $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_94dadf8e-8158-4aaf-8c88-ebeaac71043b" contextRef="C_e76e6912-e263-4b3a-800f-e5564ea50f5f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share exercise price for each pre-funded warrant</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. The net proceeds from the November 2022 follow-on offering were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_30e2e1d7-d789-471c-8892-37cbc38dc34b" contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">See Note 2 for a summary of the Reorganization and Liquidation of Rallybio Holdings that was completed prior to the Company's IPO, which resulted in a change in reporting entity. In accordance with the applicable accounting guidance related to changes in reporting entities, the financial statements for all periods presented have been retrospectively adjusted giving effect to the Reorganization and Liquidation as applicable to all periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company evaluated the liquidation of Rallybio Holdings units and subsequent issuance of common stock awards of the Company, discussed in Note 2, as a modification under ASC 718, Share Based Payments. Under ASC 718, a modification is a change in the terms or conditions of a stock-based compensation award. In assessing the modification, the Company considered the fair value, vesting conditions and classification as an equity or liability award before Liquidation and replacement, compared to the Company&#x2019;s common stock received as of the Liquidation to determine whether modification accounting must be applied. As the number of shares of common stock of the Company that the unitholders of Rallybio Holdings received in the Liquidation was based on the fair value of those units in Rallybio Holdings immediately prior to the Liquidation, unvested units were replaced with restricted common shares with the same vesting terms as the initial awards, and the classification of the awards as equity awards did not change from this action, no incremental stock-based compensation expense resulted from the modification.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company had </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fa561747-b0a6-4d19-b9a7-44bfe9cb1a46" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_07cb7add-86bb-4e38-81fc-bcd7a7dcf4d2" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock authorized as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, respectively, of which </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_db87573d-e0cb-4d8a-879e-0d7728106f94" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e9d05c5a-30a5-457d-a754-18e495b623ac" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,837,369</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_306030d4-b6aa-4202-8301-aaa129721ab8" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_afcb0a1d-eb80-4cc0-af1a-bed1d7c734fb" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,129,970</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares were issued and outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preferred Stock<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company had </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0d8972df-dd39-4e6b-9e66-04381a6c26ff" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_cf6308b3-bef0-4d59-8e48-9916b9a9d20c" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of preferred stock authorized as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ae06cb0d-9f07-42c3-82d1-b07aa851ff35" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8ad48997-2b86-4e95-8277-6ee5821ef95a" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares were outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pre-Funded Warrants <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the follow-on offering entered into in November 2022, the Company entered into an agreement with certain investors for pre-funded warrants in lieu of common stock to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ba776847-d457-47f9-83b4-ce8c49d9e38e" contextRef="C_cfa92b31-04bb-40fe-917d-31a1f4c22c5e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,333,388</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0e508746-42bc-4500-9e42-d00258746b75" contextRef="C_e76e6912-e263-4b3a-800f-e5564ea50f5f" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">5.9999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, which represents the per share public offering price at the November 2022 follow-on offering for common stock less a $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1ab111c6-cbff-4d00-92c4-748067a6811c" contextRef="C_cfa92b31-04bb-40fe-917d-31a1f4c22c5e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share exercise price for each pre-funded warrant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would exceed </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_12a60e96-b27a-45c4-bec7-a06638d2ba5a" contextRef="C_96ab8a98-bc35-4ad3-930b-5cede1b585c6" name="rlyb:ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#x2019;s election upon </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_9d5d669e-ed65-494d-bd12-bdf58a564eff" contextRef="C_96ab8a98-bc35-4ad3-930b-5cede1b585c6" name="rlyb:PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">61</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> days&#x2019; notice to the Company subject to the terms of such pre-funded warrants, provided that such percentage may in no event exceed </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_05e490d9-e927-4617-8a97-6339633896c9" contextRef="C_96ab8a98-bc35-4ad3-930b-5cede1b585c6" name="rlyb:PercentageOfCommonStockBeneficiallyOwnedNotExceed" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">19.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has assessed the pre-funded warrant for appropriate equity or liability classification. During this assessment, the Company determined the pre-funded warrant is a freestanding instrument that does not meet the definition of a liability pursuant to ASC 480 and does not meet the definition of a derivative pursuant to ASC 815. The pre-funded warrant is indexed to the Company&#x2019;s common stock and meets all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the pre-funded warrant classified as equity and accounted for as a component of additional paid-in capital at the time of issuance. All of the pre-funded warrants related to our November 2022 follow-on offering remain outstanding and unexercised as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_43791948-f7d8-478b-b7bf-93d6b81cf0f2" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-based compensation which comprised of stock options, restricted stock awards, restricted stock units and the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> employee stock purchase plan is classified in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 and was as follows: <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">17</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.921%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:22.053%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.64%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:22.386%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br />DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_938b27bf-9eec-453d-bc10-2531ccdf23b4" contextRef="C_428be2be-619b-438c-84e3-581e1bff5f22" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,542</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3847e17d-1a01-457f-baa4-5cbce7ed2cc4" contextRef="C_8c1e2b90-2c05-4121-b927-020165db9017" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,168</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_87978824-5565-40df-8f77-77ace7089dcd" contextRef="C_6767ad15-fcb8-4673-8113-97780ad364b8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,957</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2d9d84ba-f524-4bc6-8c52-d39eb9608b2e" contextRef="C_effcd34e-4aab-4920-ac25-05c20a2a8e59" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,477</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f967ba8d-2a4f-4e5c-a69d-cd8aa7d1bf45" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,499</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ad64f970-c94b-481d-9fd0-35e7efb65bf0" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,645</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">2021 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In 2021, the board of directors adopted the Rallybio Corporation 2021 Equity Incentive Plan (the &#34;2021 Plan&#34;). The 2021 Plan reserves</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_013d1e78-6727-4d6d-a520-2039bb85b45e" contextRef="C_25fa2078-2908-479e-9ea7-121c863893fd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,440,344</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> for shares of the Company's common stock that have been issued in respect of outstanding equity awards granted prior to the registrant&#x2019;s IPO and for future issuances of shares to employees, directors and consultants in the form of stock options, SARs, restricted and unrestricted stock and stock units, performance awards and other awards that are convertible into or otherwise based on the Company's common stock. Dividend equivalents may also be provided in connection with awards under the 2021 Plan. The share pool will automatically incr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ease on January 1st of each year from 2022 to 2031 by the lesser of (i) five percent of the number of shares of the Company's common stock outstanding as of such date and (ii) the number of shares of the Company's common stock determined by the board of directors on or prior to such date. On January 1, 2022, the 2021 Plan share pool was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_40eccbda-c39b-466a-a85c-cb1d46391b07" contextRef="C_e1789f82-5498-493f-9c96-de21198bf03e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,606,549</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares.  As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the total number of shares of the Company's common stock that were issuable under the 2021 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_673d5210-4c48-47ed-ba82-b3da51b82d2f" contextRef="C_25fa2078-2908-479e-9ea7-121c863893fd" name="rlyb:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,796,071</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares, of which </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2c4c9b0f-16d5-48cd-b39c-9ff89bebc495" contextRef="C_25fa2078-2908-479e-9ea7-121c863893fd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,058,157</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares remained available for future issuance.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span><ix:nonNumeric id="F_e57ae343-4365-4086-8d59-05c65900e678" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_e57ae343-4365-4086-8d59-05c65900e678_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022:<br /><br /></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_e57ae343-4365-4086-8d59-05c65900e678_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.387%;"></td>
        <td style="width:0.633%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.453999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.81%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.387%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.633%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.209999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.077%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.41%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number of Option Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Contractual Term <br />&#160;&#160;&#160;(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Aggregate Intrinsic Value<br />&#160;&#160;&#160;(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2dbc36a9-f4d5-4c3f-9c92-fca53944f5bd" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,357,784</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ae184c8c-1b7a-4b46-8099-9123d9075eb6" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.72</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4277f0d8-315a-4c31-96b5-4278c609c9df" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6c510202-f81f-4a76-a4c5-c202aa3e169c" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_40a4c661-9b47-460a-9787-aab4155df619" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,458,800</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9be2ebad-498f-4df6-88dc-6809f6906e3f" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ebe3386e-0c87-4ca9-a64c-db984282dcc5" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">183,151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b6f3f5c0-e2af-4176-b83e-d60b0e56ff6d" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7b6cb4cf-0d5c-430f-aca4-157ef1ddde4b" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">22,105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d8efa7a7-f618-44a3-bad0-6628e4bfdae7" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.38</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b90ac1d0-9d09-4600-b834-9580f1f268b0" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8624d46a-d8ea-4273-8c88-4b9759cbbcdf" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.38</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_25027256-08f8-4b81-a4b3-1602fbf59918" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,609,314</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_12b8a206-ecf9-430e-b36c-e10393fcda55" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a1eafa99-acf8-4b13-8ce3-d771b94a27f7" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_02098f49-2772-4c50-ba31-94f32cc35930" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_686969ff-a95f-4cdf-a003-eef6f22ebdfc" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">685,155</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_37f652ce-5e31-4026-ac8b-e3cfb5cec225" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_134b3db2-8292-4084-87fb-4d82b972928f" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f5f0ab6a-328f-439e-a62c-485e1e3dd7bf" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br />The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company's common stock. Options outstanding and exercisable with an exercise price above the closing price as of December 31, 2022 are considered to have no intrinsic value. Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the year ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6a9dff5f-884b-45d9-bf50-0ce1bd6c2951" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">9.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d1f953ba-badc-497c-b981-33feba78c053" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">9.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, respectively. Options vested during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> with an exercise price above the closing price are considered to have </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_495d666e-fe83-4637-b216-4553f0c2210f" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_67872697-5aa0-41ab-8b2a-7f046952df36" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> intrinsic value. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was unrecognized share-based compensation expense related to unvested stock options of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a605466e-aafe-495d-a806-8595723173e9" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which the Company expects to recognize over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_35877aba-65b1-481e-a7e9-1cb610e4dca4" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_04b16b26-8119-4e6c-bcd8-91c1f74cf75d" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The fair value of the stock options granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.905%;"></td>
        <td style="width:1.064%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.349%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.074%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.608%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_68cfc55a-9532-4103-bdff-0ff912f55956" contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">89.31</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_55108d79-155d-48bd-8254-3877db1b645b" contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">91.62</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9f81c69b-5852-4fe0-be2b-c6b0e4e3252c" contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">86.90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d2caa7e7-ea35-4d89-addc-0c5958cc73f4" contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">87.90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_25f02735-ebc1-4c2a-b8f4-622ee5c6d603" contextRef="C_70c6b661-e569-4779-8379-10ef41316fc7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.50 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_2bbafdff-cd90-4eb9-a43a-2f63c6f2b7c9" contextRef="C_e6740c4f-f839-42cf-8933-5c00be44fad6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_39de5cba-c7a6-4f7b-9342-e469c5c37973" contextRef="C_3b5ba2a5-21d0-491d-a212-155407944f28" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.50 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_2867265a-8bda-47ce-98ca-2acac4aef168" contextRef="C_e57589c1-5d53-466f-b251-aaba3c58effd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2945490f-081a-468f-b2f8-4850a51eac4b" contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.42</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8decc89-39d4-4317-afce-5107bce7e117" contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.94</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_99a7512d-0b35-43aa-9203-173afb5c9207" contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.79</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b0666cd8-3abe-4727-9e67-36aa868fdc1e" contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.33</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_245b4c66-f2a9-4f3d-be7c-3961c481afe3" contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ba905d5d-7825-4c4e-862e-e5a1c2408a13" contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercise price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a7a73ac8-a2df-4e94-a635-47e43bc65126" contextRef="C_b92e8ce1-fdcf-4c2d-a2d7-c1581bdfc31f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.54</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0fc920b2-570f-49bf-835c-800d9a150142" contextRef="C_9b380165-d0ba-48ca-8553-1fc3c5916d47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">15.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_530014fe-f74f-4472-a0e7-40a0738c8775" contextRef="C_c135ce81-16f6-4644-8431-2f49154ea889" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.76</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8538b570-556e-46a8-bd40-52349bb2045d" contextRef="C_c7a1f81b-226a-425e-9556-8238ac7cd556" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f038aabd-994c-468b-8aed-2534246985e6" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" escape="true" continuedAt="F_f038aabd-994c-468b-8aed-2534246985e6_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A summary of the status of the Company's nonvested restricted common stock awards at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and changes during the year ended December 31, 2022 was as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_f038aabd-994c-468b-8aed-2534246985e6_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.034%;"></td>
        <td style="width:1.209%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.017%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.626%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.113000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted Stock Awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Nonvested restricted stock awards at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0b40da3d-95e7-4b06-9133-578c3a53205d" contextRef="C_eed08da7-0a3b-4480-a783-cde12cc17f8e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,272,707</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4041cba5-64c3-4326-b077-b88d7eb84dab" contextRef="C_eed08da7-0a3b-4480-a783-cde12cc17f8e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8ff9ee44-5a9d-4382-b1ac-47e21927d15d" contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9ab95786-8b2a-4db3-a492-6ce0ef959ff0" contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2cb19f7b-57bf-478e-bd65-7992e859e86e" contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,127,224</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e1226b60-3ec8-4e31-9368-51488ad56b5e" contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d3a9239d-84ab-4e4a-b74d-dd79b45f3cbf" contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">139,115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c0213d8c-4eab-4fde-aec6-4a9b1d0cdc7e" contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding nonvested restricted stock awards at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_859645ad-c2b6-449f-ba46-804ee06f2589" contextRef="C_cbf9eec7-f7b0-4d37-8259-cb61089f9136" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,006,368</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3e40540a-8c20-4b92-aab2-895c43987d96" contextRef="C_cbf9eec7-f7b0-4d37-8259-cb61089f9136" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was unrecognized share-based compensation expense related to unvested restricted stock awards of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6eec898b-6d5f-4a99-ac48-01586a9d935a" contextRef="C_cbf9eec7-f7b0-4d37-8259-cb61089f9136" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which the Company expects to recognize over a weighted-average period of approximately</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_7ef2c092-597b-433e-b718-870caf1dbf7d" contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.1</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_93c3708f-b257-4c18-89d2-91ff3b3d39e0" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A summary of the status of the Company's nonvested restricted common stock units at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and changes during the year ended December 31, 2022 was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.034%;"></td>
        <td style="width:1.209%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.017%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.626%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.113000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Nonvested restricted stock units at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_defaba76-f919-4134-9ee6-a747815ea87f" contextRef="C_283e6bfc-26b6-4abc-bae8-943016a346b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b79cb8ae-48cc-44ba-8c94-47fb7f22414a" contextRef="C_283e6bfc-26b6-4abc-bae8-943016a346b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1fa08715-882a-4542-ae67-53b9736546dc" contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">151,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5e80960a-b19b-46c8-98eb-16c9a2503626" contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5a03e20c-8343-46d8-8058-1cbd34a9ce89" contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">22,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9e499a42-a346-40e6-9ab2-1ba988ea6309" contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_90a7759e-6644-4fa6-ab05-3485ee7bbbaa" contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7492db3d-fe24-4091-b170-442f94207824" contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding nonvested restricted stock units at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_93aa7779-ef09-4dec-9136-c874c3170cec" contextRef="C_86c28a70-242c-4117-a116-d03b63d2edf8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">128,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_548c0cf6-b15f-4238-a1f6-71ca3cb7c32b" contextRef="C_86c28a70-242c-4117-a116-d03b63d2edf8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br />As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was unrecognized share-based compensation expense related to unvested restricted stock units of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d32641a8-a4dd-47b5-ad08-4f6144c1ab49" contextRef="C_45070b2f-cf01-42c1-887f-e78f1a625a2b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which the Company expects to recognize over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_765de5e2-c501-4a1a-a51e-ec3c908c29dd" contextRef="C_1df02247-1abd-4b9e-b9a2-5286622dd357" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the Company's IPO, the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> board of directors adopted the Rallybio Corporation 2021 Employee Stock Purchase Plan (the &#34;2021 ESPP&#34;), which reserves </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4f9d1f0e-fc41-4c3c-9ce5-537a8006ed18" contextRef="C_6c8eb427-a9b9-4fd2-8278-278c9bafa4ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">291,324</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock for future issuances under this plan. The share pool will automatically incr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ease on January 1st of each year from 2022 to 2031 by the lesser of (i) one percent of the number of shares of the Company's common stock outstanding as of such date (ii) </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f33b367c-737d-46bf-8a2c-1416f5c6be15" contextRef="C_6c8eb427-a9b9-4fd2-8278-278c9bafa4ec" name="rlyb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">582,648</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock, and (iii) the number of shares of the Company's common stock determined by the board of directors on or prior to such date.  On January 1, 2022, the 2021 ESPP share pool was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fcb2c749-c64d-4fc9-ad92-e34f3bbba351" contextRef="C_d4c6a782-6462-4fbb-ab36-0733d6a1beb2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">321,309</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the total number of shares of the Company's common stock that were available for future issuance under the 2021 ESPP was </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3d726580-781c-4867-a0d2-9717b67f0110" contextRef="C_6c8eb427-a9b9-4fd2-8278-278c9bafa4ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">573,788</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_760a2675-166c-4e80-b5e0-cb7d64cde976" contextRef="C_d937f0f8-a8e7-46a1-90c2-541038ce8510" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,845</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock under the 2021 ESPP. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f4276d11-318e-4ecc-ad7f-5e29883c9da1" contextRef="C_9608e295-9fc8-4f1c-8325-defd050a4e3e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares were issued under the ESPP as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the total share-based compensation for the 2021 ESPP was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ad648594-bb6c-4357-93c9-f422747505a7" contextRef="C_d937f0f8-a8e7-46a1-90c2-541038ce8510" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_2abe5c8a-4d70-4fd8-a05f-377fb08169c0" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8. INCOME TAXES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During each of the years ended  December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> , the Company did </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_07cef878-f1e0-4739-ae33-4dbc3389dbbd" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0adc42bf-6002-4709-8cff-782ab649b9ec" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">t record any income tax benefits.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e2b230f6-a529-4363-8bea-960eb0b1894d" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s effective income tax rates are different from the federal statutory tax rates in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022 and 2021 predominantly due to the valuation allowance, tax credits, and state taxes described below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.046%;"></td>
        <td style="width:1.692%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.335%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.701%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.225%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. federal statutory tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_23bed1a3-e286-4c1b-bf92-c902f4c2033b" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_64e8ff5a-685c-4330-8a5f-723f77a608d1" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State income taxes, net of federal income tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_01ea137b-de9a-43ee-92af-6996fc29cd62" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f8fcc10f-462f-4f7b-a073-9f8db1c87ee8" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_22636195-79d7-4f89-935b-912e286f6a51" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ce2ea2f3-2aa9-4704-948b-a19daf4b16bb" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6a45dfce-b6d3-455e-8612-f47a6c67fabb" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ef53f407-a967-4eac-8e23-c1becd23a507" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_97b257db-0e8e-41ab-8750-f39ce68437b1" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">28.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_667d08be-20f5-4863-bc20-404ecde3eb18" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">33.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7fb8244c-b993-4471-af98-568dac651693" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a634786f-59bd-40c2-9691-8d6366e0c60d" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_53804e73-32d7-4031-94f5-c6fbc692e43a" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_53804e73-32d7-4031-94f5-c6fbc692e43a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The combined temporary differences and carryforwards of each tax paying component of the Company that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_53804e73-32d7-4031-94f5-c6fbc692e43a_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.529%;"></td>
        <td style="width:2.473%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.762%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.473%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.762%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0e5c4891-6cc8-4b71-a25e-3dcdcfdcb589" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,576</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a47a65b9-b5f4-431c-8589-85c7e5cb8fa0" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,789</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8eebb780-a0f3-43ac-b653-ab1be2d6e520" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,306</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7c103421-34f7-4bc8-bbc3-0cbcd108957c" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,685</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Section 174 capitalization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1f9ccda7-eeaa-4d77-a5b3-694a94479ecb" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="rlyb:DeferredTaxAssetsSection174Capitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,895</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_29c7b0ff-38bd-433e-9016-11636db8ee57" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="rlyb:DeferredTaxAssetsSection174Capitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_96bc1d4e-a4e5-466c-aecd-f2bf69a4b0ae" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,242</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d3e446d6-9bd3-4258-850d-86388470c2b7" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ab2fba8c-2883-4a41-91d6-9d97c9af639e" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,196</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_569cfc35-ed0b-4c59-a284-21f2cdd4591a" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_51e014c6-36a0-4f74-a990-67297ea36137" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b416e4a2-81bd-4ec0-a126-650a29b037e4" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,161</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_716c0b16-496c-4fda-9866-40bd6c3575d2" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dd59111b-089f-4382-8ca3-170fe3e2720e" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,161</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_335b7007-e881-490f-b095-0b8d35d7c243" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2b61b85e-a346-4b25-9c0e-a9537cb6e939" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company has approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cc97c627-b9fc-4f24-9e91-9f09104e6270" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">98.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of federal net operating loss carryforwards, which do not expire, and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a5b07ec1-65e6-4553-8a8c-54b6be89d03d" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">98.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of state net operating loss carryforwards, which begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_56a7ffc2-ebc6-4a66-9918-6101e0e29313" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:StateOperatingLossCarryforwardsExpirationPeriod"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2038</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has provided a valuation allowance against the Company&#x2019;s deferred tax assets, since, in the opinion of management, based upon the history of losses by the Company and insufficient future federal and state taxable income; it is more likely than not that the benefits will not be realized. All or a portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective January 1, 2022, a provision of the Tax Cuts and Jobs Act (&#34;TCJA&#34;) changed the treatment of research and experimental (&#34;R&amp;E&#34;) expenditures under Section 174 of the Internal Revenue Code (&#34;Code&#34;). Previous to the TCJA being effective, businesses have had the option of deducting Section 174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The new TCJA provision, however, eliminates this option and will require Section 174 expenses associated with research conducted in the U.S to be capitalized and amortized over a five-year period. For expenses associated with research outside of the United States, Section 174 expenses will be capitalized and amortized over a 15-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 and Section 383 of the Code, and corresponding provisions of state law, due to ownership changes that may have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income and tax liabilities. In general, an ownership change, as defined by Section 382 of the Code, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1876ac9e-c8a5-4121-ae32-41d9172388c9" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:IncreasingOwnershipPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% over a three-year period. The Company recently completed a Section 382 study and concluded that we underwent an ownership change as defined by the Code during the year ended December 31, 2020. We do not currently believe that the annual limitation will result in the expiration of any net operating losses or research and development tax credit carryforwards before utilization. Future ownership changes may limit our ability to utilize remaining tax attributes. Any carryforwards that will expire prior to utilization as a result of such additional limitations will be removed from deferred tax assets, with a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has no material uncertain tax positions that qualify for either recognition or disclosure in consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">It is the Company&#x2019;s policy to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company has accrued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fb5939e1-6f95-4692-8df3-a284e3e3f7b8" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0c491fdc-b657-4d4a-b97c-5bec6cc953af" contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> interest and penalties related to uncertain tax positions. The Company does </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b6842026-27e3-492e-8918-b2a3db6dea5c" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">t have any outstanding U.S. federal income tax or material state and local tax matters for periods through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. There are </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ef632ec5-c3be-481b-ad89-afc0a4363615" contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816" name="us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> federal or state and local income tax returns currently under examination. The Company&#x2019;s tax returns from inception to date are subject to examination by the taxing authorities.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_6206d864-8cbb-496c-becd-dc03d190911a" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9. INVESTMENT IN JOINT VENTURE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company, through one of its wholly-owned subsidiaries, has a </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d49a97df-1f2c-4e8b-afd1-aaf0d4bbcf86" contextRef="C_91e37f8e-3f15-4cf1-a0ed-4b07ba1acb40" name="rlyb:PercentageOfInterestOfJointVentureEntity" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% interest of the joint venture entity, REV-I.  For the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021 the Company funded $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8d0f0ed8-d0b5-414f-80b0-a66cf1e7b38f" contextRef="C_91e37f8e-3f15-4cf1-a0ed-4b07ba1acb40" name="us-gaap:PaymentsToAcquireInterestInJointVenture" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f713fbaf-53f8-4248-9665-b3ca1773b1f6" contextRef="C_f4c85d43-b21c-4db7-af84-cec208374d89" name="us-gaap:PaymentsToAcquireInterestInJointVenture" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, associated with the Company's commitment and its share of REV-I development. The Company did not provide any additional financial support outside of capital contributions to REV-I during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021. While the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company held a 50% interest in the joint venture as of December 31, 2022, based on management&#x2019;s analysis, the Company is not the primary beneficiary of REV-1 and accordingly, the entity is not consolidated in the Company's consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, the Company recorded its allocable share of REV-I&#x2019;s losses, which totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_40ab21e8-6c27-4591-b3a1-1f3180f8fa32" contextRef="C_91e37f8e-3f15-4cf1-a0ed-4b07ba1acb40" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_82ecc8fc-e8f5-49b3-af96-e37c90e07ce7" contextRef="C_f4c85d43-b21c-4db7-af84-cec208374d89" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, as a loss on investment in joint venture within the consolidated statements of operations and comprehensive loss. After recognition of its share of losses for the period, the carrying value and maximum exposure to risk of the REV-I investment as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5419a1c9-4adf-4360-90e4-a273c65ddb82" contextRef="C_e04c4b7c-8231-4981-815c-01cc0725ee41" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> thousand and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_77babd9f-9a0c-43f1-b8b3-2860cae669f6" contextRef="C_e29c70d6-5177-4a18-b728-136ccc6f1118" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, which was recorded in investment in joint venture in the accompanying consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_570af4b5-d78f-4cbe-b587-432ca92a666d" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10. COMMITMENTS AND CONTINGENCIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchase Commitments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company enters contracts in the normal course of business with contract research organizations and other third-party vendors for clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments that may be due upon cancellation consist of payments for services provided or expenses incurred prior to cancellation. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> there were </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cf0baa6d-82e2-48d9-9ec8-dcf9a888c163" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="rlyb:TerminationCharges" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_35536f02-4332-43cb-9de3-229b2eb85085" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="rlyb:TerminationCharges" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> amounts accrued related to termination charges.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_c3c729d2-6f1e-4aa4-8d1d-6483299c63be" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11. NET LOSS PER COMMON SHARE</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_3220ec8d-4a90-41ee-9581-acc1b82b38f5" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic and diluted loss per common share were calculated as follows: <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.441%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.922%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.116%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.84%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br />DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br />(in thousands except share and per share amounts)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c958d0d9-28d1-4fe9-b1c0-2ccd8254810f" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2029ef3a-9965-4fd6-bc4f-f435cb85bdd0" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,013</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-average number of common shares <br />&#160;&#160;&#160;outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_abeb7816-f6ed-4f25-bace-7d052a9b6dc9" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_de947f15-e5c3-40a8-bbac-f4591156376d" contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,821,311</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_49a23390-2f51-4a28-8f35-0e6a2556472e" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_cfdfe76a-9ca6-4f3c-a0c2-4fb87edb289f" contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,519,114</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(2.09</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(1.84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic net loss per share of common stock is based on the weighted-average number of shares of common stock outstanding during the period. Pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_53c6cdce-2bd9-4255-9c06-8c83cfe56408" contextRef="C_17a4f0c1-9607-4df6-8818-c739af03c27b" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,333,388</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock that were issued in connection with the November 2022 follow-on offering were included in the weighted-average number of common shares outstanding for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022. The weighted-average number of common shares outstanding diluted for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> excludes approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5decc35b-3387-4628-a3da-65dc913247d1" contextRef="C_8a26e436-c6db-4d63-858b-564767b5ca18" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million stock options and unvested restricted common shares, which were not dilutive and not included in the computation of net loss per common share. The weighted-average number of common shares outstanding diluted for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> excludes approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_856543e2-7185-405e-9190-9a38044f52e6" contextRef="C_027b9ced-d4c4-4cc7-bebc-9fecdde23fc4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="6" decimals="-5" format="ixt:numdotdecimal">3.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million stock options and unvested restricted common shares, which were not dilutive and not included in the computation of net loss per common share.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>2
<FILENAME>rlyb-ex4_4.htm
<DESCRIPTION>EX-4.4
<TEXT>
<html>
 <head>
  <title>EX-4</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 4.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REGISTERED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following description of the securities of Rallybio Corporation (&#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;we&#x201d; or the &#x201c;Company&#x201d;) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorporation, amended and restated bylaws, applicable provisions of the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;) and form of pre-funded warrant.  Copies of our amended and restated certificate of incorporation, amended and restated bylaws and form of pre-funded warrant are incorporated by reference as Exhibit 3.1, Exhibit 3.2 and Exhibit 4.3 respectively, to the Annual Report on Form 10-K to which this Exhibit 4.4 is an exhibit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our authorized capital stock consists of 200,000,000 shares of common stock, with a par value of $0.0001 per share, and 50,000,000 shares of preferred stock, with a par value of $0.0001 per share. Our common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended, and is listed on The Nasdaq Global Select Market under the symbol &#x201c;RLYB.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined, in an uncontested election, by a majority of the votes cast by the stockholders entitled to vote on the election and, in a contested election, by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive an amount of our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-Funded Warrants</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we had pre-funded warrants outstanding to purchase 3,333,388 shares of our common stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each pre-funded warrant entitles the registered holder to purchase one share of common stock at an exercise price of  $0.0001 per share of common stock.  The exercise price of the pre-funded warrants and the number of shares of our common stock issuable upon exercise of the pre-funded warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock, as well as upon any distribution of assets, including cash, stock or other property, to our stockholders. The pre-funded warrants have no expiration date and are exercisable, at the option of each holder, in whole or in part, by delivering notice and payment of the exercise price or by means of cashless exercise  as further described in the pre-funded warrant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any such warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder&#x2019;s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with the holder&#x2019;s for purposes of Section 13(d) or Section 16 of the Exchange Act) would exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of such pre-funded warrant, which percentage may be increased or decreased at the holder&#x2019;s election upon 61 days&#x2019; notice to us subject to the terms of such pre-funded warrants, provided that such percentage may in no event exceed 19.99%.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the consummation of a fundamental transaction (as described in the pre-funded warrants), the pre-funded warrants will automatically be converted into the right of the holder of such pre-funded warrant to receive the same kind and amount of securities, cash or other property that such holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction, without regard to any limitations on exercise contained in the pre-funded warrants.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to applicable laws, the pre-funded warrants may be offered for sale, sold, transferred or assigned without our consent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-takeover Effects of Our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and the DGCL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors, but which may have the effect of delaying, deferring or preventing a future takeover or change in control of us unless such takeover or change in control is approved by our board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These provisions include:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Classified board.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our amended and restated certificate of incorporation provides that our board of directors is divided into three classes of directors, with the classes as nearly equal in number as possible. As a result, approximately one-third of our board of directors will be elected each year. The classification of directors will have the effect of making it more difficult for stockholders to change the composition of our board of directors. Our amended and restated certificate of incorporation also provides that, subject to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by our board of directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Action by written consent; special meetings of stockholders.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our amended and restated certificate of incorporation provides that stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in lieu of a meeting. Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted by a majority of our board of directors. Except as described above, stockholders will not be permitted to call a special meeting or to require our board of directors to call a special meeting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Removal of directors.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our amended and restated certificate of incorporation provides that our directors may be removed only for cause by the affirmative vote of at least 75% of the voting power of our outstanding shares of capital stock, voting together as a single class. This requirement of a supermajority vote to remove directors could enable a minority of our stockholders to prevent a change in the composition of our board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance notice procedures.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder&#x2019;s intention to bring that business before the meeting. Although our amended and restated bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, our amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Supermajority approval requirements. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The DGCL generally provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#x2019;s certificate of incorporation or bylaws, unless either a corporation&#x2019;s certificate of incorporation or bylaws requires a greater percentage. Our amended and restated certificate of incorporation and our amended and restated bylaws provide that the affirmative vote of holders of at least 75% of the total votes eligible to be cast in the election of directors will be required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to our amended and restated certificate of incorporation and our amended and restated bylaws could enable a minority of our stockholders to exercise veto power over any such amendments.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Authorized but unissued shares.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive forum. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state or federal courts within the State of Delaware will be exclusive forums for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, (4) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws or (5) any other action asserting a claim against us</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that is governed by the internal affairs doctrine; provided that, the exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Exchange Act or to any claim for which the federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation also provides that, unless we consent in writing to the selection of an alternative forum, the U.S. federal district courts shall be the exclusive forum for the resolution of any claims arising under the Securities Act. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware and certain federal securities law, these provisions may have the effect of discouraging lawsuits against our directors and officers.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Section 203 of the DGCL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#x201c;business combination&#x201d; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#x2019;s voting stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: before the stockholder became interested, the corporation&#x2019;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A Delaware corporation may &#x201c;opt out&#x201d; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#x2019; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Agent and Registrar</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>rlyb-ex10_24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.24</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EMPLOYMENT AGREEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) dated as of February 1, 2023 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by and between Rallybio, LLC, a Delaware limited liability company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and Jonathan Lieber (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">W I T N E S S E T H</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company desires to employ the Executive as the Chief Financial Officer and Treasurer of the Company; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company and the Executive desire to enter into this Agreement as to the terms of the Executive&#x2019;s employment with the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in consideration of the foregoing, of the mutual promises contained herein and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POSITION AND DUTIES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GENERAL</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Employment Term (as defined below), the Executive shall serve as the Chief Financial Officer and Treasurer of the Company and the Parent.  In this capacity, the Executive shall have the duties, authorities and responsibilities commensurate with the duties, authorities and responsibilities of persons in similar capacities in similarly sized companies and such other duties, authorities and responsibilities as may reasonably be assigned by the Rallybio Corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) board of directors (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to the Executive from time to time that are not inconsistent with the Executive&#x2019;s position with the Company and do not unreasonably interfere with his duties to the Company.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OTHER ACTIVITIES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Employment Term, the Executive shall devote all of the Executive&#x2019;s business time and energy, business judgment, knowledge and skill and the Executive&#x2019;s best efforts to the performance of the Executive&#x2019;s duties with the Company, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that the foregoing shall not prevent the Executive from (i) serving on the boards of directors (and board committees) of non-profit organizations (provided, that the Executive provides the Board with advanced written notice prior to accepting or serving in any such position), (ii) serving on the boards of directors (and board committees) of for-profit organizations (provided, that the Executive receives prior written approval from the Board, which shall not be unreasonably withheld, delayed or conditioned), (iii) participating in charitable, civic, educational, professional, community or industry affairs, (iv) spending a de minimis amount of time on activities that provide de minimis compensation to the Executive, and (v) spending a de minimis amount of time managing the Executive&#x2019;s passive personal investments; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, such activities do not interfere or conflict with the Executive&#x2019;s duties hereunder or create a potential business or fiduciary conflict or otherwise violate Section 11 of this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, each of the Executive&#x2019;s activities listed on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> attached hereto is permitted under this Agreement so long as such activities listed on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> do not materially interfere or conflict with the Executive&#x2019;s duties hereunder.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EMPLOYMENT TERM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company agrees to employ the Executive pursuant to the terms of this Agreement, and the Executive agrees to be so employed, for a term of one (1) year (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) commencing as of the Effective Date.  On each anniversary of the Effective Date following the Initial Term, the term of this Agreement shall be automatically extended for successive one (l)-year periods; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that either party hereto may elect not to extend this Agreement by giving written notice to the other party at least sixty (60) days prior to any such anniversary date.  Notwithstanding the foregoing, the Executive&#x2019;s employment hereunder may be earlier terminated in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof, subject to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof.  The period of time between the Effective Date and the termination of the Executive&#x2019;s employment hereunder shall be referred to herein as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BASE SALARY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Employment Term, the Company agrees to pay the Executive a base salary at an annual rate of, initially, $460,000.  The base salary shall be paid in cash in accordance with the regular payroll practices of the Company with respect to salaried employees, but in no event less frequently than semi-monthly.  The Executive&#x2019;s base salary shall be subject to review by the Board or the Compensation Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the Board (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and may be increased from time to time by the Board or the Compensation Committee in its respective sole discretion.  The base salary as determined herein and increased from time to time shall constitute the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; for purposes of this Agreement, and any section herein providing for payment of the Base Salary to the Executive shall mean payment of the Base Salary rate in effect at the time of payment.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL BONUS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  With respect to each fiscal year during the Employment Term, the Executive shall be eligible to receive an annual cash incentive payment (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  The target amount of the Annual Bonus shall be (forty percent) 40</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Base Salary; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in any event, the actual Annual Bonus to be paid in respect of any fiscal year, if any, which may be more or less than the target bonus amount, will be based on the attainment of individual and/or Company performance goals for such year established by the Board or the Compensation Committee as determined by the Board or the Compensation Committee in its respective sole discretion.  Any Annual Bonus awarded hereunder shall be paid in the calendar year following the calendar year to which such bonus relates at the same time annual bonuses are paid to other senior executives of the Company, except as otherwise provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof, but not later than March 15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of such following calendar year.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EMPLOYEE BENEFITS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BENEFIT PLANS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Employment Term, the Executive shall be entitled to participate in any employee benefit plan that the Company has adopted or may adopt or maintains or contributes to for the benefit of its employees generally, subject to satisfying the applicable eligibility requirements, and except to the extent such plans are duplicative of the benefits otherwise provided hereunder.  The Executive&#x2019;s participation will be subject to the terms of the applicable plan documents and generally applicable Company policies.  Notwithstanding the foregoing, the Company may modify or terminate any employee benefit plan at any time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BUSINESS EXPENSES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Upon presentation of reasonable substantiation and documentation as required by the Company&#x2019;s expense reimbursement policies, that the Company may modify from time to time, the Executive shall be reimbursed for all reasonable out-of-pocket </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business expenses incurred and paid by the Executive during the Employment Term and in connection with the performance of the Executive&#x2019;s duties hereunder or otherwise incurred at the direction of the Company, including, without limitation, reasonable travel and business expenses incurred when visiting the Company&#x2019;s headquarters in accordance with the Company&#x2019;s expense policies, as updated from time to time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VACATION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Executive shall be entitled to take vacation in accordance with the Company&#x2019;s policy then in effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERMINATION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Executive&#x2019;s employment and the Employment Term shall terminate on the first of the following to occur:</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DISABILITY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Upon ten (10) days&#x2019; prior written notice by the Company to the Executive of a termination due to Disability.  For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall be defined as the inability of the Executive to have performed the Executive&#x2019;s material duties hereunder, with or without reasonable accommodation due to a physical or mental injury, infirmity, limitation or incapacity which has lasted or can reasonably be expected to last for one hundred eighty (180) days (including weekends and holidays) in any three hundred sixty-five (365)-day period as determined by the Board in its reasonable discretion.  The Executive (or the Executive&#x2019;s representative) shall cooperate in all respects with the Company if a good faith question arises as to whether the Executive has become disabled (including, without limitation, submitting to reasonable examinations by one or more medical doctors and other health care specialists reasonably selected by the Company and authorizing such medical doctors and other health care specialists to discuss the Executive&#x2019;s condition with the Company).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DEATH</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Automatically upon the date of death of the Executive.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BY THE COMPANY FOR CAUSE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Immediately upon written notice by the Company to the Executive of a termination for Cause.  &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean (i) the Executive having been indicted for, or having pleaded guilty or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">nolo contendere</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to, (A) a felony or (B) a crime involving dishonesty or moral turpitude; (ii) the Executive&#x2019;s commission of any act of fraud, or embezzlement, theft, or material dishonesty or intentional misappropriation of the property of the Company, Parent or any of their respective direct or indirect subsidiaries (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company Group</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) or any of their respective affiliates or of any customer or supplier of the Company Group; (iii) the Executive&#x2019;s repeated use of illegal drugs or repeated abuse of alcohol that materially impairs the Executive&#x2019;s ability to perform the Executive&#x2019;s duties contemplated hereunder; (iv) the Executive&#x2019;s material breach of this Agreement or any other agreement with the Company Group, or a material violation of any of the Company Group&#x2019;s written policies or procedures; or (v) any other willful misconduct or gross negligence in the performance of the Executive&#x2019;s duties to the Company Group that has caused material injury (including by way of reputational harm or other damages) to any member of the Company Group.  Notwithstanding the foregoing, the Company shall not terminate Executive&#x2019;s employment for Cause pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 6(c)(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iv)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless the Company has first given Executive written notice of the acts or omissions constituting Cause thereunder, and, if such acts or omissions are susceptible to cure, the Executive has failed to cure such acts or omissions to the Company&#x2019;s reasonable satisfaction within thirty (30) days after receipt of such notice.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BY THE COMPANY WITHOUT CAUSE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Upon thirty (30) days&#x2019; prior written notice by the Company to the Executive of an involuntary termination without Cause (other than for death or Disability); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the Board may, in its sole discretion, elect to provide Base Salary to the Executive in lieu of such notice (in whole or in part).</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BY THE EXECUTIVE FOR ANY REASON</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Upon sixty (60) days&#x2019; prior written notice by the Executive to the Company of the Executive&#x2019;s voluntary termination of employment without Good Reason (and in accordance with the procedures set forth below with respect to termination for Good Reason); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the Board may, in its sole discretion, elect to accelerate the date of termination without the payment of additional compensation.  &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means: (i) a failure by the Company to pay the Executive his Base Salary when due, (ii) any involuntary material diminution in the Executive&#x2019;s duties, authorities or responsibilities (other than temporarily while physically or mentally incapacitated or as required by applicable law), (iii) any change to the Executive&#x2019;s title to which the Executive did not consent in writing, or (iv) the Executive being required to relocate to a principal place of employment more than fifty (50) miles from the Executive&#x2019;s principal place of employment with the Company Group at such time; which, in each case, is not cured by the Company Group within thirty (30) days of the Company&#x2019;s receipt of written notice thereof from the Executive specifying the particulars of the conduct constituting Good Reason; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the Executive gives such notice to the Company within ninety (90) days of the Executive having knowledge of the occurrence of such event and, if such event is not cured by the Company, the Executive terminates his employment within thirty (30) days after the end of the Company&#x2019;s cure period; otherwise, Good Reason shall be deemed waived with respect to such event.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXPIRATION OF EMPLOYMENT TERM; NON-EXTENSION OF AGREEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Upon the expiration of the Employment Term due to a non-extension of the Agreement by the Company or the Executive pursuant to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSEQUENCES OF TERMINATION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DEATH OR DISABILITY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In the event that the Executive&#x2019;s employment and the Employment Term end on account of the Executive&#x2019;s death or a termination by the Company due to the Executive&#x2019;s Disability, the Executive&#x2019;s estate or the Executive, as applicable, shall be entitled to the following:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any earned and unpaid Base Salary through the date of termination;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reimbursement for any unreimbursed business expenses incurred through the date of termination;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all other accrued and vested payments, benefits or fringe benefits to which the Executive is entitled in accordance with the terms and conditions of the applicable compensation, or benefit plan, program or arrangement of the Company (collectively, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sections 7(a)(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7(a)(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof shall be hereafter referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;);</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of termination, payable as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof (without regard to any continued employment requirement); and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to the Executive&#x2019;s continued compliance with the obligations in this Agreement (in the event of a termination by the Company due to the Executive&#x2019;s Disability), a monthly amount equal to the Base Salary rate (as in effect immediately prior to the date of Executive&#x2019;s termination), which amount shall be paid in cash to the Executive or his estate, as applicable, in equal installments commensurate with the Company&#x2019;s regularly scheduled payroll in accordance with the payment procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for six (6) months, commencing on the first regularly scheduled payroll date following the date the general release of claims in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is effective and irrevocable (only with respect to a termination by the Company due to the Executive&#x2019;s Disability); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that if the sixty (60)-day period in which the release of claims must be effective and irrevocable begins in one tax year and ends in a later tax year, the payments will commence on the first payroll date following the effective date of the release of claims that begins in the later tax year.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERMINATION FOR CAUSE, BY THE EXECUTIVE WITHOUT GOOD REASON OR AS A RESULT OF THE EXECUTIVE&#x2019;S NON-EXTENSION OF THIS </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGREEMENT.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  If the Executive&#x2019;s employment is terminated (i) by the Company for Cause, (ii) by the Executive for any reason (other than for Good Reason), or (iii) as a result of the Executive&#x2019;s non-extension of the Employment Term as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof, then the Company shall pay to the Executive only the Accrued Benefits.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERMINATION BY THE COMPANY WITHOUT CAUSE, BY THE EXECUTIVE FOR GOOD REASON OR AS A RESULT OF THE COMPANY&#x2019;S NON-EXTENSION OF THIS AGREEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If the Executive&#x2019;s employment by the Company is terminated (x) by the Company other than for Cause (and not on account of the Executive&#x2019;s Disability or death), (y) as a result of the Company&#x2019;s non-extension of the Employment Term as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof or (z) by the Executive for Good Reason, in any event other than within the twelve (12)-month period immediately following a Change in Control, then the Company shall pay or provide the Executive with the following:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Accrued Benefits;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of termination, payable as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof (without regard to any continued employment requirement); and</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to the Executive&#x2019;s continued compliance with the obligations in this Agreement, (1) an amount  equal to the Executive&#x2019;s Base Salary (as in effect immediately prior to the date of Executive&#x2019;s termination), which amount shall be paid in cash to the Executive in equal installments commensurate with the Company&#x2019;s regularly scheduled payroll in accordance with the payment procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for twelve (12) months following the date the Executive&#x2019;s employment terminates, and (2) provided that the Executive timely elects to continue his coverage and that of any eligible dependents in the Company&#x2019;s group health plans under the federal law known as &#x201c;COBRA&#x201d; or similar state law, a monthly amount equal to the monthly health premiums for such coverage paid by the Company on behalf of the Executive and any eligible dependents immediately prior to the date of termination until the earlier of (x) the date that is twelve (12) months following the date that the Executive&#x2019;s employment terminates, (y) the date that the Executive and the Executive&#x2019;s eligible dependents cease to be eligible for such COBRA </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">coverage under applicable law or plan terms and (z) the date on which the Executive obtains health coverage from another employer, in each case commencing on the first regularly scheduled payroll date following the date the general release of claims in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is effective and irrevocable; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that if the sixty (60)-day period in which the release of claims must be effective and irrevocable begins in one tax year and ends in a later tax year, the payments will commence on the first payroll date following the effective date of the release of claims that begins in the later tax year.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments and benefits provided in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall be in lieu of any termination or severance payments or benefits for which the Executive may be eligible under any of the plans, policies or programs of the Company or applicable law (including the Worker Adjustment Retraining Notification Act of 1988 or any similar state statute or regulation).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">change in control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> If the Executive&#x2019;s employment by the Company is terminated (x) by the Company other than for Cause (and not on account of the Executive&#x2019;s Disability or death), (y) as a result of the Company&#x2019;s non-extension of the Employment Term as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof or (z) by the Executive for Good Reason, in any event within the twelve (12)-month period immediately following a Change in Control, then in lieu of the payments and benefits described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company shall pay or provide the Executive with the following:</font></div></div>
  <div style="margin-left:20.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.33375%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Accrued Benefits;</font></div></div>
  <div style="margin-left:20.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.33375%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of termination, payable as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof (without regard to any continued employment requirement); and</font></div></div>
  <div style="margin-left:20.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.33375%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to the Executive&#x2019;s continued compliance with the obligations in this Agreement, (1) an amount equal to one and one half (1.5) times the sum of the Executive&#x2019;s Base Salary and the Executive&#x2019;s target Annual Bonus (in each case, as in effect immediately prior to the date of Executive&#x2019;s termination), which amount shall be paid in cash to the Executive in equal installments commensurate with the Company&#x2019;s regularly scheduled payroll in accordance with the payment procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for a period equal to eighteen (18) months following the date the Executive&#x2019;s employment terminates,  (2) provided that the Executive timely elects to continue his coverage and that of any eligible dependents in the Company&#x2019;s group health plans under the federal law known as &#x201c;COBRA&#x201d; or similar state law, a monthly amount equal to the monthly health premiums for such coverage paid by the Company on behalf of the Executive and any eligible dependents immediately prior to the date of termination until the earlier of (x) the date that is eighteen (18) months following the date that the Executive&#x2019;s employment terminates, (y) the date that the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:20.0%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.33375%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive and the Executive&#x2019;s eligible dependents cease to be eligible for such COBRA coverage under applicable law or plan terms and (z) the date on which the Executive obtains health coverage from another employer, in each case commencing on the first regularly scheduled payroll date following the date the general release of claims in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is effective and irrevocable; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that if the sixty (60)-day period in which the release of claims must be effective and irrevocable begins in one tax year and ends in a later tax year, the payments will commence on the first payroll date following the effective date of the release of claims that begins in the later tax year.</font></div></div>
  <div style="margin-left:20.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.33375%;">(4)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any outstanding and unvested equity awards, the vesting of which is based only on the passage of time, held by the Executive as of the date of termination shall vest in full immediately prior to such termination of employment.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As used herein, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean the consummation of (i) the sale of all or substantially all of the assets of Parent on a consolidated basis to an unrelated individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act) (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); (ii) a merger, reorganization or consolidation pursuant to which the holders of Parent&#x2019;s outstanding voting securities immediately prior to such transaction do not own more than fifty percent (50%) of the outstanding voting securities of the surviving or resulting entity (or its ultimate parent, if applicable); (iii) the acquisition of more than fifty percent (50%) of the outstanding voting securities of Parent in a single transaction or a series of related transactions by any Person; or (iv) the complete dissolution or liquidation of Parent; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that any subsequent public offering or another capital raising event by Parent, a merger effected solely to change Parent&#x2019;s domicile or any acquisition by Parent or any employee benefit plan (or related trust) sponsored or maintained by Parent or any of its subsidiaries or affiliates shall not constitute a &#x201c;Change in Control&#x201d;.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments and benefits provided in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall be in lieu of any termination or severance payments or benefits for which the Executive may be eligible under any of the plans, policies or programs of the Company or applicable law (including the Worker Adjustment Retraining Notification Act of 1988 or any similar state statute or regulation).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OTHER OBLIGATIONS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Upon any termination of the Executive&#x2019;s employment with the Company, and as a condition to receipt of any funds pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Executive shall promptly resign from any position as an officer or director of any Company Group-related entity and will promptly cooperate in the execution of the appropriate documents to effect the resignation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXCLUSIVE REMEDY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The amounts payable to the Executive following termination of employment and the Employment Term hereunder pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sections 6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof shall be in full and complete satisfaction of the Executive&#x2019;s rights under this Agreement and any other claims that the Executive may have in respect of the Executive&#x2019;s employment with the Company or any of its affiliates, and the Executive acknowledges that such amounts are fair </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and reasonable, and are the Executive&#x2019;s sole and exclusive remedy, in lieu of all other remedies at law or in equity, with respect to the termination of the Executive&#x2019;s employment hereunder or any breach of this Agreement. For the avoidance of doubt, Executive&#x2019;s rights to indemnification and advancement of fees survive in accordance with the Indemnification Agreement between the Executive and Parent, as may be amended from time to time in accordance with its terms.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RELEASE; MITIGATION; SET-OFFS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Any and all amounts payable and benefits or additional rights provided pursuant to this Agreement in connection with the Executive&#x2019;s termination of employment beyond the Accrued Benefits shall only be payable if the Executive (or his legal representative in the case of a termination due to the Executive&#x2019;s Disability) delivers to the Company and does not revoke a general release of claims in favor of the Company Group, including with respect to any claims the Executive may have related to the Executive&#x2019;s employment with the Company Group or the termination of such employment, in a form reasonably satisfactory to the Board. The Company agrees that such release will include a mutually agreeable provision that requires the Company to provide instructions to the Parent&#x2019;s directors and officers not to disparage Executive.  Such release shall be executed and delivered (and no longer subject to revocation, if applicable) within sixty (60) days following termination.  In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, and such amounts shall not be offset by any amount received by the Executive from any other source.  Subject to the provisions of this Agreement and the limitations of applicable wage laws, the Company&#x2019;s obligations to pay the Executive amounts hereunder is subject to set-off, counterclaim or recoupment of amounts owed by the Executive to the Company or any of its affiliates (including any member of the Company Group).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 280G</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If any payment or benefit that the Executive may receive, whether or not payable or provided under this Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Excise Tax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), then such Payment shall be reduced to the Reduced Amount.  The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reduced Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall be either (A) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (B) the largest portion, up to and including the total amount, of the Payment, whichever of the amounts determined under (A) and (B), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Executive&#x2019;s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in payments or benefits constituting &#x201c;parachute payments&#x201d; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order: reduction of cash payments; reduction of employee benefits; and cancellation of accelerated vesting of outstanding equity awards. In the event that acceleration of vesting of outstanding equity awards is to be reduced, such acceleration of vesting shall be undertaken in the reverse order of the date of grant of the Executive&#x2019;s outstanding equity awards.  All calculations and determinations made pursuant this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> will be made by an independent accounting, consulting or valuation firm, or independent tax counsel appointed by the Company prior to the Change of Control (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Counsel</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) whose determinations shall be conclusive and binding on the Company and the Executive for all purposes.  For purposes of making the calculations and determinations required by this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Tax </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Counsel may rely on reasonable, good faith assumptions and approximations concerning the application of Section 280G of the Code and Section 4999 of the Code.  The Company shall bear all costs the Tax Counsel may reasonably incur in connection with its services.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding anything to the contrary in this Agreement, if at the time the Executive&#x2019;s employment terminates, the Executive is a &#x201c;specified employee,&#x201d; as defined below, any and all amounts payable under this Agreement on account of such separation from service that would (but for this provision) be payable within six (6) months following the date of termination, shall instead be paid on the next business day following the expiration of such six (6)-month period or, if earlier, upon the Executive&#x2019;s death; except (A) to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation Section 1.409A-1(b) (including without limitation by reason of the safe harbor set forth in Section 1.409A-1(b)(9)(iii), as determined by the Company in its reasonable good faith discretion); (B) benefits that qualify as excepted welfare benefits pursuant to Treasury regulation Section 1.409A-1(a)(5); or (C) other amounts or benefits that are not subject to the requirements of Section 409A of the Code.  For purposes of this Agreement, to the extent required to avoid adverse tax consequences under Section 409A of the Code, all references to &#x201c;termination of employment&#x201d; and correlative phrases shall be construed to require a &#x201c;separation from service&#x201d; (as defined in Section 1.409A-1(h) of the Treasury regulations after giving effect to the presumptions contained therein), and, for purposes of this Agreement, the term &#x201c;specified employee&#x201d; means an individual determined by the Company to be a specified employee under Treasury regulation Section 1.409A-1(i).  Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.  In no event shall the Company or any of its affiliates have any liability to the Executive or any other person relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RESTRICTIVE COVENANTS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NONCOMPETITION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Executive acknowledges that (i) the Executive will continue to perform valuable services for the Company, and that the Executive&#x2019;s performance of such services to a competing business will result in irreparable harm to the Company Group, (ii) the Executive has had and will have access to certain confidential information which, if improperly disclosed in violation of the Agreement, would unfairly and inappropriately assist in competition against the Company Group, and (iii) the Executive has generated and will generate goodwill for the Company Group in the course of the Executive&#x2019;s employment.  Accordingly, during the Executive&#x2019;s employment or service with the Company Group and for a period thereafter equal to twelve (12) months, the Executive agrees that the Executive will not, directly or indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise, and whether or not for compensation) or render services to any person, firm, corporation or other entity, in whatever form, engaged in the Business (as defined below), in any locale of any country in which the Company Group conducts the Business.  For purposes hereof, the term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean the business of developing biological medicines for treating patients with devastating diseases, or any business in which the Company Group is engaged in upon the termination of Executive&#x2019;s employment or in which the Company Group has actively and in writing planned, on or prior to such date, to be engaged in on or after such date.  Notwithstanding the foregoing, nothing herein shall prohibit the Executive from being a passive owner of not more </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">than two percent (2%) of the equity securities of a publicly traded corporation engaged in a business that is in competition with the Company Group, so long as the Executive has no active participation in the business of such corporation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NONSOLICITATION; NONINTERFERENCE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Executive&#x2019;s employment or service with the Company Group and for a period thereafter equal to twelve (12) months, the Executive agrees that the Executive shall not, except in the furtherance of the Executive&#x2019;s duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or other entity, (i) solicit, aid or induce any customer of the Company Group with whom the Executive had direct dealings while employed by the Company Group to purchase goods or services then sold by the Company Group from another person, firm, corporation or other entity or assist or aid any other person or entity in identifying or soliciting any such customer, (ii) solicit, aid or induce any employee, representative or agent of the Company Group to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or other entity unaffiliated with the Company Group, or hire or retain any such employee, representative or agent, or take any action to materially assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such employee, representative or agent, or (iii) knowingly interfere, or knowingly aid or induce any other person or entity in interfering, with the relationship between the Company Group and any of their respective vendors, joint venturers or licensors.  An employee, representative or agent shall be deemed covered by this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> while so employed or retained and for a period of nine (9) months thereafter.  Notwithstanding the foregoing, the provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall not be violated by general advertising or solicitation not specifically targeted at Company Group-related persons or entities.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NONDISPARAGEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Both during the Employment Term and at all times thereafter, regardless of the reason for termination, the Executive agrees not to make comments materially injurious to the reputation of the Company Group or otherwise disparage the Company Group or any of their officers, directors, employees, shareholders (in their capacity as such), members, agents or products.  Any disclosure by the Executive in good faith in connection with any legal proceedings between the Executive and the Company Group, in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings) shall not be deemed to violate this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RETURN OF COMPANY PROPERTY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  On the date of the Executive&#x2019;s termination of employment with the Company for any reason (or at any time prior thereto at the Company Group&#x2019;s request), the Executive shall return to the Company all property belonging to the Company Group or its affiliates including, but not limited to, any Company-provided laptops, computers, cell phones, wireless electronic mail devices or other equipment, or any property belonging to the Company Group and any Documents.  The Executive also agrees to disclose to the Company, at the time his employment terminates or at such earlier time or times as the Board or its designee may specify, all passwords necessary or desirable to obtain access to, or that would assist in obtaining access to, any information which the Executive has password-protected on any computer equipment, network or system of the Company Group or any of its affiliates.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REASONABLENESS OF COVENANTS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In signing this Agreement, the Executive gives the Company Group assurance that the Executive has carefully read and considered all of the terms and conditions of this Agreement, including the restraints imposed under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Executive agrees that these restraints are necessary for the reasonable and proper protection of the Company Group and their confidential information and that each and every one of the restraints is reasonable in respect of subject matter, length of time and geographic area, and that these restraints, individually or in the aggregate, will not prevent the Executive from obtaining other suitable employment during the period in which the Executive is bound by the restraints.  The non-prevailing party will reimburse the prevailing party for all costs (including reasonable attorneys&#x2019; fees) incurred in connection with any action to enforce any of the provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  It is also agreed that each member of the Company Group will have the right to enforce all of the Executive&#x2019;s obligations to that member under this Agreement, including without limitation pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REFORMATION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If it is determined by a court of competent jurisdiction in any state that any restriction in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is excessive in duration or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the laws of that state.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOLLING</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In the event of any violation of the provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Executive acknowledges and agrees that the post-termination restrictions contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall be extended by a period of time equal to the period of such violation, it being the intention of the parties hereto that the running of the applicable post-termination restriction period shall be tolled during any period of such violation; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that tolling period shall not exceed sixty (60) days after the Company Group has knowledge of such violation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SURVIVAL OF PROVISIONS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The obligations contained in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sections 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof shall survive the termination or expiration of the Employment Term and the Executive&#x2019;s employment with the Company and shall be fully enforceable thereafter.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COOPERATION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In connection with any termination of the Executive&#x2019;s employment with the Company, the Executive agrees to assist the Company Group, as reasonably requested by the Company Group, in its succession planning efforts to facilitate a smooth transition of the Executive&#x2019;s job responsibilities to the Executive&#x2019;s successor.  In addition, upon the receipt of reasonable notice from the Company Group (including outside counsel), the Executive agrees that while employed by, or providing services to, the Company Group and thereafter, the Executive will respond and provide truthful information with regard to matters in which the Executive has knowledge as a result of the Executive&#x2019;s employment with the Company Group, and will reasonably cooperate with the Company Group and their respective representatives in defense of all claims that may be made against the Company Group, and will cooperate with the Company Group in the prosecution of all claims that may be made by the Company Group, to the extent that such claims may relate to the period of the Executive&#x2019;s employment or service with the Company Group and the Company reasonably believes that the Executive has pertinent knowledge or information related to such claims.  The Executive agrees to promptly inform the Company (to the extent that the Executive is legally permitted to do so) if the Executive becomes aware of any lawsuit involving such third party claims that may be filed or threatened against the Company </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Group.  The Executive also agrees to promptly inform the Company (to the extent that the Executive is legally permitted to do so) if the Executive is asked to assist in any investigation of the Company Group (or their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company Group with respect to such investigation, and shall not do so unless legally required.  Upon presentation of appropriate documentation, the Company shall pay or reimburse the Executive for all reasonable out-of-pocket travel, duplicating or telephonic expenses incurred by the Executive in complying with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EQUITABLE RELIEF AND OTHER REMEDIES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Executive acknowledges and agrees that the Company&#x2019;s remedies at law for a breach or threatened breach of any of the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof would be inadequate and, in recognition of this fact, the Executive agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company Group shall be entitled to seek equitable relief in the form of specific performance, a temporary restraining order, a temporary or permanent injunction or any other equitable remedy which may then be available, without the necessity of showing actual monetary damages and without posting any bond or other security.  In the event of a violation by the Executive of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof, any severance being paid to the Executive pursuant to this Agreement or otherwise shall immediately cease, and any severance previously paid to the Executive shall be immediately repaid to the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NO ASSIGNMENTS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement is personal to each of the parties hereto.  Except as provided in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, no party may assign or delegate any rights or obligations hereunder without first obtaining the written consent of the other party hereto.  The Company may assign this Agreement to any successor to all or substantially all of the business and/or assets of the Company or to any of its subsidiaries or affiliates; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that the Company shall require such assignee to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such assignment had taken place.  As used in this Agreement, &#x201c;Company&#x201d; shall mean the Company and any successor to its business and/or assets or assignee of this Agreement, which assumes and agrees to perform the duties and obligations of the Company under this Agreement by operation of law or otherwise.  Each member of the Company Group is an intended third party beneficiary of this Agreement and shall be entitled to enforce the provisions of this Agreement as if a direct party to this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTICE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  For purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a) on the date of delivery, if delivered by hand, (b) on the date of transmission, if delivered by confirmed facsimile or by electronic mail, (c) on the first business day following the date of deposit, if delivered by guaranteed overnight delivery service, or (d) on the fourth business day following the date delivered or mailed by United States registered or certified mail, return receipt requested, postage prepaid, addressed as follows:</font></div></div>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If to the Executive:</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the address (or to the facsimile number or email address)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shown in the books and records of the Company.</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If to the Company:</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rallybio, LLC</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234 Church Street</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 1020</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New Haven, CT 06510</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attention:  Michael Greco</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Email: </font><font style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mgreco@rallybio.com</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION HEADINGS; INCONSISTENCY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The section headings used in this Agreement are included solely for convenience and shall not affect, or be used in connection with, the interpretation of this Agreement.  In the event of any inconsistency between the terms of this Agreement and any form, award, plan or policy of the Company Group, the terms of this Agreement shall govern and control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">17.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEVERABILITY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The provisions of this Agreement shall be deemed severable.  The invalidity or unenforceability of any provision of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in such jurisdiction or the validity, legality or enforceability of any provision of this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by applicable law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">18.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COUNTERPARTS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">19.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GOVERNING LAW; JURISDICTION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement, the rights and obligations of the parties hereto, and all claims or disputes relating thereto, shall be governed by and construed in accordance with the laws of the State of Connecticut, without regard to the choice of law provisions thereof.  Each of the parties hereby irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of the State of Connecticut and the United States District Court for the District of Connecticut, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, for the purpose of any suit, action or other proceeding arising out of or in connection with this Agreement or any of the transactions contemplated hereby, and irrevocably and unconditionally waives, to the fullest extent permitted by law, any and all objections such party may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.  In that context, and without limiting the generality of the foregoing, each of the parties hereto irrevocably and unconditionally (a) submits in any proceeding relating to this Agreement or the Executive&#x2019;s employment by the Company or any affiliate, or for the recognition and enforcement of any judgment in respect thereof (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), to the exclusive jurisdiction of the courts of the State of Connecticut and the United States District Court for the District of Connecticut, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, and agrees that all claims in respect of any such </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeding shall be heard and determined in such Connecticut State court or, to the extent permitted by law, in such federal court, (b) consents that any such Proceeding may and shall be brought in such courts and waives any objection that the Executive or the Company may now or thereafter have to the venue or jurisdiction of any such Proceeding in any such court or that such Proceeding was brought in an inconvenient court and agrees not to plead or claim the same, (c) WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE&#x2019;S EMPLOYMENT BY OR SERVICE WITH THE COMPANY OR ANY AFFILIATE OF THE COMPANY, OR THE EXECUTIVE&#x2019;S OR THE COMPANY&#x2019;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT, (d) agrees that service of process in any such Proceeding may be effected by mailing a copy of such process by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such party at the Executive&#x2019;s or the Company&#x2019;s address as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof, (e) agrees that nothing in this Agreement shall affect the right to effect service of process in any other manner permitted by the laws of the State of Connecticut and (f) expressly waives any and all rights to bring any suit, action or other proceeding arising out of or in connection with this Agreement in or before any court or tribunal other than the courts of the State of Connecticut or the United States District Court for the District of Connecticut and any courts to which an appeal may be taken from such courts, and covenants that such party shall not seek in any manner to resolve any dispute other than as set forth herein or to challenge or set aside any decision, award or judgment obtained in accordance with the provisions hereof.  Except as may be explicitly set forth in this Agreement, the parties acknowledge and agree that in connection with any dispute hereunder, each party shall pay all of its own costs and expenses, including, without limitation, its own legal fees and expenses.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">20.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MISCELLANEOUS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by the Executive and such officer or director of the Company as may be designated by the Board or the Compensation Committee, and in any case must be approved by the Board or the Compensation Committee.  In addition, notwithstanding anything to the contrary in this Agreement, the Company may not terminate this Agreement (including by notice of non-renewal) or the Executive&#x2019;s employment without Board or Compensation Committee approval.  No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.  This Agreement together with all exhibits hereto (if any) set forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersede any and all prior agreements or understandings between the Executive and the Company with respect to the subject matter hereof.  No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement.  Any references in this Agreement to &#x201c;$&#x201d; shall mean U.S. dollars.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">21.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPRESENTATIONS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Executive represents and warrants to the Company that (a) the Executive has the legal right to enter into this Agreement and to perform all of the obligations on the Executive&#x2019;s part to be performed hereunder in accordance with its terms, and (b) the Executive is not a party to any agreement or understanding, written or oral, and is not </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to any restriction, which, in either case, could prevent the Executive from entering into this Agreement or performing all of the Executive&#x2019;s duties and obligations hereunder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">22.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TAX MATTERS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company Group may withhold from any and all amounts payable under this Agreement or otherwise such federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">23.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OTHER</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nothing contained in this Agreement limits, restricts or in any other way affects the Executive&#x2019;s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to such governmental agency or entity and the Executive will not be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or (ii) in a complaint or other document filed under seal in a lawsuit or other proceeding; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that notwithstanding this immunity from liability, the Executive may be held liable if he unlawfully accesses trade secrets by unauthorized means.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*	*	*	*	*</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the parties hereto have executed this Agreement as of the date first written above.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:40.994%;"></td>
    <td style="width:8.002%;"></td>
    <td style="width:25.0%;"></td>
    <td style="width:26.004%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RALLYBIO, LLC</font></p></td>
   </tr>
   <tr style="height:17.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;/s/ Martin Mackay</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Martin W. Mackay, Ph.D.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:36.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:36.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;/s/   Jonathan Lieber</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:36.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.03in;vertical-align:top;padding-right:0.03in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jonathan Lieber</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Salarius Pharmaceuticals (Nasdaq: SLRX) &#x2013; service as a member of the Board of Directors and its committees</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Schedule A to Employment Agreement]</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>rlyb-ex10_25.htm
<DESCRIPTION>EX-10.25
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.25</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of this Exhibit have been redacted because they are both (i) not material and (ii) the registrant customarily and actually treats such information as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#x201c;[***]&#x201d;.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONFIDENTIAL RELEASE AND SEPARATION AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;" id="saveserver"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Confidential Release and Separation Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is made by and between Jeffrey M. Fryer, [***] (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">you</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on behalf of yourself and your agents, assignees, heirs, executors, administrators, beneficiaries, trustees, legal representatives and assigns (collectively &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and Rallybio Corporation, its subsidiaries, parents, affiliates, divisions and related entities (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), on behalf of its and their successors, predecessors, assigns, present or former directors, officers, executives, agents, attorneys, shareholders, fiduciaries or employees or any person acting on behalf of any of them (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company Released Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> you entered into the Amended and Restated Employment Agreement between you and Rallybio, LLC, a wholly-owned subsidiary of Rallybio Corporation, on July 15, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, you and the Company wish to enter into this Agreement to fully resolve any actual or potential claims, including without limitation claims arising out of your employment with and/or separation from the Company;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in consideration of the promises and mutual covenants set forth herein, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">End of Employment.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Your employment with the Company ended effective February 15, 2023 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separation Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Regardless of whether you sign this agreement, you will be paid your base salary through the Separation Date.  You acknowledge that (i) with the receipt of your final paycheck, you will have received all compensation and benefits that were due to you through the Separation Date as a result of services performed for the Company; and (ii) you have reported to the Company any and all work-related injuries incurred during your employment.  You acknowledge that you have resigned from your employment, from any and all officer positions you hold with the Company, from any and all memberships you hold on any board of managers or any other governing board of the Company and from any and all memberships you hold on any of the committees of any such boards (together, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Resignations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) with such Resignations having been effective as of the Separation Date (as defined below).  The Company hereby accepts the Resignations as of the Separation Date.  You hereby acknowledge and agree that you will execute such additional documents as requested by the Company to evidence the Resignations. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Status of Employee Benefits; Equity Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Except for any right you may have to continue your participation and that of your eligible dependents in the Company&#x2019;s medical, dental, and vision plans under the federal law known as &#x201c;COBRA&#x201d; or similar applicable law (together, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COBRA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), your participation in all employee benefit plans of the Company ended as of the Separation Date, in accordance with the terms of those plans.  You acknowledge that you have not continued to earn paid time off or other similar </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">benefits after the Separation Date.  You will receive information about your COBRA continuation rights under separate cover.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Your rights and obligations with respect to any restricted stock, stock options and other equity or equity-based awards granted to you by the Company which had vested as of the Separation Date shall be governed by the applicable equity incentive plan and the award agreement evidencing such award.  All equity awards that were unvested as of the Separation Date have been cancelled for no consideration as of that date, except as set forth below in Section 3.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consideration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  In exchange for your execution of and compliance with this Agreement, and provided that you do not revoke this Agreement as set forth in Section 18, the Company will provide you with the benefits set forth below in this Section 3, which shall be in full satisfaction of any severance benefits owed to you under the Employment Agreement.  In consideration for your execution, non-revocation of and compliance with this Agreement, the Company will accelerate the vesting of the unvested equity awards set forth on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> attached hereto, which are issued and outstanding shares of common stock of the Company subject to a risk of forfeiture, effective on the Effective Date (as defined in Section 18 hereof).  On the Separation Date, all other unvested equity awards granted to you will be cancelled and/or forfeited in accordance with their terms.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Admission</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company&#x2019;s offer of this Agreement to you and any payments made under this Agreement do not constitute an admission by the Company that you have any claim of any kind against the Company or that the Company admits to any liability.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  In exchange for the consideration described in Section 3 of this Agreement, and provided that you do not revoke this Agreement as set forth in Section 18, you and the Employee Parties agree to release the Company and the Company Released Parties from all known and unknown claims of any type through the date you execute this Agreement, including without limitation, any known or unknown claims arising out of anything having to do with your employment with the Company or the end of your employment.  This means that you and the Employee Parties give up these claims to the fullest extent permitted by law, including without limitation:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claims for any pay, compensation or benefits, bonuses, commissions, incentive pay, paid or unpaid leave or time off, salary, separation or severance pay or benefits, wages, unpaid accrued vacation or other paid time off, overtime, unvested equity, or any other form of compensation whatsoever (including penalties for non-payment), costs, damages, interest, expenses or insurance;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claims concerning any express or implied employment contracts, covenants or duties;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claims for defamation; detrimental reliance; fraud; impairment/loss of business/economic opportunity; insufficiency of termination notice; intentional/negligent infliction of emotional distress; interference with contractual or legal rights; invasion of privacy; loss of consortium; misrepresentation; negligence including negligent hiring/retention/supervision; personal injury; premises liability; promissory estoppel; public policy violation; retaliatory discharge; tortious interference; posting requirement violations; records access violations; wrongful termination; or any other federal, state, local or common law claims;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claims of discrimination based on age, ancestry, benefit entitlement, color, concerted activity, disability, failure to accommodate, gender, gender identity or expression, genetics, harassment, income source, leave rights, marital status, military status, national origin, parental status, perception of a protected characteristic, political affiliation, race, religion, retaliation, sex, sexual orientation, union activity, veteran status or other legally protected status; claims that any payment under this Agreement was affected by any such discrimination; or any other claims under Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1866; the Civil Rights Act of 1991; the Equal Pay Act of 1963; the Age Discrimination in Employment Act (&#x201c;ADEA&#x201d;) and the Older Workers Benefit Protection Act; the Americans with Disabilities Act; the Family and Medical Leave Act; the Employee Retirement Income Security Act; the Sarbanes-Oxley Act of 2002; or the False Claims Act; each as amended;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claims arising under state or local law, including, but not limited to, the Connecticut Fair Employment Practices Act, Conn. Gen. Stat. &#167;&#167; 46a-51 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">et seq.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; the Connecticut Human Rights and Opportunities Act, Conn. Gen. Stat. &#167; 46a-60; the Connecticut Equal Pay Law, Conn. Gen. Stat. &#167; 31-75; and the Connecticut Family and Medical Leave Law, Conn. Gen. Stat. &#167;&#167; 31-51kk </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">et seq.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, each as amended; and</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> any right to be or remain a member of any class or collective action against the Company or the Company Released Parties.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You acknowledge and agree that, as a condition of this Agreement, you and the Employee Parties expressly release all rights and claims against the Company or the Company Released Parties that you know about, as well as those you may not know about.  For the purpose of implementing a full and complete release and discharge of the Company, the Company Released Parties, and others released herein, you expressly acknowledge that this Agreement is intended to include and does include in its effect, without limitation, all claims which you do not know or suspect to exist, and that this Agreement contemplates the extinguishment of any such claim or claims, except to the extent precluded by federal, state or local statutes.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the foregoing, and in further exchange for the consideration described in Section 3 of this Agreement, you specifically represent and warrant that as of the date that you execute this Agreement, either you  (i) have disclosed to the Company&#x2019;s General Counsel or to another member of the Company&#x2019;s internal Legal Department in writing any matter that you know, suspect or have reason to know or suspect could constitute an actual or potential violation of the Company&#x2019;s Code of Business Conduct and Ethics, or similar code of business conduct and ethics, or of any internal or external legal, regulatory or compliance requirement applicable to the Company in any jurisdiction in which it does business, or (ii) have no information concerning any such matter.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Promise Not to Sue</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Without limiting your rights under Section 12 of this Agreement, you promise not to sue the Company or any Company Released Party for any claims covered by Section 5 of this Agreement, and not excluded by any other section of this Agreement.  This promise not to sue is separate from and in addition to your promises in Section 5 of this Agreement.   </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nondisparagement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Subject to the second and third sentences of Section 12 of this Agreement, you agree not to make comments injurious to the reputation of the Company or the Company Released Parties or otherwise disparage the Company or the Company Released Parties.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any disclosure by you in good faith in connection with any legal proceedings between you and the Company, in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings) shall not be deemed to violate this Section 8.  The Company agrees that it will instruct members of the Rallybio leadership team not to make any disparaging or defamatory statements about you at any time, oral or written (including in any electronic form), to any other person or entity.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continuing Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  You acknowledge and agree that the restrictive covenants in Section 11 of the Employment Agreement and in the Confidential Information and Invention Assignment Agreement which you signed in connection with your employment (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continuing Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), survive your separation from the Company and remain in full force and effect, subject to the second and third sentences of Section 12 of this Agreement.  Without limiting your obligations under the Continuing Obligations, you agree to comply with the covenants listed below following the Separation Date.</font></div></div>
  <div style="text-indent:14.133%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:14.13%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.6960491476124%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Confidentiality</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognize that an unauthorized disclosure or use of Confidential or Proprietary Information (as defined below)</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">could cause damage to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(7,7,7,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Therefore</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, you agree</font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to hold in confidence and not to disclose or use, or authorize anyone else to disclose or use, any </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidential </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proprietary </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information of the Company </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any time following the Separation Date without the express consent of the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  For </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">purposes of this Agreement, </font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidential or Proprietary Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall be deemed to include any information, knowledge, </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">records, </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">data or trade secrets of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(whether or not reduced to written, electronic, magnetic or other tangible form) coming into your possession, or which </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">you </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have learned, or to which you have access, </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which you developed or discovered as a result of your employment with the Company.  Trade secrets hereunder shall include without limitation information that has commercial value to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from a negative viewpoint, such as the results of research which proves that certain processes used to attempt to develop new technology will be unsuccessful.  Notwithstanding the foregoing, this Section 9(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">apply </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to any matter </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is now or becomes part of the public domain, other than through your </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improper act </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or omission, which you can reasonably demonstrate was known to you prior to the commencement of your employment with the Company or which you can reasonably demonstrate was disclosed to you by a third party which did not obtain </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">information, directly or indirectly, under any obligation of confidence to the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Further</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">this Section 9(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(50,50,50,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not apply to information which you are required to disclose by enforceable legal processes</font><font style="background-color:rgba(0,0,0,0);color:rgba(7,7,7,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:14.133%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:14.13%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.6960491476124%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Noncompetition.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You acknowledge that, (i) prior to the Separation Date, you performed valuable services for the Company, and that your performance of such services to a competing business will result in irreparable harm to the Company, (ii) you have had and will have access to certain confidential information which, if improperly disclosed, would unfairly and inappropriately assist in competition against the Company, and (iii) you have generated and will generate goodwill for the Company in the course of your employment.  Accordingly, for a period of twelve (12) months following the Separation Date, you agree that you will not, directly or indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise, and whether or not for compensation) or render services to any person, firm, corporation or other entity, in whatever form, engaged in the Business (as defined below), in any locale of any country in which the Company conducts the Business.  For purposes hereof, the term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean the business of developing biological medicines for treating </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:14.13%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patients with devastating diseases in which the Company is engaged in upon the Separation Date or in which the Company has actively evaluated and pursued as a potential business, on or prior to the Separation Date, to be engaged in on or after such date.  Notwithstanding the foregoing, nothing herein shall prohibit you from being a passive owner of not more than two percent (2%) of the equity securities of a publicly traded corporation engaged in a business that is in competition with the Company, so long as you have no active participation in the business of such corporation.</font></div></div>
  <div style="text-indent:14.133%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:14.13%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.6960491476124%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nonsolicitation; Noninterference</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a period of twelve (12) months following the Separation Date, you agree that you shall not, directly or indirectly, individually or on behalf of any other person, firm, corporation or other entity, (i) solicit, aid or induce any customer of the Company with whom you had direct dealings while employed by the Company to purchase goods or services then sold by the Company from another person, firm, corporation or other entity or assist or aid any other person or entity in identifying or soliciting any such customer, (ii) solicit, aid or induce any employee, representative or agent of the Company to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or other entity unaffiliated with the Company, or hire or retain any such employee, representative or agent, or take any action to materially assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such employee, representative or agent, or (iii) knowingly interfere, or knowingly aid or induce any other person or entity in interfering, with the relationship between the Company and any of their respective vendors, joint venturers or licensors.  An employee, representative or agent shall be deemed covered by this Section 9(c) while so employed or retained and for a period of nine (9) months thereafter.  Notwithstanding the foregoing, the provisions of this Section 9(c) shall not be violated by general advertising or solicitation not specifically targeted at Company-related persons or entities.</font></div></div>
  <div style="text-indent:14.133%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:14.13%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.6960491476124%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Remedies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You acknowledge that you have read and considered the restraints imposed upon you pursuant to this Section 9.  You agree without reservation that these restraints are necessary for the reasonable and proper protection of the Company, and are reasonable in respect to subject matter, length of time, and geographic area.  If you commit a breach, or threaten to commit a breach, of any provision of this Section 9, the Company shall have the right and remedy to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Company and that money damages may not provide an adequate remedy to the Company.  You therefore agree that the Company, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by the Company of any of the provisions of this Section 9, without having to post bond.  </font></div></div>
  <div style="text-indent:14.133%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:14.13%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:8.6960491476124%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Severability; Modification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If any of the covenants contained in this Section 9, or any part thereof, is hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect without regard to the invalid portions.  Moreover, if any of the covenants contained in this Section 9, or any part thereof, are held to be unenforceable because of the duration or scope of such provision or the area covered thereby, you and the Company agree that the court making such determination shall have the power to reduce the duration and/or area of such provision, and you and the Company intend for the court to modify the duration and/or area of such provision to the maximum extent permitted by law.  You and the Company agree that, in its reduced form, such provision shall then be enforceable.  In the event that the courts of any state of the United States shall hold any such covenant wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:14.13%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hereto that such determination not bar or in any way affect the Company&#x2019;s right to the relief provided above in the courts of any other states within the geographical scope of such other covenants, as to breaches of such covenants in such other respective jurisdictions, the above covenants as they relate to each state being, for this purpose, severable into diverse and independent covenants.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Return of Company Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You agree that you have returned or will return immediately, all property belonging to the Company, including, but not limited to, any Company-provided laptops, computers, cell phones, wireless electronic mail devices or other equipment, or any property belonging to the Company and any Company documents.  You also agree to disclose to the Company all passwords necessary or desirable to obtain access to, or that would assist in obtaining access to, any information which you have password-protected on any computer equipment, network or system of the Company.  By your signature below, you warrant and representation that you have conducted a thorough search for Company property in all such electronic document storage accounts and electronic devices, as well as all files and hard copy documents in your possession, custody, or control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cooperation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  You agree to cooperate with, and assist, the Company to ensure a smooth transition of your work responsibilities.  For two years following the Separation Date, you will provide such information as the Company may reasonably request with respect to any Company-related transaction or other matter in which you were involved in any way while employed by the Company.  You further agree to assist and cooperate with the Company in connection with the defense, prosecution, government investigation, or internal investigation of any claim or matter that may be made against, concerning, or by the Company.  Such assistance and cooperation shall include timely, comprehensive, and truthful disclosure of all relevant facts known to you, including through in-person interview(s) with the Company&#x2019;s internal Legal Department or outside counsel for the Company.  You shall be entitled to reimbursement for all properly documented expenses incurred in connection with rendering services under this Section 11, including, but not limited to, reimbursement for all reasonable travel, lodging, and meal expenses.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Interference with Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Release set forth in Section 5 of this Agreement excludes any claims for breach of this Agreement, claims challenging the enforceability of this Agreement under the ADEA, and claims which cannot be waived by law, such as claims for unemployment or worker&#x2019;s compensation benefits, or claims for vested/earned benefits under ERISA-covered employee benefit plans.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, you understand, agree and acknowledge that nothing contained in this Agreement, including but not limited to Sections 5 (Release), 6 (Disclosure), 7 (Promise Not to Sue), 8 (Nondisparagement), 9 (Continuing Obligations), 10 (Return of  Company Property), 11 (Cooperation), will prevent, prohibit or restrict you from reporting possible violations of any law or regulation to, making disclosures to, and/or participating or cooperating in any investigation or proceeding conducted by the National Labor Relations Board (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NLRB</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), the Equal Employment Opportunity Commission (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EEOC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), the U.S. Department of Labor, the Securities and Exchange Commission, and/or any other governmental agency or entity charged with the enforcement of any laws, or from exercising rights under Section 7 of the National Labor Relations Act to engage in joint activity with other employees, except that you acknowledge that, to the maximum extent permitted by law, you are waiving your right to recover any benefits, including without limitation monetary damages, in connection with any such claim, charge or proceeding brought against the Company, regardless of who filed or initiated any such complaint or </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">charge and/or in what forum such complaint or charge is brought in. Notwithstanding any other provision in this Agreement, you are not required to seek authorization from the Company or to notify the Company before making any such report or disclosure, or before participating or cooperating in any investigation or proceeding. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> You acknowledge that you have been notified in accordance with the Defend Trade Secrets Act of 2016, 18 U.S.C. &#167; 1833(b), that you will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.  You further acknowledge that you have been notified that if you file a lawsuit for retaliation against the Company for reporting a suspected violation of law, you may disclose the Company&#x2019;s trade secrets with your attorney and use the trade secret information related to that suspected violation of law in the court proceeding if you: (a) file any document containing the trade secret under seal; and (b) do not disclose the trade secret, except pursuant to court order.  Notwithstanding this immunity from liability, you may be held liable if you unlawfully access trade secrets by unauthorized means.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remedies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  You agree that if you are found to have violated this Agreement, you will pay the Company&#x2019;s reasonable attorneys&#x2019; fees, court costs and other expenses to enforce this Agreement, in addition to any other available relief.  Without limiting the foregoing, you further acknowledge and agree that, if you violate the terms of this Agreement by, without limitation, violating the covenants in Sections 5 (Release), 6 (Disclosure), 7 (Promise Not to Sue), 8 (Nondisparagement), 9 (Continuing Obligations), 10 (Return of Company Property), or 11 (Cooperation), the Company may (a) recapture the value of any proceeds from the exercise or sale of equity awards that were unvested as of the Separation Date, (b) require you to return all but $100.00 of the payments and benefits provided to you under this Agreement, and (c) suspend payment of any further payments and benefits provided to you under this Agreement.  Nothing herein shall limit your rights under Section 12 of this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Choice of Law and Forum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  This Agreement shall be governed by and construed under the laws of the State of Connecticut, without regard to its conflicts of law rules.  You and the Company hereby consent to the jurisdiction of the federal and state courts located in the State of Connecticut to resolve any disputes arising out of the interpretation or administration of this Agreement.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Successors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement shall be binding upon and inure to the benefit of you and the Employee Parties, the Company, the Company Released Parties, and their respective heirs, representatives, executors, administrators, successors, insurers, and assigns, and shall inure to the benefit of each and all of them.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The provisions of this Agreement are severable, and if any part of it is found to be unenforceable or invalid, the other Sections shall remain fully valid and enforceable.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">17.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Representations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  You acknowledge and agree that:</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">you are advised, and by being given a copy of this Agreement, have been advised to consult with an attorney of your own choice, and you have been given the opportunity to do so prior to signing this Agreement;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:40.0%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">you have not been promised anything besides what is in this Agreement;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the benefits described in this Agreement exceed the amount that you otherwise would receive at the end of your employment with the Company and provide adequate and sufficient consideration to support this Agreement; </font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">you have reviewed this Agreement and are signing this Agreement knowingly and voluntarily;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">you have not been coerced or threatened into signing this Agreement;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">you do not have any pending court or administrative complaint or action against the Company; </font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">you were not required to waive any attorneys&#x2019; fees as a condition of this Agreement; and</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">this Agreement can only be modified in a written document signed by both you and the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">18.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Time Periods</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  You are given twenty-one (21) days from the date you receive this Agreement to consider it before executing it (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consideration Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  You may sign this agreement any time after your Separation Date and before the close of business on the final day of the Consideration Period.  If you sign this Agreement prior to the end of the Consideration Period, your signature constitutes a voluntary waiver of this Consideration Period.  You agree with the Company that changes to this Agreement, whether material or immaterial, do not restart the running of the Consideration Period.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You will have seven (7) calendar days after you sign this Agreement to revoke it (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revocation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by providing written notice to the Company during the Revocation Period.  Any revocation must be made in writing, postmarked no later than the close of business on the 7th day of the Revocation Period and addressed to:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kim Stepanski</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Head of Human Resources</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rallybio Corporation</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234 Church Street, Suite 1020</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New Haven, CT 06510</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Agreement will not become effective or enforceable until the Revocation Period has expired (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  If you do not revoke this Agreement, you will receive the consideration described in Section 3 of this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding anything to the contrary in this Agreement, if the Consideration Period or the Revocation Period spans two calendar years, any payments to which you become entitled under this Agreement following the Effective Date will be paid in the second calendar year to the extent such payments constitute &#x201c;nonqualified deferred compensation&#x201d; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IRC &#167;409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">19.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  This Agreement is intended to comply with the applicable requirements of IRC &#167;409A and shall be construed accordingly.  All references in this Agreement to termination of employment, a termination, retirement, cessation of employment, separation from service, and correlative terms, that result in the payment or vesting of any amounts or benefits that constitute &#x201c;nonqualified deferred compensation&#x201d; within the meaning of IRC &#167;409A shall be construed to require a Separation from Service (as defined below), and the date of such termination in any such case shall be construed to mean the date of the Separation from Service.  Each of the payments required to be made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments for purposes of IRC &#167;409A.  If you are a Specified Employee (as defined below) on the Separation Date, if any payment hereunder that is payable by reason of the termination of your employment constitutes &#x201c;nonqualified deferred compensation&#x201d; subject to IRC &#167;409A and would otherwise have been required to be paid during the six (6)-month period following such termination of employment, it shall instead be delayed and paid, without interest, in a lump sum on the date that is six (6) months and one (1) day after your termination of employment (or, if earlier, the date of your death).  You are solely responsible for any tax penalties that may be imposed on you as a result of IRC &#167;409A.  In no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of IRC &#167;409A.  For purposes of the foregoing: </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separation from Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean a &#x201c;separation from service&#x201d; (as that term is defined at Section 1.409A-1(h) of the Treasury Regulations under IRC &#167;409A after giving effect to the presumptions contained therein) from the Company and from all other corporations and trades or businesses, if any, that would be treated as a single &#x201c;service recipient&#x201d; with the Company under Section 1.409A-1(h)(3) of such Treasury Regulations.  The Board of Directors of Rallybio Corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) or the Compensation Committee thereof (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) may, but need not, elect in writing, subject to the applicable limitations under IRC &#167;409A, any of the special elective rules prescribed in Section 1.409A-1(h) of the Treasury Regulations for purposes of determining whether a &#x201c;separation from service&#x201d; has occurred.  Any such written election shall be deemed part of this Agreement; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specified Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean an individual determined by the Board, the Committee, or their delegate, to be a &#x201c;specified employee&#x201d; as defined in subsection (a)(2)(B)(i) of IRC &#167;409A.  The Committee may, but need not, elect in writing, subject to the applicable limitations under IRC &#167;409A, any of the special elective rules prescribed in Section 1.409A-1(i) of the Treasury Regulations for purposes of determining &#x201c;specified employee&#x201d; status.  Any such written election shall be deemed part of this Agreement.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">20.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  This Agreement and its exhibits (if any) set forth the entire agreement between the parties.  You are not relying on any other agreements or oral representations not fully addressed in this Agreement.  Any prior agreements between or directly involving you and the Company are superseded by this Agreement (including the Employment Agreement; provided, that, Sections 7(e), 7(f), 8, 11, 12, 13, 17, 21, 22 and 23 of the Employment Agreement will survive the Separation Date and remain in full force and effect in accordance with its terms), provided however, that this Agreement shall not in any way affect, modify, or nullify any prior agreement that you entered into with the Company regarding confidentiality, trade secrets, inventions, or unfair competition, including, without limitations, the Continuing Obligations referenced in Section 9, and in the event of any conflict between this Agreement and any such prior agreement, the agreements </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">will be interpreted to provide the Company with cumulative rights and remedies such that the terms most protective of the Company are enforced.  Further, and for the avoidance of doubt, to the extent of any conflict between the terms of this Agreement and any other document concerning severance benefits, the provisions of this Agreement shall prevail.  The headings in this Agreement are provided for reference only and shall not affect the substance of this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">21.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Execution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Agreement may be executed in two or more counterparts, including by electronic delivery, each of which shall be deemed an original, and together, all of which shall constitute one original document.  Original signatures that are transmitted by fax or electronic mail shall be considered original signatures under this Agreement.  This Agreement is and shall be deemed to be executed under seal.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	INTENDING TO BE BOUND, the undersigned have executed this Agreement under seal as of the date written below.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:4.031%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:6.062%;"></td>
    <td style="width:26.256%;"></td>
    <td style="width:9.098%;"></td>
    <td style="width:20.205%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JEFFREY M. FRYER</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;/s/ [***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ Jeffrey M. Fryer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;03 February 2023</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Signature</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notary Public, State of South Carolina</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RALLYBIO CORPORATION</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ Martin Mackay</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;15 February 2023</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Martin Mackay</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule A</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:44.824%;"></td>
    <td style="width:19.241%;"></td>
    <td style="width:35.936%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of Holder</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificate Designation Numbers</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:0.51875in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,767</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:0.51875in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,767</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:0.51875in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,466</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:0.51875in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;75,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>5
<FILENAME>rlyb-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(32,33,36,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUBSIDIARIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.962%;"></td>
    <td style="width:1.058%;"></td>
    <td style="width:47.981%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsidiary Name</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jurisdiction of Organization</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rallybio, LLC</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rallybio IPA, LLC</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rallybio IPB, LLC</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IPC Research, LLC</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rallybio IPE, LLC</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rallybio IPF, LLC</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Roboto&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Roboto&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Roboto&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>6
<FILENAME>rlyb-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="margin-left:86.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement No. 333-266668 on Form S-3 and Registration Statement Nos. 333-258383 and 333-265443 on Form S-8 of our report dated March 6, 2023, relating to the financial statements of Rallybio Corporation appearing in this Annual Report on Form 10-K for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Hartford, Connecticut</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 6, 2023</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>7
<FILENAME>rlyb-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">I, Martin W. Mackay, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Rallybio Corporation;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date: March 6, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Martin W. Mackay</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Martin W. Mackay, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>8
<FILENAME>rlyb-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">I, Jonathan Lieber, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Rallybio Corporation;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date: March 6, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Jonathan I. Lieber</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Jonathan I. Lieber</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>9
<FILENAME>rlyb-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the Annual Report of Rallybio Corporation (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date: March 6, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Martin W. Mackay</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Martin W. Mackay, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>10
<FILENAME>rlyb-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the Annual Report of Rallybio Corporation (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date: March 6, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Jonathan I. Lieber</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Jonathan I. Lieber</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img114804231_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_0.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
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MI_8=46)FPDZ%#E]J[A\R''0G(VC_ 'N/0Q5CS1?D!ZQ1117*(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M_P 0_P#(,O?^O2?_ -%M6A6?XA_Y!E[_ ->D_P#Z+:FMUZ@>(4445V#"BBB@
M#K_A?_R$Y?\ KT?_ -&1UZA7E_PO_P"0G+_UZ/\ ^C(Z]0KFK?%\A,****S
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M7BO2;-0[WD1!./D;S3Z](]QQQUQBO(+_ %2[U1M]S,\ARQ&YB0-W)P.BCV
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M110 4444 %%%% !7G_Q6_P"7'_MX_P#:=>@5Y_\ %;_EQ_[>/_:=72^-?/\
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M])__ $6U:%9_B'_D&7O_ %Z3_P#HMJ:W7J!XA11178,T/#W_ "$[+_K[@_\
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MID<#CU)W_B1XC_YA<)_NF?*_[KHH)_,X'ISU%<!6]*%O>?R&@HHHK8 HHHH
M***VM)\(:GK!!CA*(0#YDH*)@@D$9&6!Q_"#U&>*3:6^@&+17?V'PL^XUW=>
MNY(E^N,2-^!/R>WO6A_PJ_3/^>MQ_P!]Q_\ QNH=6*ZA<\PHKT__ (5?IG_/
M6X_[[C_^-UFWGPK8!S;78)S\BR)@8ST+J3R!W"\GL*%5B^H7."HK6U;PMJ.B
M@O<0G8"1YBD.G! !)'W0<C&X FLFK33VU ****8!1110 4444 %>G_"__D&2
M_P#7V_\ Z+CKS"O3_A?_ ,@R7_K[?_T7'6=;X?F#.PHHHKF$%9_B'_D&7O\
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M 5H>'O\ D)V7_7W!_P"C%K/K0\/?\A.R_P"ON#_T8M)[/T ]OHHHKC$%%%%
M&#XUT=M9TR1(\EXR)4 _B*@@K@ DDJ3@#OBO'J]_KQCQ7HO]A:A) HQ&WSQ_
M[C$X'4GY2"O/)QGO6]&6\1HQZ***V *T- U3^QK^"[QD(_S#&3M8%6QR.<$X
MYZUGT4FKZ >_T5S?@'5AJ6EQQELR0?NV'R@X'^K.!VVX&2.2#]:Z2N1KE;78
M04444@"BBB@ KE_B)J?V'2VB5L/.X08?:VT?,YQU(P-I_P![GT/45Y;\2M2-
MUJ*VP)VV\8&"!C>X#D@CD@KM'/<?G=-7DO+4#DJ***ZAA1110!U/P[TDW^HB
MX8 I;C<<@,"[ A!@G@CE@<'!7Z5ZM7+_  [TS[#I:RLN'G<N<IM;:/E09ZD8
M&X?[W'J>HKEJRYI/RT$%%%%0 5G^(?\ D&7O_7I/_P"BVK0K/\0_\@R]_P"O
M2?\ ]%M36Z]0/$****[!A115C3[&74[B*VA&7D<*.I SU)P"< <DXX% &YX+
M\+_\)!<%YU;[/']XC@.W&(\YSTY..@],@UZS'&L*JB*%50  !@ #@  = *KZ
M9IL.D6T=K #LC&!DY)R222?4DD^GIQ5JN6<^=^7004445 !1110 4444 %%%
M% !1110 5P/Q \)KM;4K1#NSF=5'&.29<=B/XL=?O'&"3WU%5&3B[H#P"BMS
MQ?X?/A^]*+_JI,O$<-@#/W,G.2OU/&">N*PZZD[JZ&36=Y-83)/ Y1T.58=1
M_B#T(/!'!KVW2-236+.&ZC&!(F<<G!'#+D@9P01G'/6O#*[WX6ZD0US9$G!
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M\/EW.IR_=7>D0PP))&&?/ ( )7OSGH17HE859W]U?,&%%%%8B"BBB@ HHHH
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M#@OGEQS_  8P.",G@Y6O2*YZTKOE70&%%%%9""O"M4OVU2[FN7SF21FP6W$
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M:2+BYEO7!Q"-J<'!=P0QSG&57@CG[P/'%3*7+%L#TB.-855$4*J@  #  '
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MT'Y<57I?Q1MT:QMYB/G6XV@Y/ =&+#'3DJ/RKS2NJD[Q0T%%%%6 5Z?\+_\
MD&2_]?;_ /HN.O,*]/\ A?\ \@R7_K[?_P!%QUG6^'Y@SL****YA!6?XA_Y!
ME[_UZ3_^BVK0K/\ $/\ R#+W_KTG_P#1;4UNO4#Q"BBBNP84444 =?\ "_\
MY"<O_7H__HR.O4*\O^%__(3E_P"O1_\ T9'7J%<U;XOD)A11168!7B'B'_D)
MWO\ U]S_ /HQJ]OKQ#Q#_P A.]_Z^Y__ $8U;4-WZ#1GT445N 5H>'O^0G9?
M]?<'_HQ:SZT/#W_(3LO^ON#_ -&+2>S] /;Z***XQ!1110 4444 ><_$_23'
M-#?H!M<")\  [QDJ2<Y)*Y'3@+UZ5PU>V^(='77;&6V.-Q&8R?X7'*G.#@=C
M@9P2*\2KII2O&W8:"BBBM "O0_A?JQD2>Q=L[,21CYB<$X<9Z  [3CCDD\]O
M/*T- U3^QK^"[QD(_P PQD[6!5L<CG!..>M3./-%H#V^BBBN00445#>72V,$
ML[@E8XW<@=<*"QQG'/% 'EOQ$U/[=JC1*V4@0(,/N7<?F<XZ Y.T_P"[SZ#F
M*DN+A[N5YI#EW=F8X R6.2<#CK4==D5RI+L,****8!7L?@S23I&EPQNNV1\R
M2#YLY;H"&Q@A0H(QU'XUY=X<TT:MJ-M;, 5:0%@20"B@NXR.<E00/?TKVVL:
MTME\P84445@(**** "L_Q#_R#+W_ *])_P#T6U:%9_B'_D&7O_7I/_Z+:FMU
MZ@>(4445V#+6E6JWUY;P.2%DGB0D=<,P4XSGGFO=:\8\(6GVW5[--VW$P?.,
M_P"K!DQU'7;BO9ZPKO5+R!A1116(@HHHH **** "BBB@ HHHH **** "BBB@
M KR?XC6GV?5V?=GSH8WQC&,#R\=>?N9_&O6*\S^*-NZWUO,1\C6^T'(Y*.Q8
M8Z\!A^=:4?B^0(XRBBBND9ZW\/;A)M&A53DQO*K<$8)<OCGKPP/%=)7'_"__
M )!DO_7V_P#Z+CKL*Y)_$_405G^(?^09>_\ 7I/_ .BVK0K/\0_\@R]_Z])_
M_1;4ENO4#Q"BBBNP9H>'O^0G9?\ 7W!_Z,6O;Z\0\/?\A.R_Z^X/_1BU[?6%
M?=>@,****Q$>=_%6X1I;.$'YU25B,'@.5"G/3DJ?RKA*Z_XH?\A.+_KT3_T9
M)7(5U4_@0PKT?X66FRUNKC=]^94VXZ>6N[.<]_,].U><5ZG\-+=X=*9F&!)<
M2,O(.0%5,\=.5(YI5OA^8,ZRBBBN804444 %%%% !1110 4444 %%%% !111
M0 5D^*[5;S2;Q') $#OQUS'^\'7/&5&?:M:J^H6GV^UGM]VWS89$W8SC<I7.
M,C.,^M-.S3\P/"****[!FUX-NEL]8M'<$@R%..N9%,8ZXXRPS[455\/?\A.R
M_P"ON#_T8M%<]?=>@,/$/_(3O?\ K[G_ /1C5GUH>(?^0G>_]?<__HQJSZW6
MR] "BBBF 45>T*-9M1LT=0RM=0 @C((+@$$'J#7=ZM\,K:X)>RE,)P?D;,B$
MX& &)W*,]2=W7@<8J93479]0/-J*V-3\):II.XRV[%!O.]/WB87JQ*Y*C'/S
M ?H:QZ::>VH!1113 **** "BBB@ HHHH **** /2_AWK]G+;KIX18IER<#I+
MZOD\[L=1Z#(X&%[2O HY&A971BK*000<$$<@@CH17J?@WQDNN*+:Y(6Y4?02
M =6 [,.X_$<9 PJT[>\OF!U5%%%8B"BBB@#S_P"*W_+C_P!O'_M.N KTGXI6
MJO9VTY)W).4 [8=2Q_'Y!C\:\VKII? OF-!1116@!7K_ ("_Y EK_P!MO_1S
MUY!7I_PQN/,TV6,ODI<-A=V2JLJD<=@3N_'/O65;X?F#.PHHHKG$%%%% !11
M10 4444 %%%% !1110!Q_P 4/^09%_U]I_Z+DKS"O1?BI=,D%I  -KR2.3WR
M@"C\/G.?PKSJNFE\*&@HHHK0 KT_X7_\@R7_ *^W_P#1<=>85Z?\+_\ D&2_
M]?;_ /HN.LZWP_,&=A1117,(*S_$/_(,O?\ KTG_ /1;5H5G^(?^09>_]>D_
M_HMJ:W7J!XA11178,**** .O^%__ "$Y?^O1_P#T9'7J%>7_  O_ .0G+_UZ
M/_Z,CKU"N:M\7R$PHHHK, KQ#Q#_ ,A.]_Z^Y_\ T8U>WUXAXA_Y"=[_ -?<
M_P#Z,:MJ&[]!HSZ***W *T/#W_(3LO\ K[@_]&+6?6AX>_Y"=E_U]P?^C%I/
M9^@'M]%%%<8@HHHH **** "O)OB!I(TS4VD0'9<#S>AQO)(<9).3GYCZ;@,8
MQ7K-<S\0-).IZ8TB ;[<^;T&=@!#C)(P,?,?7:!C.*NG+EEZ@>34445U#"BB
MB@#UOP#JPU+2XXRV9(/W;#Y0<#_5G [;<#)')!^M=)7E/P[U8V&HBW8@)<#:
M<D* Z@E#DCDGE0,C);Z5ZM7+4CRR?F(*X_XEZI]DL$M ,FX?DXX"QE6/?KG;
MV/&?:NPKR+Q[J0U'5I0I!6$"$$ @_+DMG/<.6'I@?C3I1O+T!'.T445TC"BB
MB@#O_A=I?_'Q?D_],5 /^Z[DC'^[CGUR.E>@5F^'--.DZ=;6S AEC!8$@D.Q
M+N,CC 8D#V]:TJY)RYI-B"BBBI **** "L_Q#_R#+W_KTG_]%M6A4=Q;I=Q/
M#(,HZ,K#)&0PP1D<]*%HP/!****[1FQX0N_L6KV;[=V9@F,X_P!8#'GH>F[-
M>SUX1I]W]@NH+C;N\J:-]N<9VL&QG!QG'I7N]85UJGY PHHHK$04444 %%%%
M !1110 4444 %%%% !1110 5YG\4;AVOK>$GY%M]P&!P7=@QSUY"C\J],KR?
MXC7?VC5V3;CR88TSG.<CS,]./OX_"M*/Q?($<Q11172,]/\ A?\ \@R7_K[?
M_P!%QUV%<[X C5-%MRJ@%C*6(&"3YC+D^IP /H*Z*N2?Q/U$%9_B'_D&7O\
MUZ3_ /HMJT*S_$/_ "#+W_KTG_\ 1;4ENO4#Q"BBBNP9H>'O^0G9?]?<'_HQ
M:]OKQ#P]_P A.R_Z^X/_ $8M>WUA7W7H#"BBBL1'E_Q0_P"0G%_UZ)_Z,DKD
M*[WXJQJ&LG"C<1."<<D#80,^@R<?4UP5=5/X$,*]3^&EP\VE,K'(CN)%7@#
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M8!7B'B'_ )"=[_U]S_\ HQJ]OKQ#Q#_R$[W_ *^Y_P#T8U;4-WZ#1GT445N
M5H>'O^0G9?\ 7W!_Z,6L^M#P]_R$[+_K[@_]&+2>S] /;Z***XQ!1110 444
M4 %%%% 'B7B'1VT*^EMCG:#F,G^)#RIS@9/8X&,@BLVO1_B;HOGP1Z@@^:+"
M2?[C'Y3R>S'' R=WH*\XKKA+FBF,****H!T<C0LKHQ5E(((."".001T(KW'2
M-236+.&ZC&!(F<<G!'#+D@9P01G'/6O#*]#^%^K&1)[%VSLQ)&/F)P3AQGH
M#M...23SVRK1O&_8&=EJE^NEVDUR^,1QLV"VT$@<+D]V. /<UX9)(TS,[L69
MB223DDGDDD]2:]+^)NI&VL8K5209Y,G@$%(\$C)Y!W%2,>A_'S*BBK*_<$%%
M%%:@%;W@C33J6K0#!VQ'SF((!&SE>O4%]H..<'\:P:]+^&6DBWLY+UE^>9RJ
MD[3^[3CC'(RV<@GG XJ*DN6+ [2BBBN404444 %%%% !1110!XEXDLS8:G=Q
M% @$[E5&,!&.Y, < ;2..U9M=C\3=-%M?172@ 3QX/))+QX!.#P!M*@8]#^/
M'5UP=XI^0PKV?PEJ?]K:7;RELN$V/E][;D^4ECURP ;GU[]:\8KN?AAJQCFF
ML'(VN#*F2 =XP& &,DE<'KP%Z=:FK&\;]@9Z-1117,(**** "BBB@ HHHH *
M*** "BBB@ HHHH ;)(L*L[L%50223@ #DDD] *\,U2_;5+N:Y?.9)&;!;<0"
M>%R>RC 'L*]-^(.M?V7IY@0_O+G<@]DQ^\/((Z$+V/.1TKRBMZ,=&^XT%%%:
M7AS31JVHVULP!5I 6!) **"[C(YR5! ]_2M6[*X'K^AV9L+"V@9 C)!&&48P
M'VC?TX)+9)/<\U>HHKC>H@K/\0_\@R]_Z])__1;5H5G^(?\ D&7O_7I/_P"B
MVIK=>H'B%%%%=@S0\/?\A.R_Z^X/_1BU[?7B'A[_ )"=E_U]P?\ HQ:]OK"O
MNO0&%%%%8B.1^)EF9],254!,4ZDMQE48%3R><%BN0/;TKRZO<=<TT:O8SVI
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MXYTO^U-*EP<-#^^'. =BG<#P?X2<>^.<5Y!7O]>.>+_#Y\/WI1?]5)EXCAL
M9^YDYR5^IXP3UQ6]&7V1HPZFL[R:PF2>!RCH<JPZC_$'H0>".#4-%; >XZ+J
MT.MVD=S$1\P&Y0<E'P-R'@<CZ<CGH:O5Y!X0\42^'[@(S9MY''F*<D+GCS!@
M$Y ZX'(X]"/78Y%F571@RL 00<@@\@@CJ#7+4AR/RZ"'4445 !1110 4444
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M[2,XR:U+?QMK-L@C6[8@9^\J2-R<\LZDG\36;H/HPL>QTV21859W8*J@DDG
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M\5Z+_;NGR0*,R+\\?^^H.!U ^8$KSP,Y[5L44T[.ZZ > 45O>-='71M3D2/
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MYE9[H:,NIK.\FL)DG@<HZ'*L.H_Q!Z$'@C@U#16H'J_ACQS;ZW^YN-L$WR@
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M>.G(K15(OK]^@'-T5I2>&]4B9D-E/E20<1.PXXX*@@CW!Q3?^$>U/_GRN/\
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M (NM32](M=&B,-I'L0N6(W,W) &<L2>@%34J*2LK@7****Q$%9_B'_D&7O\
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MYZW'_?<?_P ;I^VB%SS"BO6;7X=Z/;J5>-Y3G.YY&!'M^[V#'X9K4L_#>F6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSN7/7/J,@'/U]:UZ#T*=2-6*E'9A11106%%%% !1110 4444 %%%% !1110
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M+A1R2>68]V8]R?\ ZPP !5RBBL=Q!1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &?_P (]IG_ #Y6_P#WYC_^)J]'&L*JB*%5
M0  !@ #@  = *=11=L HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img114804231_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" :-$!8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU=NQ\JT5]-P_"CPK+X@M=<TZ"UETV:-C+:'][#(&&5DC/..<<#C!XQC!\_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXD_]"-98).,I)E5W=)E.BO;OAO\ !VWNK&'6?$\;.)@)+>QW$#:>0TA'//\
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MC[Q]NG.#FMZE:$(\S,XTY2=D>"T5]7>;\-8)#I7_ !3"LS[6M]L&"X[$=,Y
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MD&%0$YVCV'2H:V("BBB@ HHHH **** "BBB@ HHHH *]$^"7_)2;;_KWE_\
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MERQ5V$:+:NW8^6**^E]<^&'@_P 9:/\ ;M %I:3NI\BZL"/)8C/RLJ_+C/7
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MA@T._<#:?LQ02J.>A3# =>E>,_$WX7_\(<D>IZ9)+/I<C['$G+P,>F2!]T]
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M^,?P_M-1T>Y\36$(BU&T3?<!  )XQU)_VE'.>X!'/&.,^ /_ "/=]_V#)/\
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M]-LM1GC=_P#298!O=2Q*Y]P"!^%?/&E^'I/$GCH:':/' ;BZD0,5^6-5W$G
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M2K24K'NGQI\ VK:9+XITV$17,++]LC08$B$XWX'\0)&?;)[<UOV=_P#F9/\
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M?#^$:@61[N5KM8GZQ(P4*.O<+N[8W<\YKYX\97Z:IXTUJ]B='BEO)3&Z'(9
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M$#OA<U\LZ_K^H^)M8FU/4YS+/(>!SMC7LJCLHST_J2:^H?!O_)*]*_[!@_\
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MHN,C:NS!^JX/XUQ2_P!WAVN;K^*SYCU75;W6]2GU#4)WFN)F+,S,3C)S@9Z
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MRUR^M'ATJT<3JTH*^<X&4V#N,X.>G&.:[ZLH>S;>QSP4N96/2OCC_P DZ?\
MZ^XOZU!\"],@M/ KWRHOGWMRY=^Y5/E5?H/F/_ C4_QQ_P"2=/\ ]?<7]:R_
M@-X@@NO#=SH3RH+NSE:5(^A:)L<^^&SGTROK7 D_JVG<Z-/:_(\F^(WB*\\0
M^-=1DN))/(MIW@MX2V5C13MX'8G&3[FN=T[4;S2=0@O["X>WNH&WQRH>5/\
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M;NH;ID0QGFNT_9W_ .9D_P"W7_VK7%_%>VFO/B]J=K;1M+/,]O''&O5F,,8
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M_FU8?QU_Y*$O_7E%_-JN/^]/T$_X*/,Z***[3G"BBB@ HHHH **** "BBB@
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MK38M/^(UQ)%@"\@CN&4#@-RI_/9G\:\\K6\1ZMK6L:N\^ORS/?QJ(F$T8C9
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M_:M:UZ<:=!QC_6I%.3E439RGQMU6XO?B'<64C-Y%A%''$F[CYD#LV.Q.['_
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M? KYDHK!X.DW<T5>:1VWCSXE:IXVE%N5%II<;[H[9"26]&<_Q'\@/UJ'X?\
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MH04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.+NCZA7XT>"&BWG49U;^X;63/Z#'ZUY]XS^.-QJEE)8>'+::QBE3;)=3$"8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"U9:G?Z:6-C?7-J7QN,$K)NQTS@]LFG7NKZ
MGJ0 O]1N[H*<@3SL^#Z\FJ=%*RO<=PHHHIB"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***<B-(ZHB
MEG8X55&23Z"@!M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %=U\)/#K:_X\M'DAWV=A_I4
MY;.,K]P?7?M.#U /I7"U]&? C0Q8^#[C5G5?-U&<[6!/^KCRH!]/FW]/;\,,
M3/DIMFE*/-(]'NM&TZ\LYK6:R@,4T;1N!&O((P>WO7QQJ^FS:/K%[IMQGS;6
M9X6.,9VG&?H>M?1/A'QT^L?%7Q)H[S.;0<6:-C"F'Y'QC^\26Y[#MTK@_CQH
M"V/B6SUB&,+%?Q%9"J_\M4ZD_52O_?)KEPK=.IR2ZHVK6E'F70\FHHKW#4/@
M981^&Y+W3[Z^N+\P!X8#L"NY PO3@9/K7;4JQIVYNIA&#EL>'T5[5/\  ^TT
MCP;J6IZIJD\NH6UG+<+';;5B5E0L%)8$L,CK\OX5Y/H6@ZEXDU6/3=*MFGN7
M!. <!5'5F)X 'K]!U(I0K0FFT]$$H2CHS-HKW[1?@!ID5M&^MZK<SW/#,EIB
M.,=,KE@2PSGGY?H*FU?X!:+/"[:1J5Y:SXRJS[98\^G !'UR>O3M6?UNE>UR
M_8SL?/=%:GB#P_J/AC6)M+U2#RKB/D$<K(O9E/=3_P#6.""*;H6@ZEXDU6/3
M=*MFGN7!. <!5'5F)X 'K]!U(KHYE;FOH96=[&;17OVB_ #3(K:-];U6YGN>
M&9+3$<8Z97+ EAG//R_05%XA^ 5F;26;P_J-PMPH++!=E65^ORA@!M[<G-<_
MUNE>US3V,[7/!J*]OB^!^G)X574KV]U"&^2S\Z:W^3"R!,E<XZ9XKQ"M:=6-
M2_+T)E!QW"BBBM" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP:[:L*?LW=:&$)2YM#VCXX_\DZ?_ *^XOZUR_P"SO_S,G_;K_P"U:ZCXX_\
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M*D6I684445J0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?1'PAU'PYX=\
M#1+>:]I<%[>2M<312WT09/X5&,\?*H.#SDGZ5X[\0==_X2/QSJE^DF^#S3%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "K6GZC>Z5>)=Z?=36MPGW9(G*G].WM56BC<9Z-9
M?&[QE:0)%)-9W97^.>W^8_7:5K/UOXL^,-<C:%]2^QP,N&CLE\K/.?O<M[=<
M8_'/$T5DJ--._*BN>6UPHHHK4@**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /J?\ X5%X!_Z @_\  R?_ .+H_P"%1> ?^@(/_ R?_P"+KK:*\+VU3^9_
M>>CR1[')?\*B\ _] 0?^!D__ ,71_P *B\ _] 0?^!D__P 776T4>VJ?S/[P
MY(]CDO\ A47@'_H"#_P,G_\ BZ/^%1> ?^@(/_ R?_XNNMHH]M4_F?WAR1['
M)?\ "HO /_0$'_@9/_\ %T?\*B\ _P#0$'_@9/\ _%UUM%'MJG\S^\.2/8Y+
M_A47@'_H"#_P,G_^+H_X5%X!_P"@(/\ P,G_ /BZZVBCVU3^9_>')'L<E_PJ
M+P#_ - 0?^!D_P#\71_PJ+P#_P! 0?\ @9/_ /%UUM%'MJG\S^\.2/8Y+_A4
M7@'_ * @_P# R?\ ^+H_X5%X!_Z @_\  R?_ .+KK:*/;5/YG]X<D>QR7_"H
MO /_ $!!_P"!D_\ \71_PJ+P#_T!!_X&3_\ Q==;11[:I_,_O#DCV.2_X5%X
M!_Z @_\  R?_ .+H_P"%1> ?^@(/_ R?_P"+KK:*/;5/YG]X<D>QR7_"HO /
M_0$'_@9/_P#%T?\ "HO /_0$'_@9/_\ %UUM%'MJG\S^\.2/8Y+_ (5%X!_Z
M @_\#)__ (NC_A47@'_H"#_P,G_^+KK:*/;5/YG]X<D>QR7_  J+P#_T!!_X
M&3__ !='_"HO /\ T!!_X&3_ /Q==;11[:I_,_O#DCV.2_X5%X!_Z @_\#)_
M_BZ/^%1> ?\ H"#_ ,#)_P#XNNMHH]M4_F?WAR1[')?\*B\ _P#0$'_@9/\
M_%T?\*B\ _\ 0$'_ (&3_P#Q==;11[:I_,_O#DCV.2_X5%X!_P"@(/\ P,G_
M /BZ/^%1> ?^@(/_  ,G_P#BZZVBCVU3^9_>')'L<E_PJ+P#_P! 0?\ @9/_
M /%T?\*B\ _] 0?^!D__ ,776T4>VJ?S/[PY(]CDO^%1> ?^@(/_  ,G_P#B
MZ/\ A47@'_H"#_P,G_\ BZZVBCVU3^9_>')'L<E_PJ+P#_T!!_X&3_\ Q='_
M  J+P#_T!!_X&3__ !==;11[:I_,_O#DCV.2_P"%1> ?^@(/_ R?_P"+H_X5
M%X!_Z @_\#)__BZZVBCVU3^9_>')'L<E_P *B\ _] 0?^!D__P 71_PJ+P#_
M - 0?^!D_P#\776T4>VJ?S/[PY(]CDO^%1> ?^@(/_ R?_XNC_A47@'_ * @
M_P# R?\ ^+KK:*/;5/YG]X<D>QR7_"HO /\ T!!_X&3_ /Q='_"HO /_ $!!
M_P"!D_\ \776T4>VJ?S/[PY(]CDO^%1> ?\ H"#_ ,#)_P#XNC_A47@'_H"#
M_P #)_\ XNNMHH]M4_F?WAR1[')?\*B\ _\ 0$'_ (&3_P#Q='_"HO /_0$'
M_@9/_P#%UUM%'MJG\S^\.2/8Y+_A47@'_H"#_P #)_\ XNC_ (5%X!_Z @_\
M#)__ (NNMHH]M4_F?WAR1[')?\*B\ _] 0?^!D__ ,71_P *B\ _] 0?^!D_
M_P 776T4>VJ?S/[PY(]CDO\ A47@'_H"#_P,G_\ BZ/^%1> ?^@(/_ R?_XN
MNMHH]M4_F?WAR1[')?\ "HO /_0$'_@9/_\ %T?\*B\ _P#0$'_@9/\ _%UU
MM%'MJG\S^\.2/8Y+_A47@'_H"#_P,G_^+H_X5%X!_P"@(/\ P,G_ /BZZVBC
MVU3^9_>')'L<E_PJ+P#_ - 0?^!D_P#\71_PJ+P#_P! 0?\ @9/_ /%UUM%'
MMJG\S^\.2/8Y+_A47@'_ * @_P# R?\ ^+H_X5%X!_Z @_\  R?_ .+KK:*/
M;5/YG]X<D>QR7_"HO /_ $!!_P"!D_\ \71_PJ+P#_T!!_X&3_\ Q==;11[:
MI_,_O#DCV.2_X5%X!_Z @_\  R?_ .+H_P"%1> ?^@(/_ R?_P"+KK:*/;5/
MYG]X<D>QR7_"HO /_0$'_@9/_P#%T?\ "HO /_0$'_@9/_\ %UUM%'MJG\S^
M\.2/8Y+_ (5%X!_Z @_\#)__ (NC_A47@'_H"#_P,G_^+KK:*/;5/YG]X<D>
MQR7_  J+P#_T!!_X&3__ !='_"HO /\ T!!_X&3_ /Q==;11[:I_,_O#DCV.
M2_X5%X!_Z @_\#)__BZ/^%1> ?\ H"#_ ,#)_P#XNNMHH]M4_F?WAR1[')?\
M*B\ _P#0$'_@9/\ _%T?\*B\ _\ 0$'_ (&3_P#Q==;11[:I_,_O#DCV.2_X
M5%X!_P"@(/\ P,G_ /BZ/^%1> ?^@(/_  ,G_P#BZZVBCVU3^9_>')'L<E_P
MJ+P#_P! 0?\ @9/_ /%T?\*B\ _] 0?^!D__ ,776T4>VJ?S/[PY(]CDO^%1
M> ?^@(/_  ,G_P#BZ/\ A47@'_H"#_P,G_\ BZZVBCVU3^9_>')'L<E_PJ+P
M#_T!!_X&3_\ Q='_  J+P#_T!!_X&3__ !==;11[:I_,_O#DCV.2_P"%1> ?
M^@(/_ R?_P"+H_X5%X!_Z @_\#)__BZZVBCVU3^9_>')'L<E_P *B\ _] 0?
M^!D__P 71_PJ+P#_ - 0?^!D_P#\776T4>VJ?S/[PY(]CDO^%1> ?^@(/_ R
M?_XNC_A47@'_ * @_P# R?\ ^+KK:*/;5/YG]X<D>QR7_"HO /\ T!!_X&3_
M /Q='_"HO /_ $!!_P"!D_\ \776T4>VJ?S/[PY(]CDO^%1> ?\ H"#_ ,#)
M_P#XNC_A47@'_H"#_P #)_\ XNNMHH]M4_F?WAR1[')?\*B\ _\ 0$'_ (&3
M_P#Q='_"HO /_0$'_@9/_P#%UUM%'MJG\S^\.2/8Y+_A47@'_H"#_P #)_\
MXNC_ (5%X!_Z @_\#)__ (NNMHH]M4_F?WAR1[')?\*B\ _] 0?^!D__ ,71
M_P *B\ _] 0?^!D__P 776T4>VJ?S/[PY(]CDO\ A47@'_H"#_P,G_\ BZ/^
M%1> ?^@(/_ R?_XNNMHH]M4_F?WAR1[')?\ "HO /_0$'_@9/_\ %T?\*B\
M_P#0$'_@9/\ _%UUM%'MJG\S^\.2/8Y+_A47@'_H"#_P,G_^+H_X5%X!_P"@
M(/\ P,G_ /BZZVBCVU3^9_>')'L<E_PJ+P#_ - 0?^!D_P#\71_PJ+P#_P!
M0?\ @9/_ /%UUM%'MJG\S^\.2/8Y+_A47@'_ * @_P# R?\ ^+H_X5%X!_Z
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M_P#\71_PJ+P#_P! 0?\ @9/_ /%UUM%'MJG\S^\.2/8Y+_A47@'_ * @_P#
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M /\ T!!_X&3_ /Q==;11[:I_,_O#DCV.2_X5%X!_Z @_\#)__BZ/^%1> ?\
MH"#_ ,#)_P#XNNMHH]M4_F?WAR1[')?\*B\ _P#0$'_@9/\ _%T?\*B\ _\
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M9/\ _%T?\*B\ _\ 0$'_ (&3_P#Q==;11[:I_,_O#DCV.2_X5%X!_P"@(/\
MP,G_ /BZ/^%1> ?^@(/_  ,G_P#BZZVBCVU3^9_>')'L<E_PJ+P#_P! 0?\
M@9/_ /%T?\*B\ _] 0?^!D__ ,776T4>VJ?S/[PY(]CDO^%1> ?^@(/_  ,G
M_P#BZ/\ A47@'_H"#_P,G_\ BZZVBCVU3^9_>')'L<E_PJ+P#_T!!_X&3_\
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M\#9O_BZ/^%3?#[_H#I_X&S?_ !=;]%'/4_F?WA:/8P/^%3?#[_H#I_X&S?\
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M,7_@=-_\<H_X53\//^@3%_X'3?\ QRM.BB\_YG]X7CV1F?\ "J?AY_T"8O\
MP.F_^.4?\*I^'G_0)B_\#IO_ (Y6G11>?\S^\+Q[(S/^%4_#S_H$Q?\ @=-_
M\<H_X53\//\ H$Q?^!TW_P <K3HHO/\ F?WA>/9&9_PJGX>?] F+_P #IO\
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M_P".5IT47G_,_O"\>R,S_A5/P\_Z!,7_ ('3?_'*/^%4_#S_ *!,7_@=-_\
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MS?\ Q='_  J;X??] =/_  -F_P#BZWZ*.>I_,_O"T>Q@?\*F^'W_ $!T_P#
MV;_XNC_A4WP^_P"@.G_@;-_\76_11SU/YG]X6CV,#_A4WP^_Z Z?^!LW_P 7
M1_PJ;X??] =/_ V;_P"+K?HHYZG\S^\+1[&!_P *F^'W_0'3_P #9O\ XNC_
M (5-\/O^@.G_ (&S?_%UOT4<]3^9_>%H]C _X5-\/O\ H#I_X&S?_%T?\*F^
M'W_0'3_P-F_^+K?HHYZG\S^\+1[&!_PJ;X??] =/_ V;_P"+H_X5-\/O^@.G
M_@;-_P#%UOT4<]3^9_>%H]C _P"%3?#[_H#I_P"!LW_Q='_"IOA]_P! =/\
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M*/\ A5/P\_Z!,7_@=-_\<K3HHO/^9_>%X]D9G_"J?AY_T"8O_ Z;_P".4?\
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M_"IOA]_T!T_\#9O_ (NM^BCGJ?S/[PM'L8'_  J;X??] =/_  -F_P#BZ/\
MA4WP^_Z Z?\ @;-_\76_11SU/YG]X6CV,#_A4WP^_P"@.G_@;-_\71_PJ;X?
M?] =/_ V;_XNM^BCGJ?S/[PM'L8'_"IOA]_T!T_\#9O_ (NC_A4WP^_Z Z?^
M!LW_ ,76_11SU/YG]X6CV,#_ (5-\/O^@.G_ (&S?_%T?\*F^'W_ $!T_P#
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M_BZ/^%1> ?\ H"#_ ,#)_P#XNNMHH]M4_F?WAR1[')?\*B\ _P#0$'_@9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *SZT*SZN!$PHHHJR HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** &O_JV^AJG5Q_]6WT-4ZN)
M$@HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )(?]:M
M6JJP_P"M6K59RW+CL%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!!<?P_C4%3W'\/XU!6D=C-[A1115""BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH LV_^K/UJ6HK?_5GZU+63W-%L%%%%(84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %R#_4K4E1P?ZE:DK)[F
MJV"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K/K0K/JX$3"BBBK("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH :_^K;Z&J=7'_U;?0U3JXD2"BBBK)"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH DA_UJU:JK#_ *U:M5G+<N.P4445)04444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $%Q_#^-05/<?P_C4%:1V
M,WN%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S;_Z
ML_6I:BM_]6?K4M9/<T6P4444AA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 7(/]2M25'!_J5J2LGN:K8****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L^M"L^K@1,****L@**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_ZMOH:IU<?_5M]#5.K
MB1(****LD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"2'_6
MK5JJL/\ K5JU6<MRX[!1114E!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 07'\/XU!4]Q_#^-05I'8S>X44450@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** +-O_JS]:EJ*W_U9^M2UD]S1;!1112&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!<@_U*U)4<'^I6I*R>
MYJM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHJKJ.I6.D63WNHW<-K;(0&EF<*HR<#D^YH M45E:3XGT+79I(=*U>RO98UW.
MD$RNRCIG [5JT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5GUH5GU<")A1115D!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 -?\ U;?0U3JX_P#JV^AJG5Q(D%%%%62%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!)#_K5JU56'_6K5JLY;EQV"BBBI
M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY(YYQUH ]CHHKP>S^/VHSZ_;Z=-H]E%%)=+ \QF8!06VEN?3K0![Q17AVO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7AO_"]O^I;_ /)[_P"UU[E7Q77;@Z<9
M\W,NQSUY-6L>Q?\ "]O^I;_\GO\ [71_PO;_ *EO_P GO_M=>.T5V_5J78Y_
M:2[GL7_"]O\ J6__ ">_^UT?\+V_ZEO_ ,GO_M=>.T4?5J78/:2[GL7_  O;
M_J6__)[_ .UT?\+V_P"I;_\ )[_[77CM%'U:EV#VDNY[%_PO;_J6_P#R>_\
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M_"]O^I;_ /)[_P"UT?\ "]O^I;_\GO\ [77CM%'U:EV#VDNY[%_PO;_J6_\
MR>_^UT?\+V_ZEO\ \GO_ +77CM%'U:EV#VDNY["WQURI'_".=1_S_?\ VNH?
M^%W?]2]_Y.__ &NO)**:P]-= YY,];_X7=_U+W_D[_\ :Z/^%W?]2]_Y._\
MVNO)**?L*?87.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'
M.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?
M^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%
MW?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\
M]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'
M.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?
M^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%
MW?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\
M]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'
M.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?
M^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%
MW?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\
M]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'
M.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?
M^3O_ -KH_P"%W?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%
MW?\ 4O?^3O\ ]KKR2BCV%/L'.SUO_A=W_4O?^3O_ -KH_P"%W?\ 4O?^3O\
M]KKR2BCV%/L'.SUU/CAL<-_PCN<?]/O_ -KJ7_A>W_4M_P#D]_\ :Z\=HI/#
MTWT'SR/8O^%[?]2W_P"3W_VNC_A>W_4M_P#D]_\ :Z\=HI?5J78/:2[GL7_"
M]O\ J6__ ">_^UT?\+V_ZEO_ ,GO_M=>.T4?5J78/:2[GL7_  O;_J6__)[_
M .UT?\+V_P"I;_\ )[_[77CM%'U:EV#VDNY[%_PO;_J6_P#R>_\ M='_  O;
M_J6__)[_ .UUX[11]6I=@]I+N>Q?\+V_ZEO_ ,GO_M='_"]O^I;_ /)[_P"U
MUX[11]6I=@]I+N>Q?\+V_P"I;_\ )[_[71_PO;_J6_\ R>_^UUX[11]6I=@]
MI+N>Q?\ "]O^I;_\GO\ [71_PO;_ *EO_P GO_M=>.T4?5J78/:2[GL7_"]O
M^I;_ /)[_P"UT?\ "]O^I;_\GO\ [77CM%'U:EV#VDNY[%_PO;_J6_\ R>_^
MUT?\+V_ZEO\ \GO_ +77CM%'U:EV#VDNY[%_PO;_ *EO_P GO_M='_"]O^I;
M_P#)[_[77CM%'U:EV#VDNY[%_P +V_ZEO_R>_P#M='_"]O\ J6__ ">_^UUX
M[11]6I=@]I+N>Q?\+V_ZEO\ \GO_ +71_P +V_ZEO_R>_P#M=>.T4?5J78/:
M2[GL7_"]O^I;_P#)[_[71_PO;_J6_P#R>_\ M=>.T4?5J78/:2[GL7_"]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %R#_4K4E1P?ZE:DK)[FJV"BBBD,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \6_:,_Y%W1?^OM__0*Y+X*:!:>*--\6Z->Y$-S;P+O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ535-1@TC2;S4KEL06L+S2'V4$G^53V\Z75M%<1Y\N5 ZY&.",BO,/CSK_\
M9?@1=-C?;/JDPBP&P?+7YG/N,[0?]Z@#B_\ AHW5?^@!9_\ ?YO\*]@\ ^+X
M_&_A6+5EB6&82-#/"IR$<<X!^A4_C7R):Z->7NCZAJL$>ZUT\Q"X;GY?,)"_
MJ,5ZQ^SQKWV;7]1T*5P$O(1/$#_?3J!]58G_ (!0!]%4444 %%%% '/>)_&_
MA[P?$C:SJ"0R2<QP*"\CCGD*.<<'DX'O7E6K?M&QK.%T?0&>$=9+R;:Q_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** +-O_JS]:EJ*W_U9^M2UD]S1;!1112&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?]<8?_18IW@WX5^(/']BNJS7J6E@JB&&:X!=I GRX11_"H&,Y'(QZX;\</\
MDJ6H?]<8?_18KZ$^&T*0?#?P\B# -E&_XL,G]2: /F7QW\.]5\!W4"WKQW%K
M<9\JYB!"D@#*D'H>?Q%>S_!GQ!>>*/A]J6C7,XENK$&WC=R2?*=#LW'GH0P^
M@'I4/[17_(GZ7_U_C_T6]9'[-O\ S,__ &Z_^UJ /,_&/P[UKP-!:2ZL]HRW
M3,L?D2%CE0"<Y ]14OA#X9:[XVTV:^TJ2R6*&8PN)Y65MV >RGCFO3_VC_\
MD&^'_P#KM-_)*O\ [.O_ ")^J?\ 7^?_ $6E '7VFD7.@_""72KS9]IM=*FC
MD\MLKD(W0U\Z_"/_ )*GH7_75_\ T6]?4_BC_D4=:_Z\)_\ T6U?+'PC_P"2
MIZ%_UU?_ -%O0!]3>(O$^C^%-/COM;O/LMM)*(5?RG?+D$@84$]%/Y5S7_"Y
M_A__ -!__P DY_\ XBIOBAX+O/'7AJVTRQN8+>6*\6X+SYVD!'7' //S"O)O
M^&=?$/\ T&-,_P#(G_Q- 'J?_"Y_A_\ ]!__ ,DY_P#XBNOTC5K'7=*@U/39
M_/L[@%HI-C+N )'1@".0>HKY]_X9U\0_]!C3/_(G_P 37N/@O09?#'@_3=&G
MF2:6UC*O)&"%)+%N,_6@#X[U[_D8M3_Z^Y?_ $,UZ$GQ]\81QJB0Z4%4  ?9
MVX'_ 'W7GNO?\C%J?_7W+_Z&:^H+7X-^ 9+2%WT'+-&I)^V3\G'^_0!XGKGQ
MH\4Z_HMWI-Y'IZV]TGER&.!@V/8EC5?X,?\ )6=$_P"V_P#Z(DKUCQU\*_!>
MC>!M8U&PT;R;NWMR\4GVJ9MK<<X+D'\17D_P8_Y*SHG_ &W_ /1$E 'K?[0_
M_(@6'_84C_\ 14M>:_!/Q+H_ACQ+J-SK-\EI#+9^6CNK$%MZG' /85Z5^T/_
M ,B!8?\ 84C_ /14M>$^$/!FJ^-M1GL=*-NLL,/G.9W*KC('8'GF@#Z0U7XT
M^"=/LGF@U,WTP!V06\+[F/U( 'XG\Z^9&%]XN\62&&(-?:K>,X10<!Y')/3L
M,_D*]!@_9]\6O.BS76EQ1D_,_G.VT?3;S7KGP^^%.E>!F-XTQO\ 574J;ET"
MB,'J$7G&1P3DD^P.* .YM+<6EE!;*Q80QK&">^!BOECXU^(3K?Q#N;:.0M;:
M:HM8P'RN\<R''8[B5/\ NC\/IS7M6BT+P_J&JS#*6EN\Q7^\0,@?B<#\:^))
M[F2[O);JZ9I99I#)*W +$G)/3C- 'T?\-/!"7'P6NK&Y3;-KJ22Y<_<R-L1X
M[#:K_C^%>#>&-6F\)^,M/U)U9'L;H><@.#MSM=?Q4L*]7L_VB(;"RM[.V\(!
M(+>-8HT&H\*JC '^J]!7D7B?5X=?\3:AJ\%F;-+R8S& R^9M8\M\V!G+9/3O
M^- 'VTCI)&LD;*Z, 593D$'N#7,:]\1_"?AC4SIVL:K]FNP@<Q_9Y7^4]#E5
M(_6L7X*Z_P#VW\.K2&1]UQIS&T?+9.U>4X]-I _X":P?B/\ "'5O&?BQM7LM
M1LH(F@2/9-OW97/H#0!TO_"Y_A__ -!__P DY_\ XBI;3XO>!;Z\@M+?7-\\
M\BQ1K]DG&YF. ,E,#DUY/_PSKXA_Z#&F?^1/_B:O:+\ M=TW7M.OYM7TYHK:
MZCF<('W$*P)QE>O% 'T#7AW[1_\ R#?#_P#UVF_DE>XUX=^T?_R#?#__ %VF
M_DE !^SA_P @WQ!_UVA_D]5_COX]N8+@>$M-G:)3&'U!D/+!@"L>>H&.2.X(
M[9S8_9P_Y!OB#_KM#_)Z\J^)SRO\3/$!F^]]K8#G^$ !?TQ0!I>"_A'XA\96
M@OXS#8Z<Q(2XN,YEZ_<4<D9XR<#TS@BK/B;X8>*OAVL>NV]RD\,#\W5F6#0Y
MR/F!' /0]1S@]>?I7PNEM'X2T9+(*+464/E;3D;=@Q^E/\1QVTOAC54O=GV4
MV<OF[\8"[#DG/M0!\C_#K_DH_A[_ *_XO_0J^RZ^-/AU_P E'\/?]?\ %_Z%
M7V70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5\5U]J5\5UZ& ^U\OU.;$= HHHKT3E"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH Z[X?>,&\):\'G9SIUQA+E!SCT<#U'\LU]*1R)-$DL3J\;J&5U.
M0P/0@]Q7Q[7L_P (/&9E3_A&]0FRZ M9.[<D=X_PZCVR.PKCQ-*ZYT;4Y6T9
MZ[1117 ;A1110 4444 %%%% $%Q_#^-05/<?P_C4%:1V,WN%%%%4(**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S;_ZL_6I:BM_]6?K4M9/
M<T6P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7(/]
M2M25'!_J5J2LGN:K8****0PHHHH **** "BBB@"EJVK6>BZ=+?7THCAC'XL>
MP'J37@GB3QKJOB#5#-'/+;6Z_+%#$Y7 ]\=2:Z3XP:JD^J6FF*L@:V0NY)^5
MMV,<>V#^=;?PJ\-00Z2=9N$BEEN"5B)&2B@X/7U(KH@E"/.QGFY\'^)8D,IT
MB\54&[=L/ '.:GT'QQK>@W1D2Y>XC<@R13L6# >A/(Z]J^BL9&#7F7Q8\/67
M]E)K42"*XC=8GVCAP>F?IBG&JIOED@N=YH6L0Z]HUOJ4"LJ3+]UNH(."/S!K
M1KR#X/:I,+^\TK:IA>,S[CG(((&!VQS7KY( R3@"L:D>65A!17.:WXXT/0_,
MCGNQ)<HH80Q@DMGIST_6L73?BQH=[<^5<13V:;<^9* PSZ?+DT*$FKV [VBL
MB;Q/HT&E1:G)?QBSE^Y)@G/X8S4FD>(=*UTRC3+M;CR<;\*1C.<=1[&IY7N!
MYA\9?^0MIG_7!O\ T*NA^$'_ "*MS_U]M_Z"M<]\9?\ D+:9_P!<&_\ 0JZ'
MX0?\BK<_]?;?^@K71+^"A]#B/BMQXVE_ZX1_RKTWX;?\B)I_UD_]#:O,OBM_
MR.TG_7"/^5>B^ [VWT[X<6EW=R"."(2,[D$X&\^E$_X: [.BL&P\9^']3O8[
M.SU*.6XDSL38PS@9ZD5O5SM-;B"BD) !)Z"N<3Q]X8DE6)-5C+LP4#RWY/Y4
M)-[ 9OQ5_P"1)D_Z[Q_UJW\-O^1$T_ZR?^AM53XK?\B3)_UWC_F:=X%O[73/
MAQ97=Y,L,""0LS?[[?G6G_+OYCZ':45PVJ?%30+%T6V\V^##),(VA?\ OK%:
MVD>.-!UDQ1P7JI<.N[R9 5*^H)Z?K4.$DKV$='7(_$*UUV[T )HC/D.#,D1Q
M(ZY&-OX]:ZX$$9!R*JZCJ-II5E)>7TPAMX\;G()QDX'3W-$79W P/A];:E:^
M%DBU5)TNO.<D3DEL=NM=35/3-5LM9LQ=Z?.)H"Q7> 1R.O6K;,J*68@ =23T
MI2=WJ M%<QJOC[P_I7VB-[T2W$)P88U))/H#C'ZUGZ7\4_#]\)/M+2V)7&/.
M7=N^FW-5R2M>P';T5%;W,%U$LL$J2(P!!4YZ\BI:@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *^>/VC?\ D.Z'_P!>TG_H0KZ'KYX_:-_Y#NA_]>TG_H0H
M P/AK\5H? 6CW>GS:3)>>?<><)$G"8^4+C!4^GZUJ>,?CQ>Z_H<^E:5I?]GK
M<H8YIWF\Q]AZA0  ,CC//!.,'FJGPM^%NF>.]%O;^_O[N!H+CR52#;@C:#DY
M!]?TKT;3_P!G[PG:W(ENKG4KU!_RQDE5%/UVJ#^1% 'EWP6\(76O^-+;57A;
M^S=,D\Z24C :4<H@/<YPQ] .V1GJ/VD/^/\ \/?]<I_YI7NNF:78Z-I\5AIM
MI%:VL0PD42X ]_<GN3R>]>%?M(?\?_A[_KE/_-* //? GP^U;Q]>R16L@M[*
MV&);J4$JA.2%4=R>3C\3VS[QI.AQ_!KX<ZW=?;QJ#(3<(SP^6ID("(I&X\%M
MO?N:I_L^PI'\/;B11\TNH2%C]$0?T_4UN?&*TGO/A9K*6X8M&L<K*.ZK(K-^
M0!/X4 ?-WAC0[[X@>,Q;7%[MDN6:>[O)3G:O5F/J22 !ZD=!7NZ_!3X?K8FW
M,MPTI&!<F]'F#WP/ES_P&OG?PUX>N_%.N0:18RV\=S.&*&=]JG )QG!YP#7?
M?\,_^,O^>VE?^!#?_$4 <QXP\/W'P\\;""PU R>5MNK.Z0C<%R=N<<;@00>Q
MQ[XKZ)<+\4O@]D*@N-0L\KNRJK<(?7J!YB?EZUXY_P *!\8;BOGZ5N R1]H;
M_P"(KW3X<>&[SPGX(LM(U!XFNHFD9_*)*C<[$8) SP1VH ^9_AQXA/A#X@6-
MY=%X8-[6UVK#!"M\ISGIM;!/^[7T]\0-?_X1GP+JVIJ^R=(3' 0V#YC_ "J1
M]"<_@:^<?C'X:/AWX@W;QIBUU'_3(B < L3O'U# G'8$5?\ B!\0U\2^ /"^
MDQS,]RL7G:AT_P!8F8USCN<,V..&4_0 Q?A5X=7Q+\0M.M9H_,M;<FZN 1D;
M$Y /L6VC\:]0_:#\5S6EE8^&;60I]K4W%WC@F,'"+]"P8G_='O5O]GSP\MGX
M9O==EC'G7\WE1,5Y\I.#@^A8MG_<'X<;^T-:3Q^-["[<,8)K!4C8],J[[E'_
M 'TI_P"!4 1_"WX6:=XHTY]9\07CPV9<I;V\<BHTN.K,3_#G(P.<@],<]EXI
M^"7A6XTB:3P_=-9ZA%&6B1KGS(Y3UPP.2,] 0>,]#7E/A+X7:]XTTE]1TJ?3
M_)24Q,LTQ5U8 'D!3V(K?_X9_P#&7_/;2O\ P(;_ .(H H?!KQ9<>'O'%K8F
M5OL&J2+;2Q]1O/$;#WW$#Z$UZ7^T5_R)^E_]?X_]%O7)>'_@;XJL?$&EW\\^
MF&V@NHIG:.=F.Q7!.!MYX'K76_M%?\B?I?\ U_C_ -%O0!Y9\+/A\GCS6[A;
MN=X=.LE5[@Q_?<MG:H)X&=I)/M[Y'I?C;X'Z!;>%KZ^T+S[>]M(6G"RS%TD5
M1EE.>A(!P?7VZ5_V;U46'B%L#<98 3CDC#_XFO7/%'_(HZU_UX3_ /HMJ /F
M'X-:K/IGQ,TR.-F\J\WV\R X# J2,_1@I_"O5?BC\+=)OXM?\8RWMZ+Q;4S"
M%2GE[HXPH_ASCY1GFO&OA=_R4W0/^OG_ -E-?3_Q#_Y)UXB_Z\)O_030!\M_
M#SPQ:^,/&-MHUY--##*DC%X<;@54D=01VKZ8\"?#K3O /]H?V?>75Q]M\O?]
MHV_+LW8Q@#^^:\"^"#*OQ3TX$@%HI@,GJ?+8U]74 ?&GQ%_Y*/XA_P"O^7_T
M*OJKQ#KR^&/ EUK+*K-:V@:-6Z-(0%0'V+%17RK\1?\ DH_B'_K_ )?_ $*O
MHKXJVD]Y\'=12W#%HX8964=U5T9OR )_"@#YRT+2-6^(?C-+4W)DO;V0RW%S
M+SM7JS$>PZ 8[#BO=$_9[\*BQ6*2]U1KC: TZR(,MW(7:0![>G?O7FGP(U:U
MTSXB^7=2!/MUH]K$3T,A9& _'81]2*^I: /C7QGX0U+X?^)19RSLVW$UI>1
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M#XX?\E2U#_KC#_Z+%?0/PQ_Y)IX?_P"O1?YF@#K**** "BBB@ HHHH ****
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MBU)R&7N5'9O0_GQ7T[!/%=6\5Q"X>*5 Z,.ZD9!KDK472?D(DHHHK$ HHHH
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MXAWL?W9!!&XG/0GG.:P=(^%W@W0=5@U/3='\B\@),<GVF9MI((/#.0>">HH
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M;IGPJ\%Z/J5OJ-AHQAN[=P\4@NYCM8>Q<@_C794 %%%% !7AW[1__(-\/_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6;?_5GZU+45O\
MZL_6I:R>YHM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"/04 4O^%\>-O^>MC_X##_&O7?@_XTU?QII&I7.KM"TEO.L:>5'L&"N:U/\
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M!'T- ';U\@Z/XGU^7Q[81R:YJ;QMJD:LK7<A!!E&01GI7U;H6M6?B+1;;5K
MN;6Y!:,NNTD D=/PKX]T3_DH6G?]A6+_ -&B@#[3HHHH \L^,GCS6_!']B_V
M.\"_:_/\WS8M_P!SR\8]/O&O+?\ A?'C;_GK8_\ @,/\:ZS]I+_F6/\ MZ_]
MHUG_  *\*:%XBLM;DUC3(+UX9(EC,H)V@ALXH R+;X^^,H9U>5=.G0=8WMR
M?Q# U[)\//BAIOCM)+;R6L]4AC#R6[,"KCH60]2 <9R.,CK6=XU^%/@]_">I
MW-MID6GW-M;//'<0$KM**6Y!."#C!KP/X;7L]C\1] DM]^Y[V.%@I(RCG:V<
M=L$G\* /?_CEJ%[IOP_6:QN[BUE-[&I>"0HQ&&.,@].!^5<K^S[J^IZG>Z\M
M_J-W=JD<)03SM)MR7SC)XKHOC]_R3A/^O^+_ -!>N1_9O_X__$/_ %R@_F]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7Q77VI7Q77H8#[7R_4YL1T"BB
MBO1.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/>ON.OE3XXW-K<?$V[%LRLT4$4<Q7^^%SC\ 5'?^@ /=_A+_ ,DMT'_KB_\
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M?(-RTGAWQ5.=.N'WZ?>,()L\G8Y .1]* /HOX_?\DX3_ *_XO_07KD?V;_\
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M/$MMI7_"/1(DUXMOO^UDD N%S]SWKV^OBS1/^2A:=_V%8O\ T:* /M.BBB@
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MJP90RD%2,@CO0 M%%>%_&/XC>)O#7BA='T>]2UMGLTD9EB5GW,S \L#C@=J
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M%%%>B<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!9TZPN-4U&VL+5-\]Q(L:#W)QSZ#WKZ?\
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M@ HHHH **** "BBB@"Y!_J5J2HX/]2M25D]S5;!1112&%%%% !1110 4444
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MWAMD*01)$I.2$4 9_"I** *\UA9W$GF36L,CXQN>,$U+%%'!&(XHUC0=%48
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M110!4NM+T^]D$EW8VT\@&T-+$K$#TR14*Z!HZL&72K(,#D$6Z\?I6C13NP
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MR@_F]>[:AIEAJUM]FU*QMKR#<&\JYB61<CH<,",\U#IN@Z/HS2-I>DV-BTH
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MQ.222N22>] &G9?\>%O_ -<E_D*GI%4*H50 H& !VI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKE=<^)/A#P[</;:CKENMP
MA(:&$-,RD=F" [3QT.*BT;XH>#-=N%M[/7(%G8A5CN%:$L2< #> "3Z GJ*
M.OJ.>:*VMY)YG6.*)2[NQP%4#))_"I*\L^,/C72K?P9K&B6FJPC5GV0O;#.\
M*64L,8[KG\#0!RGB;]H6Y%W)!X:TZ#R$? NKP,QD [A 1MSQU)/L.WIWPR\4
M7_B_P9#JVI+ MRTTD9\E2JX4\<$FOFWX<:;X7U#Q&Y\77D=OIL,)<(\I3S9,
M@!<CG&"3P1T%?4_A3_A'O[#3_A&/LW]F>8VW[-]S=_%0!MUYI\3_ (GWG@'4
M;"VMM.@NUNHFD)D<KMP<=J]+KYX_:-_Y#NA_]>TG_H0H /\ AHW5?^@!9_\
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M^2/_ -LKV2BG"O4@N6+T \;_ .%#?]3)_P"2/_VRM+P_\'/["U^RU3^WO/\
MLT@D\K['MW>V=YQ^5>I44WB:K5FPN%8WBO0?^$G\-7>C_:?LWVC9^]\O?MVN
MK=,C/W<=>];-%8IM.Z \;_X4-_U,G_DC_P#;*]@@B\BWBBSNV(%SC&<#%245
M<ZLZGQ, KB?'?P^_X36XLI?[4^Q?9D9<?9_,W;B#_>&.E=M14PFX.\0/&_\
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MK=HJ)UIS5I, HHHK( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIUC!96L:QV\$:QQHHP%4# %?.7[0]M#%XUT^:.)5DFL09&48+D.P!/J<<9]
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M^#)-86-6O;R=T:4@%E13@*/09!/OQZ"O6)8HYX7AFC62*12KHXRK \$$'J*
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M_CY2OKB@ HHHH *^*Z^U*^*Z]# ?:^7ZG-B.@4445Z)RA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M=M\-?!I\4:YY]R@.F6;!I]W21NR?CCGV^HKE=*TN[UK5+?3K&/S+F=MJ+G';
M))]@ 3^%?4GA[0K7PWH=OI=IDQP@Y=OO.Q.2Q_'^@KGQ%7DC9;LTIQN[FDB+
M&BHBA44855& !Z"G445YATA1110 4444 %%%% $%Q_#^-05/<?P_C4%:1V,W
MN%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S;_P"K
M/UJ6HK?_ %9^M2UD]S1;!1112&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!<@_U*U)4<'^I6I*R>YJM@HHHI#"BBB@ HHHH **** "JUUI
M]K>8-Q"KD# )[59HH%**DK-& ?".GG^.;\U_PK2L])LK'8T$"AU7;O[FKM%*
MR,H8>E!WC%!1113-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\:^-_
MQ$NM"CB\-Z/,T-Y<Q>;<W$;8:.,D@*I'(8X))XP,>O'LM?)'QD>5_BMK?F]5
M,(49Z+Y*8_Q_&@"'P5\+O$'C>![NS$%M8H2OVFY8A788^50 2>O7IUYSQ4_C
M'X2>)/!UC_:%P(+VP!Q)/:L3Y7IO! (!/<9'KC(KZ1^'B6\?PZ\.BU"B,V$)
M.W^^5!?_ ,>+5KZW';2Z%J"7J(]J;>3S5D&5*[3G/MB@#Q/X&?$.ZFO/^$3U
M:X:960M82R-EE(Y:,GN,<CTP1W&,3XS> ]8M-<U7Q;(UL=-GGC50LA\P90+R
M,>H]:XGX<M.OQ'\/&WQO^W1@Y&?ES\W_ ([FOH'X[?\ ),KC_KYA_P#0J /G
MCPAX,U7QMJ,]CI1MUEAA\YS.Y5<9 [ \\U]0?#'PQJ'A'P;'I.I&$W*32.3"
M^Y2&.1R0*\A_9U_Y&[5?^O#_ -J+7T?0 5\\?M&_\AW0_P#KVD_]"%?0]?/'
M[1O_ "'=#_Z]I/\ T(4 <Y\.OBO_ ,(#H]UI_P#8OV_S[CSO,^U>5M^4+C&Q
ML]*['_AI+_J4_P#RH_\ VJN;^%OPMTSQWHM[?W]_=P-!<>2J0;<$;0<G(/K^
ME=W_ ,,Z^'/^@OJOYQ__ !- 'H'@CQ3_ ,)EX5MM;^Q_8_.9U\GS?,QM8K][
M ]/2OC2UB6:[AB8D*[JIQUP3BOM+PEX9M?"'AV#1K.:::&%G8/-C<=S%CT '
M>OC#3_\ D)6O_79/YB@#?\7>&=2^'WB\VGFR*\#K/9W:C:74'*N/0@C\"*]G
MU/QM#XW^ NLW9(74+>&.*]C'&)-Z_,/]ENH].1VKK_B=X&C\<>&&AB4#5+0-
M+9.3CYN,H<]FP![$ ]L5\H)=:AH[7]BKO;F9#;741 Y 8$J0?1E'OQ0!UWP8
M_P"2LZ)_VW_]$25];5\D_!C_ )*SHG_;?_T1)7TUXQUT>&O!^JZOG#VUNQBX
M'^L/RIU_VBM 'S!\6?$+>(?B'J4B2E[:T?[+ -V0 G#$>Q;<?QKV'PUX"\_X
M!R:,T7^F:E;M? -Q^^.&BZ<CA8P?Q^E?-D4B?:DEN4>:/>&D4/M9QGD;L'!/
MK@U[DG[1Z1QK''X15$4 *JZA@ #L!Y5 'EWP]U__ (1KQWI.I,^R!9A%.2VT
M>6_RL3[ '/X"OLROAS6KZ'5-<OM0M[8VL5U.\RP&3?Y>XYV[L#(&>.*^K_A1
MK_\ PD/PZTR=WWW%LGV2?+;CNCX!)]2NUOQH ^??C/\ \E9UO_MA_P"B(Z^@
MOA+_ ,DMT'_KB_\ Z,:OGWXS_P#)6=;_ .V'_HB.OH+X2_\ )+=!_P"N+_\
MHQJ .TKX=U[_ )&+4_\ K[E_]#-?<5?#NO?\C%J?_7W+_P"AF@#[;LO^/"W_
M .N2_P A4]067_'A;_\ 7)?Y"IZ "BBB@ HHHH **** "BBB@ HHHH ****
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M@;CNY.>OH!TZ^@!D?L^^%KBXUJZ\33*5M;9&MX"0/WDC8W8]E7_T(>AK)_:
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M!X4CEFNRRDW-Q%MC50V2-IY8D#'; .<YJOK?[.L<ER\NAZWY43$D07<9;;Z
M.#R.@Y&?<U#HO[.D@N0^N:W&858?NK.,Y<=_F;&W\C0!W_PS^(K^/K&Z:;2Y
M+2XM-HDD4[H7)S]TGD'CH<XR.:^:-$_Y*%IW_85B_P#1HK["T30M-\.:7%IN
ME6B6UK'T5>K'NS'J2?4UY/8_ #['XAMM5_X2;?Y-VMSY7V#&<.&VY\SVQG%
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M[^5'\OX?/OZ>@_#UZL_0])AT'0;#2;=BT5G D*L1@MM&-Q]R>?QK0H ****
M"OBNOM2OBNO0P'VOE^IS8CH%%%%>B<H4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>A?"OP<=>UD:I=QG^
MSK%PP/&))@00I'< ')_ =ZF<U"/,QI7=CO/A3X,71=)&L7T(_M"\4&,,OS0Q
MGH/8GJ?P'K7HU%%>3.;G+F9UI65@HHHJ!A1110 4444 %%%% $%Q_#^-05/<
M?P_C4%:1V,WN%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"S;_ .K/UJ6HK?\ U9^M2UD]S1;!1112&%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!<@_U*U)4<'^I6I*R>YJM@HHHI#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7M6_\ I/_B:/^$2\2_\ 0O:M_P" 4G_Q-'-'N%F8]%;'_")>)?\ H7M6_P#
M*3_XFC_A$O$O_0O:M_X!2?\ Q-'-'N%F8]%;'_")>)?^A>U;_P  I/\ XFC_
M (1+Q+_T+VK?^ 4G_P 31S1[A9F/16Q_PB7B7_H7M6_\ I/_ (FC_A$O$O\
MT+VK?^ 4G_Q-'-'N%F8]%;'_  B7B7_H7M6_\ I/_B:/^$2\2_\ 0O:M_P"
M4G_Q-'-'N%F8]%;'_")>)!_S+VK?^ 4G^%)_PBOB+_H :I_X!R?X4<R[A9F1
M16O_ ,(KXB_Z &J?^ <G^%'_  BOB+_H :I_X!R?X4^9=PL9%%:__"*^(O\
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M &J?^ <G^%',NX6,BBM?_A%?$7_0 U3_ , Y/\*/^$5\1?\ 0 U3_P  Y/\
M"CF7<+&116N/"GB,G T#52?^O.3_  I?^$2\2_\ 0O:M_P" 4G_Q-+FCW"S,
M>BMC_A$O$O\ T+VK?^ 4G_Q-'_")>)?^A>U;_P  I/\ XFCFCW"S,>BMC_A$
MO$O_ $+VK?\ @%)_\31_PB7B7_H7M6_\ I/_ (FCFCW"S,>BMC_A$O$O_0O:
MM_X!2?\ Q-'_  B7B7_H7M6_\ I/_B:.:/<+,QZ*V/\ A$O$O_0O:M_X!2?_
M !-'_")>)?\ H7M6_P# *3_XFCFCW"S,>BMC_A$O$O\ T+VK?^ 4G_Q-'_")
M>)?^A>U;_P  I/\ XFCFCW"S,>BMC_A$O$O_ $+VK?\ @%)_\31_PB7B7_H7
MM6_\ I/_ (FCFCW"S,>BMC_A$O$O_0O:M_X!2?\ Q-'_  B7B7_H7M6_\ I/
M_B:.:/<+,QZ*V/\ A$O$O_0O:M_X!2?_ !-'_")>)?\ H7M6_P# *3_XFCFC
MW"S,>BMC_A$O$O\ T+VK?^ 4G_Q-'_")>)?^A>U;_P  I/\ XFCFCW"S,>BM
MC_A$O$O_ $+VK?\ @%)_\31_PB7B7_H7M6_\ I/_ (FCFCW"S,>BMC_A$O$O
M_0O:M_X!2?\ Q-'_  B7B7_H7M6_\ I/_B:.:/<+,QZ*V/\ A$O$O_0O:M_X
M!2?_ !-'_")>)?\ H7M6_P# *3_XFCFCW"S,>BMC_A$O$O\ T+VK?^ 4G_Q-
M'_")>)?^A>U;_P  I/\ XFCFCW"S,>BMC_A$O$O_ $+VK?\ @%)_\31_PB7B
M7_H7M6_\ I/_ (FCFCW"S,>BMC_A$O$O_0O:M_X!2?\ Q-'_  B7B7_H7M6_
M\ I/_B:.:/<+,AT#1+KQ%K5MIEH/WDS8+D9"+W8^P%?4.A:-:Z!HUMIMH@$<
M*!2P7!=L<L?<GFN7^&?@S_A&-%^U7D175+Q09@V"8E!.U!Z=B??Z5W->?B*O
M/*RV1T4XV5V%%%%<QH%%%% !1110 4444 %%%% $%Q_#^-05/<?P_C4%:1V,
MWN%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S;_ZL
M_6I:BM_]6?K4M9/<T6P4444AA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 7(/\ 4K4E1P?ZE:DK)[FJV"BBBD,**** "BBB@ HHHH ****
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MKT3]HK_D;M*_Z\/_ &HU=M\ M"M+3P4^L"!3>WL[J9B/F$:D */09!/N?H*
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MAV@$C\0*R[O3O%GPO\1032K-IUY@M%+&X:.9 >1D<,O RI]LBNI_X: \9?\
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M317-O'/"ZR12J'1U.0RD9!'X5)0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9]:%9]7 B844459 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% #7_U;?0U3JX_^K;Z&J=7$B044459(4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $D/\ K5JU56'_ %JU:K.6
MY<=@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+C^
M'\:@J>X_A_&H*TCL9O<****H04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %FW_U9^M2U%;_ .K/UJ6LGN:+8****0PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** +D'^I6I*C@_U*U)63W-5L%%%%(84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=T*U\,Z!::-92326]JI5&F(+D$D\D #OZ5R?C#X0>&O%MVU\RRZ??N<R3VN
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M[5K..[M7Y,;YX/J".0?<$&@#QGPU\>-+N-!%AXRL9[BY VR31PH\=P,Y!9.
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &O_ *MOH:IU<?\
MU;?0U3JXD2"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH DA_UJU:JK#_K5JU6<MRX[!1114E!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 07'\/XU!4]Q_#^-05I'8S>X44450@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** +-O_ *L_6I:BM_\ 5GZU+63W-%L%
M%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %R#_4K4E1
MP?ZE:DK)[FJV"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K/K0K/JX$3"BBBK("BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH :_\ JV^AJG5Q_P#5M]#5.KB1(****LD**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"2'_6K5JJL/^M6K59RW+CL%
M%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!<?P_C4%
M3W'\/XU!6D=C-[A1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH LV_\ JS]:EJ*W_P!6?K4M9/<T6P4444AA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 7(/]2M25'!_J5J2LGN:K8****0PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L^M"L^K@
M1,****L@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_P"K
M;Z&J=7'_ -6WT-4ZN)$@HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** )(?]:M6JJP_ZU:M5G+<N.P4445)04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $%Q_#^-05/<?P_C4%:1V,WN%%%%4(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S;_P"K/UJ6HK?_ %9^
MM2UD]S1;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!<@_U*U)4<'^I6I*R>YJM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"[1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5EUJ5EU<")A1115D!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 -D_P!6_P!#5"K\G^K?Z&J%7$B04445
M9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $D'^N7\?Y5=J
ME!_KE_'^57:SEN7'8****DH**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"O=?P?C5:K-U_!^-5JTCL9O<****H04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %NU_P!6?K4U0VO^K/UJ:LGN:+8****0PHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +]M_J%_'^=2U%;?ZA
M?Q_G4M9/<U6P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9=:E9=7 B844459 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% #9/\ 5O\ 0U0J_)_JW^AJA5Q(D%%%%62%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!)!_KE_'^57:I0?ZY?Q_E5V
MLY;EQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K
MW7\'XU6JS=?P?C5:M([&;W"BBBJ$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!;M?\ 5GZU-4-K_JS]:FK)[FBV"BBBD,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"_;?ZA?Q_G4M16W^H7\?YU+63W-5
ML%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !676I675P(F%%%%60%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 V3_ %;_ $-4*OR?ZM_H:H5<2)!1115DA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 20?ZY?Q_E5VJ4'^N7\?Y5=K.6Y<=@HHHJ
M2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]U_!^-5JLW7
M\'XU6K2.QF]PHHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 6[7_ %9^M35#:_ZL_6IJR>YHM@HHHI#"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH OVW^H7\?YU+45M_J%_'^=2UD]S5;!1112&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5EUJ5
MEU<")A1115D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -D
M_P!6_P!#5"K\G^K?Z&J%7$B044459(4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $D'^N7\?Y5=JE!_KE_'^57:SEN7'8****DH**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O=?P?C5:K-U_!^-5JTCL9O
M<****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %NU_P!6
M?K4U0VO^K/UJ:LGN:+8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** +]M_J%_'^=2U%;?ZA?Q_G4M9/<U6P4444AA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>"_\+\_ZEK_ ,G_
M /[77O5?#U=N#IQGS<R['/7DU:Q[/_POS_J6O_)__P"UT?\ "_/^I:_\G_\
M[77C%%=OU:EV.?VDNY[/_P +\_ZEK_R?_P#M='_"_/\ J6O_ "?_ /M=>,44
M?5J78/:2[GL__"_/^I:_\G__ +71_P +\_ZEK_R?_P#M=>,44?5J78/:2[GL
M_P#POS_J6O\ R?\ _M='_"_/^I:_\G__ +77C%%'U:EV#VDNY[/_ ,+\_P"I
M:_\ )_\ ^UT?\+\_ZEK_ ,G_ /[77C%%'U:EV#VDNY[/_P +\_ZEK_R?_P#M
M='_"_/\ J6O_ "?_ /M=>,44?5J78/:2[GL__"_/^I:_\G__ +71_P +\_ZE
MK_R?_P#M=>,44?5J78/:2[GL_P#POS_J6O\ R?\ _M='_"_/^I:_\G__ +77
MC%%'U:EV#VDNY[/_ ,+\_P"I:_\ )_\ ^UT?\+\_ZEK_ ,G_ /[77C%%'U:E
MV#VDNY[/_P +\_ZEK_R?_P#M='_"_/\ J6O_ "?_ /M=>,44?5J78/:2[GL_
M_"_/^I:_\G__ +71_P +\_ZEK_R?_P#M=>,44?5J78/:2[GL_P#POS_J6O\
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M.=GKW_"\O^I=_P#)W_[71_PO+_J7?_)W_P"UUY#11["GV#G9Z]_PO+_J7?\
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M_P!2U_Y/_P#VNC_A?G_4M?\ D_\ _:Z\8HH^K4NP>TEW/9_^%^?]2U_Y/_\
MVNC_ (7Y_P!2U_Y/_P#VNO&**/JU+L'M)=SV?_A?G_4M?^3_ /\ :Z/^%^?]
M2U_Y/_\ VNO&**/JU+L'M)=SV?\ X7Y_U+7_ )/_ /VNC_A?G_4M?^3_ /\
M:Z\8HH^K4NP>TEW/9_\ A?G_ %+7_D__ /:Z/^%^?]2U_P"3_P#]KKQBBCZM
M2[![27<]G_X7Y_U+7_D__P#:Z/\ A?G_ %+7_D__ /:Z\8HH^K4NP>TEW/9_
M^%^?]2U_Y/\ _P!KH_X7Y_U+7_D__P#:Z\8HH^K4NP>TEW/9_P#A?G_4M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!;M?]6?K4U0VO\ JS]:FK)[FBV"BBBD,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"_;?ZA?Q_G4M16W^H7\?YU+63W-5L%%%%(844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'U%<MX0^+7A;QG>?8;&>>UO6^Y;WB!'DZD[<$@\#.,YKHO%?_(GZW_UX3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OAZON&OAZO0P'VOE^IS8CH%%%%>B<H4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*X#<**** "BBB@ HHHH KW7\'XU6JS=?P?C5:M([&;W"BBBJ$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!;M?]6?K4U0VO^K/UJ:LGN:+8
M****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +]M_J%_'
M^=2U%;?ZA?Q_G4M9/<U6P4444AA1110 4444 %%%% !1110 44FY?[P_.EH
M**** "BBB@ HHHH **0D#J0* 0>AS0 M%(6 ZD4H(/2@ HHHH **** "B@D#
MJ: 0>E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!1NM9TNQF\F[U*SMY<9V33JC
M8]<$U#_PDN@_]!O3?_ N/_&OGKXQ?\E)O_\ KG#_ .BUK@Z[H812BI7W'8^P
MAXDT)F"KK6G$DX %TG/ZUIU\55U?@[Q]K'A&_C:*>2XT_.);.1R48=]O]UO<
M>G.11/!-+W6%CZJJA<ZYI%G.T%UJEC!,F-T<MPBL,C(R"<]#3M(U2UUO2;74
M[)BUO<QB1"1@CV/N#P?<5\R?$[_DI&M?]=E_] 6L*-'VDG%Z"/IZSU.PU'?]
MAOK:Z\O&_P B57VYZ9P>.A_*K5>*_L_?\S%_V[?^U:]JJ*L.2;B!7N[ZTT^(
M2WMU!;1EMH>:0(">N,GOP?RJG_PDN@_]!O3?_ N/_&D\2:';^)/#]YI5R/DG
M3"MW1ARK#Z$"ODG4M/N-*U*YT^[39<6TC12+VR#CCU'O6M"C&JGKJ,^R4=)8
MUDC971@&5E.00>A!IU>7?!7Q1_:GAZ31+A\W.G\QYZM"3Q_WR>/H17<>*M?B
M\,^&KW59=I:&,^4C'&^0\*OY_IFLITW&?((L3:_HUO,\,^KV$4J':R/<HK*?
M0@GBI+35],U"4Q66HVES(%W%(9U<@=,X!Z<C\Z^/+FYFO+J:ZN)&DGF=I)';
MJS$Y)/XFOH?X.>$_[#\-G5;J("^U$!QN7!2$?=7GIGECZ_+Z5O6P\:<;MZC.
MYGU[1[6=X+C5K&&5#AHY+E%93[@GBH_^$ET'_H-Z;_X%Q_XU\O\ CO\ Y'W7
MO^OZ7_T(USU:1P::3N%C[%@U[1[F58H-6L99&.%2.Y1B3TZ UH5\55Z!X!^)
MFI^'-0M[._N7N='=@CQR')A!/WU/7CKCH>>_-3/!M*\7<+'TK37=(HVDD941
M069F.  .I)KD/B9XBU3POX2.H:2D9F,ZQ/)(NX1(0?F ]<A1WZU\X:QXFUO7
MY-^JZG<W0R2$=\(I/HH^4?@*SHX9U%>^@K'U9_PDN@_]!O3?_ N/_&M"&>*Y
MA2:"5)8G&5=&#*P]01UKXNKZ>T74+O2O@W9ZA80I-=6VEB5(W^Z=JY.<$$\9
M. >:=;#*FE9[CL=O6;)XAT2*1HY-8T]'4X*M<H"/PS7R[K?CCQ)XAW+J.K7#
MPMG,$9\N/![;5P#^.:YZM8X+^9A8^S;2^M-0B,ME=07,8;:7AD#@'KC([\C\
MZL5YM\#_ /D0I/\ K^D_]!2O2:XZD>63B(*S'\1Z'&[(^LZ<KJ<,K72 @^AY
MKF?B?XT_X1+P_P"7:N5U2]!2W(P?+ QN<Y] >/<U\SQQRW5PD4:M)-*X50.2
MS$\?CFMZ.&]I'F;L.Q]BV>K:;J$C1V6H6ERZC<RPS*Y ]2 :N5R/P\\&Q^#O
M#B02*AU&XQ)=R+SEN<*#Z*#CZY/>NNKGFDI-1V$%%%%2 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5/5=+L];TJZTS4(5FM+F,QRQMW!]/0CJ
M#U! -7** /COX@?"[6? ]](_E27FD,<PWL:Y '/ROC[K8'T/;T#=)^+_ (YT
M:T2UM]<>2!!M1;B))2HXQ\S MVZ9Q7V(Z)+&T<BJZ,"K*PR"#U!%<M?_  S\
M$ZE)YEQX:T\-W,,7E9Z]=F,]: /E/Q'\1?%GBRV^RZQK$LUKG/D(BQ(><C(0
M#=CMG-=]\)O@]J.I:I:Z]X@MI;+3K=UF@@D7;)<,#D94\JG&<GJ,8X.:]WTK
MP%X3T2XCN-.\/V$%Q$<QS>2&=#ZACD@^]=%0!XW\>O!>M:_IEIJNDO=W268V
MW&GQNS*1SB5(QU89()')!'8&O"O#7CWQ1X,\R'2-3EMX6)WVTBAX]W<[6!"G
MW&#QS7VS7.ZQX#\*:_,9]3T&QGG;):7R]CMWY9<$_B?7UH ^2?$_Q"\4>,(4
MM]9U1IK9&#K B+&F['4A0,GKUSUKV;X#_#J^T=Y?%.KPO;RSPF*SMW&&"$@L
M[#&1G  ]B3CD5Z;I7P]\(Z).L^G^'K"*9/NRM'O9?H6R1UKI: "BBB@#XQ^*
MW_)4?$/_ %]'_P!!%?3_ (&_Y)-HG_8*C_\ 1=:MWX/\,W]U)=7GAS2+BXE.
MZ26:RC=W/J25R:U(+2VM;1+2WMXH;:--B0QH%15Z8"C@#VH ^+_AM_R4KPY_
MU_Q?^A5]K5B6W@WPO97,=S:^&]'@N(F#1RQ6,2LC#H00N0:VZ /DGX[?\E7U
M#_KC!_Z+6O</"_\ R;_#_P!@27_T!JZ^_P#"OAW5;MKO4= TN\N6 #37%G'(
MY X&68$U>BT^R@T\:?#9V\=D$,8MDB41A#U7:!C'M0!\@_![_DK&@?\ 763_
M -%O7V/6-9^$?#6G7<=W8^'M)M;F,Y2:"RC1UXQPP7(X-;- 'QQ\8?\ DK&O
M_P#76/\ ]%I7T!>?\FYK_P!BS'_Z3K777GA'PUJ-W)=WWA[2;JYD.7FGLHW=
MN,<L5R>!6@=/LFT[^SFL[<V/E"'[,8E\KR\8V;<8VXXQC% 'RE\"?^2KZ?\
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MC\1T)KZBM;J"]M(KJVE66"9 \<BG(93R#7EUZ7LY:;'5"7,B:BBBL"PHHHH
M**** *]U_!^-5JLW7\'XU6K2.QF]PHHHJA!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 6[7_5GZU-4-K_JS]:FK)[FBV"BBBD,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2?3K18#E_BT[)X&D96*G[1'R#[FK?PR8MX!TXL23^\Y)_P!MJI?%S_D1)/\
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M9HY7:]@.DHI%974,I!4C((/!%+2 **** "BBB@ HHHH **** "BBB@ HHHH
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M9U>*WN" 1 JM))@YQE5!(!QU.!5+1/BMX*\07D=G8ZY%]JD.%BGC>(D^@+
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MKP]8-?:O?0V=L#C?*V,GT ZD^PKCXOC;\/Y;D0C72NX@"1[695)/N4X^IP*
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M+_DI-_\ ]<X?_1:UK_ _3K'4-<U1;VSM[E4ME*B:)7"G=VR*R/C%_P E)O\
M_KG#_P"BUJI\/?&\7@B_O+J2Q>[^T1",*L@3;@YSG!KU>5RH)1WLAGT/?>#/
M#>HV<EK/HE@(Y!C=' J,ON& R#]*^6-?TP:+XAU'3%D,BVMP\*N1RP5B 3[X
MKUF[^/Q-JXLM VW!&$::YW(I]2 H)^F1]:\;NKJ:^O)[NYD,D\\C2R.>K,QR
M3^9J<-3J0OS@CWGX$7DDWA;4+1^4@N]R'TW*,C\QG\:\M^)W_)2-:_Z[+_Z
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M]/4445Y)U!1110 4444 5[K^#\:K59NOX/QJM6D=C-[A1115""BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH MVO^K/UJ:H;7_5GZU-63W-%L
M%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %^V_U"_C
M_.I:BMO]0OX_SJ6LGN:K8****0PHHHH **** "BBB@#Y^^+O_(]2_P#7"/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME>2>W9%^Z<#+#KG% 'U%1110!\0>._\ DH?B7_L*W7_HUJ^R/"G_ ")^B?\
M7A!_Z+6OC?QW_P E#\2_]A6Z_P#1K5]D>%/^1/T3_KP@_P#1:T :]?,O[1NF
MP6WC/3K^(;9+RSQ*/4HQ /UP0/\ @(KZ:KY*^-_BRV\3^.O*L)EFLM.B^SJZ
MX*N^278$=1R!_P !X]P#UKX&7KW7PBGA9]PM+BXA48^Z"H?'YN3^->"?#;_D
MI7AS_K_B_P#0J^C/A#H\VC_!^V^T1F.6\26[VELY5_N'VR@4_C7SG\-O^2E>
M'/\ K_B_]"H ^@/CYXDOM#\$0VMA*T+ZC<>1+(AP?*"DLH/;/ ^F1WKQ#X:_
M#6;XBW5^B:I%81600R,T1D=M^[&U<C^[SSW%?3GC_P $VGCSPR^E7$I@E1Q-
M;S@9\N0 C)'<$$@CW]0*^8]7^&?COP9>&Z33[LB(D)>Z8Y<8(()!7YE&,CY@
M/UH Z&'X&^-]/\8I;Z=-%'% 1-#JPD\M%QR" ,L&R,8P?KCFOI"YO_\ A'?#
M$E_K-V+@V-J9+FX2,1^:57)(3. 3C@9ZG%?,/A7XY>+-"N(4U&Z.KV"D!XKG
M'F;?:3&<_P"]GI7L?Q6UF+6O@7>ZKIK,;6\CMI 6X8(TJ<'GKG@CGO0!\^:M
MJ_B/XI^-(UP]Q>74A2UM5;Y(4Z[5[  #)/L2:]!3]FO6C8L[Z_8"\V\1"-S&
M3Z;^N/?;7E?A;5/$&DZQY_AHSC46C9!]G@$K[>"< @^G45V__":?&/\ O:Y_
MX+/_ +70!@6=YXD^$?CI@RF&[MF"S0[LQW,1YQGNI'0]0?0BOK)/%6FMX,'B
MDNPT_P"Q_;#TW;=N=N#_ !=L>M?)&O6OCOQ/J"WVLZ5J]W=+&(A(U@RG:"2!
M\JCU->IW%OJ6F_LI26]U;S6TJR8:.52CJAN\\@X/)/?L?2@#R;7-;U_XE>,!
M*T<EU>W3^5:VD?(C7/"+Z #DD^Y/>N^M_P!G'Q)+IRS3:KIL-VRY^SDNP4^A
M<#KZX!'UJE^SREL_Q)E:<*9$T^5H,]GW(#C_ ("7KZGH ^'?$>F:]X9N&\-Z
MRLL(MI#,D+-E,L,;T/<$ <CTYY%>]_LW?\B9JO\ V$#_ .BTK"_:8CMA=>')
M%V_:REPKX R4!CVY[XR6Q]36[^S=_P B9JO_ &$#_P"BTH \1^(OB2^\3>-]
M3NKR5F2*X>"WC)XBB5B%4#]3ZDDUW>K?L[ZU9>'S?:?JMOJ5ZJ[VLXHB@8?[
M#EOF..<$"M?XF_ [4KO6;O7/"RQW"74C33V+.$=78Y8H6.""<G!(QT&>@\QM
M];\>?#RY6U6ZU722NY4MYU/E'G)*HX*'DYR!W]Z />?@QX&\5^#[.=M:OHHK
M*Y7<NEC]XT;Y^^6Z*<#H,YR,X(K)^/7Q"N]%C@\,:1</!<W,7FWDT;898R2%
M0$<@G!)Z'&.S&M7X2_%R7QK<2:-K$$<6JQQF5)81A)D!Y&/X6&1['GIBO%_C
M4\K_ !;UP2]5,(49Z+Y*8_Q_&@";P)\'M=\<:?\ VFD\%AII<HDTP+-+@X)1
M1U ((R2.>.<'%CQQ\%-=\':7)JL=U!J6GQ8\YHE*21Y_B*'/R].03UZ <U6T
M;Q=\4;;1[2#1VU7^SHHPEOY&GADVCC@A#GZU-?>)OBUJ>GW%C>IK<UK<1M%+
M&VF\,I&"/]70!Z+\!?B%=:M')X5U69IIK:+S+*9SEC&, QD]\9!'MD=A7-?M
M$>)+Z?Q1;>'EE9-/MK=)VB!P))6)^8^N!@#TY]:Q/A%X=U^Q^*6B7,^C:A;Q
M(\N^6:U=%4&)P<DC ZXKU_XM?"AO'/DZKI<T<.L6\?E;920DZ D@$C[K#)P<
M<YP>Q !Y1X+^"%WXR\(1Z]%KEO;&?>(8#"7Y5F4AVR-O*YX!X-=!\+/A;XZT
M'Q6NJ33QZ/;02&.='82FZ3/*A%."IQ]XD8R",XKS>XT?QY\.[AIW@U72.59I
MH'/E,02 "Z$HW4\$GK[UZ/\ #GXZZK)K-KI'BDI=P7+K#'>(@22-B< L!@,O
M('0$=>: /H>6*.>%X9HTDBD4JZ.H*LIX((/45S5M\//#%EHVL:3:Z8D-EJS%
MKF-&/4C VY^Z >0!P">,5U%% %#2-%TS0-/2PTFRAL[53D1Q+@$^I]3P.3S5
M^BB@ HHHH **** "BBB@#YF^,7_)2;__ *YP_P#HM:PO"O@_4_&%S<6^F-;B
M2! [B9RO!...#6[\8O\ DI-__P!<X?\ T6M=!\!/^0]J_P#UZK_Z%7K<[A04
MEV0SS;7] U#PSJ\FF:G$$N$ ;Y6W*RGH0>XKM_@SIF@:EXFD_M,-)J$"B:SB
M<CRVQ]XX[L."!]3VX]"^,7A$Z[X=&K6J WNFJSL .9(>K#IDD8R/^!>M?/VE
MZG=:/JEMJ-E)Y=S;N'C;&1D=CZ@]*(3]M2=M&!]E5\K_ !._Y*1K7_79?_0%
MKZ5\/ZY:^(]"M-5LV_=7"!BN>4;^)3[@Y'X5\U?$[_DI&M?]=E_] 6N;!IJH
MTP1WW[/W_,Q?]NW_ +5KVJODCPWXQUKPG]I_L>Y2'[3L\W=$KYVYQU''WC6]
M_P +B\:?]!&'_P !8_\ "KK8:<YN2"Q],T5YE\(O&.M>+/[8_MBY2;[-Y'E;
M8E3&[S,]!S]T5Z;7%4@X2Y6(\-^/MG!'?:'>)&!/,DT<C <L$*%<_P#?9K@O
MA[9P7_C_ $6WN8Q)$;@,5/0E06&?;('%>B_M _\ ,N_]O/\ [2K@?AC_ ,E(
MT7_KLW_H#5Z-)_[/\F,^J****\L1\E^._P#D?=>_Z_I?_0C7=_![PCH7B/3-
M3FU?3TNI(ID5"SL-HVD]B*X3QW_R/NO?]?TO_H1J3PSXZUOPE;SP:5)"B3N'
M?S(@W(&*]>492I)1WT&>\:A\)/!]Y8RP0Z8+25E.R>*5]R'L<%L'Z&OF6:,1
M3R1A@X1BH93D'!ZBNUU'XM>+]1LI+1[^.%) 5=H(55B",$9ZCZC!KB8XWFE2
M*)&>1V"JBC)8GH .YHH0J03YW<#Z=^$^J3ZI\/;!K@LTENSV^]FR6"GY?R!
M_"MOQC_R(^O_ /8-N/\ T6U5/A_X?E\,^#+'3[@YN<&688QM9CG;^&0/PJWX
MQ_Y$?7_^P;<?^BVKS9-.K==Q'R+7UEX!_P"1 T+_ *\X_P"5?)M?67@'_D0-
M"_Z\X_Y5VXWX4-G1U\;:O_R&K_\ Z^)/_0C7V37QMJ__ "&K_P#Z^)/_ $(U
MG@MY CZ ^!__ "(4G_7])_Z"E>%^+)I9_&&M23Y\TWTVX'/'SGCGTZ5[I\#_
M /D0I/\ K^D_]!2O,_B]X:FT3QC-?@,UGJ1,\;GL_P#&I_'GZ,/0U=&25>2
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M4 %%%% &5XDUZU\,>'+[6KP$P6D1<J" 7/15&>Y) _&O)O\ AI31?^@!?_\
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MPVT"0.7EFD"*H\Q^I/ H [ZBL"V\<^$[N?R+?Q-I$DN=H1;R/+'VYY_"M^@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:V\<$,:1Q(-JHBX 'L*J?NQY>HR2BBBL1!1110 4444 %%%% !1110 4444
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MTU/!#<P/!<1)+"XVO'(H96'H0>M><ZE\"? VH7+SI97-F7;<5M;@JN3UP&R
M/8<#MB@#YQ\=>*1XW\6S:O%IJ61F"QB&/#,V. 6( W,>/R [5]-^#/!S+\&K
M/PMJZ20M<6<B3K_'$969^XX9=XX/0CO5CPW\*/!_A:Z2\LM,\V\C(*7%TYE9
M".A4'Y0>^0,UVM 'Q3)'XA^%OCD':;;4K%R49ERDT9R,_P"TC#(_/H1QZQ;_
M +2ZBV_TGPN3< ?\L[S"M^:9'ZU[3KWAO1O$]B+/6M/AO( 25$@Y0D8RK#E3
M[@BN"D_9_P# [S!UCU"-<_ZM;GY?U!/ZT ><:5\>?&-[XN4PZ;#>V]RRQQZ5
M"AW< _<< MN/4D@CCH*^A]9TF'Q#X>O-*O0T<5[;M#)M()3<,9!Z9!Y'TK/\
M,^!?#?A!3_8NEQ02LH5YV)>1OJS$G\!@>U=%0!\27EIX@^&OC0*2]GJ=C)OA
ME ^613D!AV96&1^)![BO4;?]I:_33UCN/#=O+>!0#,ET40GUV;2?PW5[AXC\
M)Z'XLLOLFMZ=%=(/N,<JZ?[KC!'X'GO7$Q_ 'P-'<B5H+Z1,C]RUT=I_(!OU
M[T ?-WBKQ%K?C#5'U_5]S>8?)C9$*Q1A>?+3Z;LXR3\V3US7O'[.)<>"-8,:
MJS_;SM#' )\M,9.#C\J] U+X;^$=6TFQTN[T6(V-CN^SPQ2/$$+8R?D89)QR
M3DD\U?\ #?A/1/"-E+9Z%9?9()9/-=/->3+8 SER3T H ^<->^,?CVR\;))?
M*M@VG2LK:4%*Q'(P1)SE\@@@YQT*@5H>+OCO%XI\'W>C-X:2*:Z38TDDXE6/
M_:4%!STQZ?A7NWBCP'X;\8QJ-9TV.:5/N3H2DJ^VY>2/8Y'M7(P_ #P-%<>:
M\-_,F<^4]T0O7IP ?;K0!Y)\ ]#O+_XC0:I'"_V33HI'EEQ\H9T9%7/J=Q./
M8UV?[07@6YO##XMTZ&27R(O)OD09VH"2LF.O&2#Z  ]B:]JTC1=,T#3TL-)L
MH;.U4Y$<2X!/J?4\#D\U?H ^4?A_\:]3\%Z4ND75@NI:?&Q,(,OER0@G) .#
MD9.<$>O..F[XD_:,U*_T][;0=*&FS.,&ZEE$KKS_  KM ''<YZ].*]5UWX.^
M"=?NGNIM*^S7#DEY+20Q;B<G)4?+G)SG%4M,^!7@73IQ,]C<7I'1;JX)4?@N
M ?QSUH =\(O'>N>.-(N9M7TM81;D*E]'E8[@DG("GNN!D@D<]JX3XU?$'QIH
MFN2:':@Z5ILBAX+RW)\RY7 SB3^'!X(7!'J01GWZ""&V@2"WB2*%!M2.-0JJ
M/0 =*I:UH.E>(M/>PU>QAO+9P04D7I[J>JGW!!H \(T_]I*X72_)U3P['<W8
M3:98KC8DAQW4J<>^"?PKR+2=*NO%WBR*QL+0"6^N21%"N%B4MDG@855&>V !
M7TG)^S_X'>8.L>H1KG_5K<_+^H)_6NR\,>"/#O@^)ET33(K>1UVR3DEY7'NQ
MR<9&<#CVH Z"BBB@ HHHH **** "BBB@ HHHH \R\8_"+_A+/$MQK']N?9?-
M5%\K[)OQM4#KO'IZ5H^ ?AM_P@]_=W7]K?;?M$0CV_9O+VX.<YW'-=Y16KK3
M<>2^@!7CVI? :WN]2N;BTUW[);RR,\=O]CWB($YV@[QD#ITKV&BIA4E3^%@<
M;X"\$7?@B&ZMFUO[?9SD.L)MC'Y;]R#O/4=1CL/QYWQ/\&?^$C\27NK_ -O_
M &?[4X;ROL>_;@ ==XST]*]4HJE6FI.2>H'BO_#/W_4S_P#DA_\ ;*/^&?O^
MIG_\D/\ [97M5%7]:J]_R"YQ7P_^'_\ P@O]H_\ $S^W?;/*_P"7?RMFS=_M
M-G.[]*[6BBL92<WS2W XKX@?#_\ X3K^SO\ B9_8?L?F_P#+OYN_?M_VEQC;
M^M8'ACX,_P#".>)++5_[?^T?97+>5]CV;L@CKO..OI7JE%6JTU'E3T ****R
M \EU[X)?VWK]_JG_  D/D_:YVF\O[%NV;CG&?,&?RK/_ .&?O^IG_P#)#_[9
M7M5%;K$U4K)A<\63]G]0ZE_$I9,_,%L<$CV/F'%=KX3^&.@>%)ENHDDO+]3E
M;FXP2G&/E X'UY/O7:44I5ZDE9L JEK.G_VMH>H:;YOE?:[:2#S-N[9O4KG&
M1G&>F:NT5BG;4#Q7_AG[_J9__)#_ .V5ZSH&E?V'H%AI?G>?]DA6+S=NW=@=
M<9./SK1HK2=:<U:3 *\;N_@-]JO9[C_A)-OFR,^W[#G&3G'^LKV2BB%65/X6
M!S7@?PG_ ,(9H#:7]M^V;IVF\SRO+Z@#&,GT]:UM8T;3]>TV2PU*V2XMY!]U
MARIQC<I[$9ZBK]%2Y-RYGN!XGJ_P%<W#/HVL((23B*[0Y7_@2]>_851MO@)J
M[R 76LV,29Y,2/(<?0A?YU[U16RQ56UKA<Y3P?\ #[1?!R&2T1I[YU*O=S<L
M1Z =%'TZ]\UU=%%8RDY.[ ****D HHHH **** "BBB@ HHHH **** "BBB@
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MK;^9)]\JN0 Q[D=,GGCFONZODCXYV%M8?%&]-M&(_M$4<\@'0N1R?QQGZYH
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MW5S(<)#!>QN[<9X4-D\"MFOG+X<?"+QAX>\?Z3JNI6,$5G;.[2.+E&(RC <
MYZD5[7X\\0#POX'U;5PX66& B G/^M;Y4Z?[1% 'RO\ %CQ&_B;XC:I<"0M;
MVK_8[<$#A(R1Q[%MS<_WOPKU>?X?%?V;%M/)/]H)&-8(V[3O^\01UR(B5]<C
M\*^?=,:R75+5M265K$2J;A80"[1Y^8+DCDCW%?2;?M$^"VA,+:5K1B*[2AMX
M=I'3&/-Z4 >2_!3Q =!^)=@CN5M]1!LI!ZE\;/\ Q\*/Q-?7E?!-S)!%JDTN
MFO,ENLS-;,_RR*H;Y2<$X;&.A//>OMGP7KP\3^#-)UG.7N;=3+P/]8/E?I_M
M!J /EWXV_P#)7M=_[=__ $GCKI/!_P >?^$4\*:?H?\ PC?VK[(A7SOMVS?E
MBWW?+..OK7-_&W_DKVN_]N__ *3QUZ)X ^"WA;Q+X&TO6+]]0^U74;-)Y<ZJ
MN0[#@;?0"@#@_B-\7KWQ_IUOIHTU-.LHI?.9!,96D8 @9;:O R>,>GI7HW[/
M7@V;3[&Z\4W1C!OH_(MD4@L(PP+,<=,D#CK\N>XK-^(7P)TC1?"UWK.@WMTL
MME&9I8;IPZR(.N" "#CGN#C''6N:^ OBJYTGQO'HC3'[!J@96C8G:LJJ2K =
MB<;??(]* +/[1W_)0]/_ .P5'_Z-EKTC]GK_ ))J_P#U_P O_H*5YO\ M'?\
ME#T__L%1_P#HV6O2/V>O^2:O_P!?\O\ Z"E 'J]>.?M$Z);W?@RUUC:JW5E<
MJ@?'+1N""N?J%/Y^M>QUXO\ M%>(+>U\*V>@JZ&[O)UF9#G*Q)GGVRV!SZ'\
M #F?V:]0=->US3=P\N:U2XVD\Y1MN0/^VG/X5]'5\Z_LUZ6[:MKFK-$XCC@2
MV20K\I+-N8 ^HV+D#U&>U?15 !7P-:RK!>03,"5CD5B!UP#FOOFO@.&)IYXX
M5(#2,%!/3).* /IS_AH[P?\ ] W7/^_$/_QVM#1/CQX7U_7++2;6PUA+B\F6
M&-I88@H8G R1(3C\*XC_ (9HN_\ H:(/_ ,__%UJ^&?@!=>'O$^F:PWB&&=;
M.X28Q"U*E]ISC.XXH ROVE_^0AX<_P"N4_\ -*Z?]G'_ ))YJ'_85D_]%15S
M'[2__(0\.?\ 7*?^:5T_[./_ "3S4/\ L*R?^BHJ .Q^*7_),/$/_7HW\Q7@
M'P _Y*?%_P!>DW\A7OWQ495^%_B$L0!]D(Y/<D 5X#\ /^2GQ?\ 7I-_(4 =
MO^T+XTO]/^R>%K&9H(KNW-Q>,O#2(6*JF>PRK9]>!TSGS+PC\)/$OC/1'U;3
M6L8[4,R)]HF*M(R]0  ?ISBO:?C3\,KWQE%:ZQHH634[2/R7MV8+YT621M)X
MW D\$@$$\Y&#X5IOB7QQ\.;IK.&XU#2SDLUI<Q'83QD['&.>.0,^] '6_"OP
M[\1]%\8M_9FG36UO!+Y.H+?$QV[#N/\ :/'!0'&0>AY]<^.O_))]2_ZZP?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>"_M'^)D2UTSPQ!(?,=O
MMER 2,*,J@/8Y.\X[;0>XKWJO./%7P7\/^,/$-QK6I:EK N)@HV131A$"J
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M()SSN1JU/!O@_3_ ^AG2=,FNI;<S--NN65FW$ 'E5 QP.U ' ?M'?\D\T_\
M["L?_HJ6N8_9H_Y"'B/_ *Y0?S>O8_&O@K3?'FC0Z7JD]W#!%<+<*UJZJQ8*
MRX.Y6&,.>WI5#P-\--&\ 37LNE7-_,UXJ+)]JD1@-N<8VJO]XT <W^T+_P D
MU3_K_B_]!>N/_9H_Y"'B/_KE!_-Z]F\9>#]/\<:&-)U.:ZBMQ,LVZV95;< 0
M.64C')[5F^!OAIHW@":]ETJYOYFO%19/M4B,!MSC&U5_O&@#PO\ :&_Y*3%_
MV#XO_0GJI\,/B[/X#@ETR^M'O=)E<R*J,!)"Y')7/!!P/EXYYSUS[GXR^$6@
M>.-;75M3O-3BG6%80MM+&J[021PR$YY/>JVI_!+PGJ7AVQTMA=1S6,9CAOU9
M?.*DDX?"[7&3Z9'8C)H XWQ-^T992Z5)!X;TR\6\D4J)[T*HBR#\P"LV2.,9
M(KR_X9^$KKQOXYMHY5>6SAE%S?S2*7!0')5B>[D8Y]2><&O6[?\ 9KT99R;G
M7[^2'/"QQ(C8^IS_ "KUGP]X:TCPKIHT_1K*.UM\[F"Y)=L8W,3R3QWH XOX
MU^"[CQ=X.6;3XQ)J&FN9XTP-TD9&'0'L>%;WV8[BO OAM\2;WX?:E,RP?:].
MNMHN+<N000?OKV#8S]?RQ]CUY[XP^#?A?Q?>27\B36&H2'+SVA $A]64@@GG
MDC!/K0!Q6L_M(V)TZ5=$T6Y^VL,(]X5$:'U(4DGZ<5Y%X4\.ZK\1O&R6SR2R
MR7,IFOKLC.Q,Y=R<8SV';) KV>T_9MT2.ZWW>NW\\ .?+CC2,D>A;GV[5ZKX
M<\*Z+X3T\66C6$5M&0/,8#+RD=W;JQZ]?6@#E/BWX+?Q+\.VLM,M]]WIQ2>U
MB'+,%&TH#UR5)X[D"OG7X>>/[_X>:[+<1P?:+2<".[M&.TMMS@@XX923V[D=
M\C[-KSSQE\&O#'C"[:_99=.U!SF2>TP!*?5U(P3UY&#SR30!R]Y^TEH*V):R
MT74I+O9Q',8TC#?[P8G'7M7SYKVN7WB37+O6-2D#W=T^]RHP!Q@ #T   ]A7
MT)IW[-^@V]RDFH:S?7<:MDQ(BQ!QZ$\G'KC!^E;^O? WPEKU[%<-)J%DD,"0
M1P6<D:QJJ].&0G//)SR: -3X0?\ )*- _P"N+_\ HQJI?&GPLWB;X?7+VZ.]
M[IS"[A5!DN ,.N,$GY23QW KK_#>@6OA?P_9Z+92326UJI5&F(+D$D\D #OZ
M5C^,/B'X<\):5=37E];7-RF46PBE5I9'_NE>JCU)''Y @'QE]JG^R&T\U_LY
MD$GEY^7=C&<>N#BOK/X'^'O["^&UG-(FVXU)C>/E<':W"<]QM /_  (U\Q^$
MO#TOBSQ=I^C0JR+=3@2&/GRXQR[#/HH/6OMZVMXK2UAMK=!'#"@CC0=%4# '
MY4 2T444 %%%% !1110 5X+^T?XF1+73/#$$A\QV^V7(!(PHRJ ]CD[SCMM!
M[BO>J\X\5?!?P_XP\0W&M:EJ6L"XF"C9%-&$0*H "@QD@<9Z]2: /$/AK\))
M_B%IE[J#:L-.@MYA A^S><9&V[F_B7& 5]<Y[8Y[;_AF7_J;O_*;_P#;:]E\
M)^%[#P=X>@T736F>WA9VWSL"[%F)))  [XZ= *VZ /D'XE_"V?X=II\W]IC4
M;>\+J7%OY7ELN#@C<V<@_H:],_9P\0>?HVJ>'Y7&^VE%U"#U*/PP^@*@_P#
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M'/XUZ#0 5\/5]PU\/5Z& ^U\OU.;$= HHHKT3E"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH MVO^K/UJ:H;7_5GZU-63W-%L%%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %^V_U"_C_.I:BMO]0OX_SJ6LGN:K8*
M***0PHHHH **** "BBB@ K+U#0+#4I/,FBQ)C&Y.,_7UK4HH)G",U:2N<>?
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MX;[TL60#N]2"1SW!&>>3A?M&ZA>V.H>'_L=Y<6^^*?=Y,A3=@IC.#SU-<?\
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MY/4C;V& /8"M76OV@6U[1+W2KSPK UO=PM$_^EDXR.HRG4'D'L0* /1/@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^'J^X:^./\
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M -"_JO\ X!R?X4?\(IXC_P"A?U7_ , Y/\*.9=PL9%%:_P#PBGB/_H7]5_\
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MJ_\ X!2?_$T<T>X69BT5M?\ "(>)O^A=U?\ \ I/_B:/^$0\3?\ 0NZO_P"
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M^V>0[MYWE>7NW,6^[D^OK1XZ\*?\)KX3N=#^V_8_/=&\[RO,V[6#?=R/3UH
M\$_9Q_Y*'J'_ &"I/_1L5>F?M P2R_#%GCC9EAO87D('W5^9<G\6 _&G_#CX
M/_\ "O\ Q#<:M_;OV_SK1K;ROLGE8RZ-NSO;^YC&.]>B:KI=GK>E76F:A"LU
MI<QF.6-NX/IZ$=0>H(!H ^6O@SX^TKP-JNIG6!,MO>0H%DB3>592< CT(8_E
M7TUX:\2Z;XLT@:II,CR6C2-&K.A0DJ<'@\UXYJ7[-4$ET\FF>)'A@+96*XM=
MY4?[P89[=J]2^'_A ^!_"D6BM>B\9)'D,HB\L?,<XQD]/6@#J**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K+K4K+JX$3"BBBK("BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ;)_JW^AJA5^3_ %;_ $-4*N)$@HHHJR0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K+K4K+JX$3"BBBK("BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ;)_JW^AJA5^3_ %;_ $-4*N)$
M@HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU7:\>^ 7A;7O#VD:K/K,%S9Q7<D9@M)P58%0VYRIY4G*CL3MY[5[#0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %9=:E9=7 B844459 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% #9/\ 5O\ 0U0J_)_JW^AJA5Q(
MD%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!)!_KE_
M'^57:I0?ZY?Q_E5VLY;EQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH KW7\'XU6JS=?P?C5:M([&;W"BBBJ$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!;M?\ 5GZU-4-K_JS]:FK)[FBV"BBB
MD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"_;?ZA?Q_G4M
M16W^H7\?YU+63W-5L%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!XC^TI_P BWHG_ %]O_P"@5C?LT?\ (0\1_P#7*#^;UL_M*?\ (MZ)_P!?
M;_\ H%8W[-'_ "$/$?\ UR@_F] 'T/7CWQS\ 66J^&[CQ-96ZQZI8 /,44#S
MX<_-N]USNSUP".>,>PUS7Q"N(K7X<>)))G"(=-GC!/\ >9"JC\20/QH ^?\
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M.53"1@\\@?-USSCTKD_A/J?P]T"*XU+Q6ZS:F9-MO#):-,D*#!WCY2-Q/?L
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MLY8V& PB"NGH588*GCL?:OCCQAX?_P"$6\7:GHGFF5;28JDA&"RD J3[X(H
M^N=2U^^L_A9+X@C:,WZ:2+H,R_+YGEALX],]J\G^&OQ?\5^*?B!I>C:E):&T
MN?-\P1P;6^6)V&#GU45Z+KG_ "0:X_[%\?\ HD5\_?!+_DKVA?\ ;Q_Z3R4
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MSOM'M,.N!+%$J21GG!5@,@C/TKXW\3:))X;\3:CHTD@D:SG:(./X@#P?Q&*
M/H[XC_$+7O"_@7PSJVG20"[U!$,YDB# DQ!C@=N37S1JVJ7.M:O=ZI>LK7-W
M*TTA5<#<3DX'I7V7I>@Z3K_@C0(=7TVUOHX[*!T6XB#A3Y8&1GI7R7X^M+>P
M\?Z]:6D$<%O#>R)'%&NU44'@ "@#TSX?_&+Q;K7C'1=$O);1K2>41/MMP&*A
M3WS[5WWQG\=:WX'L](FT9X%:ZDE642Q!P0H4C'IU-=9I'@CPM9_8[^U\/Z=!
M=HJR)-%;JK*V.H('%>7?M+_\@SP[_P!=I_Y)0!V'P<\9ZOXV\.W]]K#PM-#=
M^2GE1[ %V*?SR:T?B)\2M,^']C'YT9NM2N%+6]HK8R 0"S'G:O/IS@@=#CCO
MV;O^1,U7_L('_P!%I7A_C;5KOQ;\0M2N,F5Y[PP6R;^ @;:B@DX'&/;))H W
MM3^.7CS4)]\6IPV,?_/&UMT"C\7#-^M;'AO]H3Q/IUTBZ['!JUH3\Y$:PRJ/
M]DJ OX%><=1UKVSPG\+O#'AC1H;5M*L[V\V#[1=W,"R-(^!DC=G:N1PHX^IR
M3P'QL^&&CP^'9_$^BVD-C<VK*;J*$;(Y4)"Y"C@,"0>,9&[.3B@#V#P]X@T[
MQ1HEOJ^ES>;:SC(R,,I'56'8@_YQ7D/Q;^*?B7P9XR33-)EM1;-:)-B6$,=Q
M+ \^G KG_P!G'79X/$>I:"\@^RW-L;E%)Z2H5''U5CG_ '165^T-_P E)B_[
M!\7_ *$] %K5/V@_$DFC6=IIPMX;[RB;N]:$$F0L2!&I^4 # )(.3],G"TWX
MX^.["Z22;54O80V6AN+>/##TRJAA^!KUGX%^"=(M_!5MXAN;&*?4;YG823H&
M,2*Y4!<CC.W.1UR/:L[]H+PGH\'ABTUZTLXK:]BN5@8PH%$B,&.& ZD%1@_4
M?0 ]+\!^-;+QWX;CU2U3R9E/EW-N6!,4@ZCW!Z@]Q^-=/7SM^S3<RC4_$%KN
M_<M##(5_V@S#/Y,?TKZ)H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\>_X7EX9_Y\=7_P"_,?\
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M_P!^8_\ XY1_PO+PS_SXZO\ ]^8__CE?/]%'U6F'M9'T!_PO+PS_ ,^.K_\
M?F/_ ..4?\+R\,_\^.K_ /?F/_XY7S_11]5IA[61] ?\+R\,_P#/CJ__ 'YC
M_P#CE'_"\O#/_/CJ_P#WYC_^.5\_T4?5:8>UD?0'_"\O#/\ SXZO_P!^8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %NU_U9^M35#:_P"K/UJ:LGN:+8****0PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** +]M_J%_'^=2U%;?ZA?Q_G4M9/<
MU6P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU)F!P#<?(!GW<@=J]L^%7P<E\'Z@FO:S=K)JBHZ1V\!S'$&X)+?Q'&?89[T
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M;N=G1"<E4Z*#[[0*Z71?@WXWUB\CA;1Y+"%C\]Q>$1J@]2/O'Z '\N:U-?\
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M1?\ %9_]1[_R-7M'[/C:W]NUY=7.H;3'"8Q=[\=7SC=]10![K1110 45\?\
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MCHOOC./>@#7BO+6>:2&&YADEC.'1'!9>W('2IJ^./A=!KY^)VE_V8MPES'=
M7C;"=L6?WHD]L9'/?'?%?8%Y=PV%C<7EP2L-O&TLA R0JC)X^@H GHKS#1OC
M=H?B/Q?I^@:1I]Y)]JD9&N9]L:J C-D#DGICG'7\_3Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *^'J^X:^'J]# ?:^7ZG-B.@4445Z)
MRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %=E\._&!\+:UY=RQ_LV[(2?_
M *9GL^/;O[?05QM%3**DK,:=CZ[!#*&4@@\@CO2UY;\)/%_VRU_X1V]D_?P+
MFU8_Q1CJOU';V^E>I5YTX.#LS9.Z"BBBI&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% $D'^N7\?Y5=JE!_KE_'^57:SEN7'8****
MDH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O=?P?C5:K-U
M_!^-5JTCL9O<****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %NU_U9^M35#:_P"K/UJ:LGN:+8****0PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** +]M_J%_'^=2U%;?ZA?Q_G4M9/<U6P4444AA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY.2?<U>KE?D(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *]U_!^-5JLW7\'XU6K2.QF]PHHHJA!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 6[7_5GZU-4-K_JS]:FK)[FBV"BBBD,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+GCG[P]J^G*X#X->&G\-?#FR6XB\N[OB;R8'J-^-@.>AV!<CL<UW] !1110
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M(M#N]*O%!BN(RH;&2C=F'N#@_A44:GLYW ^9/A_XG;PKXMM;UV(M)#Y-R/\
MIFW4_@<'\*[[XX>*5FDM?#EK(&10+BY*]"2/D'3T.>#W%>2:IIMSH^JW6G7B
M;+BVD:-QS@D'J,]0>H/<$5!//+<RF6>1I)" "S').!@?RKU'2C*:J#-WP3X9
MD\6>*K33%#"#/F7+@XV1*1N.>Q/ 'N17UA!#';01P0H$BC4(B+T50, "O/\
MX0^$_P"P/#"ZC<H!?:DJRG."4BZH,^X.2/<>E>B5Y^*J\\[+9 SY+\=_\C[K
MW_7]+_Z$:[OX/>$="\1Z9J<VKZ>EU)%,BH6=AM&TGL17">._^1]U[_K^E_\
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MB9W>QF2..-<DDQD  #^5 'R;\'O^2L:!_P!=9/\ T6]?6'BO_D3];_Z\)_\
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MA2RF,?B=YX^OID<]H_@;QIXUU!7CL+Z8R'#7M[O6,<9Y=NO'89//O7T_\./
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** *]U_!^-5JLW7\'XU6K2.QF]PHHHJA!1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!D%K;I$'(Z9V@9ZU?H ^,_"?Q/\ %/@BWDL=.N4:UW$_9;J,NL;=]HR"O/4
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M?H#/3:***\P04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7P]7W#7P]7H8#[7R_4YL1T"BBBO1.4**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "N@\&^)YO"NOQ7JY:W?]W<1@_>0_U'4?\ UZY^
ME1&D=412SL<*H&23Z4FDU9C/K:VN8;RUBN;:198)5#HZGA@>AJ6N>\$Z#/X;
M\*VNG74IDG7<\@#95"QSM7V'\\GO70UYC23T-T%%%%( HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** )(/]<OX_RJ[5*#_7+^/\JNUG+<N.P4445)
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>Z_@_&JU6;K^
M#\:K5I'8S>X44450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** +=K_JS]:FJ&U_U9^M35D]S1;!1112&%%%% !1110 4444 %%%% !1110
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M_>\P^OI7K=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(X!0#OZU[316D:\XPY%L 4445B!X?XE^#?B+6?$VI:E;WNEK#=7#RHLDL@8
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M444 %%%>??&'QAJO@KPC::EH[0K<2WZ0,98]XVF.1CQZY44 >@T5\H_\+_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZY\)/!I9QXDOXR N
M5LXW7KZR?3L/Q/I7#>"?"\GBKQ#%:=+6+$MRV2/W8(R ?4]!^?:OI6WMXK2V
MBMH$$<,2".-!T50, ?E7-B*EERHTA'J24445QF@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!)!_KE_'^57:I0?ZY?Q_E5VLY;EQV"BBBI
M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KW7\'XU6JS=?
MP?C5:M([&;W"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!;M?]6?K4U0VO^K/UJ:LGN:+8****0PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** +]M_J%_'^=2U%;?ZA?Q_G4M9/<U6P4444AA1110
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M^%>EOIO@R*1Y5?[8YN  ,;00!@_]\UP4=KKOQ4\0P7=Q;_9=.B&!($RJ+GD
MX^9LU[A;P16MO'!#&D<2#:J(N !["JG[L>7J,DHHHK$04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS]\'O^2L:!_UUD_]%O7L/Q7^$LWB;5+[Q0FL);I;V6XVYMRQ/EJ3][<.OTH
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MAL=<8!XXR>* /,/"7_(YZ%_V$+?_ -&+7UGXI^*/AOP=JXTS67NXKAHEF39
M75D)(!!'N"/PKY,\)?\ (YZ%_P!A"W_]&+7T+^T)X5;5/"EOKUM&6N-+?$N/
M^>#\$X[X;:?8%C0!Z9X;\2:;XLT2+5M*E:2UD9E!==K J<$$5:U74[71=)N]
M3O9/+M;6)II6[[5&>/4^@[FOGW]G'Q(MMK&I>'9Y0JWB"XME8@9D3AP.Y)7!
MQZ(:[+]H3Q =,\#0Z3&Y6;5)PK =XH\,W_CWEC\30!O:%\8?"?B/6[72--EO
M)+RY8K&IMF X!))/8  G\*N?"X-%X%@M9<"YM;R\AG4$G$@N9,YSWYS^->2_
MLY>&!<:IJ/B:<'9:K]EM\KP9& +G/J%P,?[=>L7UCJ'A/Q!>:_I-E-J&FZ@0
M^I6,'S31R*N!-$I/S9  9!R< C/2@#YKLKKQ#9ZQXUET)$>(P7":AN16Q;M+
MAB ?K^6:]O\ V?-.LK7X?R7MK>-//=W+?:8R ! Z\!/^^<-GT8<"M'P\/A58
MS:AJ&F7NF6UQ?1.EZEU?,KE6.75XY7^7GKP,=*JZ/!HVGI=:5\+K!RUX=ESJ
MGG2RV-MC@L&=R)) #PJ=<C) % &_X!S+>>+KM6)@FUV81\Y!V1QH2,'^\I'_
M  &NSK,\/:':>&] L]'LMY@MDVAG.6=B268GU9B2?<UIT %%%% !1110 5\/
M5]PU\/5Z& ^U\OU.;$= HHHKT3E"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "IK6UGOKJ*UM8GFGE8*D:#)8U#7LOPC\("" >)+V,&64$68.<HO*L
MQ'OT'MGUJ*DU"-QI79V_@WPQ#X5T"*R7#7#_ +RXD ^\Y_H.@_\ KUT%%%>:
MVV[LW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"2
M#_7+^/\ *KM4H/\ 7+^/\JNUG+<N.P4445)04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% %>Z_@_&JU6;K^#\:K5I'8S>X44450@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** +=K_JS]:FJ&U_U9^M35D]S
M1;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?MO\
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M,G-6**+L"*:Y@MT9YIDC55+$LV, =Z^>?B+XJ7Q-K_\ HLKM86X*0AE !/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0>A!KB/C#=6EM\+-;^V-'B6)8HE?!W2%AMP#U((S[8)[5\_^'_BYXU\#VO\
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M]Q;7/PU\.26A0QC3XHSLQC>JA7Z=]P;/O70WMS;V=C<75Y(D=K#$TDSO]U4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4459T^QGU/4;>QM4WSW$@C0>Y..?:@#HO 7A!_%FM[)@ZZ?;_/<2+QGT4'U/
M\@:^D$18T5$4*BC"J!@ >E8_A;P];^&-!@TZ #> 'G<?\M)"!N;]./8"MFO.
MJU.>7D;Q5D%%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"2#_7+^/\JNU2@_UR_C_*KM9RW+CL%%%%24%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO9]7:,AEA=!%"3_M*"2W/.,X[$&O7E4*H50 H& !T% "T444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !676I675P(F%%%%60%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V3_ %;_ $-4*OR?
MZM_H:H5<2)!1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 20?ZY?Q_E5VJ4'^N7\?Y5=K.6Y<=@HHHJ2@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** *]U_!^-5JLW7\'XU6K2.QF]PHHHJA!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 6[7_ %9^M35#:_ZL_6IJ
MR>YHM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH OV
MW^H7\?YU+45M_J%_'^=2UD]S5;!1112&%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5EUJ5EU<")A1115D!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 -D_P!6_P!#5"K\G^K?Z&J%7$B0
M44459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $D'^N7\?
MY5=JE!_KE_'^57:SEN7'8****DH**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"O=?P?C5:K-U_!^-5JTCL9O<****H04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% %NU_P!6?K4U0VO^K/UJ:LGN:+8****0
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +]M_J%_'^=2U%
M;?ZA?Q_G4M9/<U6P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %9=:E9=7 B844459 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% #9/\ 5O\ 0U0J_)_JW^AJA5Q(D%%%%62%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!)!_KE_'^57:I0?ZY?Q
M_E5VLY;EQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH KW7\'XU6JS=?P?C5:M([&;W"BBBJ$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!;M?\ 5GZU-4-K_JS]:FK)[FBV"BBBD,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"_;?ZA?Q_G4M16W^H7\?YU+6
M3W-5L%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]
MO04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%5_
M/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15
M?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L4
M57\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +
M%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@
M"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@
MH L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>W
MH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'G
MMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1
MY[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O0
M4>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;
MT%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?S
MV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457
M\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%
M5_/;T%'GMZ"@"Q15?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q
M15?SV]!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV]!1Y[>@H
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M L457\]O04>>WH* +%%5_/;T%% $5%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6?6A6?5P(F%%%%60%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 U_]6WT-4ZN/_JV^AJG5Q(D%%%%62%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!)#_K5JU56'_6K5JLY;EQV"BBBI*"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @N/X?QJ"I[C^'\
M:@K2.QF]PHHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 6;?_5GZU+45O_JS]:EK)[FBV"BBBD,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"Y!_J5J2HX/]2M25D]S5;!1112&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5GUH5GU<")A1115D!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -?_5M]#5.KC_ZM
MOH:IU<2)!1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 20_ZU:M55A_UJU:K.6Y<=@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** (+C^'\:@J>X_A_&H*TCL9O<****H04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %FW_U9^M2U%;_ZL_6I:R>YHM@HHHI#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH N0?ZE:DJ.#_4K
M4E9/<U6P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %9]:%9]7 B844459 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% #7_U;?0U3JX_^K;Z&J=7$B044459(4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $D/^M6K558?]:M6JSEN7'8****DH**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""X_A_&H*GN/X?QJ
M"M([&;W"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M9M_]6?K4M16_^K/UJ6LGN:+8****0PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** +D'^I6I*C@_U*U)63W-5L%%%%(84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?6A6?5P(F%%%%60%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_]6WT-4ZN/_JV^
MAJG5Q(D%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M)#_K5JU56'_6K5JLY;EQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH @N/X?QJ"I[C^'\:@K2.QF]PHHHJA!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 6;?_5GZU+45O_JS]:EK)[FBV"BBBD,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"Y!_J5J2HX/]2M2
M5D]S5;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45Y5\?KNYLO EC):W$L#G4XU+1.5)'E2\9'T% 'JM%?'G@OQ]JOAGQ39ZC/?
M75S:AO+N89)6</$W#<$]1U'N!7U[:W4%]9P7=M*LMO/&LD4B]&5AD$?4&@":
MBJ]_?6^F:?<7UW(([>WC:61SV51DU\?^*_'>K^)/$M[JB7MU:PROB&".5E$<
M8X48!QG'4]SF@#[(HKS+X$W-Q=_#Z26YGDFD-](-\CECC:G<UZ;0 4444 %%
M%9^MZS9^'M&N=5U!V6UME#2%%W'!(' ^I% &A17GOA+XM:9XT\4G1M+T^Z2-
M;=YC<7!53\I48"C/7=U)'3IZ>A4 %%%% #)98X8VDED6.-1EF<X ^IHAFBN(
MEE@E26-NCHP8'\17CO[0T6KR>'M+-F)FTQ9I#>B,9&["^66QV'S^V2.^*H?L
M[1:PL.K22>:NC,%$6]?E:7)R4/L.N/44 >Z4444 %%%% !14-Y=16-E/>3DK
M#!&TLA SA5&3Q]!7G6C_ !IT7Q#XLL-"TFPO)/M4C(;B;;&J@*S9 Y)Z8YQU
MH ]+HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1F"J68@*!DD]J %J
M/SXO-\KS4\S^YN&?7I7S5\2/C#JNLZG<Z;X?O)++287*">W?;)<$$@MN'(4]
M@.HZ]<#S=-(UF^M9-233K^XMRQ+W0@=T)R<Y?&,YSWH ^X:*^5OAW\6M5\*W
M\%GJ=S+>:(QVO'(=S0 G[R'KQ_=Z'GH>:^IT=)(UDC971@"K*<@@]P: '444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6?6A6?5P(F%%%%60%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 U_P#5M]#5.KC_ .K;Z&J=7$B044459(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH N0?ZE:DJ.#_ %*U)63W-5L%%%%(84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%>8_&?QW=>$="M['2Y1%J.HEE$H^]#&H&YAZ,20 ?KCD4 =UJ7B70M'8IJ6L
M6%HXQE)[A4;GIP3FC2_$FAZVQ72]7L;UU&62"X5V7Z@'(Z&OC_1O#/B3QG=S
MR:997.HS!@9IF<<$]-SL0,G!ZFFZQX8\1^$;F"74].N]/DW!H9NVX<C:Z\;A
MC/!R* /M:BO(_@S\2KGQ-#)H.LR/-J=M'YD5PP_UT0(&&P/O#(Y/7/KG/KE
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5Y)^T/_P B!8?]A2/_ -%2UZW7DG[0_P#R(%A_
MV%(__14M 'S6D,KQR2)&[)& 78*2%!.!D]N:]Y^ GCDR(_A&_F!*AI=/+=2.
M2\?X<L/^!>@KF/@=I-IKNJ^(-*OD+VUUIACD Z@%UY'H0>1[BN)U;3=3\!>,
MWM6DV7VG7"R12J,!L896'L1@X_"@#UGX^>-PQC\(V$V1\LU^5((SG*1GWX#'
M_@/O7ADEM/%!#-)$Z13 F)F& X!P2/49R,^H/I6WHFE:IX]\91VOFO+>W\YD
MGN&7.P$Y=R!C@<\<=A7;?'/2K/0]7T#2["+R[6VTT1QKG)P)&Y)[D]2?4T >
ME? '_DG#_P#7_+_Z"E=9XT\=:/X&TU;K4G>2:4D06L6#)*>YY/"CN3^IP#R?
MP!_Y)P__ %_R_P#H*5X;\1M>NO%7Q U&<[Y%CF-I:Q@9(C5B%  '<Y./5J .
MON_VAO$\ET7M-.TN" '*QNCR-CT+;AG\ *Z30_V@5NM+O5U:P@M]3B@>6V:,
ML(9V49"'))4GG')'X]>D\)_!3PSHVEQ_VO9KJ>HNF9I)B=B$XRJ*#C QU.3U
MY .*Y+XL?"/2=+\/RZ_X=@:U^RX-S:ABRLA(&Y<G(([CN/IR ;/@'XRZAXQ\
M76VBSZ3;6T<J2,9$D9B-JD]_I7-_%;XIWLDVO>#?[-MQ '$/VC>V[ *MG'3M
MBN7^!_\ R5+3_P#KC-_Z+->H_%CX?>&T\-:]XG6R<:KM63S?/?&XLJYVYQTH
M \-\#^,;CP/KYU:VM8KEVA:$QR,0,$@YR/I7TG\,?'MSX]TR^N[FQBM#;3+&
M%C<MNR,YYKP7X1>&=*\5^,9-.UBW:>V%F\H59&0A@RX.5(]3^=?2_ACP?HW@
M^WN+?1;=X(IW#R*TK/E@,9Y)H \K\3?';4M!\3ZGI,>BVDR6=P\*R-*P+ '&
M2*L>,/CU'I-VVGZ!907L\:@2W4KGR@_=548+ 'ON'?KUKQ[XB_\ )1_$/_7_
M "_^A5Z5X%^!-MJVA6NJ^(KRYB-T@FBMK5E4A" 5+L0>2.PZ9'.<B@#O/&GQ
M%O?"G@C0]=2QM[F;4!&)(V9E52T>\D=3U%2_"WX@7/CRTU&2XL(+-;-HT186
M)SN#>OT%<K\>[./3OA]H-C"S-%;720H7.6(6)@,X[\5!^SA_R#?$'_7:'^3T
M :'C[XRZAX.\77.BP:3;7,<21L)'D92=R@]OK6=KG[00MM+LTTK3X9]2D@22
MX:0DPPLRY*#!!8C(!Y'^'"?'#_DJ6H?]<8?_ $6*[/X3_"/2=4\/Q:_XB@:Z
M^U9-M:EBJJ@)&YL'))[#L/KP 8EI^T-XGCN@]WIVESP$Y:-$>-L>@;<<?B#7
MM_@OQUH_CG36NM-=XYHB!/:RX$D1['@\J>Q'Z'('+^+O@IX:UC29CHUDFFZF
MB$P/$Q$;L,X5U.1@D]0,CCJ!@^$_#G7KKPK\0-.G&^-9)A:749&"8V8!@01V
M.#CU6@#U[XK?%.]\.:K?^&8=-MYHKBRV^>[L&7S%(Z#TKPKPOK\OA?Q)9:U!
M"D\EJQ81N2 V5*]OK7T]X_\ A]X;UNSU/7K^R>34(;%RD@G=1E$)7@'%?./P
M[T>QU_Q[I6EZC$9;2X=UD0.5SA&(Y!!Z@4 ?0'PP^)]YX^U&_MKG3H+1;6)9
M 8W+;LG'>NE\:>.M'\#::MUJ3O)-*2(+6+!DE/<\GA1W)_4X!/#'@'P]X/N9
M[C1;62"2= DFZ9GR <C[Q-?,/Q&UZZ\5?$#49SOD6.8VEK&!DB-6(4  =SDX
M]6H Z^[_ &AO$\ET7M-.TN" '*QNCR-CT+;AG\ *Z30_V@5NM+O5U:P@M]3B
M@>6V:,L(9V49"'))4GG')'X]>D\)_!3PSHVEQ_VO9KJ>HNF9I)B=B$XRJ*#C
M QU.3UY .*Y+XL?"/2=+\/RZ_P"'8&M?LN#<VH8LK(2!N7)R".X[CZ<@&SX!
M^,NH>,?%UMHL^DVUM'*DC&1)&8C:I/?Z5Z!XR\8:;X*T)]3U!BS$[((%/S3/
MCA1Z#U/8?@#\Y_ __DJ6G_\ 7&;_ -%FNP_:/M[LW.@7)5S9A)HPP'RK(2I(
M/H2 /KM/I0!D:A^T-XEGN2UAIVFVL'\*2*\K?BV0#^ %==X&^.\&LW\6F^);
M6"PFF;;'=PL1"2>@8,25^N2/I7!?"[7_ (?Z78W5KXNTN*6[DE+)=SVOGQB,
MA0$QR0V=QR%Z=^U>F>&/AA\.+[5KC6--N(=7@+[XK3SQ)%;G@X*CD_1\C!Y!
MZT >KUY!XS^.^FZ)>RZ?H5HNIW$9*O<-)MA5@>0,<O\ @0/0FN@^,/B&7PU\
M.KDV;&*>\=;*)TXV!@2V/3Y%8#T)!KY^^'&A^'=8U]W\4:I;6>F6R!VCEG$3
M7#$\(#D''!)(YZ#C.0 =1%^T+XL6Y#RV.D/%D;HUBD7CO@[S@_7/TKUGX??%
M;2O'+&S:$V&JHI8VSN&$@'4HW&<#DC (]P,UDW&G_!>XL3:-)X?2/& \=P$D
M'_ P=WZUX#J8C\)^-96T#5%NH[*<26EY$P.X<,,D<'K@_C]* /M.BN4U7Q9+
M!\,I/%=A%$93IZ7<<<P)4%E!PP![9QUKQ/\ X:'\6_\ 0.T3_OQ+_P#'* /I
M>BOFC_AH?Q;_ - [1/\ OQ+_ /'*]:^%/C?4O'6@WM]J<%I#+!=>2HMD95*[
M5/.YCSS0!-KGPH\*Z[KMMK$MB(;F*823+%@1W(!SB1.A^HP3WS7;*H50J@!0
M, #M2UX_\8/BD?#\<GAS19%.IS1_Z1< @_9U/\(_VR/7H"#U(P >'>.TL(_'
MFN)IFS[(+R38(QA1SR%]@<XQQCI7UOX/26+P1H$<X83+IUNL@;J&$:YS^-?,
M?PN\ 7'C3Q%%)/ PT6U<-=R] Q'(C'J3QGT!SZ9^M54*H50 H& !VH 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *^7/\ A:GC3_H,_P#DK#_\17U'7Q77?@HQES778YL0VK6.Q_X6
MIXT_Z#/_ )*P_P#Q%'_"U/&G_09_\E8?_B*XZBN_V4.R.?FEW.Q_X6IXT_Z#
M/_DK#_\ $4?\+4\:?]!G_P E8?\ XBN.HH]E#L@YI=SL?^%J>-/^@S_Y*P__
M !%'_"U/&G_09_\ )6'_ .(KCJ*/90[(.:7<['_A:GC3_H,_^2L/_P 11_PM
M3QI_T&?_ "5A_P#B*XZBCV4.R#FEW.Q_X6IXT_Z#/_DK#_\ $4?\+4\:?]!G
M_P E8?\ XBN.HH]E#L@YI=SL?^%J>-/^@S_Y*P__ !%'_"U/&G_09_\ )6'_
M .(KCJ*/90[(.:7<['_A:GC3_H,_^2L/_P 11_PM3QI_T&?_ "5A_P#B*XZB
MCV4.R#FEW.Q_X6IXT_Z#/_DK#_\ $4?\+4\:?]!G_P E8?\ XBN.HH]E#L@Y
MI=SL?^%J>-/^@S_Y*P__ !%'_"U/&G_09_\ )6'_ .(KCJ*/90[(.:7<['_A
M:GC3_H,_^2L/_P 11_PM3QI_T&?_ "5A_P#B*XZBCV4.R#FEW.Q_X6IXT_Z#
M/_DK#_\ $4?\+4\:?]!G_P E8?\ XBN.HH]E#L@YI=SL?^%J>-/^@S_Y*P__
M !%'_"U/&G_09_\ )6'_ .(KCJ*/90[(.:7<['_A:GC3_H,_^2L/_P 11_PM
M3QI_T&?_ "5A_P#B*XZBCV4.R#FEW.Q_X6IXT_Z#/_DK#_\ $4?\+4\:?]!G
M_P E8?\ XBN.HH]E#L@YI=SL?^%J>-/^@S_Y*P__ !%'_"U/&G_09_\ )6'_
M .(KCJ*/90[(.:7<['_A:GC3_H,_^2L/_P 11_PM3QI_T&?_ "5A_P#B*XZB
MCV4.R#FEW.Q_X6IXT_Z#/_DK#_\ $4?\+4\:?]!G_P E8?\ XBN.HH]E#L@Y
MI=SL?^%J>-/^@S_Y*P__ !%'_"U/&G_09_\ )6'_ .(KCJ*/90[(.:7<['_A
M:GC3_H,_^2L/_P 11_PM3QI_T&?_ "5A_P#B*XZBCV4.R#FEW.Q_X6IXT_Z#
M/_DK#_\ $4?\+4\:?]!G_P E8?\ XBN.HH]E#L@YI=SL?^%J>-/^@S_Y*P__
M !%'_"U/&G_09_\ )6'_ .(KCJ*/90[(.:7<[$_%/QF00=9X/_3K#_\ $5'_
M ,+.\8?]!?\ \EH?_B*Y*BCV<.R#F?<ZW_A9WC#_ *"__DM#_P#$4?\ "SO&
M'_07_P#):'_XBN2HH]G#L*[.M_X6=XP_Z"__ )+0_P#Q%'_"SO&'_07_ /):
M'_XBN2HH]G#L%V=;_P +.\8?]!?_ ,EH?_B*/^%G>,/^@O\ ^2T/_P 17)44
M>SAV"[.M_P"%G>,/^@O_ .2T/_Q%'_"SO&'_ $%__):'_P"(KDJ*/9P[!=G6
M_P#"SO&'_07_ /):'_XBC_A9WC#_ *"__DM#_P#$5R5%'LX=@NSK?^%G>,/^
M@O\ ^2T/_P 11_PL[QA_T%__ "6A_P#B*Y*BCV<.P79UO_"SO&'_ $%__):'
M_P"(H_X6=XP_Z"__ )+0_P#Q%<E11[.'8+LZW_A9WC#_ *"__DM#_P#$4?\
M"SO&'_07_P#):'_XBN2HH]G#L%V>I^"/B;J4^NI9>(+M9[>YPD<IC1/*?MG:
M!P>G/M[U['7R37OOPT\7?\)!HWV&[DSJ-FH#$_\ +2/H&^O8_AZUS5Z27O1-
M(2Z,[FBBBN8L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"2'_6K5JJL/^M6K59RW+CL%%%%24%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!!<?P_C4%3W'\/XU!6D=C-[A1115""BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH LV_^K/UJ6HK?_5GZU+63
MW-%L%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %R#_
M %*U)4<'^I6I*R>YJM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>P.=+X,\8SS/--X:UV261BSN]C,69CR225Y-,_X0?Q;_ -"MK?\ X+Y?_B:
M/K_1[31=!TJ#3-,-M;VD"[417'XDG/)/4D]:U%8,H92"I&01WKXL_P"$'\6_
M]"MK?_@OE_\ B:^IOAA9W6G_  WT6UO;::VN(XF#Q3(4=3O8\@\B@#KJ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KXKK[4KXKKT,!]KY?J<V(Z!1117HG*%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5H:+K%WH.K6^HV3[986S@]'7NI]B*SZ*35]!GU-H>LVNO
MZ1!J5FQ,4H^Z<;D/=3[BM"O OAIXN_X1_6?L5W)C3KQ@&)_Y9R= WT['_P"M
M7OM>?5I\DK&T7=!11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH DA_P!:M6JJP_ZU:M5G+<N.P4445)04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% $%Q_#^-05/<?P_C4%:1V,WN%%%%4(**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S;_ .K/UJ6HK?\
MU9^M2UD]S1;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!<@_U*U)4<'^I6I*R>YJM@HHHI#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BO'?V@[VZLO#^CM:7,T#-=."8I"I(V>U9/[/-_>7U_KWVN[GN
M-D4.WS9"^W)?.,].@H ]XHHKYE^.&J:A:?$:2*VO[J&/[+$=D<S*,X/8&@#Z
M:HKA_@_<377PLT::XEDEE;S]SR,68_OY!R37<4 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /E+XX?\E2U#_KC#_Z+%?1'P\_Y)UX=
M_P"O"'_T$5#KGPU\(^)-5DU/5M)^T7D@56D^TRID 8'"L!T'I71:=I]KI.G6
M^GV47E6MM&(HH]Q;:H& ,DDG\: +-%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\5U]J5\5UZ&
M^U\OU.;$= HHHKT3E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *U:M5G+<N.P4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $%Q_#^-05/<?P_C4%:1V,WN%%%%4(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"S;_ZL_6I:BM_]6?K4M9/<T6P4444AA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 7(/]2M25'!_J5J2LGN:K8***
M*0PHHHH **** "BBB@ HHHH **SE\0:,SA%U:Q+$[0!<+DGTZUHT6 **** "
MBBB@ HHHH **J7>IV%@ZI>7MO;LPRHEE"DCVR:DM;VUOHC):7,-Q&#M+1.&
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MT^&OPNOSHT30Q6$+"U5F+[))'PI.[.?G?/- &3X^^,6E>#KAM-M(/[2U5?\
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M9IWY/_\ %5ZKX5U.3Q)X$L;US^_N+8QNS=W7*,?Q()KRK_A1NN?]!/3OS?\
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M/3OS?_XFN&\2Z"?#6KOIDE];W<\8!E,&=J$_PDD#GU^OKG'3&&'F[10'<_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*^*Z^U*^*Z]# ?:^7ZG-B.@4445Z)RA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ,^#6I6>IW.L>&K5[VQG<R26D0S+ Q/(51RRY/&.1Z8&: /HM'22-9(V5T8
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MS?!+Q)XAD\?0Z<+NXNK&YBD-TD\C.$55)#C/0[MH]]V/<?3- !1110 4444
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MA_*L;XT?\CV/^O./^;5[-X/\+6WA'0DT^!_-D9O,GF(QO<CG\., 5XS\:/\
MD>Q_UYQ_S:LJ4U/$.2 L? __ )'2\_[!S_\ HR.O?:\"^!__ ".EY_V#G_\
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MB:)_UYQ_RKH:X)_$Q!1114@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M=)AU?7-2>Q2Y7S(H(X]\C*>0S$G SUQ@GGG'2LOXA?!R^\&V#:M8WG]H::I
ME)CVR0Y. 2!D%>G/')Z=Z /J&*6.>%)H9%DBD4,CH<JP/(((ZBO+?B5J/PU7
M78K7Q?82RZ@D*NDD2."8R3@%D(R,@\'I7,? 'QG<-=3^$[V5GA\LSV19L["/
MOQCV(.X>F&]:YW]H#_DHL7_7A%_Z$] 'O&F>(?#]CX BUS3X3;:%! 7C2.+:
M50,0<+]<FOG?XO\ C'2?&?B&QN]'>9X8+7RG,D>SYM['I]"*]C\&Z*?$?P%L
MM'6<0-=V<D8E*[MO[QN<9&:\'^(/@23P#JMK8R:@MZUQ!YV]8MFWYB,=3Z4
M>D_#+XK>&/"_@:TTG4YKE+J&20L$@+##.2.1[&O=K>=+JVBN(\^7*@=<C'!&
M17S)X,^"\_C'PO;:W'KD=JLS.OE-;%MNUBO7<,],]*]F\?\ BB3X?_#U)H&1
M[\JEG;$C(\S;]['L%)YXZ#O0!=\5_$CPSX.D,&IWQ:\V[A:6Z^9)TR,CHN<C
M&XC-<C;_ +0OA26?9+8ZM"A.!(T2, /4@/G\LUXAX0\(:S\0_$,EM;S$D#S;
MN\N"S!%SC)/5F/8=\'H 2/3=0_9RDCTYVT_Q")KU0"J3VWEHY[C(8E?R/]:
M/:-"\1:/XFL/MNC:A#>09P2APR'T93@J?8@4_7=:L_#NBW.K7Y<6ML TA1=Q
M ) Z?C7R)X<U[5_AWXQ\\(\,]K*8;RU8\2*#AD..#['UP:^D/B;>0:C\'=5O
MK9]]O<VD4T3?WE9T(/Y&@"QX=^*?A?Q/J$EEI]S,)(H6GD:>+RT1%QDECP.M
M)HWQ4\,^(?%$6@Z3+<W4\BNPG6';$-HR>6(;MV%?)NGK?37/V+3Q,\UX!!Y4
M.2TH+ [<#KR!^5>[_#'X1^(O"WBJSUW5)K%(XTD5K>.5FD&Y2/[NWKCH30!V
MOC+XL^'_  5JL>F7D=W=794/(EJBGRE/3)9AR>H'YXXSTOAOQ)IOBO18M5TJ
M5I+9R5(9=K(PZJP[&O&OBK\)/$&L^+IM;T"!;V.]"F6'S4C:%E4+U=@"#C/'
M?/'2O1_A?X,G\$>$A87DRR7D\S7$X0Y1&(5=H]<!1D^N>V* .THHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXKK[4KXKKT,!]KY?J
M<V(Z!1117HG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVW/IV_.O5/$/@OP[XJ3&LZ5!<N!A9L%)%'LZX/X9Q7'_ /"A?!7G;]FH;?\
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M,F8#GD@A5!([$GGIUKO?$7[/^AW&FR-H%Q<VE^BYC6>3?$Y]&XR,],@\>AH
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ML[HHB026'9F(''4 =LD5P'[0'_)18O\ KPB_]">@#VKX2_\ )+=!_P"N+_\
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M';"[O^!'Z4 =K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7Q77VI7Q77H8#[7R_4YL1T"BBBO1.4**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_17D6D_%"^T6Q2QUS3;B:YC^[(Q*,5[9R.3UYJU/\9(GMY%MM(E6<J1&7D!
M;MD <BI]C/L%C8^*.OIIOAUM.0QM<7OR%&SD1\Y8?B /QJ[\-]*73/!]NX=R
MUT?/8,,;20!@?E7%:5X;U_QUK,6JZ^9(;%>0#\IQG[J*>1GKFO8E 50!T Q1
M.T8\J 6BBBLA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B?[1&O>1I&F:!$XWW,
MIN9@.H1.%'T))/\ P"O;*^//B;XD;Q1X\U&\#AK>!S:VQ&<>6A(!&?4Y;\:
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MLGN:+8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LZ3P_HLTP
MFETBP>4'(=K9"WKUQ6C10 U$2.-8XU5$4 *JC  '8"G444 %%%% !1110 44
M44 %%%% $%U96E]'Y=W:PW"<_++&''Y&FV>G66GH4LK.WME/588E0'\A[G\Z
MLT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !117,>.O&MMX$T2'5+JTEND
MEN5MPD3 $$JS9Y_W#^= '3T5YCX3^->B^*?$,&C_ &&XL9;@$123.I5G'(7C
MH3SCWP.]>G4 %%%>7>)_CAHOAOQ#=:0+"XO7M6V22PR+M#_Q+SW!X/N#0!ZC
M17-^"/&%OXWT%M6MK62VC$[0[)&!.0 <\?6NDH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BH[B0PVTLB@%D0L,^PKY_\ "/QL\4ZWXOTG2[N'3?L]
MW<I#)LA8-ACC@[NM 'T)1110 4444 %%%% !1110 4444 %%%% !14=Q(8;:
M610"R(6&?85\_P#A'XV>*=;\7Z3I=W#IOV>[N4ADV0L&PQQP=W6@#Z$HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1171>"O#,GBGQ!%:=+6+$MRV<?N
MP1D ^IZ#\^U)M)78SM_A/X/+./$=_&0%RMI&Z]?63Z=A^)]*]=J.W@BM;:*W
M@01PQ($C0=%4# 'Y5)7FSFYRNS9*R"BBBI&%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $D/^M6K558?]:M6JSEN7'8****DH****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""X_A_&H*GN/X?QJ"M
M([&;W"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!9M
M_P#5GZU+45O_ *L_6I:R>YHM@HHHI#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH N0?ZE:DJ.#_ %*U)63W-5L%%%%(84444 %%%% !1110
M 56NM/M;S!N(5<@8!/:K-% I14E9HP#X1T\_QS?FO^%:5GI-E8[&@@4.J[=_
M<U=HI61E##TH.\8H****9L%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5Y)^T/_ ,B!8?\ 84C_ /14
MM>MUY)^T/_R(%A_V%(__ $5+0!\V03RVMQ%<02-'-$X='4X*L#D$?C7V!\.?
M&D/C;PK!>ED%_"!%>Q#^&0#[P']UNH_$=C7S%X0\(3>+H=9CM#(;VRLS<P1(
M,^:0P!3'J03CWQ5[X8>-'\%^+89Y6/\ 9UT1#>+_ +)/#_52<_3([T ?17Q.
M\:)X+\)37$;#^T;D&&S3_;/5_HHY^N!WKY"DD>61I)'9W<EF9CDL3U)-=A\2
M_&C^-?%DUW&[?V=;YALTY V _?P>A8\^N,#M5?QEX0E\'P:+!=AEO[RS^TW"
M,?\ 5L7("?@ ,^Y/M0![M\ ?^2</_P!?\O\ Z"E>I5Y;\ ?^2</_ -?\O_H*
M5S/QE^*-[::A)X8T&Y>W,0Q?7,>5?<<$(AZC ZD=<X['(![!J7BSP[H\_D:C
MKFG6LPZQ2W**X_X#G/8U<T_5M-U>)I=-U"TO8U.&>VF60 ^Y4FOD;P]\-/%O
MBBQ%]INE,;0DA9II%B5_]W<06'N..#S574-)\4?#S78FN([K2[Y<M#/$_#CO
MM=3AAR,CWP1VH ^SZJS:GI]O*T4]];12+U1YE4C\":XSX5^/_P#A./#[_:]J
MZK9$)<A1@.#]UP.V<'(]0>V*\/\ CA_R5+4/^N,/_HL4 ?4-UJVFV5FMY=ZA
M:06K'"SRS*J'@GAB<= ?RJGIOBSP[K$_D:=KFG74QZ117*,Y_P" YSW%?+NA
M^#_&/Q(BBFMD\RSL8DM(IKB39$BJ  B^I[G [\\D9Q_$OA+7?!&IPPZI";>5
MOWD$T3Y5L8Y5AW!(H ^TJ*\[^#?C&Z\6^$'749#+?V$OD22DY:52,JQ]^H]]
MN>]<7\9?BC>VFH2>&-!N7MS$,7US'E7W'!"(>HP.I'7..QR >P:EXL\.Z//Y
M&HZYIUK,.L4MRBN/^ YSV-7-/U;3=7B:73=0M+V-3AGMIED /N5)KY&\/?#3
MQ;XHL1?:;I3&T)(6::18E?\ W=Q!8>XXX/-5=0TGQ1\/-=B:XCNM+OERT,\3
M\..^UU.&'(R/?!':@#[/HK@OA7X__P"$X\/O]KVKJMD0ER%& X/W7 [9P<CU
M![8KC_C3\3;S1[L>&=!NGM[H('O;B/Y7C##*HK=0<'<2/5<'K0!ZQJ7B?0=&
ME,6IZUI]G+C/ESW*(^/]TG/>I=+UW2=;B:72M2M+U%.&-O,K[3[X/%?(OA[X
M?>*O%L1N]+TN6:W).;F5UC1CWPS$;N>.,U#JGA_Q3X!U.VGOK6ZTNZ^_!<1R
M C/0[70D9QU&<X//6@#[)O?^/"X_ZY-_(U\=_#K_ )*/X>_Z_P"+_P!"KZ5\
M!:[K?B#X??;/$%C+;WHC=?,DC$?VA=N5D"]L@^F#C(X.!\U?#K_DH_A[_K_B
M_P#0J /LNJ][?V>FVQN;^[@M8!P99Y BC\2<5A^.?%UMX)\+SZO.GF29$5O#
M_P ]92#@9[# )/L#WP*^5;BY\4?$GQ-DBXU/49?N1I]V),] /NH@SUX'.2<G
M- 'UE:>,_#%_="VM/$.ES3DX6-+M"S'V&>>G:MROD+6/A-XTT33Y+ZZT@O;Q
M#=(UO*DI0>I53G'N!QC)Q70_"CXI7^@ZO::+J]T\^C3E84,K9-J>BE2?X,X!
M'8<CI@@'TQ/<06L?F7$T<4><;I&"C\S45OJ%E=R&.VO+>9P,E8Y58@>N :X3
MXW_\DLU'_KK#_P"C%KYGT&769IY='T03-/JBBW>.'[TJYR5SV7C)]ASQF@#Z
M_N/&OA:TNVM+CQ'I44ZG#(]V@*GT//!]C6S;W$%W D]M-'-"XRLD;!E8>Q'!
MKY0U;X->,M'TB74I[."2*&/S)4AF#NBCKQWP.>,U/\(/&M[X<\76>FO.[:7J
M$JP20LWRH['"N/0@GGU'7H, 'U95/4-6TW2(EEU+4+2RC8X5[F98P3[%B*QO
M'GBZ'P5X4N-6D19)\B*VB;.))6S@'V !8^RGO7RFS^)OB'XCQ_I6J:E,20@.
M0BD]L_*B#(] * /KG3?%GAW6)_(T[7-.NICTBBN49S_P'.>XJ]-J>GV\K13W
MUM%(O5'F52/P)KY7O_@[XYT:T_M :>)?)'F$6DX:2/'.0 <DC_9R:Y#6M;O_
M !!?B^U.8SW7E)$TI'S.%&T$^IP!SWH ^U[F6.;3)Y(I%DC:)BK(<@\'H:^/
MOAU_R4?P]_U_Q?\ H5?3_@G_ ))7HW_8+3_T"OF#X=?\E'\/?]?\7_H5 'V7
M1110 5\U_M!:]]N\76FBQN3%IT&YQ_TUDPQ_\="?F:^C+^]ATW3KJ_N25@MH
M7FD([*H)/Z"OBJ\NK_Q7XGDG<&6_U*Z "@=7=L #'U H I7-E<VD5K)<0M&E
MU%YT)/\ &FYDW?\ ?2,/PKZV^%&O_P#"0_#K3)W??<6R?9)\MN.Z/@$GU*[6
M_&O/_C;X-AT_P)H%S9)E-'"V;D #,;* &(]=RC\7/6L[]G?7C#JNJ:!*QV7$
M8NH1V#+\K?B05_[Y_, ^A:I+K&ELP5=2LR2< "=>?UJ[7PX]W+8>(&O+<@36
M]UYL9(R ROD<?44 ?:&J>(M%T0@:IJUE9,0"%N)U1B#D @$Y/0_D:DTS6]*U
MJ,R:7J=G>HOWC;SK)M^N#QU%?,&G_";QSXJM3KDD* W9,P>\GVR39_BQR><Y
MYQ_+/*P7&N^!O$Q:-IM/U6S?#KGIT.UNS*1CCD$4 ?:D]Q!:Q^9<31Q1YQND
M8*/S-?-/QB\9ZR/&]YIVG:]<+IJ1Q8BM;C:F2@)R5//)[UZ7XV6_^(OP<M+G
M1;(S75YY$YMTD'RD'YP"2,X.1^%?->LZ)J/A_4GT[5;9K:[0!FB9@2 1D="1
MTH ^LOA[JNG+\/\ P]$U_:B06,2E#,N0=H&,9ZU#\2O!.D^--+M8M0U)=-N+
M=V-O<-M(&X#<I4D9!P#P1T%?/WAOX;^+KB[TG58=%E>Q>2*X6998\&/(;.-V
M>G;K7JW[17_(GZ7_ -?X_P#1;T =%\,? 6D^"[>\:TU:/5+ZXVB>:/:%11G"
MA03COR3SCM7B7QP_Y*EJ'_7&'_T6*[S]G#_D&^(/^NT/\GK@_CA_R5+4/^N,
M/_HL4 >_^";^STWX8^'[F_NX+6 6$(,L\@11\OJ3BM*T\9^&+^Z%M:>(=+FG
M)PL:7:%F/L,\].U?+&F:5XP^(Q@L[&*:[M].@2%%+A(8%"X'4XW'!]S]*7Q-
M\,/%?A2S^VZAIV^S&-\]NXD5"?[V.5^I&.0,YH ^PJ*\!^"OQ,OI=3C\+:W=
M/<1S _8IY6+.KCGRR>ZD9QGIC'0C'J'Q%\:Q>!_"\E]M$E[,3#9QD<&0CJW^
MR.I]>G>@#I+_ %.PTJW^T:C?6UG#G'F7$JQK^;$"L^P\7^&M4G6"QU_3;B=C
MA8H[I"['V7.37R4L7BGXC^))'CCN=5U*0%FY^6-<DXR<*B@GCH.<=ZOZ[\+/
M&'AW3FU"^THFU3_6202++Y8ZY8*20/?H.] 'V!17SE\'_BE?6>KVWAS6[I[B
MPN2(;669LM _15W'^ ],=N,8&:]O\9>)X/"'A:\UF:/S3" (XLX\QR<*,]N>
MOMF@#4O]3L-*M_M&HWUM9PYQYEQ*L:_FQ K/L/%_AK5)U@L=?TVXG8X6*.Z0
MNQ]ESDU\E7VH>)OB-XE'F&XU"_G8^3;H3MC'4A 3A5 ']2>];]S\%_'5C9B\
M&FI(RJ',<%PK2*>., \GZ9Z4 6_CQ_R4N7_KTB_D:]K^%MW;6GPKT!KFXBA#
M1. 9'"Y_>-ZU\KZOJ^HZS=1RZI.\]S#$L&^3[Y5> &/<CID\^M?0>F>&CXJ_
M9SL].C7-R+=I[;C)\Q)&( ^HRO\ P*@#U>WO[.[9EMKN"9E&2(Y V/RJQ7R+
M\)/$C^'/B%I[M(%M;UOL=P"0!M<C:<GIAMISZ ^M?6EY=PV%E<7ERX2"WC:6
M1R>%51DG\A0!%+JNG0R-'+?VL<BG#*\R@CZC-64=)(UDC971@"K*<@@]P:^+
MXHK_ ,>^.BJ _:]6O&;D[O+#$D]<<*N?3@5]F6=I#865O9VR!(+>-8HT X55
M& /R% $U%%% !7Q77VI7AO\ PHG_ *F3_P D?_ME=N#J1AS<S['/7BW:QX[1
M7L7_  HG_J9/_)'_ .V4?\*)_P"ID_\ )'_[97;]9I=SG]G+L>.T5[%_PHG_
M *F3_P D?_ME'_"B?^ID_P#)'_[91]9I=P]G+L>.T5[%_P *)_ZF3_R1_P#M
ME'_"B?\ J9/_ "1_^V4?6:7</9R['CM%>Q?\*)_ZF3_R1_\ ME'_  HG_J9/
M_)'_ .V4?6:7</9R['CM%>Q?\*)_ZF3_ ,D?_ME'_"B?^ID_\D?_ +91]9I=
MP]G+L>.T5[%_PHG_ *F3_P D?_ME'_"B?^ID_P#)'_[91]9I=P]G+L>.T5[%
M_P *)_ZF3_R1_P#ME'_"B?\ J9/_ "1_^V4?6:7</9R['CM%>Q?\*)_ZF3_R
M1_\ ME'_  HG_J9/_)'_ .V4?6:7</9R['CM%>Q?\*)_ZF3_ ,D?_ME'_"B?
M^ID_\D?_ +91]9I=P]G+L>.T5[%_PHG_ *F3_P D?_ME'_"B?^ID_P#)'_[9
M1]9I=P]G+L>.T5[%_P *)_ZF3_R1_P#ME'_"B?\ J9/_ "1_^V4?6:7</9R[
M'CM%>Q?\*)_ZF3_R1_\ ME'_  HG_J9/_)'_ .V4?6:7</9R['CM%>Q?\*)_
MZF3_ ,D?_ME'_"B?^ID_\D?_ +91]9I=P]G+L>.T5[%_PHG_ *F3_P D?_ME
M'_"B?^ID_P#)'_[91]9I=P]G+L>.T5[%_P *)_ZF3_R1_P#ME'_"B?\ J9/_
M "1_^V4?6:7</9R['CM%>Q?\*)_ZF3_R1_\ ME'_  HG_J9/_)'_ .V4?6:7
M</9R['CM%>Q?\*)_ZF3_ ,D?_ME'_"B?^ID_\D?_ +91]9I=P]G+L>.T5[%_
MPHG_ *F3_P D?_ME'_"B?^ID_P#)'_[91]9I=P]G+L>.T5[%_P *)_ZF3_R1
M_P#ME'_"B?\ J9/_ "1_^V4?6:7</9R['CM%>Q?\*)_ZF3_R1_\ ME'_  HG
M_J9/_)'_ .V4?6:7</9R['CM%>Q?\*)_ZF3_ ,D?_ME'_"B?^ID_\D?_ +91
M]9I=P]G+L>.T5["WP*PI/_"1]!_SX_\ VRH?^%(_]3#_ .27_P!LIK$4WU#D
MDCR2BO6_^%(_]3#_ .27_P!LH_X4C_U,/_DE_P#;*?MZ?<7(SR2BO6_^%(_]
M3#_Y)?\ VRC_ (4C_P!3#_Y)?_;*/;T^X<C/)**];_X4C_U,/_DE_P#;*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?CO9SVWQ*FGD3$=U;121-Z@#8?U4_I0!] _#S_DG7AW_ *\(?_017!?M%?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** (+C^'\:@J>X_A_&H*TCL9O<****H04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% %FW_ -6?K4M16_\ JS]:EK)[FBV"BBBD,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"Y!_J5J2HX/\ 4K4E9/<U
M6P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[XS\
M&:=XYT>'3-3FNHH8K@7"M;,JMN"LN#N4C&&/;TKHJ* .)\%_"_1/ NHW%]IE
MUJ$TL\7DL+F1&4#(/&U%YXKMJ** "N)\:?"_1/'6HV]]J=UJ$,L$7DJ+:1%4
MC)/.Y&YYKMJ* ,#PAX1L/!6BG2M-FN98#*TVZY96;) !Y50,<>E:>J:58:WI
MTNGZG:QW5I*,/%(,@]Q]#[U<HH \<U+]G?0;B<OI^K7UHA_Y9R*LH'T/!].N
M:UO#OP-\*:)=+=78GU653E5N]OE#_@ &#^.1[5Z;10 BJ%4*H 4#  [5Y_XJ
M^#WA_P 7Z_-K.H7FIQ7$JJK+;RQJ@"@ 8!0GMZUZ#10!1T;2H-#T6RTJV>1X
M+2%88VE(+%5&!D@ 9_"LCQIX(TWQUIMO8ZG/=PQ03><IMG56+8(YW*>.:Z6B
M@#DO!'P[TCP%]N_LNXO9OMOE^9]J=&QLW8QM5?[Y]>U=#JFE6&MZ=+I^IVL=
MU:2C#Q2#(/<?0^]7** /'-2_9WT&XG+Z?JU]:(?^6<BK*!]#P?3KFM;P[\#?
M"FB72W5V)]5E4Y5;O;Y0_P"  8/XY'M7IM% "*H50J@!0, #M5;4=-L=7L9+
M+4;2&ZM9!AXID#*?3@]QZ]JM44 >/ZI^SSX>NIVDT[4KZQ5O^638E5?IG!_,
MFKOAWX#^&-(N$N=0EN-5E1LA)@$B]LH.3^)Q[5ZG10!&T$9MC;JH2(IL"H,;
M1C&!7F^B_ WPSH6M6>JVM]J[SVDJS1K+-&5)!R,@1@X_&O3** "N \7?"#PS
MXLNY+YTFL;^0Y>>U( D/JRD$$\\D8)]:[^B@#QBT_9TT6.YWW>MWTT .?+CC
M6,D>A;GV[5ZAX>\,:-X5L!9Z/8QVT9 WL!EY".[-U)Z_G6O10!C>*O#-EXNT
M"?1M0EN(K:9E9FMV"N-K!A@D$=1Z5A>"_A?HG@74;B^TRZU":6>+R6%S(C*!
MD'C:B\\5VU% !7EL7P&\+0ZFE^M_K!E283 &:+;N#9_YY]*]2HH *\Y\5_!?
MPSXFO6OH_.TV[=BTK6N-DI)R2RD8S[C'4YS7HU% 'CNE?L\Z!:W22ZEJEY?1
MJ<^2JB%7Z<,1DXZ]"#[UN>(/@IX7\0ZH;Z:;4+0^4D2P6CQI$BHH4  H<<#U
MKT:B@#.TO1K?2/#]MHUN\K6UO;BW1I""Y4#&20 ,_A7":+\#?#.A:U9ZK:WV
MKO/:2K-&LLT94D'(R!&#C\:],HH **** /*[WX!^&-0OKB]N=4UQY[B5I9&,
M\7S,QR3_ *OU->F6%E#ING6MA; K!;0I#&#V50 /T%6** "N/\;?#?1?'DUG
M+JDU[#):*ZHUJZ+N#8.&W*W3'&,=37844 <GX)^'VF> UO$TN]U":.[*ETNI
M$95*YY4*JX)SS]!Z5SEK\"O#%IK,&J1W^KF>&X6X56FBVE@VX _N\XS[UZ?1
M0 5PGC#X3Z#XUUI=5U*[U**=85A"VTB*NT$D<,A.>3WKNZ* ,CPQX=M/"GAV
MUT2QDGDMK;?L:=@7.YRYR0 .K'M5?Q5X-T3QE8I:ZQ:^9Y1)AE1MLD1.,[3[
MX&1TXK?HH \GM/@!X:LM2@NX]3U8B&19%1GCY(.1D[/45V?C3P1IOCK3;>QU
M.>[AB@F\Y3;.JL6P1SN4\<UTM% '*^"? &E> X+R+2[B]F6[96?[4ZL05! Q
MM5?6LCQ5\'O#_B_7YM9U"\U.*XE559;>6-4 4 # *$]O6O0:* /.M;^"WA?6
M=+LK;%Q;75I"D"WL17S)51=H\P8PW&.< \ 9QQ7.VG[.FBQW.^[UN^F@!SY<
M<:QDCT+<^W:O9Z* ,_1=#TSP]IL>G:39QVEJG(C3/)]23R3[DDUH444 >=>*
M?@OX7\2WDM\@GTZ\E.YWM2 CL3DED(QDY[8KG[#]G70X9U>^UF^N4!R8XT6+
M</0GD_E^E>RT4 9FA>']*\-:<MAI%E%:P+R0@Y<XQN8]6/N:TZ** //_ !A\
M(/#7BV[:^99=/OW.9)[7 $I]74C!/7D8//)-<WIW[.VAP7"27^L7MW&K9,2(
ML08>A/)Q],'Z5[)10!YQKOP2\*Z[>17#27]DD,"01P6<D:QJJ].&0G//)SR:
M[/P[H5KX9T"TT:RDFDM[52J-,07())Y( '?TK4HH X;Q]\0?#OAWP]?137=M
M>WDL;0I8Q2JSL6!'S '*KUR3^&3Q7S7X!\,GQ=XST_2F5C;,_F7)7M$O+<]L
M],^I%=GJ7P7\::SXKU2=;*VM;:>\EECGN+E-K*SD@X0LPX/I7M/P_P#A[I_@
M+3'BA?[3?SX-Q=LNTMCHJCG"C]>I[8 .P50JA5 "@8 ':EHHH **** "L^M"
ML^K@1,****L@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K
M_P"K;Z&J=7'_ -6WT-4ZN)$@HHHJR0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** )(?]:M6JJP_ZU:M5G+<N.P4445)04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $%Q_#^-05/<?P_C4%:1V,WN%%%%4(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S;_P"K/UJ6HK?_
M %9^M2UD]S1;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!<@_U*U)4<'^I6I*R>YJM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *SZT*SZN!$PHHHJR HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** &O_ *MOH:IU<?\ U;?0U3JXD2"B
MBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH DA_UJU:JK
M#_K5JU6<MRX[!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 07'\/XU!4]Q_#^-05I'8S>X44450@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** +-O_ *L_6I:BM_\ 5GZU+63W-%L%%%%(84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %R#_4K4E1P?ZE:DK)[FJV
M"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** )_L_^U^E'V?\ VOTJ:B@"'[/_ +7Z4?9_]K]*FHH
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MI1]G_P!K]*FHH A^S_[7Z4?9_P#:_2IJ* (?L_\ M?I1]G_VOTJ:B@"'[/\
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MOTJ:B@"'[/\ [7Z4?9_]K]*FHH A^S_[7Z4?9_\ :_2IJ* (?L_^U^E'V?\
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M?I1]G_VOTJ:B@"'[/_M?I1]G_P!K]*FHH A^S_[7Z4?9_P#:_2IJ* (?L_\
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M\K_:_2JT'^N7\?Y5=K.6Y<=B/RO]K]*/*_VOTJ2BI*(_*_VOTH\K_:_2I**
M(_*_VOTH\K_:_2I** (_*_VOTH\K_:_2I** (_*_VOTH\K_:_2I** (_*_VO
MTH\K_:_2I** (_*_VOTH\K_:_2I** (_*_VOTH\K_:_2I** (_*_VOTH\K_:
M_2I** (_*_VOTH\K_:_2I** (_*_VOTH\K_:_2I** (_*_VOTH\K_:_2I**
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M HHHH **** "BBB@ HHHH **** "LNM2LNK@1,****L@**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ;)_JW^AJA5^3_5O]#5"KB1(****LD**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"2#_7+^/\JNU2@_UR_C_*KM9RW+CL
M%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7NOX/QJ
MM5FZ_@_&JU:1V,WN%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"W:_ZL_6IJAM?]6?K4U9/<T6P4444AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 7[;_4+^/\ZEJ*V_U"_C_.I:R>YJM@HHHI#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R
MZU*Y'_A+_#/_ $,6D?\ @;'_ /%5I33>QG-FU16+_P )?X9_Z&+2/_ V/_XJ
MC_A+_#/_ $,6D?\ @;'_ /%5IRR[$71M45B_\)?X9_Z&+2/_  -C_P#BJ/\
MA+_#/_0Q:1_X&Q__ !5'++L%T;5%8O\ PE_AG_H8M(_\#8__ (JC_A+_  S_
M -#%I'_@;'_\51RR[!=&U16+_P )?X9_Z&+2/_ V/_XJC_A+_#/_ $,6D?\
M@;'_ /%4<LNP71M45B_\)?X9_P"ABTC_ ,#8_P#XJC_A+_#/_0Q:1_X&Q_\
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MJKO,=O<)(P7(&< GC)'YT<K[!=&A1114C"BBB@ HHHH **** "BBB@ HHHH
M;)_JW^AJA5^3_5O]#5"KB1(****LD**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"2#_7+^/\JNU2@_UR_C_*KM9RW+CL%%%%24%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!7NOX/QJM5FZ_@_&JU:1V,WN
M%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"W:_ZL_6
MIJAM?]6?K4U9/<T6P4444AA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 7[;_4+^/\ZEJ*V_U"_C_.I:R>YJM@HHHI#"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH X3QS\2X/!.I6UE)IDEV\\/F[EE"!1DC'0YZ&N6
M_P"%_6O_ $+TW_@4/_B:Q/CS_P C5IO_ %X_^SM7G.BZ'J/B'45T_2K?[1=,
MI8)O5.!UY8@5Z-*A2=-2DAGL/_"_K7_H7IO_  *'_P 35G3OCG:ZAJEI9?V%
M-']HF2+?]I!V[F SC;SUKSK_ (5)XX_Z G_DW!_\75[1?A9XSM-=T^YGT;9#
M#<QR.WVJ$X4,"3@/Z4W2P]MU]X:'N'C3Q7%X-T$:I+:/= S+$(U<+R03G.#Z
M&N1\._&G3=;URWTVYTY[!;AMB3/-O7>?N@@*,9/&:G^.'_(A1_\ 7]'_ .@O
M7SG6>'H0J4[O<#[5K*\2ZVGAOP[>:O)"TZVR!O+5L%LD <]NM<A\*?'1\3Z0
M=.OYBVK62#<S=9H^@?W(X!^H/>M7XH_\DVUK_KFG_HQ:YO9N-10EW$<5_P +
M^M?^A>F_\"A_\37KME<_;+"WNMFSSHEDVYSC(!QG\:^,:^Q]%_Y .G?]>L?_
M *"*WQ5*%-+E0V>6S_'JTAN)8AH$S!'*@FY S@^FVH_^%_6O_0O3?^!0_P#B
M:\4O/^/VX_ZZ-_.NBT'X>^)/$NFC4-,LXY;8N4#-.BY(Z\$YKH>'HQ5Y?F!Z
MC9_'O2I)@MYHUW!&?XXI%D(_ [:],T;7-,\06"WNE7D=S;MQN7((/H0<$'ZB
MOEGQ!X*\0^&$675=.>&%B LRL'0DYXRI.#P>#4G@GQ9=>$/$4%]$[&U9@EU#
MGB2/OQZC.1[^Q-1/"PE&],+'TMXN\21^$_#L^KR6S7(B9%$2MMR68#KVZUYO
M_P +^M?^A>F_\"A_\372_&!TE^&EU)&RNC20LK*<@@N,$&OFFHPU"$X7D@1[
MC_POZU_Z%Z;_ ,"A_P#$ULZ)\;/#NI7*6]]#<::S 8DEP\><]"PY'U(QUSBO
M,#\'O&H4D:9$2!T%U'S_ ./5R.J:1J&B7S66IVDMK<* 2D@QP>A'J/<5JJ%"
M>D?S ^QD=)8UDC971@&5E.00>A!K(UKQ7H/AT?\ $UU2WMFZ^66W2$>NQ<MC
M\*\G^"7B^X%\WAB\E+P.C26>X\HPY9![$9./8^M<1\3-+ETKX@ZLDA9EN)3<
MQLQSE9/F_0DC\*YXX;]XX286/3]0^/.D0W&RPTF[NHP.9)'6+GV'/'UQ6MX+
M^*D/C'7O[+CTF2U/DM+YC3A^F.,;1ZU\YSVEQ:^7]HMY8?-3?'YB%=ZY(R,]
M1D$9]C7H7P1_Y']O^O.3^:UO4P].--M(+'T;1117FB"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO)OVA;RZLO
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M44 %?#U?<-?#U>A@/M?+]3FQ'0****]$Y0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *OZ+K%WH.L6VIV4A2
M>!]P]&'=3[$9%4**35]&,^NO#^N6GB/0[;5+,_NYER4)R4;NI]P:TZ^<?A9X
MU'AG6C8WTH32[U@'9ND4G0/[#L?;![5]'5Y5:G[.5NATPES(****R+"BBB@
MHHHH **** "BBB@!LG^K?Z&J%7Y/]6_T-4*N)$@HHHJR0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** )(/\ 7+^/\JNU2@_UR_C_ "J[6<MR
MX[!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5[K^#
M\:K59NOX/QJM6D=C-[A1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH \R^)_B_6O#>I6$6EW0A26%F<&-6R<X[BMGX::_J/B+P]<7>ISB:9;DHK!
MN%VJ<<?4UQ7QM_Y#&E_]>[?^A5T?P9_Y%*Z_Z_&_] 6MW%>R3'T,?XA^.=?T
M#Q7)8Z=>+%;B)&"F)6Y(YY(KO/ NJ7FM>$+*_OY1+<R[]SA0N<,0.!QT%>0?
M%W_D>I?^N$?\J]2^&/\ R3_3O^VG_H;43BE33 Z^BBBL!!1110!RGQ#UJ^T'
MPH]]ITPBN!,B[BH;@]>#5GP+JEYK7A"RO[^42W,N_<X4+G#$#@<=!6-\7/\
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M74\D\\AW/)*Y9F/J2>34T<*X3YFPL=/\,HY9/B/HBPC+B8L>GW0C%NOL#7U
M^GV4EZM[)9V[W:J$6=HE+A020 V,XR2?QKR?X->!KG3RWB74X?+>6/;9QO\
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M1_R#/$7_ %V@_D] ''_M#?\ )28O^P?%_P"A/7N'P@_Y)1H'_7%__1C5X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 20?ZY?Q_E5VJ4'^N7
M\?Y5=K.6Y<=@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *]U_!^-5JLW7\'XU6K2.QF]PHHHJA!1110 4444 %%%% !1110 4444
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MJ:Y_X+IO_B:/^$$\8?\ 0J:Y_P""Z;_XF@#[:CN8)FVQ31NP&<*P)KY6^/\
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MB@ HHHH **** "BBB@ HHHH *^'J^X:^'J]# ?:^7ZG-B.@4445Z)RA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '9?#CQF_A'7L3DG3;LB.Y7^[SPX]QD_4$^U?3*.LB*Z,&1
M@"K*<@CU%?&E>Y_!SQI]MM/^$:OI,W%NI:T8_P <8ZK]1V]OI7'BJ5USHVI2
MZ,]:HHHK@-PHHHH **** "BBB@!LG^K?Z&J%7Y/]6_T-4*N)$@HHHJR0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )(/]<OX_RJ[5*#_7+^
M/\JNUG+<N.P4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %>Z_@_&JU6;K^#\:K5I'8S>X44450@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** +=K_JS]:FJ&U_U9^M35D]S1;!1112&%%%% !1110
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M9->SZ1IL.CZ3;:?;ES% @12YR?QK62Y8<KW8R[1116(@HHHH **** "BBB@
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MU Q/^$.\+_\ 0MZ/_P" ,7_Q-.3PCX:C=73P[I*NIRK+91@@^H^6MFBCGEW
MK7VG6.IVXM]0L[>[A#!O+N(ED7/K@@C/-9Z>$?#4;JZ>'=)5U.59;*,$'U'R
MULT4E)K9@%%%%(#&?PCX:D=G?P[I+.QRS-91DD^I^6M=$2*-8XU5$4!551@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY*Y X&>2*W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH MVO\ JS]:FJ&U_P!6?K4U9/<T6P4444AA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 7[;_4+^/\ .I:BMO\ 4+^/\ZEK)[FJ
MV"BBBD,**** "BBB@ HHHH ;)&DL;1R*&1AAE/0BN6U+P;'-,9;*01 C)1AD
M9]JZNB@RJT(55::.#32O%$5L+>,R+$!MVB5<8_.K6F^"BLT,U]*K* &:)1W]
M"?2NRHI<J.>. I)IRN[=V1PPQV\2Q0HJ1KT51P*DHHIG:E8**** "BBB@ HH
MHH **** *,VCZ=<ZE%J,UG#)>1+M29ERRCGC]35X #H*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
M<?VE?^0_H7_7K)_Z$*^CJYOQ+X"\,^,+B"?7=-^UR0*4C;SY(]H)R1\C#/XT
M >>?LW?\B9JO_80/_HM*]GK%\-^$]$\(V4MGH5E]D@ED\UT\UY,M@#.7)/0"
MMJ@#XQ^*W_)4?$/_ %]'_P!!%?5W@3_DGGAK_L%6O_HI:S-5^$_@G6]4N-3U
M'1?.O+AM\LGVJ9=Q]<*X _ 5U=A8V^F:=;6%G'Y=K:Q)#"FXG:B@!1D\G  Z
MT ?".G_\A.U_Z[)_,5][5P,?P6^'T4J2)X?PZ$,I^V7'!'_ Z[Z@ HHHH ^$
M?$'_ ",FJ?\ 7W+_ .AFON>Q_P"0?;?]<E_D*XNX^#/@"ZN9;B;0-TLKEW;[
M9.,L3DGAZ[E$6.-8T&%4  >@% #J*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BN>U[QSX<\,WR66L:C]FN'C$JIY$CY4D@'*
MJ1U4_E4>F?$#PMJ\=U)9ZO&T=I&))WDC>)44G )+J!UXJ^25KVT Z6BO.KGX
MU^$()=D;WUPN<;XK? ^OS$']*WO#WQ \-^)G6&PU "Z89^SSJ8W_  SP?P)I
MNE-*[0'3T45SVO>.?#GAF^2RUC4?LUP\8E5/(D?*DD Y52.JG\JA1<G9(#H:
M*P-"\:^'O$LL\6DZB+AX$\R7,,D85?7+*!5.T^(_AB_U^#1;+4#<W4Y*JT4;
M&/(!.-V,'@=LU7LY=@.KHHKDM?\ B5X7\.W+VMU?^;=(=KP6R&1E/H3T![8)
MS2C%R=D@.MHKSJV^-?A">79(]];KG&^6WR/K\I)_2NZTW5+'6+);S3KJ*YMV
M) DB;(R.H]C3E3E'XD!;HHJ&ZN[:QMGN;NXBMX(QEY9G"*O;DG@5 $U%>>7G
MQI\(6LQCCEO+H XWP0?+_P"/%?\ (K:\._$3PUXFG6VL;\)=MTM[A?+=OIGA
MC[ DUHZ4TKM =317%?\ "V_ _P#T&_\ R4G_ /B*ZS3[^VU33X+ZSD\VVG02
M1OM*[E/0X."/QJ90E'=6 LT5QLWQ6\%0320RZUMDC8JP^RS'!!P?X*UQXOT$
M^'8]?.I1II<A*I/(K)N(8K@*1N)RIXQVING-;H#;HK!\->,-'\6"[;2)I)4M
M7"NSQE <YP1GG!P:U=0U&RTJRDO+^ZBMK:,?-)*P4#V^OMWJ7%IV:U LT5YS
M<_&SPC!/Y<;7UPN<>9%;X7_QX@_I6YHOQ&\+Z[;R26NHA)(HFED@F0K(JJ"2
M0/XL $_+FK=*:5V@.JHKBO\ A;?@?_H-_P#DI/\ _$5V%M<Q7EI#=0/OAF19
M(VP1E2,@X//0U,H2C\2L!+17%?\ "V_ _P#T&_\ R4G_ /B*MZA\2/"FFZ=;
MWLVJHR7*>9#'&C&1U]=F,J.#RV.E/V4^S ZJBO.[/XU>$;JX6*22]M58D>9/
M!\H^NTD\_3ZXKK-9\4Z)X?TV/4-1U"&*WE&82IWF7I]P#);J.1QS0Z<T[- ;
M%%>;?\+O\)^:4\O4=O\ ?\A<?^A9_2NXT;7M+\0V(O-)O8KJ#."4R"I]&4\J
M?8@42ISCK) :-%%%0 4444 %%%% !1110 4444 %%%% !1110 4444 %>/\
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MJ)_P(LI;\A^-<C-\%O&ECXR72K"(2>65FBU.-S'$B[CM8MU5@5Y49(QQD8)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*]U_!^-5JLW7\'XU6K2.QF]PHHHJA!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC^\>I].G:OH+Q\_V/X>ZZT"HA-HR'"\88!#^AQ7RC6.'M4E*K8#6T;PQK?B
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M** "BBB@ HHHH **** "BBB@ HHHH *\?_:._P"2>:?_ -A6/_T5+7L%>/\
M[1W_ "3S3_\ L*Q_^BI: .(_9M_Y'#5_^O#_ -J+6G^T'X%$4B>,;"([7*PZ
M@JC@'HDA],\*??;W)K,_9M_Y'#5_^O#_ -J+7T=J%A:ZII]Q87T"3VMPACEB
M?HRGJ* /"?V?_ )4OXPU*#@@QZ<KX/?#R>H/!4?5O8UC_M)?\CAI'_7A_P"U
M&KZ0L[.WT^R@L[2%(;:!!'%&@P%4#  KYO\ VDO^1PTC_KP_]J-0!Z!^SU_R
M35_^O^7_ -!2OG&[Q9^-9_[33<(=1;[2C)G.)/G!4_0\5]'?L]?\DU?_ *_Y
M?_04KB?C?\,+V+59_%>BVTD]K<9>^BC&6A?@;\9R0V<G XP3T/ !]%12QSPI
M-#(DD4BAD=&!5E/(((ZBN"^-=Y:VOPIU=+ET#7'E10JV,N_F*P SU("EOHI/
M:OGWPS\8?%WA72TTVTNH+FTC&(DNXS)Y8]%((./09P*RO$7BWQ/\1-7@6]>6
M\FSMMK*UB)521SL09))Q[F@#L?V=TE;XD3F-RJ+ITID _B7?&,?F5/X5G_';
M_DJ^H?\ 7&#_ -%K7MOP=^'LG@CP_+<:BBC6+_:TZ@[O)09VIGUY).._K@5X
ME\=O^2KZA_UQ@_\ 1:T >OWL4TO[,JK;@EQHD3' S\H"EO\ QT&OFOP[;:S>
MZY;VN@-.-3FW+%Y$WE.?E)(#9'8'O7U_X!MXKOX6:#;7""2&;3(XY$/1E*8(
M_*OF;QQX'USX<>)VN+=;A+))O-L=0AS@#.5!8=''<?CTH U_^$+^,?\ =US_
M ,&?_P!LJE??#/XH:HR-J&EZC=M&"$-Q>)(5SUQESBMNT_:+\6068BGL=+N9
M@"!,\;J3]0K ?EBLW2OB;\2/$'C2.YTF>6YO9%"BPACS 4&>J9P!R<L3GGKT
MH ]0\*^&M=T'X!^(M*U&UD@OV@O&2 D.=ICZ#&1DX/3UKQCX0W5I9_%709KU
MHUA\UT!DQ@.T;JG7_:*X]Z^P;07$FGP"_2+[2T2^>L?*;\?,!GMG/6ODGXG?
M#?4/ VOS7-G;S-H<C[[6Z0$B')_U;MV8'@$GYA@]<@ 'U]48GA-PUN)4,ZH'
M,>X;@I) ..N,@\^QKY+TOXY>.=,T\69OX+P* $FNX0\B@=MV1N^K9/O6-IM]
MXV\:^,X[VPN[^[UQB +B)MGE+]1A43KQP/SH ]J_:1_Y$S2O^P@/_1;UC?LR
ML-WBA<C<1:D#O_RV_P :[OXA^"M5\3_"J/27G74-<LQ%.LO^K$\R##8'0$JS
MXSQDCIU'S-X8\5Z[X#UR6ZTUS;W(!AN+>="5;!Y5U.#D$>Q'YT ?9?B.=+;P
MOJT\AQ'%93.Q] $)-?(GPI_Y*CX>_P"OH?\ H)K<U[XK>-/B':?V!#;VT,4P
M_>Q6,;*90 "=S,QPHQGC''7-8?PI_P"2H^'O^OH?^@F@#V?]I'_D3-*_[" _
M]%O6?^S1_P @SQ%_UV@_D]:'[2/_ ")FE?\ 80'_ *+>L_\ 9H_Y!GB+_KM!
M_)Z /%O',4\/C_Q$EP")?[2N"V1C.9&.?H<Y'L:ZVV\)_%Z\M8;FW.N20S(L
MD;C4N&4C(/\ K/2NR^.GPTOKK4SXKT2SDN1*@6_AA!9PRC D"CMM !QTQGN2
M.&\)?&GQ3X2TR+3(_LM_90C$27:L6C7LJL"#@=@<XZ#M@ FNO 'Q:OK9[:\M
M-7N('QNBFOU=6P<C(+X/(!KM/@IX \5>&/&\]_K&ER65JUC)'O:1"&8NA"X4
MGTS^%<3XB^-GC'Q&T,,$\>FQI(KJE@&5G8'C+$DD9[=#@<&OH3X97_BO4?",
M5QXNMTANRV(?DV2218&&D7/#$Y[#Z4 =E1110!\(^(/^1DU3_K[E_P#0S7VA
MKO\ R3_4O^P7+_Z*-?%_B#_D9-4_Z^Y?_0S7VAKO_)/]2_[!<O\ Z*- 'RI\
M(463XK: &&0)G/XB-B/U%?9-?''P>_Y*QH'_ %UD_P#1;U]CT ?''QA_Y*QK
M_P#UUC_]%I7T!>?\FYK_ -BS'_Z3K7S_ /&'_DK&O_\ 76/_ -%I7T!>?\FY
MK_V+,?\ Z3K0!X;\"XU?XL:8S#)2.=E]CY3#^1-?7-?)/P)_Y*OI_P#UQG_]
M%M7UM0!\4_$G_DI7B/\ Z_Y?_0J^D/B)_P D*OO^P?!_-*^;_B3_ ,E*\1_]
M?\O_ *%7TA\1/^2%7W_8/@_FE 'CW[//_)29?^P?+_Z$E=!^TO\ \A#PY_UR
MG_FE<_\ L\_\E)E_[!\O_H25T'[2_P#R$/#G_7*?^:4 =%^S?<VK^"M3M8W7
M[5'J!DE3/(5HT"'Z':P_ U[+7Q)X>U3Q-X-\CQ-I!FMK>5VMQ/M#12D8)C8=
M.G.#SW'3-=9JOQ\\::GIS6B-86)88,]I"RR?@68@?4 =: ,7XO75I>?%77IK
M)HVA\U$)CQ@NL:*_3_:#9]Z]S\3QRP_LTQQ3*5D31K-64J5*D"/@@]Q7BGPQ
M^'=]XZ\0QS7,,G]C02![RX<E1(,_<4]2Q[XZ#G/3/T3\75"_";7E4 *($  Z
M#]XM 'B'[//_ "4F7_L'R_\ H25] ?$?_DFWB/\ [!\W_H)KY_\ V>?^2DR_
M]@^7_P!"2OI'Q/I+:[X5U724?8]Y:20HWHS*0#^>* /E_P"!/_)5]/\ ^N,_
M_HMJ^LY0YA<1$+(5.TGH#VKX<L+W6? _BI+J)6L]6T^4@I*@)4X*L"#U!!(^
MAXKZ0^"_Q USQV=;_MDVY^QBW\H0Q;/O^9NSR<_<% 'S?X8DAT_QKHTFHJ(X
M+?48&N5E7 55D7<&!]@<YK[E5@RAE(*D9!'0U\Q_&CX87FCZS=^)=)MI)M*N
MG,UR$&?LTA.6)&<[2<G.,#...,X'A_XU>,?#VE1Z=%<V]W!$ L1O(R[(H& H
M((./KF@#VSX^W=M!\,9[>9T$UQ<1+ IQDD,&./H ?S]Z\Y_9M28^+M7D5R(%
ML,.G8L9%VG\ &_.O/-9U[Q/\1M>B-T;C4;PC9!;6\9*H.^U!T[9/YFOIWX4>
M O\ A!/"QBN@AU6]82WC*<A<?=C![A03^+-SC% 'SI\8?^2L:_\ ]=8__1:5
M]4^"+5++P'H%O&!M33X,D#&24!)_$DFOE;XP_P#)6-?_ .NL?_HM*^L/"G_(
MGZ)_UX0?^BUH UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "OAZON&OA
MZO0P'VOE^IS8CH%%%%>B<H4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !115O2]-NM8U2VTZRC\RYN'"
M(O09]3[#J:'H,ZKX:^#6\5>(5>X0_P!FVA$L[%<K(01B/\>_L#[5]+(BQHJ(
MH5% "JHP /05C>$_#=MX5\/6^F6X&\ //(,_O)2 &;]./8"MNO*K5?:2\CIA
M'E04445B6%%%% !1110 4444 -D_U;_0U0J_)_JW^AJA5Q(D%%%%62%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!)!_KE_'^57:I0?ZY?Q_
ME5VLY;EQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH KW7\'XU6JS=?P?C5:M([&;W"BBBJ$%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!;M?]6?K4U0VO\ JS]:FK)[FBV"BBBD,**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M20?ZY?Q_E5VJ4'^N7\?Y5=K.6Y<=@HHHJ2@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *]U_!^-5JLW7\'XU6K2.QF]PHHHJA!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 6[7_5GZU-4-K_JS]:FK)[FB
MV"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M].A\-Z3X7\)ZC8Z/9I;0-%+(P7)+$@]2>3Z?2OG#X%''Q2LC_P!,)O\ T T
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M=B,FWN=OSQN!QSUQZBOF[X,(T?Q;TE&&&4S CW\MZ /KJBBB@ HHHH ****
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M/#/_ $+ND?\ @%'_ /$T?7(]@]D^Y\F45]9_\(AX9_Z%W2/_  "C_P#B:/\
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M/_0NZ1_X!1__ !-'UR/8/9/N?)E%?6?_  B'AG_H7=(_\ H__B:/^$0\,_\
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MFH?C+I.GZ+\(KBSTRTBM;8743".(87)89-8?A3]GB*UO([KQ-J$=TB$'[+;
MA6_WF.#CV _&O1_B#X/F\7^#'T*QFAM3OC*-(#M55/3CVH \[_9L_P"01K__
M %WA_P#06KU3QO\ \B)K_P#V#Y__ $ USGPK^'MY\/[+4H+R]@NC=R(ZF$$;
M=H(YS]:[#Q!IKZQX=U+38I%CDN[:2%7;HI92,G\Z /F[]GG_ )*'/_UX2?\
MH2UN_M*?\?\ X>_ZY3_S2NI^&?PBU'P+XFDU6[U*UN8WMFAV1*P.20<\CVK0
M^*OPSOOB!<Z9+9W]O:BT216$P8[MQ7I@>U &C\&O^24Z)_NR?^C&KP;XW_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K+K4K+JX$3"BBBK("BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ;)_JW^AJA5^3_5O]#5"KB1(****LD****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"2#_7+^/\JNU2@_UR_C
M_*KM9RW+CL%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!7NOX/QJM5FZ_@_&JU:1V,WN%%%%4(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@"W:_ZL_6IJAM?]6?K4U9/<T6P4444AA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 7[;_4+^/\ZEJ*V_U"_C_.I:R>
MYJM@HHHI#"BBB@ HHHH **** &R1I+&T<BAD8892,@BN UWP7- [7&F*983R
M8OXE^GJ*]!HKDQ>"I8J/+47H^IUX3&5<++FIOU70\EU@?8XK;2UX\A?,F]Y6
MY/Y# _.LFO9KO3+*^'^E6L4I]67G\^M9;>#M$9L_967V$AKQ,1DE:4[PDK?H
M>WA\[HQA:<7<\MK3TK0;_5I ((BL>?FE?A17H]MX:T>U(:.QC+#N^6_G6JJA
M5"J  .@ Z55#(7>]:6G9?YDU\^5K48Z]W_D9NBZ';:+:^7%\TK?ZR4CEO\!6
MG117T-.G&G%0@K)'SU2I*I)SF[MA1115D!1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %9=:E9=7 B844459 4444 %%%%
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ME.0"K<9Y&/0G!KVKX%_$2Y\2:?-X?U><S:C9('@F<_--#P,-ZLIQSW!'<$D
M]&UKQCX=\.74=MK&K6UE-(GF(DI(++DC(_$&G+XO\/-H0UO^V;-=,+%%NGD"
MHS#.0">IX/ YXKP+]I+_ )'#2/\ KP_]J-7G.E67B;QE'9>']+@N+Z.Q5FBM
MX\!(][Y9F)( R6 R?;TH ^R- \1Z3XHT]K_1KP75JLK1&0(RC<,9'S $]1ST
MHU[Q)HWABQ%YK6H0V<!)"F0\N0,X51RQ]@#7GW@6WO\ X6?"'4[CQ%:K!/:R
MR7 B\U&W[E0(N5)&2WRU\]7-SXC^)?C$,P>^U2\?:D:<+&H[#LJ*,_J3SDT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %>Z_@_&JU6;K^#\:K5I'8S>X44450@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** +=K_JS]:FJ&U_U9^M35D]S1;!1112&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!?MO]0OX_SJ6HK;_4+^/\ZE
MK)[FJV"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?29]#\#Z+IETNVXM[1%E7.=K8R1^!-;] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\<>+_P#D=M>_["-Q_P"C&K['KXX\7_\
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MH04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?4FO,/C1_P C59_]>:_^AM7<?"+_ )$6/_KXD_I1**]FF!W=%%%8""BBB@#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7QQXO\ ^1VU[_L(W'_HQJ^QZ^./%_\
MR.VO?]A&X_\ 1C5WX'XF<V(V1BT445Z1RA1110 4444 %%%% !1110 4444
M7=(U6[T35K;4K&39<V[AT/8^H/L1D$>A-?5'A?Q#:^*- M]4M3@2#;(G>-Q]
MY3_GIBODJNX^&7C,^%=?$-U)C3+PA)\GB,]G_#H?;Z5SXBESQNMT:4Y6=CZ5
MHI 0RAE(((R".]+7F'2%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #9/]6_T-4*OR?ZM_H:H5<2)!1115DA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 20?ZY?Q_E5VJ4'^N
M7\?Y5=K.6Y<=@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *]U_!^-5JLW7\'XU6K2.QF]PHHHJA!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 6[7_5GZU-4-K_JS]:FK)[FBV"BBBD,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"_;?ZA?Q_G4M16W^H7\?YU+
M63W-5L%%%%(84444 %%%% !1110!XM\;)9/[6TV+S&\KR"VS/&=QYQZUT?P:
MAB'A.>81H)6NF4N%^8@*N!GTYKFOC9_R'-,_Z]C_ .A&L;X>^.6\+WAM;O<^
MFSL-P'6-O[P_3/TKJY7*DDAGT)7,?$0 ^ M6R <1#'_?0K:M-8TZ_M4N;:]@
MDA<95@X&?SKRWXF>/K&]TO\ LC1[GSO-/^D2*OR[03\O/.<@&L:<6Y(1R_PH
M_P"1_L_^N<O_ * :]WUK6;+0-,DO[^7RX4].K'LH'<FO)/@[X>DGU.3795D2
M&W!CA88VNQ!# ]^ 14/QBUN>XU^/2!E8+5 Q /WV8 Y/TK6<>>I894USXM:Y
MJ3LECLL;<H5*KAF;GKDC(./2N9T_Q5KNFWB74&IW)D7.!)(77\CD5Z1\./A[
MIUUI$>LZJB71N!F&+)"H >IZ<Y!]L5ZC-IUE<020RVL+1R*4==@Y!&"*'4A'
MW4@/'+7XM:E+X?N()I(X]4C!:.YV+AQZ;<8!K>^&/C'6O$NK7L&IW*RQQ0!U
M C5<'<!V%<[\3O EGH44>KZ8!#:NXB>WR3M;'!7/8X.<FI/@G_R'M2_Z]A_Z
M$*<E!P<D@-+XW_\ 'OHW^]+_ .RU-\$O^05JO_79/Y&H?C?_ ,>^C?[TO_LM
M3?!+_D%:K_UV3^1I?\N0Z&!\:/\ D:K/_KS7_P!#:NO^&2W;_#25;%T2[,DP
MA9Q\H?'!/MFN0^-'_(U6?_7FO_H;5W'PB_Y$6/\ Z^)/Z42_A(#@K3XH^);/
M6TAU&Y2>"*;9-&D2#< <'! KW=3N4-ZC-> ?%;0WTOQ4UXH007H$B*@(VD
MY]R037I?PNU@ZKX.AC< /:,8/O9+  ')_/\ 2IJ13BI(&=9J%]%ING7%]/N\
MFWC:1]HR< 9.!7B>F_$+Q?K7B"+3[&_A7[1,5B\R%  .3SQZ5V_Q9US^S/#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4R)N7#.%.1]#0!V-%>&_"/XI^)?&7C*32]7>U:V%H\H\J'80P90.<^YKW*@
MHKQ[XR_$?Q!X(U72[?1GMUCN8'>3S8MYR&P,5M_!SQIJ_C;PW?7NL- T\%V8
MD,4>P;=BGD?4F@#T:BBB@ HHHH **** "BN3^)7B"^\+?#_5-9TTQB[MO*\L
MR+N7YI44Y'T8UYS\)/BGXE\9^,GTS5I;4VRVCS8BA"G<"H'/IR: /<J*\-^.
MGQ"\0^&M8T_1M%N&L8Y+<7,ES& 6D)9E"#(X VY..NX>G/3?!3QGJWC#PM<M
MK&99[*80BZP!YH*@\@?Q#N>^10!Z91110 4444 %%%% !117QOHWBGQ#+\0=
M/BDU[5'C?58U9&O)""#*,@C/2@#[(HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **XGXJ^)]2\(^!YM6TIHENDGC0&5-PPQP>*X[X.?$KQ%XV\17]GK$E
MLT,%IYJ"*$(=V]1R?H30![/1110 4444 %%%% !1110 4444 %%%% !1110
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M-%\!:MXAT-=2TSRYCY[1/$S!2N #G)//6NG^-G_(<TS_ *]C_P"A&NI^#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGJ-I8QL<*]S.L0)]BQ% %VBL73/%WAO69_(TW7M-NYSTBAN49S[[<YQR*VJ
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MCQ?_ ,CMKW_81N/_ $8U=^!^)G-B-D8M%%%>D<H4444 %%%% !1110 4444
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH D@_P!<OX_RJ[5*#_7+^/\
M*KM9RW+CL%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!7NOX/QJM5FZ_@_&JU:1V,WN%%%%4(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"W:_P"K/UJ:H;7_ %9^M35D]S1;!1112&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!?MO]0OX_P ZEJ*V_P!0OX_S
MJ6LGN:K8****0PHHHH **** "BBB@#A/'?@*?Q=J%K<Q7<<"PQ&,A@>><UK>
M"/#,OA30WL)9TF9IFEW*.,$ 8_2M'7+N]LK+[19K&P0_.'&<#\Q46A:]%JL.
MR0JETOWEZ!O<?X53F[<IDZ\54]F]S9IDR&2"2,'!92,_44^JU[?6]A TUQ*J
M*HSC/)^@J31M)79Y7I_P>O++4[6[.I0L(9DD( /(!!]/:O7&574JRAE(P01D
M&N:T/7K_ %C4W"PHMDN23CE1CCG/)_"NFJG-SU9%*M&K'FCL>6>(_@]#>7#W
M.BW*V[22;FAF)\M%Q_"0">OK6%_PI76_^@A8?F__ ,37N%%6JTT:W/-8OA'9
M6NAW%O#<>9?SJ%,\HX3CY@H'8G\:O^!/ -QX1U&ZN9KN.=9HA& H/!SFN[HJ
M74DU9BN<=X]\&3>+X[%8;E(/LY<G>#SNQ_A3_ ?@^;PA:7D,URDYGD5@4!XP
M,5UU%+G?+R] . \<_#VX\6ZQ#>Q7D<*QP"(JP.202<_K6]X,\.R>%_#ZZ;+,
MLS"5GW+TYKH:*'-M<H!7BOQHFL&U:RA2%O[06+,DN?E\O)PO7KG)_&NF^(_C
M?5?"E_90:>ENR3Q,S>:A8YSCC!%>1:?I.L^+M9!2.:XGN)/WEPX^4'&26;IT
MK:C"WOO8:/1/@QHO%YJ\]J<\1V\Q/UW@#\J]=K.T+1X-"T:VT^W1%6) &*#&
M]L<M]2>:T:RG+FE<05SGBKP9IOBR"-;O=%/$?DGC^\!W'H171T5*;3N@/&/^
M%2>)$8K#K4"Q@_+^]D'';M4UI\'=3GNT&KZPCVH!SY+,SY]MPQ7L-%:>VF.Y
MGZ+HMCH&FQV-A"(XD')[L>Y)]:K^*M)FUWPS?:9;NB2W"!5:3.T88'G'TK8H
MK.[O<1S/@7PY<^%O#QTZ[EBED\]I-T6<8('J!Z5MZCIEEJ]F]I?VZ3P-U5O\
M\5;HH<FW<#R+4/@_?0W &B:OLMV&66=V4AL]MHY&,55_X5'XD?Y9=;MS&>&'
MFR'C\J]GHK3VTQW.6\+> ])\+A9HD,][M(-Q)UP>H Z#^==3116;;;NQ!111
M2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *^>/VE_P#D(>'/^N4_\TKZ'KYX_:7_
M .0AX<_ZY3_S2@#H/V;O^1,U7_L('_T6E>SUXO\ LW,/^$.U9<C<-0R1W_U:
M_P"%>T4 ?&/Q6_Y*CXA_Z^C_ .@BOI_P-_R2;1/^P5'_ .BZ^8/BM_R5'Q#_
M -?1_P#017U!X(4K\)]$# @_V3&>?^N= 'QQINHW.D:E!J%E)Y=U;MOB?&=K
M#H?PZUW]G\%?'FM6(U5[6-9+C][LN[@+,^[G<P/0G_:(//-<QX"M4O?B#X>M
MY0#&^H0;@1D$!P2/QQBOMV@#X?T?6-<\!^*//MVEM+ZSE*3P,<!L'#(XZ$=?
MYCL:^R[3Q!9W'A.+Q&[>79/9"]8]=B;-Y_(9_*OEWXZJJ_%C4B  6B@)('4^
M6H_I7I.LW,MM^RO;F'<"]G!&S#LIF4'\QQ^- 'D/C?Q_KGQ"UO#&9+-G"6FG
M0L64<X7@??<YZX]AQQ6I#\#/'LUA]I_LN%&(R('N4$A_7 _$BKW[/EC;7GQ*
M:6X4%[6QEF@SC[^Y$_\ 07:OJJ@#X9UR[UV&&W\.ZV;A/[)>18K>X'S0;PN5
M&?X?E4@=.<CK7O\ ^S=_R)FJ_P#80/\ Z+2N>_:6L+:+4?#U^D8%S<13Q2./
MXE0H5_+>WYUT/[-W_(F:K_V$#_Z+2@#Q_P",/_)6-?\ ^NL?_HM*^FEUH>'?
MA-!K'EB1K/1XY50]&81#:#[$XKYE^,/_ "5C7_\ KK'_ .BTKZ@L=(M]?^&5
MEI%T6$%YI,4+LO5=T0&1GN.H^E 'R3!%K_Q(\9K$9OM>KZ@[$-*X5?E4L1Z
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M/TRJ_I0!X+XD\5^)OBAXEBMRLLQFEVV6FPG*1Y]/4XZL?<\#IN/\ _'2V*W
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M<$>H(@CE?@"1"<*3T&0QZ]P*^@YIXK:%YIY4BB099W8*JCU)/2L<5.HJED]
M9\E^,/#C^%?%%YI+2>8D3!HI#U:-AE2??!P?<&O7?@1K$MSHFI:1*^Y+.59(
M03R%DSD#V!4GZL?6O-/B;X@MO$?C>[N[)M]K$JV\<F1APO5A[$DX]L?2N]^
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MIPR,#V(Z$&O>[O4;SQA\ +JZG)>\$&9G('S^3*&+<>JIFLZU&TXR;NK@?/\
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M\;?'ZV8MAK8X7;YIMHB^/KMZ^_7\: .K_:2N87\4Z/;*X,T5FSNH_A#.<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)W%(D"@GUP*L44[O8 HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3Q1Q _=+*&+D?@R9^@_#RGXF^$+KP/XXN(XU:.SGD-U831C: A;(4$="AX_
M'C(KZ_T[3K/2-.@T_3[>.WM+= D448P%'^>_>JNO>'=)\3Z:^GZQ8Q7=NW(#
MKRAQC<IZJ?<4 >(^'?VCA!IB0>(-'EFNHD"BXM'&)2.[*WW3TR03DYX'2N=\
M0_'[Q'?Z_;WFB1IIUE;!E%LY\WSP2.9.@[#&,$9/)S7<ZA^S=H4T[/8:U?VL
M;-D1R(LH4>@/RG\\_C70>$_@AX5\,W$5Y.LNJ7L?*O=X\M6SP50#'YDT 5?%
M>M:CXA_9\U#5=4TX6%U<VR.80V1M\U=K#/(!&#@],UY;^SS_ ,E)E_[!\O\
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MRU.V-M?V=O=VYY,5Q$LBG\",5RO_  J;P)YWF_\ "-6>[TRVW_OG./TKLZ*
M*.EZ-I>B6[6^E:=:6,+'<R6T*QACC&3@<G ')J]110!C7GA'PUJ-W)=WWA[2
M;JYD.7FGLHW=N,<L5R>!6M%%'!"D,,:1Q1J%1$4!54<  #H*?10!0U/1-)UI
M8UU72[*_6(DQBZMTE"$]<;@<=*73=%TK18WCTK3+.QCD.YUM8%B#'U(4#)J]
M10 C*&4JP!4C!!Z&N1N/A9X&N9Q-)X9L P.<1H8U_P"^5('X8KKZ* ,J'PSH
M5OHS:/%HU@NF,07M/LZF)R,$%E(PQRH.3SD"C3O#&@:1<FYTS0],LIRI0RVU
MI'&VT]1E0#C@5JT4 9VIZ!HVM-&VJZ187[1 B,W5LDI3/7&X''05-IVEZ?I%
MM]FTRPM;*WW%O*MH5C7<>IPH SP*MT4 9^KZ'I6OV@M=7T^VO8 =RI/&&VGI
MD9Z'W%<]#\*? L%QYZ>&K(OG.'#.O7/W22/PQ78T4 1P00VT"06\210H-J1Q
MJ%51Z #I4E%% &#K/@GPQX@E\[5=#L;F8C!E:(!R/]X8/?UJ+1O /A3P_/Y^
MEZ#903Y!$I3>ZD?W6;)'X5T=% !6''X,\+17*W,?AK1DG1Q(LJV$08,#D,#M
MSG/.:W** "J>I:5IVL6IM=3L;:\@/6.XB#K^1JY10!Q\?PK\#17(N%\,V)<$
M'#*67C_9)V]O2NKM[:"TMTM[:&.&%!A(XU"JH]@.!4M% !7/ZWX&\+^([@W&
MK:'9W-P1@S%-LA'&,LN">@ZFN@HH YO2/A_X2T*Y2YTW0+&&XC.4F,>]T/J&
M;)!]Q72444 ,EBCGB:*6-9(V&&1QD'ZBN2NOA7X%O)3)+X9L58G.(E,0_)2!
M7844 9>C^&M$\/1E-(TJSL@>&:&(*S<YY;J?QK4HHH 9+%'/"\,T:212*5='
M4%64\$$'J*Y*7X5^!I;DW#>&;$.23A5*KS_L@[>_I7844 98\-Z$-(72/[&T
M\Z:IW"T-LAB!SG.TC&<\YI=-\.:'HTSS:7HVG6,KKM9[6U2)F7K@E0,BM.B@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *^./%__([:]_V$;C_T8U?8]?''B_\ Y';7
MO^PC<?\ HQJ[\#\3.;$;(Q:***](Y0HHHH **** "BBB@ HHHH **** "BBB
M@ K5\.:#=^)M=MM*L\"28G+M]U% R6/X#\\#O66 68*H)). !WKZ2^&/@H>%
M=#-S=*1J=ZJM.&_Y9 9P@_/GW^E8UJOLXWZEPCS,ZW2=*L]$TJWTVPB\NVMU
MVHN<GKDDGU)))^M7:**\MN^IU!1112 **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!LG^K?Z&J%7Y/\ 5O\ 0U0JXD2"BBBK
M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH D@_UR_C_ "J[
M5*#_ %R_C_*KM9RW+CL%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!7NOX/QJM5FZ_@_&JU:1V,WN%%%%4(**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"W:_ZL_6IJAM?]6?K4U9/<T6P4444AA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7[;_ %"_C_.I:BMO
M]0OX_P ZEK)[FJV"BBBD,**** "BBB@ HHHH **** "BBDS0 M)G%96I^(;#
M2P5EEWR_\\TY;_ZU<7JGBR_O]T<)^S0G^%#\Q^I_PII'EXW-\-A%:3O+LCL]
M3\16&E@K)+YDW:*/D_CZ5Q]WXQU&>Y1XML,2,#Y8Y+>Q-84,$UU,(X8WDD;L
MHR35S4=$O=+@AEND"B7C@YVGT-59'R^*S?'XJ+J4DXP7;]6>G:?>QZA917,1
MRDBY^A[BK5>?^#M7^RWAL96Q%,?DSV?_ .O7?YJ6K'UN6XU8S#JIUZ^HM%%%
M([PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\<>+_\ D=M>_P"PC<?^C&K['KXX\7_\CMKW_81N
M/_1C5WX'XF<V(V1BT445Z1RA1110 4444 %%%% !1110 4444 .1&D=412SL
M0%51DD^@KZ=^'O@R/P?H(CE5&U*X^>ZD4YY[(#Z ?KDUY_\ !OP4TUR/$^H1
M,L<1Q8J<8=N0SD>@Z#WR>U>W5P8JK=\B-Z<>K"BBBN,V"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LG^K?Z
M&J%7Y/\ 5O\ 0U0JXD2"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH D@_UR_C_ "J[5*#_ %R_C_*KM9RW+CL%%%%24%%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=6/^O0_^B*G^+FMZWJOC+1? 6C7K6*WZJ]Q,A(+!B1@D<[0%)QWJ#_FZQ?\
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M6"^<0T@!91UP5P0>_>O5_AGXCN?%7@'3=5O<&Z=6CF8#&YD8KN_'&:\L\7?
MWP]X;\(ZGJZ:SJ)EM8&DC69XPKN.@/R]S7<_ K_DE.G_ /7:?_T8: /2****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "LNM2LNK@1,****L@**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!LG^K?Z&J%7Y/]6_T-4*N)$@HHHJ
MR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )(/]<OX_RJ[5
M*#_7+^/\JNUG+<N.P4445)04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %>Z_@_&JU6;K^#\:K5I'8S>X44450@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** +=K_JS]:FJ&U_U9^M35D]S1;!1112&%%%%
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MRI !C<DC[L?@H/ZUZ3<^';NZ^'DWAR:_\^\DTXVC7D@/SL4V[R,D^_6NCHH
MY+X<>$;CP3X2CT:YNHKF1)GD\R)2!ACGO63\2/AH_C.>RU73-0_L[6K'B&?G
M##.0"1R"#R"/4UZ'10!X;<_!?Q;XEBD;Q7XR:Y>-#]FB3<Z!\<%LX 'K@9]Z
M])^'OA6?P9X/MM$N;F.YDA>1C)&I .YB>_UKJ:* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K+K4K+JX$3"BBBK("BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ;)_JW^AJA5^3_5O]#5"KB1(****LD**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"2#_ %R_C_*KM4H/]<OX_P JNUG+
M<N.P4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>Z_
M@_&JU6;K^#\:K5I'8S>X44450@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** +=K_ *L_6IJAM?\ 5GZU-63W-%L%%%%(84444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% %^V_U"_C_ #J6HK;_ %"_C_.I:R>Y
MJM@HHHI#"BBB@ HHHH **** "J&K:7#J]D;:9F49W*RGD&K]&*"*E.-2+A-7
M3/+]5\-7VEY<KYT _P"6B#I]1VJA9:A=:?-YMK,T;=P#PWU'>O7B,C!'%<[J
MWA&SORTMOBVG/.5'RD^XJU(^5QG#\Z<O:X*5GV_R97TGQG;W!6*_402GC>/N
M'_"NH1UD4,C!E/((.0:\GU'2+W2Y-MU"0N>''*G\:ETO7;[2F'D2;HL\Q/RI
M_P *&B<)GU:A+V.-C\^IZKFF2S1PQF25U1!R68X KD9?'47V0&*U?[0>JL?E
M'X]ZY74-6O=3DW74Q8=D'"C\*2B>AB^(<-1C^Z]YG7:KXUAAW1:>GG/T\QN%
M'T]:XZ]U"ZU"7S+N9I#VR>!]!VJ?3=$OM58?9XB(^\C\*/\ '\*[;2O"-E8%
M9)Q]IG'.7'R@^PIZ(\94\RS9WE[L/N7_  3CM+\.W^J8:./RX3_RUDX'X>M=
MMI7A>PTW;(5\^<?\M)!T^@[5N!0!@# I:EL^@P.2X;"ZVYI=V(!2XHHI'L!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5EUJ5EU<")A1115D!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 -D_U;_0U0J_)_JW^AJA5Q(D%%%%62%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!)!_KE_'^57:I0?ZY?Q_E5VLY;EQV"BBBI*"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KW7\'XU6JS=?P?C5
M:M([&;W"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M;M?]6?K4U0VO^K/UJ:LGN:+8****0PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img114804231_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 67"<L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BJ]]>V^FZ?<WUW)Y=M;1--*^TG:B@EC@<G@'I7&#XR^ ",C7_\ R3G_
M /B*=FPN=W17"?\ "Y? /_0>_P#).?\ ^(H_X7+X!_Z#W_DG/_\ $468KH[N
MBN$_X7+X!_Z#W_DG/_\ $4?\+D\ _P#0>_\ ).?_ .(HY6%T=W17"?\ "Y/
M/_0>_P#).?\ ^(H_X7)X!_Z#W_DG/_\ $4<K[!='=T5PG_"Y/ /_ $'O_).?
M_P"(H_X7)X!_Z#W_ ))S_P#Q%'*^P71W=%<)_P +D\ _]![_ ,DY_P#XBC_A
M<G@'_H/?^2<__P 11ROL%T=W17"?\+D\ _\ 0>_\DY__ (BC_A<G@'_H/?\
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M!7_0:_\ )6;_ .(H_P"%J^"O^@U_Y*S?_$4>RG_*_N#GCW.RHKC?^%J^"O\
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MS?\ Q%+_ ,+0\&_]!C_R6F_^(I^PJ_RO[@]M3_F7WG7T5R'_  M#P=_T&/\
MR6F_^(I?^%G>#_\ H,?^2TW_ ,11["K_ "O[A>VI_P R^\ZZBN2_X6;X//\
MS%__ "6E_P#B*7_A9GA#_H+_ /DM+_\ $4>PJ_RO[@]M3_F7WG645RG_  LK
MPB?^8M_Y+2__ !-+_P +(\)?]!;_ ,EY?_B:/85?Y7]S#VU/^9?>=517*_\
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M $'O_).?_P"(H_X7+X _Z#W_ ))S_P#Q%%F.YW=%<)_PN7P!_P!![_R3G_\
MB*/^%R^ /^@]_P"2<_\ \119A<[NBN$_X7-X _Z#_P#Y)S__ !%)_P +F\ ?
M]!__ ,DY_P#XBBS [RBN#_X7-X _Z#__ ))S_P#Q%'_"YO '_0?_ /).?_XB
ME8#O**X/_A<W@#_H/_\ DG/_ /$4?\+F\ ?]!_\ \DY__B*+ =Y17!_\+G\
M?]!__P DY_\ XBC_ (7/\/\ _H/_ /DG/_\ $4 =Y17!_P#"Y_A__P!!_P#\
MDY__ (BC_A<_P_\ ^@__ .2<_P#\10!WE%<'_P +G^'_ /T'_P#R3G_^(I#\
M9_A^/^8__P"2<_\ \10!WM%<%_PNCX?_ /0?_P#).?\ ^(H_X71\/O\ H/\
M_DG/_P#$4 =[17!?\+I^'W_0P?\ DG<?_$4?\+I^'W_0P?\ DG<?_$4 =[17
M!?\ "Z?A]_T,'_DG<?\ Q%'_  NGX??]#!_Y)W'_ ,10!WM%<%_PNGX??]#!
M_P"2=Q_\11_PNGX??]#!_P"2=Q_\10!WM%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&FUDSH@-[TE*:2LS="&@TM)2&)1112&@HHHH&%%%% !1BBB@ Q1110 4444
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M^XIQC<.OK6#_ ,+G^'__ $'_ /R3G_\ B*I0DU=(#O**X/\ X7/\/_\ H/\
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MW>7%]FF3=M4L>60 < GK76TW%K< HHHI %%%% !1110 4444 %%%% !1110
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M]I?;O+&/[1\SS=G./O\ ..OZT4*7O/FZ ?3'P0_Y);I__76;_P!&-63^T/\
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M-)N?(P/=J*^.[OXC^)+OPK'H4FJ7K+YSRSW$ERSR3 @!4)/(48/&<'/M76_
M"._G\;3>5=3I8V]L\LT2R$1NQPJ@KT)YS_P&M)8=QBY-@?2]%%%<P'P=7WC7
MP=7UK_PN?X?_ /0?_P#).?\ ^(KNQ47*UD(ZW6_^0!J/_7K+_P"@FOBS0_\
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M% !1112 *2EHI )1110,****0!24M% Q#24N**0Q**#10 4AI:,4AC:*,44
M%!YXHHH ;BDI^*:12 :124[%)C'- "4M)10!][4445(SP?\ :2_YEG_MZ_\
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M -@N3_T;%7>_M#_\B!8?]A2/_P!%2UP7[/'_ "/]_P#]@N3_ -&Q5WO[0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_)+=/\ ^NLW_HQJR?VA_P#D0+#_ +"D?_HJ6M3X'.K?"ZQ .2LTP/L=Y/\
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M.Z^ /BJTLY[F34-&*0QM(P6:7) &3C]W7G.A_P#(P:;_ -?47_H8K[3UO_D
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M?&%S]I\6:CW"3%17)5=['=@H6DV85 I:6LST!**7%+B@!M+BBEH 3%%+BC%
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M>6D=2J@#N<G/T!)X!-?*G@?_ )'_ ,.?]A2V_P#1JT8=>Y(#ZC^)_ANY\4^
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M:A::W9?99Y;OS$7S4?*[%&<J2.H->E445,I.3NP"BBBI ^2O^%,?$#_H ?\
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MC4DJ"5*DCH>HI:*NI4=3< HHHK, KY;U_P"$/CJ]\1ZI=V^A[X)[N62-OM<
MW*SD@X+YZ&OJ2BM*=5T]@*FEPR6VD64$J[9(X$1USG!"@$5YW\7OAK<>-+:W
MU+2=AU:T0Q^6[!1-'R=N2/O GC) Y->GT5,9N,N9 ?(%EX2^(FBZB\.G:3K]
MG<$A6DM%D13_ -M%^4CGUKJ'^!GBB7PS/J5T?.UUY5\NR$Z$[,X8O(QVENA
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MJZZBHG6E-68!11160!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKU72?^0-8_\ 7O'_ .@BO*J*E.QZF,PGUF*5[6/8:R&\,:.[%FL\DG)_>O\
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MOF=)U,.[;K4X_P /P6EUK=M!>KN@D)4C)&3@XZ<]<5WW_"(Z%_SX_P#D5_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=!6I!)TYKEJPNC6E-PD?-.LZ3/HNK7%A.I!B8J"?XJH5[C\4/"W]KZ4NJ6J
MW5N,;5'+#N:\.S_A7#:VA[4)J<;H3%%+24%!24M)2904AI:*0"4E+BB@8E+2
M44#%HI*6D-"48I:2D,*2EI*0!1112$%%%%(84E+12 2BBB@84444@$HI324F
M4C[NHHHK,HYGQ%X=N]7U".XMY(%18@A$C$'.2>P/K5+3_"-_::C;W$DUL4BD
M5B%9LX!_W:[.BE9'9''UHT_9K8****9QA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^;J*DG@>VN)() 0\;%2#[5'6)Z0F**6DI %)2T4AB4E.I*0Q**6DH&)2T4E
MQ:***D8E%+24#"DI:2D 4444@"BBCM4@)12T4#$HHHI %)2T4#/NVBBBLBPH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM%%%8F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 87C;_D0O$7_8,N?_ $4U?'*?<7Z5]C>-O^1"\1?]
M@RY_]%-7QR@^1?I75A]F85=T.QFEHQ2UT&0444N*8!2BBB@!: **44  I:*4
M"F,!2T44""EI*=3&)TI0**6@1WOPNU$Q:E-I+-A)P9,'VKL-4@VN:\?T>^?3
M=8MKE"0V\*3[$\U[AJ:QSQ+-$049001]*WH2L['FXV&JD<=<)UK+F7!-;=RF
M":RKA:[XG ^YG2"JD@J](M5)5Y-)HWB[HJ/41J9Q41%9LTB--,/6GFFFLF=,
M&---IQIM9LU04E*:2I*$HHHH&%%%% !0*** '"E%-%+3$QXIXJ/M3P>*TBS*
M:T)HSS6A;M68IJ[;MR*WBSBDCHM-EVL*Z^6W75O#UQ:OT"%_Q KA;-]KCFNW
MT.;>#&3PXVG\:5:-XF,'RRN>,@,I(8<@FBM?Q18_V?XEO+=1B-6^6L^TM)[Z
MY2WMT+R.< "N/H>TG?49;V\UW<)! A>1S@ >M>R>#/ L.CJE[> 27C#.TC[G
MM4GA'P;;:'"MS,HDO6')/11Z8]:[2,5A4G?1%1)T'2K*"H$%68Q7))F\43(*
M>YP*$'%-D-9;LV(7-5G-3.:K.:M"$5N2*9(:13\](YK1$LA<U YJ5S5=C6B(
M&,:B:GL:S-8U>UT6R:YNG  Z+GDU:0B2^O;?3[22ZNI!'$@R2:\;\8>.KG6Y
M6M;)C%:#C@_>JCXH\4W?B.\/S-':J?DCS_.L!8ZU43*53L1+'FIDB]JD6+VJ
MPD=:J)SRF1QQ>U64CIRI4H7%:*)DY#52G@8I0*=56$I#<4M+24#"D-+0:"D-
MHHHJ"@HHHH&@HHHH&)1110 E%%)2 ****12"BBB@ I*** "BBDI %%%% S8T
MA,1F3UXK5JAI2XLA_O5?/6N:?Q'I4E:""BBC'%0S=*[L.;_5@>]0FII.P]JB
M/ J2RC>OM0BLW1V#:Y"#W:K.H/UK-TR7R=;MI#]T/S0R)/4],1<9J-QFZ1.V
M,U+&=RANS<TQUQ>H3TVUA(TI[LQO%RD646/ND<UQ++BO3-5L?[1TN6W7_6XR
MIKSB6-HW:-U*LIP0:M;$V*C#FF8J5Q3"*86&44N*2D 4M)10,0BMGPO/+%JZ
MQQN0LN%<>HK'KJ/!>GF:[ENG7]VH^0^]2]AI:G6W=MA=R<;#D_2H6Q(@<< ]
M*U64;#GOUJ@\2ID+T)K+J;K5&-8^-Y=$UZ73[_Y['@ M_!4GC#P=;:C:'7-"
MP\9&Z2->WO7*ZWI=YJ/B66.&!BK$?/C@5T/AQ=>\+:F+<H]S9.!O&,C'I6\9
MJUI'GU*3C+GI[_F>>_/&^"&5E/IC!KH?",+7.NI,Y+!0<D\UZ%XH\)S>(;9)
MM/>W@M20SQ[/G#?6LW1-#LM"61'E#2.<DYJ9>[N:TI>TU1JH<G J802-VVCU
MI\=Q:J,"1*<;N$#Y&WGT%9\R.CED^@T6J*<D9;UJ"YE5#M'+GHHJ1GFGZ#RU
M[AJA98X0<<GU-.[>P^5+<I&"2:4!OO-T7TK'U6$VTIC?[V,U?O+SDA&^;U':
ML*ZE9LDL2>Y)JEV0./67W&5/]XU;TRX\IS#(<+)TK/N+I%8A/F;U[50WR--O
M+'=G-:HYW/E>AV##!IO6FVMP+RT2;^+H1Z4_%6;Z-70VKME:6MS#,UQ>"!T^
MXN,[JIG.*2FC.2 CYB <C/%/A<I,"/H:9CG-(0P&2"/>JWV):26IJ'GFDIEO
M(7AQW%/J:::TW"NT[.UE_70!3@:9WI173!<IY]6;D_(LV[[9-IX!JX&V]:S0
M<8/I5Y6WH&]:U3Z(YI12U9<@<[ADTEZFUA*O0\&HT;I5O EA*GTX^M:0]TXZ
MZYBK$U7[>3!%9:Y1BAZCK5N)R,5NT><]#H+66M>VEZ5S=M(1BMFUER!6$XW*
M3L[G$_%OP\)[&+6K>/F$;9,=R:\=KZDN[2'4]-GL[A=R.AP/?'%?-.L:;-H^
MKW%C.I$D;=_0UY\ERNQ[%"ISP*%%+12-A****0Q#12TE(84E+12&)BDI:2D,
M*2EHH&%%)2TAB44M%(8E(:6BDP$HHHI %%%%)@%)2T4@/NRBBBL34**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@XJ%JLR"H&%9LU1$::>E/---9,Z8,;3#3Z;63-T(:2EI#4E"4444#"BBB@
MHHHH *=3:=0@%%/6HQ3Q5HSD/%6H6P1505-&>:V@SDJ(V;=^175Z-<;)$.:X
MVW;(%=#I3LTJ*N22>@K66L3EDO>&>/\ 29+C4["6V0M)<YW8%=W\/?!-CIL1
MFN\-=[023T'TJS#9)Y43S(&FC'RD_P -7X69/NDC->75NTTF>M0DU%*1=GA6
M&Y958,N<Y!J2,5!&,_6K48KG>QT1)XQ5E!4$8JT@K"1O%$@X6H9#4S' JO(:
MA&A YJNYJ9S5=S6J)9&&P](YII/S"AS6B)9"YJ%C4KUCZYK5MHEDUQ.PW8^1
M/4U:(;MJR+7M<M="L6N+AAOQ\B=R:\.U_P 07OB&\,MPQ$8/RQCI5C7M9NM>
MOFN+ASLS\B9X K*6+GI71")RSJWV(%B]JE6+VJRL7'2GK'BMHQ,93(5CXJ54
MJ0)3@,5LHF+D-"T[%+BEIV)YAM%+24F,*2EHI&B$HHHI%H;1114%!1124%(6
MDHHH *2BBD 4AI:2@ H-%%(H**** $HHHI %)2TE !110:!G26*[;=1[9JR3
MSTJ*W&(D_P!T5*:XJNNI[>&:32:W 4H!)I/I3H^7%9)N]IG2XQ4>>DO\Q).6
MJ*3A34K<D_6H9SA#6ASHQ+TY)K+4$RY'4=*TKSO5.)/FS00]ST32;H7>GQ2#
M^$!#]15Z6(2IC.#U!KD/#]_]CN!"Y_=2< >AKL0V#C.1ZUE)%)M:HA$TL)_>
MH2?]@5F:MHMKK'[V+]Q<]@> ?K6\&%->&.7[RC/8^E1JMC3FB]T>:7VAZA9N
M5>!I/>-<BLUH)U.&@D4^ZUZRLD]N"K#=%Z]Z0+8W!RT()]6&*?/W!TWNM4>2
M^3*>D+_E3A:7;_=M)C]%KUP65@#Q!%5B.*)/N*H^E/G)L>11:/J,O2SF'U0U
MH6_@[5[C&!&G^]Q7J8D8<9I-V>IJ>8:1Y_#\/;\X,\T6.^UJ[/3M)M]-LTMX
M<X7G/O5W<!U(H\U.[+^=2W<I(3RE]*0PI_<'Y5#<7\-NN6)/T&:J-JK/P(R%
M/\6.:ER2-8TIR5RXT,*'?M1#W;I5:6Z"G:NY_P#=Y%0&52<M(9!_=:HC?^1E
M8X /I4N12H_,TM/OKRUFWMM\D]5]JMWMA!.IO+=%96Y9<<BL'[9<R*66)?Q-
M:%KJBV5IN4[IF^]$>E:1DK6>QS5*,E+GAH_S&!8>T:_E2N4A/S1A#[C%0ZE&
M2JWEJW[EN2!_#5:>XGUJXW)M7RXP"N<#BDU9[&D'S*]RVEP+B984D4,QP"3Q
M67JAFM[N6VDD4E#@LAX-9]Q="TWMM;*=2@SBN;O-<GO7/EG /\?<U23>XW*,
M'H:=]J,,"G+9/HO6N?N;Z:Y8\[5[8IIB9VW-RQ[FD,6*T2L8RDY$&,4H&6I2
M,&E0?-5(R:-+1+GRKEH&/$O"^U;I&"1Z5R(9HW$B?>4Y%=7%*L]NDJ'(P ?K
M5^AK0DOA8[^$BFXQUI3FK$MLD=I%.),LXR5]*F*:Z[G14G%I:;%5N1Q6A?ZH
MVH0PQ&WAB6-0,HN"<>M9]*HZ_2K>D=#&*YYJY-:R;9L'[IJXPK+!PP-:BMOC
M#>M;15E9''5;D[L2DI:2J;>RW,E!?%+8>M6;9OE93^%5<U)&VR56[5<)=&95
MH7]Z+NOR+Z&K<+XJCT-6(VP16Z."2"\CV3*XZ-R:(FJQ*OG6Y ZCFJ,;9K>+
MNCSZL;,U;=\5KVLF"*P87QBM.VDZ5,D9(Z2VDZ5YA\7]! DM]8@4EI,^>?3'
M2O1;:3@4:[I8UWP_=Z?M!>5?E)[8KAKQZG9A:G+*S/F3J**EN8&MKJ:!P08G
M*_E458'J"44M)0,****D!*.U!I#0,****0Q**6DI#04444#"DI:*3&)12T4A
MB4E+24@"BBBDQ!1114C/NRBBBL34**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH X7XC_P#,,_[:_P#LE<)7=_$?_F&?]M?_ &2N$KU<-_"1SS^(
M****W("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%4=O6JHUW.&NYE6IJ#T+4:)%&L:#"*, 5(*:*44S$T=(A6:]17Y'I77J J@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRKINC7^K^;]AM_-\K&_YU7&<XZD>AJI/#);7$D$J[9(V*.N<X(."*[?X<?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*6DH&%+244#%I*6DJ2@HHHI ?==%%%<QJ%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 <+\1_\ F&?]M?\ V2N$KN_B/_S#/^VO_LE<)7JX;^$C
MGG\0444JHSN$12S$X  R36Q E;'A_0)]<O J@I;(?WLN.GL/>M;0_ ]S=LL^
MI;K>#KY7\;?7^[_.O0;:U@LK=(+:)8HDZ*HKEK8E1TCN:1A?5CH(([:"."%
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M5;3?:+6&;;M\Q%?&>F1FI:K:=_R#+3_KBG_H(JS7*]S0\9UO_D/ZC_U]2_\
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M*2<:DF[Z]BEJD9GC/6M*U:QMA9W'FSQR'_EFRX4CGJ!W K>C_P"2>'_KP/\
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MR(Z[HW7C(]QV-=C8Z?X6T6\&H1:LKO&&*J;A7QD8X"C)XSZUR_BK7$UO4U:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZU@G:YYM:2O:Q=B/%78C5"*KD1H9BC4@/2M&(\"LJ UI1'BL9K0J.YYG\8K
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MK7TE[>2F2:0\D] .P ["MZ-!S]Y[&%6LH^ZMQNIZE=ZO?R7M[*9)I#R>P'8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\$&O-*ZZQ\4V-KX1?27BN#<&&6/<JKMRQ;'.<]QVHQ$7))+N$'9F!_;>K?\
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MR0*24>/&X9.<8/OGO6<HS]DE'<I-<VIN>&=?@U#4I+.QTJ*TMPI<L@&3V&<
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MFPTFF$TI--J2D@IM*:2H;-$@HI**DU2"D)H-)2;+2"BBBI*04E%)0,***2D
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M(HPN,E@.6ZC@8^M5&+D[(#T*BO-/@SXHU?Q9HFJZAK-V9YQ>[$ 4*J+L4A5
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M)'%-*[L!;U#7]&TEPFI:O863'H+FY2,G_OHBI;#5M-U12VGZA:7:@9)MYED
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MFZA?2PX4]>E,%/7I38#Q4B]*C%2+TI,!PIZTP4]:EC'_ ,)^E-%._A/TIHI
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MDM"TE!I*!A1124@"BBBD4%%%% !1244 %%)12 ****!A1110 4444 %%%)0
MM)110,**** "BBBD H&2*<_RC%(G+CZT2<LU0]9V-X^[2;[NQN639M8OI5JJ
M%@W^C(/05=KGJMIZ'?AHQFM1]*/O"FBE'!%2K]367*G9(DF&;>4>E<]<CDUT
MF-T<H]:YZ[7#&F92,N3K49J23J:A-)B0^*62"5986*NO0BNQTCQ)#>*(;LB.
M<<;CT?VKB\\4PG!SG!'0BH:*3L>IK!#N!8'GD<U+ ZP3%&^ZW(/I7GNG>([O
M3P(W/F0]]W+5TUIK]C?(/W@A/_30\UFX=CHC4OI)G1.@C?S8Y F?O#UH74C@
M[(6?'<5GQ2JWS(QD'J#D5/\ :U0?="UGRLUYHVU5RQ]J,O,DPC4]4(YJ2)[1
M/N-D^_-4&O8^ZJ?PJ%[N,] !]*.1CYT]-C9,\?8BH))T ^]6*\XQU:J[W'NQ
MIV8K1-66[B'5Q5*6Z0].:I-< ]A^-1%RW0@4[,I<I)-.#VJE+)FK*6LLYPC+
MFHYM-GCY:A(&UT1FR,<YISRB>W*/U'0T][<KG(J!D(ID&>XPQ%,(_P BK3Q9
M-,\DTR6B:SU6^LN()OE]&YK23Q&Y'[^ R'U'%92Q>U2"+% D:AUV ]+1A^-1
MOKDG_+&(H??FJ'ET%/:@H6XOKNYXEDX]N*J$?4_6K!6HV% F0FHS4K"HV%-&
M;$!V1.WL162.E:=T=M@Q[[JS!TJCFGN.6NA\'Z]<^'?$5O<V\RPQRL([AF&?
MW>>:YY:D'2IJTHU:;IS5T]"4[.Z/0_'_ (PT;Q-.5M]/D^UVS;8;S?\ *R?2
MLZP"W<<'F2B,/P7/:N3C'&*WM(DW1,I_Y9L"!4X3"T\)25&E>R[NYK";E+7J
M=QK/@NZTS0+>]1#,^2TS#^%>QKF-/MYKV^6*VC:1_0"O:=.EL_%7AD%%F6"X
M3R9%SR,>E9^JZCX<T;38XH!%)<1$1@08WC']ZO#P.?59U_J]>F^;FM[O1?\
M >A52G.%)\CN_/JSSR>%X)FAE4I(APRGL:BJS=S?:+J28Y^<YYZU7/%?3V<7
MW)YE.*NVG^ AZ4@ZT&@=:TC.)C.C-:I7]!5^_2CK2*.32BM5)=SFE3DUL3)U
MJY;\M5%1TJ];]::7/-2Z(F4O94G![O\  T)O^/%OK5.(U:G_ ./%OJ*IQ&NR
M&QXE;XB]&:NQ'I5&(U=BYH9@B[%VK2MCR*S8JT+?J*SD,TU^]CVKSCXOVI:Q
M@O>R$)FO1D^^*Y/XI6PN/!+<<K.IKCJ';AG[Z/"S24O:DJ#TA*::?332 2@T
M44 --)2FDI"$HI:0TAB4444,84AZTM%2 E%%%)E(2DQ2T4@/NFBBBN,Z0KXL
M\<?\C_XC_P"PI<_^C6K[3KXL\<?\C_XC_P"PI<_^C6KJPOQ,#ZU\#_\ (@>'
M/^P7;?\ HI:T-8T>PU_2I],U.W6XM)UVNC?H0>Q'4$=*S_ __(@>'/\ L%VW
M_HI:WJYY.T@/B/Q%I,GAWQ/J.EEFW6=R\:/GD@'Y6R/48-?8'@W5WU[P9H^I
MRLK37%JC2E>A<##?J#7R[\6-G_"T=>V;<><O3UV+G]:]@\-:Q<:#^S6NHQRM
M%<16MPL4C'!5FG=4(_[Z&/PKKKKFA%]1%7XB?&\Z+J4VC^&X89[B!BD]W+\R
M*PZJ@!Y(Z$GC/8UYO'\;/'J3%VU>.1<_ZMK2+;^B@_K6#X#T_2=3\:Z;;:[<
MPVVE[R]P\TJQH0JE@I8D<,0%]>>*^H+W6_A[J.DG2KO6/#<M@5VBW:[AV*.V
MT;OE([$8([424*=H\MQF%\-/BU;^-ICIFH6R6>KJF]5C),<X'4KGE2/[I)XY
MR><=UKNMV/AS1+K5]1D9+2V3<Y5<DY(  'J20!]:^-Q</X7\7M/IMVLYTV])
M@N(F!64(_# C@JP'T(-?0WQP2XU/X6QW=CN-NMS#<3#')B*L!Q_O,A_"HJ48
MJ:MLP/-M;^/?BJ^NY#I0M]-MN0BB-97QSR2P(SR.V.*SK3XW^.[>0M+J<%T/
M[LUI& /^^ IJC\-?&]CX'UJ>[OM'2^69 @E4@2P8.<IG@YXSTZ#GL?8M1\<_
M#'XB:6VGZO=FU)"LK747E21G(^[)@J#S@\^O45K)1@[<F@C?^''Q)L_'ME*C
M0BUU2W&9K<'(*YP'4]QV/<'\"?G+QMX_U7QY-9RZI;V4+6BLJ?94900Q&<[F
M;TKZ2\'?#OPEX;FCU?0E>>26+$=U]J,BNAQTP=I!P#G'TKR7X^Z+I6C7^AKI
M>F65BLD4Q<6L"Q!R"N,[0,]:SHN'M+10SDO!?Q0UOP+IUQ8Z9:Z?-%/-YS&Y
MC=F!P!QM<<<5]+^(/$-WI/P\N?$$$<#7<5DMPJ2*3'N(!P0"#CGUKS#X#^'M
M$UCPOJ4VIZ/I][*E[M5[FV25E&Q3@%@<"O1?B6B1?"_78XU5$6T*JJC  !&
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M5[FV25E&Q3@%@<"NARA[*]M!'I_B#Q#=Z3\/+GQ!!' UW%9+<*DBDQ[B <$
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MH^EZ/&\>EZ;9V*2'<ZVL"Q!CZD*!FJQ,H[6U NT445Q@%%%% !1110 4444
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M+4@I@IXJD03QBM/3)-E[&&.$8X:LR.K<><C%6AIV=SW9HY]"\)WT5K<1)9"
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MY@I8#&1UQCK7K?\ PS;_ -39_P"4[_[;7G7C'P3KGPZ\0B6,W'V6.026>HQ
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M+W6E1SL5& 2RJW [=:SJP:J*7=C/G_X3HK_%'00PR/.8_B$8BOKZOD+X2_\
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MC_A#=?\ ^?#_ ,C1_P#Q5>L44?7)]D'LT>3_ /"&Z_\ \^'_ )&C_P#BJ/\
MA#=?_P"?#_R-'_\ %5ZQ11]<GV0>S1Y/_P (;K__ #X?^1H__BJ/^$-U_P#Y
M\/\ R-'_ /%5ZQ11]<GV0>S1Y/\ \(;K_P#SX?\ D:/_ .*H_P"$-U__ )\/
M_(T?_P 57K%%'UR?9![-'D__  ANO_\ /A_Y&C_^*H_X0W7_ /GP_P#(T?\
M\57K%%'UR?9![-'D_P#PANO_ //A_P"1H_\ XJC_ (0W7_\ GP_\C1__ !5>
ML44?7)]D'LT>3_\ "&Z__P ^'_D:/_XJC_A#=?\ ^?#_ ,C1_P#Q5>L44?7)
M]D'LT>3_ /"&Z_\ \^'_ )&C_P#BJ/\ A#=?_P"?#_R-'_\ %5ZQ11]<GV0>
MS1Y/_P (;K__ #X?^1H__BJ/^$-U_P#Y\/\ R-'_ /%5ZQ11]<GV0>S1Y/\
M\(;K_P#SX?\ D:/_ .*H_P"$-U__ )\/_(T?_P 57K%%'UR?9![-'D__  AN
MO_\ /A_Y&C_^*H_X0W7_ /GP_P#(T?\ \57K%%'UR?9![-'D_P#PANO_ //A
M_P"1H_\ XJC_ (0W7_\ GP_\C1__ !5>L44?7)]D'LT>3_\ "&Z__P ^'_D:
M/_XJC_A#=?\ ^?#_ ,C1_P#Q5>L44?7)]D'LT>3_ /"&Z_\ \^'_ )&C_P#B
MJ/\ A#=?_P"?#_R-'_\ %5ZQ11]<GV0>S1Y/_P (;K__ #X?^1H__BJ/^$-U
M_P#Y\/\ R-'_ /%5ZQ11]<GV0>S1Y/\ \(;K_P#SX?\ D:/_ .*H_P"$-U__
M )\/_(T?_P 57K%%'UR?9![-'D__  ANO_\ /A_Y&C_^*H_X0W7_ /GP_P#(
MT?\ \57K%%'UR?9![-'D_P#PANO_ //A_P"1H_\ XJC_ (0W7_\ GP_\C1__
M !5>L44?7)]D'LT>3_\ "&Z__P ^'_D:/_XJC_A#=?\ ^?#_ ,C1_P#Q5>L4
M4?7)]D'LT>3_ /"&Z_\ \^'_ )&C_P#BJ/\ A#=?_P"?#_R-'_\ %5ZQ11]<
MGV0>S1Y/_P (;K__ #X?^1H__BJ/^$-U_P#Y\/\ R-'_ /%5ZQ11]<GV0>S1
MY/\ \(;K_P#SX?\ D:/_ .*H_P"$-U__ )\/_(T?_P 57K%%'UR?9![-'D__
M  ANO_\ /A_Y&C_^*H_X0W7_ /GP_P#(T?\ \57K%%'UR?9![-'E(\':]_SX
M?^1H_P#XJG#P?KP_Y<?_ ",G_P 57JE%'UN?9![-'EH\(:[_ ,^/_D5/_BJ>
M/"6N ?\ 'C_Y%3_&O3Z*/K<^R#V:/,AX3UO_ )\O_(J?XTX>%-:_Y\O_ "*G
M^->ET4OK4^R'[-'E][H.I:?I]Q>W5MY=O;Q-+*_F*=JJ"2< Y/ [5R*^+]"P
M#]NX/_3%_P#XFO8_&7_(C^(/^P;<?^BVKY)3_5K]!710J.HFV95%RO0]5'C#
M0O\ G^_\@O\ _$TX>,-!_P"?[_R"_P#\37E0I:VL9\S/51XPT'_G_P#_ ""_
M_P 33O\ A,=!_P"?_P#\@R?_ !->4TM'*'.SU<>,= _Y_P#_ ,@R?_$T[_A,
M] _Y_P#_ ,@R?_$UY-11R(.=GK0\9^'_ /G_ /\ R#)_\33AXT\/_P#/_P#^
M09/_ (FO)*6CD0>T9ZX/&OA__H(?^09/_B:</&OA[_H(?^09/_B:\AI:/9H/
M:,]>'C;P]_T$/_(,G_Q-._X3;P]_T$/_ "#)_P#$UX_2T>S0>T9["/&_AW_H
M(_\ D&3_ .)IW_"<>'?^@C_Y D_^)KQT44>QB'M&>QCQQX<_Z"/_ ) D_P#B
M:</'/AS_ *"/_D"3_P")KQN@4>QB+VK/91XY\.?]!'_R!)_\33AXZ\-_]!+_
M ,@2?_$UXS3XH7FD"H/J?2E*E"*NWH.$YSDHP5VSV9/''AQSM7423Z>1)_\
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M%5T8%65AD$'J"*R%\(>&5N!<+X=TD3 Y$@LH]P_';FMFBFFT BJJ*%4 *!@
M#@"EHHI 5;W3-/U*,QW]C;749&"L\2N"/H15.T\*^'=/G6>RT'2[:52&62&S
MC1@1T.0*UJ*=V 4UT26-HY%5T8%65AD$'J"*=6+/XQ\,6MQ);W'B/2(IHG*2
M1R7T2LC X((+9!![4)-[ .3PEX;CN1<Q^'M)6<=)5LHPPXQUQGIQ6NJJBA5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+_MQ=F-NW[%/C'ICRZ^8_$3Z=%XJOY=!G9K 7+26DBJ8R%SD8! (QT' Z5]
M?\,\>$O^@CK?_?\ B_\ C=<FO@3X/-<20?\ "9WJR1R-&V^YC4;E.#@F+!''
M!'![9I4I4XWY;@=C\4-0;5O@5'J3C#7<-G.1Z%RC?UKS7X _\E&D_P"O"7_T
M)*]+^*6FVNC_  /.G64KRVML+:.&1V#%E#K@D@ 'CTKS3X!,!\1V!(!-C*![
M\K2A_!E8#Z.U^PEU3PYJFGP2>7-=6DL"/_=9D*@_F:^-]*U'4O!OBB&]2W2/
M4-/F.8;J+(##((9>O<^A'4$&OM"_U"STNREO;^ZAM;6( O-,X15R<#)/J2!]
M37FVNP_"WXB:W#8RWUO-K,X:.*>R9ED;"D\L!M; 7C=GH .N#G0GRIIJZ&8N
MD_M#Z7<*D6MZ)/!N.UWMW$J8/<J<''7(Y_'I70^#+/X5:]/Y_A_3],DO$)?R
M)XSYJ$8Y"/V''(X![UR.K_LY_>?1M>_@XBO(NK?[Z]!_P'CWKQJ0:AX5\2RI
M%/Y.HZ9=-'YL1R%D1B"1ZC([]16JITYI^S=A'V]1573+MK_2K.\:,QM<0)*4
M/\)90<?K5JN(9YQ\<=4ET[X:W,<14&]GCMF)/.TY8X^H3'T)KR;X#:/;:GX^
M>ZNHUD^P6K3Q!N@DW*H..^ S'V.#VKU'X]V+7?PV,PW8M+V*8X]#NCY_[[%>
M9_ #48;/Q]<6TTB(;NR>.+<<%G#*P _ -^5=E/\ @.P'TG?65OJ-A<65U&LE
MO/&T<B,,@J1@UP>C?!7P?HM];7L<5[<7%M(LL3S7)&'4@AODV]",UZ#++'!"
M\TTBQQ1J6=W.%4#DDD]!7D.E_M :;J&IPV)T"^\R><0P^1(LA?+ +P=O)STK
MG@IM/E [SQ?X+T'Q?;P?VZDACLP[(Z3&,)G&XGMT4=>G-<;HWB/X9_"ZRNM-
ML-;-S)+-YLGEC[0['  7>BA<*.Q/'/>N<_:#\47T%W8^&;>5X;62W%U<;&QY
MV6954^H&TG'0DCT%<Y\-?A OC32O[8U#4WMK+SC&L4" R/C[QW'A?0<'_':$
M%[.\WH!7^*_Q(TKQT+*#3=-FB6T=B+JXVAW! ^4 9P,C/7TXKKOV;F8KXF7)
MV@VI SQG][_@*Y[XN> O#G@?2-*CTHSM>W$K[WGFW.R*!S@  <D=JZ#]FW_F
M9O\ MU_]K5I/E]@^7;_@B*'[1G_(?T3_ *]7_P#0JUOV==(M/[/U?66C5KOS
MEMD=E&40+N.#U&2PS_NBLG]HS_D/Z)_UZO\ ^A5TO[.W_(HZK_U__P#M-:EO
M_9T,UOCO9PW'PVFN'C0RVUQ$\;%<E<MM.#VR#7D_P&=E^)2 ' :TE!]QP?Z"
MO8/C?_R2W4/^NL/_ *,6O'O@1_R4R'_KUF_D**7\&0CZEHHHKC&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;\!507+KP#3S=6=TNYF\EA_#US5=F@W8$F??%9\O<[XU(VT)Q=/D9K8L=3"
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MO0]1Z5Q4\;2Q%50Z?FSV<1DF+P&%E6=FWO;HNIGBBBBO3L?-IA1110(*.U%
M&2!0!IVW$"8]*N"JT PBKZ"K K%VN=J;:39(M2#I4:U(M0S:*ZEB/[\=,U,;
MH3]*DA'[U?:H]0Y0U!IT.8B_U3 _WJ>*:!B9T_&G+42'#8-S)R#BIX]4*$+)
M&-O=N]0,.*K.*DNYU5E<)*H>)LCT/6MFWG[5YY#/+;2"2)BIKIM,UJ*X 2?]
MW)TS_>J66G<ZZ*0$=:G4YK+BD*@9J[%+D=:EE6+6.*:R4Y#FI,5((JRV\5U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@!*0]*6B@!E%*:2D AI*=332$)24ZFF@84E+24@"BBBI&?<]%%%<)UA1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCP,5&35(VD--(.6H-&<*35HQD*G+,?2G4B#$?O3A5.2BKLSC!SDHH45/$*B
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M[GHHHK@.L*^'=<_Y&#4O^OJ7_P!#-?<5?*VJ_!_QY<ZQ?3PZ%NBEN)'1OM<
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MAOQ]9ZGJVD_9[...56D^TQ/@E"!PK$]3Z5]!5GB&G.Z ^%K_ /Y"-S_UU?\
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M;IG^$^M>5:]X;GT2[(P7MV.4?V]Z]='!J.]L8-0M6@G0,K#H?6FG84H*1XS
M G.P$U9W2/C)./2M#4M&DTJ_>W<$IGY7QUJ..#VJQ)$4331_<8BM*"[N, ;
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M4@$-)3C3:0A*2EI*!A24M)2 ^YZ***\\[ HHJEJ>L:=HML+C4KV"UB)VAI7
MW'T [GV%&X%VBBN'\9?%30_ ^L0Z9J=KJ,LTMN+A6MHT9=I9EP=S@YRI[>E.
M,7)V0'<45@>$/%UAXUT4ZKIL-S% )FAVW*JK9 !/"L1CGUK?H::=F 4444@"
MBBB@ HHHH **** "BBB@ HHHH **** "BN,\:_$O1O EY:VVJ6U_,]S&9$-K
M&C  ''.YUJ]X+\;Z;XZTZXOM,@NX8H)O)87**K$X!XVL>.:KDE;FMH!TM%%%
M2 4444 %%%% !1110 4444 %%%% !1110 4452T_6-.U9K@:?>P77V:3RI3"
MX<(^,[<CC/\ *@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%<#XM^+F@>#=<;2-1L]2EN%C60M;QQLN&Z<LX/Z548N3L@.^HK%\*^)K+Q?H
M$.LZ?%<16\K,JK<*%<%20<@$CMZUM4FFG9@%%%%( HHHH **** "BBB@ HHH
MH **** "BBB@#S;X@_\ (?@_Z]5_]">N3KK/B#_R'X/^O5?_ $)ZY.O6H?PT
M<T_B84445L2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5*E15*E(:)TJ=:@2IUJ&,F6IUJ!:G6
MH8R=.M3)4*=:F2H8R9>E3+4*]*F6H8R5:LV\KP2+)&V&%5EJ9:EE%[Q)>)=^
M!-?(X<:;<;E]/W;5\K)_JU^@KZ6U");C2;VW<D1S6\D;X."592#^AKP#6]!G
MT.X$;Y>W;_52XZ^Q]#6F'2C=&5;74RN]%% KI,!:***8"BEHHI@%+VI*EA7=
M,@]Z&[*XXQ<Y**ZFQ:)LMUQW&:FSB@#: !VI'/&*^,JS=2HY/JS]BPU)8;#1
MIK[*'NW^BL/:LL_>K18_Z.WTK.?[M.!PU^Y8M^9 *L2C)%5H."K5>E ^6E+<
MNG\)F3#]Y4UG<M:SAP 1W!'45'/_ *PTU.35]#G:]XTY[=;E'N877).?+[U0
M(P:DB=HSD$C%+<ZB[*J^3$,=P*E7-6TE=C!3PV*E@DLW0>9OW=\4+?"WG_=Q
M(Z]MXHU*C-)7+=G9AE^T3,$B7G)[U0UK43?G*KMC7[B^E1W=W+.[$L50G.Q>
ME4V^92#3C&VIA5FY:%91FC&#4FT"FXYK0Y+$B=*DS@4ZWM9YP3#"\@'7:,XJ
M26RNHXR[V\JH.I*X%(U6B*AYS30,&I /2FXP:9#0X&IHYI,X,C_G4('2ITB=
M@75257[Q':DS2-RW;17%VY6)7E<#..M2'2[H'+QE2>QK3TU2VBJ;4_Z1O.[9
M][%4IUO0Y,CR9SW-9.6ITQ@YK<@DTF^.-EN[CV%5GC:(E'4JPZ@UH1/?9PDL
MI^AK;,<#:/)]OB".!PV,,U'-T%*#CJ<LAQ'5=QN.:ORBT^[$7V^]7-.TVTNC
M()3)A8RP*^HIJ2'.#Y;F$ <U9B.9!2%1C/%$'^M%4]B$N4[KP-9"ZUAF./W2
M;QFO3(R5+2?@0:X'P"C+=S/C"F/&:] /R0\=Z^-S:HWB?\*/!Q\KUFCC?'RV
MLMO;D0K'* =NT8KSR-_+%Y'V9 !7HWC-E26QPN]R#A>M<1>0V]QJ415UC)/[
MW!PH%>YE<Y2H1<MST\OBXT4^AB11&16&?NC-5&7[Q%=$T-K9K.YE5]P*J%.:
MYYN,BO4BSNJ6967DT]N4(IBC#^U2OR,BM#F2T*>WYJ:4ZFIMO)IP0%>:=S'E
M*ZC-2Q0//.L<8R['"@4U5P:O:85&HQ ML);ACVH;",;FDSI86RVT&5F)R[ \
M_2J.H7+3!%9]V%YSSBKFI*ED7=)4ED<]0<C%4=-L+G6-0CM+9"\TAZ"LXJ^I
MTU9QA'EZ&;'$\\RQ1(7=CPH[UTEGX$\27,(D&ESJIZ96O;?!_P /].\.V"&X
MACGO&&7=AD*?:NR "@ # '0"NR-%M:GS=7->65J:/EZY\#>([-3(^E7!3N0O
M2N>N4>*4QR*5=>"#VK["90ZE6 *GJ#7!^.OAW8:_8/<6<2P7L2DKL& WUI2H
MM:H='->9\M16/G93TS3I1P*)K:6SNY+>=2LJ'!4T.<@5B>NG="Q##K73>&=1
M2TU$Q2R*D+\DGUKFD]:#DG=GFM*51TYJ:Z&.*PT<11=*74Z_Q3KSSJ+"-V"I
M]X@\,#7'N2QYJ0.\G+L2?4TC+Q2JU/:5'-]183"1PU%4X]" ]:!BI"N12%<
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M!I6JW#SZ),ZQ_O7)^R9.-RYZ)ZK^(YZVZ":O!W ^HJ9++'!$TLTB1QJ,L[G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ;/JDV$!6(?><]A746^D6%I&%$*RL/XV'-6XTCMX1#"H5!14-DWN*C"-=B*
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ME-)2 2BBBD,^YJ***\\[ KX>_P"9A_[>_P#V>ON&OAN:18=;DE8$JER6..N
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MGAJ0#YF%RI/L/*Q_,U9_9QM$73]?O,Y=Y88NG0*&/Z[OT%0?M)?\RS_V]?\
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M_KU7_P!">N3KK/B#_P A^#_KU7_T)ZY.O6H?PT<T_B84445L2%%%% !1110
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M>.HGL_LNL69N!C#.@#;Q[J>*R<)+EFE>R*33NB'X>PS'5;F8!O($)5CVW$C
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M #%05**%5&(VG'M4BQ-WK7V\.NAS_4ZS^%77=;?\#YBHNXX[5,2"0H.0*9D
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MY:M<&[UN^N,Y$DQ85Q/61Z>%C97*=%+WI*#L$IM.--H&%(:6BD(;333C332
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MFEO6N%:V9F7:41<'<H.<J>WI7SG\4/\ DIFO_P#7T?Y"OL2OCOXH?\E,U_\
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MV?+^8*X'L2RGZ_6O>J^:/V>/^1_O_P#L%R?^C8J^EZQQ"M48!1116 !1110
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MTX+Q6B1QR;;NQ@%."YIX'M3@O3@GZ"J1#$"U(BY. ,^PKHM$\%:MK!5U@:*
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M QC<V>E8OQ#^$G_">Z_!JG]M_8?*M5M_*^R>;G#NV<[U_OXQCM6D:D55<KZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ';-=LL Z]&S=FSNP^ YJ5Y:-GH$<K #YQ^=)=3E;9V)R0./K7$QZK.B_*Y
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M.B:G]JN8XC,R?9Y4P@(!.64#JP_.O#OVA_\ D?[#_L%Q_P#HV6O3/AY\)/\
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MH **** "BBB@ HHHH **** /-OB#_P A^#_KU7_T)ZY.NL^(/_(?@_Z]5_\
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M****9(4444 %%%% !1110!GZZYCT&\9>H3BOG G?=S[NI<FOHKQ/)Y/A?4)
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MW+:WH\PY^ZK*1G\]H_&LXIQK:]P.:_9P_P"0CX@_ZY0_S>O6OB,P7X<>(22
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M&<'!V8!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \V^(/_(?@_Z]5_\ 0GKDZZSX@_\
M(?@_Z]5_]">N3KUJ'\-'-/XF%%%%;$A1110 4444 %%%% !1110 4444 %%%
M% !6EJ&OZGJMNL%[<^;&K;POEJO.",\ >IK-HJ7%-W8[CD=HW5U.&4Y!]ZT-
M0U_4]5MU@O;GS8U;>%\M5YP1G@#U-9M%#BF[M!<U+/Q%JMA9_9+:ZV0<_+Y:
MGKUY(S67110HI;(+DUI=SV-U'<VS[)HSE6V@XXQT/%6-1UB_U9HVOI_-,8(3
MY%7&>O0#TJC11RJ][:A<*U;+Q+J^G6J6UK=F.%,[5\M6QDY/4>M95%#BI:-
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MA\2:PU\EX;US.BE%8JN #U^7&/T[5E45/)%N]@NR]<:O?7>H17\TP:ZB*E9
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MB.0.QJ]JEP?LD7'!P33YM#%T[35M+E2]NI61$V(J*,*0,$BJ<5]+;ME51O\
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M]O\ _$UZ311]:J![.)YM_P *^U;_ )^++_OM_P#XFC_A7VK?\_%E_P!]O_\
M$UZ311]:J![.)YM_PK[5O^?BR_[[?_XFC_A7VK?\_%E_WV__ ,37I-%'UJH'
MLXGFW_"OM6_Y^++_ +[?_P")H_X5]JW_ #\67_?;_P#Q->DT4?6J@>SB>;?\
M*^U;_GXLO^^W_P#B:/\ A7VK?\_%E_WV_P#\37I-%'UJH'LXGFW_  K[5O\
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M%%%><=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8OC#_D2=>_[!UQ_Z+:OD]/N+]*^L/&'_ ").O?\
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M",^F/>I%@SUY^E(I(B ]!DU*D1)^;GVJPD&/I4RHJ]!18T5D1+'P,\#TJ3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:)9;M+LQ8CD/[K_T&M(CH0<@\BL*K=I=>6/+<_*3U/:O(S++O:KVM->]^?\
MP3ZOAW/GA9K#8A^X]GV_X!H%0PP:J2QLC>U7>,9'(/0TA /7I7S2;B]3]"JT
MHU8W0EK;B3;N0L/I78Z-H]FL/GRP[CG ![5:\/WUC)IRP0Q(C)R589-;+ SQ
M;$08'/ KZ+ 8.FTJK=T?EF?YWB8RG@^5PDNO=?\ !*-Q8Z=/$WG6JNP0[>>E
M><W5IY;'![FO5[;3Y'BF98R0J')].*\OO7^<_4UAFWLHR2A:_4[N#YUIQG[6
M3:TM?YF?L(I.14V^C(KQ[GW/(B($TH-28!I=@-%Q\HP$T]1NXS08\=*;R*!H
MD:)?2F %#Q2AN*?D&EJ.R').1P>:E$P/05!@&C81T-(I,L^:<8I_G-MP>15/
M<PZTX24BKEC;"WWD!-2101,XVC;542BI8Y0&!S2>PFDT>D>" JP749?<21M%
M=3&<.*\R\/:H+*^27DC.,9]:]*!Y4],@&OD,WI>SK*HNI\MF%%PJM]&3S_,0
M0*S]5LDU+298'. H+_E6@S;H1QT-5S\Z21Y^^I7\ZXH5.2NJBZV9P4VU9KH>
M.W*(K<+WJIOP>!6MK=B]C?26SGE#UK$96S7W%*5XW/M*,^:":)_.:CSS5;!H
MP:U-;EKSZ:9S54\?Q"D&"?OBBPN8L&8TW>34?RC^(4PO@\&BP<Q; "\D\TXS
MXJCYA]:-Q-.PN8NF4GO49EQUJL6P.M,+C-"0.=BT)=U-:4 =<U6W\5&6]Z:B
M0ZA9,_M3#.:KEL]*0*35<J,G5?0E:=C41D9J>$]34L>Q.HS3T0K2ENR (QZU
M+';Y.6Z5*H+'.,"I!Q42F=-'#)^](  !@4R658D+L>*6218U+,<"L:ZN6N']
M%'05U8+!RQ$KOX4<.=9S#+Z?+'6H]EV\V,N)VGD+$\=JBHHKZB,5%*,=C\PJ
M5)U9N<W=L****HS"BBB@ HHHH&%%%% "T444$A1113 **** "BEQ10(2DI:*
M!W$HHQ12* F@'FDH% #LTN:;13N18E5B*?YIJ#=BD!YI\Q/)<T(9RISFM6SU
M22!LHV*Y\/BI4D]ZT4C)Q.FEMM-U08D403'K*.:R;SP[=VJF2(>= /\ EI_]
M:H8[EE/!K3L]7EA8'=D>AY%)Q3V&I2CYG/ <X((/N*>*Z]X],UD'ST$=P>D@
MX _"L74?#UY89=/](@')E0< 5#36YK&:9FJ:>"*@5A3P:1=R8&G \5$":>,F
MBP^8F4U(IJ)%)J55Q][BBP^;N2 U,F3T%1*T0_Y:#Z5(MS&.-A)]15*#8G6@
MMV3JI[\586 XSM!'UJH+J0<+@#W%.B2>[G$<89Y&Z!:M4>K9A+&).T5<L9A4
MX$A9O[@%=AX<\-%F6ZO(?+'54/.:CTG0X=%CCNKV+S9WY5?[OUKI+-]2DG0L
MF8&/&!T%<N(J0A'F<DEW;M]QI"M+F49W;[);>IKHH50J@ #@"IT%1JN#BIT%
M<39Z)*@JQ&*B1<58C%9MC)XQ5E!4,8JP.!64BD-<U6<U,YJM(:J*(DR"0U4D
M-6)#524UO%&$F5I#55SS4\AJL>6KHB<LF)116/XA\2V/ART,MRX,K#]W'GEJ
MHD7Q'X@M?#NF/<SL#(1^[CS]XUX)K&KW>O7[W=U(6+'Y0>P[5+K>MWGB+4FN
M;N0[2?E7L!56.(9Z4N3FFK]#KIS5.E)K=Z#8H:O10^U.BAZ5=CCKKA$X9S$B
MBQ5I%Q0B5,%Q71%'/*0BK3P* *<!FK2,I2 4X"@"G@51DV %/49-(!FID6F3
MN.1:L(M-1:L(M2V4D*BU8C3FD1,U9C3FH;!L=%&35^"+..*9#%TK2MX?6LY,
M:)K:''45J01=^.!G)J*WASBN2^('BE=+LFTJSD_TJ48D*GF/ZURU)WT1T4*3
MF[G+?$#Q1_;%_P#8+60FS@/4=V[BN*I3G)).2>2?>DI)65CU(JRL@I*6DH&)
M2&G&FFD,2BB@T@$-)112 ::*#24#"D-+2&D E)2FDI )24M)0 TTAI32&D E
M)2TE !33UIU--(!*#12&@!*2EI*0C[EHHHKSCM"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCX'%>I&!RRJ#8XL591*5$Q4H6MXQ,)3$"T[%*!3@*T2,W(0"G 4H%. IF;8
M4X"E"U(J4R05>*G1.*$2K")4ME) B582.A$JS''FI;!L6./-788NG%)%#[5H
MP09Q6;D-(6"#IQ6I!#TXID$/08HU?5[3P]IK7ETP!QB-.[-VX]*YZD[&E.FY
MLH^*O$D/AK2V8$-=2#$:=\'O7A]Q<37ES)<7#EY7.2Q.:N:UK%SKNI27MRQY
M)V)GA!Z"LZLHJVK/5A!15D%)2TE4:(.U)2TAI, III:0TAB4=J*#2 ;0:*#2
M :>M)2TG:D,*2EI#0 TT444@$-(>E*:2@8VD/2EI#2$)VI*6DH *8>M.--I
M%(:6D- #:*6D-(#[EHHHKSCL"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[D(ESVI_F8Z5 $(I0"*5D6IRZDXE-(92:B!Q2@TK(M38XMGM3U4&F@#UJ50
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M/I3EU!OXU!'L*E6_MS]Z%OSIJ<273J(@\NFF,U?5[20?ZQ4]C3A:B49B8/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI0N:3)IP>@:L."<48I/,%(9!2U*O$7%!8TT.32X)H%>^P;J/,(H*F@1D]J-
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M $--I324@"FFG4TTA"4E+10,^Y:***\X[ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?&'_ ").O_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;4H=ORAMWO58ZE*&R%7'O5.BNF&78:'V;^IYM;B#,:V]1KTT)'N)9&)+D9[
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MI8\B(=)EX8UP\LDD\IEF<O(W5CU-1RREN=U.@H[FQKOBG4M?F+32F.$=(T.
M1[BL3  P.!2TE79+1'0A****"A*2BBD 4E%% !2&E[4VD-!1112&)24M)2 2
MDI:2D,0TE*>M)2 0TAI324#$-%%':D E)110,2D-+24A#32&E-(:3 0TG:EI
M#0 E%%(>E #3UHHHI (:2E-)2$)24M)2&?<U%%%>>=@4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@X[^6*7[/".1!$/HHH]L+V*ZL\4C\+ZW=H!%8LQ/3FKUO\/]9E_UT1B_6O8
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MK6?@>E<E;38(K:M+CH,UC.%P3>Z*6OZ2+>;[5"O[J0_-CUK)6&N[C*7$+12
M%6&.:Y^XTTV=P8\?)_"?44J=1KW9%35_>1E+;D]JLQV>:OQV_3BK4< ]*MS(
ML48K,#M5Q+8#M5I8\5($J'(5RNL0':I GM4PC)[5(L!/:I<DAI-E<(33UBS5
MH6^T$MP!R2:Y[5?&VCZ0S(I^U2+P5C/0UFZG8UC0E(W4@)J&_P!2T[1X]]]<
MK%QP.N:\RU7XB:K>AHK7;# W&"OS?G7)S3S7#EIII)">S-FCEE+<ZH8>*W.]
MUKXE2R;H=*B\H=!/G.?PKA;R^NM0G,]W,TDAZG-0?2BJ44MCIBDMA.]%%%,
MIM.--I,H*#124AA2444@$HH[44@$I*6DH*04E+24F 4AHI#2&)12TTT@"D-+
M24@$-)0:2@8&@T4AI )24M(: $HI33:0"&DH-%(!M)WI:2@ I":6FGK2 2BB
M@T (:2BDI" TE!H[4AGW-1117GG8%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ(#CI.P4FN@1H[A-\$BRK_>0Y%?'/E%7#KD,.A':MO3?&7B322JVVJ3B(?\
M+//!K%T.S-%574^IW0CJ,5"RUXKI7QOU"WC$5]812#_GH6YKM-,^+7AB_C03
M3R13GJFS@?C64Z3<7&2T9HIK='7K&=YW"ED(487DU#9ZMIU_")K>\A*GIN<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\8?\
M(D:__P!@ZX_]%M7R:GW%^E?67C'_ )$C7_\ L'7'_HMJ^38_N+]!7?A/A9S5
M]T.I:2BNLP%I:2C-,!U%(*6F HI:;2TQ"THI**9(M+244P8ZDHHIDBTM-IU-
M$A2BDHI@Q:***HAA1110&Z"EI*6F0%%%% ,*Z;P%+Y7B0DGK$17,UL^%I?*U
MZ$^I I35XL#U:Z7K6/<#DUNWBX8UC7*\FHINZ.![F1,.M9\PZUI3CFJ$PZUT
M(2,V4=:K,*NRBJC"J!;D#"H&'-6&%0N*DZ%L5VZU&>M3,*B85+ B84RI#3#2
M*0E)2TE0S:+$-)2FDJ6:B44M)4C"BBDI#"DI:*!CATI#0O2E-/H9K=C324M)
M2-$%%6;33[N^D"6T#R$^@IMY:36-T]O.NV1#@BE87,KV(****104444 %%%%
M !24M% "4F*=24 ,*TPI4U(10T-,K-'4;1>U6R*0K4V+N46BJ(P_A]*T2E,,
M=38=RE%)<6[[HII%/^\:W+#QWXGTL@6NHLJC@@C/%9IBJ,Q4G&Y2DSN;'XQZ
MS;L#>1&Y ZC.,UT=O\;;*;'GZ48?7+YKR PTPP#TJ'2B4JC/H"R^*'ABZ'^D
M7RVY[ @G-:D7C+PY<?ZK4T;\*^9S;C^Z*-DB_==E^AQ4^R'[0^J;?4+*\8+!
M<(Y(R!G%6"H_O)_WT*^4!->)]R[N%/M(14\>K:K$H5;ZXQ[R&E[-C]HCZG*C
M^\OYBFE?<?G7S*/%.N*H O'Q[DU<C\>^(XT"+=+@>HHY&/G1]&E?<?G2;:^=
M/^%@>)/^?E?RJ[!\5/%EO"L23VY5?[T>31R,.='ONVC:/4?G7@-S\3O%-[&$
MEGA&#D;4Q5(_$#Q*#C[2G_?-'(PYT?1FT>H_.C:/[R_F*^;9_'/B&X3:]T /
M]D8JI)XGUN5"K7D@!]&-'(PYD?3NP'^)/^^A5.;5=/MBPFND4KUYKYBEU/4Y
MP ]]<C'I(14!ENV^]<SMGU<T<C#G1]*2^-/#<!_>ZHB_A61>_%+PS;Y^SW:W
M&/0$5X 8W;[S,?J:06X_NBGR"YT>R7/QJMU;R[32FG=N%P^*]0TNZ;4-+LKN
M6(PM-&':,G[OM7S+X3A7_A+](#*"#<KD$<&OIG6,KH^I>7\N+:3;MXQQVKXC
MC":<J.&[N]_P._!/24C-T0ZY_;>NC4\_V?YJ_8#Q@ICG%<O\6]=U+0++2)M,
MG,,KR-\PYKI/ DDDO@/2/.=W?RSEG.2>37EWQ:U.>\\3G2W_ -1:@,GU(KAR
MK#?6<Z<9I-0NGYJ*Y=C2K4Y*%UHV=!'\8[:+PS!<FU\S52WEO!NYX'W_ ,:\
MBU.\FU;5;F^E+9G<N4)R!2" 9SCFGK%CM7W& RG"X%R="-G+^K>AYM3$3J:2
M95$'?%/6'VJX(\4X1UZ=C!,K+%[5*L53!,4\+32%<B$=2!,4\"EQ5)";$"TX
M"BG52(%%.IHIU6C.2%%.!IM**TBS"2)E;FID;FJRFI%-6F9%Z-\U.K521C5E
M#5ID25T7X9,$<UHP2]*QD;!J[!+TIM7,5H[&_;2X(YK:M)\8YKF89.G-:EK-
MC S64HC78ZR%TEC*2 ,C#!'K7F?BC0SHNI$IS;2G*M[GM7=VD_ &:L:EI\6M
M:8]M(!Y@&8CZ-7.G[.7-T-Z;NN5GDBU8BZBF3VTEG=26TH(>-MN?6I(>HKN6
MJ,9[FK:CI706 Y%8-J.E=#IXY%93#J;CG;I-X?\ I@W\J\#!SDGU->[:A)Y.
MAW3>L3#]*\(3[OXFN6/Q,[\,O<'4E+251TH*2EI*0!2$TM(:12$HHHI#$I*6
MDI %)2TE "&BEI#2&)1112&)1124@ TVE-% Q#24M-I %(>*6FFD E%%)2&!
MI#2FD- (2B@T&D VD-+2&AC$I/:EI#2$(:2@T4 (>E-IQIM( I#TI:0T"$I#
M2TVD,*2EI*0'W/1117GG8%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &+XQ_Y$C7_ /L&W'_HMJ^38_N+
M]*^LO&/_ ")&O_\ 8-N/_1;5\F)]Q?I7?A/A9SU]T/HI*6NLYQ:*2EI@**6D
MI130!2TE**8A:*2EH)8M%)2TP%HI*6F2PIU)15"%HHHIB%HHHIDL***6F(0T
M444R6+124M @J[I$IBUBT([RJ/UJE4ENVR[@?^ZX-#U0(]TN\,21T-8UR*T[
M:3[1I=O-UWIFJ%R*QH['#-6D8TXYK/E'6M.X7K6?**Z42MS-E%5'%7YAUJDX
MK1 5V%0N*G8=:B8<5+-H/0KL*B:IWJ%A4E$)%,-2-3"*12&44M)4,TBQ#333
MJ2H9LA*2EHI#$I#2TAJ2@HHHH&*M*:1?O5JZ3HEQJLHV_NX ?GE;H/IZFJ2O
MHC*<E%W>QF(AEE2-?O,0H_&NZLO"VGZ;&LEZ?M5R1DI_ OL?6MC2]*T2R,<<
M=HLI!^:649)/J/2K>K6WERDK]UN0?:MZ-'W[5$>7B\PO#]RRA'.%PJ*J(.BJ
M.!6-XSTX7-G'J42_O(_DEQW'8UJ1QEF '4U?CMQ/&UK(-R2+M;-=F(I1<;(\
M["8B<*JD]3R.BKVL:9+I.IS6DRE2IRN>Z]C5&O(/J@HHHH&%%%% !1110 44
M44 %%%% "$4F*=24%(3%)MIU% #-M-*5+BDQ18+D13VIOE@U/BC%*P7*QBII
MB]JM;:3;18+E0P^U-,-7-M(4I<H^8I>32>35W92;/:E8=RGY-'DU<V4OET6%
M<IB*E>WR-P%6PE/5.V*I1N0Y6U1F^3[4OD^U7GAVGIQVI/+J>4T4KHI>33A#
M[5;\L4NRCE"Y4\GVI1%5K92[118+G9?"?2K:_P#$T[W*Y-O$)(_9LUZIXIUB
M31M.@G2-)//N4@=7'!5C@UQOPET9XH[C6BW[N4&$+[BNXU-=,U2\@T2[<_:0
M1=(F.,+WK\WSNM&KG:4O>A36OE9:GKX:+CA^S9IB*&T79#$L<,:Y"(, #KQ7
MS]XXU&VUKQ?=WMIN\D@*-PYR.#7O>I7]OIUA<75V^R%4*D^Y'%?-4F&GE8=&
MD8CZ9KKX+P_-.KB9+R3_ !?Z&>8SLHP(@E+MIX%&*^_L>7<;MI<4ZB@!,48I
M:* "EHHIB%%+3:7-,ECJ44T4M4A-#J7-(.E+5(QDAP-/!J.G UHF82185JL1
MM5-34R-5IDEY6JQ&]4D:IT:K3,IQZFM;R].:TX):P89,&M*"7IS2:(6IT=K/
MTK<M9^A!YKD[>;!'-;5I/TYK"<1IE3QEH@NH%U*V3]ZGRLJCJ.YKB8.2*];@
M=9(VC;E'&UOI7GNN:0=)U4JJX@E.8L>E*A.W[M_(TFN9<R$M1TKHM/'2L"U'
M2NBL!TK29F2^)I/)\+S-G&>*\4 P,5[#XZ?R_!KGUE KQZN:.[/1H? @HHHI
MFXE%%% !FDH-)2*"DI:0TAB4444@$HHHI %)FBDH&@HHI*0PI#2TAI -HI:2
MD,0TE*>M)2 0]*3-*324#$HH-%(!M%!I* "D/2EI#2 2FTZFTF E)2TE "44
M4&@!IZTE%%( ---*:0TA"4E*:0T, I*6DI#/N>BBBO/.P**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!B^,?\ D2-?_P"P;<?^BVKY+3[B_2OK3QC_ ,B1K_\ V#;C_P!%M7R6
MGW%^E=^$^%G/6W0ZEI*6NLP8M+244"%HHHI@+2TE+3 6EIM+3$+1113)8M%)
M2T +1115$BT"B@4"%HHHJ@"EI*6F0PHHHIDA2TE+3!A11102=W\-KK9+<VG>
M5MV/I7;W*]:\O\#W8M?%,#.<(5(->JW*]_QK!Z5##$+9F%<+P:RY1UK:N%Y-
M9,Z\FNB+.8S915&45HRBJ4HK1#91<5"15AQUJ%A381W('%0L#5EA4+#BI9NB
MNPJ,BIF%1'K4L"(BFFI"*C-(I"4E+25#-4Q*2EI,5+-$)1WHHJ2Q****12"K
M%C<O:744\9PT;!A5:G+UH0IKW3Z-TJZM=0TBWO;155)4!( Z&K:M@UYM\+-;
M&9]&F;[W[R')[]Q7I##!K\8S_"U<+CIPFV^J;ZI['TV#J1J44T7P1+#CN!Q5
M)UP2*G@DP5([=:6YC&=PZ&O/J?O*:EU1M'W96*Z'D5POQ3T+[9I<>JPKF6V^
M63'=/7^5=P.M27$,5U:R6LZAHI5*,#WKHRG&RP6)C671Z^G4C$TE4@XGS%16
MEKVDR:+K5S8R@YC<A3ZCUKH_!W@&XUUEO+[=!IX/7^*3V%?L=?'8>C0^L5)6
MC:_KZ'SD:4I3Y$M3(\->%-0\3782W39 I_>3L/E4?U->WZ#X>TSPW9""RCS,
M1\\Q^\Q_PJY:VEOIMHEK90+# @P%4=?K4G)-?F&=<0UL?)TX>[3[=_4]O#8.
M-)7>X9)JKJ-DMS!OV_O(^0?6KJ)GM4FTMN1 "YZD]%KAR>O6P^*A5INUG^'4
MTQ=.%6E*G):,XU+-I)2VT #FN'\4>$YYKV6\MKI9RW)C;@CV'K7HNLI<6:[,
M#8?XE[US$CN[\YK]PPW+BH*HI7CTL?G4ZL\%4<(QL^MSRF2-X9&CD4JZG!![
M4VNM\96 18+T  L=C>I/)S^E<E64X<DG$]RA656FI]PHHHJ#8****0!1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,7QC_R)&O\ _8-N/_1;5\EI_JU^E?6GC'_D2-?_ .P;<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH Q?&/_(D:_\ ]@VX_P#1;5\E)]Q?H*^M?&/_ ")&O_\
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MS1114@(3Q332FDH&%(:6FFD 4&C-(:0"4E+2'BD,*0TM)0 AI***0 :0T4E
M"$TE!I#TI )24M(: "D-+330 E%%%(!#Q3:4TE(0&D-*:;2&+2444#"BBDJ0
M/NBBBBN$ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_2LD,0."1FG3R>;<22G^-BWYFF"OW2A35.E&FNB2/E9OF;D)10:*U$%%%%(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#$\9?\B/X@_P"P;<?^BVKY)7_5K]*^MO&7_(C^(/\
ML&W'_HMJ^24^XOTKMPNS.>MNAX-+3*=769"THI*!0(6E%)15 +2T@I:!!2TE
M% A:4&DHI@.HI!2TP%H%)2TQ"T444R1:*2EH *6DHIB8ZBDHIB%I:2BF(6C-
M%%,0M%)2TR6@(R,&O4OA[J8N]'DM)&S-&WR#_9%>6UO^#=4_LKQ!&Y/RRCR\
M>YJ*JO$AJZL>J7,>0>*R+E.M=#<QX)Q6/<Q\FBG*ZN<#5G8P9EJC(N<UK7"<
MFL^5<5T(2,R5:K,*ORK51Q@UHA/0JL,&F&IG%1$4F7!D3"H&%66%0N.*EFQ
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M HI**3*1]TT445Q'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS189)FDS3,T9HL _-+FH]U&ZBPA^:,TS-&ZBPQ^:,TS=1NHL _-&:9NHW46
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MLC#!4E3^%-I'IA1112 2BBBD A-)110,2D-+2&D E&:*0T@$I***0PI*6D-
M!244E(84E*:;0(#332DTE)@(:2E-)0 F:*** $)IM+WI*0!2$TM-- A*,TM(
M:0"=J**2D,****3&!IM+12&!I***D9]TT445QG2%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^&CAT[VOKZG+B:CKS<K&74]K975[)LMH))6_V5R!]3VKM+#P=9P@/>LUP_\
M=!*J/ZFNCABBMXA%#&L:#HJC %=CEV"--M:G'Z?X(E8J^H3A%ZF.+D_B>@_6
MNKL-*L=-'^BVR1MT+=6/XGFK&:-U0VV:J*6Q+NHW5'NI,TK%$NZC=46:,T6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D9592K $'J"*6B@"G
M)IT1.Z/]V?;I2+%)">1D>HJ[16BJR1S5,)3GMH/M9.1S6Y:2^]8 X.1UJ[;7
M:HP#\>]4YJ1PU,)4AMJCIC&EW:2V\BAA(A4 ^IKY_P!:TQ]&UJYT]^L3<'US
M7O-I,& *L#[@UPOQ3T3=%!JT"8" ^>P[^E<LU:1MA*GV6>8DTE'49HJ3O$-(
M:#24#%[4E%%( /2F]*6D- (*2@T4@$)HI*":!B$TE%(32$!I**2@ HHI#P*
M TVBBD 4TG-*:2D(2BBB@!*2EHI#$HHHI#"DH-%(8444E(84E*:;2&+24M%
MS[JHHHKC-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH P_&?_ "(OB#_L&W/_ **:OD1/]6OTKZ[\9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFBD)H&)11FDZTA"4E*324 %(32TTGFD E%%%  ::32DTVD(**#24#"@T4E(
MHHHI##-)0:*0PI*6DI#"DH-%(8E%% H&+11128T?=5%%%<AL%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &'XT_Y$7Q#_ -@RY_\ 135\A)_JU^E?7OC3_D1?$/\ V#+G_P!%-7R"GW%^
M@KLPVS,*NZ'TM-I0:Z3,=0*044"'44E+0 HI:;FG TQ"YI:;2BF ZDHHH =F
MEIM*#3 6C-%% A:***8!2TE+3"PM%)2T" 4M)10(6CM113 7O2TVES3 6EI*
M* #-**2B@0ZBDS2TQ6"E[4E%,6PN:*2EH WO"?\ R%)?^N!_]"6NQKCO"?\
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MRXG1OH <D_@ 322]HY2;V!Z62.P^(G_'E8_]=&_E2:IIUC'\/H[E+.W6X-M
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M7"]IMD?(&U=O)R:S='N/"VI7!TZUTU-R@[7E@!W@=PW)_/%6HSCX>'_KP/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2NT.P"[![*,BN+HHJH4XP5H@VWN%%%%:$A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8WBO_D6KO_@'_H:UYD37IGBS_D6;S_@'_H:UYE6-3< I
MII<TE0(*0\TM)0 4A/%+3*0!1110 9Q330:*0A**#24# T44E( HHHI,84E%
M%(8444E(84E+24AA24M)0,*6BBDQH*0TM)2&%%%)2$?=E%%%<QL%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MITMV+WR=DACV>5NS@ YSD>M:%M\.[AX US?QQ2'^!(]X'XY%:OP^_P"0!/\
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M:5(J,F]PY8NZ(O!>C_V=IQN_/\S[:D;[=F-F,]\\]?:L#QGX?^Q/)JWVK?\
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M4/GU/5?#VG:=H4\NGPW?GWLB>9+V^53@<=!R3QUYKDM0NY-#\>2WCH^P2;B
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M?^O&+_T%:Y?P%_R,1_ZX-_,5S%%$:-HN-]P<M4SN_$6I?V3XYL[L[C&L"K(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,+QM_P B%XB_[!ES_P"BFKXZC/R+]*^Q
M?&W_ "(7B+_L&7/_ **:OCE/N+]*ZL/LS"KNB2BD!I:Z3(6BDH!H <*6FTM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!A>-O^1"\1?]@RY_\ 135\<)]Q?I7V/XV_Y$+Q%_V"[G_T4U?'"?<7
MZ5U8?9F%7<=3@:2DKH,A]%-!IPI@+124N: %SQ124N: ' TM-HS0 ^EIHHI@
M.HI!2T +FC-(*6F M+24"@!:6DHH 7-+FFT4 /HIH-.IB%HS244 .HI,TN:8
M!2TE+3 7/%'44VES0 ZBD!HS0(6ES244 +124M.X'0^#_P#D+R_]<#_Z$M=M
M7$^#O^0O+_UP/_H2UVU4BD%%%%,9T'@S4%L/$$:N<1W"F(D]B>1^H _&O5:\
M*!(((.".]>H>%?$L>JVRVMRX6]C&#N/^M'J/?U%<.+I-^^C:G+H:VL:7%K&F
M2V<IQNY1O[K#H:\IU+1-0TJ8QW-NX Z2*"4;Z&O9:*PI5Y4].A4H*1XWINAZ
MAJLRQVUN^T]9&!"+]37JVD:9%I&FQ6<1SM&6;^\QZFKU%%6O*IIT",%$*\S\
M=:DMYK*VT;92U7:?]\]?Z#\*ZGQ-XGBTB!K>W=7OF& HY\OW/^%>7.S.[.Y+
M,QR2>YK;"TG?G9-2702BBBN\Q"BBB@#T?P/HQM+)KRZM56:7#0R$ACY9 (QS
MQ_.L&?1[^Q\6VUW<P;()]27RVWJ=V9,C@'/2ND\#7US>Z/(MQ)O$#B*/Y0-J
MA1@<=:YN?6+^^\6VUI<S[X(-27RUV*-N),#D#/2N&+G[21L[<J-WQW:SWL.G
MP6T+RRM(V%09/05Q]WX9UFQ@:>XL76-1EF5E; ]3@FN^\7:U/HVG1M:[1/,^
MT.1G:,9) Z>E)X0U:ZUC2IFO6622.0INV@;A@'D#CO4TZDX4DTM <4Y6/+0"
MS!5!))P .];,?A+79(A(NGN%(SAG53^1.:WO!^E6Y\0ZE*T?_'G)LB4\A<LP
MS]0%K5U2?Q:-58Z?:1&S1OD#%/W@P.N6SUSTQ6TZ[YN6-OF2H:79YQ-:7%M<
M_9[B)H9<@;9/E_GV]ZO7_AW5=,MOM%W:&.+<%W!U;!/K@FNT\=62W&A1WIC"
M30,N<X)VMP5S]2*FL"/$?@;R"0TWE&(Y;/[Q/NDGKSA3^-+ZP^52Z7LPY-;'
MG-E8W.HW2VUI$9)F!(7('09ZGBI-1TN\TJ98;V(12,NX+O5N.F>"?2NM^'EA
ME[O4&'W0(4/OU;_V7\ZYGQ!J)U36[FXW9CW%(_\ <' _Q_&M54;J.*V1+5HW
M,RM"PT/4M40O9VCR(#@MD*/S.*SZ[C2M=UN?18[+2](.Z.,(ER/N\<$\C!/X
M^M.K*45[H12>YSMWX9UFQ@:>XL76-1EF5E? ]3@FKGA'19-1U2&XEM5FL8V8
M2EB,9VG'&<GG%=_H::LMB1K+QO.6R-H&0,=#@8S]*X_PW>7%GXPDTN"399O<
M3;H]HYVAL<XR.@K#VTIQDM+HOE2:-'QCH&H:G=VK:?:B2..+8<.J@<],$BM*
MUT5K7P?+916JI>2VS*Z@C+.1W;/]<5G>,]=U+2;VVCLKGRD>,LPV*V3GW!K7
M2_N3X--^9?\ 2OLADW[1][;G.,8K%N?LX]BM+L\TFT348-06P>U?[4P#"-2&
MX/?@D5=_X0_7MN[[ <?]=4S_ #JYHWBC4UU*:=K1M1N9453L7#!5)Z;1[^GI
M73Z6_BFXU;SKU(K>QSS"VTG&.,$<Y''4UT5*M2.]B%&+/-)[>:UG>">-HY4.
M&1A@BK%AI5]J;E;.UDFQP2!A1]2>!74_$6)%NK"4* [(ZL?4 C'\S6]J$H\*
M>%%%I&OF(%0$C^,]6/K3==\L6EJPY-7<X*[\-:Q8P--<6+K&HRS*RM@>IP34
M_@W_ )&NR_[:?^@-6MI'CN:&.9=6#W).#&T:*"/4'H,?_7JCX:EAG\<PS6\7
MDPN\K+'D':"C<<"ARFX24UT%975B]\0@6U.R5023$0 ._P U85QX9U>TLVN[
MBT\J!%W,S2H,#Z9SGVZUZA/I,%SK$&HS99X$VQ+V!)ZUP/C/6;NZU273V!BM
M[=L!,_?/]X_TK.A4;M"/3<J<5NSEZD@@EN9TA@C:25SA549)J.MKPUJL^E7[
MO;6'VN21-H50=P&>V ?Y>E=<FTKHS6XX>#]>*[OL!Q[RIG^=9-S:SV4[07,+
MQ2KU5Q@UZ+8S>++O54GFBBM;'>"T,FT_)Z9'S;L?09JC\184\JPGQ\X9TSZC
M@_Y^M<\*\G-1E;7L6X*UT<I%H.IS:8=1CMLV@5F,GF+T7(/&<]CVJ>+PIKDT
M(E33WVGIN95/Y$YKN_"CK%X,MI&&519&(/L[&L+0O%NIZAXDAAG=/LTY9?*5
M!\G!(P>O;O[TO;5&Y<J6@<L=+]3C)[>:UG>">-HY4.&1A@BKFGZ'J6J(SV=H
M\B#JQ(4?F2 :ZCQ[:";5M-\L 2SJ8MQ/'WAC/_?5;>OZ@?#'A^!+") =PACW
M<A1@G/N>/UINNW&/*M6'(KNYA^#=,O=,\1S1WMN\+-:MMSR#\Z=".#69XY_Y
M&:7_ *YI_*NA\'>)+S5;J:SOBLDBQ^8DH4*<9 (...X_(USWCG_D9I?^N:?R
MJ8<WMWS;V&[<FAS=7-/TF_U1V6RMGE*]2, #\3Q5.O4V?_A%_!BR01(TL<:D
MC)P78@$^N,G].U;5:CA9+=D1C?<YCP[HVHZ5XKL#>VKQ*Q<!L@J3Y;<9&14W
MQ$_Y"5G_ -<3_.K'A?Q7?W^LK97S)*DVXHP0*4(!/;M@$>O2IO%=DNH^*M(M
M'SLD7#8ZXSD_I6%Y*LG/L79<NAR-AX?U74X?.M+-Y(^SDA0?H21FH[_1]0TL
MC[;:R1 \!CRI/ID<9XZ5Z9K?]L6]K!;Z!:QXP0S94>6!C  ) ]?RI;.WO]4T
M":TURW6.=@8R05.X8X?C(!S^HH^LR^)VM^(>S6QY3;VT]W,L-O$\LC=%09-:
M_P#PA^O;=WV X_ZZIG^=;GP^6&.\U".0*+I0H&2,[<G<!^.W/X5K7\7BZ"]E
MGL[BVN+?=E(-JJ<>AR >/][M^%7.O)3Y5;YB4%:YYO=6EQ93F&ZA>&0?PN,?
MC[CWKT[PMHK:7I!%Q:K%>N6WG(8D=N03VKA/$6HZI>W21ZK (9(L[4\O;P?Y
MCCK7H/AF_N=0\/)=74OF3$OEMH'0G' &*C$N3IIC@ES'G4OAO5H;V"SDM,7$
MX8QIYB?-@9/.<"I!X4UMKEK<6+>8JAR/,7 !Z<YQV/%:7A[5[[5O%VG-?3^:
M8Q(%^15QE&] *Z7Q5XEET)H(K:&-YI06)DS@ 8'08SW[]JN56JI*"2N)1BU<
M\WN[&ZL;LVMS"T<XQ\G4\],8ZUI1>$M=FC61-/;:P!&YU4_D3FNC\'P'6=5O
M=<O@KS!PL8QPIQV'L, 55UOQIJ$.LRPV12."!S&59 ?,(X)/X],8INK-RY(I
M76X<JM=G*7EC=:?-Y5W!)"_8..OT]:NS>&]6@L#?/:?Z,%#^8LB-\IZ'@DXY
MKNKY8?$_@W[48P)A$TB8_A=<Y SV."*A\'7$>J^&)=/G.[RMT+ MDE&''TZD
M#Z5+Q$N6]MGJ'(KV/.K>WENKB.W@0O+(P55'<FK>HZ+J&DK&;Z 1"0D)^\5L
MXZ]"?45T'@O27'B2X:8 FQW*<=-^2O\ 1JI>,]1-]K\L0;,5M^Z7Z_Q?KQ^%
M:^T;J<JV%R^[=G.UZAX+TFXTS39C=P+%-+)D'()*8&.1[YKR^O4_!FHW6I:-
M)+=R^8Z3F-3M PH5<#@>YK/%WY--AT[7.9\87^LR1QVVI6<$%NTS/"4.6;;Q
MR0Q[-Z"LN'PGKD\0E33W"D9&]U4_D2#71^'Y;C7_ !%))J4@G33]QA4HH"L3
MC/ YZ?G6GK,WBK^TB-+M8_LB%2&+)F3CG.3D#/'&*A5'"T%9/\!\J>K/-KJS
MN;&<PW4$D,@_A=<9'J/4>]>C^#-$?3;&2:\M4CNWD.U\ACY>%QR"<<YI/%]D
MU]X6%U/ ([N +(5!!*YP&7/<<_H*G\&:C=:EHTDMW+YCI.8U.T#"A5P.![FI
MJU7.E=?,<8I2.!UC1M0T^\'VFW*?:)&\H!@Q;GT!/J*F3PAKTBAAI[ '^](@
M/Y$U:7Q-J7]OQS3(+UK=I$AC* $9X.-HZ\#UKH1=^+]1NTEMK6.PMN#LGP<]
M,[LC=Z] *UE4J12V)2BS@KW3[O3I_)O+=X7QD!AP?H>A_"O1O"/_ ")R_P#;
M3^9IGCZ%'T!)"/GCF4J?J"#_ )]J?X1_Y$Y?^VG\S652I[2DF^Y48VE8\PHH
MHKO,37N/"^M6OE^;8/F1MJA&5R3C/12?3K1<>%M:M8&FEL'V*,DJRL0/H"37
MH_B35FT;2'NHE1IBPCCW=,G^? -8?@_Q-?:G?2V5\XE.PR))M"D8P,8 QWS_
M )XXHUZKASV5D:N$4['->#?^1KLO^VG_ * U7_B#_P A^#_KU7_T)ZOKI\6G
M_$RW6$!8YE:4*.BDHV?U!/XU0^(/_(?@_P"O5?\ T)ZI24JR:["M:+1CV7AW
M5M1A$UK9.\9/#$A0?IDC--O_  _JNF0^==V;QQ]W!# ?4@G%=:FN^(]3L%32
M](-N1MQ-QM*]@H< ?SKI;2"\DT4P:LT4L[(RR%!PP.?;TI2Q$XO6WIU&H)['
M%^"-$>:]^WW-JDEIY;>4[$']X&';.?7M2^-])OFU*?4Q!FS5$!DWKP>!TSGJ
M?2I? &HW3WLFGM+FUC@:18]HX;<O.<9[FG^*+Z\N?$2:&;@BRN&A5D"KGEAW
MQGK2O/V_];!IR'+:?H6IZHA>SM'D0'&\D*OYD@&B_P!$U+3%#7EG)&G3?PR_
MF,BO3-634[+3(;?0+6,L/EYV@(N.HR0,Y^M&DQZE>Z5-;:_;('/RY&T[U(ZD
M D9S].U'UF7Q:6_$/9K8X_X??\A^?_KU;_T)*H>,O^1KO?\ MG_Z M:G@> V
MOBF]MV.6BAD0GUPZBIY].BU+XE3Q3KNB0+(RGHV(UP#[9Q5<R59R\A6O%(YV
MT\,ZS?0+/;V+M&PRK,RID>HR15.^TZ\TV41WEM)"QZ;APWT/0]>U>E^()/$8
MF2+1;=/)V M+E,[L] &/ICMWHU.TN-6\(RKJ-LL5ZL9DVJ0=KKD@@\XR!^I%
M)8F6C=K/[QN",CP-H;Q++?7EHGSJC6TC$,<<Y(YX[5A^+-)OK;4[J_F@VVLT
M^$?>IR2,] <]C71> =1NKRVNK>>7?%;+&L2[0-H.[T'/0=:H76L33>-(['4)
MU:PAN\HC(N%;!"Y.,]3WI*4U6D^P-+E1AP>%-<N(EDCL'VL,C>ZJ?R)!JM?Z
M'J6EH'O+1XT)P&R&'YC->FZW!KTK1G1[NWA0#YQ(OS$^Q((Q^72N1U[4?$\.
MG-:ZG;1+ XV-*L88-[D\@'\![55.M.;6WZBE%(Y"BBBNLS&N<(:LVDF"*J3'
M$1_"G6[X(K>FO=/*QW\1>AU=G+T.:\\^+VD#%GJ<2\MGSF'Z5V]C)TIWB;3?
M[9\*WEFJ;I67Y/;%<U>.ER<+/EJ'SAVS29ISKY<LD9',;%3^%-KF/6"CI124
M@"BBBD,*2EI*0!1124B@HHHS2 2C-%% PI**44#"DI:2I&%!HHH&)1114@%%
M%%# #112&I ,T444#/NVBBBL30**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+QM_R(7B/_L%W/\ Z*:O
MC=#\J_2OLCQM_P B%XC_ .P7<_\ HIJ^-E^XOTKJH;,PJ[HDHI :4&N@R"E!
MI** 'BBD!I<TP"EI** '9I:;2YH 7-.!IM% #Z,TW-+3&.HI,TM A>]%)2YI
M@+2TW-% 6'=*,T=J*!"T4E% QV:6FT4P'44F:6@0N:6FT4P'44F:7- !2TE%
M #@:6F4N:8"TM)FE% '0^#O^0O+_ -<#_P"A+7;UQ'@[_D+R_P#7 _\ H2UV
M]4MAH****H84JLR,&4E6!R"#@@TE% '5Z9X[O[11'>1K=H. Q.U_S[_E6_%X
M_P!*=1YD-U&W<; 1_.O-:*PEAZ<M;%J<D>E2_$#2D!\N&ZD/;Y !_.L#4_'=
M_=H8[.-;1#U8'<_Y]JY2BB.'IQUL#G)BLS.Y=V+,QR23DDTE%%;$!1113 **
M** /0_AVZG3;Q PWB8$CT!''\C61<Z)>V'BNVO+A%6&;4E\LA@2V7SG%<[8:
ME>:7.9K*=HG(P2 ""/<'@U:NO$6K7LD#W%V7:"021_(H"L.AP!@US>RFIN2V
M9IS*UCK?B)_QY6/_ %T;^52?#S_D%7?_ %W_ /917%:CKFHZLB)?7'FK&25&
MQ5P?P I=.UW4M*B>*RN?*1VW,-BMD_B#2]A+V7)U#G7-<ZSPK?1P>*]8M'(#
M7$S%">Y5FX_(D_A3]:T7Q(^KN^G7UR;69MPQ=%1%GJ,9Z?3M7!R3R2W#W#N3
M*[ERPX^8G.>*UH_%NNQ1"-=0<J!C+(K'\R,T2HR4N:-OF"DK69H^)M+U'2[-
M?M6NR74<K "%Y&RV.<X)(P.*F^'^H>5J$]@[?+,F] 6_B7K@>I'_ *#7*75Y
M<WTYFNIY)I#_ !.V<#T'H/:NR\+^$[J.ZL]6EN8UBVB5$C)+'(Z'@8Z^]%1*
M-)J;".LKHW-<EC\/>&[LV_$DTC;,_P!YR2?R&<?05Y778^/M32XO8;")P5@R
MTF#QN/;\!_.N.JL-&T+O=BF]0KUW5[>]DT 0Z&ZQOM4)M.TE,=%/8].:\BK4
MLO$>KZ= (+6]=8AT5E5P/IN!Q^%.M3<[-= C)+<]&\,:=?:=I[C49S)<2MOP
MS[B@QTS_ (5QVCG9\1FW<?Z3./T<5EQ^)-8BO)+M+U_.D4*S,JG@=!@C _"J
M5Q>W%U>M>2R?Z0S!BZ@*<COQC!XJ(T9)RN]T-R6ECN?'.CWM]+%>6\8:""!S
M*Q8#:!ST[_A6II\37_@6."W*L\EH8UYXW8(Q^=<'+XKUN:W:"2_8QLI4X102
M#[@9J#3]?U32X3%9W;1QDYVE589_$'%3[";@HW6@^=7N=]X-TJ32K.YBNHT2
M[:0,P!!(7:-H)'ONJKI^D^(&\2&[U*Z/V:)RP D^1QV"KG@=.OZUQ?\ PD&J
M_;_MWVV07&W;N& "/0C&".?2GW?B36+Y%2XO7958. %51D'(S@#/-#HU+MW6
MH<RL=)\1@=^G'MB3_P!EK:O8AXK\)I]F=!+(JN 6R%<=5)_,5Y[J.NZEJL21
M7MP)41MR_NU4@_4 &HK#5;[2V9K*Y>+<.0.0?P/%5["7)%7U0N=79UV@>"?E
MFDUN #( C19>1UR25./2L[0H[.+X@1QV#%K57D$9+9S^[;H>XSG'M69=^)=8
MOH&AN+YVC889555R/0X JA9WMQI]VEU:R>7,F=K8!QD8/!XZ&J5.HU+F>_W"
MNM+'HOB7Q#/HVL:?&"/LK?/,,<L,X_3K5/QSI27EE#K%J5?8H#E>=Z'[K#Z9
M_(^U<9J.JWNK2))>S>:Z#:IV*N!^ %6(O$FK0V L5N\VP4IY;QHWRGMR"<5$
M:$H\KCNMQN:=[F57??#I8/(OF&/M&Y0>.BX./US^0K@:L6=[<Z?<">TF>*4#
M&Y3U'H?45M5ASP<43%V=SO?['\0W/B?[1=796QBG$BXD^5D!R%"C\ <_K3/B
M(I^P638X$K#]*Y*]\2:OJ%NT%S>L\3?>4(JY^N *;?\ B#5-3MA;WER)8@0P
M!B0$'UR!FL8T9\T9.VA3DK-'>>'/^1"3_KC-_P"A/7$^%/\ D9['_?/_ *":
MBMO$6JVE@+&"ZV6P#*$\M3P22>2,]S5&TNY[&ZCN;9]DT9RK8!Q^!JXTI+G\
MQ.2T.V\?2FWO=)F R8R[@?0J:U]=LAXI\.Q/82*Q+":/<< \$$'T/)_$5YUJ
M.L7^K&,WT_FF/.SY%7&>O0#T%+I^LZCI0865T\2L<E< J3ZX.14>PDHQL]4/
MG5V=MX/\-7>DW$MY?!8Y&3RTC#@D<Y)...PQ@^M<]XY_Y&:7_KFG\JI'Q/K)
MNUNC?.954J,JNT ]?EQC\<51OK^YU*Y-S=R^9*0 6V@<#V JX4YJISR8G)6L
MBM7J>(_%/@[RH) )'C53D_=D7!P?Q'Y'->65;L-3O=,E,EE</"S?>QR#]0>#
M55:;G9K="C*VYV'A?PG?6&KK>WZI$L.X(H<$LQ&,\=L$^^<5+XKO1I_BK2+I
ML;(QELC.%W8/Z$URTOB?69IXII+YRT1W( JA0?7:!@_B*JZCJM[JTB27LWFN
M@VJ=BK@?@!6:I3<^:;*YDE9'HWB>QU2_MK>?1KN5'3.8XIBGF*<8.<@<>_K6
M*=!\01:6UW=^()K9U4LT;SN0H]V!_D#7,6'B#5=,A\FTO'CBSD(0& ^@(.*;
M?ZWJ6IJ%O+R21.NSA5_(8%*-&<?=NK?B#DGJ:'AO0I]9EDGAU);:6)N2,F3G
MJW4<?C736<?C"ROE@9H[NT5@OFRLO*^O7=G'KFO/K:ZGLYUGMI7BE4\,IQ6O
M_P )AKVW;]O./^N29_E5U*<Y/2S7F*,DCIOB&\']GVD9*_:/-W*.,A,'/OC.
M/RJ]X)99/"R(K LKNK>QSG^1%>:7-S/>3&:YF>60]6=LFK.G:QJ&E%_L5RT0
M?[PP&!_ @BI>'?LN1/4:G[US?T'1;W1_%NFK>(J-)YI4!@> C>E'Q")_MVW7
M)P+92!_P)JQI/$6K2WT-[)=EKB$$1ML7"Y&#QC'2JVH:G>:K<+/>S>;(J[ V
MT+QDG' 'J:I4Y\ZG+L)M6LCJ_A_J4<4UQI\KJIE(>+/&2."/RQ^1J+6_!FI2
MZQ++9(LT$\ADW%PNPDY(.3V]LUQX)5@RD@@Y!':MF+Q9KL,0C74'*CNZJQ_,
M@FB5.:FYP>X*2M9G:WIB\+^#3:-,&F,;1H>,L[9R0/09_(5R?@K4/L7B".)F
MQ%<J8B"V!GJI]SGC\:PKJ\N;Z<S74\DTA_B=LX'H/0>U='X<\)W6H"UU+[3'
M%;[]PVDE_E;Z8'3KFI<(TZ;YWN.[;5CN+UH-$LM2U)1EW_>$-T+!0JCZ9 _,
MUY!)(TLC2.=SN2S'U)KOO'^IHMM#IL;@N["20 ] .@/U//X5Y_1A8VCS/J%1
MZV"O2?A]_P @"?\ Z^F_]!2O-JTM/U_4]*MV@LKGRHV;>5\M6YP!GD'T%:5J
M;G#E1,79W-[P??I:^)KNWD*JMR652?[P;('Y9_2M/Q#I'B*75FFTR\N#;2X.
MQ;DH(C@ \9Z=^/\ ]?GSNTCL['+,<D^];$/BS7((EC34'*J,#>BL?S()J)TI
M<W/&WS*4E:S-3Q#I.J:7IGF7.O2W".0K0O(_S?0$G./PK:^'I']A7"YY%RQQ
M_P !6O/[R_N]0F\V[N))GZ N<X^@[5)I^JWVE2M)97#1,PPV "#]0>*)492I
M\K>HE)*5SN?#6BS:9K]U+?1HLLH<V_S!LJ&&YN.GWE]^M&MZ/XAU/7"D5V8M
M..-K+)@(,8.5')/7\^HKC;KQ#JUY/#-->R&2$DQLH"[2>O0"II_%6MW,#0RW
M[%&&"%15)'U S4^QJ<W-=7'S1M8[?QR"WAIR.0)4)I/"/_(G+_VT_F:X.3Q!
MJDNG#3Y+D-:A @C,2' '3G&>,=:6S\1:K86?V2VNMD'/R^6IZ]>2,TOJ\O9\
MGF/G7-<RZ***[#(]?\1Z4VLZ/):QE!-N#QE^FX?_ %LBL+PAX9OM,OWO;Y5B
M/EE%C#!B<GJ<<=OUK1\:3RVVA":"1HY4F0JRG!'6N#N/%.M74#0RW[[&&"%5
M5)'U !KSZ,*DJ=HO1FTFE*[.D6_2_P#B; T3*T<2M$K*<@XC8G]2:B\7+$WC
M33%G ,)2(.&Z;?,;.?PKD+.]N-/NTNK63RYDSM; .,C!X/'0U)J&IWFJW"SW
MLWFR*NP-M"\9)QP!ZFNA46IIK9*Q'-H>F^*+;6+FPCCT=RIW?O%1]C$=L'(P
M/6K.BV-S8:,EM=3>=<8)=MQ/)[9/6O-K?Q3K=K;K!%?OY:C W*K$?B033+;Q
M+K%I),\-ZP:9M\A95;)Z=P<5C]6GR\MT7SJ]S6^'Y U^8$];9@/^^EJ_XHT^
M\MO$"ZZ(E:TMC%(6W#)(8#&.N?TKC$O;B*]^V1RF.XWE]Z +@GKP./PZ5?O/
M$VL7]L]O<WI>)_O*$5<_D!6TJ4O:<Z(4ERV/0/$%K?:KI<%QHUY(D@^=1%*4
M$JD>N1[=?>L.'P_XB^P-<7FO3VCKDE'N&(51W+!L"N5T_7=3TM"EG=O&A.=A
M 9?R((%+?Z]JFIQ^7=WDDD?=!A5/U P#TJ(T9Q]U-6_$;DGJ;O@)F?Q'=,[F
M1C;N2Y).X[UYYYJW+?II_P 39GE*K')MB9CVS&N/UQ7(Z?J=YI5PT]E-Y4C+
ML+;0W&0<<@^@J.]O;C4+M[JZD\R9\;FP!G P.!QT%6Z+<VWLU87-96/1/%.E
MZY<7,5QI%U.%*['ACG,>#S\W4#V_#\LG4M%UJPT9[NY\039"_/"TSX)/\(.>
M3^%8%IXFUFQ@6"WOG6-1A595; ]!D&JM_JM]J;AKRZDFQR 3A1] .!4PI5(V
M5U9#<DSK?ARPW:DO<B,_^A?XU4UOPU>S^(Y)96B@MKJXV13.XP25) QU[8^M
M<S97UUIUP+BTF:*4#&Y>X]".]6M0U_5-4@$-Y=F2,'=M"JHS^ %4Z<U4<XO<
M7,N6S.N.D>*M&2)--O\ [9"N,QOM&WV^8_=P!T(Z].];TTLB>&9VUSR%8Q,)
M0A^4YR ![].G>O.8/%6N6T8CCU"0J.F]5<_FP)JKJ&LZCJ@47MT\JJ<A> H/
MK@<5FZ$Y-<UOU*YTMBC111789$5QQ WX?SJ.!N13[LXMG_#^=5X6Z5T4OA/+
MQW\1>AOV4G2NAM)/U!%<G:/@BNALY,@5%2-T<D7:S/"O'6D-HOBJXM\?*X\S
M(Z<USE>N_%[2!+96FJ1C,A?;)]!7D6>.*\[9V/<IRYHIB44=Z*3+"C-%)2 *
M***3&@I***0PI***!A244M Q,4M%%)C"DH[T&D,**.])2$% HHI,84445("4
M444#"BBBD!]VT445D:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!A>-_^1!\1_\ 8+N?_135\;(?D7Z5
M]D>-_P#D0?$?_8+N?_135\;)]P?2NJALS"KN/HI**W,1]%-S3J8PI:2B@!U+
M3<THH 6EI**8"TN:2B@!U*#3:6@!U+FF9IU,8N:6FTM A:44E% "THXIM+3
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M26PPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O#BU?\
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MC_F6=9_\ )?_ (FOL>BG]8?8/8KN?'/_  A?BK_H6=9_\ )?_B:/^$+\5?\
M0LZS_P" $O\ \37V-11]8?8?LEW/CG_A"_%7_0LZS_X 2_\ Q-*/!?BH?\RS
MK/\ X 2__$U]BT4?6'V#V2/CO_A"_%7_ $+6L_\ @!+_ /$TO_"&>*O^A:UG
M_P  )?\ XFOL.BCZP^P>R1\>?\(7XJ_Z%K6?_ "7_P")H_X0SQ5_T+6L_P#@
M!+_\37V'11]8?8/9(^/?^$,\4_\ 0M:S_P" $O\ \32_\(;XI_Z%K6?_   E
M_P#B:^P:*/K#[![)'Q]_PAGBG_H6M8_\ 9?_ (FE_P"$,\4_]"UK/_@#+_\
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MTG_H%V7_ (#I_A1_8FD_] NR_P# =/\ "CZY'L'LF>,T5[-_8FD_] NR_P#
M=/\ "C^Q-)_Z!=E_X#I_A1]<CV#V3/&:*]F_L32?^@79?^ Z?X4?V)I/_0+L
MO_ =/\*/KD>P>R9XS17LW]B:3_T"[+_P'3_"C^Q-)_Z!=E_X#I_A1]<CV#V3
M/&:*]F_L32?^@79?^ Z?X4?V)I/_ $"[+_P'3_"CZY'L'LF>,T5[-_8FD_\
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MHKV;^Q-)_P"@79?^ Z?X4?V)I/\ T"[+_P !T_PH^N1[![)GC-%>S?V)I/\
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M_"$>+/\ H5]:_P# "7_XFOL^BCG#E/C#_A"/%G_0KZU_X+Y?_B:/^$(\6?\
M0KZU_P""^7_XFOL^BCG#E/C#_A"/%G_0KZU_X+Y?_B:/^$(\6?\ 0KZU_P""
M^7_XFOL^BES!RGQ?_P (1XL_Z%?6O_!?+_\ $T?\(1XL_P"A7UO_ ,%\O_Q-
M?:%%',.P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img114804231_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <&!Y # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&J=%'+'L%V7/[8U3_G_G_P"_AH_MC5/^@A<?]_#5.BCECV"[+?\ :VI_\_\
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M?W!^5.  ["CZE3[L/:L]F_X3+0_^?O\ \=--/C70Q_R],?\ @!KQLHIYVC-
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MJ!_B-I:C(CE(]<'_  KRX8IU+ZG2'[61Z4?B5I_:!S^)_P *9_PLNS[6K?\
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M6CV#VDCT4?$^#_GP;_OO_P"M3E^)UL>MDP_X%_\ 6KS?!HH^J4NP>TD>E?\
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M.CU[2Y1E+V$CUW5874+-@"+J$Y_VQ4<K[!<LT5$+JW/2>(_\#%.$T1Z2(?\
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MK[>-]%'2=S_P U&WCW14ZRR>WR&O)=J^@I<#TI_4Z?F+VLCU1OB%HPZ&4_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "DI:* "BBB@ I*6DH *6DI ?6@!U%(*6@
MI**6@ HHHH *2EHH 2EI** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 2BEI* "BC%)NP>: '4444 +FBDHH =2TVC- #Z4&F@T4@)E/_UZPI(Q8:P
M.(W_ )&MI35#68?,BAD'W@<9H&B8C!Q3EJ.WD\ZW20]2,'ZU(*8A:44E** %
MHI** %HI** %I*** "BBDH **6DH **** "D-%% !1110 8HQ110 8HQ110
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M98L?F17I%>5BW^\.BG\(4445S&@4444 %%%% !1110 4444 >*^*^/%-^/\
M;'\A6/6UXN&/%=__ +X_D*Q:]VG\"]#DENPHHHJQ"44M)0 44M% "4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%!H 3-+2"EH **** "DI:* $H(I:* &\T9IU(PQ0
M(3O2T@I:!@*6BB@ HHHH 2BEHH **** "BBB@ HHHH *2EHQ0 4444 %%%%
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M0 HI:;WI<T +129HH <*6FTO2@!:*2EI %%%+0 4444 %%%% !1110 4444
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MH *6DI: $HHI* %HI*6@ HHHH **6B@!**** "BB@T %%':B@ HHHH ****
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M "BG4T4ZD 4444#"BBB@ I*6B@!.U%%% !1110 4444 %%%% !1110 M%%%
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MHHH 2EI** %%+24M "&BEI* $I:2B@!:*** "BBB@ HHHH **** "BC.#10
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MHMV\0@A5._4GWJ:@PCJK'Z&FE)1Z&K$.S2U"9"OW@0:>K9HL(?1112&%%%%
M!1110 M%%% "TM(*6@ I:2B@!:*!10 4=Z** %HHHI %%%% !2TE+0 "G"DI
MZB@"IJ<FRRV#[SG]*RB2>IJ]J3C[4 3P%P:ST^[6D5H N*:14E--,8T"FD<T
M^D[T  %.0X-)2CUH$3]1Q4BC"U'&>U6,4F(%&*D%1]ZD%(8M%)2T@%HI,TM
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MBB@ I*6DH *2EHH 2DI:#0 AIAI],/6F(.]+VIHIPH 6BBB@8M(>*7J*.HH
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MYIU !0*** %I*<>E-H 3O12T4 )0*** %HHIISF@!3THS2T$9H 3-+3<4Z@
M/2D!S2TT\'/YT .HHHH **2ES0 4444 %%%% !1110 4444 %%%% !1110 4
MM)2T %-(IU!Z4 -I:2B@!32"G=:C/RGF@!]%-!IU $5SD6I(.#N'\ZDSD ^M
M.\H3QR0YP7'RGT/:JUK*71D<8EB.UQ_6@"Q2TT4Z@ HHHH **** "BBB@ HH
MHH 2BBB@ I*6DH ;36IU-:F @IPIM.% "T4M%  *6BEI )1BEI* #%1LH)J2
MFGBF S%-8&GT4 -0]J>>*0"G4 %'2EH- !124M !11FB@ S2444 %'?-+24
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M6DH **** "BBB@ HHHH *2X!\@2KR4'(]12U)$>H/0T 5XR&0,IRI&0:DJM
M##=SVW\ ^=/8&K- !2TE H <?NBFT[-,[D4 +132VV@'- "]12TE!H 6D-+1
M0 44E+0 44"@T %'UHHH 8?D/L>E.H/3!IHXX[4 .HHS2T )2T44 %%%% !1
M110 4444 %%%% !1110 4M)10 M%)10 4E+10 HI'&:*=U% $0X-.S012"@"
M1#AA52](M]4BGZ).NQC[U94\BDU" 7-A(G\2_.I]Q28(!Z4M5+"<SVJLQ^9?
ME:K=,!:*2EH 2EI** %HI*6@ HHHH 2BBB@ I*6D- #::U/IC4P$%.%,%.%
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M 'Q_(5C5[M/X%Z')+=BT4458@HHHH **6B@!*6BB@!**6DH **6DH **6DH
M**** $HHHH *6DI: $IHZTZFGALT .Z@C\:2D)VLI]33CUH 44E%+0 E%%%
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MI9.E-4TQ$E+31TI12&*0"*2EI* "BBB@ H[444 %%%% !1110 4444 %%%%
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M8<.?[Q]A^M>EUY^*Q-O<@;4X=6( %    '  [4M%%><;!1110 4444 %%%%
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M #U%95P^^=V_ 5IR-LA=O:LAN:<0(S313J;TK0!1UH-)0: %S0#S28S2A<4
M.%*.HH IZH#R:0$R# IU(.E+4@%%%% "TE+VHH 04O6BE- !VI:2EH$&***2
M@84=J#2T -I*4TG:@!***2F 4M)10 M%%% !2TE+2 ****!!1110,2EI#10
MM&<TE H [WX6_P#(1OSC_EFN?S->HUYC\+!F]U$^BI_,UZ=7CXS^,SHI_"%%
M%%<IH%%%% !1110 4444 %%%% !1110!X9KQSXBU$_\ 38_R%9]7]<_Y&#4/
M^NQJA7O0^%'&]PHHHJ@"EI** %HHHH **** %[49I** %S1FDHH =1312T %
M+244 +24M%(!*44E H 6DI:* &-49J0U&:H %/%,%.% AU%%%(9MZ9X6U#6-
M*DOK'RY/+E,9B+;6. #D9X[^M95S:W%E.8;J"2&4=4D4J?UKTSX;?\B[<?\
M7VW_ * E=1>V%IJ,/DWEO'/'Z.N<?3T/TKAEBW"HXM71JJ::NCP0TE>DZM\-
MX)2TFE7)A8\^3-EE_!NH_'-<-JFAZEH\FV]M)(US@/U0_1AQ733KPJ;,B4&M
MRAFE!S3* >:V('T49HI#"BBE S0 E%&** "BBB@!PJ53D5"*D2DP&R+@[O6J
MEQS+#GLV:T.",&JEQ$>&':F@,Z\'ER1L#WQ5E&R*KWPW(OL:6VD\R,9ZC@U?
M0#L/!FA'7-6 E0FS@P\Q['T7\?Y U[( %4*H  & !VKG_!>GV^G^&K<02QRO
M+^\EDC8,"Q[9'IT_"NAKQ,35YY^2.F$;(****YRPHHHH **@N[RVL+=KB[F2
M&)>K.<"N+U+XD01L4TZT:;'_ "TE.U?P'7^5:0I3J?"B7)+<[NBO)9O'VO2D
ME)88?9(@?_0LU''X\\0QMEKN.0>C0K_0"M_J53R)]K$]>HKSW3?B4VX)J=D,
M'K);GI_P$_XUW-C?VNI6JW-G.LL3=U[>Q'8UC4HSI_$BE)/8LT445D4%%%%
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MQIFY@_>0^I/=?Q'ZXK?HJH2<9*2$U=6/GRBMWQ?IG]E^([F-1B*4^=']&_\
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M71?['UQVC7%M<YDCQT!_B7\#^A%>C@JO_+M_(QJQZG-44I%)7H&(49HHQF@
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MEHH C:F&GMUIAIH!!3Q3:<*8"T444@/4OAM_R+MQ_P!?;?\ H"5V-<=\-O\
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MR)G[Z=Q_GO7N5K<Q7EK%<P.'BE4.K#N#7D8FA[*6FS.F$^9$M%%%<Q84444
M>2>/-*_L_P 0-.BXANQYH_WOXA^?/XURU>N>/M.^V^&WF5<R6K"4>NWHWZ'/
MX5Y'7L86ISTUY'-45I!2TE%=! M;VA>$]1UQA(B>1:YYGD'!_P!T?Q?R]ZS-
M,NH+/4H+BYMDN84;+Q.,AA_GUXKW*SN(+NSAN+5E:"104*],?T^E<N)K2IKW
M5OU-*<5+<\(N[66QO)K6==LL3E&'N/Z5LZ1X2O\ 6M*GOK8H-C[8XWX\SCG!
M[=OUZ8KI_''AF:^U*TO+*/,EPX@EP.A_A8^V."?85VFG6,.F:?!90#$<*!1[
M^I^I.3^-9U,7:FG'=CC3U=SPJYMI[.=H+F)XI5.&1Q@BHJ]&^(NI6(ACT_R(
MI;TX;S"/FA7Z^I]/3\*\YKIHS=2"DU8SDK.P4M)2UJ(<*D!V@D]J8HI)VVPG
MWI 9LA)=F/4FH3UJ5SS4)ZUJ(::2E-)3&%*@P:2G 4 28H4<T#K3T'-(!X&*
M6@T4@%[4HZTE**0"T4=Z6@ HQ24HH **6DH *6DHH 7O2TE%(0M)110 AIM+
M24QA24II*8!12T=Z0"44M% "4444P"BBCM0 M%)10 4E+24"$/6@4M)0!Z)\
M*.9-4_X!_6O3*\T^$XP=4]24_K7I=>+B_P",SJI_"@HHHKF+"BBB@ HHHH *
M*** "BBB@ HHHH \'U;_ )#5]_UV-4ZMZJ<ZQ>G_ *;&JE>_'9'&]PHHHI@+
M2TE+0 E+244 +2TE% "TE%% !2TE% !BDI:6@!*6DQ10 HI:**0!1110 M%%
M+0!&U,I[4PTP$IPIM+WIB'4444AGJ7PV_P"1=N/^OMO_ $!*[&N%^'-]:1Z5
M-9O<1I<-<%EC9@&8%5''KT-=U7C8A6JLZ8?"@HHHK L**** "BBB@"GJ&DV&
MJQ>5?6L<Z]BPY'T(Y'X5Q.J_#;[TFDW7OY,_]&']1^->A45K3K3I_"R7%/<\
M(U#2K_2I?+OK62$] 6'RGZ$<'\*IU] 30Q7$3131I)&PPR.H(/U!KDM6^'NF
MWFZ2Q=K.4\[1\R'\.H_ _A7;3QL7I-6,I4GT/+**VM5\*:OH^YY[8R0C_EM#
M\RX]^X_'%8M=D9*2NF9--;BTX&FTHJ@)5Y%+34IU(""Y&8ZQG7YJW95W1,*Q
M6'S$5< )X3E,'M4HJO$<<5.*; DJ6&1XW5XW9'4Y5E."#]:A%/%2Q'17?B_5
M+[1&TRYD$BLPS+C#LH_A/KSCGKQWK!I!2U$81CI%#;;W"BBEJ@$HI:2@ HHH
MH ZSX=N5\3%1T>W<'\P?Z5ZO7E_PVMFDUNYN,?+%!M_%B,?H#7J%>3C'^].B
ME\(4445RF@444C,%4LQP ,DT >"WX U"YQT\UOYFJ]/E<RS/(>K,6_.F5[ZV
M.,2BEI*8"&G(V1BDH7I0!;L=2O-+N!<65P\,G?:>&'H1T(^M6M=\07?B"XAE
MN@B^4FP*F=N>Y_'C\JR\YI.]3R1OS6U"[M86BD-**H!:2@$&EZT )1110 O2
MO5/ARY;PY*IZ)<L!_P!\J?ZUY6.:]:\ 6S6_A:-V&/.E>0?3[O\ [+7)C'^[
M-*7Q'44445Y1T!1110!S_C< ^#[_ #Z)_P"AK7CE>N^/91'X3G7_ )Z2(O\
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M**YBPHHHH **** "BBB@ HHHH *#THI#T- '@VI'.JW?_75JJU:U'_D*7?\
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M:T8<]1(F3LKGFN<T4GTI:]LY0I*6D%  *48I#Q0!0 'K2GK1VH[4 %)1FEH
M:>H-.!HQFD8<9'6@!U)0.E% %BQM9+V]AM81NDE8(H^M>Z65I'8V,%I%]R%
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MQ_9-U]NM$_T*9N54<1-Z?0]OR]*Y&NAU_P 7W^N[H?\ CWLR?]2A^]_O'O\
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M@$K9\*<^*=._Z["L:MWP<GF>+-/7T<G\E)_I45/@?H..Z/9Z***\(ZPHHHH
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M "EHHH *2EHQ0 TT 4-2H: "E%*PIA.* '&@4TNH')I5((R#D4 *:3-.I,4
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M-]#HA%6N%%%%<IH%%%% !1110 4452U'5]/TF+??74<.1D*3EF^@')II-NR
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M3:*[84XP5HHR<F]Q*::<:;6@A*7M110 4E+24 %***3.*!$H-.O!OTZ0 9)
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M>*I2MA\&K-BY:!QZ-0UH,9Y@\TQ.-L@[>M=YX,\'_:S'JFI1_N!\T,+#[_\
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M>ZYZ6W_?W_ZU)_PKW7/2V_[^_P#UJ]8HH^N5/(/91/)O^%>Z[_=M_P#O[_\
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M"TXU"_'JB_S->H5Y;\+S_P 32]'_ $S7^9KU*O&QG\9G33^$****Y2PHHHH
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MV?0M=M=>L1/ P60#$L1/*'_#WKR<3A_9OFCL=$)WT9J4445R&@4444 %%%%
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MBC,!T89Q4@VLN1P?2@!**#24@"G"FTX=: 'BEI!10 TTE+24 %%%% !24M%
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M0HK/_M[1_P#H+6/_ ($I_C1_;VC_ /06L?\ P(3_ !HY)=@NC0HK/_MW2/\
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M.J]#(HHHKTC *]&^&4!%MJ-P1PSH@_ $G_T(5YS7K/P]M_)\+B3_ )[3._\
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MC/%)2H#GF@!PI1R*3DTX4  &*7M1B@4@ =* ,T=*6@!,48H[TX4 )BEHHQ0
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MZXKV*O,QS]](WI+0****XC4*\K^(M[]HU]+4'Y;:( C_ &FY/Z;:]4) &2<
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MZ&I8RM>_)<6Q(RKMM84Q\;SCIFG:AD7%FW\.\BF,<$U2 4'D4\5"&Q4BMVH
M=1FBB@0E'>D-*.E !1110 M%)WI: %%+24M(84444 %%%+B@!O>EI"*3- #J
M*0]*,T .I*.,9%% !3<<TZDH 7%%%&* "BEI* "BEI* #%-8''%.Q0* $'/2
MFGBGXIK>E "A@>.]+3%&13N0.: %S13<TX>M ':?#: OK=U.1Q';[?H2P_P-
M>GUXEH?B.]T S_8UA/G;=WF*3TSC'(]36Q_PL;6_^>=I_P!^S_\ %5P8C#U*
MD^9;&T)J*L>JT5Y3_P +%UO^Y:?]^S_C1_PL76_[EI_W[/\ C6'U.J5[6)WW
MBF]_L_PU?3 X8QF-?JWR_P!<_A7BE;NL>+-2URS6UNQ"(@X?]VA!) (]?>L*
MN[#4G3C9[F4Y<ST"BBBN@@:#3QZTW@-BG"@!33:7O24 )2TE+0 #I2TE+0 [
M'>BBEI )12T&@!*BQ^]<^M2U'CDFF@$[YI*7I24P"DHHZT %+2=J7K0 =Z4&
M@<T#B@!U%%%( HHHH **** "DI:* $-)FE/6DH .II>](*=0 "GBFBG"@!32
M4$TTT@"BBBF 444=J "EZ4E#-@4 (QS3<4[M2B@ Q@4444 )29XI::>M  W*
MD>M4RN./2K@/:H' W&F@(0*7M3B*3&*H!RGFG@\U$.E/!I 2@\T\5&M2+UI
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M6V!;[AQN)/\ 2IU.14 7;##CH$%/4D,/0TP)1S13>]+FD M%&:* "E%)2YH
M=2TVEI +1110 E(:=330 TTAI324P&XS12]LBDZTP$- HH'6@!:*.]** %HH
MHI %%*** "BDI: "BBDH 6DHHH ,TX5'WI^X#CL* %S0*3K2CTH 6D-+24
MZT=#2TG>@!:2BB@!#1110 4M)10 M!I** "F&G&FFF T\TE*>!32>U #3S24
MH% %, IPZBDQ3AUH >N,TX4@&*<*D!:AE/SCZ5-4#_>-- "\L*FJ*,#=4M#
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MF-DURV?<FDMSR[QQX973)EU"RB"6DA"NBCB-O\#_ #_"N.KWR[M8;VTEM;A
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MA"1J !QZ5S@KJOB&/^*LE_ZY)_*N5KLHN]./H92^)BT4E+6@@HHHH$%%%)0
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M$$=J9FO0?B!X<P3K-JGH+E1^C_T/X>]>>FO8I5%4CS(YI1Y78];^'W/A6/\
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MC%*F^6.K+A3YM6>:VWPPOW0&YO[>)CU5%+X_E27/PQU&-2;:^MY2/X7!3/\
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MDI)21@U9V$[T44M4(2BBBF 4444 %%%% "4M%':@!*#2TAH 2BBEH *,TE%
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M(/6O:O'/_(FZA]$_]#6O%E&*K _PWZBJ_$7M-)_M.TY_Y;)_Z$*]\KP/3?\
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MO8JJV&GV^G1.EN@7S)&DD;NS$Y)->71K>R3MNSHE'F%T^PMM,LHK2UC"0QC
M'<^Y]ZX_QMXL^RJ^E:?)^_;B>53_ *L?W1[^OI]>FCXU\0SZ)8)%:HXGN,A9
ML?+&!UY_O>GYUY*6+L68DL3DD]ZWPU#G?M)D5)VT0E*#32U*&!KTC >#FBFT
MN:0"UL^$_P#D:=/_ .NO]#6-6SX3_P"1IT__ *Z_T-14^!^@X[H]GKQ;Q9_R
M-.H?]=?Z"O::\7\6?\C3J'_77^@K@P/QOT-JNQB'I7I_PZTA;72GU)U_?71(
M0^B X_4@_D*\Q(KW+0HA#X?TZ-1TMH_SVC-;XV;4++J126MQ=9U6#1=,EO9\
MD)PJCJS'H*\9U?6[[6[II[R8D9^2,'Y$^@KLOB?<.%TZV!^0EY"/4C '\S^=
M>>BC!TDH<_5A5D[V%K<\/>)KW0;A=KM):$_O(">".Y'H:PZ*ZI14E9F:=MCW
MZUNHKVTBN8&W12J'4^QKSWXD:4D5Q;ZI&N/._=2^[ ?*?KC(_"MSX=W#3>&3
M&Q.(9W1?H0&_FQJQX\A67PE=,>L;(X^NX#^1->73_=5^7SL=$O>A<\EM?^/R
M#_KHO\Z]^KP&U_X_(/\ KHO\Z]^K7';Q)I=3&\2>((?#VG><RB2>0E88\_>/
MJ?85Y1?^(M6U*5FN+Z;!_@1BJC\!6[\2)VD\00PDG9%;C ]R3G^GY5QU;X6C
M%04K:LFI)MV'.[2.6=BS'J6.32445U&84444 >A?##_F*_\ ;'_V>O0:\^^&
M'_,5_P"V7_L]=]*YCB=QR54FO'Q7\9_UT.FG\*';1Z"C:/05YK_PLO4/^?&V
M_-O\:3_A9>H?\^-M^;?XT_JE7L+VD3TO:/05PWQ+ &GV&!_RU;^59W_"RM0_
MY\;;\V_QK'\0>*KGQ#!#%/;Q1")BP*$\Y'O6M'#5(5%)DSG%JR,"OH*OGVOH
M*JQWV?G^@4>IY]\3O^85_P!MO_9*=X \1[@-&NGRP!-LQ[CNG]1^/M3?B?\
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MVBO,QWQKT-Z6QX_XX&?&%[](_P#T!:YNZG6UA))Y[5TGCN1(?%5](YQQ'_Z
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MB>G/]WV[5ZO7SI7O>A7+W>@:?<2'+R6Z%CZG S7F8VDHM374VI2OH<=\4O\
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MWA: 2J5>=C,0>P. /T /XURWACX:31W$=WKK(%0AA:H=VX_[1Z8]AG/K7IP
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M_D;;7_=D_P#037KU>0^!/^1NM?\ =D_]!->O5Y>-_B?(Z*7PG@^LC_B>7_\
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MK79@A@"""#R"*\3LO#&LW\PCBT^=,_QRH44?B:]FLK?[)86]MNW^3$L>X]\
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M82CG-%% !1110 4444P"BBB@!**** "BBB@!:*2B@!:**,T@%HI*6@ HHHH
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M[L2#"+^'?ZFG'#5:CO,3G&*T)?$^OOK^KM*JE;:/Y(%/9?4^Y_PK&&>]&*4
MUZ48J*Y48-W=P%+FBBF E(:6D-,!**6DH *0]*,TE  ***3VI@%!YI:;C(]Z
M ')G%!SBA3QBG8I ,QSFB57>)E3_ %B_,OUIQ%*G#@],<T ,C?S(ED7HPS2Y
M*^X[BF*C1N3&?D8Y*'M3B<LR^E,!^?F*^V112#[JD]1Q1TI +BB@44 %(.M+
M10 44M)0 44=:* "EI** "BBCM0 4X=*;1G% #Z*0&EI %':DI: &&DIQI*8
M"444M "4M%% !111WH 0T"BEH 3M2T44 )0***  <"C%+10 "BBEH 2BBB@
MHHHH **** "BBB@ HHHH .])1010 44=Z* $/W2::KXIYX!J/&X9';K3 E4Y
M'%!J *YEX)"X_6I<F@!U(324@'-( )YIZ#=UX%"KFH;RZ%O$0.M/<"OJ-R[$
M6L/5NN/2GV\ MX@@Z]2?>HK.(X,\G^LDY'L*M4P"EHQ12 !1WH%+0(#3A24H
MH&*!3A313J0#EIXIBT\4@'BH+\_Z.$_O&IQ56]/S#T H6X&8U-ZT]NM,[5J
MF,FK"C"@5$HYJ8<B@!:6D'-+2 <.E.%-%.%(0N:0T4O:@!*6DI10 "BCO2T
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M0@SPHQDQV#8P/T)_&N%KIHS<X*3,Y*SL%%%%:""BBB@ HHHH **** "BBDH
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MI2T4"$HI:3H*!A1WHHH 6DI:2@ H%% IB"CO11WI +24M)3 .]!II.#2YXH
M**0&E% "BEI**0!24M%, -)BEHH 3&:*6B@!M%'>EH 2C%*** #M1VI*6@!*
M*6DH ***#0 E(:6B@9ZS\-/^1;?_ *['^0KLZXOX:?\ (N2?]=S_ "%=I7AX
MG^+(ZH?"@HHHK$H**** "BBB@ HHHH **** "O.?B5_Q^V/^X?ZUZ-7G/Q*_
MX_;'_</]:Z<)_%1%3X3AJ*6DKUCF$HI>])0 4M)10 4444 %%%% !1110 44
M44 )2BBEI@!I*6BD 4444 )12TAI@%%%%( HHHIB"BBB@84TTM-- !2TE**
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M0RG*D9!'>N'$4?92TV9K"7,CSGXF_P#'WI__ %S?^8K@>@KOOB;_ ,?>G_\
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MZ@MKK4EJ[82Z3"^[CD?INKTR6))H7BD&4=2K#U!K@Q4;57?J;4W[I']MM/\
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MR1QDV,K$Q.!PN?X3]*YZO3A-37,CG:L[,*WO!<;R>+;';GY2S$^VTU@BO3/
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M/4? L;Q^$+/?GYB[ >V\U0^)+*/#D*GJ;I<?]\M766MM%9VL5M"NV*) BCV
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MZUGB:3J0TW*A+E>I['7%?$;4FATJ'3HG >Y?<_\ N+_B<?D:I_\ "SO^H/\
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M0I!!'XTHQU%(!:*!S^%% !111WH 7O1110 E+24M !1244 ':BBB@ HH'-%
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M)_Z:$?I71A?XJ(J?"SSL4ZF4X5ZYS"TAI:#0 E%)10 44M)0 4444 %%%%,
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MF&G$TTTP&GK24II*8"CBEI*6D 4HI*<* "EHH[T %+B@4HI )CBG*:2E7K0
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MT444 )2TE% "T444 )12TE !2TE+TH *6DI: "BBB@ HHHH **** "DI:0T
M)1113 2DI:2@ HHHH *6DI: %S2TE% "T444@"BBB@ I:2EH 7M2CI2#K2T
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M* "EI** %HHHH **2E% !112T %(:6DH ;12TE A*2G4E,8VBEHH ,T9I**
M'4M-I: %I:;2T +124M(!:*2EH 44M-IU !3A3:44@*VJ M:*/\ :S6'(O-;
MU^,VZCMGFL:9*UAL!%"2C[JG9N/K5=:EW?+5"$@.)F'0$5;C.UZKQ@$Y]*L+
MZTF!:'!]JD'2H5.14BU# D'2E4\TVG"D,E%!IH-.I 1,*;4CBHZ8!1110 44
M44 ***** %HI*6@ I124M( I:2B@ HI:* $HHHH **** $I*=24P&T'K2FFT
M %%%+0 8.:CEDW-L7[HZTZ1MJ'!P?6JIC:1"JG /4TT@)$Q(/E^[TS4Z@(H
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MH <*4TE+U%(0 4M(*6@!12T@I:0!BEH'2B@ HHI.] #FYC:HEJ3.$;/I3$'
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M&*=28H 3%)BG4AI@-Q24[%)0 E*#1BDH =2TT4M "TM)12 6BDIU !3J;2T
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M**8"T444@%HI*6@ I*6DH ***0=: '44&B@!**** "DI:2@ HHHI@)THHI:
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M@!*2EI* "BBB@8E%%+0(2BBEH *2EI#0 N*2ES10 444E "TM)1F@ HHI30
MTTG>G4G>F ZCM1VHI )11WHH *2E[4E !2&EHZTP"DI:2@ -%!HH 0T4&DH
M6BDI<T %-ER8GQUQ3J0\"@#WS0T\K0[)/2(5H54TL;=*M1_TR7^56Z^?E\3.
MQ;!1114C"BBB@ HHHH **** "BBB@ KSOXF-^]T]/J?YUZ)7F_Q+8?;K%?\
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M444 %)2TAI@!HHHH 2BCM24 *:2EI#TH .M(:6DH ***6@ I#V^M+WH/5?\
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MJ?\ U[/_ "KP]17N/B7_ )%G4_\ KV?^5>'"L\#\#*J[G<?#3_D,7@_Z=_\
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M@Y !_J*BHJUO?O8:Y;Z$7B7_ )%G4_\ KV?^5>'CFO</$O\ R+.I_P#7L_\
M*O$%ZUV8'X&9U=SN/AI_R%[S_KA_[,*],KS/X:?\A>\_ZX?^S"O3*Y<7_%9=
M/X3P6]_X_KC_ *Z-_.J]>['2--8DMIUH2>23"O/Z4G]CZ7_T#;/_ +\+_A70
ML<NQ'LGW/&-*TB\UB[6"SB9CGYGQ\J#U)[5[3I>GQZ5IEO91'*0KC)[GJ3^)
M)-6(H8H(Q'#&D:#HJ* /TJGJVL6>BV9N;R3:.BJ.6<^@%<]:O*LU%(TC!1U.
M;^(VHK!H\5@K#S+B0,P_V%Y_GBO+\UH:SJUQK>I27EQ@%OE1!T11T%4*]&A3
M]G!19A.7,[DEO!)=7$4$0S)*X11ZDG KW:QM(["P@M(ON0QA <=<#K7F/P_T
MS[9KYNF7,=HF_P!MYX7^I_"O5JXL;.\E'L:TEI<X;XD:EY=C;:<C?-,WF2 '
M^%>@/U/_ *#7G5O-);3Q3Q-MDB<.C>A!R*V/%NI?VGXCNI5;,<9\F/G/"\<>
MQ.3^-8?:NRA#DII&4W>1[U8W:7]A!=Q?<FC#@9Z9'2N.^)&F^;8VVHHOS0MY
M<A']UNA/T/\ Z%4_PZU'[1HTMBY^>U?*C_8;G^>[]*Z?5+%-3TNYLGQB:,J"
M>Q['\#@UYR_<UO0W^*)X10*?)&T4KQR*5=258'L13*]@YA>M)7L'@;_D4++Z
MR?\ H;5T5<,\;RR<>7;S-52NKW/GVBOH*BI^O?W?Q_X _8^9\^TE>_77_'I-
M_P!<V_E7@7:NBA7]K?2UB)PY0I:2EZ5T$'N.@_\ (NZ9_P!>D7_H KF_B5_R
M [7_ *^1_P"@M72:#_R+NF?]>D7_ * *YOXE?\@.U_Z^1_Z"U>/1_CKU.F7P
M'F%>A_#[P^AC.LW,>6R5MP1T]6_H/QKSU5+L%'+$X KWJPM%L-/M[1/NPQJF
M?7 ZUV8RHXPY5U,J2N[DLTT5O"\TSK'&@W,S'  K@M5^) 25HM*ME=1QYTV<
M'Z*,?J:;\2-6</;Z5&V$*^=+COSA1^A/Y5Y_WK/#8:+CSS*G-IV1U\7Q&UA)
M 9(K5TSRNPC]<UV/A[Q?9:ZP@*FWN\?ZICD-_NGO]*\?J2&:6WF2:%RDD9#*
MRGD$5O4PM.2T5F0JC1[]7(_$7_D6D_Z^4_DU=!HVH#5='M;T  RH"P'0,."/
MS!K ^(O_ "+2?]?*_P FKSJ*:JI/N;2UB>5"BBEKVCF =:<!FD]Z<!Q2 ]/^
M''_(O7'_ %]-_P"@)77UR'PY_P"1>N/^OIO_ $!*Z+5]072M(N[]P"((BX![
MGL/Q.!7CUTW5:1TP^$R_$/B^QT%_LY!N+PC/DH<;1V+'M_.N-F^(VL/(3'#:
MQIGA=A/ZYKC%FFN9'NKEV>>=B\C,>234E>A#"TXJS5V8RJ-['H&E_$EC(J:I
M:*$/66#/'U4_XUWUO<0W5ND\$BR1.,JZG((KP&N\^'&K.MU/I4C$QNIEBR>A
M'4#ZCG\*QQ.&BH\T"H5'>S+?Q \/I);G6+9,2I@3@?Q+T#?4<?A]*\WKWZZM
MTN[2:VD^Y*C(WT(Q7@DT30SR1/\ >1BI^H.*O!U'*+B^@JL;.YVW@'P['=R-
MJUVFZ.)L0*>A8=6_#C'O]*])9E12S$*H&22< "J>CV2Z?H]I:*,>7$H/N>I/
MYYKDOB-J\D%O!ID+%?.'F2X/50< ?0G/Y5R2;Q%6QJK0B)JWQ'B@F:'3+83[
M21YTIPI^@')'Y5DQ?$G5UE_>VMFZ>BJRG\]QKC"*7/K7H1PU)*UC%SD>Q^'O
M%UEKQ\D V]V!DPN<[O\ =/>MF]LX-0LY;6YC#PR###_/>O!X)Y+6=+B%V22,
M[E93R#7N&BZ@-5T:TOL &:,%@.S="/S!KAQ-#V34H[&L)\VC/'M:TJ31=6GL
MG)*J<HQ_B4]#5SP?9I?>)[2.1<HA,A!'7:,C]<5T_P 2K(&&RO@.0QA8^N>1
M_(_G7*>%M0CTSQ%:7$S!8MQ1V/0!AC/ZUV1FZE&ZWL9-)3L>T5YQKWCS4(]2
MGMM.$<,4+E-Y7<S$<$\\ 5Z/UKB]?\!)J%U+>6$ZPRR$L\<@^4L>I!'3]:X,
M.Z:E^\-I\UM#%TSXAZA#<*-12.X@)^8JH5Q],<&NRU/Q;I.F6R2M<"9Y$#QQ
M1<L01D$^@^M>9W_A76M.W--8R.@_CB^<?IT_&L<UVO#TJC4H_@9<\HZ,OZUJ
M0U?5)KT6R6_F')1"3^)/K^5;WPY_Y&27_KV;_P!"6N1KKOAS_P C)+_U[-_Z
M$M:5DE2:78F.LCU.O )_^/B3_?/\Z]_KP"?_ (^)/]\_SKFP/VOD:5NAWP^)
MP  _LC_R9_\ L:[;2[W^TM,MKWR_+\Y ^S=G&?>O!Z]M\+_\BQIW_7!:G%48
M4XIQ0Z<FWJ0^)?$?_".V\$OV7[1YK%<>9LQ@?0US?_"SA_T"/_)G_P"QJ;XF
M?\>-A_UU;^0KS>KP]"G.FI26I,YR4K(LW]U]NU&ZN]FSSY7EVYSMW$G&?QKT
MGX;_ /(NW'_7VW_H"5Y::]1^&W_(NW'_ %]M_P"@)6F+5J5A4_B-+QI_R*-_
M]$_]#6O'T=HI%=&*LIR".H->P>-O^10O_HG_ *&M>.4L%_#?J%7<]TT?4%U7
M2+6]7&94!8#LW1A^8-<Q\1M,\_3(-01?FMVV/_NM_@<?G5;X;ZINCNM,=N5_
M?1CVZ,/Y?F:[74+--0T^XLY/N31E"?3(Z_AUKD?[BM_6QK\<3P;'-*%+$!1D
MG@ 5)/"]O/+!*NV2-RC#T(."*W/!>F_VEXDM]RYBM_W[_AT_7%>K*:C%R.=*
M[L>HZ'IPTG1;6RP T:#?CNQY;]2:YGXD:GY&DPZ=&WSW+;G_ -Q>?U./R-=M
M7C'BS4_[5\17,RMF*,^5'_NKW'U.3^->9A8NI5YGTU-ZCM&QAP6TMS<1P0J7
MED8*BCN37M^@:)!H.EQVD(!?[TLG=V[G_"O.OA_9"Y\2K,P^6WB:0?7[H_G^
ME>LUIC:C;4$32CI<P?$GBFS\.PJ'4S73C,<*G''J3V%<!<?$/7II"8I(+=>R
MI$#_ .A9I-7T#Q)JVJW%[+ILQ,KDJ"1\J]AU["J!\'>(/^@9-^:_XUK1I48Q
M]YILF4I-Z&UIWQ)U*&51?PQ7,7\11=CCW';]*])T[4;;5;&.\M)-\3CCU![@
MCL:\<_X0_P 08_Y!DWYK_C78^ M.UG2;NYM[VSDBM94W L1@."/?N"?R%9XF
ME2Y>:#5RH2E>S&_$#P^AB&L6R8<$+< #J.@;^GY5P"U[K?VJWVGW%J_W9HV3
MZ9&*\,4$$@]16F$J.4.5]":D;.Y%=\1!O2LYFXK1O/\ 4$5DNV*[H;&8N<FG
M4Q#GI3ZH!U+35Z4M(!U/44VG"@0X4\4T4X=*D!:4T44 )2BDI: #I12TE PI
MK\D4ZF,<F@0T=:<*2E% #C0*3-+0 4444 %--.I#TH 92T$4E,!:*2EH 6BB
MBD 4444 )12FDH ****8!12TE(!:*2B@8I[44G6BF( ,&EHSQ2 T@$/%%*1D
M4G:F 4444 %(:7-)0 M%)2T )111WH *2EQ10 AI#D,A'9A2]Z0]OJ* /H>U
MYLX/^N:_RJ:J]B=UA;G_ *9K_*K%?//<[0HHHI %%%% !1110 4444 %%%%
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M?\C+IW_7=?YUE5I^'&"^)--)_P"?E!^M=LU[C7D9+<]LKQSQ;_R->H?[X_\
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MC>,9Y]ZM^+HDF\*Z@K@86/<,^H((KFI2G1J\C+DE*-SQBCO117K'.%+FDH-
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M%% "44M)0 M% HQ0 5W_ ,,^NJ?]LO\ V>N!K?\ #/B;_A'/M7^B?://V?\
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MD-** '444&D,8U,IY.:;CFF(*!110 M'>CO10 4HI*#0 N>:3-(** %I***
M#K0/2BB@!*44E+0 8HQ110 8XI,<4O:D% "XXI,4M)0 M)WHHH 6BDI: "D-
M+24 %+FDHI@/HIN:7-(!<4TKFE!IV: (BE,(Q5BFE0:=P(:*D:(]1S3=IHN
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M6GS2TN4=S#:'5$)^5C^-,,M^.#&PQ[5T(=P/O&C>_7=2Y7W"YSIN;Q>JL/\
M@)IJW]RDBL),,ISBNC,C^BGZBJ=TEO)_KX N?XU'2CEET871EQWWEW;7&P!7
M^^@K9MKB.X0M"V<=1W%8TT%NHW))C!P1FFO'+93AXWQGE'!X847FMQV3.A5L
M&I,@C(K.L[X7 ^<A9?3UJ\C_ #8/6J)'TE+2&@!**** "BBDH **** "BBBF
M 444M( HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ HHHH 2EHHH 44HI
MM.% #9?O#W%1$5-+]U345- 5W7KBF]1]*G85$15(0G6C% SFC=0 M%+1C*T
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M;^M<+\5K_P W4K'3U/$,9F;'JQP/R"_K6%'X\\0VEO%;07B+%$@1%\E#@ 8
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M4P#O1F@TE "=Z,"BB@ QQ2@4"E% "$4N.*6BD VBE/-!YI@)1VHHH **,44
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M5*M(!U.%-I0<5("L<8 [TO:D YR>M+WH *3O0324 *:!UH/2@=* %I3249H
M#TIO:G4AH !12#K2GB@!**!24 +24+2F@!!UI:2EH *2BB@!:*** "BBB@ H
MHHH **2EH 2CM2TE !1113&+1112$%%%% "4M)2T )1113 2BEI* $I110#S
M0 "EI*6@ IO>E-)0 M% HH *L6/_ "$K0>LR?S%5ZLZ;SJUD/^FZ?^A"D]AH
M]_3_ %:_04ZD7[@^E+7SQV!1110 4444 %%%% !1110 4444 >5>/X/*\1B0
M#B2,'\L"N6KO/B5#B6PG Y.4)_6N#KV<.[TD<L_B8E(:6BMB1**** "BBEH
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MW-.QQ2;>: $!I*-HYHQ@4Q" 4HH%+0 "E[TG>EH *6D[4M(8M%%%  31110
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MG\@:]B5510JJ%4#  & *6N)XV5]$:^R1X1<6MQ9RF.X@DA?^[(I4_K7:?#9
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MI W]X,<UUGASQO>65Q';ZC*UQ:,0I=SEX_?/<>U6Q\,[D#_D)1?]^S_C2_\
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M>)Y-9CDL[P@W<*[@X&/,7IG'J./SKI+ZTCO[">TE *3(4.?<=:\L\!,1XJ@
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M;L^C1_\ H8KRS2;9;O6;*W8962=%8>Q89JL)+]UKT%47O'J?@W0UTC18Y)$
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MR^$=0NM4\/PW5Y+YDS.P+;0O0\< 5'XQU*[TK03<V4OE3>:J[MH;@Y[$&H?
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MC6QGO_#4J6\;221NLFQ1DD#KC\Z\_;$:]S;[!X_12D$'!&"**]4YST#X8_\
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M%/ZI5V#VD3TNZN[>RMVGNIDBB7JSG KR;Q9XIDU^X$, :.QB.44]7/\ >/\
M05D:AJM_JD@DOKJ29AT#'@?0#@51/K770PJIOF>K,YU+Z(0U8L+ZXTZ]BN[6
M0I-&<J?Z'VJN:2NIJZLS(]H\/>*K'7H%4.L-X!\\#'GZKZBMR2-)4*2(KH>J
ML,@U\^*2K!E)!!R".U='8>-M<L0%^U"= ,!9UW?KU_6O/J8)WO!F\:O<]0;P
M]HS/N.EV>?\ KBO^%7H8(K>,1P1)%&.BHH4#\!7FW_"R=3QS9VF?7#?XU0O/
M'>N7:E5FCMU/7R$P?S.36?U6M+1L?M(K8]$UWQ%9:#;%IG#SD?NX%/S,??T'
MO7D.I:A<:K?R7ET^Z1ST[*.P'L*KR2232-)([.[')9CDG\:9791H1I+S,YS<
M@KT/PCXSC$4>FZI)M9?EBN'/!'8,>WUKSVBKJTHU(V9,9.+NCW\$,H92"",@
MCO4<EK;S-F6"*0^K(#7C&F^(M5TD!+6\=8A_RS;#+^1Z?A6\GQ(U54P]K:,W
MKM8?UK@E@ZB?NFRJQ>YZ:JJBA54*HZ # %4-7UJRT2T,]W*!_<C'+.?0"O-[
MKX@:W<(5C:"W![Q1\_\ CQ-<S<74]W<--<RO+(W5G;)JJ>"DW>;!U5T+FO:W
M<:[J;74_RJ/ECC!R$7T_^O69GM3L<TA'?O7HQ2BK(P>IZ'\/-?A6%](N) C[
M]T!/\6>J_7O^)KT&OGM6 ; Z^M;EGXPUNR18XK^1D QME ?'Y\UQ5\(YRYHL
MUC4LK,]D,$);<8HRWKM%>(Z\<>(M3 [7<O\ Z&:U6\>Z^R$+<1J?40K_ (5S
M<T\EW/+<RONEE<N[8QEB<G@>]7AJ$Z;;D*<U+8N:5J<^CZC%>6S8=#RIZ,.X
M->P:'X@L=>MA);2!90/WD+'YD/\ 4>]>)8!J6":2VG66"1XI5.5=#@@_6KKX
M>-77J*$W$]\9%=2KJ&4\$$9!JJNE:<DGF)86JO\ WA"H/YXKS&S\?ZW:H$D:
M&Y [RIS^8Q5B7XD:LRXCMK1/?:Q/\ZXOJE5:(U]I$],N+B&T@>>XE2*)!EG<
MX K/T'6X]=MKFYA0K#'<&)">K *IR?3K7D.IZWJ.L.&OKIY IRJ=%7Z <5-I
MGB35=(MFM[&Y\J)GWE?+5OFP!GD'T%:?4GR[ZD^UU/3?&_\ R)]__P!L_P#T
M8M>.ULWWBO6=2LY+2[O/,@DQN7RD&<$$<@9Z@5C5TX>E*E'E9$Y*3NCU?X>?
M\BR?^N[_ ,A4_CO_ )%*Z_WD_P#0A7F^G>)=6TFU^S65WY46XMM\M&Y/N13K
M_P 4ZQJ=H]K>78DA?!*^4@Z'(Y S6+PT_:\]]+E>T7+8QZ6D[TIKN,CI/ 8_
MXJRW_P!Q_P#T$UZ[7@UAJ%UI=VMU9R^7,H(#;0W7@\&MC_A.?$/_ $$!_P!^
M8_\ XFN+$8:=2?,C6$U%69F:Q_R&[_\ Z^9/_0C5&I)IGGGDFE;=)(Q=CC&2
M3DTP^HKL2LK&1Z;X!UV*XTU=+FD5;B#/E@G[Z=>/<?RKM*^?PQ5@RD@CD$=0
M:W+7QEKUH@1;]I% P!*H?]2,UPUL&Y2YH,UC5LK,]@%O"#D0QY]=HKP>?_CY
MD_WS_.M]_'FOL,"ZC7W$*_U%<XS%F+$\DY)K3#494[\PIR4M@I#THH-=1F-K
MTGX9_P#'A?\ _75?Y5YO6EI>OZGHT<B6%SY2R$%AY:MD_B#65>FZD'%%0=G<
M]:\3_P#(L:E_UP:O$ZV[KQ?KEY:R6UQ>AX95*NOE(,C\!6)4X:C*E%J0YR4G
MH&>*]/\ AM_R [K_ *^3_P"@K7F%:FF>(M5T>W>"PN?*C9MY'EJV3@#N#Z"J
MKTW4ARH4)6=SU#QI_P BC?\ T3_T-:\>' QVK7O?%>M:C:26EU>>9!)C<OE(
M,X.>H&>U8^:G#TI4XV8YR4G="YKU#X<'/AR;_KZ;_P!!6O*V:M72_$>K:/;-
M;V-UY41<N5\M6Y( ZD'T%.O2=2'*A0DHN[/3?''_ ")]]_VS_P#1BUX]6SJ'
MBK6=1LY+2[O!)!)C<OE(,X((Y SU K%)HP]*5./*QSDI.Z-KP[XAN- OO.C!
MD@?B6+/WAZCW%>MZ7J]EK%J+BSF#K_$O1D/H1VKPG). .M3VMW<65P)[6=X9
M5Z,C8-37PT:FJT80FXGO4D4<R;)45U]&&13(K2VMVW0V\49]40#^5>76GQ"U
MJW0++Y%R/61,'_QTBIY?B1JK+B.VM$/KM8X_6N/ZI56AK[2)Z<[I&C/(RJBC
M)9C@ 5YUXO\ &27D4FFZ8Y,)XEG'\8_NK[>_>N6U+7M3U<8O;MY$SD(/E7\A
MQ6=711PB@^:6K(E4OH@H[445VF1V7@'7H=/NI;"Z<1Q7!!1VZ!^F#]1_*O3Z
M^?JUK'Q/K.FHL=M?2"->B/AP/H#G%<5?"\\N:+U-(5+*S/9V@B=MS1(Q]2H-
M>1>-@%\77P  '[OI_P!<UJ8^/-?(Q]HB!]?*6L*^OKC4KV2[NY/,FDQN;:!G
M  ' XZ 48?#SIRO(<YJ2LCN/AE_S%/\ ME_[/78Z[_R+^I?]>LO_ * :\>TS
M6]1T;S?L%QY/FXW_ "*V<9QU!]35R?QAKUS;RP2W^Z*5"CKY*#((P1PM*KAI
MSJ\ZV"-1*-C#-%%%=ID:&A?\C#IG_7W%_P"ABO<*\#@GDM;B*XA;;+$X=&P#
M@@Y!YK<_X3?Q%_T$/_(,?_Q-<F)H2JM-&D)J.XOCC_D;[WZ1_P#H"USZLR.'
M4E6!R"#@@U/?7USJ5X]W=R>9.^-S;0,X&!P..@JO73"/+%19#=W<]1\+^,X-
M2BCL]0D6*\48#L<++_@?;\JZ\@$8(R#7S\:V=/\ %6LZ8JQP7C-$O2.4!UQZ
M<]/PKCJX.[O TC5[GJ\N@:/.^^33+1F/4^2N3^E6K6QM+%"EI;0P*>HB0+G\
MJ\X3XDZH%P]I:,?4!A_6JMU\0M;N%*Q&WM_>./)_\>)K+ZK6>C_,KVD3TS4M
M5L](M&N+V=8T'0?Q,?0#N:\;\2>(;CQ#J'GR I!'E88L_='K]3WJC=W=S?3F
M:ZGDFD/\4C$FJY6NRAAHTM7JS.<W+06#_CXC_P!X?SKZ%KYX&48,IY!R*Z ^
M._$@_P"8C_Y C_\ B:6)H2JVY>@Z<U'<O_$K_D98O^O5?_0FKC\U;U/5KW6+
ME;F_F\V4($#;0N "3C@#U-4OI6]*#A!1?0B3N[CP:>#40/>G U9)**44Q6R.
M:D4$FD,],^&__((N_P#KO_[**V_%?_(KW_\ US_J*\NT_P 0:GHUNT-C<^4K
MMN8>6K<].X-2S^+=;O[>2VN;T/ ZX=?*09_$"N&>&FZO.MC55$HV.<GDW7#X
M[<5ZMX+\8PZK:QV%],%U!!M4N<><.Q'^UZC\:\C[LYZEC302'!!P1SD5UUJ$
M:L;,B,G%GT>RAE*L 5(P01P:S#X;T,R%SI%EN/7]PO\ +%>3Z?XZU_3D6-;H
M7$:C 6X7=^O7]:U_^%HZJ5_X\K+/KA__ (JO/^IUHOW6:^TB]SU..-(HUCC1
M411@*HP!^%<9X\\3PV>GRZ5:R*]W.-DNT_ZM#US[GICWKC-0\=:]J*-']I6W
M0]5MUV_KR?UKG<DDEB22>2:UHX-QES39,JMU9"BO:?!^FVEEX<LY((T\R>(2
M228^9B><$^W2O%EKH='\8:KHEK]FMVBD@!)5)ER$SZ8(-;XFE*I&T2(247J;
M/Q'TVTM-0M+FWC2.2X5_,51@$C&&QZ\_I7$XJYJNK7FLWANKV7?)C: !@*/0
M"J=:4HN$%&6XI--W04445H2)0:*#0 =J*** "BBB@ I*6B@ HHHH 2BBB@ H
MHH- "444M "4=J*6@ %)2TE !1110 4444  HHHH *2EI* "BBEH ***3O0
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MG!HY!Q0 A&#2CBC((HS[4 !%)2Y0#&\4F1Z@T !I>,"D[T#.>30 ASG(Z>E
M=B0!&WXT[&VC.#P: &YD/_+(BFLS#DQ8 ]*EW$9YI-Y"G/- #-^2"!P:4-DG
M!_"EX-)@4 .S1CFD QTIVT\<4 )2]Z,'..](>M "T4F?>DSZF@!312;AG!HR
M#0 O:BDW#I2T %.IH%.QCK0 9XII.:-PQZF@$D=,4 &WN:0[B, XQ^M-();/
M:G"@ "GJ3^%&!M]Z4T@Z4 '& !2 <]:0\&@?>H =2YI#1UH 6BDSQ1F@!:*,
MTA- "T4F11GF@!V:*3-% "T4F12Y'6@ I:3M1F@!:*!24 +124HI %%% .*
M%IN*=10 PBC;3Z2F!%MYIK+4^*:0,T7 @8=JC!Q5EDR*;Y1SS3N!!NPX'J*=
MN&*=Y)]*BFC*KN .>X%,"<-@<U:C^6,%NU4H%S,L1)8A=P)]*LS'YE4=NM2^
MP"2-N-.&!"Y]JCSDTZ8[+1CW) % %)B-YI*#U-':K$*.:44@ZT[M0 M.[4@%
M/[4@$7I3EIO2G+2 =WHI#UHSS0 M%!HH #1244 %%%% !1110 4444 %%%%
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M"?ED&1]:VJY57,4BR+]Y3D5U$4JSQ)*G1QFM(OH0Q]%%%4(*8YXIQ-1F@!*
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M2#I4:X= RD%3R"*E'2J8A:5>M(*<.M(8X4M(*6D 4M%%(!**#2=Z8"T4E+0
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M HHHH **** "J&M:G!H^D7-]<'Y(T)QZGTJ_7G_Q6NRFD6=F#_KI=S#V&/\
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MOQ,1GMM.V]FD_DM>:,,$^H[5U83^$B*GQ'>?"U0+S4O^N:?S--^*0SJ&G?\
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MHFIOI&KV]XI(5& D _B0]1^59UL/&:O%68XS:>I?\6^'CH.ICRLFSGRT1/\
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M *Z+_.H:FM/^/V#_ *Z+_.D]@/9O$'_(N:E_U[2?^@FO$C7MOB#_ )%S4O\
MKVD_]!->)UQX'X6:U=Q Y!YJ0,#TJ(TJ<"NTR)@:Z[X>?\A^?_KU;_T)*XX5
MV'P[.?$$_P#UZM_Z&E8XC^&RH?$C4^(_^HT__>?^2UYW-&KKN ^85Z)\1_\
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M?*SL^15QG&>@'H*SJ!2U22BK(3=Q*N:5_P ABQ_Z^(__ $(54JWI7_(8LO\
MKXC_ /0A1+9@MSU_Q3_R*^H_]<37BO>O:O%/_(KZC_UQ->*UQX'X'ZFM7<]5
M^'84>&W(ZFX8GZX6N'\3NS>*-0W=?-(_#''Z5T_PUO@8+W3R?F5A,H]0>#_)
M?SK*\?Z:]KKHO57]U=*#N'9@,$?R-*G[N(DGU"6L$<R"*I2P& G;DQGD>U60
MU/!!&#R*[5H9% ,&XSS3E/:I9K-9!F,[33-.L;R_U6VL(T)EF<+GL!W/T R:
MJZM<+'N>D,S>';%G^\;2,GZ[!7AU>^K$D%J(HQA$3:H] !BO  >>:\_!.[D_
MZZFM7H/H%)[T5WF0ZM#0?^1BTS_K[B_]#%9U:.@_\C%IG_7W%_Z&*B?PL%N>
MF>.R1X3N0.[(#_WT*\C%>N>._P#D4[G_ 'T_]"%>15S8+^'\S2K\04445V&9
MZ)\,O]3J7^]'_P"S5B>/_P#D:7_ZXI_*MKX9?ZG4O]Z/_P!FK%^('_(TM_UQ
M3^M<,/\ >I?UV-7_  T:7PS4&[U!OXA&@'TR?\*[B^T;3M2E62]M(YG4;5+]
MA7G/P]O1;^(6MV( N(BH_P!X<C] :U_B182&.TU&/.U,PR8[9Y7^M9U8.6(M
M>UQQ=H'2_P#"*:%_T#(/R-'_  BFA?\ 0,@_(UXOO;^\?SI=[_WC^=:_59_S
MO^OF+VB['L__  BFA?\ 0,@_(T?\(IH7_0,@_(UXOO?^\?SH\QO[Q_.CZK/^
M=_U\P]HNQ[M?1H-)N8@,)Y#+]!M->)Z6%;5[(-]TSH#_ -]"JA9O[Q_.G12-
M%*DBG#(P8?45K1H>R35[W)E/F:/8/&S,OA&^V]P@/TWK7CE>VW*1^(?##K'C
M%W;Y3/9B,C\CBO%9(G@F>*12LB,593V(X(K+!/W7'K<JKO<;2#H<]:6DKM,@
MQD5U7P^+#Q0NWH87#?3C^N*Y4"N_^&^F/YMUJ;KA-ODQD]SD%C^@_6L,1)*D
M[E05Y(G^)G_'MIW^^_\ (5P5@JMJ5JK?=,R _3(KO?B;_P >NG?[[_R%>=HQ
M1U=3AE.14X7^"AU/B/8_&3,OA*_*]=JC\-PS^E>-]\U[8XC\0^&3MP!>6_'^
MRQ']#_*O%IH9+:>2"9"DD;%64]01U%9X)VBX];E5=TQE!I.]'>NTR%KI_ +,
M/%407H8G!^F/\<5S!KO/AOICM<7.INN(U7R8R>Y."?R&/SK'$-*D[E05Y(N_
M$O\ Y!MC_P!=F_E7FW:O2?B7_P @VQ_Z['^5>:FHPG\)#J?$)7MWB,X\,:B?
M^G9_Y5XE7MGB/GPOJ/\ U[-_*L\7\4/Z[%4]F>)_RHS2=!2XR,5VF0>M>W:O
M_P BK?\ _7E)_P"@&O$!7M^K_P#(JW__ %Y2?^@&N'&?%#^NQK3V9X@>:57:
M-U9"0RD$$'D&DZ&F\Y/I7<9'M^GW,'B3PU')(,I=0E)5'8XPP_/.*\9O+22P
MOI[288DA<HWO@]?I7;_#;5-LESI4C<,/.B^O1A_(_@:@^(^E>1J,.IQK\EPN
MR0@?QKTS]1_Z":X:/[JLZ?1FLO>BF<KHVG-JNK6MBA(\V0!B.H7JQ_  UZUX
MFU%-#\-3/#B-RH@@ XP2,#'T&3^%<S\-M+YNM5D7_IC%^A8_R'YU2^(NJ?:=
M6BT^-LQVJY?_ 'V_P&/S-%3][74.B!>["YQ==/X"53XK@)ZB-R/KM-<Q6OX6
MO18>);&=C\ADV,?0,-N?UKJJINFTNQG'='L5]IMGJ<:QWMNDR*=RJW0'UJA_
MPBF@_P#0,@_(UG^/K&6[\-M+""7MI!*<==N"#_//X5Y.'?\ O'\ZX*%&52%U
M*QM.23U1[1_PBF@_] R#\C1_PBF@_P#0,@_(UXJ7?/WS^=*'?^\?SK;ZK/\
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MUH *2@T4 %)110 M I*44 +BCO2XHH 0BDIU)B@!M+124#%I.U+24""BBBF
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M.,XQVKK_ !OKNG:O%9"QN?-,;.7^1EQG&.H'I7(*VX5&&3C328YZR.U^&O\
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M*D6DP&79VV4A_"LDY4(?;FM6\_U"KZFLYA\XJX[ .^]],8J1?E&*8/2G4P'
MT \TT4X>HI"%'!IU)2CK2 44M% ZT .I#TI>U(:0P[44"C%,04444 %%%+0,
M2DI110(*2BB@ HHHH **** "BBEH *2G8I* $I*6DH 2D-*:0T %%)0:8"TH
MI*44 .HH%+2 2BEHH 924^D- #:*6DIC"BBB@04444 %%%)0 #TI:3O10 44
MAI1TH **#10 4AHHH #1110 E+244 %+2=J7M0 E7M$YU[3^,_OT_P#0A5"M
M#0?^1AT\?]-T_F*4_A8UN>^CH**!THKYX[ HHHH **** "BBB@ HHHH ****
M "BBB@ KYGUF3S-9O6S]Z8FOI65_+A=S_"I-?,_E>??W$C_=\QC]>:]'+_M,
MRJ]!MM"?]:X^@K:M3F(508\?RJ]:$&!<=NM>@]C%EBBBBI$% I.:6@!P.#5'
M4]/^T@S18$@'(]:NYIRM@T; <B05)!&".HJ>QG^SWL;YPI.#6EJ]B2?M,8^7
M^(>E8I&:F2:]Z)2=SJ+B-;F!XR.H_6J>BADMIE8\+)@4FF7@FB6)S^]3_P >
M%78+?RI[D#[DGSK]:K1ZB*]X=U_8)UPQ/\Z@U2/=.)DX<# ]ZKQW)EUF,MP%
M)05HS('<9YP:(O43+$3%X4+??"C<*4CBJX+!@0<$5))<;8#(1]TC=]*=@%*T
MH&#3^#RIR#R#1BE< 7I[TII.]+2 ;3:7/-(1S3 =24=J* %HS24A- #CTHQQ
M3-_%()!G:3@T /[T#GBFDTJD9ZT +112T )1110 444=Z "BBB@ HHI#0 #@
MT-P*0>M+UH 04HI".>*4\4 .[4JM@YI@-.!H E(R/:H'6I4.1M-#+Q2 HR+B
MF1M^\'UJQ,ORU3YW\=:T0C1EVLQ]1P:BQ2N/W@8?Q*,T5(Q" 1@@$5-"_P N
MQC]#45** +# BF&GHV1@\TC+CZ5($)%--2$?E32*H!AIE/-(:!#,4E.QQ28S
M3 2BEI*8"T44O>D =#3A313Q0 M+244ABT444 %'>BEH **** %I<TE+2 7-
M)U%%% #E=EXSD56DL8'):+]V6ZKVJ>@T; 9[P7EJ2RCS8_U%-COL<.I7ZBM(
M,RGY30ZQR#YD!-5S=P*HO8@P63Y=W1NU6.&!*D''I4+VD3*5*_*>U5GL9(OG
MM9F5UZ G@^U&@%[K15*UOUG;RI5\N<<$=C5T'M4@)0>G'6EQDT8S3 ;TIWO3
M2#FG=* "D%+BCO0 A]*![T&CI0 'K0>32T8H V-#\-W^O2'[,JI AVO,YX7V
M]2:AUW19]"U-[2;++]Z.7& Z^M6?#/B&3P_J)<@O;2X$T8[CL1[BO3Y8-(\5
MZ6I)2X@/*LIPR'^8/M7)5K3I3O)>Z:1BI+3<\4'6EKOKOX:/O)LM04KV69,$
M?B/\*J+\-=3+?->6@'J"Q_I6BQ-)]2?9R['&5Z/\.]&DMX9M5G4J9E\N$$<E
M<Y)^A('Y59TGX>V%E();Z4WCCD(5VI^(YS_GBK'B7Q=:Z);M:V;1R7V-H1>5
MB]S_ (5SU:WM?W=/6Y<8<OO2.5^(6I+=ZW':QL"MJFUO]\\G],5R-*[M+(TC
ML6=B69CU)--KLIPY(J*,Y.[N+1115B"BB@T )BEI.U% "TAHI* ' ]*2@44
M%(:444 )[4444 %%+WS2=S0 8YS1110 4 444 *!BD%+FCVH *2BEH *2BEH
M 2BBB@ HI*6@ HHHH **.]% "T4PMBG9H **#1F@ HI:2@ H!HH'K0 4444
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M !6AH'/B/3A_TW3^8K/S6CX>_P"1FTW_ *[K_,4I_"QK<]\HHHKYX[ HHHH
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MC/0TTGFJ :13>AIYYIAZTQ!0>M%+P10 E+32.]*2<9 H 6G XI@8'BE!QUH
MDHI%.:6D,6BBB@ [T4&CM0 M)WHI: "EZ4G.:6@!>U%)12 6BBB@ HHHH *3
M%+10!G:I9>;']HB'[U.N.XIMI>>=$-Q^<<'WK5%8]_9FVF\^(8C/7'8TXI7
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M::OI3EZTA"THH'-!% "T444AB4M%%,!#TH[44M @H%)10,*2EI*!"]J*2EH
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M&!?Q(QJ]#"D/%6M/^\^/2J\@ XJ?3O\ 6,/:O2>QB7Z6DI:S 2BBB@ HHHH
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M(!'3FD \L!\W6G#)0>I[5$HQ0<D<'%%@'A2&S4ZG(J!6]:D7BDQDE% .112
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M/(!-:6T$:2]*>*BA.4S4PJ& M%%%2 AI*4]:2F 8HQ12T %'>@<44 %)2TE
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MR:9_U]1_^A"I^KTX1=D/GDV>G^./^1/O_P#MG_Z,6O':]B\<?\B??_\ ;/\
M]&+7CM1@OX;]1U?B"BBBNPS"BBK6G6$VIW\5G;[?-E)"[C@=,_TI-V5V!5I:
MVM8\*ZEH=HEU>>3Y;.(QL?)R03Z>QK,M+*ZOYQ!:0232'^%!G\3Z4E.+5T]
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M !ZDU0_MG1/^@EI__?\ 3_&O+P]9TTTHW.B<;O<\3QS25[;_ &SHG_02T_\
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M0ZG?6VG3V%O=2PV\S;G6,X).,=>O(Z^N*PF@DM3M&60=/<5I TN PP1D4U9
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MPQT5^X_J/Q]*Y\,_9S=.6Y=35<R.2HSQ3GCX^6FE6 Z5Z!B>Z:S_ ,@+4/\
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M^8W^[6A>G_3I_P#KHW\ZSIL[LUV1,F>@_"G_ %.J_P"]%_)JP?B1_P C<_\
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M$J1MN4"-5P?P%$*%7VBG-H'./+9&92TE+7:9!1110 444M "4M%% !12TE
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MQD]Z )0W%+FHE# X/-.YS0!(&KU[P7_R*5C_ -M/_1C5X[SFO8?!/_(H6/\
MVT_]&-7%C?X:]32EN>:Z]_R,.I?]?,G_ *$:SZ]IET'29Y7EETZV>1R69C&,
MDGJ:9_PC>B_] RV_[X%1'&122L4Z3/&:DB5Y'"1HSLW 51DG\*]A_P"$<T5>
M?[-MOQ04XW&B:.IP]E:>H7:I/X#DT_KB?PQ%[+NSA=!^'1N+N.]U5#% /F^S
M9^9S_M>@_7Z5U7BOQ);^&=)*P^7]L=-MM"!P.V2.RC_ZU9FK_$""-6BTJ,RO
MT\Z084?0=3^.*\^U!WU2=KBZD:2X;J['K3C3G6DI5=NP.2BK1.<N+F:YN'GG
MD:261BSNQR6)ZFE21=P)Z'K4M[9/"2X7COBL_<,<&O35K&6Y[C\,<?\ ")M@
MY'VE_P"2UPGCY-WC74,2%>8__1:UVWPJ.?!Y_P"OI_Y+7#^/C_Q6VHC/>/\
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M;Q^%KA)RN^0J(E/4MN!X_#->15.'JNI"[0YQY78W/">LC1=<BFD.+>4>5+[
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MA]#Q7G4.>G'VD=5U1O.S?*SRPBCOBO8KKP;H%^?-%H(RW.Z!RH/X#C]*BM_
M6@P.&:"6;':20X_3%='UVG;9F?LF>::+H=[KEX(+5#M!^>4CY4'O_A7K8^P^
M%?#^"=L%NG?J[?XDU'?:SHOANT$3/%$%'RV\ &X_@.GU->8^(O$EUX@N09/W
M=LA_=0@]/<^IK/W\3)75HE:07F9=]>2ZA?SW<YS),Y<^WM5K0M5?1M7@O4R5
M0X=?[R'J*SJ3N#7>XIKEZ&-];GM>L:;:>*-#"1RJ5<"2"8<X/8_3L:\@U'3;
MO2KM[:\A:.1>GHP]0>XK9\,>+;C0'\B4--8L<M&.J'U7_"O1X;O1/$]F%!@N
MD//E2#YE/T/(^M<"<\,[-7B;.T_4\4'(HKUN7P!H,C[EBFC&>B2G'ZYJW9^%
M-"TL^>MHA9.?,G;=CWYX%:/&T[:)D^R9Q_@OPE+=7,6IW\92VC.Z*-AS(PZ'
M'I_.MOQ]KJ6>FG3(9!]HN1^\ ZK'_P#7Z?3-/\0>.[*PC>#3F6ZNNFX<QH?<
M]_PKS&YN9KRYDN+B0R32'<SMU)J:=.=6?M*FB6R')J*Y40UW>@^ X;_1_MMQ
M=!GGB)A6/[J$C@L>Y![>W>N$KJ_"7BTZ&3:789[)VSD<F,^H]O:NBNJG)^[W
M(A:^ISE]8W&G7<EK=1&.:,X(/\QZBJ]>VRV^B^)K16807D0^ZZGYE_$<CZ5E
M_P#"OM"W[MMQC^[YO'\LUA'&1M::LRG2?0\PTVUGO=2M[>V!,KR +CMSU_#K
M7KOC"5(O"M^7(^9 HSW)( J2VT[1/#5NTR)!:KC#2R-\Q]LGG\*\^\8>*AKD
MJ6UIN6RB.<G@R-ZD>@[5',\143BM$5;DB[G,"O9O"7_(K:?_ -<_ZFO&17L_
MA/\ Y%;3_P#KG_4U>.^!>HJ6YY#?'_39_P#KHW\ZH2<U=OS_ *9/_P!=&_G5
M%N:[([&3/0/A7( VJQ9&3Y3#_P >S_2LGXEV\D?B9)BIV2P*5;L2,@C^7YUE
M>&-</A_6X[L@M P\N91U*GT]P0#7K3QZ%XLL$W>1>PCYAAL,A/TY4UQ56Z-?
MVC6C-8^]#E/"0*>*]C'P^\.AL_9)"/0S-C^=>5ZS;Q6FMW]M NR**XD1%R3A
M0Q &3732Q$:KM$B4''<[?X6?\Q;_ +8_^SUF_$K_ )&:'_KU7_T)JTOA9_S%
MO^V/_L]9OQ*_Y&:'_KU7_P!":N>/^]O^NB+?\,X\4HXI.]+VKN,3U_P)JO\
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M&Z@!"M(!BE)I,GO0 ZDHS24 +03110 4M)WH[4 .I0:;2B@!U+3:6D M%%%
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MN> ?],I"O\C4\NNZM.I634[QE[@S-@_K6?173RIZV(NP))Y/-%%+3 2BBB@
MI58JP9201R"*2B@#1CU_5XEVIJEX%]//;_&J]S?WEY_Q]7<\^.GFR%OYU6HJ
M5&*UL%V%%%%4 4444 /BFE@??#(\;C^)&(/Z5?'B'60NW^U;W'_7=O\ &LVB
MDXI[H+LEFN)[E]\\TDK_ -Z1BQ_6HZ2EI@.6IDZ'Z5"M3#[C4F!"_>H#UJ5C
MFHFIH!A&:1"R$,K%6'0@X-*:050B5KRZ8;6NIBOH9"14?6DQS2B@!>E+24M
M!WIQXIM+UI +VH!I.U'0T (>M.7/X4&E% Q1TI*6BD E307,]J^^":2)_P"]
M&Q4_I4/>E[T,#2_X2'6MNW^UKW'_ %W;_&J4]S/<MNN)Y)6]9'+']:BI:2BE
ML@NQ*6BBF 444M !112T )12T4 %)2TE  :::6D- #:2E---,0$TG>C-(33
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M@!**#10 4E+10 E%%':@!!2T49S0 F*4<"BB@ -%![4=: %I**#0 =:*,4M
M"&DQ3J2@!,44M(10 M%(** 'CK6?.6759'8=5 4^U7P:ANTRX;VIK<",<TM-
M7BGXIB'"EI%I:0Q:44E*.E "T"DIPZ4 )12T4@$H[4M% "48HQ2T )BBBB@
MHHHH **** %HHHH =129I: %HS24M(!:*2B@!X-5[^Q2^AQTE7[C?TJ:GJ:!
MG'%61V1QAE."*LPN-F._>M/5M/\ -(N(A^\Z,/6L9>#Z$=:JFK,>Y<C?:<&K
M:MNQ@_2L^-L-[5/&1T!QCI6C1)>#'\:D5@1UJLCGJ>:D!SG'%2T!9%+UJ%&[
M&I1S4@+U-)0#2T@$I:0T TP%Q2=^:**0!1113 **** "BBB@!#1FEX_"@B@
MHHI".* %[44@Z44 *!12#B@4 '>CO2TG2@ I:3O10 [M2TF>U I +BCD8- I
M>M #)8EDY[]:@VE:M XI&4&FF!7!IV:5H\'BDQUS3$*#Q1FF]Z7M0 Z@TWO2
M@TACNHHIN:6@!>U%)FEZB@!#3<X S3\>E-8=Z $P,Y% X/7B@#G-(HH >>M-
M[&G4F,]:  # J_HNI#2=8MKYHC*(224!QG@CK^-4::<XQ2:35F"T.M\3^,4\
M0:;':+9- 4F$FXR;LX!&.@]:Y04@.X4ASQBE"$8+EB-MMW8[%% HJA!12TE
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M:!3J0"4444 (:9G)I2:2F M%*** "BDI: "BBBD 4444 %%%% "BBD%+0 4
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M.&I5Z50A1TI:**0Q:0TM% A10.:!2CK2& H'6EI* %HHHH *2EI* #M12TE
M!1110 4444 %%% H ***.] "T9I*6@!<\THIM** '4"DI:0"TH.*;2T 1W-J
MMRN1\L@Z&N?N8I[63;,N,]#V-=+FB2*.>,QRJ&4_I5*5@.664@DGG-6%<-SG
M'I3+ZQ>QGV]8V^XU0HVTX/2K3N,T(YOE"L-RGK4P120R'%4DX('K5F)\'%#1
M),"5./6I%;< 1^-1 Y^M. QGM2 G5L\&G <5$AYYJ0&I&.I!UH'2B@ Z44&B
M@ %%%% "TE':B@ HHHH */:BB@ I#2T4 )2]Z*!0 E%+24 %%+24 %+24=:
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MH[=?WP]ZM;"-$4HI!2UF,6BBBD E%%%, HHHH ****0"$4E.IM, [T&BEZT
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MQ@@^XK2%2,_A=Q--;C:6CM2U9(@I124HI#%I.^:Z/P[X2G\06TUP+A8(XWV
ME-VXXR>XZ<?G4?B/PO-X>6W=IQ/'*2-P3;M([=?\XK/VL.;DOJ/E=KF#1116
M@@HHHH **** $HHHH ***2@!:*<B/(X1%9G/ 51DFN@T[P1K5_AG@%K&?XIS
MM/\ WSU_2IE.,=9,$F]CG:#78ZEX!DTW3+B];4%<0H7V"+&?QS7'4H5(S5XL
M;BUN%%%)VK00M+3:6D X&EIF>:7- #Z*0&BD ZE!S3:44 )<6ZW-N8G&>X/H
M:YN6V:)F4YR*Z<'%5;Z -B0#C^*JC*V@&)"23@]15BF20E'##M3ZU$3(> :E
M7D560X&*G1N*E@2J<4]348Z>]*#S4@2TN:8#FE!I#'"BDS2T %%%% !1110
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MSR::::NA!UH XHQ2TP$YS2T44 %+244 %%%% !112T )1110 444M !2444
M%%%% !1110 4444 %.'6FT]: )(^HIDAY/UJ2/[PJ%S\S?6EU A;J:8:<U--
M6(#2=J*44 +124M #J44@I12 4T44HH 2BEHH& I#2BEI  Z44"EH **** "
MEK4T'0+K7[QH+=E14&Z21^BC^IJ]XA\(7>@0I<&9+BW9MN]5*E3[BH=2"ER-
MZCY7:YSM%%%6(**** "EI*6@!*:[8%.)P*KL2S4(!<YIII:0U0AI-(:#UI*8
MPI:2G 4 *HIU*HI32$-H!I&-** '4E*.E&*0!2TE% !11FB@ I*6B@  IU%%
M !29I:8QH 1CS244M, HHI: "EI**0"T444 )1110 4E+24 %+244 %+24M
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MOP/\ZY*]#V7[RGI8TA/F]V1YS+#);SO#*I22-BKJ>H(ZBFUUGQ!L5MM?6X0
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MIQY8@VV[L]D\'?\ (I:?_N-_Z$:\DU'_ )"EV/\ IL__ *$:]<\'?\BGI_\
MN-_Z$:\EU,?\3:\_Z[O_ .A&N7#?Q9FE3X45.U':C&>G6K*Z=?.H9;.X*^HB
M;_"NUM(R*M%.9&C8JZE6'4$8--Q3 *2BEH !1110 HHS3XH99VVQ1/(?1%)J
M26QO(1NEM9T7U:,BE= 0=J*2BF HH-)FB@ HZT4E !15B*QNYDWQ6D[J>ZQD
MBH9 T4QADCDCD R0Z$?SI706$[5ZO\//^18_[;O_ $KR@5ZO\//^18_[;O\
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MVM0./-E(W-_P(\GZ56?QMX>1]IO\^I$3D?RKR;4=0O-1NWN;R9Y68Y!)X7V
M["JP8,,@U"P:>LW=C=6VR/:5NM \21^2)+6[XX1A\X^@/(KB_%'@EM-C>^TX
MM):KR\3<M&/4>H_E7&([1N'1BK*<A@<$5Z3X-\6/J+_V9J3AIMO[J1NL@[J?
M?^?\TZ4Z'O0=UV!24]&=!HUM ?#FGL8(RQM(R24&<[!7BU>]B)(+811*$C1-
MJJ.@ & *\$I8-W<F%5;"YHS3:.U=YD.S2AN:95G3K&74M0@LH!^\F<*#Z>I_
M 9/X4G9*[ U?#WA^[UVYQ'^[MD/[R8C@>P]37I%CX>T;1(?-,46Y>6N+C!(_
M$\#\*ED>P\*Z 2%VV]NN !]YV_J2:\KU;Q!?:U=&6YD/E@_)"I^5/H/7WK@]
M_$-V=HFVD%YGID_C/0+=BK:@K$?W(V8?F!BG1:[X=UQ?LWVJUN W'E3KC<?8
M,!FO(F4.,CFJTL)'*\CN*M8*'1NXO:L[_P 3?#N)HGN]$!1U&6M2<AO]T]C[
M5K> +6)O"D)F@0N)9 =R#/WJYOP;XSFM;B/3M2F:2U<[8Y7.6C/8$_W?Y?2O
M3HXHXMPC0*&8L0!U)ZFL*\JD(^SGKV9<%%OF1X3XC 7Q+J:J  +F0 #_ 'C2
M:& WB#300"INH@0?]\4[Q)_R,^J?]?4G_H1IF@_\C#IO_7W%_P"ABO27\/Y&
M'VCUGQ?IPN/#%U#:6J-.[1*@1!DDR+5;1/"&EZ#:"ZU PS7"C<\LV-D?TSQ^
M)_2NI=UC1G=@JJ"23V%>+>)?$EQK^H.Q8K:1L1#%G@#U/N:\S#JI47(G9=3>
M;47<]*E\;>'8&V'4 Q''[N-F'Y@8JW::UHFNJ8(;FWN=P_U4BX)_X"PYKP^G
M([1NKHQ5U.5*G!!]JZ7@86T;N9^U9Z%XL\$QPP/J&DQE509EMQD\=V7_  KS
M^O8O!^M/K>A*\YW7$)\J4_WO0_B/US7F7B33UTOQ#>6D:[8U?<@]%(R!^N*>
M&J2NZ<]T$XJW,CN?!][H\/AJV2\N;!)@SY6:1 P^8XZ\UTUE=Z5/*RV-Q9R2
M!<D0.I./P[=*\+KL_AM_R'KG_KU/_H2UG7PR2E.XX3V1Z'>W6FV[(+^>TC8@
M[//=02/;-5/[2\._\_NE_P#?V/\ QKD/B9_Q^:?_ -<W_F*X2HHX53@I7'*I
M9VL;OC"6VF\37+VCQ/ 0FUHB"OW1G&.*T?AW&DOB"<2(KC[*W##/\25R-=A\
M./\ D8I_^O5O_0DKJJQY:+79&<7>5R[\2HHXCIGEQHF?-SM4#/W*X*O0/B=U
MTO\ [:_^R5Y_1A?X2_KJ.I\3/9?!W_(I:?\ [C?^A&N'T[PI<:_KE]*[&&R2
MXD#28Y8[CPO^/:NX\'?\BGI_^XW_ *$:K>)_$$7AJP2WM$3[5*"8UQPHSRQ_
M'\S7%&<U4E&&[9JTG%-EN*TT#PQ IQ;6O'^LD(WM^)Y/X5 ?''AX/M^W''][
MR7Q_*O);FZGO;AI[F9Y96Y+.<FH370L&GK-MLS]J^B/;%ET/Q'"5#6MZ /ND
M LH^AY%<9XD\!&UB:[TG?)&O+V[<LH]5/?Z=?K7$PS2V\JRPR/'(IRKH<$'Z
MUZEX-\4MK,36=X1]MB7(;IYJ^OU]:B5.>']Z#NBE)3T9Y2:*[#Q[H*Z=?I?V
MT86WN20X'19.OZ]?P-<=7;3FIQ4D9-6=B:VMIKRXCM[>-I)I#A44<DUZ5H/@
M&SLT2?4\7-QC)B_Y9J?_ &;^5/\  >@+8Z<-2GC'VFY&4)'*1]OSZ_3%8?C#
MQC-<7,FG:=*8[>,E9)4.#(>X!]/YUR5*DZL_9T]$MV:**BKR.TGU[0=''D-=
MVT.SK%$,[?P4<5#!XS\/SMM74%4_]-$91^9&*\;H-/ZE#JV'M6>RZAX;T37K
M;S%BBRW*W%L0"?Q'!_&O,_$'AN[\/W(67]Y;.?W4P'#>Q]#[5!HVOWNAW0EM
M9#Y>?WD3'Y7^H_K7K44FG^*] #%=]O.N"I^\C?T(-2W4PSU=XCTGZGB=!]:M
M:G8RZ5J4]E/]^)MN<?>'8_B,&FV-G+J%]!:0C,DKA5_QKNYE:_0QMT-#P_X<
MN_$%T4A'EVZ'][,PX7V'J?:O3-.\,Z+H5OYIBB9D&6N+G!(]\G@?A5C%AX5T
M G&RWMTYQU=O\2:\GUK7[[7;DR7,A$0/R0J?E0?U/O7!>>);L[1-M(+S/3Y_
M&OA^W?8VH*[#_GFC,/S Q4D'B#P]K(^SB[MIMW'E3KMR?HP&:\7Q16GU*'1L
MGVK/1_$?@&&2)[K1E\N4#)ML_*W^[Z'VZ?2M+X?*R>&=K*583N"",$'BN8\(
M^,9K&XCL-0E,EFYVK(YR8CVY_N_RKTZ.&.(N8T"[VWMCN?7]*YJ[J0C[.>O9
MFD$F^9'BWBG_ )&G4?\ KL:[CP#=VVHZ.UI/#$\]HV,L@)*'H?YC\!7#^*?^
M1HU'_KL:D\*:M_8^OP3NVV"3]U,3T"GO^!P?PKLJ4^>BDM[&2=I$WC32/[*\
M02&-<07/[V/'09^\/P/Z$5SM>O>.-(_M/0'EC7,]IF5,=2O\0_+G\!7D5/#5
M.>FK[H*D;,.U%)5[2-/;5-7M;)<_O9 &([+U)_ 9K=M)79!Z7X'T6*U\.QS3
MPHTMR?-^=02%_A_3G\:\_P#$^H)J7B"YEA"B!&\N+:!C:O&?Q.3^->G^)]07
M1/#4[PD1N5$$ '&"1@8^@R?PKQ@5QX5.<I56:U-$HA1117:9!7??#2*.5M3\
MR-'P(L;E!Q]^N!KT'X8?>U3Z1?\ L]<^*_A/^NI=/XD6]?\ "[:YXLA1!Y%I
M':J99$4#G>_ ]ZW$7P_X5MU0M;VN1U8YD?W]32>*M=_L'2#-'@W,IV0@^OK^
M'^%>.W%Q-=3O//(TDKG+.QR2:Y:5.=:*YG:*+E)1>FYZZOCCP\S[?MY'N87
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M:4MSROQ(/^*FU,_]/4G_ *$:BT+_ )&+3/\ K[B_]#%6/$B_\5)J9_Z>9/\
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M7_XJE'Q,T0_\L+[_ +]K_P#%5I[?$?R$\D.YS'A;0M>TKQ%97+Z=.D6_9(Q
MP%;@Y_//X5UOQ$M%G\->>1\UO*K ^Q^4C]1^51?\++T0_P#+"^_[]K_\567X
MD\;Z7J^@75C;Q70EEV[3(B@<,#V8]A67[Z=6,Y1M8KW5%I,\_I:2EKT3 *6D
MHH 0TAI32&@!**** "EH%'2@ S2[@O)IM-(S0 N2QR:6@=** "BBB@ HHHH
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M_LE< *6%_A+^NHZGQ,]E\'?\BGI_^XW_ *$:Y+X@:$\-Y_:\"YAEPLV/X7Z
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M4&V&/^ZOO[FLJ->563LO='*"BO,QZ44E%=1F+1244 !I#2FDZ"@!*7'I2=:
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M#PM)N]B_:2[F_JOC'6-61HGF$$)ZQP#;D>YZFL"DHK:,(Q5HHAMO<6BDH%4
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MBURM:$IM.Y;U+4)M5U*:^G5%EE(+! 0O3'&2?2JPI*=5))*R *Z'1_%VK:1
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MBI<TM2W4=K(**2EKI("BBB@ HHHH **** "BBB@ HHH[T %)0:* "ES24=J
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MG$TV@ HHI:!A1110(**** "BBB@84444""BBB@ (S24M% "4N>*0TM, KO\
MX7?\?&H_05P!KOOA=_Q\ZC]%KGQ7\&1=/XD>E4445XIU!1110 4444 %%%%
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M]% "8I*6B@!**6DH **** "D[\4&CO0 =J0'BE-)CF@!:"*3%% "8I:*,4
M-*.M(!2B@"&^&'#>HJM&=U6;\9MD-5K89//2K6PBPF0<5,*C%.!YJ6,?VHHH
M[4@ 4444 (32&CN:*8!G%+FD/2DS0 [K0#U%-I<9-  <YH)R:6DQSUH 0'G%
M**"*4#O0 #K2TT]<T[-( /(I.E+1UXH 3-&<&CI2=13 .]%% - "CI1F@&C/
M-( H%)FE%, H%%)G!H 7O24"B@!12&EZT'I2 0T9HH[4P$(S0.*.U+0 4JG#
M4@H- $X-9VJ#RRDW\/0UH*<J*IZKC^SWSZC'YTD[,!+9MT"GUJP#5:(@(N/[
MHJ<&J8$@I0:8#3A4@.HI,TM(!:7-(** %SF@9!!'6DI0: ,?5+ K,9XA\K_>
M'H:HPRF-Q_*NF90ZE6&0:Q;VT,$I<#*-6D9= ) =P&.E+UYJO$=@YZ5.IYQ3
M$.SS2C@4VEH&.7BG@U&.M.[\4A$N:4&H\\4Y:0$@I:8#S3A2&+11WHH 7-%)
M10 N:6DHH ,TM-HH =1C--I0: #.*=G(IIZT$>E #J*:#2YH ****0!1113
M2D%+10 E%%%  :*** "BBCO0 E%%% !2&EHH 0CBDQ3J2@ %+0*6@!*=3:<*
M '"I4J):E7O28%2?EC50GFK,QY-5&ZU:$/'(S4B]*C7[M2)TH8#A3Q313A2
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M_AV ?C3;V0T;-+244A!2T44 )24M%, %%%%( HHHI@!I!2T4 %%%% !1110
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M2T4 &:1J6H7.WBF@!UR<?C28YI1ZFG 9IB&TM+BCM2 *3%+2T -[T48YI<4
M)UIIZT[M2&@!M%%&.:8!1G%+2'O0  T[-14X'F@!]**:*<*0 >*=BDI: $IM
M.--- !2&DH!YI@.I,T9I,T .%+2"EI )1113 **** "O0/A;_K]1_"O/Z] ^
M%O\ KM2_X#7/BOX++I_$CTFBBBO%.H**** "BBB@ HHHH **** "BBB@ K&\
M5MM\,7Q_Z9X_6MFL+QBVWPM>_11_X\*NE\:]12V9X^OW5^E+0/NCZ45[AR!1
M110 4444 %%%%( HI:2@!:*** "BBB@ H'6BG)UR>@YH ANG'E2Q9YVX_$U0
MT./;92.>K/C\JE8>:LTN\,A^?@]"*31P?[-5C_&Q-#5FAK8O4444"%HHHH 2
MBBB@ HHHH **** "BBBF 4444 %%%% !1110 E%%% !1110 4E+10 E%%% !
M1110 44N** &F@&@TT'%,!]%'6E%(!R<&J&H'RMJCJ<U>%9VK<W$9[!>:<=P
M9%"QVC-7$JHF.!5E#C%4Q$P-.%-4T_%2,#Q1[T>M -(!#28H[XHI@(30#2=:
M4#% "YYH ZT8I: %I#UH!YHSGM0 E.S24 4 +11BBD 4T#FEHH "*8V>U/I&
MZ4P$!XH[4 <9H[4 **.]&*6@!": U*1FD'!H  <T4A&#2T  H'-)W.*4=* $
M/K1VHQFE P* $()-+@TM% "4H%%**0"@4ZD%+0 X"DE020LGMQ2BG4@,)E\N
MY)QVP:F5J6^0K+GL:B1N/>M=Q%@'(J13BH4;*U*O3-)@3J:?FH5-2 U+ D'2
MBFYIU(8M%%%( I*6DH 4&FNBR*584M% &?-"8SCMZU">#6JP#+@C(JE+;[22
M.16BD(@5NQIX.146,&G9]:8$@%.4]:8#FG4@'9I::.#0#S0!(#BI%-0YS4BG
MBDP'T4E+2&!I*4FB@ I*6DH 6BDI: $HHHH **** %HHI* %I:2D)Z4 .S1U
MI** %I*3-+VH *.U%% !1244 %%%% !1110 4444 %%+1WH !2CK24M #Q3I
M#B TU:2Y.(![FD!2D--'-*V2V*<JXJP&[>14@&.E(!2T (13T%-%/%(0X44@
M.:44AB4M!]:*!!0?:BB@8S-/7I2 4X4Q"T44'K2&**2BB@!*2EIK4 .I#0*"
M0 2>@&: *MY)(L(CC'[R0X%200_9X%CSDCJ?4U7L]\KO<R'.>$'H*ML>*I]@
M%I"<4F<4'K2 ,\T[----+#.* '9HSVINXF@ ]Z '9IP:F8IP% #LTN:;2T"%
M!I:04$TA@3BH7^9J>QIE-"#M3UZ4VG+0 M%%% !10:* "BBEH :>E-J0]*90
M F*,4M*!0 W'%,:I3TIF,FF!'0*D*YINV@ !IXJ/O3U- $E%(#FEI (:::<:
M:: $Q28YIU(:8"444E "BES24M "T4E% "T4F:6@ KT#X6_Z[4O^ UYZ=V1C
MIWKT+X6G,^I?\!KGQ7\%ET_B1Z31117BG4%%%% !1110 4444 %%%% !1110
M 5SWC5MOA:Z]RH_\>%=#7.>./^19F_WE_F*TH_Q(^I,MF>3]A]*2G4E>T<HE
M%%% !1110 444M !1110 4444 %%%% !3+N00V4CYP2,"I*H:RQ6"W3^](.*
M:W HJ#96]SN.4FCPH]ZUK:'[/9PQ?W5Y^M9EP%NM4@@4Y2,9:NJT/3&UK6+>
MSRRHYS(RC[JCD_3T^I%*4EK)]!VZ&;17=>*/#>C:'H[3Q+,;AV"1!GR,]S^0
M/Z5PM13J*HN9#E&SLQ:*2C-62%%%% !1110 4444 %%%%, HHHH **** "BB
MB@ I*6B@!*2EHH 2EHHH 2BBB@ HHHH =VHHI5&30!$YYIH'-)G<Q(]:>HIB
M'"G"FBG4ABU0U@8@AD]'YJ_5358R^FN1U4@BB.X&;%-N8\U>0\<]:Q > 0:U
M+:7S(^3RM:O:X-%U.M2U#&<C-3"LV(*,4=#0:0P[TA&:#1F@  HQ2T4 % HH
MH 2EHHH 3.*!113 6BBBD =Z"*** $HQVI:*8"8Q24ZDI %+1VI* %IOO3J;
M0 8XHZ4M-/7%, %+D4A&.>]** %HHH[4 %%%'>D 8I112T **6D%** '#I2T
M@I:0%'45X4^IK/#<X[UJWRYA7V-9)^]]*UAL)EA#BIP>*K(:E4XH8$ZFI!4*
MU*#FI8$E.!J,&GYJ1CJ*2EI +24M)0 4&BB@ IK 4II#3 J7$'&]!]14##BM
M C\J@EC!Z528BH6VL#4PYZ=*C>,BF1/U]!5 6*3-+FF]Z0#L\T]34?>E7.:
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MW6YF$LK,I;K@GC],5V?PT_YBG_;+_P!GI55R8>R\A1=YE+Q_86=C<V0M+:*
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M/_7!_P"8KH/B2Q&C6BYX-QDC_@)KSJ\.?$*+-H.T+E:/XF1FX DTQU@SRRS
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M/W_/&['^[C'ZUVFEZMI?BO26D@ F@?Y)895&5]F'-?.I^]CO7;?#*]>#Q;%
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MS;E@6BN"<<9"L!C]0U/&7]D%+XCE_B3>/<>)1;;ALMX54 'H6Y/X\C\A7'J
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M#O\ D;=._P!\_P#H)KT+Q_\ \BE<?[Z?^A"O/?!W_(VZ?_OG_P!!->A>/_\
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M)=(U30C;65WYLWF*VWRW7@>Y KSZHPU/]TXS0YR]ZZ/;-0L;'Q)H_E%UDAE
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MY5YCJNBZK)K-\\>F7C(UQ(598&((+'D<5V>A^+M#M-#LK:>^V2QPJKKY3G!
M]A6A_P )MX>_Z"'_ )!D_P#B:\N#J4YR:C>YT/EDEJ>8_P!A:O\ ] J^_P#
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M+PQ:;2!);*()%]"HP/S&#^/M7G7C?5K+6-=CN;";SH1 J%MC+R"QZ$#U%4-
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MBN24;FKC&6J9QG@7PO=)?KJE]"\,<0/E)("K,Q'7'IC\ZZ3QY_R*%Y_O1_\
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M _0D;32YY%!P10 X\4E+WI.](8F.*6BB@ '6@THHH 3I1110 4444 %% HH
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M**!B4444 %%%% !1110 M%)2T %(:6DH :::W(XIYIN,TP'BB@=**0!110:
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M6F4Y>] &7K'$T3'H%Q5&/I^-:6M+_HRO[UE0MEL5M'X1,M19Y%2XJ) 0:EH
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MO:H(90A>5SA(QD_6CS&5]3N3YHMD^XGWO<U/8.'MN!C!K(D<R.TAZL2:VK-
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MT+2'IQ3ATI +2YXI*.](!P-.!I@IW:@!PI::.E+2&.S3A4>:<#Q0 ZEIM+2
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ME%+24" 4444 )12TE !VI*6DH **** "E7K3:<M $E%(*6D,*0TM)0 4E%%
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M&*@C/.*F!IL1(.*<.E,!I]2 HI:0>E+2 6EI!10,<**04M "T444@"BCO10
M4444 '2@44M "4M)2T %)2T4 )24ZD[T )1113 **** "DI:2@!:***  4ZF
MTHI .I:04M !1112 6BBB@ I124"@"3&5(KFY_EU)_KBND4US^I+Y=^W'?-7
M#<"0<4_.#4,;?*,U)FK$29IPYJ/M3XR3G/2D ^BDI<4@%/-+24M( %% I>]
M!2T44 %%%% "]Z4&F]Z6@!3ZT"DI10 O>C-)THS2&.HIN:* '4E%% !1110
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MBB@!:**!0 M**3O2T@%H'2BEH **** "BBB@ I0,FDIQ.U?<T@ GM3:7M24
M)@[LYX]*,4M-#;G(QTI@.HHHI +2444 ----.-,-,!#3&IU--,0A]:*#Q2BF
M Y>*D%,%2"D X4M(*=4C%%+2"EH 6EI**0S$DB\NY<CH33F&15JZ3YB14!&!
MTYK6Y)$O#5/VS4 !S4PX6FP' \T\&F+3QUI,!U+G--!YI12 <*6DI12&**6F
MTZ@ I:**0!12&BF M%)12 6@444 %+24M !1110 4E+10 E)VI313 2DI:*
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MLR!["1^V5%9P\-:U-RNFS9]"*]_(!ZBC ]!6RQ\DMB?9(\$3P5XB<?\ (-D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !2;1Z"EHH ;L0_PK^5-,$1ZQ(?^ BI** *YLK5CDV\9
M_P" BH)M%TZ=&22TC(88.!BK]%-2:V8K(X.7X9V4MT\AF8(3\J^@JW!\.-%B
M RKMZC/4UV-%;/$U7]H7)'L<[%X'T"+!%B"1WW&KL?AK1X\;;&/CUR:U:*S=
M6;W;'RHJIIME'C9:Q#'^R*G$4:](T'T44^BINV,0 #H!2T44@"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img114804231_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 5)!X$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNE^';=9]2N/*C;H<4 :]%9FB:_IWB&T-SIT_FQ#O6G0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%(2!U(%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M-=UC1G8X51DF@!U%<O!\0?#EQJITV.^!N@VS;CO74=: "BBB@ HHHH ****
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M(+CPQJ::U)>^85B)""@#U?5?$.F:* ;^ZCAS_>.*S;;Q_P"&[N810ZG"SDX
M#"OFGQQJNH>(/'<]A?7+0VXFV*3G %=/IOP:BNO+EL?$,?F'!&TD'- 'TG'(
MLL8=&#*1D$4ZN=\'Z)?Z%I*VE]=_:77@-G-=%0 UW6-"[$!0,DFN<N_'OARR
MF:*?4H5<'!!85/XKTB]UG2'M+&Y-O(W&ZO$-2^!TT DN-0UQ-QRV6)- 'NVE
M^)](UDXL;R.4^BM6O7QQX?O;SPQXXALK2\:2+S@A(/!YK[ LW,EE"[=60$T
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M_&PO;O71;W!()@W@9YKH?@WXQG\2Z0T%RQ:2 8)->/\ Q0+#XJ !F^\O?WH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-
M]T_2ODOXE,J?%1F<@*)5R37UH>017@7CWX/ZYXA\4W&HVDL8CD(P&/2@#UK3
M-?T :7;#[9:#$8!!*^E6_P#A(- _Y_;3_OI:^>!\#O%P&!=KC_>-'_"C_%__
M #^+_P!]F@#Z52]MI+%[BU=)(U4D%#Q7SGK?Q%U/7_&PTI+HV]GYA5CG%>R_
M#SPS>^'/"JZ;J,QEEP023GK7G'C7X(W-_JKWNC2K&SG)R<4 <I\5['0[*SMA
M878N+DCYR&S7I?P,!/@!AZ@C^=<WHOP'F>PN/[7N#)<$?N^<@&NP^&/A#7/"
M"2V=W*KVA/R@'M0!XC)G1/BV)[P%(Q,3D^E>]^)?BIX?T'389_,2Z+@81>:I
M_$3X6V_BI?M%KB*Z'1AQ7G&E? ?66U&,ZG<*]NK=,D\4 >T^#_%MMXOT*2^M
MK<PIM/!&*^;9 #\8FR,_Z17U+HGA^TT'218V:!%VX./6O&G^$.MMX_;6/,C^
MS&7?UYH ]ON\#1IL#CR#Q^%?*G@S_DKR?]=6KZON(&ETZ2 ?>:,K^E>'>'OA
M%K6F>/$UB:5# KEN#SS0![ROW1]*BNO^/.?_ *YM_*I0, "F3H9+>1!U9"!^
M5 'R1HG_ "6%?^NYKU/]H/\ Y%FT^O\ 45F:;\(M;M?'XUAY(_LXD+]>:[;X
MK>"[_P 8:/!;6#*'CZ[NE &-\"?^1$G^A_D:\AB /QB;(R/M'^%>_?#+PA?>
M%/#,MA>LIE<?P].]<"GPAUM?B VL&2/[.9=_7F@#V[4,#1;C X\D\?A7RMX$
M_P"2N)_UT:OJZ[@:?398%/S-&5'Y5X?X9^$>M:3X[35YI4,"L3P>3F@"[^T)
M9S3Z+9S1H66,?-CZUY)X0\#'Q):^:-72T_V68#^M?6>N:':Z[IKVET@967 R
M*\'UCX%ZQ%>.VCW>R$G(7=B@#)/P:#.,^(K=CGNP/]:^@?!6D'0_#%K8F83>
M6N-X[UY#X9^">L1W\<VK:@^Q3G:K5[KIUA'IME':Q$E4& 30!:KYZ_:)_P"/
MBQ^AKZ%KRCXL_#W4_&<]J]A(JB($$,: -;X.(J^ K,@ $KS5SXJ6LMWX&NXX
ME+-UP*M?#WP]<^&?"UOIUTP:6,8)%=+=6T5W;O!,H9'&"#0!\5>%O#3:_?R6
MQO1:,IP2QQ7<O\&]P^?Q' WU<'^M=9XN^"-Q<ZC)=Z)-Y)<Y(!Q6)IOP0\2O
M=I]NU$K$#SL<T >E_"OPD?"FCW47VU+D2<@J1@?E7@?CFY6S^*%Q</\ =2<$
MU]2>&_#D/AO2?LL4CR';\Q:OESQO:K??%&XM7^[).%- 'T':?$#0F\%BY-U%
MN$)4QY&<XKP'P:DFL_%$7ELA,7G;LCMTKK-2^!6J2-"VFW6+=P"RLW2O4/A]
M\-K3PC:AY%#W1ZM0!S'[0W_(KVW^^O\ .K7P!1?^$2E? W;AS6S\6?!E_P",
M=&BMK!E$B,#\W3K5CX6>$;WPAH,EG>LK2,P/% &_XQA>X\+7T<8RQC./RKX]
MTO0)-1\02:?)<?97#'+,<5]NR1K+&R.,JPP17CGCKX-#5[UKW2)/(F8YXXH
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MUKP>7X#:]'J#+;706U+=F.<4 <1<)9Q_$F%+!]T N5"G/7FOL33_ /D'V_\
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M $&I_BWX%U'QG9V\>GL@:,@G=TK5^'WA2\\->#I-+NW!F;."/IB@#Y]\/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!'&48#N*^?M<^
M$_B&^^(3:O$H^S&8/G'85]!44 0VL;16L4;?>50#4U%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7DOQB\":QXP-J=,0-Y8P0:]:HH Y'X<Z!>>'/"
MD%A>C$R8S^5==110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MG?Q1\-Z]XAL8X=%E9#_%M.*\X\)_!+6%UF.[UMB51@<DYKZ+HH BM8%M;6*!
M/NQJ%%2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !37=8T+L<*!DFG5FZ^S)H%\RG#"(X- %FUOK>]#&"17V
MG!P:LUY1\&+NXNH-2,\A?$S 9^M>KT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5F>(?^1>OO^N)K3K,\0_\ (O7W_7$T >;?!+_CWU/_ *[/_.O7*\C^
M"7_'OJ?_ %V?^=>N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116-XAUV/1;,
MR$;I#PJBE*2BKLTI4IU9J$%=LV:*\Y1?%.J)]KCN_L\3<J&8BG6NOZMH-ZD6
MK.98W. P.16/MUU6AZ3RF;34)IR71;GHE%1P3+<0K*ARK#-25N>4TT[,****
M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M04444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ&A-/8*M&I2?+45F%%%%,S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA*V&GR58V8^BBBK.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=:-\+Q-ITBZB?*G\PLK)Z5Z1IMD-/T^&U#%A&H7)[T 6Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *S/$/_(O7W_7$UIUF>(?^1>OO^N)
MH \V^"7_ ![ZG_UV?^=>N5Y'\$O^/?4_^NS_ ,Z]<H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** $9%<890P]",URGB/P!H_B"-C
M) J2XX*C%=916U&O4H2YZ<K,32>Y\T^)?A#JNEEY[7]Y#V %>>W-G=6+F.XA
M:,CCYA7VNR*ZX901Z&N7\1> M'\0Q,)X%1\<%17UN XLG&T,4KKNC"=!?9/D
MU&BV_,/FJU#!<K%YT5RRXZ ,:[WQ/\(=3TR22>R7S(!R .M>=SVUW8RE)HY(
MRI_B! K[##XNABX\U&:9SN+B]3J-*\=^)=%C BE<QC^\,UW-C\7+#4K'[+KD
M18'@D5Y;#K<AC6"5%,70^M:B6.A:A$(;9MERW<\<UYV.RS"5U:O2WZK]32G5
MG3DI0=FCT:WT;P]KZE]/O! 6Z M4<_@36K ^=9WAF4=-K9_K7GUUX1UC2X!/
M!/N'4"-\FK.E>/\ Q+H"!2LA4?\ /4$5\IB>#*%9.>"J?(^AP_%&.H^[4?,O
M-'8QZWXJTB58VMV89QRN<U[+H,DMUI,,UU$JR,,D;:\ET/XRV,ZA=8M5+>N*
M])T3QMHFKHHMKA$'8,<5X53(\;@6W53:_ 6/S>CCH)1IJ,NK74Z$VT#?>AC/
MU45DZEX<T>ZB8W%O$@/\6 *UXYHI?]7(C_[IS7.^--/U#4M'>"P<JY'45S2J
MU*:;C<X<-3C4K1C*5DWOV.3O/A=87;LUG,A!Z 5@7/PCU1"QA=&7Z522X\5>
M&GP/-< ^A-:5I\4-;@D O(&V>I!KR'.BW[Z:9]Y&EFM-?[/4C4CYG.7O@#5[
M5B"CG_=J&+X:>([E?.MII8\<XW&O5-.^)VDWA2*XCQ(W'2NZM)8KBW66)0$8
M9'%>QEF.JX6JJE&I=+H]4>!G&(Q$J7L\3146^I\WOI'CC1_N/,^WWI$\<^.M
M.^66.3:.N5KZ5:&-OO(I^HJI=Z39WEN\4EO&0PQG;7TCXAA-/VM",F?+QHKF
M5WH>(6'Q8U>-0;H9]1BNBM?C59Q@"ZMV/TJYJ7PIMYI7> @;CG%<Y=_";458
MF#:P]#7STLR;DW4H)KRT/J8Y=E-6*]G6<7YG6P?%[0[@#,;#/J:\Y\5:Q=ZI
MK_\ :%K*GV=3E5HN_AOJ\ .Z'IZ5S5YI5W#<+8@LLK'&#7=EV9TE65/#T^6<
MM/>U2)J9#0A!UG64X1U=MQOB+4KSQ&R&<HOE# V@"D\*7NH:+J22PR[8D.6]
MZJZUX=U+PS)$;TY67G(-16=R&8,Q(B[U]/BOKN%P?-"I&<'IMM?L>?A(Y?C:
MOL_9N+6N][H]4U;XAZIJQ$&FHP&,$@4S1/ &JZY,+K4'8(QR0U=A\.=-T:XT
ME+NVC5W/7(KT!55!A0 /:OSN>!J1J-8AZKH>M4SZE0A[++X<J[O<P-$\(:9H
MJ@PPJ9!_$170=***Z(Q459(^<K5ZE:7/4=V%%%%49!1110 4444 %%%1SSQV
M\1DE<*H[DT#2;=D245R%UX_L+>9HUAEDVGJJYJ_I'BVPU>3RTS&_HXQ6:K0;
MLF=<\OQ,(<\H.QT%%%%:'&%%%% !1110 4444 %%%% !67K^F?VMI4EMW/(K
M4HI-)JS+IU)4YJ<=T>=:+XCET%SI5[;N8TX5JRO$R:'JDNZ"U9KF0]17IE]I
MEE=KF>- ?[QJO9:+IMN^Z)4=OSKFE1DUR-Z'N4LRH0G]8C%J?6ST9QV@?#33
MFLA-?1DL_(&>E;8^'>@@8^S_ *UU8  P!@4$@=2!]:TCAZ:5K'%5S?&5)N7M
M&K^9B:7X4TS2)O-M(=K>M;E5I[^UMD+RSQJ!_M"N8U#XBZ-8LRF3>P]*;E3I
MKL91HXO&SNDY,[ C(Q6%?>$M*U&;S;B ,_K7"2_%*XN-0C2S@9HF;!P*]0LI
MS<V<4Q&"RYQ4QJ4ZUTM;&]?!XS+N6<O=<NS,$>!-#!_X]17-^+K/2?#]MF.T
M!8^U>E50U+2+358PES&& HG13C:*U#"YE4C64J\FX]KG@<>HZO/,1I]LRJ>F
M%K7M? OB+6V$L\[H#UR:]FL](LK&()# @ [XJZJA1A0 /:L(X+^=W/7K\3-?
M[M34?-ZLX#PW\.8M*G6>=RT@[YKJ;WPWIU^,3PAB.YK7HKIC1A%<J1X5?,<3
M7J>UG-W/'_$7@1;#46NTBWVW4*!66]O8W2_9XM.D5^F<5[DZ+(,.H(]ZB%G;
M Y$* _2L)82-_=/5I<0U5!*JFVMG>QYOX:^&UNT+RZBF0_W1Z50USX6W,4K3
M:5(54<X!KUX  8 P**MX2DX\MCGCQ!C8UG54M^G0XSP%IVI6%H\>H,Q(X&:W
M=3\.Z?JQS=Q!S6J !T&*6M8TTH\KU."MC:E2NZ\?=;['*'X>Z"3G[-2'X=Z"
M1C[-^M:7B;5I-'TI[F)"[#H *X;1?BJKSE-20H">.*PFZ$)<LD>GAH9KB:+K
M49MI>>IU5GX!T2QN%FB@.]>1DUU"J$4*.@K-T[7M/U.(207"<]BPK2!##(((
M]JZ(1@E[AY6*JXB<K8AMM=Q:Q-<\,66O*!=+G%;=%5**DK,QI5IT9<]-V9P,
MGPLTDGY13?\ A5>E8KT"BL?JU+^4]#^VL?\ \_&>+ZAX0_X1?5X[L(7MPW:O
M3M/U_39-.CD^T(N%Y4GD5I7EE#?0&*= RGUKEIOASIDTWF>=*O.=HZ5$:4J3
M?LUHSIJX^CCX16,DU*/5*]S$UR\/BO6X+:T0F.!P=_8X-=K>Z!9ZKIT5M>Q[
MPBXJ72M#L](BV6Z#/]XCFM*M(4MW/=G)B<<FX0P]U&&W?U.5B^'VA18Q;9^M
M7(_!^CQ_=ME_*MZBJ5*"V1A+'XJ7Q5']YEP^']-@8,EN@(]JTD144*HP!3J*
MM12V.>=2<_B=PI" >H!I:*9 @51T _*EHHH ****  @$8(R*R;_2-,N&W3JB
MMZCBF>(]:&C:<THYD/"BN.MX-7U6!K^^F\J C*@FL*E1)\MKGIX/"5)0]MS\
MJV]?0[NPT^QM4_T9%/OUJQ<36\"%IV15']ZO&+CQW>:'>/;VTGF(..M49=6\
M2^,IO*CWJA/;I6'UR"7+%:GJKAS$3E[2M-*'=GIDOB'PY<ZHEN5C,P. 0.]=
M='M\M=GW<<5YEX9^&C6TZ7>HRDRJ=P%>FH@CC5!T Q6]!S:;FK'F9I#"TY1A
MAIN26]]OD.KS_P ?7]YI@273+8-+GYF"YKT"HY((I1B2-6^HJZD'.-D['+@L
M1'#UE4E'F2Z'CNG_ !.U*T95U&%MHXZ8KK-/^*&D7C!'!C;W-;6I>#M)U//F
MP 9]!7):G\*+0J38N5;M7+RXFGL[H]_V^2XO^)%TY>6QWMGK=A>J##<(2>V:
MT <C(KR'0/ .LZ?JZR2S-Y*GUZUZW$NR)5/88KHHSG->^K'CYEA</AYI4*G.
MF/HHK/NM:LK.813S*K'L36K:6YP0A*;M%7-"BH8KNWF0-'-&P/HPK)U7Q38Z
M6=K,9&'9.:3G%*[95.A5J2Y(1;9N45RMCX[TZ\G$922+)QEUQ741R)*@=&#*
M>011&<9?"RJ^&K4':K&PZBBBJ, HHHH *S]2T:RU6 Q7,*L#WQ6A12:35F5"
M<H2YHNS/(?$?PRGMY&NM)<JHYV@UDZ+XPUKP[="UO8Y'C4XP17NA&1@UEWWA
M[3M0E62:!2P[XKDEA;/FI.S/HZ&?^TI^QQT.>/?J3:1J2ZKI\=TJ%0PZ&KU1
M6]O':PK%$H5!T J6NM7MJ?.U'%S;@K(**C>>*-@KR(I/0$U)D8SGCUIDV844
MP31DX$BD^F:?0*U@HHHH **** "BBB@ HHI"0HR>E "T5FW.NZ?:L5DN$!';
M-9L_C?1[<$M<+^=0ZD5NSIAA*]3X8-_(Z2JM_J%OIUNTT[@ #IZUR4GQ/T*-
ML;V/T%<XVOQ^-?$D=E$[+;<?C64\3#:+NST,/DV(;<Z\7&"U;.BE^(]NLA$=
MC*ZC^(5MZ)XIL]:&$S')_=;K5ZTT>RM+98$@0A1C)'6N&\7V4?A^_M]0LSL,
MCX912DZE-<TG=%4J>"Q<O8TH.,NCO>YZ1152PNH[BR@?S%+,@)Y]JMUT)W/&
ME%Q=F%%%%,D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **Q_$OB"V\-Z2]]<MA1PON:\O
MB^(OC;4BT^FZ.)+4GY&P.10![117C9\:_$7'&B#\EKO_  =J>LZGIS2ZS:_9
MY@>%XH Z6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/$/_(O7
MW_7$UIUF>(?^1>OO^N)H \V^"7_'OJ?_ %V?^=>N5Y'\$O\ CWU/_KL_\Z]<
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 1E5U*L 5/4&N8\0>!-'U^(K+;HC'^)1BNHHK6C7J49<U.5F)I/<^<_
M%GP>OM-9IM,!EA')[UYO+;7%A=%9XWA=>X&*^TV574JP!!Z@US6N^!M'UR!D
MDMT1V_C KZS+^*IP2ABE==S"=!;Q/F32O$&IV+^<)6N(U_A<YKL;+Q?H>NH(
M-;M8[=>A90!4_B?X/ZAI9:32F:6/KBO/KRVFM9A:W]LT9!Y;%?1P>"QZYZ3U
M\M&OD8^]#1GH=Q\.M%UN(OX?O0S'D M7+:CX)\3>'59P) J]XB:HV;WUE(K:
M->,,<X#5V>D_%J^LMMGJ]F+A!PS,,UG)8^A_":J1[/<?NO?0YS1_B#X@T!P#
M)(VWM)FO1O#WQNAE(&JH(_4BM",^!_&MN(U$5O<..1TYKGM=^"(BA:72KCSL
M\@ UYE6ME>)ER8NFZ<W_ %N6E..L7<].TWQ?X;UXCRY(F+?W\5=O/#6C:FA_
M<1<]U KYCO?#'B3PZQ9H9HU7NIJYHGQ&UW1'&Z224#L]<6(X4IU8\^$FI+^N
MIO2QU6D[IM'N*?"[2HKT7",PP<[>U=O:VZVMND*]%&!7CF@_&]+F14U*(1^I
MKT;2_&^AZMM%O=KN/8U\[7R3$X)OFIV]#KKYC6Q:2JSO;N='7)^,/%4GAV)6
MCB+D^U=4LB. 5=2#Z&JE_I5IJ4>RYB#_ %KSJD9.-HZ,>$J4J=92K1YH]CS_
M $SXKVTF!>IY?K74V/C?1;_'E7 Y]36-J/PNTN]<LC&,^U<U?_"V[L\M83L3
MVQ7)S8F&ZN?1.CDF*^"3@_P/6DN+:YCRCHX(]:\9\<>&=2@UXZO&H$0.0!4F
MA:#XJL=;A69I?LX/S$MQBNAN6GU[Q4-+DE(@CQD?A6U/%24;J-I=#.G@(X2O
M>%53A9N7IV/+=>U*YURT$-S!(S)P&(KDI46"/[.H(<U]8IX:TI(!']DC/&,D
M<UX?\1/"46DZM]HB 57.0*]G"9M4IS@L:[THZV7?S(H+#8A3I8"'+4EM?].Q
M'\)O$TFCZS_9MY)MA;IDU]$HZR('4Y4C(-?(HMR+Q+I)"LBG/%>C6?Q,U:.S
MCMHHB^P8R.:>>YKE^)JJMAV[O?0YJ'"^9)6FDOF>ZY'K2UXOIOC37KW4X4:%
MPC-SQ7LD#%H$9NI49KQZ5:-6]CES#+:N!<54:=^Q)37D2,9=@H]S3JXGQ_IN
MKWUJG]ELV[N%.*NI)QC=*YSX2A&O65.4N5/JSJI-4LHOO7"?G563Q'ID?WKA
M/SKR"/P9XJG ,DTBY[$U9C^'>N2?ZRX?\ZY/K-5[0/H/[&P$/CQ"^1Z@/%ND
MM*(Q<*6/3FMJ-UE0.IRIZ5Y)8_#.]CNHY9+AOE.>M>K6D)M[6.(G)48K>C.I
M*_.K'EYEAL)1Y?JT^;N3UYS\1M:>W46FXHG<BO1JXKQWX:?5K/SK==TJ]J,0
MI.F^4G)YT88N+K;'%6'C/3-.LUC-DLS]V9<YK+U7Q3!+<1W5G%]G<')"C%;6
ME66D6D0CU6#;*OM4-QH$>OZBD6GV^V 'EL5Y[]HXV3/LH/!PK.4HM+JV]#<T
MGXHQ2)%#,IW\#->CV=P+NTCG7HXS7'6OPVTR$1N?OKR:[*UMUM;=(4^ZHP*[
MZ"JK^(?(YI/ 3:>$37<FJAJFKVND6YGNFVH.]7ZR=?T*'7K(VTS;5/>MI\W+
M[NYYV'5)U$JOP]3#_P"%F>'L_P#'Q^M2CXC>'R,_:1^=<^?@]8\XNV_6H3\'
M[?/%T<5Q\^*[(^B]AD+VJ2.KB\>Z',P"W(R?>NBMKF.[@6:(Y1NAKR\?"013
M*R7!P#FO1](L/[.TZ.VSG8,9K:C*JW^\5CSLQH8"G%/"3<GYE^HYIX[="\C!
M5'<U)6/XCL9]0TN2&!B'(X(K:3:5T>91A&=11D[)EA-;T^0X%PGYTR[U[3[2
MW:9[A, =C7D#^!/$B,2D\G7UJGJ'A#Q);VC2322.@ZC-<3Q-5+X#Z>&1X&4E
M;$([4:SJ7B*^=(9%CM0>#FGW,>NZ%MN;=C-%_%WXKSS1]&U^Y&+*5E*GD;L5
MZ]I33:9X49=8D4R;",$U-*3J7<KKS.C,*5/!N,:3C);<MM35T'6HM8LU<']X
M!\X]#53Q:U\NFDV.?,QVK!^'4<@>]D((C9\KFN^95<88 CWKK@W4IZGS^*C#
M!XU\BNET/"H_#OBO79R9))53//)KH],^$\3XDOY6+=QGK7J*1I&,(H ]J=64
M<'36LM3MK\1XJ:Y:5H+R.=TOP9I.F ;+=6(]170JJHH50 !T I:*Z8PC%62/
M%K5ZM:7-4DVPHHHJC$**** "BBB@ HHHH **** "BBB@"*>WBN8C'-&KJ>Q%
M<1KOPTT[4=\MN/+D[ <5WE%1.G&:M)'5A<;7PLN:C)H\%O\ P;XCT(F6!Y/*
M4Y&TFM+PY\0-5@NH[&ZB9N<$D<BO9I(TE4JZAE/8UD/X8TQKP7(MU#CG@5R?
M590=Z<K'O?V_2Q--PQM)2?1HT[64SVT<I&"PS4U(BA%"J, =*6NY'S$K-Z!1
M65>>(M-L;Q;6>X596Z"M*.:.5 R.K ],&DI)Z(N5*<$I25DQ]%%)N [BF9BT
M444 %%%(2!U(% "T57GOK:V&99E7\:DAGCN$#Q,&4]Q2NBG"27-;0DHHK+\0
MW$]KH\TMN"90. *&[*XZ<'4FH+J:1D1>K ?C6??:[I^GC,UP@_&O%9M0\6:K
M*5B$J\]!Q4UKX)\2:G(/MCR*AZY-<3Q<I:0B?31X?HTO>Q-=+R6YZ)=?$K0H
M&VB;<WUKI=*U*+5;%+J'[C#(KSJS^$-N5#7-PV?3FO0]'TN/1[!+2(Y11@5K
M1=9O]XM#S\QIY;"FEA)-RZW.8\<H\4<=PZEH589%2SPKK_A*.*RN!&VSH#74
M7UC#J%JT$ZAE:N,?P1=6,S/8WKA&/W,GBB<)*3:5TRL+B*4Z482ERR@[KJF<
M;?\ @RVT:V2:\G\VX9ON@YKTGP?IL5KI4;B%5+#(..:SK#P0[7:W.H7+38.0
MAKM(XUBC6-!A5& *FA1Y9<UK&N:YFZU-4N?F?5[+T0ZBBBNL^?"BBB@ HHHH
M **** "O//&G@V_UFZ-Q9RL&'0 UZ'16=2FJD>61UX/&5,)5]K2W/ ;C3O%7
MAV)I)))?+'N:HZ1XEGM;\W-[$UPI/(89%>]ZWIJZIIDMNP!+#BO-+6"STB=[
M'5;(" 'B3%>?5P[IR5GH?88+-Z>+HR]I33EY:-HL6VI:9XN1K>WMUMYD7=E1
MBMWP-J4TDUSI\K%A;DJ"?:N>:XTBQ<MH"%YY.,8-=9X-T6:Q26\N!B6?YB/K
M6U+F<UWZGGYA[*.&FK-1=N5/>_4ZRFEU!P6 _&E;.TXZUY+XQN/$<6K;K/?Y
M0]*Z:M7V:O:YX>7X'ZY4]GS*/J>M @]#2UX;!\0=>TM@L\#,1ZBM6U^+MP7Q
M<VFT>N*Q6-I/?0]*IPSCHZP2DO)GKM%<AX?\<V^N3B%!AC77UT0G&:O$\7$8
M:KAI\E568444FX#N*LP%I#T.*7.:* /(O'EOXACU#[9"9! AR N:R8?B;JBV
MZ6DJX(^4MWKVJ^MTN;.2-T#Y' ->.S^&+/5-;FLR?)E!..U>=7ISA*\'N?9Y
M5C<+B:/L\537N=4;D#7T]D+ZUN\R8W;2U;_A3Q4VI2-9W6!,G%>=R^"_$MD\
MD<%P?)7H0_:KG@BUN8]<,;%FE4_.U33J3C-)JQIB\%AJN'G)34K:JVZ]3VBF
M32"*)G/0#-.4$* >N*21!)&R-T(Q7IGQ*M?4X'5/B7:6-T\ 7++6)/\ %F49
M\FV)_"NIN?AUIEU?-<R<LQY%6[?P-H\'_+!6_"N)PQ+>]CZ6GB,FIP5Z;DSS
MR7XK:NXQ%:@?5:[7P3XEOM<4F[B*'W%;\?AK28A\MG'^*BKUO96UK_J(E3Z"
MKITJL97E*YSXW,,!4I.G0H<K[EBH[A#) Z+U(P*DHKJ/"3L[GD6L^ -:OM4>
M5)G$3'UI(/A5<2?\?$S?G7KU%<OU.FW=GNKB+&Q@H1:5O(\U@^$6G@ RS/GV
M--N_ ;^'MM[HVYI5ZYKTR@@$8/2J^JT[:*QBL]QKE[\^9=GLSAK3QVMM;"*_
MA<7 &#Q65<6VJ>,9G9XRMNO,>17H$NCV$S[WMHRWKBK4,$<";(D"KZ 4>QE+
M2;T".84*+]IAZ=IOJ^GH>'7B>*O#=SYA\QHD/RCGI6QH_P 5IUF6/4H=JCJV
M*]7GM8+E=LT:N/<5S&L_#_2=54[8Q$3W45B\/5@[TY'HPS? XJ/)C:5GW1>T
MSQAI&JX$%PN3V)K=1U<95@1[5XQJ?PUU3390VES.1GL:]&\(6%]8:8$OI&>3
M'>M:-6HWRSB<.8X'!TZ:K86K=/IU.CHHH) ZG%=)X@44@(/0@TM !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!PGQ7L[6\\)XNY"D:/NS^%8O@OXE>&+71(;"2<1>0H4$@<XKT;5M(L]
M:LS:WT0DA/)!K@+SPU\-;"8PW+VD4B\%3CC]* -W_A9OA/\ Z""_D/\ &M_1
M]<T_7+<SZ?,)(P<9%>?VWAWX9WDHB@FM9'8X !'/Z5WVB:#IVA6ODZ=$(XFY
MXH U**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0_\B]??]<3
M6G69XA_Y%Z^_ZXF@#S;X)?\ 'OJ?_79_YUZY7D?P2_X]]3_Z[/\ SKUR@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** $(!&",USNN^"](UR!UFMD$C?Q@5T=%:4JU2E+FINS$TGN?/G
MB3X1:EHY>XT>1I >=HKC#=2Z7NMM7L#YAX+E:^MNM<]K?@W2-<C?[3:IYC#A
ML5]/@^)964,7'F7=;F,J/\I\VC1H"HN=(O2+@\A W2MO2O&OBKPC(IO_ #)8
M>P:MKQ!\(=0T>5K[1YBQ!R%%<DVN:CIT_D^(K)I4' #+7TD*M#'0]UJI'L_B
M,;.+['K6C?%'P]XC@$6JQ1QD\8<5H:AX!\,^)K8R6 B3<.J5X_%H.B^) ;FT
MNDM'[1DXI(+GQ=X3DW6S326BG[P)((KRY95",[X*JZ<OY7L7S_S*YNZ]\$[R
MR1I+&4RCLM<)/H/B+P^Y<PS0E?XES7JWASXV1R,EKJ415NA<UZ3'?^'O$MNH
M\R";>/NGK2EFV98%\F,I\T>X_9PEK%GSAH_Q&UW29AYER\JKV:O2]"^-\-RZ
MQ7T(C/=JZ37/A/HFI1L;:)(7/<"O,]=^"^HZ<C26LGG+V JOK.2YCI47)+[A
M6J0V/:M/\<:%J040WJ;S_#D5T$<L<R!HV#*>XKX[FT?7="F+M;SQ%3]X#BMK
M1OB9KNE.JO</)&/X2:YL1PHI+FPE2Z*5?^9'U9@>E>=:W97N@^(O[8M8C(C'
MY@!7/:1\<K>;9%=VY4]-U>A:?XOT+6K0DW473E6-?,X[)L717[R#7F>C@<<J
M$V]TU9KR(X_&^GFS#R';/C[GO7)7.G7OCNZE\^,QPK]QB*R=5\1>'U\<16D<
M:F$MAF&,5[%8);+:1FU"B,@$8KEQ&78F@H2KJR>J_P""=L,PPU%2>%B^9]7T
M]#Y3\5Z3>>&-9>UD)*9X-6O 6M1V7B&&*^4/#(><U[-\4_!Z:YI#7,$?^DH,
MY KYLD$UI=%6)62)J_1<KC@\RP3CR)2M9Z+[SQ*N*Q*E=U'][/L>ST_3)(HY
M[>WCVD9! K2  &!TKS;X4^+4U?2$L9&S-$/6O2:^ QF$EA*TJ,EL;>UE45V[
MA1117,(,"BBB@ HHHH **** ,ZXT+3;M]\UJC,>]6+73[6R&+>%8Q[59HI<J
MO>QHZU1QY7)V"BBBF9A1110 4444 %%%% !1110 8IDL231M&Z@JPP0:?10"
M=MCA[WP==P7C7.FW)C!.=@JM_P (CJFI3J;V[;R@>5]:]!HK%X>!Z<<VQ$5T
MOWMJ5-.T^'3K5885  ')]:MT45JE;1'G2DY-RD]0HHHIDA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2,,J0.XI:* /+_ !AX!O+^[:_M
MIF:4<@5R<&L>)O"\X^U"5HE/0U[Y5*^TFRU%"MS K@^HKCJ85-\T'9GT6$S]
MQIJCB8*</Q/.5^+<9L@3#^^Z$59L]0U;6X3>6SMZ[17*^(O"4/\ PE36=MB&
M(DX->D^"O#UQH5F4FEW@_=.>U94G5G/EGLCT,='+\+AE6PZ]Z6MGV*NA>*[C
M[8;#4XC$PX#'O75WMV+6S:X W #-<)X^:/\ M2R6VQY^\;MOUKN8(1<:7''*
M,ADP:Z:<I7<+['B8VE2Y:>(4;*6Z]#SC4?BS]GG>"&UW,IQFL"\\:^(M9XM(
M9$SZ UZ:G@;11.TSVRN['/(K4MM#T^TQY5LBX]JR=&O/XI:'HQS+*\.DZ-"\
MO,\231_&&I2+YIGVD]37K7A&PO+#3UBNR2P'>NC"A1A0 /:EK2EAE3=[W.',
M,YGC*?L^117D%->-9%*NH*GL:=172>*5XK&VA;='"BGV%6,"BBBUAN3>K844
M44""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG>:797XQ<VZ2?6KE%)
MI/<J,Y0=XNS,NU\.Z59R>9!9HC>M:@&!@444));#G4G4=YMOU"HI+>&7[\:M
M]14M%,E-K8SIM!TR<YELXV_"LF^\"Z-=J=MLJ'V%=/14.G![HZ*>,Q%-WA-K
MYG+Z-X+LM&N?.A'-=1113C",5:)%?$5:\N>J[L1\[#CKBO)_%6I^);74F-K&
M_D@]J]9J*6WBF&)(U;ZBHJTW-63L=.7XR.%J<\X*2\SQJU^).KZ=\MU;,V.N
M0:U[3XO12,%GMMGN*[R?PUI5SGS+5#GVK'O?AWHMPI\J!8R?05S>RQ$?AE<]
MKZ_D];^+1<7Y%G0?&5EKC%8R 17'^+-^H:YY.D+MN1U=:Z71O!$.AQS-"VYV
M!Q67X?GM[?Q1-%/@3D\$_6G/GE%1J=2,.\/2K5*V$NU%:)_J9$WA[Q<MH#]L
MD)QR*V/ =S##<RVUVJI>#JQ[UZ$S*J%F("@9)KP77I-2G\67+Z1O8@G[GUJ:
MD50:DM3?!5IYK"I0FE!6O=:?>>]Y![TM>"'4?&\7!6ZP/K3U\1^,HA\T<Q^H
M-5]=76+,7PS4^S5B_F>\45YEX(U_7-0OS%?HX7U->FUTTJBJ1YD>)CL%/!U?
M93:;\@HHKSOQ+\1&T'5FM?)+@>U%2I&FKR%@\%6QD_9T5=GHE%>4I\8HOX[)
MOPJPGQ>LVZV["LEBZ/<[WP_F*_Y=GIU%<;X?\?6>O7HMHE(>NRK:$XS5XL\W
M$X6KAI\E:-F%%%<+XT\6?V>XL(9/+E;^+/2BI44(W8\)A:F*JJG3W.PDU&UB
M?8\RAOK5A)$D4,C!@>XKS33["VO85:;6%:XDZ#?WJ6UO-1\+ZFL=[,9;60X4
MYK%5WNUH>A/*HN\:<[R71JU_0](HID,@FA21>C $4^ND\=JV@4444""N8\;2
MZE'H[?V8K&7U%=/2$ C!&14SCS1:-L/55&K&HU>W1GA^G>/M:T.3R]0B=_7<
M*[S1/B-I>HQC[1((7/8UN:CX7TO4@WGVR%CWQ7":O\)T=FELIMA'(6N+DQ%+
MX7='TKQ&48_^+'V<NZV/2[6_MKU-\$RN/8U9KQ31-)\3Z7K*6P:3R W+<XQ7
MLULKK;H)#EL<UTT:KJ+56/'S+ 0PDE[.HI)]B6BBBMCS HK-NM?TRR<I/=QJ
MP[$TZSUO3K]MMM=1NWH#4\\;VN:^PJ\O-RNWH:%%%%49!1110 4444 %%%%
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M_P"N)H \V^"7_'OJ?_79_P"=>N5Y'\$O^/?4_P#KL_\ .O7* "BBB@ HHHH
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M,PX7)KZ;B; QKT8XREK;?T,:,K/E9Z]1117P1U!1110 4444 %%%% !1110
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MA&8M/MT/58P/TJQ533)))=.A:48?:,BK=>NMC\]J74W<****9 4444 %%%%
M#=BYSM&?7%.HHH #P*\I\?\ B?6;#4A%9;HXNYQUKU:N1\;Z4;K3S/%$&=1V
M'-88B,G3?*['JY-5I4\5'VL5)/34\TT;Q#I5U/C6U=I&.-V375:AH]O96D>J
MZ#,=O4C=FL>3P[H^I:*77$%Z@YW<5RUGKM]I4ATXS;X-V.M>=S<BM/KU/LG0
M6*DYX9M..\7LUY'O7A_4CJ.G(S_ZP#YJUJP?"EL(M*24'/F#-;U>K3;<5<^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !436T#OO>)&;U(J6B@:;6P@ 48 P*6BLF?Q%IUO>+:
MO.!*QP!2<DMRX4YU':"N:U%(K!E##H1FEIF84444 %%%% !1110 4C*KJ58
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZY\8-(OM)N+.TMYI)YT*)E#P3^%:GPCTG4]/T>>742W[Z0N@/8&@#TBBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/$/\ R+U]_P!<36G69XA_
MY%Z^_P"N)H \V^"7_'OJ?_79_P"=>N5Y'\$O^/?4_P#KL_\ .O7* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/UO38]6T
MJ:U=0=ZX&:T**J$W"2E'= ?'_B?1)?#7B%X'! 5\@_C70:U"/$?A^&^MQ\UL
M.<5Z)\8_"JWFG'4K>/,R]<"O+?!NI2,[Z(XPL^1S7Z7A<8\9A(8J/Q0W_4XI
M1Y9<IZI\*=?BUW0)-%N2&*+MP:\\\;:'=>!_%(N[(,L1?<&'2F>';V3P7XZ^
MSAOW;,,GZU[EXP\/0>+?#1"JK2%-RM7EUJL<NQZJ?\NJNYHESQMU1)X%\3P>
M(M#B<.#,JX89KIY8UEB:-QE6&#7S'X,UZ[\&>+#I\Q*PE]K U],6EU%>6R3P
ML&1AG(KP,ZR[ZG7YH?!+5&M.?,M3YP^*WA/^PM;^V6<;"%SN)':O2OA1XP36
M-*6PE<"6 8&3R:ZOQCX?C\0Z%/:E 9"/E-?->DWEQX,\8&)G9$23#CU%>[AI
M1SC+G0G_ !(;&4OW<[]&?6M%9^BZM;ZSIL5W;-N1E%:%?%3A*$G&2U1TA111
M4@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S7BSQ2GARV#%"6;
MH:3PEXJA\0VI;<!(#]VK_B'0[?6].DAE0%]ORGWKQ&SFO?!/B;#[A'O_  QF
MN.M5G2J)OX3Z7+L!AL=@Y4X:55KZGT+15'2=1BU2PCN(F!W $XJ]76FFKH^<
MG"4).,MT%%%%,D**** "BBB@ HHHH **** $8[5)]*Y"_P#']A8:NMC*""3@
MDUV!&1BO,?B)X--TC:C:*?,7D@5A7E.,;P/4RFEA:U?V>)T3V]3TBVN8[N!9
MHF#(PR"*FKR#X?>,VMI_[+U!B/X5+5Z\K!U#*<@C(-51JJK&Z,\RR^I@:SIS
MVZ/NA:***U//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:C!93V;B_C1X%&2'
MZ5S&CVW@[6YIHK'3K=VB)#?+Q_.J'Q?N;RV\(@V3LKM)M8KZ8K0^'.F6=EX8
MMKB)5\^9 TK=R<<T /U>V\)>'?*EO-.@CW-A6"=_SKIK*:WN+2*2U*F%E!7;
MZ5B>--,LM2\.79N55FBC+(?0UR7P;N[VXTJ[CNG9ECE*IGL* /4**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0_\B]??]<36G69XA_Y%Z^_Z
MXF@#S;X)?\>^I_\ 79_YUZY7D?P2_P"/?4_^NS_SKUR@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *U_9QWUG+;RJ&
M5U(P:^6?%^C7?A#Q7YJC8"Y*5]7UYC\7/":ZMI#:BI_>0#-?0\.X]8;$^SG\
M,]&95HW5T>4^)(8[G1K76(VW775L=:]B^%/B(:SX=2.9\S(,8)KQ'PE>V[)=
M6.H/E2,1JWK6S\.]6E\.^+_L\[%()&X!Z5]+FF"=;"SH_:AJO3LC&$K23.K^
M+W@IL#6+"+#+RY45;^$/C1;JU&DW<G[U. 6->J7MK!J^EO"V&CE6OFCQ)I-W
MX$\7_:;<,L&_((Z5Y.6U(YEA)8&L_?C\++FN27,CZCX(]C7AGQB\&["NJ6<6
M2V2^!7J7@[Q'!XCT6*YB8%@H#5HZWIL>JZ5/:NH.]2!7B8'$U<MQB<M+.S1K
M)*<3QGX.>,VBD&C7+ )T4DU[L"& (.0:^1-<L+KPAXG9(W9"CY!]LU]'^ ?$
M\7B+0XV# R1J W->OQ'E\;K&T?AEN9T9_99UM%%%?)FX4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5R4(U*4_9O5'O9K5PF.PZQ<'RU-FNYU]%%%=I\T%%%% !1110 4444 %%%%
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M ,B]??\ 7$UIUF>(?^1>OO\ KB: /-O@E_Q[ZG_UV?\ G7KE>1_!+_CWU/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %9GB'_ )%Z^_ZXFM.LSQ#_ ,B]??\ 7$T >;?!+_CWU/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU:D?=D]4?4YC@<'7M7I0O&3LVMT_0]9CD66,.ARI&0:=7.^$;F6;30DASL&
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MP.<#\JZC7O'_ (>U'2+BWLYX[FY="(E7!PU4?!UQ>:-X0O9_$QVP.6,8?TH
M['PSXILO$=HK0N//5?WB>AK?KQOX0V\K^(M6OHT*V4K,8SVZU[)0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %9GB'_ )%Z^_ZXFM.LSQ#_ ,B]??\
M7$T >;?!+_CWU/\ Z[/_ #KURO(_@E_Q[ZG_ -=G_G7KE !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>,_&GPZTEO'J5M'\Z<L0*]FK*\1:<NJ:)<VQ0,60XXKORS%O"8J-5?
M,F<>:-CQ70I4\6^ WTH@-<0KR3UKSW1=0F\,>)T?<1Y3X85T'AJZF\'>,9;*
M<E4D8J0:B^)>@_V;J4=[&OR7'S9%?H6'4*>(EAW\%177SW.1ZJ_5'TEX?U>+
M6M(@O(R#O7D"M)HT8Y903[BO O@[XO:WNCIMW+^[/" FO?@00".AKX'-<!+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5:^&?Q),A72=4;;(ORJ6KT?PQ*FK>&HEG(E5DP<\UY%\2/A[<:1=_P!L:0I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"6Z.M.X4445 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5'-/';QF25PJCJ34E8_B:W:YT2>-"0=O:ID[)M&E&"G4C&3LFRS9:S
M97\C1VTRNPZX-7Z\,\!W,MAXFDMWD8Y;&":]R4Y4'U%98>M[6-V>CFV7K UE
M"+NFKBU1UB$3Z5<1D9RAJ]3)4\R)D/<8K9JZL>;3ERR4NQX%X8D;1_&A4\?/
M7OL,@EB5QW&:\$\5(=(\9+)T&X&O;]%G%QI-O(#G*BN'!NSE#L?4<21]I"CB
M5]I%^BBBN\^4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDJ"2)
MD89!%/H/2@:=CY]F9M-^(/'RKYO->^VTBRVT;J<@J*\:\;:+=#Q&ES;Q$_-G
M(%>I^'#*='A$P(8"N'"IQG*+/J<^E"MAJ%9/6UC7HHHKN/E3A_%/@9=>U);K
M.,&NHT>P.FZ?';$YVC%:%%9QI1C)R6[.NKCJU6C&C-^['8****T.0**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK-UO6;;
M0]-DO+E@JJ.,]S7.^&/&\FLVUU>WMM]ELXL[92, @4 =I17D.I?%^]BU-UT_
M2C<:>C8,X!(Q7HGAKQ):>)--6ZMF&>CKZ&@#:HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "LSQ#_P B]??]<36G69XA_P"1>OO^N)H \V^"7_'O
MJ?\ UV?^=>N5Y'\$O^/?4_\ KL_\Z]<H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KQWXQ^$5N+3^U[9/WR<G KV*JM_90W]G);S(
M&5E(YKMR_&2P>(C6CTW]"9QYE8\C^#WC'SX3I5Y+^\7A0:]FKY<U_3KOP)XT
M6[12L1DR/I7T1X6UV+7]%@ND8%BOS"O7S_!P4HXRC\$_S,Z4OLLN:II%IJ]H
MUO=1*ZL,9(Z5\^?$#X7W&B2/>V"&2W)R0!TKZ2J*YMHKNW>"= \;#!!K@RS-
MJV J7@[QZHN=-21\U_"OQA_8&K"VNY"MNYVX/:O5/B#X2T[Q'H;ZE%M$@7<&
M'>O*/BCX1.@:PUW;1[+=FRN.U9]K\1]3A\-OI+R,X(P&)Z5]A6P3QE2GF&!E
M9NUSG4N5.$CC[J VUS)"3]TXK3\-:[-X?U>*[A/1AGZ4RUT6_P!4BEND7<HY
M+&LME*.5/45]*U3K1=*6O<QU6I]C>&=?M=?TF*YMY0S;1N'H:VJ^3O OC6Y\
M,:@B[R;=C\PS7TYH6O6>O6"7-M(K;AD@'I7YCG.3U,!5;6L'LSLIU%)&K111
M7AFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME>1_!+_CWU/_ *[/_.O7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IDT23Q-'(H96&"#3Z*$[ ?-?Q+\-3>&O$
M0U2U0I"7# BO8_AYXIB\1Z#$<@2QJ 15[QGX<A\1:)+;R*"P4E:\"\(ZS=>"
M_&!L[AF2W+X(/2OL86SC+^1_Q:?XHYW^[G?HSZ@HJ"RNX[VTCN(CE'&14]?'
MM-.S.@\Y^)'@"'Q#8/=VR@748R,#K7F?P_\ &=[X1UHZ3J1;R2VW#=J^DB 1
M@]#7C?Q5^'_VE&U73H\3+\S;17TV3YA3JTW@,7K![/LS&I!I\T3JO&OA>R\9
M:";FW"M-MW*PZU\RZC9W&DZB]O(&62)L UZ[\+OB UI,-%U5R/X06K:^*/@&
M+5+$ZMIRC>HW';WKU<NQ-3*L3]2Q+]Q_"S.:4US+<J_"/QW]IB72;U_F485B
M:[?QOX*L_%.FN=BBX RK@=:^6["\N=&U))D+))&W(KZH\!^*H?$NAQR!AYJ
M!AFN;/L#/ UUCL-HGV[_ /!*I24ERR/G@1W?A;59--U&,^06V@L.,5+=6-YH
M<Z:UHTC>23N.TU[K\0? ]OXDTUY(XP+E1D$#K7AFEZE<^&=0;2=8B+6Q.W##
MI7K8#,%CJ7M*:]]?%'N9RARNS/:?A[\1K;Q'9I;73B.[48()ZUZ'7R_KGA^X
MT6XCUW092T#?.=G:O4_AW\2[?78$L;UQ'=(,98]:^<S7)X\KQ6$UAU75&T*G
MV9'IM% ((R.117S)L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-D&Z-AZBG4
M4 CP/Q.)-+\8++O8 OZU[7H<_P!ITBWESG*UY5\6;+RM2AN(UP.]=]X$OENO
M#D"9^9!7!A_=K2@?6YNO;Y90KKT9U%%%%=Y\D<9\1[!K[0&"C[N37)?"O4A#
M</8D\YZ5ZKJ5DM_8RV[?QC&:X[PUX _L+5GO#+NR<@5QU*4O;*<3Z+!XZA_9
MM3#5GKNCO****[#YT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@#S;X)?\>^I_]=G_ )UZY7D?P2_X]]3_ .NS_P Z]<H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>9(('ED
M8*JC))J2N:\<6FHWWAZ:VTT'SG]*UH4U4J1@W9-[B;LCR/Q=I]QXTU*\DM4&
MRWS@CO7%>#]<F\+^(%+[E(?:0:]'\.Z'XNT6U:,VA9GSN)!YKB/&OA+6K69]
M3N+0QQDY. :_1<%6HRYL%*47!JRU.22?Q=3Z:TN_34=.AN48-O7)P:N5X[\%
M?$!GL9+*YGRZD! QKV*O@\QP;PF)E1?0ZH2YE<*R]=T2UUW39+6YC#;AP2.E
M:E%<<)RA)2B[-%-7/EO5K#4OAQXG,UL6$ ?@^HKUR.73?B=X0Q\GVM4_'-=!
MXU\(6OBG2GBD4"91E6Q7S_I>HZI\.?%'E2[Q#OP0>A%?:T:JS:@JD';$0_$Y
MFO9NSV9B:A97WA'Q"5PR-$_RGU%?2'P]\6IXDT2(R./M"J 1GFN8\8:%8^/O
M#*ZOI^W[4BY8+UKR?P?XBO/!_B)5EW*F[:RFNG$4XYS@WI:M#=?UW)3]G+R9
M]8D!@01D&O)OB;\-X]2@?4M/3;.OS, *]-TK4H=5T^*ZA8,'7)P>E7&4.I5A
MD$8(-?&83%UL#7YX:-;HZ914E9GS?X"\<R:+<_V'K2EK5CL(?M6CX[^'WV<#
MQ#X=8M$WSD)VK:^)WPT6X5]5TM-L@Y95%8/PX\>2:?.="UDEH2=N'[5]E&K[
M6/\ :& W^W'N<]K>Y(U?A_\ %/R;5K+66*F(8!;K7::!\2]-U[5S8P?>[5YC
M\5?"FG6;+JND.I$O+)'VS7$^%-770M6BNR"L@8#FD\HP>/H2Q5%-2?3LP]I*
M+Y6?7]%9N@ZHFKZ1!=HP)=<G':M*O@YP<).,MT=6X4445(!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEK<JK(P[]JPO"WA%?#AN(S>">WE)VQL>%KB!\-?&'_0Q/^E'_"M?&'_0Q/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH^ROKN>IF>9_7E"\;.*L+1116YY04444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 $9&#TKQ/XM>!V#?VSIT9\P'<VT=*]LJ"[M8[RUD@E4,C@@@UW9=CIX*NJ
ML?GYHF<5)6/)OA+XZ^UVXTF_D_?IPI8U[ #D9%?,WCC0+OP3XG6_L0R0E\[A
MTKVWP)XK@\2:+$RN#,B@.,UZ^=X&$HK'8;X)[^3,Z<G\+.LHHHKYHV&21I-&
MT<BAE88(->$?%3X?M8S?VSIB' .XJHZ5[U4%Y:17MJ\$R!D<8P:]#+<PJ8&L
MJD=NJ[D3@I*QX7X5\0V_BWP\_A_4B/M87",W6N$(U'P%XF(4L%1^HZ,*Z/QW
MX1OO!^MC5=.#"+=NRO:IKV:W\>>&PT>U=0@7YR>IK[JA*E'][2UHU-UV9S.^
MSW1[7X/\46WB;1X[F)@'P-RUO7$RV\#RMT49KY:\"^+;GPCKBPW)80%MK+7T
MU:75KK>F)-$P:*5<\&OD<YRMX&O=? ]O\C>G/F7F>+7NOP:_XVFM=1YLD8X!
MZ5S_ ([\/:87%UHY554<J*]P;P#H;3F;R")#U(IW_""Z*008F(/8FO0HYWAZ
M$XRI722M;H2Z;>YXCX!^((L VD:P/-M)/E&[^&F>,?#']DW2:]H+[K=CO^3M
M7=^,_A!9W5JT^CIY<RC)'K7FNG:WJ'AR9M'UJ)FM<[1OKVL+6HXF;Q6">K^*
M#ZF<DU[LCUKX:_$*'7+1;&[D"W*# R>M>F5\FZE$^C:G'JVCR?(3NPIKW7X>
M>/K;Q-8)!,X6[08()ZUX&=Y0H+ZUAU[CW79FM.I?W6=[1117S!L%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %9^LZ8-5T^2V)QN&,UH44FDU9EPG*G)2CNCB_"W@@^'KUY_-#9.<9
MKM***F$(P5HFN)Q57%5/:57=A1115G.%%9^LW3V6ES7$?WD7-<-X-\<7.M:V
M]K<<*#@5E.K&,E%]3NH9?6KT)UX;1W/2:***U.$**** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>4[WSZF@#JJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0_\
M(O7W_7$UIUF>(?\ D7K[_KB: /-O@E_Q[ZG_ -=G_G7KE>1_!+_CWU/_ *[/
M_.O7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HHHH **** "BBB@ HHHH **** "LSQ#_ ,B]??\ 7$UIUF>(?^1>OO\
MKB: /-O@E_Q[ZG_UV?\ G7KE>1_!+_CWU/\ Z[/_ #KUR@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\5:"UD6PRG<OUKRJV\%^,=4FCT/4E9-)B(4-Z@<5Z[XKU'4M,T=KC2[;[1<
M\)7FX\=^/BO/AX_K_A0!TNL^']3T;PE'HGA^/>DGR2-Z#%:O@7PDOA;2?+)S
M-+\\GL3UKSN]^)WC334WW.@$*>^#_A7H7@3Q)?>)-*-U?6X@?/"T =;1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?!MWX/UC^U=,#"(MNPO05]OE&:O%P6'J2M47POOY,YJE/E=UL5="\5ZW\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\B]??]<36G69XA_Y%Z^_ZXF@#S;X)?\ 'OJ?_79_YUZY7D?P2_X]]3_Z[/\
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MF22I"A>1@JCJ30 ^BF12QS('B<.I[@T^@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBJFI7+VEE),BY*C.*3=E<J,7*2BNI;HKS31_B#+?:Z;&5-OS8%>E*<J#ZB
MHIU8U%>)U8S UL')1JJU]1:**;(XCC9ST K0XSC_ (DP>?X:DPVTCO7(?"[7
M[2PCFMKJ;:6.!DU>\1/?>)-4EM(7(MD'(KB?#VF+)XB;3FW!MV U>75J/VRG
M%>1]U@,)!Y9/#UI?WM.A]"PS1SQB2-@RGH14E>=Z'<WNAZZ;"YD+PG&W->AJ
M=R@CO7H4Y\Z/D,9A?J\TD[IZIBT445H<@4444 %%%% !1110 4444 %%%% !
M1110!Y[\8;^XL?!X:W8JSR;21Z8KCC\.-'G^&QU1D9[Z2'S-X)SDBO5_%6DZ
M=K&CO:ZBZI&?NLQZ-6)X.\.7^G6<]C?SK<:>V?)&<_+VH \TT'X:Z+JO@6:\
M8LMW!EFY/0"NW^#\MI_8UQ;VJ%1%(5;/<BLO6/ 7B>/69!HMX(M.FX>/)Z&N
M]\(^&(?#6G>4@'FN=TA'<T =%1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %9GB'_D7K[_KB:TZS/$/_ "+U]_UQ- 'FWP2_X]]3_P"NS_SKURO(
M_@E_Q[ZG_P!=G_G7KE !1110 444UP60@=2* .>\2^,]*\-6$ES<SH60?<!Y
M-6/#?B.#Q#H2ZK&NR)L]?:N!^(7@FUD\,ZCJ%Y(S2JI91GBK?@%S'\(967C:
M'Q^E #]>^+*:7J#6MEILEX5."4!/\JN^&?B7!KER+>XM&M)2<!7!'\ZP?@]!
M#?P:A<W,22R>:P#.,XYJM\1TBTOQII#VL:Q>9( VP8SQ0![("" 1T-+7 ^(]
M8UC0?LFH)F2R*+N4=N*J3>.KG7;BWM-#4EVQO8?PT >AW-W!:)OGE6-?5CBN
M/L/B1IFI^+/["M/WCY WCI6E?Z!<:Q86\%Y*01_K"#UXKR?1-%M- ^-D=M9Y
M*G;DF@#USQ1XJMO#5F995WR8X0=37"V_QFDDF43:)-'"3CS"K8JI\2)6D^(>
MD6CG,+LNY>QXKT#Q!I5B?"=P!:Q#9!E2%'% &II.L6^KZ>+N _+C)'I7F]]\
M:5BU:XL+/29;EX"0Q52?Y5-\'KF2YT2_1V)".ZC/UK@/#7BVU\)^,-:$^F->
M>8Y&57)'S4 =U;_%^_GN8XCX<N%#'&=C<5VNM>+;;1M*CN95S.ZAA#W_ "KB
M;7XM:;<74<(\/3J7.,E!Q5+Q>LTOQ TO4)D9=-8*6#?=''>@#8TSXKS7EX(I
M]&F@B)QYC*0*]'M+R&]MUF@<,I'8UQ/C#7-!@\(7C6LEO))Y>$$8&0:K?!V[
MFO/"IDF8L3(V,_6@#T:BBB@ HHHH **** "BBB@ HHHH **** "L'Q;XFB\*
MZ.^HS1ET7L*S_'WBH^&=+1H^)ICM3ZUY'XU/BV7PD+C5I-]K*<@<],T >[Z!
MK$>NZ/!J$2[4E&0*TZ\]TF_DTKX1B\M>)(H<K]:QOAMKOB?6=(OM4U*8-"N[
MRQSVS0!ZW17F_P ,?%.I>(O[5-\V1 Q"?F:J^#/%VK:KX[U+3;ILV\)&P4 >
MI45YCXT\6ZHWB!?#^AMMO/6N9E\6>+]$\9:?I6H2YCE;#=?2@#W2BFQG=$C'
MJ5!IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ5QJ$L,*L0H0]ZGT;[=X(\70Z/+<O-#,P"ECV- 'M%%(IW*#ZBEH *S/$/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN61AAE,AY%=UX/\ "%IX1TXVEL=VXY9CW-=)10 4444 %%%% !1110 4444
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ME1PTBH U?&D6E7TS;8[=V([ 5[A\$M0U+2KB2QNX7$<G W=J /H*B@'(!HH
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M10 5F>(?^1>OO^N)K3K,\0_\B]??]<30!YM\$O\ CWU/_KL_\Z]<KR/X)?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M075G#>1[)T#+Z&IZ*&KCC)Q=T06UI!:)LAC"#VJ>BBC8&W)W84444""BBB@
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M\@BY_P!RKU4=9_Y!%S_N4 >:?#W_ )#LW^\:]9KR;X>_\AV;_>->LT %%%%
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MMCGOB5K-GI>AMYENLLS' !&>*\TBT/PYJOAMKU_W=ZZY">]>TZSX;LM<Q]I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %1S017$9CE0.AZ@U)10G;5 <'XG^%^CZ[$?)B6"4_P 2
MBO+-5^'_ (F\(3&72)Y70<DI7T?37174JR@@]C7M8//<5AUR2?-'L]3.5*+/
M ?#OQ>U'1I5LM9@9CG#,PY%;'CCXH*UK;/HLNYR 64'I74^./!V@2:9->S6Z
M1R] P '->)2> -9,;WEA$TD/5<=Q7T&"AE>,FL2X\C6Z>S9E+GCH?0/@+6WU
MOP]%-<L//(&Y3UK%^(GP]@\0VCW5L@6Y49X'6O)?"/C74O!NK;-1B?RSP4/:
MO?- \::3KUNK17"+(W\!/->7CL'BLLQ7UF@O=W36WH7&49QLSY.O["[T:_:&
M96CEC;@UZ'X>U2T\6Z.='OP!=*OR2-UKTOXB?#NV\16;W=HBK<J-WRCK7SJR
MWWAW5\,&BFB;Z9KZG"XNEF^'O%VJ1_!_Y&$HNF_(LZQI%QH=Y+9W49\O)"/Z
MBNB\"^)A92/I5X?,MY_D7=VS71Q&S^(7ATJQ5=0@7 '=L5Y9>V=UH^H&&56C
MFB;C-=-*4<;3EAZRM-;_ .:)?NNZV.QNEG\"^,8[V!B8)FW#'0 FOH_P_K$.
MM:3!=1N"64%A[U\]6=W!XK\.&SG >_C7Y6[\5L?"SQ;)H.K2:+J+G!;:N3TK
MP<WP,L7A^9K][3W\UW-:<N5^3/H*BFHZR('0Y4C(-.KX4Z@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S
MSXH::)M,^TX^Z*J_"F_,]H\!ZI7;>(]'_MO2);/=M+C@U@^#/!4OAF:21YP^
M_L*XY4I*NII:'T=+'4)93+#U)>\GHCM:***[#YP**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#*U^RTV^T_R=4*B$G@L<<UYW?>$O%\;X\/ZDJ6)
M_P!6,CI72?$[RQX7+R)(X5\XC&3TKB_#_P 7[?3M,BM)],NR(U"@^7S0!H6'
MA+QU-*(M5U)9+5N'4$<BO1-$T&ST*U\JTC"YY8^IK@#\;-. _P"0;>?]^Z[7
MPMXHA\3V)NH8)(@#C$@P: -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *S/$/_ "+U]_UQ-:=9GB'_ )%Z^_ZXF@#S;X)?\>^I_P#79_YUZY7D
M?P2_X]]3_P"NS_SKUR@ KROXD?\ (?L_JM>J5Y7\2/\ D/V?U6@#T+0?^0/!
M_NUI5FZ#_P @>#_=K2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *HZS_P @BY_W*O51UG_D$7/^Y0!YI\/?^0[-
M_O&O6:\F^'O_ "'9O]XUZS0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\A^S^JT >A:#_R!X/\ =K2K-T'_ ) \'^[6E0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51UG_ )!%S_N5>JCK
M/_((N?\ <H \T^'O_(=F_P!XUZS7DWP]_P"0[-_O&O6: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J*>VAN4*31)(I&,,,U+133:U0
M'FGBOX2Z;JX>XLU$4_8#BO$O$O@/6/#LC&XA9X\\,!VKZXJM>:?:W\1CN85D
M4C'(KZ#+N(\3A;1G[T?/<RG14MCY=\"^+VT.]%G?$M92?*RMVK0\>>%;< :S
MI+!H)OF*KVS73?$?X71VT4FIZ8IQU***\PL?$=]IT,EE,2\?0JW:OK\-.GBY
M+&8-V?VEW.>5X^[(K).UY9_9R,.@R">M>K_"#QGY$O\ 8UW(<YPNXUXY-,//
M,L9VY.<58M-0EL;Z*]@)5T(Y%=V/P$<7AY4I+?;R9,9\KN?:(((R.E%<EX!\
M30^(="A;S TZ* XKK:_)Z]&="HZ<]T=R=U=!1116(PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(_Y#]G]5H ]"T'_D#P?[M:59N@_\@>#_ ':TJ "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<MXN\
M3-X>MQ(%)S4G@_Q'_P )#9-,>HK/VL>?DZG8\!66'^LV]TZ6BBBM#C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *S/$/\ R+U]_P!<36G69XA_Y%Z^_P"N)H \
MV^"7_'OJ?_79_P"=>N5Y'\$O^/?4_P#KL_\ .O7* "O*_B1_R'[/ZK7JE>5_
M$C_D/V?U6@#T+0?^0/!_NUI5FZ#_ ,@>#_=K2H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZS_ ,@BY_W*O51U
MG_D$7/\ N4 >:?#W_D.S?[QKUFO)OA[_ ,AV;_>->LT %%%% !1110 4444
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M1110 4444 %%%% !1110 4444 %%%% !1110 5F>(?\ D7K[_KB:TZS/$/\
MR+U]_P!<30!YM\$O^/?4_P#KL_\ .O7*\C^"7_'OJ?\ UV?^=>N4 %>5_$C_
M )#]G]5KU2O*_B1_R'[/ZK0!Z%H/_('@_P!VM*LW0?\ D#P?[M:5 !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'
M6?\ D$7/^Y5ZJ.L_\@BY_P!R@#S3X>_\AV;_ 'C7K->3?#W_ )#LW^\:]9H
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MBTCDE!R&*C->+7Q>'P>:SJNG=+9>?<U47*"5SQKP]\%%U+3([O4;F2.64;L
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MPUF*^Q^)7MH'ME]D64VT<[37SGJ'A[49?%DUW):EH-Q.2/>NWMOC993#$L0
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M1_>+VD#U8^&M%/\ S#;?_OBOG_XLK;6OB$6EG9>7&N&)5>M=,?CR.UG69?\
MQ;TK4-TESHJ2RD8W%17J95@,QP=?VE2FY+M<B<H25DSG;7Q5IMG:06YLD8X
M8E>:PS<17'B6*6*W)A=A\H%9.IW<=]?RW$<8B1SD)Z5W/A[X@Z7H^FQ6\VBI
M/,G_ "T*C-?45*$J$.>E!RE+=7,$[Z-GLFG^ M$O-,MYC;*&= QXJ0_#/0R<
M^0OY5YT/CS<(H2+2\(!@ 8I?^%]W?_0,/Z5\@\KSJ[:O]YT<],] ?X7Z&_\
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M+_9X?^>:_E2^1$/^6:_E7JPXEKQ;:6_F1[%%;2(_*TJVCVX*Q@$>^*NT  #
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MU\FZ0[61CR376UXU\-](O=7UB77Y8VMXBYQ&1CWKV6@ HHHH **** "BBB@
MHHHH ***1F"J6)P!0 M<]XO@U>?22NCOLN,]:TK+5[6_N)(8'#-'UQ7+^)?B
M-9^%[SR;V!]AZ, : .=\/^-=6T+5H](\1QLS2$8FZ 5ZM%-'/&)(F#(>A%>'
MZYXH'CW5;6QTZPD3<1^_*$?K7L&@:?)I>D0VLK;G08)H TZ*** "BBB@ HHH
MH **** "BBB@ J&YNH+.+S)Y%C3U)KS'XA_$'4-)NH]-TJ-DG=MOF$8%8=Y+
MK@T?[1XGU%)H)$RJ1N"?TH ]4F\7Z'#@&_B+'H :U;2ZCO+=9HCE&Z&OGCP7
M\,I=>UHZE)-,EB&W*K9Z5]":?8Q:=9I;0_<08&: +5%%% !1110 4444 %%%
M% !1110 456EU&R@?9+=0HWHS@&H_P"U]._Y_K?_ +^"@#S/Q+_PFNEZQ+J5
MO*7T^,[O+ ZBNP\'^,K;Q-9#(\JY7Y6C8\YH\5>+=/TO19Y(Y([J0J0(XSNS
M7$?#+1[R_P!4?Q!-&T$;,<1D8H ]@HHHH **** "BBB@ HHHH **** "L7Q)
MXGL/#6GR7-W(-P&5CSRQJOXJ\767AFP::1A),>%B4Y8GZ5YSH7AK5O'VL?VS
MKY=+-6S%$?3Z4 9TUQXV\63RZW8.\%A'RL1[BN]\#^/(=:C^P7P\B^B^4J_5
MJ[6UM(+.V6W@C5(U& H%>,^+[*.Q^*EG/;_NBQ4D+P#Q0![;145LQ>VC8]2H
MJ6@ HHHH **** "BBB@ HHHH *9)(D,;22,%11DD]J2>XBMHC)-(J(!DEC@5
MY#XH\6ZIXNU$Z#X=5UA)VS3 <$?6@"QXP\<WNLWS:!X7W-<$X,Z]!6=HOB#Q
M!X$U-+3Q)OGBG(S+V6O0/!O@FR\+62X4273C+R-US4?Q)L(+SP=>&2,%U *M
MCD<T =/97MOJ%JEQ;2!XW&015BO._A$[#PR(2Y8*3C/UKT2@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ IKHLB%74,IZ@TZB@#QOQ3<S>*O% \)0'[/:
M@Y;R^.M/UCX2Z)H6@O<07;V\L:Y+[L;C4WBGPQKFD^*CXBT&+SIFP"IJG<6'
MC3QO<16>KPFTM#]\K@?RH ZWPE:_VSX2_L^ZD:6#&W>><UJV=KH_@C2Y$601
MQC+;2>369?ZIIOPW\+I:B7S)@,1+U+-7):%X>UOQUJ']KZW(\%MGY(NQ':@#
MT+0/&ND>(99(K27;(AQM<\FNCKQ#QSH5GX3U*UO-+G,5R",1*?O5ZKX6O[O4
MM!@N;Q-DK#D4 ;5%%% !1110 4444 %%%% $36T!E\YHDWC^(CFN%\<?$"/1
MU_L[3/W^HR_*@3G!KK-=%V^FR)9#]ZPQ]*Y/PG\/(=+O9-3U%OM-W(<C?SMH
M H^"O US)<C7?$3-->2?,L;\A?2O3  BX  4?I1P!Z"O-?B5XF\0Z5(MKI%L
M9(Y!AG Z4 =7K7C+1]#ECCNKA=SG&%/2MFSO(+ZW2>WD62-AD$&O%O"?A+2?
M%MO.UY?R/?D9=&)^0UL>%M/\3>%O$1TE T^F$\2-V% 'K%%(,X&>M+0 4444
M %%%% !7FOQ@TF]U'1H)+12ZQ-N=1Z5Z53)(DF0I(H93U!% 'DVG?%G2K/18
M]/@M)A>1H$VXXW56T?P?JWC35AJWB%G2U5MT4?K7IB^%=$6?SAI\/F9SG8*U
MT18T"(H51T H 9;V\5K D,**B*   ,4KSQ1L%>158] 3UK+\1>)+#PUI[7=[
M(%'\*YY)KPS5+OQWXTUM=6TJ*2.SB;,8' (H ^BZ*X+P9XX;4[D:/J*[-1C
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MM\0/',5G'_8NG-YE[/\ *-G..U6OAUX/DT6S^VWZYO9>230!WU%%% !1110
M4444 %%%% $5RAEM947J5(%>*Z7XFG\%>+;X:U#,T$K'RV45[?5&\T?3[]@U
MU:12D=V4&@#RK7?&.H^,[F+3O#]O(L>X%RP[5WPO[7PAX7BFU)PKHGSC/)-:
M7V&PT>VFNK>UBB*(6RJ@=J\D@@O/B=XG9YI62PM'VE >&Q0!974O$/Q#NY5L
MU>#2B3M;D'%06&H:S\.];2SO9C-ITAZL<FO3[JZTGP=HI.$AAB7A1P37ENG6
MU]\2/%/]INK#2XFX![T >T65W'?6<5S%GRY!N&:GJ*VMX[2VC@B&$08 J6@
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M0+JW6WOHAAE QFO2: "BBB@ HHHH **** "H+R-IK.6-3AF4@5/10!X9X?\
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M"",@Y%>/>(?A['%8W'B"QUJ0M$OF*H<X/MUKIOA=XCNM>T$_:^9(B5SZX.*
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MBBCM3#+&K;2X!]": 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@5#\ENE7(I!+$L@Z,,UQG@[2M4N])6X\0,7G<AE![5VB((T5%Z 8% #J***
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MH4.!NDE;U[T =/17 #XEV]UXJCTBP@,Z%MK2J,@<UW] !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYUTW3/B'!K!\42E_))WM&3QM^E>P^#O&5MXIMF"<3Q<2#WH ZFBBB@ HHHH
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M\B"-/^!.:FUO5=,\%:/)<+;A%/147J>U>;:5H>L?$C5QJFL,\.G(V8H^@84
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M%4"@#"\>^,K#P_I3V49#W4J[$C3G%8WP@\.WVF6EU>W\/E/<$NH]B<U7\&>
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MX&\ 6OAZT6YNQY^H2_.[N.5-=1!HFG6U^U[%:QK<-UD"\UH4 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *3 SG S2T4 %%%% !1110 4444 %%%% !1110 4444 %!
M /49HHH   .E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHKC_  ?XZA\5ZC?VD<!C-H2"?7!Q5FP\27UUXDFTV33FC@3I,0<&@#IZ***
M"BBB@ HHHH **XSQ%X]AT#Q-9:.\!=KD@!O3-=BC;XU;^\ : '4444 %%%<K
MJ7C.'3O%MMH+1YDGQAOJ* .JHH'2D)"@DG % "T5P^H_$K3;3Q3!H<.V::1L
M$J<XKMU;<@;U&: %HKF?%GC"#PS:[@GG3]HQU-<;8?%^ZEND2^T62VB<X$C*
M1_.@#UBBJMG?PWMDMU&P,;#.:X+Q+\4&TF_^R:=IS7S@X.P$X_*@#T>BO/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.Q01*O[L@<@YJI\'/^1C\0?[[?\ H55?"O\ R634?I_6@"]=^%?B(]Y,\.M
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MWE2L?F;VK?7[H^E+0!\X:AX9;PY\3=*,LIDGD<%V)]J^C(O]2G^Z*\8^(/\
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MEM T:;[+)&V"YXSSBID/CKPH\5U?SM?P,<$(2:U_&/@.+5[QKO0[F.+4\Y8
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MLC4K$BGJ% IU% &#XN\.1>)M%DL9#C/(KSRQT?QMI.-(M%0:<.-P)SBO8:*
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MP3R*]BHH Q+/08M+\/3:?:#!>)E_$C%<I\-/".H^&KG47OB,3REEQZ5Z-10
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img114804231_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &0 A$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P!_Q&\0^,6^
M+,?ASP]K4UHL\4?EQA@%#$')Z5'J.I?%WP# -2U.XCU.P0_O<X? ]\<CZT[Q
M.P7]IG2BQ &V+D_[IKTWXC>(=)TKP5J8O;F$M- T<<6X$NQ'&!2VC<>\K%_P
M5XLM?&?AN#5K9=A;Y98R>4<=1715Y#^SS8W-KX(N9YE98[BYW1 ]P!@FO7JJ
M6Y*V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@#RWQS
M\'?^$P\4MKB:S)9R&-4"HG(QWS6?IG[/^F)=QSZSK-YJ(0Y\IC@'\>M>QT4+
M0'J065E;:?9Q6EI"D,$2A41!@ 5/110!FSZ_IEMK-OI$ETGVZX!*0CDX'KZ5
M6U;Q7IFC7R65T9VN&C\P)#$7.W.,G%9&MZ?:6OC7P_<PP(D\]Q*99 .6^3N:
MLZKHNL-XD;5])OK2)_LHA:*="V<'/;I0!IS>)--MM*AU&>5XH9N(U9"'8^@7
MKFK&EZO9:Q;&>RF\Q%;:P((93Z$'H:X[3]7;7O$WAZ[N8EC(AN!LSE1,IP<?
MA6MI&%\>Z\L7$1BA9\=-^/YXI@=37.>&_%2^(-5URQ%L8CI=R+<L6SOXSFF^
M+_$&KZ!;VTFDZ!/J[RN5=(3C8,=37'?!V\N+_5O&-W=VCVEQ+J"L]N_6,[>A
MI >J22)#&TDC!449+'H*H_VYI?\ S_P?]]4SQ%_R+U]_UR->+US5Z[IM)(X,
M7C)4)))7N>ZV]U!=QE[>5)5!QE3FL[4O$VE:3="VNK@B7&Y@B%MB^K8Z"LCX
M>_\ (#E_ZZFDTQX(]7\5"\*A]X)W]XMG'X=:VISYHJ1U4*CJ4U-]3JEN(WMA
M<1L'B*;PR]",9J#2]0BU738;Z%66.4$@-UZX_I6/X3$@\#VOF9_U+[<_W<G'
MZ5SFA3:OI7A_0[TZ@'MY[D6[6OEC:$9FYSUS6G6QH>CT444AA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "444
M4 +1110 4444 4;S2K>]O[*\EW>;9LS1X/&2,'-4M3\,6NIWINS=7EO*R;)/
ML\Q4.OH16W10!B7'A73)],M;&-'MUM#F"2%MKQGN0?>K6D:+:Z+#(EN9'>5M
M\LLK;GD;U)K1HH *\V^&O_(V>.O^PF/_ $"O2:\V^&O_ "-GCK_L)C_T"@#T
M&^M$OK*:U=BJRKM)'45RW_"N]/\ ^?J?]*WO$-_+I?A^^OH IE@B+J&Z9KQK
M_A<7B'_GE:_]\5<<)[?6VQQXGV',O:J[/9M%T6'1+1K>"1W5FW9:FZAX>TK5
M;A9[RS2651C=DC(]#CJ*QOA_XEO/$^B2WEZL:R+*4&P8&*R]2U1CXOO[6]\0
MW>F01F,0+&GR-D<Y;&.M2Z?LWR=CHI<O(N38[Y8HUA$2H!&%VA0. /2J@TBP
M%G;V@MU\BW<21)V5@<@_K2:BS1Z#=,DI9EMF(DSR?EZUB>%O%&G7FGZ=9&Y=
MKJ2$89U($C <@,>II%G54444#"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $HHHH &940LQ 51DD]A6?<Z]I=G
MIR7\]Y&EM(<(YS\WT'4TW7]3L=+TJ:74&80.I0[5))R.G%<#H6K:'NL[V]U6
MYN8K>,BUMWM3B+/J0/F..] 'I%C?VNI6JW5G.LT+='6K-<WX,*2:9=W$:2*D
MUW)(I=-FX$]0O85TE !1110 4444 %>;?#7_ )&SQU_V$Q_Z!7I->;?#7_D;
M/'7_ &$Q_P"@4 =?XNADN/"6IQ0HSR/ 0JJ,DFOG/_A&M;_Z!=U_W[-?45Q<
M16MN\\\BQQ(,L[= *Q_^$Q\._P#08M?^^ZZ*.)]DK6,JF"EB'S13T[(YWX36
M-U8>&9XKNWDA<SDA77!Q6MK<6O7JWNFQ:;9RVMRNQ+AI,; 1R64]2/:MZPU*
MRU2$S6-S'/&#@LAR,U0U+Q1IFE79M9WE:95WNL49?RU]6QT%8SGSR<NYI&FZ
M2Y'T)SISQ>&SIJ-YDBVIA#,?O';BLA=!NTT_PW L<:M82JTP!Z #!QZUN3ZO
M8VVD-JDDZ_8UC\SS!R"OM4FG7\&J:?!?6K%H)T#H2,$CZ4AEFBJ.F:I'J8N3
M&C+]GG:!MW<KWJ]2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%P&/X4 <E_PLG2?^?#5__ )Z/^%DZ3_SX:O_ . 3UV5% '&_\+)TG_GPU?\
M\ GH_P"%DZ3_ ,^&K_\ @$]=E10!QO\ PLG2?^?#5_\ P">F3?%#1;>%YIK/
M58XT&69K-@ *[6N=\>_\B%K?_7H] &W9W<5_907<!)BF0.A(QP1D5/61X5_Y
M%/2?^O2/_P!!%:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 )1110!#>"-[*=)I/+C>-E9LXP"*\^MM/U^VGTR735TFYM
M+1'6*8R;"ZL,98>M=MKNF:?JFF2QZE&7MT4N<,1C Z\5YU9V.EA+2VM/",\R
M31,\#R7>UI%'?&>* .W\)6RVVG7(-U#<3O<N\YA&$1SU4?2N@K"\)/;MHNVW
MTY=/$<K(]N'W%6'7)]:W:; ****0!1110 5YM\-?^1L\=?\ 83'_ *!7I->;
M?#7_ )&SQU_V$Q_Z!0!Z31110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%96N>(]*\.013:K=K;)*VR,L"=Q].*Q_^%F^$?\
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MQG4)6D#8^YG'^% %*PU_3]2UAK.UT='A5_+:?Y 0<9^YUQ[UTGV"S_Y](/\
MOV*YA?!]V^J6=Q->P>5:R+(K10!)6P,;2PZBNOH K_8+/_GT@_[]BL?0/#?]
MB:SK=Z)4,>HSK*L:+CR\+C%=!10 4444 %%%% !1110 4444 %%%% !1110
M5PVL>)_$W_":7&@:#IUA.(+9)W>YE9#\W;BNYK#@\/+#XQN_$'GDM<6R6_E8
MX&T]<T 8?V[XD_\ 0'T/_P "7H^W?$G_ * ^A_\ @2]=Q10!P_V[XD_] ?0_
M_ EZ/MWQ)_Z ^A_^!+UW%<U_PF-O_P )5_8?V:X\WR]W^K.<Y_ECF@#,^W?$
MG_H#Z'_X$O1]N^)/_0'T/_P)>NXHH X?[=\2?^@/H?\ X$O1]N^)/_0'T/\
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M*J_VC\2?^@#H_P#X&'_"HM)\/SZW:Z9<74?V(:;?M/"%A\OSUQ@$K_#FN^H
MX;^T?B3_ - '1_\ P,/^%:?@KQ#?>(=/NWU*UAMKJUN7MW2)MRY7WKIJQO#V
M@+H*WX6<R_:[I[DY&-I;M0!LT444 %%%% !1110 4444 %%%% !1110 4444
M %%%>5Z1HE[XJ\0>(WG\0ZI;):WQBBC@EPH7&: /5**X;_A7$G_0UZY_W_%'
M_"N)/^AKUS_O^* .YJI_9EE]K^U?9T^T;MWF8YSC'6N1_P"%<2?]#7KG_?\
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MO)J]9\(?\BI#]&I83XWZ"RS^*_0\LN_^/R?_ *Z-_.NC\ _\C'_VR:N<N_\
MC\G_ .NC?SKH_ /_ ",?_;)JRI?Q5ZG/AO\ >(^I?^(__'Y9?]<S_.N('WA]
M:[?XC_\ 'Y9?]<S_ #KB!]X?6GB/XK*QW^\2/7[_ /Y$Z3_KU'\J\?KV"_\
M^1.D_P"O4?RKQ^M<7O'T-\R^*'H>@_#?_47W^\O\JY_QK_R,]Q]%_E70?#?_
M %%]_O+_ "KG_&O_ ",]Q]%_E1/_ '>(ZO\ N4/7_,S-&_Y#5G_UU7^=>C^/
M/^1:?_KHM><:-_R&K/\ ZZK_ #KT?QY_R+3_ /71:*'\*883_=JAY57JO@3_
M )%I/^NC5Y57JO@3_D6D_P"NC5.$_B$99_&^1TU%%%>F>^<WK7CK0= U+^S[
M^YD6YV!RB1,^ >AXK/\ ^%I^%O\ GYN?_ 9_\*;:PQ_\+/U*^E: VLEC%$CL
MZD%PW('/6NQ^S0?\\8_^^10!Q[?%7PHBEGNKA5'))MG 'Z5UUG=PW]G#=V[[
MX9D#HWJ#67XITW[9X6U.VMK9'GDMW6-549)(XJ7PO;36?A;3+:XC,<T5LB.A
MZ@@=* -:BH+R[BL;.:ZG+"*)2[;1DX'M7+:/\3?#6NZK'IMA/</<NVT*T#
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MZ?38;U+R62W6=':-59/FPP4=#[5N^%=2>_LIXYKJ6>XMY2D@FB$;IZ @?SH
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MY#5G_P!=5_G7H_CS_D6G_P"NBT4/X4PPG^[5#RJO5? G_(M)_P!=&KRJO5?
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M3#?[I4/,J]9\(?\ (J0_1J\FKUGPA_R*D/T:EA/C?H++/XK]#RR[_P"/R?\
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M(+2".&(=%08%6** "O-OAK_R-GCK_L)C_P! KTFO-OAK_P C9XZ_["8_] H
M])KQ[Q9_R,U[_OU[#7CWBS_D9KW_ 'ZY,9\"/-S3^$O4@\/?\C#8_P#745W7
MQ"_Y D/_ %U%<+X>_P"1AL?^NHKNOB%_R!(?^NHK&E_!D<F&_P!TJ'F5>L^$
M/^14A^C5Y-7K/A#_ )%2'Z-2PGQOT%EG\5^AY9=_\?D__71OYUT?@'_D8_\
MMDU<Y=_\?D__ %T;^=='X!_Y&/\ [9-65+^*O4Y\-_O$?4O_ !'_ ./RR_ZY
MG^=<0/O#ZUV_Q'_X_++_ *YG^=<0/O#ZT\1_%96._P!XD>OW_P#R)TG_ %ZC
M^5>/U[!?_P#(G2?]>H_E7C]:XO>/H;YE\4/0]!^&_P#J+[_>7^5<_P"-?^1G
MN/HO\JZ#X;_ZB^_WE_E7/^-?^1GN/HO\J)_[O$=7_<H>O^9F:-_R&K/_ *ZK
M_.O1_'G_ "+3_P#71:\XT;_D-6?_ %U7^=>C^//^1:?_ *Z+10_A3#"?[M4/
M*J]5\"?\BTG_ %T:O*J]5\"?\BTG_71JG"?Q",L_C?(Z:N&^+/\ R(\O_75/
MYUW-<-\6?^1'E_ZZI_.O8H_Q(^I[5?\ AR]#Y]KW[X0_\B.O_7Q)_.O :]^^
M$/\ R(Z_]?$G\Z]#&_P_F>=@OXGR/%/$7_(QZC_U\/\ SKH_A5_R/-O_ -<W
M_E7.>(O^1CU'_KX?^=='\*O^1YM_^N;_ ,JTJ?P7Z&=/^,O4ZSXV?\>NE_[[
M?RKQVO8OC9_QZZ7_ +[?RKQVIPG\)%8O^*SZ4TS_ ))M%_V#S_Z":^:Z^E-,
M_P"2;1?]@\_^@FOFNL\)O+U-,9M'T/5?@G_R$-3_ .N2_P Z]FKQGX)_\A#4
M_P#KDO\ .O9JY<7_ !6=>$_A(****YCI"BBB@ HHHH **** $+*OWF ^IH#*
MWW2#]#7$?%/1+;4O!M[>RRW,<]C"TL)AF*?-[XZU:^'.AVNC^$[26WDN'>\B
M2:4SS&3YL=L]!0!UU>?>'/\ DL'BK_KV@KKM;U_3_#]LEQJ,ICC=MJD+GFO,
MM%\8Z+9_$;7]7FN2+.[@B2%]IR2O7BDY);F]/"UJD>:$&UZ'L'2O+?C5+')H
M.D".17(U.$D*<X^85Z#'J%OJFA/>VCEH986*-C'8U\R7<TLEQ('E=@)"0&8G
M'-1.?*=V7Y8\6Y)RY>7R/J>&:*1%"2(QP.%8&I:\4^$$\LGB2Y$DKL/(Z,Q/
M>O:ZJ,N97.;'87ZK6=*]PHHHJCC"BBB@ HHHH **** "BBB@!**** (;T%K"
MX4.4)B8!AU7CK7 6_AN)M+TS4++2[/4I$C9+B)F ,N?XMQ[_ %K>UKQ;;Z-X
MBCTV^#BVFM#*&CC9FW;L8X[8KE0G@)7=D&IH78LVT3#)- ':^$].N=,T<PW%
MO%;;I6=+>(@B)3T7(ZUNUD>&O[._L9/[+,YM=QQYV[=GO][FM>FP04444@"B
MBB@ KS;X:_\ (V>.O^PF/_0*])KS;X:_\C9XZ_["8_\ 0* /2:\>\6?\C->_
M[]>PUX]XL_Y&:]_WZY,9\"/-S3^$O4@\/?\ (PV/_745W7Q"_P"0)#_UU%<+
MX>_Y&&Q_ZZBNZ^(7_($A_P"NHK&E_!D<F&_W2H>95ZSX0_Y%2'Z-7DU>L^$/
M^14A^C4L)\;]!99_%?H>67?_ !^3_P#71OYUT?@'_D8_^V35SEW_ ,?D_P#U
MT;^=='X!_P"1C_[9-65+^*O4Y\-_O$?4O_$?_C\LO^N9_G7$#[P^M=O\1_\
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MBK/@?XA6]PNE>'A92"18UA\TL,<#KBO./&__ ".>J?\ 78U8^'O_ "/&F?\
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M$^-^@LL_BOT/++O_ (_)_P#KHW\ZZ/P#_P C'_VR:N<N_P#C\G_ZZ-_.NC\
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MB=)_UZC^5>/UKB]X^AOF7Q0]#T'X;_ZB^_WE_E7/^-?^1GN/HO\ *N@^&_\
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M>@6RRQ7\!D-NH\RVB?(>(GJF?[OL:2[@;]C>1W]E%=1?<D7.#V]JY[6YWBU
M"\N'2P+#R[BW;:UN_P#M^Q]:2XUV.UTJTCTZ);>6[F,*F4'9$^3G=BJ.EZ&\
MK/%,A@U.(XNF;+17:,>O/^10!OZ3?7*W;Z;?.LDRH)(9UX$T?K]15C6OM7]G
M-]C>,39^Y(<"0=USV)JK&ECI-[:V0MW_ '<#M!(3N/'5!^%<V\\NOS0ZG?VX
MGTEBT*Q0EA);MG 9AZ_RH!%[3]5>RC6YBGFELE<1W5M.<R6K'C.>XKL 01D'
MBN=31(]/LY[NZ!O)DB*$C@RQ]@WJ1ZU7U?5Y[L6NDZ0T<,MW;ETDF!"E<?=4
MCO0!#<RW*:PR3WQ@GD.+2ZC;]U)_L.O3-=!I&H/?VSB>,1W4#^7,@Z!AW'L:
MY[2] M[V !87MH_]7>6DN2"X_C4]CWR*TY-1M='_ +2Q;2>;;0K(2/F:50,
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M%;K4;Q]2TN]G,\2FQ* _NSCIP?E.>: '>=<^(+2*_N[:.\L7D9&MT3;-:'.
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M'4&JMCXB-O>2R:C(=4M(&0I?0P )"S<$9]*M:9%JL>M7^_%EIHO6G,[D9G!
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M>K>EM:Z[X=M[?5&C:ZN-PR/E=F0D;A[\5LV&F+;)"]RRW-W$AC%RR#?M],T
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:%%% !1110 4444 %%%% !1110 E%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img114804231_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .V!>X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO#\%CJ=TMS-%\HD']WMFF^,M*U/6O#TUCI=TMM-+A6<_W<\_I3J?W>FPJ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ[_X$-_\50!]>45\A_\ "%_%7_GQUW_P(;_XJC_A"_BK_P ^.N_^!#?_ !5
M'UY17R'_ ,(7\5?^?'7?_ AO_BJ/^$+^*O\ SXZ[_P"!#?\ Q5 'UY17R'_P
MA?Q5_P"?'7?_  (;_P"*I&\&_%-%+-9:Z !DG[0W_P 50!]>T5\I_!C5M5N/
MBC86]WJ-Y*FR4-'+.S#(0]B:^K* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHZ4 %%9=_P"(=*TP$W=Y'%CU-<K?_%GPW;9$
M6H1.1[U/,A\K.^HKRK_A<-G,Q%LT<A]J:GQ=5"QN$1%'<U0CU>BO,['XQ:%.
MV)KN)/7FNJT[QSX>U,A;;48F<_PYJN5BYEU.BHID<J3('C8,I[BGU(PHHHH
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M"%L[05&,UD?L[_\ )0[C_KPD_P#0EH ^I**** (YY1#!)*1D(I;'K@9KB_\
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MIN>DUXMXU_Y+QX7_ .N;?^S5[!8:C::I:)=64Z3P.,JZ'(->/^-?^2\>%_\
MKFW_ +-54U:M'Y_DPO>G+T/::***D HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FG]I'_D;=)_
MZ\O_ &=J]R^'_P#R3[0/^O&+_P!!%>&_M(_\C;I/_7E_[.U>Y?#_ /Y)]H'_
M %XQ?^@B@#I**** "BBB@ HHHH **** "BJ.LZK;Z'HMYJET'-O:1-+($&6P
M/2O,_P#AH?P=_P ^^I_]^5_^*H ]:HKR7_AH?P=_S[ZG_P!^5_\ BJ/^&A_!
MW_/OJ?\ WY7_ .*H ]:HKR7_ (:'\'?\^^I_]^5_^*H_X:'\'?\ /OJ?_?E?
M_BJ /6JANO\ CSG_ .N;?RKRO_AH?P=_S[ZG_P!^5_\ BJCG_:$\'R6\B"WU
M/+*0/W*^G^]0!Y3\&?\ DL-I_P!M_P#T$U]:5\8?#WQ18^%O'T&MWZS-:Q^9
MD1*"WS @<9]Z]U_X:'\'?\^^I_\ ?E?_ (J@#UJBO)?^&A_!W_/OJ?\ WY7_
M .*H_P"&A_!W_/OJ?_?E?_BJ /6J*\E_X:'\'?\ /OJ?_?E?_BJ/^&A_!W_/
MOJ?_ 'Y7_P"*H ]:HKR7_AH?P=_S[ZG_ -^5_P#BJZOP5\1]&\=R7::5'=(;
M4*7\] O7.,8)]* .OHHHH **** "BBB@ HIKNL:%F(  R2:\_P#%'Q6TWPZY
M01&X<=D.:ESBG9E*#>J/0J*\,_X:%B)XT>?'^Z:/^&A8O^@//_WR:HD]SHKP
MS_AH6+_H#S_]\UZ1X)\9+XOTS[6ML\/.-K"K5.3BY+9$RDH[G5T445!0AX%>
M0^.O&.OQWTFG:(3YP..E>OUGMH>G/=&Y:U0S'JV.:APYI*[T+A-13TUZ'A>G
M>!O&'B7,FO ^4_H:Z6P^ WA_:#=I(3WYKUY5"*%48 I:U;7V58RM)ZR9P%C\
M'_"VGMNA@?/N:M77PM\-W:%)8&Q[&NUHJ7[VY2TV/*[KX$>%74F&*16/O7-7
M_P (+_1R9M 5O,'3)KWFBE9]'8=UU5SY[TGQ!X[\-ZE';:M_J6;:*]WTNZ:[
MLHY7^\5!-%WI-C?.KW-NDC*<@D5:BB2% D:A5'85ISWA:2U(<$I7CL/HHHJ"
M@HHHH *XWQ]\0-/\%Z6[NRRWSC$-NIR2?>F?$'X@67@O3<9$NHS#$$ ZD^IK
MA_ GP]O_ !%JW_"6^,<R2R'?!;/R .HR#VZ4DG/;1=6-M05WOT1'X \#ZGXJ
MUP>,O%A9B6WVUN_8=N/2O<<8&!345(T5$ 55& !T%1W-S':6LEQ+GRXU+-CT
M%5*2M9:)$QB[W>K9Q\GPJ\*W>J7.HZCIZWMQ<-N8S<@?3%9GB'X+>%=2T^1-
M-L$T^Z )CD@XY[9KH?#'C[0_%EQ<P:;.WF6[;620!2?<<UNZEJ5KI.GS7MY,
ML4,2EF9C425H]BHN\M-SRCX->(-0BOM1\):K*TDUBQ\IFZ[0<?UK/^-JE/%_
MA:9ON?:T'_CPI/A)%+KWQ!USQ.D96T8F)&[-R,?RK?\ CEHD]]X8MM4M(R\^
MG3"7 ],C)_2M)2Y73J2W5FQ02;G".VMCU" AK>(CH4!_2J/B!UC\.ZBS' %M
M)_Z":RO ?B:T\3^%;.ZMY5:1(UCE7/*L!@_RK%^+?BJWT'PA<6RR*U[>#RHH
M@>3G@_H:BNFDX]1T'>S.-^#4+R^ O$3KTED;;_X]5[]GU@-&UB/^(7C$C\!7
M4?"?PX^A_#ZVMKE2);@&5P1V;D?SKA/ -ZO@7XG:OX>U$^3!>/NMV;@,>O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 </XV^%VB^.]1
MM[W4[B[CD@B\I1 P (R3SD'UKJ]'TR'1='M-,MV=H;6)8D+G)( QS5VB@ HH
MK+U'Q'I&DW<-KJ%_#;S3?ZM9&QN^E &I17FFLZM-_P +:T2*&^D%G);,S(LA
MV-SU(Z5VL'B;1;K5O[+@U&"2]QN,*ME@*%JD^]_P$W9M=K?B:U%%% PHHHH
MR?%&D2:_X7U/28I5B>\MVA61AD*2.IKP?_AFK5O^AALO^_+_ .-?1U% 'SC_
M ,,U:M_T,-E_WY?_ !H_X9JU;_H8;+_OR_\ C7T=10!\X_\ #-6K?]##9?\
M?E_\:/\ AFK5O^AALO\ OR_^-?1U% 'SC_PS5JW_ $,-E_WY?_&C_AFK5O\
MH8;+_OR_^-?1U% 'SC_PS5JW_0PV7_?E_P#&C_AFK5O^AALO^_+_ .-?1U%
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M_P"OB7_T%:X_]G?_ )*'<?\ 7A)_Z$M=A^TM_P @?P__ -?$O_H*UQ_[._\
MR4.X_P"O"3_T): /J2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^+>H^//$-QIMWIMK;)%;F8/"S$D@@8Y^M>MU\P_LZ?\ (]WW_7BW_H2U]/4
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M110!X7^TM_R!_#__ %\2_P#H*UQ_[.__ "4.X_Z\)/\ T):[#]I;_D#^'_\
MKXE_]!6N/_9W_P"2AW'_ %X2?^A+0!]24444 4]6_P"0-??]>\G_ *":^4*^
MK]6_Y U]_P!>\G_H)KY0KT<#M(\['[Q"BBBN\\\*]^^$'_(C#_KZD_I7@->_
M?"#_ )$8?]?4G]*Y,9_#^9UX+^+\CO:ANYFM[.>9 &:.-F /0D#-355U+_D%
MW?\ UQ?^1KR)NT6T>O'5H\RT[XSPSZ3-)<Z?NU(7#0Q6EL2Q?!(SS]/UJH_Q
MAU[2YO.UWPC-9Z>6 693DX]QFJ/P+T*UDO==U>6-7G6[>-"1]T;CG^5>L>*;
M*WO?#&I0SQJZ&W<X([A3BJG[BYO)/\!0]]\OG;\2UI&K6FMZ9!J%E('@F4,I
M_I7C.MZQ9Z%\=#?WTFR&.V)/O][@5T7P'D<^")82Q*17+JN>PW&N9UW1H-;_
M &@;6"Y4-$D>\J>^,D?RJG&U>*CY_D2_X4N;I^C-NY^+/B.1A<Z;X-N)M,ZF
M:3AL>H -=CX(\>:?XULY'MD>&YA.)H)."IKJ5BC1 BHH4#  %>,>%H4TWX\Z
MY;6H\N&5 60=.@I1LY<G=/\  J2?*Y]K?B["_&O_ )&;PI_U\G^:U[):_P#'
MI#_US7^5>-_&O_D9O"G_ %\G^:UZKJ%RUGX9FN4^]';;A]=M2GRT6_-E35ZD
M5Y+\V<EXO^*^F>&]0&EVL$FH:D3CR81G:?>L*#XL>);9S/K'@RXM[#/^MB.X
M@>I!-4O@9I$&J07_ (IO0)KZXG9=S<E<?_KKVAXHY(RCHK*1@@BJ<7"U]R;I
MMVV/.+7XK)J7CG3]$TZWAFL;N#S?/+'>IYXQT[5SOQNO)]2UK0_"\+E4NY-S
MX/7';]:S3H5KH7[0]M%9H$AFB,NP= 3G_"K?QA5M)^(/AO79%/V:-L,W8'-$
M5&7LF^K*E>+FETC^FY['HFE6VBZ/;6%K&$BB0* !5JYNX+.$S7,JQ1CJS' H
MM9X[FUBFB8,CJ""#UK.\2^'++Q5HTFEW[3+!(<DPMM;\\4IN5V^I$%&R70=_
MPDNB_P#03MO^^ZTHI8YXEEB<.C#(8=#7SU\3/A-X?\(>$I=4TV>_:X1U $TP
M9>2!TP/6O9? 9SX&T?/_ #ZQ_P#H(JDDXN79V!W32[G1U'//%;0O-,X2-!EF
M;H!4E>9_''5;C3? ,J6[%3<2+$Q']T\&LY-]-RXJ[LRIJ7QCDN+Z>S\*Z'/J
MTD1P7Z(3['-+I?Q>NH]1M[#Q-X>N-,FG(564;ES]<UUW@'0K+1/"-A%:Q*I>
M(.[ <L3SS703V5K=,C3P1R-&=REAT-:-*$K;F:?-&^Q4UC7].T/2'U._N%BM
MU7=D]_I7F4GQ@US4\R>&O"4]];AL>9+\N1^!JC\5Y'UKXB>'/#4KE;&5MSJ.
MA(S7LMC86VG6<=K:PK'#&N%51P*F*O'G?R^1<M'R^6IYYH/Q>M;O54TK7M/F
MTF]?A?-'R$^F<UZ-<3F*REGCPQ2,NN3P<#->?_&/P_9ZAX)N]0:-5N[)?-BE
M'!!%7O &J3ZO\+[:YN6+3?965F/?@T-WIR?5!:TH]F8.G?&>&;2KF2ZL,ZBE
MRT$5I;$L7P2,\_3]:IO\8-?TR7S]<\(3VFG%@!,IR<>XS5#X':%:RZKK^KRQ
MJ\\=V\<9/\(+-G^5>M^);."]\-ZA#/&KH;=S@CT4T3]R*EY)_@*'O-Q\[?B%
MEKL.K^'AJNE@7"O'OC7U..AKYX^)OBGQ;JTVEKK'A@:>L%V&MSO)\UAT%>D_
M >1_^$-N("Q*17+A >PR:S_COU\-?]?ZU3BE6C;9M#A?E:>ZO^!J>%O&OCK4
M=5M+/4_!@LK%L![GS"=HK8\<>/)?!^JZ1;FVADMKV3;+([$&,8)R/RKLK7_C
MUB_W17C/QXM1>ZCX;MFZ27 4_3FE*_/&*[D1^!M]ON-J\^+-[=:E]G\-Z!-J
M%NLH1[EN$QGDCFN]U37[+0]$_M/5)5@C"!F!/?'05/I.EVNDZ9!96L2I%$@4
M "O'_BM(^M_$7PYX:E<BRE;?(O8D9HM=J$=V]RHZIS>R6Q>D^,&N:GF3PUX2
MGOK<-CS)?ER/P-:F@_%ZUN]532M>T^;2;U^%$H^0GTSFO0[&QMM.LX[6UA6.
M&-<*JCH*X+XQ^'[/4/!-WJ#1JMW9+YL4HX((I.2AKNAQBYZ;,]"E8-;.RG(*
M'!'TKQWX)?\ (<\7?]?[?^A-79_#C5)]7^'-A<W+%IO(*LQ[\5QGP2_Y#GB[
M_K_;_P!":M(QY:DUY?JB6[TD_-'LU%%%9C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MY.^/'_)5KK_KA!_Z"*^I]-_Y!=I_UQ3^0KPOXJ_"SQ5XJ\>SZKI5G#+:/%$H
M9[A4.57!X)KW>RB:&QMXG&'2-58>X% $]%%% !1110 4444 %%%% !17&_%*
MZU>R\ 7T^A/=+J"M'Y9M5)DQN&< <]*^=?\ A*/BQ_S]>)/^_$G_ ,30!]>4
M5\A_\)1\6/\ GZ\2?]^)/_B:/^$H^+'_ #]>)/\ OQ)_\30!]>45\A_\)1\6
M/^?KQ)_WXD_^)H_X2CXL?\_7B3_OQ)_\30!]>5B>,O\ D2=<_P"O&;_T U\O
M?\)1\6/^?KQ)_P!^)/\ XFHKG7_BE>6TMM<2^(I(95*2(T$F&4\$'Y: .C_9
MT_Y'N^_Z\6_]"6OIZOB?1K7QMX>NFNM(L=:LYW78TD-K("5ZXZ5N?\)1\6/^
M?KQ)_P!^)/\ XF@#Z\HKY#_X2CXL?\_7B3_OQ)_\31_PE'Q8_P"?KQ)_WXD_
M^)H ^O**^0_^$H^+'_/UXD_[\2?_ !-'_"4?%C_GZ\2?]^)/_B: /KRBOD/_
M (2CXL?\_7B3_OQ)_P#$U[=\%-0\2:CX>U"3Q-)?O<+=8B-ZC*VW:.F0.,YH
M ].HHHH **** "BBB@ HKSWXQ:SJ.A>##?:;>S6LR3+EXC@D;AD5RFG^*O&_
MCZT@C\+L+2TBA5)[V889Y,#..1WS0M;VZ ]+7ZGMM%>#:CJ_Q'^&\MO>:U?C
M5=-9P)';DJ/SXKUJ;Q790^#CXC.3;"W\[ Z],XH=E'FZ(%?F4>YOU2_L?3/M
M/VG^SK3S]V[S?(7=GUSC.:\8L+WXE_$.*34=*U%-)TTL?(*'#,/SK<\):I\0
M=*\4IHOB&W^W6K#(NU[#U)R1^%-)WL]&)M)76IZQ1112&%%%% !5&;1=*N)6
MEGTRRED8Y9W@5B3[DBKU% #418T5$4*BC"JHP /04ZBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+JV2[@:*095A@BO
M-=2^#FD7-R]Q!;QI*QSGWKTF]NA9VSS-T4$UXWX@^/$6F7$D%M;I*Z$CBLKQ
M4M-S1*3CY%?4OA+XFC);3-32!1T&ZL*7PUX^T7YY/$:A5Y(WU<L/BOKOB:79
M'92(C<96K]WX$UGQ8@WW5Q"#UY-:\M6.J(4J<G9F+%\6[[076"]G:Y<<$J<U
M[#X$\7IXLTH7:QLG.,-7GVF_L^6T,@EN]0,K=2&&:]4\.>&K;PY9"VM\;1Z#
M%;1<?9OFUD8R3O[FQN4445B:A117G?Q'^(DO@VS#Q0"1F.T5$YJ-D^I48.5[
M=#T%I8T^\ZK]3BLZ]U_3K%"9+J(D=@XKYGOOB[J&N,89";8/QN#=*=IOANQU
M:037?BUH]W)4R5:C.7DB7**]3U[7?C'I>CJ=MM),1_<YKC;CXL7_ (FW06%K
M<0YX!*UKZ/HW@O38E2YUJVNB.[D&NML]=\!V*@0SV*D=P!1R1^T[ASR^RK'C
M<_PO\4^*K@32W/RMSAZ]%^'WPFD\*72W=PZ/,!R0:[!/'?A6,834K=1[$5>T
M_P 7:'JEQY%G?Q2R?W5-:4Y.":IHB:Y]9LV@, "EH!R**S+04444 %%%% !1
M152XU33[0XN;^UA/I+,J_P S0!;HJ*"Y@N5W03QRKZQN&'Z5+0 44R26.%"\
MLB(HZLQP*K0:MIMU(8[?4+65QU6.96/Y T 7**** "BJ]S?V=D,W5W! /^FL
M@7^9IUO>6UVNZVN(9E]8W##]* )J**1F5%+,P51U).!0 M%4DUC3))O)34;-
MI?[@G4M^6:N@@C(Y% !1110 4444 >%_M+?\@?P__P!?$O\ Z"M<?^SO_P E
M#N/^O"3_ -"6NP_:6_Y _A__ *^)?_05KC_V=_\ DH=Q_P!>$G_H2T ?4E%%
M% %/5O\ D#7W_7O)_P"@FOE"OK+4(GGTVZAC&7DA=5'J2"!7S_\ \*M\6_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 UY$C(#L%R<#/>N)\?>)M2T"_T&+3Y41+RZ
M\J;<@;*X)XSTZ5L>+/"EOXLTT6D]U/;E6W(\+8(-?._C2U\16&NKIMEKD^K1
M::?.WXR;<].3CG@TD_>5^_X#<6XNW;\>A]2M*B;0S@$\#)ZT^O)O W@PZRMA
MXFU'Q+=:G. '558!%/7!&*]9' JY1Y='N0G?;8****DH**** "BBB@ HHHH
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MM&TV:^N[N)(HU+??'/TK6M--^TZ/4B$6FX=4SQV8?;/VD%\OGR54M_WR*?\
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M>$G_ *$M=5^T?9VUMI&@FWMH8BT\N3&@7/RKZ5RO[.__ "4.X_Z\)/\ T):
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M %%%% !7+_$>ZGLOAWKMS:S/#/':EDDC;:RG(Y!KJ*Y'XH?\DR\0?]>C?S%
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MDKAAUKE?A7XJU'7K)FOY&D;>0"?2B%ZO-Y%2BJ=-3\[&WXU\)6.I::S+$J2
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MGZDUQ>F@^-/C#=7S?/I^CKY<>>ADYY'Y"NU\8:FGA?P3<R0(2T<(BA51R2<
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M]V*,(/P%6*JI+FFV9P344F%%%%04%%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_VEO\
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MDY*C/KBAE5OO*#]12T4 ,\J/_GFOY4HBC'1%_*G44 %)M7=G:,^N*6B@ I"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M7^(O_(A:O_U[O_(UU%<O\1?^1"U?_KW?^1K.K\#+I_$CF?@3:Q0_#N"5% >5
MV+'UPQ%=WXB4-X;U,,,C[++Q_P !-<7\#_\ DFME_O/_ .A&NV\0?\BYJ?\
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M_H9H ],HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>?F'XDUV-S<PV=M)<3N$BC4LS'H *EKRGXZ:S/9^&K32K60I-J,XBR#VR/\
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MP6RMB4L-6!/EC@#_ "12A9RY.^P2347-=-SWBBBBD,**** /"_VEO^0/X?\
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M /037R[\#+&[@^*-J\UK/&@@F^9XR!]WWKZKHH **** "BBB@!&^XWTKY/\
MA=8W<7QDLI)+6=(Q/-EFC('W6[U]8T4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+W[1/\
MR/\ :_\ 7BG_ *$U>J_ ;_DEEG_U\3?^AFO*OVB?^1_M?^O%/_0FKU7X#?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[N-*RL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEZ9?ZKY;;6:W0X'Z5M^%_BEH/B:\^PJ9;.]QGR+A2I_4"FES; _=W.XHHHI
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M.?"^BZMX7OEN[.!2L1991& RGZUX]X'\6_$33O"EI;:+X>M+JQ0?NY7SEO\
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M_P#KW;^5<U;^'+T-J7QKU."^ _\ R)]U_P!?3?RKU*6188FD<X51DD]J\M^
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M]?553=N9OE)^F*W?A#XIU#7-'N=/U=R]_82&-W/5A[T15[KJA-VL^C,#2_\
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M+_Z":ZCT3Y5^$W_)4] _Z^#_ .@-7V97QG\)O^2IZ!_U\'_T!J^S* "BBB@
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M HHHH *XKQAX,NO%6MZ6\UV!I=J_F26^.68=.?RKM:*.J?8.C7<;'&L42QH
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M_7P?_0&K[,KXS^$W_)4] _Z^#_Z U?9E !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W%S';1EY#A1
M647TKQ)$\1"R!>#ZU:UJS:]TV:-9 A*'#'M7AVB^(V^'^O2VM_>K=+<2<8;[
MO-*FHU)N$_EYE23C3YX;K<[Z_P#@SX5U"<S20-O/O55/@7X25PQA?CT-=9I_
MC/1[^)7%W"F1T+BK_P#PD.D?]!"W_P"^Q56Y2.;FU,_1O!.C:&%^QP8QZUT8
M  P*S/\ A(=(_P"@A;_]]BKEM>6UXF^WF21?53FFW*6K$DEL3T445)04444
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MO"3_ -"6@#ZDHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **8)HC+Y8D3S!_#N&?R
MI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8OC#_ )$O6_\
MKQF_] -;58OC#_D2];_Z\9O_ $ T ?/7[.O_ "/E[_UXM_Z$M?3]?,'[.O\
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M*\&O_@E<7M_-<274Q+L2,]J^AZ*A02DY=2^=\O+T/G,? ^^7A=1N5'LQI?\
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M.3[,SIWBD>&_"?7D\):UJ?A'6G%LPF+6[2':I'ID\=Z];UKQ+I6AZ7-?75[
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M;_-7&/SKQ;PR9/B'\8)M?1"=-TW*PN1PW&/ZUM)\!-/,VVX\0ZE-9=!:L2%
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M&&S,5R$^6X!^?/KFLWX)ZC>);:GX?O)FE;3I2J,>P]*]7E_U+_[IKR#X1?\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT_D;M<#XF^']WKOCO2?$,5]#%#9+M:)E)9N3T/XUWU%"TDI=@Z-=PKS?Q/\
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M(KR&**Q;+1LI+-R.GY5W%%"TDI=@:NG%]0'2N&M? MU;_$^?Q6;R$P2Q>6(
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M984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHHH **** "BBB@ HHHH **** /"_VEO^0/X?_P"OB7_T%:X_]G?_ )*'<?\
M7A)_Z$M=A^TM_P @?P__ -?$O_H*UQ_[._\ R4.X_P"O"3_T): /J2BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZY3X;_\ (C:?]&_]"-=77AU?C?J>]3^!!1116984444 %%%% !1110 4444
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MPXWH>/FOV?F,HHHKA/(.@\%_\C-;?\"_D:];KR3P7_R,UM_P+^1KUNO2P?\
M#^9[V6?P7ZGCOQJ_X^=/_P!S^IKR:O6?C5_Q\Z?_ +G]37DU?187^$C#%_Q6
M%%%%=!S'TA\-_P#D1M/^C?\ H1KJZY3X;_\ (C:?]&_]"-=77AU?C?J>]3^!
M!1116984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[7H7P@_Y&J7_ *Y?UK'$?PI&V'_BQ/>:***\4]L**** "BBB@ HHHH ****
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M***Z#F/I#X;_ /(C:?\ 1O\ T(UU=<I\-_\ D1M/^C?^A&NKKPZOQOU/>I_
M@HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH "<#)KG=9\;Z'H.?MUT$([59\37SV.CSR1DAMAP:^?_"OAS4OB
M#J=[+?3>9#%(1@GMFI@IU)24-H[ERY80YY]=CU3_ (77X0R?]-I/^%U^$/\
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MQ_[._P#R4.X_Z\)/_0EH ^I**** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5\<^)]"OA';7++&#Q@9KI="^-.IPVXDU+SG ZX6JCRS7,F*7-%V:/I&BO+-
M^-NAZK*MNZ2I(>,D8KTRTNX;V!9H6#*PR.:IPDE?H)33=NI/1114%&'XH-^N
MERMI\9>8*=H'K7A+ZC\41-)C29-NXXXKZ2HJ(PM)N^Y3E=)'RAXKO?'DNFJ-
M8T]HH,\$BH?"MYXYBC;^Q[!I5QS@5[A\86(\* <<R54^$#DV,HXQM%5AO?\
M:]+6^9.)]R%)[W;^1Y[_ &C\4B>=)D_*O:? SZO)H43:Q"8KG^)374T5JIVA
MRV)E&[3N%%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >%_M+?\@?P__P!?$O\ Z"M<?^SO_P E#N/^O"3_ -"6NP_:
M6_Y _A__ *^)?_05KC_V=_\ DH=Q_P!>$G_H2T ?4E%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX+_Y&:V_X%_(UZW7I8/^'\SWLL_@OU/'?C5_Q\Z?_N?U->35ZS\:O^/G3_\
M<_J:\FKZ+"_PD88O^*PHHHKH.8^D/AO_ ,B-I_T;_P!"-=77*?#?_D1M/^C?
M^A&NKKPZOQOU/>I_ @HKR_X[:KJ&C^!X+C3;V>TF-XBF2%RI(VMQD5\X_P#"
M>>+?^ACU/_P);_&LRS[>HKXDC\=^+#*@/B/4\;A_R\M_C7VG8,SZ?;,Q)8Q*
M23W.* +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH/(7H:<(2E4]GUM<=U[-U%LCUNBFH<H#3JD2=U<****!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!X7^TM_R!_#_P#U\2_^@K7'
M_L[_ /)0[C_KPD_]"6NP_:6_Y _A_P#Z^)?_ $%:X_\ 9W_Y*'<?]>$G_H2T
M ?4E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'G/Q'_Y"5E_UQ/\ .N*KM?B/_P A*R_ZXG^=<57D
MXC^*SYK&_P >04445B<I[1X?_P"0':_[@J;6?^0'J'_7M)_Z":A\/_\ (#M?
M]P5-K/\ R ]0_P"O:3_T$U[=/9'U</X:]#Y1/6B@]:*^A/""O0OA!_R-4O\
MUR_K7GM>A?"#_D:I?^N7]:QQ'\*1MA_XL3WFBBBO%/;"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+W_CPN/^N;?R
MKPZ;_7R?[QKW&]_X\+C_ *YM_*O#IO\ 7R?[QKAQO0\?-?L_,91117">0=!X
M+_Y&:V_X%_(UZW7DG@O_ )&:V_X%_(UZW7I8/^'\SWLL_@OU/'?C5_Q\Z?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!I3*3,P9LD =@/2N@H *^8O%/_(WZU_U_P __HQJ^G:^8O%/_(WZU_U_S_\
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M8%>0-YI^TC]K0E0ETU/I*.\MI1F.>-A[,#4P((R#FOD=?B%?:/.(-+F:Y5>
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M"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#PO]I;_ ) _A_\ Z^)?_05KC_V=_P#DH=Q_UX2?^A+78?M+?\@?P_\
M]?$O_H*UQ_[._P#R4.X_Z\)/_0EH ^I**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M444 %%%% !1110 4444 %%%% !1110 4444 07O_ !X7'_7-OY5X=-_KY/\
M>->XWO\ QX7'_7-OY5X=-_KY/]XUPXWH>/FOV?F,HHHKA/(.@\%_\C-;?\"_
MD:];KR3P7_R,UM_P+^1KUNO2P?\ #^9[V6?P7ZGCOQJ_X^=/_P!S^IKR:O6?
MC5_Q\Z?_ +G]37DU?187^$C#%_Q6%%%%=!S'TA\-_P#D1M/^C?\ H1KI;O\
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MV]96J:!9ZLNVYC5Q_M#-1-2;7*5%QUN>0#]H5" ?[&G_ .^:/^&A$_Z T_\
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M?_DH=Q_UX2?^A+0!]24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?_7 _P Z]LKQ/XQ?\C!9_P#7 _SKP:OPGV61_P"^+T9YO1117,?;!7U+H?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME)&<\5#<HU85(_9=S2-G"47U13\-?$+PS;^'K*.75(5=8@"">E:P^)'A4_\
M,6A_.O.?^%":?C_EI_WU1_PH33_^FO\ WU6LY<S;[F,(\L;&-XK\5:-=^*&G
MAO(VCW?>!KU32OB)X7BTFV1]5A#*@!&:X8? ;3@/NO\ G2?\*$T\_P#/3_OJ
MII^Y25);7;^\<USU?:O>R7W'HO\ PLGPK_T%8?\ OJKFF>--!U>Y^SV5_'++
M_=4UY?\ \*"T_P#O./\ @=;7A'X8Z=X8UO[3$[&0>K9K2FH-M38IMJ-T>K Y
M&:*1>%%+68UL%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/.;_ *YM_*N:^&__ "(VG_1O_0C72W?_ !YS?]<V_E7A5?C9[]'X8GRUJ/\
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M.^N;C4=1\VPMUVE/(C7<YZ<J 1@<U[%/&0J248IGYQC.&\5A*,J]6<;+S?\
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MX?\ ^0':_P"X*FUG_D!ZA_U[2?\ H)J'P_\ \@.U_P!P5-K/_(#U#_KVD_\
M037MT]D?5P_AKT/E$]:*#UHKZ$\(*]"^$'_(U2_]<OZUY[7H7P@_Y&J7_KE_
M6L<1_"D;8?\ BQ/>:\3^,7_(P6?_ %P/\Z]LKQ/XQ?\ (P6?_7 _SKP:OPGV
M61_[XO1GF]%%%<Q]L%?35OIT&K^#+?3[E<PW%DB-[948(]P>?PKYEKZET/\
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M'@O_ )&:V_X%_(UZW7DG@O\ Y&:V_P"!?R->MUZ6#_A_,][+/X+]3QWXU?\
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M6!HG=7"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >%_M+?\@?P__P!?$O\ Z"M<?^SO_P E#N/^O"3_ -"6NP_:6_Y _A__
M *^)?_05KC_V=_\ DH=Q_P!>$G_H2T ?4E%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>&_&"61/$EN$D91Y78X]*]RKPOXQ_\C+;_
M /7+_"NG"?Q3EQG\)GG;2R.NUY'8>A8FFHS1G*$J?4'%)17KGD7+-M<3?:HO
MWTGWQ_$?6OJ;2.='LB?^>"?R%?*MM_Q]0_[X_G7U3I'_ "!K+_K@G\A7GX[H
M>C@?M%VBBLS5O$6C:"8O[6U.ULO-SY?GR!=V.N,UYYZ!IT5S7_"P_!W_ $,N
MF?\ @0M26_COPI=W,=O;^(=.EFE8(B).I+$] !0!T-%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!YS\1_P#D)67_ %Q/\ZXJ
MNU^(_P#R$K+_ *XG^=<57DXC^*SYK&_QY!1116)RGM'A_P#Y =K_ +@J;6?^
M0'J'_7M)_P"@FH?#_P#R [7_ '!4VL_\@/4/^O:3_P!!->W3V1]7#^&O0^43
MUHH/6BOH3P@KT+X0?\C5+_UR_K7GM>A?"#_D:I?^N7]:QQ'\*1MA_P"+$]YK
MQ/XQ?\C!9_\ 7 _SKVRO$_C%_P C!9_]<#_.O!J_"?99'_OB]&>;T445S'VP
M5]2Z'_R -._Z]H__ $$5\M5]2Z'_ ,@#3O\ KVC_ /016U'=GSG$7P4_5DFJ
M:=!J^EW.GW*YAN(RC>V>A'N#S^%?,6J:=/I&J7.GW*XFMY"C>^.A'L1S^-?5
M%>3?&#P[_P >_B"W3TAN<#_OEOZ?E6&.I<T.=;H.%<P]AB'AIOW9[>O_  =O
MN/,-+T^;5M4MK"W&99Y B].,]^2*^G=+T^'2=+MK"W&(H(PB]>??DFO,/@_X
M>_X^->F7UA@Y_P"^CP?PY%>M48&ERPYWNPXJS#V^(6&@_=AOZ_\  V^\****
M[CY4**** "BBB@ HHHH **** "BBB@ HHHH **** (+W_CPN/^N;?RKPZ;_7
MR?[QKW&]_P"/"X_ZYM_*O#IO]?)_O&N'&]#Q\U^S\QE%%%<)Y!T'@O\ Y&:V
M_P"!?R->MUY)X+_Y&:V_X%_(UZW7I8/^'\SWLL_@OU/'?C5_Q\Z?_N?U->35
MZS\:O^/G3_\ <_J:\FKZ+"_PD88O^*PHHHKH.8^D/AO_ ,B-I_T;_P!"-=+=
M_P#'G-_US;^5<U\-_P#D1M/^C?\ H1KI;O\ X\YO^N;?RKPJOQL]^C\,3Y:U
M'_D)W7_79_YFJU6=1_Y"=U_UV?\ F:K5YY^FP^%!7=?"G_D;E_W#_(UPM=U\
M*?\ D;E_W#_(U4/B1R9C_NE3T/>J9+%'/"\,J!XY%*LIZ$'@BGT5UGY^G;5'
MS+XJT*3PYXBNM.;)C5MT+'^*,\J?Z?4&LF*)YYDBC&YW8*HSC)/ KVWXL^'?
M[1T--6@3-Q8_?P.6B/7\CS],UR7PF\/?VCKCZK,N8+'[G/60].ASP.>A%>)4
MPS5?V:V?Y'ZA@\[A+*WBZGQ15GZ]/OT/5_"NAIX>\.VNGK]]5W2GU<\GN?TK
M9HHKVHQ44DC\SJU9UJDJDW=MW84444S,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K(KC#*#]:B6SM
MDD\Q8(P_]X+S4]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'A?[2W_('\/_ /7Q+_Z"M<?^SO\ \E#N/^O"3_T)
M:[#]I;_D#^'_ /KXE_\ 05KC_P!G?_DH=Q_UX2?^A+0!]24444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+_ !'\[_A7.O\
MV?S/.^QOL\O.[/MCFNHKF]0\6"QO'M_LA?;WWX_I6&(Q-+#QYJKLC:C0J5GR
MTU=GQS+/X@MXS)-+J<:#JSM(!^9I(;C7KE-\$VI2K_>1I&'Z5],^.K[_ (3+
MPO<:,$^RF4J?-)W8P0>GX54^'9_X070&TQO]+)D+[Q\G4^G-<?\ ;."_G_!_
MY'1_9N*_E_%'6_"S[1_PK/0OM7F^?Y!W^;G=G>W7/-=A7+6WC$7%S'#]C*[S
MC._I^E=377A\71Q*<J3ND<];#U*#2J*UPHHHKH,0HHHH **** "BBB@ HHI&
M=44LS!5'4F@#$\0>,- \*F#^V]1CL_/SY6]6.['7H#ZBL3_A;_@+_H8[?_OW
M)_\ $UYO^T1&^IMH7V!3<[!+N\H;MN=O7%>&_P!BZG_SX7/_ '[-+F7<GGCW
M/L"S^*G@F_O8;.UUZ"2XG<1QH$?+,3@#[M=C7Q3X.TN_@\::+++9SI&E[$S,
MR$  ,.37VA#=6]P2(9DD(ZA6S0FF"E%[,FKPOXQ_\C+;_P#7+_"O=*\+^,?_
M ",MO_UR_P *Z\)_%1SXS^$SSBBBBO6/();;_CZA_P!\?SKZITC_ ) UE_UP
M3^0KY6MO^/J'_?'\Z^J=(_Y UE_UP3^0KS\=]D]' ?:+M>-?';P?K_BI]&.B
M:;)>>0)?-V,HVYVXZD>AKU#Q)>S:=X?N[NW($L:94D9[UXI_PM/Q/_SW@_[]
M?_7KS)34=SZ#!Y;6Q<7*G;3N>&:KI5]HFI3:=J-NUO=P$"2)B"5.,]O8UW?@
M3X=>+)-?T'6ET:8Z<;B*?S]Z8\O<#NQG/2EUN*/Q!K%QJE^BO=7!#2,HP"0
M/Z5UNF?$+7](TRVTZTEA6WMHQ'&#'DA1T[U/M8G8\@Q/='T517 ?#;Q3J?B1
M;PZBZ-Y1 7:N*[^M(NZN>5B*$L/4=.>Z$9@B,['"J,D^U<4WQ=\!JQ4^(K<$
M'!_=R?\ Q-=/?ZA90Q2P2W<$<K(0%=P#R*^0O$'PXUS1;*?4KB2PDA5_NP72
MR.<G ^455F86/I7_ (6_X"_Z&.W_ ._<G_Q-=%H/B32/$]D]YHUZEW;H_ELZ
M*0 V,XY ]:^._#O@36/$T4\ED;2(0L%874XB)SZ9ZU]$?![2F\&^&+C3M7O+
M%;B6Z,BB*X5P05 ZCZ468[,]1HI 0P!!R#T(I:0@HKE_%_Q T+P0;4:U).AN
M=QC\J(OG&,Y_.N8_X7[X%_Y^;[_P%- 'I]%>=:;\;O!FJZE;:?:W%X9[F18H
MPUL0-Q.!DUZ+0 4CLJ(SL<*HR3[4M5KJ>W\J2"2>.-F4K\QZ9% ')-\7? :L
M5/B*W!!P?W<G_P 32?\ "W_ 7_0QV_\ W[D_^)KP[QM\'D\,>'[G68=?BOG2
M10+=(<$[FQUW'IFLKX?_  P_X3:TO9I]6333;.J!9(MV_()SU'I0*Z/JC0?$
MFD>)[)[S1KU+NW1_+9T! #8SCD#UK5KAOAOX5M? 6@S:8=7AO#+.9MX&S&0!
MC&3Z5W(((R.10,**** "BBB@#SGXC_\ (2LO^N)_G7%5VOQ'_P"0E9?]<3_.
MN*KR<1_%9\UC?X\@HHHK$Y3VCP__ ,@.U_W!4VL_\@/4/^O:3_T$U#X?_P"0
M':_[@J;6?^0'J'_7M)_Z":]NGLCZN'\->A\HGK10>M%?0GA!7H7P@_Y&J7_K
ME_6O/:]"^$'_ "-4O_7+^M8XC^%(VP_\6)[S7B?QB_Y&"S_ZX'^=>V5XG\8O
M^1@L_P#K@?YUX-7X3[+(_P#?%Z,\WHHHKF/M@KZET/\ Y &G?]>T?_H(KY:K
MZET/_D :=_U[1_\ H(K:CNSYSB+X*?JR_535-.@U?2[G3[E<PW$91O;/0CW!
MY_"K=%;-)JS/EXR<)*479HJ:7I\.DZ7;6%N,101A%Z\^_)-6Z**$DE9!*3G)
MRD[MA1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@""]_X\+C_ *YM
M_*O#IO\ 7R?[QKW&]_X\+C_KFW\J\.F_U\G^\:X<;T/'S7[/S&4445PGD'0>
M"_\ D9K;_@7\C7K=>2>"_P#D9K;_ (%_(UZW7I8/^'\SWLL_@OU/'?C5_P ?
M.G_[G]37DU>L_&K_ (^=/_W/ZFO)J^BPO\)&&+_BL****Z#F/I#X;_\ (C:?
M]&_]"-=+=_\ 'G-_US;^5<U\-_\ D1M/^C?^A&NEN_\ CSF_ZYM_*O"J_&SW
MZ/PQ/EK4?^0G=?\ 79_YFJU6=1_Y"=U_UV?^9JM7GGZ;#X4%=U\*?^1N7_</
M\C7"UW7PI_Y&Y?\ </\ (U4/B1R9C_NE3T/>J***ZS\_&2Q1SPO#*@>.12K*
M>A!X(K.\/Z';>'=)CTZTR8T9FW$G))/7K]*U**7*KWZFBJS4'33]UZV\U_PX
M4444S,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *\>\=>-];U7Q0OA#PBX6YSBXN ,[*]:O9Q;64TYZ(A->,?
M ZW&HZSX@UZ<;IY)S'N/MBE%<T[/9*_^0Y/EA=;MV%D^$OBZSB;4+/Q;</J0
M7.QG)0GT Q6_\,?'U[K-S=>']?7R]7LN"3QY@]?UKTZO"O&"#PY\=-%OX!Y:
MWJYEQ_$>1S^0JH/WU![/\'T)DO<<ENM?\SW6BBBD,**** /"_P!I;_D#^'_^
MOB7_ -!6N/\ V=_^2AW'_7A)_P"A+78?M+?\@?P__P!?$O\ Z"M<?^SO_P E
M#N/^O"3_ -"6@#ZDHHK"U/Q7IVDWK6ER9/,4 G"D]:F4E%7;(G4C!7D[&[17
M+?\ ">Z-_>E_[X-'_">Z-_>E_P"^#4>VI]S+ZU1_F1U-%<PGCO2))%0-+EB
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M3[+(_P#?%Z,\WHHHKF/M@KZET/\ Y &G?]>T?_H(KY:KZET/_D :=_U[1_\
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M8Q7<0(25=PS5FD="=PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:I%->94*DZ;O!V/E?_A8OB?_ )_Q_P!^E_PH_P"%B^)_^?\ '_?I?\*^J/\
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MQI__ '[H_P"%7^!_^A8T_P#[]T#/F_\ X7=X]_Z#"_\ @/'_ (5'/\9_'-S
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M_P#X5?X'_P"A8T__ +]T?\*O\#_]"QI__?NG=F?U>E_*ON/D*/Q%J<4BR).
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M:OI/_A5_@?\ Z%C3_P#OW1_PJ_P/_P!"QI__ '[K1:&ME:Q\?_V[J'_/8?\
M?(H_MW4/^>P_[Y%?8'_"K_ __0L:?_W[H_X5?X'_ .A8T_\ []UI[:I_,R/8
MT_Y4?'_]NZA_SV'_ 'R*T=&\=>(- NS=:=>"*4C:6,:MQ^(KZO\ ^%7^!_\
MH6-/_P"_='_"K_ __0L:?_W[I.K-JS8U2@G=(^;_ /A=WCW_ *#"_P#@/'_A
M6'K7C_Q'X@N$GU*^$LB+M4B)5P/P%?5G_"K_  /_ -"QI_\ W[H_X5?X'_Z%
MC3_^_=9M)[FU.I.G+F@[/R/D#_A(-2_Y[C_OD4?\)!J7_/<?]\BOK_\ X5?X
M'_Z%C3_^_='_  J_P/\ ]"QI_P#W[I<L>QO]>Q/_ #\?WL^0/^$@U+_GN/\
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MNGN=,O1#*Z[6)C5N/Q%;_P#PN[Q[_P!!A?\ P'C_ ,*^D/\ A5_@?_H6-/\
M^_='_"K_  /_ -"QI_\ W[J6V]6)MO<^8[WXL^,]0!%QJ[$%2I"QJN0?H*XF
MOM+_ (5?X'_Z%C3_ /OW1_PJ_P #_P#0L:?_ -^ZA0C%MI:L;DVDF]CXMKH-
M&\:^(/#]D;/3-0>" N7* #J>_P"E?67_  J_P/\ ]"QI_P#W[H_X5?X'_P"A
M8T__ +]T3A&:M)701E*+O%V/FY/C9X\1%0:PN%&!FW3_  IEQ\9O'-U;R02Z
MLIC=2K 0(.#^%?2G_"K_  /_ -"QI_\ W[H_X5?X'_Z%C3_^_=5L2]=SY"?Q
M'JDI!DN2^.FX TS^WM0_Y[#_ +X%?8'_  J_P/\ ]"QI_P#W[H_X5?X'_P"A
M8T__ +]T[LR]A2_E7W'R NOZBK!EG (Z$**U]'^(OBC09Y)M/U(QO(NUBR*W
M&<]Q7U1_PJ_P/_T+&G_]^Z/^%7^!_P#H6-/_ ._=*XXTJ<7=11\W_P#"[O'O
M_087_P !X_\ "C_A=WCW_H,+_P" \?\ A7TA_P *O\#_ /0L:?\ ]^Z/^%7^
M!_\ H6-/_P"_=!H?-_\ PN[Q[_T&%_\  >/_  H_X7=X]_Z#"_\ @/'_ (5]
M(?\ "K_ _P#T+&G_ /?NC_A5_@?_ *%C3_\ OW0!\W/\:_'<D;(VKJ58$$?9
MTZ?E6"WCKQ S%C>C).3^[7_"OJ__ (5?X'_Z%C3_ /OW1_PJ_P #_P#0L:?_
M -^ZF4(RW1$Z<)_$KGR?_P )SX@_Y_!_W[7_  H_X3GQ!_S^#_OVO^%?6'_"
MK_ __0L:?_W[H_X5?X'_ .A8T_\ []U/LH=D1]7H_P J^X^6+'XC^)].NEN;
M:_5)5Z'RE/\ 2M?_ (7=X]_Z#"_^ \?^%?2'_"K_  /_ -"QI_\ W[H_X5?X
M'_Z%C3_^_=7&*CHD:0A&"M%6/E;7/B)XF\1-&VIWZS&,87$2KC\A61_;NH?\
M]A_WR*^P/^%7^!_^A8T__OW1_P *O\#_ /0L:?\ ]^ZT52:5DQ.G"3NT?'_]
MNZA_SV'_ 'R*/[=U#_GL/^^17V!_PJ_P/_T+&G_]^Z/^%7^!_P#H6-/_ ._=
M/VU3^9B]C3_E1\R:9\6_&>D6$=E9:HL=O'G:OD(<=^XJT_QK\>.C(VKJ588/
M^CI_A7TC_P *O\#_ /0L:?\ ]^Z/^%7^!_\ H6-/_P"_=9MWU9HM-CY#E\2:
MI-*\CW +N2Q.P=33/^$@U+_GN/\ OD5]?_\ "K_ _P#T+&G_ /?NC_A5_@?_
M *%C3_\ OW4\L>QU?7<3_P _'][/D#_A(-2_Y[C_ +Y%:&D^.?$&AW@N["\$
M4P&-QC4_S%?5_P#PJ_P/_P!"QI__ '[H_P"%7^!_^A8T_P#[]T^5=B98O$37
M+*;:]6?-_P#PN[Q[_P!!A?\ P'C_ ,*Q]=^(WB?Q&L:ZI?K,(SE<1*N/R%7[
M'2;"3XTQZ2]I&U@=7,)MR/EV;R-N/3%?3/\ PJ_P/_T+&G_]^ZI-K5&";6Q\
M>_VW?_\ /8?]\BC^V[__ )[#_OD5]A?\*O\  _\ T+&G_P#?NC_A5_@?_H6-
M/_[]U7M)]Q\\NY\>_P!MW_\ SV'_ 'R*ZG3_ (O^--,LH[.TU14@C&%7R$./
MTKZ9_P"%7^!_^A8T_P#[]T?\*O\  _\ T+&G_P#?NDY2>[$Y-[L^;G^-?CQT
M9&U=2&&#_HZ?X5DGXC>)V))OQD\_ZI?\*^I_^%7^!_\ H6-/_P"_='_"K_ _
M_0L:?_W[K"K0I5?XD4_5%PJU*?P2:/E?_A8OB?\ Y_Q_WZ7_  H_X6+XG_Y_
MQ_WZ7_"OJC_A5_@?_H6-/_[]T?\ "K_ _P#T+&G_ /?NLOJ.%_Y]Q^Y&GUJO
M_._O9\P67Q4\7Z?*9;;4E1R,9\E#_2K_ /PN[Q[_ -!A?_ >/_"OI#_A5_@?
M_H6-/_[]T?\ "K_ _P#T+&G_ /?NMZ=.%./+!67D8SG*;O)W9\K:W\1/$WB)
MHVU._68QC"XB5<?D*R?[?U'_ )[C_OD5]?\ _"K_  /_ -"QI_\ W[H_X5?X
M'_Z%C3_^_=:7,94:<G>44SY _M_4?^>X_P"^11_;^H_\]Q_WR*^O_P#A5_@?
M_H6-/_[]T?\ "K_ _P#T+&G_ /?NB[)^KTOY5]Q\TVGQC\;V-K';6^JJL48P
MH\A#@?E4W_"[O'O_ $&%_P# >/\ PKZ0_P"%7^!_^A8T_P#[]T?\*O\  _\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***JW&IZ?:2>7<7UM"^,[9)E4_D3
M0!:HJA_;ND?]!6Q_\"$_QJQ#>VMR,P7,,N?^><@;^5 $]%%% !1110 4444
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M44 %%%% !1110 4444 %%%% !14$][:VI47%S#"6X7S) N?IFI@00"""#W%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^=/B+H4'B3XX6VEW+LL4UNN2O7JU?1=>$^(O^3B
M]/\ ^O=?YM1!)U8ICDVJ4VNQI_\ #._AW_G\N?S/^-4;[X,Z]H2_:O"OB.Y#
MQ\K;LQ4'';.:]QHHUZ,6G4\D^'OQ-OKK5V\,>*HOL^K(=J.1@/7K=>$_'?2O
M[*O]+\4V7[JYBD",R\9/8_I7K^E:O%/X6MM5F;$9@$C$#/0<_P J?,I0YWNM
M&)KEGRK9ZHUZ*\=N_C/J>H7<UOX6\-37WEDJ)900I_446'QHU&RU*WLO%GAY
M].,S;?-C^X#^)-**N-Z'L5%9>K:A<0^'[C4-+2*XF6$R0J^=K\9'2N8^&OC^
M7QO8W9O+:&VO;60H\41./KR:$KMKL#=DGW.[HJ.XG2VMY)Y#A(U+,3Z"N"^'
M_CW4O&FJZHKV-O#IUI(8XY4W;G(/N<4+5V7J#T5V>@U%<W$=I;27$K;4C4LQ
M-2UQOQ4OWT[X=ZM+&2',14$5$VU%M%05Y),\TM_[=^,7B6[,>H36/A^V<J/+
M)&_V[5HZQ\&9_#^GR:AX4U:[AO8?G\LN<2'\ZZGX+V"6?PZLI54!KC]ZQ]2?
M_P!5>A, 5(/0UK4AR>['=?F1&7,^:6W8X+X6^-I/%NAO%>_+J-HWES#UQWKO
MJ\+\#$Z-\<M>TY/EBG/"CITS7NE#:E&,UU06Y92AV?\ P0HHHJ1A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<9\5?^2;:U_UP-=G7&_%7_DFV
MM?\ 7 U%3X672^-'DOP_^#>C>*O"EOJEW<S)++U"GC^==-)^SYID*%M.UBZM
M;C'RR $X_6NC^"O_ "3BQ_&O0ZWJI*32,:;O&[/GZ>[\=?"2[CEO;E]5T1G
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M$7&:K:[JEKHVC75[=R*D4<9))/6B348^[I8(WE+74X;X2>-;SQ'IUQIVK?\
M(2L3MD)ZD= 3^1KK_%'BG3?">DOJ&HS!$'"+W<^@KRWX&VDU]JVN>(FC9(+M
M\(.W!)_K7KFLZ'I^OV7V34K9)X<YVMZU=5-VZ-I7_4F%DVMTFSYD\>Z[XI\:
M:1+KL\3VN@QR!88\D;\GK[]17T/X _Y$?2?^O=/Y"N-^.%I!9?#,V]M$L422
MH%51@#YA79> /^1'TG_KW3^0IPMR22V37Y"G=RBWV9TM%%%04%%%% !1110
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M]/BRT%JBSW/IN&"P/Y5]$Q1K#$D:#"HH4#V%)1Y(MO=O\%_FP;YG%=E?YO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC&1)'S%*APR'ZUQ%M\(-:BF\F3QG>MIH&!;ID''IG/\ 2O7**E*PV[GF=_\
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M =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %-,:,<LBD^I%%% #@ !@#%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 WRTSG8N?7%.HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!" 1@@$>](J(OW54?0444 .HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img114804231_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /)#F4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#-HHHKZP\0
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KVWP#_P B3I__ &T_]&-7B5>V^ ?^1)T__MI_Z,:O.S+^$O7]&=6$
M^-^ATE%%%>(>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZC_^+H_X7#X?_P"?/4_^_4?_ ,77B=%7[*)/.SVS_A</A_\ Y\]3_P"_4?\
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MV?\ "X?#_P#SYZG_ -^H_P#XNC_A</A__GSU/_OU'_\ %UXG11[*(<[/;/\
MA</A_P#Y\]3_ ._4?_Q='_"X?#__ #YZG_WZC_\ BZ\3HH]E$.=GMG_"X?#_
M /SYZG_WZC_^+H_X7#X?_P"?/4_^_4?_ ,77B=%'LHASL]L_X7#X?_Y\]3_[
M]1__ !='_"X?#_\ SYZG_P!^H_\ XNO$Z*/91#G9[9_PN'P__P ^>I_]^H__
M (NC_A</A_\ Y\]3_P"_4?\ \77B=%'LHASL]L_X7#X?_P"?/4_^_4?_ ,71
M_P +A\/_ //GJ?\ WZC_ /BZ\3HH]E$.=GT)X;\>:7XHU&2QL;>\CECB,Q,Z
M*!@$#LQY^85U->)_![_D;;O_ *\7_P#1D=>V5C-).R-(NZ"BBBH*"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-Z'H>G^2#4-E\0]6U$3&ST#SQ"N^39(3M'Y?I]:L1^/?#6K6ZKJUEM=<'9-
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M_N)E&&V#@  X# >N:NI0G&-.4%K'H3&I%N2ELSA88);B58H(GED;[J(I8GZ
M5[-X3TEO"_A:1KTA)CNN)^<A,#IGV Y]\\UCW/Q/TJ.-WLM.N7N#_P ]0J _
M4@D_I6OXAOKBU\ 7$VH86[FMPCHN!AWX*CZ9/X"LL34JU5&$H\J;+HQA"\D[
MV.'^',/VOQ>9Y69Y(H9)=Q.26.%)/K]XU'\1[I;CQ;)&N?\ 1X4B.?7EN/\
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MO(Z];\+WMQI_P>O[NTE,4\3R,C@#(.5]:<]D*&YQG_"NO%G_ $"'_P"_T?\
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M?\C;=_\ 7B__ *,CKVRN>K\1M#8****S+"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KS_XV_P#)(==_[=__ $HCKT"O/_C;_P DAUW_ +=__2B.@#T"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#YNHHHKZP\0**** "BBB@ HHHH ****
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M'_0=U/\ \"Y/\:33O=#35K&__P *K\4?\\+?_O\ BN5U33;C1]2FL+L*)X2
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M6_\ A5VB?\_6H?\ ?Q/_ (BC_A5VB?\ /UJ'_?Q/_B*/[0HA]5J'DE%>M_\
M"KM$_P"?K4/^_B?_ !%'_"KM$_Y^M0_[^)_\11_:%$/JM0\DHKUO_A5VB?\
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MS]:A_P!_$_\ B*/[0HA]5J'DE%>M_P#"KM$_Y^M0_P"_B?\ Q%'_  J[1/\
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M ,11_P *NT3_ )^M0_[^)_\ $4?VA1#ZK4/)**];_P"%7:)_S]:A_P!_$_\
MB*/^%7:)_P _6H?]_$_^(H_M"B'U6H>245ZW_P *NT3_ )^M0_[^)_\ $4?\
M*NT3_GZU#_OXG_Q%']H40^JU#R2BO6_^%7:)_P _6H?]_$_^(H_X5=HG_/UJ
M'_?Q/_B*/[0HA]5J'DE%>M_\*NT3_GZU#_OXG_Q%'_"KM$_Y^M0_[^)_\11_
M:%$/JM0\DHKUO_A5VB?\_6H?]_$_^(H_X5=HG_/UJ'_?Q/\ XBC^T*(?5:AY
M)17K?_"KM$_Y^M0_[^)_\11_PJ[1/^?K4/\ OXG_ ,11_:%$/JM0\DHKUO\
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MU\NL32I^[.23]4>NZ4Y:I'@M%>]?\()X%_Y](/\ P-D_^+H_X03P+_SZ0?\
M@;)_\73^NT/YE]Z%["IV/!:*]Z_X03P+_P ^D'_@;)_\71_P@G@7_GT@_P#
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M\71]=H?S+[T'L*G8\%HKWK_A!/ O_/I!_P"!LG_Q='_"">!?^?2#_P #9/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KS_P"-O_)(==_[=_\ THCKT"O/_C;_ ,DAUW_MW_\
M2B.@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N:^(<C1?#CQ(R@$G39UY]"A!_G72UR_Q(_P"2:^(_
M^P?-_P"@F@"[X-C6'P/X?B4DJFFVZC/7 C6MNL?PG_R)NA_]@^W_ /1:UL4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'G_ (2_Y*]\1?\ N&?^D[5Z!7G_ (2_
MY*]\1?\ N&?^D[5Z!0 5XEX^_P"1VU#_ +9_^BUKVVO$O'W_ ".VH?\ ;/\
M]%K7H9;_ !7Z?JCEQ?P+U.;K2\._\C-I7_7Y#_Z&*S:TO#O_ ",VE?\ 7Y#_
M .ABO9J? S@C\2/9O$O_ "#H_P#KL/Y&N6KJ?$O_ "#H_P#KL/Y&N6K\5XC_
M -^?HC[; ?P0HHHKP3M"BBN8U/Q]H>DZC-8W4D_G0D!]L1(R0#U_&NC#82OB
M9.%"#DUKHKF=2K"FKS=CIZ*XW_A9_AO_ )Z7/_?DUT&D:_I>NQ,^G7:3;0"Z
MX(9<^H//:MJ^68S#PYZU*45W:=B(8FC4?+"2;]32HK(\2ZY_PCNB2ZC]G^T>
M6RKY>_9G)QUP?Y5=TV\_M'2K.]\OR_M$"3;,YV[E!QGOUKG>'JJBJ[7NMVOY
MK7U-/:1<^2^NY:HHHK$L**** "BBB@ HHHH **** "BLK6/$-CH4EJEZ9 ;I
MRD>Q<\\=?S%:M:2HU(0C.2LI7L^]MR5.+;BGJ@HHHK,H**** "BBB@ HHHH
M**** "BBB@#9\-?\A&3_ *XG^8KJ:Y;PU_R$9/\ KB?YBNIK]!X<_P!Q7JSP
ML?\ Q@HHHKWCB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_XV_P#)
M(==_[=__ $HCKT"O/_C;_P DAUW_ +=__2B.@#T"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7^)'_)-
M?$?_ &#YO_03745RGQ,D6+X9^(F8$@V,B\>I&!_.@#3\)_\ (FZ'_P!@^W_]
M%K6Q65X8C,/A/1HF(+)8P*<=,A!6K0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O/_C;_ ,DAUW_MW_\ 2B.O0*\_^-O_ "2'7?\ MW_]*(Z /0**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *X_P"*G_)+O$/_ %Z'^8KL*X_XJ?\ )+O$/_7H?YB@#H-!_P"1
M>TS_ *](O_0!6A6?H/\ R+VF?]>D7_H K0H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@J-2+;:<7)+EE;1KWKI7Z/\ '4QQ$)3<*TXNUK-)ZK[OQ)_^$7\9_P#0U_\
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MQ48X' _5)23J2DI-)W44DTE=:7=^G0NDW6K^U2M%*R\[_H34445X)W!1110
M4444 ;/AK_D(R?\ 7$_S%=37+>&O^0C)_P!<3_,5U-?H/#G^XKU9X6/_ (P4
M445[QQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=WNK'BXV495;Q=PHHHKVCD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKS_XV_\ )(==_P"W?_THCKT"O/\ XV_\DAUW_MW_ /2B.@#T"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*S:TO#O_ ",VE?\ 7Y#_ .ABO9J? S@C\2/?Z***^6/9"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS
M_P"-O_)(==_[=_\ THCKT"O/_C;_ ,DAUW_MW_\ 2B.@#T"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_GUT_P#[]O\ _%UM3PE2HKP$\1&/Q'K=>)>/O^1VU#_MG_Z+6M+_ (6CK?\
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MTOKY[O0;DA0[9VA> 2%).UEXXS@C]/7[MBME.RDAA&Q!';BO./C4!_PC^G'
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M#DP%SM5A  P ]-P.#7L]>.:-IT.E?'>XM8 !$#)(JJN N^+?@#T&['X5['0
M4444""BBB@ HHHH **** "BBB@ HHHH Y'PE_P E3\:_]N/_ *(:O0B 000"
M#U!KSWPE_P E3\:_]N/_ *(:O0ZRGN=%+8\*\6:*="U^>V52+=_WD)_V#V_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Q'Q>_P"26:W_ +D7_HU*[>N(
M^+W_ "2S6_\ <B_]&I0QK<],HHHKG.L**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:/LT/]S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/\
M<_4T<Z#V3.!\)?\ )4_&O_;C_P"B&KT.O/\ PD!_PMOX@I_#'_9VP>F8&S7H
M%1)W9I"+BK,*S[H SN",@]OPK0J-H(W8LRY)]Z(NS"<7)61XW?\ AJ6/Q6--
MA4^5,V^-N>(SU['IR*].MX([6WC@B4+'&H50!BM%M/M&G29H%,J JKGJ >N#
M^%2?9H?[GZFNJMBG423Z'/##<C;1GT5H?9H?[GZFC[-#_<_4UASHT]DS/HK0
M^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_P!S
M]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/]S]31]FA_
MN?J:.=![)F?16A]FA_N?J:/LT/\ <_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG
M0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5
MH?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#_ '/U-'V:'^Y^IHYT'LF9]%:'V:'^
MY^IH^S0_W/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0
M_P!S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31
MSH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ
M*T/LT/\ <_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#
M_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC[-#_ '/U-'.@]DS/HK0^S0_W/U-'
MV:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_W/U-'V:'^Y^I
MHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_P!S]31]FA_N?J:.=![)
MF?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F?16A]F
MA_N?J:/LT/\ <_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZF
MC[-#_<_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC[-#_<_
M4T<Z#V3,^BM#[-#_ '/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]
MDS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_P!S]31SH/9,SZ*T
M/LT/]S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/]S]
M31]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/\ <_4T?9H?
M[GZFCG0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0
M>R9GT5H?9H?[GZFC[-#_ '/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%
M:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y
M^IH^S0_W/U-'.@]DS/HK0^S0_P!S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT
M/]S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/\ <_4T
M<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^
MBM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#_
M '/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_W/U-'V
M:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_P!S]31SH/9,SZ*T/LT/]S]31]FA_N?J
M:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F
M?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/\ <_4T?9H?[GZFCG0>R9GT5H?9
MH?[GZFC[-#_<_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC
M[-#_ '/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/
MU-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]D
MS/HK0^S0_P!S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/
MLT/]S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/\ <_4T<Z#V3/&-8N?'7C-Y
M=&ATEM,L3(5FGD5HPZ XY+<D>R@Y^E>A>'- M?#6BP:;:994Y>0CF1SU8_YX
M&*Z7[-#_ '/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S
M0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_P!S]31SH/9,SZ*T/LT/]S]3
M1]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/]S]31]FA_N?
MJ:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/\ <_4T?9H?[GZFCG0>
MR9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5H?
M9H?[GZFC[-#_ '/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^
MIH^S0_W/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W
M/U-'.@]DSS?XJV%YJ/A!(+&TGNI?M2-Y<$9=L8;G [5TGAJ*2#PKH\,T;QRQ
MV4*NCJ0RL$ ((/0UTGV:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_W/U-'V:'^Y^I
MHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_P!S]31]FA_N?J:.=![)
MF?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F?16A]F
MA_N?J:/LT/\ <_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZF
MC[-#_<_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC[-#_<_
M4T<Z#V3,^BM#[-#_ '/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]
MDS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_P!S]31SH/9,SZ*T
M/LT/]S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/]S]
M31]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/\ <_4T?9H?
M[GZFCG0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0
M>R9GT5H?9H?[GZFC[-#_ '/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%
M:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y
M^IH^S0_W/U-'.@]DS/HK0^S0_P!S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT
M/]S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/\ <_4T
M<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^
MBM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#_
M '/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_W/U-'V
M:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_P!S]31SH/9,SZ*T/LT/]S]31]FA_N?J
M:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F
M?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/LT/\ <_4T?9H?[GZFCG0>R9GT5H?9
MH?[GZFC[-#_<_4T<Z#V3,^BM#[-#_<_4T?9H?[GZFCG0>R9GT5H?9H?[GZFC
M[-#_ '/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/
MU-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:'V:'^Y^IH^S0_W/U-'.@]D
MS/HK0^S0_P!S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/]S]31SH/9,SZ*T/
MLT/]S]31]FA_N?J:.=![)F?16A]FA_N?J:/LT/\ <_4T<Z#V3,^BM#[-#_<_
M4T?9H?[GZFCG0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#_<_4T?9H?[
MGZFCG0>R9GT5H?9H?[GZFC[-#_<_4T<Z#V3,^BM#[-#_ '/U-'V:'^Y^IHYT
M'LF9]%:'V:'^Y^IH^S0_W/U-'.@]DS/HK0^S0_W/U-'V:'^Y^IHYT'LF9]%:
M'V:'^Y^IH^S0_P!S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F?16A]FA_N
M?J:/LT/]S]31SH/9,SZ*T/LT/]S]31]FA_N?J:.=![)F?7$?%[_DEFM_[D7_
M *-2O1_LT/\ <_4UP/QIB2+X2:XZ+AL0#.?6>,4<Z!4F>AT445D;A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>?\ A+_DKWQ%_P"X9_Z3M7H%>?\ A+_DKWQ%_P"X9_Z3M7H% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O/_C;_P DAUW_ +=__2B.O0*\_P#C;_R2'7?^W?\ ]*(Z /0*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2G^-'_"1:)_T&-/_ / E/\:/9S[!S1[FE16;_P )%HG_ $&-/_\  E/\:/\
MA(M$_P"@QI__ ($I_C1[.?8.:/<TJ*S?^$BT3_H,:?\ ^!*?XU%<>)]%@M99
MAJMC(8T+!%N5); S@ '.:/9S?0.>/<SM05M:\96EB#FTTQ1<W P"#(P_=CZX
MR>G3-=17.>"X&.B?VC-(DEUJ$C7$KHV1DDX'7 P.,=NG:NCJZSM+D733_/\
M$5/;F[A1116)8C,J*69@J@9))P *YKPK$]]<ZAXAEW_Z<^RW5C]V%. <<=3S
M_P#KI?&MX4TF/38[A()M0D\G>YP$CZR,2>@ Z_6KMKK'A^SM(K:#5M.6*)0J
M@7,8X'T-=$8R5.Z6_P"7_#_D9-ISL^AL45F_\)%HG_08T_\ \"4_QH_X2+1/
M^@QI_P#X$I_C67LY]B^:/<TJ*S?^$BT3_H,:?_X$I_C1_P )%HG_ $&-/_\
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M_P# E/\ &G[.?87-'N:5%9O_  D6B?\ 08T__P "4_QH_P"$BT3_ *#&G_\
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M2G^-'_"1:)_T&-/_ / E/\:/9S[!S1[FE16;_P )%HG_ $&-/_\  E/\:/\
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MD6B?]!C3_P#P)3_&CV<^P<T>YI45F_\ "1:)_P!!C3__  )3_&C_ (2+1/\
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MT_\ \"4_QH]G/L'-'N:5%9O_  D6B?\ 08T__P "4_QH_P"$BT3_ *#&G_\
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M2G^-'_"1:)_T&-/_ / E/\:/9S[!S1[FE16;_P )%HG_ $&-/_\  E/\:/\
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MD6B?]!C3_P#P)3_&CV<^P<T>YI45F_\ "1:)_P!!C3__  )3_&C_ (2+1/\
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MT_\ \"4_QH]G/L'-'N:5%9O_  D6B?\ 08T__P "4_QH_P"$BT3_ *#&G_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!\,,EQ/'!"A>61@B*.I). *
M]]T+28]$T:VL(\$QK\[#^)SRQ_/],5YQ\--'%WJ\FI2IF.U&(^F/,/\ @,_Y
M%>L5XV8UKR5-=#T,)3LN=A1117F'6%>2^,M>2[U*[EA92(P;& CTZROGWSL'
MJ"37HGB35?[(T2:=.;B3$-NN<;I&X'Y=?PKP_495DN0B-O2)=@<G)<Y)9NIZ
ML2:]++Z/,W-G)BJEERHJ4445[1YX4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5A^+_P#D5KS_ (!_Z&M;E8?B_P#Y%:\_X!_Z&M8XC^%+T?Y&E+XU
MZGU;1117S)ZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]#DQ<[+E(Z***]H\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH P],_P"1IU[_ +=__0#6Y6'IG_(TZ]_V[_\ H!K<
MK&C\+]7^;-*F_P E^04445L9A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %8?B_P#Y%:\_X!_Z&M;E8?B__D5KS_@'
M_H:UCB/X4O1_D:4OC7J?5M%%%?,GKA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>4_'+_D&^&O^PNG_H#5ZM7D
MWQQ<F'PO#QM;4BY/?*H<?SK2E_$CZHF?PLX>BBBOJ#Q@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G(C22*B EF(  [FFU
MV/PYT<ZAKYO9%!@LAOR>[G[HZ_4_A[UG5J*G!S?0N$7.2BCT[0=*31=%M;!-
MNZ-/WC#^)SRQ_/\ 3%:5%%?,2DY-MGKI)*R"BBHKB=+6UEN)3B.)"['V R:6
MXSSKXH:N2]MI$3C:/WTP'KT4?S/Y5YQ5O5-0FU;5+B_G_P!9,Y8C/W1V'T P
M/PJI7TN'I>RIJ)Y%6?/-R"BBBMS,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH P],_Y&G7O^W?_P! -;E8>F?\C3KW
M_;O_ .@&MRL:/POU?YLTJ;_)?D%%%%;&84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>X^#=#_L/
MP_#%(N+F;][/GJ&/1?P&!]<^M>9^!M'_ +6\20EUS!;8FDR,@X/ //<U[97D
M9E6VIKYG=A*>\V%%%%>4=H5YY\3=8"QP:5&03Q--QG']P=#[G'H/>O0)IH[>
M"2>9PD4:EW8]  ,DUX#KFHG5M8N;XJ09G+ $Y(7HHZ]@!7?E]+GJ<SV1S8J?
M+"RZF?1117NGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#B*];HH_M"L'U6F>2?\*NUO_GZT_\ [^/_ /$4?\*NUO\ Y^M/_P"_C_\
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M_'_^(KUNBC^T*P?5:9Y)_P *NUO_ )^M/_[^/_\ $4?\*NUO_GZT_P#[^/\
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MPJ[6_P#GZT__ +^/_P#$4?\ "KM;_P"?K3_^_C__ !%>MT4?VA6#ZK3/)/\
MA5VM_P#/UI__ '\?_P"(H_X5=K?_ #]:?_W\?_XBO6Z*/[0K!]5IGDG_  J[
M6_\ GZT__OX__P 11_PJ[6_^?K3_ /OX_P#\17K=%']H5@^JTSR3_A5VM_\
M/UI__?Q__B*/^%7:W_S]:?\ ]_'_ /B*];HH_M"L'U6F>2?\*NUO_GZT_P#[
M^/\ _$4?\*NUO_GZT_\ [^/_ /$5ZW11_:%8/JM,\D_X5=K?_/UI_P#W\?\
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M\?\ ^(KUNBC^T*P?5:9Y)_PJ[6_^?K3_ /OX_P#\11_PJ[6_^?K3_P#OX_\
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M:?\ ]_'_ /B*/^%7:W_S]:?_ -_'_P#B*];HH_M"L'U6F>2?\*NUO_GZT_\
M[^/_ /$4?\*NUO\ Y^M/_P"_C_\ Q%>MT4?VA6#ZK3/)/^%7:W_S]:?_ -_'
M_P#B*/\ A5VM_P#/UI__ '\?_P"(KUNBC^T*P?5:9Y)_PJ[6_P#GZT__ +^/
M_P#$4?\ "KM;_P"?K3_^_C__ !%>MT4?VA6#ZK3/)/\ A5VM_P#/UI__ '\?
M_P"(H_X5=K?_ #]:?_W\?_XBO6Z*/[0K!]5IGDG_  J[6_\ GZT__OX__P 1
M1_PJ[6_^?K3_ /OX_P#\17K=%']H5@^JTSR3_A5VM_\ /UI__?Q__B*/^%7:
MW_S]:?\ ]_'_ /B*];HH_M"L'U6F>2?\*NUO_GZT_P#[^/\ _$4?\*NUO_GZ
MT_\ [^/_ /$5ZW11_:%8/JM,\D_X5=K?_/UI_P#W\?\ ^(H_X5=K?_/UI_\
MW\?_ .(KUNBC^T*P?5:9Y)_PJ[6_^?K3_P#OX_\ \11_PJ[6_P#GZT__ +^/
M_P#$5ZW11_:%8/JM,\D_X5=K?_/UI_\ W\?_ .(H_P"%7:W_ ,_6G_\ ?Q__
M (BO6Z*/[0K!]5IGDG_"KM;_ .?K3_\ OX__ ,11_P *NUO_ )^M/_[^/_\
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M\_6G_P#?Q_\ XBC_ (5=K?\ S]:?_P!_'_\ B*];HH_M"L'U6F>2?\*NUO\
MY^M/_P"_C_\ Q%'_  J[6_\ GZT__OX__P 17K=%']H5@^JTSR3_ (5=K?\
MS]:?_P!_'_\ B*/^%7:W_P _6G_]_'_^(KUNBC^T*P?5:9Y)_P *NUO_ )^M
M/_[^/_\ $4?\*NUO_GZT_P#[^/\ _$5ZW11_:%8/JM,\D_X5=K?_ #]:?_W\
M?_XBC_A5VM_\_6G_ /?Q_P#XBO6Z*/[0K!]5IGDG_"KM;_Y^M/\ ^_C_ /Q%
M'_"KM;_Y^M/_ ._C_P#Q%>MT4?VA6#ZK3/)/^%7:W_S]:?\ ]_'_ /B*/^%7
M:W_S]:?_ -_'_P#B*];HH_M"L'U6F>2?\*NUO_GZT_\ [^/_ /$4?\*NUO\
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M\_6G_P#?Q_\ XBC_ (5=K?\ S]:?_P!_'_\ B*];HH_M"L'U6F>2?\*NUO\
MY^M/_P"_C_\ Q%'_  J[6_\ GZT__OX__P 17K=%']H5@^JTSR3_ (5=K?\
MS]:?_P!_'_\ B*/^%7:W_P _6G_]_'_^(KUNBC^T*P?5:9Y)_P *NUO_ )^M
M/_[^/_\ $4?\*NUO_GZT_P#[^/\ _$5ZW11_:%8/JM,\D_X5=K?_ #]:?_W\
M?_XBC_A5VM_\_6G_ /?Q_P#XBO6Z*/[0K!]5IGDG_"KM;_Y^M/\ ^_C_ /Q%
M'_"KM;_Y^M/_ ._C_P#Q%>MT4?VA6#ZK3/)/^%7:W_S]:?\ ]_'_ /B*/^%7
M:W_S]:?_ -_'_P#B*];HH_M"L'U6F>2?\*NUO_GZT_\ [^/_ /$4?\*NUO\
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M_P"%7:W_ ,_6G_\ ?Q__ (BC_A5VM_\ /UI__?Q__B*];HH_M"L'U6F>2?\
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M_P#OX_\ \11_PJ[6_P#GZT__ +^/_P#$5ZW11_:%8/JM,\D_X5=K?_/UI_\
MW\?_ .(H_P"%7:W_ ,_6G_\ ?Q__ (BO6Z*/[0K!]5IGDG_"KM;_ .?K3_\
MOX__ ,11_P *NUO_ )^M/_[^/_\ $5ZW11_:%8/JM,\D_P"%7:W_ ,_6G_\
M?Q__ (BC_A5VM_\ /UI__?Q__B*];HH_M"L'U6F>2?\ "KM;_P"?K3_^_C__
M !%'_"KM;_Y^M/\ ^_C_ /Q%>MT4?VA6#ZK3/)/^%7:W_P _6G_]_'_^(H_X
M5=K?_/UI_P#W\?\ ^(KUNBC^T*P?5:9Y)_PJ[6_^?K3_ /OX_P#\11_PJ[6_
M^?K3_P#OX_\ \17K=%']H5@^JTSR3_A5VM_\_6G_ /?Q_P#XBC_A5VM_\_6G
M_P#?Q_\ XBO6Z*/[0K!]5IGDG_"KM;_Y^M/_ ._C_P#Q%'_"KM;_ .?K3_\
MOX__ ,17K=%']H5@^JTSR3_A5VM_\_6G_P#?Q_\ XBC_ (5=K?\ S]:?_P!_
M'_\ B*];HH_M"L'U6F>2?\*NUO\ Y^M/_P"_C_\ Q%'_  J[6_\ GZT__OX_
M_P 17K=%']H5@^JTSR3_ (5=K?\ S]:?_P!_'_\ B*/^%7:W_P _6G_]_'_^
M(KUNBC^T*P?5:9Y)_P *NUO_ )^M/_[^/_\ $4?\*NUO_GZT_P#[^/\ _$5Z
MW11_:%8/JM,\D_X5=K?_ #]:?_W\?_XBC_A5VM_\_6G_ /?Q_P#XBO6Z*/[0
MK!]5IGDG_"KM;_Y^M/\ ^_C_ /Q%'_"KM;_Y^M/_ ._C_P#Q%>MT4?VA6#ZK
M3/)/^%7:W_S]:?\ ]_'_ /B*/^%7:W_S]:?_ -_'_P#B*];HH_M"L'U6F>2?
M\*NUO_GZT_\ [^/_ /$4?\*NUO\ Y^M/_P"_C_\ Q%>MT4?VA6#ZK3/)/^%7
M:W_S]:?_ -_'_P#B*/\ A5VM_P#/UI__ '\?_P"(KUNBC^T*P?5:9Y)_PJ[6
M_P#GZT__ +^/_P#$4?\ "KM;_P"?K3_^_C__ !%>MT4?VA6#ZK3/)/\ A5VM
M_P#/UI__ '\?_P"(H_X5=K?_ #]:?_W\?_XBO6Z*/[0K!]5IGDG_  J[6_\
MGZT__OX__P 11_PJ[6_^?K3_ /OX_P#\17K=%']H5@^JTSR3_A5VM_\ /UI_
M_?Q__B*/^%7:W_S]:?\ ]_'_ /B*];HH_M"L'U6F>2?\*NUO_GZT_P#[^/\
M_$4?\*NUO_GZT_\ [^/_ /$5ZW11_:%8/JM,\D_X5=K?_/UI_P#W\?\ ^(H_
MX5=K?_/UI_\ W\?_ .(KUNBC^T*P?5:9Y)_PJ[6_^?K3_P#OX_\ \11_PJ[6
M_P#GZT__ +^/_P#$5ZW11_:%8/JM,\D_X5=K?_/UI_\ W\?_ .(H_P"%7:W_
M ,_6G_\ ?Q__ (BO6Z*/[0K!]5IGDG_"KM;_ .?K3_\ OX__ ,11_P *NUO_
M )^M/_[^/_\ $5ZW11_:%8/JM,\D_P"%7:W_ ,_6G_\ ?Q__ (BC_A5VM_\
M/UI__?Q__B*];HH_M"L'U6F>2?\ "KM;_P"?K3_^_C__ !%'_"KM;_Y^M/\
M^_C_ /Q%>MT4?VA6#ZK3/)/^%7:W_P _6G_]_'_^(H_X5=K?_/UI_P#W\?\
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MO[SQQX @'WCJ,LF3TPL>3_.O0*\_\;_\E'^'W_7W=?\ HF@#T"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ,FFCMX))YG"11J7=CT  R37/>$+662WN=;NQ_I.
MI2F5=R@%8NB+], 'KTQ6[>6<%_:2VMS'YD$J[77)&1]1S4L<:Q1)&@PB*%4>
M@%:*:4&EN_R)<;R3'4445F4%8?BN[D@T9K2V)^V7S"U@ .#EN"?8 9.:W*BE
MMX)GC>6&.1XFW1LZ@E#ZCT-5"2C)-DR3:LB+3;&/3-,MK&(DI!&$#'J<=_QJ
MU112;;=V4E;0****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-&!.JAB1C)P">.:=F+F3T-FBBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKUGX?^(=1\4>%TU74H((9))G5! C*I1>,_,3WW#KVK:_L;2_^@;9_P#?A?\
M"H=9FBT;PQJ-Q $MTMK6610@"A2%)XQ[TFT]BDFM6SQJ^^-_B"+4+F.VL=+\
MA)66/?'(6V@G&3O&3CV'TJO_ ,+S\3?\^.D?]^9/_CE0?!C2XM1\83RW$:20
MV]HS%'0,"Q( Z_4G\*]Z_L;2_P#H&V?_ 'X7_"F[+H1%2DKW/-/ 'Q,U_P 6
M^*8]-NK/3TMO*>65X(I R@#CDN0.2!R.]:'Q+^(FI>#M1L;/3;:TE::%I9#<
M*S<9P,;6&.A]?P[^@6^GV5I(9+:TMX7(P6CC"DCTR!7SU\6YVU'XDS6T;[S#
M'%;J,YP2-V/S<T*S94KQCN>\^&;^\U7PSINH7Z0I<W4"S,L((4!AD8R2>A'>
MN;\>_$>R\(1-:6P2ZU=E!2$\K&#T9\?RZGV'-4O'/CRV\#Z1#HNFNDVK+ L:
M# VP*!@,P]<=%_$\=>/^'?P[N/$EW_PDGB0226LC^;''*26NFSG<V?X?Y_3J
MDNK!R?PK<[KX?^(_%OBE#J&JV>GVFEXQ&4AD$DQ]5RY 4>N.>@[D=Y2*JHH5
M0 H&  . *6DRTK(YOQ5XXT;P>L0U-IVEF!:.*&(LS =3DX7\SWKS'4_COJ+S
M#^RM(M88AU-TS2,W_?)7'ZUZ9XK\#:5XQN+&74GN%%H'"K"P7?NV_>)!.!M[
M8ZUX?\4]+T?1/%46FZ-:);0PVR&50S,2Y)/)))^[MJHI,SFY(]X\&:Q>Z_X3
ML=5U!(([BY#,4@5E4#<0.I)Z '\:X?Q?\9K?2KV2PT&VBO98F*R7,I/E9]%
M.6^N0..,]:[[1M)CM_!]CI$\15!8I!,BDH?N -R,$$\\C!S7*Z%\(M"T;7+B
M^ES?0'!MH+A01$<DG/9NV,^_7K25NI3YK)(\VA^-'BR.9'D>SE0')1H,!AZ9
M!S7LO@GQG:>,]):YAC,%S 0EQ 6SL)'!![J><'V/I47Q"T_2Y_ &J"]@B\NV
MMF>W.W_5R ?)MQTYP..QQTKS7X$+.=>U9E#?9Q;*'..-V[Y<^^ WZT]&KDJ\
M96;/=:***@U"O/\ XV_\DAUW_MW_ /2B.O0*\_\ C;_R2'7?^W?_ -*(Z /0
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\_\6_\ )7OAU_W$_P#TG6O0*P=5\,IJGBSP_KS731MHWVG;
M"$R)?.C"')SQC&>] &]1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?^$O\
MDKWQ%_[AG_I.U:7Q/OQ8?#S5FWE'F18%P>3O8 C\LUH:5X972_%OB'7A=&1M
M9^S;H2F!%Y,93@YYSG/08KBOCG?^3X7L+$$AKB[WG'0JBG(_-E/X4X[DR=HL
MX[X6>!=*\6V^I7&JB=E@=$B$4FWD@DY_2O09/@MX2>-E47T9(X99^1^8(I?@
MQ9-:_#^.8XQ=W,LP^@PG_LE>A4VW<F,5;4^:/&/@S4OAYK%M>V=V[VS/NM;M
M/E=&'.UAZ^_0C\0/>/!?B'_A*/"EEJC*%G=2DZCH)%.&Q['&1[$5S7QI\O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPGMFU7XE0W4H+&%9;I]HXR1C/TRXHCU8ZFK2/H^BBBH- HHJIJEZ-.TB]OB
M1;0/,0>AVJ3_ $H ^<[3;XE^,JL%\V&?52X '6-7)YQ_LKS7TO7SK\&+)KSQ
M^+ECG[+;23$GG).$Z^OSG\C7T553W,Z>UPHHHJ30**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3_PM'1/^?74/^_:
M?_%T?\+1T3_GUU#_ +]I_P#%UY)17O?V?1/-^M5#UO\ X6CHG_/KJ'_?M/\
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MG_/KJ'_?M/\ XNO)**/[/HA]:J'K?_"T=$_Y]=0_[]I_\71_PM'1/^?74/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#YNHHHKZP\0**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KVWP#_R).G_]M/\ T8U>)5[;
MX!_Y$G3_ /MI_P"C&KSLR_A+U_1G5A/C?H=)1117B'HA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\W4445]
M8>(%%%% !1110 4444 %%%% !1110 4444 %%%=/X#T9-7\1H9D+6]LOG.,<
M$@_*"?KS[X-14FJ<7)]"HQ<I)(W?"WP\6XMX[_6]RHPW):@[3CU<]1ZX'X^E
M;Y\4>#]%+VUL]N-O)%K!N4G']X#![=ZQ/B3XBE29=$M9-B[0]R5/)ST0^V.2
M.^17F]<%.A+$KVE5NSV2.F52-)\L%\SVN&X\*^,%:%4M[B4 _*T>R11Z@\''
MTKS;Q=X7?PW?H(V>6SF&8I&QD$=5.._\\_6L2SNYK"\AN[=RDT3!E(]1_2I[
M[4]1UN[5[RXEN9F.$4]B>RJ.!GC@"M:6&G1G[LO=[,B=6-2.JU*-%>FZ)\/+
M&TL?MOB&0%MFYXO,V)$/]I@>3^./KUK6AL_ VJRFTMX]/>5L@+&=C'_=/&?P
MI2QT$WRIM+J@6&DUJ['CE=K\--.CO=<N9YX8Y8H(,8=0<,Q&.#[!JI^,_"?_
M  CES'-;N9+&<D)N/S(W]T^OL?\ )ZCX5VJKIFH7?.Z298O;"C/_ +/_ "HQ
M-:,L,YP>X4J;551D<CXZ=#XMNXHXXXXX0D:JB[1]T$_J37.5ZS/8^#=(U*Y?
M5KB&>^N)F>02Y?87.[&T#"CW/Y]J9XB\&Z/J.B/J.C)%%*D9E1H3\DJ@9QCH
M#[_G4TL7""C!IV[E3H2DVTUZ'E-%7-+TN[UC4([*SCWROW/ 4=R3V KTZV\'
M^&/#EHLNL3132-_'<MM4D=E3O^IKHK8F%+1ZOLC*G2E/5;'DM%>PCP]X/\1P
M.E@MOO0??M6VLF>Y'X=Q7F&NZ+<:!JLEC<$.5PR2 8#J>A_SW!I4<3&JW&UG
MV8ZE%P5]T9M%>JZ5X$TB]\*6TAM\7UQ;!Q.TC_*S#(.T$ XSTQV_&HM2T'PC
MI=HE@);3[4\\*3/-<?O%4,&<GGY,J#V'4>U9_7J;ERI.Y7U>5KMG'>%_"T_B
M:>=8[A((H I=V4L><XP/P/>L_6K*+3=9N[*&4RI!(8][8R2.O3WS7M6@V.B6
M%G+)HOE?9Y&R[I,9%)'N2:XOQ;;^$%TF\O+![:;4I7#*4NF<EF;+'&[TSVK*
MEC'.LU9VV6GYESH*-.]U<\ZJ_HNE2:UJT%A'*D1E/+N> !R>.Y]JH45Z$DVM
M#E5KZGLQA\+>";>$3+$DQ&%=T\R9_4\#('Y"K$9\.>-K&54CCN!&=I.S9)&3
MR"#U&<?0X^M>+W5W<7LWG74\DTNT+OD;)P!@<UZI\.M&GTG2KF_O5\DW6UE5
MSC:B@G)],Y/X"O)Q&']E3]HY/G.ZE5YY<J7NGF.K:=)I.JW-A*<M Y7=C&X=
MC[9&#^-4ZU/$FH+JGB._O$QY;RD(1W4?*#^0%9=>K!MQ3EN<4K7=CU+X::9;
MR:%<W-Q:1NTEP55I(P<J%'3(Z9)J]_PEW@OU@_\  -O_ (FI= SHWPV2XX9T
MM9+@9XR3E@/U KQJO-IT5B*DY2;LF=<JCI0BDCV>.S\(>*XI%MHK21^[1)Y4
MH]^@/;OQ7F?B?PY/X;U(0.QD@D&Z&7&-P[@CU&:SM-OYM+U&WO8#B2%PP]_4
M?B,BO4_B7;QS^%X[@_>BG4J<XX(((_E^57%2PU:,+WC+N2VJL'*UFCR*BNQ\
M(>"'UU%OKUVBL-Q"A?O2XX.#V&>__P"NNH8_#[39!9N+)G!ZE&FP<XY;!_GQ
M6]3%QC+DBG)KL9QH-KF;LCR:BO1O%7@BP72I-8T0G8J>:T2MN1DZEE)]N>OT
MKG?!WAC_ (234)!+(4M;<*TNWJV3PH],X//M5QQ-.5-U.B)=&2ERG-T5ZW+%
MX!TJY_LR>.U$ZD*WF([D$^KX('Y\>U<IXY\.:9HDT,FG7"#S3\]JTFYD&.&'
M?;P>O?\ 2*>+C.2CRM7VN5.@XJ]TQ_P\O=&L;Z[EU.2".;:OV=Y1P/O;L'L>
ME8GBF_L]2\1W=U8*%MG*[2%*[L* 3CMSFNN\%>%-)U'PZ]_JEH)F,K;")'7"
M #L".X-<5I.E7&O:NEG:1JC2$L<9VQKW)ZG ]_;UJ82INM.=WIH^W]:#DI>S
MC'N9U%>O0>%/"OANT1]4>&64C!ENF^\>^U,X_F?>J\WASPIXHMIO[%EABNU0
M%3$2 /3<A[=NE)8Z#=[.W>V@_JTNZOV/*:*]%\9^&M$T+PU'-;V16[DD2(2>
M:YP<$DX)Q_">W>G>!O".E:KH!O-2M!,[S,(R)77"C [$=\U?URG[/VMG:]B?
M82Y^3J><45ZI%IG@?09EMK^:VFO2")-Y9U4]2,<A?09Y]SS47BWP7ICZ+)JV
MCJL31IYQ6)MT<J8R2/3CD8X_G4K&P<DFFD]F-X>5F[K0\PHHHKM.<**** "B
MBB@ HHHH **** "BBB@ HHHH *]M\ _\B3I__;3_ -&-7B5>V^ ?^1)T_P#[
M:?\ HQJ\[,OX2]?T9U83XWZ'24445XAZ(4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-U%%%?6'B!1110 44
M44 %%%% !1110 4444 %%%% !7HGPI91=:FIQN*1D?0%L_S%>=UL>&-=;P]K
M4=[L,D1!CE0=2AQG'OP#^%88FFZE*45N:T9*,TV6O'2.GC+4-X(W%&!]1L&*
MYVO:=6T+1_&]A#>0W $@7$5S%@D#KM8=\$YQP1[9-<[%\*6\X>;JX,0;G;!A
MB/\ OK@_G7-1QM*--1GHUH:U,/-R;CJF>=QQ22AS'&[A%W/M4G:OJ?0<BNI^
M'=A%>^*T:9=PMHFG4$ C<" #^!;/U KN9#X=\!Z3)&%4RRK@QD[I)SCOZ#\@
M,^_/!>%_$,&G^+S?S116UM<!HW6(86)3@C ] 0*;K2KTY\D=+:>8O9JG./,R
M_P#$O5I;G7%TU7/D6J E.@+L,Y/KP1^9]:XN(R+*AB+"0,"A3KGMCWKU[Q5X
M+B\2317]I<I#<%0&8C<DB]CQWJKH?P_L]$N!J6IWJ3&#]XH(V1QD<[B2><=>
MW2LZ.+HTZ*77MYE5*%251OH6?B'L_P"$,'VC:9?-CV9_O]\?ANI?"\C:-\.!
M>M'\Z0RW&T\;N25Y]P!7&>.O%*:[>I:V;9L;<DAL?ZQ^F[Z8X'X^M=AXK_XE
M'PW2S\TA_*AMPPX+$8SW[A3QZ5BZ3C2A3E]IW->=.<IKHCR.21Y9&DD=G=R6
M9F.22>I)KU[0'ETSX8>>P'F);32HK<CDL5Z'OD?G7C]>O>+PND_#I;(.5.R&
MW7)P3C!/Z*?UKJQOO<E/NS##Z<TNR*7PLLD73KV^P/,>;R0>X  /_LWZ5P/B
M#5I-:UNYO7<LC.1$#_#&#\H]N/U)KK_AGKD-M)<:1<.J><WFPD\ MC##/K@#
M'T/M5W6OAG]LU&:ZL+U(4E8N8I$.%)ZX([>V*S52-+$S=7KL6XN=**@<IX#,
MX\8V(A+#.\28Z%=ISGVZ?CBM[XGHLVLZ9#"JM<O&5P/O$%L*/SW8_&N@TC0=
M*\"V$^H7EUYDY7#2D8X_NHOOQ_\ 6KBK6_D\5?$2SN7!C4SJR(>=J)\V/QP?
MSH4U4K.M'X8K?N#CR4_9O=L[?QSJ<VA^%DBLW,<DK+ KJ<%5P22/P&/;->-U
MZ+\5;K,^FV@D/RJ\K(#ZD $C\&_6O.JVP$.6BGU9GB97J6['K^F9TCX6&4-B
M0VDDBL!T9\E?RW#\J\@KVV73D\1^!+>RMIE@2>WAVMMR%V[3C /MBO*O$F@M
MX=U)+)KE9V:(2%E7;C)(Q^GZUE@JD7*:?Q-LO$1=HM;)&/2JI9@J@EB<  <D
MTE>L>!?"-K:6-OJ]THFNYE$D0(XB4CC [DCG/Y>IZZ]>-&/,S"E3=25D4_"/
M@1;4+JFN*%=/G2W?&$ _B?\ GCMW]!G^-/'']HJ^F:5(1:'B:8<&7_9'^S_/
MZ=>T\2>'K[Q @@35_LEH.3$D!)<_[1W#(]L?G7&:I\-ETO2KJ^?6-X@B9]OV
M;&X@<#._C)XKSJ-6G4FJE:5WT5GH==2$XQY8+3N<%116GX<MWNO$FFPHN2;E
M">>P()_0&O6D^5-G"E=V/4?&++I/@![2)]F(XK9,GD@8!'O\H/ZUXW7NGBGP
MZ?$NGQ6GVO[,(Y1+N\O?G@C&,CUKF(/A3 LH-QJTDD?]V. (?S+'^5>5@\32
MI4WSO5L[:]&<Y>ZM#B?#6BRZYK=O;+&6A#AISR J \\CUZ#W-=]\2;M;B+3]
M%BD N+B=7(SP!RHW=^I].QJ_<7^@^ M*:VM@&N2-PA#9DE;IECV'Z=<#M7E-
M_J][J.K-J4\O^DEPP*C 3'0 >@K:'-B*JJ6M%;$2M2AR=7N>X7NFP'0QI<5T
MUE!Y8B5T;Y@@&, GV&*Y'_A6VB?]!:;_ +[3_"M>Z@L/'_A>,Q3B.0$."!DQ
M2 8(8>G)_0URUM\+-0-SBZO[9(!_%$&9CSZ$ #CW-<E!\B:E4Y7U5C:HN9JT
M;H[2SM=/\/\ AB:S%Z);>&*1BSL"<')/ _&N!^'WB2TT6XN;6_D,<-R5*28X
M5AD<^QR.>V*J^-="TC1+N*+3KLM*?];;EMQCX&"3VSUP?7TK<T#P5HNN>%A/
M#<R&]D&&E)SY+CJNT$<?7L<UNHTHT7*;;4_(S<IN:45K$TM1\":-X@>74--O
M_+:9BY:)A+&6+$D]?J, \5YSKFC7NAZDUK?[3*R^8'5MP<$GG/7J#U]*] \,
M> ]2T374OIK^$11Y&V$L3(".C9 P.A[]*P_B-J4&IZ[;V=FWG/;*8VV#.7)^
MZ/4\#\:K#U9*K[.,N:-ON)JP7)S-69T\&W2/A/NWLI:S+!N^Z4\=/=Q5/X66
M4:Z=?7V"9'F$//8* >/KN_05;^(+IIW@J*RC0!'DC@4 \*%&?_90/QK!^&VO
MP64\VE74@C6X</ 3TWXP03ZGC'T^E8J,IX:<UU=_D:-J-6,7T1R>OZE-JVN7
M=U-([9D98P_&Q 3M7'; JUX.:X7Q;IPMFP[2@-SU3^+],UW6M_#:#4=1DO+.
M]-MYSEY(VCW@$]2.1CGM[]JTO#/AC3?#5UY7VD7&IRQEBQ&"$!&<+S@<CDGG
M]*WGC*/L>6.]MC.-"?M+R,+XJW+"/3;48VL7D;UR, ?S-:ME,= ^%R7"2%)!
M:&1'(Y#R'*_JPKD/B/-]K\7B")6>2*&.+:!DECE@!Z_>%=5\0773O!<-E$@"
M/)'  /X54$\?]\BL>3]W1I]W?^OO-.;WYS['DK,68LQ)8G))/)->O[UT_P"%
M&9&P&L, X[R# '_CPKR**-YI4BC4L[L%51W)Z5ZS\0Y%T_P;#91JH622.$*.
M JJ">/\ OD#\:Z<9[TZ</,QH:1E+R/(Z***[SF"BBB@ HHHH **** "BBB@
MHHHH **** "O;? /_(DZ?_VT_P#1C5XE7MO@'_D2=/\ ^VG_ *,:O.S+^$O7
M]&=6$^-^ATE%%%>(>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'S=1117UAX@4444 %%%% !1110 4444 %
M%%% !1110 4444 6K'4[[3)#)8W<UNS<-Y;D;OJ.]:,WC#Q!/$T3ZK.%;KL(
M4_F #6)14.G"3NTBE*25DQ\LLD\K2S2/)(QRSNQ))]R:9115$FGI_B'5]+B\
MJRU":*+^X#E1] >!3-0UW5-4&V]OYYDX^1FPO_?(XK/HJ?9POS6U*YI6M<*M
MW6JZC?1"*[O[JXC#;@DTS. ?7!/7DU4HJFD]6*["K=UJFH7T8CN[^ZN$4[@L
MTS. ?7!-5**&D]0N%;-MXLUZTB\N+5;C9G.';?C\6S6-12E",OB5P4FMF6+R
M_N]0E\V\N99W_O2.6Q],]*9;W$]I.L]M-)#*N=LD;%6&1C@CVJ*BG96L%W>Y
M/=7MU?2B6[N9KB0+M#S2%R!Z9/;DU!110DEH@+ECJVHZ;G[%>SP G)6.0@$^
MXZ&H;N\N;ZX:XNYY)Y6ZO(Q)J&BERJ][:A=VL%:$>NZQ#$D46JWR1HH546X<
M!0.@ SP*SZ*'%/= FUL:7_"1:W_T&-0_\"7_ ,:9-K>K7,+0SZI>RQ.,,CW#
MLI'N":H44N2/8?,^X5)!<36LRS6\TD,J_=>-BK#Z$5'15;B-+_A(M;_Z#&H?
M^!+_ .-(VOZRXPVKW[#T-RY_K6=14^SAV'S2[A1115DEBSO[O3Y?-L[F6!_[
MT;E<_7'6M.?Q?X@N(C&^JW 4]=A"'\Q@UB45#IPD[M%*4EHF*S%F+,26)R23
MR35BRU"\TZ;SK*ZE@DXR8V(SCU]1[&JU%4TFK,5[&S<^+->NX6BFU2X*,,$*
M0N1^&*R$=HW5T8JZG*LIP0?44VBE&$8Z15AN3>[+=UJFH7R*EY?7-PBG(6:9
MG /KR:Z;PIX)@\0Z=-=RZB(R-R+%&,LC=BV>WMW'<5QU7-.U2^TFY^T6%R\$
MG0E3PP]"#P?QK.K"3A:F[,J$ES7FKG5/X=\=VS&WBGO7C7A3%?80CVRPQ^(%
M=7X>T1/"=E>:QK=XKW<B_O96.X*N>@)Y))Q]>!VYY!?B9KRIM*6;'^\8CG]#
M6#J_B+5-<8?;[IG16W+$H"HOT _+)YKD="O4]V=DNMMV;*I3AK&[?F1:KJ<N
MI:W<ZEN9'DE+H0<% /NC(] !^51W6J:A?(J7E]<W"*<A9IF< ^O)JI17>H15
MM-CF<FQR.T;JZ,5=3E64X(/J*LW6J:A?(J7E]<W"*<A9IF< ^O)JI13LF[A=
MA1113$%%%% !1110 4444 %%%% !1110 4444 %>V^ ?^1)T_P#[:?\ HQJ\
M2KVWP#_R).G_ /;3_P!&-7G9E_"7K^C.K"?&_0Z2BBBO$/1"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YNH
MK2_X1W6_^@/J'_@,_P#A1_PCNM_] ?4/_ 9_\*^I]I#NCQN678S:*TO^$=UO
M_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#
M/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P (
M[K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]
M0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\
M*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.6
M78S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^
M$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#Z
MA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1
M_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_
M $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\
M 9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0
M[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:
M*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO
M_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#
M/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P (
M[K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]
M0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\
M*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.6
M78S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^
M$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#Z
MA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1
M_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_
M $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\
M 9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0
M[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:
M*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO
M_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#
M/_A1_P ([K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P (
M[K?_ $!]0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]
M0_\  9_\*/:0[H.678S:*TO^$=UO_H#ZA_X#/_A1_P ([K?_ $!]0_\  9_\
M*/:0[H.678S:]M\ _P#(DZ?_ -M/_1C5Y)_PCNM_] ?4/_ 9_P#"O7_!-O/:
M>$+&"YADAE7S-T<BE6&9&/(/M7GYC*+I*SZ_YG3A4U-W['04445XQZ 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%5WO[..
M^CL7NX%O)4+QV[2 2.HZD+U('K5B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<G^-9-%%D%V:W_"4>(/^@[J?_@7)_C1_PE'B#_H.ZG_X%R?XUDT46079K?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ\-_9W%Y<V<-W
M!)=6NW[1"D@+Q;AE=RCE<CD9ZU8H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_5_^2Y>'/\
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M94=S3OO$W@:PU"YLW\*!GMY6B9EB3!*DC(Y]J9!K?PZUF5+.ZT-K .PVSX"
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MFQP8<G]X?H <CU!%0G;1E-7U1L?#_P -V,UK>>(M=C0Z7:HP195)5V[M[X'
M'.2?45F^&Q8Z]\1[8/I\"6,\KXM0F$"A&VC'X GWK8^(VKV]A:VOA#2ODM;-
M5-QMR-S8R%/KUW'W([BL+X=?\C[I?^\__HMJ-6G(?5([+7=:\$Z#K-QID_A9
M))(" SI$F#E0>,GWJ@OB;X>7Q^S7/AQ[:)S@RK&!M]\H=WY5SGQ%_P"1]U3_
M 'D_]%K7.6UM/>7,=M;1-+-(P5$09+&A15K@Y:G4>.?"">&KJ"XLI6FTR[&8
M7/)0\':3T/!R#W&?3-6? OA+3]7MKK6=:N!'I=FVUDW;=Y !.2.0 ".G)SQT
MK:^(8_LOP-X>T2X93>QA6=0<[0J%3^&6P/7%>8K)(J.BNP1\;E!X;'3/K1&[
MB)V3/2F\=^$+9S:6OA*&2R)VO(T<89@.AP0<\^IJKXF\,Z-J?AS_ (2CPOF.
MW0_Z5:\DH<\\<[2,C(Z8Y''7SVO4/"*/8?"?Q#=W9V6URLJP@CJ2FS(^K$#_
M (#2:Y=4-.^C,#PSX>\,W6D_VIKVNBW42,AM4X?Y<'W+ @CH/QS74:]I/A9_
MAE>:GH5B@"E!'.ZGS,^:JMRW/J*\FKU"#_D@MS_UT'_I0M.2::=PBSC/"/AQ
MO%&O)8>;Y42H99G'4(,#@>I) _'/:NUO?$?@OPI<M8Z7H$.HS0?*T[E2"W0X
M=@Q]<X&*\OCDDA</&[(XZ,IP13:;C=ZB3L>III?A;X@Z?<?V):II6LP+N$6
MJL/]U>"N3C<!D'&>, ^7.CQ2-'(C(ZDJRL,$$=017??"*TN)?%4US'D00V["
M5L<'<1M7]"?^ FN/UZXBNO$6IW$!!AENY70CNI<D?I2CHV@>JN9]%%%62%%%
M% !1110 5]+^%_\ D4M&_P"O&#_T6M?-%?2_A?\ Y%+1O^O&#_T6M95=D:4]
MS6HHHK U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O /
M$7_(S:K_ -?DW_H9KW^O /$7_(S:K_U^3?\ H9KT\L^.7H<>,^%&;72> ?\
MD=M/_P"VG_HMJYNND\ _\CMI_P#VT_\ 1;5Z>(_A2]'^1R4OC7J>VT445\R>
MN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@'B+_ )&;5?\ K\F_
M]#-9M:7B+_D9M5_Z_)O_ $,UFU]33^!>AXTOB9TG@'_D=M/_ .VG_HMJ]MKQ
M+P#_ ,CMI_\ VT_]%M7MM>-F7\5>GZL[\)\#]0HHHKSSJ"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^-_Z E>25ZW\+O\ D6;G_K\;_P! 2KS#^"+"_P 0[:BBBO!/2"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \_\ "7_)7OB+_P!PS_TG:O0*\_\
M"7_)7OB+_P!PS_TG:O0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_N_^2]Z=_V+\O\ Z.KT
M"O/[O_DO>G?]B_+_ .CJ] H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@_B7\"?R(KJHXY)O@0$C1G<R<*HR3^_H=K*P*]W<\LHJS_9U]_SY7'_?IO\
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MUZGMM%%%?,GKA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW72>/O\ D=M0_P"V?_HM:YNOIL/_  H^B_(\BK\;]32\._\ (S:5_P!?D/\
MZ&*]_KP#P[_R,VE?]?D/_H8KW^O,S/XXG7@_A84445YAV!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '$_%'_D6;;_ *_%_P#0'KR2O6_BC_R+-M_U^+_Z
M ]>25[V7_P 'YGFXK^(%>V^ ?^1)T_\ [:?^C&KQ*O;? /\ R).G_P#;3_T8
MU1F7\)>OZ,>$^-^ATE%%%>(>B%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '-^/O^1)U#_MG_ .C%KQ*O;?'W_(DZA_VS_P#1BUXE7MY;_"?K^B/.
MQ?QKT"O6_A=_R+-S_P!?C?\ H"5Y)7K?PN_Y%FY_Z_&_] 2KS#^"+"_Q#MJ*
M**\$](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_PE_R5[XB_
M]PS_ -)VKT"O/_"7_)7OB+_W#/\ TG:O0* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_G_>_
M'^T1>L/AMY&SW!N-HQ^->@5Y_P#\W"_]RI_[=UZ!0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_A+_DKWQ%_
M[AG_ *3M7H%>?^$O^2O?$7_N&?\ I.U>@4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y__P W
M"_\ <J?^W=>@5Y^/F_:$8KR%\+!6([$W60#^%>@4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?^?C_P <7_"O&_UKPO\ ++[E_F=G]EU.Z_'_ ",__A3WA_\ Y_-3_P"_L?\
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M[E_F']EU.Z_'_(S_ /A3WA__ )_-3_[^Q_\ Q%'_  I[P_\ \_FI_P#?V/\
M^(K0_MS4?^?C_P <7_"C^W-1_P"?C_QQ?\*/]:\+_++[E_F']EU.Z_'_ ",_
M_A3WA_\ Y_-3_P"_L?\ \11_PI[P_P#\_FI_]_8__B*T/[<U'_GX_P#'%_PH
M_MS4?^?C_P <7_"C_6O"_P LON7^8?V74[K\?\C/_P"%/>'_ /G\U/\ [^Q_
M_$4?\*>\/_\ /YJ?_?V/_P"(K0_MS4?^?C_QQ?\ "C^W-1_Y^/\ QQ?\*/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!Y_X2_P"2O?$7_N&?^D[5Z!7G
M_A+_ )*]\1?^X9_Z3M7H% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >?VG_)>]1_[%^+_ -'5
MZ!7G]I_R7O4?^Q?B_P#1U>@4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_P 4
M_P#F2O\ L:['_P!GKT"O/_BG_P R5_V-=C_[/7H% !7-^/O^1)U#_MG_ .C%
MKI*YOQ]_R).H?]L__1BUKA_XL?5?F15^!^AXE1117TYXYZW\+O\ D6;G_K\;
M_P! 2J=7/A=_R+-S_P!?C?\ H"53K\LXV_C4_P#M[_VT^KR7^&_E^H4445\.
M>T%%%8_B3Q!%X;TL7TT#S*9!'M0@')SZ_2M:-&I7J*E35Y/1(F<XPBY2V1L4
M5P2_$U70,OA_4&5AD$#((_*I;;XG:8UR(;^QO+'<0 \BY ^O<=NQKTY9!F*3
M?LGIV:;^Y.YS+'8=_:_,[BBFHZ2QK)&ZNC ,K*<@@]"#7,:#XDO-4\5:SI<\
M4"P63$1LBD,?FQSDD?H*\^EA:E6$YQV@KO[[&\ZL8N,7UV.IHHHKG- HHHH
M**** "BBB@ HHHH **9+)Y4+R8SL4MCUQ61X8\1Q>)]-DO8;=X%28Q%7())
M4YX_WJVCAZDJ4JR7NQLF_78AU(J2@WJS:HHHK$L**** "BBB@ HHHH ****
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MOT.DHHHKQ#T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ]_R)
M.H?]L_\ T8M>)5[;X^_Y$G4/^V?_ *,6O$J]O+?X3]?T1YV+^->@5ZW\+O\
MD6;G_K\;_P! 2O)*];^%W_(LW/\ U^-_Z E7F'\$6%_B';4445X)Z04444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'G_A+_DKWQ%_[AG_ *3M7H%>
M?^$O^2O?$7_N&?\ I.U>@4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_:?\ )>]1_P"Q?B_]
M'5Z!7G^E?-\<_$);DKI%LJD]@6)('XUZ!0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWU71+A+2T;(NK8Y(8>BCT/N?E(!&>E4?'-[=:KK>G^$[&5HOM7SW+CNO/'T
M5B?P]ZRCEU#$8F,,-4]QIR;:UBEO?HVK=-]"GB)TZ;E4C[U[*W7M8U;SXB>&
M[.=HOMIF93@F",LOX-T/X5?T?Q9HNNR"*QO5:?&?)<%'_ 'K^&:-+\)Z)I$
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M\SS,R^")8HHHK[8\@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\ \1?\C-JO_7Y-_P"AFO?Z\ \1?\C-JO\ U^3?^AFO3RSXY>AQXSX4
M9M=)X!_Y';3_ /MI_P"BVKFZZ3P#_P CMI__ &T_]%M7IXC^%+T?Y')2^->I
M[;1117S)ZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 > >(O^1FU
M7_K\F_\ 0S6;6EXB_P"1FU7_ *_)O_0S6;7U-/X%Z'C2^)G2> ?^1VT__MI_
MZ+:O;:\2\ _\CMI__;3_ -%M7MM>-F7\5>GZL[\)\#]0HHHKSSJ"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \2\??\CMJ'_;/_ -%K7-UT
MGC[_ )';4/\ MG_Z+6N;KZ;#_P */HOR/(J_&_4TO#O_ ",VE?\ 7Y#_ .AB
MO?Z\ \._\C-I7_7Y#_Z&*]_KS,S^.)UX/X6%%%%>8=@4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!Q/Q1_Y%FV_P"OQ?\ T!Z\DKUOXH_\BS;?]?B_^@/7
MDE>]E_\ !^9YN*_B!7MO@'_D2=/_ .VG_HQJ\2KVWP#_ ,B3I_\ VT_]&-49
ME_"7K^C'A/C?H=)1117B'HA1110 4444 %%%% !1110 4444 %%%% !1110
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MY6HI/?\ K3R,[X72BTBU;1IMJW=O<EF'<]%/X K^M>A5QGB;PA=7&IIKN@7
MM=50C>"<+)VSZ9QP0>#_ #ICQ%X\C0POX:A><<>8,[?T;'ZU.,PT<TJ_6\/4
MBG*W-&4E%IVUWW75-#HU'AH^RJ1>FS2O=?YG=R7$$4L<4DT:22Y$:,P!?'7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \ \1?\ (S:K_P!?DW_H9K-K
M2\1?\C-JO_7Y-_Z&:S:^II_ O0\:7Q,Z3P#_ ,CMI_\ VT_]%M7MM>)> ?\
MD=M/_P"VG_HMJ]MKQLR_BKT_5G?A/@?J%%%%>>=04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'B7C[_ )';4/\ MG_Z+6N;KI/'W_([:A_V
MS_\ 1:US=?38?^%'T7Y'D5?C?J:7AW_D9M*_Z_(?_0Q7O]> >'?^1FTK_K\A
M_P#0Q7O]>9F?QQ.O!_"PHHHKS#L"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** .)^*/_(LVW_7XO_H#UY)7K?Q1_P"19MO^OQ?_ $!Z\DKWLO\ X/S/-Q7\
M0*]M\ _\B3I__;3_ -&-7B5>V^ ?^1)T_P#[:?\ HQJC,OX2]?T8\)\;]#I*
M***\0]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;\??\B3J'_;
M/_T8M>)5[;X^_P"1)U#_ +9_^C%KQ*O;RW^$_7]$>=B_C7H%>M_"[_D6;G_K
M\;_T!*\DKUOX7?\ (LW/_7XW_H"5>8?P187^(=M1117@GI!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >?^$O\ DKWQ%_[AG_I.U>@5Y_X2_P"2
MO?$7_N&?^D[5Z!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'G_AW_ )+1XT_Z]+'_ - ->@5Y
M_P"&/WOQC\>OT\F+3X\>N8F;->@4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0X\9\*,VND\ _P#([:?_ -M/_1;5S==)X!_Y';3_ /MI_P"BVKT\1_"EZ/\
M(Y*7QKU/;:***^9/7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME>1UX(!KSY4JD5>46OD=2G&6B9;HHHK,H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /$O'W_ ".VH?\ ;/\ ]%K7-UTGC[_D=M0_[9_^BUKFZ^FP
M_P#"CZ+\CR*OQOU-+P[_ ,C-I7_7Y#_Z&*]_KP#P[_R,VE?]?D/_ *&*]_KS
M,S^.)UX/X6%%%%>8=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&T5<6&:4[L]-HKF_^$^\,_\ 03_\@2?_ !-.C\=>&Y94C34<N[!5'D2<D_\
M :\3V%7^5_<ST/:0[HZ*BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \_P#"7_)7OB+_ -PS_P!)VKT"O/\ PE_R5[XB_P#<,_\ 2=J] H ****
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ML0R\KA17MEC:1V%C#:1#Y(D"BN'&U>6'(MV;48W=RQ1117DG2%%%% !1110
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M !1110 444UW2.-I)&544$LS'  '<T .HKA]5^+O@K29Q"VKK=/W^R(95'_
MA\OY&NQLKN*_L+>\AW>5<1+*FX8.UAD9_.E<;31/16'XD\7Z'X2M5GUB^2#>
M"8X@-TDF" =JCD]17#1_'_PD]SY;6FK)'G'FM"F/K@/G'3M^%#:0U%O8]5HK
M-T/Q!I/B33Q?:/?17=N3M+)D%3Z,IP5/L0*TJ8@HHHH$%%%% !1110 450UK
M6+/0-'N=5OV9;6W4-(57<<$@<#ZD4S0-=LO$NB6^KZ<SM:7&[RRZ[3\K%3Q]
M5- [&E1110(**** "BN8\3_$#PWX1;RM5OP+HKN6VB4O(1]!T_$BN1MOC]X3
MGNA%+:ZI;Q$\320H0..X5R?R!I712BV>JT50T?6],U^P2^TJ]AN[=QD/&>GL
M1U4^QP:OTQ!1110(**** "BJ]]?6NF64U[?7$=O;0KNDED;"J/K7GEM\;O#5
M_P"(+/2+&VU"=KJXCMTG,:I'EV"@\MNQD\\#I2;2&DWL>ET444Q!1110 444
M4 %%%% !1110 4444 %%<OKOQ T/P[J;:??O<"=5#$)%N&#TYK-_X6YX6_YZ
M7?\ WX/^- SNJ*X7_A;GA;_GI=_]^#_C7;Q2"6%)%R%=0PS[T"'T444 %%%9
M^NZD='T*^U%8A*UM"T@0G&[ Z9H T**Y_P &^(I/%.@#4I+=;=C*R>6K;L8]
MZH/XSE3XCQ^%?L2&-UW?:-YR/W1?ICVQ0,Z^BBB@04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!R/A+_DJ?C7_ +<?_1#5Z'7GGA+_ )*GXU_[<?\ T0U>
MAUE/<Z*6P4445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'FOASY_BQ\095Y0OIZ ^ZP$$5VM<5X5_
MY*/X^_Z^[;_T37:UM#8YJGQ!1115$!1110 4444 %%%% !1110 4444 9?B+
M6X?#V@W>J3C<L*_*@_B8G"C\R*\KTOP]XG^),!U35=8-KITC$1Q*"5;:<';&
M" !D8R3G([UVGQ3LYKSP)=&$9\B1)G4=2H.#^6<_A2_#37K#4_"=G90S1B[L
MXO+E@SA@ ?O8[@Y'/J:!G,W'PEU+25:[\.:]*MVG*HV8BPQTWJ>OL1CGDBMO
MX?\ C:\UFXN-%UQ!%JUMDY*[#( <,"O0,/;J.W!KOJI1:1IT.J3ZG'9Q"^G
M$EQMRY   &>PP!T]* +M%17%Q#:6TEQ<2I%#&I9W<X"@=R:\VO/BE?:CJ+V7
MA+17U IG]](C$$<8;:,$+]2.W2@#TZBO*G\>>.=)0W.K^%T:S7)=HXW3;SW;
M+ #MR*[CPSXMTSQ7:--8.RR1X$L$@ =,^W<>] &[17#Z_P"/FT+QI;:--!"M
MD\2R37+L<H/FR<#V%9EK\1M;UW6(HM!\//)IIF6-[F5&;"E@"Q(PJ\=B3ZT
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M>Q:Q"O[N?]W-CLX'!_$#]*X"OH*%55::FCSZD.23B%%%%;$!2JK.P55+,3@
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MN="TYX<'"_9U&W/4J0,J?<5XGX;\0:Q\%M3NM$\0Z9+/I-Q*94GM^[8QO0G
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M]!C3_P#P)3_&@92_X0GPQ_T K'_OR*W54*H50 H& !VJ@NO:.[JB:M8LS'
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MK8BO)"6*K_>#'D@9Y4\CMQU];5@RAE(*D9!'>@!:***!!1110 4444 %%%%
M!1110 4444 %%%% !1110!R/A+_DJ?C7_MQ_]$-7H=>>>$O^2I^-?^W'_P!$
M-7H=93W.BEL%%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYE\4=.MF\?Z1+J+RQ:==Q)'+,A *X<AB"01P&4]ZZ#_A3'AS_G]U7_O['_\
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M HHHH *P/%^C_P!K:')Y:YN+?]['CJ<=1^(_4"M^BJA-PDI+H#5U8\#HK?\
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MK=B/XF_A^O3K/A_\/-/\#Z6  EQJDH!N+LKW_NIZ*/UZGL /71 ERZL7X=>
M[7P/H8CXDU.Y56O)LY!8#[B_[(R?KU]AV5%%4E8EN^H5YA\<]#;4?!":G"I^
MTZ7.)0RKEA&V%;'<<[6/^[7I]9^NZ5%KF@W^E3'"7<#PEO[N1@'\#S^%)JZ'
M%V=S*T[Q;;7/P\B\52E?*%B;F50PQO53N0'UW K]>U>:_#7PD_B;X>^)]0U
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M00!QG/X5+\5O^1!N_P#KK%_Z&*[6N4^)-E)?^ ]22%&>2,)*%49R%<$_IDT
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MWKUKP8C1^"M%##!-G&?P*@C^=><^)]<G^)&MVOAW0(W>PAD\R>X(P&QQO]E
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M \7Z/_:VAR>6N;BW_>QXZG'4?B/U KR*O?*\SU+PHQ\9I:1+BUN3YP(Z*O\
M$.HZ']"*]'!5U%.,O4PJPOJC=\ Z1]DTQK^0?O;G[OL@Z=^]=?38T6*-8T&%
M4!0/0"G5PU:CJ3<F;1CRJP4445 PHHHH **** "BBB@ HHHH **** "BBB@
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M!8]_>GT4TDMA.3>X4444R3S9_A#9O\2O^$M_M'$/VD7?V%;8#]X!G._=_?\
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MIH^S0_W/U-2U5L-1M-4M?M-E,LT.XKO (Y!P>M/WK7%:)+]FA_N?J:/LT/\
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MB^S0_P!S]31]FA_N?J:EHHNPY5V(OLT/]S]31]FA_N?J:EHHNPY5V(OLT/\
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MB^S0_P!S]31]FA_N?J:EHHNPY5V(OLT/]S]31]FA_N?J:EHHNPY5V(OLT/\
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MB^S0_P!S]31]FA_N?J:EHHNPY5V(OLT/]S]31]FA_N?J:EHHNPY5V(OLT/\
M<_4T?9H?[GZFI:*+L.5=B+[-#_<_4T?9H?[GZFI:*+L.5=CS_P ) ?\ "V_B
M"G\,?]G;!Z9@;->@5Y_X2_Y*]\1?^X9_Z3M7H%*X));!1110,**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ^M7&%TY/H3*5FDCJ:***@H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%<SXN,M_P#8M MWVOJ$G[YE/*0KRQ_SUZ5=.'/*Q,I<JN=-13418XU1<[5
M R<\4ZH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@##\5WLEMHS6UL2;
MR]86T"CKENI^@&>:T=+TZ'2=+M["#_5PH%!Q]X]S]2<G\:PH%37/&LMR2KVV
MCKY,?/69OO'\ ,?7Z5U%;5/=BH?-_P!>GYF<=6Y!1116)H%<OJ>S6_%MGI7W
MK?3Q]KNAG@O_ ,LU(_4]>#70WEW#864UW<-MBA0NY]A_6L;PE9R)I\NIW2%;
MS4I#/*"N"J_PKT'0?S-;4_=BY_)>O_#&<]6HG04445B:!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?^$O
M^2O?$7_N&?\ I.U>@5Y_X2_Y*]\1?^X9_P"D[5Z!0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_XI_\
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MQK$C<ZUXVD)4_9-'3:N1PT[CD_@./U[BNGK:?NP4/F_T_#\S..LG(****Q-
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MU20W#X&-JG[BCU '/XFMJ?NQ<_DO7_AC.>K43H:***Q- I&944LS!5 R23@
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MK6T^RBTW3X+.$8CA0(.O]:V7N4V^KT^7]?J9OWI6[%FBBBL30**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:A_X$O\ XUFT4>SAV#FEW-+_ (2+6_\ H,:A_P"!+_XT?\)%K?\ T&-0_P#
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MS2[FE_PD6M_]!C4/_ E_\:/^$BUO_H,:A_X$O_C6;11[.'8.:7<TO^$BUO\
MZ#&H?^!+_P"-'_"1:W_T&-0_\"7_ ,:S:*/9P[!S2[FE_P )%K?_ $&-0_\
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M^$BUO_H,:A_X$O\ XUFT4>SAV#FEW-+_ (2+6_\ H,:A_P"!+_XT?\)%K?\
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M.'8.:7<TO^$BUO\ Z#&H?^!+_P"-(VOZRZE6U>_92,$&Y<@C\ZSJZ#P;H?\
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M_08U#_P)?_&C_A(M;_Z#&H?^!+_XUFT4>SAV#FEW-+_A(M;_ .@QJ'_@2_\
MC1_PD6M_]!C4/_ E_P#&LVBCV<.P<TNYJQ7^MZQ/'IW]HWL_VAQ&(Y+AV4DG
MN">G>O=+&U%C86]J)'D\F-4WN<LV!U->;_##2!+>7&K2*"L(,41/9R.3T]#C
MKWKU"O&S"HG/V<=E^9WX6+Y>9]0HHHKSSJ"O(/&7B-KGQ!++93E&MLVT,D;8
M9<<NP(Y&3\H(/0'UKTCQ+JPT?0YKA2//?]U "<9D;@?ER?H#7A=S+YLO#%E4
M8#-U;N2?J23^.*]/+J-VYLX\54LE%%S_ (2+6_\ H,:A_P"!+_XT?\)%K?\
MT&-0_P# E_\ &LVBO6]G#L<7-+N:7_"1:W_T&-0_\"7_ ,:/^$BUO_H,:A_X
M$O\ XUFT4>SAV#FEW-+_ (2+6_\ H,:A_P"!+_XT?\)%K?\ T&-0_P# E_\
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MA_X$O_C6;17N>SAV/.YI=S2_X2+6_P#H,:A_X$O_ (T?\)%K?_08U#_P)?\
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M_08U#_P)?_&C_A(M;_Z#&H?^!+_XUFT4>SAV#FEW-+_A(M;_ .@QJ'_@2_\
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M#&H?^!+_ .-9M%'LX=@YI=S2_P"$BUO_ *#&H?\ @2_^-'_"1:W_ -!C4/\
MP)?_ !K-HH]G#L'-+N:7_"1:W_T&-0_\"7_QH_X2+6_^@QJ'_@2_^-9M%'LX
M=@YI=S2_X2+6_P#H,:A_X$O_ (T?\)%K?_08U#_P)?\ QK-HH]G#L'-+N:7_
M  D6M_\ 08U#_P "7_QH_P"$BUO_ *#&H?\ @2_^-9M%'LX=@YI=S2_X2+6_
M^@QJ'_@2_P#C1_PD6M_]!C4/_ E_\:S:*/9P[!S2[FE_PD6M_P#08U#_ ,"7
M_P :/^$BUO\ Z#&H?^!+_P"-9M%'LX=@YI=S2_X2+6_^@QJ'_@2_^-'_  D6
MM_\ 08U#_P "7_QK-HH]G#L'-+N:7_"1:W_T&-0_\"7_ ,:/^$BUO_H,:A_X
M$O\ XUFT4>SAV#FEW-+_ (2+6_\ H,:A_P"!+_XT?\)%K?\ T&-0_P# E_\
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M0_\  E_\:/\ A(M;_P"@QJ'_ ($O_C6;11[.'8.:7<TO^$BUO_H,:A_X$O\
MXT?\)%K?_08U#_P)?_&LVBCV<.P<TNYI?\)%K?\ T&-0_P# E_\ &C_A(M;_
M .@QJ'_@2_\ C6;11[.'8.:7<TO^$BUO_H,:A_X$O_C1_P )%K?_ $&-0_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMV?R^E<Q7T.#I>SI*^[U/+Q$^>84445UF 4444 %%%% !1110 4444 %%%%
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M3.K/D@V>=3327$\D\SEY9&+NQZDDY)IE%%?2GD!1113 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M]1\)?\E>^(O_ '#/_2=J] KS_P )?\E>^(O_ '#/_2=J] KY,]L**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC^U/[GX_\ /J?][\#YNHKZ1HH_M3^Y^/_ #ZG_>_ ^;J*^D:*/[4_N?C_P
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MC^U/[GX_\ /J?][\#YNHKZ1HH_M3^Y^/_ #ZG_>_ ^;J*^D:*/[4_N?C_P
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MH_VI_<_'_@'+]3_O?@?-U%?2-%']J?W/Q_X ?4_[WX'S=17TC11_:G]S\?\
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MM3^Y^/\ P ^I_P![\#YNHKZ1HH_M3^Y^/_ #ZG_>_ ^;J*^D:*/[4_N?C_P
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MS\?^ 'U/^]^!\W45](T4?VI_<_'_ ( ?4_[WX'S=17TC11_:G]S\?^ 'U/\
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MH_M3^Y^/_ #ZG_>_ ^;J*^D:*/[4_N?C_P  /J?][\#YNHKZ1HH_M3^Y^/\
MP ^I_P![\#YNKV[P1I']D>&H Z;;BX_?2YZ\]!_WSC]:CU5_[7\66.C[6-M:
M+]MN>.&8<1J?;/)'.?PKIZQQ>*=2"C:U]?\ (NA14)-WN%%%%>>=05QWQ%UO
M^SM"^PPN!/>Y0X/(C_B_/I^)KL:YC0G_ +9\0:CK+JWE0-]BM-PP-HY=A[D]
M_3BMZ%HR]I)72_I&=2[7*NIXK17TC17?_:G]S\?^ <WU/^]^!\W45](T4?VI
M_<_'_@!]3_O?@?-U%?2-%']J?W/Q_P" 'U/^]^!\W45](T4?VI_<_'_@!]3_
M +WX'S=17TC11_:G]S\?^ 'U/^]^!\W45](T4?VI_<_'_@!]3_O?@?-U%?2-
M%']J?W/Q_P" 'U/^]^!\W45](U0UK4ETC1KN_8!O)C+*I. 6Z ?F13CF3D[*
M'X_\ 3PEE=R_ \P^&^D&^U\WSH##9KN^89RYX7^ISVP*]>K&\+Z=+INAQ"YW
M&[N&-Q<%L9\QN3GCK6S7#BZWM:K?1'30AR0L%%%%<QJ17$Z6MK+<2G$<2%V/
ML!DU\_ZMJ$FJZM=7TI)::0L,]AV'X# _"O8/%C2WS6&@V[#=?RYGY.5A3ENG
M3/'<9Z=ZZ..-8HDC081%"J/0"NW#UEAUS-7;_(YZM-U7:]DCYPHKZ1HKI_M3
M^Y^/_ ,OJ?\ >_ ^;J*^D:*/[4_N?C_P ^I_WOP/FZBOI&BC^U/[GX_\ /J?
M][\#YNHKZ1HH_M3^Y^/_   ^I_WOP/FZBOI&BC^U/[GX_P# #ZG_ 'OP/FZB
MOI&BC^U/[GX_\ /J?][\#YNHKZ1HH_M3^Y^/_ #ZG_>_ ^;J*^D:*/[4_N?C
M_P  /J?][\#YNHKZ1HH_M3^Y^/\ P ^I_P![\#YNHKZ1HH_M3^Y^/_ #ZG_>
M_ ^;J*^D:*/[4_N?C_P ^I_WOP/FZBOI&BC^U/[GX_\  #ZG_>_ ^;J*^D:*
M/[4_N?C_ , /J?\ >_ ^;J*^D:*/[4_N?C_P ^I_WOP/FZBOI&BC^U/[GX_\
M /J?][\#YNHKZ1HH_M3^Y^/_   ^I_WOP/FZBOI&BC^U/[GX_P# #ZG_ 'OP
M/FZBOI&BC^U/[GX_\ /J?][\#YNHKZ1HH_M3^Y^/_ #ZG_>_ ^;J*^D:*/[4
M_N?C_P  /J?][\#YNHKZ1HH_M3^Y^/\ P ^I_P![\#YNHKZ1HH_M3^Y^/_ #
MZG_>_ ^;J*^D:*/[4_N?C_P ^I_WOP/FZBOI&BC^U/[GX_\  #ZG_>_ ^;J*
M^D:*/[4_N?C_ , /J?\ >_ ^;J*^D:*/[4_N?C_P ^I_WOP/FZBOI&BC^U/[
MGX_\ /J?][\#YNHKZ1HH_M3^Y^/_   ^I_WOP/FZBOI&BC^U/[GX_P# #ZG_
M 'OP/FZBOI&BC^U/[GX_\ /J?][\#YNHKZ1HH_M3^Y^/_ #ZG_>_ ^;J*^D:
M*/[4_N?C_P  /J?][\#YNHKZ1HH_M3^Y^/\ P ^I_P![\#YNHKZ1HH_M3^Y^
M/_ #ZG_>_ ^;J*^D:*/[4_N?C_P ^I_WOP/FZBOI&BC^U/[GX_\  #ZG_>_
M^;J*^D:*/[4_N?C_ , /J?\ >_ ^;J*^D:*/[4_N?C_P ^I_WOP/FZBOI&BC
M^U/[GX_\ /J?][\#YNHKZ1HH_M3^Y^/_   ^I_WOP/FZBOI&BC^U/[GX_P#
M#ZG_ 'OP/FZBOI&BC^U/[GX_\ /J?][\#YNHKZ1HH_M3^Y^/_ #ZG_>_ ^;J
M*^D:*/[4_N?C_P  /J?][\#YNHKZ1HH_M3^Y^/\ P ^I_P![\#YNHKZ1HH_M
M3^Y^/_ #ZG_>_ ^;J*^D:*/[4_N?C_P ^I_WOP/FZBOI&BC^U/[GX_\  #ZG
M_>_ ^;J*^D:*/[4_N?C_ , /J?\ >_ ^;J*^D:*/[4_N?C_P ^I_WOP//_"7
M_)7OB+_W#/\ TG:O0*\_\)?\E>^(O_<,_P#2=J] KR3M"BBB@ HHHH ****
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MC78_^SUZ!7G_ ,4_^9*_[&NQ_P#9Z] H **** "BBB@ HHHH **** "BBB@
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M\&K-:<Z4.5=2>7WKA1116904444 %%%% !1110 4444 %%%% !1110 4444
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MGUJH1YI),F3LKD/A*-KM+S79T82ZA*6C#-G9"/N*.3COG^5=)3(88[>"."%
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MY@0\S<$D9SP.F1[YK;K632@HKU9$4W)MA1116184444 %%%% !1110 4444
M%%%% !1110 5FZMI/]JO9!Y]L%O<"=XBF1+CH#STSSWK2HIQDXNZ$TFK,***
M*0PHHHH HII<":U+JN^1KB2$088@JJ@YXXR.?>KU%%-MO<25@HHHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#S_PE_P E>^(O_<,_])VKT"O/_"7_ "5[XB_]PS_TG:O0
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \_^#'_).+?_ *^[G_T<U>@5Y_\ !3Y_A5I4Y^]/
M)<2,.P/GR#C\J] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=4LK!921&;JX2(.1UQN(SUK!\?>/M,\!:*;N[(FO)05M;16PTK?T4=S_ #)
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M(:".18$S]^1V4\GG@>F #@D@'T91573K>YM-.@@N[V2^N40"2YDC5#(W<[5
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M] U,6UO!#$K1+;12%I&&[.65CG#*,<=!QW(!]"45#:I-%9P1W$OG3K&JR28
MWL!R<# &3S7B'Q(^-T\-_P#V!X(;S;P2B.2^2-90S9QLB4@AB3QG'TSP: /=
M:*XKX=6GC5=+-]XTU9IKJ<?N[$00H(%]6**"6/IG 'OT[6@ HKD?B!\0--\
M:,MU=*;B\G)6VM48!G8#.3Z(.,GGJ.*\#D^)OQ1\97CMHBWBQ(<&'2[,LJ9Z
M;FP3^9QQ0!]545\IZ5\7_'W@_5EM=>^T72(0TMEJ47ER[2.S%=RY&""<CO@U
M].:)K-GXAT2TU;3W9[6ZC$D988(]01Z@Y!^E &A1110 4444 %%%% !1110
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M[/$G[QF 4Y5 <8#]_2O<: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <#\%8WB^$FAI(C(P\_*L,$?OY*[ZBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU9C;Q[201&.9&R/8A?\ @=>/>!E&E?M$1P !1%J=W;@$=,B1,<?6I/%US/\
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M3(].CRUO?PR13A6RHV*75N.O*X_X%7U90 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\P_M&VC1>/+"ZYV3Z>HY_O*[Y_0K7T5X:NA?\
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MUKLO^%9?%W_GUO\ _P &T7_QV@#ZNKYV_:5U+?J>@Z6&7]U#)<,O?YV"@_\
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MX[\-> ?B%JVAPZCX?M;HZ=<EFC:*_CB#$,4)VEP<Y4CD=JUO^%9?%W_GUO\
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MLWO7"?%?PSX8\&?"Z_.CZ/8V=S<O#:I,$#2D;@Q =LL<JASSZGWKV15"J%4
M*!@ =!7AO[2NH^7HNA:6.?/N)+@\]-BA1Q_VT/Y&@!W[->GHF@ZYJ6SYYKI(
M-WLB[L?^1/Y5[C7G?P/T\V'PJTQF4J]T\L[ C'5R ?Q55/XUZ)0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\O<6_P!G)Q@ #K7S5XPMI?&GQTO].1_+:ZU-;'S%3=Y:IB(MCC. A.,\XZT
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M%(P<$@@<9'3O2;Z(J,;:O<^=_&.KW'Q"^(,=EI[%[<2_9;,9RI&?FD^AY;Z
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M#+)#;P B*-P<ABQP7[8& /7->S4 %%%% !1110 4444 %%%% !1110 4444
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M,\#^%[WPA\/+;1 ]JVI0QRDR(3Y;2LS,"3M!(Y Z9P.]>&_\,X^,/^@EH?\
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MKVQV^9,"%EC/\+,H)XZC@]2.^:V?AMH7B3PSX871O$-S8W(M3MM)+5W8B/\
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M2.I/S9&-JMZGTK4^$GPVF\ :;?-J,EK/J=W*-TMNS,JQ*/E4%E!SDL3QZ>E
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M[NX/663';T4= /ZDUU=%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBG,L? 63CNO0_P"SCH%K>^"7Q!/BKP__ &/J$Q;5]-0 L[9:>'HK^I(X5O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img114804231_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,Y#D4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P ^>I_]^H__ (NC_A</A_\ Y\]3_P"_4?\ \71R2[!S(]!HKS[_ (7#X?\
M^?/4_P#OU'_\71_PN'P__P ^>I_]^H__ (NCDEV#F1Z#17GW_"X?#_\ SYZG
M_P!^H_\ XNC_ (7#X?\ ^?/4_P#OU'_\71R2[!S(]!HKS[_A</A__GSU/_OU
M'_\ %T?\+A\/_P#/GJ?_ 'ZC_P#BZ.278.9'H-%>??\ "X?#_P#SYZG_ -^H
M_P#XNC_A</A__GSU/_OU'_\ %T<DNP<R/0:*\^_X7#X?_P"?/4_^_4?_ ,71
M_P +A\/_ //GJ?\ WZC_ /BZ.278.9'H-%>??\+A\/\ _/GJ?_?J/_XNC_A<
M/A__ )\]3_[]1_\ Q=')+L',CT&BO/O^%P^'_P#GSU/_ +]1_P#Q='_"X?#_
M /SYZG_WZC_^+HY)=@YD>@T5Y]_PN'P__P ^>I_]^H__ (NC_A</A_\ Y\]3
M_P"_4?\ \71R2[!S(]!HKS[_ (7#X?\ ^?/4_P#OU'_\71_PN'P__P ^>I_]
M^H__ (NCDEV#F1Z#17GW_"X?#_\ SYZG_P!^H_\ XNC_ (7#X?\ ^?/4_P#O
MU'_\71R2[!S(]!HKS[_A</A__GSU/_OU'_\ %T?\+A\/_P#/GJ?_ 'ZC_P#B
MZ.278.9'H-%>??\ "X?#_P#SYZG_ -^H_P#XNC_A</A__GSU/_OU'_\ %T<D
MNP<R/0:*\^_X7#X?_P"?/4_^_4?_ ,71_P +A\/_ //GJ?\ WZC_ /BZ.278
M.9'5:WXDT_P_Y'V]I!Y^[9L3=]W&?YBLG_A9'A[_ )Z7'_?DUP?C#QAI_BS[
M%]@ANH_LV_?YZJ,[MN,88_W37+UZF'P-.I24I7N<=7$2C-I'LG_"R/#W_/2X
M_P"_)KI[2YCO+."ZA),4T:R)D8.",C^=?.E>_P#AW_D6=*_Z\X?_ $ 5CC,+
M"C%./4TP]:51M,TJ***\\Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5,3\)/$2T9//&<#!XZ&DI)[ XM&'1113$%%%% !1110 4444 %%%% !1110
M4444 7M._P"6GX?UJ]5'3O\ EI^']:O5[&%_A+^NIQ5OC85[_P"'?^19TK_K
MSA_] %> 5[_X=_Y%G2O^O.'_ - %<>9_!$WP?Q,TJ***\<[PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(\UMNZSBQP3_  +7'F?P1-\'\3->BJW]H6O_ #U_\=/^%']H6O\ SU_\=/\
MA7CG>6:*K?VA:_\ /7_QT_X4?VA:_P#/7_QT_P"% %FBJW]H6O\ SU_\=/\
MA1_:%K_SU_\ '3_A0!9HJM_:%K_SU_\ '3_A1_:%K_SU_P#'3_A0!9HJM_:%
MK_SU_P#'3_A1_:%K_P ]?_'3_A0!9HJM_:%K_P ]?_'3_A1_:%K_ ,]?_'3_
M (4 6:*K?VA:_P#/7_QT_P"%']H6O_/7_P =/^% %FBJW]H6O_/7_P =/^%'
M]H6O_/7_ ,=/^% %FBJW]H6O_/7_ ,=/^%']H6O_ #U_\=/^% %FBJW]H6O_
M #U_\=/^%']H6O\ SU_\=/\ A0!9HJM_:%K_ ,]?_'3_ (4?VA:_\]?_ !T_
MX4 6:*K?VA:_\]?_ !T_X4?VA:_\]?\ QT_X4 6:*K?VA:_\]?\ QT_X4?VA
M:_\ /7_QT_X4 6:*K?VA:_\ /7_QT_X4?VA:_P#/7_QT_P"% %FBJW]H6O\
MSU_\=/\ A1_:%K_SU_\ '3_A0!9HJM_:%K_SU_\ '3_A1_:%K_SU_P#'3_A0
M!9HJM_:%K_SU_P#'3_A1_:%K_P ]?_'3_A0!9HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,?0/$EGXC_M3[''.G]FZA+I\WG*!N
MDCQN*X)RO(P3@^U;%>?_  L_YG7_ +&N^_\ 9*] H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH R?%'_(I:S_ ->,_P#Z+:OFBOI?Q1_R
M*6L_]>,__HMJ^:*WI;,RJ;A1116IF%>J_#JYFLOA]XCNK=]D\ EDC; .UEBR
M#@\=17E5>H>!/^29>*?^N<W_ *)J)[%0W.:_X65XN_Z"W_DM%_\ $UW5MJE_
MX\^'=PEI=S1:S:X$JQ.$,Y R,@= PSZ?,#V'/C5=%X+\2/X9\017+$FTEQ'<
MKD_<)^]CN1U_,=Z)15M 4NYSM>H0?\D%N?\ KH/_ $H6LGXF>'AIVLKJ]HH-
MCJ/SAD'"R8R?;G[P]>?2NH\,:-+X@^$!TN&5(I)Y&P[@D#;*&[?2E*2:3&EJ
MT>.T5Z5_PIO4O^@I:?\ ?#5F^(/AI?>']$N-4FO[>6.#;E$5@3N8+W^M5SQ[
MBY6</7J?PAFD6P\0 2, BQ.HSP&Q)D@>O _(5Y97J'PC_P"/'Q'_ -<XOY24
M5/A"&YY@S,[%F8LS')).2324451)ZAX[_P"29>%O^N</_HFO+Z]NU'PM<>*_
M /ARUM[B* Q6T,A:0$Y_= 8X^M<W_P *;U+_ *"EI_WPU9QDDM2Y1;90^%^O
M7MGXF@TOS9'LKO<IB)R%8 L& [=.?K["L3QQIUOI7C/4K2U0) KJZHHP%W*&
MP!Z#=7H&E>'M$^' DU?6=1BN;X(1!$B@,/78I.23G&>  :X"W$OC;QNHN)/)
M:_G)) SL7' '3.%&*:?O-K8&M+!X2\)7GBK4?*BS%:1D&>X(X4>@]6/I78>+
M?%EEX<TT^%O#&(_+!2XN$.2I[@'NY[GMT'/3NKOPY/;>&UT;P]<QZ:F-KS%2
MSX[D$$?,?[WY=L<)_P *9NO^@U#_ -^#_C4<RD[L?*TM#R^BNQ\6^ 9O"FFP
MWDFH)<"681!5B*XX)SG/M7'5LFGJB&K'J'Q<_P"/'PY_USE_E'7F,<;S2I%$
MC/([!511DL3T '<UZ=\7/^/'PY_USE_E'6I\+?"UE#I$/B&0":\GWB+<.(0&
M*G'N<'GT./7.<9<L+E-7D5M#T/3OAWH_]O:]MDU5UQ! ""4)'W5_VO5N@' ]
M_./$&O7GB/5I-0O6&\C:B+TC09PH_,_G7J/B#X<ZQXDU-[V]UV'/2.,0';&O
MH.?_ -=97_"F;K_H-0_]^#_C2C*.[>HVGLCR^BI;F'[/=30[MWEN4SC&<'%1
M5J9A1110 4444 %%%% !1110 57ENXX;NWMF#%Y]VT@<#:,G-6*RK_\ Y#VD
M_P#;;_T$4F[#1JT444Q%[3O^6GX?UJ]5'3O^6GX?UJ]7L87^$OZZG%6^-A7M
MEI_R+.B?]><?_H"UXG7MEI_R+.B?]><?_H"UQYG\$3?!_$Q****\<[PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Q] \26?B/\ M3[''.G]FZA+I\WG*!NDCQN*X)RO
M(P3@^U;%>?\ PL_YG7_L:[[_ -DH ] HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,?_ (22S_X3+_A%_+G^W?V?_:'F;1Y?E^9Y
M>,YSNSVQC'>MBO/_ /FX7_N5/_;NO0* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \_P#A9_S.O_8UWW_LE>@5Y_\ "S_F=?\ L:[[
M_P!DKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)\4
M?\BEK/\ UXS_ /HMJ^:*^E_%'_(I:S_UXS_^BVKYHK>ELS*IN%%%%:F84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %>?_"S_ )G7_L:[[_V2O0*\_P#A9_S.O_8UWW_LE 'H
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_P#\
MW"_]RI_[=UZ!7G__ #<+_P!RI_[=UZ!0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'G_PL_P"9U_[&N^_]DKT"O/\ X6?\SK_V-=]_
M[)7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15>__
M .0==?\ 7%_Y&N%KQ,USCZA.,>3FNN]OT9V8;">W3=[6/0J*\]HKRO\ 6O\
MZ<_^3?\ VIT_V9_>_#_@GH5%>>T4?ZU_].?_ ";_ .U#^S/[WX?\$]"HKSVB
MC_6O_IS_ .3?_:A_9G][\/\ @GH5%>>T4?ZU_P#3G_R;_P"U#^S/[WX?\$]"
MHKSVBC_6O_IS_P"3?_:A_9G][\/^">A45Y[11_K7_P!.?_)O_M0_LS^]^'_!
M/0J*\]HH_P!:_P#IS_Y-_P#:A_9G][\/^">A45Y[11_K7_TY_P#)O_M0_LS^
M]^'_  3T*BO/:*/]:_\ IS_Y-_\ :A_9G][\/^">A45Y[11_K7_TY_\ )O\
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MY;PA&+:/,$=PAF"C[JX('X9(_2J_PSLYKV?5?$]T!YM],R1YY(7.6Y],X'_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_ ,+/^9U_[&N^_P#9
M*] KS_X6?\SK_P!C7??^R4 >@4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'G_\ S<+_ -RI_P"W=>@5Y_\ \W"_]RI_[=UZ!0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_ ,+/^9U_
M[&N^_P#9*] KS_X6?\SK_P!C7??^R5Z!0 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** //_P#FX7_N5/\ V[KT"O/_ /FX7_N5/_;NO0* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#/+_QX_P"- &%16[_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C0!A45N_V?:_\
M/+_QX_XT?V?:_P#/+_QX_P"- &%16[_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C0
M!A45N_V?:_\ /+_QX_XT?V?:_P#/+_QX_P"- &%16[_9]K_SR_\ 'C_C1_9]
MK_SR_P#'C_C0!A45N_V?:_\ /+_QX_XT?V?:_P#/+_QX_P"- &%16[_9]K_S
MR_\ 'C_C1_9]K_SR_P#'C_C0!A45N_V?:_\ /+_QX_XT?V?:_P#/+_QX_P"-
M &%16[_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C0!A45N_V?:_\ /+_QX_XT?V?:
M_P#/+_QX_P"- &%16[_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C0!A45N_V?:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !13))HX5W2R)&I.,LP S3Z "BBB@ HHHH **** "BD9E12S$!0
M,DD\ 4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>?\ PL_YG7_L:[[_ -DKT"O/_A9_S.O_
M &-=]_[)0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >?_P#-PO\ W*G_ +=UZ!7G_P#S<+_W*G_MW7H% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH **** "BBB@ HHHH **** "O/_A9_P SK_V-=]_[)7H%>?\
MPL_YG7_L:[[_ -DH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_A&K/\ YZS_ /?0_P */^$:L_\ GK/_ -]#_"C_ %<QW9?>'U^B<M174_\
M"-6?_/6?_OH?X4?\(U9_\]9_^^A_A1_JYCNR^\/K]$Y:BNI_X1JS_P">L_\
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M,'QK??V;X*UFZ'WEM'5><?,PVC]2*^>/ /A ^,O$/V.25X;2%/-N)$QN"YP
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MGQ#^)Q,8D,-]=A5^7E(%P,D#IA!D^_?O7KGQFOA:^ )+?< UW<1Q8QR0#O\
M_9!_DU3W1G%V3:/)_AGX1A\6^)3'>ACI]K'YLZJ<;^<*F1R,GG([ ].M?0Z>
M'-#CL_LB:/8"VQCROLR;3]1CGJ?SKSKX$67EZ#JM\4(,]RL6[U"+G_V<UZQ4
MR>I5-*Q\KZYID>F?$:YTZP79''J 6!>NT%@5'?.,X_"OJBOF/PLJ^(_BU:S%
M=ZW&HO=D-QD M)S^72OIRG,5/JPHHHJ#4**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\_^%G_ #.O_8UWW_LE>@5Y_P#"S_F=?^QK
MOO\ V2@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \_\ ^;A?^Y4_]NZ] KS_ /YN%_[E3_V[KT"@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** //_A9_P SK_V-=]_[)7H%>?\ PL_Y
MG7_L:[[_ -DKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_\6_\E>^'7_<3
M_P#2=:] KS_Q;_R5[X=?]Q/_ -)UH ] HHHH \W^+'_,(_[;?^R5YM7I/Q8_
MYA'_ &V_]DKS:OH<#_N\?G^;/+Q/\5A7O_AW_D6=*_Z\X?\ T 5X!7O_ (=_
MY%G2O^O.'_T 5S9G\$37!_$S2HHHKQSO"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-\
M1?\ (LZK_P!><W_H!KP"O?\ Q%_R+.J_]><W_H!KP"O9RSX)>IP8SXD%>D_"
M?_F+_P#;'_V>O-J])^$__,7_ .V/_L]=&._W>7R_-&6&_BH\Y\9^&_$.N_$+
M4IH=&U)H9KH1).;239M&$#;L8VX'7IBOHR-%BC6-!A5 4#T IU%?/MW/2C&P
M4444BCYZ\9>'=?\ $7Q-NY%T74/LLUU' LWV9_+V *F[=C&WC.<XKZ!N+>*Z
MMI;>XC62&5"DB,,AE(P0?8BI**;=R5&USYK\5_#K7_"NJ/<:?!<W-B'W075L
M"6C'HP'*D>O0^O:E@\9_$?4$_LZVN]1F8_+MBM1YGK]X+N'0]Z^DZ*KF[D^S
M[,^7]8^'_BRS6VN+G3KV\N;H-)(((GG:/GC>P!&X\G'ICZ#W3X:Z5+H_@+3;
M:X@>"Y(>25)$*L&9R1D'D'&!^%=912<KCC!1=SA/BKX3OO%/AR$::OF7=I-Y
M@B+ >8I!! SWZ'J.A]J\<TN3X@>&U-EI]MK5HKMN\D6KD$GC(!4]<=17T]10
MI6T"4+NY7M(I%TZ"&Z8RRB)5E9\'><8)/;FO!?&7PRUGPYJK:IX=CN9[$-YL
M;6Y_?6S9Z8'S$#L1T'7&,GZ"HI)V'**9\W1_$?XA1H+47=P9   6LD+@8]TY
M^IYK6\(^ ?%VM^(X-;UFXOK 1N':YG<BY; 'RJ#R...> ,]>E>]T4^;L3R=V
M87C1KI?!>KK96TMQ<R6SQ)%"A9R7&W( YXSG\*\T^"_AK5=-UW4K[4=-N[-1
M;"%/M,+1[BS G&X#.-G/U%>T44KZ6*<;NYS'CKP?#XRT+[&9?)NH6\RWE/0-
MC&&]C_@>V#X;!'X[^'MU)';Q7UJA8EML?FP28[]"IX'7KBOIFBFI6%*%]3YM
MN-:^(GC>(6 2_N+=R$9(+?RXSD_QL !CC^(XXKUKX:>#=0\):1(NHWK/-<$.
M;5'S%#]/5O4CCCC/4]Q10Y7T!0L[LR_$FDG7?#>HZ6KB-[F!D1CT#?PY]LXS
M[5\Y0Z+XX\'ZE)):6&IVLP_=M+;Q,Z..N-P!5AQFOJ&BA2L$H7.5^'<NM7/A
M&"YUY[AKV:1VQ<)L95SA1C P.,_C75445+*2L@KF_'XNV\":O'8V\]Q<RP^4
ML5NA=V#,%. .3P3GVS7244#>IXG\&?#6J:=XCOK[4M,O+0+:^7&;FW:,$LP)
MQN YPO;UKVRBBFW<F,>56/*/C78:IJL.CVNFZ;>W@1I9)3;V[R!/NA<D ]?F
M_*NG^&&D3:-X#L8+JWDM[J1I)9HY%*L"6.,@\CY0M=A11?2P<NMPKY\\??#'
M5-)U:?4M#LWN--E<R!+9<O;DG.W:.=H[$=!UQW^@Z*$[!**D?,]GXU^(44*Z
M;;7FH.=H18_LHDDYX !*EL].],U;P+XQDLH]8U"ROKJZNI,>4$>:8#&=SXSM
M'0 'GKT[_3=%5S$^S[L\]^#NB76C>$K@WUI-:W5Q=LY2:)D<*%4#(/N&/XUY
MYXP\.Z_XA^)UW(=%U VDUW' )A;.(_+&U-V[& ,#.<X[U]"T4N;6XW"ZL%>:
M_&>UU34?#^GV&FZ==WF^Y,LGV:%I-H52 #M'?=^E>E44D[%-75C@OA%HMUHW
M@LK>VDMK<W%R\K),A1\<*,@\C[O?'7WKS;QK\/\ Q#X>\0RZOI*W=W:F0W$5
MQ!EI83G.&QSQ_>Z8_*OH:BGS:W)<$U8^;6\=?$/4[5M-2>]E+CRV\FS'FG/&
M,JN0?IS79_"OX;W^DZD-?UJ(V\\09;:V)^8%A@NV#QP2 /?/&!7K]%#EV!0U
MNV>>_&&WU"^\)06.G6%W>2RW2LRV\+2;54,<G ..<5'\&]"N]&\,WDE_9SVM
MU<71^2>,HVQ5 7@@'J6KT:BE?2P^7WKF'XO\/+XH\+WFDF3RI)5#1.>BNIRN
M?;(P?8U\Z16OB[P+J\DD,%[87*90R+%N1USZX*L,X]17U/134K"E"^I\[&V^
M(GCNUD_M)[\Z=%&TCEH/+5]H)PL:@>8V1@  \XZ5=^$WA76+7QS%>:AI5[:0
MVT$CA[FW>,%B-F 2.OS'CT!KWRBCF$J>MS@_BAX+O/%VCP/ITA^V6;,R0,^%
ME!QD<G ;C@GZ5X_IVO>.?!2/80"]M(@Y)@GMMR@\_=W*<9Z\<'K7TY10I6T&
MX7=T?-L/ASQM\1=:BN]1BN1&WRF[N(_+CC0'G:O&?HO4]>YKUOQAI#Z7\*KG
M1=(M;FY=88[>*.&-I';YUW' ![;C_D5V]%#D"A8\B^"OAS4-+FU>]U/3KJSD
M98XH?M$31EA\Q; 8#T6NL^(?@>/QEI""%UBU&UW-;NWW6SU1O8X'/8UV-%*^
MMQJ*M8^78?\ A-_ EW)#"NHZ>P.YE5=\3GCGNC=AGGTJTUO\0?'I$<J:C>0%
MMW[P>5 &QG/9,X/UY]Z^F**KG)]GYG$?#_X>6_@VW>XN)$N=4F4+)*H^6,?W
M4R,X]3WP.!7/_&JRU?5(-(L]-TR]O(U:264V\#R!3A0N=N<=6ZUZO14WUN4X
MJUCD/ACI,^C^ K"WNX)8+ES)++'*I5E)<XR#R/E"\5N^(I9X?#>IR6L$L]P+
M63RHHE+,S;3@ #GKZ5I447UN-*RL>%?"#PMJUEXQDO=2TJ\M(H+5]CW-NT8+
MD@8&X#G!:O=:**&[BC'E5@HHHI%!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7G_PL_YG7_L:[[_V2O0*\_\ A9_S.O\ V-=]_P"R
M4 >@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G
M_P#S<+_W*G_MW7H%>?\ _-PO_<J?^W=>@4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_D6=5_Z\YO\ T UX!7O_ (B_Y%G5?^O.;_T UX!7LY9\$O4X,9\2"O2?A/\
M\Q?_ +8_^SUYM7I/PG_YB_\ VQ_]GKHQW^[R^7YHRPW\5'I%%%%?/'J!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>?_"S_F=?^QKOO_9*] KS
M_P"%G_,Z_P#8UWW_ +)0!Z!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >?_ /-PO_<J?^W=>@5Y_P#\W"_]RI_[=UZ!0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_PL_YG7_L:[[_V
M2O0*\_\ A9_S.O\ V-=]_P"R5Z!0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>
M?^+?^2O?#K_N)_\ I.M>@5Y_XM_Y*]\.O^XG_P"DZT >@4444 >;_%C_ )A'
M_;;_ -DKS:O2?BQ_S"/^VW_LE>;5]#@?]WC\_P V>7B?XK"O?_#O_(LZ5_UY
MP_\ H KP"O?_  [_ ,BSI7_7G#_Z *YLS^")K@_B9I4445XYWA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!F^(O^19U7_KSF_P#0#7@%>_\ B+_D6=5_Z\YO_0#7@%>S
MEGP2]3@QGQ(*])^$_P#S%_\ MC_[/7FU>D_"?_F+_P#;'_V>NC'?[O+Y?FC+
M#?Q4>D4445\\>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_
M\+/^9U_[&N^_]DKT"O/_ (6?\SK_ -C7??\ LE 'H%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!Y_\ \W"_]RI_[=UZ!7G_ /S<
M+_W*G_MW7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_P#S
M<+_W*G_MW7H%>?\ _-PO_<J?^W=>@4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y_\+/^9U_[&N^_]DKT"O/_ (6?\SK_ -C7??\
MLE>@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7G_BW_DKWPZ_[B?_ *3K7H%>
M?^+?^2O?#K_N)_\ I.M 'H%%%% 'F_Q8_P"81_VV_P#9*\VKTGXL?\PC_MM_
M[)7FU?0X'_=X_/\ -GEXG^*PKW_P[_R+.E?]></_ * *\ KW_P ._P#(LZ5_
MUYP_^@"N;,_@B:X/XF:5%%%>.=X4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OB+_D6=
M5_Z\YO\ T UX!7O_ (B_Y%G5?^O.;_T UX!7LY9\$O4X,9\2"O2?A/\ \Q?_
M +8_^SUYM7I/PG_YB_\ VQ_]GKHQW^[R^7YHRPW\5'I%%%%?/'J!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %>?_"S_F=?^QKOO_9*] KS_P"%
MG_,Z_P#8UWW_ +)0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >?_ /-PO_<J?^W=>@5Y_P#\W"_]RI_[=UZ!0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_PL_YG7_L:[[_V2O0*
M\_\ A9_S.O\ V-=]_P"R5Z!0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?^+?
M^2O?#K_N)_\ I.M>@5Y_XM_Y*]\.O^XG_P"DZT >@4444 >;_%C_ )A'_;;_
M -DKS:O2?BQ_S"/^VW_LE>;5]#@?]WC\_P V>7B?XK"O?_#O_(LZ5_UYP_\
MH KP"O?_  [_ ,BSI7_7G#_Z *YLS^")K@_B9I4445XYWA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!F^(O^19U7_KSF_P#0#7@%>_\ B+_D6=5_Z\YO_0#7@%>SEGP2
M]3@QGQ(*])^$_P#S%_\ MC_[/7FU>D_"?_F+_P#;'_V>NC'?[O+Y?FC+#?Q4
M>D4445\\>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_\+/^
M9U_[&N^_]DKT"O/_ (6?\SK_ -C7??\ LE 'H%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y_\ \W"_]RI_[=UZ!7G_ /S<+_W*
MG_MW7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M?_"S_F=?^QKOO_9*] KS_P"%G_,Z_P#8UWW_ +)7H% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5Y_XM_Y*]\.O^XG_P"DZUZ!7G_BW_DKWPZ_[B?_ *3K0!Z!
M1110!YO\6/\ F$?]MO\ V2O-J])^+'_,(_[;?^R5YM7T.!_W>/S_ #9Y>)_B
ML*]_\._\BSI7_7G#_P"@"O *]_\ #O\ R+.E?]></_H KFS/X(FN#^)FE111
M7CG>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &;XB_Y%G5?^O.;_ - -> 5[_P"(O^19
MU7_KSF_] -> 5[.6?!+U.#&?$@KTGX3_ /,7_P"V/_L]>;5Z3\)_^8O_ -L?
M_9ZZ,=_N\OE^:,L-_%1Z11117SQZ@4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7G_PL_YG7_L:[[_V2O0*\_\ A9_S.O\ V-=]_P"R4 >@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_P#S<+_W
M*G_MW7H%>?\ _-PO_<J?^W=>@4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!Y_\+/^9U_[&N^_]DKT"O/_ (6?\SK_ -C7??\ LE>@
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7G_BW_DKWPZ_[B?_ *3K7H%>?^+?
M^2O?#K_N)_\ I.M 'H%%%% 'F_Q8_P"81_VV_P#9*\VKTGXL?\PC_MM_[)7F
MU?0X'_=X_/\ -GEXG^*PKW_P[_R+.E?]></_ * *\ KW_P ._P#(LZ5_UYP_
M^@"N;,_@B:X/XF:5%%%>.=X4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OB+_D6=5_Z\
MYO\ T UX!7O_ (B_Y%G5?^O.;_T UX!7LY9\$O4X,9\2"O2?A/\ \Q?_ +8_
M^SUYM7I/PG_YB_\ VQ_]GKHQW^[R^7YHRPW\5'I%%%%?/'J!1110 44$X&3T
MJ""Y6XDD5/NICGUZT 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 445!/<K;R1J_W7SSZ=* )Z* <
MC(Z44 %%%% !7G_PL_YG7_L:[[_V2O0*\_\ A9_S.O\ V-=]_P"R4 >@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_P#S<+_W
M*G_MW7H%>?\ _-PO_<J?^W=>@4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!Y_\+/^9U_[&N^_]DKT"O/_ (6?\SK_ -C7??\ LE>@
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7G_BW_DKWPZ_[B?_ *3K7H%>?^+?
M^2O?#K_N)_\ I.M 'H%%%% 'F_Q8_P"81_VV_P#9*\VKTGXL?\PC_MM_[)7F
MU?0X'_=X_/\ -GEXG^*PKW_P[_R+.E?]></_ * *\ KW_P ._P#(LZ5_UYP_
M^@"N;,_@B:X/XF:5%%%>.=X4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %9FK_ /+'_@7]*TZS-7_Y8_\  OZ4 16-]Y1$4I_=]C_=
MK8!R,CI7,U>L;[RB(I3^[['^[0!L44 Y&1THH *\_P#A9_S.O_8UWW_LE>@5
MY_\ "S_F=?\ L:[[_P!DH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** //_P#FX7_N5/\ V[KT"O/_ /FX7_N5/_;NO0* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_P#A9_S.O_8U
MWW_LE>@5Y_\ "S_F=?\ L:[[_P!DKT"@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\_P#%O_)7OAU_W$__ $G6O0*\_P#%O_)7OAU_W$__ $G6@#T"BBB@#S?X
ML?\ ,(_[;?\ LE>;5Z3\6/\ F$?]MO\ V2O-J^AP/^[Q^?YL\O$_Q6%>_P#A
MW_D6=*_Z\X?_ $ 5X!7O_AW_ )%G2O\ KSA_] %<V9_!$UP?Q,TJ***\<[PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH S?$7_(LZK_UYS?\ H!KP"O?_ !%_R+.J_P#7
MG-_Z :\ KV<L^"7J<&,^)!7I/PG_ .8O_P!L?_9Z\VKTGX3_ /,7_P"V/_L]
M=&._W>7R_-&6&_BH](H)P,GI03@9/2L>^OO-)BB/[ON?[U?/'J!?7WFDQ1']
MWW/]ZJ-%% !5NRNUM=^Y2V['2JE% &K_ &LG_/)OSH_M9/\ GDWYUE5R>O\
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MZ/[63_GDWYUE44 :O]K)_P \F_.C^UD_YY-^=95% &K_ &LG_/)OSH_M9/\
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M\F_.LJB@#5_M9/\ GDWYT?VLG_/)OSK*HH U?[63_GDWYT?VLG_/)OSK*HH
MU?[63_GDWYT?VLG_ #R;\ZRJ* -7^UD_YY-^=']K)_SR;\ZRJ* -7^UD_P">
M3?G1_:R?\\F_.LJB@#5_M9/^>3?G1_:R?\\F_.LJB@#5_M9/^>3?G1_:R?\
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M\F_.LJB@#5_M9/\ GDWYT?VLG_/)OSK*HH U?[63_GDWYT?VLG_/)OSK*HH
MU?[63_GDWYT?VLG_ #R;\ZRJ* -7^UD_YY-^=']K)_SR;\ZRJ* -7^UD_P">
M3?G1_:R?\\F_.LJB@#5_M9/^>3?G1_:R?\\F_.LJB@#5_M9/^>3?G1_:R?\
M/)OSK*HH U?[63_GDWYT?VLG_/)OSK*HH U?[63_ )Y-^=']K)_SR;\ZRJ*
M-7^UD_YY-^=']K)_SR;\ZRJ* -7^UD_YY-^=5;V[6ZV;5*[<]:J44 %%%% %
MZQOO*(BE/[OL?[M; .1D=*YFKUC?>41%*?W?8_W: -BO/_A9_P SK_V-=]_[
M)7H .1D=*\_^%G_,Z_\ 8UWW_LE 'H%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Y__ ,W"_P#<J?\ MW7H%>?_ /-PO_<J?^W=
M>@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_P#"
MS_F=?^QKOO\ V2O0*\_^%G_,Z_\ 8UWW_LE>@4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7G_ (M_Y*]\.O\ N)_^DZUZ!7G_ (M_Y*]\.O\ N)_^DZT >@44
M44 >;_%C_F$?]MO_ &2O-J])^+'_ #"/^VW_ +)7FU?0X'_=X_/\V>7B?XK"
MO?\ P[_R+.E?]></_H KP"O?_#O_ "+.E?\ 7G#_ .@"N;,_@B:X/XF:5%%%
M>.=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 9OB+_D6=5_Z\YO_ $ UX!7O_B+_ )%G
M5?\ KSF_] -> 5[.6?!+U.#&?$@KTCX4' U<GI^Y_P#9Z\WKN/AY(ZQZFBG"
MMY6??&^NC'?[O+Y?FC+#?Q4>@WU]YI,41_=]S_>JC117SQZ@4444 %%%% !7
MF=ZBR?'&R5U#*8#D$9'^I>O3*\SO76/XXV3.P51 <DG _P!2]5$F70]&^QVO
M_/M#_P!\"N#^(GA2Q&COK>GPI:7MF0Y:!=F\9')Q_$,Y!_\ K8[S[9:_\_,/
M_?8K@_B)XKLSI$FAZ?,+J^NRJ,L/S[%R#CCN>@ ]?I1&]PE:QOZ5JKZWX!74
M)?\ 6RV<@D.,9=058_B0361\)O\ D3W_ .OM_P"2UKZ5I,FA^ 1ITN/-BM)-
M^#D!FW,>?J361\)O^1/?_K[?^2T=&+JCN20JEF(  R2>U8EQXQ\.VTS0RZQ:
M!UX(5]V#]17(>(;[4?&?BF3POIDS6^GVQ(O9EYW$'D''8= O<YSTXW[/X;^&
M+6#RVL&N&(P9)I6+'\B /P HLEN.[>QTL%]:75L;FWNH)8!DF6.0,HQR>1Q3
M;;4+*\MFN;6\MYX%R&EBE#*,<G)!Q7G?B'PK+X/@GUKPY+(MML*7=G(Y92C9
M&0>IQGODCKZUH?"R))_!,\4@W(]S(K#.,@JH-%M+@I.]C.^*&O65WH5K#INK
M6\Q:?]ZEM<!LKM/W@IZ?6N[3Q'H4LBQQZUISNQ"JJW2$DGH ,UYA\1?"&D>'
MM+M+C3H9(Y))]C;I"P(VD]_I7;6_PX\-6MS%<16DHDB<.I,['D'([TW:Q*YK
MLZRL_4==TK2<"_U"WMV/17<;C^'6L3Q]XDE\/Z*J6>?[0O&\J# R5Z;FQW/(
M ]R*S=#^&>GBW%UX@\V_U&;#R^9*V$8\D9!RQ]22<U*75E-N]D=3I_B31=5F
M\FQU.VFE[1JXW'OP#R:U*XG6OAGHUY;%]+C.GWJ?-%)&[;2W;<#G ]Q@CWZ5
M)\/_ !%=:M8W.FZH6_M/3W\N7?\ >9>0"?4@@@_AZT6ZH$W>S,RP_P"2X:I_
MUZK_ .BXZ]%KSJP_Y+AJG_7JO_HN.M/X@>(KK2;&VTW2RW]IZ@_EQ;/O*O )
M'H22 /Q]*;5V).R;.@U'Q!I&DL$O]1MH'S]QG&[UZ=:-.\0Z/JTABL-1MYY
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M8:1=^(/'7B'28[A[>REO)9+MTZE5D;"^G)8<'TSVKU'0O"VD>'/,.FV[1O*
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MR/&I'3_A*K[_ -DK:KF/A+<,DGBV':2K>);P\=C\E 'IM%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!Y_P#\W"_]RI_[=UZ!7G__
M #<+_P!RI_[=UZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'G_PL_P"9U_[&N^_]DKT"O/\ X6?\SK_V-=]_[)7H% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Y_XM_Y*]\.O^XG_ .DZUZ!7G_BW_DKWPZ_[B?\
MZ3K0!Z!1110!YO\ %C_F$?\ ;;_V2O-J])^+'_,(_P"VW_LE>;5]#@?]WC\_
MS9Y>)_BL*]_\._\ (LZ5_P!></\ Z *\ KW_ ,._\BSI7_7G#_Z *YLS^")K
M@_B9I4445XYWA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[YX)4XS@,^<?B1^8KTBO/O%.@ZMI'B >*O#:&69@%N[55),@X'"CJ#@9'4$
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MW%K>1WLK+$R*BE0Y('!W=,GOS7>4FK%)I[!7F/@F9?#?C?6/#D^46>3=;9&
M<9(_-2/RKTZN2\:>#%\1QQ7EE*+;5+?F.7IO'4 D<C!Z'MS0NPI)[HZVBO,K
M3X@:SX>"V?BO1KC*':+F-0"W_LK'KR"*NS_%S1!%FVLK^:8_=1D51GT)W']
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M3V6O:XI@FNIQ'#:8QY48Y&<]"2>G7K]*<5KJ*4DUH>N^)_\ D4]9_P"O&?\
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MF3JWACX@ZY9?9-1U"QG@W!]OR+R.AR$![UTWB&VFL_A?/:W!4SPV$<<A7IN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Y__P W"_\ <J?^W=>@5Y__
M ,W"_P#<J?\ MW7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >?_  L_YG7_ +&N^_\ 9*] KS_X6?\ ,Z_]C7??^R5Z!0 4444
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M-^5'EO\ W&_*NDHH YORW_N-^5'EO_<;\JZ2B@#F_+?^XWY4>6_]QORKI**
M.;\M_P"XWY5!+IEO/)YDUE%(_3<\0)_,BNKHH YH0LJA5C( &  O2E\M_P"X
MWY5TE% '-^6_]QORIGV4>;YOD#S/[^SG\ZZ>B@#F_+?^XWY4R:T6X39-;B1,
MYVNF1^M=/10!RL-A%;9\BT2+/79&%_E4WEO_ '&_*NDHH YORW_N-^5'EO\
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MRH\M_P"XWY5TE% '-^6_]QORH\M_[C?E7244 <WY;_W&_*H9M/AN6#3V<<I
MP#)$&Q^8KJJ* .9CM_*C$<<.Q%X"JN /PIWEO_<;\JZ2B@#FC"S*5:,D$8(*
M]:@CTNVA</%80HPZ,L(!_E7644 <WY;_ -QORH\M_P"XWY5TE% '-^6_]QOR
MH\M_[C?E7244 <WY;_W&_*CRW_N-^5=)10!S?EO_ '&_*CRW_N-^5=)10!S?
MEO\ W&_*J[:7;/*97L(6D)R6,()SZYQ7644 <T(650JQD #  7I2^6_]QORK
MI** .9DM_-C,<D.]&X*LN0?PJ.'3X;9BT%G'$2,$QQ!<_D*ZJB@#F_+?^XWY
M4>6_]QORKI** .4FTZ"Y<//9QRL!@,\08X].14R0&-0J1%5'0!<"NEHH YOR
MW_N-^503:=!<N'GLXY6 P&>(,<>G(KJZ* .:2 QJ%2(JHZ +@4OEO_<;\JZ2
MB@#F_+?^XWY4>6_]QORKI** .;\M_P"XWY57;2[9Y3*]A"TA.2QA!.?7.*ZR
MB@#FA"RJ%6,@ 8 "]*7RW_N-^5=)10!S?EO_ '&_*CRW_N-^5=)10!S?EO\
MW&_*CRW_ +C?E7244 <WY;_W&_*CRW_N-^5=)10!R<FEVTSEY;"%V/5FA!/\
MJG$+*H58R !@ +TKI:* .;\M_P"XWY4>6_\ <;\JZ2B@#F_+?^XWY4>6_P#<
M;\JZ2B@#F_+?^XWY4S[*/-\WR!YG]_9S^==/10!S?EO_ '&_*D*LOWE(^HKI
M:S-7_P"6/_ OZ4 9E%%/CC>60(@RQH (XWED"(,L:W+6U2VCP.7/WFHM;5+:
M/ Y<_>:IZ "O/_A9_P SK_V-=]_[)7H%>?\ PL_YG7_L:[[_ -DH ] HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //_ /FX7_N5
M/_;NO0*\_P#^;A?^Y4_]NZ] H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#S_X6?\ ,Z_]C7??^R5Z!7F_PW_U/C3_ +&R^_\ 9*[.
MKC&Z,Y5.5V-6BLJBG[,GVOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD
M:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:
M^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP
M]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>
MS#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K1651
M1[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M>?
M^+?^2O?#K_N)_P#I.M=77%>*)!%\1_!4C D*NH,<#)XA':CV8>U\CTJBN6_X
M6'X<_P"?N3_OR_\ A1_PL/PY_P _<G_?E_\ "J^KUOY7]Q7M8=T8'Q8_YA'_
M &V_]DKS:NX\=^(=-U[[!_9\S2>3YF_<A7&=N.OT-<=7N8.+C1BI*SU_,\S$
M33JNQ!7O_AW_ )%G2O\ KSA_] %>#UZ5IGB_1K;2;.WEN'$D4"(P\IC@A0#V
MK''TY5(I116&K*+=ST"BN)_X3;0O^?E_^_3?X5;T[Q)INJW7V>SE>23:6(\L
M@ #OD_A7EO#5$KM/[CM6)B]$=716516?LRO:^1JT5E44>S#VOD:M%95%'LP]
MKY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S
M#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511
M[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K17%ZQXMLM$O?LMU;798J'5HT4JP/
MIEA5#_A8ND?\^U]_WPG_ ,56T<)4DKI$O$16C.Q\1?\ (LZK_P!><W_H!KP"
MO1-2\>Z7>:7=VL=O>!YH7C4LBX!*D#/S>]>=UZ>!I2IQ:DCDQ%13::"O2?A/
M_P Q?_MC_P"SUYM73^$/$=GH'VS[5'._G[-OE*#C;NSG)'J*VQ<'.BXQW_X)
M%&2C--GM5%>>?\+%TC_GVOO^^$_^*H7XAZ2S!5M;\L3@ 1IDG_OJO'^IU>QV
M_68GH=075JES'@\./NM6?&_F1J^UEW ':PP1[&G5A[,OVOD49(WBD*.,,*T-
M(_Y;?\!_K5>XMUG3!X8=#4%@C1O,K#!&/ZT>S#VOD=%16511[,/:^1JT5E44
M>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K165
M11[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%
M95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1J
MT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY
M&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#V
MOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,
M/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'
MLP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E4
M4>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16
M511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K69J__ "Q_X%_2FU2OT:1X549)
MS_2CV8>U\A(XWED"(,L:W+6U2VCP.7/WFK+M[=8$P.6/4U-1[,/:^1JT5E44
M>S#VOD:M>?\ PL_YG7_L:[[_ -DKJZXSX>?\S5_V,5W_ .R4>S#VOD>D45E4
M4>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16
M511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M
M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1
MJT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]K
MY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#
MVOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[
M,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%
M'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E
M44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K1
M6511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:
MM%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^
M1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]
MKY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S
M#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511
M[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95
M%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5
ME44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K
M16511[,/:^1JT5E44>S#VOD:M%95%'LP]KY&K16511[,/:^1JT5E44>S#VOD
M:M%95%'LP]KY'*?\W"_]RI_[=UZ!7G=K_P EX7_L66_]*EKT2H:L[&L7=7"B
MBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-_AO\ ZGQI
M_P!C9??^R5V=<9\-_P#4^-/^QLOO_9*[.M8;'/4^(****LS"BBB@ HHHH **
M** "BBB@ HHHH *ANKNVLH&GN[B*WA7K)*X11^)J:O&]3AN?B+\3+G1Y9Y8=
M+TXNK+&>@0[6//&YF.,XX&.N*!G;2_$[PC%,(SJV[KED@D91^(7G\,UT6G:K
MI^KVYN-.O(;J('!:)PVT^A]#]:P(OAMX2BMO)_LA'&,%WE<L??.>#],5P_B/
MPA?>!-2MM>\+RSM;^8$>WSN8$GA<?Q*>GJ#^@!['14%G.]U8V]Q) \#RQJ[0
MR?>C)&2I]QTJ>@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5S
M=065M)<W,R0P1C<\CM@*/<U#IVJ6.KV@NM/NH[F DKOC.1D=0?0U#KNC6_B#
M1;G2[IG6&< %D."""&!'X@52\)^%;3PEI;V=M-),9)#))))P2<8& .@P* -Z
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC/$G_)
M2_!'_;__ .B179UQGB3_ )*7X(_[?_\ T2* .:\;Z'_8OB"3RUQ;7.98L=!G
MJOX']"*YNO;?&^A_VUX?D\M<W-MF6+'4XZK^(_4"O$J]G!UO:TM=T<^(I\D_
M)CX^]25''WJ2NHY);A11102%>F^!])^PZ3]LD7$UUAAGLG\/Y]?Q%<+X?THZ
MQK$-K@^5G?*1V0=?SZ?C7L*J%4*H 4#  Z"O/QU6R5-'5AH:\S%HHHKS#K"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH YCQQH_]HZ*;B-<SVF7&.I7^(?U_"O*J]\(!!!&0>H->-^)M
M(.C:W- HQ"_[R$_[)[?AR/PKT\#5NG39SUH_:,>BBBO1, HHHH *Z?P3H_\
M:6L"XE3-O;?,<CAF[#IBN952S!5!+$X  Y)KV/PSI T?18H2H$SC?*<<Y/;H
M#Q[URXNKR4[+=FM*-Y&Q1117BG4%'?-%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!,A21#T93P17D7PJLCIOCO7+!F#&VBDA+#OME S^E 'L=%%% @HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^(6J/I/@C49HR1+*@@0@X(+G:3^ )-5_AGI;:9X&LMX DNLW+8'9ON_7Y0M
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M?JS4 =_1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .0M?^2\+_V++?\ I4M>
MB5YW:_\ )>%_[%EO_2I:]$K&>YTT_A"BBBI+"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML.D_;)%Q-=889[)_#^?7\17"^']*.L:Q#:X/E9WRD=D'7\^GXU["JA5"J %
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'F_PW_U/C3_L;+[_ -DKLZY#
MX8Q>:GC1<X_XJN^/3_<KNOL7_33]*TC))&,X-NZ*E%6_L7_33]*/L7_33]*K
MG1'LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?\ 33]*/L7_ $T_2CG0>SD5
M**M_8O\ II^E'V+_ *:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_
MZ:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z
M:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/9R
M*E%6_L7_ $T_2C[%_P!-/THYT'LY%2BK?V+_ *:?I1]B_P"FGZ4<Z#V<BI15
MO[%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C
M[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG
M0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_P!-/TH^Q?\ 33]*.=![.14H
MJW]B_P"FGZ4?8O\ II^E'.@]G(\P\;V7BC3-?M_$FB3SW<$0VR6/+*@QR0O<
M$#DCD'](+7XT:.T6+[3+^"8$Y2/;(H_$E3G\*]6^Q?\ 33]*JSZ#8W3[[BVM
MY7X^:2%6/'3K1S(/9R['DNJ_$K4?$L#Z7X4TF[,TP*/,Z@LBGT R%R,\D\?K
M78>!/"*^$M$:&5DDO;AA)<2*. <<*#W Y_$FNPATN&VC\N 1Q)G.U(PH_(5)
M]B_Z:?I1S(/9R[%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?]-/TH^Q?]-/TH
MYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?\ 33]*/L7_ $T_2CG0>SD5
M**M_8O\ II^E'V+_ *:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14KC/$G_
M "4OP1_V_P#_ *)%=]]B_P"FGZ5POBF+R_BKX!AW9\W^T><=,0*:.=![.1Z)
M1116)TE6]_@_&O'/%FD_V5K4FQ<6\_[R/T'J/P/Z8KVB:'SMOS8Q[5C:WX7@
MUNWABFEV^7*'#!><9^8?B/Z5V83$*E+78Y,11E4V,#P/I/V'2?MDBXFNL,,]
MD_A_/K^(KJ*M+8A5"JX"@8 "\"E^Q?\ 33]*BI64Y.3"-%Q5DBI15O[%_P!-
M/TH^Q?\ 33]*CG17LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?]-/TH^Q?]
M-/THYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?\ 33]*/L7_ $T_2CG0
M>SD5**M_8O\ II^E'V+_ *:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJ
MW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:?I1
M]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1S
MH/9R*E%6_L7_ $T_2C[%_P!-/THYT'LY%2BK?V+_ *:?I1]B_P"FGZ4<Z#V<
MBI15O[%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_T
MT_2C[%_TT_2CG0>SD5*YCQQH_P#:.BFXC7,]IEQCJ5_B']?PKLOL7_33]*0V
M(((+Y!Z@K5TZRA)2704J4FK6/(/!.C_VEK N)4S;VWS'(X9NPZ8KU6HM)\-V
MNC6[PVK85Y"Y)49YZ#/H.E:'V+_II^E:8C$*K.ZV)IT915BI15O[%_TT_2C[
M%_TT_2L.=%^SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG
M0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_P!-/TH^Q?\ 33]*.=![.14H
MJW]B_P"FGZ4?8O\ II^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_I
MI^E'V+_II^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_II^E'V+_II
M^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J
M45;^Q?\ 33]*/L7_ $T_2CG0>SD5**M_8O\ II^E'V+_ *:?I1SH/9R*E%6_
ML7_33]*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L
M7_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=!
M[.14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_ $T_2C[%_P!-/THYT'LY%2BK
M?V+_ *:?I1]B_P"FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>SD5**M_8O^FG
MZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ
M4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI1
M5O[%_P!-/TH^Q?\ 33]*.=![.14HJW]B_P"FGZ4?8O\ II^E'.@]G(J45;^Q
M?]-/TH^Q?]-/THYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?]-/TH^Q?
M]-/THYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'L
MY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?\ 33]*/L7_ $T_2CG0>SD5**M_
M8O\ II^E'V+_ *:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:?I
M1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1
MSH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6
M_L7_ $T_2C[%_P!-/THYT'LY%2BK?V+_ *:?I1]B_P"FGZ4<Z#V<BI15O[%_
MTT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[%_T
MT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>SD
M5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_P!-/TH^Q?\ 33]*.=![.14HJW]B
M_P"FGZ4?8O\ II^E'.@]G(J5QGP\_P"9J_[&*[_]DKOOL7_33]*X7X:1?:/^
M$P^;;Y?B:]CZ9SC9S1SH/9R.OHJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]
M*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_ $T_2C[%_P!-
M/THYT'LY%2BK?V+_ *:?I1]B_P"FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>
MSD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>SD5**M_8O
M^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^
MFGZ4<Z#V<BI15O[%_P!-/TH^Q?\ 33]*.=![.14HJW]B_P"FGZ4?8O\ II^E
M'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J45
M;^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?]-/TH
M^Q?]-/THYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?\ 33]*/L7_ $T_
M2CG0>SD5**M_8O\ II^E'V+_ *:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.
M14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z
M:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z:
M?I1SH/9R*E%6_L7_ $T_2C[%_P!-/THYT'LY%2BK?V+_ *:?I1]B_P"FGZ4<
MZ#V<BI15O[%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O
M[%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[
M%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_P!-/TH^Q?\ 33]*
M.=![.14HJW]B_P"FGZ4?8O\ II^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%
M2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_II
M^E'V+_II^E'.@]G(J5YKXF^(.I'4+WP]X?TFXDU)',7GK\^W_:"@?J>!UKU7
M[%_TT_2C[%_TT_2CG0>SEV.%^'_A!O"VDNUV0^I79#SD'.WT4'OC)R?4UU]6
M_L7_ $T_2C[%_P!-/THYT'LY%2BK?V+_ *:?I1]B_P"FGZ4<Z#V<BI15O[%_
MTT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[%_T
MT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>SD
M5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_P!-/TH^Q?\ 33]*.=![.14HJW]B
M_P"FGZ4?8O\ II^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_II^E'
MV+_II^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_II^E'V+_II^E'.
M@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2N6^(W_)/]6_ZYK_Z&M=I]B_Z:?I1]
MB_Z:?I1SH/9R.&^&'_).]*_[;?\ HUZZZK?V+_II^E'V+_II^E'.@]G(J45;
M^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?\ 33]*
M/L7_ $T_2CG0>SD5**M_8O\ II^E'V+_ *:?I1SH/9R*E%6_L7_33]*/L7_3
M3]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.1
M4HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:
M?I1]B_Z:?I1SH/9R*E%6_L7_ $T_2C[%_P!-/THYT'LY%2BK?V+_ *:?I1]B
M_P"FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z
M#V<BI15O[%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[
M%_TT_2C[%_TT_2CG0>SD5**M_8O^FGZ4?8O^FGZ4<Z#V<BI15O[%_P!-/TH^
MQ?\ 33]*.=![.14HJW]B_P"FGZ4?8O\ II^E'.@]G(J45;^Q?]-/TH^Q?]-/
MTHYT'LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2
MBK?V+_II^E'V+_II^E'.@]G(J45;^Q?]-/TH^Q?]-/THYT'LY%2BK?V+_II^
ME'V+_II^E'.@]G(J45;^Q?\ 33]*/L7_ $T_2CG0>SD5**M_8O\ II^E'V+_
M *:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/
M9R.%M?\ DO"_]BRW_I4M>B5Y[$GE?'\1YSCPN6S];H?X5Z%6<G=F\$U&S"BB
MBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_X6?\ ,Z_]
MC7??^R5Z!7G_ ,+/^9U_[&N^_P#9*] H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ&M:DND:-=W[ -Y
M,995)P"W0#\R*<4Y.R$W979?HJAHBWJZ+:?VB[/>&,-*6 !!/.#@ <=/P[]:
MOT25FT"=U<****0PHKG/$\]S/<:;H]C*T<UY,&E=&(9(D^9CD<CMW&>G>NCJ
MW"T4^Y*E=M!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5Y_P"+?^2O?#K_ +B?_I.M>@5Y_P"+?^2O?#K_ +B?_I.M 'H%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_ ,+/^9U_[&N^
M_P#9*] KS_X6?\SK_P!C7??^R4 >@4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4-W=0V-G-=7#A(84+NWH!4U<QXHVZK>V'AQ6
M_P"/E_/N<-C$*<X^K$8'TJZ<>:5GL3.5E<Z2&9+B".:,DQR*'4E2#@C(X/(_
M&GTBJJ*%50J@8  P *6H*"BBB@"AK&KV^BV0N;A7?=(L21IC<[,>@R0.F3U[
M5?KEYFCUWQK%;<-;:.OG/QG=.WW1GV S]?I745I.*BDNO]6(B[M]@HHHK,L*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** //\ _FX7_N5/_;NO0*\__P";A?\
MN5/_ &[KT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* //_A9_S.O_ &-=]_[)7H%>?_"S_F=?^QKOO_9*] H **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Y_\ \W"_]RI_[=UZ!7G_ /S<+_W*G_MW7H% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M $$__($?_P 31_PGWB;_ *"?_D"/_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\
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M !-'_"?>)O\ H)_^0(__ (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\
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M *"?_D"/_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\ 03_\@1__ !-'_"?>)O\
MH)_^0(__ (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@
MG_Y C_\ B:YNBCZO2_E7W(/:S[LZ3_A/O$W_ $$__($?_P 31_PGWB;_ *"?
M_D"/_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\ 03_\@1__ !-'_"?>)O\ H)_^
M0(__ (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@G_Y
MC_\ B:YNBCZO2_E7W(/:S[LZ3_A/O$W_ $$__($?_P 31_PGWB;_ *"?_D"/
M_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\ 03_\@1__ !-'_"?>)O\ H)_^0(__
M (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@G_Y C_\
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M $$__($?_P 31_PGWB;_ *"?_D"/_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\
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M !-'_"?>)O\ H)_^0(__ (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\
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M *"?_D"/_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\ 03_\@1__ !-'_"?>)O\
MH)_^0(__ (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@
MG_Y C_\ B:YNBCZO2_E7W(/:S[LZ3_A/O$W_ $$__($?_P 31_PGWB;_ *"?
M_D"/_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\ 03_\@1__ !-'_"?>)O\ H)_^
M0(__ (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@G_Y
MC_\ B:YNBCZO2_E7W(/:S[LZ3_A/O$W_ $$__($?_P 31_PGWB;_ *"?_D"/
M_P")KFZ*/J]+^5?<@]K/NSI/^$^\3?\ 03_\@1__ !-'_"?>)O\ H)_^0(__
M (FN;HH^KTOY5]R#VL^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@G_Y C_\
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M'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\
M$US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=
M%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>
ME_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*O
MN0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>U
MGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9T
MG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?
M>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^
M@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y
M C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^
M)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X
M3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-
M_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!
M/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!
M'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\
M$US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=
M%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>
ME_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*O
MN0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>U
MGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9T
MG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?
M>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^
M@G_Y C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y
M C_^)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^
M)H_X3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X
M3[Q-_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-
M_P!!/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!
M/_R!'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!
M'_\ $US=%'U>E_*ON0>UGW9TG_"?>)O^@G_Y C_^)H_X3[Q-_P!!/_R!'_\
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M_P#R!'_\37-T4?5Z7\J^Y![6?=G2?\)]XF_Z"?\ Y C_ /B:/^$^\3?]!/\
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M_P#D"/\ ^)H_X3[Q-_T$_P#R!'_\37-T4?5Z7\J^Y![6?=G2?\)]XF_Z"?\
MY C_ /B:/^$^\3?]!/\ \@1__$US=%'U>E_*ON0>UGW9TG_"?>)O^@G_ .0(
M_P#XFC_A/O$W_03_ /($?_Q-<W11]7I?RK[D'M9]V=)_PGWB;_H)_P#D"/\
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M -@%O_2A*]VKP,2E&M)(].BVX)L****P- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ^95_Y&;Q9_P!AZ\_]#JS59?\ D9O%G_8>O/\ T.K-
M?1X3^#'T/)K_ ,1A111729!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %*JL[!54LQ.  ,DFDKKOAWI U'Q"+J10T-D!(0?
M[YSM[>HS^%9U:BIP<WT+A%RDHH]+\,:,NA:#;V>!YV-\Q'=SU_+@?0"MBBBO
MF92<I.3W9ZZ22L@HHJ"\NX;"RFN[AML4*%W/L/ZTDKNR&>??$75P;Z*R1U9+
M1?,=<9_?,"$!^BY;I[=Z\VJYJ=W->7TTT[$O)(TK MG!;G'X# Q[53KZ3#TO
M94U$\BK/GDV%%%%;F84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6'J?_(TZ#_V\?\ H K<K#U/_D:=!_[>/_0!6-;X5ZK\
MT:4]_D_R-RBBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P_#
M?_,7_P"PE-_2MRL/PW_S%_\ L)3?TK&?\2/S-(_"S<HHHK8S"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"WI>G3:MJEO80
M?ZR9PH./NCN?H!D_A7O]G:0V%E#:6Z[8H4"(/8?UKS[X7Z1_Q\ZO(O\ TPBR
MOT+$?H.GK[UZ17AYA6YZG(ME^9Z.%I\L>9]0HHHKSSJ"O(_B-K1O=<^P1L?)
MLUVGJ,N?O'\L#\_6O3=:U)=(T:[OV ;R8RRJ3@%N@'YD5X!--)<3R3S.7ED8
MN['J23DFO3RZC>3J/H<F+G9<J&4445[)YX4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!M_"[_DK]S_ -@%O_2A*]VKPGX7?\E?N?\ L M_Z4)7
MNU?-XO\ C2/6H?PT%%%%<YJ%%%% !1110 4444 %%%% !1110 4444 %%%%
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M9_Y'D_\ BJ]6AB:>&AR23ONSBJTIU9<RV/$J*]M_X0'PS_T#/_(\G_Q5'_"
M^&?^@9_Y'D_^*K;^TJ79_A_F9_5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\
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M@/AG_H&?^1Y/_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\
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MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
MD>3_ .*H_M*EV?X?YA]4GW1XE17MO_" ^&?^@9_Y'D_^*H_X0'PS_P! S_R/
M)_\ %4?VE2[/\/\ ,/JD^Z/$J*]M_P"$!\,_] S_ ,CR?_%4?\(#X9_Z!G_D
M>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\
M(\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\51_P@/AG_H&?^1Y/
M_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\ A ?#/_0,_P#(
M\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_ !5'_" ^&?\ H&?^
M1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_^*H_X0'PS_T#/_(\
MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
MD>3_ .*H_M*EV?X?YA]4GW1XE17MO_" ^&?^@9_Y'D_^*H_X0'PS_P! S_R/
M)_\ %4?VE2[/\/\ ,/JD^Z/$J*]M_P"$!\,_] S_ ,CR?_%4?\(#X9_Z!G_D
M>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\
M(\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\51_P@/AG_H&?^1Y/
M_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\ A ?#/_0,_P#(
M\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_ !5'_" ^&?\ H&?^
M1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_^*H_X0'PS_T#/_(\
MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
MD>3_ .*H_M*EV?X?YA]4GW1XE17MO_" ^&?^@9_Y'D_^*H_X0'PS_P! S_R/
M)_\ %4?VE2[/\/\ ,/JD^Z/$J*]M_P"$!\,_] S_ ,CR?_%4?\(#X9_Z!G_D
M>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\
M(\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\51_P@/AG_H&?^1Y/
M_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\ A ?#/_0,_P#(
M\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_ !5'_" ^&?\ H&?^
M1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_^*H_X0'PS_T#/_(\
MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
MD>3_ .*H_M*EV?X?YA]4GW1XE17MO_" ^&?^@9_Y'D_^*H_X0'PS_P! S_R/
M)_\ %4?VE2[/\/\ ,/JD^Z/$J*]M_P"$!\,_] S_ ,CR?_%4?\(#X9_Z!G_D
M>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\
M(\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\51_P@/AG_H&?^1Y/
M_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\ A ?#/_0,_P#(
M\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_ !5'_" ^&?\ H&?^
M1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_^*H_X0'PS_T#/_(\
MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
MD>3_ .*H_M*EV?X?YA]4GW1XE17MO_" ^&?^@9_Y'D_^*H_X0'PS_P! S_R/
M)_\ %4?VE2[/\/\ ,/JD^Z/$J*]M_P"$!\,_] S_ ,CR?_%4?\(#X9_Z!G_D
M>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\
M(\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\51_P@/AG_H&?^1Y/
M_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\ A ?#/_0,_P#(
M\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_ !5'_" ^&?\ H&?^
M1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_^*H_X0'PS_T#/_(\
MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
MD>3_ .*H_M*EV?X?YA]4GW1XE17MO_" ^&?^@9_Y'D_^*H_X0'PS_P! S_R/
M)_\ %4?VE2[/\/\ ,/JD^Z/$J*]M_P"$!\,_] S_ ,CR?_%4?\(#X9_Z!G_D
M>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\
M(\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\51_P@/AG_H&?^1Y/
M_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\ A ?#/_0,_P#(
M\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_ !5'_" ^&?\ H&?^
M1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_^*H_X0'PS_T#/_(\
MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
MD>3_ .*H_M*EV?X?YA]4GW1XE17MO_" ^&?^@9_Y'D_^*H_X0'PS_P! S_R/
M)_\ %4?VE2[/\/\ ,/JD^Z/$J*]M_P"$!\,_] S_ ,CR?_%4?\(#X9_Z!G_D
M>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\
M(\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\51_P@/AG_H&?^1Y/
M_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\ A ?#/_0,_P#(
M\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_ !5'_" ^&?\ H&?^
M1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_^*H_X0'PS_T#/_(\
MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
MD>3_ .*H_M*EV?X?YA]4GW1XE17MO_" ^&?^@9_Y'D_^*H_X0'PS_P! S_R/
M)_\ %4?VE2[/\/\ ,/JD^Z/$J*]M_P"$!\,_] S_ ,CR?_%4?\(#X9_Z!G_D
M>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\
M(\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\51_P@/AG_H&?^1Y/
M_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\ A ?#/_0,_P#(
M\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_ !5'_" ^&?\ H&?^
M1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_^*H_X0'PS_T#/_(\
MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
MD>3_ .*H_M*EV?X?YA]4GW1XE17MO_" ^&?^@9_Y'D_^*H_X0'PS_P! S_R/
M)_\ %4?VE2[/\/\ ,/JD^Z/$J*]M_P"$!\,_] S_ ,CR?_%4?\(#X9_Z!G_D
M>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\ BJ/^$!\,_P#0,_\
M(\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\51_P@/AG_H&?^1Y/
M_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#BJ/\ A ?#/_0,_P#(
M\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_ !5'_" ^&?\ H&?^
M1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_^*H_X0'PS_T#/_(\
MG_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\ Q5'_  @/AG_H&?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y_P#"S_F=?^QKOO\ V2O0*\_^%G_,Z_\ 8UWW_LE>@4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C,J*69
M@J@9))P *YGPM%_:%[J'B*0/F[?RK;>N"L"].W<\_@*F\7W3?V;'I4#?Z7J;
M_9X^<84_?;Z <?B*VK.TAL+*&TMUVQ0H$0>P_K6R]RG?J_R_X?\ (S^*?H3T
M445B:!61XEU3^R=#FF3FXD_<VZYP6D;@<^W7\*UZY>=DUSQK%; *]MHZ^=)Q
MUF;[H_ #/U^E:THIRN]EJ1-V5ENS6T'3$T?1;6S4'>B9D)ZLYY8G\<UI445G
M*3DVV4DDK(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KS_Q;_R5[X=?]Q/_ -)UKT"O/_%O_)7OAU_W$_\
MTG6@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_X6?\
M,Z_]C7??^R5Z!7G_ ,+/^9U_[&N^_P#9* /0**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Y_\ \W"_]RI_[=UZ!7G_ /S<+_W*G_MW7H% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >?_"S_F=?^QKOO_9*] KS_P"%G_,Z
M_P#8UWW_ +)7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 5)=,M)M4@U&2/=<P(R1MG[H;KQZ]?S-6Z**;;>XK6"BBBD
M,*AAM;>WDFDAA1'F;?(RC!<XQD_E4U%%P"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_\6_\ )7OA
MU_W$_P#TG6O0*\_\6_\ )7OAU_W$_P#TG6@#T"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KS_X6?\SK_P!C7??^R5Z!7G_PL_YG7_L:[[_V
M2@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M_P#^;A?^Y4_]NZ] KS__ )N%_P"Y4_\ ;NO0* "BBB@ HHHH **** "BBB@
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M6%XB^"6H:?:2W6C7POUC7<;=X]DI'?;C(8^W'XGJ[1)O-=#W9'22-9(V5D8
MJRG((/<&G5\^?"GQO<Z-K<6AW\S-IUT_EH)#_J)3P,9Z ]"/<'US]!U+5BXR
MYD%<KXC^(7A_PMJ*V&HS2_:#&)"L4>_:"3C/H>.E;NL:I;Z+H]WJ5TV(;:,R
M-[XZ >Y.!^-?+%TVJ>,-;U34RAEF\N2\GP21%&H_/ &%'X4XJXIRML?3'AGQ
M9I?BRVGN-+:5HX7"/YB;3DC/2MRO#?@/>[-7U>P+G][ DP7_ '&P3_X^*]RI
M25F.#NKG'ZY\2_#_ (=U:;3=1^UQW,6"0(<@@C((.>1S746%];ZGI]O?6K[[
M>XC66-L8RI&1QVKRKXX>'!/IUKX@@C_>6[""X*K_  -]UB?9N/\ @0J[\%/$
M)U#PY-HT\NZ>P?,0/7RFY'/LV[\"*=M+B4GS69ZA7$:C\6/"NF:C<6,MS</+
M YC=HH2R[AU /?!XK-^*WCO_ (1_3O[(TZ9?[3NE_>,.3!&>_P!3T'IU]*Y#
MX2> 3J5TGB'5(#]B@;-I&PQYL@/W_=1^I^A!$M+L')WLCW*TN1>6<-RL<D:R
MH'"R## 'D9'8U-114EE#4];TO18?-U/4+:T4]/-D"EOH.I_"N/D^,GA!)&5;
MFZD /#K;M@_3.#^E>8P?"?QAK%]<23QK"-Y N+Z<YDQQG@%NPY(KF?#.G_;?
M&FF6*2*ZM>HN\="H;DC\ :M11BYR['UG1114&P4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%?//CGQWXB@\<ZI:Z;JEU;VT4PA
MCAC;@%0%...Y!/XTTKDRERGT-17S'_PEGQ _Y_M7_P"_9_PIUO\ $KQKI-T/
M.U*9R.3#=Q @@_49_(BJY&3[5'TU17#> OB/:>,5:TGC6UU2-=S0@Y61>Y0_
MS!_6NYJ&K%IIZH***\(^)7Q'U1/%4NG:'J,MM;6(,,C1<>9+GYNW0?=^H/K3
M2N*4E%7/=Z*\E^#GBS5=<O=5L]6OI;MECCEB,A'R $AOSROY5ZU0U8<7=7"B
MO*OB]>^(M":RU72=4N;>SD_<31QMP'Y(;IQD9'X5M?"KQ3+XE\+,E[<M/J-G
M(4F9_O,K$E&/X9'_  &BVEQ<VMCNZ*@O;VVTZRFO+R98;>%"\DC=% KY^O\
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M^ - %JBD9E12S$!0,DD\ 52_MG2_^@E9_P#?]?\ &@"]15'^V=+_ .@E9_\
M?]?\:EM]0LKN0QVUW;S.!DK'(&('K@&@"S1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBIE5Y!:6*#C*Y."?J26)/0'T%'Q,'[D;=6<WI6IW.C:G!J-F8Q<0-NC,D8<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%%0:A1110!X_P#'F^VV.C:>L@_>2R3N@/\ = 52?^^F_6MWX+V/V7P$MP4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7A7QWMPNO:5<\9DM6C/\ P%L_^S5[K7D'QZM]VGZ)<Y/[N66/IQ\P4_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \ \8_#WQEKGC
M#5-1ATDRPS3GRG-S"-R#Y5."^1P!UK#_ .%3^-O^@+_Y-0__ !=?3=%5SLS=
M-,^<++X-^+KJ15GM[:S4GEIKA6Q_WQN_R:]2\&_"S2O"\J7MRPO]14 K(ZC9
M$>.47UR/O'GZ5WM%#DV-02,'QE_;3>&+N#0+4W%_.OE+B54\M3U;+$#('ZFO
M-/AM\,=5TWQ*-4\0V0MX[1=UNGG(^^4]#\I/"C)YQR5ZX->TT4D[*PW%-W"B
MBBD4?/VM_#3Q<GC*]U'2M+$UO]M:XMW-Q$N07W#@OGCIZ\5] *25!*E21T/4
M4M%-NY,8I;'.^.]/O]5\%:G8:9!Y]Y.BHD>]5R-Z[N6('3)KB/A-X'UOPWK&
MH7VLV2VV^W$,7[U'+98$_=)QC:.N.HZ]O6:*+Z6!Q3=PHHHI%!1110!X/XP^
M'OB[Q!XYU#4$TL&TGG"I*+B(?NU 4'!;/0#MFO=%MX5MA;"-?(">7Y9&1MQC
M'TQ4E%-NY*BD>!>+?@WJME>R7'AZ,7MB[96#S )8L]CG 8#USGU'&:YM?!?C
MF<K9_P!E:F4X4*Y(C Z#DG:!S7U#13YV2Z:/'_ WP>>QO8]2\2^3(T9W162'
M>N[U<]#CT&1ZGM7L%%%)NY:BEL%%%%(84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5@^*_"6G^,=-BL=1DN(XXIA,KV[*&R 1C)!X^;]!6]10#5SCO"OP
MUT3PCJCZC8RWDT[1&(?:71@H)!)&%&#QC/IFNQHHH;N))+8Y[Q;X-T[QE:6]
MOJ,MS$L$A=&MW53DC&#D'BJ?A/X=Z-X.OI[S3Y;R6>:/RBUPZMM7() VJ.I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_P)?_&C^S)_S!]<CV/?Z*\ _P"$BUO_ *#&H?\ @2_^-'_"1:W_ -!C4/\
MP)?_ !H_LR?\P?7(]CW^BO /^$BUO_H,:A_X$O\ XT?\)%K?_08U#_P)?_&C
M^S)_S!]<CV/?Z*\ _P"$BUO_ *#&H?\ @2_^-'_"1:W_ -!C4/\ P)?_ !H_
MLR?\P?7(]CW^BO /^$BUO_H,:A_X$O\ XT?\)%K?_08U#_P)?_&C^S)_S!]<
MCV/?Z*\ _P"$BUO_ *#&H?\ @2_^-'_"1:W_ -!C4/\ P)?_ !H_LR?\P?7(
M]CW^BO /^$BUO_H,:A_X$O\ XT?\)%K?_08U#_P)?_&C^S)_S!]<CV/?Z*\
M_P"$BUO_ *#&H?\ @2_^-'_"1:W_ -!C4/\ P)?_ !H_LR?\P?7(]CW^BO /
M^$BUO_H,:A_X$O\ XT?\)%K?_08U#_P)?_&C^S)_S!]<CV/?Z*\ _P"$BUO_
M *#&H?\ @2_^-'_"1:W_ -!C4/\ P)?_ !H_LR?\P?7(]CW^BO /^$BUO_H,
M:A_X$O\ XT?\)%K?_08U#_P)?_&C^S)_S!]<CV/?Z*\ _P"$BUO_ *#&H?\
M@2_^-'_"1:W_ -!C4/\ P)?_ !H_LR?\P?7(]CW^BO /^$BUO_H,:A_X$O\
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MJ)6VQ^:X4N?8=ZO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 444R26.%=TLB(I.,LP S0 ^BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHI&8(I9B H&22> *6@ HHHH **** "BD9@HRQ &0.3W-+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 445076],;6&TE;Z Z@HRUL&^<#&[)'T(/XT 7Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#YNHHHKZL\0****8!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'I/PG_ .8O
M_P!L?_9Z](KS?X3_ /,7_P"V/_L]>D5\]CO]XE\OR1ZF&_A(****Y#<****
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MG6<MY>3QP6\2[GDD. HI6&FF3T5Y;>?%F]U*]>S\'^'[C4]C<W#HVTCUV@9
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M?G!/X"CE8.2/7:*\Y\-_%FSU:PU(ZC:"QOK"W>=HC)Q*%SD+GD-G QSUK?\
M ?B.^\5^'O[5O;2*U#RLD*QY(95X+9/OD?A19H:DGL=/17G^O?$J/1?'(T1X
MX%LH(1+>7,K$&/Y2V% ZDC8 .Y:LRX^(OBW5O](\+>$Y); Y$=Q=1L?,Y/(
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M6^AF2 V4LG1VY'(Y*[0Q!P,[372-KVJ1^ DUPZ4\^I/;K*ME C,2SD;1@9/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;J***^K/$"B
MBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_AG/X5F?"72%TOP#:28'FWK-<R'Z\+_XZ!^9JNER+:I'<5YS\9=8:R\(QZ9
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MXH6'RO(3G!]548X[Y'H0?<%4(H50 H&  . *Y_P/HO\ PC_@W3+!DVS"(23
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MU\3M>D\4^( W]D02%+*R)^5@#T/J!QD_Q'V&*]@BBCAB2*)%CC10J(HP% Z
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M=V;/^[7I].784%I<\>^,\"ZKKWAG2((]U[,[KD'!VNR*!^8/7IBO0/'&M?\
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M( _*O1Y$BG22"54D1EP\; $%3D8(]#S7G>N?!CPYJ3/+8//IDS$G$1WQY/\
MLG^0(%":M9@T[W1W>J:58ZU8/8ZC;K<6SLK-&Q(!*D$=/<#^536MI;V-LEM:
M6\5O @PD42!%7OP!P*\>^'&H:UH/C^Z\&W5\;RR@615!.50J 05SRHQQM'&3
M^->MZMJ,6D:/>:C/CR[6%I2"<9P,X^IZ?C2:MH-.^IYA<_\ %6_':"%?GL]"
MC#,5X^=.>_?S&4?1?QKUNO,/@SITK:5J7B*[RUUJ=RV'8<LJDY(/N[-G_=KT
M^B78([7/*OC->SWJ:-X7L0'NK^X#E.AX.U 3TP2Q_P"^:[;PEX2T_P ):1':
M6D:F<@&>X(^>5N_/IZ#M]<FN \.2KXT^,]_K0#/8:3'Y<!89&>47Z9)D<5Z]
M3>BL*.KN><?$KQ/J"W5GX2\/L?[5U$@22*P!CC.1C_9)ZY[ >^1T'@SP3IW@
M[35B@19;UU_?W;+\SGT'HO'3^M<+X0N$U3X[>(;BZ.Z6W2:.#/&-CK'QS_=S
M^9->PT/30(ZNX5XC\5K"*P^(>@:A8J([RX9&<(,9=)!M;CG)R!G_ &17MDLL
M<,3RRNL<:*6=V. H'4D]A7D&CJ_Q'^*3:^$D71M'*K QQ\[J25Q]3ECZ# [B
MB/<)ZZ'H'CC6O^$?\&ZG?J^V81&.$AL'S&^52/H3G\*\U^%7PXMKRUC\1:U"
MLL;'-I;/@J0/XV'?G( /IGTJ;X[:T0FF:'&Q&[-W,/;E4_\ 9_TKUS3H;>WT
MRTAM#FVCA1(B/[@4!?TQ1L@WEZ%A5"*%4 *!@ #@"N6^(VEVFI^!=5^U11LU
MM;O<0N_!1U!((/J>GOG%=57FGQ6\1&2SC\(Z7MGU34G1)(TR3&F01G'0G Z]
MLGT-);CEL6?@Q-++\/T20G;%<RI'G^[PW\V:N/T[1X_B5\5=5U"Z!?1[*3:=
MN0)57Y44'J-VTL?;/3/'<:K+'\.?A5]GCD)N(+?[/$R'&Z=\Y8>@#%F^@]:/
MA)HO]D>!+:9TVSW[&Y?*X.T\)SW&T _\"-5?=DVO9';PPQ6\*0P1)%$@PJ(H
M55'H .E>9?'*6#_A%+"W*AKF2]!B'? 1MQ'YJ,>XKU"O)-=_XJ[XVZ;I0_>6
M6CH)IA]Y=PPYR.G)\M#]/PI1W*GM8]&T>'^P_"=A#>N$^PV,:3-U"[(P&/'T
M->>_"."76-7\0>+KE"KW<YAB] "=[#UP/W8'T[UL_%W7UT;P5-:(S"YU$_9T
MVG&$ZN3[8^7_ (%6MX6TP^%/A[;0>6!<06C3RJRX)D(+D'Z$X_"CH+KZ''>+
MK_4?'GC)O!6DW/V?3K8;M0G"GD@\@^H!P .[=>@QZ-H7A_3/#>G)9:9:I#&H
M&Y\#?(1_$Y[G_(P*\R^!2Q30Z[>.5>\>6,.QQNVG<?PR<_7'M7L%$M- CKJ%
M<MH/@+2?#WB&_P!:M#(+B[+@1@[8XT8@E0H]Q_@.*Z2XNK>TC$ES/%"A8(&D
M<*"Q. ,GN3Q4M259!5/5M1BTC1[S49\>7:PM*03C.!G'U/3\:N5YI\:]:-AX
M2ATV-B)-0FPWO&F&;_Q[9^M-*[!NRN<;\-_ W_"8:A<^(M=S+9^<S!"?^/B4
MG+9YS@$_B3[&O>H88K>%(8(DBB085$4*JCT '2N?\ PV\'@'0TMCF,VB.?\
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M@ HHHH **** "BBB@ HHHH ^;J***^K/$"BBBF 4444 %%%% !1110 4444
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M>S; +B-D?'WF;#=F9AS_ +->GT47';6YRWC_ ,)GQ?X9>QB=([N)Q-;N_3<
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MEBD=<GV7RR1T]31J&G>,_%^G3ZAXAADL-+MXFEBTFT1C+=. <(P!W8)'?UX
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MNEC'\*:.- \*Z;I>,/!"!)R#\Y^9^G^T37 _$KP1JTVMP>*_#0=K^/;YT<6
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M0:AJJWFKZU=2D"&TA>2*SB&20-HQDDKC\>IY'LWAG1UT#PSIVEJ!FWA57(&
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M#Q/PP)0C!]P<9KHP?,ISC!-1Z7,J]N6+EJSU77-3@\'>'8GM;(R1QLL,<:G
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MVYG8****T)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ])^$_\
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MK6A110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %/4M*L-8LS::C:0W5N2&V2KD ^H]#[UQDOP:\(2
M2EUM[N)<YV)<' ]N<G]:[^BG=H32>YSNA^!?#?AV43:=ID:W  'G2,9'^H+$
MX/TQ71444AI6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K+USP]I?B2S2TU:V:XMT?S @E=!NP1
MD[2,]3UK4HH CMX(K6VBMX$"11($11_"H& /RJ2BB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5!)_04AW/+_$FIW/B/XO:3X=L;N:.TL?GNQ'(45S]]U)4\C:%7GH2>G6NO\
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ML^&-=NHK3S9[*YE8(B72 !F/8,I(]N<4[,GF7<[FBBFNZ1QM)(RJB@EF8X
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M^(FF:5H%K91V=U)/! %.0JH7QSSDG&>^*\WHK&K1A524S2%24-8FQK_B2_\
M$5UYMT^V%2?*@7[J#^I]S_\ 6K'HHK2,8P7+%61#;D[L****H04444 %%%%
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M"L5#O&6R';893Q[@*/H,TUKN)Z:HF\->!+SQ?,OB7QP\L[3#-M8[BBI&<D9
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ME'[_ %&5IBQ)SL'RJ#^3'_@58FM:MJ_Q+\0R^'= F>UT*V;;>WJYQ+V(]QU
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M_=QJ>=S+T8M@''3&,YZ#TR;P[HD]NUO+I%@\+#!0VZ8Q^5:*J$4*H 4#  '
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M\2? ^D:AX5OM0MK*&WO[*$SI+"@3<J#+*P'4;<^^<?0XW_"'_%3_ *&VT_\
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M&>2&^_\ ^.@C\10M1MV5SSCPAX=G^(WBW5M;OI9HM*>9O.6.38TH)RL7'\(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#YNHHHKZL\0****8!1110 4444 %%%% !1110 4444 %%%% !1110
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M\6S7$>E?:&-NJM(TD14#.<#/KP?R-<U\9/#=SK7ANWOK.%II].D9F102QC8
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M;3YQ-;:%9+(,X9X]^.<\;LXIW3W)2DM$<#)<^)?BO.MO#;S:1X5+*TDKC#W
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MFU)=2:PM3?*,+<F%?- QC ;&>A(Z]Z$[!)75B>W@BM;:*W@0)%$@1%'\*@8
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MKS#XV:NUOX;M-&ART^HS@E%!)*)@XP/5BGY&O3ZIW>D:;?W$5Q>:=:7$\/\
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MXN?#?B2UGACAE8HZIEH6/56'=3U!&>O<'COKGXN>#((?,34Y+ANT<5M)N/\
MWT /S-=+JWAW1]="?VIIMM=,G"M)&"RCT#=0/:J-EX%\+:?.)K;0K)9!G#/'
MOQSGC=G%.Z8DI+1'+>'_ !'XO\9^(;74;"U72_#D)_>?:$W&Y7/(4XY/'!&
M.<D]#T/Q%UH:'X&U*X5@)IH_L\7^\_R\>X&3^%=356^TVQU2!8-0LK:[A5MX
MCN(ED4-@C."#S@G\Z5]1V=CC_A)HO]D>!+:9TVSW[&Y?*X.T\)SW&T _\"-=
M/XBFU*W\/7\VD1K)J$<):!&7=N8=@.YQG'OCK6C%%'#$D42+'&BA411@*!T
M'84ZB^MQI65CR3P;\8;'^SS:^*IY(;V-V/VCRBRR DG!"#*D=,8Z 5>\1_%?
M2KJPDTWPRMQJ>I7B&*+RX74(6!&?F )(ZX _&NOU/P5X:UBX>XOM&M99WY>0
M+L9CZDK@D^YJ[I>@:1HB%=,TZVM<C!:*,!FYSRW4_C3NB;2VN<_\./"$GA#P
MX8+IE:^N7\Z<*<A.,!!V./7U)ZC%=C114MW*2LK!1110,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /)/^%7:W_S]:?_ -_'_P#B
M*/\ A5VM_P#/UI__ '\?_P"(KUNBN[^T*QS_ %6F>2?\*NUO_GZT_P#[^/\
M_$4?\*NUO_GZT_\ [^/_ /$5ZW11_:%8/JM,\D_X5=K?_/UI_P#W\?\ ^(H_
MX5=K?_/UI_\ W\?_ .(KUNBC^T*P?5:9Y)_PJ[6_^?K3_P#OX_\ \11_PJ[6
M_P#GZT__ +^/_P#$5ZW11_:%8/JM,\D_X5=K?_/UI_\ W\?_ .(H_P"%7:W_
M ,_6G_\ ?Q__ (BO6Z*/[0K!]5IGDG_"KM;_ .?K3_\ OX__ ,11_P *NUO_
M )^M/_[^/_\ $5ZW11_:%8/JM,\D_P"%7:W_ ,_6G_\ ?Q__ (BC_A5VM_\
M/UI__?Q__B*];HH_M"L'U6F>2?\ "KM;_P"?K3_^_C__ !%'_"KM;_Y^M/\
M^_C_ /Q%>MT4?VA6#ZK3/)/^%7:W_P _6G_]_'_^(H_X5=K?_/UI_P#W\?\
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MM/\ ^_C_ /Q%'_"KM;_Y^M/_ ._C_P#Q%>MT4?VA6#ZK3/)/^%7:W_S]:?\
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M:?\ ]_'_ /B*];HH_M"L'U6F>2?\*NUO_GZT_P#[^/\ _$4?\*NUO_GZT_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<EXX\%R>-(K&W?5#:6E
MO*99(A#O\T]!SN&,#<.AZFNMHH3L)JXU$2.-8XU544 *JC  '8"G444#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img114804231_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6J!H(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<.CCU!'!%34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%17,AAM9I5 +(A89Z<"OG;_ (:5U;_H7K+_ +_O_A0!]'452T:]?4M#T^_D
M14>YMHYF5>@+*"0/SJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !163XHU>30/"VJ:O%$LLEG;/.L;G ;:,X->%V_P"T?JT]S%#_ ,(_9+YC
MA<^<YQDXH ^BJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PK]H[Q*L.FZ;X:B;]
M[._VR<>B+E4'XMN/_ *^=:Z[XF^(/^$E^(>KWZ.&MUF\B CH8X_E!'UP6_&M
M2T^'[7'P5O?%WEO]I2^5H\*3FW7Y&(_X&V2>PC_( [K]F[Q$J2ZMX;FD4&3%
MY;J>I(PLGZ;./8_A]!U\/>"M>/ACQII.L$XCMKA3*<$_NV^5^G^R6K[@5@RA
ME(*D9!'0T +117$>)?B-X6L]-UBQ77[)=2AAFA$)<AA* 1M^N[B@#YN^)_CJ
MY\;>*IY5F?\ LJV<QV4)/ 4<%\#NV,Y],#M5;PK\,_%7C&U-YI6G?Z'DJ+F>
M01HQ'9<\MZ< BN1K["T7XA> M)T.QT^'Q%IL26T"1!$; &  ?UH TOAMX>OO
M"O@'3-%U'ROM=L9M_E-N7YI788/T85P/Q]\=7.BZ=;^&M-F>&YOXS+<R(<$0
M9*[0>HW$'/LI'<UZ-<>/O"EIIUEJ%QKMI':7N_[-,S?++L.UL?0\5\Q_&77;
M+Q#\0Y[S3KR*[LQ;Q1Q2Q-D' R1^9- '(:'H.J>)-333='LI+N[<$B-,# '4
MDGA1[D@<U] _!SX8>)/!?BFYU36([9()K!X L<V]@Y>-AG QT4]^U8/P'\1^
M%_#6C:K/K&IV=G>W%PJ+YIPYC50>OIDG\J]NT7QGX<\17CV>CZQ:WEPD9E:.
M)LD*" 3],D?G0!\C_$/PYJ?AOQIJ<.HPR*L]S+-!.P^6=&8D,#^(R,\'@U[C
M^SSX?U72?#FI7VH12P6]_+&UM%(NTD*&!?'7!R!R/X<]#7>:KX\\':=?2Z=J
MNM6,5S V)(9NJG&>F/0_K6QHVNZ7XALC>:3>Q7EL',9DB.1N !(_44 ><?M"
M_P#)-4_Z_P"+_P!!>O#_ (/?\E8T#_KK)_Z+>O</VA?^2:I_U_Q?^@O7A_P>
M_P"2L:!_UUD_]%O0!]CT5DZ[XHT/PS;K/K6IV]DCG""1OF;Z*.3^ KB6^/7@
M,3%!?7;*&QY@M'VD>OKC\,T >F45SWA[QUX8\5;5T?6+:XF8%OLY;9+@=?D;
M#<>N,5T- !1110 45D:]XHT/PQ;"XUK4[>S0@E1(WS/C^ZH^9OP!KBYOCSX#
MBD*I?W4H_O):.!^H!H ]+HKDM ^)W@[Q+/';Z=KD!N9,!8)PT+LQQ\H#@;CS
MT7-=;0 4444 %%9FM>(]&\.6OVG6-2MK*+MYK@%O95ZL?H*X>;X\^ XI"J7]
MU*/[R6C@?J : /2Z^<?VE?\ D/Z%_P!>LG_H0KVGP_\ $'PIXH=8])UJVFG;
MI Y,<I^B, 3^&:\6_:5_Y#^A?]>LG_H0H /V:O\ D/Z[_P!>L?\ Z$:^CJ^<
M?V:O^0_KO_7K'_Z$:]LU7QYX6T/4)+#4];M;6[C +12L00",CMZ&@#HJ*R-#
M\4Z'XE\_^Q=3M[W[/M\WR6SLW9QGZ[3^5:] !117/ZOXX\,:!?FQU76K6TN@
MH8Q2M@X/0T =!4%Y>6^GV4]Y=S)#;0(9)9'. J@9)-9^A^*=#\2^?_8NIV][
M]GV^;Y+9V;LXS]=I_*O,_'LUQ\0OB+9_#NRN6ATVS07FKR)G+8P0G;. R=R,
MN"1E* &'4/%/QBN'71;B?0/!R.%:[(VW%V0?F"X/ [=<<<DGY1W'AOX8^$?"
MR1&QTB&2YC'_ !]70$LI.,%LGA2?]D =>*Z>SL[?3[*"SM(4AMH$$<4:# 50
M, "O+?B?\7;[P#XEMM*MM*M[M);-;DO)(RD$NZXX_P!S]: /6:H:IH>E:Y 8
M-5TVUO8R,8GB5\?3(X^HKP%?VE=5W#=X=LRN>0)V!_E78>$?C]H6O7T-AJUG
M)I%Q*0J2M*)(2WH6P"N?<8]30 :K\-]8\%74FO?#:\DC(.^XT6=R\-P,]%!(
MZ G )SZ$'KVG@;QS8^-=+>6)&M=1MCY=]82\26\G0@@\D9!P?;!P0174UX_\
M3='N/!OB"T^)&@1[)(I%BU:!%R)XF(!8]AT )]=IZB@#V"BJ]C>P:EI]M?6K
M[[>YB6:)O[R, 0?R-6* "BBFNZQQM(YPJ@DGT H =17(?\+2\#?]#-8?]]G_
M  K8U+Q1H>CZ-'J^HZG;VUA*@>.61L>8"NX;1U8D<X )]J ->BO-'^//@-9S
M&+^Z=0<>8MH^T^_(S^E=GX?\5Z%XJM6N-$U*&\1#APF59?JK ,/Q% &Q15#5
MM:TS0K,W>JW]O9VX.-\\@4$^@SU/L*X.;X\^ XI"J7]U*/[R6C@?J : /2Z*
MYWPYX[\,^+,KHVK0W$H&3"P,<@Z_PL 3T/2NBH **** "BN*UGXM>"-#GDM[
MK789+B/(,=LC3<CJ,J"H/L2*RH/CQX"FEV/J-S N/OR6DA'_ (Z"?TH ]*HK
M/TC7-*U^T-UI&H6U[ #M9X) VT]<''0^QK0H @OO^0?<_P#7)OY&O@>OOB^_
MY!]S_P!<F_D:^!Z /NCPI_R)^B?]>$'_ *+6M>LCPI_R)^B?]>$'_HM:UZ "
MBJ.J:SIFAVAN]5O[:R@'\<\@0$^@SU/L.:X2Y^.W@.WG:)=1N)P/XXK5]OZ@
M4 >DT5PNC_&'P-K4Z00ZVEO.YP$NXVB'7'WF&WOTSFNY5@RAE(*D9!'0T +1
M110 452U35].T2R:\U2^M[.V4X\R>0("<9P,]3P>!R:X2Z^.O@*VF\M-3GN
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[X!Q7L7[/VAZOIGCR^FO]+OK2)M,D0//;O&I;S8CC)'7@_E74_LW?\B9JO\
MV$#_ .BTKV>@#XX^,/\ R5C7_P#KK'_Z+2O</V>O^2:O_P!?\O\ Z"E>'_&'
M_DK&O_\ 76/_ -%I7N'[/7_)-7_Z_P"7_P!!2@ _:%_Y)JG_ %_Q?^@O7S;X
M9U^X\+^(;76K2..2XMMYC63[NXHR@GU SG'?%?27[0O_ "35/^O^+_T%Z^8]
M)TV?6=8LM,MAF>[G2!/JQ _+F@"^D/B3QUKLLJ1WNKZE,=TC %V ]^RJ.@Z
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MO(_@4NZW\63JRLCZQ(%(.<X&<_J*]<H *@OO^0?<_P#7)OY&IZ@OO^0?<_\
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M/_9M_P"1PU?_ *\/_:BUH?M+_P#(0\.?]<I_YI6?^S;_ ,CAJ_\ UX?^U%H
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MD8*/J6( ]Z]U_:%_Y)JG_7_%_P"@O7RY:W,UG=PW5NYCGA=9(W'56!R#^8H
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M^?O@S\6M/L=+A\,>(KI;80DBSNY,+&$Z[';/!!S@GC'!(P,^_HZ2QK)&RNC
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M!?C/2_&^A1ZEISA7  N+9F!>!_1O;@X/<?E53Q1\-O#'C'4X]0UJRDGN8X1
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M'K0!@VW@WQ1>6T=S:^&]8G@E4/'+%8RLKJ>A!"X(J7_A!/&'_0J:Y_X+IO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "ODGX[?\E7U#_KC!_Z+6OK:B@#QC]F[_D3-5_["!_]%I7L]%% 'QQ\8?\
MDK&O_P#76/\ ]%I7N'[/7_)-7_Z_Y?\ T%*]7HH \H_:%_Y)JG_7_%_Z"]?/
M'@;0(/%/C+3]$N)7BCN_,3S$&2A$;$''?! X[U]O44 ?%'C#X?\ B#P3>O%J
M=HS6V<1WL(+0R?1L<'V.#_.L.75M2G@\B74+N2+&/+>9BN,8Z9]*^\71)$*2
M(KJ>H89!K$;P5X4><SMX9T9IBV\R&PB+%LYSG;US0!\9Z!X8UKQ/?)::/IT]
MU(QP61#L3W9NBCW)KZD^%OPMM_ 5G)=74L=UK-RBB654^6%>I1#UQGJ>,X'
MQ7H%O;06ENEO;0QPPH,)'&H55'L!P*EH *Y+Q]X!TSQ[HIM+L"&\B!:UNU7+
M1-_53W'\B :ZVB@#XE\5^ ?$7@RY:/5[!U@W;4NXLO#)]&[?0X/M6!%=7$"E
M89Y8U)SA'(&?PK[W=$EC:.15=&!5E89!!Z@BL6?P9X6NI#)<>&M'ED/5I+&)
MC^96@#XGTW2[_6;Y++3;.:[N7.%CA0L>N,^PY')XKZ*^%'P7?P_=V_B+Q'L;
M44&ZWLAAEMR1]YCT+^@' ZY)QCV&RT^RTZ$0V-G;VL0  2"((H &!P!5F@ K
MGO&G@[3O''A^32M1W)SYD$Z?>AD (##UZD$=P?Q'0T4 ?%?C#X=>(_!5RZZE
M9.]F"-E] I:!L]/FQ\I]FP?PP:YVUU"]LL_9+RX@SU\J4IG\C["OO5E#*58
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "C-<UXG\2PZ-"HW@2,>!FH_#7B%M5W;A]*CG5^4=G:Y
MU.:*B#T\&K$.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J*9L1MSCY2<^E2UC^(=0.GZ9/*!R8V _*DW97!'D'BG4
M9-6U^2(<K Q0$'(;WKOO!EG]CT[>RX+#@UY[H<'VC4%>3DNV3FO58<00)&O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUA6WB_4]1U=;2RM[8QR2$(9$;(3U.&]*N>-]5^RZ>MC&V);CE_9!_B?Y&H?
MVD^5;OJ<JC=+\D7LH/)_$C]*TJ3G]8A@\.[**U_K^M63%+V;JU%=O8U/$VO-
MHEK%Y*QO<2M\JOD@*.I."/:N7_X3W5/^?>S_ .^&_P#BJ[RXL+.[</<VD$S
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MN[+86Z11]GE^9OK@<#]:RXX]1\7:RQ+X[DG.R)?0?YYKNM/\,Z7I\:A;9)I
M.9)AN)/X\#\*U5?%X]OZN^2"Z]7_ %_3)Y*5%>_JSBHO&FLHX9Y8I #RK1@9
M_+%;=[XW":9:S6<<9N9"?,CDR1'CZ8Z]N:T_$6CZ=+HUU,UO#%+%$7215"D$
M<@>^>GXUYYI6GOJFIP6B9&]OF8?PJ.2?RKBKSQV$G['GYG+;[_,VA&C57/:U
MCTKP[J%]JFF_;+Q(4#L1&L:D94<9.2>^?R]ZQ==\87%AJC6EC'#(L8VN9%)^
M?N!@CV_'-;VJWL6A:&\D8"B)!'"GOC"C_/I7$>$M,;5-8-U-\T5N?,<G^)ST
M'Y\_A7=BZU:'L\)2E[[W?]?U9&%*$'S59+1'?P7,L.EK<ZD8XI%CWR[ =J]_
MK7&)X[O'N\-%;16Y8\E&9@O_ 'T,G\OPJ[XYU81P)IL3?-)\\N#T7L/Q//X5
M4\+^%8[N!;_4%+1-_JH<XW#^\<=O:HQ6(Q%3$QPV&?P[O_/^MQTX4XTW4J+?
M8AOO'5]*Y%E%'!'G@L-S?X?I3+#QOJ,5POVLQS0D@-\FT@>HQ7=FPL(X64VE
MLL6/F'EJ%Q[UY1;6AU+5EMK9<":4A1_=7/\ 0?RKFQOUW#5(/VMW+I_P#6C[
M&I%KELD>P A@"""#R"*6D "@   #@ 4M?4'FA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !36'%.I#0!S'BC3A=6;,%Y -
M<;I5TT7RM]Y#@BO3[J(2Q,A&017FNJV$FGZD9%7]V_!%>?C*;TG$WI2Z,ZVU
ME$D:L.XK5MWZ5S^E[A;+GIVK:MSTKMIRYHIF,E9V-5#Q4E01'BIA5B%HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPX-/!K(M[]' &>:OI,#WKUHSC)7BSE::W+-%,#YIP-4(6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %!HH- '(^/].%_H$IYW(.E?
M-LZF&X>,]CBOK+4HUEL9T8 @H:^6_$L8AUNX11@!C6-5'HX&HU=%%7J:,%B
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MD2+@D5KPOO3%4+J/:YJTSGJ1*#BH0F^8+5A^*C@^\7/TK5/0\^4$YI,NC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 UNE>=?$3PX-1MS<1I\P'I7HQJE>6ZSPM&PR"*4E=6-*51TYJ2
M/F%%:"0Q2#!!QS5M37;^+?!K1RO/ N1UR!7"M'+;2>7*IX[UY=:DXL^ZR['0
MJP2N3BG9J-&#=#3Q7,>TK-:#LTX4VE% V//2H'J4]*A>J1E(B:H)#V'6IW.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\T5$LF:D!K4D6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD0$?2N!UCP<0DCQ+TKEJ4.J-(S[GG-+N(JW>Z?+:2%74C%4ZYFK;EFGI1+S
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *0TM% %>5<BL'6-'M]0B*2H/KBND89JM+%D4 G8\#\4
M^!Y+9FEA0E3G%>?W%K);N5=2,5]3WEBDRE70,/<5YSXG\#I.K26Z<X).!64H
M=CNHXFVDCQ8T^$?.*O:II4VG3%'0@51AXD%8RV/2I-.2:.HLEVVJ?2K*G!JO
M:G_1T'M4V:\Q[GW%->XO0O1/D8J*X3/--A;!JQ(-R4(4D9+C%5IN!CN:NS+@
MFJD)$ESD_=%:)VU.6<.9V)X+1ECW$<FE,;"M!)XR .*<5C?TK)ZG=!J*LC+P
M10&(Z&K[6P/2H'MB.U*Q=TQ]GJ$MK(&#'BNVTOQ-&\(24C/K7 &-AVH5WC/!
M(K:E7E3V/.QN5T<6O>6I[-"8[F,.A!!J46@/:N!\/^)3;E(Y#D>]>D:?<1WD
M"R(00:]6E6C46A\%C\OJ82=I+0B6R]JYOQU:^7X=E;%=]'$"*S/$VCKJ>B3P
M]]N16DE=''2ERS3/E1I?WC?6E$M3^(-+FTG4I(G4@;CBLL2UP.F?64\9=&@)
M*<)*H"6I!+6;@=4<471)3A)5,2TX29J7 Z(XDTK=&GE5%&237IOAO2#91!G7
M#D5R'@RQ2XNVF?D1XP#WKT.34+>Q"^8X&1Q71AX17OL\?.,15J-8>FKW-ZSB
MY%;4-S;VS!97"FN)C\66D49^89Q7!Z[XPN)KYS'*P Z8-=$Z\8K0\C#Y76JN
MTE8^A(M7LE'^N6IAK=@/^6XKY9D\7Z@AR)G_ #JLWC/4B?\ 7/\ G25:XZF6
MN&ESZR76K)V $PR:NAP>]?)-GXUOQ/'NE?@^M>I^'OB*ZLBW#9&,<FCV\4[2
M&LIJS@Y4];'LH:ES7)Z9XPLKZ79YBCBNBANDF3>C KZUK&2EL>?5HU*3M-6+
M51LF:4/FG9S5&12E@![5GW%F&!R*W"N:A>(&@#@-;\,Q7J,RH Y]J\TU?P_/
M8RM\AP#7OTUL#VK$U+1X;N,JZ#GOBLJE)2*C)H\8\.R_9-8B,G'->LPSI*@*
ML.17)ZCX5,,X9%(&?O 59M+:XMD"^8YQZUX6-PDYRNCMHU4D=5D>HJS;7@A8
M9;BN9+RX^^U2VY:%6D9RQ/8UPQP56^QK*M"VIUEWJ%H]N=[<XKD+Z3<S-$ 5
M'-/>8R*5-5ILK$Y/3%>@LNG:[.:-9+1%/19S&\TO0EB*W$U1Q_$:Y2TN BN.
MGS&K(NO>O/J4VY,ZHO0ZA-8<?Q5.FML.]<F+KWIPNO>L^1CT9V::[ZFK":XA
MZD5PPNO>GB[/K1:0N2+.]35X6ZD56U._ADA1$(RQKCA>'^]4JW)=ER>E73C*
M4U$B4(Q5T:\$O[WK7063Y KEK0Y;-=+8]!7V$59)'FLW(3D"K J@ES$G#. :
M9>ZQ:V5N9'D'L*.9#L:=%<DOCBQ9PN]>N*V;36(+O.UAC&14>UA>UQ\K-2BH
M5E##(-/#BM"1]%(#2YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **QO$.OKH,$+FW,[2L0%W[< #DYP?:CP]KQUZ&>3[+Y B8+_ *S=
MG/X"LO;T_:>RO[Q/.K\O4V:**1F5%+,0J@9))P *U*%HKACX_D;40L=HGV0N
M "Q._'KZ?A7<UC1Q%.M?D>Q,9J6P4445L4%%%% !17(6/CC[=J4%HFG8$L@0
M.9^@)ZXV_I77UE2K0JJ\'<F,E+8****U*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZTD2-(V6Y->W@LNLU.H<56LMHFC:N216_9DX%8UG <CBM^UBP!7N'*:,72K
MJ&-<"IA0 M%%% !1110 4444 %%%% !1110 5E>([:YO-"N+:TB,DTNU0 P'
M&X$\DCL*U:*F<5.+B^HFKJQY5_PA^O?\^'_D9/\ XJC_ (0_7O\ GP_\C)_\
M57JM%>?_ &71[O\ #_(Q]A$\]\/^%M4M=<MKB\M3'!&2Q82(>0#CH?7%/\2^
M'M8U+79[FWL]\)"JC>8@R H]3ZYKOZ*T^H4_9^SN[7O_ %H5[&/+RE."&6UT
M:.")<S16X1%R/O!<#]:XKP_X6U2VUVVN+VU,<,;%RWF*><''0YZXKT&BMJF&
MA4E%O[)4H)M-] KF?&6FZAJEM:PV,!E57+N-ZJ!Q@=2/4UTU%:5::JP<'LRI
M1YE9G/\ A#2;C2=+E2[A\N>24L1N#?+@ =./6N<UWPYK>I:[<W*6FZ)WPC>8
M@^4# XSZ"O0Z*QG@X3IJDV[(ATTXJ(R*-884B3.U%"C/H*X/7O"%Z-4-QI$.
MZ*0[\*ZIY;9[9(X[C'2N_HJZ^'A6CRR'*"DK,H:.]\^G1C48/)N4^5OF#;L?
MQ<$]:RO$WA8:R1=6SK'=JNW##Y9![^A]ZZ2BJG1C.G[.>J&XIJS/*&T'7[&1
MD2UNE]X22#_WS4UKX3UO49-\L1B!/,EPV#^77]*]1HKB664[ZMV,O81[F5H>
MA6^AVK1Q,9)),&20C&['3CL.36!XOT75=6U*%[.U,D$<6W/F*OS9.>I^E=I1
M754PT)T_9;+R-'!./*9N@64FG:%:VLR[9$4[UR#@DDGI]:TJ**VA%0BHKH4E
M96"BBBJ&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !4$]W% NYV&/K6?K.JI8P-\PW8Z>M<)/?ZCJUP8X795_04TB)3MH=]_;MCG
M'GI^=*-9LV.%F0_C7+_\(JL5LCNZ2;@"<#D&I[;P]&S?NW$>.[<T:"O/L=7'
M=1RKN5@14@D!Z&N*9=0M+DHDN8L]ABK5IKC!V1PPQW;O3MV$JCO:2.M#4[-9
M4.I1NH^;FKB3JP!S4FERU148?-.#4#'44F:,T +132P R:@NKV&UA,LC@*/>
M@"P2 ,D\5GWVLVEBJF25>?>N U_XBK'Y\-NW<@$5YOJ?BB\OVYD.*]S!Y)5K
M>]/1&4JB6Q[P?%FG_P#/5?SJW8ZY:7[E8I%R/>OFG^T[K_GH?SK7T#Q+<:?>
MJ[.<?6NRMP_RP;B]255/I .*<&KD-"\66VI1(I<"0^IKI8YPP!!R*^;J4ITI
M<LU9FR=RYFBHU?-/!K,8M%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV-+-%0K(#WJ0-6 QU%)FEH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M GM4T,&>U78X/:MB"HMO[4_[/[5H+$*=Y0H RS 1TIH!1LJ,'UK3:*H'@]J
M,Z[CCDMFBD19&?YM[#)%8TNFWE@[26P:5 H;'I71/%QR,U"Y=DV$X7N/6G<E
MQN9ECKBDJDQ"R'@K70P7*N 0:YK4M/CNY&D@C$3G&"/:H(9K[2VC22-WC?I(
M:"4VM&=LDF:E#5@6VJQM\I8;O2M5+A2!S2+N7,T5$KYIX:@8ZBDS2T %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU;0I1AL2Y-[D2J6-7H(>E)%![5?BBQ6A))#'@"K*C%-5<5(* "BBB@ HHHH
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M,2N><UZ!I^M6]Y]QQGZU\MB<'5H2M):&ZDF= #2U624'O4P;-<A0^DQ1FEH
M:5II0&I** *S1 ]JKR6X/:M#%-*@T 8<UH#GBLFXTF)F),8R:ZQX@:K26P/:
MFFUL!QTFDQ?\\Q4!TJ/_ )YBNO>S![5";(>E/GEW Y0Z7'_<%<[XNT]8M*9E
M3!%>EFQ'I63X@T@7>DS)LRVW(K2C5<:BDV)K0^="<$TF:L:E;-:7LD3@C!JG
MNKZR.*31ARDF:,U'FC=6BQ K$F:3-,S1FJ6("Q(#S7H_@J'9IYD9-K,W!/<5
MYIFO0[/5UT_0[,8W-Y0'':L,93GB:')#JQQ=G<[=M5M]/QYC#=C.,USVJ^.W
M$+Q0L1]*XK4-6N+N8NS'_P"M68S%CDG-84,GA35YZL;J7V-+4-?N[U]S2-61
M-+)*V68DTI%-(K>I125DA)D2DJ_4UH6NHSVK*4<C%9[##"I*]#+Z2E2:?<B;
MU/4?"WCYXBD-PY*YYR:]+TWQ#:7X)251CWKYE1V0Y4X-:^G>(+JQ;*R'\ZX<
M;D4*C<J>C+C5MN?3L<RN 0<@U,&S7C&E?$5X[=$D8DBN]TGQ;9WR1#S ';@Y
M-?-8C+J]#XEH;*:9U@-+56*Y20?*P/TJ8/FN$HDHI :6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWUI'<1E)%!6N)UKP;:7<V]8P.*[*6*<59DN)\_$%3@C%)FO0M;\#R0RL8ER
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[M7I5AVKR<Q_WF1I#8Z2UZ"M!.E9UIT%:*=*XBA]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$5&R U+1B@"F\(/:J[VH/:M(K32@H R_L@STIRV@]*T?+]J78* *:VP':I!
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M7XDT;6G*:=J,%PX&2BMAL?0\UHJD&[)HXI83$1ASRIM+O9V-2BBBK.<****
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MV'>K4>J^IKE%NAZU*MU[T!JC*^).K&:"*!6ZGFO/[-.K&NRU?0KC6[SS2Y5
M.*GLO#D-I&%EPWUKT,'5I4GS3Z'5&:C"W4Y1%:0X09-3?8+K_GD:ZI[2V@R4
MC7-4+J],8^5:ZJN;1O[B!3OL89L+K_GD:KRQ/$<2+M-:@UEE?E:TM/ELM2G5
M9D4'WKF_M!3W1?.UNCGK;3+R^&;: R#VJ>]T&\L;(SW<9B.< >M>K0I;:9HK
MI96JO-)\@ '(SWKAO%%ZYT1+29B9UN,G/4#%8TJKJUE%(V33C=')ELJH]!3:
M:#Q2YKZU3LK&(ZEIF:7-5SA8=3@Q'0TS-&:.<+'6^$]9DMKQ8W8E2:]3M[H,
M <]:\(LYC%<HP/0UZQI-VSVT98Y.*^7SFDHU%-=3>F]#L(I,U.#67:RY K1C
M;(KQ30EHH%% !1110 4444 %%%% !1110 4444 %%%% "8II4&GT4 59(@17
M(^-+))M)<,@;O7;,*YKQ8N-,?Z&G'1DS^%G"^&XTM]@10 17:P#!%<AHB%1&
M*[&/C%5-W=V94'HS5MCP*T8SQ69;'I6C&>*@W)J*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** .4\?^*?\ A&- +0,OV^ZS';@]O[S?@"/Q(KS/X=>$3XGU234]1#26-O)E
M]_/GR==I/X@GZ^]5OBAJCZAXUN8=^Z&S588QC&. 6_\ 'B?RKV'P5IB:3X/T
MRV4#<T(ED.,99_F.?IG'X5YR_P!HQ#OM$^SDWE.41=/2I5Z]E:_X+\6V;RJ%
M4*H 4#  Z"EHHKT3XP**** /'OBYXH,]TGAZU?\ =0XDNB#]Y^JK^ Y^I'I7
M$^'/%-_X7EGET^.W,LRA6>5"Q '.!S_G%>\3^"O#EU<23SZ3!+-(Q9W<L2Q/
M4DYJ%_A_X5D0HVBP '^Z64_F#FO.J86M*I[125S[+!Y[EU#"+"2I2:Z[:OJ]
MS@]&^,=X+M$UFR@:V. 9+8,KK_M$$D-]!C^E>O0RQW$,<T3AXY%#HPZ$$9!K
MYE\3:=;Z3XEU"PM'+P03%$+=0/0_3I^%?0GA^VN-*\'V$#0M)<P6:YA&%8N%
MSMYX!SQSBJP=6I*4HSUL9<18#"4J=*OAER\_3RM>_EYFH]U;QN4>>)6'4,X!
M%-^VVG_/U#_W\%>$ZCX"\;ZIJ-Q?W6E;I[B0R.?M,6,GL/GZ#H!Z56_X5GXO
M_P"@1_Y,Q?\ Q=#Q56^E-_C_ )$QR' .*YL9&_K'_P"2/?\ [;:?\_4/_?P5
M*[K&C.[!4499F. !ZFO$O#'PPUH^(+5];L!#81MYDF98WWXY"8!/!/7VS7K^
MNV=QJ&@:A9VKA)Y[=XXV/3)4C\/K712JSG%RE&QY./P.&P]:%*E64T]VK67W
M-GC'B7Q9J_CG7!H^D>:+*1_+A@C)7SL<[W]N,X/  _&M)O@QJ L#(-6MFNP,
M^2(SL)QTWYS_ ..UPL+ZMX3UZ.;RI+/4+9B0LJ>H(/!Z@@GGN#7I7A_XPQRO
M';Z[:"(LP4W-OG:!ZLIY'N03]*\VE*E4D_;[GVF.I8["4H+*DO9I:VLV_/7?
MY:F+X$\&^*+?Q!9ZFL#6-M%*/->9MID3/S*%ZD$=#C'0YKT+XB>)#X>\,R&"
M0I>W1\F J<%?[S#Z#]2*ZQ6#*&4@J1D$=#7S]XSU>?QCXT%M99DB606MHF<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"O>H8^%31Z,ZH58R,$4N:1U>)MLBE&]#29KL50UL.S2YIF:4&JYPL6+4%KA
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MAW6I3X(B7Y$SC>YX _/],U0\%^&1X6T!+-S&]T[%YY$Y#-V . < 8Z^]97Q
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M;GYKR_7I<2@ (?\ 87M^I]ZZZNV@JMFZCW_ ^6S.I@'*,,%%I1W;^U\O^&]
MHHHK<\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<+\4?$8T?PXUC!(!>7^8P >5C_ (C^/3\3Z5W5
M4KW1M+U*59+[3;.ZD4;5:>!7('H"1TK.K&4H.,79G7@:U*AB(U:T>9)WM^1Y
MC\'_  [EKC7YTZ9AML_^/-_3\Z];J*VMH+.W2WM8(X(4X6.) JK] .!4M*C2
M5*"BC3,\=+'8F5>6E]EV70****U. **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $(IC)FI*,4 4I( >U49[0'/%;)7-1/&#0!P6N>
M&X[Q2RJ V#7G.IZ--92'*G'TKW>:W!!XKG]7T:.\B8%1NQBFF1*-SR+1$#:S
M;JW]ZO:P/D7Z"O,9_#=U8WZS1C[K9KM+'5WE18W!# <DUK!G!B(-O0V2*@E0
M56.H80[NN:JRZ@'Y':J<D91I3?0?.RH"36=-*"..])).TI/7%,6)VZU#F=4,
M,^I3D21FP2,5;TBVCBU82 <"I1:G&<4MNRK*Q'44HN["O%0CH=DNIKZU*NHH
M>]<F+@^M/%R?6M+(Y54DNIURWJ'N*D%S&>XKD1=L.]2+>L.]+E17MI'5[XF]
M*-L1]*YE=08=ZE74V]:.4?MNZ-?48HUL)FX^Z:^?KU=VK7 7IO->R:EJA_LR
M?)_@->.I^\GDE/5C7=@(MSL;46FVTA^,"DQ3C3:]6:-QN*0BGXSTI-K?W6_*
MN::*(R*8W J0C'7BF'YF"BL:<'*HD@;T%'04X'!R.M(>#BBOJ.56L8FUI6MS
M64J_,< UZ1HGB2*\15=@'->/ U;M+Z6UD#(Q&*\O&9;"LKK1EQFT>_0SAAP<
MU:5\UYIH'BP,$BF;BNWLM1BN5S&X.*^7KX:I1E:2-TTS7!I:@23-2@U@,=11
M10 4444 %%%!H SM7<QV+L.PKEK -+"LC_>9LUO^)9#'I$S+P5%9&GKBTM\=
MP36D-CBQ/QHMR'FI8!S4#G+U:MQS69V+8TH!Q5M:KPCBK(H&+1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'6=5@T
M31[K4KG_ %5O&7QG&X] H]R2!^-7J\>^+_B(S7D&@6[G9!B:YQW<CY5Z=@<^
MGS#TK&O5]E3<CTLIP#QV+C1Z;OT6_P#EZLU/!7CWQ%XJU]+-[33TM8T,EQ(D
M3Y51P ,OC)) _,]J]-KA? ]A8^#/"27.K7,-I<7G[Z0S.%.,?*H&>2 >@YRU
M:\7CWPM-,(DUJV#$XR^47_OH@#]:BA+E@O:2U9TYI05?$R>"I/V<=+I-IVW?
M]=#HZ*:CK(BNC!D895E.01ZBG5TGB''>._'*^$[>*"VB6;49QN19 =B+G[S8
MP3Z #_\ 71^&OBC7/$OV]]3$3V\.T)*J!3N.<KQUXQ^GK5_5[#P5XNU&U-UJ
M-E<W2?)&D-\NYQG.W"G)[].:Z!!I'AO38XMUIIUDA"+O=8US]3U)_,US)3=7
MG<O=1[DZF%IX%8>-%^VENVMM>G7R-"BJ5MK&F7L,TUKJ-I/%",RO%.K+&.N6
M(/'0]?2LF7Q[X6AF,3ZU;%@<93+K_P!] $?K6SJ16K9Y4,+7FW&$&VNR9T=%
M5[*_M-1MA<65S#<0G@/$X89],CO5BK3OL8RBXNTE9A14-U>6MC"9KNYAMX@<
M%YG"+^9K!/Q \*B4QG6H-P[@,1^>,5,IQCN[&U+#5ZRO3@Y>B;.DKC/B!XVD
M\)VUK'9)!+?7#$[)@2JQCJ2 0<DX ^A]*ZF'4K*XL#?PW4,EH%+F9'!4 #).
M17@%[/=_$'QX%C+;;B7RX@>?*A'^ R3[DUS8JLX12AN]CV,BRZ.(KRJ8A?NZ
M:O*_Y?K\CV'P+KFL>(M&?4=4@MH4=]MN(49=P'4G<3D9X&/0UP_BCXLWJZG)
M:Z"L26T+;3/(FYI".N > OX9^G2O4?,TSP_IEO#-<6]E:1!88S-(J+P.!DXY
MP#^M<[HGA'P8^HRZGIBVM[(LF[*W F2)CD\ $C/?G.,<8HJ0JN,81EKU[CPF
M(P,*U7$UZ+<?LI+W?G^'?KH=#H=Q>7>A6-QJ$:QW<L*O*BC !(].WTK0JC>Z
MUI6G3"&^U.SM967<$GG5&(Z9P3TX/Y4EQKFE6MBE[/J5HEJX+)*9EVN!_=.?
MF_"NE-)6;V/&E3J3ES1@TI/2R?W(OT5SL'CSPO<7 @CUFWWDX&[<HS]2 *Z%
M6#*&4@J1D$=#1&<9?"[BJX>K1LJL7&_=-?F+116?J6N:5I SJ&H6UL< A9)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!..,O]T#UY)]C7GJ_!WQ$9"K76FJHQ\WFN<_3Y/YXI?$'A'2? ^B^;>71O\
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MXA;5+E=]O8D.-W.Z4_=[]NOX"M+5?@_?-/''I-Q9BV1 #)<RN))'[D@(0!V
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M]6P>@ZX_$^UK2_@]K%RX;4;JWLH\\A?WK]/08'MUKTWPWX.TCPO$?L4)>X8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1BBB@!I7-1M&#4U&* *;P ]JJRVH/:M0K3&0&@# GL@01BL:]T6&92&C'Y5
MV3P@]JJRVH/:@&KGFCZ%+9W)N("5P?NBNCTS4I1:_OE/F!]H![CUK8GL@<\5
MG2V>UMP'(JXSL<U7#J>QK6>H#KC(Z&J6JZA&6*A 3WK/)EB!"Y&3FJLJR2$D
MYR>]/GUN0L.^7E94N[EI%=57'RGFL^QG,43 ]=U:;6[[37+3W7DW,B'^\::E
M<FI1Y5H="+OWIPO/>N<6^]ZD6\![U5S'D.B%W[T\7GO7/"\'K3Q=^]%Q<AT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5B <9P">.*TZEJSLR@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$6!_O%03^I-:5Y7IKS)IJTF;=?/GQ:\1MK_BM-(LR7M]/8PA1_'.3AORP%_
M^M>O>.O$R>%?"UU>JZB[<>5:J>\AZ'&#]T9;GTQWKR7X/^&6U?Q$VLW(+6VG
MD,I.?GF/3\NOY>M9T4HIU'T*J.[Y4>L^%-%MO!'@M(;APGDQM<WDN/XL98\9
MS@ #CLHKPR+[7\2OB+N<%%NYLD9SY,"]NW11^)^M>@_&GQ0;73X?#MLX\RZ
MEN<=1&#\J^V2,_\  ?>O-?"GB34]"BN(- L]^JWA">>(_-=$&,*B8(R3UR#V
MXK6E&7*Y]61-JZCT1].VUO#9VL-K;QB."%%CC0=%4# 'Y"I:^9=7T?Q]<Q27
M^JVVL2HB[F>0LVQ1[=@,GMQS2>#O'NJ^&M6MS)>3SZ<6"S6\KEE"GJ5'.".O
M'7&*S^KMJZ=RO:ZV:/INBFNZ1QM)(RJB@EF8X  [DU\\7_BKQ%XS\>?9="U6
M_M8+J816\<4\D:J@_C90?0%C65.FYW-)2Y3Z)HJ&U@^RV<%N)991%&J>9,VY
MWP,98]R>YKEOB1XH_P"$7\*3202!;^Z_<6V#RI/WGZY^49Y]2OK4QBY.R&W9
M79U]%>/_  @&OZQ?7.KZEJ^I3V5N/*CCFN9&220CG@D@X'ZD4_XP>-;K3[BV
MT/2KN:VG7$]Q-!(R.,@A4R".N<G_ (#5^R?/R(GG]WF/7:*^<M!\1^/M2TZ>
MRT:34[QI''FW3.\K)QPH=CA/7U/K7.:N/$6D:J4U:34+>^QYFZ:5MY!)^8-G
MD9SR#US6BPSO:Y#JZ7L?6%%> Z7\4_$TGA^WT73X9;S6"S*+IE\U]G&W QRW
M4$MGMU[<_P"(M/\ &\-O_:6OIJ?DDA?-FD)"^@QGY1U].OO26'=[-V&ZJZ(^
MGJ*\0^#OBK5)M??1;N[FN;26%GC$KEC$RXZ$] 1GCUQ[Y]?UK6[#P_IDNH:E
M.(;>/C/4L>RJ.Y-9SIN,N4N,E)7-"BO ]?\ BWK^O7/V'0('LXY6V1B)=\\F
M<8&1T/\ N\\]:YK4]%\;20/J6IVFL.GWGEGWDJ/<'D#BM%AW]IV(=5=$?4-%
M?-'@[X@ZMX;U2'S[N:YTYWQ/!*Y8 'JRYR01UXZU]+UG4I.F]2H34D%%>6>-
M?B_;Z7(]AX>$5W=*2)+E_FB3V7!^8^_3ZUYN?^$[\8JUQ_Q-KZ$G.5W"+/L!
MA?3@5<:#:N]!.HD[+4^FZX[XE>*3X8\*RF!]M]>9@MR"05R/F<8_NCI[D5X5
M!JOBGP7JR;I+VSG3!,$^[8ZYS@J>"#5GQKXIF\<>(X98HS% JK#;PLWW2>N3
MZDG]!6D</:2;U1#JZ>9U/P8\++?:E-K]W$&AM#Y=N&'!E/5O^ C]3[4SQ9J^
ME>-/B,+#4]3^Q:%IJO%YP89=Q]XJ<'DM@=QA<UZ+J&GWOA'X=C2_#EK+=7JQ
M^3&T:X;>V=TOL>I'O@5YUJ7PQN[7X=Z?);:7+/K\UT)+@)DM'$5;Y<9QQA<^
MYIQFI2<F_) XM*R)/A3I3/X]OK[1YKK^P[8/'YDJX,X/"JW&,]&[=!P,UZ5J
MBQZGX^T6T4%CIL4M[.0.%W#RXP3[G><?[([&H;/4?^$<\)Z-IL-B)=;FLXEC
MT^,!&:0(-S/V500<L?YUL:!HSZ7!-/=RK/J=XPEO)U& [8P%7_94?*/85C.5
MWS%QC96->BBBL30**** "BBB@ HHHH **** "BBB@ HHHH *,444 )BDVTZB
M@!C+52YA61"K#(/6KIJ-UR* //?$/A:*Y#R1* ?2N$O_  W/;*6VFO;YX-P/
M%9%Y8+*I5ER*=R'!,\,EMI(CAE-0UZEJ7AF*=B47'%<=J'AV: L0IP#3N9N#
M1SM7=,;%R!4,MO)"<,I%%J^RY0^]49M:'NNFL1IUOC^X*T82I^\ ?J*Q]$G$
M^DP,#T4"M!3M.:UL>?S-,U5BC8?<3\JS=4DCMT(V\GIBI#?+%"Q8]*YV_P!4
M-Q+M7H.E9-\K.Z,?:QT$=@YR>]/C%5HLL<U?AB)Q4-W.F%-06@]$S3;A=D1/
M>KT4''2J>H,!+'&/7FA;CJ.T6,0?(%]J8(_FS4\2YR:<%^:G)ZD48VC<LVJ=
M*UX!@"L^V3I6I$.*DV)UI:0=*6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTL:$2[8J<@RU(1A /:I(1DTF:Q5DD7[=>E:,8XJG;KP*O(*10^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEQBHJR"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRVHI[4ZSCQ%FKZ'.M:A87EJTK8=*SXQ\U:=L.E0=!H1#BIA448XJ6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)ET6ZO)KFTN(W*K,Y?RV49^4D\#@\42P]H\R=P56[LT>ZT50UC6;#0=.DO\
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M*])TS3;71]-M]/LHO+MH$V(N<X'U[GO7&?"FTU9O#IU;6-1OKJ6].84N;AY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT!?6KT@Y BB4]N=Q/\EJ7%4Z3L[COS31ZSJ^J6^BZ1=:E='$-M&7;W] /<G
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M/M7/3@ZD]364E")1\!:-/XV\>->:A^]B20WEVQ& Q)R%Q[MV] :]#^,GB?\
MLW0DT2W<BYO^9<?PP@\_F1CZ UL?#_P_#X-\%?:+[]S<2QF[O7?(\L 9"GC(
MVKU'KNKQMC=_$OXBC >-;N;'8F&!?TR%'XGZUNFIU.;HC+X8VZL[CX/^"(&M
M4\3:C"'D9S]B1N0H!P9,>N00,],9]#7J&OZS!X?T&\U6YYCMHRVW.-[=%7.#
MC+$#/O5NUM8;*S@M+9!'!!&L<: YVJHP!S["O%?C3XH%W?0>';9LQVI$UR01
MS(1\J_@"3_P+VK)7K5-31VA$Y+P1X9D\:^+/*G)6U4FXNW7@[<]![DG'MR>U
M?2UI9VVGVD=K9P1P6\8PD<:A54>P%<C\,/#!\.>%(WG7%[?8GF]5&/E7\ ?S
M)JW\0?$X\+^%9[F)P+R;]S;#ON/5L9[#)^N**LG4GRH4%RQNSQKXHZNOB+QZ
M\%FHD%LJV<90<R,&.?K\S$#Z5Z];?9_AO\-H_M!5WM(<L,@>9,QS@>OS''T'
MM7FWP;\,G5->EUVZ0M;V/$189#SD=>1@[1SZ@E34GQF\4&^UB/0+9\V]EAYR
M#PTI'3T.T$?B2.U:R7-)4ELB$[)S?4Q_A[H4WC3QP][J(:6WA<W=VYSAV)RJ
MYQW;G'HK5Z;\6_% T3PR=.MWQ>:B#&,'E(_XCZ\]/Q/I6C\//#2>$_",8N0L
M=W<#[3=L^!L)'"D]@H_7<>]>+ZW?W?Q'^(2Q6F[9/*(+4'.(XAGYB.W&6/XT
M*U2I?HA_#&W5G3?"7P'!J@;7]6MQ+:HQ6UAD7Y9&!Y<^H!R,=,Y]*]RJKIFG
M6VD:9;:?9QB.WMXQ&B^P[GU)ZD]R:YKXD^)_^$9\)3O#)MOKO]Q;8.&4D?,X
MY!^49Y[$KZUA*3JS-$E")XS\0[\^)_B)<Q:<C3[66S@"#)D9>#CU^8G!],5[
M3OMOAU\.D5W5S8V^T>DLS'/ XX+$GUQ7FWP8\,?;=5FUZYCS!:?)!N'#2D<G
MD=A^I%>ZUI6DDU#HB::;O+N?,3_$OQ@\C/\ VW,NXDX5$ 'TXIO_  LGQA_T
M')_^^$_PKZ?HH]O'^47LY?S'B_PQUKQ;XI\0,][J]P^FV8WS#"@.Q^ZOW?;)
M]A73_%OQ0-$\,G3K=\7FH@QC!Y2/^(^O/3\3Z5W[ND<;22,JHH)9F.  .Y-?
M+7C?Q*_BKQ/<W^6^S*?+ME.>(P>#@]">I]S3IKVM2]K)!)\D;7.I^&7PY3Q%
M_P 3C5XV_LQ&*Q19(^T,."<CG:#QQU/'8U[W##%;PI#!$D42#"HBA54>@ Z5
ME>$X[6/PCHZV>S[/]CB*E!@'*@DX]2<D]\YS5W4]4L=&L7O=1NH[:W3J\A[^
M@]3["LJDW.1<(J*..^,$MK'\/;E;@ RR3Q+;Y'1]V3_XX'KB/@;ISR:]J.I&
M,^5#;"$,1QN=@>/?"G\_>L+Q;XCO_B5XIM;'3+5S"K&.S@S\S9Y+MV' R>P
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M=(F\07"$7%[F.#/\,(/)_P"!,/R48ZUZG6=>=WRK9%TXZ<SW9Y]\8=9M]/\
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M%K)]EMD0Y\V0G#$=N6X![@"O<O"WA^#PSX<M-+A"EHTS,ZC_ %DAY9OSZ9[
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MB:\!^)7Q#'BF4:9IN5TF%]^\@AIW'&<'D*,\#\3V QI0<Y&DY**,?X>>&/\
MA*?%<%M,A:R@_?W7H4'1?^!' ]<9/:OIZN'^%OA@>'?"B33+B]U#$\N>JKCY
M%_ $GZL:[BG7GS2\D*G'E04445B:!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %!HHH 8PS431YJ?%)B@" 1XJ55Q3L4H%  *6BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .=\9:[J&AZ*9-)TNZU"_E.R)(8'D"<<NVT=!Z=S
M^./'O"/P\UCQ/XBEN_$=M?6UJ&\VX>XC:-YV)SM&<'GG)'3\17T'16L*KA%I
M$2AS.[&QQQPQ)%$BQQHH5448"@= !V%.HHK(L\>^,VGZSJVIZ7;:?IE_=P00
MM(S6]L[J&9L8) ZX4<>_O6M\,;"[\,> =1O+S3+L7AFDE%MY#B:0*H"J%QGD
M@X..]>ET5K[7W.2Q')[W,?/7AKP9KWBCQRMYX@TR\@MGF-U=O<V[1J_.=@W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<8N3LA-I:L[&BL;PMXC@\5:%%JEO!+"CLRE),9!!P>1U%;-#33LQIW"BBBD
M4444 %%%% !1110 4444 %5-3TNRUG3Y;#4;9+BVE&&C;^8(Y!]QS5NBC8#R
MF\^!FE2S,UGJUW;H3D)(BR8]L\5+8_ [1(6W7VI7MR1T6,+$OX\$^G0BO4:*
MU]M4[D>SCV*.E:/IVB68M-,LXK:$<[8QU/J3U)^M7J**R;N6%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !17GOCCXI6/AII+#352]U13A@3F*$^C$')/^R/Q
M([^42:GXZ\;22M&^IWD1/S);AEA7T&%POY\UM"A*2N]$9RJ).R/IFL/Q?XBC
M\+>&KK5'"M(@V01MT>0_='T[GV!KYRE/BKPC>123-J.G3?>0L6 ;^A^E:7C;
MQU=>,H-+@:(QBWB!E1>DDYX9@/3C@>YK18;WEK=$NKH^Y?\ A?X>D\4>,'U/
M4 T\%HWVB=Y/F\V4DE0<]<G+'Z>]?1%<OX(\.P^#O"45O<,D<Y7[1>2,0 KD
M9()SC"@8SGMGO7!>+/C0RRR6GAJ)2JG'VV9<YZ<HI[=>3^53/FK3]W8<;0CJ
M>RT5\SSV/Q!\10BYG@UNZB(WH7#A2#SE0< @\=!Z5D:;XCU_PYJ >VO;JWFB
M.&AD8[3SRK*:?U:^S%[7R/J^BLCPQKB>)/#=EJZ1^7]H0EDSG:P)5AGZ@UYS
M\8/&MUI]Q;:'I5W-;3KB>XF@D9'&00J9!'7.3_P&L8TW*7*:.22N>NT5\Y:#
MXC\?:EIT]EHTFIWC2./-NF=Y63CA0['">OJ?6N<U<>(M(U4IJTFH6]]CS-TT
MK;R"3\P;/(SGD'KFMEAG>US-U=+V/K"BO =+^*?B:3P_;Z+I\,MYK!9E%TR^
M:^SC;@8Y;J"6SVZ]N?\ $6G^-X;?^TM?34_))"^;-(2%]!C/RCKZ=?>DL.[V
M;L-U5T1]/45XA\'?%6J3:^^BW=W-<VDL+/&)7+&)EQT)Z C/'KCWSZ[KFOZ;
MX<TV2_U.X6*)1\JY^:0_W5'<_P">E9SIN,N4N,DU<TJ*^?M;^*OB;Q'>FTT*
M.6SA?Y4BME\R=_\ @0&0<_W<>G-8-WX9\<8:]N=/UAV'SM(V]GZYSUSWS6BP
M[^T[$.KV1]/T5\Y^'OBAK&DZ)J5A=74UTTD!%G+(Q9XI"0/O9SC:21Z%1CJ:
MZ;X1#7]=U6XU34=9U2:PLQL6.6[D*2RD=""<$*.2/4K2E0<4VV-5$VDCV:O*
M]6^#IUGQ;>:G<ZP4L[F8RM&D7[SD\J"3@=\'GMQ3OB_XSGT>UM]%TRZEM[V?
M$TTT,FUDC!X (Y!)'8CA<=#6I\*;35F\.G5M8U&^NI;TYA2YN'D"1CH0"2,D
MY.?3%$5*$>=.UP;4I<IV>F:;:Z/IMOI]E%Y=M FQ%SG ^O<]ZMU\[>/?B!JF
MH^*K@:1JEW:6-M^XC%M</&),$Y<X/.23CV J9-6^(?B?1[:VTJ'4Q81H$\U'
M;?,V#N9I6(+9R> <8P,<4_82M=L7M5LD?0=%?)EV=>T#4BES)?V-ZOS?,[(_
M/<'/ZU]!_#/7[SQ%X.ANK]_,N896@>3'+[<$$^^"*52BX+FO<<:G,['84445
M@:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*16<$4DRV<!=UA3<\K %FVCN2<X'T%>(V/A7Q#XS\>_:M<TJ_M+>ZF,MQ)-
M\:K&.B!B/0!17T116<*KC=]65*"=CC_B'>ZCI_A&2RT/3KJXNKH?9T%K S^3
M'CYF^4''' Z=<CI7'?"#P5=V5]<:YJ]C-;2Q Q6L=Q&48$CYGP<'H<=.YKV&
MBDJC4'%=0<+RN%>%_%.+Q'XD\3BVL]$U22PLAY<3K:2%'<_>8'&,=!GT%>Z4
M4J<^1WL.4>96,+P?X>C\,>&+335 \U5WSL/XI#RQ_H/8"MVBBI;;=V-*V@44
M44AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !112,P52S$!0,DGH* %HJ#[=:?\_4'_?P5/0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 44R26.%=TLB(I.,L<"E1TD0/&ZNIZ%3D&@!U%%%
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M1@?GG% '2T5%;W,%W;I<6TT<T+C*21L&5A[$<&F&_LUNOLK7< N,@>49!O\
M7IG- %BBBJ]M?V=XS+:W<$[*,D12!B/R- %BBJ>H:KIVDQK)J.H6MG&V<-<3
M+&#CKRQ%9-OX^\(74RPP^)M):1B J_:T!8DX &3R?:@#HJ*16#*&4@J1D$=#
M2T >"?&7QUXS\/>.+*QT>:XM++RD> )"&%U)GGG!W8R%V_IR*]OTJ>ZNM'L;
MB^@\B[EMXWGAQCRW*@LN,GH<CJ:?=7UC:.@N[JWA;[R"615/ID9JS0 4450U
M/6]*T6+S=4U*TLH\9#7$RQY^F3S0!?JIJDTEMI%[/$VV2.!W1L9P0I(-9ECX
MW\*ZE<+;V?B/2YIV.%C6[3<WT&<GIVJ_K?\ R -1_P"O67_T$T >5_ ?QCK_
M (L_X2#^W-2>\^S?9_)W(J[-WF[ON@==H_*O8Z^?_P!F7_F:?^W3_P!K5] 4
M %%%% !1110 445BZGXN\-Z-/Y&I:]IMI..L4URBN/?;G..#0!M45E:9XGT'
M6G":9K6GWCG.$@N4=N.O .:U: "BBFNZ11M)(RHB@LS,<  =230 ZBN<F^('
M@ZWD,<GBC2 XZ@7B''UP:V;'4K'5(!/I][;7<)Z26\JR+^8)% %JBBFNZ11M
M)(RHB@LS,<  =230 ZBH;:\M;Q6:UN89U4X)B<,!^59.H>,_#&DW)MK_ ,0:
M9;W"Y#127*!E^HSD?C0!N454T_5-/U:W^T:;?6MY!G'F6TRR+^:DBIKBY@M+
M=[BYFCAA09>21@JJ/<G@4 2T5S?_  L'P;YWE?\ "5:-N]?ML>/SSBNABECG
MB66*19(V&5=#D'Z&@!]%%5Q?V;77V5;N W&2/*$@W^O3.: +%%0W-U;V4#3W
M5Q%!"O625PJC\36 /B%X,:7RQXIT?=DC)O(P/SSB@#I:*BM[F"[MTN+::.:%
MQE)(V#*P]B.#4M 'C'[2/_(F:5_V$!_Z+>NX^%O_ "3#P]_UZ+_,UP_[2/\
MR)FE?]A ?^BWKN/A;_R3#P]_UZ+_ #- '7T455OM2L=+@,^H7MM:0CK)<2K&
MOYD@4 6J*YR'X@>#KB01Q^*-(+GH#>(,_3)KH4=)8UDC971@&5E.00>A!H =
M37=(HVDD941069F.  .I)IU<UXIUK2F\(:TJZG9DFPG  G7G]VWO0!=T+Q7H
M?B:2[31=1BO?LC*LS1 [5+#(PQ&&Z'H36Q7@/[.-]:6>F:_]JNH(-\T.WS9
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M97,3Q/CD;CL(SZ$-G\!Z5\V^#]+AUKQGHNF7*[K>YO8HYEW%=R%AN&1R.,T
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MSQ-J]E-X(\--]G?4I_.N[H/MVPA=K GLO.3CD\ >_JUE^S;H2686^UO49;K
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M\567@SPU<ZU?*SI%A8XE(#2N>%4?U/8 GM7SUINC>-OCIJLM_?W_ -DT>"3
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MH **** "BBB@ HHHH **** "BBB@ KF/B/\ \DV\1_\ 8/F_]!-=/7,?$?\
MY)MXC_[!\W_H)H ^)Z^\-$_Y &G?]>L7_H(KX/K[PT3_ ) &G?\ 7K%_Z"*
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M'XD5Y'K6M^(?C=J\T&GPRV/AG34,\H<\# )RY'#.<$*O0?F: -G]F7_F:?\
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MV;9$VW,MMSC;@GYX^XP>!TR,  ':?\,X^#_^@EKG_?\ A_\ C5'_  SCX/\
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MX_\ )/-0_P"PK)_Z*BKV"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2_L^^"!+O(U(KDG8;D8_]!S^M>J44 87AOP=X?\ "5N8=$TR&UW##RC+2/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.M:=%J&FW4=U:39\N:,Y5L$J<?B"/PKYT_:2_P"1PTC_ *\/_:C4 ?2]%%%
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MO5]/UNP2^TN\AN[5R0LL+AAD=1]?:KM !117(:Y\4?!GAZ=[>_UV#[0AVM%
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M<M^SC_R3S4/^PK)_Z*BH ]@HHJAJNM:7H=M]IU74+6RAP<-<2A,X[#/4^PH
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MQC$5K=7:1<Y^3R9=O_CN*^CO%?\ R)^M_P#7A/\ ^BVH \6_9E_YFG_MT_\
M:U=S\=?^23ZE_P!=8/\ T8M<-^S+_P S3_VZ?^UJ[GXZ_P#))]2_ZZP?^C%H
M \0\!Z!XA^)%E;>%X;MK/P_ISM/<RA<J9')QQQN;' !.  3]?:[3X#> [:U\
MF6PNKI^/WTUVX?\ \<*K^E4_V>[.*W^&[7"*OF7-[(SMCDX"J!G\/U->KT ?
M-?Q+^$O_  @=I'XJ\+WUS'!:RH9$=_WENQ8!71AU&X@<\C(Z]O9OAGXM?QIX
M'LM4G*?;5)@N@A&/,7J<#IN!5L=MU6OB#"D_PY\2(XR!IEP_XK&S#]0*\V_9
ML=CX7UI"?E%ZI ]R@S_(4 =O\3_'T?@+PS]JB6*74KIC%:0N>"<<N1U*KD9]
MR!QFO'O!7PHUCXD/)XH\7ZG>Q6]T=T;<&:X']X%LA$Z8X/'0 8RSXY:K!>?%
M;3M/U%V_LNQCA$R+G(5VW2'CG)7 X]!7I,7QX\ P0I%%/>+&BA546K8 ' %
M%H? KP (&C.E3EB !(;N7<ON/FQ^E>8>-_A;JWPTE7Q5X0U*Z:VMV)DZ>;;
M\9..'3G!XX[@C)'I'_"_/ O_ #\WO_@*U17/QT^']W:S6UQ->20S(8Y$-JV&
M4C!'Y4 =)\-O&\7COPG%J)58[V$^1>1#H)  20/[ISD?B.<4SXE^.H? GA:2
M]78^H3DQ643#(9^['_94<G\!WKQO]GK44M?'VK:;!+(UI=6K-'NXWF-QM)'K
MM9OIDU)\9#+XH^,VC>&FD9;=?L]L @Y0RN"[=/0K[?+]: (?!OPNUOXG2_\
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MM*WD]Y^\@LKN:0+C@K!\D?;CD(3^/<T :O@SX"RZK$NL>-;V[\^X'F?8T?\
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MAN\F%G)*?*:0\Q/U,;8^\I7/U (/J?J.O+/V@8$E^&+.XRT-["Z>Q^9?Y,:
M/./#'AK6/CAXIN_$6OW3P:/;R>4%C/3N(8^PP""6]QU)X]0G^ _@*6S\A-/N
M89-I'GQW;E\^N&)7/X8]JE^!EM%!\)M*DC7#7$D\DA]6$K+_ "45Z+0!\MV_
M]I_ SXH0V\UU+<:+<;?,?:56:%L!FV@D;T.?R]&KZDKY^_:911)X8D ^9A=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2,,%R+9\G';)R<5]%^*_^1/UO_KPG_\ 1;4 >+?LR_\ ,T_]NG_M:NY^.O\
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MV8<[>W)!ZY'#>$_CAJ?A*/\ L#QII=[/+:?N_.'RW"CC"NK8W<?Q9!QCKG-
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M>(?^OK4/_1IKZ.H H:W_ ,@#4?\ KUE_]!->'?LR_P#,T_\ ;I_[6KW'6_\
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M%;EQ_%L0+G]*\:^%'PUU6]UW_A.O%YF^VM(TUO;SKAV<_P#+1P?N@?PKQV/
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MMKJ)9493G@CH?<=".Q!K,\:^$[/QKX7NM&N\(SC?!-MR891]UQ^9!]02.]>
M:'XL\7_!/4SH6N6!N=*D?>B%CMQ_$T#].XRI[^A)H ^H**\G@_:&\%RV_F21
M:I#( ,Q-;J3^!#8KAO%OQBUKQZI\->#M)O(5NB4=E^:XE3N,+PBXZG)XSR!F
M@" 7 \>?M*P3V95[2TNT97R2-EN =WXLO';YA7;?M%:/)>^"K+4X@2-/NAYG
M!X20;<_]]!!^/Y[?PE^&@\":7)=7SK)K-ZBB?;@K"HY$:GOSU/0D#'3)[O5=
M+L];TJZTS4(5FM+F,QRQMW!]/0CJ#U! - '*_";Q!#XA^&^D2+(K3VD*VDZ
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MN44 06=E:Z?:1VEE;0VUM&,)##&$11UX4<"I71)8VCD571@596&00>H(IU%
M'(WOPN\$:A<-/<>&K'S&.28E,0)^B$"M/1?!WASPY)YND:+96DVS9YL<0\PK
MZ;CS^O:MNB@ HHHH Q-5\'>&M;G,^IZ%I]U.1M,LENI<C_>QFK&D>'=%\/K,
MNCZ59V(F(,OV>%4+XSC..N,G'U/K6G10 52U/2--UJV^S:II]K>P9R([B)9
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M:3K2QKJNEV5^L1)C%U;I*$)ZXW XZ5;@@AM;>*WMXHX8(D"1QQJ%5% P  .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M./"WQ\L=<<E())+6]9MF0%4A'QZ\(3QZU]-*P90RD%2,@CH: %HHHH ****
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M_)5=:_Z\)_\ T?%7TO7S1\ ?^2JZU_UX3_\ H^*@#W#XC_\ )-O$?_8/F_\
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MQU]%ZEI.FZS;K;ZII]I?0*X=8[J%95#8(R P(S@D9]S7SIX[_P"3F=*_Z_\
M3OYQU]+T ?._[0GA_1M%T_0FTK2+"P:6682&UMDB+@!<9V@9ZUZIX:\$^%)_
M"NCS3>&-%DEDLH6=WL(BS,4!))*\FO//VE_^09X=_P"NT_\ )*]@\*?\B?HG
M_7A!_P"BUH NZ?IMAI-J+73K*VL[<$L(K>)8T!/4X4 5\Y>._P#DYG2O^O\
MT[^<=?2]?-'CO_DYG2O^O_3OYQT ?2]?,.L7&I?''XHC3+"9H=$L]P23DK'"
MIPTI'=G. ![J#T)KW[QW=267@#Q#<1$B1-.G*,#@J=A /X=:\K_9KL8%T;7-
M0PIN'N(X">X55W?@"6_''M0!Z?X;\ >&?"EHL&F:5 '_ (KB91),Y]W//X#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZ+_ #->.>+O@[<>&/AE:Q6-G<:OK\^HQM=O9PO+L01R_*B@9" D98CDD=.
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M!![$"OG.Z\"?$/X5:U-J'A9[B_L6 W26T0?S%_NR0\GC)Y&<#)!% 'TW7/\
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M@O#VMZUK>C2:5H^H7Z1VSJ[6ML\H4[AP2H.* /?**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img114804231_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -M#2X# 2(  A$! Q$!_\0
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MVHH^HX?^7\6'UFKW/2?^%L?]07_R:_\ L*/^%L?]07_R:_\ L*\VHH^HX?\
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M\FO_ +"C_A;'_4%_\FO_ +"O-J*/J.'_ )?Q8?6:O<])_P"%L?\ 4%_\FO\
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MRM)G24445Y9VA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?-U%%%?6'B!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>V^ ?\
MD2=/_P"VG_HQJ\2KVWP#_P B3I__ &T_]&-7G9E_"7K^C.K"?&_0Z2BBBO$/
M1"BBB@ HJAJVM:;H5JMUJEW':P.XC5Y.A8@G'Y _E6/_ ,+%\(?]!ZT_,_X4
M6%='3T5S'_"Q?"'_ $'K3\S_ (4?\+%\(?\ 0>M/S/\ A3LPNCIZ*9%*D\*2
MQL&C=0RL.X/(-/I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBL[5M?TG0EA;5-0M[03,5C\U\%B.N!Z#(R
M>V1ZT :-%(K!U#*05(R"#P12T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4457O;VVTZREO+R98;>(;I)&Z** +%%4],U6QUFR6\TZY2XMV)4
M2)G!(ZU<H **** "BBB@ HHK-TOQ#I&MR3QZ9J-O=M <2"%PVWW]QQU'% &E
M1110 4444 %%9L_B#2+75X=*GU&WCOYL;(&<;CGI^?;UK2H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BL_5M<TO0H$GU2^AM(W;:ID;&X^P[U>BEC
MFB26)UDC=0R.IR&!Z$'N* '4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /T(->/5T_@*![OQE:R$Y\H/*Y8\GY2/YD5CBX2<.92LE?YFE"24K-7N=/\
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M10 4444 %%%% !1110 4444 %%%% !7MO@'_ )$G3_\ MI_Z,:O$J]M\ _\
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M'+;585$;/E98@<^6XZC^OT(I- I7T,;5?AKI6K>,XO$DUQ<+*KQR20*1M=D
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M)_YA["E_*ON1H_VYJ/\ S\?^.+_A1_;FH_\ /Q_XXO\ A6=11_:&,_Y^R_\
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MO,D8'T!)_F*XSQ9=?;/%>I3 Y F,8/J%^7^E>E_#BV$'A&*3&//F>3Z\[?\
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M3_[,/RK&,OW%6IW?]?F:-?O(1[(YSXB:A)=^*I;<D^5:HL:+GC) 8G'KDX_
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MP_ZZ7/\ Z45[#7CWPY_Y*_XP_P"NES_Z45[#52W(AL><?&W_ )$2/_K]C_\
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M_P#DG5G_ -=9?_0S6;\<_P#D2;+_ +"*?^BY*?VB7\!W^C?\@+3_ /KVC_\
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M';_D6M,_Z_/_ &1J[*^OY-*^',M]"<2P:7OC/HPCX_7%<;\=O^1:TS_K\_\
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M(\W@[0Y)&+.^GP,Q/<F-<UQ_QM_Y$2/_ *_8_P#T%ZZWP?\ \B3H/_8.M_\
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M7?$>HMJFJJP=!DF.-P>&RW+$<$< #T/!KT>BCF%RH*\Q\3_"J2356USPG?\
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MRH!X^60$+UZ _P!*]@HH3L)Q3U/'_P#A7/C+Q3*C>+O$ 6V1L^3"=Q/_  $
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M+IGB"RM!*07$-U,N['3.(_<U?_X07XH_]#?%_P"!LW_Q%>PT57,R.1'D5O\
M!_5-4NHY_%?B2:\"Y)2)V<@G' 9^@P/3L*]/TC1[#0M.CL--MDM[=!]U1RQQ
MC)/<G'4U>HI-ME**05YCXG^%4DFJMKGA._\ [-U#=YAA)*HS9R2K#[O?C!!]
MA7IU%"=@:3W/(_[*^,4Q^ROK%K'$0%\W,0X]<A-W]>:MV_PE>+0M3>YOQ?\
MB*]B9!=7#ML3.,\\DG@_,>>>@KU&BCF8N1'-> _#UWX7\*6^E7LD$D\;NQ:!
MB5PS$CD@']*Z6BO/?&?Q(N-"U>;0=,T>:\U-HE,++\RY8<?*!DX].]&['I%'
MGGB;PE;ZE\9WT2Q;;'=2K-. N/*RN]^_ID]OO8KZ#1$CC6.-55% "JHP !V
MKSWX;>"[[29+KQ#KQ+:S?Y)5L$QJ3DYQ_$3V'08'J*]$IR9,%;4****DL*X*
M/P3J2?%R7Q89[3[ Z;1'O;S?]2(^FW'4>O2N]HIIB:N%%%%(84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% '"W__ "$;K_KL_P#,U7JQ?_\
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M?\(#XF_Z!G_D>/\ ^*H_X0'Q-_T#/_(\?_Q5>]]8I?S+[T<GLI]F<W172?\
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M_P"$!\3?] S_ ,CQ_P#Q5'UBE_,OO0>RGV9S=%=$_@3Q)&,MIN!T_P!?'_\
M%4S_ (0KQ#_T#_\ R-'_ /%4_;TOYE]XG"2Z&!16_P#\(5XA_P"@?_Y&C_\
MBJ/^$*\0_P#0/_\ (T?_ ,51[:G_ #+[Q<DNQ@45O_\ "%>(?^@?_P"1H_\
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M_D:/_P"*H]M3_F7WAR2[&!16_P#\(5XA_P"@?_Y&C_\ BJ/^$*\0_P#0/_\
M(T?_ ,51[:G_ #+[PY)=C HK?_X0KQ#_ - __P C1_\ Q5'_  A7B'_H'_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"W_\ R$;K_KL_
M\S5>K%__ ,A&Z_Z[/_,U7K\FQ'\:?J_S/IZ?P(****Q+"BBB@ HHHH ****
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M80A4G4]K45K*R6XM%%%>6=84444 %%%% !1110 4444 %%%% !1110 4444
M=#X7_P"7O_@'_LU=#7/>%_\ E[_X!_[-70U^CY#_ ,B^G\__ $IGS^-_CR^7
MY!1117L'*%%%% !1110 5E5JUE5I3,:O0****T,0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#5HHHKG.P**** "BBB@ K-E_US_[QK2K-
ME_US_P"\:N&YE5V&4445J8!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %/B_P!<G^\*93XO]<G^\*&-;FE1117.=84444 %%%% %>\_U(_WJI5=
MO/\ 4C_>JE6L-CGJ?$%%%%69A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %7;/_ %)_WJI5=L_]2?\ >J9[&E/XBQ1116)T!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <+?\
M_(1NO^NS_P S5>K%_P#\A&Z_Z[/_ #-5Z_)L1_&GZO\ ,^GI_ @HHHK$L***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_GA9_P#?#?\ Q5'_  GFJ?\ /"S_ .^&_P#BJY>BC^Q,O_Y](/KM?^9G4?\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH U:***YSL"BBB@
MHHHH *S9?]<_^\:TJS9?]<_^\:N&YE5V&4445J8!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %/B_UR?[PIE/B_UR?[PH8UN:5%%%<YUA1110 4
M444 5[S_ %(_WJI5=O/]2/\ >JE6L-CGJ?$%%%%69A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %7;/_4G_ 'JI5=L_]2?]ZIGL:4_B+%%%%8G0
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>?ZD?[U4JUAL<]3X@HHHJS,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J[9_ZD_P"]5*KMG_J3_O5,]C2G\18HHHK$Z HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+_KG_P!XU<-S*KL,HHHK4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *?%_KD_WA3*?%_KD_WA0QK<TJ***YSK"BBB@ HHHH KWG^I'^]5*KMY
M_J1_O52K6&QSU/B"BBBK,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "KMG_J3_ +U4JNV?^I/^]4SV-*?Q%BBBBL3H"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A);/_GE/_WR/\:Y:BC_ %CQW=?<'U"B=3_PDMG_ ,\I_P#OD?XT?\)+9_\
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M?_/*?_OD?XT?\)+9_P#/*?\ [Y'^-<M11_K'CNZ^X/J%$ZG_ (26S_YY3_\
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MSTJ.9K=%671C]922P^">G6]^K)<22KY2MU +LZY_X!^7 I/"2_\ "3?#'5M
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M(:26IRWB+41JWB/4;Y7WI-<.T;8Q\F<+Q_NXK,HHJR#TKP%_R3[Q=_U[R?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<MXE_Y",?\ UQ'\
MS74URWB7_D(Q_P#7$?S->#Q'_N+]4=N _C&-1117Y\>Z%%%% !1110 4444
M%%%% !1110 4444 %%%% !116?JFN:;HT8>_NTB)^ZG5F^BCG\:NG3G4DH05
MV^B)E)15Y.R-"BN1/Q'T$2%<W1']_P KC^>:W]-UK3=70M87D<^WDJ#AA]5/
M(KHK8#%4(\U6FTN]C.&(I3=HR39?HHHKD-@HHHH **H-K%DFLII+2D7CQ^8J
M;3@CGOT[&K]7.G.%N96OJO3N2I)[,****@H**** "BBB@ HHHH **** "BBL
MW6-=T_0HHI+^4H)250*I8G'7I5TZ<ZLE"FKM]$3*48KFD[(TJ*9%+'/"DT3A
MXY%#(RGA@>013ZAIIV90445FV.O6&I:A<V5K(SS6Q(E^4[1@XZ]*N-*<TY15
MTM_(ERBFDWN:5%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !6CH?
M_(8@_P"!?^@FLZM'0_\ D,0?\"_]!-=F7?[Y2_Q1_-&5?^%+T?Y'8T445^IG
MS04444 %%%% 'S1XH_Y&W6?^OZ?_ -&-636MXH_Y&W6?^OZ?_P!&-6378MCG
M>X4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K<\):^GAOQ!#J$EJEQ& 4=2 64'
MJR$]&'ZC([UAT4-7T#8].N?#/@CQ%(;O2O$$&F-*?^/>7  8GH$8J?; ./3B
MFVN@>"O"LHOM3UY-5G@?=';VX!RPY *J3SD?Q$#L:\SHJ>5]RN9=C=\6>)KC
MQ3K!NY5,<*#9!#G(1?\ $]S_ (5A44525M"6[A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'J_P6_YCG_;#_VI7JU>4_!;_F.?]L/_ &I7
MJU<U3XF;P^$****@H**** "BBB@ K*K5K*K2F8U>@4445H8A1110 4444 %%
M1SK*]O*L+A)2A".1G:V.#7#?#W1_%NEW>HMXAN'>"3_5I).)2SY^\.3@8^G;
MCB@#O&4,I5@"I&"#WKA]7^%'AO4YFFACFL)&.2+9@$)S_=(('T&!47BO1O'%
M]KKS:%JBVUCL4+&9MOS8Y.,&L3_A&_BA_P!!U/\ P(/_ ,30,W-+^$GARPF$
MMQ]HOF!!59W 08]E S^/'M7=QQI#$D42*D: *JJ,!0.@ ["O*/\ A&_BA_T'
M4_\  @__ !-:_AG1/'EGXAM9]:U9)]/7?YL8FW;LH0.-H_BQ0!Z%1110(***
M* "BBB@ HHHH U:***YSL"BBB@ HHHH *S9?]<_^\:TJS9?]<_\ O&KAN95=
MAE%%%:F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3XO\ 7)_O
M"F4^+_7)_O"AC6YI4445SG6%%%% !1110!7O/]2/]ZJ57;S_ %(_WJI5K#8Y
MZGQ!1115F84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5VS_P!2
M?]ZJ57;/_4G_ 'JF>QI3^(L4445B= 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<MXE_P"0C'_UQ'\S74UR
MWB7_ )",?_7$?S->#Q'_ +B_5';@/XQC4445^?'NA1110 4444 %%%% !111
M0 4444 %%%% !1110!B>*M>7P_HSW"X:XD/EPJ><MZGV'^'K6)X?\&QW,8U7
MQ!F\O;C]YLD)VH#SR.Y]N@IGB]5NO&?AVTE/[H/OQCKEAQGWV@5W->S*K+!X
M.FJ+M*I=M];7LDG\KLXE!5JTG/51T2\^Y4&EZ>$""QM0@& HA7&/3I7*^(/!
MBQ9U3P\&M;^([_*B.%?Z#L?;H>F*[6BN+#8ZOAY\\)>J>J?DT;U:%.I&S7_
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M6O7DUJ4J-25.6\6T_D=<)J<5);,****S*"BBB@ HHHH **** "BBB@ HHHH
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M10!ZO\%O^8Y_VP_]J5ZM7E/P6_YCG_;#_P!J5ZM7-4^)F\/A"BBBH*"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*G<I4YP0>A/>NQ_X7#X@_P"?/3/^_4G_ ,77(:!>6&GZW;W6IVGVNS3=YD&
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M"BBB@ HHHH *S9?]<_\ O&M*LV7_ %S_ .\:N&YE5V&4445J8!1110 4444
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M +_K_C1_;.E_]!*S_P"_Z_XUY#11_JA0_P"?C^Y!_:T_Y4>O?VSI?_02L_\
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M +_K_C7D-%'^J%#_ )^/[D']K3_E1Z]_;.E_]!*S_P"_Z_XT?VSI?_02L_\
MO^O^->0T4?ZH4/\ GX_N0?VM/^5'KW]LZ7_T$K/_ +_K_C1_;.E_]!*S_P"_
MZ_XUY#11_JA0_P"?C^Y!_:T_Y4>O?VSI?_02L_\ O^O^-']LZ7_T$K/_ +_K
M_C7D-%'^J%#_ )^/[D']K3_E1Z]_;.E_]!*S_P"_Z_XT?VSI?_02L_\ O^O^
M->0T4?ZH4/\ GX_N0?VM/^5'KW]LZ7_T$K/_ +_K_C1_;.E_]!*S_P"_Z_XU
MY#11_JA0_P"?C^Y!_:T_Y4>O?VSI?_02L_\ O^O^-']LZ7_T$K/_ +_K_C7D
M-%'^J%#_ )^/[D']K3_E1Z]_;.E_]!*S_P"_Z_XT?VSI?_02L_\ O^O^->0T
M4?ZH4/\ GX_N0?VM/^5'KW]LZ7_T$K/_ +_K_C1_;.E_]!*S_P"_Z_XUY#11
M_JA0_P"?C^Y!_:T_Y4>O?VSI?_02L_\ O^O^-']LZ7_T$K/_ +_K_C7D-%'^
MJ%#_ )^/[D']K3_E1Z]_;.E_]!*S_P"_Z_XT?VSI?_02L_\ O^O^->0T4?ZH
M4/\ GX_N0?VM/^5'KW]LZ7_T$K/_ +_K_C1_;.E_]!*S_P"_Z_XUY#11_JA0
M_P"?C^Y!_:T_Y4>O?VSI?_02L_\ O^O^-:?AW4["XUVVBAO;:21MV$2523\I
M[ UX=75_#7_DH&F?]M?_ $4]:T>%J-"I&JJC?*T]ETU%+,YSBX.*U/H*BBBO
M>.,**** "BBB@#YH\4?\C;K/_7]/_P"C&K)K6\4?\C;K/_7]/_Z,:LFNQ;'.
M]PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'J_P6_YCG_;#_P!J5ZM7E/P6
M_P"8Y_VP_P#:E>K5S5/B9O#X0HHHJ"@HHHH **** "LJM6LJM*9C5Z!1116A
MB%%%% !1110 4444 (S!5+,0% R2>U<)K'Q6\,V4C6R";4?4P(IC[=V(S^&>
ME97Q&U.^US7K+P5I1*O.P>Y;. 1C(!_V0 6/KQZ5UOA_P/H?A^Q2&.RAN)\?
MO;F:,,[GOUSM'L/U/- S#TGXL>&+F5;=XKC3]Q)+2Q+Y>?JI/IZ5WT<B31)+
M$ZO&X#*RG(8'H0>XK"UOP9H6NV+V]Q801OCY)X8PCH?4$?R/%</X#O+WPEXO
MN/!FI2>9%*2]JX/ .-W'/ 9<\>H]S0!ZO1110(**** "BBB@ HHHH U:***Y
MSL"BBB@ HHHH *S9?]<_^\:TJS9?]<_^\:N&YE5V&4445J8!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %/B_UR?[PIE/B_UR?[PH8UN:5%%%<Y
MUA1110 4444 5[S_ %(_WJI5=O/]2/\ >JE6L-CGJ?$%%%%69A1110 4444
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MN?05%%%<AT!1110 4444 ?-'BC_D;=9_Z_I__1C5DUK>*/\ D;=9_P"OZ?\
M]&-6378MCG>X4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS.8HI65D8JRE64X((P0:2F(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJ_AK_ ,E TS_MK_Z*>N4K
MJ_AK_P E TS_ +:_^BGI2^%CCN?05%%%<AT!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !656K656E,QJ]
M HHHK0Q"BBB@ HHHH **** ,/4_!WA_6;UKS4--2>X8!2[.PX'3H:I?\*Y\)
M?] 6+_OX_P#\574T4 <M_P *Y\)?] 6+_OX__P 51_PKGPE_T!8O^_C_ /Q5
M=310!RW_  KGPE_T!8O^_C__ !5=);6T-G:0VMN@2&%%CC0'[J@8 _(5+10
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I 0P!!!!Y!'>N:\=^(?\ A'?#$\T3[;N?
M]S;X/(8CEOP&3]<>M97PM\0_VIX>.G3OFYL,(,GEHC]T_AROT ]:KE=KBOK8
M[NBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5E5JUE5I3,:O0****T,0HH
MHH **** "BBB@ KD=6^)?AC29S UZ;J5?O"U7S /^!?=_(]JP/B1K=_J&JV?
M@[1&875R0;AE)! /(4D=%QEF]@/>M[P]\.- T6Q2.YLH-0NB/WLUS&'!/^RI
MR /U]Z!C--^*'A;4;A8?MCVKMT-TFQ?Q;D#\378JP90RD%2,@CO7+:W\//#N
ML630II\%C-C]W-:Q",J>V0,!A[&N6\ :KJ'AWQ)/X+UJ4MC)M'.2,@9PI/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $<MQ#!CSIHX\]-[ 9_.H_M]G_S]P?]_!_C
M6-XH_P"73_@?_LM<]7R^8Y_4PF)E0C!-*WXI,]+#X&-6FIM[G=?;[/\ Y^X/
M^_@_QH^WV?\ S]P?]_!_C7"T5P_ZTUO^?:^]FW]FP_F.Z^WV?_/W!_W\'^-'
MV^S_ .?N#_OX/\:X6BC_ %IK?\^U][#^S8?S'=?;[/\ Y^X/^_@_QH^WV?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >@_![_ )&V[_Z\7_\
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MX:O3/"EAH?A#6;;1HKE+[6[TNL\R#_5(J%]O7Y0<#CJ>O85YGXW_ .1UU?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M Y[Q1_RZ?\#_ /9:YZNA\4?\NG_ _P#V6N>K\XS[_D85/E_Z2CW\%_ C\_S"
MBBBO'.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBH)[ZTM3BXNH(C
MZ22!?YTXQ<G9*XFTMR>BHX9X;A-\$L<J=-R,&'Z5)0TT[,$[A1112&%%%(S*
MBEG8*HZDG H 6BBB@ HHHH **** "BBB@ HHHH **** "BD)"@DD #DDT*RN
MH9&#*>A!R*+ +114;3PHQ5Y8U8=06 --)O85R2BHOM5O_P ]XO\ OL4Y)8Y<
M^7(KXZ[3G%#BUN@NA]%%%(84444 %%%% !1110 4444 %%%% !1110 4444
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M';Z;H.FRO#;P6=G!&9)/*C"@*H))( Y[TNE:O8:W9_:].N!/;[BN\*0,CKU
MJKXK_P"1/UO_ *\)_P#T6U<Y\(_^1%C_ .OB3^8H [JBBB@04444 %%%% !5
MVS_U)_WJI5=L_P#4G_>J9[&E/XBQ1116)T!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#FEV/0?^%E>$?^@M_P"2TO\ \31_PLKPC_T%O_):7_XFO/O^%/>(/^?S3/\
MO[)_\11_PI[Q!_S^:9_W]D_^(HY8=PYI=CT'_A97A'_H+?\ DM+_ /$T?\+*
M\(_]!;_R6E_^)KS[_A3WB#_G\TS_ +^R?_$4?\*>\0?\_FF?]_9/_B*.6'<.
M:78]!_X65X1_Z"W_ )+2_P#Q-'_"RO"/_06_\EI?_B:\^_X4]X@_Y_-,_P"_
MLG_Q%'_"GO$'_/YIG_?V3_XBCEAW#FEV/0?^%E>$?^@M_P"2TO\ \31_PLKP
MC_T%O_):7_XFO/O^%/>(/^?S3/\ O[)_\11_PI[Q!_S^:9_W]D_^(HY8=PYI
M=CT'_A97A'_H+?\ DM+_ /$T?\+*\(_]!;_R6E_^)KS[_A3WB#_G\TS_ +^R
M?_$4?\*>\0?\_FF?]_9/_B*.6'<.:78]!_X65X1_Z"W_ )+2_P#Q-'_"RO"/
M_06_\EI?_B:\^_X4]X@_Y_-,_P"_LG_Q%'_"GO$'_/YIG_?V3_XBCEAW#FEV
M/0?^%E>$?^@M_P"2TO\ \31_PLKPC_T%O_):7_XFO/O^%/>(/^?S3/\ O[)_
M\11_PI[Q!_S^:9_W]D_^(HY8=PYI=CT'_A97A'_H+?\ DM+_ /$T?\+*\(_]
M!;_R6E_^)KS[_A3WB#_G\TS_ +^R?_$4?\*>\0?\_FF?]_9/_B*.6'<.:78]
M!_X65X1_Z"W_ )+2_P#Q-'_"RO"/_06_\EI?_B:\^_X4]X@_Y_-,_P"_LG_Q
M%'_"GO$'_/YIG_?V3_XBCEAW#FEV/0?^%E>$?^@M_P"2TO\ \31_PLKPC_T%
MO_):7_XFO/O^%/>(/^?S3/\ O[)_\11_PI[Q!_S^:9_W]D_^(HY8=PYI=CT'
M_A97A'_H+?\ DM+_ /$T?\+*\(_]!;_R6E_^)KS[_A3WB#_G\TS_ +^R?_$4
M?\*>\0?\_FF?]_9/_B*.6'<.:78T/B1XNT+7_#MO:Z9?>?.EVLC+Y3KA0CC.
M64#J14WP6_YCG_;#_P!J5D_\*>\0?\_FF?\ ?V3_ .(KMOA]X/U#PF-1^WS6
MLGVGR]GD,QQMW9SE1_>%.3BHV3!)N5V=M1116)H%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5E5JUE5I3,:O0****T,0HHHH **** "BBB@ HK#U/QCX?T:]:S
MU#4D@N% 8HR,>#TZ"J7_  L;PE_T&HO^_;__ !- '4UY5?(GAKXUV L,10ZG
M$IN(@ %)<LI_50WUKIKKXG^$K:$N-3,[#I'%"Y8_F /S(KDO# O/'7Q&/B>2
MUDBTRR&V'>3U (50>YR2Q X&??D&>N4444""BBB@ HHHH **** -6BBBN<[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Y[Q1_RZ?\#_ /9:YZNA\4?\
MNG_ _P#V6N>K\XS[_D85/E_Z2CW\%_ C\_S"BBBO'.L**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "HIK:"XQYT,<FWIO4''YU+133:=T)J^XV.*.)=L:
M*B^BC IU%%)N^XPJ%K2V>4RO;Q-(>KE 3^=344U)K832>X4444AA1110 4A
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M_;+_ -&FO4:X?Q-X7U/4_'NA:Q:I&UI9[/.)<!AAR3@=^#0,[BBBB@04444
M%%%% !1110 4444 :M%%%<YV!1110 4444 %9LO^N?\ WC6E6;+_ *Y_]XU<
M-S*KL,HHHK4P"BBB@ HHHH *R+'POHNG:M/JEII\45[/DO*"3UZX!.%S[ 5K
MT4 9VHZ!I.KRI+J.GV]TZ+M4RINP/:J7_"$^&/\ H!6/_?D5C_$/QG+X9M(+
M33@'U2[/[L%=VQ>F['<D\ ?7TP>:B^'/B_5HEN=6\2R0W##/E&1Y-GMP0!^'
M% SO?^$)\,?] *Q_[\BI(/"'AVVN([B#1K*.:)PZ.L0!5@<@C\:X#_A4VM_]
M#4__ 'R__P 55O2_ACJ]AJ]E>2^)7FCMYTE:/:_SA6!(^]WQ0!Z=1110(***
M* "BBB@ I\7^N3_>%,I\7^N3_>%#&MS2HHHKG.L**** "BBB@"O>?ZD?[U4J
MNWG^I'^]5*M8;'/4^(****LS"BBB@ HHHH *P_&5_/IG@[5;NV9EG2 A&7JI
M/R[A[C.?PK<JGJNG0ZOI-WIUP2(KF)HV(ZKD=1[CK0!Q/PFT&QMO"L&K^2CW
MMT\A\YE&Z-0Q3:I[#Y2??/L*]"KR#PWXIE^'=W-X8\1PGR(W,D-S"-V%;G..
MI4GGU!)!]NP7XH>#RH)U8J2.AMI>/_':!G7T5R/_  L_P=_T&/\ R6F_^(K?
MTC6;#7;$7NFW'GVY8J'V,O(Z\, : +]%%% @HHHH **** "KMG_J3_O52J[9
M_P"I/^]4SV-*?Q%BBBBL3H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!!*\_[_M_C1_;.J?\ 02O/^_[?XT?ZH5_^?B^YA_:T/Y6>O45Y#_;.J?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K*K5K*K2F8U>@4445H8A1110 4444 %%%% '">+/&^L>%M9*G0
MFNM)VJ?M"[EY(Y&[!&?P_P :GT?XI>&=4VI+<O83' VW2[5S_O#(Q[DBNTK
MU3P3X<U>,K<Z3;JV#B2%?+<9[Y7&?QS0,VK>ZM[N+S;:>*:/.-T;AA^8J6O%
M]>\(Z+X3EDN=-\92:==KRL#,6D],'R_F Z]1_4U<^'OCKQ%JOB*#2;QTOK0A
M@]SY)#(%1BIR,=2 /F&?QH ]<HHHH$%%%% !1110 4444 :M%%%<YV!1110
M4444 %9LO^N?_>-:59LO^N?_ 'C5PW,JNPRBBBM3 **** "BBB@ HHHH \K\
M9?NOC!X;EN&"V^R(*QX ;S'_ *D?F*]4KR_XO:AIBP6=A>6TYNMK36US"1F,
MYP00>H.!TQT'I61HOQFNK:U2#5M/%TZ+CSXI-C-]5(P3[@CZ4#/9Z*\M_P"%
MV:?_ - >Z_[^K5O3/B]8ZGJMG8)I5PC74Z0AC(I"EF S^M 'H]%%% @HHHH
M**** "GQ?ZY/]X4RGQ?ZY/\ >%#&MS2HHHKG.L**** "BBB@"O>?ZD?[U4JN
MWG^I'^]5*M8;'/4^(****LS"BBB@ HHHH *R_$>J'1?#FH:B!EX(69 >F[HN
M?;)%:E9^NZ6-:T*^TTOY?VF%D#XSM/8_GB@#S'P#X#LO$6G'Q#K[2WDEU*S(
MC2$!L$@LQ!R26!XXZ=\UVO\ PKGPE_T!8O\ OX__ ,57/?#[Q##H=LWA/72N
MGWUF[>7Y[!4D5FW8#=,Y;CU!&*])5@RAE(*D9!'>@9R__"N?"7_0%B_[^/\
M_%5N:5I%AHEG]DTZW$%ON+; Q(R>O4FKM% @HHHH **** "BBB@ J[9_ZD_[
MU4JNV?\ J3_O5,]C2G\18HHHK$Z HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \I^-'_,$_[;_P#M.O**
M]7^-'_,$_P"V_P#[3KRBNFG\*,)_$%%%%62%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &MX7_P"1MT;_ *_H/_1BU]+U\T>%_P#D;=&_Z_H/_1BU]+UA5W1K3V"B
MBBLC0**** "O$_C#_P C;:?]>*?^C)*]LKQ/XP_\C;:?]>*?^C)*TI?$1/8\
M^HHHKH,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *ZOX:_\E TS_MK_ .BGKE*Z
MOX:_\E TS_MK_P"BGI2^%CCN?05%%%<AT!1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \I^-'_,$_[;_^TZ\HKU?XT?\
M,$_[;_\ M.O**Z:?PHPG\044459(4444 %%%% !1110 4444 %%%% !1110
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M(T"BBB@ KEO$G@/2_%&HQWU]<7D<L<0A @=0, D]U//S&NIHIIM;":N>??\
M"GO#_P#S^:G_ -_8_P#XBC_A3WA__G\U/_O['_\ $5Z#13YY=Q<J//O^%/>'
M_P#G\U/_ +^Q_P#Q%'_"GO#_ /S^:G_W]C_^(KT&BCGEW#E1Y]_PI[P__P _
MFI_]_8__ (BC_A3WA_\ Y_-3_P"_L?\ \17H-%'/+N'*CS[_ (4]X?\ ^?S4
M_P#O['_\11_PI[P__P _FI_]_8__ (BO0:*.>7<.5'GW_"GO#_\ S^:G_P!_
M8_\ XBC_ (4]X?\ ^?S4_P#O['_\17H-%'/+N'*CS[_A3WA__G\U/_O['_\
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M_P _FI_]_8__ (BC_A3WA_\ Y_-3_P"_L?\ \17H-%'/+N'*CS[_ (4]X?\
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M<06FKPM*QPJR*T9)]MX&:Z*@ HHHH$%%%% !1110 4444 :M%%%<YV!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#RGXT?\P3_MO_ .TZ\HKU?XT?\P3_ +;_ /M.
MO**Z:?PHPG\044459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4?VYJ/\ S\?^.+_A1_K1@_Y9?<O\P_LZKW7X_P"1V-%<=_;FH_\ /Q_XXO\
MA1_;FH_\_'_CB_X4?ZT8/^67W+_,/[.J]U^/^1V-%<=_;FH_\_'_ (XO^%']
MN:C_ ,_'_CB_X4?ZT8/^67W+_,/[.J]U^/\ D=C17'?VYJ/_ #\?^.+_ (4?
MVYJ/_/Q_XXO^%'^M&#_EE]R_S#^SJO=?C_D=C17'?VYJ/_/Q_P".+_A1_;FH
M_P#/Q_XXO^%'^M&#_EE]R_S#^SJO=?C_ )'8T5QW]N:C_P _'_CB_P"%']N:
MC_S\?^.+_A1_K1@_Y9?<O\P_LZKW7X_Y'8T5QW]N:C_S\?\ CB_X4?VYJ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH UO"__(VZ-_U_0?\
MHQ:^EZ^:/"__ "-NC?\ 7]!_Z,6OI>L*NZ-:>P4445D:!1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!C>)?\ D'1_]=A_(URU=3XE
M_P"0='_UV'\C7+5^?<1_[\_1'NX#^"%%%%>"=H4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>A5Y[7H5?7\*?\OO^W?_ &X\K,_L_/\ 0****^P/*"BBB@ HHHH
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M$G ;'4UUFD:-8:%9FSTV PP%R^PR,^"<9QN)QTZ5%22D7"+1?HHHK(L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M![K_ +^K6KX<^*-GXCUZVTJ+39X7GW8D=P0-JEOZ4 =[1110(**** "BBB@
MHHHH U:***YSL"BBB@ HHHH *S9?]<_^\:TJS9?]<_\ O&KAN95=AE%%%:F
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &-XE_Y!T?\ UV'\C7+5U/B7
M_D'1_P#78?R-<M7Y]Q'_ +\_1'NX#^"%%%%>"=H4444 %%%% !1110 4444
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MMXDT.7P[KUSILI+"-LQR8QO0\J?RX/N"*R:M.Y(4444 %%%% !1110 4444
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M_P EI?\ XFCEEV#F1U=%<I_PLKPC_P!!;_R6E_\ B:/^%E>$?^@M_P"2TO\
M\31RR[!S(ZNBN4_X65X1_P"@M_Y+2_\ Q-'_  LKPC_T%O\ R6E_^)HY9=@Y
MD=717*?\+*\(_P#06_\ ):7_ .)H_P"%E>$?^@M_Y+2__$T<LNP<R.KHKE/^
M%E>$?^@M_P"2TO\ \31_PLKPC_T%O_):7_XFCEEV#F1U=%<I_P +*\(_]!;_
M ,EI?_B:/^%E>$?^@M_Y+2__ !-'++L',CJZ^??B5_R4#4_^V7_HI*]7_P"%
ME>$?^@M_Y+2__$UX[XWU*TUCQA?W]A-YUM+Y>Q]I7.(U!X(!Z@UI233U(FTT
M>[^%_P#D4M&_Z\8/_1:UK5D^%_\ D4M&_P"O&#_T6M:U9/<M;!1112&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB"BBBK,PHHHH **** "JFIW\6E:7=7\^3%;Q-(P'4@#.*MU@>-[:6[\%:O#
M"TAMV8 =3CDC\A0!YMI&@:S\4+F;6-8OY+;31(5AB09Z=D!X &<;N23D>N-S
M_A2NC_\ 03OO_'/\*UOA1=6\_@*TAB8&6"21)@.H8N6'_CK"NVH&>9_\*5T?
M_H)WW_CG^%=GX9\.P>%](&FV\TDT8D9PTF,\_2MFB@ HHHH$%%%% !1110 5
M=L_]2?\ >JE5VS_U)_WJF>QI3^(L4445B= 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME0VNA1Z@P#WEYEY)2<MC)P,G\S[U#X<L#JGPRCL0VUIHIE5CT!\QL9]LXI/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 5Z%7GM>A5]?PI_R^_[=_P#;CRLS^S\_T"BBBOL#R@HHHH ****
M/*?C1_S!/^V__M.O**]7^-'_ #!/^V__ +3KRBNFG\*,)_$%%%%62%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7J'C7_DE'AG_M
MC_Z*:O+ZWM4\6W^K>'['19X;9;:RV^6T:L'.U2HR22.A]!4R5VAI[F#7L7A'
M4+;QOI=C;7[*-8T:>*:*5CN9XU9<GKDY VMUYVGT%>.U>TC5KS0]3AU"QD"3
MQ'C(R&'<$=P11*-T.+L=/\5/^1XF_P"N,?\ *N736-4BC6./4KQ$4!559V
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M^OZ#_P!&+7TO7S1X7_Y&W1O^OZ#_ -&+7TO6%7=&M/8****R- HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3H[92*]=(_8;4)'YDG\: /0Z***!!1110 4444 %7;/_ %)_WJI5=L_]2?\
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MC'_,/[0PW\WX/_([6BN*_P"%@_\ 4,_\F/\ [&C_ (6#_P!0S_R8_P#L:/\
M5W,_^?7XQ_S#^T,-_-^#_P CM:*XK_A8/_4,_P#)C_[&C_A8/_4,_P#)C_[&
MC_5W,_\ GU^,?\P_M##?S?@_\CM:*XK_ (6#_P!0S_R8_P#L:/\ A8/_ %#/
M_)C_ .QH_P!7<S_Y]?C'_,/[0PW\WX/_ ".UHKBO^%@_]0S_ ,F/_L:/^%@_
M]0S_ ,F/_L:/]7<S_P"?7XQ_S#^T,-_-^#_R.UHKBO\ A8/_ %#/_)C_ .QH
M_P"%@_\ 4,_\F/\ [&C_ %=S/_GU^,?\P_M##?S?@_\ ([6BN*_X6#_U#/\
MR8_^QH_X6#_U#/\ R8_^QH_U=S/_ )]?C'_,/[0PW\WX/_([6BN*_P"%@_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y]\8?^12M/^OY/_1<
ME>)U[9\8?^12M/\ K^3_ -%R5XG732^$QGN%%%%60%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7U;7RE7U;6-;H:T^H4445B:!1110 4444 >4_&C_F"?\ ;?\
M]IUY17J_QH_Y@G_;?_VG7E%=-/X483^(****LD**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** -;PO_ ,C;HW_7]!_Z,6OI>OFCPO\ \C;HW_7]!_Z,6OI>L*NZ-:>P
M4445D:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_\ DG_]G1_PI;_J/_\ DG_]G7JU%'M)=PY(GE/_  I;_J/_ /DG_P#9T?\
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MJU%'M)=PY(GE/_"EO^H__P"2?_V='_"EO^H__P"2?_V=>K44>TEW#DB>4_\
M"EO^H_\ ^2?_ -G1_P *6_ZC_P#Y)_\ V=>K44>TEW#DB>4_\*6_ZC__ ))_
M_9T?\*6_ZC__ ))__9UZM11[27<.2)YGI?PD_LW5[*__ +<\S[-.DVS[)C=M
M8'&=_'2O3***ER;W&DEL%%%%(84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=E=D$OA3X>V5P+.[\1W!N3E&*R+M5@><D(0OI@FLCQ/\/GTG3!K&E7R:CIA
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MV@OT#Q+&S%@"H;YL@#H>Q-8=4G<D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OJVOE*OJVL:W0UI]0HHHK$T"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHI'=41G=@JJ,EB< "@ R,D9&1SBEKQ_1?'[3_$J:XED(TV](
MM45N B@GRV]N22?3>U>P54HN.XD[A1114C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "LJM6LJM*9C5Z!1116AB%%%% !1110 4444 <_XM\6V7A+3!<W(,L\A*P6
MZG!D(Z\]@,C)]Z\WU'5OB)JNCW&N&0Z7ID:&1$7$993Z?QGMR< ]16EJ$$?B
M3XW)8WHWVFGQ*RQ/T;"!^G'\3#/7('IT[/Q]_P B)K'_ %P_J*!E/P7JE_/\
M-;;49/.O[X1SL S9>5ED<*,GZ 4WP-XW_P"$HCN+2]@6UU6UR985! 9<XR 3
MD8/!!Z<>M/\ AA_R3O2O^VW_ *->N8U>)=%^-^ESVBJ@OXU:90."6W(3@?[H
M.?7GUH ]5HHHH$%%%% !1110 4444 :M%%%<YV!1110 4444 %9LO^N?_>-:
M59LO^N?_ 'C5PW,JNPRBBBM3 **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I\7^N3_>%,I\7^N3_>%#&MS2HHHKG.L**** "BBB@"O>?ZD?[U4J
MNWG^I'^]5*M8;'/4^(****LS"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *NV?^I/\ O52J[9_ZD_[U3/8TI_$6****Q.@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^^,/
M_(I6G_7\G_HN2O$Z]L^,/_(I6G_7\G_HN2O$ZZ:7PF,]PHHHJR HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KI?A__P CUI7_ %T;_P!!
M:N:KI?A__P CUI7_ %T;_P!!:E+9C6Y-\2O^2@:G_P!LO_125T?Q<!^R^'3_
M  ^3)C\HZYSXE?\ )0-3_P"V7_HI*ZC7H6\5?"G3=4B7?=:<,2X SM4;7_DK
M?2H_E97='EE=+\/L_P#"=Z5MSGS&Z?[C5S5>@?"C1WN->DUB5,6UBC8<@X+L
M,<=CA22?3(JY.T63'<Q_B( /'NJ8&/F3_P!%K7+UI^(M1&K>(]1OE?>DUP[1
MMC'R9PO'^[BLRA; ]SUCX47<=AX;UV\ESY=N1*V/14)/\J\SU/4[S6-0EOKZ
M8RSR'))Z =@!V ]*[[P%_P D^\7?]>\G_HIJ\UJ8KWFQO9'L7P^UZZB^'NJ7
M,[>>=,\PP"0YPHC#!,]<9S^!QT%>2WU_=ZG=R7=[<///(<L[G/Y>@]AQ7HO@
MG_DF'BC_ '9?_15>9416K'+9'I]C/<>)/@]J27SK++ITN8)7&6 0*W7UP67/
MH:@^&]G9Z;HVJ^++I!*]D&CA0K]TA020?4[@/S]:E\(?\DE\2_[TG_HM:;X%
M@CUWX?:_X?0@W9?ST4MC)PNW_P >CY^HJ7LQK='"ZSKFH:_?O=ZA<-([,2J9
M.R,'LH[#@?ESFK?ACQ1?>&-22>WE8VS,//MR?ED7OQ_>]#_3(K%DC>&5XI49
M)$8JR,,%2.H([&I;*RN=1O(K.SA::XE;:B+U)_SW[5I96L1=W/4_BT\4GA_1
M'@7;"S$QC&,+L&./I7DM>K_%2S73O#&@6*,62V_<JS=2%0#)_*O**FG\(Y[A
M1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7U;7RE
M7U;6-;H:T^H4445B:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PGQ2\0_V7X>&G0/B
MYO\ *'!Y6(?>/X\+]"?2NZ=U1&=V"JHR6)P *^;_ !?KS>(_$ES? GR,^7;J
M>T8Z?3/)^I-:4XW9$W9&'7T/X$\0_P#"1>&()I7W7<'[FXR>2P'#?B,'ZY]*
M^>*['X;^(?[#\3I#,^VTOL0R9/"MGY&_ G'T8UK4C=&<'9GOE%%%<QN%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %95:M95:4S&KT"BBBM#$**** "BBB@ HHHH \
MF\6S'PA\5+'Q'(CO97D864@=,+L8#UP-K5V'C6Z@O?AWJES;3)-!);;DD1LA
MAD=#6UK.C6.O:9+I^H0B2"3\&0]F4]B*\QOOA7K]C;SVNAZZ)+&<8DMYV:/<
M/0XR#UZ\4#.L^&LT5O\ #7399I$CC03%G=@ !YK]2:Y72)CXW^+CZO;[FTS3
M% 23&,@ A?\ OIBS#V%1:?\ "WQ+=64>G:KKJV^F0ME+:%VD!Y+'Y>!U)Y.>
MM>F:!X?T_P -Z8MAIT16,'+.W+R-_>8]S0!J4444""BBB@ HHHH **** -6B
MBBN<[ HHHH **** "LV7_7/_ +QK2K-E_P!<_P#O&KAN95=AE%%%:F 4444
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -'0_P#D,0?\"_\
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M?QJTR@<$MN0G _W0<^O/K0!ZK1110(**** "BBB@ HHHH U:***YSL"BBB@
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MS-8U?F6<?[]5]3Z+"_P8A1117FG0%%%% !1110 4444 %%%% !1110 4444
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MH%__ &%XTADBEC 5+O;DXZ MC[P./O#/OW-1_&7_ (_/#?\ UTF_G%7H6O\
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M_0)*[JM,T^'#_P#7M?G(G"[U/\3_ "04445Y1UA1110 4444 %%%% !1110
M4444 %%%% !1110!HZ'_ ,AB#_@7_H)KL:X[0_\ D,0?\"_]!-=C7W?"_P#N
M<O\ $_R1XN9?Q5Z?JPHHHKZ0\\**** "BBB@#S[XP_\ (I6G_7\G_HN2O$Z]
ML^,/_(I6G_7\G_HN2O$ZZ:7PF,]PHHHJR HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *]Z\/7UC9?#O1EU%5:UNE%L^X97YRP&?;
MM^->"UZIKG_)$M+_ -Z/^;5%17LBX.USC?&?AF7PQKLEOAC:2YDMI#W3/W2?
M4=#^![UF:'_R']-_Z^HO_0Q7HNA7$'Q#\(OH-_*JZM8C?;3')9E  #$]^NT_
M@>M>?Z9;3V?BBRMKF)HIH[R-71Q@J=XIIZ68FM;HZKXN_P#(X0_]>:?^A/7$
MK87CJ&6TG96&01&2"/RKMOB[_P CA#_UYI_Z$]5],^*.MZ5IEM806NGM%;QB
M-"\;EB!ZX<4HWY58;M=W.2_LZ^_Y\KC_ +]-_A3);2Y@4--;RQJ3@%T(&?QK
MN_\ A</B#_GSTS_OU)_\769KWQ%U?Q%I,FG7=M8I"[*Q:%'#<'(ZL1^E-.78
M5D<C5BPMQ>:C;6Q.!-*D>?3) JO15$GJ/Q1UF\TB>QT#39&M+%;17*PG!8;B
MH7/7 "?CGFN"TCQ#JFAWRW=E=R*P?>Z,Q*2>NX=\_G^->L#1X_B-X2LKS5H;
MC3[V%"([CC:XQR^T]5. ><'T..34T7X4:9;WRSW>JC44B(801QA%;!_B^8Y'
MMQ62E%*S-&FW=&)\7;.W35--U&--DUW ?-7 &=N,$^^&Q]%%><UU?Q UK4-7
M\22+?6<EFEMF.&WD'S!<_>)Z'/7(XZ8)ZGE*N"M%$RW"BBBJ)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZMKY2KZMK&MT-:?4
M****Q- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_OCM^5GP-\1]8U;Q);Z'J*VMR)2ZBZC78WRHS9P."#M]!UH ]7HHHH$%%%%
M!1110 4444 :M%%%<YV!1110 4444 %9LO\ KG_WC6E6;+_KG_WC5PW,JNPR
MBBBM3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I\7^N3_ 'A3
M*?%_KD_WA0QK<TJ***YSK"BBB@ HHHH KWG^I'^]5*KMY_J1_O52K6&QSU/B
M"BBBK,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KMG_J3_O52
MJ[9_ZD_[U3/8TI_$6****Q.@**** "BBB@#EO$O_ "$8_P#KB/YFL:MGQ+_R
M$8_^N(_F:QJ_,LX_WZKZGT6%_@Q"BBBO-.@**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[_;.J?\ 02O/^_[?XT?VSJG_ $$KS_O^W^-4J*/JU#^1?<@]I/NR[_;.J?\
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M[_;.J?\ 02O/^_[?XT?VSJG_ $$KS_O^W^-4J*/JU#^1?<@]I/NR[_;.J?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5]6U\I5]6UC6Z&M/J%%%%8F@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%95:M95:4S&KT"BBBM#$**** "BBB@ HHHH *\N\;?\ )6O"W_;+_P!&FO4:
M\N\;?\E:\+?]LO\ T::!GJ-%%% @HHHH **** "BBB@ HHHH U:***YSL"BB
MB@ HHHH *S9?]<_^\:TJS9?]<_\ O&KAN95=AE%%%:F 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !3XO\ 7)_O"F4^+_7)_O"AC6YI4445SG6%
M%%% !1110!7O/]2/]ZJ57;S_ %(_WJI5K#8YZGQ!1115F84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !5VS_P!2?]ZJ57;/_4G_ 'JF>QI3^(L4
M445B= 4444 %%%% 'B?QA_Y&VT_Z\4_]&25Y]7H/QA_Y&VT_Z\4_]&25Y]75
M#X482W"BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPB_B#_H!:G_X"2?X4?\ "+^(/^@%J?\ X"2?X5]+T4>U?8/9H^:/^$7\0?\
M0"U/_P !)/\ "C_A%_$'_0"U/_P$D_PKZ7HH]J^P>S1\T?\ "+^(/^@%J?\
MX"2?X4?\(OX@_P"@%J?_ ("2?X5]+T4>U?8/9H^:/^$7\0?] +4__ 23_"C_
M (1?Q!_T M3_ / 23_"OI>BCVK[![-'S1_PB_B#_ * 6I_\ @))_A1_PB_B#
M_H!:G_X"2?X5]+T4>U?8/9H^:/\ A%_$'_0"U/\ \!)/\*/^$7\0?] +4_\
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MOX@_Z 6I_P#@))_A1_PB_B#_ * 6I_\ @))_A7TO11[5]@]FCYH_X1?Q!_T
MM3_\!)/\*/\ A%_$'_0"U/\ \!)/\*^EZ*/:OL'LT?-'_"+^(/\ H!:G_P"
MDG^%'_"+^(/^@%J?_@))_A7TO11[5]@]FCYH_P"$7\0?] +4_P#P$D_PH_X1
M?Q!_T M3_P# 23_"OI>BCVK[![-'S1_PB_B#_H!:G_X"2?X4?\(OX@_Z 6I_
M^ DG^%?2]%'M7V#V:/FC_A%_$'_0"U/_ ,!)/\*/^$7\0?\ 0"U/_P !)/\
M"OI>BCVK[![-'S1_PB_B#_H!:G_X"2?X4?\ "+^(/^@%J?\ X"2?X5]+T4>U
M?8/9H^:/^$7\0?\ 0"U/_P !)/\ "C_A%_$'_0"U/_P$D_PKZ7HH]J^P>S1\
MT?\ "+^(/^@%J?\ X"2?X4?\(OX@_P"@%J?_ ("2?X5]+T4>U?8/9H^:/^$7
M\0?] +4__ 23_"C_ (1?Q!_T M3_ / 23_"OI>BCVK[![-'S1_PB_B#_ * 6
MI_\ @))_A7TO114RGS%1C8****@H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"1MM/^O%/_ $9)7GU=4/A1A+<****HD**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "G-'(J([(P1\[6(X;'7'K7I]K=>&/ ?A^S
MO(H[;5M:ND#AE<,$Z@D''R 9(Z9)&.QQ%:_%DWDWV?7='M)K&1L.$4G:ONK9
M#8Y],U/,^B*LNK/,Z*[/XA>%K70;ZVO=.).GWP+QKCB,\' /H0<C_P"M7&52
M=U<35M HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M -%/7T%7S[\-?^2@:9_VU_\ 13U]!5A5^(VI[!1116184444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %95:M95:4S&KT"BBBM#$**** "BBB@ KD/&/P^T[Q6?
MM(?[)J"C G1<AP.@<=_KUKK)I4@ADFD;;'&I9CC. !DUQO\ PM;PE_S^S?\
M@._^% SF!H?Q1T(K#IVHB^@7Y5_>HPV]N)<$?A3A??%N<;$LUC8#[VR!<^_S
M'&:Z7_A:WA+_ )_9O_ =_P#"C_A:WA+_ )_9O_ =_P#"@#F%\ >,O$SJ?$VM
M^5;AR3$'WGZA5P@_/CTKTG0M T_PYIRV.G0[(\[F9CEG;U8]S7._\+6\)?\
M/[-_X#O_ (5=TCX@^'M<U2'3K&ZE>YFW;%:%E!PI8\D>@- '44444""BBB@
MHHHH **** -6BBBN<[ HHHH **** "LV7_7/_O&M*LV7_7/_ +QJX;F57891
M116I@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4^+_ %R?[PIE
M/B_UR?[PH8UN:5%%%<YUA1110 4444 5[S_4C_>JE5V\_P!2/]ZJ5:PV.>I\
M044459F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5=L_\ 4G_>
MJE5VS_U)_P!ZIGL:4_B+%%%%8G0%%%% !1110!XG\8?^1MM/^O%/_1DE>?5Z
M#\8?^1MM/^O%/_1DE>?5U0^%&$MPHHHJB0HHHH **** "BBB@ HHHH ****
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ME>V5XG\8?^1MM/\ KQ3_ -&25I2^(B>QZ#\-?^2?Z9_VU_\ 1KUU=<I\-?\
MDG^F?]M?_1KUU=3+XF5'8****D84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_&K%AX1\/Z7>QWECI<$%S'G9(@.1D$'OZ$UMT4 %%%% !1110 4444 %%%%
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M5+@F5S,VO$7BK5?$]PLNH2KY:?ZN"(;8T]<#KGW)-8M%%4E8D**** "BBB@
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MD_QH_P"$H\0?]!W4_P#P+D_QKZ7HH]JNP<C[GS1_PE'B#_H.ZG_X%R?XT?\
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M'X;L?A70445DW=W-$%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "KMG_ *D_[U4JNV?^I/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !656K656E,QJ] HHHK0Q"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -6BBBN<[ HHHH **
M** "LV7_ %S_ .\:TJS9?]<_^\:N&YE5V&4445J8!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %/B_UR?[PIE/B_P!<G^\*&-;FE1117.=84444
M %%%% %>\_U(_P!ZJ57;S_4C_>JE6L-CGJ?$%%%%69A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %7;/_4G_>JE5VS_ -2?]ZIGL:4_B+%%%%8G
M0%%%% !1110!XG\8?^1MM/\ KQ3_ -&25Y]7H/QA_P"1MM/^O%/_ $9)7GU=
M4/A1A+<****HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** +.G?\ (4M/^NR?^A"O0?C)_P AK3?^O=O_ $*O/M._Y"EI_P!=D_\
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M7F]%3R1*YF2W-S/>7,ES<RM+-(Q9W<Y+&HJ**HD**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#J_AK_R4#3/^VO_ **>OH*O
MGWX:_P#)0-,_[:_^BGKZ"K"K\1M3V"BBBLBPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LJM6LJM*9C5Z!
M1116AB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :M%%%<
MYV!1110 4444 %9LO^N?_>-:59LO^N?_ 'C5PW,JNPRBBBM3 **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!U?PU_Y*!IG_;7_P!%
M/7T%7S[\-?\ DH&F?]M?_13U]!5A5^(VI[!1116184444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !656K656E
M,QJ] HHHK0Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -
M6BBBN<[ HHHH **** "LV7_7/_O&M*JS6FYV;?C)STJX-+<SJ1;V*=%6_L7_
M $T_2C[%_P!-/TJ^=&7LY%2BK?V+_II^E'V+_II^E'.@]G(J45;^Q?\ 33]*
M/L7_ $T_2CG0>SD5**M_8O\ II^E'V+_ *:?I1SH/9R*E%6_L7_33]*/L7_3
M3]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.1
M4HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7_33]*.=![.14I\7^N3_>
M%6/L7_33]*5;3:ZMOS@YZ4<R&H2N6:***Q.@**** "BBB@"O>?ZD?[U4JT9H
MO-0+G'.>E0_8O^FGZ5I&22,9P;=T5**M_8O^FGZ4?8O^FGZ57.B/9R*E%6_L
M7_33]*/L7_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_33]*/L7
M_33]*.=![.14HJW]B_Z:?I1]B_Z:?I1SH/9R*E%6_L7_ $T_2C[%_P!-/THY
MT'LY%2BK?V+_ *:?I1]B_P"FGZ4<Z#V<BI15O[%_TT_2C[%_TT_2CG0>SD5*
M*M_8O^FGZ4?8O^FGZ4<Z#V<BI5VS_P!2?]ZF_8O^FGZ5-#%Y2%<YYSTJ9231
M<(-.[)****S-@HHHH **** /$_C#_P C;:?]>*?^C)*\^KW?QA\/O^$LU:*_
M_M3[+Y< AV?9]^<,QSG</[WZ5S__  I;_J/_ /DG_P#9UT1G%*QE*+;/***]
M7_X4M_U'_P#R3_\ LZ/^%+?]1_\ \D__ +.G[2/<GDD>445ZO_PI;_J/_P#D
MG_\ 9T?\*6_ZC_\ Y)__ &='M(]PY)'E%%>K_P#"EO\ J/\ _DG_ /9T?\*6
M_P"H_P#^2?\ ]G1[2/<.21Y117J__"EO^H__ .2?_P!G1_PI;_J/_P#DG_\
M9T>TCW#DD>445ZO_ ,*6_P"H_P#^2?\ ]G1_PI;_ *C_ /Y)_P#V='M(]PY)
M'E%%>K_\*6_ZC_\ Y)__ &='_"EO^H__ .2?_P!G1[2/<.21Y117J_\ PI;_
M *C_ /Y)_P#V='_"EO\ J/\ _DG_ /9T>TCW#DD>445ZO_PI;_J/_P#DG_\
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MC_\ Y)__ &='M(]PY)'E%%>K_P#"EO\ J/\ _DG_ /9T?\*6_P"H_P#^2?\
M]G1[2/<.21Y117J__"EO^H__ .2?_P!G1_PI;_J/_P#DG_\ 9T>TCW#DD>44
M5ZO_ ,*6_P"H_P#^2?\ ]G1_PI;_ *C_ /Y)_P#V='M(]PY)'E%%>K_\*6_Z
MC_\ Y)__ &='_"EO^H__ .2?_P!G1[2/<.21Y117J_\ PI;_ *C_ /Y)_P#V
M='_"EO\ J/\ _DG_ /9T>TCW#DD>445ZO_PI;_J/_P#DG_\ 9T?\*6_ZC_\
MY)__ &='M(]PY)'E%%>K_P#"EO\ J/\ _DG_ /9T?\*6_P"H_P#^2?\ ]G1[
M2/<.21Y117J__"EO^H__ .2?_P!G1_PI;_J/_P#DG_\ 9T>TCW#DD>445ZO_
M ,*6_P"H_P#^2?\ ]G1_PI;_ *C_ /Y)_P#V='M(]PY)')_#7_DH&F?]M?\
MT4]?05>?>&OAC_PCOB"UU7^V/M'D;_W7V;9NW(5Z[SCKGI7H-95))O0T@FEJ
M%%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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$V<C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img114804231_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #H 9T# 2(  A$! Q$!_\0
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MNY/F#$8([]:QKW_@H3\(K&XN8GF\1.(%N':6/P_=-&8[=RES(K!,%(B/G;H
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MO3;Z1]JY_<I O.6(:,G.?O''2G^"OA?J-]KWCK3->\4>*0V@ZE;64<EGJXA
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M&6P.!GI5;QQX;B\7>%-2TF8#%S$0A/\ "XY4_F!4/%.5>-9[JU_NLQ/1&/\
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M'BC1;#6-*NDO=,OX$N;:YCSMDC=0RL,\\@CKS5ZO+_V7_P#DW7X<?]@.U_\
M18KU"OB:D>2<HKHSUSX?UGX:Z@UO+) LC(^$\S'J.E<_KWPDU)5A6>-V#KYK
M;?FVYQ@_4U[/I/[2/A&^DEDU2Q:((RI%' ,+L QT'X5R'CC]HK1WUC2Y=)L2
M+2 C[3#)TF (./TKVOD?/7MU.0M_A[/8V$<IR[* 06S\F./Z"N'\1Z_J'A%I
MA&",EI1Y@R,D=?SKZ \/_'#0?B#K7V*ZMK;1[$0F5RV!N=1\H&.]>>?'ZWT7
M7/#NF3Z3J-O>7"*?-BC&#\Y.,>H4#]:]C*:D*>*CSK<Z*#_>(^3?%^O75]9R
ME!^_D<!F4<X/6L7P7'!)'(64F7?M+'KBN^ET'5H=/N[Q-.DN+:!59F";E0MD
M*3Z9P<?C7G?AF&[CO9R8RD;R?-D?=.:_0(R4JECUV>I>,+;1M-MY%L-UO*L0
MY8Y+OC^M>6V>H.T=P[HK2/(%#$<UTT,>D:MK$UOKFJS:/9QP&3[1#$96$F0
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M?E/$%25+.<,X_:<?P9YLL>G_ &IM\3 ,@3=GD$'K4>L:#I,RK+ ZD/)@H!R
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/%(8I^:H64;CFBBD-'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img114804231_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #H 9T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[I_X1S5?^
M@;=?]^6_PI&\.:K_ - VZ_[\M_A6G^U1\6]3^!?P'\3^.-(MK6[U#2OLI2&]
M1WB(DNHHGR%(8X61B,'J!7E'@C]O'0/$?Q(\7VMW#-%X'LM0T72M.U9M/FMI
M(I[R*=G:[$Q4I'OA"JVT#YAUR#75"A4J0=2*NO\ AO\ ,Q]FNYZ%_P (YJW_
M $#;O_ORW^%'_".:M_T#;O\ [\M_A7(W?[?_ ($MXX)H?#7C'4+9M*_MV>XL
MM)$J6NG?:9;?[5+A\B/="S# )*E2!S71Q_MG?#^X\=0>'K:/6+K3YKV+2D\3
MPV).DF_EC$D5IY^?]8RD8^7&3C.:/J]9?98O9KN6_P#A'-6_Z!MW_P!^6_PH
M_P"$<U;_ *!MW_WY;_"O,_$'_!0CP_J'PLU_7_#&@ZUINI_\(]=Z[X?D\3Z:
MT-EJRV^/-$3(^7V9!(R..0373Z7^W-X1G\/R&[\.^*8_%L-[::;_ ,(HNE_\
M3&ZN+BW-Q&88]^"C1J[AF885><<53PM9*_*'LUW.E_X1S5O^@;=_]^6_PH_X
M1S5O^@;=_P#?EO\ "LC1?VXOAYXD\5>"_#VEV^MWFH>*(WDB46/EBR*2M"Z7
M&]@599$92%#8QD\$$\CKG_!0#PY?_#WQ#JWAW0M<T_41H.J:KX>NO$>FM#I^
MJRV43O-%&ZOEMFW+#C(S@\4EAJS=N4/9KN>B_P#".:M_T#;O_ORW^%'_  CF
MK?\ 0-N_^_+?X5R?A_\ ;L\)WGA4RZEX?\36_BR&73;/_A&DTLB]OKB\@:6$
MVT9<AD=8IF!9@0J9..*I0_M\Z!JGBKP=INF>#?$CZ?K6IW^F7U]>VOD-ILEH
MJF8O'DY"[LMDC:JL>>E/ZM6_E_K</9KN=S_PCFK?] V[_P"_+?X4?\(YJW_0
M-N_^_+?X5R5K_P % /A]+;7MW=:'XMTRPBT6X\06EW>Z28X]0L8I$C\Z#YLL
M&:1<9 XY.!55_P!MS0X]:TS6[HSZ9X*NO"4^NFQN=/9]2>9;Z.UC5"DC(=S.
M%5!DDL#GT/JU;^4/9KN=O_PCFK?] V[_ ._+?X53N+6:SD,<\3PR?W9%*G]:
MZ?X,?M!:/\:M4\3Z59Z'K_AS6/#;6J:EIWB&R%M/$T\;21C:&;/RKG/3D8SF
MNE^)-G%+H2SLH\V*10K=\'J*YY1E"7+):BE35KH\O'6G4RGTC(?135-.H :W
M6DI6ZTUNE QM%%%!#"BBB@04Y:;3Q04API:%YHQ2+L%%%%( HHHIH HI&IN:
M8A])FFT4 .R*4<\#FF5Y[^T%J%UI?P;\37-G<26MRL4*K-"Q5E#7$2M@CIE6
M(_&@%J['HOXTY37Q9\'?AMJ/Q4\*ZO?KXDO;2]L=5T^T N-5%O$T,S,)3ESR
M^%^4 \GL:Z2Q^&F@3:IX[CNO&7B"R@\%:G<_VC&]Z3+<V"[DA,7&!*90J'/'
MS XJ3?D\SZQW49KY*\-_#G1?$OASP99#Q%XLM/%WBC2[W4;687@DL(3!)* D
MJ\.%*Q<L#P3^%6]4^#,$/P5TOQ7%XB\16>I7>G6MVMU=:BK64L\TWEBV"#$B
MMCY@QR.#0/D/JG=2?C7R3XH^'NB6(\:Z'I7B/Q:WB?P9:_:]0N+ZY"V5X%=5
ME6,#YH^6^1F)R!3OB%X!\.?#J;P'=7OB+Q@^D>*'6]:22X,;V=BT:<-E2&F5
MW)..-JCC)S0'(?6E-/UKYAT_X&VZ_%*W\'W?BSQ!J"Z5ILVJ>(;S2[EGVIG]
MQ' N"2Q#1DYS]XXZ5)X#^ QU#Q%\0M)\1:YXD#>'-4M;&*6RU-( (9FE_?R&
M;@JJHK8!&><4A<A]-45\G?\ "D;UO@OKWBRW\2ZY?:G:SW-Q8&":3[)=:?!,
ML3RYZAB2S 9^ZA/-6T\!^$=<UCX96.D:UXV@/B]'NF:]U*-O)@1I4*C:OWRT
M8.>1@GO3N'L_,^IJ*^.(]$\,R?"&U\0C5O&0UR76AH)7^T4^S>?M#F3&-VS:
M<8SG-0?M&>$K3X4Z]::5H6N:Y/)NE6>2[UN*Y)V[<?)$0T1^8_+(,G\#1</9
M^9]N:/I,FL7HMT/E@#<[L.%'K6I=>%8+5PK7Q)_ZY_\ UZ\;^$_Q+?0_@WX5
MN;NX>>YN+4B:YE;<S%6( )/HN*SM=^/<37?$X_.D-074^GOBK\,=%^,?@/4O
M"'B$7#:/J!A,PM9?+D_=3)*N&P<?-&OX9KRGX^?LJV_Q.\._$.WT"XM;'6/'
M_P#9MKK-YJP>:.&WM,JDEO&N-LRJQ*DG&[!-7C<R_P#/5_\ OHTW[3-_SU?_
M +Z-;PJ3IVY7_6G^2)]IY'(>(OV%](\6?$J&\O-:U+3?!%OX.L?"J:3HFH2V
M<MS'!-*[QW&T8>%U=05SG(/2NTD_8Y^'D?CA/$]I!J5IY-S'J,6@QZA(ND"_
MCB\J*[-J/E\U5 P>G&<9YJ$W4W_/5_\ OHTGVF;_ )ZO_P!]&M'B*S^T+VB[
M'"?"+_@GSX7\,?"^RT#QIJVK>)-7&A3Z'(RZG*]G8QSMF?[#&X_<[P%R<=CC
M&3GT7Q5^Q_X#\5ZEJVJR2ZWINMW]QI]W'JVEZBUO=64UG;-;0R6[J/D/E,RM
MU#9/%5?M,W_/5_\ OHT?:9O^>K_]]&B6(K2ES.0O:+L5Y?V'_ALTW@LH=<CM
MO"<JW-G8_P!JR&">X68S^?.IR7D,K%BP(W=#D "N.^$O_!/[PUX<^'\6E>-=
M6U7Q'JK:7J.ELD>IRFPL4O"ZSO9Q./W+O&P4G![X'-=S]IF_YZO_ -]&C[3-
M_P ]7_[Z-'UFM:W,_P"O^'%[1=BQXD_8\\ ^)KB^NY9-:L-4N%TOR-3T_4&@
MNK&33XI(K:6W<#Y'"2R*QYSNZ5!H_P"QA\/M#TW0[.WFUYVTG6;G7(KJ;5'>
M>::Y4+<I,Y&9(Y5&&5NH)YYI/M,W_/5_^^C1]IF_YZO_ -]&I]O5M;F8_:+L
M9VA_L*_#_P /37,EIK'B_#:3/H=HDFO2N-.LI71S#;9YC4,@P,GC(.X&ETG]
M@WX4Z3H+Z5]EU:[@DTRXTR26YU!FE<372W3S;@!ME$R*RLN ,=*T/M,W_/5_
M^^C1]IF_YZO_ -]&G]8K?SL/:+L=5\&OV??#_P $;_Q)J&DZGKVM:IXB:W?4
MM0\0:BU[<3M C)&2[ '[K8].!C&*W?B1JD$>E+9!PUQ(ZML!Y"CN:\X^TS?\
M]7_[Z-,W%F))R?4UC*4IOFD[L3J75D@ I:*4=:1F&VDI]-:@8E%%2+"6&1S2
M*C%S=HHAI*>RTRF0U9V844HIU AN*=13MM R.;5+/2E66]D,<.<%@,FLC1_&
M5EXAO[B"T.[R@"2/<U<UC1[?6[-[6ZC\R%^HR1^((Z54\-^$=/\ "\+QV,'E
M!SEV)+,WU)I:=3WZ>)PBP,J3A^\[]#=HHHI6/%$*TE.I&I"8TTVGTC59(VBG
MK&2,TRD5*$DN9K0*YGXE>#C\0? NK^'ENA9M?(@6=EW!&619!D>F4 /L:Z4T
M"F9GS/I/[+OC;1-+FTVR\::5!937<%])"+:0@S0DF)\E,_*2?;UJQ-^S3X]N
M+GQ+<2>.=+:;Q&"-5;[-)_I(,@E.?DX^< _+BOI):=2L:\[/ [7X+_%2R\%Q
M^$[;XC:=;Z#'"]NMO#:.C")V+.GF!-^TECD;N<XK/F_9Y^(MQHCZ/+X]TN33
M'LHM.:V:U<IY$;EXU^YU5B2&^\,GFOHRBD/G9X+K7P;^*_B+P[#H>I?$C3[O
M3(_+!BDM7W2A,;%E?9ND P.')'%9_BG]GWXD>-K.2UUSQ_INI0/=_;MDUM)\
MDVP)E,)\@VJHVK@<#BOHJB@.=GSY_P *+^*"WFLW<7Q'L;>[UA(8[VXMX)(I
M)5BQY8W*@*@8'W<9[YJ'7OV??B1XHM=3M]4\?Z;>1:E]F^V>9;2;I_LZE82S
M!,DJ"1GOWS7T4JEV"J"S'@ #FK#:7>+R;68#WC-(.:1\[VGP3^*MC9VMG;_$
MJSAL;:P.F1V:PR>1]G*LI0Q[-K9#'+$$\]:S[+]G'X@Z==>'KFW\=Z7%/X?B
M:#3'%K(?LZ,S,0/DYY=CSGK7T?R.#P:2JL+G9\K:I^SKXKT'0;?2;CQSI2:;
M]O.JI!]FEP+D*%,F=N<X XSCVK'^)VA^)O''V9O$_CW2]4:U+&)DL/+;YL9R
M412W0=<U],?$OPC=>-/"=U8Z>VS5%'F6C'@&0?PGV(X_*OE'4?@#\9[F1B_A
MF8+GO<1__%4C6,KH[SX=VTGCC2_^%=Z9(\TOV/-I=;?]7-'SO8#HK9(/L1WK
M"OOV._C T[%QI8YXS?"O<?V;?!B_!3PS-?Z\L8\3ZED2C<&^SQ \(#ZD]:[7
M7/C%:+= "50/K2&:)-,)HS259QW"B@U'/J5MI<?GW3;8@<$TC;#T98BK&E#=
MDC9%-S64OC?2-8UC['8.6R"5SR<#UK4'-,Z,=@JF!J^RJ[[C\T9%-HHT//'9
MI-U(%+=*&4KUH'9[ADTX&FT4$CJ6DJ>V@:>0(HW,QP!2-:<95'RQ6I%N]:6G
M3*(96C)&Y3@KW%,S074ISI2Y9JS';J2DR*3=3,QV:YGQAXRU+PS ?L=F]S',
MNPLB;L'^E='36C#<FD>C@<9]1K*KRJ7DS$\'WNH:AI"3ZC$8)Y&+"-NH7MFM
MVD50O2GK3.;$5GB*LJK5KNXHHHI]!@(!2T44AA3L8I&D2!2[G"J,DUDW7C+2
MUU"WLX;@2R3$*,#!#'M2U;/5PV7UL53E5IK2.YKT4BMN&:6G<\T*=L)%-/'-
M<7XT^(TGAAFL_LC,TN/+D"DD^PI;GK9=@?[0J^RYK'94AK-\.W5S?:3;37<9
MBGD3<R'J/K6GBF>;5I^RJ."=['&^./%FK:"IBL[*2YBF  :./=@YZ>U:OA*2
M_FT:!]13R[I@69#U7)X!]\5LM$&H>2.UC+N=J*.31LCUZF/GC,/3P48)6>ZW
M?06BLR3Q3IK:I%8PW"RR2< J>IQG%:B]*9Y^,P57 S4*RLVKCJ,8JK?:O:Z1
M&LMVY2(M@D#-9&A>-+3Q%J%Q;VQW"(;MWMG%+5G3#+*TL(\6OA1T-%%%2>0%
M%%*%IW&:V@WUKHT@O;EE\SD1*>WJU9OC+XH6D,#A)QG']ZN)^+,=_#X/N=0T
MT.]S8J96B3DO'_%@>HZ_@:^,]>^-5U?.Z^8^/J:1O'8^P?!?Q$MM<UZYTQY@
M99 98<GKC[P_K^==YM/H?RKP3]COPDVK7LGCO705L[<M%812?\M9"/F?'H!_
M.OI3Q9\0+2U@;RY5''; IW)<.9W#0;^TT1_MERRB4@B)3V]6_I61XT^*%I#
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MI/A=\*Q^SS\/]&\'PW/]L3PQ.TFJ3 0H269G"+D[1D]R2:\W%XNG.*]B]?\
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M8J\"GYHHHZ#+.C:/J/B35K;3-*LI]0U"X?9#;6Z%W<^@ KT*3]FOXIVZEI?
MVK(!_>B'^-%%<M2HX221W4:,:D')GG=Y:S6-U-;7,,EO<0N8Y(I%*LC X((/
..0@U3;[WK1170<>S/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img114804231_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114804231_13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #H 9T# 2(  A$! Q$!_\0
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MJ+A8#+OS\P/'';G&16/U:KK97L/V:[G1?\(YJW_0-N_^_+?X4?\ ".:M_P!
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MX8-(Y[9( X%==36<+41N$_O5/O2=WJ4E&*45HB2BG$4 5)0;:;3Z90 4444
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MN2WA/E#:QXSWYKH=#TRRU#3XY)5"MT88JU!I<#W8BC"X[9%58PE4BM$CVO\
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M,K2MI:QQU*5.7-*3V/T\TS]J_P"'EOK"32^(K4VKVK!HFN%*I*<=!VKO;?\
M:N^%=Y_9KMXY\.QQ&W5)_M=PWGQ\C(R%Z_0]J^&?&'PM\(+\2OA[=:18Z3/H
M#:F=&U"VL;E+A)3'@H\I4_*[KG(/.14/_"M_ 47B'X>)IL5M?Z)JDNM2S221
MAI515!2*09Y:(Y ^@K=Y1&_Q'SJS#"N,9*,M4WTTLI.S\_=T/O2W_:T^#VGS
M7DD?CK3;B3!CC6:X+(5ST&1T^N:N7'[6GP?'RP^/O#]LA8!EMG)+KCW  YK\
MY#X(\*GQSK]C<V-O:>$K?PK]ITW4K>(3R3QX7%WU&Z4L6!&1C&.W/F_QYT/1
M] \7V%MH<:+I[:-8S*ZQA#*6A!,C+DX9NI'J:B64PBK\S.W#U:&(J*E%--J_
MY?CKJC]:-:^+_A:*UF6T!U:*>>-]\LH9'CQN !]-O/O7/Z[^T-%::U;VFE0H
M+)-Q6.49V KT^GH*^5_ ,5]=>$?#T>UC;BUA:/;Z^6 #^M=;/X7N[A?M&YQ,
M20=H^[Z?TKYR4>6378J249-'NEA\?+72-)L9[:$W%Y>W!>Z\_!4X)&%_V14.
MI?M.2V\=J8+>*W197CV <;<GJ/3OBO%8_#-P]I9JH8X!"-Z$'FE;X=ZC=0I&
M$8_O,JV#D'!)J;$W1WOAW]H349+C5)99RUO)(I,'48#'I^M=S8_M#Z?)YL,L
M<EO&S2D-$_[PX[ECGC(_2O$=,^$]]';F18VA9%=E$G 91GL>M9<W@74]TN58
MQJ&)8#D;NH_2C4?NGJ-K^TE.VM6KR1I=-NB"2./NYSGGL,5!X^^/$&N^&U$@
ME69KQH2H/RF/.2![^]>/0^!;Z+5!% ),1Y;;SQM'6H-4\"ZK''!;&*1I=RG/
M/#,<]/KFEJ+W6=+\7/'5CJD4%O:P;%2/,)8[VCQC[S=3^->!>-O%=QJ5K%;2
MN7$/" ]%^GXUZGXD\#:A#:&ZFB8;5((QP #C/YXKR'4-#EOM82)%+ '+8]!6
M4[FM)QCZ'-:?"KS,9V\N.,!G_O$'L!ZFM7Q->65U:W=K;_*EJ0;<_EN7\>?R
MJ>X\(W2,QP1YKC)Z9(YJK<>#[K>YVGGD\5CR.UCH]I"33;.2TJXV7W#,JG .
M/K79WT-CJFH6]K:O]G:<JHEE;<%XY)P*Y=M)DL]04,FP,H/U]ZTK;3YIK]6C
M4D)_,BHBGL=,G&W,F>I> &LO#>J02W5Y'<A96AV(N =O5LFO</"?C#1-1O+7
MS)XDBF1]BA 3'M/!KY173-0W;X_X0S].OJ?TK0TB^U/3Y/,59&98F3 Z\]_Y
M?G73%N.AY]2C&H[MGW#IM]HJ\W#V\\3JC0.@&<G^^/I74GX>VDFG[;><P:?<
M2&49PWE(.X8GH6[5\(P^,M3AF1@7,"ND9Z\8.1Q[=/PKTT_'+4K?PRD,EY*Y
MCML*&/0LQP/Y?K6O.V8K#J.S+7QD_9_MVUNXO=)U&"(3(T\D%PFS;W."..3T
M'O7S9J&DW'A_6I;>;"S0GGOVS_6OHCQ1\:;G6O!=U'<XFG!C4.Q^;.WG\,$5
MX7JMC<ZO8S:K$5+12%9%9OF*G&",^G2N"K!;H]"ES;,YV\O)+J7!.X?2IEN#
M##P?PJW>:E91:-$!$J3*,.?XB:YV76$\K/EL*Y#H2YNAHV"SZE?"&/+2R<!1
MR3SQCWKWGPQX(USX5^%=7U*_M-MMJ%FVGM"Y!8F3NP[!<9]<X%<+\$]/TN*X
M&O:G"T[PS!8(U? 5NS,/K7OFI>)1J.AM;W.Z>SD8JP8JQ3)XSZ\UV4Z-US,Y
M*U2SY4?-_B6[B^RR6H^9-NT9KG--T>06BR>9F'?@+GGZXK4\9Z>NGZU?112E
MK=92(V;J5[5DV^H"*$H#7+)6=C:,;1T.WAU*#1]+%J=LDA;<6';VJA)K,2J7
M5\'%<7?:L\K84DFJ1NIY/EW8%*Y*P]]6=WI'C">WOD'F$+]:^K_V;?BY>VNO
M66F-.TME=2",Q,<@$\ CTYKXBL()I)DZYSQ7U_\ LQ_"'6Y-8TS7KUEL["%A
M,@9LR28Y'R]0/KVJXQ<M$*453DI)GWI!)YD:FI*H6=POEJ <XZ]JMK(#2E3E
M$[8U8RZDE2:@ ]Q,K#<K$@@]P>M1!JEOO^/J7ZUD:W/DO5_^":'P?U?5+N^-
MQXFM#<3-,8+?4(A%&6))"AH6..>Y-5/^'8/P>R";_P 6'ZZC!_\ (]?7-%=Z
MQV)_Y^,5S*\*^&=/\%^&=*T#283;Z9IEM':6T18L5C10J@D\DX'4]:U:**XF
MVW=B/R5^U2*WWC39)'DY)S4JV^?>I5M\\;:^DL?)\QG>=+%RI(IKWD[]7.?4
M&MJ/1)K@$HA(^E5I],>W;:ZXHBW"7-%ZHZ$YQ2G8YK7/%VK:7I:VL=W+$K2B
M3"-@-M'!_"H+6![S2X9FC9+R3+RLQ^^2<YK-\:2"77[*P0Y;"@CW8_X5VB6>
M&6-!D#@5[E3,*R4)]3OEBIJ,--6<9]ADFN+J%(U/GE1D]1CJ:OZ;X5=KA Z^
M5&#DX KOT\'WRV/VS[))Y'_/;RSM_.J*QF)L$8.:XJV-EB)7-,1B:U%?!RI]
MSM/#OA_3K'RBEU&KPQH\0)SA\U:;]D7X?WEU+JDE[=6MM)=*&:UNR-F[EBH/
MIDUR-K(VX8-;]O?SK#Y>]MF<[<\5RPE4BVXRM<\KZ[*-[&MI/[(7PJNKR>!M
M>U:$+=HD82ZY93C+=.O6NNF_X)W^#H/.>.ZUHPPERLJWH(^Z"3P/?FN*L[V6
M-PZN0WKFNFA^)6NVD+QQZE<!6!5@7)X/6M'4K])DK,9/=E^W_8$^&-TUE';:
M[K5T+G<B+%>J" !D@C' XI)_^">_PVCFB^V:YJ,&Z+<%FO@6XR-OW>.@_.N8
MM?%6H6-RLT%S)%(N<,K$$9ZU%>>(K^\;=)<RN?5G)H]IB/YV']HR[GO6D:;\
M/O"LVB:3'?+]CM[,P*P;(C95 7)[]._>L&\^*V@+-J%E%8H/,588;D'Y5(."
M^/R/X5X=/=2OG+$UF32/N)!YKG]EU;.;ZTY'U'/\1O!_AB673>-2MU@S'<1C
M_EH<<_7C]:SM:_: T.!;N.QL&,3Q#R2W!27NWZ"OFGSI&[FF2,Q'6CV:#V[Z
M'TAX?_: L-6L8K/7$\MX8I,748^9CCY1BN@E^,7A6'19;VR*+/;M&4LYDYE/
M&23^ KY'#%3P<4-</C&XU/LT6JS/I+1?C1X:6ZO+B[L3'+/$P(C'&[<"!^E3
M^(/B+X9NO'&CWGVY4LO)$LY@7&'V\)],]Z^9%9^NZHGF?/WC2]F-53W_ .(G
MQ2\/:[X9OC;[H+Z20(L"\)L[G\?Z5\_Z5X@2/7'>*)68HRG<.QJM<LUPNTM@
M5!I&F&WU*7/4#!K%Q]](Z4TZ3D>C::-+N;*-[N;]_P#-E=O'3 I9IM-NK&.'
MRA%.S!6DQPJ\#-8=O =HJ>2W95KJ]FCS?;:G)_$RWT>/Q%%;6&#% F#,/XR3
M_08KH?AOX?L;_3;B24QQM'NEW,<;NV*XOQ!I<T^H37 &5W8'X5V'AVS>TTJ!
M&X;;D_B<UR4X<TV>G6GR48GHMOI/A>WBNX#,KS-&BQ-C@D]:VM%^%.CWT=V%
MNH&N5G2%%##Y@0#D?E7E<VY><T^UU2[LY%DBF='4Y#*W.:Z'2[''&NNIZBWP
M9L+BV46\B_;?.EEE@[C'RC'YYKG/$'P+N(+&3;$68,L0P/XAU_G6+IOC;4]-
MU"*[%S(TL9!&YB0<'.#[9KL)?CYJLVH6UQ<)'(D,IE,./E)-9NFSIC771GE7
MB;X6WVFZ;)\K^5YA..O3@<_G7*ZQX9U#1]'6+R9"MP?,VGIQV_&O>O&?Q?L/
M$.FVMK:60MB8PLZ\8W#."/S-=5KUEX:\0:/IFH275M:JUAO\LD9\Q5  -<\J
M9UQK,^![ZS=+IS(I!/(J)8Q@LW)]Z]?^*/A*VAN'NK%DF@ 7/E=%R,X_0UYG
M#IKS3+$!DL<5YDXVE8]6%12C<Z_P[XHMM"L;.WA4[LJSMZ_+EOYX_"N^M/'E
MG#:R,CB!MCRD8'8UY3-X5F29=H<D'@+56XL;FVC=&W$'BNI<T48.,)&O\3?$
M4&N7%O/;[=Q7YPHP<\=:YW28H+K<96(('2JEQ _VHJ>?2K4L(A3Y?E;U%<<G
M>1NDHKE1--9J)/W2[L]!UKT;X4^$;&\9[G5;!;B)7 'FL=J_[RCG'N:X[P_J
MR:3:2'RU>Y;D2,,D>PKU+P3XDT^&-+>X4HKP[)FS@G/6NFE!)W9E4O:R.]T/
MX7^'FU1]172)!&I!2W5P4#>P!Z5[EX+\40HL]NC,5@<*\:I@J>O.#C]*^>--
M\<6<CP6Z2;8^5W!\.=K#!./;IZ\^E==I]Y';R+=:&))UGG\JZ5I<F3/\6#^/
M3CI7H1<>B/.G&6[/I.Q\:FWGBF7<+:;Y3M4[AZ$UU]CXJB\Z.)Y6D>0X'7(!
MZY^AKP70]6F0FVC2Y5)"=LD@W!0.J_A7?^%=26[F1)Y?-GV-\ZJ4 7N1G[U6
MXIF/,T>IQ:Y#'(D32['QRKYR?I7B'[9G[6%_^S;9Z#)H^A6FM7NKSRK_ ,3"
M1UBB1%4YPA!).\8Y X[YKH+C7M4.NWELMGL:'YK>:Z# ,N 2H]2:^1/^"D-]
M_:GAWX>W*"0Q)/=1EWC*[24C(!_7'T-7A\/3J5HJ:NCNPU64I\K.[_X;I^*3
M> X_%$7A;P)-$VGMJATY;J]%VMJLGEM(5+!<!O1B:ZO]D?\ ;DUK]H?XD77A
M/6_#&FZ2WV&2\@N=-EE(RA&Y7$C-G(/!&*_//4/C!J^M>$/#_@^.Y?3-#L[=
M;.YCAFXN@92Y=^.!\PXY'R@U[_\ \$[;..P_:DU46!:ZL+33+Q!<)\ZA"RA6
M+  <^O&:]G&9?A8T)2IPLTOQ-L/*O%3^LVW;5NW2_F?J;14$=TK<9]_2E>X5
M3S7Q+IR70Z/:Q?4_*&.4"K<+*S FJ&VIK=SNQ7T2/E7W/HOX'^+/#'AK2;M]
M0LH+J_DRH:89VKC@K^.:\N^(^H6.L>(;NXL8%@@9N%48'N<5SEK)*%PA/X4R
MY60??!%<\:/+4<[GVF+X@IXC*(9?&@DU:\O3R[OJ>/6LCZQ\5YLHPCMW9AN!
M'"+@'\\5Z?8S+#=(SC*@\TZ0 MG STSCFJL@_"NVM+VEM+65CY18CWXS2^&Q
M]-:U\=-(F\ II5K9VZ1+#Y:QA #R,8-?-]Q,))V8#C-5(6DE<(":[K2OA/KV
MI:(VJP:=/+9*,F4+QQZ>M>?3A&AN]S[7-LTQ/$T84Z-#X$_A3?K\BKX(\.S>
M)]8M[&W ,LS;5R<#ZFO3_B/\&KCX?V,,TM[;W6[&X0G[I(S^->8:!J5SX7U*
M.XMW,<T9X-;WB7Q]?^)E1+F1F1>=N>]:2]K[1<NQR8"GDO\ 9E;ZX[5U?E6O
MR\M][F7#)M.*LY#"J%OECFKVW"UZ"/SB5KD87YJ>T?RT*IS4ZKQS3)N4)(3S
M52:WK891TJO-%QTI#4C(:+:#BHV7-7)8]M4IFVDXI&L7<K2+M:H#G=5EEW>]
M0F,^E0T;)CE7<*BFA]*L1K3I(\K18.;4S880SX)X/%:%O!Y.KW$;?W5-16-N
MEQJ"QN2(UY;'?VIOBK4+.&YCDMV9;@':S9XP!7%*252YZL*;E1:[G46L8P/2
MI[C9'"Q)P%&:R=(U#[98QS@_*R@US^H:X-2N"OGO'#\P"K[=,_6NN511C<\J
ME1E4G;L:,.GRWDL$<P4!O](/K@]!6Z8Q&,5S&C:FT>L0JQW)(OECV(''\JZ]
MTWKFLZ"5KF^-DU-1Z&?(NZHUC/I5IHR&Z5)Y?RYKIL<',9\D8JA<Q]JU)UK,
MN&PU2S6+,Z2-E;.:=]JEVA=QV^F:G;#"HF4=:RL=*DS+UR29M-FC61E1RI=<
M\-CIG\ZRO#NG10ZI9RW*[HA)\P%;&K+NT^;'4#(J"-O+DL8\88D$UY=>/[U'
MI4:C5-G8VJ:?YQ+Q,%:-4W9Y!!Y-1^(=%TEH1-#(I#.04[A0.N*JJ=J\5A>*
MM0:STV5E/SGY5^IKLG3C&-S"G7E*21Q#6"37T\@P54G&*T=%\,RZMY\WE[HX
M5R1[DXK,L1(,*I)+'IZUW>AZM-H<3I#M"R*%<$9S7E4J;J2N>O4J<FERI%\/
M1NE>>2.SM8(6N9[JX.R.*,#)9CCH!V ))P "2!65;ZAX4A)8^.]&+$]UN^?3
M_EA77>+O%SZQ\/?%MJT$4872&&Y>IQ+%7FO[/T-U+X=\=G2;;1KKQ"L-G]@7
M64MV3_7'S<>?\OW,YKZ3 X&&)BW)M>GH14K*GAW6>MFEO9:M+5_.[-V/5O#%
MK.DUOXYT42+T.+L?^T*VM(^(6BZ4UGL\=:,!"Y=MHN_F.,9/[C_.*S]<\ _#
MOQ%-XNUR)U@301&]_%IDVVUN)98%4+;D\ +<[L\XVGCBMRZ\#_#[X>#Q$([>
M&:&\T2%8VN-026>W\RX6*1L88*VUMV5)X4X(S7J?V-2_F?X?Y'"\SH624)<S
MMIZVT^YIF]9_'72;-(0/'VDN0KLWR78^=CT_U'0"NQ\$?M/>%-%D@.J^,-)O
M/(@9(VV79VN2.1^X]J\/U#X,^"_"<>HW6K;KM+>/5KN"UM]53=-##)!]E&Y<
MX+)(_N?3BJ^O?"?P1I&CZ_?Z=!-KXMIF=HUUR&V;3X?*CD0'<,S%BSKD#^''
M6C^R(+[3_KY%+'X2I:T6T_2V]M[_ -=-=#Z^@_;$^%_D0W,OCB'^TRRM)^ZN
MC$,'! 'D=,9KII?VQ/@->7:2WWC"SO5'R>7+I]T8POKM,)Y%?(NO> _ >I:G
M=Z; MKI&B7.H6<MM!;WT1^U VDC +*03$'=0AR>#DGJ*PQ\*/AQ8:I''?I.)
M;J^TZQDT^/6$8Z:]PK^9NE4$2!-JM[;L$U7]DP_F?]?(YXX["M7<))V3MIUM
M_7;SOH?7M_\ M2? 2%I9+#Q-H<H*A1#-H]R"3GD@^1QQ78?#[]ISX-:]K4&A
M^%]=TO\ M>]^6"TCLYH3=2 $[-[Q*N<9QDCTKX3TGX2>"]/T"'4T;[7):QQ7
M*:L^J1;);@7:HT!MNH"IDYZ?F*YOP;>6MA^V!97<)C%E!XH>53#C9L61C\N.
M,8':LZN6PIP<G)_U\CMP]6CBIRIT[Z7W\K?Y^OD?K=)J<UO(;>*"9GB EER
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MM+Z$6F_LWZE)XDT71M0OTTR\OM,GU.:%K=GFB\J5HS$D8.9')7( Z@U1\'?
MF?QEX\UWP];ZQ;VT&E(2=0N('C21RP6./8P#*S,P&#[UT,FO?$_4M6T2_P!:
M^'U]KTNEZ:=+47^CW+&6/=D.6 !60= ZD''U-7U^('QCMM2UK4++P7?V5]JU
MS;SSS+H,LA"0IMBB D1A@=<_>SSFKYZ'<\]QS6S2:NUY63YO1OX?Z?3R6Y\
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MV#).W'7O7H?C+0;OQ1X+UW2;!5DOYXHW@A9@IE9)48H">-VT,1GKC'4BO)_
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B4V2FQ5X%.SQ110,C9SNQ4JL>M%%(8I^:H64;C112&C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>rlyb-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T16:22:49.9216+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://rallybio.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:rlyb="http://rallybio.com/20221231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails2" id="DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Future Minimum Annual Lease Payments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical" id="StatementConsolidatedBalanceSheetParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheet (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity1">
        <link:definition>100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1" id="StatementConsolidatedStatementsOfCashFlows1">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBusiness1" id="DisclosureBusiness1">
        <link:definition>100090 - Disclosure - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1" id="DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements" id="DisclosureLicenseAndCollaborationAgreements">
        <link:definition>100110 - Disclosure - License And Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>100120 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>100130 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>100140 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquity1" id="DisclosureStockholdersEquity1">
        <link:definition>100150 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureCollaborationAgreement" id="DisclosureCollaborationAgreement">
        <link:definition>100170 - Disclosure - COLLABORATION AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVenture" id="DisclosureInvestmentInJointVenture">
        <link:definition>100180 - Disclosure - Investment In Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>100190 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1" id="DisclosureNetLossPerCommonShare1">
        <link:definition>100200 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies">
        <link:definition>100210 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationTables" id="DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationTables">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>100230 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>100240 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>100250 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>100260 - Disclosure - Stockholder's Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100270 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>100280 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" id="DisclosureBusinessAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful" id="DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful">
        <link:definition>100310 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Summary of Property and Equipment Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" id="DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails">
        <link:definition>100330 - Disclosure - Marketable Securities - Summary of available-for-sale marketable securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails" id="DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails">
        <link:definition>100340 - Disclosure - Marketable Securities - Schedule of Available-for-Sale Securities by Balance Sheet Location Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails" id="DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails">
        <link:definition>100350 - Disclosure - Marketable Securities - Schedule of Fair Values of Available-For-Sale Debt Securities By Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails" id="DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails">
        <link:definition>100380 - Disclosure - Leases - Summary of Company's Operating Lease on the Condensed Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails" id="DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails">
        <link:definition>100390 - Disclosure - Leases - Schedule of Future Minimum Annual Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details" id="DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details">
        <link:definition>100400 - Disclosure - Leases - Schedule of Future Minimum Annual Lease Payments Adopting ASU 2016-02 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" id="DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100410 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails" id="DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails">
        <link:definition>100430 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails">
        <link:definition>100440 - Disclosure - Balance Sheet Components - Schedule Of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails" id="DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails">
        <link:definition>100460 - Disclosure - Stockholders' Equity - Summary of Equity-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" id="DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>100470 - Disclosure - Stockholder's Equity - Summary of stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails" id="DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails">
        <link:definition>100480 - Disclosure - Stockholder's Equity - Summary of Assumptions of Fair Value of Option Pricing Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails" id="DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails">
        <link:definition>100490 - Disclosure - Stockholder's Equity - Summary of Nonvested Restricted Common Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails" id="DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails">
        <link:definition>100500 - Disclosure - Stockholder's Equity - Summary of Nonvested Restricted Common Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Benefits and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails" id="DisclosureInvestmentInJointVentureAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Investment In Joint Venture - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails" id="DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails">
        <link:definition>100570 - Disclosure - Net Loss Per Common Share - Summary of Basic and diluted loss per common share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" id="DisclosureNetLossPerCommonShareAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Net Loss Per Common Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rlyb_BusinessAndLiquidityAbstract" name="BusinessAndLiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_CollaborationAgreementAbstract" name="CollaborationAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_LicenseAndCollaborationAgreementsAbstract" name="LicenseAndCollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments" name="AggregateDevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_AggregatePurchasePriceOfCommonStock" name="AggregatePurchasePriceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rlyb_AssetAcquisitionTransactionCosts" name="AssetAcquisitionTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance" name="CommonStockCapitalSharesRemainedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic" name="DeferredTaxAssetsOperatingLossCarriedBackDomestic" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_DeferredTaxAssetsSection174Capitalization" name="DeferredTaxAssetsSection174Capitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" name="ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_FederalOperatingLossCarryforwardsExpirationPeriod" name="FederalOperatingLossCarryforwardsExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_FollowOnOfferingDiscountsAndCommissions" name="FollowOnOfferingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_FundAssociatedWithDevelopmentCosts" name="FundAssociatedWithDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rlyb_IncreasingOwnershipPercent" name="IncreasingOwnershipPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_InitialInvestmentInJointVenture" name="InitialInvestmentInJointVenture" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rlyb_InitialPaymentInInvestment" name="InitialPaymentInInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_LiquidationCommonStockSharesIssued" name="LiquidationCommonStockSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" name="ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses" name="OfferingCostsInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_OperatingLeasesFutureMinimumPayments" name="OperatingLeasesFutureMinimumPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" name="OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome" name="OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization" name="ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization" name="ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned" name="PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_PercentageOfCommonStockBeneficiallyOwned" name="PercentageOfCommonStockBeneficiallyOwned" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed" name="PercentageOfCommonStockBeneficiallyOwnedNotExceed" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_PercentageOfInterestOfJointVentureEntity" name="PercentageOfInterestOfJointVentureEntity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" name="PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_PrepaidResearchAndDevelopmentExpenses" name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" name="ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_StateOperatingLossCarryforwardsExpirationPeriod" name="StateOperatingLossCarryforwardsExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues" name="StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" name="StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_StockIssuedDuringPeriodSharesVested" name="StockIssuedDuringPeriodSharesVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_TerminationCharges" name="TerminationCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rlyb_UnderwritingCommissionsAndDiscounts" name="UnderwritingCommissionsAndDiscounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering" name="UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rlyb_LicenseAndCollaborationAgreementsLineItems" name="LicenseAndCollaborationAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_AtTheMarketSaleAgreementMember" name="AtTheMarketSaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_CapitalizedSoftwareMember" name="CapitalizedSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_CommonStockAllocatedToCommonUnitHoldersMember" name="CommonStockAllocatedToCommonUnitHoldersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember" name="CommonStockAllocatedToIncentiveUnitsHoldersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember" name="CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember" name="CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember" name="CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_CommonUnitsMember" name="CommonUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember" name="ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_FollowOnOfferingMember" name="FollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_IncentiveUnitsMember" name="IncentiveUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_InitialPublicOfferingMember" name="InitialPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_LeaseCommitmentsMember" name="LeaseCommitmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_LicenseRightsMember" name="LicenseRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_OverAllotmentOnFollowOnOfferingMember" name="OverAllotmentOnFollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_OverAllotmentOnInitialPublicOfferingMember" name="OverAllotmentOnInitialPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_PerformanceBasedIncentiveCommonUnitsMember" name="PerformanceBasedIncentiveCommonUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_PreFundedWarrantMember" name="PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_PriorToIpoMember" name="PriorToIpoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember" name="RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_RestrictedStockUnitsMember" name="RestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_ReVenturesILlcMember" name="ReVenturesILlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_SanofiAgreementMember" name="SanofiAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_SanofiMember" name="SanofiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_SeriesA1AndA2FinancingMember" name="SeriesA1AndA2FinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember" name="SeriesA1AndA2RedeemableConvertiblePreferredUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember" name="SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember" name="SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_SeriesBFinancingMember" name="SeriesBFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember" name="SeriesBRedeemableConvertiblePreferredUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_StockOptionsAndUnvestedRestrictedShareMember" name="StockOptionsAndUnvestedRestrictedShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" name="TwoThousandAndTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" name="ScheduleOfLicenseAndCollaborationAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rlyb_AssetAcquisitionPolicyTextBlock" name="AssetAcquisitionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock" name="AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_IpoAndReorganizationPolicyPolicyTextBlock" name="IpoAndReorganizationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock" name="LicenseAndCollaborationAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock" name="LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_PreferredUnitsPolicyTextBlock" name="PreferredUnitsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock" name="PropertyAndEquipmentUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock" name="ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rlyb_StockWarrantsPolicyTextBlock" name="StockWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>rlyb-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T16:22:49.5130+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rlyb-20221231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="rlyb-20221231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical" xlink:href="rlyb-20221231.xsd#StatementConsolidatedBalanceSheetParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity1" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfCashFlows1" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBusiness1" xlink:href="rlyb-20221231.xsd#DisclosureBusiness1" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1" xlink:href="rlyb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements" xlink:href="rlyb-20221231.xsd#DisclosureLicenseAndCollaborationAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeases" xlink:href="rlyb-20221231.xsd#DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponents" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquity1" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquity1" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="rlyb-20221231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureCollaborationAgreement" xlink:href="rlyb-20221231.xsd#DisclosureCollaborationAgreement" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVenture" xlink:href="rlyb-20221231.xsd#DisclosureInvestmentInJointVenture" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="rlyb-20221231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:href="rlyb-20221231.xsd#DisclosureNetLossPerCommonShare1" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:href="rlyb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationTables" xlink:href="rlyb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesTables" xlink:href="rlyb-20221231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="rlyb-20221231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="rlyb-20221231.xsd#DisclosureNetLossPerCommonShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful" xlink:href="rlyb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails" xlink:href="rlyb-20221231.xsd#DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails" xlink:href="rlyb-20221231.xsd#DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details" xlink:href="rlyb-20221231.xsd#DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="rlyb-20221231.xsd#DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails" xlink:href="rlyb-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails" xlink:href="rlyb-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureInvestmentInJointVentureAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails" xlink:href="rlyb-20221231.xsd#DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_PreferredStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnPublicOfferingMember" xlink:label="rlyb_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockIssuedDuringPeriodSharesVested" xlink:label="rlyb_StockIssuedDuringPeriodSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_16"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_17"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_StockIssuedDuringPeriodSharesVested" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnPublicOfferingMember" xlink:label="rlyb_FollowOnPublicOfferingMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" xlink:label="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses" xlink:label="rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_UnderwritingCommissionsAndDiscounts" xlink:label="rlyb_UnderwritingCommissionsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_UnderwritingDiscountsAndCommissions" xlink:label="rlyb_UnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnOfferingDiscountsAndCommissions" xlink:label="rlyb_FollowOnOfferingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering" xlink:label="rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="rlyb_UnderwritingCommissionsAndDiscounts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="rlyb_UnderwritingDiscountsAndCommissions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="rlyb_FollowOnOfferingDiscountsAndCommissions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBusiness1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAndCollaborationAgreementsAbstract" xlink:label="rlyb_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock" xlink:label="rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_LicenseAndCollaborationAgreementsAbstract" xlink:to="rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureCollaborationAgreement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CollaborationAgreementAbstract" xlink:label="rlyb_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_CollaborationAgreementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVenture" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_IpoAndReorganizationPolicyPolicyTextBlock" xlink:label="rlyb_IpoAndReorganizationPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock" xlink:label="rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AssetAcquisitionPolicyTextBlock" xlink:label="rlyb_AssetAcquisitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PreferredUnitsPolicyTextBlock" xlink:label="rlyb_PreferredUnitsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockWarrantsPolicyTextBlock" xlink:label="rlyb_StockWarrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock" xlink:label="rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlyb_IpoAndReorganizationPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlyb_AssetAcquisitionPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlyb_PreferredUnitsPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlyb_StockWarrantsPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock" xlink:label="rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock" xlink:label="rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock" xlink:label="rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_BusinessAndLiquidityAbstract" xlink:label="rlyb_BusinessAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesA1AndA2FinancingMember" xlink:label="rlyb_SeriesA1AndA2FinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PreFundedWarrantMember" xlink:label="rlyb_PreFundedWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnOfferingMember" xlink:label="rlyb_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBFinancingMember" xlink:label="rlyb_SeriesBFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_InitialPublicOfferingMember" xlink:label="rlyb_InitialPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" xlink:label="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnFollowOnOfferingMember" xlink:label="rlyb_OverAllotmentOnFollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnInitialPublicOfferingMember" xlink:label="rlyb_OverAllotmentOnInitialPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_BusinessAndLiquidityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesA1AndA2FinancingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rlyb_PreFundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_FollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesBFinancingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_InitialPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_OverAllotmentOnFollowOnOfferingMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_OverAllotmentOnInitialPublicOfferingMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember" xlink:label="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PriorToIpoMember" xlink:label="rlyb_PriorToIpoMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBRedeemableConvertiblePreferredUnitMember" xlink:label="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LiquidationCommonStockSharesIssued" xlink:label="rlyb_LiquidationCommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AtTheMarketSaleAgreementMember" xlink:label="rlyb_AtTheMarketSaleAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PublicOfferingMember" xlink:label="rlyb_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember" xlink:label="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonUnitsMember" xlink:label="rlyb_CommonUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PerformanceBasedIncentiveCommonUnitsMember" xlink:label="rlyb_PerformanceBasedIncentiveCommonUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization" xlink:label="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_IncentiveUnitsMember" xlink:label="rlyb_IncentiveUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization" xlink:label="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember" xlink:label="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AggregatePurchasePriceOfCommonStock" xlink:label="rlyb_AggregatePurchasePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember" xlink:label="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToCommonUnitHoldersMember" xlink:label="rlyb_CommonStockAllocatedToCommonUnitHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember" xlink:label="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember" xlink:label="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_PriorToIpoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_LiquidationCommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_AtTheMarketSaleAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_PublicOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonUnitsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_PerformanceBasedIncentiveCommonUnitsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_IncentiveUnitsMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_AggregatePurchasePriceOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonStockAllocatedToCommonUnitHoldersMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CapitalizedSoftwareMember" xlink:label="rlyb_CapitalizedSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rlyb_CapitalizedSoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:label="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAndCollaborationAgreementsAbstract" xlink:label="rlyb_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SanofiMember" xlink:label="rlyb_SanofiMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseRightsMember" xlink:label="rlyb_LicenseRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:label="rlyb_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_UpfrontPayment" xlink:label="rlyb_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SanofiAgreementMember" xlink:label="rlyb_SanofiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAgreementMember" xlink:label="rlyb_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" xlink:label="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AssetAcquisitionTransactionCosts" xlink:label="rlyb_AssetAcquisitionTransactionCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_LicenseAndCollaborationAgreementsAbstract" xlink:to="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rlyb_SanofiMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="rlyb_LicenseRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_UpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlyb_SanofiAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlyb_LicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="rlyb_LicenseAndCollaborationAgreementsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_AssetAcquisitionTransactionCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_MarketableSecuritiesMember" xlink:label="rlyb_MarketableSecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="rlyb_MarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseDescription" xlink:label="us-gaap_LessorOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LessorOperatingLeaseDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:label="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OperatingLeasesFutureMinimumPayments" xlink:label="rlyb_OperatingLeasesFutureMinimumPayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rlyb_OperatingLeasesFutureMinimumPayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CapitalizedSoftwareMember" xlink:label="rlyb_CapitalizedSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rlyb_CapitalizedSoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PrepaidResearchAndDevelopmentExpenses" xlink:label="rlyb_PrepaidResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="rlyb_PrepaidResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="rlyb_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="rlyb_AccruedResearchAndDevelopmentExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockAwardsMember" xlink:label="rlyb_RestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PreFundedWarrantMember" xlink:label="rlyb_PreFundedWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnFollowOnOfferingMember" xlink:label="rlyb_OverAllotmentOnFollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnInitialPublicOfferingMember" xlink:label="rlyb_OverAllotmentOnInitialPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnOfferingMember" xlink:label="rlyb_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" xlink:label="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockCapitalSharesRemainedForFutureIssuance" xlink:label="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfCommonStockBeneficiallyOwned" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned" xlink:label="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" xlink:label="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" xlink:label="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rlyb_RestrictedStockAwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rlyb_PreFundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_OverAllotmentOnFollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_OverAllotmentOnInitialPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_FollowOnOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_PercentageOfCommonStockBeneficiallyOwned" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember" xlink:label="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockAwardsMember" xlink:label="rlyb_RestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rlyb_RestrictedStockAwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockUnitsMember" xlink:label="rlyb_RestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rlyb_RestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic" xlink:label="rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FederalOperatingLossCarryforwardsExpirationPeriod" xlink:label="rlyb_FederalOperatingLossCarryforwardsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StateOperatingLossCarryforwardsExpirationPeriod" xlink:label="rlyb_StateOperatingLossCarryforwardsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_IncreasingOwnershipPercent" xlink:label="rlyb_IncreasingOwnershipPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome" xlink:label="rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rlyb_FederalOperatingLossCarryforwardsExpirationPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rlyb_StateOperatingLossCarryforwardsExpirationPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rlyb_IncreasingOwnershipPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_DeferredTaxAssetsSection174Capitalization" xlink:label="rlyb_DeferredTaxAssetsSection174Capitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rlyb_DeferredTaxAssetsSection174Capitalization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ReVenturesILlcMember" xlink:label="rlyb_ReVenturesILlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfInterestOfJointVentureEntity" xlink:label="rlyb_PercentageOfInterestOfJointVentureEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FundAssociatedWithDevelopmentCosts" xlink:label="rlyb_FundAssociatedWithDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_InitialPaymentInInvestment" xlink:label="rlyb_InitialPaymentInInvestment"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_InitialInvestmentInJointVenture" xlink:label="rlyb_InitialInvestmentInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="rlyb_ReVenturesILlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="rlyb_PercentageOfInterestOfJointVentureEntity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="rlyb_FundAssociatedWithDevelopmentCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="rlyb_InitialPaymentInInvestment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="rlyb_InitialInvestmentInJointVenture" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LeaseCommitmentsMember" xlink:label="rlyb_LeaseCommitmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TerminationCharges" xlink:label="rlyb_TerminationCharges"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="rlyb_LeaseCommitmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="rlyb_TerminationCharges" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockOptionsAndUnvestedRestrictedShareMember" xlink:label="rlyb_StockOptionsAndUnvestedRestrictedShareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rlyb_StockOptionsAndUnvestedRestrictedShareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>rlyb-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T16:22:49.5670+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="rlyb-20221231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical" xlink:href="rlyb-20221231.xsd#StatementConsolidatedBalanceSheetParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity1" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful" xlink:href="rlyb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails" xlink:href="rlyb-20221231.xsd#DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureInvestmentInJointVentureAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:href="rlyb-20221231.xsd#DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndOtherIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnPublicOfferingMember" xlink:label="rlyb_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockIssuedDuringPeriodSharesVested" xlink:label="rlyb_StockIssuedDuringPeriodSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_StockIssuedDuringPeriodSharesVested" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnPublicOfferingMember" xlink:label="rlyb_FollowOnPublicOfferingMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_FollowOnPublicOfferingMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesA1AndA2FinancingMember" xlink:label="rlyb_SeriesA1AndA2FinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PreFundedWarrantMember" xlink:label="rlyb_PreFundedWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnOfferingMember" xlink:label="rlyb_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBFinancingMember" xlink:label="rlyb_SeriesBFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_InitialPublicOfferingMember" xlink:label="rlyb_InitialPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" xlink:label="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnFollowOnOfferingMember" xlink:label="rlyb_OverAllotmentOnFollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnInitialPublicOfferingMember" xlink:label="rlyb_OverAllotmentOnInitialPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesA1AndA2FinancingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rlyb_PreFundedWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesBFinancingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_InitialPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_OverAllotmentOnFollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_OverAllotmentOnInitialPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember" xlink:label="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PriorToIpoMember" xlink:label="rlyb_PriorToIpoMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBRedeemableConvertiblePreferredUnitMember" xlink:label="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LiquidationCommonStockSharesIssued" xlink:label="rlyb_LiquidationCommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AtTheMarketSaleAgreementMember" xlink:label="rlyb_AtTheMarketSaleAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PublicOfferingMember" xlink:label="rlyb_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember" xlink:label="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonUnitsMember" xlink:label="rlyb_CommonUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PerformanceBasedIncentiveCommonUnitsMember" xlink:label="rlyb_PerformanceBasedIncentiveCommonUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization" xlink:label="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_IncentiveUnitsMember" xlink:label="rlyb_IncentiveUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization" xlink:label="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember" xlink:label="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AggregatePurchasePriceOfCommonStock" xlink:label="rlyb_AggregatePurchasePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember" xlink:label="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToCommonUnitHoldersMember" xlink:label="rlyb_CommonStockAllocatedToCommonUnitHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember" xlink:label="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember" xlink:label="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_PriorToIpoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_LiquidationCommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_AtTheMarketSaleAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_PublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_PerformanceBasedIncentiveCommonUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_IncentiveUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlyb_AggregatePurchasePriceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonStockAllocatedToCommonUnitHoldersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CapitalizedSoftwareMember" xlink:label="rlyb_CapitalizedSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rlyb_CapitalizedSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:label="rlyb_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:label="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SanofiMember" xlink:label="rlyb_SanofiMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseRightsMember" xlink:label="rlyb_LicenseRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_UpfrontPayment" xlink:label="rlyb_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SanofiAgreementMember" xlink:label="rlyb_SanofiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAgreementMember" xlink:label="rlyb_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" xlink:label="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AssetAcquisitionTransactionCosts" xlink:label="rlyb_AssetAcquisitionTransactionCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rlyb_SanofiMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="rlyb_LicenseRightsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_UpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlyb_SanofiAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlyb_LicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_AssetAcquisitionTransactionCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_MarketableSecuritiesMember" xlink:label="rlyb_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="rlyb_MarketableSecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseDescription" xlink:label="us-gaap_LessorOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LessorOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CapitalizedSoftwareMember" xlink:label="rlyb_CapitalizedSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rlyb_CapitalizedSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockAwardsMember" xlink:label="rlyb_RestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PreFundedWarrantMember" xlink:label="rlyb_PreFundedWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnFollowOnOfferingMember" xlink:label="rlyb_OverAllotmentOnFollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnInitialPublicOfferingMember" xlink:label="rlyb_OverAllotmentOnInitialPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnOfferingMember" xlink:label="rlyb_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" xlink:label="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockCapitalSharesRemainedForFutureIssuance" xlink:label="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfCommonStockBeneficiallyOwned" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned" xlink:label="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" xlink:label="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" xlink:label="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rlyb_RestrictedStockAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rlyb_PreFundedWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_OverAllotmentOnFollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_OverAllotmentOnInitialPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlyb_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_PercentageOfCommonStockBeneficiallyOwned" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember" xlink:label="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockAwardsMember" xlink:label="rlyb_RestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rlyb_RestrictedStockAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockUnitsMember" xlink:label="rlyb_RestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rlyb_RestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ReVenturesILlcMember" xlink:label="rlyb_ReVenturesILlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfInterestOfJointVentureEntity" xlink:label="rlyb_PercentageOfInterestOfJointVentureEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FundAssociatedWithDevelopmentCosts" xlink:label="rlyb_FundAssociatedWithDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_InitialPaymentInInvestment" xlink:label="rlyb_InitialPaymentInInvestment"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_InitialInvestmentInJointVenture" xlink:label="rlyb_InitialInvestmentInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="rlyb_ReVenturesILlcMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="rlyb_PercentageOfInterestOfJointVentureEntity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="rlyb_FundAssociatedWithDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="rlyb_InitialPaymentInInvestment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="rlyb_InitialInvestmentInJointVenture" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LeaseCommitmentsMember" xlink:label="rlyb_LeaseCommitmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TerminationCharges" xlink:label="rlyb_TerminationCharges"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="rlyb_LeaseCommitmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="rlyb_TerminationCharges" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockOptionsAndUnvestedRestrictedShareMember" xlink:label="rlyb_StockOptionsAndUnvestedRestrictedShareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rlyb_StockOptionsAndUnvestedRestrictedShareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>28
<FILENAME>rlyb-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T16:22:50.0112+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="rlyb-20221231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails2" xlink:href="rlyb-20221231.xsd#DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1" xlink:href="rlyb-20221231.xsd#StatementConsolidatedStatementsOfCashFlows1" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails" xlink:href="rlyb-20221231.xsd#DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails" xlink:href="rlyb-20221231.xsd#DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails" xlink:href="rlyb-20221231.xsd#DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details" xlink:href="rlyb-20221231.xsd#DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:href="rlyb-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails" xlink:href="rlyb-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails" xlink:href="rlyb-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestAndOtherIncome" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="12" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" xlink:label="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rlyb_OperatingLeasesFutureMinimumPayments" xlink:to="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rlyb_OperatingLeasesFutureMinimumPayments" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rlyb_OperatingLeasesFutureMinimumPayments" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rlyb_OperatingLeasesFutureMinimumPayments" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rlyb_OperatingLeasesFutureMinimumPayments" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OperatingLeasesFutureMinimumPayments" xlink:label="rlyb_OperatingLeasesFutureMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:label="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="rlyb_PrepaidResearchAndDevelopmentExpenses" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PrepaidResearchAndDevelopmentExpenses" xlink:label="rlyb_PrepaidResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rlyb_AccruedResearchAndDevelopmentExpensesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="rlyb_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>29
<FILENAME>rlyb-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T16:22:52.1657+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AtTheMarketSaleAgreementMember" xlink:label="rlyb_AtTheMarketSaleAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OperatingLeasesFutureMinimumPayments" xlink:label="rlyb_OperatingLeasesFutureMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_DeferredTaxAssetsSection174Capitalization" xlink:label="rlyb_DeferredTaxAssetsSection174Capitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToCommonUnitHoldersMember" xlink:label="rlyb_CommonStockAllocatedToCommonUnitHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" xlink:label="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockUnitsMember" xlink:label="rlyb_RestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember" xlink:label="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAgreementMember" xlink:label="rlyb_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_BusinessAndLiquidityAbstract" xlink:label="rlyb_BusinessAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesA1AndA2FinancingMember" xlink:label="rlyb_SeriesA1AndA2FinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CapitalizedSoftwareMember" xlink:label="rlyb_CapitalizedSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LiquidationCommonStockSharesIssued" xlink:label="rlyb_LiquidationCommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SanofiAgreementMember" xlink:label="rlyb_SanofiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" xlink:label="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StateOperatingLossCarryforwardsExpirationPeriod" xlink:label="rlyb_StateOperatingLossCarryforwardsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering" xlink:label="rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FundAssociatedWithDevelopmentCosts" xlink:label="rlyb_FundAssociatedWithDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_MarketableSecuritiesMember" xlink:label="rlyb_MarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnOfferingMember" xlink:label="rlyb_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_InitialPaymentInInvestment" xlink:label="rlyb_InitialPaymentInInvestment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AssetAcquisitionTransactionCosts" xlink:label="rlyb_AssetAcquisitionTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic" xlink:label="rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" xlink:label="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SanofiMember" xlink:label="rlyb_SanofiMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PrepaidResearchAndDevelopmentExpenses" xlink:label="rlyb_PrepaidResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="rlyb_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses" xlink:label="rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned" xlink:label="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBFinancingMember" xlink:label="rlyb_SeriesBFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AssetAcquisitionPolicyTextBlock" xlink:label="rlyb_AssetAcquisitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBRedeemableConvertiblePreferredUnitMember" xlink:label="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockAwardsMember" xlink:label="rlyb_RestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockOptionsAndUnvestedRestrictedShareMember" xlink:label="rlyb_StockOptionsAndUnvestedRestrictedShareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnInitialPublicOfferingMember" xlink:label="rlyb_OverAllotmentOnInitialPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock" xlink:label="rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:label="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TerminationCharges" xlink:label="rlyb_TerminationCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PreFundedWarrantMember" xlink:label="rlyb_PreFundedWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember" xlink:label="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnPublicOfferingMember" xlink:label="rlyb_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_InitialInvestmentInJointVenture" xlink:label="rlyb_InitialInvestmentInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PublicOfferingMember" xlink:label="rlyb_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_IncreasingOwnershipPercent" xlink:label="rlyb_IncreasingOwnershipPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock" xlink:label="rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_UpfrontPayment" xlink:label="rlyb_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAndCollaborationAgreementsAbstract" xlink:label="rlyb_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PriorToIpoMember" xlink:label="rlyb_PriorToIpoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfCommonStockBeneficiallyOwned" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ReVenturesILlcMember" xlink:label="rlyb_ReVenturesILlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockIssuedDuringPeriodSharesVested" xlink:label="rlyb_StockIssuedDuringPeriodSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockCapitalSharesRemainedForFutureIssuance" xlink:label="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CollaborationAgreementAbstract" xlink:label="rlyb_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockWarrantsPolicyTextBlock" xlink:label="rlyb_StockWarrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_IncentiveUnitsMember" xlink:label="rlyb_IncentiveUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AggregatePurchasePriceOfCommonStock" xlink:label="rlyb_AggregatePurchasePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome" xlink:label="rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock" xlink:label="rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LeaseCommitmentsMember" xlink:label="rlyb_LeaseCommitmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" xlink:label="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember" xlink:label="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember" xlink:label="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization" xlink:label="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PreferredUnitsPolicyTextBlock" xlink:label="rlyb_PreferredUnitsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock" xlink:label="rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:label="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseRightsMember" xlink:label="rlyb_LicenseRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PercentageOfInterestOfJointVentureEntity" xlink:label="rlyb_PercentageOfInterestOfJointVentureEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PerformanceBasedIncentiveCommonUnitsMember" xlink:label="rlyb_PerformanceBasedIncentiveCommonUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_UnderwritingCommissionsAndDiscounts" xlink:label="rlyb_UnderwritingCommissionsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_UnderwritingDiscountsAndCommissions" xlink:label="rlyb_UnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock" xlink:label="rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:label="rlyb_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseDescription" xlink:label="us-gaap_LessorOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember" xlink:label="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_OverAllotmentOnFollowOnOfferingMember" xlink:label="rlyb_OverAllotmentOnFollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember" xlink:label="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember" xlink:label="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_CommonUnitsMember" xlink:label="rlyb_CommonUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" xlink:label="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock" xlink:label="rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization" xlink:label="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_InitialPublicOfferingMember" xlink:label="rlyb_InitialPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_IpoAndReorganizationPolicyPolicyTextBlock" xlink:label="rlyb_IpoAndReorganizationPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FederalOperatingLossCarryforwardsExpirationPeriod" xlink:label="rlyb_FederalOperatingLossCarryforwardsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="rlyb-20221231.xsd#rlyb_FollowOnOfferingDiscountsAndCommissions" xlink:label="rlyb_FollowOnOfferingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AtTheMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Sale Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AtTheMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market sale agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OperatingLeasesFutureMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OperatingLeasesFutureMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OperatingLeasesFutureMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases future minimum payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions and offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows from Financing Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_DeferredTaxAssetsSection174Capitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 174 capitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_DeferredTaxAssetsSection174Capitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Section 174 Capitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_DeferredTaxAssetsSection174Capitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets section 174 capitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of stock options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, number of shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating loss carry forwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToCommonUnitHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Allocated to Common Unit Holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToCommonUnitHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Allocated to Common Unit Holders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToCommonUnitHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Allocated to Common Unit Holders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From The Issuance Of Common Stock Under Follow On Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From The Issuance Of Common Stock Under Follow On Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from the issuance of common stock under follow on public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Allocated To Performance Based Incentive Common Unit Holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Allocated To Performance Based Incentive Common Unit Holders Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Allocated To Performance Based Incentive Common Unit Holders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock from the stock purchase plan (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares reserve issued to founders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average grant date fair value, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value, shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_BusinessAndLiquidityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business And Liquidity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_BusinessAndLiquidityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business And Liquidity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesA1AndA2FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 and A-2 Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesA1AndA2FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 And A2 Financing Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesA1AndA2FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A1 and A2 financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Weighted Average Remaining Lease Term (Year)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CapitalizedSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CapitalizedSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CapitalizedSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LiquidationCommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidation common stock shares issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LiquidationCommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidation Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LiquidationCommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued on liquidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Building [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants upon completion of the follow-on offering, net of underwriting discounts and commissions and offering costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and Pre Funded Warrants Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and pre funded warrants issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock from the stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from the stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due, Next 12 Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SanofiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sanofi Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SanofiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sanofi Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SanofiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">sanofi agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock and pre-funded warrants upon the completion of the follow-on offering, net of underwriting discounts and commissions of $3,289</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance of Common Stock and Pre Funded Warrants Under Follow On Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre funded warrants under follow on public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StateOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State operating loss carryforwards expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StateOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State Operating Loss Carryforwards Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StateOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net state operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents - end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents - beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting commissions and discounts of follow on public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Commissions And Discounts Of Follow On Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting commissions and discounts of follow on public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FundAssociatedWithDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fund associated with development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FundAssociatedWithDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fund Associated with Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FundAssociatedWithDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fund Associated with Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-On Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">follow-on offering [MEMBER]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares outstanding,basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture of restricted common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture of restricted common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, end of period - aggregate intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, beginning of period - aggregate intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, end of period - aggregate intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited - shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment In Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction In Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_InitialPaymentInInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial payment in investment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_InitialPaymentInInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Payment In Investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_InitialPaymentInInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial payment made in investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AssetAcquisitionTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs associated with asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AssetAcquisitionTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AssetAcquisitionTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition transaction costs incurred.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carried back domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carried Back Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carried back</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days of notice</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Notice Days Affects Exceed Limit Percentage With Exercise To Aggregate Shares Of Common Stock Beneficially Owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period Of Notice Days Affects Exceed Limit Percentage With Exercise To Aggregate Shares Of Common Stock Beneficially Owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SanofiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sanofi</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SanofiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sanofi [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SanofiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sanofi .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share,diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering Costs In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering costs in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock beneficially owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Number Of Shares Of Common Stock Beneficially Owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate number of shares of common stock beneficially owned.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Financing Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate, Type of Property [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation for Stock Options, Restricted Stock Awards and Restricted Stock Units and the Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities called by warrants or rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net accretion of discounts/premiums on debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expired - weighted average exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, end of period - weighted average remaining contractual term (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AssetAcquisitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AssetAcquisitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AssetAcquisitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for asset acquisition.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross unrealized gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Interest in Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock beneficially owned not exceed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Common Stock Beneficially Owned Not Exceed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock beneficially owned not exceed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, shares issuable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding,diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares outstanding diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding U.S federal income tax or material state and local tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense, restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer and Other Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Unit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Redeemable Convertible Preferred unit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents - beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents - end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockOptionsAndUnvestedRestrictedShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options And Unvested Restricted Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockOptionsAndUnvestedRestrictedShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options And Unvested Restricted Share Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockOptionsAndUnvestedRestrictedShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options and unvested restricted share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OverAllotmentOnInitialPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over Allotment On Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OverAllotmentOnInitialPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment On Initial Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OverAllotmentOnInitialPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Over allotment on IPO.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property and Equipment Useful Lives [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and Equipment Useful Lives [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of License and Collaboration Agreements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of license and collaboration agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_TerminationCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_TerminationCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_TerminationCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination charges.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions and offering costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period, shares, new issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 and A-2 Redeemable Convertible Preferred Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A-1 and A-2 Redeemable Convertible Preferred Unit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 and A-2 redeemable convertible preferred unit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Joint venture investment payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited - weighted average exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Follow-On Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow on public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_InitialInvestmentInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_InitialInvestmentInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Investment in Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_InitialInvestmentInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Investment in Joint Venture.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination, Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_IncreasingOwnershipPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increasing ownership percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_IncreasingOwnershipPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increasing ownership percent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_IncreasingOwnershipPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increasing Ownership Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of available-for-sale debt securities in an unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Redeemable Preferred Unit Previously Classified As Mezzanine Equity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Convertible Redeemable Preferred Unit Previously Classified As Mezzanine Equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently Issued Accounting Pronouncement Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, end of period - aggregate intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stockholders' Equity Attributable to Parent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPR&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination, Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAndCollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and collaboration agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAndCollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Continuous unrealized loss position for more than twelve months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expenses):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due after one year through two years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Operating Lease on the Condensed Consolidated Balance Sheets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of Real Estate Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases, Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value, shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COLLABORATION AGREEMENT</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised - weighted average exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total available-for-sale debt securities by contractual maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PriorToIpoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior to IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PriorToIpoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior to IPO.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PriorToIpoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior to IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock beneficially owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Stock Beneficially Owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock beneficially owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ReVenturesILlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RE Ventures I, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ReVenturesILlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RE Ventures I, LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ReVenturesILlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">RE Ventures I, LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional Paid-In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Nonvested Restricted Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Nonvested Restricted Common Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions of Fair Value of Option Pricing Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockIssuedDuringPeriodSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from the stock award plan, vested (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockIssuedDuringPeriodSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockIssuedDuringPeriodSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares vested.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government agency securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock consideration received on transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows from Operating Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Capital Shares Remained For Future Issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Remained For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares remained for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from continuing operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from continuing operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CollaborationAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CollaborationAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement Abstract.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in one year or less</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carry forwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Warrants [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_IncentiveUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_IncentiveUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_IncentiveUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AggregatePurchasePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Purchase Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AggregatePurchasePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Purchase Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AggregatePurchasePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase price of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ANTIDILUTIVE UNITS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation costs, weighted average period for recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, end of period - weighted average remaining contractual term (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate development and regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Development and Regulatory Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate development and regulatory milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Annual Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards limitations on use percentage of taxable income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Limitations On Use Percentage Of Taxable Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards limitations on use percentage of taxable income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows used in Investing Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase In Number Of Shares Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase In Number Of Shares Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 10)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U S Treasury Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Securities by Balance Sheet Location Classification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities By Balance Sheet Location Classification [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities by balance sheet location classification.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, end of period - weighted average exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LeaseCommitmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Commitments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LeaseCommitmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commitments Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LeaseCommitmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commitments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exceed Limit Percentage With Exercise To Aggregate Shares Of Common Stock Beneficially Owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exceed limit percentage with exercise to aggregate shares of common stock beneficially owned.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value, shares forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal or state and local income tax returns</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Allocated to Series A-1 And Series A-2 Preferred Units Holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CommonStock Allocated to Series A1 And Series A2 Preferred Unit Holders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CommonStock Allocated to Series A1 And Series A2 Preferred Unit Holders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible redeemable preferred units previously classified as mezzanine equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Redeemable Preferred Units Previously Classified as Mezzanine Equity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible redeemable preferred units previously classified as mezzanine equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense, restricted stock awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of stock options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Financing Receivable, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Financing Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Parent ownership percentage of LLCs that elect to be treated as corporation and filed separate US federal tax return prior to reorganization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent Ownership Percentage of LLCs That Elect To Be Treated As Corporation and Filed Separate US Federal Tax Return Prior To Reorganization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage by parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PreferredUnitsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred Units [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PreferredUnitsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Units [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PreferredUnitsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and Ability to Continue as a Going Concern [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity and Ability to Continue as a Going Concern [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Ability to Continue as a Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, number of shares available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Rights [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfInterestOfJointVentureEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest of joint venture entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfInterestOfJointVentureEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Interest of Joint Venture Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PercentageOfInterestOfJointVentureEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of interest of the joint venture entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, beginning of period - weighted average exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, end of period - weighted average exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PerformanceBasedIncentiveCommonUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Incentive Common Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PerformanceBasedIncentiveCommonUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance Based Incentive Common Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PerformanceBasedIncentiveCommonUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Incentive Common Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss on investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocable share of losses recorded</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Equity Method Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants upon completion of the follow-on offering, net of underwriting discounts and commissions and offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and Pre Funded Warrants Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and pre funded warrants issued during period value new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UnderwritingCommissionsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting Commissions And Discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UnderwritingCommissionsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting commissions and discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Collaboration Agreements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of License and collaboration agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leashold improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions of $6,488</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal statutory tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Collaboration Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Loss Per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessor Operating Lease Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, end of period (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted - shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expired - shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Allocated To Incentive Units Holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Allocated To Incentive Units Holders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Allocated To Incentive Units Holders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted units unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Existing units of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses, right-of-use assets and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based compensation arrangement by share-based payment award, options, outstanding, number, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based compensation arrangement by share-based payment award, options, outstanding, number, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OverAllotmentOnFollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over Allotment On Follow-On Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OverAllotmentOnFollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment On Follow On Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_OverAllotmentOnFollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Over allotment on follow-on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax penalties and interest accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Other Income, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share,basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepaids</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Allocated To Series B Preferred Units Holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Allocated To SeriesB Preferred Units Holders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Allocated To SeriesB Preferred Units Holders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Stock Awards Granted Prior To IPO And Liquidation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards Granted Prior To IPO And Liquidation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards Granted Prior To IPO And Liquidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid expenses and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pre-funded warrants purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and members' deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_CommonUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Nonvested Restricted Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Nonvested Restricted Common Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets, Net of Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of the Company's common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Other Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Income Tax Benefits and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to payment upon maximum achievement of certain clinical and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligation To Payment Upon Maximum Achievement Of Certain Clinical And Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligation to payment upon maximum achievement of certain clinical and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions of Fair Value of Restricted Common Shares Pricing Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Share Based Payment Award Restricted Common Shares Valuation Assumptions Table [TextBlock].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Restricted Common Shares Valuation Assumptions Table [TextBlock]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Redeemable Preferred Unit Common Units And Incentive Units Previously Classified As Mezzanine Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Redeemable Preferred Units Common Units And Incentive Units Previously Classified As Mezzanine Equity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible redeemable preferred units common units and incentive units previously classified as mezzanine equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total share based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits and Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted common units fully vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Parent ownership percentage of all subsidiaries the parent elect to include in consolidated federal income tax return following reorganization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent Ownership Percentage of All Subsidiaries The Parent Elect To Include In Consolidated Federal Income Tax Return Following Reorganization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiaries, ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_InitialPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_InitialPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_InitialPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_IpoAndReorganizationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO And Reorganization [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_IpoAndReorganizationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO and Reorganization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_IpoAndReorganizationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IPO and reorganization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised - shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Values of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation for Stock Options, Restricted Stock Awards and Restricted Stock Units and the Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FederalOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal Operating loss carryforwards expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FederalOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal Operating Loss Carryforwards Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FederalOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net federal operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Marketable Securities by Type of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property plant and equipment useful lives [Table text block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant and Equipment Useful Lives [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross unrealized losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FollowOnOfferingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow on offering discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FollowOnOfferingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Offering Discounts And Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rlyb_FollowOnOfferingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow on offering discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted common shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted - weighted average exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No of shares increased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosures of Noncash Investing and Financing Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_AtTheMarketSaleAgreementMember" xlink:to="rlyb_AtTheMarketSaleAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_OperatingLeasesFutureMinimumPayments" xlink:to="rlyb_OperatingLeasesFutureMinimumPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_DeferredTaxAssetsSection174Capitalization" xlink:to="rlyb_DeferredTaxAssetsSection174Capitalization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_CommonStockAllocatedToCommonUnitHoldersMember" xlink:to="rlyb_CommonStockAllocatedToCommonUnitHoldersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering" xlink:to="rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_RestrictedStockUnitsMember" xlink:to="rlyb_RestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember" xlink:to="rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_LicenseAgreementMember" xlink:to="rlyb_LicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_BusinessAndLiquidityAbstract" xlink:to="rlyb_BusinessAndLiquidityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_SeriesA1AndA2FinancingMember" xlink:to="rlyb_SeriesA1AndA2FinancingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_CapitalizedSoftwareMember" xlink:to="rlyb_CapitalizedSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_LiquidationCommonStockSharesIssued" xlink:to="rlyb_LiquidationCommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues" xlink:to="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_SanofiAgreementMember" xlink:to="rlyb_SanofiAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering" xlink:to="rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_StateOperatingLossCarryforwardsExpirationPeriod" xlink:to="rlyb_StateOperatingLossCarryforwardsExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering" xlink:to="rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_FundAssociatedWithDevelopmentCosts" xlink:to="rlyb_FundAssociatedWithDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_MarketableSecuritiesMember" xlink:to="rlyb_MarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_FollowOnOfferingMember" xlink:to="rlyb_FollowOnOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_InitialPaymentInInvestment" xlink:to="rlyb_InitialPaymentInInvestment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_AssetAcquisitionTransactionCosts" xlink:to="rlyb_AssetAcquisitionTransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic" xlink:to="rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" xlink:to="rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_SanofiMember" xlink:to="rlyb_SanofiMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PrepaidResearchAndDevelopmentExpenses" xlink:to="rlyb_PrepaidResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="rlyb_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses" xlink:to="rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned" xlink:to="rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_SeriesBFinancingMember" xlink:to="rlyb_SeriesBFinancingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_AssetAcquisitionPolicyTextBlock" xlink:to="rlyb_AssetAcquisitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed" xlink:to="rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable" xlink:to="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember" xlink:to="rlyb_SeriesBRedeemableConvertiblePreferredUnitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_RestrictedStockAwardsMember" xlink:to="rlyb_RestrictedStockAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_StockOptionsAndUnvestedRestrictedShareMember" xlink:to="rlyb_StockOptionsAndUnvestedRestrictedShareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_OverAllotmentOnInitialPublicOfferingMember" xlink:to="rlyb_OverAllotmentOnInitialPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock" xlink:to="rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable" xlink:to="rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_TerminationCharges" xlink:to="rlyb_TerminationCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PreFundedWarrantMember" xlink:to="rlyb_PreFundedWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember" xlink:to="rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_FollowOnPublicOfferingMember" xlink:to="rlyb_FollowOnPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_InitialInvestmentInJointVenture" xlink:to="rlyb_InitialInvestmentInJointVenture_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PublicOfferingMember" xlink:to="rlyb_PublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_IncreasingOwnershipPercent" xlink:to="rlyb_IncreasingOwnershipPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember" xlink:to="rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock" xlink:to="rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_UpfrontPayment" xlink:to="rlyb_UpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_LicenseAndCollaborationAgreementsAbstract" xlink:to="rlyb_LicenseAndCollaborationAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PriorToIpoMember" xlink:to="rlyb_PriorToIpoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PercentageOfCommonStockBeneficiallyOwned" xlink:to="rlyb_PercentageOfCommonStockBeneficiallyOwned_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ReVenturesILlcMember" xlink:to="rlyb_ReVenturesILlcMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_StockIssuedDuringPeriodSharesVested" xlink:to="rlyb_StockIssuedDuringPeriodSharesVested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance" xlink:to="rlyb_CommonStockCapitalSharesRemainedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_CollaborationAgreementAbstract" xlink:to="rlyb_CollaborationAgreementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_StockWarrantsPolicyTextBlock" xlink:to="rlyb_StockWarrantsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_IncentiveUnitsMember" xlink:to="rlyb_IncentiveUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_AggregatePurchasePriceOfCommonStock" xlink:to="rlyb_AggregatePurchasePriceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments" xlink:to="rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome" xlink:to="rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum" xlink:to="rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock" xlink:to="rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_LeaseCommitmentsMember" xlink:to="rlyb_LeaseCommitmentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned" xlink:to="rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember" xlink:to="rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember" xlink:to="rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization" xlink:to="rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PreferredUnitsPolicyTextBlock" xlink:to="rlyb_PreferredUnitsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock" xlink:to="rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:to="rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:to="rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_LicenseRightsMember" xlink:to="rlyb_LicenseRightsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PercentageOfInterestOfJointVentureEntity" xlink:to="rlyb_PercentageOfInterestOfJointVentureEntity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PerformanceBasedIncentiveCommonUnitsMember" xlink:to="rlyb_PerformanceBasedIncentiveCommonUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues" xlink:to="rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_UnderwritingCommissionsAndDiscounts" xlink:to="rlyb_UnderwritingCommissionsAndDiscounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesMember" xlink:to="us-gaap_AccruedLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_UnderwritingDiscountsAndCommissions" xlink:to="rlyb_UnderwritingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock" xlink:to="rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_LicenseAndCollaborationAgreementsLineItems" xlink:to="rlyb_LicenseAndCollaborationAgreementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseDescription" xlink:to="us-gaap_LessorOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember" xlink:to="rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_OverAllotmentOnFollowOnOfferingMember" xlink:to="rlyb_OverAllotmentOnFollowOnOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember" xlink:to="rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember" xlink:to="rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_CommonUnitsMember" xlink:to="rlyb_CommonUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" xlink:to="rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock" xlink:to="rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember" xlink:to="rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization" xlink:to="rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_InitialPublicOfferingMember" xlink:to="rlyb_InitialPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_IpoAndReorganizationPolicyPolicyTextBlock" xlink:to="rlyb_IpoAndReorganizationPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_FederalOperatingLossCarryforwardsExpirationPeriod" xlink:to="rlyb_FederalOperatingLossCarryforwardsExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlyb_FollowOnOfferingDiscountsAndCommissions" xlink:to="rlyb_FollowOnOfferingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446809552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001739410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-40693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RALLYBIO CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1083789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">234 Church Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-3820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RLYB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,075,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Portions of the registrant&#8217;s Definitive Proxy Statement for its 2023 Annual Meeting of Stockholders scheduled to be held on May 17, 2023, which Definitive Proxy will be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> are incorporated by reference into Part II and Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Hartford, Connecticut  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753448133376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 56,958<span></span>
</td>
<td class="nump">$ 175,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">112,036<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">10,502<span></span>
</td>
<td class="nump">5,535<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">179,496<span></span>
</td>
<td class="nump">180,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in joint venture</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">180,435<span></span>
</td>
<td class="nump">182,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,449<span></span>
</td>
<td class="nump">5,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,744<span></span>
</td>
<td class="nump">6,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued expenses, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,118<span></span>
</td>
<td class="nump">6,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">330,208<span></span>
</td>
<td class="nump">269,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(214)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(160,681)<span></span>
</td>
<td class="num">(94,027)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">169,317<span></span>
</td>
<td class="nump">175,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 180,435<span></span>
</td>
<td class="nump">$ 182,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446705984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">37,837,369<span></span>
</td>
<td class="nump">32,129,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">37,837,369<span></span>
</td>
<td class="nump">32,129,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446860464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 40,689<span></span>
</td>
<td class="nump">$ 26,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,195<span></span>
</td>
<td class="nump">18,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">67,884<span></span>
</td>
<td class="nump">45,648<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(67,884)<span></span>
</td>
<td class="num">(45,648)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">2,305<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(65,579)<span></span>
</td>
<td class="num">(45,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on investment in joint venture</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,654)<span></span>
</td>
<td class="num">$ (47,013)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share,basic</a></td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share,diluted</a></td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">31,821,311<span></span>
</td>
<td class="nump">25,519,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding,diluted</a></td>
<td class="nump">31,821,311<span></span>
</td>
<td class="nump">25,519,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss on marketable securities</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(214)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (66,868)<span></span>
</td>
<td class="num">$ (47,013)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753445229552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total IPO</div></th>
<th class="th"><div>Total Follow-On Offering</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th">
<div>Common Shares </div>
<div>Total IPO</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>Total Follow-On Offering</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Total IPO</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Total Follow-On Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 136,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (47,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,410,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions and offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,589,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">3,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,129,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">175,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,027)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and pre-funded warrants upon completion of the follow-on offering, net of underwriting discounts and commissions and offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,803,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and pre-funded warrants upon completion of the follow-on offering, net of underwriting discounts and commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">9,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock from the stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock from the stock purchase plan</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_StockIssuedDuringPeriodSharesVested', window );">Issuance of common stock from the stock award plan, vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised - shares</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (214)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,837,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 169,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (160,681)<span></span>
</td>
<td class="num">$ (214)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and pre funded warrants issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and pre funded warrants issued during period value new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_StockIssuedDuringPeriodSharesVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_StockIssuedDuringPeriodSharesVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446467936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Total IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnPublicOfferingMember', window );">Total Follow-On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 3,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446820768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,654)<span></span>
</td>
<td class="num">$ (47,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Net accretion of discounts/premiums on debt securities</a></td>
<td class="num">(435)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,499<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on investment in joint venture</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, right-of-use assets and other assets</a></td>
<td class="num">(4,645)<span></span>
</td>
<td class="num">(4,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">487<span></span>
</td>
<td class="num">(976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and operating lease liabilities</a></td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">1,704<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,284)<span></span>
</td>
<td class="num">(45,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows used in Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">201,316<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">89,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in joint venture</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(112,170)<span></span>
</td>
<td class="num">(2,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering', window );">Proceeds from the issuance of common stock and pre-funded warrants upon the completion of the follow-on offering, net of underwriting discounts and commissions of $3,289</a></td>
<td class="nump">51,533<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from the issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions of $6,488</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">86,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the issuance of common stock from the stock purchase plan</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the issuance of common stock from exercise of stock options</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of offering costs</a></td>
<td class="num">(693)<span></span>
</td>
<td class="num">(3,233)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">51,078<span></span>
</td>
<td class="nump">82,967<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(118,376)<span></span>
</td>
<td class="nump">35,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of year</a></td>
<td class="nump">175,334<span></span>
</td>
<td class="nump">140,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of year</a></td>
<td class="nump">56,958<span></span>
</td>
<td class="nump">175,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses', window );">Offering costs in accounts payable and accrued expenses</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Costs In Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre funded warrants under follow on public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446739056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_UnderwritingDiscountsAndCommissions', window );">IPO Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_FollowOnOfferingDiscountsAndCommissions', window );">Follow on offering discounts and commissions</a></td>
<td class="nump">$ 3,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_FollowOnOfferingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Follow on offering discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_FollowOnOfferingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753530310080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1. BUSINESS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Corporation and subsidiaries (the "Company", "we", "our", or "us") is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since our launch in January 2018, we have built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of maternal fetal blood disorders, complement dysregulation, hematology, and metabolic disorders. We have assembled a team of experienced biopharma industry leaders with extensive research, development, and rare disease expertise to deliver on our mission of becoming a leader in the development of therapies for patients with rare diseases. We are drawing on our decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible &#8211; and change the odds for rare disease patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In August 2021, the Company completed its initial public offering ("IPO"), pursuant to which it issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,130,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company&#8217;s common stock, inclusive of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">930,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share. The gross proceeds from the IPO, including the exercise of the underwriter's option to purchase additional shares were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">92.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and the net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">83.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In November 2022, the Company completed a follow-on offering of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">54.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million consisting of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,803,655</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock, inclusive of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">803,654</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock sold pursuant to the partial exercise of the underwriters' option to purchase additional shares at the price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,333,388</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.9999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which represents the per share public offering price for the shares less the $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share exercise price for each pre-funded warrant</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. The net proceeds from the November 2022 follow-on offering were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">Prior to the IPO and Reorganization, the Company was a 100% owned subsidiary of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Holdings, LLC ("Rallybio Holdings")</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">, a Delaware limited liability company which</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was incorporated in Delaware on March 22, 2018 and Rallybio Holdings held 100% of the outstanding membership units in five wholly-owned subsidiaries; Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, Rallybio IPD, LLC, and IPC Research, LLC. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">On June 30, 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rallybio Holdings</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> completed a series of transactions pursuant to which (i) Rallybio IPD, LLC, a direct subsidiary of Rallybio Holdings that was formed in Delaware in May 2020, was converted from a Delaware limited liability company to a Delaware corporation and changed its name to Rallybio Corporation, and (ii) four direct subsidiaries of Rallybio Corporation, each a Delaware limited liability company (collectively the "Merger Subs"), each consummated a separate merger with one of Rallybio Holdings direct subsidiaries, other than Rallybio IPD, LLC (collectively the "Asset Subsidiaries"), with the Asset Subsidiaries surviving the mergers and Rallybio Holdings receiving common stock of the Company in exchange for its interest in each Asset Subsidiary, which resulted in the Asset Subsidiaries becoming subsidiaries of the Company and the Company becoming the only direct subsidiary of Rallybio Holdings. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On July 28, 2021, immediately prior</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> to the completion of the IPO, Rallybio Holdings liquidated and distributed 100% of the capital stock of the Company, consisting solely of common stock, to the unitholders of Rallybio Holdings. The liquidation of Rallybio Holdings and distribution of the capital stock of Rallybio Corporation to the unitholders of Rallybio Holdings is referred to as the &#8220;Liquidation&#8221; and these other transactions are collectively referred to as the &#8220;Reorganization.&#8221; As a result of the Reorganization and subsequent Liquidation, the unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation, and the Company's consolidated financial statements are subsequently reported from Rallybio Corporation. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Note 2, "Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation" for the basis of presentation of these financial statements after the Reorganization and Liquidation discussed herein.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753452023040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">IPO and Reorganization </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212; As discussed in Note 1, "Business," in connection with the Reorganization, all of Rallybio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Holdings' direct subsidiaries, other than Rallybio Corporation, became direct subsidiaries of the Company prior to the Liquidation of Rallybio Holdings. Prior to the completion of the Company's IPO, Rallybio Holdings liquidated and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation. Subsequent to the Reorganization and the Liquidation of Rallybio Holdings </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">the consolidated financial statements are reported from Rallybio Corporation. </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The capital structure of Rallybio Holdings prior to the Liquidation consisted of four classes of membership units: common units; Series A-1 preferred units; Series A-2 preferred units; Series B preferred units; and incentive common units ("incentive units"). The number of shares of common stock that the holders of each class of units received in the Liquidation was based on the value of Rallybio Holdings prior to the Liquidation, determined by reference to the initial public offering price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. The common stock of the Company was allocated to the holders of existing units in Rallybio Holdings as follows:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33,478,255</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Series A-1 preferred units and Series A-2 preferred units of Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,257,590</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company; </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">104,442,965</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Series B preferred units of Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16,402,235</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> common units and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,200,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> of performance based incentive common units of Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">706,701</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">188,454</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, respectively, in shares of common stock of the Company. Shares of common stock issued in respect of unvested common units and performance based incentive common units as of the Liquidation are shares of restricted common stock and subject to vesting in accordance with the vesting schedule applicable to such units; and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,869,704</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> incentive units in Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,444,990</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company. Shares of common stock issued in respect of unvested incentive units as of the Liquidation are shares of restricted common stock and continue to be subject to vesting in accordance with the vesting schedule applicable to such incentive units. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a result of the Liquidation, the holders of units in Rallybio Holdings collectively were issued an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24,999,970</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company prior to the completion of the IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Reorganization and subsequent Liquidation resulted in a change in reporting entity as described in ASC 250. In accordance with the guidance applicable to these circumstances, the equity structure has been adjusted in all comparative periods up to the Liquidation to reflect the number of shares of the Company&#8217;s common stock, issued to Rallybio Holdings unitholders in connection with the Liquidation. As such, historical Rallybio Holdings convertible redeemable preferred units, common units, and incentive units have been retroactively adjusted in these financial statements to shares and earnings per share in accordance with the ratio of common shares received by each membership unit class. Rallybio Holdings' convertible redeemable preferred units previously classified as mezzanine equity, including the Series B Preferred Unit Agreement executed during the year 2020 with a total aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">145.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, have been retroactively adjusted in these financial statements, converted into common stock, and reclassified to permanent as a result of the retrospective application of the Liquidation and change in reporting entity.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span></span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basis of Presentation&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). </span></span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Principles of Consolidation&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Use of Estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the fair value of its common un</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">its and incentive units awarded to employees prior to the Company's IPO, for purposes of recording stock-based incentive compensation, the fair value of stock options, as well as contracted research and development expenses incurred.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liquidity and Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued. Since its inception, the Company has incurred net losses and negative cash flows from operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company incurred a net loss of $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">66.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">47.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million, respectively. In addition, as of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">160.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million. The Company expects to continue to generate operating losses and negative cash flows in the foreseeable future.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">The Company currently expects that cash, cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">169.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million at December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the consolidated financial statements are issued. However, w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">e do not anticipate that the current cash, cash equivalents and marketable securities as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> will be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates, if approved. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">The Company considers the nature and contractual terms of an arrangement to assess whether an arrangement involves a joint operating activity that expose two or more parties to significant risks and rewards dependent on the commercial success of the activity. If the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts for such arrangement as a collaborative arrangement under ASC 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">("ASC 808"). ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition matters subjected to other authoritative guidance, in certain cases by analogy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">For arrangements determined to be within the scope of ASC 808 for certain research and development activities where a collaborative partner is not a customer following the guidance of ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Recognition </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">("ASC 606"), the Company accounts for payments due to a collaboration partner as research and development expense and for payments owed to us from our collaboration partner for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. The Company classifies payments owed or receivables recorded as other current liabilities and other current assets, respectively, in the Company&#8217;s consolidated balance sheets. See Note 3, &#8220;License and Collaboration Agreements&#8221; for additional details.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Acquisitions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this screen criteria is met, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire in-process research and development ("IPR&amp;D") with no alternative future use is charged to research and development expense at the acquisition date. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Note 3, &#8220;License and Collaboration Agreements&#8221; for additional details.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Variable Interest Entity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company evaluates its ownership, contractual, and other interests in entities to determine if it has any variable interest in a variable interest entity (&#8220;VIE&#8221;). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. If the Company determines that an entity in which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company&#8217;s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The Company evaluated its investment in RE Ventures I, LLC, a limited liability company (&#8220;REV-I&#8221;), defined in Note 9, and concluded that it represented a VIE and was not deemed the primary beneficiary. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Note 9, &#8220;Investment in Joint Venture&#8221; for additional details.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity Method Investments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Investments &#8211; Equity Method and Joint Ventures </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">323"). The Company recognizes its pro-rata share of income and losses in &#8220;loss on investment in joint venture&#8221; on the consolidated statements of operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">comprehensive loss, with a corresponding change to the investment in joint venture asset on the consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company&#8217;s principal financial instruments are comprised of cash, cash equivalents, available for sale marketable securities, accounts payable and accrued liabilities. The carrying value of all financial instruments approximates fair value.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Concentrations of Credit Risk&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company invests its excess cash in money market funds and marketable securities in government insured financial institutions that are subject to minimal credit and market risk. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and Cash Equivalents&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company classifies amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market funds, with original maturities of three months or less at the time of purchase as cash and cash equivale</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nts. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable Securities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#8212; We invest our excess cash balances in highly rated United States ("U.S.") government-backed debt securities and treasuries.  We classify our marketable securities as available-for-sale and accordingly, record such securities at fair value. Debt securities with original maturities of greater than 90 days are classified as available-for-sale marketable securities and debt securities with original maturities of less than 90 days from the date of purchase are classified as cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unrealized gains and losses on our marketable debt securities that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. If any adjustment to fair value reflects a significant decline in the value of the security, we evaluate the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to our consolidated statements of operations and comprehensive loss. Credit losses are identified when we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and Equipment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;Property and equipment are recorded at cost and consists of computer and other equipment, capitalized software, furniture and fixtures and leasehold improvements. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, or for leasehold improvements, over the remaining term of the lease, if shorter. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The estimated useful life for each major asset classification are as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.519%;"/>
          <td style="width:2.398%;"/>
          <td style="width:38.083%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Classification</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer and other equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized software</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">lesser of lease life or useful life</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> such impairments were recorded during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leases </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;At the inception of an arrangement, we determine if an arrangement is, or contains, a lease based on the facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease we (i) identify lease and non-lease components, (ii) determine the consideration in the contract, (iii) determine whether the lease is an operating or financing lease; and iv)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recognize lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of fixed, or in substance fixed, lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable we use our incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have elected to combine lease components with non-lease components on our office real estate asset class. Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed, or in substance fixed, are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our consolidated statements of operations and comprehensive loss. Some leases include options to extend or terminate the lease and the Company includes these options in the recognition of the Company&#8217;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise such options.  We have elected the short-term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with an original term of 12 months or less.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company uses the asset and liability method of accounting for income taxes, as set forth in ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Accounting for Income Taxes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC 740"). Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company evaluates whether deferred tax assets are more likely than not of being realized in determining whether a valuation allowance is necessary. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company determined that it is more likely than not that deferred taxes will not be realized and as a result recorded a valuation allowance against its deferred tax assets. Following the Reorganization, the Company files a consolidated U.S. federal income tax return and has elected to include all subsidiaries owned more than </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%. Prior to the Reorganization, the LLCs owned </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% by the Company have each elected to be treated as and taxed as a corporation and each filed a separate U.S. federal income tax return.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and Development Expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;Research and development expenses are comprised of costs incurred in performing research and development activities including personnel salaries, benefits, and equity-based compensation; external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; the cost of developing and manufacturing clinical study materials, program regulatory costs, expenses associated with obligations under asset acquisitions, license agreements and other direct and indirect costs. Costs incurred in connection with research and development activities are expensed as incurred. Costs are considered incurred based on an evaluation of the progress to completion of each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. Depending upon the timing of invoicing by the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These prepaid expenses or accrued expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred Offering Costs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212; The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such equity financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders' equity as a reduction of additional paid-in-capital generated as a result of the offering. Should the planned equity financing no longer be considered probable of being consummated, the offering costs are expensed immediately as a charge to operating expense. Deferred offering costs are included in prepaid expenses and other assets on the consolidated balance sheets.  Deferred offering costs as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. There were </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> deferred offering costs as of December 31, 2021.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock Warrants </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for stock warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance included in ASC 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC 480") and ASC 815,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> ("ASC </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">that </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">meet all of the criteria for equity classification are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and remeasured each balance sheet date thereafter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-Based Compensation&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for share-based compensation in accordance with ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC 718"). Generally, share-based compensation is measured at the grant date for all equity-based awards made to employees based on the fair value of the awards and is recognized over the requisite service period, which is generally the vesting period. Share-based compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition is probable. The Company has elected to recognize the actual forfeitures by reducing the share-based compensation in the same period as the forfeitures occur. The Company classifies share-based compensation in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipients&#8217; payroll costs are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company estimates the fair value of options granted using the Black-Scholes option pricing model ("Black-Scholes") for stock option grants. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Black-Scholes requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. Due to the lack of a public market for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company. The historical volatility is calculated based on a period of time corresponding with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted where the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date corresponding with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair Value Measurements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liabilities and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3&#8212;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Segment Information</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;Operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">segments are defined as components of an enterprise for which discrete financial information is regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The Company manages its operations as a single segment for the purposes of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">allocating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">resources, assessing performance, and making operating decisions. All tangible assets of the Company are held in the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic and Diluted Net Loss Per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Basic shares outstanding includes the weighted-average effect of the Company's pre-funded warrants to purchase shares of our common stock requiring little consideration upon exercise. Unvested restricted common shares as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> are not considered participating securities and as such are excluded from the weighted-average number of shares used for calculating basic and diluted net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially dilutive securities include restricted common shares and stock options. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;In February 2016, FASB issued ASU 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(ASU 2016-02"), that requires lessees to recognize leases on-balance sheet and to make certain disclosures associated with their leasing arrangements. The new standard establishes a right-of-use ("ROU") model that requires a lessee to recognize an ROU asset and lease liability on the consolidated balance sheets for all leases with a term longer than twelve months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss. The Company adopted ASU 2016-02 Leases on January 1, 2022 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative periods consolidated financial statements and recognize a cumulative-effect adjustment to the consolidated balance sheets on the date of adoption. The Company elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and initial direct costs. At adoption we recognized approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of ROU assets and corresponding lease liabilities. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Note 5, &#8220;Leases&#8221; for additional details.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/><br/>In June 2016, the FASB issued ASC 2016-13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">, Financial Instruments - Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> ("ASC 2016-13"),</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. We adopted the new standard on January 1, 2022 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments. Our significant financial assets that are within the scope of the new standard consist of available for sale debt securities. There was no impact to our consolidated statements of operations and comprehensive loss or consolidated balance sheets upon adoption. See Note 4 for discussion of unrealized losses on our available for sale marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company qualifies as an emerging growth company ("EGC") as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either irrevocably elects to &#8220;opt out&#8221; of such extended transition period or no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451023456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License And Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License and collaboration agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LICENSE AND COLLABORATION AGREEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Asset Acquisition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In May 2022, we obtained worldwide exclusive rights to RLYB331, with Kymab Limited ("Sanofi") a preclinical antibody. We believe RLYB331 has the potential to address a significant unmet need for patients with severe anemias with ineffective erythropoiesis and iron overload, including beta thalassemia and a subset of lower risk myelodysplastic syndromes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the terms of the license agreement, we made an upfront payment to Sanofi of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in the second quarter of 2022 for the exclusive license to KY1066. We could also be required to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> pay up to an aggreg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">43.0</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">in development and regulatory milestones and up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">150.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in commercial milestones for a product in its first indication, plus tiered low-to-mid double digit percentages of such milestone amounts </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">for up to three additional indications, and mid to high single digit royalties on net sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The license was accounted for as an asset acquisition as substantially all of the fair value of the asset acquired was concentrated in a single asset and thus the acquisition was deemed not to be a business combination. The acquired license rights represent an IPR&amp;D asset that was determined to have no alternative future use. Accordingly, the Company recorded an IPR&amp;D charge of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million to research and development expense, including transaction costs associated with this asset acquisition of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, in the accompanying consolidated statements of operations and comprehensive loss for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">AbCellera Collaboration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2022, the Company entered into a multi-year, multi-target collaboration with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Under the terms of the agreement, AbCellera and Rallybio will co-develop and share the development costs of up to five rare disease therapeutic targets, which will be chosen together by both companies. At the point one party in the collaboration opts-out of future co-development cost sharing, that party will be entitled to a share of future profit sharing from commercialization of the collaboration target, dependent on the proportion of their co-development contributions compared to the total development costs of a target as defined within the agreement. The agreement also has defined profit sharing floors that correspond to the stage of development at the time a collaboration party opts-out of co-developing a target.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company concluded that the agreement with AbCellera will be accounted under the scope of ASC 808 as both parties will actively participate in joint operating activities and are exposed to significant risks and rewards that depend on the commercial success of those activities. Under ASC 808, certain transactions between collaborative arrangement participants should follow the accounting for revenue under ASC 606 when the collaborative arrangement participant is a customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company determined that co-d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">evelopment arrangement as defined in our agreement with AbCellera does not meet  the definition of a customer as defined by ASC 606. As a result, these activities will be accounted for as research and development costs. Payments due because of the co-development will be recorded as research and development expense in the period such expenses are incurred and for payments owed to us from our collaboration partner for the reimbursement of research and development costs will be recorded as a contra-research and development expense in the period such expenses are incurred. Costs related to the AbCellera collaboration were not material for the year ended December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451158624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4. MARKETABLE SECURITIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of our marketable securities by type of security as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.675%;"/>
        <td style="width:2.053%;"/>
        <td style="width:11.199%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.404%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.41%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.564%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.671%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair Value Hierarchy Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross Unrealized Holding Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross Unrealized Holding Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,647</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,647</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">39,372</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">169</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">39,203</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">76,860</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">82</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">76,815</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,879</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">251</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The fair values of marketable securities by classification in the consolidated balance sheets was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.107%;"/>
        <td style="width:2.332%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.561%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16,629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The fair values of available-for-sale debt securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, by contractual maturity, are summarized as follows:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.107%;"/>
        <td style="width:2.332%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.561%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">127,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Due after one year through two years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/>The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">70.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. We did </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">t have any investments in a continuous unrealized loss position for more than twelve months as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, we believe that the cost basis of our available-for-sale debt securities is recoverable. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> allowance for credit losses was recorded as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2021, the Company held money market funds that were classified as cash and cash equivalents on the Company's consolidated balance sheets of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. These money market funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451038544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5. LEASES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have operating leases for approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nine thousand</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet of corporate office space. The weighted-average remaining lease term is </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The weighted-average discount rate utilized on our operating lease liabilities as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating leases are included in operating lease ROU assets, operating lease liabilities, and operating lease liabilities, noncurrent in our consolidated balance sheets as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes the presentation of the Company's operating lease as presented on the consolidated balance sheets:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.024%;"/>
        <td style="width:1.937%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.039%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">524</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">374</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Future minimum lease payments from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 until the expiration of the operating lease are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.272%;"/>
        <td style="width:2.912%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.816000000000003%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">230</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">156</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less: imputed discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Carrying value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">555</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in operating lease rent expense for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, respectively.  Lease payments made were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, with such amounts reflected in the consolidated statements of cash flows in operating activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As the result of adopting ASU 2016-02 using the modified retrospective transition method, we did not restate periods prior to the adoption date of January 1, 2022. These periods continue to be presented in accordance with ASC 840. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2021, the future undiscounted minimum lease payments on our operating leases were as follows:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.272%;"/>
        <td style="width:2.912%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.816000000000003%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">YEAR ENDING DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">170</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">195</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">176</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">771</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451197808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6. BALANCE SHEET COMPONENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and Equipment&#8212;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.523%;"/>
        <td style="width:1.602%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.122%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.142%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer and other equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">154</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">89</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">89</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">338</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">315</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">373</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">206</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment&#8212;net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">385</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation expense totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">million</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prepaid Expenses and Other Assets&#8212;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prepaid expenses and other assets consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.641%;"/>
        <td style="width:2.66%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.505%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.69%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.505%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,303</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">933</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,467</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other prepaids</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">615</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">370</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,050</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">395</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued Expenses&#8212;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.523%;"/>
        <td style="width:1.602%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.122%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.142%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,582</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Compensation and related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,703</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,955</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">510</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">539</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">654</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">517</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,449</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,948</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451081856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7. STOCKHOLDERS' EQUITY</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Common Stock<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In August 2021, the Company completed its IPO, pursuant to which it issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,130,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company&#8217;s common stock, inclusive of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">930,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">share. The gross proceeds from the IPO, including the exercise</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the underwriter's option to purchase additional shares were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">92.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and the net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">83.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In November 2022, the Company completed a follow-on offering of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">54.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million consisting of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,803,655</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock, inclusive of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">803,654</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock sold pursuant to the partial exercise of the underwriters' option to purchase additional shares at the price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,333,388</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.9999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which represents the per share public offering price for the shares less the $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share exercise price for each pre-funded warrant</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. The net proceeds from the November 2022 follow-on offering were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">See Note 2 for a summary of the Reorganization and Liquidation of Rallybio Holdings that was completed prior to the Company's IPO, which resulted in a change in reporting entity. In accordance with the applicable accounting guidance related to changes in reporting entities, the financial statements for all periods presented have been retrospectively adjusted giving effect to the Reorganization and Liquidation as applicable to all periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company evaluated the liquidation of Rallybio Holdings units and subsequent issuance of common stock awards of the Company, discussed in Note 2, as a modification under ASC 718, Share Based Payments. Under ASC 718, a modification is a change in the terms or conditions of a stock-based compensation award. In assessing the modification, the Company considered the fair value, vesting conditions and classification as an equity or liability award before Liquidation and replacement, compared to the Company&#8217;s common stock received as of the Liquidation to determine whether modification accounting must be applied. As the number of shares of common stock of the Company that the unitholders of Rallybio Holdings received in the Liquidation was based on the fair value of those units in Rallybio Holdings immediately prior to the Liquidation, unvested units were replaced with restricted common shares with the same vesting terms as the initial awards, and the classification of the awards as equity awards did not change from this action, no incremental stock-based compensation expense resulted from the modification.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company had </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock authorized as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, respectively, of which </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37,837,369</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32,129,970</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares were issued and outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.<br/><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preferred Stock<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company had </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of preferred stock authorized as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares were outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.<br/><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pre-Funded Warrants <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the follow-on offering entered into in November 2022, the Company entered into an agreement with certain investors for pre-funded warrants in lieu of common stock to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,333,388</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.9999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, which represents the per share public offering price at the November 2022 follow-on offering for common stock less a $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share exercise price for each pre-funded warrant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would exceed </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#8217;s election upon </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">61</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> days&#8217; notice to the Company subject to the terms of such pre-funded warrants, provided that such percentage may in no event exceed </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has assessed the pre-funded warrant for appropriate equity or liability classification. During this assessment, the Company determined the pre-funded warrant is a freestanding instrument that does not meet the definition of a liability pursuant to ASC 480 and does not meet the definition of a derivative pursuant to ASC 815. The pre-funded warrant is indexed to the Company&#8217;s common stock and meets all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the pre-funded warrant classified as equity and accounted for as a component of additional paid-in capital at the time of issuance. All of the pre-funded warrants related to our November 2022 follow-on offering remain outstanding and unexercised as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-based compensation which comprised of stock options, restricted stock awards, restricted stock units and the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> employee stock purchase plan is classified in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 and was as follows: <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.921%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.053%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.64%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.386%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br/>DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,542</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,957</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,477</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,499</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,645</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">2021 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In 2021, the board of directors adopted the Rallybio Corporation 2021 Equity Incentive Plan (the "2021 Plan"). The 2021 Plan reserves</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,440,344</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> for shares of the Company's common stock that have been issued in respect of outstanding equity awards granted prior to the registrant&#8217;s IPO and for future issuances of shares to employees, directors and consultants in the form of stock options, SARs, restricted and unrestricted stock and stock units, performance awards and other awards that are convertible into or otherwise based on the Company's common stock. Dividend equivalents may also be provided in connection with awards under the 2021 Plan. The share pool will automatically incr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ease on January 1st of each year from 2022 to 2031 by the lesser of (i) five percent of the number of shares of the Company's common stock outstanding as of such date and (ii) the number of shares of the Company's common stock determined by the board of directors on or prior to such date. On January 1, 2022, the 2021 Plan share pool was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,606,549</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares.  As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the total number of shares of the Company's common stock that were issuable under the 2021 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,796,071</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares, of which </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,058,157</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares remained available for future issuance.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022:<br/><br/></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.387%;"/>
        <td style="width:0.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.453999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.81%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.387%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.209999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.41%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number of Option Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Contractual Term <br/>&#160;&#160;&#160;(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Aggregate Intrinsic Value<br/>&#160;&#160;&#160;(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,357,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12.72</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,458,800</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">183,151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,105</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.38</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,014</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,609,314</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.01</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">685,155</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.4</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/>The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company's common stock. Options outstanding and exercisable with an exercise price above the closing price as of December 31, 2022 are considered to have no intrinsic value. Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the year ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, respectively. Options vested during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> with an exercise price above the closing price are considered to have </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> intrinsic value. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was unrecognized share-based compensation expense related to unvested stock options of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">17.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which the Company expects to recognize over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The fair value of the stock options granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.905%;"/>
        <td style="width:1.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.349%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.608%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">89.31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">91.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">86.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">87.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.50 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.50 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.94</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercise price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.54</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.76</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A summary of the status of the Company's nonvested restricted common stock awards at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and changes during the year ended December 31, 2022 was as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.034%;"/>
        <td style="width:1.209%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.626%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.113000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted Stock Awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Nonvested restricted stock awards at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,272,707</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,127,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">139,115</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.87</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding nonvested restricted stock awards at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,006,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was unrecognized share-based compensation expense related to unvested restricted stock awards of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which the Company expects to recognize over a weighted-average period of approximately</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A summary of the status of the Company's nonvested restricted common stock units at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and changes during the year ended December 31, 2022 was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.034%;"/>
        <td style="width:1.209%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.626%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.113000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Nonvested restricted stock units at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">151,300</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11.68</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.76</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding nonvested restricted stock units at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11.12</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/>As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was unrecognized share-based compensation expense related to unvested restricted stock units of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which the Company expects to recognize over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the Company's IPO, the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> board of directors adopted the Rallybio Corporation 2021 Employee Stock Purchase Plan (the "2021 ESPP"), which reserves </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">291,324</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock for future issuances under this plan. The share pool will automatically incr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ease on January 1st of each year from 2022 to 2031 by the lesser of (i) one percent of the number of shares of the Company's common stock outstanding as of such date (ii) </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">582,648</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock, and (iii) the number of shares of the Company's common stock determined by the board of directors on or prior to such date.  On January 1, 2022, the 2021 ESPP share pool was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">321,309</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the total number of shares of the Company's common stock that were available for future issuance under the 2021 ESPP was </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">573,788</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">38,845</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock under the 2021 ESPP. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares were issued under the ESPP as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the total share-based compensation for the 2021 ESPP was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451079856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8. INCOME TAXES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During each of the years ended  December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> , the Company did </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">t record any income tax benefits.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s effective income tax rates are different from the federal statutory tax rates in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022 and 2021 predominantly due to the valuation allowance, tax credits, and state taxes described below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.046%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.335%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.701%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.225%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. federal statutory tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State income taxes, net of federal income tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The combined temporary differences and carryforwards of each tax paying component of the Company that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.529%;"/>
        <td style="width:2.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.762%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.762%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,789</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,306</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,685</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Section 174 capitalization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,242</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,213</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,196</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">474</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50,215</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31,161</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50,215</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31,161</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company has approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">98.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of federal net operating loss carryforwards, which do not expire, and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">98.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of state net operating loss carryforwards, which begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2038</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has provided a valuation allowance against the Company&#8217;s deferred tax assets, since, in the opinion of management, based upon the history of losses by the Company and insufficient future federal and state taxable income; it is more likely than not that the benefits will not be realized. All or a portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective January 1, 2022, a provision of the Tax Cuts and Jobs Act ("TCJA") changed the treatment of research and experimental ("R&amp;E") expenditures under Section 174 of the Internal Revenue Code ("Code"). Previous to the TCJA being effective, businesses have had the option of deducting Section 174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The new TCJA provision, however, eliminates this option and will require Section 174 expenses associated with research conducted in the U.S to be capitalized and amortized over a five-year period. For expenses associated with research outside of the United States, Section 174 expenses will be capitalized and amortized over a 15-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 and Section 383 of the Code, and corresponding provisions of state law, due to ownership changes that may have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income and tax liabilities. In general, an ownership change, as defined by Section 382 of the Code, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% over a three-year period. The Company recently completed a Section 382 study and concluded that we underwent an ownership change as defined by the Code during the year ended December 31, 2020. We do not currently believe that the annual limitation will result in the expiration of any net operating losses or research and development tax credit carryforwards before utilization. Future ownership changes may limit our ability to utilize remaining tax attributes. Any carryforwards that will expire prior to utilization as a result of such additional limitations will be removed from deferred tax assets, with a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#8217;s effective tax rate.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has no material uncertain tax positions that qualify for either recognition or disclosure in consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">It is the Company&#8217;s policy to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company has accrued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> interest and penalties related to uncertain tax positions. The Company does </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">t have any outstanding U.S. federal income tax or material state and local tax matters for periods through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. There are </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> federal or state and local income tax returns currently under examination. The Company&#8217;s tax returns from inception to date are subject to examination by the taxing authorities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451081856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment In Joint Venture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment In Joint Venture</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9. INVESTMENT IN JOINT VENTURE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company, through one of its wholly-owned subsidiaries, has a </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% interest of the joint venture entity, REV-I.  For the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021 the Company funded $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, associated with the Company's commitment and its share of REV-I development. The Company did not provide any additional financial support outside of capital contributions to REV-I during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021. While the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company held a 50% interest in the joint venture as of December 31, 2022, based on management&#8217;s analysis, the Company is not the primary beneficiary of REV-1 and accordingly, the entity is not consolidated in the Company's consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, the Company recorded its allocable share of REV-I&#8217;s losses, which totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, as a loss on investment in joint venture within the consolidated statements of operations and comprehensive loss. After recognition of its share of losses for the period, the carrying value and maximum exposure to risk of the REV-I investment as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> thousand and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, which was recorded in investment in joint venture in the accompanying consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451088032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10. COMMITMENTS AND CONTINGENCIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchase Commitments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company enters contracts in the normal course of business with contract research organizations and other third-party vendors for clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments that may be due upon cancellation consist of payments for services provided or expenses incurred prior to cancellation. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> there were </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> amounts accrued related to termination charges.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753452011232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11. NET LOSS PER COMMON SHARE</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic and diluted loss per common share were calculated as follows: <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.441%;"/>
        <td style="width:1.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.116%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.84%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br/>DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/>(in thousands except share and per share amounts)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">66,654</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">47,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-average number of common shares <br/>&#160;&#160;&#160;outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31,821,311</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25,519,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(2.09</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(1.84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic net loss per share of common stock is based on the weighted-average number of shares of common stock outstanding during the period. Pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,333,388</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock that were issued in connection with the November 2022 follow-on offering were included in the weighted-average number of common shares outstanding for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022. The weighted-average number of common shares outstanding diluted for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> excludes approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million stock options and unvested restricted common shares, which were not dilutive and not included in the computation of net loss per common share. The weighted-average number of common shares outstanding diluted for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> excludes approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million stock options and unvested restricted common shares, which were not dilutive and not included in the computation of net loss per common share.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446833376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_IpoAndReorganizationPolicyPolicyTextBlock', window );">IPO and Reorganization</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">IPO and Reorganization </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212; As discussed in Note 1, "Business," in connection with the Reorganization, all of Rallybio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Holdings' direct subsidiaries, other than Rallybio Corporation, became direct subsidiaries of the Company prior to the Liquidation of Rallybio Holdings. Prior to the completion of the Company's IPO, Rallybio Holdings liquidated and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation. Subsequent to the Reorganization and the Liquidation of Rallybio Holdings </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">the consolidated financial statements are reported from Rallybio Corporation. </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The capital structure of Rallybio Holdings prior to the Liquidation consisted of four classes of membership units: common units; Series A-1 preferred units; Series A-2 preferred units; Series B preferred units; and incentive common units ("incentive units"). The number of shares of common stock that the holders of each class of units received in the Liquidation was based on the value of Rallybio Holdings prior to the Liquidation, determined by reference to the initial public offering price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. The common stock of the Company was allocated to the holders of existing units in Rallybio Holdings as follows:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33,478,255</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Series A-1 preferred units and Series A-2 preferred units of Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,257,590</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company; </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">104,442,965</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Series B preferred units of Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16,402,235</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> common units and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,200,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> of performance based incentive common units of Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">706,701</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">188,454</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, respectively, in shares of common stock of the Company. Shares of common stock issued in respect of unvested common units and performance based incentive common units as of the Liquidation are shares of restricted common stock and subject to vesting in accordance with the vesting schedule applicable to such units; and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">holders of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,869,704</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> incentive units in Rallybio Holdings received an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,444,990</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company. Shares of common stock issued in respect of unvested incentive units as of the Liquidation are shares of restricted common stock and continue to be subject to vesting in accordance with the vesting schedule applicable to such incentive units. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a result of the Liquidation, the holders of units in Rallybio Holdings collectively were issued an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24,999,970</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock of the Company prior to the completion of the IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Reorganization and subsequent Liquidation resulted in a change in reporting entity as described in ASC 250. In accordance with the guidance applicable to these circumstances, the equity structure has been adjusted in all comparative periods up to the Liquidation to reflect the number of shares of the Company&#8217;s common stock, issued to Rallybio Holdings unitholders in connection with the Liquidation. As such, historical Rallybio Holdings convertible redeemable preferred units, common units, and incentive units have been retroactively adjusted in these financial statements to shares and earnings per share in accordance with the ratio of common shares received by each membership unit class. Rallybio Holdings' convertible redeemable preferred units previously classified as mezzanine equity, including the Series B Preferred Unit Agreement executed during the year 2020 with a total aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">145.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, have been retroactively adjusted in these financial statements, converted into common stock, and reclassified to permanent as a result of the retrospective application of the Liquidation and change in reporting entity.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basis of Presentation&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Principles of Consolidation&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Use of Estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the fair value of its common un</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">its and incentive units awarded to employees prior to the Company's IPO, for purposes of recording stock-based incentive compensation, the fair value of stock options, as well as contracted research and development expenses incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock', window );">Liquidity and Ability to Continue as a Going Concern</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liquidity and Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued. Since its inception, the Company has incurred net losses and negative cash flows from operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company incurred a net loss of $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">66.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">47.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million, respectively. In addition, as of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">160.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million. The Company expects to continue to generate operating losses and negative cash flows in the foreseeable future.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">The Company currently expects that cash, cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">169.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> million at December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the consolidated financial statements are issued. However, w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">e do not anticipate that the current cash, cash equivalents and marketable securities as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> will be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates, if approved. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">The Company considers the nature and contractual terms of an arrangement to assess whether an arrangement involves a joint operating activity that expose two or more parties to significant risks and rewards dependent on the commercial success of the activity. If the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts for such arrangement as a collaborative arrangement under ASC 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">("ASC 808"). ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition matters subjected to other authoritative guidance, in certain cases by analogy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">For arrangements determined to be within the scope of ASC 808 for certain research and development activities where a collaborative partner is not a customer following the guidance of ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Recognition </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">("ASC 606"), the Company accounts for payments due to a collaboration partner as research and development expense and for payments owed to us from our collaboration partner for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. The Company classifies payments owed or receivables recorded as other current liabilities and other current assets, respectively, in the Company&#8217;s consolidated balance sheets. See Note 3, &#8220;License and Collaboration Agreements&#8221; for additional details.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_AssetAcquisitionPolicyTextBlock', window );">Asset Acquisitions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Acquisitions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this screen criteria is met, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire in-process research and development ("IPR&amp;D") with no alternative future use is charged to research and development expense at the acquisition date. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Note 3, &#8220;License and Collaboration Agreements&#8221; for additional details.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Variable Interest Entity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company evaluates its ownership, contractual, and other interests in entities to determine if it has any variable interest in a variable interest entity (&#8220;VIE&#8221;). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. If the Company determines that an entity in which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company&#8217;s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The Company evaluated its investment in RE Ventures I, LLC, a limited liability company (&#8220;REV-I&#8221;), defined in Note 9, and concluded that it represented a VIE and was not deemed the primary beneficiary. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Note 9, &#8220;Investment in Joint Venture&#8221; for additional details.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity Method Investments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Investments &#8211; Equity Method and Joint Ventures </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">323"). The Company recognizes its pro-rata share of income and losses in &#8220;loss on investment in joint venture&#8221; on the consolidated statements of operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">comprehensive loss, with a corresponding change to the investment in joint venture asset on the consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company&#8217;s principal financial instruments are comprised of cash, cash equivalents, available for sale marketable securities, accounts payable and accrued liabilities. The carrying value of all financial instruments approximates fair value.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Concentrations of Credit Risk&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company invests its excess cash in money market funds and marketable securities in government insured financial institutions that are subject to minimal credit and market risk. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and Cash Equivalents&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company classifies amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market funds, with original maturities of three months or less at the time of purchase as cash and cash equivale</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nts. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable Securities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#8212; We invest our excess cash balances in highly rated United States ("U.S.") government-backed debt securities and treasuries.  We classify our marketable securities as available-for-sale and accordingly, record such securities at fair value. Debt securities with original maturities of greater than 90 days are classified as available-for-sale marketable securities and debt securities with original maturities of less than 90 days from the date of purchase are classified as cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unrealized gains and losses on our marketable debt securities that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. If any adjustment to fair value reflects a significant decline in the value of the security, we evaluate the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to our consolidated statements of operations and comprehensive loss. Credit losses are identified when we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and Equipment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;Property and equipment are recorded at cost and consists of computer and other equipment, capitalized software, furniture and fixtures and leasehold improvements. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, or for leasehold improvements, over the remaining term of the lease, if shorter. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The estimated useful life for each major asset classification are as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.519%;"/>
          <td style="width:2.398%;"/>
          <td style="width:38.083%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Classification</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer and other equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized software</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">lesser of lease life or useful life</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> such impairments were recorded during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leases </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;At the inception of an arrangement, we determine if an arrangement is, or contains, a lease based on the facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease we (i) identify lease and non-lease components, (ii) determine the consideration in the contract, (iii) determine whether the lease is an operating or financing lease; and iv)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recognize lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of fixed, or in substance fixed, lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable we use our incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have elected to combine lease components with non-lease components on our office real estate asset class. Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed, or in substance fixed, are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our consolidated statements of operations and comprehensive loss. Some leases include options to extend or terminate the lease and the Company includes these options in the recognition of the Company&#8217;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise such options.  We have elected the short-term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with an original term of 12 months or less.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company uses the asset and liability method of accounting for income taxes, as set forth in ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Accounting for Income Taxes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC 740"). Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company evaluates whether deferred tax assets are more likely than not of being realized in determining whether a valuation allowance is necessary. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company determined that it is more likely than not that deferred taxes will not be realized and as a result recorded a valuation allowance against its deferred tax assets. Following the Reorganization, the Company files a consolidated U.S. federal income tax return and has elected to include all subsidiaries owned more than </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%. Prior to the Reorganization, the LLCs owned </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% by the Company have each elected to be treated as and taxed as a corporation and each filed a separate U.S. federal income tax return.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and Development Expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;Research and development expenses are comprised of costs incurred in performing research and development activities including personnel salaries, benefits, and equity-based compensation; external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; the cost of developing and manufacturing clinical study materials, program regulatory costs, expenses associated with obligations under asset acquisitions, license agreements and other direct and indirect costs. Costs incurred in connection with research and development activities are expensed as incurred. Costs are considered incurred based on an evaluation of the progress to completion of each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. Depending upon the timing of invoicing by the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These prepaid expenses or accrued expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred Offering Costs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212; The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such equity financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders' equity as a reduction of additional paid-in-capital generated as a result of the offering. Should the planned equity financing no longer be considered probable of being consummated, the offering costs are expensed immediately as a charge to operating expense. Deferred offering costs are included in prepaid expenses and other assets on the consolidated balance sheets.  Deferred offering costs as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. There were </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> deferred offering costs as of December 31, 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_StockWarrantsPolicyTextBlock', window );">Stock Warrants</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock Warrants </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for stock warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance included in ASC 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC 480") and ASC 815,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> ("ASC </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">that </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">meet all of the criteria for equity classification are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and remeasured each balance sheet date thereafter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-Based Compensation&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for share-based compensation in accordance with ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC 718"). Generally, share-based compensation is measured at the grant date for all equity-based awards made to employees based on the fair value of the awards and is recognized over the requisite service period, which is generally the vesting period. Share-based compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition is probable. The Company has elected to recognize the actual forfeitures by reducing the share-based compensation in the same period as the forfeitures occur. The Company classifies share-based compensation in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipients&#8217; payroll costs are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company estimates the fair value of options granted using the Black-Scholes option pricing model ("Black-Scholes") for stock option grants. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Black-Scholes requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. Due to the lack of a public market for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company. The historical volatility is calculated based on a period of time corresponding with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted where the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date corresponding with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair Value Measurements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liabilities and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3&#8212;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Segment Information</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;Operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">segments are defined as components of an enterprise for which discrete financial information is regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The Company manages its operations as a single segment for the purposes of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">allocating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">resources, assessing performance, and making operating decisions. All tangible assets of the Company are held in the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic and Diluted Net Loss Per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Basic shares outstanding includes the weighted-average effect of the Company's pre-funded warrants to purchase shares of our common stock requiring little consideration upon exercise. Unvested restricted common shares as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> are not considered participating securities and as such are excluded from the weighted-average number of shares used for calculating basic and diluted net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially dilutive securities include restricted common shares and stock options. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;In February 2016, FASB issued ASU 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(ASU 2016-02"), that requires lessees to recognize leases on-balance sheet and to make certain disclosures associated with their leasing arrangements. The new standard establishes a right-of-use ("ROU") model that requires a lessee to recognize an ROU asset and lease liability on the consolidated balance sheets for all leases with a term longer than twelve months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss. The Company adopted ASU 2016-02 Leases on January 1, 2022 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative periods consolidated financial statements and recognize a cumulative-effect adjustment to the consolidated balance sheets on the date of adoption. The Company elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and initial direct costs. At adoption we recognized approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of ROU assets and corresponding lease liabilities. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;ARIAL&quot;, sans-serif;min-width:fit-content;"> Note 5, &#8220;Leases&#8221; for additional details.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/><br/>In June 2016, the FASB issued ASC 2016-13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">, Financial Instruments - Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> ("ASC 2016-13"),</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. We adopted the new standard on January 1, 2022 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments. Our significant financial assets that are within the scope of the new standard consist of available for sale debt securities. There was no impact to our consolidated statements of operations and comprehensive loss or consolidated balance sheets upon adoption. See Note 4 for discussion of unrealized losses on our available for sale marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company qualifies as an emerging growth company ("EGC") as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either irrevocably elects to &#8220;opt out&#8221; of such extended transition period or no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_AssetAcquisitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_AssetAcquisitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_IpoAndReorganizationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>IPO and reorganization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_IpoAndReorganizationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Ability to Continue as a Going Concern [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Issued Accounting Pronouncement Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_StockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_StockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451078624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock', window );">Summary of Property and Equipment Estimated Useful Lives</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The estimated useful life for each major asset classification are as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.519%;"/>
          <td style="width:2.398%;"/>
          <td style="width:38.083%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset Classification</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer and other equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized software</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">lesser of lease life or useful life</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753452033296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Fair Value of Marketable Securities by Type of Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of our marketable securities by type of security as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.675%;"/>
        <td style="width:2.053%;"/>
        <td style="width:11.199%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.404%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.41%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.564%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.671%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair Value Hierarchy Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross Unrealized Holding Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross Unrealized Holding Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,647</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,647</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">39,372</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">169</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">39,203</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">76,860</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">82</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">76,815</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,879</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">251</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock', window );">Schedule of Marketable Securities by Balance Sheet Location Classification</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The fair values of marketable securities by classification in the consolidated balance sheets was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.107%;"/>
        <td style="width:2.332%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.561%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16,629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Values of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The fair values of available-for-sale debt securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, by contractual maturity, are summarized as follows:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.107%;"/>
        <td style="width:2.332%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.561%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">127,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Due after one year through two years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities by balance sheet location classification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451102480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Summary of Company's Operating Lease on the Condensed Consolidated Balance Sheets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes the presentation of the Company's operating lease as presented on the consolidated balance sheets:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.024%;"/>
        <td style="width:1.937%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.039%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">524</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">374</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Annual Lease Payments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Future minimum lease payments from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 until the expiration of the operating lease are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.272%;"/>
        <td style="width:2.912%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.816000000000003%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">230</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">156</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less: imputed discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Carrying value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">555</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2021, the future undiscounted minimum lease payments on our operating leases were as follows:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/></span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.272%;"/>
        <td style="width:2.912%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.816000000000003%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">YEAR ENDING DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">170</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">195</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">176</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">771</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753452158576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.523%;"/>
        <td style="width:1.602%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.122%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.142%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer and other equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">154</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">89</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">89</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">338</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">315</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">373</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">206</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment&#8212;net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">385</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prepaid expenses and other assets consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.641%;"/>
        <td style="width:2.66%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.505%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.69%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.505%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,303</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">933</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,467</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other prepaids</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">615</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">370</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,050</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">395</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.523%;"/>
        <td style="width:1.602%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.122%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.142%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,582</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Compensation and related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,703</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,955</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">510</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">539</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">654</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">517</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,449</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,948</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753448987680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Share-Based Compensation for Stock Options, Restricted Stock Awards and Restricted Stock Units and the Employee Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Share-based compensation which comprised of stock options, restricted stock awards, restricted stock units and the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> employee stock purchase plan is classified in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 and was as follows: <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.921%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.053%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.64%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.386%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br/>DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,542</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,957</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,477</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,499</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,645</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022:<br/><br/></span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.387%;"/>
        <td style="width:0.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.453999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.81%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.387%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.209999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.41%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number of Option Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Contractual Term <br/>&#160;&#160;&#160;(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Aggregate Intrinsic Value<br/>&#160;&#160;&#160;(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,357,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12.72</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,458,800</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">183,151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,105</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.38</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,014</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,609,314</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.01</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">685,155</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.4</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions of Fair Value of Option Pricing Granted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The fair value of the stock options granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.905%;"/>
        <td style="width:1.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.349%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.608%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">89.31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">91.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">86.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">87.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.50 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.50 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.94</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercise price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.54</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.76</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Nonvested Restricted Common Stock Awards</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A summary of the status of the Company's nonvested restricted common stock awards at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and changes during the year ended December 31, 2022 was as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.034%;"/>
        <td style="width:1.209%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.626%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.113000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted Stock Awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Nonvested restricted stock awards at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,272,707</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,127,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">139,115</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.87</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding nonvested restricted stock awards at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,006,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Nonvested Restricted Common Stock Units</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A summary of the status of the Company's nonvested restricted common stock units at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and changes during the year ended December 31, 2022 was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.034%;"/>
        <td style="width:1.209%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.626%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.113000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Nonvested restricted stock units at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">151,300</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11.68</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.76</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding nonvested restricted stock units at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11.12</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753452357888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s effective income tax rates are different from the federal statutory tax rates in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022 and 2021 predominantly due to the valuation allowance, tax credits, and state taxes described below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.046%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.335%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.701%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.225%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. federal statutory tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State income taxes, net of federal income tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Tax Benefits and Liabilities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The combined temporary differences and carryforwards of each tax paying component of the Company that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.529%;"/>
        <td style="width:2.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.762%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.762%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,789</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,306</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,685</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Section 174 capitalization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,242</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,213</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,196</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">474</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50,215</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31,161</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50,215</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31,161</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753447527296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Loss Per Common Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic and diluted loss per common share were calculated as follows: <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.441%;"/>
        <td style="width:1.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.116%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.84%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOR THE YEAR ENDED<br/>DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/>(in thousands except share and per share amounts)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">66,654</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">47,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-average number of common shares <br/>&#160;&#160;&#160;outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31,821,311</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25,519,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(2.09</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(1.84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753445085504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rlyb_PreFundedWarrantMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 5.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre-funded warrants exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Total IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,130,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnOfferingMember', window );">Follow-On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">5,803,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 54.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">3,333,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 50.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnFollowOnOfferingMember', window );">Over Allotment On Follow-On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">803,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnInitialPublicOfferingMember', window );">Over Allotment On Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rlyb_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rlyb_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnFollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnFollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnInitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnInitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753442463744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jul. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_LiquidationCommonStockSharesIssued', window );">Common stock, shares issued on liquidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,999,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (66,654,000)<span></span>
</td>
<td class="num">(47,013,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,681,000<span></span>
</td>
<td class="nump">$ 94,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,837,369<span></span>
</td>
<td class="nump">32,129,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization', window );">Subsidiaries, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember', window );">Convertible redeemable preferred units previously classified as mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_AggregatePurchasePriceOfCommonStock', window );">Aggregate purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember', window );">Common Stock Allocated to Series A-1 And Series A-2 Preferred Units Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,257,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember', window );">Common Stock Allocated To Series B Preferred Units Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,402,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToCommonUnitHoldersMember', window );">Common Stock Allocated to Common Unit Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember', window );">Common Stock Allocated To Performance Based Incentive Common Unit Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember', window );">Common Stock Allocated To Incentive Units Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,444,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">7,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_PriorToIpoMember', window );">Prior to IPO | Series A-1 and A-2 Redeemable Convertible Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Existing units of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,478,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_PriorToIpoMember', window );">Prior to IPO | Series B Redeemable Convertible Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Existing units of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,442,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_PriorToIpoMember', window );">Prior to IPO | Common Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Existing units of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_PriorToIpoMember', window );">Prior to IPO | Performance Based Incentive Common Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Existing units of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_PriorToIpoMember', window );">Prior to IPO | Incentive Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Existing units of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,869,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_AggregatePurchasePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Purchase Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_AggregatePurchasePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_LiquidationCommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidation common stock shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_LiquidationCommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Parent ownership percentage of all subsidiaries the parent elect to include in consolidated federal income tax return following reorganization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Parent ownership percentage of LLCs that elect to be treated as corporation and filed separate US federal tax return prior to reorganization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToCommonUnitHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToCommonUnitHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_PriorToIpoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rlyb_PriorToIpoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_SeriesBRedeemableConvertiblePreferredUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_SeriesBRedeemableConvertiblePreferredUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_CommonUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_CommonUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_PerformanceBasedIncentiveCommonUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_PerformanceBasedIncentiveCommonUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlyb_IncentiveUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlyb_IncentiveUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446707872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Summary of Property and Equipment Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and Other Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlyb_CapitalizedSoftwareMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlyb_CapitalizedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlyb_CapitalizedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753445434352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,689<span></span>
</td>
<td class="nump">$ 26,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rlyb_LicenseAgreementMember', window );">License Agreement | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments', window );">Aggregate development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones', window );">Obligation to payment upon maximum achievement of certain clinical and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rlyb_LicenseAgreementMember', window );">License Agreement | License Rights | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_AssetAcquisitionTransactionCosts', window );">Transaction costs associated with asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D | License Agreement | License Rights | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate development and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition transaction costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligation to payment upon maximum achievement of certain clinical and commercial milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rlyb_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rlyb_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rlyb_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rlyb_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=rlyb_LicenseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=rlyb_LicenseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446841344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of available-for-sale marketable securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 128,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">128,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">12,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">12,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U S Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">39,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">39,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">76,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 76,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753442564176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Available-for-Sale Securities by Balance Sheet Location Classification (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-Sale</a></td>
<td class="nump">$ 128,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-Sale</a></td>
<td class="nump">16,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=rlyb_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-Sale</a></td>
<td class="nump">$ 112,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rlyb_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rlyb_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753452527232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Fair Values of Available-For-Sale Debt Securities By Contractual Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 127,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through two years</a></td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total available-for-sale debt securities by contractual maturity</a></td>
<td class="nump">$ 128,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753442175216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value of available-for-sale debt securities in an unrealized loss position</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Continuous unrealized loss position for more than twelve months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Allowance for credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 56,958<span></span>
</td>
<td class="nump">$ 175,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (3)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753447572880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term (Year)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease Payments</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseDescription', window );">Lessor Operating Lease Description</a></td>
<td class="text">We have operating leases for approximately nine thousand square feet of corporate office space. The weighted-average remaining lease term is 2.6 years. The weighted-average discount rate utilized on our operating lease liabilities as of December 31, 2022 was 4.00%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753442570320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Company's Operating Lease on the Condensed Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 524<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 555<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753442193584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Annual Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed discount rate</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Carrying value of operating lease liabilities</a></td>
<td class="nump">$ 555<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446723568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Annual Lease Payments Adopting ASU 2016-02 (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_OperatingLeasesFutureMinimumPayments', window );">Total lease payments</a></td>
<td class="nump">$ 771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_OperatingLeasesFutureMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases future minimum payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_OperatingLeasesFutureMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446499936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">$ (373)<span></span>
</td>
<td class="num">$ (206)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and Other Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlyb_CapitalizedSoftwareMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leashold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction In Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlyb_CapitalizedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlyb_CapitalizedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753451927616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753442570608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_PrepaidResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">$ 7,904<span></span>
</td>
<td class="nump">$ 3,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">1,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaids</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">$ 10,502<span></span>
</td>
<td class="nump">$ 5,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446706640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule Of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development</a></td>
<td class="nump">$ 3,582<span></span>
</td>
<td class="nump">$ 1,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Compensation and related expenses</a></td>
<td class="nump">4,703<span></span>
</td>
<td class="nump">2,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 9,449<span></span>
</td>
<td class="nump">$ 5,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753445474272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,837,369<span></span>
</td>
<td class="nump">32,129,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,837,369<span></span>
</td>
<td class="nump">32,129,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.99<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, end of period - weighted average remaining contractual term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized compensation costs, weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rlyb_PreFundedWarrantMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre-funded warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rlyb_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, end of period - weighted average remaining contractual term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense, restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized share-based compensation expense, restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized compensation costs, weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable', window );">Common stock issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,796,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,440,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,058,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">No of shares increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,606,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">No of shares increased</a></td>
<td class="nump">321,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,845<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnFollowOnOfferingMember', window );">Over Allotment On Follow-On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnInitialPublicOfferingMember', window );">Over Allotment On Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnOfferingMember', window );">Follow-On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,803,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnOfferingMember', window );">Follow-On Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre-funded warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned', window );">Exceed Limit Percentage With Exercise To Aggregate Shares Of Common Stock Beneficially Owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed', window );">Percentage of common stock beneficially owned not exceed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned', window );">Days of notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exceed limit percentage with exercise to aggregate shares of common stock beneficially owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock beneficially owned not exceed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period Of Notice Days Affects Exceed Limit Percentage With Exercise To Aggregate Shares Of Common Stock Beneficially Owned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Annual Increase In Number Of Shares Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, shares issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rlyb_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rlyb_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rlyb_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rlyb_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnFollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnFollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnInitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rlyb_OverAllotmentOnInitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rlyb_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753442561184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Equity-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 9,499<span></span>
</td>
<td class="nump">$ 3,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 5,957<span></span>
</td>
<td class="nump">$ 2,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753445373712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Summary of stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number, beginning balance</a></td>
<td class="nump">1,357,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted - shares</a></td>
<td class="nump">1,458,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised - shares</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited - shares</a></td>
<td class="nump">183,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired - shares</a></td>
<td class="nump">22,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number, ending balance</a></td>
<td class="nump">2,609,314<span></span>
</td>
<td class="nump">1,357,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, end of period (in shares)</a></td>
<td class="nump">685,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning of period - weighted average exercise price per share</a></td>
<td class="nump">$ 12.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted - weighted average exercise price per share</a></td>
<td class="nump">13.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised - weighted average exercise price per share</a></td>
<td class="nump">10.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited - weighted average exercise price per share</a></td>
<td class="nump">14.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired - weighted average exercise price per share</a></td>
<td class="nump">13.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, end of period - weighted average exercise price per share</a></td>
<td class="nump">13.01<span></span>
</td>
<td class="nump">$ 12.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, end of period - weighted average exercise price per share</a></td>
<td class="nump">$ 13.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, end of period - weighted average remaining contractual term (years)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, end of period - weighted average remaining contractual term (years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, beginning of period - aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, end of period - aggregate intrinsic value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, end of period - aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753445088752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Summary of Assumptions of Fair Value of Option Pricing Granted (Details) - Employee Stock Options - Two Thousand and Twenty One Equity Incentive Plan [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">89.31%<span></span>
</td>
<td class="nump">86.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">91.62%<span></span>
</td>
<td class="nump">87.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">2.94%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 15.04<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 7.54<span></span>
</td>
<td class="nump">$ 10.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753447574144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Summary of Nonvested Restricted Common Stock Awards (Details) - Restricted Stock Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, beginning balance | $ / shares</a></td>
<td class="nump">$ 3.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, shares granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, shares vested | $ / shares</a></td>
<td class="nump">3.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, shares forfeited | $ / shares</a></td>
<td class="nump">2.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending balance | $ / shares</a></td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance | shares</a></td>
<td class="nump">2,272,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested | shares</a></td>
<td class="num">(1,127,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited | shares</a></td>
<td class="num">(139,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance | shares</a></td>
<td class="nump">1,006,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rlyb_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rlyb_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446518080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Summary of Nonvested Restricted Common Stock Units (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance | shares</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted | shares</a></td>
<td class="nump">151,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited | shares</a></td>
<td class="num">(22,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested | shares</a></td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance | shares</a></td>
<td class="nump">128,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, beginning balance | $ / shares</a></td>
<td class="nump">$ 10.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, shares granted | $ / shares</a></td>
<td class="nump">11.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, shares forfeited | $ / shares</a></td>
<td class="nump">14.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, shares vested | $ / shares</a></td>
<td class="nump">10.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending balance | $ / shares</a></td>
<td class="nump">$ 11.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rlyb_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rlyb_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753452584944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rates (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal income tax benefit</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(2.80%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(28.60%)<span></span>
</td>
<td class="num">(33.50%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753445246640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carry forwards</a></td>
<td class="nump">98,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carry forwards</a></td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_StateOperatingLossCarryforwardsExpirationPeriod', window );">Net state operating loss carryforwards expiration year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_IncreasingOwnershipPercent', window );">Increasing ownership percent</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Income tax penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority', window );">Federal or state and local income tax returns</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax examination, Penalties and Interest Accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_IncreasingOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increasing ownership percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_IncreasingOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_StateOperatingLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State operating loss carryforwards expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_StateOperatingLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753445249232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Income Tax Benefits and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 26,576<span></span>
</td>
<td class="nump">$ 22,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization', window );">Amortization</a></td>
<td class="nump">2,306<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_DeferredTaxAssetsSection174Capitalization', window );">Section 174 capitalization</a></td>
<td class="nump">9,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">10,242<span></span>
</td>
<td class="nump">6,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">50,215<span></span>
</td>
<td class="nump">31,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(50,215)<span></span>
</td>
<td class="num">(31,161)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_DeferredTaxAssetsSection174Capitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets section 174 capitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_DeferredTaxAssetsSection174Capitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446787792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment In Joint Venture - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in joint venture</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocable share of losses recorded</a></td>
<td class="num">(1,075)<span></span>
</td>
<td class="num">(1,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in joint venture</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rlyb_ReVenturesILlcMember', window );">RE Ventures I, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_PercentageOfInterestOfJointVentureEntity', window );">Percentage of interest of joint venture entity</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in joint venture</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocable share of losses recorded</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in joint venture</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_PercentageOfInterestOfJointVentureEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest of the joint venture entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_PercentageOfInterestOfJointVentureEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rlyb_ReVenturesILlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rlyb_ReVenturesILlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446668288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rlyb_TerminationCharges', window );">Termination charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlyb_TerminationCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlyb_TerminationCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlyb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753446513200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Summary of Basic and diluted loss per common share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,654)<span></span>
</td>
<td class="num">$ (47,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding,basic</a></td>
<td class="nump">31,821,311<span></span>
</td>
<td class="nump">25,519,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding diluted</a></td>
<td class="nump">31,821,311<span></span>
</td>
<td class="nump">25,519,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share,basic</a></td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share,diluted</a></td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139753445176928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">3,333,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rlyb_StockOptionsAndUnvestedRestrictedShareMember', window );">Stock Options And Unvested Restricted Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rlyb_StockOptionsAndUnvestedRestrictedShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rlyb_StockOptionsAndUnvestedRestrictedShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>rlyb-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rlyb="http://rallybio.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rlyb-20221231.xsd" xlink:type="simple"/>
    <context id="C_283e6bfc-26b6-4abc-bae8-943016a346b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8c1e2b90-2c05-4121-b927-020165db9017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2f72d314-6340-48e4-a0cb-90c92493675d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fa0c8ed8-7c96-41b2-acbc-bd397cca2e41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonStockAllocatedToIncentiveUnitsHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_72dc7c73-c37f-40b1-ac29-eb5aba9c919a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e29c70d6-5177-4a18-b728-136ccc6f1118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rlyb:ReVenturesILlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9608e295-9fc8-4f1c-8325-defd050a4e3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f0a66521-307e-45f2-b9e4-4aaa00c5d3cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_12986d42-bc40-4315-b656-9d19b413c96d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d937f0f8-a8e7-46a1-90c2-541038ce8510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_91e37f8e-3f15-4cf1-a0ed-4b07ba1acb40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rlyb:ReVenturesILlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_548746fb-814e-4818-9836-b487dff1ca83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_eed08da7-0a3b-4480-a783-cde12cc17f8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8a26e436-c6db-4d63-858b-564767b5ca18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rlyb:StockOptionsAndUnvestedRestrictedShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_18a5ceed-0060-4aa3-9c6c-c98a4ad6ca26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_effcd34e-4aab-4920-ac25-05c20a2a8e59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_46cd10da-534a-45a6-8e92-23bccca412b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_58bb02df-6ead-4192-bfb4-4babb5d12fd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3f129d90-d234-416a-9fec-871604aa4382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1df02247-1abd-4b9e-b9a2-5286622dd357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3b5ba2a5-21d0-491d-a212-155407944f28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e6740c4f-f839-42cf-8933-5c00be44fad6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c135ce81-16f6-4644-8431-2f49154ea889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_82d6c3cd-26a6-4fbe-bd6e-fb539f862b2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6b6ed73d-3d7a-4d4e-ad0c-6cf1487dd354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_77017543-72b8-463e-b4d8-4744e243dddf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <instant>2021-07-28</instant>
        </period>
    </context>
    <context id="C_65531b3d-72ed-4e61-b9c1-459069ccf882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ed90055c-50cc-4284-9412-3619d9ee515a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:OverAllotmentOnInitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_023380b6-8582-4311-9388-b97a86a5ebc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_35605b6e-be30-43c7-8f50-20c9ee13c798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_e04c4b7c-8231-4981-815c-01cc0725ee41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rlyb:ReVenturesILlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9ef707b6-6cf6-44ea-a226-c236562f6196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f9a8b852-841f-4a26-95af-c55e17becf4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_049edda4-c91f-4ae4-ac5b-361c6c909078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonStockAllocatedToCommonUnitHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_739866d4-323a-4be2-8ffe-a4e8744c785c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d08dcb07-924b-4a3a-9c4a-4828ff956a08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bb11c8d1-4dd0-4a80-b4f9-1d7bcbb74fd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rlyb:CapitalizedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_83726cf3-dbf7-458d-b892-83b3f6200320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a09cca07-b477-48a1-96b3-6e73343c9cfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_70c6b661-e569-4779-8379-10ef41316fc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6c8eb427-a9b9-4fd2-8278-278c9bafa4ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e1e1819d-7e08-4d58-9f61-b60962efde73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_428be2be-619b-438c-84e3-581e1bff5f22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5134fef2-9d7d-4ee4-a874-8036c0bffab9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c7a1f81b-226a-425e-9556-8238ac7cd556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cfa92b31-04bb-40fe-917d-31a1f4c22c5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rlyb:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_e1789f82-5498-493f-9c96-de21198bf03e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_25fa2078-2908-479e-9ea7-121c863893fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cb2bd404-8085-4064-9e41-d047d221dbff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rlyb:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_7f078dfa-939c-4606-85c9-ea74c47eccf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cbbe5259-ca6b-485d-bfa6-99647ffab256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_027b9ced-d4c4-4cc7-bebc-9fecdde23fc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rlyb:StockOptionsAndUnvestedRestrictedShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_86e82aa6-b04b-4ef2-95b4-8a74005d949f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e81591b1-65b4-4ea6-b99c-cc189388ddfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a4381cd1-83ec-453c-b2da-602cb3171ce9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9b380165-d0ba-48ca-8553-1fc3c5916d47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_86c28a70-242c-4117-a116-d03b63d2edf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a304c311-7529-4e1e-a84f-c3b32740f27f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_90ca1d69-a91f-474d-9d24-d97bc3609482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_de3e32cc-aea0-4d0f-927a-9048039d7772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4ef647fa-f912-4e8a-ab8e-43e6ba78d2c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7770416e-82d7-4b9d-9294-67c572a1763b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f34bb779-7894-494b-b952-272e8729ec8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_96ab8a98-bc35-4ad3-930b-5cede1b585c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rlyb:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1d27a7c8-536f-4ccb-8034-2a8478fce538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rlyb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_97b56dc7-df26-44a2-b55c-c37821ed5567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cbf9eec7-f7b0-4d37-8259-cb61089f9136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17a4f0c1-9607-4df6-8818-c739af03c27b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3b90c853-7aaa-440f-a295-28aae572ec3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlyb:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rlyb:LicenseRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlyb:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f58e8139-a6dd-456f-af79-4387faed9da6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e76e6912-e263-4b3a-800f-e5564ea50f5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rlyb:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_b92e8ce1-fdcf-4c2d-a2d7-c1581bdfc31f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_896be549-e10a-4adb-b5c3-195576990921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_ae3fd3df-ccaf-4d78-a4b5-c90ef740f58a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6767ad15-fcb8-4673-8113-97780ad364b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8e52f2ef-b76e-43c9-a29f-eee88975b5b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rlyb:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_291895eb-b1c2-4869-bbc2-c46ab5500661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="C_8de022cc-ebdd-40ce-9a3d-5efc20768011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_115c7363-4207-4550-8e08-adb9ff8a9635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_7c0b1833-e4eb-4b6b-a37a-11f4af7b61ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_46b5d7b6-c58d-45f0-9c8d-0874f28c30ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_34ce8dda-3f7a-4174-a6cc-40dc210ea8ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:PerformanceBasedIncentiveCommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ae8060f7-9d9e-4228-a650-4909d1ec8e45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rlyb:CapitalizedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d6d9b87b-c787-4fdd-889d-759840ee3096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlyb:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rlyb:LicenseRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlyb:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ae469bc2-9800-4dc5-bcf4-0fdac12554b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_13887808-dda9-4f62-b93c-5568ce0ac531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_05f50029-fc68-47b8-9fa9-e99bbdb4f94a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:SeriesBRedeemableConvertiblePreferredUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bd12daa8-050e-4026-94a2-6adc935a3816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_45070b2f-cf01-42c1-887f-e78f1a625a2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e57589c1-5d53-466f-b251-aaba3c58effd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7ec8e39c-7a88-422a-a74f-d98b410d67ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_239aad29-ce03-4108-838f-d640e267ee47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rlyb:CapitalizedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6e128323-fbea-4fe5-84d7-e5c466f1a588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ec08abe0-0fe7-4c99-8d7a-a6994ffdb9c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_52dabac6-294d-46ca-a017-e4ded6aceebe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f4c85d43-b21c-4db7-af84-cec208374d89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rlyb:ReVenturesILlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_38646d43-f81a-4024-b133-4680c40d4fef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2d89fc97-b610-46e8-adf8-5e121995a4ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d4c6a782-6462-4fbb-ab36-0733d6a1beb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_3145b273-e2d9-4683-a591-82fa75386376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:IncentiveUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1a27f538-6112-4043-acae-7f43c3d21b17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlyb:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlyb:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_59253fec-c553-4ded-aad6-b2d0ecef61ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a9e6864c-0599-4c62-be7b-906252ee6393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0419c87f-3e9a-4f46-8744-7ba8ebb85189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlyb:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlyb:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_420228b8-f02f-4ea0-8120-8161b9596926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_14f240d5-c0ae-4980-979c-1550d7d172d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlyb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6215fc9c-66e2-43ef-b652-b9895d59b307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:SeriesA1AndA2RedeemableConvertiblePreferredUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_28193283-a9f2-41e6-9349-c6552278982f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="C_96275cfa-74c5-412d-adca-3d72d0a97037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:OverAllotmentOnFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_a256dcbc-4261-4079-a35a-af552e6fd37e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlyb:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlyb:PriorToIpoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_47aa72fa-e49a-471b-b726-9f400a561be4">0001739410</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_84dd8f7d-ddeb-46c7-9071-71361a486b29">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      id="F_a8b218a9-357a-4bed-96d6-b4ed1c8b213d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_75ef69ec-1699-43a1-8661-5fb4744a1488">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      id="F_c061875b-de88-45aa-8ea1-324496d0e556"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_898355c9-91b8-4668-b906-0ac3fdb3ad20">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_6be49bc8-7261-44a8-9cb4-3c22017b8dfb">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_08ffe394-9bb7-4114-b678-1681fc3209ab">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_a67428a7-0123-4178-93ee-63f2659705b8">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_0b159ddc-d0f6-47c5-a31b-097380a68563">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e84f35fc-2f62-4c95-a031-48582c18d2b7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_af67fafe-1d9c-4042-80e2-bb57029e2ef8">001-40693</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_5baa59e0-c2ab-4f5a-a94c-223f475f4e8a">RALLYBIO CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_4ddbb509-20d9-40e0-9021-3553aed44029">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_4627e352-7fdd-42db-afda-60db180938fe">85-1083789</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_b67df06e-336e-46f8-ab31-db0969755bce">234 Church Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_49f07723-c55d-456c-a6f3-1d382a5524a7">Suite 1020</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_4baf4474-e3f8-42ec-b9bc-c6ecbcbf634f">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_c353d93a-855f-475d-8b97-ecae8497c7d5">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e863fed7-ecae-454a-a7cb-52ac3b9397e1">06510</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_69610e1c-804f-49fa-92bf-132149098034">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_01302eef-1d3e-4043-9d38-ad34a65b33a8">859-3820</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_cacf6c3a-3eb7-4a97-bd35-aa5e160683ab">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_38d1a776-7c67-4a80-b024-2bb5a8d718ee">RLYB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_f78b77fa-62da-40b4-b24c-1053d09d0f20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_52633e53-3fb0-41f2-9cc4-080c93a060a1">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_4d3a32b2-ce5d-40c3-9b99-437d6f0aa233">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_0c6d82cf-9f4a-4799-9c19-89e88ef2ea31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_3ae36845-1776-4afb-87cf-88561b1c2511">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_119c2f55-52fb-44e2-b928-3bd149d8fe1f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_1062ff33-aa92-4c7c-adc2-fc521a58e79c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_bd4b7756-d157-4128-9bef-f997c9819bac">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_8931c161-8ee5-4eaa-888a-f8fcc48a7443">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_bbb760ab-9f3d-40e8-a1a4-dea9af27cad7">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_436810b6-6229-4e6f-b585-bd9e480e1a23">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_90ca1d69-a91f-474d-9d24-d97bc3609482"
      decimals="-5"
      id="F_48b0a523-b5c0-404e-9684-633812d1cb57"
      unitRef="U_USD">120700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_28193283-a9f2-41e6-9349-c6552278982f"
      decimals="INF"
      id="F_1a1bdcf8-cd16-444a-a863-0eca6b5ed63c"
      unitRef="U_shares">38075024</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_babeb532-e01b-45b9-9be3-9c6ac75f3628">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement for its 2023 Annual Meeting of Stockholders scheduled to be held on May 17, 2023, which Definitive Proxy will be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year end of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; are incorporated by reference into Part II and Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_623447f0-9c2b-4d5c-a7b1-adaa9fc75e3c">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_dd25e305-b6e4-4b3f-a6a2-6c5884d8b9e6">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_76007439-a328-443b-8360-2493ceb8d0fb">Hartford, Connecticut</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_d1f6fafb-bb4c-40d5-b9d7-bac7be71a5d5"
      unitRef="U_USD">56958000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_4ccb2c4b-5617-4d2e-b093-26805e9524ea"
      unitRef="U_USD">175334000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_debc5f8c-8bf5-400e-bb88-707009082b8a"
      unitRef="U_USD">112036000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_b8533377-a725-44d9-b65d-27d3cafaa86d"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_50168457-1880-4b7f-90fe-80568625a937"
      unitRef="U_USD">10502000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_3185d271-13cb-4f59-9232-d4e91ae3508d"
      unitRef="U_USD">5535000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_0faeed35-df74-491c-b259-2800712fc34c"
      unitRef="U_USD">179496000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_d334b39d-7032-4009-bd1f-7a7adfd608bf"
      unitRef="U_USD">180869000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_b835f877-0598-4c6d-bf53-7970e935bec1"
      unitRef="U_USD">385000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_f0edc15a-5b00-4860-9966-432214500398"
      unitRef="U_USD">511000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_a0d894e0-bf5b-418e-9f54-8583790a20ea"
      unitRef="U_USD">524000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_41298e9a-7b05-4a84-8daa-6438c07f8e73"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_c16bda1a-d736-4d34-94b4-2569812da560"
      unitRef="U_USD">30000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_ff877fcc-ce2a-45c4-bc0d-4d7bf70927b4"
      unitRef="U_USD">805000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_fbd57c65-4240-4ff7-a324-894e5fbfd242"
      unitRef="U_USD">180435000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_10126d67-31ae-4067-81a1-e1028ef70fce"
      unitRef="U_USD">182185000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_3a0f3875-aecd-4aa1-95ce-cc8097913332"
      unitRef="U_USD">1114000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_4b0bcc2a-8ccc-409b-9a86-28358d734d0b"
      unitRef="U_USD">603000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_e63e5fed-ea1e-41c6-8ca2-7a503fe44427"
      unitRef="U_USD">9449000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_9317c292-808f-4479-929b-b25a4bb5e101"
      unitRef="U_USD">5948000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_3d969406-1a71-4752-a9c7-9c3605686c8b"
      unitRef="U_USD">181000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_f1128fbc-2adf-476b-a57f-2f149550ec88"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_26117cdd-9a3f-4043-afd3-82d8e5d7e5c9"
      unitRef="U_USD">10744000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_6625a7ec-db4a-4ca6-9434-e457b9f9105a"
      unitRef="U_USD">6551000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_63e7fcee-3fa7-4036-9dbe-705b294fe926"
      unitRef="U_USD">0</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_de743be1-53fb-4634-9f6f-88c86c4ae5ba"
      unitRef="U_USD">32000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_c334a01a-8595-4e32-b4a5-cf4126a761d9"
      unitRef="U_USD">374000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_4d0fbe14-ae6d-4510-97b7-c1ca028bde29"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_75b75d33-3033-4a6a-8deb-dbb3a0a10c01"
      unitRef="U_USD">11118000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_76153cda-5415-48a9-a10b-89325fbaaf7a"
      unitRef="U_USD">6583000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_232c6faa-b4f9-4999-ac99-6b581e043acc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_7b72da09-8620-4915-88ab-37996b56d904"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_2b4a86bc-e673-4f81-9ef6-35cdeae8b456"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_f99945b7-7e4f-40ef-a513-75210f7b57d1"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_169959d9-1b34-4c29-ad54-caf57cbef8ad"
      unitRef="U_shares">37837369</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_9e1c8508-f82e-4e66-918b-504bd38c0418"
      unitRef="U_shares">37837369</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_77d69187-bfc2-4931-87a0-cf286f95f04f"
      unitRef="U_shares">32129970</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_3a9e68d8-3cc1-4da6-9e57-8c78ac041166"
      unitRef="U_shares">32129970</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_21f5a16d-f72c-4468-967b-03d00606a9fe"
      unitRef="U_USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_5375908b-0cfe-478e-8746-b6a5e06333c1"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_d4edb4dd-4da5-41a2-97ef-2ce6e2fcb3dc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_e3001728-8b55-43cb-9166-e18401fcba25"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_91b18dd3-2cba-491a-b5d4-19271e0ae889"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_ffcfc074-95d5-4504-82bc-7425a94ea773"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_a5a1aca6-684a-40b8-a5a1-45a2996a561e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_789fd225-4e5f-41d0-943d-b2b5bda0e81a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_d6a6f1c8-cdbb-400c-b5c9-f9980c1f3588"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_1a2e68dd-8899-450a-94d0-810463e19655"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_ce8451b8-e363-491e-a63c-fde6ce8ff831"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_37a5c09e-ae9b-4f32-8d61-e46015e1b6bf"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_a8a0875e-c3ec-41cc-8505-a82a0b43b3ee"
      unitRef="U_USD">330208000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_330b9f74-6a33-474c-9a39-2c92e32eb66c"
      unitRef="U_USD">269626000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_ed3f5a2d-6ff6-403c-83be-9c168bca7dd7"
      unitRef="U_USD">-214000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_c31b3882-1b88-4930-b09f-2dd727aebc70"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_38f444a4-0e0e-481c-a9df-78e76c9bf839"
      unitRef="U_USD">-160681000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_ce4a49d4-7aa6-4e19-8f47-3c7af17d6c40"
      unitRef="U_USD">-94027000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_e410dd53-6f3d-428f-8dc3-78b02ddb85ab"
      unitRef="U_USD">169317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_6e29f6ac-c5de-49e5-8d90-3193a4d4eecf"
      unitRef="U_USD">175602000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_3c27778c-aa8a-41dd-a70a-bb89ffcddaff"
      unitRef="U_USD">180435000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_dc9a5c45-5f9b-4a12-829a-3447f5dcbdb0"
      unitRef="U_USD">182185000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_193cf31c-db93-498a-82e8-b5ace982fba6"
      unitRef="U_USD">40689000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_af125654-3a90-40b2-a92c-96b13290c97b"
      unitRef="U_USD">26909000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_b989eaab-8763-40da-b439-d18134bbee95"
      unitRef="U_USD">27195000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_f6a81bda-438c-45b3-bcac-2f3bcefc1761"
      unitRef="U_USD">18739000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_a9ebf353-8f9d-4e90-a0a1-e6fbe89e5b20"
      unitRef="U_USD">67884000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_c7ca376d-a0f5-4c78-a694-638a39547aed"
      unitRef="U_USD">45648000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_96aa7b4f-118a-4576-aa78-fe82234a46aa"
      unitRef="U_USD">-67884000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_c0d7d315-3da4-4382-8c2d-2fa6b52318aa"
      unitRef="U_USD">-45648000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_66635418-2ccc-46f5-99ab-8768544cef71"
      unitRef="U_USD">1963000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_6061a1e6-fe82-42da-90d5-e2e7c3c7b70e"
      unitRef="U_USD">54000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpense
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_721aa855-0509-4ef9-a8e0-c3ac92874c66"
      unitRef="U_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_2551e0c4-f93e-4af4-a8ce-42bff4d113ba"
      unitRef="U_USD">10000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_018d693d-743b-46c1-8257-33aeba9cdafc"
      unitRef="U_USD">342000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_6a0f0b12-bb2c-4651-b3c0-94bb76f97b2a"
      unitRef="U_USD">96000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_d00462c2-3b55-4e3a-8172-19b734e2da07"
      unitRef="U_USD">2305000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_4caf4f16-e53b-4d08-b848-789c9b76537a"
      unitRef="U_USD">140000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_56f230e6-e803-4c28-84bd-88734e58561a"
      unitRef="U_USD">-65579000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_ae5cacd9-fe9e-4bf5-90a4-3d1dc2c1259e"
      unitRef="U_USD">-45508000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_aacfb863-544d-4fbf-bc5c-c375135e907b"
      unitRef="U_USD">-1075000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_17c69429-25f4-4d3f-bcdf-37f9a7a4648b"
      unitRef="U_USD">-1505000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_a423bed1-deb2-4c8d-bcbd-69dde24a5c51"
      unitRef="U_USD">-66654000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_071c0bbb-0be5-430b-babb-01ea4c09aa57"
      unitRef="U_USD">-47013000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="2"
      id="F_7c6452e5-5e34-4874-b060-328f8352f685"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="2"
      id="F_32aa08c9-9507-47f0-9a24-44bd150a810b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="2"
      id="F_778d6191-a33b-4294-8205-06d999022c6f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="2"
      id="F_1f843658-0ca8-43f5-b2f9-ccc1560e96a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="0"
      id="F_55fd906f-29b2-4e85-bb04-1a4572c7bc95"
      unitRef="U_shares">31821311</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="0"
      id="F_d7bb24b0-936a-4f07-b705-26ca2fdef305"
      unitRef="U_shares">31821311</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="0"
      id="F_752f137b-a011-4fd3-91b4-9a54b3041d74"
      unitRef="U_shares">25519114</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="0"
      id="F_309f88e7-f2f3-4910-af9d-fd67bae5415a"
      unitRef="U_shares">25519114</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_58688980-6fed-4089-9f89-bbfc52abf1b5"
      unitRef="U_USD">-214000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_49085c58-b586-457b-aca9-ba27ac7ed19b"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_3b8bd350-fcd5-468c-840f-2d48cfb49a3c"
      unitRef="U_USD">-214000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_68174710-227b-45e2-bafc-63408141c065"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_ca333fe0-5c1f-4530-b786-ffe4b7dca5f0"
      unitRef="U_USD">-66868000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_f9dea46b-78f3-4578-88d7-6f36b3d88f3b"
      unitRef="U_USD">-47013000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_18a5ceed-0060-4aa3-9c6c-c98a4ad6ca26"
      decimals="INF"
      id="F_e6c54a0e-b53f-4958-b1da-35b3a78235e1"
      unitRef="U_shares">23410348</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_18a5ceed-0060-4aa3-9c6c-c98a4ad6ca26"
      decimals="-3"
      id="F_e1d3a9b2-8852-43e9-b3f6-4ee6faf71057"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_13887808-dda9-4f62-b93c-5568ce0ac531"
      decimals="-3"
      id="F_9e812cd8-f2c1-4ac0-8685-3d17ff80ede3"
      unitRef="U_USD">183015000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cbbe5259-ca6b-485d-bfa6-99647ffab256"
      decimals="-3"
      id="F_53b76de2-ad8e-483c-a4ad-d19c4aed1fa4"
      unitRef="U_USD">-47014000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7ec8e39c-7a88-422a-a74f-d98b410d67ed"
      decimals="-3"
      id="F_159809a8-8e69-4878-8080-9d2423fa6902"
      unitRef="U_USD">136003000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_6e128323-fbea-4fe5-84d7-e5c466f1a588"
      decimals="-3"
      id="F_284f9ab9-2064-4f71-aef5-902662cd696c"
      unitRef="U_USD">9721000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a9e6864c-0599-4c62-be7b-906252ee6393"
      decimals="INF"
      id="F_ada15448-b502-4062-b63e-15aca79ae5d2"
      unitRef="U_shares">7130000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a9e6864c-0599-4c62-be7b-906252ee6393"
      decimals="-3"
      id="F_349c3b90-cc53-48c3-ba99-863034253c3b"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ae469bc2-9800-4dc5-bcf4-0fdac12554b2"
      decimals="-3"
      id="F_45a2104c-12e5-4428-8b65-9464c891f0e4"
      unitRef="U_USD">82966000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6e128323-fbea-4fe5-84d7-e5c466f1a588"
      decimals="-3"
      id="F_3ef24a1c-649b-4880-8158-0a0eabcaaee8"
      unitRef="U_USD">82967000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_7770416e-82d7-4b9d-9294-67c572a1763b"
      decimals="INF"
      id="F_367e228c-90b3-4c89-b82f-e05ca46cf49c"
      unitRef="U_shares">1589622</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6b6ed73d-3d7a-4d4e-ad0c-6cf1487dd354"
      decimals="-3"
      id="F_c8442630-cabb-4f89-b13c-f033cdb55ae7"
      unitRef="U_USD">3645000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_08af3b31-acd4-4cb1-ad50-c28aa63e37dd"
      unitRef="U_USD">3645000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_46cd10da-534a-45a6-8e92-23bccca412b7"
      decimals="-3"
      id="F_51958e02-d2f8-4160-a7ff-a38e41ec7b18"
      unitRef="U_USD">-47013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_3e095d91-43ee-4452-89b1-45221f6c34bb"
      unitRef="U_USD">-47013000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_83726cf3-dbf7-458d-b892-83b3f6200320"
      decimals="INF"
      id="F_9637d7b1-243f-4b68-aaf9-f1b5bdee5b09"
      unitRef="U_shares">32129970</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_83726cf3-dbf7-458d-b892-83b3f6200320"
      decimals="-3"
      id="F_c7a18699-bed7-4345-a123-c9e7de42b62f"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_46b5d7b6-c58d-45f0-9c8d-0874f28c30ef"
      decimals="-3"
      id="F_c2adcda2-f137-40b7-868f-a39c4e9d8950"
      unitRef="U_USD">269626000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_59253fec-c553-4ded-aad6-b2d0ecef61ec"
      decimals="-3"
      id="F_429dac8f-5b23-4782-b316-722e097cb708"
      unitRef="U_USD">-94027000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_597a428a-987c-44d2-b667-39191e82798f"
      unitRef="U_USD">175602000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_e81591b1-65b4-4ea6-b99c-cc189388ddfa"
      decimals="-3"
      id="F_ace88c0c-cf8e-4ba0-a277-39dc15bba420"
      unitRef="U_USD">3976000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues
      contextRef="C_f58e8139-a6dd-456f-af79-4387faed9da6"
      decimals="INF"
      id="F_992a46a5-3089-4488-95bf-9aa5656a2a71"
      unitRef="U_shares">5803655</rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues>
    <rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_f58e8139-a6dd-456f-af79-4387faed9da6"
      decimals="-3"
      id="F_07e2c769-881d-4ed6-9513-a3f685cab24c"
      unitRef="U_USD">1000</rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues>
    <rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_ae3fd3df-ccaf-4d78-a4b5-c90ef740f58a"
      decimals="-3"
      id="F_b55e08ee-025c-4c33-b564-2c148137a25d"
      unitRef="U_USD">50845000</rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues>
    <rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_e81591b1-65b4-4ea6-b99c-cc189388ddfa"
      decimals="-3"
      id="F_4e943cdb-c07d-477c-9fdf-cd2b7b942b32"
      unitRef="U_USD">50846000</rlyb:StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a09cca07-b477-48a1-96b3-6e73343c9cfc"
      decimals="INF"
      id="F_d6a4dd79-ddb7-4bf3-ad5c-919149a696f6"
      unitRef="U_shares">38845</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7c0b1833-e4eb-4b6b-a37a-11f4af7b61ab"
      decimals="-3"
      id="F_87fce7fa-d2ac-400d-8e87-3ab7728a8956"
      unitRef="U_USD">217000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_bf514d28-974a-4cd4-8742-3c448dee5fa5"
      unitRef="U_USD">217000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <rlyb:StockIssuedDuringPeriodSharesVested
      contextRef="C_a09cca07-b477-48a1-96b3-6e73343c9cfc"
      decimals="INF"
      id="F_ae659d3f-fb1e-4199-a8f4-f270f8f65eb9"
      unitRef="U_shares">2000</rlyb:StockIssuedDuringPeriodSharesVested>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a09cca07-b477-48a1-96b3-6e73343c9cfc"
      decimals="INF"
      id="F_9f7cd3cd-3067-4c43-a160-d92dc546d201"
      unitRef="U_shares">2014</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7c0b1833-e4eb-4b6b-a37a-11f4af7b61ab"
      decimals="-3"
      id="F_aafe9bdf-af7e-40da-b936-d80ceb7bad4d"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_b544bb1c-b033-468b-a112-27cc2fa0e27c"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_a09cca07-b477-48a1-96b3-6e73343c9cfc"
      decimals="INF"
      id="F_19ea3342-6810-4495-bf3b-2bf5a0b9462f"
      unitRef="U_shares">139115</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7c0b1833-e4eb-4b6b-a37a-11f4af7b61ab"
      decimals="-3"
      id="F_aed77a97-4a5d-4c15-a32e-1b01f840c820"
      unitRef="U_USD">9499000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_8306edf3-133e-4692-9012-04d0e7d466b2"
      unitRef="U_USD">9499000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_420228b8-f02f-4ea0-8120-8161b9596926"
      decimals="-3"
      id="F_f4b4e499-dfee-4ec1-8b43-5f9bd5c9b472"
      unitRef="U_USD">-66654000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_5729bced-f2c1-4bc2-a460-4f68efa97172"
      unitRef="U_USD">-66654000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f0a66521-307e-45f2-b9e4-4aaa00c5d3cd"
      decimals="-3"
      id="F_6f7e8b86-f349-4701-a2db-3ef742104265"
      unitRef="U_USD">-214000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_d27aa9f2-0d5f-4a86-aba3-ec31780a3475"
      unitRef="U_USD">-214000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_548746fb-814e-4818-9836-b487dff1ca83"
      decimals="INF"
      id="F_3f0e17e4-57ea-4b03-8ac8-09960cbd7130"
      unitRef="U_shares">37837369</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_548746fb-814e-4818-9836-b487dff1ca83"
      decimals="-3"
      id="F_4dde25bd-0016-45f3-82d7-281383f0dabc"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8de022cc-ebdd-40ce-9a3d-5efc20768011"
      decimals="-3"
      id="F_ab67f8fc-398b-492a-a966-bc8d9a6d8a37"
      unitRef="U_USD">330208000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_38646d43-f81a-4024-b133-4680c40d4fef"
      decimals="-3"
      id="F_bd41e661-dc8c-4df2-a211-406214f992de"
      unitRef="U_USD">-160681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f34bb779-7894-494b-b952-272e8729ec8a"
      decimals="-3"
      id="F_0a5fa738-a102-43b2-827c-04e0addf3756"
      unitRef="U_USD">-214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_5dc8a32d-e770-41fc-a324-b30d51f0260a"
      unitRef="U_USD">169317000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_becb830e-3670-4ec0-a064-7ee02175e0af"
      unitRef="U_USD">-66654000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_2c3dfc40-bff2-4508-9d04-5a0867f2246c"
      unitRef="U_USD">-47013000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_339d6ed5-3dfa-48f3-aab3-7ef339924e65"
      unitRef="U_USD">167000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_bd1879c5-e65a-4210-955c-d1a8adfa47ba"
      unitRef="U_USD">109000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_3e032a83-414d-467b-b221-6c69c0df7f5e"
      unitRef="U_USD">-435000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_5dc679e9-0bdd-4d94-8af9-b972f2309b63"
      unitRef="U_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_a5b8105d-0a92-4e6d-b882-ad5310b1f807"
      unitRef="U_USD">9499000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_26a092fa-67dd-4676-9da0-7c1648be10ae"
      unitRef="U_USD">3645000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_1fc86c7a-35eb-4ed5-8489-6c2cf32165e9"
      unitRef="U_USD">-1075000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_5ae21fe1-5dff-4346-b659-4a8d31dceb7b"
      unitRef="U_USD">-1505000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_98f5ae5a-895f-482d-9979-1c117e6bb901"
      unitRef="U_USD">4645000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_0fdcabb1-0a3d-4315-9966-a64314c6c466"
      unitRef="U_USD">4507000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_494a691b-ad15-42db-92f8-06bf6e69f3c1"
      unitRef="U_USD">487000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_56f0a6bb-c23b-4bdf-acf6-aaa23ae6228e"
      unitRef="U_USD">-976000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_328017a4-1043-44cd-8c05-0c57b595de69"
      unitRef="U_USD">3222000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_81259ea6-9009-4f5d-9f81-7504a22a9e58"
      unitRef="U_USD">1704000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_bfa83ca2-fc75-4aa2-87b1-f624b796de0e"
      unitRef="U_USD">-57284000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_9ff9772e-dcdd-4c73-9df0-d337a0fe1aff"
      unitRef="U_USD">-45533000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_3fe4e0a4-41a3-46d1-b570-e52ee4341005"
      unitRef="U_USD">201316000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_49931a66-8b97-47d1-a853-63183b5a5885"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_eed6f1ec-cc38-468d-a01c-f9bc4a89b0a7"
      unitRef="U_USD">89500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_151e7f55-94b6-4af4-a3a1-ceb5f6bbe056"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_9b3e1717-70bb-49b3-b967-68b05a72085a"
      unitRef="U_USD">54000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_a5af9333-7791-484f-b708-a97be71e8383"
      unitRef="U_USD">333000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_a2178a4e-2c7c-47f4-9b10-2597ce4f5593"
      unitRef="U_USD">300000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_dd9b68fe-6b6e-4f0b-b9f0-1684b38f7718"
      unitRef="U_USD">2000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_b5bf4e74-bee1-4936-b285-322034bae269"
      unitRef="U_USD">-112170000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_37c2b7a4-7598-4ded-866e-1289c4ad8472"
      unitRef="U_USD">-2333000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <rlyb:FollowOnOfferingDiscountsAndCommissions
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_fe7fd682-183a-498d-96fa-7a9cf4caa008"
      unitRef="U_USD">3289000</rlyb:FollowOnOfferingDiscountsAndCommissions>
    <rlyb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_67a2e726-870c-4267-b9e4-d4bea4a381cd"
      unitRef="U_USD">51533000</rlyb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering>
    <rlyb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_2473fc2d-eb50-4529-96c6-b057cebd6a57"
      unitRef="U_USD">0</rlyb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering>
    <rlyb:UnderwritingDiscountsAndCommissions
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_6587058c-8df5-4a02-8f67-3a95b5d51eb1"
      unitRef="U_USD">6488000</rlyb:UnderwritingDiscountsAndCommissions>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_38c4848a-67c2-4774-8683-795dc88c1d3f"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_2093b93e-06e7-4447-bcfe-5e8eb16c5a61"
      unitRef="U_USD">86200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_c4d4034e-63a8-4c83-9824-457eaab4fc6b"
      unitRef="U_USD">217000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_ab4787f0-b166-4531-a57c-b18136c2c4f4"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_5fc0b3e1-784c-479c-9adf-9fde3fb95cbb"
      unitRef="U_USD">21000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_87972ec6-c6c5-4bd1-9386-6cbb7cbb3cf9"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_86a310f2-ed93-4e3f-85b9-962e9b707a4d"
      unitRef="U_USD">693000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_9f6eb2cd-f592-4a0d-a516-f6bcbfa13be4"
      unitRef="U_USD">3233000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_c5903c59-9da3-4a41-9023-9f76cd6aec0a"
      unitRef="U_USD">51078000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_ec143e9a-351f-4c1d-8338-87ab10773353"
      unitRef="U_USD">82967000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_45a88792-315d-4e22-8239-a38fff8f0349"
      unitRef="U_USD">-118376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_b7072223-0cd5-4748-bd81-9f78f1b83768"
      unitRef="U_USD">35101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_f173d3a6-6c4c-45ad-b155-6581ed446a87"
      unitRef="U_USD">175334000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7ec8e39c-7a88-422a-a74f-d98b410d67ed"
      decimals="-3"
      id="F_5041cb17-d380-402f-9938-7d5c3a2aaa79"
      unitRef="U_USD">140233000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_3176d56a-b68e-4eb8-8043-a487260bc81b"
      unitRef="U_USD">56958000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_d5323f93-f4aa-4e35-b17d-d9c034eafd04"
      unitRef="U_USD">175334000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <rlyb:OfferingCostsInAccountsPayableAndAccruedExpenses
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_c0ffb44b-1814-4157-878d-aafc3f67d210"
      unitRef="U_USD">139000</rlyb:OfferingCostsInAccountsPayableAndAccruedExpenses>
    <rlyb:OfferingCostsInAccountsPayableAndAccruedExpenses
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_7f0365ce-b04c-4927-bbb2-33e73cd07350"
      unitRef="U_USD">0</rlyb:OfferingCostsInAccountsPayableAndAccruedExpenses>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_6dbba0e8-bad6-4648-b276-a692c79ddc35"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_3c7492f6-bef5-484c-9ce8-934ae1ac9878"
      unitRef="U_USD">13000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_4215e2da-a694-4c27-bc55-b715e388df29">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1. BUSINESS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Rallybio Corporation and subsidiaries (the "Company", "we", "our", or "us") is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since our launch in January 2018, we have built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of maternal fetal blood disorders, complement dysregulation, hematology, and metabolic disorders. We have assembled a team of experienced biopharma industry leaders with extensive research, development, and rare disease expertise to deliver on our mission of becoming a leader in the development of therapies for patients with rare diseases. We are drawing on our decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible &#x2013; and change the odds for rare disease patients.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In August 2021, the Company completed its initial public offering ("IPO"), pursuant to which it issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,130,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, inclusive of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;930,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share. The gross proceeds from the IPO, including the exercise of the underwriter's option to purchase additional shares were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;92.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and the net proceeds were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;83.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In November 2022, the Company completed a follow-on offering of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;54.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million consisting of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,803,655&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock, inclusive of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;803,654&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock sold pursuant to the partial exercise of the underwriters' option to purchase additional shares at the price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,333,388&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.9999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;which represents the per share public offering price for the shares less the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share exercise price for each pre-funded warrant&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;. The net proceeds from the November 2022 follow-on offering were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;Prior to the IPO and Reorganization, the Company was a 100% owned subsidiary of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Rallybio Holdings, LLC ("Rallybio Holdings")&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;, a Delaware limited liability company which&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; was incorporated in Delaware on March 22, 2018 and Rallybio Holdings held 100% of the outstanding membership units in five wholly-owned subsidiaries; Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, Rallybio IPD, LLC, and IPC Research, LLC. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;On June 30, 2021, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Rallybio Holdings&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; completed a series of transactions pursuant to which (i) Rallybio IPD, LLC, a direct subsidiary of Rallybio Holdings that was formed in Delaware in May 2020, was converted from a Delaware limited liability company to a Delaware corporation and changed its name to Rallybio Corporation, and (ii) four direct subsidiaries of Rallybio Corporation, each a Delaware limited liability company (collectively the "Merger Subs"), each consummated a separate merger with one of Rallybio Holdings direct subsidiaries, other than Rallybio IPD, LLC (collectively the "Asset Subsidiaries"), with the Asset Subsidiaries surviving the mergers and Rallybio Holdings receiving common stock of the Company in exchange for its interest in each Asset Subsidiary, which resulted in the Asset Subsidiaries becoming subsidiaries of the Company and the Company becoming the only direct subsidiary of Rallybio Holdings. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;On July 28, 2021, immediately prior&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; to the completion of the IPO, Rallybio Holdings liquidated and distributed 100% of the capital stock of the Company, consisting solely of common stock, to the unitholders of Rallybio Holdings. The liquidation of Rallybio Holdings and distribution of the capital stock of Rallybio Corporation to the unitholders of Rallybio Holdings is referred to as the &#x201c;Liquidation&#x201d; and these other transactions are collectively referred to as the &#x201c;Reorganization.&#x201d; As a result of the Reorganization and subsequent Liquidation, the unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation, and the Company's consolidated financial statements are subsequently reported from Rallybio Corporation. See&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; Note 2, "Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation" for the basis of presentation of these financial statements after the Reorganization and Liquidation discussed herein.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_896be549-e10a-4adb-b5c3-195576990921"
      decimals="INF"
      id="F_d582d7a5-d03a-4fb5-8682-0ba6802a5140"
      unitRef="U_shares">7130000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ed90055c-50cc-4284-9412-3619d9ee515a"
      decimals="INF"
      id="F_c282481d-c666-4bfd-93a6-8dffb5fa658e"
      unitRef="U_shares">930000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_291895eb-b1c2-4869-bbc2-c46ab5500661"
      decimals="2"
      id="F_530dcd12-bd18-4bb7-bbaf-d0364a18631f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_896be549-e10a-4adb-b5c3-195576990921"
      decimals="-5"
      id="F_59057fbb-89fb-48a7-8bd8-28ea92fbcd06"
      unitRef="U_USD">92700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_896be549-e10a-4adb-b5c3-195576990921"
      decimals="-5"
      id="F_d5a755e3-0cea-47df-b15e-d95d5dd8f8e4"
      unitRef="U_USD">83000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6"
      decimals="-5"
      id="F_3fb31b3b-05b2-4aef-bd12-6b6300b54df3"
      unitRef="U_USD">54800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6"
      decimals="0"
      id="F_cf42ca05-053a-4c73-b633-58576c191248"
      unitRef="U_shares">5803655</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_96275cfa-74c5-412d-adca-3d72d0a97037"
      decimals="0"
      id="F_4d3483d6-bf88-432d-9634-a3d061f6bd1d"
      unitRef="U_shares">803654</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_115c7363-4207-4550-8e08-adb9ff8a9635"
      decimals="2"
      id="F_2e3815a1-b189-4a81-a1cc-846ff751d411"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_115c7363-4207-4550-8e08-adb9ff8a9635"
      decimals="0"
      id="F_f69f03cc-ff7c-449b-a548-1d8151216fa5"
      unitRef="U_shares">3333388</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cb2bd404-8085-4064-9e41-d047d221dbff"
      decimals="4"
      id="F_684e794f-53bc-426b-9111-e32167a2652d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.9999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_cb2bd404-8085-4064-9e41-d047d221dbff"
      decimals="4"
      id="F_677125e8-ea48-43f1-bf44-6423851a7780"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6"
      decimals="-5"
      id="F_c9f0ecd8-2f0d-43d2-b84c-9c69be4f5aa7"
      unitRef="U_USD">50800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_7af4ea22-3a42-4680-b63d-54d62bfacf30">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;IPO and Reorganization &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014; As discussed in Note 1, "Business," in connection with the Reorganization, all of Rallybio&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; Holdings' direct subsidiaries, other than Rallybio Corporation, became direct subsidiaries of the Company prior to the Liquidation of Rallybio Holdings. Prior to the completion of the Company's IPO, Rallybio Holdings liquidated and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation. Subsequent to the Reorganization and the Liquidation of Rallybio Holdings &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;the consolidated financial statements are reported from Rallybio Corporation. &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The capital structure of Rallybio Holdings prior to the Liquidation consisted of four classes of membership units: common units; Series A-1 preferred units; Series A-2 preferred units; Series B preferred units; and incentive common units ("incentive units"). The number of shares of common stock that the holders of each class of units received in the Liquidation was based on the value of Rallybio Holdings prior to the Liquidation, determined by reference to the initial public offering price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;. The common stock of the Company was allocated to the holders of existing units in Rallybio Holdings as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;holders of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;33,478,255&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Series A-1 preferred units and Series A-2 preferred units of Rallybio Holdings received an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,257,590&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock of the Company; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;holders of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;104,442,965&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Series B preferred units of Rallybio Holdings received an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;16,402,235&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock of the Company;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;holders of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; common units and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,200,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; of performance based incentive common units of Rallybio Holdings received an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;706,701&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;188,454&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, respectively, in shares of common stock of the Company. Shares of common stock issued in respect of unvested common units and performance based incentive common units as of the Liquidation are shares of restricted common stock and subject to vesting in accordance with the vesting schedule applicable to such units; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;holders of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20,869,704&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; incentive units in Rallybio Holdings received an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,444,990&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock of the Company. Shares of common stock issued in respect of unvested incentive units as of the Liquidation are shares of restricted common stock and continue to be subject to vesting in accordance with the vesting schedule applicable to such incentive units. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As a result of the Liquidation, the holders of units in Rallybio Holdings collectively were issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;24,999,970&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock of the Company prior to the completion of the IPO.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Reorganization and subsequent Liquidation resulted in a change in reporting entity as described in ASC 250. In accordance with the guidance applicable to these circumstances, the equity structure has been adjusted in all comparative periods up to the Liquidation to reflect the number of shares of the Company&#x2019;s common stock, issued to Rallybio Holdings unitholders in connection with the Liquidation. As such, historical Rallybio Holdings convertible redeemable preferred units, common units, and incentive units have been retroactively adjusted in these financial statements to shares and earnings per share in accordance with the ratio of common shares received by each membership unit class. Rallybio Holdings' convertible redeemable preferred units previously classified as mezzanine equity, including the Series B Preferred Unit Agreement executed during the year 2020 with a total aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;145.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, have been retroactively adjusted in these financial statements, converted into common stock, and reclassified to permanent as a result of the retrospective application of the Liquidation and change in reporting entity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basis of Presentation&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;), and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Principles of Consolidation&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the fair value of its common un&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;its and incentive units awarded to employees prior to the Company's IPO, for purposes of recording stock-based incentive compensation, the fair value of stock options, as well as contracted research and development expenses incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Liquidity and Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued. Since its inception, the Company has incurred net losses and negative cash flows from operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021, the Company incurred a net loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;66.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;47.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively. In addition, as of December 31, 2022, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;160.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. The Company expects to continue to generate operating losses and negative cash flows in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company currently expects that cash, cash equivalents and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;169.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; million at December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the consolidated financial statements are issued. However, w&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;e do not anticipate that the current cash, cash equivalents and marketable securities as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; will be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates, if approved. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Collaboration Arrangements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company considers the nature and contractual terms of an arrangement to assess whether an arrangement involves a joint operating activity that expose two or more parties to significant risks and rewards dependent on the commercial success of the activity. If the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts for such arrangement as a collaborative arrangement under ASC 808, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 808"). ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition matters subjected to other authoritative guidance, in certain cases by analogy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;For arrangements determined to be within the scope of ASC 808 for certain research and development activities where a collaborative partner is not a customer following the guidance of ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 606"), the Company accounts for payments due to a collaboration partner as research and development expense and for payments owed to us from our collaboration partner for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. The Company classifies payments owed or receivables recorded as other current liabilities and other current assets, respectively, in the Company&#x2019;s consolidated balance sheets. See Note 3, &#x201c;License and Collaboration Agreements&#x201d; for additional details.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Asset Acquisitions&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this screen criteria is met, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire in-process research and development ("IPR&amp;amp;D") with no alternative future use is charged to research and development expense at the acquisition date. See&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; Note 3, &#x201c;License and Collaboration Agreements&#x201d; for additional details.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Variable Interest Entity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company evaluates its ownership, contractual, and other interests in entities to determine if it has any variable interest in a variable interest entity (&#x201c;VIE&#x201d;). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. If the Company determines that an entity in which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company&#x2019;s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The Company evaluated its investment in RE Ventures I, LLC, a limited liability company (&#x201c;REV-I&#x201d;), defined in Note 9, and concluded that it represented a VIE and was not deemed the primary beneficiary. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP. See&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; Note 9, &#x201c;Investment in Joint Venture&#x201d; for additional details.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Equity Method Investments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Investments &#x2013; Equity Method and Joint Ventures &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;323"). The Company recognizes its pro-rata share of income and losses in &#x201c;loss on investment in joint venture&#x201d; on the consolidated statements of operations&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;comprehensive loss, with a corresponding change to the investment in joint venture asset on the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company&#x2019;s principal financial instruments are comprised of cash, cash equivalents, available for sale marketable securities, accounts payable and accrued liabilities. The carrying value of all financial instruments approximates fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Concentrations of Credit Risk&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company invests its excess cash in money market funds and marketable securities in government insured financial institutions that are subject to minimal credit and market risk. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash and Cash Equivalents&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company classifies amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market funds, with original maturities of three months or less at the time of purchase as cash and cash equivale&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;nts. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#x2014; We invest our excess cash balances in highly rated United States ("U.S.") government-backed debt securities and treasuries.  We classify our marketable securities as available-for-sale and accordingly, record such securities at fair value. Debt securities with original maturities of greater than 90 days are classified as available-for-sale marketable securities and debt securities with original maturities of less than 90 days from the date of purchase are classified as cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unrealized gains and losses on our marketable debt securities that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. If any adjustment to fair value reflects a significant decline in the value of the security, we evaluate the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to our consolidated statements of operations and comprehensive loss. Credit losses are identified when we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;Property and equipment are recorded at cost and consists of computer and other equipment, capitalized software, furniture and fixtures and leasehold improvements. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, or for leasehold improvements, over the remaining term of the lease, if shorter. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The estimated useful life for each major asset classification are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.519%;"/&gt;
          &lt;td style="width:2.398%;"/&gt;
          &lt;td style="width:38.083%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Asset Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer and other equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Capitalized software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;lesser of lease life or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; such impairments were recorded during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; or 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;At the inception of an arrangement, we determine if an arrangement is, or contains, a lease based on the facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease we (i) identify lease and non-lease components, (ii) determine the consideration in the contract, (iii) determine whether the lease is an operating or financing lease; and iv)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;recognize lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of fixed, or in substance fixed, lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable we use our incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;We have elected to combine lease components with non-lease components on our office real estate asset class. Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed, or in substance fixed, are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our consolidated statements of operations and comprehensive loss. Some leases include options to extend or terminate the lease and the Company includes these options in the recognition of the Company&#x2019;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise such options.  We have elected the short-term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with an original term of 12 months or less.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company uses the asset and liability method of accounting for income taxes, as set forth in ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Income Taxes &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 740"). Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company evaluates whether deferred tax assets are more likely than not of being realized in determining whether a valuation allowance is necessary. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company determined that it is more likely than not that deferred taxes will not be realized and as a result recorded a valuation allowance against its deferred tax assets. Following the Reorganization, the Company files a consolidated U.S. federal income tax return and has elected to include all subsidiaries owned more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%. Prior to the Reorganization, the LLCs owned &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% by the Company have each elected to be treated as and taxed as a corporation and each filed a separate U.S. federal income tax return.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;Research and development expenses are comprised of costs incurred in performing research and development activities including personnel salaries, benefits, and equity-based compensation; external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; the cost of developing and manufacturing clinical study materials, program regulatory costs, expenses associated with obligations under asset acquisitions, license agreements and other direct and indirect costs. Costs incurred in connection with research and development activities are expensed as incurred. Costs are considered incurred based on an evaluation of the progress to completion of each contract using information and data provided by the respective vendors, including the Company&#x2019;s clinical sites. Depending upon the timing of invoicing by the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These prepaid expenses or accrued expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014; The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such equity financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders' equity as a reduction of additional paid-in-capital generated as a result of the offering. Should the planned equity financing no longer be considered probable of being consummated, the offering costs are expensed immediately as a charge to operating expense. Deferred offering costs are included in prepaid expenses and other assets on the consolidated balance sheets.  Deferred offering costs as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; deferred offering costs as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock Warrants &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company accounts for stock warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance included in ASC 480, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 480") and ASC 815,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; ("ASC &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;that &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;meet all of the criteria for equity classification are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and remeasured each balance sheet date thereafter.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Share-Based Compensation&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company accounts for share-based compensation in accordance with ASC 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 718"). Generally, share-based compensation is measured at the grant date for all equity-based awards made to employees based on the fair value of the awards and is recognized over the requisite service period, which is generally the vesting period. Share-based compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition is probable. The Company has elected to recognize the actual forfeitures by reducing the share-based compensation in the same period as the forfeitures occur. The Company classifies share-based compensation in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipients&#x2019; payroll costs are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company estimates the fair value of options granted using the Black-Scholes option pricing model ("Black-Scholes") for stock option grants. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company. The historical volatility is calculated based on a period of time corresponding with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted where the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date corresponding with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liabilities and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;Operating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;segments are defined as components of an enterprise for which discrete financial information is regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The Company manages its operations as a single segment for the purposes of&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;allocating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;resources, assessing performance, and making operating decisions. All tangible assets of the Company are held in the U.S.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Basic shares outstanding includes the weighted-average effect of the Company's pre-funded warrants to purchase shares of our common stock requiring little consideration upon exercise. Unvested restricted common shares as of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; are not considered participating securities and as such are excluded from the weighted-average number of shares used for calculating basic and diluted net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially dilutive securities include restricted common shares and stock options. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;In February 2016, FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(ASU 2016-02"), that requires lessees to recognize leases on-balance sheet and to make certain disclosures associated with their leasing arrangements. The new standard establishes a right-of-use ("ROU") model that requires a lessee to recognize an ROU asset and lease liability on the consolidated balance sheets for all leases with a term longer than twelve months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss. The Company adopted ASU 2016-02 Leases on January 1, 2022 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative periods consolidated financial statements and recognize a cumulative-effect adjustment to the consolidated balance sheets on the date of adoption. The Company elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and initial direct costs. At adoption we recognized approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of ROU assets and corresponding lease liabilities. See&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; Note 5, &#x201c;Leases&#x201d; for additional details.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;br/&gt;In June 2016, the FASB issued ASC 2016-13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;, Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; ("ASC 2016-13"),&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. We adopted the new standard on January 1, 2022 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments. Our significant financial assets that are within the scope of the new standard consist of available for sale debt securities. There was no impact to our consolidated statements of operations and comprehensive loss or consolidated balance sheets upon adoption. See Note 4 for discussion of unrealized losses on our available for sale marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company qualifies as an emerging growth company ("EGC") as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures during the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <rlyb:IpoAndReorganizationPolicyPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_f5f4fccd-8174-4c81-91af-79301aeac1ef">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;IPO and Reorganization &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014; As discussed in Note 1, "Business," in connection with the Reorganization, all of Rallybio&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; Holdings' direct subsidiaries, other than Rallybio Corporation, became direct subsidiaries of the Company prior to the Liquidation of Rallybio Holdings. Prior to the completion of the Company's IPO, Rallybio Holdings liquidated and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;unitholders of Rallybio Holdings became the holders of common stock of Rallybio Corporation. Subsequent to the Reorganization and the Liquidation of Rallybio Holdings &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;the consolidated financial statements are reported from Rallybio Corporation. &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The capital structure of Rallybio Holdings prior to the Liquidation consisted of four classes of membership units: common units; Series A-1 preferred units; Series A-2 preferred units; Series B preferred units; and incentive common units ("incentive units"). The number of shares of common stock that the holders of each class of units received in the Liquidation was based on the value of Rallybio Holdings prior to the Liquidation, determined by reference to the initial public offering price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;. The common stock of the Company was allocated to the holders of existing units in Rallybio Holdings as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;holders of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;33,478,255&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Series A-1 preferred units and Series A-2 preferred units of Rallybio Holdings received an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,257,590&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock of the Company; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;holders of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;104,442,965&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Series B preferred units of Rallybio Holdings received an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;16,402,235&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock of the Company;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;holders of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; common units and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,200,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; of performance based incentive common units of Rallybio Holdings received an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;706,701&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;188,454&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, respectively, in shares of common stock of the Company. Shares of common stock issued in respect of unvested common units and performance based incentive common units as of the Liquidation are shares of restricted common stock and subject to vesting in accordance with the vesting schedule applicable to such units; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;holders of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20,869,704&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; incentive units in Rallybio Holdings received an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,444,990&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock of the Company. Shares of common stock issued in respect of unvested incentive units as of the Liquidation are shares of restricted common stock and continue to be subject to vesting in accordance with the vesting schedule applicable to such incentive units. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As a result of the Liquidation, the holders of units in Rallybio Holdings collectively were issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;24,999,970&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock of the Company prior to the completion of the IPO.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Reorganization and subsequent Liquidation resulted in a change in reporting entity as described in ASC 250. In accordance with the guidance applicable to these circumstances, the equity structure has been adjusted in all comparative periods up to the Liquidation to reflect the number of shares of the Company&#x2019;s common stock, issued to Rallybio Holdings unitholders in connection with the Liquidation. As such, historical Rallybio Holdings convertible redeemable preferred units, common units, and incentive units have been retroactively adjusted in these financial statements to shares and earnings per share in accordance with the ratio of common shares received by each membership unit class. Rallybio Holdings' convertible redeemable preferred units previously classified as mezzanine equity, including the Series B Preferred Unit Agreement executed during the year 2020 with a total aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;145.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, have been retroactively adjusted in these financial statements, converted into common stock, and reclassified to permanent as a result of the retrospective application of the Liquidation and change in reporting entity.&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;</rlyb:IpoAndReorganizationPolicyPolicyTextBlock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_291895eb-b1c2-4869-bbc2-c46ab5500661"
      decimals="2"
      id="F_de5d3a98-fd94-4837-9bcf-fd3d22894af8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesOutstanding
      contextRef="C_6215fc9c-66e2-43ef-b652-b9895d59b307"
      decimals="INF"
      id="F_a644caea-f81c-4939-b4c9-4893d377a96b"
      unitRef="U_shares">33478255</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d08dcb07-924b-4a3a-9c4a-4828ff956a08"
      decimals="INF"
      id="F_6583ad2c-69d5-4cc9-be2f-5bd8bc727d41"
      unitRef="U_shares">5257590</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="C_05f50029-fc68-47b8-9fa9-e99bbdb4f94a"
      decimals="INF"
      id="F_ca7fd9b6-c9b1-4be5-8207-35e5b68751fe"
      unitRef="U_shares">104442965</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2f72d314-6340-48e4-a0cb-90c92493675d"
      decimals="INF"
      id="F_a4ca5c59-1787-47ec-8f99-9245d3aba253"
      unitRef="U_shares">16402235</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="C_a256dcbc-4261-4079-a35a-af552e6fd37e"
      decimals="INF"
      id="F_f29bf6ad-4ee9-42ad-a56d-96008e11235a"
      unitRef="U_shares">4500000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_34ce8dda-3f7a-4174-a6cc-40dc210ea8ca"
      decimals="INF"
      id="F_2156c277-21c0-4b47-a9c8-8d617d19fd93"
      unitRef="U_shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_049edda4-c91f-4ae4-ac5b-361c6c909078"
      decimals="INF"
      id="F_0bd7d0e9-6922-4026-811b-19754c9470ba"
      unitRef="U_shares">706701</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_5134fef2-9d7d-4ee4-a874-8036c0bffab9"
      decimals="INF"
      id="F_f07004fe-9540-4ec1-b138-1b796557958c"
      unitRef="U_shares">188454</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="C_3145b273-e2d9-4683-a591-82fa75386376"
      decimals="INF"
      id="F_b4663b2c-8ae2-42ce-942f-2aa5c32f0af2"
      unitRef="U_shares">20869704</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fa0c8ed8-7c96-41b2-acbc-bd397cca2e41"
      decimals="INF"
      id="F_fb88986f-d181-46ac-b75e-46b853519b3c"
      unitRef="U_shares">2444990</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <rlyb:LiquidationCommonStockSharesIssued
      contextRef="C_77017543-72b8-463e-b4d8-4744e243dddf"
      decimals="INF"
      id="F_b09de4c4-a801-4249-b7a0-0ae079a0917d"
      unitRef="U_shares">24999970</rlyb:LiquidationCommonStockSharesIssued>
    <rlyb:AggregatePurchasePriceOfCommonStock
      contextRef="C_72dc7c73-c37f-40b1-ac29-eb5aba9c919a"
      decimals="-5"
      id="F_f7a29c4e-cc38-4fea-98fa-50610ed8a51f"
      unitRef="U_USD">145200000</rlyb:AggregatePurchasePriceOfCommonStock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_6a8e6505-bd16-437c-b687-1a6e042b64ff">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basis of Presentation&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;), and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_87c8a05b-a2e9-4107-be1b-593ba24134f3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Principles of Consolidation&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_ea374159-1cb7-4ec0-81af-deb0f8c44bd0">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the fair value of its common un&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;its and incentive units awarded to employees prior to the Company's IPO, for purposes of recording stock-based incentive compensation, the fair value of stock options, as well as contracted research and development expenses incurred.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <rlyb:LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_8fd7e9ad-6eeb-418a-b500-32b267d00a27">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Liquidity and Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued. Since its inception, the Company has incurred net losses and negative cash flows from operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021, the Company incurred a net loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;66.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;47.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively. In addition, as of December 31, 2022, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;160.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. The Company expects to continue to generate operating losses and negative cash flows in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company currently expects that cash, cash equivalents and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;169.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; million at December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the consolidated financial statements are issued. However, w&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;e do not anticipate that the current cash, cash equivalents and marketable securities as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; will be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates, if approved. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources.&lt;/span&gt;&lt;/p&gt;</rlyb:LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-5"
      id="F_efd94498-e2bc-4753-a29e-9049ee6aac65"
      unitRef="U_USD">-66700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-5"
      id="F_0cba8663-0b5d-40cb-bb0c-387491307ace"
      unitRef="U_USD">-47000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-5"
      id="F_fb0b8660-5d2b-430a-af80-eb3f0ac1e957"
      unitRef="U_USD">-160700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-5"
      id="F_e577d2c7-5c53-451f-8434-5d8980faba14"
      unitRef="U_USD">169000000.0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e77238fc-48ae-453c-aa64-f7c0dfc9f84c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Collaboration Arrangements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company considers the nature and contractual terms of an arrangement to assess whether an arrangement involves a joint operating activity that expose two or more parties to significant risks and rewards dependent on the commercial success of the activity. If the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts for such arrangement as a collaborative arrangement under ASC 808, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 808"). ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition matters subjected to other authoritative guidance, in certain cases by analogy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;For arrangements determined to be within the scope of ASC 808 for certain research and development activities where a collaborative partner is not a customer following the guidance of ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 606"), the Company accounts for payments due to a collaboration partner as research and development expense and for payments owed to us from our collaboration partner for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. The Company classifies payments owed or receivables recorded as other current liabilities and other current assets, respectively, in the Company&#x2019;s consolidated balance sheets. See Note 3, &#x201c;License and Collaboration Agreements&#x201d; for additional details.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <rlyb:AssetAcquisitionPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_40126778-ab72-4e4f-8fc3-7f5633a041eb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Asset Acquisitions&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this screen criteria is met, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire in-process research and development ("IPR&amp;amp;D") with no alternative future use is charged to research and development expense at the acquisition date. See&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; Note 3, &#x201c;License and Collaboration Agreements&#x201d; for additional details.&lt;/span&gt;&lt;/p&gt;</rlyb:AssetAcquisitionPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_be167d73-99d9-41bd-8870-22d7e996625f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Variable Interest Entity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company evaluates its ownership, contractual, and other interests in entities to determine if it has any variable interest in a variable interest entity (&#x201c;VIE&#x201d;). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. If the Company determines that an entity in which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company&#x2019;s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The Company evaluated its investment in RE Ventures I, LLC, a limited liability company (&#x201c;REV-I&#x201d;), defined in Note 9, and concluded that it represented a VIE and was not deemed the primary beneficiary. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP. See&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; Note 9, &#x201c;Investment in Joint Venture&#x201d; for additional details.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_3b3be1f1-ffe1-48c6-9072-f46f9074dad8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Equity Method Investments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Investments &#x2013; Equity Method and Joint Ventures &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;323"). The Company recognizes its pro-rata share of income and losses in &#x201c;loss on investment in joint venture&#x201d; on the consolidated statements of operations&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;comprehensive loss, with a corresponding change to the investment in joint venture asset on the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_89f4be34-583d-44f5-84dc-399ed3cf7dc0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company&#x2019;s principal financial instruments are comprised of cash, cash equivalents, available for sale marketable securities, accounts payable and accrued liabilities. The carrying value of all financial instruments approximates fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_5d5ac865-a1fe-42d4-bbd2-3d996734fb7d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Concentrations of Credit Risk&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company invests its excess cash in money market funds and marketable securities in government insured financial institutions that are subject to minimal credit and market risk. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_c68b0449-952c-4836-90bc-1004f9f06604">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash and Cash Equivalents&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company classifies amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market funds, with original maturities of three months or less at the time of purchase as cash and cash equivale&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;nts. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_9b01a260-1fad-4639-856e-78e6f5909e33">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#x2014; We invest our excess cash balances in highly rated United States ("U.S.") government-backed debt securities and treasuries.  We classify our marketable securities as available-for-sale and accordingly, record such securities at fair value. Debt securities with original maturities of greater than 90 days are classified as available-for-sale marketable securities and debt securities with original maturities of less than 90 days from the date of purchase are classified as cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unrealized gains and losses on our marketable debt securities that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. If any adjustment to fair value reflects a significant decline in the value of the security, we evaluate the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to our consolidated statements of operations and comprehensive loss. Credit losses are identified when we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_ee87beff-9cd5-49ea-86b6-f03640ba91e1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;Property and equipment are recorded at cost and consists of computer and other equipment, capitalized software, furniture and fixtures and leasehold improvements. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, or for leasehold improvements, over the remaining term of the lease, if shorter. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The estimated useful life for each major asset classification are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.519%;"/&gt;
          &lt;td style="width:2.398%;"/&gt;
          &lt;td style="width:38.083%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Asset Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer and other equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Capitalized software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;lesser of lease life or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <rlyb:PropertyAndEquipmentUsefulLivesTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_4660d55e-aaf6-4555-b6eb-4cd69e5c6b19">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The estimated useful life for each major asset classification are as follows:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.519%;"/&gt;
          &lt;td style="width:2.398%;"/&gt;
          &lt;td style="width:38.083%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Asset Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer and other equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Capitalized software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;lesser of lease life or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</rlyb:PropertyAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_52dabac6-294d-46ca-a017-e4ded6aceebe"
      id="F_732f61a3-3788-487c-9a69-a227fb7c69be">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_239aad29-ce03-4108-838f-d640e267ee47"
      id="F_32a449e8-1038-454e-a83f-13f8fd7c8570">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_3f129d90-d234-416a-9fec-871604aa4382"
      id="F_c4b0b84e-763a-42e7-9c96-ebce65d8c5be">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_dac7788a-e29f-4ace-8e75-3c105f80ec49">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; such impairments were recorded during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; or 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_c0f566f6-65c3-4ed9-a9b5-2155b23d262e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_ce244a9a-2c0a-45c9-9ff5-4d47ec94df93"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_26db5623-1536-46f9-9771-b929ae25e07e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;At the inception of an arrangement, we determine if an arrangement is, or contains, a lease based on the facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease we (i) identify lease and non-lease components, (ii) determine the consideration in the contract, (iii) determine whether the lease is an operating or financing lease; and iv)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;recognize lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of fixed, or in substance fixed, lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable we use our incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;We have elected to combine lease components with non-lease components on our office real estate asset class. Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed, or in substance fixed, are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our consolidated statements of operations and comprehensive loss. Some leases include options to extend or terminate the lease and the Company includes these options in the recognition of the Company&#x2019;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise such options.  We have elected the short-term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with an original term of 12 months or less.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_d1668185-d925-4578-9d49-e4a4ad02e2e2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company uses the asset and liability method of accounting for income taxes, as set forth in ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Income Taxes &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 740"). Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company evaluates whether deferred tax assets are more likely than not of being realized in determining whether a valuation allowance is necessary. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company determined that it is more likely than not that deferred taxes will not be realized and as a result recorded a valuation allowance against its deferred tax assets. Following the Reorganization, the Company files a consolidated U.S. federal income tax return and has elected to include all subsidiaries owned more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%. Prior to the Reorganization, the LLCs owned &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% by the Company have each elected to be treated as and taxed as a corporation and each filed a separate U.S. federal income tax return.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <rlyb:ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization
      contextRef="C_65531b3d-72ed-4e61-b9c1-459069ccf882"
      decimals="2"
      id="F_1c3dd352-232c-4290-a3c9-db083ede9fd3"
      unitRef="U_pure">0.80</rlyb:ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization>
    <rlyb:ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="2"
      id="F_2bdd2466-c6ea-4a52-9563-9c229e3ef648"
      unitRef="U_pure">1</rlyb:ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_38586a8b-9d2a-471a-b662-52b66f303cca">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;Research and development expenses are comprised of costs incurred in performing research and development activities including personnel salaries, benefits, and equity-based compensation; external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; the cost of developing and manufacturing clinical study materials, program regulatory costs, expenses associated with obligations under asset acquisitions, license agreements and other direct and indirect costs. Costs incurred in connection with research and development activities are expensed as incurred. Costs are considered incurred based on an evaluation of the progress to completion of each contract using information and data provided by the respective vendors, including the Company&#x2019;s clinical sites. Depending upon the timing of invoicing by the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These prepaid expenses or accrued expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_f1871ac0-63e2-41e9-aeed-4a5b63eb8540">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014; The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such equity financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders' equity as a reduction of additional paid-in-capital generated as a result of the offering. Should the planned equity financing no longer be considered probable of being consummated, the offering costs are expensed immediately as a charge to operating expense. Deferred offering costs are included in prepaid expenses and other assets on the consolidated balance sheets.  Deferred offering costs as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; deferred offering costs as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-5"
      id="F_f2a58fb5-54dc-45c9-8264-7b6ec8988987"
      unitRef="U_USD">100000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_266b5919-b246-4389-8267-4f4c862af832"
      unitRef="U_USD">0</us-gaap:DeferredOfferingCosts>
    <rlyb:StockWarrantsPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_07cdcff9-d4c0-4cac-9334-e5e325a8f8c5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock Warrants &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company accounts for stock warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance included in ASC 480, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 480") and ASC 815,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; ("ASC &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;that &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;meet all of the criteria for equity classification are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and remeasured each balance sheet date thereafter.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</rlyb:StockWarrantsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e1136fbd-9d85-4bab-a545-7e116273f8aa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Share-Based Compensation&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company accounts for share-based compensation in accordance with ASC 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 718"). Generally, share-based compensation is measured at the grant date for all equity-based awards made to employees based on the fair value of the awards and is recognized over the requisite service period, which is generally the vesting period. Share-based compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition is probable. The Company has elected to recognize the actual forfeitures by reducing the share-based compensation in the same period as the forfeitures occur. The Company classifies share-based compensation in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipients&#x2019; payroll costs are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company estimates the fair value of options granted using the Black-Scholes option pricing model ("Black-Scholes") for stock option grants. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company. The historical volatility is calculated based on a period of time corresponding with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted where the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date corresponding with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_3c34d672-125c-42e0-b47b-77856497c34b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liabilities and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e8d5f92b-8b71-42ea-a561-68c20172c1bb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;Operating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;segments are defined as components of an enterprise for which discrete financial information is regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The Company manages its operations as a single segment for the purposes of&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;allocating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;resources, assessing performance, and making operating decisions. All tangible assets of the Company are held in the U.S.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_0d5b9015-5ff5-4602-b2df-9d1157d76492">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Basic shares outstanding includes the weighted-average effect of the Company's pre-funded warrants to purchase shares of our common stock requiring little consideration upon exercise. Unvested restricted common shares as of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; are not considered participating securities and as such are excluded from the weighted-average number of shares used for calculating basic and diluted net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially dilutive securities include restricted common shares and stock options. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e7106077-6178-406f-bff3-63ec35bef387">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;In February 2016, FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(ASU 2016-02"), that requires lessees to recognize leases on-balance sheet and to make certain disclosures associated with their leasing arrangements. The new standard establishes a right-of-use ("ROU") model that requires a lessee to recognize an ROU asset and lease liability on the consolidated balance sheets for all leases with a term longer than twelve months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss. The Company adopted ASU 2016-02 Leases on January 1, 2022 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative periods consolidated financial statements and recognize a cumulative-effect adjustment to the consolidated balance sheets on the date of adoption. The Company elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and initial direct costs. At adoption we recognized approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of ROU assets and corresponding lease liabilities. See&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;ARIAL&amp;quot;, sans-serif;min-width:fit-content;"&gt; Note 5, &#x201c;Leases&#x201d; for additional details.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;br/&gt;In June 2016, the FASB issued ASC 2016-13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;, Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; ("ASC 2016-13"),&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. We adopted the new standard on January 1, 2022 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments. Our significant financial assets that are within the scope of the new standard consist of available for sale debt securities. There was no impact to our consolidated statements of operations and comprehensive loss or consolidated balance sheets upon adoption. See Note 4 for discussion of unrealized losses on our available for sale marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_35605b6e-be30-43c7-8f50-20c9ee13c798"
      decimals="-5"
      id="F_854f809b-c49a-4fca-8776-24e4229dcc1b"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_35605b6e-be30-43c7-8f50-20c9ee13c798"
      decimals="-5"
      id="F_abd60e8e-e10e-4561-bcc8-10300ace49d1"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseLiability>
    <rlyb:RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_07cb7548-9a26-4801-8152-6ac51b9640b3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company qualifies as an emerging growth company ("EGC") as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures during the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</rlyb:RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock>
    <rlyb:LicenseAndCollaborationAgreementsDisclosureTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_fa16da91-9040-436d-b669-345fc7c30c44">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;LICENSE AND COLLABORATION AGREEMENTS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Asset Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In May 2022, we obtained worldwide exclusive rights to RLYB331, with Kymab Limited ("Sanofi") a preclinical antibody. We believe RLYB331 has the potential to address a significant unmet need for patients with severe anemias with ineffective erythropoiesis and iron overload, including beta thalassemia and a subset of lower risk myelodysplastic syndromes. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Under the terms of the license agreement, we made an upfront payment to Sanofi of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in the second quarter of 2022 for the exclusive license to KY1066. We could also be required to&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; pay up to an aggreg&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;43.0&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;in development and regulatory milestones and up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in commercial milestones for a product in its first indication, plus tiered low-to-mid double digit percentages of such milestone amounts &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;for up to three additional indications, and mid to high single digit royalties on net sales.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The license was accounted for as an asset acquisition as substantially all of the fair value of the asset acquired was concentrated in a single asset and thus the acquisition was deemed not to be a business combination. The acquired license rights represent an IPR&amp;amp;D asset that was determined to have no alternative future use. Accordingly, the Company recorded an IPR&amp;amp;D charge of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million to research and development expense, including transaction costs associated with this asset acquisition of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, in the accompanying consolidated statements of operations and comprehensive loss for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022.&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;AbCellera Collaboration&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In December 2022, the Company entered into a multi-year, multi-target collaboration with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Under the terms of the agreement, AbCellera and Rallybio will co-develop and share the development costs of up to five rare disease therapeutic targets, which will be chosen together by both companies. At the point one party in the collaboration opts-out of future co-development cost sharing, that party will be entitled to a share of future profit sharing from commercialization of the collaboration target, dependent on the proportion of their co-development contributions compared to the total development costs of a target as defined within the agreement. The agreement also has defined profit sharing floors that correspond to the stage of development at the time a collaboration party opts-out of co-developing a target.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company concluded that the agreement with AbCellera will be accounted under the scope of ASC 808 as both parties will actively participate in joint operating activities and are exposed to significant risks and rewards that depend on the commercial success of those activities. Under ASC 808, certain transactions between collaborative arrangement participants should follow the accounting for revenue under ASC 606 when the collaborative arrangement participant is a customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company determined that co-d&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;evelopment arrangement as defined in our agreement with AbCellera does not meet  the definition of a customer as defined by ASC 606. As a result, these activities will be accounted for as research and development costs. Payments due because of the co-development will be recorded as research and development expense in the period such expenses are incurred and for payments owed to us from our collaboration partner for the reimbursement of research and development costs will be recorded as a contra-research and development expense in the period such expenses are incurred. Costs related to the AbCellera collaboration were not material for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</rlyb:LicenseAndCollaborationAgreementsDisclosureTextBlock>
    <rlyb:UpfrontPayment
      contextRef="C_0419c87f-3e9a-4f46-8744-7ba8ebb85189"
      decimals="-5"
      id="F_6cd27037-951f-4376-b629-3931408003ab"
      unitRef="U_USD">3000000.0</rlyb:UpfrontPayment>
    <rlyb:AggregateDevelopmentAndRegulatoryMilestonePayments
      contextRef="C_1a27f538-6112-4043-acae-7f43c3d21b17"
      decimals="-5"
      id="F_878f7171-b237-4723-8fff-683da37b5c34"
      unitRef="U_USD">43000000.0</rlyb:AggregateDevelopmentAndRegulatoryMilestonePayments>
    <rlyb:ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones
      contextRef="C_1a27f538-6112-4043-acae-7f43c3d21b17"
      decimals="-5"
      id="F_b1065631-93dc-401b-a28f-d7373642e92f"
      unitRef="U_USD">150000000.0</rlyb:ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d6d9b87b-c787-4fdd-889d-759840ee3096"
      decimals="-5"
      id="F_6d073e44-84bf-4e7a-949a-4409f0b84b42"
      unitRef="U_USD">3100000</us-gaap:ResearchAndDevelopmentExpense>
    <rlyb:AssetAcquisitionTransactionCosts
      contextRef="C_3b90c853-7aaa-440f-a295-28aae572ec3c"
      decimals="-5"
      id="F_835a5813-b3d6-4d19-8c4b-6fa7ff0e90f1"
      unitRef="U_USD">100000</rlyb:AssetAcquisitionTransactionCosts>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_4ddbdd58-3b38-446f-aad9-69e4b5c355ca">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4. MARKETABLE SECURITIES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of our marketable securities by type of security as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.675%;"/&gt;
        &lt;td style="width:2.053%;"/&gt;
        &lt;td style="width:11.199%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.404%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.41%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.564%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.671%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;39,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;39,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;76,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;76,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The fair values of marketable securities by classification in the consolidated balance sheets was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.107%;"/&gt;
        &lt;td style="width:2.332%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.561%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;16,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;112,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The fair values of available-for-sale debt securities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022, by contractual maturity, are summarized as follows:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.107%;"/&gt;
        &lt;td style="width:2.332%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.561%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;127,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Due after one year through two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. We did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;t have any investments in a continuous unrealized loss position for more than twelve months as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, we believe that the cost basis of our available-for-sale debt securities is recoverable. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; allowance for credit losses was recorded as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;For the year ended December 31, 2021, the Company held money market funds that were classified as cash and cash equivalents on the Company's consolidated balance sheets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. These money market funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_581eb9df-4962-4dd4-913e-4ec201aaafa0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of our marketable securities by type of security as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.675%;"/&gt;
        &lt;td style="width:2.053%;"/&gt;
        &lt;td style="width:11.199%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.404%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.41%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.564%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.671%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;39,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;39,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;76,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;76,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89"
      decimals="-3"
      id="F_3765e758-663a-4a97-9b5d-bfabd362d215"
      unitRef="U_USD">12647000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89"
      decimals="-3"
      id="F_bd59f00f-d51e-49a0-a706-8802aae8d084"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89"
      decimals="-3"
      id="F_047ab01e-b6b2-470d-a43d-9ccc77c395d4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9d6a9947-fe9a-46c5-ad08-60ae76da8e89"
      decimals="-3"
      id="F_77bbc26b-ca16-4f14-b3e4-91f7e7d99505"
      unitRef="U_USD">12647000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453"
      decimals="-3"
      id="F_e6b072fc-7661-4c5f-b3c9-880f2255f1fa"
      unitRef="U_USD">39372000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453"
      decimals="-3"
      id="F_0c6fca46-1827-4db0-bdf0-afb84be8e751"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453"
      decimals="-3"
      id="F_142d2c3f-6b38-4f65-a46e-5690f57af095"
      unitRef="U_USD">169000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ebfb5afe-3d45-47fe-a457-2fcbe20a8453"
      decimals="-3"
      id="F_d403f73a-c50d-4e70-b8b3-7f86178ea91f"
      unitRef="U_USD">39203000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f9a8b852-841f-4a26-95af-c55e17becf4f"
      decimals="-3"
      id="F_198c4641-5a21-425a-be64-5db8eaf0e5f0"
      unitRef="U_USD">76860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f9a8b852-841f-4a26-95af-c55e17becf4f"
      decimals="-3"
      id="F_f8366da2-ebed-49ab-8371-53ddf72f83c2"
      unitRef="U_USD">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f9a8b852-841f-4a26-95af-c55e17becf4f"
      decimals="-3"
      id="F_63f6a48a-a914-4161-9650-47a351a8a430"
      unitRef="U_USD">82000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f9a8b852-841f-4a26-95af-c55e17becf4f"
      decimals="-3"
      id="F_70fef430-4b71-4804-9fe3-181f4d7df277"
      unitRef="U_USD">76815000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_bc8d9ba2-ab7d-4dd6-817c-457dddf69a22"
      unitRef="U_USD">128879000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_a81c6c75-772e-493b-bef1-36c23dfbf05c"
      unitRef="U_USD">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_57a1c39d-a26d-45eb-8b14-aeae44b40ddb"
      unitRef="U_USD">251000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_97acc497-9103-4f17-901d-7413b6440c5e"
      unitRef="U_USD">128665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <rlyb:AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_5d82f845-8b0d-4876-b0a3-6c91e60ad434">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The fair values of marketable securities by classification in the consolidated balance sheets was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.107%;"/&gt;
        &lt;td style="width:2.332%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.561%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;16,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;112,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rlyb:AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_739866d4-323a-4be2-8ffe-a4e8744c785c"
      decimals="-3"
      id="F_e416a5cb-89d7-4157-8c75-2693e0a62e98"
      unitRef="U_USD">16629000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1d27a7c8-536f-4ccb-8034-2a8478fce538"
      decimals="-3"
      id="F_7d2ab123-4fb5-42b4-a595-5f99d0b4120c"
      unitRef="U_USD">112036000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_94be3d26-b311-4ac7-97ac-9e81621b23f5"
      unitRef="U_USD">128665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_9cef2594-f8e7-4ca2-87ae-92967d9d97db">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The fair values of available-for-sale debt securities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022, by contractual maturity, are summarized as follows:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.107%;"/&gt;
        &lt;td style="width:2.332%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.561%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;127,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Due after one year through two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_b5c5eb0c-0ec7-487c-a85a-96c14d4db986"
      unitRef="U_USD">127667000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_293f688e-df37-4d1c-a546-19abf386e4ef"
      unitRef="U_USD">998000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_d5bd9cb6-6405-41bc-b76e-373358ffc4e9"
      unitRef="U_USD">128665000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-5"
      id="F_efcb23be-b220-4fca-a7e9-fa4640ee0cc1"
      unitRef="U_USD">70000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_7115181d-e0ef-4996-9a64-8ca790a38a21"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_069379e7-92ff-4912-a331-326fb17bebad"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ec08abe0-0fe7-4c99-8d7a-a6994ffdb9c1"
      decimals="-5"
      id="F_7a5a11f0-aa17-41b1-a1d8-fadb7888c22e"
      unitRef="U_USD">4000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e8e85bc5-34d3-418b-88a0-dbddb7a6dd1e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5. LEASES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;We have operating leases for approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;nine thousand&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; square feet of corporate office space. The weighted-average remaining lease term is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; years. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The weighted-average discount rate utilized on our operating lease liabilities as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating leases are included in operating lease ROU assets, operating lease liabilities, and operating lease liabilities, noncurrent in our consolidated balance sheets as of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes the presentation of the Company's operating lease as presented on the consolidated balance sheets:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.024%;"/&gt;
        &lt;td style="width:1.937%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.039%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Future minimum lease payments from &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 until the expiration of the operating lease are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.272%;"/&gt;
        &lt;td style="width:2.912%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.816000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: imputed discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Carrying value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in operating lease rent expense for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, respectively.  Lease payments made were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively, with such amounts reflected in the consolidated statements of cash flows in operating activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As the result of adopting ASU 2016-02 using the modified retrospective transition method, we did not restate periods prior to the adoption date of January 1, 2022. These periods continue to be presented in accordance with ASC 840. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2021, the future undiscounted minimum lease payments on our operating leases were as follows:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.272%;"/&gt;
        &lt;td style="width:2.912%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.816000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;YEAR ENDING DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LessorOperatingLeaseDescription
      contextRef="C_a4381cd1-83ec-453c-b2da-602cb3171ce9"
      id="F_907f0f31-e4e0-44e8-a421-280c772b6f6b">We have operating leases for approximately nine thousand square feet of corporate office space. The weighted-average remaining lease term is 2.6 years. The weighted-average discount rate utilized on our operating lease liabilities as of December 31, 2022 was 4.00%.</us-gaap:LessorOperatingLeaseDescription>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_de3e32cc-aea0-4d0f-927a-9048039d7772"
      decimals="0"
      id="F_0ad019b7-fb0b-449f-b205-b87df95e2135"
      unitRef="U_sqft">9000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      id="F_10147747-d1aa-4219-866c-8bdfc707cb12">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_de3e32cc-aea0-4d0f-927a-9048039d7772"
      decimals="4"
      id="F_ba0afd44-eb47-4383-996b-f080f9af1bee"
      unitRef="U_pure">0.0400</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_4cd40d3c-d744-49a3-8afc-5449d33dc79f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes the presentation of the Company's operating lease as presented on the consolidated balance sheets:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.024%;"/&gt;
        &lt;td style="width:1.937%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.039%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_7fde4a6f-4e03-4d7e-9534-9845a932abc0"
      unitRef="U_USD">524000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_f5270af1-b83a-4e4d-b3e9-a7e53267fe28"
      unitRef="U_USD">181000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_055f6b54-af6a-4bd1-9655-27e99ad6dc4b"
      unitRef="U_USD">374000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_f79b62bf-5c9d-4b41-8d75-6c61d9d4cbc6"
      unitRef="U_USD">555000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_07546d94-65ef-4f29-a8c7-e8dd3a1b3f4b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Future minimum lease payments from &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 until the expiration of the operating lease are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.272%;"/&gt;
        &lt;td style="width:2.912%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.816000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: imputed discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Carrying value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2021, the future undiscounted minimum lease payments on our operating leases were as follows:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.272%;"/&gt;
        &lt;td style="width:2.912%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.816000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;YEAR ENDING DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_49604e88-1a0f-4a26-a529-803d36c86613"
      unitRef="U_USD">200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_fff07461-ffe2-4220-aba8-59cb8199d7a6"
      unitRef="U_USD">230000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_15c73110-92ef-41bf-b0ae-e6c02808e14c"
      unitRef="U_USD">156000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <rlyb:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_e6984a8b-dd61-46d8-86b1-807272f23059"
      unitRef="U_USD">0</rlyb:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_1e226369-8649-4006-8dd3-af3ee3b1c65a"
      unitRef="U_USD">586000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_af766f97-368c-43af-a170-508187be0088"
      unitRef="U_USD">31000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_4a34dd2a-d78c-45f9-b691-6d9d90f8a53c"
      unitRef="U_USD">555000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_a4381cd1-83ec-453c-b2da-602cb3171ce9"
      decimals="-5"
      id="F_aabeb5e9-2652-4f8f-9a8b-d325c9611b95"
      unitRef="U_USD">200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_58bb02df-6ead-4192-bfb4-4babb5d12fd7"
      decimals="-5"
      id="F_b097c8e7-d9ab-47f1-a45f-a994ad159af6"
      unitRef="U_USD">100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_a4381cd1-83ec-453c-b2da-602cb3171ce9"
      decimals="-5"
      id="F_f902924b-5197-456d-95b6-13fab47debd0"
      unitRef="U_USD">200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_58bb02df-6ead-4192-bfb4-4babb5d12fd7"
      decimals="-5"
      id="F_8633e8c4-4c0b-4c43-ad30-0a1e526a4784"
      unitRef="U_USD">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_37eb3ed4-864f-4d8c-a0c6-9089610a592f"
      unitRef="U_USD">170000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_759cbf73-c31a-4237-9012-f89f823b8136"
      unitRef="U_USD">195000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_4d6c5e00-6eb7-44d0-80cd-5a73fe2f9586"
      unitRef="U_USD">230000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_1e050bd3-33e6-463e-97e5-d24f19140cc9"
      unitRef="U_USD">176000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <rlyb:OperatingLeasesFutureMinimumPaymentsDueAfterYearFour
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_5d0e09ed-ded9-4971-82ec-c11de9aff417"
      unitRef="U_USD">0</rlyb:OperatingLeasesFutureMinimumPaymentsDueAfterYearFour>
    <rlyb:OperatingLeasesFutureMinimumPayments
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_c0594f80-7567-4c27-a72a-9b39ef0372d4"
      unitRef="U_USD">771000</rlyb:OperatingLeasesFutureMinimumPayments>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e225ae59-4cc5-4c74-b252-ab5db952992c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6. BALANCE SHEET COMPONENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and Equipment&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment consisted of the following as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.523%;"/&gt;
        &lt;td style="width:1.602%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.122%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.612%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer and other equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Capitalized software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment&#x2014;net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Depreciation expense totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Prepaid Expenses and Other Assets&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Prepaid expenses and other assets consisted of the following as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.641%;"/&gt;
        &lt;td style="width:2.66%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.505%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.69%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.505%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other prepaids&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued Expenses&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued expenses consisted of the following as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.523%;"/&gt;
        &lt;td style="width:1.602%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.122%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.612%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Compensation and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_b054e016-8481-433d-915b-ad47644fba18">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment consisted of the following as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.523%;"/&gt;
        &lt;td style="width:1.602%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.122%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.612%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer and other equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Capitalized software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment&#x2014;net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8e52f2ef-b76e-43c9-a29f-eee88975b5b8"
      decimals="-3"
      id="F_81157749-7681-40c7-bce3-34a23ae79b96"
      unitRef="U_USD">180000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9ef707b6-6cf6-44ea-a226-c236562f6196"
      decimals="-3"
      id="F_ea27ba9d-6222-47dc-8758-f8c1805ee6e1"
      unitRef="U_USD">154000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ae8060f7-9d9e-4228-a650-4909d1ec8e45"
      decimals="-3"
      id="F_bed40e38-c872-4121-aca6-86922a9b6aaa"
      unitRef="U_USD">89000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bb11c8d1-4dd0-4a80-b4f9-1d7bcbb74fd2"
      decimals="-3"
      id="F_e91d3240-2c53-4040-a174-25d22ea680ec"
      unitRef="U_USD">89000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_82d6c3cd-26a6-4fbe-bd6e-fb539f862b2d"
      decimals="-3"
      id="F_2b5449ef-d961-4466-8ab3-515f5b1d31c4"
      unitRef="U_USD">151000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4ef647fa-f912-4e8a-ab8e-43e6ba78d2c3"
      decimals="-3"
      id="F_1f6dd207-6450-4d9c-8020-2e3e481a6fd2"
      unitRef="U_USD">151000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e1e1819d-7e08-4d58-9f61-b60962efde73"
      decimals="-3"
      id="F_802b0317-d912-4faa-b65e-afba72c59730"
      unitRef="U_USD">338000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7f078dfa-939c-4606-85c9-ea74c47eccf4"
      decimals="-3"
      id="F_43ad0f22-e209-4839-82a0-632f86a0d4ca"
      unitRef="U_USD">315000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2d89fc97-b610-46e8-adf8-5e121995a4ef"
      decimals="-3"
      id="F_47259e6d-26e0-4034-a1a8-807eb6269e45"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_86e82aa6-b04b-4ef2-95b4-8a74005d949f"
      decimals="-3"
      id="F_b973e122-01a9-45e9-8442-225c0af6464d"
      unitRef="U_USD">8000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_e45eaea8-3963-4512-beb6-55dff73634a0"
      unitRef="U_USD">373000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_deae7597-f13e-4b71-b051-f20da2b85afd"
      unitRef="U_USD">206000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_5fe94ee3-4b27-4cc7-aa4b-c115f40b8116"
      unitRef="U_USD">385000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_5c200454-3e5c-4dd9-a2e2-5829f7ccd750"
      unitRef="U_USD">511000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-5"
      id="F_18af30c5-0f42-450f-839e-88a6c3904056"
      unitRef="U_USD">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-5"
      id="F_a1424356-782a-48aa-a8dc-20964b3a8bcf"
      unitRef="U_USD">100000</us-gaap:Depreciation>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_82ed632b-b809-4d44-a9ad-db9b57efeba5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Prepaid expenses and other assets consisted of the following as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.641%;"/&gt;
        &lt;td style="width:2.66%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.505%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.69%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.505%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other prepaids&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <rlyb:PrepaidResearchAndDevelopmentExpenses
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_d09e87a6-b5f4-4cee-a186-ffe742218829"
      unitRef="U_USD">7904000</rlyb:PrepaidResearchAndDevelopmentExpenses>
    <rlyb:PrepaidResearchAndDevelopmentExpenses
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_6cf0e4d8-02ec-427f-b71e-4e7562b7de0e"
      unitRef="U_USD">3303000</rlyb:PrepaidResearchAndDevelopmentExpenses>
    <us-gaap:PrepaidInsurance
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_d4085c3e-f2c8-402c-86cf-01d6b1aeec95"
      unitRef="U_USD">933000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_4a20b2de-b5ad-4697-9512-b438830e3262"
      unitRef="U_USD">1467000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_0e884a80-2980-49f4-bf20-e45e888f002a"
      unitRef="U_USD">615000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_e200655a-e7b0-4655-95eb-859eb1563607"
      unitRef="U_USD">370000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_f2512657-6823-45a4-8b9e-8fb96da9e9b5"
      unitRef="U_USD">1050000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_6ce39510-f922-47cd-a1e4-483bac63a810"
      unitRef="U_USD">395000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_274134fd-b5aa-4138-b92a-855c4fcdfcdf"
      unitRef="U_USD">10502000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_7815f89f-6532-4f06-80dc-d44f450a351f"
      unitRef="U_USD">5535000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_53f931d9-2e28-458f-9cce-65e3f4042db4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued expenses consisted of the following as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.523%;"/&gt;
        &lt;td style="width:1.602%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.122%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.612%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Compensation and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <rlyb:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_1225503e-1049-4001-ae67-7a043bbb4420"
      unitRef="U_USD">3582000</rlyb:AccruedResearchAndDevelopmentExpensesCurrent>
    <rlyb:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_5b4b1446-4257-4464-b74b-0820fda19ec0"
      unitRef="U_USD">1937000</rlyb:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_51177cc3-0b60-41aa-82aa-eb939eeafd9b"
      unitRef="U_USD">4703000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_b2fd7490-3aa3-4e79-9337-ca09f7d1fa8f"
      unitRef="U_USD">2955000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_b2b32f80-1afa-4c66-a85a-048f521a1c50"
      unitRef="U_USD">510000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_47a02380-3e18-478c-baaf-5f652d18be0c"
      unitRef="U_USD">539000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_44406a6f-9212-4a5b-b319-dc43e34490a8"
      unitRef="U_USD">654000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_9aad53a7-222f-4992-a2f0-bac18c0c257f"
      unitRef="U_USD">517000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_dd7668f4-5834-4b80-8641-764a9b98f659"
      unitRef="U_USD">9449000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_38db96fa-2992-4698-b5dc-a84b8331d8c2"
      unitRef="U_USD">5948000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e3af9a01-8980-41b9-ba43-db6358be4b08">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7. STOCKHOLDERS' EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Common Stock&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In August 2021, the Company completed its IPO, pursuant to which it issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,130,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, inclusive of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;930,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;share. The gross proceeds from the IPO, including the exercise&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;the underwriter's option to purchase additional shares were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;92.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and the net proceeds were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;83.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In November 2022, the Company completed a follow-on offering of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;54.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million consisting of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,803,655&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock, inclusive of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;803,654&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock sold pursuant to the partial exercise of the underwriters' option to purchase additional shares at the price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,333,388&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.9999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;which represents the per share public offering price for the shares less the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share exercise price for each pre-funded warrant&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;. The net proceeds from the November 2022 follow-on offering were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;See Note 2 for a summary of the Reorganization and Liquidation of Rallybio Holdings that was completed prior to the Company's IPO, which resulted in a change in reporting entity. In accordance with the applicable accounting guidance related to changes in reporting entities, the financial statements for all periods presented have been retrospectively adjusted giving effect to the Reorganization and Liquidation as applicable to all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company evaluated the liquidation of Rallybio Holdings units and subsequent issuance of common stock awards of the Company, discussed in Note 2, as a modification under ASC 718, Share Based Payments. Under ASC 718, a modification is a change in the terms or conditions of a stock-based compensation award. In assessing the modification, the Company considered the fair value, vesting conditions and classification as an equity or liability award before Liquidation and replacement, compared to the Company&#x2019;s common stock received as of the Liquidation to determine whether modification accounting must be applied. As the number of shares of common stock of the Company that the unitholders of Rallybio Holdings received in the Liquidation was based on the fair value of those units in Rallybio Holdings immediately prior to the Liquidation, unvested units were replaced with restricted common shares with the same vesting terms as the initial awards, and the classification of the awards as equity awards did not change from this action, no incremental stock-based compensation expense resulted from the modification.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock authorized as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, respectively, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;37,837,369&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32,129,970&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares were issued and outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Preferred Stock&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of preferred stock authorized as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively, of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares were outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Pre-Funded Warrants &lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In connection with the follow-on offering entered into in November 2022, the Company entered into an agreement with certain investors for pre-funded warrants in lieu of common stock to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,333,388&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.9999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, which represents the per share public offering price at the November 2022 follow-on offering for common stock less a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share exercise price for each pre-funded warrant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#x2019;s election upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; days&#x2019; notice to the Company subject to the terms of such pre-funded warrants, provided that such percentage may in no event exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has assessed the pre-funded warrant for appropriate equity or liability classification. During this assessment, the Company determined the pre-funded warrant is a freestanding instrument that does not meet the definition of a liability pursuant to ASC 480 and does not meet the definition of a derivative pursuant to ASC 815. The pre-funded warrant is indexed to the Company&#x2019;s common stock and meets all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the pre-funded warrant classified as equity and accounted for as a component of additional paid-in capital at the time of issuance. All of the pre-funded warrants related to our November 2022 follow-on offering remain outstanding and unexercised as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Share-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Share-based compensation which comprised of stock options, restricted stock awards, restricted stock units and the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; employee stock purchase plan is classified in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 and was as follows: &lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.921%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.053%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.64%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.386%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;FOR THE YEAR ENDED&lt;br/&gt;DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In 2021, the board of directors adopted the Rallybio Corporation 2021 Equity Incentive Plan (the "2021 Plan"). The 2021 Plan reserves&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,440,344&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; for shares of the Company's common stock that have been issued in respect of outstanding equity awards granted prior to the registrant&#x2019;s IPO and for future issuances of shares to employees, directors and consultants in the form of stock options, SARs, restricted and unrestricted stock and stock units, performance awards and other awards that are convertible into or otherwise based on the Company's common stock. Dividend equivalents may also be provided in connection with awards under the 2021 Plan. The share pool will automatically incr&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ease on January 1st of each year from 2022 to 2031 by the lesser of (i) five percent of the number of shares of the Company's common stock outstanding as of such date and (ii) the number of shares of the Company's common stock determined by the board of directors on or prior to such date. On January 1, 2022, the 2021 Plan share pool was automatically increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,606,549&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares.  As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the total number of shares of the Company's common stock that were issuable under the 2021 Plan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,796,071&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,058,157&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares remained available for future issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes stock option activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022:&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.387%;"/&gt;
        &lt;td style="width:0.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.453999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.81%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.387%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.209999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.41%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Number of Option Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-Average Contractual Term &lt;br/&gt;&#160;&#160;&#160;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;&#160;&#160;&#160;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,357,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,458,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;183,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,609,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;685,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company's common stock. Options outstanding and exercisable with an exercise price above the closing price as of December 31, 2022 are considered to have no intrinsic value. Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the year ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share, respectively. Options vested during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; with an exercise price above the closing price are considered to have &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; intrinsic value. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, there was unrecognized share-based compensation expense related to unvested stock options of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;17.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, which the Company expects to recognize over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The fair value of the stock options granted during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.905%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.349%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;FOR THE YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;89.31&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;91.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;86.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;87.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.50 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.50 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.42&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.94&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.54&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;15.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the status of the Company's nonvested restricted common stock awards at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and changes during the year ended December 31, 2022 was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.034%;"/&gt;
        &lt;td style="width:1.209%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.626%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.113000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Nonvested restricted stock awards at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,272,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,127,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;139,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding nonvested restricted stock awards at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,006,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, there was unrecognized share-based compensation expense related to unvested restricted stock awards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, which the Company expects to recognize over a weighted-average period of approximately&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the status of the Company's nonvested restricted common stock units at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and changes during the year ended December 31, 2022 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.034%;"/&gt;
        &lt;td style="width:1.209%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.626%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.113000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Nonvested restricted stock units at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;151,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding nonvested restricted stock units at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, there was unrecognized share-based compensation expense related to unvested restricted stock units of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, which the Company expects to recognize over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In connection with the Company's IPO, the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; board of directors adopted the Rallybio Corporation 2021 Employee Stock Purchase Plan (the "2021 ESPP"), which reserves &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;291,324&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company's common stock for future issuances under this plan. The share pool will automatically incr&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ease on January 1st of each year from 2022 to 2031 by the lesser of (i) one percent of the number of shares of the Company's common stock outstanding as of such date (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;582,648&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company's common stock, and (iii) the number of shares of the Company's common stock determined by the board of directors on or prior to such date.  On January 1, 2022, the 2021 ESPP share pool was automatically increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;321,309&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the total number of shares of the Company's common stock that were available for future issuance under the 2021 ESPP was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;573,788&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;38,845&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company's common stock under the 2021 ESPP. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares were issued under the ESPP as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;For the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the total share-based compensation for the 2021 ESPP was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_896be549-e10a-4adb-b5c3-195576990921"
      decimals="INF"
      id="F_66df7464-2376-4f32-9f37-f726a9fac594"
      unitRef="U_shares">7130000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ed90055c-50cc-4284-9412-3619d9ee515a"
      decimals="INF"
      id="F_5150f54c-2f2d-4750-9f98-e6a71d7c7274"
      unitRef="U_shares">930000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_291895eb-b1c2-4869-bbc2-c46ab5500661"
      decimals="2"
      id="F_6adf870f-9ffc-4dab-a55d-8bc47a5a71a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_896be549-e10a-4adb-b5c3-195576990921"
      decimals="-5"
      id="F_32b05afc-8c7e-4c26-9062-f119898c2bb5"
      unitRef="U_USD">92700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_896be549-e10a-4adb-b5c3-195576990921"
      decimals="-5"
      id="F_9487ce89-f8f2-4d62-9804-7f2e6b60bbce"
      unitRef="U_USD">83000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6"
      decimals="-5"
      id="F_660f02d1-f9ad-4245-91a4-c73ad4ae4433"
      unitRef="U_USD">54800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6"
      decimals="0"
      id="F_a8bf4fff-9b7b-4ecb-a6f4-425a03829fff"
      unitRef="U_shares">5803655</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_96275cfa-74c5-412d-adca-3d72d0a97037"
      decimals="0"
      id="F_94165224-201d-4702-b6dd-fa5fabbf4329"
      unitRef="U_shares">803654</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_115c7363-4207-4550-8e08-adb9ff8a9635"
      decimals="2"
      id="F_38938d41-03b5-4c71-8577-88548f3aa2c3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_115c7363-4207-4550-8e08-adb9ff8a9635"
      decimals="0"
      id="F_0707b6b7-c41e-4d56-b9fb-090d064ebbf7"
      unitRef="U_shares">3333388</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_e76e6912-e263-4b3a-800f-e5564ea50f5f"
      decimals="4"
      id="F_ec5c80c1-5eef-4361-b94e-06c081774c8e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.9999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e76e6912-e263-4b3a-800f-e5564ea50f5f"
      decimals="4"
      id="F_94dadf8e-8158-4aaf-8c88-ebeaac71043b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_023380b6-8582-4311-9388-b97a86a5ebc6"
      decimals="-5"
      id="F_30e2e1d7-d789-471c-8892-37cbc38dc34b"
      unitRef="U_USD">50800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_fa561747-b0a6-4d19-b9a7-44bfe9cb1a46"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_07cb7add-86bb-4e38-81fc-bcd7a7dcf4d2"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_db87573d-e0cb-4d8a-879e-0d7728106f94"
      unitRef="U_shares">37837369</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_e9d05c5a-30a5-457d-a754-18e495b623ac"
      unitRef="U_shares">37837369</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_306030d4-b6aa-4202-8301-aaa129721ab8"
      unitRef="U_shares">32129970</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_afcb0a1d-eb80-4cc0-af1a-bed1d7c734fb"
      unitRef="U_shares">32129970</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_0d8972df-dd39-4e6b-9e66-04381a6c26ff"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_cf6308b3-bef0-4d59-8e48-9916b9a9d20c"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="INF"
      id="F_ae06cb0d-9f07-42c3-82d1-b07aa851ff35"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="INF"
      id="F_8ad48997-2b86-4e95-8277-6ee5821ef95a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_cfa92b31-04bb-40fe-917d-31a1f4c22c5e"
      decimals="INF"
      id="F_ba776847-d457-47f9-83b4-ce8c49d9e38e"
      unitRef="U_shares">3333388</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_e76e6912-e263-4b3a-800f-e5564ea50f5f"
      decimals="4"
      id="F_0e508746-42bc-4500-9e42-d00258746b75"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.9999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_cfa92b31-04bb-40fe-917d-31a1f4c22c5e"
      decimals="4"
      id="F_1ab111c6-cbff-4d00-92c4-748067a6811c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rlyb:ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned
      contextRef="C_96ab8a98-bc35-4ad3-930b-5cede1b585c6"
      decimals="4"
      id="F_12a60e96-b27a-45c4-bec7-a06638d2ba5a"
      unitRef="U_pure">0.0999</rlyb:ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned>
    <rlyb:PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned
      contextRef="C_96ab8a98-bc35-4ad3-930b-5cede1b585c6"
      id="F_9d5d669e-ed65-494d-bd12-bdf58a564eff">P61D</rlyb:PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned>
    <rlyb:PercentageOfCommonStockBeneficiallyOwnedNotExceed
      contextRef="C_96ab8a98-bc35-4ad3-930b-5cede1b585c6"
      decimals="4"
      id="F_05e490d9-e927-4617-8a97-6339633896c9"
      unitRef="U_pure">0.1999</rlyb:PercentageOfCommonStockBeneficiallyOwnedNotExceed>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_43791948-f7d8-478b-b7bf-93d6b81cf0f2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Share-based compensation which comprised of stock options, restricted stock awards, restricted stock units and the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; employee stock purchase plan is classified in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 and was as follows: &lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.921%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.053%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.64%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.386%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;FOR THE YEAR ENDED&lt;br/&gt;DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_428be2be-619b-438c-84e3-581e1bff5f22"
      decimals="-3"
      id="F_938b27bf-9eec-453d-bc10-2531ccdf23b4"
      unitRef="U_USD">3542000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8c1e2b90-2c05-4121-b927-020165db9017"
      decimals="-3"
      id="F_3847e17d-1a01-457f-baa4-5cbce7ed2cc4"
      unitRef="U_USD">1168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6767ad15-fcb8-4673-8113-97780ad364b8"
      decimals="-3"
      id="F_87978824-5565-40df-8f77-77ace7089dcd"
      unitRef="U_USD">5957000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_effcd34e-4aab-4920-ac25-05c20a2a8e59"
      decimals="-3"
      id="F_2d9d84ba-f524-4bc6-8c52-d39eb9608b2e"
      unitRef="U_USD">2477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_f967ba8d-2a4f-4e5c-a69d-cd8aa7d1bf45"
      unitRef="U_USD">9499000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_ad64f970-c94b-481d-9fd0-35e7efb65bf0"
      unitRef="U_USD">3645000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_25fa2078-2908-479e-9ea7-121c863893fd"
      decimals="INF"
      id="F_013d1e78-6727-4d6d-a520-2039bb85b45e"
      unitRef="U_shares">5440344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_e1789f82-5498-493f-9c96-de21198bf03e"
      decimals="0"
      id="F_40eccbda-c39b-466a-a85c-cb1d46391b07"
      unitRef="U_shares">1606549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <rlyb:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable
      contextRef="C_25fa2078-2908-479e-9ea7-121c863893fd"
      decimals="0"
      id="F_673d5210-4c48-47ed-ba82-b3da51b82d2f"
      unitRef="U_shares">4796071</rlyb:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_25fa2078-2908-479e-9ea7-121c863893fd"
      decimals="INF"
      id="F_2c4c9b0f-16d5-48cd-b39c-9ff89bebc495"
      unitRef="U_shares">2058157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e57ae343-4365-4086-8d59-05c65900e678">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes stock option activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022:&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.387%;"/&gt;
        &lt;td style="width:0.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.453999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.81%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.387%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.209999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.41%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Number of Option Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-Average Contractual Term &lt;br/&gt;&#160;&#160;&#160;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;&#160;&#160;&#160;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,357,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,458,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;183,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,609,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;685,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="0"
      id="F_2dbc36a9-f4d5-4c3f-9c92-fca53944f5bd"
      unitRef="U_shares">1357784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="2"
      id="F_ae184c8c-1b7a-4b46-8099-9123d9075eb6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      id="F_4277f0d8-315a-4c31-96b5-4278c609c9df">P9Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_6c510202-f81f-4a76-a4c5-c202aa3e169c"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="0"
      id="F_40a4c661-9b47-460a-9787-aab4155df619"
      unitRef="U_shares">1458800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="2"
      id="F_9be2ebad-498f-4df6-88dc-6809f6906e3f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="0"
      id="F_ebe3386e-0c87-4ca9-a64c-db984282dcc5"
      unitRef="U_shares">183151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="2"
      id="F_b6f3f5c0-e2af-4176-b83e-d60b0e56ff6d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="0"
      id="F_7b6cb4cf-0d5c-430f-aca4-157ef1ddde4b"
      unitRef="U_shares">22105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="2"
      id="F_d8efa7a7-f618-44a3-bad0-6628e4bfdae7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="0"
      id="F_b90ac1d0-9d09-4600-b834-9580f1f268b0"
      unitRef="U_shares">2014</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="2"
      id="F_8624d46a-d8ea-4273-8c88-4b9759cbbcdf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="0"
      id="F_25027256-08f8-4b81-a4b3-1602fbf59918"
      unitRef="U_shares">2609314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="2"
      id="F_12b8a206-ecf9-430e-b36c-e10393fcda55"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_a1eafa99-acf8-4b13-8ce3-d771b94a27f7">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_02098f49-2772-4c50-ba31-94f32cc35930"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="0"
      id="F_686969ff-a95f-4cdf-a003-eef6f22ebdfc"
      unitRef="U_shares">685155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="2"
      id="F_37f652ce-5e31-4026-ac8b-e3cfb5cec225"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_134b3db2-8292-4084-87fb-4d82b972928f">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_f5f0ab6a-328f-439e-a62c-485e1e3dd7bf"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="2"
      id="F_6a9dff5f-884b-45d9-bf50-0ce1bd6c2951"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="2"
      id="F_d1f953ba-badc-497c-b981-33feba78c053"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_495d666e-fe83-4637-b216-4553f0c2210f"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_67872697-5aa0-41ab-8b2a-7f046952df36"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-5"
      id="F_a605466e-aafe-495d-a806-8595723173e9"
      unitRef="U_USD">17100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_35877aba-65b1-481e-a7e9-1cb610e4dca4">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_04b16b26-8119-4e6c-bcd8-91c1f74cf75d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The fair value of the stock options granted during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.905%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.349%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;FOR THE YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;89.31&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;91.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;86.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;87.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.50 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.50 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.42&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.94&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.54&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;15.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567"
      decimals="4"
      id="F_68cfc55a-9532-4103-bdff-0ff912f55956"
      unitRef="U_pure">0.8931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567"
      decimals="4"
      id="F_55108d79-155d-48bd-8254-3877db1b645b"
      unitRef="U_pure">0.9162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4"
      decimals="4"
      id="F_9f81c69b-5852-4fe0-be2b-c6b0e4e3252c"
      unitRef="U_pure">0.8690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4"
      decimals="4"
      id="F_d2caa7e7-ea35-4d89-addc-0c5958cc73f4"
      unitRef="U_pure">0.8790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_70c6b661-e569-4779-8379-10ef41316fc7"
      id="F_25f02735-ebc1-4c2a-b8f4-622ee5c6d603">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e6740c4f-f839-42cf-8933-5c00be44fad6"
      id="F_2bbafdff-cd90-4eb9-a43a-2f63c6f2b7c9">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3b5ba2a5-21d0-491d-a212-155407944f28"
      id="F_39de5cba-c7a6-4f7b-9342-e469c5c37973">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e57589c1-5d53-466f-b251-aaba3c58effd"
      id="F_2867265a-8bda-47ce-98ca-2acac4aef168">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567"
      decimals="4"
      id="F_2945490f-081a-468f-b2f8-4850a51eac4b"
      unitRef="U_pure">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567"
      decimals="4"
      id="F_a8decc89-39d4-4317-afce-5107bce7e117"
      unitRef="U_pure">0.0294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4"
      decimals="4"
      id="F_99a7512d-0b35-43aa-9203-173afb5c9207"
      unitRef="U_pure">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4"
      decimals="4"
      id="F_b0666cd8-3abe-4727-9e67-36aa868fdc1e"
      unitRef="U_pure">0.0133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_97b56dc7-df26-44a2-b55c-c37821ed5567"
      decimals="2"
      id="F_245b4c66-f2a9-4f3d-be7c-3961c481afe3"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_14f240d5-c0ae-4980-979c-1550d7d172d4"
      decimals="2"
      id="F_ba905d5d-7825-4c4e-862e-e5a1c2408a13"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_b92e8ce1-fdcf-4c2d-a2d7-c1581bdfc31f"
      decimals="2"
      id="F_a7a73ac8-a2df-4e94-a635-47e43bc65126"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_9b380165-d0ba-48ca-8553-1fc3c5916d47"
      decimals="2"
      id="F_0fc920b2-570f-49bf-835c-800d9a150142"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_c135ce81-16f6-4644-8431-2f49154ea889"
      decimals="2"
      id="F_530014fe-f74f-4472-a0e7-40a0738c8775"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_c7a1f81b-226a-425e-9556-8238ac7cd556"
      decimals="2"
      id="F_8538b570-556e-46a8-bd40-52349bb2045d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_f038aabd-994c-468b-8aed-2534246985e6">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the status of the Company's nonvested restricted common stock awards at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and changes during the year ended December 31, 2022 was as follows:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.034%;"/&gt;
        &lt;td style="width:1.209%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.626%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.113000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Nonvested restricted stock awards at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,272,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,127,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;139,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding nonvested restricted stock awards at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,006,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_eed08da7-0a3b-4480-a783-cde12cc17f8e"
      decimals="0"
      id="F_0b40da3d-95e7-4b06-9133-578c3a53205d"
      unitRef="U_shares">2272707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_eed08da7-0a3b-4480-a783-cde12cc17f8e"
      decimals="2"
      id="F_4041cba5-64c3-4326-b077-b88d7eb84dab"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d"
      decimals="0"
      id="F_8ff9ee44-5a9d-4382-b1ac-47e21927d15d"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d"
      decimals="0"
      id="F_9ab95786-8b2a-4db3-a492-6ce0ef959ff0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d"
      decimals="0"
      id="F_2cb19f7b-57bf-478e-bd65-7992e859e86e"
      unitRef="U_shares">1127224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d"
      decimals="2"
      id="F_e1226b60-3ec8-4e31-9368-51488ad56b5e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d"
      decimals="0"
      id="F_d3a9239d-84ab-4e4a-b74d-dd79b45f3cbf"
      unitRef="U_shares">139115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d"
      decimals="2"
      id="F_c0213d8c-4eab-4fde-aec6-4a9b1d0cdc7e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_cbf9eec7-f7b0-4d37-8259-cb61089f9136"
      decimals="0"
      id="F_859645ad-c2b6-449f-ba46-804ee06f2589"
      unitRef="U_shares">1006368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_cbf9eec7-f7b0-4d37-8259-cb61089f9136"
      decimals="2"
      id="F_3e40540a-8c20-4b92-aab2-895c43987d96"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_cbf9eec7-f7b0-4d37-8259-cb61089f9136"
      decimals="-5"
      id="F_6eec898b-6d5f-4a99-ac48-01586a9d935a"
      unitRef="U_USD">3400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_12986d42-bc40-4315-b656-9d19b413c96d"
      id="F_7ef2c092-597b-433e-b718-870caf1dbf7d">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_93c3708f-b257-4c18-89d2-91ff3b3d39e0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the status of the Company's nonvested restricted common stock units at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and changes during the year ended December 31, 2022 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.034%;"/&gt;
        &lt;td style="width:1.209%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.626%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.113000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Nonvested restricted stock units at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;151,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding nonvested restricted stock units at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;128,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_283e6bfc-26b6-4abc-bae8-943016a346b1"
      decimals="0"
      id="F_defaba76-f919-4134-9ee6-a747815ea87f"
      unitRef="U_shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_283e6bfc-26b6-4abc-bae8-943016a346b1"
      decimals="2"
      id="F_b79cb8ae-48cc-44ba-8c94-47fb7f22414a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb"
      decimals="0"
      id="F_1fa08715-882a-4542-ae67-53b9736546dc"
      unitRef="U_shares">151300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb"
      decimals="2"
      id="F_5e80960a-b19b-46c8-98eb-16c9a2503626"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb"
      decimals="0"
      id="F_5a03e20c-8343-46d8-8058-1cbd34a9ce89"
      unitRef="U_shares">22700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb"
      decimals="2"
      id="F_9e499a42-a346-40e6-9ab2-1ba988ea6309"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb"
      decimals="0"
      id="F_90a7759e-6644-4fa6-ab05-3485ee7bbbaa"
      unitRef="U_shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_50bf6daf-6a75-4159-a8d8-6128f8fb51cb"
      decimals="2"
      id="F_7492db3d-fe24-4091-b170-442f94207824"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_86c28a70-242c-4117-a116-d03b63d2edf8"
      decimals="0"
      id="F_93aa7779-ef09-4dec-9136-c874c3170cec"
      unitRef="U_shares">128600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_86c28a70-242c-4117-a116-d03b63d2edf8"
      decimals="2"
      id="F_548c0cf6-b15f-4238-a1f6-71ca3cb7c32b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_45070b2f-cf01-42c1-887f-e78f1a625a2b"
      decimals="-5"
      id="F_d32641a8-a4dd-47b5-ad08-4f6144c1ab49"
      unitRef="U_USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_1df02247-1abd-4b9e-b9a2-5286622dd357"
      id="F_765de5e2-c501-4a1a-a51e-ec3c908c29dd">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_6c8eb427-a9b9-4fd2-8278-278c9bafa4ec"
      decimals="INF"
      id="F_4f9d1f0e-fc41-4c3c-9ce5-537a8006ed18"
      unitRef="U_shares">291324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <rlyb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum
      contextRef="C_6c8eb427-a9b9-4fd2-8278-278c9bafa4ec"
      decimals="INF"
      id="F_f33b367c-737d-46bf-8a2c-1416f5c6be15"
      unitRef="U_shares">582648</rlyb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_d4c6a782-6462-4fbb-ab36-0733d6a1beb2"
      decimals="0"
      id="F_fcb2c749-c64d-4fc9-ad92-e34f3bbba351"
      unitRef="U_shares">321309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_6c8eb427-a9b9-4fd2-8278-278c9bafa4ec"
      decimals="INF"
      id="F_3d726580-781c-4867-a0d2-9717b67f0110"
      unitRef="U_shares">573788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_d937f0f8-a8e7-46a1-90c2-541038ce8510"
      decimals="INF"
      id="F_760a2675-166c-4e80-b5e0-cb7d64cde976"
      unitRef="U_shares">38845</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_9608e295-9fc8-4f1c-8325-defd050a4e3e"
      decimals="INF"
      id="F_f4276d11-318e-4ecc-ad7f-5e29883c9da1"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_d937f0f8-a8e7-46a1-90c2-541038ce8510"
      decimals="-5"
      id="F_ad648594-bb6c-4357-93c9-f422747505a7"
      unitRef="U_USD">100000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_2abe5c8a-4d70-4fd8-a05f-377fb08169c0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8. INCOME TAXES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During each of the years ended  December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; , the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;t record any income tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s effective income tax rates are different from the federal statutory tax rates in &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022 and 2021 predominantly due to the valuation allowance, tax credits, and state taxes described below:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.046%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.335%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.701%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;State income taxes, net of federal income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;28.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The combined temporary differences and carryforwards of each tax paying component of the Company that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.529%;"/&gt;
        &lt;td style="width:2.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.762%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.762%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;26,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Section 174 capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company has approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;98.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of federal net operating loss carryforwards, which do not expire, and approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;98.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of state net operating loss carryforwards, which begin expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has provided a valuation allowance against the Company&#x2019;s deferred tax assets, since, in the opinion of management, based upon the history of losses by the Company and insufficient future federal and state taxable income; it is more likely than not that the benefits will not be realized. All or a portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Effective January 1, 2022, a provision of the Tax Cuts and Jobs Act ("TCJA") changed the treatment of research and experimental ("R&amp;amp;E") expenditures under Section 174 of the Internal Revenue Code ("Code"). Previous to the TCJA being effective, businesses have had the option of deducting Section 174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The new TCJA provision, however, eliminates this option and will require Section 174 expenses associated with research conducted in the U.S to be capitalized and amortized over a five-year period. For expenses associated with research outside of the United States, Section 174 expenses will be capitalized and amortized over a 15-year period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 and Section 383 of the Code, and corresponding provisions of state law, due to ownership changes that may have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income and tax liabilities. In general, an ownership change, as defined by Section 382 of the Code, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% over a three-year period. The Company recently completed a Section 382 study and concluded that we underwent an ownership change as defined by the Code during the year ended December 31, 2020. We do not currently believe that the annual limitation will result in the expiration of any net operating losses or research and development tax credit carryforwards before utilization. Future ownership changes may limit our ability to utilize remaining tax attributes. Any carryforwards that will expire prior to utilization as a result of such additional limitations will be removed from deferred tax assets, with a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has no material uncertain tax positions that qualify for either recognition or disclosure in consolidated financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;It is the Company&#x2019;s policy to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company has accrued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; interest and penalties related to uncertain tax positions. The Company does &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;t have any outstanding U.S. federal income tax or material state and local tax matters for periods through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;. There are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; federal or state and local income tax returns currently under examination. The Company&#x2019;s tax returns from inception to date are subject to examination by the taxing authorities.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_07cef878-f1e0-4739-ae33-4dbc3389dbbd"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_0adc42bf-6002-4709-8cff-782ab649b9ec"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_e2b230f6-a529-4363-8bea-960eb0b1894d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s effective income tax rates are different from the federal statutory tax rates in &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022 and 2021 predominantly due to the valuation allowance, tax credits, and state taxes described below:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.046%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.335%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.701%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;State income taxes, net of federal income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;28.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="3"
      id="F_23bed1a3-e286-4c1b-bf92-c902f4c2033b"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="3"
      id="F_64e8ff5a-685c-4330-8a5f-723f77a608d1"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="3"
      id="F_01ea137b-de9a-43ee-92af-6996fc29cd62"
      unitRef="U_pure">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="3"
      id="F_f8fcc10f-462f-4f7b-a073-9f8db1c87ee8"
      unitRef="U_pure">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="3"
      id="F_22636195-79d7-4f89-935b-912e286f6a51"
      unitRef="U_pure">0.060</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="3"
      id="F_ce2ea2f3-2aa9-4704-948b-a19daf4b16bb"
      unitRef="U_pure">0.068</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="3"
      id="F_6a45dfce-b6d3-455e-8612-f47a6c67fabb"
      unitRef="U_pure">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="3"
      id="F_ef53f407-a967-4eac-8e23-c1becd23a507"
      unitRef="U_pure">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="3"
      id="F_97b257db-0e8e-41ab-8750-f39ce68437b1"
      unitRef="U_pure">-0.286</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="3"
      id="F_667d08be-20f5-4863-bc20-404ecde3eb18"
      unitRef="U_pure">-0.335</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="3"
      id="F_7fb8244c-b993-4471-af98-568dac651693"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="3"
      id="F_a634786f-59bd-40c2-9691-8d6366e0c60d"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_53804e73-32d7-4031-94f5-c6fbc692e43a">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The combined temporary differences and carryforwards of each tax paying component of the Company that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.529%;"/&gt;
        &lt;td style="width:2.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.762%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.762%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;26,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Section 174 capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_0e5c4891-6cc8-4b71-a25e-3dcdcfdcb589"
      unitRef="U_USD">26576000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_a47a65b9-b5f4-431c-8589-85c7e5cb8fa0"
      unitRef="U_USD">22789000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_8eebb780-a0f3-43ac-b653-ab1be2d6e520"
      unitRef="U_USD">2306000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_7c103421-34f7-4bc8-bbc3-0cbcd108957c"
      unitRef="U_USD">1685000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization>
    <rlyb:DeferredTaxAssetsSection174Capitalization
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_1f9ccda7-eeaa-4d77-a5b3-694a94479ecb"
      unitRef="U_USD">9895000</rlyb:DeferredTaxAssetsSection174Capitalization>
    <rlyb:DeferredTaxAssetsSection174Capitalization
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_29c7b0ff-38bd-433e-9016-11636db8ee57"
      unitRef="U_USD">0</rlyb:DeferredTaxAssetsSection174Capitalization>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_96bc1d4e-a4e5-466c-aecd-f2bf69a4b0ae"
      unitRef="U_USD">10242000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_d3e446d6-9bd3-4258-850d-86388470c2b7"
      unitRef="U_USD">6213000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_ab2fba8c-2883-4a41-91d6-9d97c9af639e"
      unitRef="U_USD">1196000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_569cfc35-ed0b-4c59-a284-21f2cdd4591a"
      unitRef="U_USD">474000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_51e014c6-36a0-4f74-a990-67297ea36137"
      unitRef="U_USD">50215000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_b416e4a2-81bd-4ec0-a126-650a29b037e4"
      unitRef="U_USD">31161000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_716c0b16-496c-4fda-9866-40bd6c3575d2"
      unitRef="U_USD">50215000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_dd59111b-089f-4382-8ca3-170fe3e2720e"
      unitRef="U_USD">31161000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_335b7007-e881-490f-b095-0b8d35d7c243"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_2b61b85e-a346-4b25-9c0e-a9537cb6e939"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-5"
      id="F_cc97c627-b9fc-4f24-9e91-9f09104e6270"
      unitRef="U_USD">98900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-5"
      id="F_a5b07ec1-65e6-4553-8a8c-54b6be89d03d"
      unitRef="U_USD">98000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <rlyb:StateOperatingLossCarryforwardsExpirationPeriod
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_56a7ffc2-ebc6-4a66-9918-6101e0e29313">2038</rlyb:StateOperatingLossCarryforwardsExpirationPeriod>
    <rlyb:IncreasingOwnershipPercent
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="2"
      id="F_1876ac9e-c8a5-4121-ae32-41d9172388c9"
      unitRef="U_pure">0.05</rlyb:IncreasingOwnershipPercent>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_fb5939e1-6f95-4692-8df3-a284e3e3f7b8"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_a304c311-7529-4e1e-a84f-c3b32740f27f"
      decimals="-3"
      id="F_0c491fdc-b657-4d4a-b97c-5bec6cc953af"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_b6842026-27e3-492e-8918-b2a3db6dea5c"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
      contextRef="C_bd12daa8-050e-4026-94a2-6adc935a3816"
      decimals="-3"
      id="F_ef632ec5-c3be-481b-ad89-afc0a4363615"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_6206d864-8cbb-496c-becd-dc03d190911a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9. INVESTMENT IN JOINT VENTURE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company, through one of its wholly-owned subsidiaries, has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% interest of the joint venture entity, REV-I.  For the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 the Company funded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, associated with the Company's commitment and its share of REV-I development. The Company did not provide any additional financial support outside of capital contributions to REV-I during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021. While the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Company held a 50% interest in the joint venture as of December 31, 2022, based on management&#x2019;s analysis, the Company is not the primary beneficiary of REV-1 and accordingly, the entity is not consolidated in the Company's consolidated financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021, the Company recorded its allocable share of REV-I&#x2019;s losses, which totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, as a loss on investment in joint venture within the consolidated statements of operations and comprehensive loss. After recognition of its share of losses for the period, the carrying value and maximum exposure to risk of the REV-I investment as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and December 31, 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; thousand and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, which was recorded in investment in joint venture in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <rlyb:PercentageOfInterestOfJointVentureEntity
      contextRef="C_91e37f8e-3f15-4cf1-a0ed-4b07ba1acb40"
      decimals="2"
      id="F_d49a97df-1f2c-4e8b-afd1-aaf0d4bbcf86"
      unitRef="U_pure">0.50</rlyb:PercentageOfInterestOfJointVentureEntity>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="C_91e37f8e-3f15-4cf1-a0ed-4b07ba1acb40"
      decimals="-5"
      id="F_8d0f0ed8-d0b5-414f-80b0-a66cf1e7b38f"
      unitRef="U_USD">300000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="C_f4c85d43-b21c-4db7-af84-cec208374d89"
      decimals="-5"
      id="F_f713fbaf-53f8-4248-9665-b3ca1773b1f6"
      unitRef="U_USD">2000000.0</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_91e37f8e-3f15-4cf1-a0ed-4b07ba1acb40"
      decimals="-5"
      id="F_40ab21e8-6c27-4591-b3a1-1f3180f8fa32"
      unitRef="U_USD">1100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_f4c85d43-b21c-4db7-af84-cec208374d89"
      decimals="-5"
      id="F_82ecc8fc-e8f5-49b3-af96-e37c90e07ce7"
      unitRef="U_USD">1500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="C_e04c4b7c-8231-4981-815c-01cc0725ee41"
      decimals="-3"
      id="F_5419a1c9-4adf-4360-90e4-a273c65ddb82"
      unitRef="U_USD">30000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="C_e29c70d6-5177-4a18-b728-136ccc6f1118"
      decimals="-5"
      id="F_77babd9f-9a0c-43f1-b8b3-2860cae669f6"
      unitRef="U_USD">800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_570af4b5-d78f-4cbe-b587-432ca92a666d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Purchase Commitments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company enters contracts in the normal course of business with contract research organizations and other third-party vendors for clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments that may be due upon cancellation consist of payments for services provided or expenses incurred prior to cancellation. As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; amounts accrued related to termination charges.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <rlyb:TerminationCharges
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="INF"
      id="F_cf0baa6d-82e2-48d9-9ec8-dcf9a888c163"
      unitRef="U_USD">0</rlyb:TerminationCharges>
    <rlyb:TerminationCharges
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="INF"
      id="F_35536f02-4332-43cb-9de3-229b2eb85085"
      unitRef="U_USD">0</rlyb:TerminationCharges>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_c3c729d2-6f1e-4aa4-8d1d-6483299c63be">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11. NET LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basic and diluted loss per common share were calculated as follows: &lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.441%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.116%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;FOR THE YEAR ENDED&lt;br/&gt;DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;(in thousands except share and per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;66,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;47,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-average number of common shares &lt;br/&gt;&#160;&#160;&#160;outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31,821,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,519,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(2.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(1.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basic net loss per share of common stock is based on the weighted-average number of shares of common stock outstanding during the period. Pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,333,388&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock that were issued in connection with the November 2022 follow-on offering were included in the weighted-average number of common shares outstanding for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022. The weighted-average number of common shares outstanding diluted for the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; excludes approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million stock options and unvested restricted common shares, which were not dilutive and not included in the computation of net loss per common share. The weighted-average number of common shares outstanding diluted for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; excludes approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million stock options and unvested restricted common shares, which were not dilutive and not included in the computation of net loss per common share.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      id="F_3220ec8d-4a90-41ee-9581-acc1b82b38f5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basic and diluted loss per common share were calculated as follows: &lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.441%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.116%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;FOR THE YEAR ENDED&lt;br/&gt;DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;(in thousands except share and per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;66,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;47,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-average number of common shares &lt;br/&gt;&#160;&#160;&#160;outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31,821,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,519,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(2.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(1.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="-3"
      id="F_c958d0d9-28d1-4fe9-b1c0-2ccd8254810f"
      unitRef="U_USD">-66654000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="-3"
      id="F_2029ef3a-9965-4fd6-bc4f-f435cb85bdd0"
      unitRef="U_USD">-47013000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="0"
      id="F_abeb7816-f6ed-4f25-bace-7d052a9b6dc9"
      unitRef="U_shares">31821311</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68"
      decimals="0"
      id="F_de947f15-e5c3-40a8-bbac-f4591156376d"
      unitRef="U_shares">31821311</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="0"
      id="F_49a23390-2f51-4a28-8f35-0e6a2556472e"
      unitRef="U_shares">25519114</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4cb860dc-2e91-4270-b9a7-a8db4c05d220"
      decimals="0"
      id="F_cfdfe76a-9ca6-4f3c-a0c2-4fb87edb289f"
      unitRef="U_shares">25519114</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_17a4f0c1-9607-4df6-8818-c739af03c27b"
      decimals="INF"
      id="F_53c6cdce-2bd9-4255-9c06-8c83cfe56408"
      unitRef="U_shares">3333388</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8a26e436-c6db-4d63-858b-564767b5ca18"
      decimals="-5"
      id="F_5decc35b-3387-4628-a3da-65dc913247d1"
      unitRef="U_shares">3700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_027b9ced-d4c4-4cc7-bebc-9fecdde23fc4"
      decimals="-5"
      id="F_856543e2-7185-405e-9190-9a38044f52e6"
      unitRef="U_shares">3600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX!NHI@HT R/G+I'>2X-IV75++)R@[ 9<SZ4TJX$]H"O%R1]02P,$%     @
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M6AEV917.UP709>;Y(O"\-OX7$SAN&!P/4_@NXP9O+DW%Z&=;^>Q'P7/#ED[
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M+@+8\L[;V!U:A2S"GNT1:80(&18B!CO/(FFW&6]C5E[]9CC3AF0+VUP88?)
M$S,GSC <J@/CN3]KJT&'H0\!XYY &GU"AO7)J@\M&J,UN^-99N8"5M,SH](9
M@>.KP@S:=EM?N>RF7N\R\AO1X@^+EJ$(F-D4]F/WNVHD"!=!>Q$YS%HA'D)O
M5(L_K%INBQQXQ!0L4,<UL$(B% A#6[V?168#:K96)L87ZQK_I+KF5-X.\]3H
M&G]8UWPYZ&2FR&CK\T3YW;3U3<"9EZY\P'[[PY[#J*<S^WOG%$<UAF.[\G.Q
M^)WO]FU!X##I?-:?[!UGI4S>V5,^A2RH\ERH?EJ?)%[9\[/6\_?X?%6>!S9N
MRN/)3U1"*U$H81MPZ;V; ?7)\L2OO-$BMX=F:Z&U2.WEEE'03,8 ?M\(H7<W
MY@7UN>OR?U!+ P04    " #O@V96Y'_@")0"  #?!@  &    'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;*U5T6Z;,!3]E2M63:VTE0!)FG8$J4D7K0_5HF;=
M'J8].' )5@$SVPG=W^_:$)9V2;1*>\'VM>_Q.=?V(:R%?%09HH:G(B_5V,FT
MKJY<5\49%DR=BPI+FDF%+)BFH5RYJI+($IM4Y*[?ZPW=@O'2B4(;F\LH%&N=
M\Q+G$M2Z*)C\-<%<U&/'<[:!>[[*M FX45BQ%2Y0/U1S22.W0TEX@:7BH@2)
MZ=BY]JZF [/>+OC*L58[?3!*ED(\FL%M,G9ZAA#F&&N#P*C9X!3SW  1C9\M
MIM-M:1)W^UOTF=5.6I9,X53DWWBBL[$S<B#!E*US?2_J3]CJL01CD2O[A;I9
M>W'I0+Q66A1M,C$H>-FT[*FMPTZ"-SR0X+<)_LN$_H&$H$T(K-"&F95UPS2+
M0BEJD&8UH9F.K8W-)C6\-*>XT))F.>7I:"I*)7*>,(T)+#0U=$1:@4AARE0&
M,SIF!:=S)BF<H>8QR\_@/3PL;N#TY Q.@)?P)1-KQ<I$A:XF3@;9C=O])\W^
M_H']/1_N!"$K^%@FF#P'<$E,I\C?*IKX1Q%O,#Z'P'L'?L_W]Q":_GNZ=X1.
MT!4XL'C! ;RNIB]*^OUZJ;2D6_QC7]$:S/Y^3/.RKU3%8AP[]'05R@TZT=LW
MWK#W89_@_P3V3'Z_D]\_AA[=SC_# YVLK"77O%Q!PE4LUN:*T86!6!0%5\82
M]MZ=H]BO+4,#=F'!C+EMHF%_- K=S1YY@T[>X*B\F<CI-('\2*0IRE<+'/S%
M*?!'EQVGAOA1"J\]/W?'*PJ4*VNA"BSEYI%UT<ZEKZTYO8A/R+T;L_T#TUC_
M'9,K7BK(,27(WOD%"9"-G38#+2KK2$NAR=]L-Z,_$$JS@.93(?1V8#;H_FG1
M;U!+ P04    " #O@V963[0J7*H(   6%P  &    'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;+586V_;.!;^*X2F.TT!Q=>D39L+D*0SF"S::5#O;!\6^T!+
MM$V$(E62BN/]]?L=4I+EZ^9E"S26J,-SOG,_Y-72V">W$,*SET)I=YTLO"\_
M]?LN6XB"NYXIA<:7F;$%]WBU\[XKK>!YV%2H_F@P>-\ON-3)S558>[0W5Z;R
M2FKQ:)FKBH+;U9U09GF=#)-FX;N<+SPM]&^N2CX7$^'_*A\MWOHMEUP60CMI
M-+-B=IW<#C_=G1%](/BG%$O7>6:DR=28)WIYR*^3 0$22F2>.'#\/(M[H10Q
M HR?-<^D%4D;N\\-]]^#[M!ERIVX-^J'S/WB.KE(6"YFO%+^NUG^(6I]SHE?
M9I0+?]FRIATD+*N<-T6]&0@*J>,O?ZGM\)H-HWK#*.".@@+*S]SSFRMKELP2
M-;C10U U[ 8XJ<DI$V_Q56*?O[FK'%:<N^I[<*.U?E;OO(L[1P=V#D?LJ]%^
MX=AO.A?Y)H,^8+181@V6N]%1CI]%UF/C8<I&@]'H"+]QJ]LX\!L?X/?-SKF6
M_^'D_I3=&^V,DCF/T:!S]FB%$]K'!3-COTO-=2:Y8A,L"H2>=^Q?MU/G+8+G
MW_M,% &<[0= "?7)E3P3UTE)LNRS2&Y^_67X?G!Y1+VS5KVS8]R/NN[XSF&/
MW?TU>?CSM\F$?>=*K:;2P#ZV-'9M'5=-G<PEMU(X=N(7@B7WIBBY7B4I2Y:"
M_IK*XL=8EE0N><>D8YQED"8SKDZ=1U8SL/8B6VBCS'S%LLB!?@OIO<B9-TSF
ML+2<K:2>!\D\RY"U! 4+)#@7SZ@>)3F$_*3D3)S")]I14:J)+"\)*%98B9W!
M=TOI%\QALQ6!L>5XR*432&/78Q.I,\&@ U.\TMF"2<W^SG6%XH00'%ZD;"G8
M@C]#B4HJ#]U@(#]#$!F"45I32$?B\917F6<9A%" "8>M"PF.)%##K>#<50)*
M\SQ'2+A-3$1'"F.-.Y*!LB.L1D3.A,??J3(F)VIC<V$AA>RI0J2R?.6LF%>J
M#G<JWCX8/0VZ%V P!?1LO;W'?M3Z<>=$,55P!V=>\()$BY=2P/<P44Y.+!<<
M11  <Q0E&$BA X!'M+%X\52GP8G"G-MLD7;U37>L'[E[O) M<J&PUS)*0W@#
M5G5U2DX%- QQ40ML++05$L<"8,OK/X)Y66[YDAC7,G.1@7VP^1,<!E/,8\RL
MS1"Y<9#")P 54P7P/<^>E BP*IT;+=+P[ TTD[.9S- AXA(V(;:A'6S-?OWE
M8C0<7@8IV8+K>61A\CQJL6&O1J4>>]#LMIK#"50FAY'O_3JM$ Z45M)3,$E/
MU:RLIN1W,YM!$ZA\DCP\?DO>I?A@7<5C/,9XE1Y)["H*!"H!1N7L0SH<#]+!
M8, <0B":J",S:/'ATH64ACW0L;*G%+(S586( /G'30:!;5<VL9M52L'8PF84
M%+4,F%/8I94PN*L%,5,V=@<+V W4R"5)B] UBD# A73=4KRT,@N\W[#AN =
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MI)@LW;H82TLG2PZSWNR)O8;]+77#&)6-OIN4[=V#^%G1X:X#,7V=QHC-4.%
MVZ';3K'#U:\3%6]#+:ZOC:@<MS=$;GU#1$99 PY&H7N"IGKO$]1C$T$##HH9
M^F\RB3>B!&LBYUKBR$C-YS8+XPE%Y".=W"DO[SB"E @W+J_B;1:ZO43"A,\;
MMUU).[U-F^WEUMU7=/E^_<(,=<!3'?>$>:I"@<DQ-E@A=6_?)5>_<U<9RB/=
MR)*9H6F\MFQ7VTO?VWC7N2:/-\:88.92TRPZP]9![\-YPFR\A8TOWI3AYG-J
MO#=%>%R$6P0B.">KP /U"PEHK\)O_@M02P,$%     @ [X-F5M.@]7]G*0
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M5Y6(CVW1KI)V97HKIDE6EHB3#_#?ZUE1)[_5Y1RP:G^"'1IX&>3=S!;S(FL
MQ6E2PQH-+)15_I73NMG4C:PW,WFV-F,OXS8(P6F]WF35=;)IBAJ6JNG#B^)K
M)S<R"LX4[] _GL,:I=&G@U5_LHB[=+A 4LH.@#'$;%<!1N [T]C1#?4@N';P
M'&R\ADU!L.5?HO<") !]P+'-UPYH4 'N721"<)=CRV&57@'V15%E0,M9"3#
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MK]$O1&*L[B5$Y*(F!9FB(2#+6O9!0*;)&T_%:,L:1!1MOET9":NB;X!D >_
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MZD#] JEG14FY"0 P.<E!YUGQ$\:DO[H8<,;P493T=,+@Z+8 $PVL_BAL,50
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M[@1%[>X12/KNEL\NGU=8.;3KSITLDOH >,%KG2)X5?5\4UBN>!X/[*:!_J;
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M_6XB)U,.RH,SM"IIGQO>"O.,3DP5P@.&F9%.HCUK.()F@T98P%SD,,$>F%8
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M*(T"K>="Z./$;-!_,2W^!E!+ P04    " #O@V96=^S7:OL.  !=,   &0
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MRLI,."]]Y8V][XGHX@%2!"$QJ Q9^ Q(*^@WK.569I4,I9^!>V01JX@5Q9
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M4I2=\].?R?A\&<>V4ORYK ]F',EWG#F,0&*4"U_?>!2@1S2C>1GH8# P]8R
M]6W0PL#!WR=,7!\R&M.WQK8?9M#$3+5+1RQF2/0] _^ I=D/L@]U]S_R<>FY
M7E\)@U0O:\<_&?:%N9[H*!HF:G@MX0WM8&S[J4*8CGV@G?4^GJ,@=OP3@:.I
MJO#A.WK[M/T5XC)\?.^6AY\P/DJ+L[H3F=I"=#X]/9X(&WX6"#?>E/PI?F.\
M-SE?IDK");0 [[<&Y\#ZAC9H?YNY^!]02P,$%     @ [X-F5MFS'A!/!
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MV 6$ C/K$!C]K?$3"N& *(R?'6;0NW2&P_$._8O/G7)9,H.?E/C!<UM.@_,
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M'NP93;8]#'N@J+-%E#^T(Q7'^^MWI"S5'5(#[8M$'N^^^[ZC[C3=._KL:\0
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ME>Z5RZK>5[6LMS#+;&=B+^,V",%EM=MGY4VRK_,*EJKHEV_S3YT2= R<";*
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MJ+M;; Q$4EV!L(5?IIBFZ. 1UG.([*[ 4V'HA&-G8,'!_5F0V(+>54V;-%X
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MSGR5<SUU:$Q@F>%5$>M0 &F-"!$EN>[$7G''L[*+/!M)G(B.96)$6;NK2 $
MLF?@QW$Z512)1\MWTU1*V/^L#L"$=9H<$EBC0NLZ0?8#XXT7%&D@J/MR7!VA
MH1AN\(Q=8U&$-P:O8N8'M.JJ6^+N(#[8T&ZW==5MMNIH5/4-:U^ B'V3@^$]
M2L,Z;2A?E-#A1\4Y.[(8W3*B7)V"X<C@#IPB1*B&N(Y"")[^6D!"1/^.5LE-
M@MJO6=_0.TRBC$R$TAT*MVX M90%D?B412DF:T NRM66&_@%UDN0R)-CH(+A
MF!Z(A+Q%9YVS<X9BA"!2:_7-:GAXB<279!IR@ 4W-9H>> VP;,JF,Q@B*&:J
MG:&(#"><<AL8QU-8JQJ6S1!9"\\N00&L5,QF"MX'( )>&-/53ZVN?CJJ12_]
MDR47=8W>)9TGII&_=JU [UK!@KE*"L91N"^C>]5(<BV&()II="DH+=V*Y,JB
M=&NLONP] #BN"C1AL^0/T&RM)S@H:D,ZD*S;SVB+)>VALH@&[4YLB!$USZBL
M\^:C.NH'<CE79H\:!U=78UM)'4.'2]-8OTLW!6T1.F)YPYJ (Z2X,XH181WX
M(\.W^C\!)E1*UE5$F4)A=Q^A9"1XC( 1)^_/0/5P"1AG?C)]DB:7P8,!+=P[
MD:<H7L$_VFAUXR_:J!F"@K]9P@TJ?1#A"#>"MU-7S'3)OE^;XQRBE#TQM+<W
M)8DPD"UMB_0GN0I&,A=19!TX#2 Z&'X-E5"F3%TU8%X =X'V9U94&[C9U\C!
M/OA>@IBS(G(>$E5T'HP8"0H0Z[KV48-=;@ZI\\ &8N].D(+ $D#*(;4D553H
M/E'*5^TE&_T1"!Y-'Z7)>[0M.\Q(."3Q=<&?3^Z/D,L^NY$CLSF2A3+3@I4U
MMSHC]/M@35"WA,!.34"L:X@NCZ^Q<YSO%EW=,&URYBJ^Z1)<QT:)&^7.J8*A
M?BTE+9@?G,E!X71QF4*IIN';I@<_0,8A=53VC?A]'.]FDE-KH<C91M>87_A7
ME'JH; 8)W%MC%:)G$JJ6 ^/YRABN37J8)A(T>ZM:#;;M27.KYR2H1JCVC $@
M]2PO1G72;.JJ\J:CFN0"#YE<+$&+-^SY1*OGOG21J!I2SPN0[3^**H=0[=U!
MDX/E"LY0$/H::B) #+(>7HCW)."=@AD+&Y,S3.9$>PNI#0OU?\TP^)"AP%GG
M-9@5&,HEWS4#65*C8]JBM0'P6+%C0?(L. QB<UG9,)A @J%&-TC/OB1SFA01
MN8;((38!"2!OP-[*4>D R9,5RP #Y+!.MZ<(A6!M^%@CRC!O] 2@ P#T/..8
M=)L.D(C:<H"]<H@F6AEN(05[K"84A"&?O%%7@3@0D!:Y/=]/=9@H]YV6,=05
M:E6-DU&$@-2KYV/7AIRRKL6W0 =M<Y C!Z*$'98=L\&\SD7:(ME98@@ER\YD
M'-B3/!%*Z#]-,SR[Q@IKBOLGF'^S"BA&9[U2*)2(1-5\8CZ12!T&7^++37 S
M)$C9%X[<1^J6#JJ7=).\/!5L'A?5]T[>O'O_CVRW?_;RY#YK\Q)6*.!>2U9^
MXAQT#24UEMNLWH@?<ZO.:<4P<HR&4O/_0TIZM<NS40'W6U8S,[U13^,5Y?*B
MLO+KEO)CXT.!2?[XH>2D<.K;[:DG-=4/HH@#91O%MG9B*L=P*[,9;'"MP'@>
M%'#%\-=2[* IG]_>O'(9GU_)4Q)8.796:Q7&YU3=@^2/;K7!"TMMU6?'Z8'C
M06_++-DUW"5!Y!4(Y"7W"G L:%>!?&8TK $S5=T,['^+!67;4L\%IQ9^:ZF6
MQ=DH@F.@+0_]#EOX("!#CM0+3>:-A.MSJGQ?F)("3_!S:-YYMD,CUH\%BV/C
MM^85?HWOPT(. 518P'H3;PQE(J 84&8UE#5;53E\G]S+[Q.UT,M@7=4VC[(R
MR[QQ,K"?&$#EYU(H($/+:I<O@WHTV1; XTJO>[FW6;4H\HTM5\D6354O-,ZF
MIB<V0K#,H0(*.;G&S9 '<K;HL-2 $QQ[$#"JG#&\X_EYDD4 <(*8L4 ,NY8<
MN 4]0U:(6)QKJ\\X8>S"?=E2M%=0UH,AH:RV%19]0U+8A;:6Z@F\/PYS9\@R
M811-:I%!332"*P9CDEPZ<,+'D7 ZFQ$JL/YA[ZH;,,P:$T(KB2]C0$7\_N3]
MJ^0W^)%TY9LT>?OV$C@QP;PD/J_F]4VB:4V5'^]?_7;ZQN7J22M[)?Q/4_4^
M2?L):P%OUD;<3HHD*^-AH:ZO?N.\$ L'#)3VD7=9+,)^(WY92W7(%CLH,8@J
M!L*TL:L=JQ/R2@<PG>FIQJ=6-;X)+N)?%'B1N_@&C3AW&G$^JL9><=CO9Z!\
M<-D<,''W872M>(K^Z 8Q11E<1.X]B_^VDGU5&;YR,A]%PH/,XXI)3P'VK@2]
M\H=SL$H&4 "20SB1'(.[T" ,O*]E]PJT9UARC59U"L9-YDK5)9J):XK@RTN]
M?LZ@E#U^Y/C;=4@&520[[87;,?1I$ST:189[V&)''. )=TI5% %BT!VN. 8D
M%3*V"/\H*.JK1"#I^\ICU.F:I6:CW4W/7?W*FQ(K)X]3YE>L$R% *[VED@E>
M<'HZ]UY5RZC.&^X<B2<L4L_BH1!A1E4#D01&ZFA_G]VPPX=6U')9=YX(SC5_
MO\SJFEQ9ZXFBBWH$6,P.?!;;S+FOHP+$=8C-QEN[+JV/JT& 2TH&)._SYF/T
MJD;7BPN1T4TT1/$Z>GA2.;ZU8,NL/1;N18J7_G8NOT$19&T8$O62%S?'K_]X
MOBJ4(,QQ+#[,9W+I:"E@/S"'S8VL08F2L208/+^IKL&W$^9%YW?5(XJ\[7H>
MKU=W#D8U'*K0\[J=Z.B!.146O$3T\9$HO(]*,1'[S+<R\&8N7+8U8.UE[>@I
MHG4X9 ? U6S!NM1=/X$30$%\=5W\>(4 C96R</V<&%1#5:L"%;1Q^>;*/V?C
M]9^7>,OD%.,/KQSE1!GG*]>*9I)<S%6+H=!_Y],A'2VR\J/FB8D2)?\&V@8S
M?$3W\!@:1577^!R7>IPQI%[10.#Z;7(T9G:8Q++I[G9;&Z,Y9\P9(BL(>8%S
M2?=I:XXSX1(+I')>8ETI*R7UD+8$+%;J%:HP9Z3VPGZ-,OQP9]QXC#!<Y>1L
MO'3R9\??KIXU2A1?L8X-ZOZNRI[R [[DL1E6P!,R$-PE1S'#ZMU[)Q\F5Y.3
M^Y[8.5UDRX]4G+%H@P0]%4!20([D'^PM1,A9ZJ-I?:M!3T&#GI(&%<W(56 8
MS.?4 /O<_MNMK^Z2ESV0QBAQ0U%(:0U^.DU6V8UH_:#N/@+<D8.40Y2,[4^4
M'VP>EF $C#  :T"4<&]PH *,U%6RR7(Q$)UTZ]U 'U*K*]3)$BEPHVD==N_R
ML#Y'TC"!%2JV\#W<^CX'\ANN@F2#JBHE_415>M)[(II!:A3( 21O@5H(-+GM
MQ>6E*886]U3/RBP+BIWU&E@IM\B'!5HZV!@8NY'F<RL[L /"X6=9*9*PI%.?
MXM6=>FA"]Y9#V(#E8$<.Q)"$U+J,3 *QE%RES-W7F_P3-96TMJEVZ0>NG2OQ
MR%*3PP5+?BS&*W\*ZXN0YZZEP@W$:]T2<5&\>J&M!YD])86Y"9W7<L&9*F5V
M3*JRN-&U.L[:5<N<Z_O4G_9>X'2$.%Y$>:Y:04IA4\\1YS61KRJ*EQ?\I$U>
M2ZC1Y1B_E)1'Q;ZKU)Z-%UJ_J_$44J")*IQ"[E&Y/[K0L6KYV.JJ#8*_&OM7
M[L77S&LK"0FM*6A:[>G;=RV5E"BN[ JIE@O11375NCUD6%NP[FK0)5K!LLX_
MMS954X":,,C[2;ZCPB:)CKY$C8Q$(?FH958LY8(P2<.!.!RE@0'%4^+0'?OS
MEE(U2(UOF'6'-4S7KE-.DS85Y\7C<*1NM=K@'!O:&82 KD*O45U6LT5KHV9C
M)++UFMU";A;+_K#92Y7F2]=2ZG6@_XWSM)?A0Z_L\A]X^;>P_-\N1VXF><@U
MH'^[C%R0_>/K^#T]DC^_C>*(]!?W(A(V^*Q4>.>._G.&T9J2NR@I0[<'&=Z(
MG+42"1YA8SUR5:S[)&O%0SH*DJ@V2^45:B<?]M01VDJY(\*SRANP>3$U8 F;
MI(-9]4I-/<ICEMAAP9W3RMY;9&JRC\'Q(11'2"2H><FL'0HP*:?P%*"(%_OX
MMT=_QIT65ZL^&R\C?[/#:](RD;=5N3E]2VV/1)9Q*W5TQ;BTNF4;%5N_HP++
MRY6P 6'"NOM(D[((DXI8]&'XUZ7GVFADI<"]"VX\ER1\$+0D,^38RT2X_050
M-I"LZG;<:XU%5Y*B9Q6,I.75;4K]<>/9A</M)LF_M?G;.S8U:%L)OKIK_7=%
MG9^S9)QH7-'D;+S2D<1$G#9&7XS3!J^F)'#12MQ22N:'Q8]DU07)TW[M(PM]
MC"2C=4S9#Y);09[_6"9(_43B4;*4[<J3A&#M2?34+ZIC22&U"E;GMDC7GG$I
M7C!#176*L#4]S5GW024=UYSS@>QQ  V8"10#\$9^2_7N57EJ%V<I!&B@5)Y#
MG$H@6TOHB25*LM(;P2M><X;LQN6;SEQ#9:M%QOR(C,&YON\DI+S[_I</?I%1
M$!9]*XHFK 6#??.Z%^_V5_&9([ALO53+R:#ZS(K(!(=_<'G0TNBO&3Y7P&8-
M#F5G?@#1@NUCIA2:E70%.4# M@5U-, &>A>,UT:C:CA(#R,KMC8'W;6#Y. [
M!&W)1 3";P&'YCPPK1Z<SDNZ>S'J<2+38A8;&*&+I".4%%J5,A%LG[)5_0<M
MX;*M(^@F$60IE01P76*+W<*D"<EY$!LK<P5D<-J4N)9->?.IXSIZ!Z_%O51:
M\8LV8VW*Z[RN2F;*WPTGCVC8'\/$Y3W>X84)M&QFR![J.%?H%B$9 42&=+)O
MQ@%K?A'A^*Q1L)Q3(A5;84A; ^N3,1N:PH3826(+5_A!6Z 95$ IDU/X> SZ
M'FB!N47G)B:\CNX9/6MH%FE3U;"%1?_RS>[Q%5I9NKFT 5?:05JI_5DQ"5*?
MKH?F?AS9U7E1N%C7$2GI5U(?Z97M"[B!3".'/6\93UE3H02XL570\;8Z\QF+
MVJDM!=A7@(HP 5HDZ+&<$CWI71DNXT%XR&ZJ#39 I6J@.Q&=.>A9F?HRUQ41
M6,]J6+A.BD$#8DK4K@M)(L*C)LG<E<S.QZM=W["!_6OV.6Z8C+]^Q&CUUHPE
MN+M&K$PI]RO]Z@KU5=?^3 7.A-.J+:Y*[7+X+ORAW>JDFL=GT]3O\<>W E@X
M>PV/8?;Z W4>4!4I[TFE&SP6!#8YHF'[O*[%$GV#%5= EJ1I/%(>9 -AW)AL
MR&Q:F/9@3,^2]7NS*>P/J[EXTA' 2FZ&#!OY>$T$D[H]>#;D(&0@J@R;]4IN
M_<4=:^Z4]DIOO@1!&D%B,Z*ZIOJJP4W&RW-<471TQ]IPPTV1?S04, ..02X$
MY"R,5#45&A)3(P%_;YM^$EO@1W6E!QUH41H,_U.!S3OK/ZVY!A\U#N4Y8S#E
M?B\NCK[A0(2Z&8XJ9*1-M>8\IU"-WY_"%]*MM ]N#6*"9N+@=OLB*TMN^\;K
MV?#$A2-]?]J^FH2NGA^ME5HD9((81NGO_GE)Z6"G7X5I1H=HKG9THV9<M"R*
MZHSB[RTE>R/H1$O>[SKI#SCU3[/.:0Y*J  Q(P.(0PN]\.@-XQY=S2T^U#[M
M+!_5>L@?X813&G'A^D&?3)/_[$TNC8'W]NVEOCN;PBLZC<0E6U'I8,S+ P*+
MMBCGPL@L&>4V,&*G?LJH)G@93[_R\P?C)Q_7&JZ$>#Y>]_O>KXM^Z=5%OQ++
M)*I*1M>,JY);-U+]\O[6407#:I6*R]?$(@=1(=61$CZ_M9/*39>"%QL<"U9@
M<8M,U=7ZS=3&DML;&=/@#V=X1L85^@Y?,&Y!VN:&I@.HLWJEC8BI=..YF0YN
MBW!TG->-RKE0J5;%PMR<^FM50 %O9R5.,[1U^200"5;27%0M4788)> H"R:)
MJ,2Y:;L5YL&I&+>@%'FUJ;.=WU9,=Y)ZE]9+@+A"VD9Q,&AC2"-=ME[D5Z88
M\U0.^8<T(5P.**(_[.TN9(&$)@?H^0*\OLQF4-?";N<*Q$NO %UM9$(6Q;UL
MV[3\E8?8Z@VS0@\\6P05:_%("Z^,'8SD>L&PM&U5U4U_8MJ@,<S>94ZFP4OJ
M':6QL7OQJ=N<^(=BM]=53O$,V0]YFD;8,AQU$PIRKX201F7D*T<'&->1*C#[
M.PTVNX&#?(N_TC_NM 1>A46[*Z"QYW75_'(+V/RM8L*RH9[+9Z,=:J6V*JD_
M;(O5."L1!+:XABE*770;Y.AU[U3@*F%2CF[9MG)KJH[4KH1>O=8#5Q8P+O!=
MA>Q\O$+VI>KH7W0:,=%R5,Q_U4KQ5F^;DFF"F$YA-IBL0"O*T# S'##@['['
MZR0.3[E/8&V"'+ZF2?H2QNLHDFD KOF?YV,*_'8N,^L1W+N0AH?A>\+R^-F
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M?MR"S6)J? #^OJY 2<@_< -L^B+PGO\O4$L#!!0    ( .^#9E;R<K*IS0(
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MUG1CMU^AU7/F\5*K,?R*;1O;BT1:(]FR368&I3+-5SZUY_ _"4F;D 3>3:'
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M- T\=IG0A(G2*-!Y+(3>;<P%]<PZ^0=02P,$%     @ [X-F5DB\7DJ< P
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M9L& 4O :A>92@,)RX:VBZ_78RCN!/SGN]=$8K"<;*3_;R<=BX866$%:8&XO
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MX8YN5ZBL 'TOI32'B34PW->6WP!02P,$%     @ [X-F5G/0?K K!@  :1$
M !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULO5A-<]LV$+WK5V"4M+5G
M:(H$29%R;,W(MO)QB..1G60ZG1Y@$A(QYH<"@)+=7]\%0%)20C,^-+U8(!9X
MV 7>/BQ\MBWY@T@IE>@QSPIQ/DRE7)^.1B).:4Z$7:YI 99ER7,BX9.O1F+-
M*4GTI#P;8<<9CW+"BN'T3/?=\.E96<F,%?2&(U'E.>%/%S0KM^=#=]AT+-@J
ME:IC-#U;DQ6]I?+S^H;#UZA%25A."\'* G&Z/!_.W-.+2(W7 [XPNA5[;:0B
MN2_+!_7Q(3D?.LHAFM%8*@0"/QMZ2;-, 8$;WVK,8;NDFKC?;M#?ZM@AEGLB
MZ&69?66)3,^'T1 E=$FJ3"[*[7M:QQ,HO+C,A/Z+MO589XCB2L@RKR>#!SDK
MS"]YK/?A)1-P/0%KO\U"VLLK(LGTC)=;Q-5H0%,-':J>#<ZQ0AW*K>1@93!/
M3F]E&3^D9990_H= \V\5DT_HZ([<9U0<GXTD+*$&CN(:[L+ X6?@7(P^EH5,
M :I(:'((, +?6@=QX^ %[D6\HK&-/-="V,&X!\]K _8TGO<,7AWB7[-[(3EP
MXN^N( V$WPVA\N14K$E,SX>0"(+R#1U.?W_ECITW/0[ZK8-^'_KT-B6<GEP
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M$'01LW>1;F+.FMI]QTDB*]%\J6J%%$]01Q:M7WOW=6S\VK_/N[-<7[8I*59
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MN>!$PGKDC</!I&/\K<//'+;J8$U,)BLA'HWQ-1UY@1$$#!)M$"C^GN$*&#-
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M:J<RY6*#&A/N-N.,2IS1!W..^Y0&$H6"QUEJ2 )(/$1^#;0)S*A[*E@NYM7
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M5XK'V>&:DH *?0/\'W*NWDYT ^6FX/1?4$L#!!0    ( .^#9E;OT1O,OP@
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M;W[N2)R24IX@CF\8J]XW9 :'CQ[=_PU02P,$%     @ [X-F5@JR^[WJ @
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MV(;V16W4&AJU3;'(DEB'X;1E./WV2W)J$ZU-L<B26 ?MK$4[,T[/IW+#X6.
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MZ!LZ"#- OU]QKNX:YM)8W_FC7U!+ P04    " #O@V96+?M7?)8"  !\"
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M*&N ^RLIS<O$7EGM!T?\!U!+ P04    " #O@V96@F$!?I@"  ##!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R%E%%/VS 0Q[_**4,32)2T*4V!
MM9$H'1H/2(@">YCVX"37QL*)B^TT]-OO[(2038&])#[[[N_?G7V>55(]ZPS1
MP&LN"CWW,F.V%[ZODPQSID_D%@M:64N5,T.FVOAZJY"E+B@7?C <AG[.>.%%
M,S=WIZ*9+(W@!=XIT&6>,[5?H)#5W!MY;Q/W?),9.^%'LRW;X K-X_9.D>6W
M*BG/L=!<%J!P/?<N1Q>+B?5W#D\<*]T9@\TDEO+9&C?IW!M:(!28&*O Z+?#
M*Q3""A'&2Z/IM5O:P.[X3?W:Y4ZYQ$SCE10_>6JRN7?F08IK5@IS+ZL?V.3C
M !,IM/M"U?@./4A*;63>!!-!SHOZSUZ;.G0"@N"#@* )"!QWO9&C7#+#HIF2
M%2CK36IVX%)UT03'"WLH*Z-HE5.<B6Z9>D;#8H&PPJ14W'#4,( 5G7Y:TJQ<
MPS7C"IZ8*&F%S,L=X\)&#*@N@Q4CIR7&IAN_V,.5+(RBFI=,P"TS=F4/ATO:
MBPM]! ? "WC(9*E9D>J9;R@72^0G#?>BY@X^X%YB<@+CT3$$PR" Q]42#@^.
M_I;QJ11M/8*V'H'3'7^@>U/L4!NZ=48?UVD1'WQ_*2U^)\-?E[%V^?WN8Z_W
M..W?P_;9A=ZR!.<>-9)&M4,O^OIE% Z_?9+!N,U@_)EZM"S1UE86"'MD"J0"
M@;JWQ+70U G9[MU%HV :AM.9O^L!.&T!3O\+P-8&U3N#R90L-QF82KJ)7II:
M->S0G)^?]:-,6I3)IR@/TM#U8^V%I4=LH.V%3>W)ZO?CC/>0="YLWES8/LQ)
M3]'.PG#R#ZG?Z4G[O%&C;7BAZ2S6%#@\F9*.JI^,VC!RZ]HTEH::W@TS>F51
M60=:7TMIW@S;^>V['?T!4$L#!!0    ( .^#9E:C-0W4* ,  -4*   9
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;+56[V_3,!#]5TYA0B"QI4U_CS92
M:868-*1I9? !\<%-KHTUQRZVTVZ(/YYSTH5VR\(VE7YH;.?N^;V7\\G#C=+7
M)D&T<),*:49>8NWJU/=-E&#*S(E:H:0W"Z539FFJE[Y9:61QGI0*/V@TNG[*
MN/3"8;YVH<.ARJS@$B\TF"Q-F;[]@$)M1E[3NUNXY,O$N@4_'*[8$F=HKU87
MFF9^B1+S%*7A2H+&Q<@;-T\G Q>?!WSEN#$[8W!*YDI=N\E9//(:CA *C*Q#
M8/18XP2%<$!$X^<6TRNW=(F[XSOTC[EVTC)G!B=*?..Q349>WX,8%RP3]E)M
M/N%63\?A14J8_!\VV]B&!U%FK$JWR<0@Y;)XLINM#SL)S?8C"<$V(7AJ0FN;
MT,J%%LQR65-F63C4:@/:11.:&^3>Y-FDADOW%6=6TUM.>3;\S/0U6C87"#.,
M,LTM1P/',(YC[GQF LYD42S.]3=3"N;"O*60J]D4WAR]A2/@$KXD*C-,QF;H
M6Z+EP/UH2^%#02%XA,(4HQ-H-=]!T B"BO3)T].;^^D^F5$Z$I2.!#E>ZU&\
MN=WQXAV,UZ38.71,/AS/&%GU_9R2X,QB:GY4"2YV:%?OX [FJ5FQ"$<>G3R#
M>HU>^/I5L]MX7R7_0&![9K1*,UIUZ.%XN=2X9!9AP;B&-1,9@EH V_/$.$]B
MYYOY6T-4%$Q")JFW"/X+8Q#*&%@ID]=5E6L%E5Y.Q76?==AKT&_HKW?MJ"7\
M0CO:I1WM6CLF2EHN,RKU1X4!&0*IT@@V(?UV@V*-M"!M4GDVB@V[.Z+O"ZZE
M]$+!G5)PI_[["VKS3$:8RXHT4E?(]6*EF,X_Q=1N]T(QW5),M_[K,9-03<80
MN0'^S#C5,TI;*:7[H!@[W4&G?T_.PZAFK]-JM<NP/:*]DFBOENAG)?$6BM8,
M'S/JJO ;SG&- II57&O1GMMN#@2V)[Q?"N__]][;/Z09!P+;,V-0FC$X7+G6
M0CU7]>!!5;=W^W"AQM^Y=+@+'Y7KDDL# A>4UCCIT5'7Q26JF%BURN\A<V7I
M5I,/$[IWHG8!]'ZAE+V;N*M->9,-_P!02P,$%     @ [X-F5F]FXYWB P
M'PT  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULM5=M;^)&$/XK(_=:
M)5(.OT" I(#$2ZI&NJB(W#6JJGY8[ %69WO=W05"U1_?V;5Q !GWDJ9?P+L[
M\\P\CV=WQ[VMD%_5"E'#<Q*GJN^LM,YN75>%*TR8:H@,4UI9")DP34.Y=%4F
MD476*8G=P//:;L)XZ@QZ=FXJ!SVQUC%/<2I!K9.$R=T(8['M.[ZSGYCQY4J;
M"7?0R]@2'U%_R::21FZ)$O$$4\5%"A(7?6?HWXY]ZV M?N6X50?/8*C,A?AJ
M!O=1W_%,1AACJ T$H[\-CC&.#1+E\6<!ZI0QC>/A\Q[])TN>R,R9PK&(GWBD
M5WVGZT"$"[:.]4QL?\:"T+7!"T6L["]L<]MVX$"X5EHDA3-ED/ T_V?/A1 '
M#EWOC$-0. 0G#L&Y",W"H6F)YIE96A.FV: GQ1:DL28T\V"UL=[$AJ?F-3YJ
M2:N<_/3@$Y(&"C[",(JX$9;%<)_FY6%DOIB@9CQ6E_ !> H//(YI6O5<3<$-
MA!L6@49YH.!,(#^ !Y'JE8*[-,+H&,"EK,O4@WWJHZ 6<8)A YK^%01>$,"7
MQPE<?+B$A?[A.[_3_;$BP_&WX_E[O)H\FZ7$38O;/(/[2X:2Q$R78,6.8*@4
M:@6_?R)#N->8J#^J],Q16]6H9GO?JHR%V'=H_RJ4&W0&1+WM55)_)[ C 5JE
M *TZ]%,!KN#);BZCQ(96E@@S-"=.:0&?429P\1LR>5FE3'VX ';DJ* #25YP
M;8C8KJIDQ[5 ;U3ENE3ENEZ5Q8*'6$6OUN^U+_Z=P(XHMDN*[?^E\MOO*< [
M@1T)T"D%Z/S'RI]P%8IUJF'&-*U/48:8ZBI1\DB^9T.9VWDS\!I>J^=N#MG6
MYO-&MMV2;?<U;-45[6MB=O=,/8>JK/0<[_J(4G#"J,K&+VV.$KTI$[VI330_
M9*9L1_V(KKS+;KXAL2J;,XGYWLMU[/U+:DH)"2=2P@15*'EFKN3*J[<>] EA
MQ38(HD2-\VN?[GE@62;%,Z?['N,=I&9GZI58*Y9&U%2MF418F'Y2+" 4,A.$
M0$CV\ );2PWXO$+8%I7]D165+<LSW08#;<YTKB!HM/,#^HQ?M-\1-M!:\YC_
M11N&>A&QEJ<4(.9L3A::$QNF3))TC6,R1_G2&FQIH=7PO.\;5>=#O79OW#+^
M0?_EU[Z;(37?)NT94N=UI[0A/96&IM[!WW7MS*A ;A]4X(WG>2=E6A__M?S<
M@U8S0;FT';@"^\;RUJV<+;O\H>UM3^9'IONW+>P+3/[I\,#DDJ>*7O""(+U&
MA[:8S+OQ?*!%9AO:N=#4'MO'%7W!H#0&M+X00N\')D#Y333X!U!+ P04
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M2&. _S,A]'9BFG5_-\?_ %!+ P04    " #P@V96X$ \/'H-  "VD0  &0
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M(1LR/8QDSPQ,!<CG"TK%=J(V*+MP_Q]02P,$%     @ \(-F5F6.E.'E!
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M'S.]G;:T&K(Z;]@=C,[PUOZ'PK?DK1?&*\1A _%U]QPP.P*SMP2NRN@56M9
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M23A# K*Q<QU<38?&WAH\$UC+O3$R2N:<OYC)73IV?$,(*"3*(&#]MX(I4&J
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M3&-JNZMGF:*KO:%RP;@B"<Q1TCOM8JF71:-8O&B1V5YK)C1V;O8QQN8:I)F
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M2)F<N?;784 $PZK&]]B#LMBQ?EOC3 7M'/!^J93=&2Y -Z6+/U!+ P04
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M8^CCMNW^I;$? ?=8K"B3*"=+H/0Z?:AE81NKG2B^-KUIP15T.C/,X%N$"!T
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M1S 'X %#HJAZ#^Z\C\+U>RIL_\,W^@U02P,$%     @ \(-F5I>*NQS
M$P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B
M#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z1
M0J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ
M0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?V
MD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #P@V96
M&+_QRF,$  "!)0  #P   'AL+W=O<FMB;V]K+GAM;,6:36_;.!! _PJA2[N'
MK*VOM WJ JF3=KU(FZ .<EW0$FT3D4B7I)*FOWY)R6Y&J3WH9:R338JFGL;B
M/)+2^T=M[A=:W[,?=:7L)%H[MSD;C6RQ%C6W?^N-4/[(4IN:.U\TJY'=&,%+
MNQ;"U=4H&8]/1S67*OKP?M?7C1G!@G:B<%(K7QDJ[J1XM,_'0Y$]2"L7LI+N
M:1*UWRL1L5HJ6<N?HIQ$XXC9M7[\1QOY4RO'JWEA=%5-HK@[<">,D\5OU?,
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MJM"U8+?\1___Q/P0$PMBIAZ$=>WD;Z;8OUKZ+W>^U)C>Z,3L$)/KH:ZEZY3
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M6?>YQ.034$L! A0#%     @ [X-F5@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #O@V96@Q-XMNX
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ [X-F5MT'OV>/ @
MV @  !@              ("!>Q8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( .^#9E:-LG<GT00  "$3   8              " @4 9
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #O@V96 ;+@
M_;,(   <60  &               @(%''@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ [X-F5O%#29>3 @  E@<  !@
M ("!,"<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .^#
M9E:33GQ#XP8  (,=   8              " @?DI  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #O@V96Y'_@")0"  #?!@  &
M        @($2,0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( .^#9E9W-DN:X00  /P+   9              "
M@9ES  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ [X-F
M5OGR]GCV P  /0D  !D              ("!L7@  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #O@V96=^S7:OL.  !=,   &0
M        @('>?   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( .^#9E;R?%:D[@D  *<9   9              " @1",  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ [X-F5MFS'A!/!   ,PH
M !D              ("!-98  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #O@V96308_'D@#   A!P  &0              @(&[F@
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .^#9E99>I%3
MJ ,  ',)   9              " @3J>  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ [X-F5C$I$6OK*@  ^)4  !D
M ("!&:(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #O
M@V96\G*RJ<T"   X!@  &0              @($[S0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .^#9E;XG[)3)@0  +\*   9
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M970R-BYX;6Q02P$"% ,4    " #O@V96:...P:X"  #9!0  &0
M    @($RYP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M .^#9E:/'UH%4P0  " 4   9              " @1?J  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ [X-F5N_1&\R_"    $D  !D
M             ("!H>X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #O@V96"K+[O>H"   8"@  &0              @(&7]P  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .^#9E8]:TBK) 0
M %,5   9              " @;CZ  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ [X-F5OXZP/JV P  _P\  !D              ("!
M$_\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #O@V96
M+?M7?)8"  !\"   &0              @($  P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( .^#9E:"80%^F (  ,,%   9
M      " @<T% 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ [X-F5J,U#=0H P  U0H  !D              ("!G @! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #O@V96;V;CG>(#   ?#0
M&0              @('["P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( .^#9E9(Q(1>RP(   P)   9              " @100 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ [X-F5BBKL5/J
M @  J@D  !D              ("!%A,! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #O@V96_M$?+WT"  !C!@  &0
M@($W%@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .^#
M9E9SGES_R@,  #43   9              " @>L8 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ [X-F5C;%E^MH @  S04  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( /"#9E9ECI3AY00  ) 7   9
M  " @;(V 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M\(-F5GO)RZP?!   5A   !D              ("!SCL! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " #P@V96U]@9LZ #   ##   &0
M            @($D0 $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( /"#9E;:(MIK@ ,   T+   9              " @?M# 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ \(-F5GBTQ"(& P
M/ D  !D              ("!LD<! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " #P@V96I-&!H6D#  "Z"P  &0              @('O
M2@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( /"#9E9W
M;SOD<0,  %P*   9              " @8]. 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ \(-F5MOPWVU5 P  '@P  !D
M     ("!-U(! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
M" #P@V966U?N9UD"  "Q!0  &0              @('#50$ >&PO=V]R:W-H
M965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( /"#9E;@G72]" ,  .D(   9
M              " @5-8 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L!
M A0#%     @ \(-F5GTRM1T< P  .@H  !D              ("!DEL! 'AL
M+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #P@V96HN-+V3H#
M  #N$P  #0              @ 'E7@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( /"#9E:7BKL<P    !,"   +              "  4IB 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( /"#9E88O_'*8P0  ($E   /              "
M 3-C 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #P@V96##^0_.4!  !_
M(0  &@              @ '#9P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #P@V96C^&W:=,!   V(0  $P              @ '@
L:0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0 !  '<1  #D:P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>115</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheet (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>Consolidated Balance Sheet (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureBusiness1</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1</Role>
      <ShortName>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - License And Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements</Role>
      <ShortName>License And Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquity1</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Investment In Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVenture</Role>
      <ShortName>Investment In Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationTables</Role>
      <ShortName>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rallybio.com/20221231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Stockholder's Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholder's Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails</Role>
      <ShortName>Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Summary of Property and Equipment Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful</Role>
      <ShortName>Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Summary of Property and Equipment Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Marketable Securities - Summary of available-for-sale marketable securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of available-for-sale marketable securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Marketable Securities - Schedule of Available-for-Sale Securities by Balance Sheet Location Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails</Role>
      <ShortName>Marketable Securities - Schedule of Available-for-Sale Securities by Balance Sheet Location Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Marketable Securities - Schedule of Fair Values of Available-For-Sale Debt Securities By Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails</Role>
      <ShortName>Marketable Securities - Schedule of Fair Values of Available-For-Sale Debt Securities By Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Leases - Summary of Company's Operating Lease on the Condensed Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Leases - Summary of Company's Operating Lease on the Condensed Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Leases - Schedule of Future Minimum Annual Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Annual Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Leases - Schedule of Future Minimum Annual Lease Payments Adopting ASU 2016-02 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details</Role>
      <ShortName>Leases - Schedule of Future Minimum Annual Lease Payments Adopting ASU 2016-02 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Balance Sheet Components - Schedule Of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule Of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stockholders' Equity - Summary of Equity-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Equity-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stockholder's Equity - Summary of stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholder's Equity - Summary of stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stockholder's Equity - Summary of Assumptions of Fair Value of Option Pricing Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails</Role>
      <ShortName>Stockholder's Equity - Summary of Assumptions of Fair Value of Option Pricing Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stockholder's Equity - Summary of Nonvested Restricted Common Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails</Role>
      <ShortName>Stockholder's Equity - Summary of Nonvested Restricted Common Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stockholder's Equity - Summary of Nonvested Restricted Common Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails</Role>
      <ShortName>Stockholder's Equity - Summary of Nonvested Restricted Common Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Benefits and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Income Tax Benefits and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Investment In Joint Venture - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails</Role>
      <ShortName>Investment In Joint Venture - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Net Loss Per Common Share - Summary of Basic and diluted loss per common share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Summary of Basic and diluted loss per common share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rlyb-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Net Loss Per Common Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Common Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate -  rlyb-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="rlyb-20221231.htm">rlyb-20221231.htm</File>
    <File>rlyb-20221231.xsd</File>
    <File>rlyb-20221231_cal.xml</File>
    <File>rlyb-20221231_def.xml</File>
    <File>rlyb-20221231_lab.xml</File>
    <File>rlyb-20221231_pre.xml</File>
    <File>rlyb-ex10_24.htm</File>
    <File>rlyb-ex10_25.htm</File>
    <File>rlyb-ex21_1.htm</File>
    <File>rlyb-ex23_1.htm</File>
    <File>rlyb-ex31_1.htm</File>
    <File>rlyb-ex31_2.htm</File>
    <File>rlyb-ex32_1.htm</File>
    <File>rlyb-ex32_2.htm</File>
    <File>rlyb-ex4_4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img114804231_0.jpg</File>
    <File>img114804231_1.jpg</File>
    <File>img114804231_10.jpg</File>
    <File>img114804231_11.jpg</File>
    <File>img114804231_12.jpg</File>
    <File>img114804231_13.jpg</File>
    <File>img114804231_2.jpg</File>
    <File>img114804231_3.jpg</File>
    <File>img114804231_4.jpg</File>
    <File>img114804231_5.jpg</File>
    <File>img114804231_6.jpg</File>
    <File>img114804231_7.jpg</File>
    <File>img114804231_8.jpg</File>
    <File>img114804231_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="506">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rlyb-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 506,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 115,
   "dts": {
    "calculationLink": {
     "local": [
      "rlyb-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rlyb-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rlyb-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rlyb-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rlyb-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rlyb-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 516,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 6
   },
   "keyCustom": 38,
   "keyStandard": 271,
   "memberCustom": 28,
   "memberStandard": 25,
   "nsprefix": "rlyb",
   "nsuri": "http://rallybio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1",
     "shortName": "Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rlyb:LicenseAndCollaborationAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - License And Collaboration Agreements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements",
     "shortName": "License And Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rlyb:LicenseAndCollaborationAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquity1",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Investment In Joint Venture",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVenture",
     "shortName": "Investment In Joint Venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Net Loss Per Common Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rlyb:IpoAndReorganizationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies",
     "shortName": "Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rlyb:IpoAndReorganizationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rlyb:PropertyAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationTables",
     "shortName": "Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rlyb:PropertyAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Stockholder's Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholder's Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Net Loss Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_cb2bd404-8085-4064-9e41-d047d221dbff",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
     "shortName": "Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_cb2bd404-8085-4064-9e41-d047d221dbff",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_77017543-72b8-463e-b4d8-4744e243dddf",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rlyb:LiquidationCommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_77017543-72b8-463e-b4d8-4744e243dddf",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rlyb:LiquidationCommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheet (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical",
     "shortName": "Consolidated Balance Sheet (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_52dabac6-294d-46ca-a017-e4ded6aceebe",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Summary of Property and Equipment Estimated Useful Lives (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful",
     "shortName": "Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation - Summary of Property and Equipment Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_52dabac6-294d-46ca-a017-e4ded6aceebe",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "rlyb:LicenseAndCollaborationAgreementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_0419c87f-3e9a-4f46-8744-7ba8ebb85189",
      "decimals": "-5",
      "lang": null,
      "name": "rlyb:UpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Marketable Securities - Summary of available-for-sale marketable securities (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of available-for-sale marketable securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Marketable Securities - Schedule of Available-for-Sale Securities by Balance Sheet Location Classification (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails",
     "shortName": "Marketable Securities - Schedule of Available-for-Sale Securities by Balance Sheet Location Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rlyb:AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_739866d4-323a-4be2-8ffe-a4e8744c785c",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Marketable Securities - Schedule of Fair Values of Available-For-Sale Debt Securities By Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails",
     "shortName": "Marketable Securities - Schedule of Fair Values of Available-For-Sale Debt Securities By Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Marketable Securities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:LessorOperatingLeaseDescription",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:LessorOperatingLeaseDescription",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Leases - Summary of Company's Operating Lease on the Condensed Consolidated Balance Sheets (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails",
     "shortName": "Leases - Summary of Company's Operating Lease on the Condensed Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Leases - Schedule of Future Minimum Annual Lease Payments (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails",
     "shortName": "Leases - Schedule of Future Minimum Annual Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_a304c311-7529-4e1e-a84f-c3b32740f27f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Leases - Schedule of Future Minimum Annual Lease Payments Adopting ASU 2016-02 (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details",
     "shortName": "Leases - Schedule of Future Minimum Annual Lease Payments Adopting ASU 2016-02 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_a304c311-7529-4e1e-a84f-c3b32740f27f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rlyb:PrepaidResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Assets (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rlyb:PrepaidResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rlyb:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Balance Sheet Components - Schedule Of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails",
     "shortName": "Balance Sheet Components - Schedule Of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rlyb:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stockholders' Equity - Summary of Equity-based Compensation (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails",
     "shortName": "Stockholders' Equity - Summary of Equity-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_a304c311-7529-4e1e-a84f-c3b32740f27f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stockholder's Equity - Summary of stock option activity (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
     "shortName": "Stockholder's Equity - Summary of stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_97b56dc7-df26-44a2-b55c-c37821ed5567",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stockholder's Equity - Summary of Assumptions of Fair Value of Option Pricing Granted (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails",
     "shortName": "Stockholder's Equity - Summary of Assumptions of Fair Value of Option Pricing Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_97b56dc7-df26-44a2-b55c-c37821ed5567",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_eed08da7-0a3b-4480-a783-cde12cc17f8e",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stockholder's Equity - Summary of Nonvested Restricted Common Stock Awards (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
     "shortName": "Stockholder's Equity - Summary of Nonvested Restricted Common Stock Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_eed08da7-0a3b-4480-a783-cde12cc17f8e",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_283e6bfc-26b6-4abc-bae8-943016a346b1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stockholder's Equity - Summary of Nonvested Restricted Common Stock Units (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails",
     "shortName": "Stockholder's Equity - Summary of Nonvested Restricted Common Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_283e6bfc-26b6-4abc-bae8-943016a346b1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_7ec8e39c-7a88-422a-a74f-d98b410d67ed",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_7ec8e39c-7a88-422a-a74f-d98b410d67ed",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rates (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Benefits and Liabilities (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Income Tax Benefits and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_bd12daa8-050e-4026-94a2-6adc935a3816",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireInterestInJointVenture",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Investment In Joint Venture - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails",
     "shortName": "Investment In Joint Venture - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_91e37f8e-3f15-4cf1-a0ed-4b07ba1acb40",
      "decimals": "2",
      "lang": null,
      "name": "rlyb:PercentageOfInterestOfJointVentureEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rlyb:TerminationCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rlyb:TerminationCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Net Loss Per Common Share - Summary of Basic and diluted loss per common share (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails",
     "shortName": "Net Loss Per Common Share - Summary of Basic and diluted loss per common share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_17a4f0c1-9607-4df6-8818-c739af03c27b",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Net Loss Per Common Share - Additional Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
     "shortName": "Net Loss Per Common Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_17a4f0c1-9607-4df6-8818-c739af03c27b",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_6e128323-fbea-4fe5-84d7-e5c466f1a588",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_6e128323-fbea-4fe5-84d7-e5c466f1a588",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_4cb860dc-2e91-4270-b9a7-a8db4c05d220",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rlyb:UnderwritingDiscountsAndCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_4cb860dc-2e91-4270-b9a7-a8db4c05d220",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rlyb:UnderwritingDiscountsAndCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://rallybio.com/20221231/taxonomy/role/DisclosureBusiness1",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20221231.htm",
      "contextRef": "C_c71573e5-8d3b-4b6c-b9fc-bc75afb81a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 54,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rlyb_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_AggregateDevelopmentAndRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate development and regulatory milestone payments.",
        "label": "Aggregate Development and Regulatory Milestone Payments",
        "terseLabel": "Aggregate development and regulatory milestone payments"
       }
      }
     },
     "localname": "AggregateDevelopmentAndRegulatoryMilestonePayments",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_AggregatePurchasePriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Purchase Price Of Common Stock",
        "label": "Aggregate Purchase Price Of Common Stock",
        "terseLabel": "Aggregate purchase price of common stock"
       }
      }
     },
     "localname": "AggregatePurchasePriceOfCommonStock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_AssetAcquisitionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for asset acquisition.",
        "label": "Asset Acquisition [Policy Text Block]",
        "terseLabel": "Asset Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionPolicyTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_AssetAcquisitionTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition transaction costs incurred.",
        "label": "Asset Acquisition Transaction Costs",
        "terseLabel": "Transaction costs associated with asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionTransactionCosts",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_AtTheMarketSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market sale agreement.",
        "label": "At The Market Sale Agreement [Member]"
       }
      }
     },
     "localname": "AtTheMarketSaleAgreementMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities by balance sheet location classification.",
        "label": "Available For Sale Securities By Balance Sheet Location Classification [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities by Balance Sheet Location Classification"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_BusinessAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business And Liquidity [Abstract]",
        "label": "Business And Liquidity [Abstract]"
       }
      }
     },
     "localname": "BusinessAndLiquidityAbstract",
     "nsuri": "http://rallybio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "rlyb_CapitalizedSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Software [Member]",
        "label": "Capitalized Software [Member]",
        "terseLabel": "Capitalized software"
       }
      }
     },
     "localname": "CapitalizedSoftwareMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_CollaborationAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement Abstract.",
        "label": "Collaboration Agreement [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementAbstract",
     "nsuri": "http://rallybio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "rlyb_CommonStockAllocatedToCommonUnitHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Allocated to Common Unit Holders [Member]",
        "label": "Common Stock Allocated to Common Unit Holders [Member]",
        "terseLabel": "Common Stock Allocated to Common Unit Holders"
       }
      }
     },
     "localname": "CommonStockAllocatedToCommonUnitHoldersMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_CommonStockAllocatedToIncentiveUnitsHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Allocated To Incentive Units Holders [Member]",
        "label": "Common Stock Allocated To Incentive Units Holders [Member]",
        "terseLabel": "Common Stock Allocated To Incentive Units Holders"
       }
      }
     },
     "localname": "CommonStockAllocatedToIncentiveUnitsHoldersMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Allocated To Performance Based Incentive Common Unit Holders Member",
        "label": "Common Stock Allocated To Performance Based Incentive Common Unit Holders [Member]",
        "terseLabel": "Common Stock Allocated To Performance Based Incentive Common Unit Holders"
       }
      }
     },
     "localname": "CommonStockAllocatedToPerformanceBasedIncentiveCommonUnitHoldersMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Allocated To SeriesB Preferred Units Holders [Member]",
        "label": "Common Stock Allocated To SeriesB Preferred Units Holders [Member]",
        "terseLabel": "Common Stock Allocated To Series B Preferred Units Holders"
       }
      }
     },
     "localname": "CommonStockAllocatedToSeriesbPreferredUnitsHoldersMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_CommonStockCapitalSharesRemainedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Capital Shares Remained For Future Issuance.",
        "label": "Common Stock Capital Shares Remained For Future Issuance",
        "terseLabel": "Common shares remained for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesRemainedForFutureIssuance",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rlyb_CommonUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Units [Member]",
        "label": "Common Units [Member]",
        "terseLabel": "Common Units"
       }
      }
     },
     "localname": "CommonUnitsMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CommonStock Allocated to Series A1 And Series A2 Preferred Unit Holders [Member]",
        "label": "CommonStock Allocated to Series A1 And Series A2 Preferred Unit Holders [Member]",
        "terseLabel": "Common Stock Allocated to Series A-1 And Series A-2 Preferred Units Holders"
       }
      }
     },
     "localname": "CommonstockAllocatedToSeriesA1AndSeriesA2PreferredUnitHoldersMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible redeemable preferred units previously classified as mezzanine equity.",
        "label": "Convertible Redeemable Preferred Units Previously Classified as Mezzanine Equity [Member]",
        "terseLabel": "Convertible redeemable preferred units previously classified as mezzanine equity"
       }
      }
     },
     "localname": "ConvertibleRedeemablePreferredUnitsPreviouslyClassifiedAsMezzanineEquityMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_DeferredTaxAssetsOperatingLossCarriedBackDomestic": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating loss carried back domestic",
        "label": "Deferred Tax Assets Operating Loss Carried Back Domestic",
        "terseLabel": "Federal net operating loss carried back"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarriedBackDomestic",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_DeferredTaxAssetsSection174Capitalization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets section 174 capitalization",
        "label": "Deferred Tax Assets Section 174 Capitalization",
        "terseLabel": "Section 174 capitalization"
       }
      }
     },
     "localname": "DeferredTaxAssetsSection174Capitalization",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exceed limit percentage with exercise to aggregate shares of common stock beneficially owned.",
        "label": "Exceed Limit Percentage With Exercise To Aggregate Shares Of Common Stock Beneficially Owned"
       }
      }
     },
     "localname": "ExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rlyb_FederalOperatingLossCarryforwardsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Operating loss carryforwards expiration period.",
        "label": "Federal Operating Loss Carryforwards Expiration Period",
        "terseLabel": "Net federal operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "FederalOperatingLossCarryforwardsExpirationPeriod",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "rlyb_FollowOnOfferingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow on offering discounts and commissions.",
        "label": "Follow On Offering Discounts And Commissions",
        "terseLabel": "Follow on offering discounts and commissions"
       }
      }
     },
     "localname": "FollowOnOfferingDiscountsAndCommissions",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on offering.",
        "label": "follow-on offering [MEMBER]",
        "terseLabel": "Follow-On Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow on public offering.",
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Total Follow-On Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_FundAssociatedWithDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund Associated with Development Costs",
        "label": "Fund Associated with Development Costs",
        "terseLabel": "Fund associated with development costs"
       }
      }
     },
     "localname": "FundAssociatedWithDevelopmentCosts",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_IncentiveUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive units [Member]",
        "label": "Incentive units [Member]",
        "terseLabel": "Incentive Units"
       }
      }
     },
     "localname": "IncentiveUnitsMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_IncreasingOwnershipPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increasing ownership percent.",
        "label": "Increasing Ownership Percent",
        "terseLabel": "Increasing ownership percent"
       }
      }
     },
     "localname": "IncreasingOwnershipPercent",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rlyb_InitialInvestmentInJointVenture": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Investment in Joint Venture.",
        "label": "Initial Investment in Joint Venture",
        "terseLabel": "Initial investment in joint venture"
       }
      }
     },
     "localname": "InitialInvestmentInJointVenture",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_InitialPaymentInInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial payment in investment.",
        "label": "Initial Payment In Investment",
        "terseLabel": "Initial payment made in investment"
       }
      }
     },
     "localname": "InitialPaymentInInvestment",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_InitialPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering.",
        "label": "Initial Public Offering [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "InitialPublicOfferingMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_IpoAndReorganizationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO and reorganization.",
        "label": "IPO And Reorganization [Policy Text Block]",
        "terseLabel": "IPO and Reorganization"
       }
      }
     },
     "localname": "IpoAndReorganizationPolicyPolicyTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_LeaseCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commitments.",
        "label": "Lease Commitments Member",
        "terseLabel": "Lease Commitments [Member]"
       }
      }
     },
     "localname": "LeaseCommitmentsMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year three.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Three",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_LicenseAndCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License and collaboration agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "nsuri": "http://rallybio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "rlyb_LicenseAndCollaborationAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of License and collaboration agreements.",
        "label": "License and Collaboration Agreements Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsDisclosureTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_LicenseAndCollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License and Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rlyb_LicenseRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License rights.",
        "label": "License Rights [Member]",
        "terseLabel": "License Rights"
       }
      }
     },
     "localname": "LicenseRightsMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_LiquidationCommonStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidation common stock shares issued.",
        "label": "Liquidation Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued on liquidation"
       }
      }
     },
     "localname": "LiquidationCommonStockSharesIssued",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rlyb_LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Ability to Continue as a Going Concern [Policy Text Block]",
        "label": "Liquidity and Ability to Continue as a Going Concern [Policy Text Block]",
        "terseLabel": "Liquidity and Ability to Continue as a Going Concern"
       }
      }
     },
     "localname": "LiquidityAndAbilityToContinueAsAGoingConcernPolicyTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligation to payment upon maximum achievement of certain clinical and commercial milestones",
        "label": "Obligation To Payment Upon Maximum Achievement Of Certain Clinical And Commercial Milestones",
        "terseLabel": "Obligation to payment upon maximum achievement of certain clinical and commercial milestones"
       }
      }
     },
     "localname": "ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_OfferingCostsInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Costs In Accounts Payable And Accrued Expenses",
        "label": "Offering costs in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "OfferingCostsInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_OperatingLeasesFutureMinimumPayments": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases future minimum payments",
        "label": "Operating Leases Future Minimum Payments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPayments",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details": {
       "order": 0.0,
       "parentTag": "rlyb_OperatingLeasesFutureMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Future Minimum Payments Due After Year Four",
        "label": "Operating Leases Future Minimum Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAfterYearFour",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards limitations on use percentage of taxable income",
        "label": "Operating Loss Carry Forwards Limitations On Use Percentage Of Taxable Income",
        "terseLabel": "Operating loss carryforwards limitations on use percentage of taxable income"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsLimitationsOnUsePercentageOfTaxableIncome",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rlyb_OverAllotmentOnFollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over allotment on follow-on offering.",
        "label": "Over Allotment On Follow On Offering [Member]",
        "terseLabel": "Over Allotment On Follow-On Offering"
       }
      }
     },
     "localname": "OverAllotmentOnFollowOnOfferingMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_OverAllotmentOnInitialPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over allotment on IPO.",
        "label": "Over Allotment On Initial Public Offering [Member]",
        "terseLabel": "Over Allotment On Initial Public Offering"
       }
      }
     },
     "localname": "OverAllotmentOnInitialPublicOfferingMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parent ownership percentage of all subsidiaries the parent elect to include in consolidated federal income tax return following reorganization.",
        "label": "Parent Ownership Percentage of All Subsidiaries The Parent Elect To Include In Consolidated Federal Income Tax Return Following Reorganization",
        "terseLabel": "Subsidiaries, ownership percentage"
       }
      }
     },
     "localname": "ParentOwnershipPercentageOfAllSubsidiariesTheParentElectToIncludeInConsolidatedFederalIncomeTaxReturnFollowingReorganization",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rlyb_ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parent ownership percentage of LLCs that elect to be treated as corporation and filed separate US federal tax return prior to reorganization.",
        "label": "Parent Ownership Percentage of LLCs That Elect To Be Treated As Corporation and Filed Separate US Federal Tax Return Prior To Reorganization",
        "terseLabel": "Ownership percentage by parent"
       }
      }
     },
     "localname": "ParentOwnershipPercentageOfLlcsThatElectToBeTreatedAsCorporationAndFiledSeparateUsFederalTaxReturnPriorToReorganization",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rlyb_PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate number of shares of common stock beneficially owned.",
        "label": "Percentage Of Aggregate Number Of Shares Of Common Stock Beneficially Owned",
        "terseLabel": "Percentage of common stock beneficially owned"
       }
      }
     },
     "localname": "PercentageOfAggregateNumberOfSharesOfCommonStockBeneficiallyOwned",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rlyb_PercentageOfCommonStockBeneficiallyOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock beneficially owned",
        "label": "Percentage Of Common Stock Beneficially Owned",
        "terseLabel": "Percentage of common stock beneficially owned"
       }
      }
     },
     "localname": "PercentageOfCommonStockBeneficiallyOwned",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rlyb_PercentageOfCommonStockBeneficiallyOwnedNotExceed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock beneficially owned not exceed.",
        "label": "Percentage of Common Stock Beneficially Owned Not Exceed",
        "terseLabel": "Percentage of common stock beneficially owned not exceed"
       }
      }
     },
     "localname": "PercentageOfCommonStockBeneficiallyOwnedNotExceed",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rlyb_PercentageOfInterestOfJointVentureEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of interest of the joint venture entity",
        "label": "Percentage of Interest of Joint Venture Entity",
        "terseLabel": "Percentage of interest of joint venture entity"
       }
      }
     },
     "localname": "PercentageOfInterestOfJointVentureEntity",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rlyb_PerformanceBasedIncentiveCommonUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based Incentive Common Units [Member]",
        "label": "Performance Based Incentive Common Units [Member]",
        "terseLabel": "Performance Based Incentive Common Units"
       }
      }
     },
     "localname": "PerformanceBasedIncentiveCommonUnitsMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Of Notice Days Affects Exceed Limit Percentage With Exercise To Aggregate Shares Of Common Stock Beneficially Owned",
        "label": "Period Of Notice Days Affects Exceed Limit Percentage With Exercise To Aggregate Shares Of Common Stock Beneficially Owned",
        "terseLabel": "Days of notice"
       }
      }
     },
     "localname": "PeriodOfNoticeDaysAffectsExceedLimitPercentageWithExerciseToAggregateSharesOfCommonStockBeneficiallyOwned",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rlyb_PreFundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrant.",
        "label": "Pre-Funded Warrant [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_PreferredUnitsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Units [Policy Text Block]",
        "label": "Preferred Units [Policy Text Block]",
        "terseLabel": "Preferred Units"
       }
      }
     },
     "localname": "PreferredUnitsPolicyTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_PrepaidResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development expenses.",
        "label": "Prepaid Research and Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_PriorToIpoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior to IPO.",
        "label": "Prior to IPO [Member]",
        "terseLabel": "Prior to IPO"
       }
      }
     },
     "localname": "PriorToIpoMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and pre funded warrants under follow on public offering.",
        "label": "Proceeds From Issuance of Common Stock and Pre Funded Warrants Under Follow On Public Offering",
        "terseLabel": "Proceeds from the issuance of common stock and pre-funded warrants upon the completion of the follow-on offering, net of underwriting discounts and commissions of $3,289"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsUnderFollowOnPublicOffering",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from the issuance of common stock under follow on public offering.",
        "label": "Proceeds From The Issuance Of Common Stock Under Follow On Public Offering",
        "terseLabel": "Proceeds From The Issuance Of Common Stock Under Follow On Public Offering"
       }
      }
     },
     "localname": "ProceedsFromTheIssuanceOfCommonStockUnderFollowOnPublicOffering",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_PropertyAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and Equipment Useful Lives [Table Text Block]",
        "label": "Property and Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment useful lives [Table text block]",
        "label": "Property Plant and Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering.",
        "label": "Public Offering [Member]"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_ReVenturesILlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RE Ventures I, LLC.",
        "label": "RE Ventures I, LLC [Member]",
        "terseLabel": "RE Ventures I, LLC"
       }
      }
     },
     "localname": "ReVenturesILlcMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently Issued Accounting Pronouncement Policy [Policy Text Block]",
        "label": "Recently Issued Accounting Pronouncement, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementPolicyPolicyTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Awards Granted Prior To IPO And Liquidation [Member]",
        "label": "Restricted Stock Awards Granted Prior To IPO And Liquidation [Member]",
        "terseLabel": "Restricted Stock Awards Granted Prior To IPO And Liquidation"
       }
      }
     },
     "localname": "RestrictedStockAwardsGrantedPriorToIpoAndLiquidationMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_RestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards.",
        "label": "Restricted Stock Awards [Member]",
        "terseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockAwardsMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_RestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units.",
        "label": "Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_SanofiAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "sanofi agreement.",
        "label": "Sanofi Agreement [Member]",
        "terseLabel": "Sanofi Agreement"
       }
      }
     },
     "localname": "SanofiAgreementMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi .",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_ScheduleOfLicenseAndCollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of license and collaboration agreements.",
        "label": "Schedule of License and Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfLicenseAndCollaborationAgreementsTable",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rlyb_ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share Based Payment Award Restricted Common Shares Valuation Assumptions Table [TextBlock].",
        "label": "Schedule Of Share Based Payment Award Restricted Common Shares Valuation Assumptions Table [TextBlock]",
        "terseLabel": "Summary of Assumptions of Fair Value of Restricted Common Shares Pricing Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardRestrictedCommonSharesValuationAssumptionsTableTextblock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_SeriesA1AndA2FinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A1 and A2 financing.",
        "label": "Series A1 And A2 Financing Member",
        "terseLabel": "Series A-1 and A-2 Financing [Member]"
       }
      }
     },
     "localname": "SeriesA1AndA2FinancingMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_SeriesA1AndA2RedeemableConvertiblePreferredUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 and A-2 redeemable convertible preferred unit.",
        "label": "Series A-1 and A-2 Redeemable Convertible Preferred Unit [Member]",
        "terseLabel": "Series A-1 and A-2 Redeemable Convertible Preferred Units"
       }
      }
     },
     "localname": "SeriesA1AndA2RedeemableConvertiblePreferredUnitMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible redeemable preferred units common units and incentive units previously classified as mezzanine equity.",
        "label": "Series B Convertible Redeemable Preferred Units Common Units And Incentive Units Previously Classified As Mezzanine Equity [Member]",
        "terseLabel": "Series B Convertible Redeemable Preferred Unit Common Units And Incentive Units Previously Classified As Mezzanine Equity"
       }
      }
     },
     "localname": "SeriesBConvertibleRedeemablePreferredUnitCommonUnitsAndIncentiveUnitsPreviouslyClassifiedAsMezzanineEquityMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Redeemable Preferred Unit Previously Classified As Mezzanine Equity.",
        "label": "Series B Convertible Redeemable Preferred Unit Previously Classified As Mezzanine Equity [Member]"
       }
      }
     },
     "localname": "SeriesBConvertibleRedeemablePreferredUnitPreviouslyClassifiedAsMezzanineEquityMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_SeriesBFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B financing.",
        "label": "Series B Financing Member",
        "terseLabel": "Series B Financing [Member]"
       }
      }
     },
     "localname": "SeriesBFinancingMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_SeriesBRedeemableConvertiblePreferredUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Redeemable Convertible Preferred unit.",
        "label": "Series B Redeemable Convertible Preferred Unit [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Units"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredUnitMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase In Number Of Shares Minimum",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase In Number Of Shares Minimum",
        "terseLabel": "Common stock shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesMinimum",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rlyb_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, shares issuable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issuable",
        "terseLabel": "Common stock issuable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuable",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rlyb_StateOperatingLossCarryforwardsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State operating loss carryforwards expiration period.",
        "label": "State Operating Loss Carryforwards Expiration Period",
        "terseLabel": "Net state operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "StateOperatingLossCarryforwardsExpirationPeriod",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and pre funded warrants issued during period shares new issues.",
        "label": "Stock and Pre Funded Warrants Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock and pre-funded warrants upon completion of the follow-on offering, net of underwriting discounts and commissions and offering costs (in shares)"
       }
      }
     },
     "localname": "StockAndPreFundedWarrantsIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "sharesItemType"
    },
    "rlyb_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and pre funded warrants issued during period value new issues.",
        "label": "Stock and Pre Funded Warrants Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock and pre-funded warrants upon completion of the follow-on offering, net of underwriting discounts and commissions and offering costs"
       }
      }
     },
     "localname": "StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_StockIssuedDuringPeriodSharesVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares vested.",
        "label": "Stock Issued During Period Shares Vested",
        "terseLabel": "Issuance of common stock from the stock award plan, vested (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVested",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "sharesItemType"
    },
    "rlyb_StockOptionsAndUnvestedRestrictedShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and unvested restricted share.",
        "label": "Stock Options And Unvested Restricted Share Member",
        "terseLabel": "Stock Options And Unvested Restricted Share"
       }
      }
     },
     "localname": "StockOptionsAndUnvestedRestrictedShareMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_StockWarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for stock warrants",
        "label": "Stock Warrants [Policy Text Block]",
        "terseLabel": "Stock Warrants"
       }
      }
     },
     "localname": "StockWarrantsPolicyTextBlock",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rlyb_TerminationCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination charges.",
        "label": "Termination Charges",
        "terseLabel": "Termination charges"
       }
      }
     },
     "localname": "TerminationCharges",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_TwoThousandAndTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Equity incentive plan.",
        "label": "Two Thousand and Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee stock purchase plan.",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rlyb_UnderwritingCommissionsAndDiscounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Commissions And Discounts",
        "label": "Underwriting commissions and discounts"
       }
      }
     },
     "localname": "UnderwritingCommissionsAndDiscounts",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting commissions and discounts of follow on public offering.",
        "label": "Underwriting Commissions And Discounts Of Follow On Public Offering",
        "terseLabel": "Underwriting commissions and discounts of follow on public offering"
       }
      }
     },
     "localname": "UnderwritingCommissionsAndDiscountsOfFollowOnPublicOffering",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_UnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions.",
        "label": "Underwriting Discounts And Commissions",
        "terseLabel": "IPO Underwriting discounts and commissions"
       }
      }
     },
     "localname": "UnderwritingDiscountsAndCommissions",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rlyb_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://rallybio.com/20221231",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r327",
      "r451",
      "r468",
      "r488",
      "r489",
      "r506",
      "r511",
      "r516",
      "r561",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r327",
      "r451",
      "r468",
      "r488",
      "r489",
      "r506",
      "r511",
      "r516",
      "r561",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "auth_ref": [
      "r475",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "auth_ref": [
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r249",
      "r452",
      "r507",
      "r515",
      "r556",
      "r557",
      "r563",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r249",
      "r452",
      "r507",
      "r515",
      "r556",
      "r557",
      "r563",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r320",
      "r327",
      "r353",
      "r354",
      "r355",
      "r427",
      "r451",
      "r468",
      "r488",
      "r489",
      "r506",
      "r511",
      "r516",
      "r555",
      "r561",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r320",
      "r327",
      "r353",
      "r354",
      "r355",
      "r427",
      "r451",
      "r468",
      "r488",
      "r489",
      "r506",
      "r511",
      "r516",
      "r555",
      "r561",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r514"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Compensation and related expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r71",
      "r172"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "terseLabel": "Less accumulated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r178",
      "r463",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r20",
      "r115",
      "r420",
      "r469",
      "r470",
      "r535",
      "r536",
      "r537",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r514"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r541",
      "r542",
      "r543",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "verboseLabel": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r104",
      "r105",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r80",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r30",
      "r40",
      "r133",
      "r300"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Net accretion of discounts/premiums on debt securities"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "totalLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "ANTIDILUTIVE UNITS"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of Real Estate Property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r137",
      "r148",
      "r174",
      "r197",
      "r237",
      "r245",
      "r247",
      "r261",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r391",
      "r393",
      "r401",
      "r514",
      "r559",
      "r560",
      "r604"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r168",
      "r181",
      "r197",
      "r261",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r391",
      "r393",
      "r401",
      "r514",
      "r559",
      "r560",
      "r604"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "negatedLabel": "Gross unrealized gains",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r252",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized cost",
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r60",
      "r254",
      "r461"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through two years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r546",
      "r547",
      "r615"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total available-for-sale debt securities by contractual maturity"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r60",
      "r253",
      "r460"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValuesOfAvailableforsaleDebtSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r57",
      "r251",
      "r272",
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Fair value",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidation1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r170",
      "r495"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash And Cash Equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r37",
      "r42",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents - end of year",
        "periodStartLabel": "Cash and cash equivalents - beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r37",
      "r42",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents - end of year",
        "periodStartLabel": "Cash and cash equivalents - beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r37",
      "r132"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r197",
      "r215",
      "r216",
      "r218",
      "r220",
      "r227",
      "r228",
      "r261",
      "r290",
      "r292",
      "r293",
      "r294",
      "r297",
      "r298",
      "r302",
      "r303",
      "r306",
      "r310",
      "r317",
      "r401",
      "r490",
      "r528",
      "r538",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Pre-funded warrants exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of securities called by warrants or rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r387",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENT"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCollaborationAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r140",
      "r153"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r284",
      "r285",
      "r476",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserve issued to founders",
        "verboseLabel": "Common shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r541",
      "r542",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Number of shares of the Company's common stock"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r514"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, value",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r184",
      "r186",
      "r193",
      "r457",
      "r465"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Comprehensive loss",
        "verboseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer and Other Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r147",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction In Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r540",
      "r596",
      "r597"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r111",
      "r374",
      "r380",
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current Income Tax Expense (Benefit), Total",
        "totalLabel": "Current Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r258",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Continuous unrealized loss position for more than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Marketable Securities by Type of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r257",
      "r273",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Aggregate fair value of available-for-sale debt securities in an unrealized loss position",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r110",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r594"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance, Total",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r110",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r110",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r110",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r110",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "terseLabel": "Less valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r40",
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r40",
      "r69"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r213",
      "r215",
      "r218",
      "r219",
      "r220",
      "r224",
      "r398",
      "r399",
      "r458",
      "r466",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share,basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r215",
      "r218",
      "r219",
      "r220",
      "r224",
      "r398",
      "r399",
      "r458",
      "r466",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share,diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Tax Rate",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r198",
      "r365",
      "r381"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r592",
      "r598"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r592",
      "r598"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r592",
      "r598"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal income tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r592",
      "r598"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Total share based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense, restricted stock awards",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Total unrecognized compensation costs, weighted average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense, restricted stock units"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r80",
      "r165",
      "r188",
      "r189",
      "r190",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r212",
      "r226",
      "r263",
      "r319",
      "r359",
      "r360",
      "r361",
      "r376",
      "r377",
      "r397",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r420",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investment In Joint Venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVenture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r36",
      "r63",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r126",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r299",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r400",
      "r424",
      "r425",
      "r426",
      "r504",
      "r505",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r299",
      "r321",
      "r326",
      "r400",
      "r424",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r299",
      "r321",
      "r326",
      "r400",
      "r425",
      "r504",
      "r505",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r299",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r424",
      "r425",
      "r426",
      "r504",
      "r505",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r276",
      "r277",
      "r301",
      "r315",
      "r395",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r502",
      "r549",
      "r550",
      "r551",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "auth_ref": [
      "r54",
      "r179",
      "r264",
      "r266",
      "r267",
      "r492",
      "r493",
      "r494",
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Financing Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Financing Receivable, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Total IPO",
        "verboseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r40",
      "r68",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r23",
      "r135",
      "r142",
      "r156",
      "r237",
      "r244",
      "r246",
      "r248",
      "r459",
      "r501"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss from continuing operations",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r24",
      "r40",
      "r62",
      "r141",
      "r154",
      "r235"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss on investment in joint venture",
        "terseLabel": "Allocable share of losses recorded",
        "totalLabel": "Income (Loss) from Equity Method Investments, Total",
        "verboseLabel": "Loss on investment in joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r198",
      "r366",
      "r368",
      "r373",
      "r378",
      "r382",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority.",
        "label": "Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority",
        "terseLabel": "Federal or state and local income tax returns"
       }
      }
     },
     "localname": "IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r593"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Income tax examination, Penalties and Interest Accrued",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax examination, Penalties and Interest Expense",
        "totalLabel": "Income Tax Examination, Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r199",
      "r211",
      "r212",
      "r236",
      "r364",
      "r379",
      "r383",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "verboseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r187",
      "r362",
      "r363",
      "r368",
      "r369",
      "r372",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization": {
     "auth_ref": [
      "r592"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxBenefitsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r592"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "Outstanding U.S federal income tax or material state and local tax"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and operating lease liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, right-of-use assets and other assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest income",
        "totalLabel": "Interest and Other Income, Total"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r134",
      "r144",
      "r191",
      "r234",
      "r409"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Values of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investment in joint venture",
        "totalLabel": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r136",
      "r146",
      "r157",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leashold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Annual Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments",
        "totalLabel": "Total lease payments",
        "verboseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed discount rate",
        "terseLabel": "Less: imputed discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeaseDescription": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessor's operating lease.",
        "label": "Lessor, Operating Lease, Description",
        "terseLabel": "Lessor Operating Lease Description"
       }
      }
     },
     "localname": "LessorOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r197",
      "r261",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r392",
      "r393",
      "r394",
      "r401",
      "r500",
      "r559",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r139",
      "r151",
      "r514",
      "r539",
      "r552",
      "r602"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and members' deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r169",
      "r197",
      "r261",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r392",
      "r393",
      "r394",
      "r401",
      "r514",
      "r559",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "negatedLabel": "Net unrealized loss on marketable securities",
        "terseLabel": "Net unrealized loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows used in Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r37",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r41",
      "r143",
      "r155",
      "r167",
      "r182",
      "r185",
      "r190",
      "r197",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r217",
      "r237",
      "r244",
      "r246",
      "r248",
      "r261",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r399",
      "r401",
      "r501",
      "r559"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of Nonvested Restricted Common Stock",
        "verboseLabel": "Summary of Nonvested Restricted Common Stock Awards"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r237",
      "r244",
      "r246",
      "r248",
      "r501"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Carrying value of operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r412",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfCompanysOperatingLeaseOnTheCondensedConsolidatedBalanceSheetsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r416",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r415",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r161",
      "r163"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details": {
       "order": 2.0,
       "parentTag": "rlyb_OperatingLeasesFutureMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r161",
      "r163"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details": {
       "order": 1.0,
       "parentTag": "rlyb_OperatingLeasesFutureMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r161",
      "r163"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details": {
       "order": 3.0,
       "parentTag": "rlyb_OperatingLeasesFutureMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r161",
      "r163"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details": {
       "order": 4.0,
       "parentTag": "rlyb_OperatingLeasesFutureMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumAnnualLeasePaymentsAdoptingAsu201602Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "terseLabel": "Summary of Company's Operating Lease on the Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r76",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusiness1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Noncurrent",
        "terseLabel": "Accrued expenses, noncurrent"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r180",
      "r514"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r80",
      "r183",
      "r186",
      "r192",
      "r402",
      "r407",
      "r408",
      "r456",
      "r464",
      "r535",
      "r536"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expenses):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r532",
      "r553"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaids"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of offering costs",
        "terseLabel": "Payments of offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Joint venture investment payments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "negatedLabel": "Investment in joint venture",
        "terseLabel": "Investment in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "terseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r514"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, value",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets",
        "totalLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r496",
      "r503",
      "r553"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from the issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions of $6,488"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock",
        "terseLabel": "Proceeds from the issuance of common stock from exercise of stock options",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r102"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the issuance of common stock from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from the issuance of common stock from the stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r70",
      "r171"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r72",
      "r152",
      "r462",
      "r514"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r1",
      "r138",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r1",
      "r138",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r106",
      "r158",
      "r612"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r87",
      "r150",
      "r472",
      "r474",
      "r514"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r165",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r212",
      "r263",
      "r359",
      "r360",
      "r361",
      "r376",
      "r377",
      "r397",
      "r469",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds",
        "verboseLabel": "Sale of stock consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAvailableforsaleSecuritiesByBalanceSheetLocationClassificationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Share-Based Compensation for Stock Options, Restricted Stock Awards and Restricted Stock Units and the Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Income Tax Benefits and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Basic and Diluted Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r100",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquitybasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r64",
      "r167",
      "r197",
      "r261",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureInvestmentInJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Nonvested Restricted Common Stock",
        "verboseLabel": "Summary of Nonvested Restricted Common Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationSummaryOfPropertyAndEquipmentEstimatedUseful"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee stock purchase plan activity.",
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "Share-Based Compensation for Stock Options, Restricted Stock Awards and Restricted Stock Units and the Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r93",
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions of Fair Value of Option Pricing Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r175",
      "r176",
      "r177",
      "r227",
      "r302",
      "r303",
      "r304",
      "r306",
      "r310",
      "r315",
      "r317",
      "r506",
      "r528",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r530",
      "r531",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Units"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r530",
      "r531",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Units"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Shares forfeited",
        "terseLabel": "Shares forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, shares forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted common shares granted",
        "verboseLabel": "Shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, shares granted",
        "verboseLabel": "Weighted average grant date fair value, shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance",
        "periodStartLabel": "Outstanding, beginning balance",
        "terseLabel": "Restricted units unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, ending balance",
        "periodStartLabel": "Weighted average grant date fair value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Shares vested",
        "terseLabel": "Restricted common units fully vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, shares vested",
        "verboseLabel": "Weighted average grant date fair value, shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "No of shares increased"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, end of period - weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Options expired - shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Options forfeited - shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted - shares",
        "verboseLabel": "Common shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Options outstanding, end of period - aggregate intrinsic value",
        "periodStartLabel": "Options outstanding, beginning of period - aggregate intrinsic value",
        "terseLabel": "Options outstanding, end of period - aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, number, ending balance",
        "periodStartLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, number, beginning balance",
        "terseLabel": "Shares Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, end of period - weighted average exercise price per share",
        "periodStartLabel": "Options outstanding, beginning of period - weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockAwardsDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonvestedRestrictedCommonStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised - weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options expired - weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited - weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted - weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsOfFairValueOfOptionPricingGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, end of period - aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, end of period - weighted average remaining contractual term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, end of period - weighted average remaining contractual term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock price per share",
        "verboseLabel": "Pre-funded warrants purchase price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Existing units of shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r197",
      "r215",
      "r216",
      "r218",
      "r220",
      "r227",
      "r228",
      "r261",
      "r290",
      "r292",
      "r293",
      "r294",
      "r297",
      "r298",
      "r302",
      "r303",
      "r306",
      "r310",
      "r317",
      "r401",
      "r490",
      "r528",
      "r538",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r80",
      "r165",
      "r188",
      "r189",
      "r190",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r212",
      "r226",
      "r263",
      "r319",
      "r359",
      "r360",
      "r361",
      "r376",
      "r377",
      "r397",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r420",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r226",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetParenthetical",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r2",
      "r3",
      "r80",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock from the stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r80",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions and offering costs (in shares)",
        "verboseLabel": "Stock issued during period, shares, new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r2",
      "r3",
      "r80",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Forfeiture of restricted common stock, shares",
        "terseLabel": "Forfeiture of restricted common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r80",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r80",
      "r87",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Options exercised - shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r2",
      "r3",
      "r80",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock from the stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r80",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon completion of the initial public offering, net of underwriting discounts and commissions and offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r80",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r55",
      "r514",
      "r539",
      "r552",
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Stockholders' Equity Attributable to Parent, Total"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r112",
      "r113",
      "r119",
      "r165",
      "r166",
      "r189",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r263",
      "r319",
      "r359",
      "r360",
      "r361",
      "r376",
      "r377",
      "r397",
      "r402",
      "r403",
      "r408",
      "r420",
      "r470",
      "r471",
      "r539",
      "r552",
      "r602"
     ],
     "calculation": {
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance",
        "periodStartLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r196",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r319",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquity1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBusinessAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity1",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r255",
      "r256",
      "r301",
      "r315",
      "r395",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r549",
      "r550",
      "r551",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r498",
      "r508",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r498",
      "r508",
      "r510",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U S Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Income tax penalties and interest accrued",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r229",
      "r230",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r214",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted-average common shares outstanding,diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r213",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding,basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted-average common shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://rallybio.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareSummaryOfBasicAndDilutedLossPerCommonShareDetails",
      "http://rallybio.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1405",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r518": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r519": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r522": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r524": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r525": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r526": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r527": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0000950170-23-006264-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-006264-xbrl.zip
M4$L#!!0    ( /"#9E8^PG]^76$  /J    2    :6UG,3$T.# T,C,Q7S N
M:G!GW+L'6%-9US]Z0D)"[Q%"#0*"($@1"4U I(E25$ Z"(B 0.A-BB!%C%0!
M"])$JE*4*B!5FG01D"*A24=Z+_?$><N,,_.],^_]W^>YWW_[;-V>[)RLO?8J
MO[7VVD<#1WB YJ*RFC( (8( S> ?X&B<XKJ:HJ*IUA5-9;5+2@ $ @ 4JI=L
M'!R): # WL'5^8K*>?1U?0,TH@,@ D@!." " .86+MC+5Y6O 6!34U)$NX"3
M@-^TS3X 0OCWDZ"J%AH-_+U&:X%U=@4 B!8X%K.T<K$ Q_? \6T/5RSA^3(X
M9KAA1Q@3P0AC9Y! <,Q$&%O_,C[U8\XO8WG"V-+>P1(<$VC&6MI;$L8-X#C,
MW<T*'$,O@>,0=QLK#W#<"XZY;[O9VX#C;<)W[:W,70  1D%X[FIE<0L<"X-C
M"N=K5Q3!L0P D%!8_VI\XU=C5RM/5\*B%!VQ7LXVUK=<T7P6)]$BDI(8M*J5
MQVTK5U=!+7,+.W-G2[2BHSW6W,$+ 'Y9\X]&1^ M&F3R61')LV<%185$?L6H
M__'#O]@(>_O+:$W[QYY!CK7]^]D?S7-, P#,!LB;J'\_N_$$ $J# 8!I\-_/
MN%, @!K<MY+.7ZWG&$%>;KFZ8J5.G_;P\!"RL;(0(C#T7^T_3O@+[5>_)T1X
MW;_8@[Y@==/<[;8KFL W"\?;CF[.:!>LN8456O!G(?ZOO_C'=)RZ8G73RMG*
M ?R&+BAE-@[6X'8[6-JXVC@ZH&T<_FP3_\NO_=1^D6NPT:<? @RF0@!-)P,
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M_<F=FOSD;CL-QTT"ZL+Y7MW[2Z#E"Y=^7'2O: $Z4)1$AD9ACE(J',"[189
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MX8(=920C)V,_$-NRI-:)!U#%W607I:JN+X!"9PM1DL(,WKRF=*I-'J"(T00
MJ5AC^#.\H*$V!'<>B8ZZ*4V-8!J$8/URX')DEU]6%+ N(D>&]OGCHE#Y2-/$
MX+!W$9[UQZYX;B)Y]_F3=_U 8\9Q\"9SL+[,",^7=P0<(C4/Y/PGJ0^_Z$N8
M4A;;N5$D7<O$#,:81?I_A8'>]GPV8R^50?C3N0Z?8Z0RFBRT46P765T[F*@P
M6;8UA"0P7^7R_.%LZ04CL0:_>:>@H,!K$V7KJ&:F5]XGSR3AJ*V703MS:O]"
M\CO[-_<H5C@J*_%X/!RU)*N,U1"X4<G\1PX@:UNE\7[^-_* PF&**/AYS/SJ
M9&R4%&XO8KONI9"Q;IU4.+@;A.P*]"<3:MWW6POZ:G?!\+0"(6%-SNP[.B"4
M4C94T?I48BC1V@[>B'5*]-:KZ _0>[NM?O6PKV=Q2C"!M'!U;\CY3GKA?#P@
M<:YJMT^\KPU5"$8_1+_+)*PEAR=<7!N4APQ'-T]NUD>]6-FA\B=;MUW)9YI3
MSYDKI6N<BJ()4VNN S(=2%G4+7%N'3Y]CW2F_)II'X#&6O7W'IL_Z:'#9OS9
M@F;A64>R@F8,?P!M=)-!N9&SA_T.00;ESZH=0UJ[D^60<B<"".X8;XB)TO@1
MP* ^3AX8/E#ZL#/^!?HL9HU*7I(K0P4:><7CD-LS\M <F[ST9+5ZZ1T?[QJ&
M/7$#6:.[GNKHM1_R#]-)$.V2HF026^]:..8B)[ 3$W@_D!1F:76W:3FHUSK\
M\LOW 3>ZC0]"ZSK+^CU,*F)X=B?H)/":+8O?#3B6<]<[=^9!'.?;= 0TSK%=
MSTMU:>/+!^UFL&F&?Z=AY-Z2W*&$?FDRV0#B;+]9XOZ#XV86LN39,G>'3_,6
MI.H\F&/$\ L8ZBZ7O$@+W*)Y'A#][215(@V$V[?+6:2,R.[$ZS.;O:!>9_PK
M'/O95[<)?/H1L8J:[N[Y'S"R61N.[01)@SM4?N]_U4FSCJSIY<LW.NSTJ6#W
M<:M8%?X!F#4,BEOKR=-6KO%DB"XZU3RG\RA*@0D=08)>/_[,V+3!E_NZ+9&K
M$4^=@YPKM8@&!^#RR89[@WMMME7/TE14LPR4L SHB^A4*]<;K])I%&IASB1<
MJ<@E*>7TIQ\2);1QI/2827P$REF^@X0+,_W:T\J;H^[@>G/L0(7U36[<G09\
M(J93'C+HU,2=Y&-E(/%P#RK="O*UX=_)<>UA(YYTS3.A)&%M33 \7PN&=3V%
M6FP[(<<W[T 0J"G5T) 41.O*[EHXFG?XYD9EYPL]W?6RQD+5N,JA&=?C,1V>
MWU+SFO.N11%(A9@\6_YX^6R?Z(@PNO,$ AT8/0F]VRS] )JLL+U37%4QTAK5
M*+HTER,*5V>%Q#89;,F>:Q04_2IP2YGN#)D4D5-O(B"JR3T1JZ\;%U<1= K<
MIHZ_ =^:N!_2MHI<#4$A$!1DT4TW2!&#SWZ <+=SE,MV=C@A!P5#*SE%3K9K
M[*W2R34N,0SI:7DUK5W[$C[Y[X=<ZW#?E)O#:""U9M0R$7!-R=EV;_8'RWN:
M/<MKD44M<W@OBZSQ<RJ*^Q=6146,>:HJ=<.X@I$TUF0Y2&4-#6#BM9K1:LY4
M29C>C_/5?^2.H1P&RQG)>5.9D;=##PU.'-,8T2!Q@)\SPTK=J%QK8(=7=34]
M3:Y^D/CFY'"*D)K5-#1?DBO"*4J@;R;WH9I*NSNTAB]?<<4_0#MJQ*9P+$2]
MKIPSQ/DB58._*U9%GJ1VK76&<(Q5]\Z1V#/+T^]F^)W'/%Q.*!XFI\K36/\'
M4 R43=CKZ<FB]%<U6[L"P=LNXU>QU5_>%IX**+K4)JD0.8);BYN36DFZJ^2A
MT\)75D$XSU']_\S_YF;/:<T>ZS'6T&ANU("KM0" K!K:VWO%1#QO7G2^/](-
M/50!T>,)S,+S=7[SMHS!BAE\Q:R<[%MJ$Q%9Y>2YYD!L7(MN6=U I*UZ3N.B
MC=I=>T+Y*T9P?&D9;]\^/;0,A DM87.DDI>AV;P!DN(IM$TLEUK#7CX) R Q
M:G@ <<7N;9<?RV7/7/&]QW$!Q\4YJJ9EU2E.SC@%^K RS\F(X(?L(5?TB-03
M65LZ&#UTM+PAGS MTRD8-J2YU C75G"KMT.T]8O4B#XDCKUL*I(;5]B":6G4
M9,N98M"5_E>.(&+\JT"12%OXC%.<%44F@@N]TE=693?VB'YJ?4<F XR,'=15
M!K##!4M>([$S F5I.:).7^Z.,0[Z-CXY&?+MQ,-&3W,<+CK*FS8*JP+/[2^;
M&Q3,*"4-_R8\3//Z;I58A$YA+=Z'?0<Y:8)>/F@*=9!Y4GXUEC7 W,C_O'3$
M5WR@1["2[%D+T=GNYJXW[T1TKY"@\8&2A R%/3*%O7[,%*DXCL%B8U,.)GTC
M[>>3<OR%/67O?\VGZG:S*5(O6[K!.\7E'!0P&UU.C0A:QZ_UZA7-;G7;NJ\8
MU3G'H,V[HI-2\-%1GEPRS-^RJ?0RVI1 1_[VKSMQH@K3D,'5+VV;],(ZCT)P
M28@G=7&SGT-$8GO-G.W",U6XSK?.?-!710<%DDS2J)SGMV*W[&+?4W(YI%FY
M8((N)6E_$-;E%8XEMX@4-H,$>N.QGNN\*7FZB<:/?YOS1K)]J#.XL*:*#<.U
M836(<+%W.R\"'U=,B@^",UND$E5'N?V_%V!D27;D!3L13-]-1 Q-^%=8/".^
MMY-=.<-B<<79*3&>"S,\LC( Z1"[7OQ9@S6W'?<#P7<M'X1N9J3:.USUKOQ8
MY5+*1S4]S;6M,.,RVV[=[[)<KR9Z67SO;C'DOBA$NH.<QB7J/-YU4L*D6.Q.
MX6UJY;1P@2@%_?><?8SG"^,G)[!,.(YQESJ<I:4'1K+F1%%N^^&)>9,[*[,S
M?M<+5OW?UT^Q1K2ZU-:.S/&GLMMP(U!.V"WGRA[6B@HQ5DA,$S?>J>]%6O@\
MP?L!.NV\:F5]><<&OS@WQ6B2O:@064 < =<MH_AZ7)\]M!VS?YUPRHM[.4?Z
M+7N-_T:(&E&5?_TA1^GR8G4L]2FL911.+'D&83XT''/I6G;+'-PQI)+:)HTX
MWNQ$,GF\&1D7M(*/!!]QSJ*3U8);[S(86 _%5A"2'3_PAT#L"J)^7O:25_Q=
M^ZG)93G742& 'V,B/Z62IR#>IWU9[<,(!-\?[W+]TK)&,!L52E/[$+T!PZH<
M3\VW63D=.K9"^>+"G,P'BAM^P::L+D&K21(4KEM )&OEVZ=UUH&N?#/85N_(
M%4065Z D\A/I6KY(5+<2TNS'B>/L$4!^!$RB3A_X5A\^B*BLJY(#(_@@'C""
M+P7]A5.?VWN.QV(%(.,?*_RO.UMG.B?>/:3_B5MUU4241UXN+ N=!W#'I..I
MMO/9\_WSF59,'AP$9ZD1X91'9?R71#!L:CNJ IV\J.^&W?$KS(3 ;H"HZ SE
MU3WF0_)*2Z[]>I3T=>1M9\E:$"Q8=ZOESB"JNXU& ]S,LVV<&@U%%?9*./@P
M'',="/LR%%<,==^[BY-V<<4#"DH,5WZXM#S3\1.9FVR":;KU'6-P#CM[#K%$
M-RZHS1'@DZS8JQ>_?['W85]:2<WSDI6[@7"),BI5KABR1=8MCN>?]&)6>ZDN
M@@M+_<%<S?HJ[M&YXV,!)QTD6 -J*HAHS))(IN[6UIJ^]"YV/@*HUCL+9NT$
MA-@]A)R?&=[:T;+.9F()W1OV3DHKM_WX5/.CPH\*B[^QHSH/SS4::XR#8,-$
MA4PJ2JPWD0B+X)ZX*\^21+Y<O<_-2#RMNR?C[QD!+66*E.S4T)"BOA1D\I;5
MCBSG>+ . , !: # !N3LWGQ&%6W/]@I8P)E93B;&J/'VQFAF9B)MRZW/>4QU
M$1*XOSO@UX.N0.OLBHL%+DB_??)9A6GRB=- Y'B3::53H*:OTC7+\:6 93(!
MEP^''.<XJOBJY](_-F 'H'(NO)("&S)F266OI.8TYF8L_ZA@K:I4M3?V^MN0
M.9&[QZU9$VGKA511M3!KUHU\BKRM,8=T1:,O=%CY)\IPN'!DIU%BGC36VZ.C
MR"'_,U26#&2,TU\NR;CEZ7-XWMUT8PMQB#,@"/B?94#UQ"9&O(KL:%E/Z=JT
MZ' %Y@@;WZV=CI(*ZE"Y.)O;5.F8S::NFSBY&+;#3P(\3)302'D_+M9!/:9W
M4:9G5=X,U.Q>D>[&3Z)I)V_>  #+&$\ TOMT8Y3$T^0T]5"H57M#F$PCAL>E
M,UY8M486ZR6S"VG?/[N\XR&56.WFD:Y(0<IMGBQ#!/#XK"7=TTO315K[N]VI
M_546X-^=/^EU^M"\[J*]<_G59JZ0JU\>;7(= :^<29'.X6>A]<6O3]C3+:G;
M*.RH#3:825DN.K7@#SQEW)#*51Z-AQS,(P^D3HK)HR8:O6:,L9 6,\R$9!.F
MW0OI=C59:FU..&]T++YX4O-$TO14PFF.O;ESYC5++V02*=]GE(7'?!U;Y%%[
M@7%UL\(@B#44:B=>2ZH\.8.HZM99WYLIEO;,,Y=4HQ&>4>W4PJHVR] F42*;
MN1K_LI<% U/R8XQKLRXO/U0L1(L5%["@B#4I2&8T;3=,*3Q;ATROW6^.F$:(
MK(4,?7Z4E++1Z"PY![=KSLI*9#CPN?M]72]N5HYV@QS(QAC>8QL2$#J+IYR(
MJ(RY%MMY[KE;?L-E]C%UF4C:CK.5M]6V#KZN1#:)!V7R]!P&2MD*R!W2L8D=
M^A-J9];]?QR"S":O[3D> ?XOCH#QG-M[D%0E\U'/?M6"9KLX]X'K)&M"WBOE
MSBF)KMP^*T9?LU=44@I*UWDR]IV)N'PE1^9$OC[-Y.VB&KK2NU@4=FGK"LDG
MM"4AM0W 8M?9)&=-],?]44;S"RN<(D.6-\Z)#GF+T?8FE74@V%3;+>;^+"7G
M^",[ X8LKW_(@:M345M6N/[C  #%G00 ;B>J\NL'I69T10PI'*"BM/L:7A:)
M%!'U7!A CWYYHK[ZUJ,Y1MHI^C /*O+I!-8C "Z,X>(-BLM7S?/NJ9@R_J4<
M4:"N6'WSL]"W\CO?U% %ADY $B/O&QQD0:#_CJG'IN#QE<VE-AZ11/]7QV76
M925N5MXH32FU *V';@V#MJ$)38]&878]"DBC/?4$$M( @CAE1=;3?N6-)R6L
M_&H\#A'+7=V"L)ZLM6^0QXN<T20PE357KERLY$0BU%B<08_+06/A7U;[GSU/
M8EPB],-BZ=#X%<M[P$!+FS[W,F1*K<-S0G)&X$W&SZEGFT:CU\(R9.%5>3:9
MJN^3>H/")CF=%7BH^=18+;/A6?TW/'[@#KW,'V&W9?7&)AB/"4FM_2X]K]^W
M[6?6 7([[S^=>/[;VA!\N]LOKIWW]($WZ%0CJLY7_BXY+^[X8/($./<FQ(03
M# M)OX)AX3!(ADCNT/Q/H-1>T6/FC#5H7<J(?V/*.G^;F5=;.  V=_G2RGX$
MR<@/^Y=[E#XD>N14RP@APP;EW/==DC18F("5V _N<6P?WADW+#>+1N!>B2HK
M4M!&=UYT2A"X1 U+>V5[3'0V@6[HDO!*^=5>:,0]2VB@)((U//\?Q;K)H=Z%
M!;U*%31T>'M)3GDW6&H+:VSKW>B8T8L;MLM\/]\G\(F(SCY1:$W9:T%TH4,2
MPQ5B%"462-(A.7]=-R)["VX$HAM: EZ@^6HLB*/KP,=%2#@CC/A..26Z?/"T
MFOIDJGEJ";#A]D"[?J1K0G6R]K\$/75P7F))S<-^.D@@E3LGZ*D#%.U9-^42
M$O24F+Y(#-\"%:.7Z+6-.V6.<?WM)VTQ_)-"XQ"9$H05BG= QV#1#V5S?/R;
M83^"YF%V;:T'3*3#*<Z$9/H[M DIFG#*$-K#]=!<YX)63@H U !8 )K",,>7
MI_"WB@"17_>%NS^W#0;AXT[P-5VA@DH[8S!H(NKS-?W$)OUC#S@6%H7Z6(6/
M(V]2UL/]G]]E8JJ](:+?%_?" =]^D9 ^^K-Z0!>_<SW*+U^VH(U:$-\9]E/P
M_J]0LB63>'95CHNK%[=VE]MO-.V);HX/4<!<I/*6F++D3LI0O4!@OI6^$&1F
M/MF7$"K.F3YWMO^4O$X4G)N.2)AO&IH8S!WI;]">5FP[5^-S@%11K)38//;I
M;:AUH&B;2.">\F$B$0LZHBF\RLA1X?^XSZ55,>H-B;:0[>82:;PX24>>1$,C
M67N#V-/-.[+A8SW\<;1 @-5S!1/1YI1"_%I K;-*Z6LO-U=MW0>^ UW7XC>_
M>_ K,GVLR,EJ1IW"PC79;*7F#EFN'V1>$Z,9"&$T4QD9'D7#)LI.R6]NBJ<G
M\SL6L#_)'/B08?C!GJ1.^:Z*O(94; !<;3+1V?;#_U2"5NG3^$YJ9C#Q/CN1
M*BP+L1S"C:P! "96R!!R0?S#OE;AVJN4<LC]\!N9K%GZ".Z5)OX4UJTMY,N3
M!B8ID6= &4^WSMP7K=Y33N:I.&> BF!D&HR0H'+J,/2_<\B45CX:XA%(>7G<
M&JT.!2K'GJN:UTQP*IHE^QL(Q.<4)3]^$OQ; W&NZ"=WVG_QBS?AQH;9_WCW
MI7#,G[HZ+/_8Z<<7*EOG$*V2-2T3IY01ID8TE"IC1P#UL&?X1$MH,).HJK(.
M8H.WX/L"A*M__?F)4:520SNKN@@UF;?L"TWE<@?F <"KN6M3W0[$#WQ<B^YS
MXLQID=<L$XF9H+Q)<3S_J!:G4AF_C7MJ9'X]H%^5"1J@W'2;0SN*NE<O02]U
M7Z?,+;R#QD_9ZSJ.ZB(QF4M_0--:ODS>4U,R9E FBH!\Q6U]BQ*!W#<,2VX/
M-5<>OG")2(26^ZQ%>).MM6XDA[KG.KYHG-.PBM&[O0Z32&@JH?$3?VY]:[?
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M^\SM=]0)WYV05?SN6\G-A+AJX(='_+\\MB*(Y/O_I[SOCFIJV_;>U"!21$%
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MKKQ:C.13 XB",#4##!K<0,N3VIV=0_/^C4;:<]819.69*,Q*<;,JK[$G+=L
MO .0C#7],%[$<CY\ 9%Z127,[9Z2DG-0YH2,T5L9C'>S,('O<=H=9:W\S""&
M!EHG>5 :QQ?U^Q\^,MFS:^K]\#3HL0, /#QCT18P\KZ9X^OB#4Y V#6P&\M&
MX&J5')Y]>[G+'2H.?_@*;5#GH<0BN[)U".G$E>PO.=&CH_K$:G(7L[DMW"@B
M>3B/><0:KU)AX4&P[+B 78#!6PNN!9RTN]0",RJ'6B\)J0PFKW9D/F_J=0B>
M:204=UM&W];S-,M-C4'7 RYH_E2.B013B=[S[+"A2H X>9AM;9Y+&^=CS9'@
M[HW\#L+K1V/J1=]W2$^<TP!_RI;-/^=36#"Q<%Z-"1;;&>5V<\LXKF6/.$20
M<T+SI-AA5D"/EN[+>52MCA/93LFH#$77[#29^3I'@23#%&U..$<^(R\N0O6_
M2SO]7$7@'?(K*\R?OX\2L[[]8V_K?ZZT%H&2\U>3U4J-;:E#!"QEPR%R6X'"
MG312"T;LVNH=\ZD\5(J.7GW*)B>UHV'U:" .V#_2%%0) #0T&!GS5W8%,ID[
MV+_O<NJ5UM!_$1TKOSZ-YG#A= ;P1C0EV-AO E]9U4B>+_W"KAD8.'VO<GW2
M/Z#<%HQ4J1]$#4_TK'- :JL-KT8UBX5'Y$JH4V.I8CM58RHGMY[Y40+.T%\>
M6#FLNTG/GK/MC*FY!V@*86GI&DH#*BH\1%TN\#(EY1,/'9_]80GI."N^(TH,
ML" &),/+OA>D[XVLE'HW0Z:V;)IFX$/@YU"I<R NI!S@ LC:F-R(2:ILK'9D
M)/4ZLD:>UI6H5[]"9'J*$C=>!\56!.)=I#HO*%YZ$I?(\]W:FWE7$,$" 5O=
M=$.-*E]AA2[;VJXPGS1Y\\E*PO#MT("GX,EHC%0#: O+%AMTP60_;(6G8^>>
M9W!+U*C#/!N"I5:?#_\&D+(EQO%#RJX4?]54^Z,8A]COK;T7<TZHXQN'SE$T
M'&!!\ZU1OW+O/&FS+3HY0E250%2VP&$PIB%.6C.<REJ1[ H(6U2V_%F*K5%%
MUM -SO>XW=NB^Y,E#<9V0EUK5<Y-5I@4O%_2K8[Z]@SC7Q,4H-Q9*"/I1!Z6
M;!$1)60'Y>Y_:#EX;O7%5/W[:CCT"&N2SMX@SR7B$L\>R 5,*6X8)GF.I=DQ
M]%C?,)7?2=59O#IYG%BS ?4;#IL^76,K4(A&MP[]J$OZRX4V?SW^24%"H">D
MS7<*2E6<1P2.7%?GT,'@@+;MVU5"LJE,C%-Y0^N'N<IDO.U?<J./Y,RH=%Z1
M8&A!!..8O8CA")3SV$#D60>=20*42Y_W$VZBHA**C]">UO--RQ#]!\ HFZ=H
M+!(\,!]053E .R( 5+2>@O,*(K_O(O")_,GN'*,<?3,!;$OG/ A>"%(S_6),
M8/W\YU=4\ZW\\?G\ROG^H\5S['H.D>,G(>ZN]@(BV,3.#Z?7.G0VN&E@,"2S
MC9Z(9.7?XUE%?ME&L]'<A58W/UG'PUL;X#0Y<!#@8A?6)WMV;Z9T9D_Y&70;
MF^M_]?@V1RX67"[GCH>NT-6%V>_.5EE$@\W&D@\ .1G\\"3F?D83#[1RA8.0
M<IE1 H8%Y[+.:;B.? 7H3GYH+9KV)KHL$L\1R',!D ;@-($W^JX*9GL7A[#K
M]'JXWFJ/D@L9ZN!0UMX'W/F606?S#QL>?RQ:ZQ5?G%)38O#JIA#N&MA?X26:
M!B:Y<.E/1)Q*=H7'WB]/93U1\08ODIUSAQ@[V-IVH]-%@_N]O;XD^COR$D71
MYY_(\&?^)4?%]-3/ X9QI^B'4-#I/X1',@IM,O2+\3V!3V&G7%2H" )H\*@8
M?9'F%4H93%[2QVK#6R8*7(UGFMHR^$:%H^@UD$(I'HL_N$X.R=ZM?+N\&231
M<%I4FEJ<7_:K JDO3_^1E]9L_KK=9;E#%])=NX_Z?ULCP"TB?3:2B/FU2U$4
M.'&*SD56>CEI[E795 EO*92;4<)2LYEA?Q7WP$5N(+A9>DZP65UTAI4ZYE+(
M4XAJ20P#C):-O)H_T+;[<M]J]$L?^^  4"$D&R0G+8A,]$ %3M!ZATPE]QY#
M'$M35@C5[@D(1\J#V5H*L]74O#>XF=DU=?Y$GB3G'R2.G+IL?Y-=,;F9QO75
MEKD\S_Y RSG.P5'+B2SN.:$3:RB(S:5MT8>.]O<J-3T>Q'X07YW\(+ZH<0#<
M- .$.P65C-OV*4[^QO^"\.@/#"2\<@S-N>U<>>/:0,H[H%B@"<0%PL#-G9PX
MYTUU37?X["1*I$/U:(\HR8/(BXQ\$6./B&R#._+MPK!.U]EO%C(W"YUCL1.]
M%1G"+VN8.6;^QL]K4*&&Z,HW,>L)DR&,.3)A2[PX\89&(A0O 2^4J UK.'&W
MVRV1GGY6.;GIJ/Q(V_K,%7L0V-)?,L7 4#;UX]P_RD/C>$<::$#=&_$S?_YF
MLI6+-^!+3X!O3P"GYG>_Q?$(Y]A'U93B+Z,5Y:"%7?EJ-UF3YG;Z?1",:U@<
MGVSI@ERF\W[Y.LWTKD3X8JS#PL!-2$L]V))M%\?0TL)=F*BCO?[M IFMYU%_
M"<WQ?%&^8X._$,=O=X1E6$E9B:>)S:C\.5N9K]] O]1KK".6R0*)J$WQ^V[\
MGCU9>XAJ:&!7)^[&H?POSY/CGJ3CO1KCS.&;DOR[(H[;SN3>/0#V"BL9A?R>
MR-#A"B?&3?,D.'1#)9R_"XG?[O :;I>:;<FWO];D@\MG'!RL$00X:$^#P=AT
M()-8Q;V;=RG"5MR(C]Q=NH"FML%O'P,DY*DY/>&Z$ T254]L/9D7\3+=E[EV
M:V3.M@35I@=%*\[XWS,3[^2:\EGO/":8O;1)%3;&2OLAK[+RC=(UYR J.D-C
M+$9F@:"W],D3UI/QAYQ#X2175Y^]QO\CF_$O+"[_CU/)W[^1'\NK8[W>*A0?
M";-,4V_N<+KP6Z64,7%.3%W-]^-4\N7E-\=2W9Q#M3\= ($0>7!P2Y'4"O^[
MFD?ZWJ7KWT_/3Q$W\QKXF/9&Q0DR5<VLVI\9<V;6+*HHD9!L.GM#TH>;K[4>
M>DP>>YY\+JL[/Q 'GTW6$V%/TG!WDI$)B+C<-OK1\3"_U.%:KI5FKM=4G<5Y
MSY?+ZF8)!P#Y(3>J1P5R-IR^@1P]5]1G-_;PO1?G:WPO5LUB[5=71GI+BA!^
M^28)3>.2MQ\7IV/@#>^.&/-L#47YF%?U"^8ZFP QX^-&%1+7ORTZQ]\Y1Z"A
MX?O>E9$>D<HH4+#$2KJT<^NP$!68+WH:I1!$U9\1C_2CE^>FC[6Q7:/AZ>BP
MVXIA.%)3U9@]%U#/DHD')OL*2/J-KT@NX&3$(LJ;__:(.3$]LAVO829ZUY^W
M='GMK+ 52OR#C%F-CR4&#L%P[:+Y5:OF=*8_WX/^"&11U.%^I9B^$$)0J6^5
MJ8U(R>*W]ONM2M? L1C2O.8!T$B7'M!9M*_X[ !X5!AB*'B/X-HB4$1VC0\.
M4]3*;NT^NGP <"KO0@WY=[</@$F#.E(ULM17K&KZ#['8A5V.C'[56&5[2I1Z
M6I42IN8D& [FSZFIY5%2G]K_+"F)E6>EW>YXF1O;%6RS$SV]H:2YUR*:;Z>7
MV9<\^!ZXU6IY5E96C, F7+UC1)VH<1R8&9!MT0' </SA 2!;MW7<<5^TXO'=
MS/CJ4X.KC,)]!\ 8]6<4D?QY^N,!\/[SSU<^+X^\PXG(T*C9H>OA/.GIK:VT
MXXI=,/O:P7(A4G73A_C+W7WR!CU)*?F_OU;&C[T(I$5AH:@Y77$@=,O2M/(=
MRSN^T4GK[ (A ;4"S*J?W=A&VHNI45Z;R"]4WT'R[??Q623TJ.5X5<3F=NN7
M-R)9=E=KFV#>M-X1JB@H@.;UPC(YT#+V2]8]6U*H&N_1#PA8?KU4]J+O94^<
M_]/V1Z3H55_?WC.$=T-W.(5>Y6,LI@V."$X@'(6\9EL*.%3>UOEC7-WTGN!/
M?CE]1\%*5B?*^=BK"1QC$,,FB'V$I%R&VEJM/ #J) )6)/5-ZCO3RT40I_*&
M%W^SA@Y@EZ@IBE(<G>I?_+O'.HJ<:WP(+.*/5VF2B5D)=5EO!:7>N\NYLL],
MV#S59'\M#@ 2: 0 S*GY,$<VMB30+\X^$Y HSC:^S-L\4 )"-5[HP\7UVOC0
MA3Y^7B*7K>XR^'ITXG$[FD"#'4_732_O$762Y261_9">T>X[;MH%6F\"E PB
M!(C)WYO%I/LR#7Y[=YM1GIKV*I<N!$2*[8EM120E131KNPXJ\ZXH[,M'!_3U
M!\Q4";<+#ZZKG>XS"%?PY%ECX6)N?X-1<LGD>=![ZZ<!VI6BR&'MC)=7I*CK
M_?L_4#_U[Q??NQNW75M^H<UW _[]G"A0.Z]2]CE=K%^Y^' \S/4R'U5R,9GD
M2PH)"@L'NE"R-_Y '#(J*ZY5XKGI-3_'A:JTW Z2D)J]\CEP](E^T<_3+6/_
MB,BQ?;^ U7,CNR9NY&>QJ)ID_P\OXNE')AI/_((PK&;]N;M+;:[W1GUS"4$/
M+S1 )YB:W*G+A(5BM#PIT#65^A>@H5_1^^?^P% [*=B3AO#_FO_= \JO(9W0
MGU-!39__/-<R*Y;U(FV$U"#E$(B!QE-!BJ[P+<A=]_3>=E&''W7MOZJ,%D%7
MEG9#%^L6(O<?JJYOKQ1QFXA,%WO,,%#+):^WV\*0%YIU)OK+,E90\AG'(P0*
M?V#FBV^D7CXVTBPO-V,LQ;SBPVC*>W*#)[.AOMOZY7W/=T6[#H")\=WGV^:I
MO)LFK5P'@"=X>]*M2*[0MNM-P=?K_\@M_3!R1T8L,+F>K@9;&2@(-K2T(-QS
M!%)9^/5(5O9.UWY3O0U'P>Y<Y:<!Q&6>6.?(5"_#WSOW/W]0IL;O'#\4P4ST
M\5\1J[T9UZJ)\S=#*9AV*MJ<*#&:XT101VP:%0AU; 5W.K)CZ:F\OE#"0:S@
M7@0>^&QBH%BE)4_UH,32NG*PR=(W2%C1Q/VZ)R(B8NT (.EN6^^NDZ?TVPER
ML]P"&HNZ4<0"PMXF[P%P,FLAG1/1&+'^[%:8#[(ZSFM8.WG1FXMM8:<VF#?4
M3JOSG8\51IXC4RZMK5AND<6%9>.#)4_R"KHW\FHC,<JF&K)1*%<6.,D-<^*2
MDVNEZV '^R3-NST/68+JOWU^QX? 1?=*/S)YF0'IE.G<0(R\FIZNF[GQ25]P
MMEH1CPN5N:DGYC,1CXB1(/!-\',C//*>:!HX_ 3R==R_]MM+K[!=NV#8 =#P
MQ3R@N!/3])!4"BQFV,@BCQQ]WLUIC?VSD3^[KH4UO>&A#4@GSZ=2$26(TL?A
M#G?=:DS,;2> Y1!?=#W'MXN:!AWWQW\'./_7F/SL&I/\:^+QR!+>K;N)!C+N
M\%.57%N!];,18^L:H0D;B9=P%< $+#R9Q_>"!03U"+&V9)JF:&RK*H.4$4.<
M^!.Q&+L1R\=W])1OM-4',;1 ERE9E[&>8\RG-QUVX,V#$V;B[H1;YPI]/ LX
MW+_XO:N:8-?/';I_J<N!2\*[F,G"%AWE=P!X@8DK[\D(C+&.(A)7P;LY&+#K
MD#>@W"[J'<(Q)[XKT?4Y#AO[BO;HBVX0!-<# GT--M3;/_2Y(%FE/$*E<]@Z
MVIMKRB0<%9XY3[[':^W7PJUJ$?YZZ9>9.JV\T=QS74Y?F8-WZFKQF9: GX]^
M;O]O#>8OH ]A6BY7!.3Q3QL#.SDDK^5O"]-UW%(D^67->GD3^BW7G1#%/<Z\
ML+3]T][<7(7DU8^?7V3HCV&M_X9VX;Y"OFB(A4AK\Z@X%ZJ)&,+5TK+HY(I1
M\XISPU]<4=[EXZ2"WME!!+CQT%1(Q7)UJM/[L%Z/-AZB""GT>5#HL!RC0.&S
ML?T82:2:I9.'4>3EM.9E.?DH)1;_V_.E6(N+SZ;4-FBZW)C/[YQH/'Q],OT^
M0>ID8OP])W@K?.+%74U%YPJ_?YC0]Y]I^C4]T.(!HNS0;P3:M68?FGG=NC%H
M,7G(U9'(SF/EHET\RJ%"1LE$UFI=-B,-@1NN+)0.CCSV,$?)0Q51<+<_8-H#
MM1QU\P#HO+5+)CVD)-V^?&/,&7"R2SYH6HG.N?0)EY]_UMV]SMU.A?02!"IW
MKQQU]LKU\ NQ'5.=QMM8C.OZ>H$/ZY44E2\13SPH9/GFGQXVXKC+I\?[?>
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M[G\]JQD*9G%*)5; YR2$>X09NW>$I_^P+?Q?9L;Q=2_W</8SE8^WS9Q.5A\
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MUV-D#%G.BG,F$D3L7MD27HY]%7NVT2*W<9WLR!%JRKYUS=(+#+.S9)W.*C.
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M!-%-(H?0IBEL3SS19AN,PXS1V*A5LH"0:O9GW8IF\0,89HF>]+W"+UL('!P
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MQ912E-%:+(/Y<R8J. +D,EY]':IH.M# "_5I5WVADS+V&9,884V>ZN@!H2L
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M79"ZJL35V%5_C2N1U1'EE>7@)7 2T14Y<:V-:*I;:U?,S3#NM=+%V.KWJ^$
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MZ23T'FJ $'9\K^_@N9_WW?OY#O8^6#E85W*MM3+G'./_6Z-,-K;$K0.CR2_
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M>H+/2*$W (4A14P/!#?,_.J\N9&\U>W_%^IQ?#9B3TM@Y!C'UJG26*[:-"[
MB?G:0VM0-R68X03\K\4X:V8T;:L_',P.>G#N+Z'^"3N*2OUR9C/K2ZZ_8/XV
M@W.DB+^T?MVK]9#V+.9EX9=H'G^7KJ>%+*?(0$:,"[\3>.5!1:*@7,?!UP^V
MR\7X>Y-7RYZB0]XD" _X)Q%_+75!8.?KD-V.WAG;K02I)!E*88R,!V>]452$
MT[YU0WW<@,B(5?Q<B: D.U9D<\7'7NS,Z/:.J9CB9#;A#6 U^=W2V=(-0''
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M+;P.N 'L1AFS]D(I3;>S1.K'#16,F*7M%8EDA)-N-[ T(S>!PU[9__CN1J]
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M.\TVR+'4E8$JJYZ=:JG,Q:R:/-WN.J7 WH*:-LOGXR !">?X#*B>#?HZV_"
M<3?P/I9)JH_G\V29:WWTA6:L#TOQLNN><HVZ'9UJF<"/%18][K+1Q')^KJ9Z
MOZC4_#1;21]VBU]]DXD#9=EDZ"&3P^Q9!:BWN=&7V>U!>O<_'V6<6&I8:E:
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MXU0?W/RP"JML$W8#,$F_ <C:[YQI%"@K>0INN*>]/QN-7F2?E $NHU-4OW8
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MYJ=<$*YE7..5\\3'2%6>&:5W-#P_SN8<DZ?>8OIOI7>F5U>@P'Y&W#2 A>/
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MO/J#.'_W:9RS*QJ/1@ZQ<P_W+."<='0K@95!#";WM?^$'>?*7H;E:3E5[PV
M<:2@<*C0VX8Q2H-?4V7 Y2>..=_>\MR8/")\Z\,B*F])RB'1M&]4QEGZ0$/>
M@^X_-O'^>_B>=T$C%ND/S4)"L]VMBP;\GHZ*')!J)+$??J-<OOXM3>YN^D+>
M5C/#GM^ FEZB*<^O-^ QB ?EE%,2$F^1BKJK-&7YAOHY_D<7(=E]=<..W,CZ
M FHKSOU]CVSR9B/63S(&+(6N3 F&,@*D.Y3!:VI$<PD$7CRG0&$3UA[6<!86
M5&_ZVT;_K!SJT])?+^8?\UR\!YD?-6P\DO8$0[]J&#1JN&MM:Z9KK(%J#K6J
M TFJPUZ$FHB^8JN<,]8+!4EO)?[)!['5I<WNT9*YWG*.?>W5OJ9TTL&"+/#,
M(OL+@ 6!,\\"_^*?JT8>0ZR]R?"V:H="WWAC6Y_ W3^&*1/8B1\CS^<87EH8
M(V-^M;_UQ[O4"_%NZF4HC#YUKK-7N_5M[DZSS]&*F2Q0W7WR&H"?G=NX9;ZB
MKM,0O:ULE"T7,+ITQ&N?_5_ RJ?BAPH&DWDC=<=$2PPX?D::K\X_#T;]+_;>
M.ZS);DT7#P*B@J+T)A%!Z2"]-Y4N(%VZ"$KOG0 1$) N(*"T($AO(KWWJA!Z
M[Z'7A!HA)+^X]\QU?7IFYMOG_+XY>\X,?]S7!<F;M9YUKW<][5WOLP+RW;^F
MF)O'I2Q[TX0?_]Q-::"% 93,G\?8]*)_J2]DF)]BK9L44Q87R3^X@PW6X(8Z
M11P>B7S=EQ^SVBXF3W, SFVZ4&"$O#HB_8SH%BWG/1/'UX+Z+T2IB3?)'(F+
M<8HOAVWD!.40N+YD^QI;.H@D-BF'-T7RG[\Z%OE<574@5'B-,'7P:\0EZ<VV
M!E<PN0\XRW/MC/F,=^X86/ICSN*G"3LV^YL)0\>O\>M$O3<<.<W0FHIFT758
MX [5AP2\%#R3',_JGOY<^:I%\WQ9(KK$[#3J;EB>C(K^X^SA6LF4<N3TPK=P
M4XYQ79VOM[[S3O.8(HOEM^9JH&0^7N7*7IPH/BNF1 )_-]</LO3Y-3U2AK[$
MX,L9-;# SZE]1E[E:EY>3KG&*AX>?'U.?)2Q\B(<:BY&#J\;&:TE":HM8P5J
MAE^]$S_>:>GGJ5$SBP#1^0ET#!J1O#&OT1_H4\0Z;4(O$74M58(9>KM<14Q[
M1)7;77#VF--QGB5@- 74R^9RB)UC99YSI(O+7:Z3T&<4SP8@2[@%MUK6B1E;
MUXL]%S:87>2-[>B;$,"EXB"L@W)-,#YGRII'U4)1R% NK)H:RM"SMV%LDFDC
MA :./A\IGPX.7B6--QV(6HA:."%_&#9%EGEEO^CM^YG4R4,Y?P3L87V0ID$E
M1*T:=]5SY-NM4[-5^NHN^PJ0)G)ED5V84"^Y[H<W7A1)((([@CA=X$"%/+!E
MJ.$;UO4>1D*[]*LB2\9L]DL-.B!WQSBV([P/1AO4]C>,@_[,YH6K&RA%W"._
M7,Z@%>MQ[<\2 ]7Y;&OD+/M?-:UF;Y>T8P!8%T$ P5F9E=WF0L:C5XAOKZU=
M1> .[6TW(Q(;)Y<E>\C&HRX]_0^^S/U_ @\(8;U=-I)9NZEV)+TNGNO.K?1*
MV1=7; ]J@AQ=M?JO.:V\E*VNRUR?1YK,D6, Z7YE&(#?"PP ]CX2<=8Z\<-U
MYSGD$=DC#,!:M]]55VID@P;DE5:PU!1%4UEJQYD6:7>>B+NKD^SWXZ,:+@&
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MGP?J['6RJ+9H(C*HYZL:OVM2E1I^.E?FM73=>DN[Z:5-<N+<&>4UX6: -P"
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M([6,<3" ]#L80',/!H"LW;+,G-9"6YR$,('H$G]K!@C/K<?% *1E, #_. P
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M/W3;YD[<[+VFI*^EBRE<"U)TXQ:()K3BJTP,P,@4 Q@,EZ:W.A/% +IG\S&
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M8P;2VW$W)1<U'/F&&>F.H$KS2.TEL=N@9E$MG6'F*5N[V#%/O@,&:3(2B2N
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MMH6;)\*8XP].BW1=<XF2W 7*R/D*3QTJV,PR1]&EN<K\N[79641 U]8F"C9
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M>J2( "YZ&QMKTF4^DC.&G<*?RP2;W!<7V0,2AX.Y$_RB3T\(S,AV")9I%')
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M6G[FG>5__US$Z6CS<"4[I<J:S=^2X%6%+FI[KIR7^6:)ZY-IJ &7ZE,^2;E
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M D>^(S%(P1_D:^ PD^(SV_9^$<FI^J+^XT-.25KJI,=8RP(T0A^7BZ[2:/H
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M..TM1=F$P4<'.;##S/6LW ( F8P7'V$UP-B(]+BP'4\T]SQ*B+E^12]NW5O
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M@7/YK;.L G^$("'7Q[N0[2[%87F&.U2R9[E6*'[A0/L6H6F9" Q9U(#_3<(
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M):?L!9/D^U!QHRDS!\/C8_'$\E3&FP_<OL4DM2\:SKU\?IF=53/RR? #S[H
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M0^'\N3\#],;%;!AJKV?RB-0^\@CC/J?O%([SS9T<_&44V7D(IL<1!M7_\+&
M9D\+4GI6LN2D#=TPS-XXRE.=5TQ$H&OB#X$#)Q)X0Z/(07MAFI%/,5[J2MYZ
MMH$DU71Y(XDO=T?]"+0FS<A$844_4VFP'L[@:SV(Y1<%\PH%N,1]GK+:B6;Y
M>FZ!P\W CUK5/#I#-9:&1("]M&B)Q)J$2>C3%_+YYSP$S>V8YR!MQ;7PXQ09
MLA:/^/%M.TLW4&%_ \$U$L0'M:N\;UUJ7W7+K.O$QDHW^GA C1<AY@"/292K
M_^"4]_1/"I?(P25R[V[R1+T=V\D';P-TD:-:Z&W[;FO'#PL)N;9<\NYM&"!(
MS&>I\6.M;=CNK,RG6GE_2J9I=7+R@U*!I^CY)E3)&T%#J(BR57UPD%[,Q9A>
M]Z 9LHR/.N=ZL%74M/"J@N!M7>,K_Q$]A7'Y9\<DX@Y:I_V:8;.'A4;^S-0S
MI,,'WNG$#%:/&*?71V+;"^6V^ ^U0A>!3800,TA+_&6[+)&&<:1)J$;2A.1?
MAZ3?@%&E1A>D38&A:>DKWI34WNXM E[S'Z]#GPBBQZ%T,4V1^Q77#%@E.>97
MVN4'BHNJK"JUU^2_?R6QCSN+.F>7^XE B#L<HU_AN+@KT3I/-X[=OSXC>V^9
MV>R^=T(:K;^:V=EU/O*U>%9<]G-<..J-G6S/*]_PRLRW(#(-ZFHJMK(6J3VW
M(6KL!>^Q9SEAP&#\J"Z^\G>HP?AM'ENVF$I-RQ/4IL6M[_DKZ9G%?O[J5;^?
M%I+%'HL?N#Z:8EHYZO=CQ-]98&RJ*R$"BWU$H/(Y);0=%'D6V19KTC^"'722
M$G+T83J8,W=5Y[Q5$:%(P>%W%K+;>'L\'U>$3MKK7%M]-68B_KLFXTV0)1FH
MBGO_TN,A6\E-"QE_].%R1#Y+%_Q5H3E79N^?^:+@0 4ABS]HY=;:]?#R72M!
MYYY=%M]<N\0OXJ[7=2CB=7J#936702$\Z.M%CM;W<JI*W*@R&ZRFJM:XV77R
M/;-H<4*0F  AIY*N4C6'/X\1'R<Z*G>M&GQHL8-/ARZ^-:TXCS3]2^)^,3]H
M"^CT;KK/A1>),*J* <:XR&5[62KTBNS-^TUV([U3D?;4%^A'?I=YLT2 ?:@D
M3J8EO:N=W<_4WUBAY=!YG]>JA4PV>>[SET4?.?45)((P7/;7\]I-?:INTP)#
M20)7MA!$81QZ[)8U<PZQJ&)56<BX547N<8\)](,*\NQ\B-R9"-@R78X_ [^W
MD7@%6:VHIOL31,4O?4806V;IS(3G.B3;FR3)^HB_M;*;^GWK"V:&2@J%E-O>
MDS[50\7VEW2USY2][>V_3:<F#-T/'X  +WT(P>1SA)M$H$=P"+[]@0AL="(^
MB_ZSG[4Q&T>2.9XJ12)0*D0$<ED:+8<A*U_M%X[I2=55HX%S[7]X[BG_R;5J
MH;74Q(K[T"H\J_9U"V*C&5K"=V"=[,;<M: 75Y#O-[A[EPB(=%TTP'=9XH\#
M1SSGGK:9.^[*CVPF&2FE+1GR/YH3D<P!24P$W<-U04?S1H\$G36<7C,EB49(
MGH"4=!6YXU)& ZA_#94&V#T48VVNC:$VZ1R/H(B-,_514AA@W/(W'&*)#,$+
M%4YIVGOD;,Z;A5%T.?_HVRO.N1'8$1#F/@+SZ=#+E%XZV3R)X<R0S8Q3D (_
M!<Z$4"?XY'?_>M2.L53MV(4(Q!.!&R2%Q0?)0.IAIO4@K>>^T;=%+)1F- 9$
MBMW,JG9(RQS\#^=*Z7.X1 XU$>"0=?-P*X:WWK>]'S<R]B#U]55*8V;WVT3@
M-QD5NXCOIK$%!8[W!PRA%F\X)M2982O97WO%IX?_0.*&.G5CY)>X9LLLZ/([
M#Q7,8ZAQRW7G#[0Q 7F7FG";]$<NX0^=A&2Y<P>MGD]7?+$P>O9*X;GXHB=)
ML4]V  'K*"(09A(95CXQ7KROFEN@%B(L?.JNDAR3F$2R_6%9?M;IF_*78/.+
M4(EWB.^V$4_LW_JP?;04Z99[W^=O>8;\A5O>F^YJ3M\YB?L E*5=WWGUX?[S
M^A.>8"IWQS6A=_<%\"^'WCW0K^^YRGW^C?<!A"Y1@2,2L]_%^&A6;4G@ZC,W
M427'=27%@(M)PF?6^%*UKX.\:-*R7_N*$I0Y-SC VD][)-V1MSB]QQT3DG!I
M77:]2OLH$_/I?BZNJ#@MY!3_23F&$GH?Z$(\"U1$Y!+89J?G J30Y],B3".=
M?#-O)!-?"H3%G8?T S##N* K6QP,(SSCY;N*7@*2E-OO[.IKN*#[9$E,7H-*
M<B ><]PME'\LQ(R#L3XMJ_/PWICP8#)?#Z<?)3-J#*27G2/65^?(3DG8PHP+
M+E=Y)S0*QQ9,-"KCW),U,."V5BJ^Y3,1=<*&U"O<#VY,#L@1AT$)E-Q2*Q\J
MWXZ("%1X;";-]NB=6Y5<U4T_[Q<RR$\!,CCC'S"TIC>2J^M9^#%K:,;40J&^
M65QP3!)L,,C1Y3@\^C5F]V,IZ..9^Y49-C>>-.:CGL%E@3$"U:"31.N<'.?]
M->4'/?*S-I#/?Q_O5R2C.P#7(*Z+K#<5HS8U0UZV=36Q/H&?EA]]UWEMZ0K*
MX<[6M;ASCP@(U_?/O]'>G?-8$#L)#]!<[OO@W\3LF"H>EV2J]4.'YV&V5T)W
MA_IQ)Q_YKHP0#EU%$E)-?+C.?]BM_;^R"/3)2\&[J[Z3UMPZH7M\RVLUFZUI
MQ704OGU(!&P<9D#XEU11]L<OMDQ22F)8 [;3DIA.V*[]56 ^[BD-:Y\G0\K>
MM[TVG\LF2!&_NA]^<OFM#7ESIR_^9^0[^(KG4-,.M\N_)!_-1):;NMS82#4Q
M1](-9"@#5U5WVN1:2L_&YZ3RAVS[I-E,/,]6OYC4)W58'H2GJ[^__!+S):L9
M)3^%*,*>RVA!=$)'6OF6*Z(NM2=BR<_.UAL"4G_:5TG+%WH46/"9?O"E=:9Z
M%H>:/*+?!U_!&UY4+!&!G:)"'Z@]RF&]J W/BSYO"CXJQB2Z1R=-,L=B%@BR
MY3IGFQ('3P\1D43@ &+7='0 242HX/9)&L6$]\(SX_2N+V7:C]E-EH\LX1F7
MJT.J.CO<R<Y8ZJ4;:/Q"Y1N^-9(Z%EZ# I]=42$"P<.D"R>8VC(T6@S.L)D>
MN(IU<I%=XM&]=$EMC'H5]C0*JE"V-]X68%8>BEI:Q8YPV@MFW>=ZZY[7_1.N
M*C:+9,48$C1*$43@+1SK;B *CP+K@D612!/!/ 86]O#\WQ01?'3Z:M^IMJ%<
MR$D&R &H\E^%R]O:^_V45;W.?]W;EDV#?WEEN9'#_I-?5USYS#4E,KGB1F=<
M#R?;DQ7/]1_T>Y%+J6'&ZM(\1MQLFB3N,%6T+L=H5#<D!A.3H52I"?-NW:X.
MZ'V)P=ZK16$B.]IO/!14E.NHQ9BG;.I_1%#94+JTZUR;PD$[DHPFI<0';SY[
MWU_=]24T[T+5=YTB4,<8+:&;)M:@J=GS2,/I..96Z^_?"/)9R(; WR-![1.C
ML;M-8P\YEM?T4A/K".3!<I&7&GP64R.=.4T';VA_EUS3^=/,[%9OPV 9* +@
M0?G2\[NLFJYRO.U!W*-XH;R>'PXW7ZG1=3;Y&>S\E(.G!(PN9]_>XG@PGGYV
MBLX5H*4.,DH=\C_+PL(*.J0C/XB]:6P,X.MMNY3]Z2Z6@U#08)7[UNLM9<L
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MV/[,PO23ZE9TQ<:^MJ;;-5F+QGFL$^K[7+O4&P;TW%G( M?>"B>UL"K1-SQ
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MJD33;OJU\=ZU8UM)>'=L\]^Q; I-;0ZKWHI?*HP5OK"M9YVE$QY?IDR$BLZ
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M=AWED&^(-@[^:.9R*EAGU0HGDJ_"JA1L$*0^_AC\(OW#'K*E]OE2FE4/$[8
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M]VG]PJX?6^AH(]!T78ZD9-#-JCIDIT?J4FRR_ODNXLM;,^C^4WTHN@&G]IQ
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M>S\['4#;2]+%>_$@M2SV.1QP^T1AGA_S%D;U'[=.YQT?&M?UM:LP]--%;0:
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M2(M$ZAFBUDU<JW:\@3EKW36RV-'5@F4XT9#BVST[29[%P?#9O:=>O_(C%7"
M#-TA5_M/(@BY!(3G@K;0CW<+I23<A(69#?LJ:,3<M.G3RI%B/K[^SF\1M)Y;
MO25*<,X#NO1BC _*)=%E?+SYS6AO/)/*LY9(ZM9V <937YG#3R"MS^<>VP8@
MRG77I,7+Q5LWDN[)2YO)*H U#*L#I7C=#+I<TTV^IGD:C)\E'8=2+ZZK3=&
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M5U20'_24+5(<+[Z]!6G^P'BC,5E<^I#HF 'F[T,PBXYY%*$]=LB_V5U")=E
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M5O^XY8O"[<NG\^4P9(ZS[>G5S\T[9S@@R-WU5\@C YV,;:N&G@H7S3CQ^\Z
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MK*@4Z(M87CU-H@Y\3[!HBG[VTI/-XT4#=$&K%P?0'[;R:]\-8EQM4C;%P)B
M#RWIQ)6S+!8X8,)"@I[)PB%,J*5<)<!?0^$)"0=GM-L*,;V$/4K+".62?+.(
M=90I*9U>8CE,68D-%IHQV#<2JV[LZZA=87O52Z/J^Q;[]TEM[$#XW22L?!KC
M_6B1:Y0^E<+'84V\EA[>G5'K5H[Z4_+?59@M&N[%^4/&AH@S,1?10<Y%"EQ!
MSGHI%L69^W=R'9,$(@D9)7=_I328&"*VJ.=5UC :ULBEQ 3UJFJE"78[SL2P
MDYB22\#!ROA7*6HW5^A7=$ZFX6"6)?TN1U^37K$1G4Q8:P\'80D/ LOKQ6W+
M<B)6DBQDMT&_>V)@QLFY>IF=1FJ#/)7%,96M W!7\,>2&*'[VJ@WOELE'75Y
MSS.0WSC1,;LVR6'+DT8PAY!!E2-MHRO ="4%0KNK1T.*IA]9 W/7!'L#M?SS
MP&YQD?Z"X?N>46!X.N4VDVN ]K"HCL4GQR4!(E^R#.YI=:*TIL-5'$#I([9>
M9G6_3B%<V:C588/<-=2/,RJLY<XE0GYV)R+G95^ID"3NE2!DBE#\+=JBK/S;
MO6[L :.ZPM:H_79Z_?M?LR?6PBB2/G>6F,I+*K9,IM<1+!*T<$7JXF73DV$A
M(T'ID>%VI;+@@3&U1_9\!%)YHRA1B;'3/R>F@M[_>:KT9WY2-$1K-ZB_L^G=
M^+PBE7A8:BG10C2%#>8%WNXDP'" (?*7(3$B;E$_ 5GB@,/UYE,ZCZEM6MKD
MEX+]E>>$3U #I3??%W30( ';Q&J>6ZLRVSS5:,'<UTS)8=G8$8J;&1?"/L\[
M2%3!9T2VV_V)1X\6AIH$W!YM-+$R5182>N86B0.B\6R?Q5[&1<:@KQ9[G>>L
MN^I+%5CG_U1:FIJL<9MD9&2-R9?D#CROY+)F )OIXCOP'V9:E^9X04KTT3&R
M%6-O)H]U21A*W.6Q-Z3F%GWH]G4[=DYN,2'.7:#G!%8?+J7DCQ"YSI8?8[Y!
MC[;P#&DU4;080X&&ZZ/2)V!?MS7!%9O[KH]*/];"-> SPHTX@"RB*_V .@1O
M!_$.'6G=#XL!&\4[WH)R[LEM_ P;QG>P/[ _:I6:^A?=#5X\[=H1E"2&..GF
M(N@415020U&S,55V"MX9,YS/U>^ILD02WZ'*,,0!LZ]J^$.J[*!H'"!771NI
M1%U#_O3@AHQ)^AN_3@_^+3P?W=LY;\!+CMMS/G@V[U'\#MLHAZU2&$=Q80?W
M3*7R,\-Y^JCWH'^:[^R*\FP3NQIZT*]F#557*;C^GHY,G"++0C*TY H<MB>U
M,7MXSH\-M%0G1V\8H!(;4!::LF'B(;![[%-^X8=+C,KQ&K,R:;OY7IPH[Z7(
M+P]SR93TU'KF$X^O;=H9X)W"9;TL:G5.DX# %QEO%UG8,NN-%.81$8?,MWC9
ML"*:TMH3)-K/_._*>\3DMY;<%)FQT.2.2U-X7AA^[UF:+^5R.%4!T<ETRZDK
M4JI J@!UU%I")I2T>73VL^S9K1,8NS2&Q[8+LL>Q@0..*&KPG<U:6PJ,]H&2
MH^_!U6M$:UN33"*M7XE.HE^"VHK1<.PC;QBVM1I\REO4GZ!6C+ '7__G(*_7
M!ZB>&S'V$049MF$!JST9A7[R\SNB:Z(9$UR*]['F\6X$XJ?P;A7^RS6\#3A%
M)^  6>$T,O<+4KYH,-XRT*8?GG-A_1.1/G=2]# FQ4I27B/>]^<<X0-N*R,Y
MGGE_GB8MB&Y$%E2H,_3[$ JG93_>_;4<7%?>[LIJ^]#8]WCM1=\M'T*+).B/
MTZ2"2J:S+2EY]3NA=(KP7!5P;R-_1YUU;C&R47;@2,C-F)C+[2S[PD.0+$BT
M--F+=_X<VGI<9KBFQ4[C>R-<>RH><+@'D9('<8U7>ZGOFG:PW1R>5'6J*J]*
M.']=1<XD<SZL!.'_DJ,%^A_LO7=4DU'7)_H@8A30"-);4%!0FH#TKM*%($B1
M*H(@O4DOH2.]@_0B72#2I'>D*+U(+Z%W$FJ D-SX?N^:>;\I:V;6G;EWUMS[
MQ\E*\JQUGN<Y9Y^]?[^]]]E'1',=*BVL=!&->%4FU"E!F[X:E @CX/"[(#Y/
MZNC8>-/JWSU(E;KL>O/S5]9X(WTW)WDH&.W8J2@//M71I&UK,]ON85J-A](_
M_!7#KQ[&#A>6^>]P$][0#A78,2)U<[S4;;K>;D'FF.VK?ZQ)NZ](B((_P@'!
M"2.P30*\0H&I9US*H7UGW)Q4AM\[,EV8/*OKN:B[(#PQ V$)SC&;UMS!J0U^
M02V]8S37FVM]:>"K,MG@^F.)]Y-==(Q)9::S9?O+;S7&S8OP:QSBH$NY JDJ
M_.PSBU#>(];N3_7"FDK78BKCV0#/I^]A"Y#H*GXB]7YI-3[%3?9K456E6UC(
MJ*V BOH:UQZSP>#>!2 6/TS0)[#< -][;,,XK<+6.0JUE5HK&^A)&L"O>V#)
M1P"T1[W\K*YJY%,:1]VCVMC5NK1?"4+]=6\&P= 4/.A66L=2> DB-T*/BT]@
MY)9F%&_[G\Z4;E$A*3Y,93HDM1$R%.](0U3T%N6Y$ZER>!4>N%W?-^B>&B]?
MB7-H.X$SH:CW:/-T#/IL<K;4MY5"+.J2C!X)GKWV5[A8P3A+\EN=SD [IJOG
M^4YON"]P/"A^REUQ8NSK&=A^^JA) V'N_ZF5=D=(N<Q2RN1[=>1;_]ZBT:I[
M040-=VZ),V54I0)G)$,1#CI>7&->>I*I1.NYA[)$J;U*P=K.?=:?SF4P#@<:
M7D_1M>#H\O+JG<:'E>/&4!$RADIE)FE6<F'FV)X6^1>AXC+(V8Z9PLY&"+B]
MF(2#7O'M;GG_-V;M]S_]6'W;DFSY1)V7<]%ZR%EYI.; _'Q++559T<#=T 6)
MDHJ>& 5BFDP%AO@I>_9K4$8OXS$,R3+1*/?QMV\I=$1?%.\5T;R7$SEH+^_I
M:&$._VE(6_D'X;<4M:?,:2OSA)!R-3K?"W'Y F^PPK'M*-@FU' ,67XZ"45+
MY<PMS'7:7)->6TN5#OO:[Y.'9"=LR?W.U>2$$*O'A,/N69 K9^10'8I7G&YD
M==1N KEA9=Y%;RV2NM>QAPNC<_8?ZA)-7J/CPX J6>.WZ-F.AJ#AFFH44Z+X
M*L)$N9JSYRHVT\.E; 9@SRVQI"O(RIN]^JK>4E,5('S$;:8S>?2>"-"#/T.U
M=AN(M3,]L*';46JHCWVOZ-6;(=WILMYX6ZK;D&;"7,\3?-<BF;^BXR?C*+7)
M;GT?/$U2"J_3H<G8YOM8.5_))"3\\P.4=K!U3=T[-Y9&]=_T,4J^/]U9MO0H
MVS'L#;75:&7$.;=Y& 6O:'!LA[]7S\JC1C%ON>[]%XPU:TV#-Y8K?I5*G[3]
M35]YDC=3D&'#(2MQ5:K.\\8]4>%@.!7H01E]YJZN,"_8NOMPL+98<4VW>V,U
M5/I\/;ZEBV90A-57=)*MN'T)3+K-GBDR\6#"N3[W*&*F])':F[A65IE7#N5O
M(MA!44YZ5#:4!]UBC9$=,C>";O[X8%TPF?+[^P;MPS>F8 2<Z2K;M#9\.2GZ
MX=P-3],QA$4NZ9M>?W=7;OE7$1'#H.*M5*-.'$#!K^\F>CH$'<]1U_)F_OPP
MFN%#;AMIO;77+YDMO07*2;MR6W@UHX,)W9^4JOXDWAINA/5NBKSU4K!AEV<8
M<BB0"C;32FLK8$/<>2DD7TU>_:-2I3Z6D5;3?34#+1E ,_3JDKM2/"L\DS()
MR%4.)]FT577GY4GX)770NB/-6/9/5SVM(>MDF1<OXO>>)?(>49[L+W\"IY$W
MYO6LX.ZF-"R=ABP.R";" 5=72JY[],N$%H@!(9G07L^MB-$5R/;*)GCB"P0-
MVCC*^=Y 9[E]@^J2Y=4[\M,%X'UK[ U?R8WADW"CNQ]==&OB;6L;0S] 7V=F
M7P;$>/_\J!WA,YAY_](NB*?ZL1&?Q=%Y[+7%PU^OT@EVV_%,WLU'<DB:Z2V>
M1$=>F >*:[CGZ%M0NY+/[,YSVN;H.7*@LLXJ=+*0HZD\5P /#CC8UD[VLL&C
ML^9R'##;BHWO,8CVER3:RGR,M,THF[,2LO_M$C' X%"LV4G6[9- ,&4!J98*
MLBM/(MD1NQ+G!QXZOV5AVGVSZB/7K-M],:91&7;8O<Z1]E9N<SVHDP/\GF,M
M.K05M(ID2KGQS:+8^T>WHE?*]<]D*R9QS;=(GX(+I0Q%6Z<[N[2YW$O<'-\J
MZY5*60?=4>V@U41Z$M:[G6 ^$K:BSGX.2+6)[M)I+J0X.[/^^.W(Q*8&</Z.
M\L2$')7K_;N!7FG]>'#.[@&[\O^*M_V5XU)W)&_/H@\Z;Y>JE"F;=2 0AW%S
MPAU!(GW&^'E<J]UC06RQ:=:/U+"_ES @%H$$RWH8!8M;X$$JC=ZSF4?YE.TR
ME[VJZ@HX8.%%0-3TIN<]0S'ORV?OYVI"0JN>,K">?M&2.KC!ZKIKU6N[YZ6(
MW/CIHU<]8_O-TC%.SNV#N*W&2$($-ON,@N#TA/*WEP0JP5 4F4#7T/5]#O1T
MKJOP_D-]<Z:NN_)_&E(!CBX8(O^9T05@A$=UXW!;N!_7\M'^^Q"71=Z.#=IN
M57;"S46TA0HUUI<:!YR=/-D/OY3>$OW36+CU>C.YHL_3B;&R42'PL0OQK=/U
M2A@BE;-UTPR/?]KP8[-<@@V]E)C>;,!FE, _%R:6EN?6DZ6I$2:\FQK<YP\#
M3L.>D*3M*$NT6C;XWSZ?7>^E%MZ)N+*PV2_;7^'3@U+TWAD=J7L'+I %5/Y1
M^^)1TELJX?$/&8/ 1:K_;=6.;:,G"Q<S%KP9L;]*8<P?KTU0:-U>C,1P&+O9
M<&/D\]OM\VY$*5<3.>T,02(!.VV>E0,Z7?2]CD/+L[O5A\_\2=QD>E+N7_=5
M%:;18KWT6&X@X=B14)K@+K7-;JB%-7*2@^0NR-K+83U8JE&,$<)U3$"OPIPF
M\4/8ACV3?@ SDYLX.>^F"N!H1(KEDU^)-#1X<-'.:1=&R\Q;_R&&U-11F"7^
M&*X)?X(V1K;*(ETJ)'.86JG@15]2A3'9117="GTSM*'B=YS\TCTG2X8)9,VV
M,YE'JE5:9QIJ(D.-$ZF%2&B-=V]M%%J:)2[;D.B_;]"J,O;8YNNSLR__?0*L
M?GI&\$V6TG =.SB0:%N^Y/?%])8I,73]X[6?E#J6@EP6#V<69M,^'JV_>F@0
M&E5OO:2E4AOEQ>8J%6NW;/- T:GZP8)\DN3<$5KMQM5?M>(E860_V3FQ^4YR
M\O>)2 4CGF;!7Z[]ST[K_M^]<5G,>'=_*]:S. UM65Z6C>*=95W)DMFVVC:Z
MZ?9^ML.'*4 UQ$KIQF6H-%YRMGTR0KY3=GDQ(M^.64LA'K1$E$V,VOS0\*>Z
M%]"XO?A[Q_";H<LC./^:'DMNNG5Y1QA[N8;:/X/RUYK_48J_]!]U^;\I[)J=
MX6]?]-\#4/]'&E&CT8GYCL8;P=;MH3\%I9GKX?]+Z@^U_K,._[C6/POSFYX)
M_&<'+8*&%JEAJQ[)V#IYS+<29'+G%4E7YNTQ'IX'22(H9G,__Q1))_]I$.NG
M<NU_%V).[H2<LUVX7E7C@.&9AH*9@E3:7DLC(F5]Y4<9)4]>1/105.S;Y;R3
M/X2+3'PR,.KPR%-TIY_5+V<->VD=)?+K^S&\F",!'9K[HA3]'-FKR5HC5Z=(
M?(/E8Q_AF'!1D+FG K<VVGD%A)*+Z7/];J1W%QY,&^-B[7P\U.QV%CUJ!6/:
M=N03-QUJOJ7.)T:VH]U"91F@@BKEI:F]*E-I<8JL9][  8QP)73X$A2M6!9T
M%4]6+)VFJ2@<2\!F5[$ZL:5:&$_HVIXZT5*+"'^,J#OZ$/4PR@OYPF]0_D_M
MSMH B\$?<;9BI5/'YJ:=+ZN1DQ''S,7['-XMG.BR& )G0+C] ='&<7$BR/M:
MSVM4FFZ-&^=QD:VK_M>41Z$>1"P1EZN?"C#_,4B\TV\X]+JENFYBG5SQKI=$
M5V#&H$,W5&/ P_5OI!EO:'FN,LL=U@J&*24%<4"OB3*>_;G\=7M_1?/C&6/B
MY)6/$-:W9M#KOY[J;_D!0\%XY]Y_?8Z::O_KU\*R.J2-4.4A.. 6*&A_=[SD
M%W5_9)@M<_$@<-8M18<"AUQ\1^(1!%?J&JV6W*6XWZS90!?I#V^.S8OSL66M
MX NI\'U3)I,7+MW.L<E DL@[L-<]I? &^W<10V1X!ACR\\PI@5R9<Y;RG?X^
MR6'$'0R!D<+'BT^B<K%6QG:M??Y/OS6MM=+A[Q!X0;]M^%AO0_$EU8M^<H+#
M@Q5BZ' \6KM5O?PT;)-T69)3EG6!Z(LL??W;V#3+>%_^..]B'\H%&8<E3YT'
M,7CBO_,$!WQ*8O4);KC\K6"W6UA=ISX\1"^WQ/!!H7V]2>MP\BU:8QE2,T-=
M/\I-3R-"O%+^9R>81OA9SH%\?!'3BJP[QHC&Z]G(XT0[LMYSW\]WP9,"R>48
MTVIE!Z80*]8JT>]\JH+GYF@%AOV+-R4:WD0F+,NFA5V28M]'CD^.N'.N/2 !
M2(0&)K<,)KNRM1'S: GISY#+/2L0 A[(\[4IOJMA& <HU%W_25&<3"NR.#0O
M[K!KE?TW+Y$5![S& 3]@%W03/^J_4@Y_@ 2B2EL A;D/=.XR3+GU6<':CA98
MX8E/Q5]D*-*FW\>OO6\/YLUZ;U6,EL>+"*O1"8KMB#(6!6D7JEJ,)OOX7L.M
MCI_3VC7N!B'/,,%H>+F%[ GA^$<X%WZ4NTD(\G.M*@9KBUR2@@C(P0<N[:=E
M)%D1DHS*%KKSW*M?[K-'TJ@-1!&(+.>,9IQ2AF=1.!=]&KH)M6PWU%N<*[$#
MBG8:&7MH,!:2E%MV!6B^QTR:L!\B=0"IS76" !S@-4G$6-Z(TNA2,YC3NTI6
M^?Q.X=Z3\$QIX?,T@7TJI*R5'</=[MBN ,M<;H"IH\1GU]TC(BZ,O?3E_]L!
MXO_!X+'^8J@7$2*+1E]&LK'@JER!(L]FHX]I6%7AG,8<E0T6OTIK77TU =ME
MAAWK:N* J):;=F1N^E9::L'CGVJXV\"I"J+?=S!2GDCA'8.S8 Q;KIO<+ST)
MXM^[,<ILJ5OK32G6!.GU;-F4E;]HE;X3*;2#<K+!B3XWT/,8D>6?(^7YW6DE
M=1'!XO)"+XVWLAJ\W8[AQNBQ)<]H&C=5D6-TJ@%4Q2SI9C)M+#W]N.?2-0F7
ME6;]^"5XY[2I.WWG+]K0]U3[S@P7 )IP2MN50IGT,7GRDS *:L=^Z1/6.&C]
MNJ\D/U*H2\(.<8(9,*72LXCBYMP 69&U299T3AX-N#8L[D%*%BT.9[=$644_
M'7*/V)_=<'FUD4C_QKR /W;7:A(#1<([)#D;K 9>J!P>T!_HZ]:'+L*YHF@N
M8Z"$Z9JWJ9<*_9\I]^Y/JL8=?HQ26U R5?-60A:B0$?9X#CNE?JH->Q4/%>G
M\>+@==XYH6M.0\P!F><#WLG_(2[\>@="W$0-WYZD*RC,/3^KO4YK>OGF=YTO
M@- G:&,D^H17O"ZP*?RG)/0"/(T=6+.5VC[=FTW?**0=_$BX*A6P>*CU#'RQ
MPX8-][ADJIN'(+3]CV_K+KX9>V;TX'0NGB++,N5'W$UQ_A@WMJ+R7[Z2+E?9
M7B2.#7'HE@[JI(4W.@>G$>>OLI^('/@_Y9_RV^8 MV4Q"D"(/R(W+Z+2!3B$
M"708E-?ZZ$[UEX():WT\4&$7L0E\B>^(8_W!+PQA95Y42+E:Q\G;!1+I@XHN
M50G=M]BD7!,9+P@FMZ29M)>A,QS:XUR!='=24TWLM(3(%1XY$O0!-H!YH0__
MF+C'4 ><=H=) +F:W-"2Q$7W2&<4X4B^$_7V311OSW,Y:(W6: L(3:V<829J
M75O>+#G-ZXQY8PQ=ONU!]T"6KH>NY(%O2<E3@!&@ +;Q"$N2&;6(29 BQP%3
M6CLX0*[&A4J*"6-4N'7Z1^U%_KD@BE.QX0:;I>\-'YB,X0$,&="6FOG5">:>
MXYZLK=XT)C6S09\1RFD/(63-3#3"4B1W#EU0MQZZK."E'@\Q%NZC?Z](D4WU
MF4A@7)(J_2OES2%)^@[MMGI,;1&K ;&Z4B18<B-TR\5M9:W:I%EI.=+^<_D&
MFEXRU*\-6EMA-I"$I-]H"Y4;BVRZBCEB%OKTZ0>+WZIOH@+=@RK0VOHEE,^+
M"*3;"+.SB<\48BV<_KY=QZ^2KP#0!'"L\ 0O'JHWB>  (Q1L4_/T:VX?O=S*
MDS9_"9ER'A6T_)(-B\:/<>M/4D_V9V0XU;W+768Z<]H=P2O2M$8T&)-E&.BC
MRYGH[73#EUUY9_TMQC_$;<ZAA")+Z5&\47)>5>V+D!H;D"J5Z'S:#G%I?S*/
MHY9QG"I-C"MIIN@[ARGM,8WVV_U@HBY%3F[!)D?V#\:;,CN&3L5>MY"".8Y'
M^8D#*2YS6G^62E9/VJQ])4((?[ 3;D 8W?+<%G]66:(LBDW-2&B"Q?D%A8D^
M$SHQ23&+:8_YD"*=>-J_29%8;K%R.9@_4&WM(4M,N8RB=8T"/Q>;B+Z-84?"
M@LKC#G^_.K)C8<[_.9;R]N;F&T@"TSFAP,PPZ">?_#(DJ$4$9/%CO%0_P4P_
M;R0=#T*J(_BD) ,==JCP7QO"[8ZS2.+M09BJIH[:]11(F:=J,Z*9ONOTP9#N
M&*+)E_R-@LAS.;Y2$8W]F^7$T&D\LSQXZARM%NF$+;/U,1J_=S$,2K<P8O(R
M\5Q>>[KU?6%VKK*'*9&8<8[PC.':;+2Z DN4?TO(GT]?O%X@=@:>'#]S,)RM
MYK-A3ICCC?$P99(?K<+P+QG=1LM 3[F3*<@K@]RGDF-;2KNRVMYY:LM*0\@-
M==T"$/#(:W&G'AD1:8@$<)*L"$&(F18M)!14!W]=>Y4/'X/J[(L+V7$MJ9'V
M?7I]ZV2Z.JO3V3/D,X8M!UWY>S=U(8-R%%S7\V0+NQ-!AF;RG+P':8,0RCL^
M_,B3]RIZKF9D!L9,?W(@#1%R^]:ENQ@A(#]YXCVP#GDD^)*#PMC]<&RK4;A/
M2A"J/]GD,_BPQU\@@.Z;U.S@< ^0Q<4;'Q#]JYE0'6V'8-13K!C=/]:)C(PZ
MJ.JDB+[[?*KOG,8TW5%547P"!]Q&0U\B(Q-^>% F3S,G007&!MSYI@A%'*'2
M>%&X[;D"B;9NLHXS>C(EF,'!82&CU.7X]&7ZVN%-Y@U&8C]=)F[T 768%\3U
MJU!PW./R>!-%UF7-Z*M\(I $[Q9:N]'M:YL//2K"4B!#4"0?6B]*'@?_L;8:
M;1*[IQ\A!8C?INQ)12[VIPPEG+WD,4P'O!N&07%>A,,'/%@6F1)YDJMXU3#Y
M)'VOG Q:2J=MUWO1)@99>T1+>FF=X/!/FZ;)O>%]+2]I9WSC*DW@M,P7 /B]
MU4QU)/6KX6?'WT>M<ZIJ-&(9E'VAQ2?B=Z "/KZ2K]$P%%P#:9C0(#OAOZWK
M9?V*^?=:WTTV5L* V/ATLIU!45MT_&G$./SX[,?PIYR"_I4;VV]?EC?A .(]
MP&%N Z[*,>&\&-!R:W(_<]N&8W?RCJ([%RNO+1O;0_G?Z>D;E,JOT)1+!J(.
M_%-SAK$CMN6W7J.Y"3!.?WP9D>$]'AM1S\)3:KRYC*E6GQC))T8MQ3E>R]SQ
MB[O%<%I^;T6["T+W,74UE;%(5"OM08C_X5P6WYH]?ZA4",B?^KI'C)SWQ<W[
M/_R8:T,?!-T8CQ(@+I$ &)\DU61O&3X86^C4K@@^G&XG8C7,W/8H/KM.!R C
MI4[CZ@QX^B;$Q1@'IE0*=,H%64,8QXM[6FYA.'JK,Y[L_%S@#.ON&+YE5ZY(
M]KQ.)^&'XI*QIISG.P(CQ;Y+*33C^IV*;;)RV$39T.\+?YCN;A/O4O0=M.0C
M@WNOPA;D#2I5%=WU/2OZNN7LA4^S[_C_%ZH%@_E0T1T\:&5Q98=2F*UW\L ;
M(X[=-%2-]$Z3AX=6M*\//:P##'-UOBH[7:Q^R3)[:L=C>\<IHT=@X;5NPYC#
M:HLOY<I,<IN59[/2^O*8P>7#IDK^'KM3B65F59> )M,[&1Q3'XN#%#70.@QV
MODUDKDN?;<O2]"Z]TU=%.VPB?/3.F \DY%]'=:(VO*!XOD(N16ZXC6<\.,#\
M4B/XL*6GU19@=(TX/H:_R2W62HV/\_!;;D4.+9[@B<\JGI!8?\727F(+8)@8
M'+"7N/=&\\H2#NOE=C "8R$XH(/DZBL.N"=5ZUWU"P<DPSC,!A;W!)T:C\O_
MA''0*@X<*=L+PS]#P#@ (8H=Q &A65,^/>LXX'=K6JO/XFDRS>S%'U"P)"F^
M)Y%E92ZC2]@>Y(/C@O;4J6TO2_E15$OB=H)FR=CK-:@T,7MN)6&?\X&_T:S'
M%;883Y7 \:?U,W8\NWH_;$6ZO=JS?E7A;Y/5NFV. _K V&G#"5G;"@'U2F.G
MG_&G,+5MHZ[\>*FG>@SD$M%?' S@@5B:32:*%-M<11Z>\35;VZ=*#M$)=T"3
M\0<&^13YAGF):4")[F#655G.-IU=VIIW^8R"^$#C#SOU^FXYA\R4;]5:CV?5
MQ+7_=71V1&\D7H5DZUCXN&:=*FCQ"-G.3S$ZQ$</5G\L8]-UTHH'X/2-Z-NG
MWZ;WI1"LL^N]0[6[(MVJ#MC*YKBP^UIOL%0@@278WTU"M-F"R:>+/VPS"H[$
MX3Q%A#1]QR=E-B9R8R=[@LJWE::YN58ASB%/'")_>9)EYL)'U%?GZC.7W#+A
M2,J!3LG(4N; ^,_EPVNP)>7)5N,W-BW7+ ^8J74'(A0S7RD<,GC?--HP/)&U
MKM"TL0H:U&C' >!J(]#]N!$ZSPUUN*L0IWPV(X6WZ-F \Z?7.K]457?Q<ES\
MW[&G8L/+?9D  2/<GJFSK^PDN'LOZZ3LL!!Z^AD/F[&<;I$8%13]FSIRJMH:
M6,6L/^@6+4OT^]FTK ,?RNTCC"3'I2!781RLFIRWE*S68O'L,TOYRY?P<GF$
MD>16I&E#_C=+90Z=T#=SG,S4'X^.B/H88O<YM@2O<KVHAK_H*?V)D'5)$$3N
ML13PKA]G@Q^B'R\39F.4O\L[_KCX+*@.5D?C;61T$"047E8>FU>5^8S6+-*7
M*2\,+;FN\&#B4;**>]R\F=D/\W-3S=N'\?[V4SW/W0^,K-$\ADQL2+/XT@T>
M)]L"0]!%^V$K]#1 #=3=<A]97HO0^_SNS_%959(I#UT5ARVP(O58P$D&"0KS
M@A;68"/SE%TM*VDBPC:_V@.Q1V3;'&,P"Z-S\*;1"1[T!G+47F6VKJ:V7L'^
M;H?+!]Q<NWANH -DQ\MK(N5?Q2UT+*_*4_3_#GZ?Y^?K- *UG0A '-S::>%(
M=:N6$%7N\7NA1);X/*"M[ST(OF;TPF=D\1#Z# =<$O?@@-S\<I/3CS@@)N0S
M#MA)@ QL$H@;?]VF ^U.YFZEYE?I&;;[>/5^\=?^%/]TE5ST+HS.:/HK]CD3
M"PXH5X,)E7>>!N& .,NL$QQ C?4_Z<$.0 [OHB!7C@'GS8 3'J (81*^M.Y"
MJ+&!)[\L! UYT'Z4F0$%LA)KY6E,+(&2O<;7X^O#&7.BH/5[!D;_23$84%NS
MY,P00BM#G+C%9C5>12QZV9B%&9,(8/ &%P>085A1T4''I^,\GT:X<DG[N$K]
M96A.WHD01M6U[5M5HCE0SR]^Z_U =E<Y/_P9M/*Y[$-B^#/R3$J9G9JH&V+D
MHJ23H[:AG#8,8>41Q)7?>YE/KFMW^K $2]!W-U33>5*$_7Z=PC5UUR4P)D@J
M.QO\7=Q]A=Z($*VUHE,'%=3_7):# S(KOXO)>9)>@WZ70'*L_@[/HO120<DI
MU$\(//9953Q[\.J8<#^7]$28834]?;(4.SK)3X&<:)E42-LC?RI! N8$=UWS
MQ &4EMB!/U3A"!6]US=;K>,N>\U6'@B\?"?AT>AC.$ZPBB<0$/I-W4_)9[J\
MGA^#M^@6WB1DGSPI%#YAMB=@HQSQ8D&7P;*MJ%*9*ES.Z%C7WKW@,)UA"GN3
MM31(P BL?FJ_2&KA0F<43F\9D3O_%KOY1\RT[E=N>A!GSF=(J+A+-K@48[7\
M19P>H3QOZX89(_:C>-OS9=?^6^9<)C1;X/#AZ=?EZ%!#-J.G<Y:B@;L+*DVF
MNZ$>,6&J9-*0 L4A@>U%>F>2;UG!3"1'L<E[CQF.@.EK,C=7)+"7/C56IY85
M-9=,S47OZ%OYV/D<#@M('!;C)Z]&MJ09B";;(4Q3;\/;"U@CPAA^$G54A[FM
M (?RER);^EH5I9:Z$^,:EE5]$OUWRUI3V!:?U .\^_*O,MW66_;A<9(B4WHZ
M7J^;!4<^8T<HG'I!SU<=80SF.ZG *83$S<'K[:78]&;A1\]P^<.4!LYP#C[(
MY2:XH^D>8O)S =*UZ[;DH;IQ^."EP'+?X5[D9W#Z\>QD[3R\H.4NK(]]6&HG
M' =L=L-OH'<03MENYP>(B+*"TH(U!0 L)!SC[10L=3 ,FAC<HK!AC2@*(^'G
M;0.<62>[+M;6-J)][AM +2,?=A=[5D[3M@;&5!2S%5!_'*KQE.CI@@J=VE^^
MK><J[J,994B>FSU7USGI^TPUI)_57=<Z?=FY.-,BX:W^<OY&(D$,>3V3U9J:
MCU[OF2YP6B8O4X?T_TC7$DHX]_/KC+?_Q0S-T<.?!02<7\4;*@]Z-.KK=YT$
MAJY9X !R<>U<MTEE%.>C/P/W-:-HQ$?8DED4_6>[QX[>^?/Q#N5[!#G59MX<
MX8:OMP:+E4E>F*38/MLIYDI]$:/X+H(RM.>A7_8=#2SE7F$@EGD>O0\F:\^?
M^J4S/P,%R"KKZ'M2FDPXA>X(,SMOZ4G2AFUT23ZJ1P7UJ[]X_Z=C3#'XPQ.L
MXOW,]\VU,76]@Q.,_+I4+3=&[C>&[>_9GHA]2?-2MW1UU/\\*T+T>JHD=LKW
MYDEYG"^O+<88D492S&4G+I^G-_?2I8]BLN)KSC'S#]D7>-N]&("?"ZMA'( T
MP8,#2D/:E8, +-^DE^NW[53O0')=_:$6-B'VO(@[7:O:>.I(S-:S>$Q:BV<Y
M=3B@VU<RHPKE&EQ#7[?'Z?4B;UZ_USZFW9.^T2&30A!Z[8?5!D\(Y&:3,>(
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MD;R7-XIH=079+'^5*'UG#.U>](I6 JHNY6%]+\9PP"XE!!N9U,QRZO'79.$
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M)5--E*E7.H1Y+%G?'_!'+.)XL;R_OE"AL1WGU*\/!$\LW4QWW'E?X5KO/!K
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MPL%Z]DE!)_<Q-[*DJ<"8;B^>I>5Z[.&= 'B@F?.P.^P%*J-YA]+34CUTI*Q
M?JHG>(OQU4VA:)YYJ^B)R6HV <2&BPX1NG0A-)8FS!JM%&E+%=U3<*TFXN)W
MV?MQU>0RE&2@*"O'WGL"Q.,*BHM4\FTL? VPG)Z5R5XQL9M=&GI/QX-QSF:W
MT$Z+&>&^S C>(8D4![528][Q)-H.9R$:I33R53Q@S>[AJ:"1;R/"=2K<4U*M
MQI^=]\CY0%\6#[CI&_PQG"Y@/ *V 5^"9!E-VC;/LNX(?*@=?7W)2DCS8OZQ
M,C&00*TSQ$^AC4$@:BFR$QST1)Y2)84NSBK<W._*(^QJ!QF!_F2#PE@&AT76
M#TRYPTXIXQ"Y"Z+<U?<9>:*V>C5,8^UZSS+K^+.:%B*UO0=[!>W'B_4OW,S4
MY;YI&4J<3Z).,^P'*(HT^DM^1\^%(D:$'W:FZ"2[.AK2T0?G'8'R%#L0CQ5]
MMTXEIKLDP;3&VV?=MRA#H).4+>!$SL&&\'_]1>7_/Y8Z'QQC<BATM8,@:^&B
M> #==<B"\:Z]^3;K ;:=80EASZD,;=Y%]6$Q&WC@: 6,D]7 BHA0XH&^&!@>
M\+?$ XAW>V<,4P?&UN#R^'W0[Y5O?_NU.7A 8\0V[*^F?S7]J^G_5-.=+71'
MBU 420SL1\?)>SR 6=;' R%#"WW'NR/0G6$H]K&G-OTH2RI=WL3V'*K&E[!!
M*!G#SDYB\4!D%HY1)PR\VJU'6.2ZA$7NOB"A>^ )DE><^JW"#=J\CEK%'MO!
MCS; N!MU5R.48,"J=>T?7\=B'BNQX8$,80/<F08>:!M[31CC/-OFD=-O%03[
MER*W)6-O^2L>F,LCC+D&E2IP4D?\,7WK/]2 %]PPKCC?<O/3 X(2RVA&I\9I
M$.!:.@/_XWL-[(T,:FA?4@&!7UEX8!'9;).U@:+V\*G\K6+M/W+'SXRHM\_C
MM_><O_$*1O8YMJ!1=F(_.52)RV96L"YI\(>IBC/+#IG+UYP.ORK+-.<,V!B[
MGN^'+QO2<O=RG*#/3V]PO5R;Q86-[\-R%:1A)I[)MRJ'BZJH1;E?:7!Z0?M>
M&"C:F:861485V^NJ,83_S^2P/!\'+3;O.-:;S &=+&.A[QX7+E<[CPM\CD@(
M^I.W O(C\R;,B%VI.Y8S6K^(I^3#-*&73W]V2+++6W]S1[\_B0<*P,:IWWU2
MA8/^"Z#\<V>5)R%8Z$<M71-H'H%_P^6)TR/_)6$\_]G"P7-Z!_JC\C-T;(I@
MW3!T^??AN ;V*7J\M<T?EI4860:H._*1U04=MWLC3L:R?)U0H;6+9W1:E?V%
M_F-"C$*[(FGQ6P^J^GI;)!>AJ.R&*WB@OQX/)%;@ :Q+@-+;#XM.05Q1M9@,
M;2X/2'#&#ZNQ$-_'F%K&R$Q<4[]OVR!#2Y]\4)'+(VRFB!4(E [I(&9;T$#=
M6J2KTN]/N@D-AW$U8M-2]SE!_KTXM9^OTH7J8YZI%@L5,6TY8EYQ.8^'8-?.
MB4RL-CWD'5,2:JBTTD[7#GRIOKGJ$^L80>-;F>-#$Z,@RQBIP)J_MAV8G7KI
M"2_B14$7V^%Q0%^%AO=41450[Z2\O2%/$.E;7N?;@7KT;@ UD&]#O!@+PI0^
M0%'#7[DZOKX[NF>L10?U#"[+.#*]AD@[)][CZ,N :L8D+O(5]$8YN T<3MR4
M$<I^\0 ZRX6H>JB+M1LJE-B)8$D=5WAF/>4LQF/=_:[=E-/%WPG#X /:/%K(
M':QC=RV<5OONH'_?DA^6D$+N/"5D>AK%>0<XJ%X-G02E+SZ*H&=-AS!=SSO@
MW8?Q#V\K_<KP\&A2X<LU=UW::U *+R5;$.O%785V8C9:=3EK$$=R\5J2$D__
M]G[T'7&^G,$7+ZE)5[F"QX.(..8-NF>O85@7>\@/\$"IPSV8!42TQREZWK7E
MBBPH9H)=MH^>2+I-YW5% ]&WX(??1ZG:RO:.!1U>!MR1X:4U"&5B2[LA<U#<
M<>@X"GL>9C3P[%5"[[2&@OS[^(L630'[H. #T&A=[]"">>Q!Y%O]?MBCQ,J?
MM4^9=#>T.-(.L8)K<Z&<U)\PT,]:;*5\[;D>>L5?5':CK$E3F"?%O!0A?>P
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M>SHD]H)93K@!J02O<Z))PC&1.U&(V0#)Q;KR=-LKH2O,?%$+ VR7S:8#![_
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MO3CHKGGAX]?.> [6FS]]KB?^<+(<*^EC6&?I0:[7<'R"L@C6EY<E7J]4U8,
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M\AUSXZ?3DQMQ->_;;_*JW2@Z%HP!UQ][2W=DL,]XOE*KZ"_KO&N0FE"J+9;
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MQ&W: &_U*3SF()85W*PFQ@I*MGOM]R>]C L#KW=>VD/=D_P$DFSWG+C_0B;
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MJ1J?@/.7IOKD%[!,P9T>R&,_49QC#'!P\B=FRNJ:<!@#?.$*IECON.3.Y<(
MWPR@Z%C'AF(_&_E)?LW13U]V,YZG/[2MKTT4GP^(+R%D)IG()7*IW&QHC)7Z
MG$ZBQAS+8*':A15:'/$ZA#_R\#HV(/96YP@,4'ALU(:R1 8L2\,//(Q#;R#6
M)H>A[,0*_3N#G#C9MXAW5-YD[O,&<</:A(^?#%-0[!I^T-U^-6ZBPE2E0$A&
MH*S @:C$O@+E/6@>A$I/PNNU)Q*ID][.#>*^0CGQ*II#@?%P97('9-8Z15RK
M05%[EJ\W?EUA.'51X6N08( 09W9 _"IT)F LPHN"\E"Z/<G6;_C"TE[!]DI"
M=]RW8DD$UA'N%=-['L+\S41%)14D")D*<9]J./M,08OD@O>?'YF%]S'.%"8;
MS[,)3TI]<-(4@+<379=/LVZ0V1$TC\VKH)^-\*"[<3& 4EN@K-YT;;"(2<2]
M&=%]C9V4AC(+^>]E]4+)],RLFH ?Y&^/,9O)2P2159WU6]W9\3F2W7#X?KPD
MY4"ET .12280)-"FWQV#[&8^2,NOB"MR\#$D?42@X.220LCQU2<TMR[DK9P(
M/*\7 ] @[R]KL$AO,D+=0;;-\<W]2^?Q8:UGP-E7OYHU@1B4W[CIGD@XT8O-
MN?DO^G8[MZ5X%]<AD^V5LS*$,,T0&[GBS[_&GKRJ;;<<<$%]7\WKO;J:SI0(
M"Q*"708=\BA6UW\D(S9D-Z>X2-1V-05.DD)7R%U:)?#:[\\>9I(K;X'XEY<5
M(B,YPC1P)Q()6>3WIV.GD(/P42O&7PJENPJ@>MZ4]QS,P?G\+2(WJQY&#3\]
MH1S3Y:G(T/5]$&!?O6)AJNW-^]LF["':P Y7TJZ+1.A F^4A[J;LG;Y<7CCY
MP?DLW8> -U\P -A!-,AE_4AY/3S>\ZW3R_T^.1"R6(:1.\\](+Y'_!Q!M+XG
MYR#^5I"(N0&7=A?-@!R#6=&8,5FQ.)P+6A"3]!^;7HX+"TDR1_+$KVXG7NXG
M'/JN4X3)\'W1RF7)F-R#;_^HK7E7$?CC^J<\+HM(>!KJK9P;O%>3,+'6WCAL
M8D_G$<?79Y^-%KT1 ]UM)$>]*]2GWTLLGSBEMS6EN0Z5);3DE0,="<'>Y7L9
M\_PIOJ7+=^_.5HM^?\]P3WZP\TB>E>M:&6DL6Y6W%N<E/]$PQ_]-RMH_H=GG
M7NA8&33>CT=!CAOQ-:T@Y>-O%QIU897?T*V0O(/(JHNUAGX:1%&L?3-?Z[A#
M8/CH!0E>FJ ,@,/^</4J+?'C=OE-#HJ%KU8BA*<MW#4WS^X[K]2CO)R!:G8@
M. N:3.%G0/)%'_ALC3.N-_%O.DS0""(.K:Z) 6X\H[!;MM+C2B!*S)5*@]=4
M,VU)C3K26UE'7O;R?G/2W_K8G#XCB3' O4,K=)O1G[0P$\WNL-2#2'^?HJ^6
MNW3'QGMW)\W,!R[6DZV3M'N66Y+>M=^9E-&N^CF?TW_R.M^@>J&W1W)1^T*A
M7R4H<2D0DA!")9V83A?]9HU@Z\>;)L #?NZ*)+ZAOS**18+-F^%;+0[E)JO#
M+M?U:3V0I\6_PI2HLBK5$1.AYR1E^1$ZM/*=@#6.%6^0%@9(3:D$0VW_*/;M
M.9-G/!8V&O73;PJIS<S[.97/99.^L! =*$ ^MG.#!U5G._:_8P4ZJ7FC[&.0
MO$KP-0C\$RNG75:N#=O*V@W@5DFN**KSHV_S"]KG8P+@O);-N1;Z+K9E,2PJ
M=E]".W9HOZ+UP @# _A)C@HG8<>$.6&/ .L*<N7Z^>%L_7APTM#<ALMEP]&H
MA_:%DN_9@*2D1GHT')PD;5%7#RG<TV4W.>)(><"!;&W+TH:2)W4:X:\Z"Z^8
M(.K37OBT5&YF,]RIP<>OS[.)#Q';!==2H(8[SK&2N;8\%&GSQR>HA%6J1C#
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M70*UM&[@'L7;+=?)_+UC:VMH&:JU)J<$J6C%2M[[!!$8P-(= SR^%&__#J=
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M2[SWZ8 Z#(4+U]HWGS@%WZEJ(+NO<B?.T\7L73*BQ3>X/=NN[460#P9(A92
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M=($X:25^-LHS_",SA^^>:^D_\AEUDS;89V)R%I_@XX496_]UJ+0C[&GX,/^
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MEL*GGT7)LF%$#FU*IHW+W6VL& W'8(7'M!6C40RFP2K!B"G/^]HD8F-4R\4
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M.[0_5E7__N4=FC@N>SL# 8X=M;MC^FWDH9SFZ)U1W=2%3G*):L=A!@8>V<C
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M%3D%)JB::<;XIA"F?Z:)73P?&*X(4@P61N<\1&RJ8B>7M2.&7>^;$"3VNWV
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MOZ-($C[3^+K0=F\"YH(:>^NFXL:_%WY+_$N^&LL4?=]L:1+^&&='IG[PH43
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MO*O(K*" [BD*D)FOF5('U]3B5Z();>O7>01ZBC0[YRI&':%@B5^H0H]OGXS
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M$Y^+Z,*9 8<IB67K=.N/ZIR+-)/)-JKYA\ )U</@QP_M>C=CS9A[/<0LF7$
M>;\Y#LBU?W4$Q@'TEF7S%MHZM &TO?N#VUL""6X#W^!782C.S!TH6K=Q^91H
M;WL !Z SEW)+7G]1I$9;FBZ?$HIO?\#S2G^W TJSRY Q>L,^38FJ)\:C!77U
M6I\G(+F$W]>T@4.)98,),GV>\CN@&Q@9=.2; -B=EKKFFKHHZUCUU^P3W%G>
MJ4XY- J7G#FHOE3P;VQLOC;)W35Y_2UKBXN0*-#0O<.=<L9XTL(E ]P4CR+R
M4-6/MB.5Q<;40W>'T7'(;3U44K7+0P=_)R*/J=C8YW4:TSK6 8M&7/KI+O)A
M"+RN\.^:^08'1'VOA R):6-R<$!\ 9;.[3T.4)*7W85@KS2XTZ[P=)DVK:9:
MF7T;9"*Y2^*7!^[4(,RQ@E9ZCC+=6]JD(_7^XP#"2];J6"32+)VE/,W,2GJ/
MJ$1#2$L.Z'>6H^6D@A8JG 4D^UR_[6I>(RI7EZG"*H\]X9O!\CJ1&B'9YY5>
M\/<U*6&WE"&(HC*6O=627CY%85]H8J-*Y<K>XVO;6;;GN$_'0KM];?8XC23^
M4+'YY?JH_?XF:>C%D<K$<I&:=[>'GRJ6DE]HF.,@51JPA=_TV*NK;3\>[<K,
M:AR,$3^]Y7/SV1)Q>KI8#:T,Q7B1]PPQ'BXNW,0!T.LX(-U'XON J=8/%]<G
M_[F=O9)T8?FQKPX)6@^N.\)RN2'UB-.&UYWUECHLN30>V'X#94<KHT#='.(H
MXOULZ.4F96)H9L35"/:I,:_01_"JOP71(MH86[G0D1VAG%75(]SUQ@ZUN^::
MY[V;@JBHA\B  UZ^)VB'!58<0(?F&#4<FY1LS-0@?.A4Z_&_V'O/L*BZ+5UT
M(2 (2 &24ZF (D$D9PI$DGP$D211!21)!DD%11 0!(H@H(CD**%$<LXY9RER
MSJ&(!13%*7??Y_2WN\_NN^\]>W?WC_XQ?U2QF&O57&/.\;YSC/F.(NV7/H1N
M1SAF"SU&P18U0DL13!KI&WHQUB?E5BE"LO9?ON#3LD<&OGLD#9K'.^*EZ< (
MH(1//T(I;;_;\!-6/T1)Y@*JI4N.^#G9TG((UE&LD$?]1)M[HOGS%V>4IM+5
ML?:D=N3:+EMAP+GB7Z@Y]QKBX^\8M5J6!]*'[FEMK$99R9.S='S7WD[Z8G97
MIF+_=1@ 2K,J@BPDA")J#><_&C]_]H%WR#UT1O::<0Z3'XLT_^9-5X/XDJQU
ME&=U<H;UF\^=MJ%Q@D==JWY\S[2%?&S5)XY6&H9W=5>'OD5;Z-RFRLQKEQVX
M?3@X=OZ?L^VT6'VA5<_]WZ. _;]$Z'Y!I5&>^^TE*]/%V/[J._>N@&S+DJ6I
MAHI!O<'<K;O<&==U&<C(Y5C+#G2\19MA=#Y%$UC*K4D([-KJ&!RE*($8?7=R
MKO?P[K?+9>L;KM*/PSB+Y&7_9P?LOV '+"O?9MSKX3?>XZ-T,3/P1]9&KUB3
M&XL:C)OUM\?(A@9XRZHQQ?*WXAI/.[1L,]%-WS//L[(_Y]^V-7^XG!)78<;L
M_1+K5K&?WZ(IG_GMS<+=>,, W;N*3SG%I'V4BSYP$!\6)]M#P8OZ4=VN']NT
MF2K>2N'UV_@0=3#.!KJ:JR941G0**$C2DA&E2476Y:\7F+^<^ +5WS]..-&R
M?78[;%%4/\5JH6DC)?M!^_>O*S&DWU:#"N015N/GGTBZ8_EF[%,# R"/;!5K
M ^=/\AXUU Z7YP4M">Z*=][V]Y]BGD#$ %UBUXKS6%_HRRFX),Y%"DF#>B.]
MBSFZ.5^1O8R9W!C0&"]VG?O(R+(S$.=$?6)=(6.>^F@@IR?V\?O$.K\]JX+0
M6HT,N2R%O"X8?4G"KDJ "]I,^%[T(@NWL4"$P(Z]5))#<W3X&HM2<=Z*M_\J
MF &VS)L-F[A^!0SFIZ'EKH"[A0.7/A78@+(!J,45$%7^Y0HPPJV:CXM"%H@P
M8160XY.Y<Y*))PT!(8.+,MQ.2]:PK?>P[CK1A0K,AT38N,;ES?S>>FY8Y\[]
M2T?XF5XZFOQD3AWM9.WN?CN2^'WXKIP8TT#6+2PC?DGZC[=2E@N7ZB>2DM)/
MQ>W9^UM_M8@Q;"HXZ$FJV=].CXK"NY]:Y"3ELQ#*H1^K$U[S2%.J8AFKS3[;
M^ :#X^C1]S3.]\#'^;";#<M/1K _8>MV.C*X&\?>OW2'GR6Z^SOLN Z$T.JY
MQ_(\NAU5(GJQ<S:><K"W*A-BK>"(S&E3N]8V9%<[-=_"WBP2= 74%QL@E2*%
M6,S;F.F^)Y#7U'[!TZI/34XIE'\?4_?>U:T3\[ALPOX(2&23D0\4>.+$5J0H
M@I6V+2*@C'+F*LK(15KK:IF8_G&G LZ4%. 4ZS\R/41GZ?A(!FQHHUM/JURF
M_>UA[1J[NLK;=UO&:L]'A UYW_0:;QR&IO+H>1 X2QSGO^T.>_$!<&,_RKKO
MGDNJX,*(@-="LGS21>NHIA\[OHI083_'#_<M2\G"/-^_W(_=X>4--3+K-YZJ
M_^JBT\5MTOCN2%OW])'QDY]-7,KA>(3J7@=<!O^?(]Y2AB?AN*%U5\ Y\0J<
M37"SG3A< ? K@.(*F."$?)U00>TIC0E'$"G#54<<^)(EXRT-]1FU,ARTJ)EU
M31M9B/2'$&[C8T)?MVCBQ9Z\V9Q9G LX:Y\7'-4DJM3K,66%+&?AJ)!)-(S-
M5&NB;XX1*HC8;*#(K!HIE7YZ,#WU)-W06X7=R,]9(#4,.$H)*K=\AF:R>%U
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MG5Y%*G?B)]NN>==(?B5-**^MB)]U%;-:T2J X&OJ[I&J]7PA#*A/1WO:GS2
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M,-J>D6G$6X=,D[L3RMXH[4A/(5,V; PU0?4=)YTD2"!['*3LF(O+DN@M7@6
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M"J/,)YQJ8):&JTQ"RS?]+C&L07"9RL8='8S%P@TH^/I'PE\6#;4E%VK-_%>
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M>)>[*>ID#AL3!5JRS.!<WUX9YIJDSX/EW!M4]L>F8[%Z:XF@KH3:N1D_#.T
M+\6*9MR"3BS##7:\FX??237F';:,L^0!A3X%VW<UV4JA-D2!# H".&4C_8P$
MV1-4\&2]HG*BMM>2JYN^4\A,F8"518$43+__G1,HQ&^=(902G.^LYDMB+T9$
M+JV4LUPAR[M]\7HOV[,4@YW55#+:LO,D(?UMMZD-MT%94N^J!?UOS$'5AUO&
M:7,[Q"^GJ8JH/:7#7?LC18OH/ BWNX>2$4G6_;*TTUS([OBPLBO[MO>?OBWX
M8F9N[4JT8'V9EHU\R%.7)@!#LYI\:<B.KZRSX+ZE1=BWYTXW[_I'ND^$]5)-
MXF#1PP:"5\=#^B5^ YI/I_V<__++BFV2E..5@7J54("[QUL/"6F68:^W7CW;
M$MD:*RNP?A<=[:AZF[:WJOU1XF@&KA,E,WU[)2X5#*CF6,7']^?T1N?>T%MK
M)H^)J">4.:B>)PM(ID&19MM_^:19)J/]H,A RI*"BU,3X'3X>@!72/<3+*NG
MGU%"GE>\L]LM+Z^OJE2(#%B2;5,&B#%432]Q,U@PS5K7LZ#@L'!O0J54H:2;
M3OM>1P=Y(*RM_N[?9,=N[8R?+^T07R&?G8N:PTI5;&94.,J[JYT-A_('PFMQ
MU)IK-2X%047<E\IN$S\[U '(^G1P0%T(;ILAV8<PJUGPY@AOWC7@SA7.2]\F
M"0S^43#(:,*DYDJI2< QF_)FPL)O!"54.W7_Y?;W>-4<\EB5E5BBO "GWCY/
M/7%K)'<S=4(7_6>WD^IDAJ J'<OT"7V16;+MO?#3T:Q^V4NODOG1&JGH40,C
M/>W:H?2DY_KW)Y5":^^QO>I0]Y#>J$WWNRLE,#>I0>3N.OJ@.-J#IZ!RTW*,
M1C*Q^AM FN^E Z5R%WV B@TUV*!NL'BO'/S8MN2!NF#9Z:RI\WPE;M)PE*'Q
MYO)X5*Y6'4CKOS5]0D6WL!@8%5,ZI&>QH''1LD%BT';317Q[+O1*W9)(3VYK
MD:+D>U2W<YDF ?=L"F!IC!^PR\,[?VA6:V9Q^BCOVN-K N5Z(R52.DBO9@S?
MZ/*(R]5N=>X0'9VX:?UA0!/XRJEA;[!/SXG?4XX(F*89<:[EMC%\:F1P/Y)G
M4][[FP[-R[W+_#],$O&_TK53]4SX]B3<<9/</JA=2R60,73(-X7=_W'J"K?
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MY1>R_$*67\CRJ_SY!8<LU2"TZID@%I"CCL("_L58 *63*33=YF0^3!6&!:Y
M@Z&K+P; 2!$PA@OV+VIFW:DE=[;5TD<@X]$6F& >5BR ;X(%YK.QP&M$,WA?
MP!*$9@!A 2K%.[67^LOE7V"!)LA<R@EM&>R,!(8%0C,P%%B & OTM7Z&SMI
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M;];L-W(Y+X\RQF>AJTKPSS+7O/6@= HG(I5LU@5-M0LNLF%.M/@<3**!T;*
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MHXT2+OLUYEF64*(,5>N[#_T;N9[HDR>ZSM=[("Q!%%22SK:<(F)L2K+@HV%
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M/<Y!QV?.4!KPXH,83 ,KQKQN01VUG47P>DM*/'VB(UZVI*Q_*3&@Y2S56>H
MKH3&3<&;;"D'*-">< KR4].A[L0=SSW?P^W%NSFL;]\+T#*O,+T,5$F:>27
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MJM<!(D$L9KH[_>WDP;Q-/HI6-@S5R(U@T>@G=[X\?J#]Y$,: $@D')O@-+I
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M5^#\Z"R4^M[<84;6Q,1:D5'!$,\-2U,N/0*FO,&-%="$'D;NA.;<\QMN (F
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MN(HBW6CYT"J%+(;O^4E/[^?4-<3#7K4H^'H_P/5)9.:O$V6S>N4D?:YR#@I
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M1=5_#E#\<G=@$\H,+1C3W;>>?RQG:^MH8<]87J9,25$Q^9P&T %'U/"M2MV
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M?2FXA2K=<&3P ADAG5<]&NH-/U8I-\\Q/F-8)EE_:C;6ZXP\R;H-1CY#\V$
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MQ%$TY,.'[&S8W^V4F;)#IS_<T#$%MIX&$NQI9"B:_Z"T^$!)<F&ABP$^3V&
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M4G JK4;<*.'< AAPY'_6W/,X='0E<7T&(V.(I-7S#>XHMLDB%7<,D<;+@(V
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M<>,X9;2#66DB:/(E=_VAA!E+4=/A'<=# 8(N:/^Q7RSGQ-O:![8W8S)LA2J
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M&-'Z8IXY+\(I>#+<;JIW6YA/4;&8PA00C]"#^%.NE7;ACL &CDY[W<4!,;?
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M-ILA. ^B*14:PFB.AU))>Q %YY!.2@%KT]'*'B;-.Z:;]12!0H!$QFW)8R6
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MMQ,3MDD^@7<ZO\ !"+/?1:17!4P(;&;O#(QK#(M71:4.BK]H4IPG3(GKU]_
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M$2AF$(E4N79PR>;!_679\QA>J=ZM85^LZL-L=AXE&]:ZK_5/1VMU$)"XTNK
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MN]>3M(7=[+>Y3G:'YVUF1-M?=/F6G'XPM4OW>YW3'^, 'U',68,/?=^FK+O
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MC,U@Q MT@OT#3*O:S=/Z\Y#5&G02\.Z-!S=RXP;(^$LMAW(@P*^([DC,\&2
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M'>#-"Q<V[M]7ECX,VS'HQ!<?>_W2%*/^\-):O&.UV0+5?@/]S8RO :5EO]>
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MRO=&FVN J!L8C>>(>1K(*XH%O[):J?DX$(VHQ0P<-3;LX+M^B7$:+/01O ;
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M0"W>#Y-5MW&DNP3)X&'ODAW\@XP':TH\I0^7)$5A7=4OA#VCW;\\G>@(VU?
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MF2??('O_#<\=(V(D6VO!\L&]C_:ZJ6U;HG,N,!;O5FE?>(S_G8/4BYAF%]3
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M_5,U*#.IV!N0@O7>39> M&KKV[TT<Z9#M8^G)J0K*DBK5C )"M;QP$XO>K^
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M;Z&KWKM.VMC)[UJ[)-?<UVMOG"._@-%2-ZP\U&B;[[=,@1X^53EF3VPAW,3
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M&IN:N[I[>OM@_0,_Q\8G)J?@TW]FEE<0JVOK&YM;VZC#HV/TR2GF[/POOX@
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M-3^JLZM].P0/+"V2.33#>L!T#J?UATJY:;]NZ@O=T:O9XX@<9MIL1Y9@V?&
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M+6VA"JQP)@CJU0^+/YR^%_=X6OZ$K84]H+^_1)(TN=Y^71+$MA5$S8!)MHS
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M1"V?46<;9UVI+5;\SKU:;2TKK,E?@"WOK,UE[LT$T=5142F]$*CK[\[:_Y7
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MX\@I<4Q&$)/LFV$WX2Y[KK4BEHZ#36UC_DQW/WM&$"EZ]]W?:&<YFE?>#7F
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M8.!P;Y")])W2U=5@DX]_W_+]70+H5<(30ERBW$)4EAO9]P=::4>:*4^"_D?
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M_QNU!B[""<T;'@Z%1I_=[')^*D2<_."(?BZC<5DZOFT!'J1':5.V3CTU,_G
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M7FO"/>)S/!Q<O+AJTT^E''#6Z41N&RAK8P&DOTL@Q@<+G%*#,:SAJ"=U3[&
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M]/GP<__U0&N=7KZIRFG&!L,K+Y(@ELI:79W6'&3*>IIC?Q3F.8A1XEK;B"+
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M=;NKIDG9M$0O;\EE7<]/N4VD_2'/Q&R?3B^VV&ZS:/9QON;;#R\RB_H)JM&
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MTI742L<</Y.H=RM0)8!OZU3",HN#$*",/@<?\@6[*Y^N[+G:U^(VJ3MTN$D
M8 87UZO'7%Q)MBF">$FD*=\(,[BY,D?[!"UAS?Q'GR@R9+%+AHK*#&TB$6F$
M8I-W+"(9[@@*(1TD:9M"?>\F/U2COO_&!IF6SS/5(F4>=O',\:MHQ.QE2+<6
MO(;W'/62V&Q%\C%5UPHDY<59JR$>2_G#B75ZVY/CR'?0N.LTN%#UEG?B\&+9
M5,M/5F@ L8LRFZ8R0V<<R"PV@F2'<^RB4HA!S,X(I&'TL8!*FO6:?#=#@Y.O
M* Q9V;1HT[TB<RE3;RM0_W&52M8!*AT&1'W! .N A(*+;+]T"D(S+P6]29XM
M38"L[YO7%UB2=(4_/[Y_I*[_SY3J>7+C[U-;)4P=,[=J7M\JE2>-JJE9F3 W
M8CX(0LE.JUX<J"*IF!Q-7Q%WJ9_RNNHGJ!=M*"6S)39-BQ@CKV+VQ_X%&A .
M_%7+@X ,HR;R2$'KRY=1(\A"T*I<,>3E)N28! -,FK91_#\W!%;XU5 Y3S$V
M2^2>U!]C_QC[Q]@_QO[/&BN0O3BKTKIL6!E",VW-:#OY.%8!Q+I#X.[B B&
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M3 :[$F-,79.[_-^]3T)$6=(DGL?2D',+4VZ&N:9:XF*6"-H&/5K-0P/F<]
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MQ8@^RJ>X(1%BT78>L?VWB>5^NJ9:#_,E>C:0@8JS+ZC^H".Z?SRA&JI\' V
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M=LB)'@ZOSO/J=^D)_-$/*<U<KA+O$7@81_O2><N6!PZ%6"6TX)FZGJN51=Q
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M5NLDI%MV E7'?$0V"YZ"5<%>>!9W'QQQ16!P&'B,WNI/2/0=PN0';SR"JM=
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MAQL>"9-81>LD&SW$BOVPPBU^7;P#6S@2#OY!X*2R&Y\=H 'PO+CI9B.*LKK
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MRB_,4]/6-KFC)O(,0GE+,;U!4=,@EX/T4:1AUG,'MK+;??37 U>@F* J#AR
M[-R#:V5G,8\]%)6_4&I.()^J!VOJX5XILE/<.+03IEM X534T\I)T=7 U.20
M??;P1=>/C^9<Q3S-[O[41V7@D\#&<]6/%8;AIALRS-N9B>2^>SV^"[V6X!>7
M[JXB_9,?RNPEGS4TS,P\0N_'$=M7>*S".0V2;&IZWM16^BQJ-IIJ/LC-^?6<
MS#1E3AZ4:,:^[5Z$7-%%!9EC08@X5,&=8N^!<^05/'64,V%IM\ '%. <A'Y>
MO:!C0NM39JV=D,Q%FTCV?G4NR5*/LMC.T//2HN2<2CEONQ-5E=X>!,@K$V'-
M($7\,$UPP#J)VD6N[*7Q2^]K:+KI9*4?/,4>@3_*34A@O7WK8$80(';8MO-T
MLF\PD5G2R)XRGBP8R?;K8,)Y134MN<9\'8_>N;9&N7685N$H"_W]+.L3Z.(;
M_G51-CI0)CZ)4U)2A RA"D*=>AQY6;,5X,1.[A<7H^]UQD9=RI'9FD T%M6A
M3#QUQ^=3S3]=R'8?'I%.E_7J'58QVRQ*"5;NWR#K<0C,G#U:SQ,%;%D%@$]?
MQ9@M7K<WMW8]$^EX2*4I=B&2X,0>L4V/C8J"V=S.#O6;)>YH^^ 5L+\E<U<[
M-M'\<-^@E2&=@^SN;9J3B:4M&(@##E@)G:E>)^S%OZ$"UR*;SEX_#3G-+GF?
M/2/H,$$<P:M4=3T.>JU*4]4ILV7SA3)&=@T7%>_@(D%ZJK?7XW1,W::>&Y\
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M&$>[ A.QY7!O>V@?*@_XY$4<<^T2=UQ=^\![C&/C[O]#"'X$B-VT[)_Q$4Q
MT*VM60F_%^RDS/,PLL^0N[MH?AB_\U,C3!CWGW=LSN,F[.N>%7LZ-TUME/9!
M=!.BI;%JNI!Z32]GD;&"09=?CA_P.U,>->=1K%MEFPMK&#F,!;242=)Z&/X_
MI%U>R>W"?40S=?6K KT/-T[W>$PN;&HG;--HXS9?;-11-!4;^M+H$7\Z9$^(
M(Y.X U %+:1YYQ1#@Y8ZQ0I"=WW2;."T42)[I2IE5E_?I9T1=.':"A:Y)#=P
MXDJ(Y$66"U1WSU5L!<E(EFS=OOIO!S+O  \/2^\ \O.PJ^.E%=.CB#N TPBN
MDM.*/SGU/U/[)DSIKXIFOMZV5$^1I:>OMM2XWVV#O'\!#]>!N$,?L'FWQ,]1
M:V]1;:7%L_9!'),NM5@^Y_1WV8H-M<F_LBR [IMO$=T9H<-0)HT7EW#O_5]]
M?YHSSZ_9FF WN,[M1P/!X2RHN-WVTT=-_S47U /&MTAFIG%8B\[B,X%UD]V4
MIJ#8@ATIIP5D05^Z)=.8\5.NS-T*E?FNSZ&AAG"7^?H5YL2FC^W(IO_D7YA4
M-K+,,STJM[XN4?=QHC?1U2]V?".QA[+%@>;UQY7W,^^]B70T?N?1@_H#BE!X
M.JF_T_[X5\A)=S&TV2PA(2_!]V]]>\Z0[U?/"@])?D.+6FT%80XJ;84'Q.X3
M]JLAWU;47I\H<M'<7WE*_"(W#9";4-SXF_7TY^\Q>;(_!2SBN$GO8.0W=?#6
M-]WMU3/Q+J?-<Z=7DQ'3(@UUW_*C8;YXSKADBMH_W&;3QK_+EBM/F($A4.:-
M!K_XX:PR6<,36.]1.#/]3-MSJ(M^ZWU9:#> -]=,EI5_2C>V>R:H.K3I?C"P
MHCA*SEE5$3+059>TRRRJELT$31LG?^A R^(2"^<\X>?]_OU+[ZRR%;)0)J!C
MM2W[!I)>@\F.O*8<SK)\_7U#O1YZ9+TX?768<(7?<H^;ZGK&\@/6ETV._<#R
M&!K<99#7V_:R#JT4)3+??.6KF&O^EXTT\5,B:23@RRU*AM+ BSSRW.V:=2)
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MY\)B+[P4E;;J^.?TY_2BFIWS<SI?BAASNT/YI4\J?::&!NTUMJ$<Z/.O+9!
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M^GA:V8I>22??IC#6NX+KE%DH*:8Q+P=AQ_*H3(3/&#:N<L@O^= V<![G] [
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M\W=!OP$+<_7%4+Z;;<7"BYWPK(0C,<G;VJW8Z_';V_EJ^33E)2G>1^9RP=;
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MQD]]:"3N,]I.]?XQYXER"9G(AC.:J=</OGYM[R P1F,J:?;!OTR*_(WDSV<
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MVW,^:[DF>YOQB!GH96MY+U>5X=H7K07S$OW^MW:]HIYHV(V](>%M6NX ($8
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M03NVGQZZXCS2@-9,_E0K*.MF_+Z]^K4UXWWYGB?NJ>8F@WV!VF^:)-:T^V=
M;+]U&^;LL4R\QF//&&2&_388#FL2#3X;7'_4(,6G@O[Y_O%<[ [.6Z9O[09'
M,6FV]C].9.[)Z('N73X2'7ZM#-)>=#['7J/D5*-;<C>[X0DWG$I/N!0I.8LJ
MI2O-Z19:].KN7)RXGSUVS^]L[A,@ZV=NSM%$C;@<M[J,Z28\ T.]$DP2^P_
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M#4:8Q"^9$Y0$CXSWMX=!/<'WUQ,(GMBR90-],9>-PB-3T]_!VHEFDAI":V@
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M3;/I-17OVPSN-HTU<IA"X:2L?N:F;& :3%]W:+5U'2Z$XZ!+B=IDVA EO^M
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MK1IZA\5-";_*YGE?V-,GDT+CJDO*WPTK-_)=%UL+U'NI)O!_.8[4'B[DEBT
MW."#7@_U^./\])@6*]([1=XE'>K\CP!_'H#A&MSY+U?_ ()H?!_5]4N[XW'B
M:T-Q,TQ@M]0B$498DD*&A8XY[DU4_P"'8/P>R";_ ,6'ZZC!_P#(]?7-%=ZQ
MV)_Y^,5S*\*^&=/\%^&=*T#283;Z9IEM':6T18L5C10J@D\DX'4]:U:**XFV
MW=B/R5^U2*Q^8TV21Y.2<U*MOGWJ5;?MBOI+'R?,C.\Z6+E2137O+A_XSGZU
MM1Z)-< E$+"JT^F/;MM=<?6B+<)7B]4="<XKGL<WKGB[5=+TM;2.[EB5IA(
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M5S__ !%=Q\$?AKXKTWXL^%[W4/#&L6&GVUX)KFZNK"6***-5)9F=E  ^IY)
MZFN:K./LY:]&>N]CV;1[K5-#M;F"-)$P2[ G&<'H?<$8KKM0^-&JI:Z?:_;)
M!Y$ 'WO\^E>KZ]\-])OH8YK1XW@D@_<*"-QW'@?7I^=<==_!FS%PPNR(0 !'
ME,Y '/ZU\=:QX7,I=#Q+Q=K=QX3\&ZYJ]B(Q?V\4:V\DB!Q$SRHI?:>"0I;&
M01D@]J\[^%/C;QU\3/&UIX?_ .$I:Q\^*:7SETVWE8>7&SX";!DG;CKWKT/Q
MEH-YXH\%Z[I-@JRW]Q%&T$+,%,K)*C% 3QN*AB,]<8ZD5Y/X#\&_$;X>^)H-
M;T_PI)/<Q1RQ>5=!6C99$*," X[,>]?383V-OWEMR,-'FP<U2MSZVVWZ'?>(
MM$^,-GXENM+T76#K44-O!.9I;*TM'!E4LD1211^]X/R DG%8'G_&[^Q;;54=
MI+6X,0C6.&R:8^9)Y:$Q!=X!?Y<D=:UT\3?%W[8)7\$V,]O"MO\ 8K.2T1H;
M%X0PB>(;\AEWMU)SGGH*S[2\^,EG,+B#PW(+Q;6WM1<^6A?$-Q]H1OOX+%^O
M&".,5Z#6$\OP(A_:$8I24'MOU[[?Y?>4-:\2?%SPGKVG:9K>I&P:\RZ2K#:2
M1[%)$AWHA7Y<'(SQCFNLLKSQ3XF\$V>M^'_'UUJ6HWUV]C;:2VB6Z'ST02.K
M2D;554;)<@#@USGC>Q^*GCZXDN+_ ,&2V\IMVMHQ: *D:NVZ5@"Y^9P-IYQ@
MD8JOX4T;XM>#M)L=.L/",KVMK>S7NR>%7$IEA$,D;_-RC(,8Z\]:7^RWZ6^1
MI*.*G1C).,9K=*UGOWOY>>Y>MT^.=UJ5W81R9FMDC=F*V(BD$@)C$<A&V0M@
MX"$DX-;VEZ#\7KNQAGG\36MK+=:/-JMM 8K,',<J1F*0LH$9_> [CP,$=00*
M=KJGQ@M[LN/ %K)91BW-EISV2FWL7@W>2\(WY#*68\DYSS69+9_%^ZT5M/N/
M!CSNUE<:>]XUNOGO#-,LS D/@X=21Q_$U.V$\OP,9?7Y-+W%M^6O7O\ \/U,
MI?'GQ-T_6]4TK5-8EM+^Q=;8P"VM<M<.P6) PC(().<@_=!(KI_$GB#Q;I>I
M'P]I'Q(;7/&<5VME-HT.C1QJTI.'6.4IM;8002VT<$UROBSP3\4/%M]]NG\'
MWMK>/<"ZEDMU"AI%540@;N-JKQR>68]ZZ6XO/B[)J%IJ<?P_LK76X;A+J;5H
M=/C%S=.H(S(V['()SM SGFE;#>7X&\XXA\LH\M[:K2U]-[INV^UGL,E7X\PS
M,GVM9 MLUWYD<NGO'Y0?87WCY<!N.M=/INB_%)=733]8\9?9WD_L]EELK6TG
MC"7(DQN. 008R/NG/7I@GD/$*?%/7= N-$3P#!I.ES6?V(6VGVXC5(_/$_RY
MD/)<=?0FK-EJ?Q?L'@DB\%QB>..RC>;[. TWV7>(2^).3MD*GU"BJ7U2_3\#
MFG''SAIR)^2]-=6_,KM>?'/^RDU**ZDEM)/+,85++SBLC[(V,6W> Q(QD<]>
ME6';X]PWUO:"]WO.)662*2P>)1'CS"S@%5VE@#N(Y.*FL]6^+MO;0Q?\(6L-
MT%MHIM6@MD%[)%!('C4L7VG;@#E><<YKJ/$7B;QQIUUIO_"%^ ;RTM(1=&[A
MO;2&)+CSF4L"D4G4% =X8$GL!Q1RX3R_ 4JF/C)15.#O?\M+Z]_O\CA_#OBO
MXHZAXLUG1M<\5R>'4T.VDO-4GN+&"4V\2;02JJGSDEU P>=V:L0^(OB3XLU:
M>'P'XPD\66,,,<DMS)86]D87<D+"PE4 N2. I.>W>LBST7XMV?C;4/$X\)S3
M7.H(\-W9SPK);30L #"R%N4P!WR,#FN@T;5OBYX>U"]ETWX>V=A8W4443:;;
M6:QP*8BQ1QB3<6!=N2QSG![4E]5ZV_ WJ1Q2]ZFHMV6FG+?KTOZ:V[CM;U;Q
M_HOP];Q%<>+[A+N.TBN)+&33[<%'>YDA*$[.WEY_&L[X)_%3Q+XT\:?V%KEZ
MFI6=S9W4JE[>)'ADA@>964HH//E[2#D88]ZI:UI_Q;UWPS-HEYX4F>VEB6%Y
M?+'F,%F>;)._KND;\,59^!WPO\3>$?' UO6]*DTNQM;*ZBW7#*#+)+ \*J@!
M.3F3<?937/7^K\CY+;?B:Q@XX>K]9M?6VVUM#V2. 9J_;Q!15:'G%78N*\D^
M.9/#;AC6C#8JRU6M6%:D+C'6J,VRI+8JHX%0K:?-TK1>0,<4^-5SG%,5R*WT
MT-@D5H1Z6!@@58LU#8K5CC %.Q#D8TEGM7I562 5O7*KMXK)G^]0"9F7$ VF
ML*^BZUT=PPVFL>Y ;-2S2+.8O+?=VK(FM>3Q7474=9<T/).*R:.J$['/26NW
MM1&A6M9X=W:HVMMO:HY3H]H9EY9I=PE)!D&LFUT%()@Q8OM/RY%=&T1Z8JHV
M58@UE*G&34FC>%645RIE.ZLUDB9",JPP:YF/09;4R1JP$;=SR3Z5V?6JTUON
MZ"LZE&-2US:E7E3ND8UG9K:0A$' YY[FF7"FM1K<K4#P[NU/ELK(M3N[LQ)$
M)-1M'6I-:X/%0-#[5'*="F40I'>IXI2M/>+TIJPFE8J]RS&Q;O4\>5-1V\)]
M*GV[35F+9;MY6XR:NQR<5GQ]*L+)\N*M&$B2>0]C445Y+&PPQX]Z1FS2*H]*
M0UH=?X7^)&I>&[^VNXI2[VYRBR'(_*NMD^/&I7#,TC)DL6P!TS7D4@Q4#-M/
M%0XHUC)G6,BM[T1V(D;[M%%=AXMW8T8=+7:,KFK4-F%_A&***LQ;-&"W7:.!
M5I(!Z"BBK,V688AGI5Z.-0O0444R&1S(O/ K/NHUV]***!HQ[B,;J(HU]!11
M4&G0E\I?0?E4D< ]***:$/*!>U1R444 4YF'3%5&4;LXHHI%(>DX4CFK2W(H
MHI#:+5O<5?AN.***M$,E5_FS5F*;-%%,@V-/DZ5J--A:**I&;*DUR*SYY 31
M12&9E[-M4UBR3<GFBBI9I$JS2;JJS*"***DU*ZQ M5G[&67@4446'<K3687/
M%9=U:\FBBH:-(2=RNMO\WK4WV;Y>E%%2D;.3();7.>*JM9XHHJ6C2,F5;BW-
M5OLN3THHK,Z(R9&]J:([//.***5D:<S+*VI7VIDD?-%%,E-BKP*?FBBCH,LZ
M-H^H^)-6MM,TJRGU#4+A]D-M;H7=SZ "O0I/V:_BG;J6E\#:L@']Z(?XT45R
MU*CA))'=1HQJ0<F>=WEK-8W4UM<PR6]Q"YCDBD4JR,#@@@]"#5-OO>M%%=!Q
M[,__V5!+ P04    " #P@V96-< @%5-C  "N9   $P   &EM9S$Q-#@P-#(S
M,5\Q,RYJ<&><N =44UVW+AQ$I(OT#DI'>B]2!*0+2.^@TL& ]!9 NM0("$A'
MZ24@O8-TD%XCH8?>)*$&".'RGO.=[]PSQAW_^.]=>X^,/<;:>ZWGF7.N.9^9
MNS]W:X G&BKJ*@ L+"S V_L+<+<(4 )@/WCPSWT_'M[?.'@X. \?XA#@XC["
M(R(@(B(D("0D?DSVA/@QZ6-"PB=43TC)*2@I*8E(J&FH*&C(*"@I_ED$"_O^
MFX<X^#@X^!3$A,04_]?C[A> % ^PBY6#C<4">$"*A4V*==<'8 8 L'"P_F,
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MEFVSQ8CR>,N.XKRF<)J]G@8N*C589W@\IU\4:V](IGVD.UM&*>/2\++D??B
MGGNZJ)?D&/9Z0U1TA=BUNFS_X#.BX^:G<JE_@# <Z:@])?&^]\_A=A-FVCJC
M0*[O3AQ)S[BJNC7C2V7WR'5(C,H](MS>_DA."\\VI*B/=7+ZGE\Y@.A,8*4"
MLO1_RTX&?MDY@TASV4C> 3Y/6S@R$><>:WY6R0S(>/VD"C<=_0IK#XH0.W'X
MC)'3]!O]X:$ZW[F>+)9$(!VM0F]J8OLDD [E<A&..D)$KY/T!_'TI(60U!^3
M_<RC.YSO;C)W75-]@DO\E$W(6B<]S.\,(3.=SOMN=.(%972.G:/&8"EFN).A
M%96ZP0JGW_&KE^7=RI,D5U-Y<']8]?_Y8X5PYIV##LG>L];-1>YJKAFT<;X3
M,_YA0]>#+"-$'4D]JPG1,Z.UFK]X,D_\&7:*_*"Q78Y*[ATX R%TQ26QE9MG
M)X)Q4=;1%R[!&(?&^Q/'9!]7IESX7%4\CQEFT_CIK>A;T/K+O[@RQJ.M74?X
MO.FJY"G@@(/.1P=TU8F=SQ3<75CYBKX(+VO.?GB:D(?@A38N@PA0(?[N;*=^
MFEK^MN]'5TQI.:L!<P9>B 8&H">!U2*]LO;%+6A\/I;[9377!2\[Q;5B_>->
M=Q485[XBL+"[;#UZ]&W'<#_[;[Z.WIY1F7Y)NPF6N!RA7L-4"4/55TK*TBE
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M0NPZGM]2G7/6VXVS*^MO]QDWOUU^<<*S/X@Z#<3)R2TK;?J:CH#\"3VI+9#
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M'VE5 ID:TB5"O66GMTP&OL>\E:)O!4\GJ/[-+7"Y4=>&S54,TUF*[X:I_:\
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M"DL*B(@*GQ+!(R4E/4M^EIZ"@E[X$M,EX?_3']P'@.H,41)I%P'>90"?"H^
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M! 0[/W60X/<?AX3A36H8L!X+P !8'^P? H-*ZT7A@#^9RS OT#2#L;F$ <>
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MK$NK_%;PRJ7+41MI<ZA;K$&6HW!LKR_G#3TY'! B<(5H;6*=]I/GP3-?!ZG
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M^<, \*FPGQ,R!5*AM^Q/2Q+&);9-^:[Z;3"5YF]I879QO;5;#3V:LB#AL#L
MJ/J9YWJ*8-&\ F^NH)=<1F>$37M85GJ%:)JMK9W(MN. 908 $ZQNDX7&H#8Y
ML*RE^]<A (>M;9.MS5@^W15.DH8*++>( 47,YX1&IR K%9S>35M<I]J.=SR0
M'\@$OCJXIIV%4#O/112.[2!D9?YZ6-VK2\?29AH>\!2!+[D8I87543SP=2%M
MC@S%GZX%S7T._-K_)$<77FY;P/0;O');]Z<0/P+'/DJQ)K,X<4C)8KA 5GW^
M)7RYJ/M,!@23:X-S32/#ML<=#<J:0&';9*RNFJ3.("X59!FM3P-N;1'JD9NZ
M2B3+M:;NX\9Y(80^_9"9X%S.[KYK^O-&>NIO?,'-U:$X.\ZU49-JX$-9V3"4
MT),9PJ60S!(X3<PC*H*R$K*+[*4'N?-W +OI3IG*GC]?()_/^-LT*8K.2B>\
M$UA%%Z(3$/22DX2QNYKHA(#960:C-K;R'THV1R2(4%.3Y-Z6_@LB@OZ9!A'\
M/\1*L"S_L*QXJ/2]?.D17^RVM+SYO2/Y-S:LY22']%I17_TQO<&"<\JT1*B,
M(_=EV)X;8HM$/WV8EZPUEA=?-WH.!<W:0=K$Q.8M-'^U:;O3+6(7\:N()=LT
M5[-O,I@>E;P==U=JTG2E'\P)O2Z+J&^1U"YPI7S6+_;;#Y36(>.=%E$\;\N+
MRQT]EYY$XW45(6T28>],-%_I^:S49M6X'QQ3M[%<ZMK1Y*Y6P$X8VJ9=\8P0
M-]H'>ZEJF&C8F54RK]?\BY.E">EM2.F-C4.GV>%8I^*(B$+Q'N(78RV4-O1Z
MGSBB.UM%L5WKVX%]RA5;(03AK<1MKO1"85N%7HU[NRCM[23$?Y=/[Z>MS]E^
M_,I 9!^!5\H:A$#QE%U$(U"[PC 1"^5E*:;]YTF!2)H'ZV,M OB$)_NH<I+^
M8M!:'#H0L/64E@A.BDJZ%_;WDV97#P\\ PY/!N^R<;SP"LG][B[V1$6VF_8[
M)_O(':"*)6)'/BDN- 3KT\?.H^/^O*NI6 VM01_3F6<UG9_PB-9!J@V>,.4&
MBD;2RTR+MBL?LM,?=M^*][)K@P+E:/:UM%.'!8@"TRCAV^GJ=370_?G%5('.
M%=PZ6F"<%:2=/>L.,)Q^*P,Y*A#]#\2NZ="CBHFG640>)$?I ^G(GMRS-RNO
M5OKD-O/"&KR:\F&C9;+TVO8.\)K_#E \<!T&.JQ!HX?T0^ -'GPHWU&J5%^/
M[5W.VB&PQ:E$!PE9Q;.X Y@<H<$^36,A-';7)W&0<=(\;L]BVNY-(W=VPRL[
MT6@7B,\=8$7/[??E8Q1DBO .,"+C;3]\[:MT>WGKKI+V%H= .#KZZYS];,FR
M3U!PG&6N=[I%R, )=\,ZH^ OX717/=:(0\;KECO +/ F*>,(X1^^3;Y&S1:(
M?N=&8;_T_A];SDK8:U W:[%/UTVJ"]!C7^'=Z>VW?VB!#4[RF*24/6M)9S:K
M!A8*S]8HGFAMX_'M6X>V-?*"YKG'-4S,2A9\&T!UL109]M]/*2!G=P R\M+2
M1+WO,6%[%F.;)<!#WV_U$Z'[//$[#;>/O*C';XEF?_^6SC/H<Q4!% I23I]C
M+'S=9Y,EG]$YU_#T"TK*1^6FA>!!P 29/R'=C0?:4YS\!@IQ_3(H.D:;.\!+
M@RK1GDPE)GN3G*IC,0_FI927A 6O*16Y^.F]"7F5')FB2<D$*$E5\3QNR8_>
M--/\.O1WPNR]$1VV.%!17"=)J7;+'B9V<QO7D-%8__\DDW&Y%;T#1%)0GQVW
M7.'H:1BU1 !7,3%O/I?<!DR,!MWRJ2I#_E;>$(@4_VZ_):Y.Z^,\&%%:#^UY
M_HO0NN",\?JO,]$NR'P7633N]NPU.H.3\?&Z*O_ZXD?5, %S)G:585)3Z)!A
M^Y7O67+1JU%)0=*P+/7&JV>"_.N/WB^>E7PL(4'#E(B"EM_ 7Q4#A8J*&HX6
M'Y=#7Z\PP4TV[ YO=;E,I=1Z0T,QZQY1WSS2[8&Z/QFK9#86C-9:8QY6#HRY
MQ-"'$+2LT]X!/K:<^\0L8SQW-&_Z(72#>3')&Q O$(>..92$A8JDCCP+PR=E
M[5.9%Y#V>/7I+F=?[&%GFA#4=2%&+\FF[XF)E_#5E-8= &N]X X@?@[YTP$Y
MTIF'!AETR:8/'A\2<9VNKAF85B<(JQBV^_C>5-PDD>P5RS%M<M6=OG:&GKS5
M+-(.?>8DXTY]F 9./SFPO@-\%K@#$!G-#W7,&P\YOU8_;A!YO(DEM!S_(A5L
M6YA,% $/*1S/AXO7ZY]&8/Y.GL?F\QB,7^UT<7$>]PNA#K+T.K^)LR]Z%DE"
M^H$RPO*V!29W>*M)W_R#@DAV.)?WEO_GBI[5$<67:*EN?]]@WAL55ZV<>.YB
M5&J5\PMO-U.]O+,_)%R=)X.1G; <#^P,3X8F7L7#XE2SCUE>M'4I$:EKQAWB
MK8>8.T9R0>8&GY4^(%*>6*V,,]->ZA5J).K&?L@D?M_/=1AK;,#:,+UV=H %
M,D(I\']]2)[S.( 1^W9ZUY<;>E)_WG^TITD?HMOXG;>*T9WT%!=\?(6,=HII
M"CWY+,I<.QY0]4>8$W 'Z%7<N46G\1K&P16.[IXY<X8SL08YQAD5S[A_Y]50
MASG?/D ;8-S4C?-M5L/56O= PG/W5<^U,JUVE^8:T;YK<@2GDIMC#OQ&Q8-,
M+ZARAU6^JZO2=<Z" YGOX O8@@9J'N6F6]+*/*P:ASK'OF:\.;M]6#>;3K$=
MO2I5*B%"9-QSMG**^#VYT\5JX-O#YI<9%&-[ FRY?3"ZLT ^9CG&81T\\SI-
M<! ZBI?MGV*1)UCR%C[ETYW]^6E=X\_Q,^-ITUYG;;L*/$6W%=N&-*NW32QC
MFGGD5,F+,Z'-Y$&J0(_=]&((PLHK3W*,S<V; X&H5EGG'%KGWO9>3-&Y SPJ
MH*+2VF&E7E,]RKO^$0V9>G?KOLXLN(SZ,9\VETFZ^#*Z06-L7Q39A"%U.!GE
MG06:,P(YQDVQ+5B$'OOB>=_XU 0#5PW+[P!.=P!>X[JO:]BV7;-:0_VV[3 #
MYIS3G>TP<CLO!/M*C?];&1(4/-H)2'9L;WTKG11R\[GO#I!)=K9]3/F??V\,
M&&\P_!I<HU?%\A2XQK@#O&$MN5JYD7&O/T_C%R-;_HWI-W^T\K<CZO+TVB[Z
MD.#Z:W'+3L09T>])_3[!9:$$)?*U4JVVXP%KU\X=9".Q[SD"R\PBH<8\9&L<
M(NI'U'.1IR;LUR"(\RU7'&R12V ZQ6_=EN1?.1E4)QB^^A%X@*]W%='=<,2M
M4WH]>B9:1)A&3MS'*=TR7D*L-N; ,4M=+]4AAK4+%-6+Z*,=H%6@?>5)__-[
M']T9_[S7@3HWJBTOVY7YA(YZ-SS]YZU.)VJVS].=J%&:D_6Q:4%^J]9J[OK5
MK>S/*CW-<AA5>K+(;XRMY=]*GWJ4%9Q^,P/GJ&\^W\:I]20%,M6,37WI&/+S
M.9:@_M5 [J6)0C'1_NJ-I-D8P<4^<23E=GSQB^"P$&V:GP-O[))Q;ZKIAZY2
M:Z=O#!\5]/3Y%?545$5?G9/KES7K86-MBNV,??S,G3,C]7(WZM=%A^A 8WKK
M(1#[Q/CMK3''K4BO#IG\R9?%J%[:,JJJEO_F9J9^Y(&R%9-'3HZOIL',]84'
MR+7?1%[FDPM]53B$S[V]3FA(.QXZ1VUZWP'$+GHMO1@4LLS+:9]HBCPW?CP<
MYLX*5T"L!HS0Y?=V:90_(%E9+W:IZI J,AO0T\*U5^3-SY-6Z]":^5@<?=Z/
M$]L]HR[^X!>/L!^1F)F7N!9C,**-VCG5KX4;.%ECUP:G4J@]MYY03Z^$D387
MH*.#.OB_JB#O+U9NWQ$\O^^PWK@#R/!_MDIW]HL[MPX'KDH<4=\$[$-.M?2Z
MO_\AWC(<G>[/J-10@L[U*H+^:4C0 L!R8+FOLQ((_VDN>5ZVY"<J U;[TW-2
MXC+E]V<1G6CJA20R--CTW/HPW=C-GXV>^&%<ZLF2+PMRS])&W=<0''*KBC]-
M*L_;(;]OE%=0L1 7)&7Z**-$B!8RP3^W7Q58T/"A7-USDW[)CI#95JX@DPUX
M<VG(%/&('F?DP'(RS/X9H8>.=OB$V0@^S?6"%SUCXR?*E,SM53^$"FGF\ )!
MY]'VSOK.%&3(&K^X2E4#!/[)NSK4SI#+;R*WQ:2@W,P7R[Q4%'> 2CLUA=H.
MYB&[B^:.O]9M2-D?]=KO+\^)!KY':"FS78)IN[AEF;2BHI2,\HH)-:!,SS3N
MV=Q$6%:H^@,%U6S"5GMV#F9G"<J(#O)LQ^78&LP?@0%BSB9MGQM+2YX<IOZ>
M_FQHYJ3VM(?_(,%45!*-?QH*.A12!+M@OZ0U*)(V'/Y.*16$J[CJI5@UD5#9
M\?Q&2-RP>.ZH*R 125K3A6<8G@4+&3[!-M_"WL#XXF+#,M[DCH6]K;"6NN>)
M95[,&O9Y.D6^X]EW>FP\T0@LL F'0QR.'-:4.'C5MT _MH1#]<HZRQL_/"L9
MXV]8X22?]^HUX.]J]%B?>Z;+(T\W:3_PT] <&<'1D((@M*:T,VCD+2Q./U]Y
M\.IBOH&R,%G)1=/1@@&JTD'H@.FO+#6JB^ ;V#E>GIPT>(N;PLQO18V_7=$\
M4>DNU$TI#QN$:CAF)LC:%=9<>):HG! &:=WLVZD2! O0<:(89G<JQ^NC]OE5
ME1<K9)=V3-(=#^M;62K_5!Q@QE&R7)OBGWX[^4EYFY6'ZH3)&JN]7FC.BADT
M/< ^[VTDRNIL4,:^70.?^I&-9(<RC['/4O:?P?8B;W[L>PFG7LZ>^#)[*-QT
MF%PE/?E!/3?&/K59>;"K0GOK/P+YS=?4$F72,WB(%W'3(3MUNU22 2GCB[C"
M1'\3GY%A!')W@ PWZC]#G(ZK5#V#EWM]:BW'-[;-X#N E][(T-+-"[46V&S-
MA&W$DN^#D7PD(D&L?71ORNP3YMSE'Y\KJ'''9-/$-59F'ZG&PY):4!YG!_NK
MC^8&+ZGG*6W_>H646O^P"IU"&'VF&=-_%7"[XOE'3;&_]D+!#[B">O_[@)\?
M1-EWSB-(+H\W/^ZQW6;0^R Y W[[>F3M\#SGHV5=L"<V_F:X'$WUOCBI5UKO
M3YTW+"UN\!-]SRN&.HHP^HG*X]KM-@6^\3$?L<>]R E2;UB.C0/MLI*WULT:
MS<]&:U+2J\D$FLY8+0S-]1_0COR<(=+<A\CU2!<G(89*Q$>I+\>A:0,*?31+
MF (?).VM3BAJ^IO/\G"Q2-HYE\$ZJD^\J&*/]/OM4TMSLEZKBU=N,SL;S,W&
M[3],(#2'DI=IA,T'96@$GEZ-&8^*G_CI\%A%AE=;G,@MZ:".,.>-;L"OFES\
MU!^+Q.S.0)Y$P+&'!%X(')&I[$.^C4Q/O!UB\[^6"MNZ63)(CBC(=C[+6MJ=
M<E4GVFV/=9W3U;>BW'H7"OR&;/A8_"[;83V7V4[,@?+3.DRIXEJJ)'%@QM3*
M,"O;8 4"CL0]Q@?'\,22C0:Q,RJRQ/#:&"$#56!#_.P?&55RTIU;RU-[.ZG!
MY37<@\W&_1CIRQA)A4R+9XB795\7TT+=KLP ?1_;QL8*"B$\J<78Z=)Z64GR
M^H06$8I5/SXMA3R@NSTL_J9;'7JR8R;<.2C7!0K;9OW!C B7GTO]EK_BL["%
MP'^20OFS@'PB/Z>H=Q7NW*0D<<:_F+!0Q9Z[J@<DC,M\U"14M.I/2<=CE=-8
M$:(]MEZ>JA.MPR) 4*_F,U2='%X%P]D@&M EEAW/71Y.$55;^AN!;Z<YT__U
MG7YBXAW@Q=4DOR_>RF\<@I>;14</SGN)F=3^R&F8BO61=]'*;NN,+P8:J1A,
MG]L.IPF0R]O:Y-C0WX_<>:BAI"#1F95018_Q"LJ4PX5VF0?R9@JJ.?_,Y[D?
M;: "^(=7Z/J7^BOGOO2$<:\[^F=^:2=?[+8#\[]H!-Z HYKK8+,[0(D[.@U,
MJNN4C9H@M$Q<)- RI@YK6>4EN/E4<OMU(B'S"VHODA;8K'4UZ>BZ[52^UMYM
M'+6P)4Q9G.!0^-S$-> XJD]\(2"U<+.Z'M80$J;K(JX@L4HU<T8$DS&.2#X_
M$[J!G8D&R*-(31@?"7/K8I8135_0'%9ZOE7V,I)/C\"\TA,KR5#Q.26XW%3;
M&++QXE"IGRVQ#@HQ=8+ I.:NV$ Z3N%J54/#)+^3[;G9(R/_L$D"=\-;!OVJ
MVECBWV=\B/G""CMJL-;U]WV->0>@<CPL"GLNO1,O@<ZY+8%10P0N3MS:I84F
M1?MNI@2SMM5'C5%%">^>6+_'']L4XP81)_DBKF5%$C4E9!_01IV*%0X1P2+2
M4\$QZ2(^:7IPVSW8MB:J; [>+U"8%I>])":)X'?_$FU>>_GT#F!7=IL>9G34
M_N 3^.(R] -UZ[W&)Z7"E?*L(73M@R:7[X[8S]-(B$'[WWF-33\F.B^7 P?7
MH*W;BQ+^$J.ZFO#]24-O64T9%@CUCHEMH<V4CW:."BFW]5HL;L'I1MEY'IVS
M)7]&UE8-8M_]ZA4LRS>:9,GF=<KK.8K']O,$C"4;H*EZ]S38 \-O41T<&%\$
M")SL^L&?/LW"9><=G=GD;H)IPBT4ZRQ<-_+>II^-;^JU$><=S!M&Y*J=%F>_
M&\M!5B[9T2T;<;^7:%7_!.&]F*(W6\'9,7^UB9-X07%=!'P^=52,ZC_'DYK@
M8/_M(K!.D/DG%S&RTB.J&<%N&M*;M\QY27P G+O-:NQO$N@T/>9<@-3=R'C'
M,3MX6%*W)Y1L^JC]9P'2H)F]M*)Z=&*Q,H#Q)-8AG"N/1#P.MN1X^6H/N BY
M(M<Q)8/TXD%VT/B95BVS357%(LET$ VDOY0H(D^;Q%48AA:Z9U(SI 9'"NCV
M*-)8A^PFW-+16>4=8*H1<O44]K+A;4PHK?5X=6&^OXY482C@"8!H-0%X=,;Y
M=^-RJO@_JI;O0LM]-XYO5"M:TX_OT%G/QSO .?CW%-N3S!PU?"RGAI6>/R%J
MA]=V&/_Y_UVT=S!RF^-V4')W[*,2E<4G )V:8IO<E+P+(UE;9."-B0G//A6\
M9HT\HO0OG<Q5!X1KK>=B6LP>"A$YMOWI_JWW5^0M;:UQ+2.&TRI$XV(<0;IM
M05-&8N)UE>K1XGU.^6I=W6FWX>6VUQU@YY9HG6C2"W71U/F6Q4^;ZIY<\:+.
M.RF&*)8)A^<]SM_<.Z&6H4A'IE29#V3D+]WDU.\<BPSC3"=3OA+;^<X@;N<G
M!E36 ZX8CK%?Z]K]>6,\M-]S!T!$#$XY =0!@ >M#QO'.D,-.P6"PE47@:\?
M"]F$LS7]_:A=J#04=YJ,4;#MA-I'%;GTC."K^%A6A2%2&%B]:,.>M@'<KZZF
M$@P6YO2-L/9R9I@>/4$18.Z J ]C=TQ/+M&I8<PU,T/4;'C[9*>""U]6V.]7
M-I$XLN/L*U@TS]=9<)\\6A$\*WY+:H*%M/E%2<*3[@PB%G\SP;&W@+5?T[F"
MVPP*O96J8!:8WFS7+%!-I]>#'(NYH)8X$.:U:@TT3ZB_%=BQ=GPT[)C\< =P
MB^A-FD \/R&RZ!.2<?N(=GRX_]E<^[]EU4&H(+WX!%>7IC>/X?G%ICWIQQB!
MM\UZ=P!)\&;['8",D0%X@_(+29TJV[H#'.-5W0&*F:^#O-8^4:7? 5[/FEXM
MI_?J^5D>=AZ7FT(A-$->7</7OBKWU-ONV0HQVE0%T*8Z;ID\L&KB62D.R9R^
M%K\#)$;<H'\2,]N.U.U[UM9<U#3R_6J9KRTNR4*6_EQW0O82;H>-W];D0<"V
M+U&ACF:Q=&YFO7< @NZLH@E1:][CZS"GTU2CABC'DO5A.B,'TE7KI-/-1M8,
ME1=*E&FK[KAY0S&1/IXE/-$"P;+A[SZX"UJ:!>"YU1/_6!UC1R*W7_+7.Q7E
MX6:/+30XNVW_8D9"OJ];GMEH)8>Y%?V%3V^W+#T?:=E 6Q<-.EDBTB&6.8RY
MZ0#_5BJ'G(,')QJ=$EY%2UHXTI ^&:/[^O#!SA?>X16C]Z2"E'9IX62-<1MO
MFZU-&$F#OD;#5'DN(:UBCBI(OGFA)+NG4MZ!C[^&MD9T)BTWNC[X8:0 "=:7
M'*ZE@X1L&.L%N<4C*[\P:-:\I#S&N!8//+Y1R+\VSFF&P;Z_(4V:3L"8<#XA
M&/'3&9;-"F8T,+9WK7@I,]'VMVSMTPP%0Z!'-6@O97]672%8_,LA)-5GWBO5
M#64:QOGQO3X'C6'^B)D2MUY/KO?PFG'B'%MA%9.#]XR#,.'+()6TO,P!%DF<
M =K'8805W+N8=%-A\ZI3>JY& @MQ,\/C*9/=9<O)\^:<%;OZ]@/6YB^4?!Y^
MNHW[3N=(&$8!U1F)LZ1]]'Q<YWWI/M3!L)R7[8,S'M/'\))6X/&+>K2E ,=U
M#T+/2-DJ'5EH0^H<V=)E>H!+%Y/$7R"K].@(;03)1YA2HAI1V@)8T6]BU@%N
MC]RO6Z]WD@K52&(;P_OQE=@=1'8NTSX9-R<O:GM9)*C7.NT%<\MU/Q%^\6GJ
MN7%WZDJMYH1%2TUB_Q>\H_<'?X1H,4^*!TVKUTP&UKTO"."N+46?&XCWKWFS
MMU RJP..=4CB]\?<=,_RJ.;M?K%F3S4:O$40S&2$MCGX';+'0THRSHM=TEZD
MRG?5E^BR^8)XD[1UHB^I$A9;+HEIT8\3<;VUP"-U2Y8:S!4:"CG( "+D%D/F
MEQ:!#;P$JQ"$P9%Y_&'7(M4W""/H>"&QY>^G,['>G2]W@!J(](#=1",WVJ+F
M$_Z&7"8=)^VZ04A06R@^W?)9Y;%W3\F=JX)=IT3=3_DW5PI4<UX$-.=%Q$WF
MR<+=*>/"]QM##-".:#WS#F#* ]F4;=)2:2(+3WT\K9(&WI]-63DJ89V$K KE
M0Z8&TZ^>%QO5\6LJI-9UQA9(*5DY7F#>2NF9GO5<00]VOOPGG4)R!UBI*&&Y
M WB8\L8?=:>>A[%S/OM\WK/>NHWPOSXR@>"6/#H:(NWH;HN]>N;".N/P.GQ]
M09Y>?;07IO^)[&BVP99M?ZTZUFS9/+>!YRIEQ.VW]-#0YK&VCI[I$+'[GMI?
M0]WH+<GGBRS,0JT8URX0LNE#CO2-;<V%&B7W]K\5#X'Q$&XCF$])<!&PXI3<
MJ]^?+G H9GNA1=+_0C>QCT5;B'9*6K2>X#GT/&:K9'"JA.\HAY/Z6XX'B8&%
MKM8V=\0ZGH^QR\);9-IQNTBOEEO\S-S#8_4[0#!0R\0#.RO(TJ^>JME:8;RC
MP:%*$.T[VFS=$;.2/@T9D7&T=!\65_+$G(W_7-,($U]?W %6T?YN&3XP\9-"
M.)I459(RS ,%B2 RQ\J?%1&DWGG3,W2&25(B3:I: =9._CO,R($(ACH5)\2
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M>ME"C05K:+RIJFV+W[H"?XO9'9\/C=AK<>\X]/<$50ZDW8K0.!G20>G,=;V
M< ^-.'YW$J%9&G-BO*U_FA]E@\0(=M8*YFM"1=PHWH&EZ,QF&U%%H$8^FNZA
M)F1JYW*PEIH[14V=#T,2TM-V \ZB[6!=MY*>!85+#QP "Q9WV_[0:WH#I_UB
M HL+L3!:J<G6_/O<\2.K,R:GCSJW) W60TR0ZA^>(Y1!!!]#YJLEV$HE,[0V
M''IV%#*2)I,>P=BI55N2G$;,Q)*[RM5SA1:0/E=W$JK$T]2HYHU16_[T6N/.
M)8!@RFA&.YY"FNT20+,"4;4Y3!1#F[W=4W(D\O[J8AC.ZRO9W.OZD8CHM22N
M+O_+ME9CL/6 _#$5@;.Y6(-TJGR!DVG?*&JB-NVAD1A!G0C&4934GHUOX+5@
M19[R-RH7@Y -Q.>6AS]M?GI;>(7>JDA?8WTWT#Q"+&3RAV^(LOT/4_(8EQAW
M?>B[O?,)4@=3_49BZ,#7LP9DO _C])(J&X'T"X.0';UQSGP.+G3^WVXTYK?7
M[6H"5X=7/L&PVI5/@.169@=6)=X!_4MS_FK+B<$]O#JE*_!?@O-"N]-<N16\
M_UW2O?_31^O_%DV8^EO!G/4@Z'\)/(SN/AYI*'KQE<<I])JOOE: A"L/V G\
MQG5ER*^0([J#'T]#39T+@,Y-) '(:]] 0JWO)N-SN[3EE'ONG62+#)+(NTBV
M$JALW?2QXQENH8);[]R75'P7<4*K' C//;-U3Z,D\WL9UG%D:K9O/$'<L]2
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MC> 2X+\-5<Y%5=5*<.LF$;N#9SX>KKFH[DJ.XJ9\P5?@<J-%<H\K0A:3GRW
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M$X%W7 H[9\Q$^,'(V,=QGPN&*>;NRFSZCSY4QP9:.Q>;]" \:7S2W:3>N6[
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M0I\F;=J0;X)FP%2Z+MP'RCI#T8AY*D55[ZJQ88@],26T(>3G!(J#JO6;!8O
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MH>:@8LRF!).-:V@@-OS$'1/26/X\. $M/]=,ZDG7 4QI*8Y^7"-? -$MIJ'
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MWX,&=/82?#05$E6RR3O#1Z47#3RDB>E=*Y4<K7$R%^4L6I#S<BF4^D!LH7V
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M[_P+_6$E8C(V>MCT&G/ ^1+KYQCS+].-DO(/!O<$-!F.;BOKC>CO^A#J9F.
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M+3/BSK5S!O6^WWEG$*)W::+Z)3(Y(-"0F\N<T#)&C;<X[S;3\97HDIM8^=2
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M9DVEC+9D!R]Z8#,\_(TWTYP8!7@5]_G"M@CN6Q\Q- ?N>0TYAWRJ!(I5E!9
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M+OONL'QRU:L<P?9) YT! 0:^N1+Q')Y?*P,-C E^0%T:\2;W3V6@-ZK[XM"
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M.(2:.%8@H;#9>PNOC[.H=[B82C#!Z_O#?ZCY\UD(9LDBHNF"&")X5=CADMZ
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MS*62KT+M^C"QOX-/Z\+>!TFZ<FO5 A3KG'KZ$97:>"MW%4HMT="8.Q^JR!?
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MZ=]&;>'&G1AMA\X*3OCE%<CE/6J>588X(VEGB'OV!-7+6/DFT2#'2-T%..^
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MT;G53/M)<3<;?@WT7[HR%UK.YYQ4CN0<'WV=SYFO9.B'$W-9D.N'+T:7GX]
M(.W,.8F5D+!OD6WP'[UE2_!OP+@0'1J-_Z\&SVJ88?_JY_+6._G!5?&!9J'A
M3J@I3F[1ON68KH\;H[VN30_S0<IWI.8%8*O_(%Y;@,1;_!/LV.W#.NZE2]R3
M2GRS %\J'?)*CK;@[?\#R0PI,+',0GW\"+-T)8C*R7.?=45OUQ2<83\6;,0
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M"N#;E$)#PS#M'LN50'E:%R0IA2^G+)Z'R5T.IBR"T5>>M"['!MSBL3(MW\>
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M^A;=:J[)LIG?7?$2'F:L092]$ND)H$U22CQAN>DCR3:QFT-$+&5V+H_$9PO
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MNEKLVW,7:N2J)% ZZ AF)[$4NZ)0OY.\ (_YW_!HNQ<=Q"T29;".SKXA6M7
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M@?T!TCDBV*.T, VB$:=HELK_K2Y__M?!L[2)]A2X_C?O_<U]XZD-7$=\)*^
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MGX UR,4G,Y.&%%!_*D3VYU"-ZG$AD=-VDP+QKU@FPM.=^I$XWI?]H#'>L;
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MDJ_/I.PU /O+*NP43.0#-]6GDLS,ZZ \NN[6U9R%%E:'U=Y7K5ABUWV;CF$
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MQ9NX[T$N?XY5$<5]A+K;V00=]<!7<$;GKYK(Q+0U(O4WYEMH=D%P>B.$TQ.
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M-:WZE0B1U]-5:LO07L)'4&89/3"4 <J6$Q!EOGIT4(\,?A9  );11UI?M2=
M<$# 5]!#U-4SNGR>M+\#)C6A$??WCWB_]UKI=7B-^-@+O%)#9/=2S25(O?W
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MD@U2^!5/ 1Y5RO1 &VDVLG@#'?CNGK*E&Q1<N"L;[?G51$M(_5BS_P&U.-2
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MP4!9=%E6Y%7E)N0)D)+:ZO,J+Q:MT'8JCFW.H5K8+=&%UVQ%K9J:F'9^G2%
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M@YJ> +T>^."$*1-CI )0!%;P3'E!JL)KM>M0ALV*W8U+[P!U/1L1V"V%Y7C
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M=KS,"2J-RUK=0?#9+U$DQ7'<;X-2Q1"[Y-M(0X-!QH'WEP%K$SG*K]AO"@^
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MZ$U+2D[Z5%1A\BF<>QU7Z';;;1TNM)J\'.$"IUF0\'ZKIRLA>7E9; 2Z?N]
M1GO*\Q$,(<;Q2??2S+[O,&2)S MAO4IV*U-I[[E9Q)VMZ-TTLIG]?VO-U&2I
MB%>S_B E->IF1[;R$-Q#UO]5];A\RWIDKIZ()6!0D"3L@^6X /7:/!7MP76;
M[.%:T4V^1\(-][191RKL9XV:,U$67J>4/RAMM3!PA@%:9GAVH+4.)W:Q5T^
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MC>(EP6'K6\<F71=2N 0NO3GA#5\;]E$--TJ=02^B"GK1J$F_$._KX.WQR&S
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M3W2.5*3[:FE9NP=8'<4I^*-:SJD2WO*%-SY12?:6[M$#(EZR.%QLM*C_L6V
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M+*N:R+JB5BN#/19W_2:D<(U,@]%QZLS;ZD&BH4BZKZ.T;!!=M;!P2KU-2UY
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M[8 O/;H8>$49YD?E:=SK'9PL2%]T5?IC@YO+-TOSU^M7 A8(I5BC;4)78<^
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MX]G31GXI":+--E%IJFVNM=!/]\JQ)'ZMR2S[8#LNS+,N>^&E?G3UZ>L,HG3
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M])1&SM;<GWU"I6Z,:HV:\<AWE'"5YT*[IQ+?V).OZPQ\YPHZ6V(=[R-8UTU
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MO#X]NC#VLAJAX@LNC&UIW%=J])\C0,SS,;*FOB^JX&?]91ND__'8*Z<QD<Q
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M5U=9+"QCR-#:$P]2?C"3;3,M>XLXN-THGV !(P-'"_#S '&'W^Y/E ZB_92
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M?_IXAO]=S?:X]>)1YHN+Y@GV4]'BQ?VSR/WR$D6;2P"7?M,EP'HM]@_CV&Y
M8/NIZ2O:GT[2@4,_=4 ZE@5$*+B:CJZNX L"1#<>@1!$1/R5G_! 3)YN*N)D
MLF!U[3!ZO#2BHX25MTJF=9X_O)AE=!;]X'-2I^$"NMS!W0'"?-8C>PHK.I[1
M(+=9E=7^XWLM&AO;*E2YUK ^$-+RREA/08J4TQ\:, H_+_7VBFLTI"%Q@ ^X
MNN6EV;^5$Z*%CV3#:S)29!9?22=O1F7R@\NERQQ:D005?4!WOTECXQZJJ.R6
M+$/ V>.P%_>O&S)]5WDM'=E0)KG:E6F>R T[-@#WDA;$N!9$/&KP5DCW>/?-
M7;5?#4@B1\Q5)-JA^HNIN,)*?-8CSN7^\V'CEM)UI%0I.Z&:58N_KX0,KZHI
MR_5F\HV#--^C#!:[]BSC$??>\3<4/<,9,1J4DMC\NA]1*)>6,E_A:QM:A0%T
MO"/\398AAN[?7VR7I&BI=\D>%)2DZRGX\*W\[E\I4UR78Y=^'*/Q.:B9W_"+
M8(E F>1<J8;W4MQD[I_F9ND/5H^R>G0%N6J>#[(@63PT;.TC CYL090_,$R%
M)I,&N!4EFJFRDWN&H@>>_Y1&".?)QT6;[8YJZ7CO4+C4M30C1:<;20=<RK<O
M2KP#^?MMPJ,V% ^.RD4B=3D_6MB--[Z^\8BS8;(JF(+.V#0QMAD:PP;.<!W=
M]:B3-\S;%(T98.3&\!3C^Z5IJ'6$$HA]I'>+X:X^BOSY,2[MXZM3+TT!MM S
MWQ>FV18G1: ]V7*S+Q\OABO][H=UF"KCE]%A;X%0>7S+IE&PY!-8HO&OG%2[
M[SUK6JGQ39 HQ[@*R[8$=^'QE^P__#BK8XZ,U$0&I I;-\\F,IP#[+.GQYLG
M MR6/X>^LZ6_)Y'[.9):#U0K%L9\*(,1Z$A^X+*I"ER39&MV2P^4M/"-_'3K
MF9?C4<!S6\$A-R&5=Z:^D('[SP36DE1Z&OGUI:+1RL]H(TL?YF;PO)R<J'H$
M#E(C(\US?>@9@!X=?UIV":@1>^33Z;@I%#?B-KWUR'0&M;L^.&0'E4*E>N*^
MU'/?'1 , ]G+.4J[5K?(#^1M%U[TO7N%4 \4$%-^I*#]R[]?B5L\6!/YM"-3
M E%@,Q5OU^*ZTBZF?2$?U/LP@O5ED<>:MGU4ZQ?@S"D%Y*:599B28,=S"%[3
M^1J&1JJ3@5FH&B/&>U99HX2@3A3H[2+#*]!]HP2#OM*G\9=+R^[FL1X4YL>Q
MD-L[O*;0)<FI5[RF;W;O]/P+W):;'SB"K@$_2MN"O:_% ]N&4/GH-"HJJ,!7
MK'&M5UFR,LRW;L*#A=$N2)ABWDBQO?N0P<6P?F8.RD9FM&8L_'MWAO]C>'7*
MUJZ*XKSNQ!JLZ>V#3:T=&PUZTX*775 "1!7->!4P<?QKJCL/"#4DIT0+"F \
M)GT0S46*A#$^G0@!:2%M8U0)M:RTA:.=D*^,J%M/?$B_BV[-U"=.,56Z-V\3
M"?7VGMC2)[6-W,32>=7QP9%1FZC3L%@O;&8?YJ>*=V? 8%G'-+3EZ4NIK)RH
M,?-^BJD=W1I]KE>-M K%9*0Q::,&7FE\X1M0BVD]!&?,_/V[ 6P'=P.'#9^^
MZRJ8ST)(:H])IN71KT-0)O<ZWNB@+*!OP*VZ32ZXWAN4XENWL4K%^G(?ZIFC
MPUZ@FHDR<D*:N5? [7F(!:X<(>2-9WP0?,S2?C'7LB"9<.V:-G[Y82M1KI+0
M-[/OFW7 D6M* A5R%L73]-=,%&/AUU4A-A:AHMHXZ(W! J55C1 E_U.H(!>'
M$JD>.)[NE5M@48M:+$:WL'@(8J=A_ZAR^_[7?9P$8#X#0=[.>*^-GV'$SZCE
MXYHII8=\<K51EM;<8?YV[=NE<3=&_]'2W(R]<^\UDY1A>$M%RQN()H A&33]
M2*]79@CSB9P*S'#3U5!):#&PZ#H#4K+?4_N6HFU%.;=,[7NH@1QI[:BU\6T-
MUK<Z4<ER# N.]<\F<)@["(W9^TB84OJ$W;V?"$N'=XG9GP*IS9Z^;993QCOJ
MR\,>4S]WJ+=4O)TT/^WYO;;[=6O:>,ER0B %@07+60Q%8P7+/?FI>K;&T\'^
MP&1<R-^63R1DQ#P9-/MV?'4J[ZSNZ[$-K8R+L1Q"PJ[\A<B?:&+P>O-Q_(+Z
M_9IH;/<N#9_#!>>*E=<SMB7A*'0467QOO4B?)ZBX0B.8'"O@)4J#AC$(NM1"
MN$-_7?<RF8^.3QZ-^[IXR^B$J9DXQ"@?UL2#9>#.:GB^*BMUB"O1*WD\K>%^
MGX=_*VN^BB"?H;$!+?$K31+QJH]@F2_E*!Q#>C.5YL8@>A9&C8.,5''TCM62
M36D'#/(H6U']2*C2 5NDR2W$.[R\J/8W'A=3&W P3W<I$W?WRE_R>DHLN?AZ
MH!#^DQE1]4^8AMBO&WDB!C86![SV%MQ]ZW;'Q18&M,YT S?V9EP?'9 U^=UO
M!'$K5#K:@O@:LMG\@M8"UC3N;M;@>;FY\VCA2WHV#&-93;*>'<W:_IA\8/_U
M_'9Z*%-80HA:/A&+&A@AP)04AJ+F^*?=D/H_G]<YU_2P+&!5F3@" <IDI">/
M=KZ9Y).+ B#^GM_UORJ7_;^*M?]G'NB)F=]_@C5EY^PM \BS#RTI<= )1) 1
MKGK5]NJ=?L\UK"$J<;7G_:-V$$Q08NWXF?0#-?FVK9+,*!NR8H:7_K1!O,A&
M"UFSD#UG:1L9F3=GF]-*[Q4KWWI)-_OJ"[<5>B%&$!92:#,T4KR(]O!YD7>@
MXEE-G[N9U9<GE*4O=!.Y7T<<;_Q-;AX?V:#8,#ICSX$EUB-FX'HTX$X"2=ZH
M6Y+%)>@:P:>TO\Y@7N'9]?%B?-6KV$I71V4\/UH/2FU ;3C_7.AMQ2CF#9.T
ML0K]AQ7/U'[/AT3922.*+9^&,_9TGXYHZR52AG704#]JME@TMFDT?H>))4/[
M5 K.J-Z01BJ;I'%Z''V1A)9H*8^)SM3EBI[I@7F,0N+1)I7^<M'A\TAF4;[(
MK6O'$.O&>A_A;F[9Z[>VS$_YRKH#:8C";.^@%GP9#HM33$GEAIN7]#4<3%B'
MG3L^&<\/;])@[C+8OQR_!( ["=(DH\_K[&?@,/9/_.-XFZ?G6,S+!_R5I4+/
MAHY7XSV&-\,TM>/L\.X-JTE?,KHH-FTU?*$.[#'"Z3N8"E=1MXG@?$'IV<3Q
M0U@&NU$5,>3AQR^6-*)N4W//4_@!.++2%P;A!VN63OH1"\F*,S9Y@]P,>^ME
M:HNC*?#DI= 6<] <_X'1^.>!:%\RKZG.I<H.(Q.?A,E3J_I+ +T?>D1]!"/*
M5;WH:M:\_"G.K[--K.Y. G%,8S'?O$[C2M1$5779ZX@8%__YS5)Z?S,WMH3"
M3(2P6#MVHJS 1[16)& $?K&I(2NDME^T=IW#6R[/^4G=(L52XVJ@$);DHU#7
M2!7;76DFT M<L;V,UZ=1-W.5-28"4/CFUX6K?]GLO ]04&>K2<Z7Q).V''?[
M!"(PX(F@6J0N#A*B2V"1D5A3I0OB>9:Q8] GR9Z:N 7KJ<S?_:,GX1#^.;".
MB7@*U^T^X \L94>ZM0^";[QZ]"*2[3UP_VUZ.3L\B4%MA#0WP6[-8.A147SG
M8 ";.QG$..M)0-3G%R-+FXZKF$KA/C/T2[!!WQBKY)9"K)J)<V+-N[FW#\1?
MJ<&>N;U,.\2=3._CW/C-_2(E?U64@'@0%HW>TK^7ZE00X@BEU'D_1:V,$FF5
M8LBKL^_=K]-:/#U?#&LP[#O]NEHQAG^1 5,U%#JD<[60@OXQ,%S@VM6BI*C[
M*W.T& 9IW.']\&.T\%@: ,P9PS'WD.QG1'F9<C39<X1QC,O:"JX)%D.E/.0]
MO)Z]N)/L\R;IP%KYV<!'/"UM-YU_3?1R^S<R4=B'C)#Q:M>#.V\_EFCPTW<R
MRZY[/<6PYN%,[AD33.$K-CB^;T.:OTK>R4G'!^983)6GW]RS6=<2/3'1%[UW
MLR@K4S<#@GK50L-D?<I6_8'4'UAB'O=54!7W4!R'(_V^&:+Q1HK78K3X-OM/
MX';KQS=04K=1L^J.$JH7MAAS:,!' M&O)EE!)3T]U#*/N5_JUH-%I-I2.:"R
M0(CF0.CMO;?"#'U\H+/BDY%0W4#!-:@HHW :LD5(->@Y_3:) E&V@!=5._WZ
M;4*BS=8@(3G<4\JE8'LB='G,TLU-3<=!KOE'+:'$SZ4E-F#-VZ?1FHR#K:")
M[48"T[CLJ)# 5V*\'=1GF)H./MWN2M%*0:+!!*"H9RHTA*6U>TE%Y%TA 4..
M8@BJ1X-+/]*P'I?V ^9/K:O!]2FLJ O9%EYJ'#>^(Y$H#$;F%Y3T(#/"&KAB
M$!^%!'*K)2D$2E1N^Z6,M*)=>N^'*%!IAI0%_G;E]?E+G:&L@#M/E5E'WD-"
M++LDBN2#7DR$#BH>'1EX>2XM>26 < >BFFN/1WD^-<1GIF7F9#<HD<@(-!7-
M1_K$!+<S/ D3TK8]+*[4LKP9,2A'UU8?25;FAX-)/BP3<H"/TX\^<\N'E:S"
M_S"$A6))L&_TB?#:RTFAE%"!?*)\(APW7SND7S=25ZW?#*+.R]ESY:^E&4NX
M1C\>LD::V('M$::<,1\^^O*&*8YG5EL*-7UZW.YBWCZ"ZH$*9-WX4_S^.&1>
M+0_QVKKVV7Y]I\HFR\J6N T!^*V\[ 8EW2;@$G"GHIQXW/LQOM3$Y5M:A:.R
MU0MQC.>#0>ZA5FA-R2 Q,8Y_=%A'K4CA43[0$$'E2E^=% 0&P_]V!32*EGGS
M]N])*?]".+"X"N;GW Q+_X>.2&P2Y070CXQGZ@*#!'+CAC@%\C"\',I+N2CA
M 87_UR2$_YL9U1.FUUV)Y:\GY1<N 1KXEUG9'J^2#\*C5!9!$U_6[WE< G*G
M/AL8U'T!;S6?BRR7-]S3T19TJ?X*A[LJ8"3_BG#C$0B! BKX7R=.($#T;EPY
M<+ASBGEUHZ2M'.WFEWT6 O<',HY=88K2*4M_NUZOW<31PW)NJ=ZFHL/JB::3
M2T"S<GFXUZ^WZ%9;]KK#P"\_6$C4J5AP(D^C-TS].K0X]H&AQ!.8EP0W<:-]
MH>H\DP</X=,1,IL/6U<L8Z+SOI4HOZS8E/M*AH=O_SF(0GLV4VE'923;))J+
M4.T\?<3$NBW\NX))WE6H=)8]Q>EDCD\JBS:Y1:?<^Q)P/<_##FMPVW^\:/WF
MQB^,?_\8-J63K+[<M&9DT:_ (2JNT#-0MER\Z77&'SV;]!<"W0+P/_J;M)F(
MCE?C>J6BK]]G5Z#T-?0^1Z%V-@,'N;BN$T*@UBR60<,>NU'71T;=%H!,.X3T
MKASG^-PG8&L26OH/==A%%GA,EZ>^%ADZ29=6S=":1>;6$$%0:A#M@7J=,>WN
MSV#@15/]DY>KS&R:,G#Q^FB\VFW9*9DQB #.+HF4#)C5@@ &: 43E=R!I,Z
M[FIX2V;(EDMM'Q:*E"=8:0](9L/W<_R-1CA83JCF4JM*BL2PO8[T%D*UPXF#
M>S=52_Z8=$N+\IFQ_A 0/S$)D?FM=8_:5$4>Q/;J-/E\#<4@)UP46?J^60_O
MV,"FX/FNM.6H*'W;CZ&T=+(I>C]EP%]]O)+97/J('N,W<P:^OQSLG#V 5-R#
M53@WE^JYP?=6"KQ@!NQM@J3D9_.1E%<+&SB[./I:X()35SRD.;>YSQP@SK.G
M?W^^\"1\/+IMI*(^L@#Z8M31PKNHO4)^A#)J*$YNLIIW5@^A>L\+5KL#23DJ
MR%4O?'S_S(AJN3AE$*R:/^:9QP_;YT5,CFIJ(OT,C*"=E?)1(\,4A)3U(&XV
MO(C/B9Q;LE!PI^Q7'!D#W?L1+:KL)@[ M3>Z*; (RLKY%!"CM$@G4659&?SG
M'_KG#&/!S;VWA+^\994;]Z+ZG"WB77AH^6FR-V+*G_)V)Q*%$E[E9J#/NQ?;
M)V2<^;B^?[8B%R44U?(O"^>OZR4:UJ"GHX=H2/SC=04]-(CH$E)09!X">?10
M ?(<-H0 /6"=L)RNH1!O"[,5O$ 4/K"-8T/LW>[V>LC<D[&,?WH XGB:9UN_
M?8R#&@0,:W>WK6!J1KS5(NC5)-<$EC\^4U3P119HAV=>[9HIV7^080HI1LVE
M"DI69F;WOK&%QX/:E<(P B<9VZP_@FGKL*BU.:7[C\D&U>XUKW#\H&VI]&:G
MM3)S&/G#=:T[F0Q@#!Q?KD0[(M%^7#DF]-N(.Y[6B*\[$"+$ E\D;=I[/>V"
M7 T^#*QS;CZ2-KV>0UK*?I^!KEK] DZ+T:Z5C)&A"]2 AMAZY]3:KV*_,-A8
MRPX,:8T74>+(*(.4VN5YLC8]6&VR-'\SED)6OX561BAH6%2F&?_0?ORECL2'
MC75[V-&\N.MEY9CA'CH6-/1SV"YF]5!<QG?)].P+?$7D.S3AN<C[-[%,]T@\
MYX4>WEKV!/FZ???(%]9YK^G[[*-Y /KW!V.A(, /BDP2S>(05":)ATP 3Z%0
MFVVN1KM9E(EK5):DB:&Q)*I"EB$)I6XQYB1]'UW*683BT@U6A_%(VZK#>*4_
M04+?P]5A%GM&7<C*I>)<?I&T)(C9!>>.:&RX*%6M&%6)BB^;/S)78X?]G>A+
MA0*EOG6JT%>;BG\6K,A+D$<!!V>SL]IFE2=JZPK&#7.U_O.BH#*W1070B6D%
M@XEL6 !T<1G]1;TL8TP>ZN*;,_FA>%A]0Q_%ENPCNU9V2]9)DBN2 7&'GLNX
MV</REI9B/E>I(@4 >PU='87AH/\A0)1% DFT)E'2U.-@QL4C$NL6X161>AK%
M-_"B27&%>%O@<OQM:4?@\H>*I\\AB:8_(F7GWU-9"H/GV.$#NL[H*59O!MQU
MR^,?3GRYM>&R93KS9"A3G8^N0@,&^SA-'B'_V#4+/'_@K>&'B>GUO2]5=[0.
MVR\!DZ+V? /$H[YN\W5%1AD)^J#%[  PZ+'9 5=)27!"RC^RKPXT@@HLD/.W
M[( >>JT 1<U+3*&NHXT )"45),21@W1 JM3 L*1_Q&'_XH/U@$%@:OJPH+_=
M(>)BZYUS47LQ0_^N7.._[-^5KMSI8-_E6?M^2%-W"1AV?<*/G7F"";19H#VA
M\]XZ([/X-[5%X_9K2KGBS7 H 3J!E*" @,#4DI17^Y .(TJ@B%14E)>^FS$E
M(05]$THP%,PUJX9H0$3J7?R7SA,\P_=+6=UOR)%]."@1JG7QL_DSD]$Y_0>]
M4T55:=($?G+'[=?XHJ*6"&_%<:;-\.$E( C9JIBR&\%E6Z("WX\E.T8-+'U*
M3\#)2.X]EUY&4;;Q&(+9]H6E).QM2^2N^Y2G)Q6UT.5GEN<I#]Y-^7E?5C._
M9&H,]-J<[8_G"LG;5@$8J<S*=]0V9>M9QR7 [Q(@O[IQCO#^$W,:V-G7^893
M<;X^O=CG:44S&7J^Y>'SZ<-8H[X6:VQ(4I[T;\-9S54V&?B[1*N87WD;Y$=&
MK3##8RP9,\9V[.%D@-7=4M4R:M T*B7:J XC27C?A0WOA/M-M:+%;>))L63+
MX5%.2X4]\9I1ILYI=< T(T-/ :I Q&YD6O8S#(<(-5#R /LL']9;XTO"8_3[
MZT39%-+#$C%LJ?@N)\I)T<-*B)VTM SC6>%/Y+L;ONV$VJN<)$&A3/&Q*G="
M#S<4UE]<G^,86;?^SM,KH&A[/]&B_2@*\YCI6\[TM-]RW6V_[W/ W-]'?)5Y
M2810:$)3U.^EZOG- ^!6^=SASX*TI>G$QYM?LP0+?AK $6CEL94.&1.M8A(F
M82XU^N@>%"+,:DWOS.C:;B7]]^HN RF68NIJA?6![ZUJ5=RX=J*5I, ]0Y#[
M9N<R<*S;]<;PAI+& ^=!4>UK=KW&:5&!F_A';OQ=\E"W?9Q:* T9L,-AD"BN
MJXOO/<I+MEW37%J[1X_"K^!VOP(PK#"\, 0PTAI@_/P .BM ;_Z-,M%(BUD1
M+R_[<-=?FM=!T$?A]U!-%2WR:8*(3GT7_3>L]LTJ]IP2E\C4NJ>UQ!5E,VRD
ML._ ZHBE7\P;(E2!F4I(GXU5^=65,O9A!8IR+;#PRH<;+4*2<':T22FT>A8<
ML_&6'F)L_]_DP8@IX& !4E'Z?Q$*41D*>JAB;7'<_,)4[4S]"O1AR6%I,Q#]
M//H26(=M(@/?E%ZU9VR: _TYU#;YC618G#?V5CL'3E2)I%]66@KER]NQV'.,
M2S""7</BY(JA]STJ<22MPE0LLY7C+#<9)N5]-1=9%MNP.<#]--P:7 -;'S6B
M]<0[#W':\][UGDW#9OY/EY1/U74C!9(S;;TA06WNW\%5KJ^&*SC?'94E?#>J
M&;5A/ UU$>@@?L#[*DG>TO:12X^\CEWDWKO?@B^/]AGJB_S@Y@XND61[&^&*
MV>F[92^#L508\Z$HEF0[4^'B M"RY*:&['VV$KU'@C_&"]MG,@/&0HN*9B9
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MMW4*90NN*A8H1@Z:W(28J%TY=F/G$#RO*&?^5\&"E#@"4Y)/;H@VZ9#S%1;
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MQU>I,[=^<2C/E^#^SPCX2_Z*)_)([QG]&V93'[V[(0FH1H'AX !A]IRRS^P
M"U"8R^^:L)/4>QK>)J<.I4G"+O04ML3L$MWGJZ/F/G)%MA_HT>._$J'CM1'K
MHONS/N8O8,*,0Y/\BN@NG$Q44BZ:34B#N?"M#G-S*5=?4>EU;M)THZZ,1:/K
M]GM# 6-F _<KV00?9H,37TH>G%PD93^=OBB5/,!]@OBD?[O!K1R6VJN<M#1Z
M]WCTUKH0[$NM2@#C^0JN+54_EV-WI>"^Z=@&#_L:@U*T+#Q"T];Z$@ .D/@4
MGV**<ISZ(MHHYHF5AL7AEC%?"=(WM/.Q%< 9$[V[_)BO5&BF!90[JV.>DG,
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M_1X1P9]M_R2>)EJ_E480_R!^2RM.R7GYX>'M=74THE@9/,1I )8;NBB%)'N
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MV-Q#YT=DG*W#W3.>0WRQ[W,^^2?5+Q4=-.>WZK5J,.6BH8.ND;$6' 72_<<
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M6334(I]K>H>'%:&J2M_>#ZW4<EPB>*).(=[<-9Q(R7V5CY94(Z.87$3P( "
M:!N^A#V'>'B!/MDT#!EOBJM^9HHSR2,CF9+[=\L0^221?^$9/4%^:U)/?&59
M)OWB$\-M0_6M*5_X'8+-J9W\J!)5F%%B8C4GRMU';Z2=/<',6'T\[1/]O)+9
M]AW-8=@\,7'#[$[[EX/^7Y-1OAD+CUL6[CE/(.[=]]W)=Z>K,)"+5(P5V*O
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M1KTT45,:_]>^\ZON?VPCEN(P[B@O2+#5",;=>5"4X;'SX$VP4U;P8Q?.#->
M'@[.-+ASK(EW3XFTIC-U[+C*E?>SW'^>#-[__85S26-W4Q6Y**/*M.:O&X2=
MD8PE5!WT_H[)B1&=^J[]4/TTU7D84A,;SX2Y%SIB4U7R2T-G+!V[H]\\H'*@
M*CQ4PBT:-=;,7#KUS9?5?<%&/?:;_>''K4%7CLAT.;#7+31]LETY'>^GD#&X
M:>BYDUB9PN50$(\V@>PC[>Q+4+FD\0+9"'J8/HX5E=;+4E)B]-V(/EX?*>78
M,UT.*M4>=^3D+V$9'WE\[2V>[0K.@:]L6-ERK/V>O>>< 05LCV*6[P8FXUVO
M0;NT [B5L5_,F6W,MFEO<9A6_2@&'F(\$J:.I"=:>"8,DCZRH#S6LWDPM.R^
M2;T7]EP^%Y=O>L^7>O9UA\$,?.?8.=AI!#3"><(SU%<H] P FW]"EV$T6$+(
M"%F/Y!2BH]9.% 1A__:4BB-#:3+\%MZ T,3]@W+/6M67C3M%*3-(R4D'H<[F
MGLY':Y""+WRG,#V@PB2,AO8)=\.@.*+E0@;R,(AV!Q@&87#>)[NYBHO%_]/,
M]W_JZ-A./7AQQ/LO2"T8-%Y):JW]]Z.4Q=2Z<S44C4V(KEZ1F44<@?P,U<(H
MP1V 0'A^ K>!=$@CE' A=3$62'B#/'/"V%,:/H- S@ */9^V!A(^(7W(L'P0
M^!=W"^9>O4K3HCN_67ACUT],X/X@YY.0PW@;2\LCQG'5ZF9USL2=/J7F  RZ
M=)NOK(RGQ(M'?:'Z!@+_Z*;DITQ3Y8$G&%#?VC*UZ6,))V0!_[(,_F$F9BC9
MPYI.>R#9I8;^M<BX%IM,_L7ATG::-(H$!YC^T$%/A(9"YBRB4^ZKM>7S%UU%
M1X9I,S/KE= 5<FCH0:$(B(;FB!W<R+D$K.<F*$<R3@J5N>IYJGA-_0C[U/E6
MCJ;/Z[-XG_5)L]L>P-/4W^)M*C[ZUZN&3A0J\Q^MQ+X6-GI:9;UL6ME37UU'
M&, V6032DKYL$X'[Z4<"C?OGP[Q!WT,^2X5L0DRV'-.KMKQ#[ZOXP#?VKJE.
ME#S1B*N+N%NE$='4H-U=/W0,L&ETSK_TX_&6\)L8P3L]]$NEARD(NF. 4L9O
MP0>#U07?[#B_1I0,L2Y^!'Y3.@:PX.KES?EAO[*)7V%;;[)#,+_W.U/#]SNF
M0]_W7)2*S959WS)A>F*U]KKZM70.."NWX$-:$@P2B/%]CM: *@P[7X:1IP0-
M^=WAI1<)T%7,6 V5?=5<S=,G'5N)\\8\""Z,BQAS/ZU#_OOGY2EVU]E3UZ.X
MKJJK^/I;8Y:.3P"%28W"7S>-7\,$T+55/-_O>?#T'\E5' /T1PB'( ^4>VEW
M>42*:B2>8<*@;,6EY$8A4\:G#9$W5Y7NH-+]/HI?5=TD8W1KP"<  /"X<"EJ
M0K^NH53GOBK8*1TC#6V_@I'6&V3/?Z,*3B>?'+G[UZSGOU$$.V5@I"'!9.LL
M#6Z@G*=<#PD.I.R3D?G!",;)>?#2J=\%X($1S'7J[SH4:W[IU/L"\"QE_[]9
M?[(=?W5^D+W0B?SSH#4%E9Q23=/-]US9,31L3^F6Z@]UYP^J*@YEEP>/ 85>
M#X.HAX^2YYRBQD$RKS(12LC-KG7#."V?!P+7-=6\NP*SB<B6VH6Y<_5(SA<)
MYC.E]3T5]H@ML>1^]NL.KF:J;P(=C@',2)&7)8F%?WB\(2YK-MQCNRU= 9XC
MX@?$V*4[E76+Z#X\0F_PP\G"ER09%Q$ZA(N\@=-&J'P.;O(QI%0"%Z.ROI8!
M<H2-8(XPO>J>K*]O$&V<?N8+!9NSGF@O-1&Q"#(VUZ5@<W5!E/HU:#J_CX*B
MA1]K'>H&&\>2F..JI6FU Y-KML<*^$_V@^WS&D<#$V&?-21FHS>UU+J)'GN;
MK0*DRS9;NS^Z3PW[H;LKN<O:TFUN.L2Y><OQ_JCP_7&O$OIDNSX)IJ,W1B%/
M<BER="HC?3'P7QDEM3YY'Z /)F'<* L0<6=/6OLFP;2= <HH1F#H=[4.+)@P
M?8L>BM!1.\,')O3]'_;>,RR*;5L;;41 0$"QR0*2LX+DG&QR1H+D# V2,XB@
M2&K)47)J<H8F1Y$LL4F2)$M&0'+\NG'MO=<ZY^SG?O?^V>L^S_DQ^V%65U47
M537?^8XQWC$F K_%,]"3Y-0G(N$/D!*; &"LFBDR>TL&03&8GD>=* )5]:1E
M_@:Z\K]C0PE9?G;V\%+\G^X3B=L2;/-=A@<T'O[7GVM%SYF*5H)O .-EPUIV
M1!;&NBX"L:1R.IL<" M0;13%ZG>UM:Q/N$A'RI_"KD@M5U9\LGR2"2&R:JP5
M=("-G1 BIZJ@21@*5U6(&E-#^EA4$53=!)[]"2JK]9-J5B0K&F+VVMLRJ)I@
M'(;M^='NT[.?PF$"JP*3#_?6- ^X,;FZ[>.7?]P][O3"Z7B3+M<ELIVBI/#B
M]6[XVT6!";.O8YH[_3X>Q<D?/I=^JD)EUMAZ"36P4=(H5"NQ^B0L]Y29D #<
MJ64\H([O1DV=;:Q.&@J)=V%PJB<@>]G/_)ROP$@,Q#[6\5*!"><^-(<KCA7.
M*B?G2B?)HP"&YJF]K(PA4V/H_^#EK%#PI#?RR>:LF@Y[6OX))4#7)^%S/#24
M*R?EVJ*!B^_U,K>Z?"VA%UU<'?$,?GJ_1>F+YVU>29><G"4[^]7,[C&70\5?
MNN-CM:)Z3Q-%YI<-\<!3?1T##LL;[UE*DJ^,#P><:B@W;@"/N,E*B\SM*O!,
MQ#'.M)2ZZ1M^N?=B 47CF2Y7RS8M \?[?.970+Y\L-&GI9AM,MIK\^@M#DE2
M2;)T]DW;VI/UIP<_M]_>;WJRF,/\\0RR%P5O&7KO<%FG$^>;.+-KN*?\C#N]
M)?N;+5#5T,)S48EK^HT5G/V%6K_2G?Q>+FKM/I;,T3=4^8;&:Y1F'R= 9ZT_
MT_<[71OL UP&A,6M OJ;OQM'G>*^S^FET5"L^C!ZB".OCK)3$A&O?-XMJ'6T
M=6K1L"/85N. YKUAL"3>"Q)4OU3>T!=[ L  J/VH='X]KBXC\R0067R<5C4<
MXH>BAL1AE5?T5@/22;RJ1K0#)/F_$ #;RREE+80 WKN)V=P4"""^HS"2%($
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M["&L$5O;7!J/RNU;VWZ$]4&%W*@\=6%3>%\S*L<3S<#DS/E-;2N3&<K+PYB
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M6;"E6:MI>RQ@JER?FG?JKC3Z3:#+/-;%T\'QD)Q%%P$D"!3CEF4+^8U\F__
M0M??N%:K^F\P"7'4)H(%(X!L\Z,K6?/Z;[!K^ = _G\^4_Y_^$0G66W2[J;@
M-X"&6EF.-EHG48KJ@7D/H5W+BA33_'##?0+$+MGNS6JVKQ4R2>P\<P;B!F(#
MGC[QZ%F.^GQ.$9A)L'%P-PY+IG!]EL XT@;WI/W8^?U$OU%,^69KG UIZJ#<
M)\MC)2'2.!R=QI%GQ?4>'W,=6T0_^1X5)B5-<1WSK1*1DUCS%#%:1W._"JLK
M>8BC3V3R^N$ ^#.#D@TY&7J9;B^\8-.TBK<$^OGQQ&I*,TOBNW/-3F@S"\F3
M P%O,#"%'<W;_WN35M<TBU4:=1S@:FR^&6>&H=KK"I;8:7**H%+7W_8VDFBO
MCBI^D33ND!>%9U75SWPHL.P;(H9R,<UFP%^F12*CC@BXI'N")6'%%0MPOV7#
MDO**&0 XTGE!Q44J=Y>\  :%(Q-]V*B0SFM&%$RD.UL,&(BDSUD0S P)4D9D
M=7I5$#T[%$&*.S>0Y4:,D1^6<R]508ZI_]39_&_[2T-G"+T!K$CM8USYV_D>
MJFOUY#N27J'YN"Z+GCULNG6"I%\!QP^H?8L,,TK[>?K;2]>C(>)R+/D=R'QF
M8)L. AT! O%).&SL1%S(--'W2!CMS('F9(C+R\HQ/KCU:""_@K4Q@1DS) .
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MPDY7X6 "H['1<_F,@X!:5'5_@X#HW[&A!"'MDS>2"/ODZZU]0HK4N$^F<=X
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M KW28TM!D.VZFZ9.$&2YVNKR*Z\G3ZFVN42%@=<Q 6^HRU=A%BT(-N.;_&G
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MYKT/I.Y[X<+CM%3I5>UIZ<"RHR(P0S7'7>EO;[IH&$B6(QSU\?RH/;AQE$@
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MFTNE#!12O?I ^]Y*1Q=,YOGMK3E?EY@0A3^\AF&_*Q6;J\$M1=-3V[-2EK2
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M-.4J V]]O>J@W(2V,X8^IOY.G'0:>*1BM1R>ROE]B2<Q:Q<X=^^#^2/J!.)
M><_R ECCCS\H=U#)5S$2M78#>OSO *D"64:%H:+QT86_J9</>?^%4V)\ 9\=
M/+L0WYT$GM 7[N9UY=V\K-61T-G0BF/8RLZR.D6"\3Y?P;D)7;H#E&K> 493
M\^45*NS*BJVKS&>]O;0F3)_HS0IWJV#*O0K\1,TS?P? V6FP$//XEMQ#X87$
M0:&&UN617W(1J5ZF 3EYZRBSH-0-:0X.!0"%MATHFV*E.6R'\"HKN'I?.;=N
MSD/BRI]\G%I,D4E/[2%<"G^TT7P=,%0@;[->&[<G>;MD.B]XNJ^X&D!W6<UX
MRHEL/XE+S%^*$C0NN!/ 9 RPY5?QHTN%;$P)D$A'6B_7L@MV^X&!(/92-O\7
M8.(ZJO[E#"V)PE0=KVY?2--MRVF93:_K7&!(_LY[H^&Q-0F7IJC"RQB$S#O
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MG[K"]C7>G@)(0!V:7R&SX/[UE05!Q"@@8I=V62*-YJG4IK:58;HW_3I8R1'
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M4C D#F6Q*'+"+IHQ1H<V5FF28UT]VZNP=K46KS-RS@GG'[0Y"?3 O1K$P#4
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M?$H+X$Y2WG0S2;1"OV-2P4O?^#U,(LWZM&B&DA7=P0P=K $D%&($81<PI-/
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MT\\#W+D_J<??"B59.[G$T-":$Q#+%@@ZLI0M.FO4DP)_L_T.1Y((W!^O C:
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M:,[Y^T::W,QW$;78+UD,>=[&33 :OBZ!Z<H30?Q@T\*8UUD%'?RD]*SR(16
MA.H-II&+CYDW^7>%.LQO*NR[&G<')_W]K:HY@D 6!IF#';KE7Y-48R3NNWL-
M%;B&$SN55$I30QX_U5  L7K7ND3\F:<9>.GZ?WMVF]G_@@)M.>GQW(9,,/ZA
MV#VD-G]YD<6)LW]AXS12!&86,UBZ+^BLYG_)<C!0 4F4C=(C*VN#B0M=(@_-
M;UG9%K:)MD&EI[B=--E3K%U&'VDRT=,X [R1<"QD7Q6-LYG1B"$>GJ.<SJ0.
M:Y)E/!^R#T'\:IX+J,/IFF01<]YK+=O$#)9%:/I7!?V;L)CKYYCYFS%L5U\0
MUQ]U9B+AHR%0%$+ %T!YQ[GJ*ZE&+.0IQ'(7JG[8UWA ^;77?)I.3X'U!UM^
M(<=3T5W0SI!#F#:4RG\X0+=W)_7$AP@:N_HJYH5<?P@G#H(!7I:FM4%IG^@(
M_L9A<3$])3[E6C:#O/%9[*(9@]ER3BH< %U"CP9<R+9. J4<QS:/OMH$DBEA
M.%SYFY$FNZ[++ I019B#'D*KL?*98UVRZ7\9).,NH@=&K^F-4D \S@-XF#,E
M> Z[2"#H=JFUAZ4X'6Y+\434>M*0$&)-TS-<6LD-#JZ7UTKGSWZ7^B#C]1 %
MB4^]E=6%=-[SJHRIG*$JSU< <6A@7O3';,W!)V9^RAFYVGA.D44ST09)D&[?
M_AGBMMG^85C#=A'D=T)C ZQ-%HF8[=!LO:U.((F#FESHD[."LM%O"KGH-)+2
ME"=-5$--3%"H:-?SN>0F%_H52%LG&+[ -"1G#>AT)GH9Z<+H/EHZ"9UT+G C
M$6Y=U=+UUG>9UG>,:SH6N9S>0F<(SP:U;ZN^"FD%E B9D'2S;5*^&X/6Z_QI
MD^U6L'06!J,4=Q!/4Z11,%6QG$\4< :_S6&Q]PE-#- *E_?3=M\&NP-CN$\U
M1@>F&U_SSTLBR7=TPXIQ+R-UW"%.&;D\KZ.#)W2)I>= 8N"7/?@OY2^6.ZMU
M:?OMJ4 EK<+VA8QMQA=3@7X068H!1 K3V&6C*Z #GOJWQ$?_RV_8?M6:L!^P
MB>=#6/@2-(B8]^_,)XTAP(3A7^K#ORH/UH;_J!' #]/-,Q:\UWJW!"DYH)>K
MS@E81=[4_' YZYQ ?($FQW'O7ARPUM8M\(*6[NE#A(+'LMM>G)BAD1U2KPL8
MJZI ZLD<LC^61%-T(%;0FN :ZG6"6(SXKM%(4 EK8TY1&BX!5/ @<0"I-N3/
MY/B7"[-=D-CA$YIL<*'S^*MHS3U<G*J(/?HP^C^4'$[*Z9=VB*=EF%3P;70D
MJ>&-M>F\'<1Q>S<G@AH.[F(AR%H\?=CL^J1QU#XI_]N1_30B:KA3A/M9@/N9
M\A! CYOY>-0)1LC@"0CH8K,FV6T1AG^2)_GRH;03":!>;$4=IM7=0)H%_A;*
M!#&#\27NE._,Z%+@\DVR@,05C43_%/5<!$ TOTI?S]7.MK-38&3\*YXD[C@X
MS80.H.Z [1Z@U0PY;-O/.HD_,.1JTV3C5#*_7-@6-F[4$\N5;LZJ*,[YB0DP
M[QC9<VH7R&S,U\T/.<R[:R']*$XG9Q_:N68HCDBL>5M+\=>.J6",SD1-2<I*
M\FA#6@U0]#]C"JAKMRLIF!1 A41"I^Q8W1I+ &V4'+N=T7XK+""'BY@X @$^
M)LL(A'@E-)G%K9PLZ*S+WS@I[II!W-W6>0_[-K8CTAG"9K<()$[(&VFR@-'
M/ ^ C1;"AQZC^/+:O0Q",,N9D B"*+TJR3'Y$1XX#]<$M:V@43\"LX,E)G#5
M9\%U$-#2#&^"= Y@PN)VJ",1(T#C!6!:&(VD%?IH%"$%L :IM5B*P 'Z23"I
M1POX4GQG)4+M) ?&-OOW=W-]Z*TY)+#<LR#?W*??E_P:!;%BS?T7?Z(;JCY$
M!>*RJ< 6>3/<R;(9#RHM%S"+!8)9K&.F;97W\7O9;N)O>-%VA%Q^JHR=G1_K
M7T3EI^XW=)DTR4X51  SZ3%OXV,?/<EI;XNQ!M &*-G?NHF)MO01A:(Y_U)%
MT-# )N)[!=7!9Z[;K^UZ6S=[]N:ZQ5JV(9)4_^B^O"$\9&I!%YL=.8S75!.0
M;SHB$.Q"QV>N!UDP;@#X,Q%TJ",0 6MP#%G;-;/MH+_-"+((X\;?4@#['X:<
MQ_LBO4^PC.)="./Z_]7>%I!.ZR$=1!P=;;-L]\D;WSE6^!3MLJ,J,&>=OH1Y
MY)I>^LJ\49*E<E+=6D(H[_(CB^\=B9ZU1\;J$*_C?Z&5"0(.P<#(8&?6&%H9
MT?R4>9[ O3TK.5>S4XF#G2%0S70,Z;?NDU9^,?+0=QK3?C3M'MON\,DF_G3T
M"0>0-(+>L!,116F4U.%7B.Q'@*&$42)%'N3$"%(T%@N\IA%8:T9)4(B 1F;^
ME49#;QNA#KK086%-$"#Q:D:*GTUT1@@O8F#3N_,>)]]HB"0+PO3(RQ?)=JMO
MMK"[S^>ZDO@O21!-![]O88]H8[V&CL=KI2F$X IM;4(LELSQ>^AU<U5@#7 J
M<(H*/%+,#JE#T.J2+5[ZNQ!EV4=ZKG(]&ML]87V";-0#OGT:Q< & Y6 )&0"
M5%".D;1]$3Q-)Q.VF;L\&"B%Q^&HG0H@K:I%AQ%=RTLWOS=U.R5$H>A!X)1W
MH];)\9G+QGK6HOM3O(R,$;4ZZZV:XR:-$.#Z(V.A%%_Z_0\M4Y3S(%[Z++ U
M5S,LCV?94D:6TP:&%F+2VP)(>,".>#-YNQ)@31/),& :)9R;#I! J<'^<SE%
MMRLJ6!K3C<>#NB3%G3^=!2, 9YW6%#:M^\X]U'UOX?DQQ2G?[TC.NQJPV'5M
MMZZ"]XTXWN\^I%5M/*Q(0?-?7(FA0<V<"DBH@SCSH6WJGJG?7$W>H)3CM$XK
M;J/LW0IHH"?:M-V#;1=I_0T7$/88\SQY358#H]]%<SR(,VT%DP9)0$=45"Y0
MP%.9D$!0-);?BVG3,T3K.\;NVA8M-,A&M_\GY3I$'.F1OJX+O;+W\A6)6;T%
M;L*>EXL<W"QQ^@./:OV%VO=_VHL0OC54D+Z?; !R;8N0#_Z+F?Q9RHR.]]BP
M3##EHA=U?<P5'==M^O:7$-6B-:Z*U#U=4=SW\&SQ0<2#[A%'_)G;EC GOP-.
M(;>R$A;IRZN.#\X47&/XAKCBE=J\@/R.S.,9%S@?E3,VMW;%\CT4JK!T?CVU
M)+AR_=X7==$G[@)&>>].!ZJT3M<>EU5ON_JUUVI>B%)2RA*!...P47BX:Z+U
M)O)^DRO:YGD!YLSS=LR89K+ELTA)HK1Z)GU2H6S:[)GZ?@OF[(R,J<QC.&Z7
M%>4%GX\84XPX&TZ^R;$O4+WU$MT1O\ZF7J<9:,*%M:[3*!O7SZKR2CDM\U6F
M@Z-Y+H2I[]%D%N<UZ+Q:<,G[9@_%K";.>E/(G0YA?8DYQ44F3#OQ#J<=5'KY
MBZ3PO<BC6]QH6POR<VMCF\\6=W7>P"./7)9Y1N8-+2(^73DF6>3.<L#I1V1
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M"*4_]=[SSM@UNYST"7]5Q^7689L!?66=U6B98]4W? S0\2@K73[I.M$NWN)
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M+%"4</A'2Z.L72,7\Q(=$^B::ND?:"DC,  A':W)X@I*L3]IA!B--\3?G30
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MO6_]%TLGR[(ARM!H:VPT8WC#AF^G]=QD:V#;$K6[OYM0V_% 6EP3<8X[("A
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M^-G3I"M)#GG>XD(F_QB@J*]V"A",B:N/OL8-X$)&%QL/+\FX[I+Z?]4;L?&
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M?].SI,>BI[9%T8I.@W%_;7R*_?$R\[-'M!O!-)0HE$J2J^TA],;FB0@!F!S
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M'#]?</Q+>58#=]'2Y5=RYOX/ A!U:U<NS^]&^C[&!5V%D_*_+&/#$A50]I,
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ME,G$( FH,4^R&(AEO(DGO$7$'KL.#G(G_;HH(0@-7W)^$%H _)#\2 -Q4*-
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MQG=[ANRLHZDGK<.\Y)6<X=R3P5<T%E,WRBM*=Y9"+"W4[J>?]Z/H?54<ZYT
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MWJI9XX8+@&^Y:G/'T[21 3?#R*X%'[U2<?V=.]EY"LB)1_5^[E+7610+32X
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M^1!&2S(4+;*2>W.>,M;S"^'BH(]_[MN?\Z).=82H,#AO%?X/Y9CZ9,@UE@5
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M-&\!/.W\T>\#-Q3/>$]&L688.8N62N 63,LP[I*K6+UZPQ_.]ZWC?R6 EB\
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M4SVW#L\]<,[O309MI.7-CJ!?=&*W(G360LYEBOW#ILCBH[Y]E7:2YH&OB5$
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MX!7^%HA"Z(@M-KYR@\\]>QTHCAGS:2.*N=X2-+X>3C(S0F^+J/DEOX]?OM_
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MC&Y!)=23.8ANLU*68:C\\.HM6996S +3Q+Y$"0W4%F+ES]&8?%TP:CY[B%$
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MK?6P/IBR').&/3-EB9D^+I;SK(3#EN%/@K<='=R^3L^NPVE#<+M%_D#LY;0
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MMF)E98<3S5IK5/"Y<@HZNEWYX.V)%KQ!\ >!!^"O#GV$YE/0GHT%LQXVS?!
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MPVN C^ZG$3NXUYBPGR]</VC1W1V;Q).95)LD11-N[D@BJ[ <-X%G2C$  C2
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M(O'H,M9'W*0AZKX@JYW<-&V Q_(A&<]Z>S,Q_VE_XSZCC"2J -V%*!%);AC
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M?:G3*8AC*2Y:P%."VN(Z&1K)1'W_57)J08;&N8)4MWQQT BLD!560.:+'IA
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MQJIUZ!W"1'HNHAMP$-K$NFQ]DHD,(#M=I]WY3YL-B68D&NV5#4#&W'>42LS
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MWB-=ZH$RQ[)-=4-]XP<7:GBOU0:U"(ZM-$X=U"S(DOCJ6!KO&^A+X[QZKK!
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MHV2*0[L55'Z\'6[>E0NR:]#];_+,<;%>$Q*W1;N&2WXS2''=5OVQ3!IC:'3
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MBC(<1 JAATH*G5!H\CWU0?9,7'XT9WUJS9YYLPV.K<0_$O&8_,>;8>BKX<@
M/SKI1_SJMZQR^.,!5?%J&#VI/3G<7'X,47V3K"&9CT4TJ,B^ AZU% <#!J<+
M 8.WB24^$P&@8!S-VDPH"(NN(Y7R77P%_R_>-W@6 >#X*L""M& 3#YHM[V%D
MMZC9,V\O1A\7C#I#BB%9F9:#7CJS>;H9EV8M/67COA^OCKE83S[9O&SV-2(3
M&?\I3:X9_K\+JD4(]B-T:K;<MT6HIB^2SW3N3J:F]RAY$,_,V2)'(H^ J(\V
M+5BP.-Z207,6QDKF?;!\Q>LV!<RI]U"..YDQ2F+'F7AWXQ^0&R]EY7_CI24
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M=%3<;=S$4+G_>3(5E$4"-E['#R'2>OD [#JYM;&)V/Q7'Q[>&R?$S8NE1P;
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M60H/3@ZWQJI'V@PT;9T>&1IV2WC+!Y6<@IUGS;#9^ME1W]X7^/=/+(1+&5V
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MX@>9DAIBU!EUYDG'84(OG>&&SW.89^4O&HN),?[R=L'MPK>A8=32[^DP;F
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M#ISW5HQJ9V'F\&#FC&#8'/2>O)YE.;S##'<ZI@\31&/NR+=SV9E=E],=0.K
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M(]L <OK;G$\#H,KC6<;?UJ:B2-T35L&C)9 1K:G>FLX/#O:9G(S*RPVS+U9
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MN=0R9)=5LH&9);F:+]80I]P/!8KMDKLFHP,8J,]/Q@?0<-]VEQHI9X=.:&
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MJ=B4.0BH/F@"SD0'DG<:PNG3@0ZF\QD!T$YE/$4  TB(TX%.-9X<B(_1G])
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M/1+M5!16KT%WXX_XN((VJ+ OB(I\;-6\#TVZ[^HB5<S"7V1?+<@?O%GH<C%
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M97=/&&O) Y4?7'>8WK[[(EQQ9R=MI=";$.W-V*W9I=EP<=E5:ULZ[.$WR=2
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M)?C6MA-[B+NQ#+%QDN8S0UWBE$4U2=#Y/@.J4ODXZX\&ST:B@1#4VRV%[%R
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M']P.[37U$)M-^/:UK,9%A]QX6RN:W-2P5VR,\'G_6+;A8BHY[H*7<*&J]<+
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M%NK@;NW\.QF&^X5T<,UG\;H4%QJ%B=%7+OB26;'A P3VV6+@"[3AHZ?$94\
M]4&1X3S 8I)D'FK1_TYM1>0RR6EL9"1?H&S?_<[0]^S^:WW#!6*1;]N/!K2_
MV15_\NI=TK[V4K609=+UUXY!3E4,@=>3>=B53WU7K[(Y(1+4R6V+\STNC_G
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M%7E$ROIK05\00P75O0HRI30'?V3ZXR9#%9<3ZT#4+>FS<:&+0,6;% ?H_FG
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M=B2EMC.<:; PVZ#DC!M*/M?9, Z);&WV%&IJKF[,A%,(_Q0H$^J]^#(CDZD
MFLMV["=N#QT\PF1BF"0U0 .CJZI!AEY4L4LG6U57.3D3"/UML%7VYX -G. K
MCGFNJBY_FK"XI<F;#'^?\RP=6%<=C0O5(Q)65X2FD^^@(53&@(##YR:Y:ST-
MH["O[QV</Z=M2( )WQ!OD&+N;Q:H[.+U"*)K=JKO?\KV3.*%'HU"Z^02&)<8
M)^5X?? \'W=>,Q=_/]=Z1)V_9)5$ 1G="JPNT?CD ^E.W5H M+;*?A^4.EE
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M.!O($M ETH<"=\;:G%+\L7V<_"AU1Y]AN=W;!4N93/*!%,\L!+,*HVN_2=0
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MP/A5M5R<,7JV>-W,WK0[2_(V9:E"HL]=YR;F7B6,(E<=+R2XNF8ZG5#CU-9
MJ.Y39\CSWVJ[\]RS6*+UX#/_.4X![AF55NF&Z0%-!79!_G0%.'J@RYN4L(;
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M]PX*7^XY&,^0%TC_*1K1&!U-8F3/7[*7@P[G5M375%(HA<7)$[Y:ICCTAHK
MM96T:>5)!F6FO#]9YSZ,95@L ;Q.C(B+6QC#SKVHM?W<_A5%_)P/;VKKX*Z
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MSZ9*@Z!2WJ:*!.#A9>!@W4? 0 J,HY?AQ<4\.+-BFP&\;-<!,9)7O/A16D.
MW)Q\$H!!M*V@%H?MBYN[YV5#A:(&]6Z_?+F_N!5%?&>W^?4B/X++?U,3@A]
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MR03L*?&L*AV(WS?U1"74F\D#\SBTKE3+]:LF8?]J#:>9DSV/*LSS3_]9!X^
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M5\S;;6,_KQDTW:.KS 50Y'D$NX3Y"_22BL8.[?+@%Y[E@W@Q$PNHD ]ZWG>
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M9I_?II<3W[#<NC/#.F6/6!!BR.A^3G,)7;:KOXB[ ]" (==1-UU.U:8M'S]
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MC!3S<C)-N#J6NX'$@[&*JX_QG&=F1$#!EN]=[/;WC899V;>>!K,/Z%=Q#(5
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M>\TUM3$#"#)(48G8Y[J:M,G=GC&&GB;& I@#$/*F"3(ZTR&\)X774P>&-1W
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M"55+,&1-=Q2R,P])\.K:0J+R6J2=EM[L3-]PWP'HNY&V8+1S4]Q5[MU2]^=
MOPA+SXO"KTPC43?*SUIV5D!(UEUYD8*0CE!$-,U>ZD1L,2!82(S_B* #IT64
M[B^2B[S(WDU!%]*?4%26K1(O0 B9?M!?DOX;F%\#Q4A?RX ^7R#Q"XL\6VW&
M1=IAC<H=X#W24)B;"'M<1/P(ZJ>Z/%^R]3C7:IIE]X.Y]H4<AM]VU5^D$"AK
M3RK9T%-1RWO$79A,JBS? ?# %Q_Z\@)>N\B()S(+LJJ<4#GY%G=6]GL:/TD*
MSO9+NGRM('>.B;P9VYWEPNX4YWDL0@?M-\:1/&XC[NM>.O9-WR^+,*4=PD%B
M$$H=PPROF>XK12HNCC(2#^DHY]EJO,:3U-^G)>6AK=XS-OO:$E>EKGXXJUTS
MD#\<CN=2"XRE/L_\]%=:S ZXNQ@G+*_I=(NA^R-J94"ZLG#RTHWBJCZ5W:O8
M[PL+OQ@]-.K%,YQ<IY*WWM^K\*3U7"-7(!/KF/.,5($KWGMA*S(GV4,4<SGD
M'XT=P]S=9+\O(]LU#C$TSV1&N+8S8HEP#>)&2YTA3T#KP#O 6\AOG^(CSGWM
M<8YGYWZ_3$\D(W=UPV%M$ T-=5AU)Y(OZ&,+2Z[Y<1T9P<JVCF:F<UNM-Q:;
MI5%T ;*4&RW.AI" .\":"I)-?X-=<17WV$TU(E>#WC?D%DECAR-TH'F%PVI1
M+C;??GEX>S0AJ2M)_AW V 6Y4&^:I-J;*0,E1A/UM,"_I>>?Y?BV.A\';G)=
M3J)6< QVRH8>P>',O0P%!(11(TU&B'[WQX_VJ&4CF"7#^R8Q2Y]I+CXS$;+3
M'@!I7,0X.KJ8553S8^5CZ/AFW&+@R+80VTD>[945>B5^5O5-U,-AL+].B,KS
M:BMH609O&9^<>]\!?.]ENV1O@$I A-\!Y !I<BNV-.-U;T$+!F$]"U21=GSC
M>]F/171/VJ.:F[A[G&^:$WYXL;P.43]ZIBB 38GUAE7VB<P+T$O<92.XMR/E
ME=OOD_?#C:\C:I&D>C+"RU57B*22:CD*R<L8U<8*=Z)\1G$%E>.S:B23%>33
M<U<<\?)#2LQ3>KD5@?:O!C#KF"NK'3]I3T[Z2=\\?D.Q_V/=TG73:W5'?_G4
MD7#J[3SZ&F9:W242=O&"$EPG%[%WF73L@(49KM^+ER>W=JZ2-_)WO;UM@2]A
MO >$Z4=EE;FVY\/PCV]'NA)B5TGU,$E7"WO*::*(?V -C9_JS^/L]#:%8W>P
M;KN4B49=\HKKY"M)2[ V/6&<]8DBFKX#A&PI$\5%)=A>?<H;KUOF0+N&@'4M
M>N&?O./PTV4M,<=@HV()P?-VHWY/V\BW="8!?D<;#U6^%C#< 21YT^FS@_B&
M576L5 IMDZV"W>#>'Z2P(BJE"/QUKUC+1&ZT) 31Y,Q)G![57E:FU\YNS8(B
M+-XKU,4:$SY[UO,CF!BK;HDP5EG4QT^R=KL]F(3@0_S9VSI-FVGJC1S;*QTH
MQVI=38>BP_(W@8Y.)'A^$AZ)R_L9B6VD^9 .NG5K%WP!\>2H"2O-DKF=;Z^7
MJ]OFBP6I NONX1%]"F32#0$/S-VMQ(=.Y7):\SG? ; A:[:@L_W[Q%-HJY/H
M8Y]MO)"@N_0@F(&1L!NS;LM([W#L#M"E^<\N9\K*Q\AZXBP@7JD+/\HBENT1
MWD8G*Q1GJ$Y9!6JW'H,3"^8::KQ@.<1R-LQ+*)K>N=*MK_GQZE)6EK)P/\</
M5.J%)S)9^/ZYAY#E%>%Q:'S OLX=H(2]4L!:$L;C5B%IW\ =<<09SV/OL]X/
M&MMX;[Q/+7XCY$<\X876X=3W<,)AV**/?I[,!07S\]6:B8_KA<6-', KF7OG
M[<<[P**244RVY#<_FLI0 !W'Z"R+@_R-$ONXY2[#/)3+X.?/(\SP$AXV[.:)
MN@8T9D:!QUNUOQ'N$59'+Q?DV^>W#IZ\NCV-\Q/+1KOY72Y47Y>XOZ\?FN(6
M6_E&;/T+CIWNTE;!]#Z+ML[0>;%T55***GQJT48:XY6( %D/XB.DMYSW7A&.
M@='X;+?EBA#)G#KL0AF']S/>,-&GL,6EH@KA*LM "'5I\)'APB(,T?09:2NV
M&YDXKZ5"-3R#!B2A$HI&,9\*PO<+H'I?EEC)&*]TZK9^5UK/,.)QL_?8XPY<
MM"Y9IISTE7,=<B;SXN+W,)29P36X+5T>;6:?"-X AQN5L,\&@D2_P?!CO2N^
M/,G&\CM?8*BAB?"^J'-5TN#+*TD1J8,7ZG<B"1>+<//P.OJJ,/<YY" =..&N
MSWJ61K R1@QT?MK;D^=3>'-H]V-?A'@%5"5'/UI%9_#\(!L9'8J';F@P<FV6
MWP$-P6C8\_5?/BV4)F#^$GP0^84FZ)EB4#8KKYN0S7;2JGKWD=Q1;ZXA:3':
M%'3?CQ3WM$GV7ESQJXAKOF]@YZA0&4,=JN5JW?5B <M1:52P\=%9P1V@%O9S
MXBRW7^)'7:I6OAE-Z.(Q4272I%F0\U1&JN-^Q(^03 2=(8>_J=41 #9M"<)7
M6;$J]\)$2 M#SA?O/6^C^07-D;8MZ%[Q1B?3Z_%_'^%"IL@J562*A&S2UQ5
M&E4V+C^# JBSETN%J( =ORNS"MZ$RP-Q5\Q>JIS> !,^KSAP4O2-\DNE\_^
M?[I!0:T6H5EI *:]7%2I3Q;@S) @"!'6EJ;D?'0P9'Y<7/_Y X^A@LR75[]'
M!.?ZT4QH6M?\)"L5N INOS[7_LRFHW4$"2FK?K[X9LT@3^PGYD#^XG4.]1W@
M4[]S.L$1>DO(@0-S7; >@>[OJ.=DF(+[TOJ3(NB^N3U,_:D?]J>]:9_(9:?/
MMZ[&7.HP&;K9J#O9<FXE*:@W3>\GBQ7CP/.9=A]N4<0"WEL%1HZ'%7F=*(_
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M/P5L(Q#R3(5_:B7VG^X 7B$_3IAIT 060T#'/#17YY!U(!( WP%H[4!7%W>
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M\5M8;ZA^Y7'QIO*7:W"RJ"V?C7QF#W'Q\AM#>=%S!O69/)/,"1\+V^]271%
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MH8)H_]>2?^7_SY(_&UW?,0WJ##2H@X"MKX4>1B-<K:$3T.[J%@0]G>Z,;=:
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M!#'&+8@B1[P. 7C14(#&9%\@8',@-)*Q_20:]]+M:>XPVM,(<N1QT-R7GLV
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M0ZFSNSZQW1-&Z:HK:/"A18L)M<IU"(P?4!C*?K=E)/4E>)50-#:WBAMPA,&
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MLC0Z]MET25VB_*&@G.18/QT<@1,-IG;)B=4YASL%\>4V_!%!'MF ^KJH1HA
MYYCEQ%7-74"1_:&I_ %D 6^(-,^?/$N./><HG4\O@B"*W,1!7.UZR,6E(T_>
MX]DZ1;&^5;6%Z6J67X8T3;&N6E]I%)@"<L5X'%I542Z+N>M:D0GINVB2930@
M<,"_@$.J@.!R@,61_AT+B0\P9&E3@#$?]T,@BJ#;?B*JN$C<]55(;4X0B^K_
M*>"FSJWPDO\_X5/[OS%=C4& "\1LJI">VZLD"MBMN&Z'PF[>)>SFS#,,QQM:
M?$5'P[TL]I:$5?NPJLN)<-5TX I9EO.(HZOX(X<<=94@1-("P;I$ZO!@+7IJ
MBGRG".3GC)YN#8>IKA=3PTA-#9G8?D+:_U7QVN[F7"E]R:14\B-C-6/!.%K7
MW88"%D#ER0,.![B3P/D #HNNVZ4*+$UVO)@%=8CF_$6GWZ\8#721SE D'R:[
MGYB1,/US455-49B48%JW'0B](#6@# -!")CY\\!!!J1$Y\HX)Q+X),B1?8&7
M&!6^N)B(\\Z[T)RA3I;.+T?@,"=2$_)G"CM 5;1R P%5%.A70-'$[F'0F^H/
M= L!9^V(WJ+KB' Z'0Y?=DPK"V]:8KU5=8)(LC$Y=-OEE\H=6\Y!;D6_^R^\
M7*(R5R8V.<?F32/TD'.Z,@]UWS#%AN-D4:7]_K.,D7?IQ]EE2/IA@14W7E:K
M9ORS#>CI+WGQM;B]\F>!3!J(!BNB,U 09?#)_=Q.64<*Q&:<F859C)[MSS=S
M3&%W5=J8$G=O-CS7(E^.]\3"=]L,$21VO;C[%F_99C2L($<18RH[D3CD[I@L
MFWUXZI3^,2KO#$2SWO7%._J3N<.(4,(JZU=E(OFR23PSC$SG2*M"%R]F8!$^
M'L_<(:TI(QRSIE<!SH*[J55TS"8:*MQ_X5GPZU7(*<49B/%KUH-AIYC-6UFL
MN:@!O9"QA.Z!OW20ALI1'^J=T7Z%Z M^R+>$><L;!BNJ[,/2EB.)(?P.$>5B
MKH^Y8C8&VX3)>[3.9W0!^P@F! 0I'([(CH4/\V\08"(U"N8J9?@=!^*MNI=2
MQ0WBN?1S*08FK*9!4]O9 ;.4!-("8D(>)SKXMY-@S- 0;>78RPEIX\LC24'&
MZI*J0 !UJ (9Y@03I!J0:L$@U*WQMX46.I<U),(4C>NT4N.TZ8('42/S<;=I
M=/=[Y8AZU<6-GY*3]$HS/A[L,%8G!R)AOR\&'.1"2,?"^#!Y@P5_B,LZC) @
MK Y<A91 +P)C_\:?GV,*5<<3!]3/L62$P4QT+N/A@.E= F-#@*P0R))(2MDI
M"7DAAL4N6YMDI-(SE>JF*=]760-Z-.1]=CR#0O^@YM<Y"73B3Q)<"?GW[(.B
M SHF_S#X@;]N7,U^Z4MCI4F=:/$BN\\/KQX-5V3NW;HHAP%']$+Z'!X0$?27
M!X$<3XR4U):$;\J1N2J)*(G 2$'L:P1PXH5L;;ML4G0OF(#;)!F"3X6,!+$H
M<H/#P&U/A.29+^T>:Q[F<8SEQ"//9Y[..^-<L_QKG@7SAW@&XQ/]!_@%_ON(
M XKG&P,Y>*BT&RTN%;(V$GOCDIO6R!NMA-=L:_!,1VT29<+\_R:!JEW$W_H@
MF[BD;4TU6)Q9)YH/'.V5R^80=/>V]=>9S+T'>35..,:P(C.DO(J]78&CG-!*
M_M*C->/'[W?/0'MA5:3&8U<.6"6U[7[RH3GLE8V!_*U--#$O_GQ"C/C&;SU(
M:Y+H9!%12XC>2V,6R-  +D-'&+A.+"@Q+!D)<@+#U0F3*H3)8!)*OMPJXO_!
MH23PO=2U"9=+ TX$A:7! ,F=I 7>QN4J-!62\@!72A;;FG,.G8M/?4& +Q*:
M/P;Z7_V!#F'BIOH$2+ YS;*&SD#\3:6?R)E]6K2@ZW=.^?E/KA \Q@00&;8T
M_YO'^-]>Q)CV%"LOVBS'JTNUQNUU6TIQ+JHJJ)N(6N0*7W&4:L<3G@1Q@9AP
MTX1GOL'+<V(IT& QNZZ=;A693Z>>JZ(&/?1P3^[!U_-:,S1./K\YGIDK'PZY
M^EPSS33+([K<=^M;QZ_R1SGE:U52-P/CI4?8PG3C?O?,L\DY-)_<O7Y417)(
M8AZJJ- VO&%8^7KI#+15DGL&RMK/Q=.C$'V_G^LO@W6.A\UG?LY]^[5Y:(
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MAZ\-"(3?=1YGJ"(?7]K%8A.#8%*X@?/9-% Z]:!^R(ZD[JLCE;V\[*8VX4M
MV%4@(!3_D#?1ZW^2\O\!;E5%_B,Y",'+&&(/.I_:).7+2=0F1L;Y(2/U(H9T
M;B3</QX]'M(7:VIKS3*.H,^Y/&YL/C1N"<YV!T(XN: 6FW&P@\UL G%30=DE
MP8F1+%2IWXSEHRF,,YE(>JWHN#&DH9O2?"POGES7<+>7_\"@1J54T"91>#XX
M\KG'T[+V\)5M^LA.Y:D5PU"/=P'046:0E<H0-6CRDS%6EMGA<-%.><E(<G=T
M_-JM+(6$=47/3UME>YYL:X^@&4H!)"4Q,Y&G-+>?J1V%Q)M%FR<:RDV1C\:>
M@0IH=CL.AP1G:/QD/P@I?X"V%X\/XJV%#+^UYV!MMO#EEQ>;=0+)^"OM#U8.
M2A;(O^OJ1(PAOY0JJO2K!R6'-K$.L_KPTAPQ9M],RRY:+($I\!+%_'!H9'HO
M<0PI>B#(.XD!7XCC-!NHZ=S-Y:VK/MUQ4.+#H,DSHXX8+S9UD>^(@G08->8&
M/FTF*,UL'C'>XK!#?Y<!HCO1,5Z/F@]X;^\F/)(:BL9THCNS'P&I8PQ<+A2=
MRSD$CUO[9\(74(B,Q@31$-(& K,F/@Z1HQ8==\T;).IVT':@7].]E)AZ*;M?
M$JYROK(9!NB*U!>Q.!PC8>XA^#4@FOXLU1J,OA3?]LK '^'UHTQ8K\ZUH9Z=
M>A04;D'E.SS\">OJ%__K_,#_TY>E'_"3ASS[?%[HO^&)_V]?2L" ODK2KZL.
MK];3/=1=SJ9<MW(X _E-B1SJ>_=C:T7JNCDSZPU"Z6$Z)L)&U^,/M9122N-)
M5ODC&XD'YKF*ZJW/0-[T0P-ZQ7HFPFYE'730EF+WK,K)NF-GDA.!NTM-C"_E
M4I]$6W24^NG3Y[3IF_VUTKI-8]*":JMD][_(]D'/P&5KI.J^0%YOU@.!Z4[R
M@ER2?H,>-JX/O&.<GZ]^-K_I>@9B'P/) NZF599X6P F8D>/&&<[]3N \1V?
M:G8",L,/&HZ:</G+<4_,"QI6E[7]O5GVY1DHU ]#3\ND][R;-S6_A>K3;"-\
ME_>$7__0Z@[S*M4QX?\:]%"3XN_/O_*F(YHK $OX(O=<+W<F,FOW,EN2GQC@
M;\M= *FQA*=/S/J%A_)#9XS4SD#0N9TST)IA+ESYC\+ZJM4BX=IVC%<^@>3/
M))Z6=RPBFAMN(F6K#6O\Q3,=GM\PC4Y915S%@P>W<%L>]0J'0+A3)ZB4C=N
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M-BHLLG"92'5A!_'U3/\#[4]TD##(']"1_G2)KOMUPN*[-JIU61:$L('UIE*
M]X6I>7QP<.<E]9U&V0C YN4YP*AZ/CO!U:*A85_N" SN7V9J;A.ML>>ORUVW
MM3!GA<@KSXBT6U76_: 5_;R6YL==A/+LR7+Z_H.QN%'MR>C61PTCP.4/0U-Y
M3ES&$% X9.S[,OTTY@.?X_F$TT?EIR2K-ND[_B3H_H!'NR1XPY2)6)_4(+>
M/NP>1"Y6QC'?7W9-?1WVPH%KECK'UXY:STE+SUWCT:Z$&"; 3(GJ:L304Z)I
MW!<';U=RX$,A^1DL?1(1$.'/DG-XF?,K=]'CB)UZ!. G5P(9?CEC169D_W!P
MN]K"^/LG00G0X.7O<*KO-WH7J=!G)SA9I6H^Q]VW ,H<"HBWZ.<MVVE\8:QY
M4],N*ZQTA$(L@;;:V[[UXP=JKA=NTWF"-M2+W/W^?)#)FV,S<])?KP>)'#XP
M=3=?RZ^11@BW4_)8SX-2WN$<F'7489W3PV>1AAG-;%H T[Z[&/[=UQD5!D(]
MTS<RF:N+[?]#<0ZM^&YIC%(*.CISL.;DV1#X G*L7S5C0]:E4T7'Q4P>6UN$
M7=[IMM:>Y>?CYP8\/+G3+(F[!2;%:YF(EA;D"A:&MGG"W9C!7G5U"/M'M;_[
MD>[_?@7Y_T/$_M:8[%!%?QG* =)D!N;K_1 YS]L@,\-;7PF^W([PU7$NG5>E
MCGO)3WVGW(VF1*X!=AX]ARG!9(%RW+OZMX"UQ^,RVQ=3-Y=&?U9]'Z ^4E.!
MXW_',B$+,.:W )GH6X#?G8WT^!P*:WRB02HL>JP4DJ!1[Y5>4PUS5/5DXL["
MKS^A!MO @TY222&?M;'[T(S2GU:IN(_4O>&9$/AJ[,A-^>\6X0HZ\1\_^@ N
M.< #MQ?<+RPL/'AYE?\,?H 788AQT5CAI2Q_X&+Y&(*T UZ9^B/B5%S_X\Q
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M4%H]6WUH$2<[^$.L>?3LB0K8B;F,JR1]%FU9:OQC;:/Q$4>"RN#3%AX=%;4
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ME.!VQ=-?IWR1_E3[WCA'M4O.3.:IF2 "M\843S9'8*+6KU"_\B$H_W>R8Y.
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M 3,2.V/?-U,Q;Y=V\\8"4NH>HV AL#BVR0DA.!=W_^7%HP)[ [?#7P4-Q3A
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MVS?#13V#Q\UZ:CM:K9*;A9H+[GB?74H7IHJSR0V3&EU4X2#PTRHM3'OY=@:
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MM=PW/J\'I2@1WZIURB?L(;#OSS7)9C"_]-6&'NIJ-IS[@V<VB1BNQ378P^H
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MGOY.Q&<HON-,9EE;'C<4ZY+D:VA%$AF,0H1Z$>&UJ9=_2_Y-6DZ319,')L^
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M-DS,>O]4'C)QNB%)*<966_E])CAMX26?H71;]6E ^R_A*[Z1!,VPB9%U"98
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M*$@F1X($VXRYC':XRN<3Q6A;;Q[5H\(KSFA;6PFG'B&KM0W:O#]$-R_'!KC
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M2+3V9*K(Z-,-$I (V7P *&A%E!)Y&)1P7RCTB&LRXFG"Z@-JDP#LBFHE]7P
MDK$J*39^SI/R3 /?,3DW24&6]:=78+XLD_S7$5_.+;!(M2'6CD-240JO.<^:
M(UM=X4Z>A,L<"OW#(J!PN^KC'Z:C[_]+O+RL F:.E!Y+/=IOS0SGFT/^2 NE
M23Z6G/*0?(+"\O_^^-$P+F+$X*77D]TE[^Y2R>M?=FCX<2O#XSHT4:KMTSV&
MD9;.3NQWN++_O]%]_!NXTX_9!(=HH=9[R0F9X)J-!CXM_G-G@NQ&4A\)/8.W
M6&0TJ;%-@,<6'81$BLP=C#:O.;&JV!J[_$MAPD:ZB^H.R(@9X0@\Z\VV&_8
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M49)KL$B(I8LC6'E;_0S^N7C6F-N2RFH>88BAB7#XL*I P]?#.B@&&G<UE'+
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M^"ZN_!A@CD\@T<GM=&F@9*.W:^7V6U.UO!G.$/(3UOWVA^ T"7PK-:4&SW
M;9L[,C"7DK5'@Q<42K'U9D_O'H IJKG 6)<,Q7^_//92A6AO1T=P6Y#!*.TR
MOND>0/MB.%[;<CKQ$^IO]W3LVY2G^<7.Y=S8\L9?Q$CGP;A]$IABE=E-M?GZ
MIFCL'PWKNR"$A8TY[(GYQ*%V-%!#6!01WS*^MQP* WC49V]]5&JCTT\0)-7[
M_O3E=\C7+KXT<PC.G; 71#K3:/-X\LL]@,2'=@YX6-+Q.>QZ#?A\C1IO,/L
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M+0#$QE,,>7(FAK4O*-0 >SD.6W;G_"6_9L#_N]9"NZF]]IO!TMNJ&!>5NN:
M(S'X&TI?&=:R^4IYYU-]*1OFW-3G?^??A99U:S13R;N*[E#G'$7_Y0G5YTK*
M.[*]!!]AX9[X$>B)S+8]6B/101LS_(R*87)ER.FH7:\+[A]2"\(DC^($]B1+
MLS[=*+(!G&+CKB=GE(&I#*4/"3"+G?6W?SSVR$+;K"%CN[@HB$EZKLV^STJG
M!7>(9'?S?#=)KS6U/> VL/O+=CH$Y<''TDQ)3@M$\OLA7H"]XO^QY0Y_SA#B
M6<*SZGP5$,TC(L%1FSF+YC+)?.MO*CR EZ\JK%QNWMR('6=G5)2<3,PX^)#"
MPN(GAS[YF,X ?6$9Q'?XX^B]E?K% C;<\Y7 'B/\V7.1B P;Y@C]JJ67K(KK
M_9$)2HT)\K,NFTHG@.6RLTBE'67!<K&,-_IIBVV[&]$Q23]<C=%NS;>J)AW(
M<7 >V%R4?;%RL$LC312U?RD)^7QK6"B_+D'07[QW^-G,KC.EP/LRX%8:M35'
MDK:!.^BJUV?.]U/41G0.?-B?T4'!V#Q3!$&P_A,:4HM2;OW@TZNCYR) 0_@P
MC-<KHVEO(?*C/?$''6CQBFZWK\W%:;:K4P Z)+/%=TV_'=,F4'M*&MVEX?!0
MWP3A6JTGH=$KHN3#S:CFZ#,IPAE)14@6_+DI*MUD(+V** MNV?LE5UBLV^>@
M8Q0$QNV;RV2=I)9K-ZE_SG^[?#!\[JT?\P"\)/_LM?D)^A%K&69(AJW8VVH\
M1+].N!)C84RVJ/4ZTNT0 QR.FL@Y!-KR7&N '[56G4 PM]OJX7<ESZKR)!VC
MR9UO9S>R2$6I:!)N]+X_X7#NP-A9;W')T=-A6908<<MS&XEY"T<+(^@QHHY6
ME3T#X!F:^XS"\WJYK86G=$<9YRG.^,YJU-DFV4)_RQ5ZDFX;P<&%*5WGLHE%
MHWAG:C+@OH]_@&CU3R6<N11Z:6UJSM#]<X8TI]E&L'<POYXAV2K'<*HI^YPQ
M-T*U.O6BWXE<()L/MD*/L,_S]FZLKXC^84_46&B]:C\E<Q?E/"H<F<2>MJE3
M:<U'Z(MU0BP;::.= ;GDU/:J)1I&*AK[*C#6-MX#8D(;;/99"_'5@7(AH3G"
M1)1"1S$BR!P0ZUZ;,P^SVD(JO%H-%"66;<D&G&MR(-.+@. 8E) ^!T/XD/H>
M%TH65A1K!)% PI\C"K[CA5V0\LW:YW-8%TW,!S(>68Q_KR%[!Z[N2;XCGC2Z
M7KOAG&OI6NS->GJ>).!EE_8S;LR4_IRR&9B-O =(UD%OA2<,W^#1V5TQ-E+C
MW*I,\(KP37'H]+$'][Z;@'UX06D,BQ:LB3F]!QP L\'\&T8-TZFUNUTJF0"Q
M,O([8MR@D-N6M'U>7'P=</3,TKPXLK//"L7H/\J[1DXB9$'-?-MH40SW>8-6
M95T+IA;B45T6H?FGYW$A2T8MVQ_X31$I46<108USMBKSG\_5$L+/R2DM,$<)
M;718J4;[1=^W[(F:0GP;9&!BE 2*IMTD-\!WE4MZ[1\@.U\QOEX]*C8*^" 8
M!>R[8YTY%Z*%+W^-?R1::P-6[-=+O Z==IMO*8MW?"RRMLC61I:F+N["\Q!$
MW(]3UTY8DQ0FE4HJ8-H*\"81(LU-)>9BFM"V;ZV0R9DG+Y%D$6-&T?XS<=K'
MV>N-2GKRY:3T&M(S3%Z!<\%%CFHU0/A [B^SB+@=_:>N-U<A<DDQ!T:M__V.
MQ[.]9YG "'HXM:@$>^DRUTH;OM?UWCRHM+27$>JD(#K4'S6OBX2-RRD)+N;)
MYJ$Q0?8,C*KATSU3HXS9-*IRHT%BK'OA4B@/T0?X#E1A&#,6.\IXP*71*15W
MGP2.5H^+9U-NKQF@'\9G@)+PZMZL>2_H?+Y/+ZN)98&71XP?Z0+HJ[R;.5F_
M,ZIC7H7/9;%U_1WES(4*.7U</1K1>8,P4A2*S:(VV0K-<LE44/40'XZ62>9S
MHRG#"F"I*RB2+-65MW/\&-<G1-1URX;X)+P2G5RM^*6X[Z62%[N?=UCW3"?4
M=2OO[4&$.E#<&E'TR0WW$4A:8[H^5,",Z%"VNE(?.=RM,/7@9P')+6@W2E^^
M=HZ-OK8IRI#$-&ZJS1Z1]8E3E*A<K+>41T](-#J@K?_%2$[,5I A2[_EZL!.
M"1IEG? ](%"<_BDI[Y=&/Y]U2;Z#A:.49Q4%2G:TJ$M%I)#XF@J3O;0SLD]O
M);&3B<[]@]T2H;PZ'!,!NIZ5./2=BKBA.DU>+_S,)Y.@K.(:B&=)+NOM3T7M
M$EFNU,5KSR2ZJ0DYFG/D,/G-/IGL5+ADD;0\OUC4*.U(C1-> Z;ZB"!X[ZB@
M>:'QM'%?9_>AD2[I59HQ_01\-XV+.>=V1-@%,\#D0=ZWI"1F>!K G4/>'V-?
M<\-?_-X'&_]4M%7"V#./)9N")5J&>T'JOXW@)\RO+#=DB4Z?@<JY# 359ER&
M,$[MJ%&.Z(I\">^  T-1/Y8H/:I\J\N"5N$5$^I#[E!2GB"U_01]$T(*(:N?
MQA_N906Y.N=<9YYO:4?NC;'=+-7549.'E*$NME6XGXDI=CZ+YX=X^M>$%FZ!
MVDN%W[[L+GK]E1FSQK5L=D\]A-[6QT@"[_"@<6%9'%:98\]1;AX:N07J9GO>
M--WBLM5/\(G;V:G7^U#K;O3;:<MJM=RVO[<#7X8-U61A1KG;5FK1S+HZ?M1,
M4AA,*.C)08W&[B[7+[,O_?<J-T&)"%:_.P),DUZ#P=.GWN]+D!)=XF1M\//J
M94DLJ#=:FCSI&&L1(CK0!<:._</.\L3,]+)LI-P/#YFGA/:CZ:;0Z[;K@QC!
MW5-.C'O ^"?JSQ6MG/)?ITRX=*2J^I0=:[<LU]NCT'^Y\:A[P'&.X65@C9**
MS'0:I?+9LH*R-,$K2O;_&'C %76I6,;$YDUMDE5MZ_:IH]Y:SG<L\'A07<^B
M1)S;@N0K4@FB<(E >AU=Q:S&FAM-,C8">7@PV QM!.3\TB^@Q*H=^_PS9/;<
M5ZVR(A%!*@114"2A^W9#2X-GMUCW0?1X[39VT4IC@:=TZ%LU$1-1S 8751Y"
M3A'DCKO%C<HZQ@5T&P]:R%_XLFRU\$6/-5.30GL\L(U:/$2H::92?-8E/41T
M LV3I$=!+$C:T]3!'S?)A21.#%LG]\/+_D^NDE-]$D/%!YG$D[D3#KJVL7AX
M0KUN6G\FW/F0-#GL?/1&A&_GJ:.\#G_7TZ*_\!E1B/8 MA:YHC?#&!&Q3Q[A
MU'Y7TW^'('IY3J1@/_HD?S;UA$* +.MCB^PKMAAR9S$97X*U=JIY</PH7H%6
M(TH24X6S/XDH67VR7:E>;VH(^T<CR@*C56M@KK> 63+/ &K;M8X-Z1&>]D+N
M[9A^DWJ]]"'&Z-R9OI)SYV%E'A;Z6MQ4RSU@_1[02^[[[EF_^CNB(42RX*A7
M^+>F8'5T,71(:,^Z$PG94K4VR,*UY 4[;J*HRUH9!&M?^;798M50K##0^I>B
MMB.:G.8HZ/$E9FR-Z?&CKD6@IK*7(TK>BVOW*US%Z$]QWN+"U#5?OO8I\PJ_
M87O&3SJ&HZ.WVJ-X;2F:]UN?F7A96TV$6E7\$TUN8>A0IA#\]HX"09C_0M-B
M",]8"HS9Y[["-$5W%;!$\R Q4\G"1P,>?^ E8BC;WAIJ>6 DKA2>J1_ERKJ;
M&3F5K[GAJHF4@WT^%Z-D8TC@Z1-).[N^PNT2WNH/]I$F=T[U+6<]P.8XY\,6
M)O]DTCE#$#X>>G)<]EZL7)S4AM!RI-P@-YQU!SO@#U#Z]\_DT;O&-^>5Q!I(
M%YR\\BCI\7G),=;FW%S7#3YKNC+,R(J@A"12W6^8(N^L;6)18O-(2W9S?]E)
M^4:17Q]8(U"W)[RCPHJ)2HNRU@+F[EK"]ODS=,V\NQ!Q>$RTL=%LVBS4'ML+
M6TDXKAA"X&.!4XE?5%U:WO7;X'^IO^,]8OV2GLFXF'L2]NGFBG8H*RW-/2E^
MO(T3^0BJ+\6?[9Q:39>\W"!2R(_K83Y:V16);"BL1Q!1A$0$M3P<A#2QKI9W
MCO/43Z1P[078SA\8T<R*4TJ6=3KZ33Y8%F#:!K@8 C_Z&%.'U[2_?('??2*?
MN>D&X8%S1H:#955P1@O&4K@#/H8*;II.M:*MKWXJA/=&PM[SB*1R[:4!#G?_
M)9('?P9-2VWTQ=0;!M6A?3F^4^)(5X)UZF?'<0+Z0\M<O;[R!M0]JQAR$"OU
MMW';,*XXHR/IS[Y O$&!(T59<VV*8>E!AUL\OK'/:7=ASU>C>C6**V,ZJ FW
MZN)<*VQC]]V/[&?C?FE-[%P0OM5"YEME]R"_62CX9MV5+)V]Q!I CUP]N83D
M]&D5'!IA4L/;@V75E)<FQ?3F]LD'GEG1 V5)'Y&M^S$CU=P.\0K# ,G/TS\.
M0CC@*3'G$FBK42+:N)LE"Q[ UKWK@IC0L]:+*=;\DH%QA:MK))NL6FB4U0'Y
M[C59"4MX_Y ?%?18E+T\C-;] 3E6[=EX4(N:*>R0!C!D4$FI!$;K&<>B1.G!
M4<-->#[FK6T9?"OIOZZ(K,QV?\EU]0%2/N)\K5M))1@NK+S@>44B9?^E6J#M
M!5);B< @_HA^$:5.\Z-A?^<JR9,*B6J._&5.^.;<4:&M.#V2>1CS108!@_=V
M"[E\VY>NMA>ZZ.9<XNB5-GB>F0]U](8O8W_RDU\RC=19SO-J T-JP><55)@U
M)HJ5;XC*C%'4\8N8GMA'UQS]\H:_^U',/Q4Y7L1BGUE25_&^DKS.'6,]* ,?
M/!'K?E&2\,V.3"T@XTV?\N"WT>1J<W\Z.3ON9IP&/K\6G@X/[GEPFJ)'7+0^
M"6/KH+(FM9KNNP-OG>7,:+N4<FQS].;"2G:UN><$>T"\N/2<LIE!C9&PV$N2
MBK2FJNWI%+;$9JK'ZV'D<H@<C?YQHQNL )VD?J<TN K1\RE1LV^NY!\A#I.6
MQ&1*+1]V6%A#4']LX?3/.-'[YC/#@ LRU\RYS>.)?\]C)I1%ON]QK1W.P7NI
M%2O!$(W*PHZK-7ENQTUZ;/Y-0%\N-842)-=S1QW3TZ2H(\_:D[_CG$YVBKQ#
M7WS-157AWBZ/#? BD\^679_39WBW)#R72/S4@'&709YXE@3/2,</\[7_-H_G
M/< ?V_V.$-Z%?-^QR#Z2L+GC&I7PBA+[KUV WW7MP_\52FXXD>7<Z+W"X8 K
M*"PEJ !^5],TFQM;N=AF-+LO@=VBF?E\PE37@'3247/N,MR5V>V0#&2MRF,G
MXF(L#G90:T3Z;_#7-RU]K=Y *_#U)65;Y'3-0E@?;D=[W#2NYHG%]$O@E/O(
M6YUTDQ7,DZJCZ2$R)+01:-V&H,'T-W;=)H'31&>]09L>%VH&/1UYD9': N&B
MSXN0F:.Y#5&O/Z\C1AVWOG=G9Q(_:RQI^XF9(7(SN03SD78I\)&"AV5.%"T2
MN42?;ZY050=LPWR?(9R<X@GX2LJMR':Z1]4*ZT[))A(Z]L*WS.< <Z:S[T0L
MEI.IDLX;_8CC(W-",O9:W]^(]XMN539G4*44[Z_BN/VZ8+ZK%B[!XU(L#E3?
M%VQ^I/4E$])A#<;HG;GDZ]S*P=7'<OP6PF;<()1-^O< ['&..)_RKPF1:>./
M]0335B:]:_/R4]R6G+6U=SU6T42-:%+/;O8"^@2E^EIA+TQ347KV][V(A"#A
M1MKU&6D+VFJ9&&F768&9G#?FV5.5%IS<9VR>$)[0$X<(4L7M=O7=F1NVBU^W
M?!O-OVZ=\F^8%=.'Q05+$E[C*J!FQ&196$S[T2!.(%]&O0]K(MAK[(MHBB%D
MB+H(5U'9%'X$P:DE#; $Z3CD"G[=$?RPP;&DSSE"O$@\D?5=L;:*O@[TE_AL
MN-((0:A\3#&:23X0[*S,D_LJ;)]%626TP*5'J.U40#(X:#_6U+ _:]47N=I,
M^4NH5N"\^KM.0ZO=6BT6I:?-6AI-2O,B+_G&D*9])R!^*+"^;M6\.D+$G [P
M\15E =&F<$KOS7RM@*&$@@"9%S_6&CZ74=@Z!%\/G*"D7V9!NGNP:X5B\Z]Q
M/OR?@% B^]>)&FKNH'4JJTQ,#UO#2U>_2_M;,K0,D.J^V6YVOC7["@Z=BU'Z
M^23=,RF&#BFV02U.4&"D>-.[+@FQ@*3P_10^[LCDU:]1KR+E%D\ZDPNJG:_]
M^0PSWT0',L(*'8<[JD=SQW1*C(PEM@USV*3)%$*LYB[56,NPS**33G=Z<(,N
MR>ACO$V"%9V=7U&R[K&$;R^P-GL$N.*28ST%!;*-EIFP&.$@]B,R^.A]H'!(
M'_4\V=>ZYMB*YHP&L;)9<1JDHC*"*O@Z4?_U1P]4RH,A<6;DZUVR;L-%N6_+
M7UBC9[- "&J-D&Z'_);(M4A4I@+?(%N"/LVBSR;F%H<N&8I)@F\VCK+YH=Q2
M*LN"%1+8H&JP/S#\B& RV"]QV/#9/4 S7#_?<$B(#<2>F)?TRY:R:A[(3"6W
MCKCI99F"+8UKH6>?*^VVL!9EUW=!-FW*<,XH>Q^N8MICQN68$1YC92N]\\Q6
MDQ3^*59[4AJJI*MHEX29#BT[$%JUR(L9==D*0C4CTN+?.WOU3^0!5G+LV\7\
M,)V;\#@\-?=B@+=&<6ZWLYWN+X?%_/33AR=BCRTY6HOX5K_+=*5ZV96=1/9L
MS$,#5-BN/6("F^M6>>8:#^9<*PIW($GF5?W>KY?3M:"IQ]UQ:2R80G.P*2%@
MCIH&5$HTE3'CMP4RZ']K.N*T/3(9*B".JV8;N64^_/BLU_$Z)M+VR(]2<OU0
MT+X='"#,O"/8ZQV=:]N;QXZ0Q'3T.*MT44+ZK@^+O;&IJ^L8Z'>TW51%8\A>
MU$."UM].[!=7+;W]]-CI%%]&!\E9M/1]3\!9B9Q6\879>$[EJ3[\[DN%5(0_
ME6GH$8G@P_(]!Q/V3\^P2:,Y4YXL$C[P^A<-+K] "42FK@N>'^++S_*(2K-^
M'/5,Z<HB',XYP"TP;M1DKV%UA^0L/WO-W$T3B6<L>JL)KVE"K4N;S8TCM>NW
M\]66#PUFC/RV?Z.X?OZRN/QJ\HQ;,(YH9A,O3KF2:;T]7*-'^)'WDN?D!XR$
M4??9T\_IHO!S<P7O/+.C2N=,,?BFW_,)ALABCO WD,\T4XK[)]93M]%/ &DW
M#(G"270TD617![#5X"SYV;ZB]T&J)V\@)>N1G7TJ3YA A_OO]*BMU@H:9LY>
M&'6:LQ(X9?9H^XX&XF;RG_(,]KJO$$RQW^J;.KMA)LF;4C^74-BT-TV0F]FL
M/14HMK5HZXIRW5=(0\[=68KH&8PK6KI:H!R=5^9U9@JTPGM/_!"1I%OR>[KE
M@2J-\O+XTDPK_38)P(GQ[\$Y5@)2MX>4I0?"6AL_REC[7E76RLW<42 HBT)K
MSAKKW>BC@7RUQG1(B3Z/-I)VJ7BN0 GN[;8O\/&P'RUR1?GP-\T#5RE\5W,N
M\3,=XVG"G3_&FMP(4U*;90B! 3:_^]B??Q+ UJ2<;\FO;X8:B;:%+:./5GN"
MQYRE[/NPO=('M[OV]KF,4&"/A(VC.OL CJ 88B'I9/DL^6ZDEV 62"'?_C#G
M>%(B%;_AB$>EU,L@UXX?#4U($LA:(9*W8TFER_O(#,_H.8)_9AX4.T[2MST&
M6CP8%6>Q5E]9[&?C2C$[J[0U\RP1H5K% 6I63:I[B>% .NN-0?"MYATF"JBD
M 5JWO/VTXE,#J0&T"H_SBB<N&F_71_:\V0Q@OZTRUTO_F^2_UO&G[;YWMD[B
MW5]O9G\]4CO^H=H2>%_>2H R\NM._61"-^>*0L[N >&L.0M7Q)*T)WVS[IW]
M6T;-,'93E4G>XYI]E@H<1Q2<\VTJ.H1_9/:TL>X4>\(-ERQPZXX,H)C!"BM8
M;DF>,J:1)P91_FQG^=%&"5:_[+K6C%L=L\B49>M)GQ.EXH9R^F [5"SV8)90
M@?LEHT$5\*QP.U&5PO*+G1VU,+0\CVR<@'_=. 8HQR6V4@,U4<R=,&YC*,S]
MI 0I:)DKV#@M/RDKH^9 ZFLUP24BL2L&S3ZTH?.=S48M><PY&?0X1S<2;;23
MM%!,X1Z6:78ST3.7&:.+6CBP2U1STC_86'<&[5?KJ8TXQO5/&9U,R3[UB=^R
M_ KDVLA N_'N/GT5CO7!#*CRIH.(YJS7IQ;C6YZ:9O3N\J]?2*-3?TNWL%EW
M&;E?/&\B O4N 5.-]V22WLU/CIFAT'N4'T>DF:?K#8]:CWRZO;%9[;P'$)*+
M3!<:"MZP(@*GVN5ZYLHTGE#X4<NS\C=?"N$K&)1ON-:&#&>];3:L%^I*/M3+
M)&I3Q+SB]57$I0BQ(9@ &B-4.F2_WP/JSO*O<$<60</?1\\PV5Y'%#?2GU=&
MBMGH7%--<<H[; Y:]\[/(K("CWC)L\3Y.$%,ST,DM419867'6*OY$P-]^'[F
MHU[^'_F^4)-8L6?;]) G&; *Z)V.DX"E#KKTOO2SF5<8W%9$SPK:JI=O?>R%
M>/IO#C>11[7N9LF!57KKC!BG\])>$(_VCS1N-RE<84I!.6]YW%/JU*L"18O%
MRO8X4<%3P[UDSL)O'JWY#"GYN+O$*Z(Q:2=_]?\XJ5S$'^-2]EO>.TKJ#Y";
M_H?3 H3YQH;H1.\Z#6RWEC;Z$X'5)9[V/1"D;43P+BNXRT'B39]_ZBU-\++M
MA8M=+O(RMYDLRKB>AZQG/'#%I*XNLZAG59 O9F ?8W,M&<<34D?J3["\L(.E
MOW^-);:OQRJ=RE_[VJF;D XOM_B"B(%0%;N^X6^77%7GJP36F11!YC,6)[/1
MCP'O?)0F.%IDUFMK:TC=$IRNWS= GB+;E:;$J?@_L@Q>] 8.LQ">][%6WP."
M(.N_H@9G^_ MB/:@]QZ XV#!8]#[Z!N5(O<]X'P7Y0N<.K*F"$ZQ0/?D\6:I
MEFK.9IQA2-<JMB'2KVOG4+%^++8IQE3S'<*X&Z3[>J+3/AY'FN5/Z_0FSG^*
M&->>GNT)]+2HHOZQUX7^O_)82:&+4J%/WSJ16Y .M<U\[@='"_;&.\?L?-2W
MD:Z]OHI&O@C%KKB#-/*EW+OKYW'1M<=F@N<A%3]*?0@F4[6B9B=GP*;Z,4:3
M.<V1@8VR3HHP0W->L6>@_D>') !@F \#PC7-J.AG@M>6Z=@$MG?K799=N9ZG
MQ@?XUS%6BOZ'7P7'],+AK7?2GQKS<M:]^"["*D;]74J2V3G<@]'"3S,D<6(J
MB*LM=69/BHJ\KCU%'^3*7;(G^A&EP(R#]2S*"D4=9:N&2M_0 %L_C<-K#L2N
MS LR!X8T\R?N 2@'%VU<\/[OE@LC$;4??_G9L+6;&,P#3H^'>*#GXP^S)_@4
M[P$A;2_XIX]T,-=V6KW/9\@\HFYY8O$E:7U:X3:6+\R0[78J>CR/;P:^'\6D
MU!PJ&Y)K1*A6V[X+WK^F7;)NQQ>ES56J<"1X=(G:YH=0";%O$2A3! ES]\@O
M]CKX\"%\VBCGU!=D)2P3U]+/()9\G3_M/SGI6![W:][D"2HFG51S&DT<W=*5
M#H*<2+V='9]0O$\MLO$PHFR+49O*-\5Q'L#VI8898^^M<$U&/)9U-\@+OZI7
MGX:(OB@?M/0D]WS\E5N0MHAU).>SAF-QZWG3D5!GY[*M+]&:/^5W9&'O@SCM
M7=Q4^6/#))\D>Z@7PX+-]=L0"P_N$H@WG+J'5850-U^](?I0%B-AKLU4<- 0
M$]I]@-,F.[-O+->XK"9#=&K1^0>X/__!? IZE!GPX5GXD#CM]./5[U%=5XU]
M2W.Y7\VQ<"3S\S/[$@H$]5/U8),RA"/C_ C+&#YL3&U]JW4J-<%EP[J@7T+$
M9J]JB:I<""*!K#9Y-B=20+%3 ;IE;P55H("H@.&P(G6%YD^I9PWE#$^V5'NF
MHM+<+3U_B6SK4\F_Y?WI>O6'U"Q[,<2HUNLF*;^BK67.QI&[(X($?;@'Q-KZ
MQ]X#,#K;IOS(K>M1,=N_]=((TL3<U=KXJ,\=\TI@L??&T<HFV,L5LD;-W5(7
M[DM@+>JV:(-V0D9/!?#&F%%*'#"0C^W>-UI5W*8JX\%?^BL<U!A2*TVQ/[2N
M8I&Z![Q<G("F@D%O(K21LGWO^Q3=V,DM<Q[6^CT]$+C.3'(B.DB^$0WF'<_.
MQE7\JYKH?T++ZO\7+Q)>)_1,#N0D!:/S7C,K=_A $9S=&F!0C[1FK51L"A8Z
MQ!3I"?O<(I?=X_RHJOB1UC$ITID:SRI^<2#[J[IV"V:7\"@TX-;$]H@T?JD-
M78SUQSO;#<Y-_]XB9%[&W9''[G@Q<S%;Y49K333LM^YR#6A_S72U,*X0,FX-
MW4?:Y-)]Z/&,*1U*A6=6]SV = 4IIR>LG*\_R%Z/O= 63X,7. &-NM5"^E\D
MV@&58P@X1Q9E?/E5/FN4*:UQ>77^N.$AB[4^?;W? EKWYB2U8MQ>8E6J=_YZ
M8,R]S^]!IIQ[<8*J2VN+8M0,;X:AZ+WE-=0:N'NJ5]?&C$1E5^_97W".VA>@
M;#V8':[BXRY7F:GB7/+'Y$G3,!AVAG1)4/XL9)AR,-Y6"WH/JD>T!Y3?:A0V
MSN>N895]G&O3_]K2.%E+GXI)'U=/VU8,IP[/07"$4'P,2?N 2EII>X,BBNT6
MW6V597\/@"L4,# ,T^U\I%P-JM7E79;EV7RV@(G#I;ZLLV+E4EB;]V9%7B1Z
MVN@ @=9Q<4<_;?1FX^&6K"1*!=@BI<0 ::EJQZ036ELEXMA=X#6/U6E:XJT
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M%BQ4ZA%[_7[IBO3Q6YSX8X5_K^7QOR),3,&-E"<<T38P+23<X;+))."^W0%
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MR7Y/2E+!FB;=?B15-B?K':1UGZ>B'A9GA^@$2NE.?3,V.BS62'<T[_RK+<R
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M,J!@]!\3!QX19N;@C^B.RE.)R##W&];9."ZK$%BRN2-)L,C.IL%'*S5,-"Z
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MYHE>'%?4-:]L"<.,$&;-+W38I&XF6%H8BI?+HM#*R46XJHL[XZ<Q'\2N:4Q
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MD9E1S3N.R]DVL.;@#+T-PQ]'[;-O+R5SN@XL&$ 2CJA*%:R-@Y@CI EH+I^
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M=/PR%LY10/KPOV/!^\-%_#>+IL?F9.F9"&_VD]!K"H5WL8:HYDC)P6E8B8'
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MY_-*U&)1H^D:]#-&/4_:JOBG,G/68KL5'@#?07A*>[ E7_/N3X_D'BA5%LQ
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M?$0X:._617^^BQ&--D]FEX-";>='CG23(E!5SS# 3H+V)H-$AX:;H"6%8CS
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M!72+@) 0MY&1;)!?":0OTK-?]V8JJ1:MC+@A'O:E8%O]><F8,;-K.ZXO+&8
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M7J\[XCS :$FE8&EY=>JY'^"JH"/N-A[P$;;?OX\[$8SE#K0:1XC",ZQ_>GR
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MTHL&*<B.3GAZ8.J3EVIJ7B'95#^6O;E0X(!M'N!&CYJ:8W.(IATQEC^P32A
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M5B54T,# <E2I@(L/0+$HM(BI-P349L'N)#91 CR"Z*&:V7P0A'1^[W%TU_L
MQ K<S^KMX?'HN:0=6.FF6IP+X:%,A75G-M/8.5$^A^&S9)O6EXV%@8V'%>XZ
MVETYM)(:B3J^PL*?9&[BJ[S<N5:@AO<":7@HL8V9?RA&"Y6=$!$5A9NT1J!4
M/FC3Q1R7L0Q.OF4B?-'/# U0 SS_C>\3# ?R;(.X*3G3\MMF70#&[X,B)>W:
M.0G@&'05 H$//OF5;8*V;%<3Y'\@V7&N-@&?%DX94*^W\QT:VU9" SQR&!0,
MJ(I<KP D"^^^VB/>+85O,,S@R+4SU# %\):1_34"86H78 ZF*,Q)X=;K"SCL
M>\U"U<+85WD]"V..]684-=?VWNO\C+K:Z 1!%KROK(!CR63F94NMXS_5L=/#
M"G8.UVZG[E#[TO57]3S//-;A/-R6TX'_8!;O84XLSB6?^.U5U4V99D\4^>2,
M 9XQ0]D[\#%@YF O4IE2K"Z(_@I@[TC#&'WY@@WNG]_-EF2*QUOH< @(!@ (
M -X%GQ [U^=4AH[@XU$D6BXN1Y0NZQV>3\^"4@/FE%Q>4 LN*/,\!&9%8N%H
MTF3?/)%JDT*!KA2LQLF7.S80@"8DI;2G?DUJ<RJ65>!\4&?-\[HKJ@BVS&DT
M]4Y8#.!PYO=!< @M9Y&I,"]ZPE_A,@0MD,J(3YC!^/BCG.A;C UQ@S7&.U,M
M5P#8FU99G$,AKF>:BOLC^Z_KW>K]255;XEAKW\0QU^#G5$1U\<XD?[$&*H9Y
M)U5OU=KT\7QZF[2BJ%.):5R!-%?\82D%^#W_+GA@#6N<48Q#:0^<Y4E^MB.E
ME26, 1Q])8.UC_$V-2?M_>'2Z0U;4J4(I1Y#^&V L,JQ&ZS>'^R/&=]WZ-Y8
M (Y!)0L6'.3,S!?FV=YKF A*X-7^GBX $L.2Z^XCP [^Q>8LATONJQN 5RV?
M2K;E7A>6.1Z?N 'S*=R%"-H57OKGJF 6((;Z]RRPEXDL>Y:"H0J"04&0;"$L
M&_-ZO,^=AD"@G@KNWN?-2_X,H^2W?>;NC^;"2P)O0](IE?4L[\CG$0Z'M/?2
M R >73X+(EC)[R_-@.;&;;QYE5H4^6MSXHH[/9Z++ +)>9W.RP/4]99?+G[&
M-,I6A'7(44<+3MRH+EELTK@U_&. 4YD,<!@CA'XBW@.K^T(\D@D(^!<.W&"_
M L0HF+]<]F?*7&O_P*(9:2RY+J<7>>0:S5ITG%T#4A3S?DHW9U( 7B ?AZH6
MM_OZD=IK<GNC<BIV3NW"#@/VZ55BW\:Y90(.]J) ]",(P>7A^BV#6/.ZLW*V
M5$OI$*AUT1S$=M#5BU!:(Y0-YN9GFU8.U9T*7"R)C-4P1@FLO(%]9800=S8Q
M1>Q6<KOR0 P]%59$5#@+4X2C.)C%LQ_0;R\IW=PV.<T(;UB\^;C12'"LV7QV
M\Z?UXJVV7/)GSXS'8=^!=SPE1?[F6QH*V-F'XT_:K0U2]!SWQ1AP8V?=K!GG
MO)>LE*%N_!V'E2833M83Y0)U&?+\ED4,B;D0P\>8 D2\2ZY-NIU+'=Z@?0YI
M'9LVG@",>$;T#Y<4=9>C/H@J*$P5%^);)+D[*$O]K2@):-VC)-LR=42-TT!(
ML*QZP-=U8W%3V9&8#]J1NJ9>+]>M9+[7V ;+[U":]1H^G?(A%>*:E_1&B'</
M1[;>4?V\F<HBS!R_Q![LCVRT(TW=4B%7,VB8O/6ER9[FO*/R?QGL5%Y6-[RY
M+SE490BP8V@P%:P UA_SJF3!Q4?D@BCOT*50/WFZLR#P_#'$L+WZ==3T0>X6
MJ-D+S#%9GG2WH^^NF\5"ZG(\=7N)XOKJPQ^V*;I"!/+M"R2U&'BJ(VNT2<O+
M)BVKCT8R@7<W/2!5F^UM3] WCP<]FC:BO8*XMF'YF_(KU<:SPOGY9--<) JR
MA0YB;N)7@ (>%X=$&, /:JBAH,WWA(79AE:ODA^G!MMF.E@TTQ'[X$I $RG;
M-N@W^5\*!'V+HA"DI9",;E)^]*C<TX^_7B!?\C7IA1T^24EZ</-2H'YG2,%R
M*<"\6^ZGDO/"O#!7MN*\/4',Q!4 WBJ\C9(W ONS>?_BYPTSDX,W1",([#CS
ME?(V3+M4;I^:%,^V%T!459\C!T(7&/9ZP-_@ :I/<3GE5P"[Y_D"&6S0[QK$
M]'@[2FR3/8VYLXX ZT$+5&'KY,N:9(-?(B"?2EP]%YD]!N+QZ J@.7&O^K%'
M'5)C681+/T<SP3D ,5"X:@<'>&&_)!-0O34LH7TH9##R]&]Y2<0?<5_;_1JB
MCW G\PQC[0/JU&;;,/1A#O%FB'K?BVA?P1+8MX,]=HBR*58]C]# TM</HHS0
MF>[+I1*T;)EH!3I> 7YDNDL8WY.FHVTO:TI(1"42;)$79VE_KX.WV5_"MV9<
MWE\KJ$'[Z":S->@Y-O. FF:G*:-+1W.SZ?'=*LJSWI]N*IP?EBZ@D,3.J=.(
M.2;VJ?#+(H:(^?/=2OE)A 9XB8MJUE[N)1-KM&6NH+R.$^Z^]J2KY]<Z2'CL
MMPWWL)E@^>>OZ1[64,7=?VIH'?\JCN>0X_;$WZ!V,LI<>P=-Y1\@9R6Z]L6X
MPJI=F?K5* N<\DGT$;&LG8N;Y84=./W$Q^S9R'1_C3>S\?!CP(J"#_8&!\_]
M0H<P--,8] -=/:1"H_,*0'FNQ:H$([K6>E?TTOV/51/SI:^1O%K-J<^F_K#8
MIOA!H>MF G5>&0C 7_R9_D@G0/!;Z4=4\-US%E2+.K+; V)EE#2H8,JV,V&3
MI,'B,4*!3(&HJ@5PHH*8< DOV<="VY\O90N-0[4J<;-=9W48S!;M1RG(W#4B
M_^FE65D 6=F&!Y;\V*HRO3DJRGPDZ?ZWN'<?/N#?#..!..6\[J0 ^IDP+"U&
M6OUH2"P%ZQQ_.):EF L!Q1M)RE0(C*\G3-9___8P1U6%/2@!&@!>WC&TLXNN
M_/S+6 )M(1J".>AJ2&UM;8B80NVLSVCP2D[B3);+9AUK'6?./ZT?!%KW]^'7
MG[]>\=>CF/EEP)""[KDIN1JFPIX1@3 LM<^^>TV'[(S_F-/TB*PTMR4K2'R9
MB=TCW301=S2$#'>Y1T&$\X9N#Z &?7JR!34EU.SK-LUO*JM,X&TS9I:;^.C@
M>YF-E$J9V4C9R"4NT!ZPMOP] O@VQ"!H2W$?NNSMFG@?$PO<]4-^'E5ACLJ\
M=DB5&WW<T7XGDJMR7:=%W?$O?DSSJEH3O+;E#8M!0QV6!JV[Y>!-L2V9CLGK
M KOYDA/3TPX@FE'$EWI50NT4/4)4L$*GX3A4;TE'5$1=1WNP+OCMO3.3(IR>
M!><MS$5]+A/GJU#P@->\]5-<<LD5P,8A:J"(]Q*+;>]VW@$)-&"4(IV7T=RQ
M\2J%[;59104 /X[+$H80_?/T+1.>).V;?7)W!]VRJ<;@VBW\+@HJW1ON+ _0
MEI^XXQF8<IGI =M_V4I\/&9>2?JR^@658(*Z0P81>KSE2X;F\<.]J*;/3:.T
M'(-K=8@$^"BD%R7!,^=P2G)F<7#^_L$(ZY;D%2#R5#"J\,!EN?,4YC&3_6%Y
M.,+,8_ON[*\,"BEUDF$)/-5'C%< *@E929W'*LB&',2^_"K2?]DRX%RM0&3'
MO(ZM"6CR$6+=T109+RF))8YB_@#=#>4=H?K40FZ%I7J_="%4%T[G>)Y,51@L
M=P>8B7&-7NQF]9B'UZKD5>5%B ,+_@;I"6#<1A9H0 #1GRI,F3 :<S&XVDTE
M9M#,&7Q>M;LVK&:46D%!4OTH27/C.V?\>V--7#0X-G4LKTM+Y,8E9L=((C&R
MB3A2X,R&9BV?A:A9_X9RYS"5SJ>"GI:2+PG:::++7R,5)F>IHT:VLV\[W_DV
M7Q"M2]%99+:*4$/IZ/6:K4#\5448$'9./V7Z]D!ARXED6PLT8U5YJB%-6N;(
M%H#GH0E B7]V'E*JR--!(,<X,U;<QXX,^KO)W?H3H2M]?CJJPNF,C1=PI7I0
M;9JD=4!T6 ;BP+I&>":2FQ,V1]MH/O DR)JNF+KL6'P*!_O_T=G32<B*2NQ0
MIB2/^-C5*<CG?>F)UR>_S77SZ IP#W77(=T9H3E/PH TASZ LQZUAA2U(<E9
M2R4&1JQCUKSF P,>GUS2[)&KK?) 4S7S63@H?5II,*\3PR4N?C)4:,X+Q^\L
M!,NUN>,55."?H2QK<"DB/!UT[MI$/@^2OJ;Y5%=#)J/:>27^9E=D#TOGGW$5
M%WP*EE&.O7T?HM@E-!CJSC16@@-V7;*/06^3P2<,OL>^IT_\(%/YH+DNXG@^
M-XO@W_1XC=-8;G3)]*##[^6C>H?7<PUP(KOFO82YP_/'7P9T/'D#'I'\>G,:
MPJ82P<*NI6#/P,-ASF#>)=?Z ;/1&5-?13F8%H<W!$Z[9BM["-,2:AI<]$">
M?%[<J7<NM2:FY\OI94I&I<M(^B6=N=$@+K%KYAJKM0SIBU?P1GE)[)% 4O3H
M'"*PZ$R 'EZ$N!#!I]^Y%F]7>@,R4QBS-?;+1_@N;,NB(;254^-3WTQ"L5I/
M;E<*>@@X E0V"]W=>)S-)OA#7I2A18@@'KO815)G?P6H]6P_CG]H]8['N[P2
ML$FZS/#!'$LTIJ:X]YVA*>Y ?QKG2(VO*AVM\# 0&?3EW;#,86F3<J2D593T
M< G8O6;K\[I0^S7=S;%&93$9?.B'MR9H*>+!8C##G! 3/8R"MW0F7SS'[$"$
MQ1'#STR^,0O[^I2!DQE^D:-N@-7?'[OX[46R'UE^S^=^=NB52\V&K$ 8K/A'
MU\5J9@\1[-=FH^ *_!@?[5&TQG&2]/T-[Y\GE;HD,>[T!#]O3^!1MI0S5@N_
MZ2DNO7OWCN._#:>H=3IJUI[](?+RS5#6&WO\AAAG+[:66ROC?/L;/\%#=3D,
MX 7:2>OQHR.'E;3J]>Q82ZO80&ZU96!2@_$0)F<%@"2J@'18<<S-/G^^E<+G
MSG6T1GV02^U<WQBS.R\0WLE+$7K'L0\S]>Y4*9KR<V+C.YM,Y-_\GPK8 ^*?
M.$S;%Q9>,$D-[H2_\>8B\U*F!3O <*%;[Y^O/M)[ %HP,-\34C;0W5)ASA0,
MEXC'(YN>O9,B*S+H' QH8Z8WY$^7L19_O!TEERY##S@]&(XRDVH!"A3D#ZF$
MK=N'G$V"NY3I)-"<+QE*V9";T)P/7&DO^[U6E.F+9CR+I*H:,,I<0\'2YRPK
M90$N\\ZN;D2G4!B;E^2L23K$<+G@*#$JH;9LCCA'MB,;.-'6UOVO:RPQA(MM
M;_*)+@C?:TBFLQ%28-TLSJ70T;X.,8+YQ&^J.V\N&T&&@-\^13['996_YU]D
M3&.SH0J..1()ZCANO476H#M+C)FBCH9J6"]QW!)V<JYUWZEG,-H.V,37 8/&
ME#@A <XPS+BUDYO84\?$L _/D4[K7['4N[#GZ5'2[,:"$5!>MQ(+Z1BHN2@]
M=(<N^YYIMAA6JGI%BRI\F>2]B/4O4V0,X'A6(D0DS7E:PCJ/6%(14A2.>%"!
MNR$?(-W-8O_9B3<;_ /F<G-W1G9%5D._(YC_;\8JBD[9G]+DXP/&L3\[U">6
M7?[SC4>))<47;2C^V'T(QV?"M>+*J:?8>\P96GZBZ]TLYG@X^P?18'.7UK4/
M S/K,!6IRXVB7K9ZXBK2C"]3A C8VA<HZC%SQ,\GUVZ@(XY]%($">[VL#='G
MNIE!D;S6#G2O3.^U,V25[K#V=L&LS\2T3<(>JW>E6!.>3JWGE6Y> 2@.W0JW
M-FL=4T29[/M%]E0X>G)>OP;+=)6Z?(M?45B'[VQ82C_!1=ZH@AK<#N++0K,H
M.)^:5.'D>XP7;M>_^*C'=)/:#[!M_Y>K-B!;5S979)>?M:D.+X^TEV2M&N"%
M_0QGVM(%7_E+WD<L#M2&(#!*C]$Q4'KR"E %E6-^\%'[[J::7WUS?F^%0XJI
M-B^/3#OPV?F]947ECN.'Y)KMT!0;WE05&LC]]JGLF^-Q^C:#W#>,%0<]_YNV
M.^S4<><B99#,;6;&5^F.@2^H#9ZS7E9? 4@^WL-9=WK;H?<I84)F1S/Y4A^L
MCU,#^)M8WMGYLH\0TR[EX*GFJWL%O'[;, ;].>91W[@7I<QH.UZ9/WZN2*?'
M([W'H:ZFA<IA<KRV_ ^="USQ4PKH3 MK!B3.I,W,+N(0C;S-?I#<I,7/<ND)
MV+L!64=V&=.27@'<?!,SI9=2+>,A G WHHWN9OM#CWI)UYQOS*#LR;U[^#PJ
M?FB67.+?[[P[<;.=30U1W\QFOUG7#P^&S30.6AO$MIFYV\OQYP7HNB5*4"!A
MD\!X\1YPB)=DDT))WRM9>KPVB&";P)0>>C  L;.E](IO5<0.JHXKG)&(+;(G
M<1%]=OX]C-L0\7+%4M7TJQ('YJ?>.EV]PY] @ABJ6#4BHG"V9OZA@2UKC:5W
M0X5T22^*!A*I%R._Y+SG=@#$IEI.R[(P++5*?X'GH 2R7/.AY;!HA>3>+=".
M8WEZ-9#K#Z'!OV=D70N1HHX+J$>M3N9=*)$O/#$L]4'Z3I??I0OH?J/^ :C,
MP,*\VXM<39PXOJDDEYHQ@<,:E5##JN;O?%/@E[Y;,B@R(.@35!F#)7CE"PY7
M._ON< WWMRZ)QWPT7.BKNNQC)Y $N==$ ;L.NVA$X8_.WOC^YIAW2X7^7 0;
M:="$I8\M^=&7"8T_J^^Y"YSY60D[(O?*GC'R?/DQS,(U(6^DSHI4C^T!H6LM
M;7"N%%ALJ<8BA[*?[^>:::OEKUQJO=]SDEHP[V%\UXAPAP2%&)MMOX$T;OP3
M]0U5I^RPK+?H_EONB 9/A/I2F JGH,),;]?@BQFSS^E-["*AQ"SX+?19=,LG
MD;7[W/'*2[J.SJY&XPH,^?UOZI?I#Y^!BN"^]6EY.UPW)=U*P128K;X?,4HA
MX8!GHX'BVR9*PAX>K[G'LJ+49T=,ZAUFLBI*G&IGOE64WV_?LD!&"Y\KYT+,
MEOGJ0P!1I=!\;S>+HG:&QI2.8Q\'A53!/C9%(0+D[]U[@6^QE1%PUYO:' A#
M9K0/Y;2BFH^G/G'RCM_G0-+Q%<QNB.U@R?>[KPDP,&5"')$3Z11\ZJ!R]=?L
M]U41'X^M=#&WXW[GT8('2:L>H)>H/19'$/=$8B14D2U4]\=JKYX9(!$EV.TS
MYL*D.\(K39</_1G&2P#W A%CT5^CZC:?8@*R3^SG$GMT.&EQ0440O]Y!Q*,O
M32__])_>#9 /:B 6G!,]X]4:NT_(K;7F.1103+!P.FK049[$T[! <..W4@C$
M"JHA<L\K7NJV"!,D.DS\ CBZQ:)ZVQ@0-CU"'-^)37P\(B$CT5N?[+H<I5'+
MH?-@>9'",5!^\D8C2L"SBAAJP*F4-KN=0U%'J6<5:9(Y_ZB:QCND?;UQF!DR
MM O.7TZD5'G4>^)B](;>,Y<$X8OE7.PX'MWB9&LX<'D6<I;7QM"\Q,6E'.5D
M'7HZ];P2T'GS[GU=C%5GLP[KG*7C'5'7U[\^]MT/PR$=&#_8$>S%S/"Y&ND+
MX4_^?H 9?PVO$+:-IF)Y%V)LGTM-.NJ%AYGM,HN?@KNLLPPX>W$69I5"=@QQ
M\=X2E12]?-Z]%T[9\SM(!=5EF')7)C0]HZH,&.?2R].86+N90X:0N0+8!C.^
M\DYJY!LA]&8%A6&&.]=W=\#S:7-K5:8?9KX,4Y^_G'0YUQ.<^2EP.90<%1=^
M@JJP;^6<O+RUO6*"9%FI-OSCT\].N)]N?I&#GT"(FX+47:[:+M/ !Q]C #]J
M$-H[S[+H2ZOZB&'72H]##5=R:/A.S)X]%LE-"LWG(/(S"4;870%(V<7-YBA
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M,_05(,_(BNP*T&\S$9@S%2QFB3-!\2X\P>RH/+)(8U$@ZQJUQ2YCGTFY;]^
M6 <MK"@"QQ"6%7.\E()/^A$9<0F3'AW9[*R2U9E!F?L&[YE';JBW5,QOWX^G
MT\P9^$HF+>5GHNC2>@]3T-<RY=HZ:DNMD U,FX*=J[EA05XC7#;3[-DY,,>=
M;&9<8MG6'KC$D9:/<F+-G@#I#&_VSZ+8C@ER9W*KE&[^BE6./;J1H=*T[_S*
M25HP<Q,U5C!ZR3@W7??)]"G! =5&S'?<_>3E'Y.75X#,'QRG(\39.TQ^;Z\
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M%L3R/*B#?E;OFZ5?@,.??#<CMD1)@^M]+IE?**ZR.Q)]2HEKJ!=<8U&8RHB
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MW1[?R8Q=@-SW3Q$%Z C9.#8M>W3D8L)T]UO7E3_:O$L$KGHOR_%(Z]:EV.,
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M+HA=Y6!*\2LN#<5VZ(X<2&"HG![ZY^F; 4==E36,VGQ!0 H[0L-6,'P*-1+
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M($&V1O>%\LNR#:J0UA=\3H7Z#XIOD600DK!6U<G S.VS1?(YD8?",5_W2*[
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MI_ZBAC*?D_:4Z8B>VN6.+<B53XZ-@L?>(P=1-UAL'R9V^'.\>?SA64R..23
MM7-GURHJO;QPJY\8V_P>B1XD429JT[M-^B3VF=Q@?I^R]GZ3A#2O6G /Q]O0
MQ\SF$,.Z?UJ*Q#<+"VSHCBCLB0.D?YROO<-7D+'ZZ4N)Z7%V\O!D%]KY<*RX
M>Y>5=U^96CI@O^0$Z57Y[O[4L]TI6W,QL>^(I G1X.:VN<G)FX4N_H*K#W:Z
MVJ?&U+PU!!MWVI,GK#8"^VUU+2W<TC0YRB!M^FY]=@B2>77*J6_?L-%6;E)"
MJUT&CRUN?X3<2#PLV4VYI*D?CX8]?-7F?G+YW8"/B*=\U\/SNSZ,PF;4ANM)
MZ>9T1Z)Z!%*=T9/2R]2CPX0.X:VU*-V4B^^M?2CCOIM\D*7AK9L^HC_<UJWT
MLYDR"-<->!:M;_2LM*?!5&2?_:5085\S(Q[HFEB$G9+&8,\T76N<FH=AHM(D
M\$#I.Y @\! .6_TGR-(J1GF^ C9G-7+\*3]OQNM'=-WL[4A=.QQ79;C1(EM(
MLI$M0Z0>]>N[E_.NF*=53>@2["RRB.I7[G6XD1K>_7;ZOA.M0<1[ :H^6A5<
M434T-*^W.PE]<\DIO0[!>C#L%SB \[N"!^!/ZU[O^$UM)'I0FWY9-NPJYY4'
ME(T(F50N9M:? +!#<LCQ_BL<-KQS4$H4&U:$],C4OKTA6%3(>%.J\>9M$R*:
M/WC57XO>A2+/]+:YG61C*\:+J4_$ B>X/>H2WF!F:DM62K_O[+8N,L$O>2U5
MM9<;'>M_MY=VN4L/=4#'@^G4CP(/G#&-J?%5!H-,)@0/! B8M-,0M&(;%M2Q
M!/L0#*FWS R*&_?RA UWMLF#M@_:8NZ(!TCU#MDF2J3F!#Q.*CZL'ILG U]/
M/=K23PC7H&BJ?;]_W+S%DW&1;7.."KI&\1%$=)6AP^TPR#[)( CF7,C:S)=B
MT%^K5IQJY@0GCTT.A/*DDH5P8![WC\HAK?[74$2(B))]%N^6GEDE>]UYP\E[
MQ]T=%VVKBL0:I<H\>Q;;9+SXA0NFO/2_/UX5S[C0 _('*I#3G&^R;9/P?\UL
ML3G=>[U-HRUG9J"4]FVS>("2;3&3;M5+/-!KS1\]M.4TG%(R9;8^>^U5&UWU
MA4\MU2ND3R)C[LBXU DB9I-QHM:#[=;S?4]M7W4F<36W#S101VH0SX843]D>
M/C*9?-86+R1;D3KE$SY2Q'9N;<]JDCO>.;93:D1JFQGJ1LZ\R?9@-O?S4A72
M\PD*&L(J%LNJ$J92'DDG*3FRKZO?:+\@_"& XYR)*'1 &MXK/&AL?8C0<T<(
M*M8;6?!36V[%W;+)+9SO$S!(X&JJF;EQX>-8>%QS4'3F&^;+K_L'*-==E-NS
MRV?]WJ6]Y^^ G$=H9<5RQ[BM!KTZ%T[K+.'8N==N:^()56D<>5J:."33=U$J
MQRS)0C)00GO2(OYYUA23#_U]);655:Z8?.[\7&)(Q#9&\XFCW2S#\.;VLB7[
M\V35CPIB[+7;KRK,U L].TS4S@8>5!$)W@^Y:N1XUW;L+^'XAC7>N#IOT=9$
M4"-Q6,7:($N,D_*5B:KG401DR:()#_C7H6BYSN511["8NC[.N;AJ:[[8H()<
MLW\TKF-M9,49S6MN/)XYN$FWH#\I;S'U&L:[<X2)%($<C.JYH<AQ=]_@ 82F
MP4BQZ(-'/EED8@5QK?WV&Z'0^:<3T('LN7<E*2JCBV-"HTU1#)05NVF->F%Z
M16@YG+R2?Y0*A:%+0C8?W<UBPVA!/S(JWWOEX7J1DP\?E+'(FPWYFM@7FV'C
M>+THJQ-[*2<;R[=Q$&X\4!*%06;M4& BH8?=!=<7;CRPX>N(EJC<^"2:TS]E
MBA)B/%^F*"1P-5:92?U!%QNE71@>B%&&WS;  V#F6MSMQ=6EKQK?/6U%RMO=
M7Q2ED=(5J9+HI_1FG1,^D<L1/KZGH;ABOQV^#/][^XM30%I*#;(<F":FL!/Y
M4-[Z2XF6G<.-'&Y:DGKI"%G4>8G=AX-MJ./[A+4'!88UD9NNJ;(_EFIB)P#Q
M1[<-H!?PP*@9M!'>4X<'?L[*@-.^V?+]0E5-K0WJ=FU]JU%U7;?$-.F*AH;P
M&?OG%SB(SL:V.]I*5'J+I#DL1Z7*$;4<K#1&*."!-V/I6#>S5=.8Q8%CNG1<
M/3]-H9KV,O?@+71!?)9X]T8X9*?,#KXZ[/A53SG+I@PIX=D0+B+/IW<!$8YZ
M<&!V!MI5F7XPE/\$V>]2&?;EZ<98?J]H3G1R.$_)R#A'LJ?]J-!P]N,=\E):
MJ@TZ1SL'W2WB .\N3B;%17U__A%X9<Y0II6AOBZ644/"'C@X+('J#64&G^J'
MV9<\*=OC7XXT;&V2(Q*7E*#<X"$T:L?Q-@V;#^O)!8Z?V"M\_YRRW.+:[WP#
M=A@#PA( \D8T/;0E<]@7(E-CFVMLHGAX-7>N<N=U2.\>@OXL;&>E80.8AU?Z
M_X0?$D40?EIQM'G?89?F/$/4&_P>C#/9%AHEU;B&U=S4FZVWZ=@Y?%E/-O?Z
M0^]A0UZ=./VD415@-_0OP/F_%R_3V$Q3=&$;*X<71J[ B*L8%<[S/8GL,D,&
MA79FK2-:CPHZB"B!SJ$4,;QAD#5;!&0;G7%QI0!J8> 'VS2S5*]TF%DQ_[#(
M8AL+<F G;NP%[U4L'J"!MM3&XX*;7'!X(!S8LBIAPM&VI>\+(]./,""C(EM0
M/V$\&#C%\1#6_:D6_?J2,)]Y1VI/DPS4Q7PWEMF,JXF\8<Y%#<H9%%J_,!F"
MG]EQR5?%U5%*UCI3.3]59BC#-FS)X(S0*S$RTG6=E%96.OD9VZ)NQQ<R/[H_
M/0\X6/H^7A.:TM+M1(IHSTNM/+9PZ^ZL,O>:NX 5@I]^'R3>#A*^?B!]J>IK
MKU3IPQVAWF'5/"8XXVR)Y6>$ALE:?%.V1J==C7/V/9K)'-GO"%75,)#<*#T!
MR0V!J?T. J<PP +]]A"Z1KLNO#)W ;IDAT)@@SIQ 7=9XTVE%P:.&6#0.=@3
M&"O*$A.)@&\CK@E^5TQ)AI)ZO_'TP2DPL9UL\-:C7^.!*TI0Y*>2RZUSN[>^
M_803$T2;P/$9,/&8R)NKH.^(WYK;2J"X S/8"<&$O\$R-B8W6;:P[=Z0V[?1
M5X\Z(>?#\>Y+_08?"C\T@-'?C0>065")-0PA*%39L.4V/4DHO?R!8#S@&9,/
M78!@_ V@"$$,,I3-T\^V!@T*#[9$LX.O>$!B@626S= S9J&\;&Z;2MH?#^#N
MKT.0H] ;J)-#\C_!@K$I:E_T:S./-^NKG3FL_-%I+Z8P'07#1!ZQR>-T!GU%
M\8"F'VX7#]Q8Q?S4R]*=0] $:CS@$;J!!^KD$)BO?4PX.5WHP1@TU1L2 UDR
MA)ZL5:TRBF*"B\#F%X"-V8>R@B&,!PZ&K#YBK@=38R<_+NML-)\%I80U!)FE
MEZ!7@*;&R6?_' *M(-Q5!DM4LZ*J/(U>KL^J:+$G4G906.#'Z>E[NM7'SF'4
M,@1KGN"3T8;^='@@/24=0PS=R9UL9</P81^<Z+Z<[#:G4?JQ(?MB.F# \(=_
M'PD&%8,[IB'HK&DW(V-/]"E\K=E];>(S6X[;N,>+N8E6#X?3^?>$6=ZO#/RO
MC_A/S-NK34Y.L'KQSYCK:,8I+>3L-%6.^].-\)=PW.ZC+>?XN'&.A8?0,#QP
M=XN72;PDCX\]3*5Z*#Y@T[@Z!B7::KA5R)KR1+IUNL&>;/ 6<)HV2O#M7P<S
M#:!CI"K1WZ$2QF\_S%T+O?,H:[LFOU G7:0IV^CKD&K^1"?[ASM2/>=D%H4(
MV$(G1EJ]XQ6^EO!/YYMF+-11E%;'8T.$FS:'57QLD"Z\=;[IO%=##XCK5U!T
M03TZ5;9G*,XR(-+'WR!Q;)(N!=:KCC/87:?]E9?BT+/&V=Z5U0_P@+7%2Z4C
MS8?]D2X8V6:DGI\^RC:-Y96,;DYN9^W2CP1BJ&$\CDJ5 A=X"$%?@B_>97RK
MK7MTRZ3E6G6R>*9##!,Q"8J6'W!N9M_IJ"K<8%]41YD<)IV[VWS_7([RP4I=
M[\#KDY6/PD4(?\G1Y;AA=1%BJ_@E7W/V)I%P8&\;?1>CA0?D*71 3JML,I-]
MQVBB]7R%T"X[D;518;J6UI]%"0G7@D%>$V+3U<<GQ8AOZOU273)7;-D'(HUI
M+2EI)_O#*:R EI_(@M&]G)MT0NJW]2UC1]B3VA&LM!$:53&&%:<Z>Q]W.>2Y
M>E8_.$LB;D/SIJZ\_M%(<9;7Y49+W.Q#/<Y]+MF^<PP;N@O3]XA*0^6G>CH@
M#Q++I41S5;.MUFTEC#@#(FAKSEX9R/4J]OZ#\//^Q_K!MK,13.$<PMNG!S^$
M%V?YP%6??(0]6>KP/;?GHCXO\(B" MK5:OX3,3S,+L&72"FP;K0MZ']&F2)K
M*+'B-2;L\,<5':3,)? YC]BR].+_04I(47#9Y^GM_B&))GB@<^EGP,%37?T)
MP"MC<!/"+DE0U#$$Z^JX:L+V$KH$UEBM:O (=^- ?&=NF_)   /FJYA>@9,5
M:*H3X39%L?L_$0]U2HRNKB1V01$V!W8ZE1OK';-L"C'] L4#[*[I!QN0!$^L
M;<2L3/!Q4CN%W* _$Q[XU(P'O* )+KB?QD':XAJ\IYX"Q*\- ?BLV;(Q'HB"
M+EG6G@CL9D*W4"QF1SS>>.#]^RQHE\T KAZV!U-$K6(BU,&QH6M<_"V3@+R^
MU0)MT)8J:-+[G+[+SXUUM=DM^(,S%+Q(;^/@PXEVK><S.0S3OZ2@J6K#:"?K
M2UWF;>?HP-GX]KRP'0ORRLZ:/K*\J5_G+L[CRY 1$QEOZ$5Q^*S"*,=,:+%O
MYL,![.E9RC>R)WK=Z?;U>Y%SUBE]'$Q''Q9'A+>AI"N)4*+"/HZN69^H_K;D
MM>)@UZP^E[3HZSI)_*$R/#;-?(.N'PL]_5>&>55<^UH&6%>>JA'S0K]$+3 (
MG5M!<1Z.F/2&T1:/V 1Q7#$?KY#A@W:+C,&GS;#G]#2SH5UTK;BF17 =R3NG
MRI<3GCEWEC4#D>9YD3XD&O/BOI7(7.[<6Z===]A]F,P.-R;&%%QVL'WP<B+
M^\+_R(KQRGOMRY]C4P\F^[PQUW<.;*?W0V<]\4"(HZ/-?OT7E/WF;,I'H1.?
M; ]^(2N&)([$3A!_,%=,:4")112#/0'I M&\^@F@CP?F/NI/OCX*$YI:W__F
M^&C7@'_<U3U*)WZEE8B%HLH!K??(Y_3Z8O*&P1;_\O4KR5>9\C*N0"6 &-PE
M 3+HX)E.');L63/ASJ?778-\+I6+1SK#0W>9S5IZW:MV'FI4JM)-A;V\5_MY
MULDDYPJ! @#X/!HD^)G#?REG?FX[J6L,"V%U[C97AON>/]/;=<*:68<< "9Z
MEU-8%'!='0OWM=_6\UX,L2Z<G OF=Q--1F4WGMZ-W%0J8:!Y(_9=CSRO?5YG
MI&>C?K;0$=J5R, =:\ T>%Z#)'?=_:BZ6H46^[WA _7I8, =R1<W-EU,B:EN
MOM2.B#_W'A-V4WF/,T;J=I]KY;>?!.-O[O=?,(!WV/;/*/%2^EJC3WOZKJ I
M"'RFK7_PC9*'EI]C1(5P5 =7?B-4C 5"X$M/RL DF=D "S7;/1N"JP_O2-IY
MYOP$/G.#];EIQ3S%,>W5$V$O8>^!(,B2=LC::&DZTSZ= 49OS>OY',;_9QPQ
M'2,4O[,=T^.!S7@]<0^0,8#R':& <QM"D^ 4(*?/QA($%F!:Z1=P*+9'>* -
MBL:4@U5:'B,NR>R<(!Q1;#@('QSY'N?61M$H4XEB:W]N#I_E] 8Y)"9L&(KX
MA--9//AQ&0_L<H-ZW#3K6"]FO+9I<<WQO:_&OC3)//PD8OLHZ5@/LFAVS+ E
M$X$IS$ [XC)/L<LXG0$TR,M\8C)!KL&-VZ8<PP/.(;#C]\F_I1*V_4*.QQ=
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MC990/SE@ZVGT;PK\U89!7&[TN[ G$,X:DH'YK<?BRO9[ Q8/S"Q(P+<T#O"
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M=?Y.I0E/-O4';JE1)>D.5RH#Q9ZRT!(3Z?^;-/V;-/W7D":MAW@@SOXR]M4
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M>,ABUKWZ*A>]- ,%R4[&Q2/U47XW7OFZBK?*E)S/SC\^.NLN;%/6*$Q;*6%
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M\!72;DI5YB"W<Y\7<F WT+0YANWSRE4:G+9U)5RO9SY\R*PA)&[2_0N,K<!
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M$$K0?^[<3T6![ZY#:NU7B5762N1#F<'E(./EO%#>H>?_2N@+F0@__?G-+3I
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M(0X X;;D(JF2E*3F@P(V8T<CPK9E>SH60LN\\=8@1H6#[_A+^&>BI:4EW7T
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M+ZUR0K_^W0"A6- &22#QG4"([\*7/^BEUW[?%C$*PE*KR?Y5T+:>4K>TCYM
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M^ #X24 !N'SI$NDEDLNDI*17KEPF(Z>E(+]ZE9R!FH:2EH41Q,K"R,Q\BT.
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M@9:;:"C.UVT6>]D1QQN->8#CQ0/]4?5X(( "#[1KD2(_0+O@J&"L'AY(8_'
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MU0L/Y<BD7=!';46Z-J_;9KESE"<W0L_=X>MFAO]0,)707& -,<;"8T9T+/"
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M*98&/BL";UE&IYT#R;B3TE>:E.NQMRS"5%,_ZR#FF8<1J^$X/0M6)L*43>R
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ME[Z(DQ$0)LP3I6C"/*E/ZZFX54QPA$FS0PR!%)DE> (Z0.)."^&H04;(.;$
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MKJNS''J/Q5MWJL'ML^FGD&=J],I6@XX,RO84=Y0=%@UY_%Y' E+^+NJ0"'<
MG0C"CY99]IV.8O\5R)?:+L2VBGATSHH2QH9WMK)"MM:9)SZ%V-DKDATB'^!\
MY^M1EV&BO6J-<8*B-\5JLW@*>QDZ@RK(1@;_J5JD'AE2V,3PUP=V(X=4]DDL
M"7\P7[W<37',/?1*3DZX"S6?K4"",P_.P00<F"!$>E84C21 ZAP<'UN#P!L"
M_"\R<5Y_.Q?SC$*XP!KAIO??JY!K001$>4ZEZS],FAQ['JFVUCM61^WX[.=E
M8/0?<WG%/6_2>'+J@%).Z"L!6HSZ.I.-;3<IMN] DS')P94E-M"$RH:4Z<Y?
MO!ILR-)29YNZUUE>%TULR@Y<:7XYQ I/B4EPID4.)6;_R-UC4N^[(:, )#"I
M1\+79#Q^9^6#Y@U@^800']#Q(#*G"OD97S")F@$FW@+>-\??P%Z<SA3U^C0I
M.2+)!?V%9YK[U<"?]^[I_%3IQD;5ZU]ZHU^B53N\;C_1<VQZ39I"S(QO7EU6
MO"@B88AF$"NXG9"J]4!\!V^:998<XZS&Z-9)8QRY.2M!!+Q#/!\[19Y2=6XC
M]\;0$4%THDBX]&"&6^W;^:(?TL"P?3-<&:W(E3S^C?9]-7:]HQYMJ'UFI2H3
MF\!&/4)+>=&5WE>XWC!$EH#))P):G>?1I]3*OU<)%D>@4,.&G6EW@;;9?? "
M)"*[NK)(.)4&>V0 J15=7#EP7C:VY_DNL/4:XP_K!+XZ%"Y?H+S6481>5;_C
M?M"%]KZPVIJNL\[Z?LH D6$%,8GISA_[?M72GHRV^I,:!YRKO-JMPAX-U;PE
M ]5Z]PL= <W-N05^7R/+'I&@K<I_EI*1..4_*C#\GRK:<JO^U?0$&."<9S)!
MIE@F;J5.LN)&^X20NW!T/$%ZR\"@1\@\'?;"*T#(*;X2'WN#1.F%?4G+]B/H
MMS>'-.J:L_"!Y_1G>_#.QLA(A#U#T1F4 X\.)@*XN^!_O4G3TL09WWI*?^19
M3?-R%JK1:.RPRFF+*0V.S*6H5&.-ZKH6$<YK:NEW,RM2*.;:A2]IH>1KOZ,N
M&&SBX[*5:C(3S7<%0+I:J@#)GEB"+W)9\W:4IRJ^<.0)F4:EC[U#?ZF@P^<+
M[W_G$ASG9KUB6R:]B,+X7BY5T>"#4VHO1H"^0D$_1FP9_)=[U[+2WCP)#)6+
M! A2%WD]<=OXW<2'#__N'ZDG O'[D!Z$*@!@F\NH^X#S.#I !AC9(.Z5UT01
M59_ENO-US0G9AM[^B!>AK:IVL:VIYKO;4=ZHKF)IR2@BMD)O[GN1;Y127BW0
MC=0H8ZJ:QVN$F9D &748ZU.JX[P372*@7QI?>/"$7*& -,]2" 9S%Z( @"/2
M6U _S QCO:"X[O"9//_W8'$L9]X70"7* N2H!3Y3K00+1_SP4"L-+[#N4+QF
M^R "\.0N8/OW_WAMZ >0)/7>9W*DV8-,-0# 7V_P =4#ZV RKH//@+N7+C(^
M(?<.I?@2=>:#E,;LAAU:&B\P9RXH!J%[S3V63=5TO&,A(^-YN@^'+)H/+3+_
ML4;GCX"'<8\::+]H7"E3O=W<875/2+EE1\A>U*1*MJC^AB+3?G^(-!' !AM6
MKAST- \+EG^I.G/07LZ9 >!7C+8<"P NHB@F-4K69V]G$ &]\BN11B+-FZ_<
MA99J(8W?Q%VTM/M]LVK%+L)Z0 PP"<7GJE1K.8^SR^GH]Y"2Y?58>$>TVN&6
MEV2> ^:1+41@OIMK$>^08!8?:YV7YAOKF]5@JXTY;H=00H]>3J*K2O*^_XK_
M:=.A7GN_PU^(62"WF3;FP6%6S_C#IBK;@G]BZ?V;:S&(%\;GR@5S412B^;7-
MQF_:T/6P>>Y:%/FN92(C&182B[\F\ZKR>T7MKFV]XRT&WXC0!]W<K#RGQKIS
MD.#C#"G,$ON2W _F@CV)$_!EFWM5<B%&1( #X@2X#=_L !WP(0UQM$0 3UD_
MH8F/1';[ 'Z*%6JS8ZP:W=$75L?)F43^>W75+]SS3O-",F#3"'?!+,[#.VS.
M'@/&52/T]L[<NS#=U)'(A!(]R2UCF5J!8W%GX!/(Y>Q'J]M!$$B <2AZ \@
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M#GNA-%5D*=+ 1E,3K %2[KN+RW_$Q>7L6ZJYWE/_(^\>I^=/\11LGYH&021
MTU+I$O_#8:#$W;4EX&;D ?BMT:!9@,BH\_R#;UTOF!YLD3'15H+3=XX.I*(,
MOA0$+L-QEDH7B(#/O_Z480F%.H*N!0B6E)7$?*-AEB7;0YPR"[_%0>8@M!NS
M%[XV- [-I?A /DV0\;\VPD,Q(6W)[#?ZQM*=CX1_76UPO=;\_?!"J7<>6D9%
MUO^,*Z^X.#,AF/XAK1%JI/B@UT-Q^\>3/T!O?U'OHX+ESE?*YX[#CM22M#0>
M:VZY/V(MAC/@5-JYY' 12:<Y^FWSWR^I#3T(L 6-I2V,C%Q5S6?A']C.Q.7.
M3>Q&I_F-6+V4O5E$=K+(-#HUW>9#W><JI,5Q)4SMNW37=( @)NK4NIS=0'!O
M^[K0J[G3E1ID:+5/Q@WLS\*YB5(NJ$DY#\=/[P(%^K$$9_[><7@-KV=M'=>H
M"7MUM (H$]UB"R_HNO%CBXD;\(WG=#'7#J^*9:[.<OS:ENDX9&DY4YU4FOUG
MD L]EN6-M AY.]>-$:^BSII1L1V5QY>_/[[6C%]7F8VS%+-)J3#??-Y?R!22
M5986QL9XG?'Z(X 77_9?0E>6E/C@K2K\H3F5F"5ZWNE5J(2]4..I7GQ5R\6^
M6E=C7/2\-AU$],PX%"C;^@P#OS*6$;O@S&&E/>F,E\2F"7N<>)5RMR"H*K1E
MU#6DWTDWC#SG6''LW&*82EDB<,.LT/,KN?DX1%OQV.M\@PQ&62.V&R@&0[N<
M;-$Z!BS?@G\?D_'CNC/O9*C70!]U+?Z!M%-8\=;E&0N[LAQQJ;*[!KIQ8&L#
M*6<?\/@V^ZH.XN=;D\*G5"LUJ'=URQVEH73OGOYJ&N6Y^IF2TG$#GN@5Q# @
M@I>9[]56HB"WN;!:+^/NJ&ZP= [ZX3[4>_JMVF*E?A%%!W,ZY5 TUC41Y>ML
M__5#1T>>3EC=:LPY )0UO>'CPLQZ]=OQ$?(CWCP/[73-!->F;W]]0V;^:50&
ML_CP(6-2F58^Y).F7!!$!/QE/I$_E#=J1YTLX30R4&^0M.O1VO_-]S-9*'PO
M:F&7L;7VW*-S]@9F!UYQ*&O-_27V8VRSQQ,8$= >TCI[M6'$X+6 Y0?[LZ[<
MEV@Z H?)AME3+.5;ZS/G\W4)&]>/ OPQM)H-J57?J^T23S/",W%=#[#L(;D;
M3WX^^FZQ[?I]W[QR$7B- )S$^74'@.=AT>G+J>&>$=M&3WSG@J37E6C'A]N;
MF,M&$H*';M+'[M+1;QJ4\$RNUXJNYYRFCB8B<;&:F+Z(QM'2H'X7BYO.N;4@
M<*[3OPEW<>+9=C5PI"J4EQS>)D'I<JT"H*>$Z/(++Z9/V;!RU?%=EZV#*92<
MO_J$Q!:WX^J(OQX,2E"E 9X> 7L:4'-H?$R&"&F3KB+9C)3*9:LAW:U/<? Z
M_0,\&/J%_6>E]6?',B?V!()V!=SW*#ZVV?!T+D@"WGUO!$2_!&6/<XL>S.'N
M$Y8L'Y:6U[;5"2-T0NY-6M<"*>R"I%UJQ<(@>V"IV-,E^ &WI<CYDEG@FW^-
MA2DQR.2KXQ;2_BEX^-P::Y2B\%B*_F[J3.K1JT?DZ*&JS1X"DVEWT49*U[O2
M<3$?P9@+\!K91<()TB!G6 ,2E&NUY_WKSS,B:-6OB? GE_/U2>!+G_\L_T3/
MG];E9<8%;!\1$.D5Z#VT1P/+'MZYHOOQ=>^5C%JET5%'I5O#7K4N6=]JKBN6
MG[B7WE7&!U4NH_\2=2):= W#TF%NJ48?KST&3I8XHN_'40_UIHCO)*-=1_2&
MTTMC,8K!D604=IY9_^](L0AM,N5DY#YI];#<O"?7ZMY::VZ*8?!EWH!MU3MN
M:Y>@O?W;Y'.OW.IUB8!F5T(CK06]ZI"GL_S#KUHW)$9%2N)Y;1_/V6\:K83)
M1_"$V=%S1O[670@6[B4"YC\'7#O?5B=!==3I ;SM 8[[;#*60 X_7//;H=&.
M51[$@W)A03/;!T4"VS;>TSV?6I0:1K7-6YHXQR_+)7UP?@G6:XY=M@#CI>B#
M08T%1,"<# D+Q.(<@!1P_W]Y'/HG9B]\ZHS#I+2OD.6M?S6WS>L@ MC'D'=^
M.V(PZL>50/PE(F!S+#^\21QFW'ZZW/0A7WJ]+NU]AAV'\2LPO]*(U;PMZK\!
M<LF7=R?Y">IGD%,L^/QRT6@0.;S[3OEO9SGJ0-+*\.P/(N [$0 E/;C@GQH6
MR&;7$]XD^"%6AA#F0#[\WZX@D&/S,$YN/ 97WV7%/X0W/!(6UCXZV8S4F,W*
M'TWLW:GU5G0Z'; RK^#!M%VJV10+8^=AD=!6+)9(?I%6XF+FY!,[[]D4IV#Q
M\=CY&,G2A*M?+!!;C1019)>R8=S:5AT1ZA%V$_X9EZPR7:)P/\>D@/GHJGJL
M:@E/-#>K*K5BT2H89Z&D1#*Z#^%H1GCK//;X_ (# ??%N>Q%;+8#,@T^[P8[
M([R^3 0$&)?@E;!\10LB-RV<JA;8R@>N&':F)E@D*VLZR:>G,^J:)JAXR$QL
M3UK8.ZQ;*2(#/)/5QGB_6=)I_&'/T>F+M$L2O_.,@X3%-IM3M&=ZP3Q/Z[U.
MG$1$_0]$L<O5^C] \YDKI X.@HR1)H@O:@V2?(@D 9M0WVQX/PF:-JD",4@I
MUY,EU/'WHIO[D+__33:!G0MRRI)[#AU"S5LYH/>[X;L?U/'"?1P$7['S/0'R
M/OC?&O:#C-6!+P58Q7?XU7QSYMWN.HZ!YOVU?8MAA1MYZ\9*@74 0FM%WESJ
MBC&?8^5..G5:@53%JZ<V2>7LO[>"2W_J!:\"KS:).!)H(Z;,J':]N(?N+!N?
M;QF;+]0[F^VVC3]9BR]F^5&C9FUUOQ O%MZ&IO.*AIBZ5D'U6G\.@>3I+B^B
M9[.T)QKC1.\-URN:-ROQU6)=0T4JH06WPTP]$M[)J_/XE&8T[,\A\?'.H#7X
M)Z1*R48N6T74TZGHB86F6[CZA7<@-K2#G&BH?>"1S5V=\_:G7BWDC2I$ (WZ
M N3\LC<"1P00 4RZ,'F"%J&1,$>"]= 9J"QRIM-RT#T('[?F!J+'ZRZ KW5Y
M!BAGJ^9+V5&U^YZ$+VA[R\C<G9C2<)-_$RE]YX<?0,AL#Q&3\N,HB+UBJ,1.
M\%ZV[+N;1Z0%P:Z?U"-L&4ZU6=JA101$34:?X\<RKF'V-Y1T;_;Q>7/Z/8TL
MSPRP?;\QZ&@E,(C6K'W_JLSVV([PO!Y,#G,?;[-B+JNH?FN8PNO+P5E^+1[Q
M\UO0'9P5&H()_#$%J*_@>J%'UK,8CR_L^^):9QYY>62OJ<LOINQVW=6>MILQ
M"S7]G %JPPTLG&X*KEZ!8J?U#K6VADK7<9':T/G#QHY>!I$J&QOPLSFXT#R!
MRU0LNHEWD^OV"&4Z4]%VM=&2X/JY4R[E]GVQ*I08[G84RN?G>/*/NB!16,^$
M]O9JB.;ZQY]+_9]B\S8.X%2P7FULTJ>C^DM"F^WOJV=5UJ"9L*%'/UPR/X11
M?VAAFK_W =Y*AFUY4?)6B]:$83F&U.L\>J%IM?);U[55^SRGCR/_I? //<UY
M+FJ)?IX(.,4EDSB-V2(18 \_$? !'L[_+HO]*^@?IR$ 3N-(K5#[H?"O75&;
ML^!SBO%NP\-2)!%PTWSW;X(ZTGN&WM;>]D; YZ0YZI5^"Z(<<(-DP1G_%/UM
M"D1^;J(C;6:1H,T-\+H%#O&J%=7L<S !&JT>&"[\DR@AE<PE/[@$+,Z)<:S-
MTF/A$5-&'SOYZ@)K*%97I-%6 3Z8AB?B9::[]EV]C)KNX$4+1.L,^:,QO.V"
M]1?'JO'7H@A7!.N+@*X\1_3U!FZ68.E->N:U)'%U>X[0FM<,U+\C=:1.E34F
MI")3&C73ZF>2_Q=U[QG65+MM#4=14*KT)D0%1*DJ38I$5)H(" BA)BI(%9 F
MG4CO(""@($0ZB!!!>@L= >DETB&AUX0:( E?V.6<YSEEG^OL\WYO^9'KXDX6
ML'*7.<>8:\PY_7A6Y#HB2%=,/6:>E7NKG5T/D.$0'#K4[XN%X=9.IXH$'*P'
MM=3TY-9GC)\*=6[^3:CST></0IT/"]D9-,8]U)&+SFD'VMOWS/^5$!FLYOXQ
M&0#>^FL.F_41MQ141(#.%49>9/7!RCP@CM2"0SIP%&8_L+_2S]_J<H/)KW<*
M^J:Y0)^@0F9,E$Z;1=CZ9,\[*+A/C&92[\Q[:\"2D%B:#T54BB432QG+<'H"
MD"&0($%7H"_C(-,GZ#P"_),,QT\(UBDS"EN+W6,I[.R4[FHIU!+^M8TX0S#_
M@>T+*I*L=J7379CCN-.<97.DO^&"$9D6++-G?S*X*3E:PTW7M@BX[XVU*\,K
MYXWU8#&:GJ*9;X4[7W4N"^>/*O!EV!GHFDS;5&QF7Y9N2CSB&BP]@$OGNJ:'
M%]%NA2IREF&1P1GE%54Q"]F*%@E7?UI*H< 1/GS(ZL$ZFV*/)[W;8\8RFQ1_
M%>@\P3E&NLY<L&&"0KLHSAQ7^1]^/CJCK"XJ.!!T;>C-:F#;M,@002!+P]M;
M*&3\D=-2LD,C.-WGRJ!X^3US75Q2#K<**N81=<O[;#BIW!+OW9Q2V3KUQB.V
M39C?^*7TFHE>7-Q$Q/ZQMX>]Z. %/D-TU'E]G7?G&;5X=RMA 2> 6PFZ!P8S
MG_B$*F1NW%V)@XB?2O)C_RK)APQ!1/\PU .B'XZP T,@L7_4YW\UCOB7GPNV
M_Y[OJ<'\[KRLPZ.W2OSAM/;\4:PL%B4*U-A8SC5MG$1[DB+G@%)\>^\+@5;,
MYF=&^ )8P0R] >X8[_8 -PLT='';3XWO4E3U>(D'^##D>HAKF-BIM6BU'/R(
MVY$] 5 _!=LZC]DOG0  SF_KV(@^R-DTUIR:<:,F!_C;&R-4L[?U=)3I9G0$
M7EEX\M96@O$[V6/(7TG2BV;UI6]3]GH!^ZSSU"$S^U%O_<Y57!%'7H3X8S1U
M[8'-<M$;R*/?:'G?<'1"?/2%[A&22"7WB(VGG^H9]$2U@B\FU?'B6(G]G9&@
MY-YZ^MO;)P"Y(ES7N/ ]AI:D_GQ#3)W^4WE:L##V  T/(=S,[4653&H63*E9
M5'T0U%4'C7[UT<+G9>';AYY$M-_\,&$:#O7"1-@[;[>Y:QX%"7C**O:(U^XI
MQOZ)Q^R<YNHPE\%9->@37K%T2SX-:$-1^$,BP5);T.I$F<V)DGD8D%]TKI#&
M-"W!--_Q%SC76D=$[GR0]:U"!_C1!80L?L>&/YTN8%M*Q+Z8-4:>-A9;? )H
M/@B'S47+H:7/&Y^;]_*/2(&U)..1CYYM]0&UAQTCKYC$7EPMJ?HI70I;OEX%
M?;?#CGWRG<F)=CUK1VK,8_%0<NO\ZH]:@&+OJL3J,W_3O,8UP0HLM>:U#;MP
MHQ, #O,X?6<7^G'5Y]8>+&XE<0$$!,VKA)(:A@ZY]FRWX;'P;;[3XF0VA.A'
MI_K]T?]2OP^DC9YF_$Y17\6Z *6V- .AP>&[*R2CQ;3Y^][O.@AVL$.8P/P)
M0"(-5HLP3)\Q96@GFX'QT#E"M/O(X@SW%KH,[^["#4^W>J:SU^,R@G_MJ(%1
M66H1/Q1,424Z@XX8OT$CQ^M*EI/&65-A.:OQ8?=Y'L2?(;DAL4>4I5CZQ,MU
MK(&"(%V[R,% CSXT<?K+F"](E?>9YS(T+NZ0>OGKA[6[]<43N]"1&"_1YHAD
M$YO5OH?]KA]WQ6E-#.]+>]YR TZWJQ/6?I8YABL*).B.N,K?/\K-VT]24V@$
MA$L,8U@W]4X '77P3?@"1 KKU<N'<60U2Z34D>[WI=1\4+=:N^^(4Y9_D%+I
M=GA'% *+:& +,'N[]31@?Q"4HJ$,N>1G1+3=0[9J,^(WQ[D=+XP+U*5#'!QR
M5IB]J'=A;->0P5("SR_<NAQH"FH,NQ;9&+7\3F)2$;/6F,/@G2*>\W'^T--X
M:NKRPE:XWU6"?$T%O%4OMS!/_3KJ ZU]G\-MR)"])P_I0[+3Y0X1D] %4W"[
M!1COY&=(47G.F]?.O#'*9&XSR3#>KV<&EZ%HZXQ4/?SBI26]!FOZS/['; !'
M'^LR(P6NRM_$A<\K0G#MC]1->(D3 )]J%&AM]P0@79R%8?Y*N#O,D@Y]#CSH
MSP//!6['+MN<]RK5KB7$Y+6XP\=YN8>*.SN3SKWTRRP73L->%J7R+_.8R"__
M2XFQ ?T1@U2-ZFB0_WDR*D[ZCS0Y^L/(>79W\M&"GKIM'#2P3M %H\W4D3EN
MJNPH$K;)_X$IR[K/]ECO7PI<DMU]U\P9\HG\.@Y#743N<@%FR SI-0JY+$M&
ML3/B)!98B[3=S.[E(=@6&5Y0'^E&  X1),X?$#*86$PEXW<DGDRY:,<0L'X7
M33+>A1*$5Q[?H%C\<2R]ULA,K,[%D<B4+]@9>>&J] F W;7*,, \7I_?O?D6
M @'=E!EL4,/KGP $<CO^^OS!^)UBU?^[K$M8>NG!T.:FPF$&G6"1C8%@A%1'
MOZ2GN"[S;>TYUCOQH75=0:8S0JO0&CL[;LH=\,&-[+@-TR3_? ^]-A=3&FZG
MANOCASQK/5+P&)ED@QWC-"9]VAQW^V*)1B2C%;:\;3+.9DLVK?M25HX9KY%L
M]:&A/KN(*,^F[[T3P(4&,E)3[%8E7#O2)AR+>FP1Q(^WC@ ]Y 5* <W!9F#]
ME(['\X.,:W(AT1DV2;I3DR;Y$5*3(\!@*2*S885H=N[OIG;AMCUD5$IRF.2A
M*WY7?:C7K'J<# ]D,LW&;'CMFR5?I;X=9<WAD%5Q,!8HD7IUH4D )X/G+5=F
M,7CUEU04%UX17$YH<!&O1KS&F;2L(E>7$D.>T*?"2UN,WU+ZVF@TY M<'#HH
MI9=MS3GUOQ8H3ZB0T%L<2L/I/],=(U-""OFD/RU^??NS"!'J)SNRMZ%E+;8@
M<@E#6<^$:O;BB?97<UVFZO*<Z/%T#[@2 ^1<%68ZKW.S$6@\'BM4V-D0XJ*;
MSNLF71[[#"<3=@U+2A"8S(@9Z3O[0^$JI@?4QBC4K)8\4)A=_[UB6.27C(Y(
M&/A]<QW3%&4PSMCZM:D( ,<U_&)]M49OK<0E>KFZPV.U+V,Y7V3^SOBCC9%D
MJ7MT1K_#:@O_GMQ[QM2J#4H&8AW$-X[S=C^*)=!D1N5K3JJ2V99*@_HG,X1S
MG@#.P^93;4X #PD]7CR>2TWDZ\=A_60C#@DUDSH!A/VZ20"A7)HV_7CPTVL=
M7L65F=-M.44M]D8"G")5O!V#T:KJ^!]S'+W94A_+U3(/LR,$5N7WSM9/7E('
M[*X]#+9XWLC*]WE4KOVF6$B-],2J$Y*>X$D571:2F+7M^%Q>,+(?!2>\?DD2
MQY9I'BB.DKTL+RNPY98HZ;9'  T0ORW4%K [565U-+(5RU9T+ATX"B!.E?\6
M\Z4T*%Y+3]2*SN5/60JU2^\&T#A>XCE[YD@?>.D:,M2-]<5[^^Q3J;YF]I3
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M(J[B8OV_U;%_Q1O<,%NL2<&X[E1WONU"#2:B9[B0\];8/*(/<+$L8[-7>G4
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M57T1R&W-O=BCV9F?HVZ*E*:*_%8$UA- O'T>D6%'JAI'O_=-X6+AKU"Z?7<
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MWTZK+HF;[16Y&EVF2*4G4MQDM]=BME\^OZ4!"+@EF(R)RLZSK6$OM=U?LE5
MGW-I.(T+E4"ZB$UKBIS[LI9;K,&]R1[OJ:@U%9;R+0VA2+I&6EOE/SWJ/]EA
M8]9&'+S]NJTS'+6#7*GOU>/YK/2F##@',VRKRL("2VNE?C+":NTA6AJZ*K4?
MX[;ZZ*_BE03O-!&8HYLY. )5PE:W=-CGE!YD[:8A(AWU1XJEY+[VIL[%H!K)
ML0OHQ/)\G+*Q\[/FQZ.;5R>R?*PP,_6.QI@;">FKKA S\\^<D>H KK.5'XH<
MF?"2_7BK3O$%>^I!OV]S=PS]G"/&^*%HT"],I\IE71\,6^B?LTAX=8;$PWGV
MG5Q[?EV?PNWMQWMQBI:N<[2,ZQRW:B**7$6B3BO=$FTZ$4S'C: F(ZV;5;V?
M<!P7DI_M(C.ULMX#KDA[I-IF&[99/Z%H.VM)42"B?YGQOI4[5=%->78Z10T=
M[=7*+U<FXN)KMIPA-'C'7*^X%HG:$LNHK;-TZO15^N>41 /WBN#A:>)E0W52
M/'&6,JYKDE6AG)&5%\F;>OG&Y,AM:A+PE37NV-$X9_YN\>K;?4/7BG'0[_M!
M[R$YZ<YB1PEK;HD+<7TEY&)J(Z#ZC#6Z>G"(>7M(BS"U9(@,I>V36W-&!E]?
M@_270<7>'<%(Y19(F$_BVWS_9<UADYM=7MK;B.;Z#2HJFH1>'++)&!SQ+*@A
M][R1_T)AB_"\IJ[_T 1<G^%QM11HKT<*6WQKHJ=DL;'"$.CIN&O C%]OJ[ME
MA0O!!-C[74R5U.AJ7G":LCP:'82='?HZZ2!S+U_C2;_QQZMWC[:0:OTRLCDX
MJ(;ZY5O3CT-]OKO,+!QD2.@L'P<8."]N5^<K,NBPQ)5X6=['""@D]Z:<6VM6
MC5 3+4NKPA>R$8#6+QI7C#X0 0VTN#&((@ VCUEO-B8+WJMGU&!3J_SDG1-C
M)4+E<$I)U C\^^-AYV1-"'?'9K';/V3JHMH14I\(>"U^<.+;202\3S[4*>&-
M>;L->J.M"%1.!&[#+S0NJ("P6-X]Y%FD+TZ1"+AV]P]30_B?>2[.MA]>7OQC
M8Z1?\\V@_,_ZW!U@32AK3 &NMA6,?F72).A7H"79XU1U&)T/]"<"VAHO/<$P
M^#,/;UL,EE@S7Q+6ZKM=DO3;Q#0W!!.,>8(07),:L#F\09O")GSV12>H-Z7,
MDDQ(+Z$KJ5[?UF9KPPCGBQX5OE!7$[G9-UEN>^@;."GK;+K<T8C#_H@9PFE7
MS92;9UF087BQT#NG\HP?\_=CO\R#LUU^:^7IJ>>WR:TDL^[*5<!CUED-\ 'V
MX/4P$K2N?+B7 ?YD+P5:,SC4JXO6OD_@N2_'( ^W/)]M*9[:11:L)]#E&P@1
MF<)IZ8;, ="WS&\.YE3O5EA'5O7XJ9IS^Q$!O/2VA.6]_)Q&/] = L4Z1L#%
M+AX!];\QF[]A;)YBGV7[P=!8B3, 2%$@>\X5! 0OI*R#L1U'81N%D;A\(H!K
MUH@(* $//]2W;ZNPE>?6X>=0_ ZGP"L.RPC:NF;@"M3O,()J7X)J];'(T_B[
MD?KK9HU)D$^OMF(GOY[A/!K+@EWF) !+WGXY;NPWL/;UMG]B??W@5I931NS7
MCN>"Q@T;J37,0R/LR!8$<)7CZ@ CM<3DAHYQ9*PQ!Y7[M[&7,.YX.Q"#C&K>
M^)F3=\M7GQ]J&:_(^&$N+9GLHB 4PA/N1@T&,=YTM)@,!WRQD!72HHUK 9GA
M&XF+P;#:E(!1+.BNE%1]>,R,2)42[6 E@07'1J"C9LFJ=135K95[TAI2X@<V
MMF[9#O%(HZ^4K'3<3S7^[I!L*W7EB&K,.V9=08V\>'*:$."8>BB\-C<6#K,C
MZ?K,9@06#4\>*_OMZ^$.W&NL4@SNR0H1P/GMUZG11TN-7=EYQ7_Z]>./%K5W
MFH[NS4*^G&KGC'#WV&-0S2[D(2^+!<TU E=G+@TL-#;&4]'&WO2WEGMN$(?3
MNC<JQ^U5#-.;NS A=.M\3W8ME8L4N[^><$B=< '^E]&QUC3^69H4MJ>#0S(W
M-U20T !F^W05B_M18LP_.O3>SB7K$3HBZ5(&A&3MY9I#(N SEQY%^MW/9P Z
M XI7TQ1V_"KW0PVGG.V?)/257*KG;?59K QQNY.JMMA<I*)R%BL;LFSNG%>P
M"B^CCFQY7>@'72SQC?E@H(A1;TY&AM=)78YZC2[JYG-=EM*[W?$Q:WO#PG'=
MP.5DUNZ$:<$*=F/ P9TMI9'%;D5C<1U4&KS.[CV_UV8!NT^"%D,HQ-'RB7%F
M)3JZ_8Z)U_= O<%8OF&!O+CG9/CS51#Z5?,[E9BE.,>"66/50A+,SU2)3-".
M&XLN-H9.*$P*Q5#@XQHV.5"8ER(XQ[S-/DW_-^*>*&]=]+;*9(2W<NYQ>_4Q
MF!+7O-LD/9,ZEU+H&Q[^ZM7SS]^:FO8Y1IB:9#WX9>[<>'%GHVXHR^:K_7 $
M]L0FH%+&#[3T2[EV$A2YOB6K@?FPG"/8YD^]@.MKNXY8J]O'[P@.RQB43.!\
M6RJ3#FX5G(W8[%P;_VY AKZCDDS-]&"45Z$X;THL'[&U,#R$6[S1O2L ;U&O
MA;Q8PWZ!/2#=LVLQ?.P,OLW]MR^M#;X_+8.'@G3!?Z%D8_U/Q1UM7C/Z:,=V
MOSNMNJ<K)-4X$S6[SI\BZ WQ/E-H3#X>>"F>R7WBX)MMB4,2%#6T"/63A_I!
MV9OUV")/B<&L&!5)0?[O8[08:)M^,E.@L#T>>VP__)0ODRQ-V7BI""%HIF$+
M]A85_ [&AQY L'NS74@89"0[6B%0OM1QKT='F^+%F"T)]TF7HZ.5DNZC@<@)
M ZO2)6NR\D>VCW!]\^=&W\_*!D?)Y'4XBI(LA\LE8:%J!>'?''<@R^F1O)T:
M?:.SDKF':=&H8AXAVI918Y@:@^)%,HYZK75S64S0=M+<^8 :Z*&G"V$3=%S]
MN<>WW&NV51X1;LY$$CV!AV%]\\646'@FVP&_VC33(=L^B*Q.[-FIX<V>S8U,
MM[@N%T^.*J3(4!FU_M"<$!'PXIDX^>/!IXXB[5OW+65H\X![KU<$V_=F#V_7
MSA[M@X_%;Z_KW8B4E04V:Q388X=V)=UI SGHDU1CF9]]-;@J9_+<'W:T5.I/
MOB89:I^/\]]YFE"VJI;)T3)8;P[!"A-6D5=^Z"!.1#AXO1*;D0+;,1."MYW3
MX&1::N2YETT$='9 B("Q-P1U\VZ!D*#A/0%%K]$DDAR^#"<"S"T/A7PO#P>P
MJ69;/G_U%7Z*I!5/<R *Q9(P3W9D<K]OY,@ZMB7>VU*&J1&NCZR[DQ#^^4>B
M6G,:NK@;CBD6V%/)]8\+3)0'_._;]@C:>_RM&76T4KAH(N"JH/#1'#S566\"
MKTQ2L@E))\[@WJJ"'6=0FW6/)3SZ1U4F??Q^-"W):J 9.VG2A8)WS@R#UR>T
M3LX.RX%(EUQ&'@?DC,(7R/+@8V6((W*D0]J7HRHXM0^(+ZWL@<\ 1,%+WCP(
M'4A0RH>O)V&1LD@%G#QI?QXV8KN/1F]'HU0F:?&&:;N*# 9AOK\G]^:?'9$R
M76YM9+(CL"3WN'5F1JA5VP\$8[%(B>$&+J\X_2$'M^/:-\8S2Z(,85<?J,4$
M]OBXH4O?><<,Z (OJ">\H_VS_ HB0+$RNN6HK:(P-R#)HZ=&PK+J3( TJ-@3
M@:Z0(6E4\&OX=VDB(,A@N,";#COA;]T?KT\6**Y>;-T\FG10@I1Y40E\D!F@
M+&^"[>;NVNBMJBU\_WM*>_]$^7G?E.%/KM/<8E%!(K!F9&UR9T<6:@9T&4L6
MTQK"\VX\^UX7T2%C,;PO3JYV:SFP%-^]I"D39Z <8@QS.N:Y-OSM968)8Y$6
M9EZ+_Y79 0="R$=HK"6:TES%*DG]5?5V6) <$TZ#67+_X?UHN\9PE^N)'=%K
M<EP8QRA>=:@X3Z\F*&IDO9&V[DH#RT"K#@\WKW-)<$O+D?D;0&F9RL<50<TR
MG8@KJ',-"ZIJ]E+U3'=)W'CK!T-?V!+=]Q89 ^XN?8J1;.N^ZJ$I.IOM1Z.D
M1.W=V H"=!:?;QPR5/0*7'0>?MCLWUY3,#*2?'R4U%6@FW!G8MF/M;6"^>6-
MGG>6N6J8OO,1N#&=%; //-5U?0YQ"7?KZZ0=R*;F"K K !H[*./IEV,W- NW
MG@*)5SKEE.7R%4RM3E/J!:?RE'O(E<>_KY1[*F'Y;JS/189W#D\$6/3B]U?U
MK#&YH3 ([;<BQJ5)3Y8K8=O^E_$R54.\9KIZSN)#-(;8@G2-=F1%6JAPW=L1
MM?A\90,A65JM3]/[?)4GFW7#>\\!-Z5UAB4]G16-N/[40.H?B6'^3S298L"2
M$#H$/E;WXS G"*X_U7/[@_FTHOB$"&@63X?W<W00\,(X/5[+<*8@]PG;B8[N
M,H-A"#K2!K)']I$(:*3\$:3YSS?J+DF!2[GQ'=WE/X'U$@2!KIB2\'P??(""
M-R.-OTT:MBQ,F+2=->K],LS7UZ_C4CT0W-05<9A2+<M)W:6<UR8$%-;MORU\
M&G=ZN]EG"0F7W1#-WNNY5F0G_T#3N\<S(GVXD"J?^<K@P+T1[G&.XN[JI1IX
MRYUIRCFJ9$)D7M.YE\NB$[<^"J5IBK29X5*^"\Y>MMV_:01IL>8N:WAZR/ .
M,PF<&5 ;4Y,-3M%Q,2EMC4,IM_(-:,MX7M1C!BA-T7:5V"*H\+ZV^2939EX3
M4M\C6V1\V98X4@7';0HT<EV,-0S)3E>Q10/,>C#2(&#X^'VZ"&:)U(X(]U4S
M+$-BK([)>SN,L^_-(C"SC0XNJ7ELXA=1KENF'1]4OK^6XDBH5N2)TW^BI'EC
M!5T+"DR3'K+7&>UN_W#OM-^PX>1II'"3'U173XO.ZY-O&1FW11=)[>W;"91P
MTK?, (=D1+)(3W+U]:O^P,2MCN&Q6%7TO5;T^EA-3LI<N(E!5<(4'1OCJ2AG
M\TU%WJ+JFH!!F7I:^A_2!4-/"/E"!&Q/PH/<S*G0PN%[E_T<W1$,.9DV%_.?
M7V7A9989R];6D"A7L$.9\D;+G'.?VS11JJNL#YY^QCW3?2T6$C,$4MM:R1Z1
M:X,HU48$43EUL$@)O+=>$>PE\,$D&S'SAFRR:I1:I8R\/3JN[WS\! =6LD:F
MQWGMZ>9$8#RX0"IU=G/I4#JETZ\F ?X/,6CD' ]\ 19-.*G$&90/Z/DY7,M)
MLI=->VOOZ"J9*N-<4(>8N>)B-\WP8'JZ-2$A^A:N/J>/.CLD=*._O#>)S_5%
M;V_N(<76'K4QM>O]\F&A\5L:S#(>X@X[@VSKJO8.%V5T\O5UI_2U@NJ$;5&R
MXD7/%A+F;D NB=SNLUCA5[X_=V*P)F4W=,A6_AF7@CJ9J9TG85X1R#T&"?7R
MC"?<*7']!/%9;85!-;/ 3+/FNME6(H!\$ZMA5![)2# 3U'$PFC\N\E-I\U%D
M*"YN1]S[8B]'L^83@0&'P]1OY++;5]U'"" L8\R1UM;G@K+T*P9>H4(5"J*:
M<S,*C@Q3H$Y%6HPK+KCHYH,_L$;[@SL!=_&%#F&)?^2,)3PU*K^.%P6UY_%]
MM1S+\4GI MEN81HGNO?M7*K(AOCMLS%I\ENYP_IM#,O;>(7HVH_SU&A+\R'5
MZ!:"4/+@5(6:>N(\&IB;#F,JK1BAUQTK9RDWB9>BO'HHNM?FD\TP9#NE 5&(
MRK:7299M*W^ADFT3IJ2"\FI[!)-#OTMCZ#>>66VM+%49U+A"N 8MSH@=W*Z:
MR;_19 H.K:-T+\'UJ8Q=JPOF*S(18N._/A6%2/!D>% 6F_3(;K4->VJP"@HY
M/6V"UT*T/=VA/_O1^S$@UVE]-M=GRR;=YK"Q^/[(F"#K>C6+GY)@&!KRHJ1.
MN&1=^N7!Z]ZD'<>'BE=RQ\0G!Q0&IGW.&.C[YY+;?A<L= QCXK@N^2'%^Q'=
MA=.IGS&]/A[Y#;Q>+VW\Z9-O1SEL@YTI:+(J0:.UQLOBR/.V$UNUE@4S8E'[
MUOQTS]+EJE:3-5SYFC8:KPT7\\HUYD-08R%$ (H=;9^:&?'+^E)G6FU*''Z]
M\#W@/)F:P.(-6PEKX)-'&6$":G^MS8W,\AP8_[*H<3V4X-YF ,6 " KZ$"R)
M1:3G"CM;X4"$>"1!)B",KTA3=T(&3 1<N0,Y.*=11((?M"2XC_R1-_  !R?<
M]6C<HD@A88#7'.DD1#@(7^&IK_'E7$/AQ5=@&3X#\NN*?N2H<SY,S;2'K"0\
M60(9K=NOIT21X2-U2,!2>-UP#AS$^0R,>>S;PZ!MSK_YCRJ/?T(FJM=V.Q)W
M.$0$3!%RZI+KK><-\+!5(F +KFNN 5$,(ERZV48$ $D+-B,3V0MI@1_2E9%,
M._B*4DW-HAP;::<B<T](/Q3$1\9"#.;]<^NUOLO_:'[_>V[Q0@>%"I(+ VFM
MMU;$@/?]&M*LPL&^P/6$2&]4JO31[J:H\EM9.QV[+*M]DXR2:JZ:^F!C*-,E
MG*TX4\BE-P?/#I"@!MS\G*#)ZGL-,I?,BS1#/;XWB@96)^Z=8XYD(.@M$VB2
M%#"*/8.OL^==+EQ+ULPVJMJHH<2YZ2:>]*H3F/I>$0$K)!.@0P.$;H"14+<"
M$4"0AHXWHB@&B(#EY_@\(N"E(.GO:6=V<C@[X"@8+IH01 3@W<8*O&C;DM($
M!A5'%G._S8(]@9Z$B\4@@A=M5[G;B<#D+^'=E6:%QDK:#VR+56+CRM_Z_,?
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M>&?SSOS<9&NAJX73!AFO;3$MS@8*.CHW!9_EJ24"< 8^POAC12( I@-OKAV
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MES%N-Y_KH(]^'?2-%3@RI=GPS$9M=Z8:$DP0K\<H9LHN289<>5Q7YB4XQU@
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M<D6KC0@)<]QD&26_ET!6W69GD CCPYGEP\##Y6PIZ\?J"35!EMKG-P)HO+\
MU]Q^CU?RGT&GEL&_<=K6SZA<BP_D4EEPN_Y^R+\#2@3(]1,!LZ>KUBQ,%Q9=
MOR*3I,O9#RMW9 3"#B ?)XB OC+PP>?,#8_&W4W:$[2 7-;Q&R+@"7@)3V'^
MEQ*@"\/2[U( SGQ@N,A\\>X5M/RV&>;@F0\F,K,+%N8S #$D IZ.P_L2*D^.
M(.C,8XD6 JRX<7N0=%!\P.:0+B<_>2) 9,?]9UE7W_CSVU2!J674-6PVEHX/
M[]*N:NLRYS*Q,6F=1XD+QOU 59[_ XWGMG^=#WMO_X[CX4$( 0?L,X\NK\AE
M%+Z 81P=_2O[(DB;+[<,VM<E.'[>0?[&;9RA;L-IWTEEUU+U@%K=[*&M[^V)
MY?2@EN,++C/+O_4<K]L6%V^)+,LSO%FM/]6QK W_SYU"JB4*Z09$1JQ;7%:M
M-CV4#COJ^'E30-\J0+N+I&_T3\(+:B&%%T6/ @F6:;\)LFE$B86>5@H+DQ:(
M.*590MZ=K)&*,?VH\K<*CO\:417#-:43D\2N/%=C?UJ7]/G R8M6MZ9TF$=)
M\M:BBJP4TF(D(Q9*;AD:5LH/"#M<U\;=*X;8Z9I*I/-S=YHNAR6+Q@NH<F?.
M?JV)T<U^BC4!*9BL,S+1D9F\>2Y7) #9%!0^/ HGB<C= CPO1IKJ1JD3V4>Q
M1G0!3)<(D*]%'*^,B(HO^=&?9).8&JP-GU7(#;/),1M0*9%]N-3@"*: Z48?
M4IN2N%JIWA4U%H*E)E,^EL4.]?'X[[(.W@P/MU_[)6ND*&KF3S"8[I4>UQYP
M'L$ L[1<OLQB*>1^I?FUX#BO3O_MRRK(,V-N^9RX0FMG;P?C<=#;<2<!3@W]
M8E87#WW'+?&(^E2IAVJ;[ TIV5Y[2FR:M5[I!#IC\#<B@ &\<FTVU8_.D@-Q
MG<(^]EH5@4Z_H8<,OP/I*D]<HO,TD+,G].%("E^>$;]>B#Z7&_5X+! J&<E=
M(4UOWK=O UZ.)3PL/*OB\C%/KKD@55-ICUSYK:'/LDV?L3%?47N9_'_MAH^J
M@V*T[J%E%R22/DZ9:EWI5 %P*S>H9/L]$TNYDRR0EI375FB;>-!?>-WUO3OU
M\)EU_4Z*[-#/[+%VR:6EW'?6@C*J:"_B'Z';7[CLSUA5CM&]$_,HK K$C2"I
M\-KHV=!E$YL;K#.KP??I(XO5Y/9;_+>6H8K &"0N117=$U,SXC!X=H-Y9U9-
M([MJL*&]'KC8C_=$UR7E, 7L\\&74?W>UECD_4$L]/+33F&QX_@T,A:JX(+>
M,9ZU_1L#B@S!_[]-T7\U IJOK4WTBG)MY&56YV$%%X8VLE./!.+,R> %7BES
MYS^@5RK/"67XE9#G:^HF<3$A8V#YRFF:7[ D^S>,@WXH2Z3'_T7',SW#!F&<
MA &%^[FS>W/5E)" Q\N7[%Y8Q6.E\K?\S]L&@Z<4@!WWDI$A<\/AN1_76!U?
MN:6:W3.:XGJ^5_P(L"*X+&O0S"&$MBKTM7:MZ!)^^URV<,2?PZM-1B.+S(-'
M[XXF5*5=-/ =QV0&U^+YZM'H_,F!/YEH(LUQJ^9 #$D"MY;:!4QJE%*3@V#"
MXENM5H\+-'*,-8^S7HD4+=+8\HX/TB]JF+@N1?*VSM*)&3(R7W\[['F-A!11
M%O@?C6<]5R%WB0#+<9)4/I=YS-%!\!*RFW38Z.2JD/,GB<<0DDGQ8C;;G>,,
M)B32W<Q-OLCHT .W'H9%;/B"#K^7X=PF#4$PYW..QC6NV@YK<['V1HSQL>_3
MRLJTC2*?D;;ZS,^H7]3]Y/&L_(!#.5L2)3N?2=SP/O(MS"QK:HUPL1K3GL=L
M.FN:5ZE$N+ #;J_G;!^+\]KMD/"G&YI*83.X!)%.DT/DY?M+3]RS0(]2FKB1
M4^E>*WCQF84AL<MO0GWPJ/&MF;><X]8 1^#WQD/ZLL:C ZT%P;>XMCG?:%JO
MNVU6QX["D,[HRTY.M"O0'!("#YV G/CF[@ 7$>S<HEZ(YM&0+;8R+C\CNW7E
M-"2OYV.^VGLIGZ3[0D T9<7T+?L'GHDQ4W:2?-R)MN>U>GK!QE]PR.]L(IF(
MBRL5J]#\;S?C8/?8GLNNCVR^5K:EH D+(UM\**-*T8<J5I-8L?_5KZ+H+6M5
M5M&2D1B*G6K'><XYXE3Q0.N\+]\2#*Q(;_#VXMU#"@]M]+5ID0S -:[NS-40
MNC:\$$&UD @XM\U!&W*T\>B=B<HD'+.&V/>/D$@I-DTS*QFG/]2OT"Q,NH\\
MB"G([EYVK-HK1)S'^6QK2%Q:U6\?+YE^07:Z+J7)10M]/)?:%V25$)7BXVG"
M+WN[;^]:_42=Z%SE$6T;G')&N>7UJ8[C'FTRNX^$_8AJ[HWL!>2/<,V/(2)9
MIQ2!O5X'#^L'8)2%:]+0C;K*0)A&I0>-LN7H<VEIP05/W B&X@I5\NM?]J;M
M H]T>-O[7EV2&!X>B<Z82"?$G\+V .<AYV#.<W!&NYHB:6Q3XNTKRJ^\3]U4
MO^AS*GG?^/][XM)_H0*#F@9$3DWVXK!3:42>Y; >!*?F!CXBES],3KI=S'9U
M),##1:D>&$,$D&N23'-Y/K"H,IY;&G1R]CV^1]B69FY_F AXZ[=4#V0757:^
MU$T?HL1"=6<H.^9JZ&),0 ;_4\MQFIRBP1-E;=-E/&\#D'08%Y%+\.9HG!9,
MD/1YW9#C%=()A)0BGBJ7A;BYN1E(D;YJ.PB^(D6"GGX@=&&R8YB8AOGWIMRU
M!Z9JY]72I=IXR86,S]VNIQ=?(6&3OU; ]]=)Z<E]:\L@[5B_<T] ]"MA*M+Q
M@*BZ9$U5A\[X>5#H^&C&)S"*GX1Y5[C)EFQ(%EGN/=*BXT%O\_=?;VE5Y.*[
MM\57BM;-?-7K4Q]5U(<9F63D+XQ&ZMAN/'S"(M@VQ5<TK=O*JAGVI28!K]_6
M_E#%9]3S/^[\9 _>7*R@]?!%KZ!2;U38,A@EBT:>D F1C*H?14&^*,@1#<D*
MG%7&\Q]+[3\F?6-45!CRB1\TWYA[Y%VW&.V!F0_K1^V/O[<2\-=AY[3A]@L(
MQ7=*Y%=I3]<A4!S()UD0.XF#C<0=F5Q;UXA=\]5KUV,^W?QB$6BN-:_U\H.=
M <CQH_>E)U(4[ZR&A_)6NHS-U.$QNB_MFA1KQ3^NB:PQN@(LJR)?[-GYFDWF
M=?_RW ^ZM/JLX>I*G+>^OH[JQ14-\6TY7K/'HCE59($O]!J;-9)QT9:8[5=[
M;V3N>#J,W>P4;%?(V7(U=6Q*X9_X5O++T]L':2)&QKS-]<KFM6';9J+WNUPK
M90S*5VJ$*D(>5U1T!UW&& ^&963SG*S2Z_L/"L3KA\XL)9"L7H;_U'M*-G\Q
M6Z7$L<-G(XT=[4?(I%AZJ$ _'M-4$EM@9_PD!VFU[_F1_!&\+B0]/]E!Z%K&
MH&UI$X$%1P0T^3,/E=PH-]/4+33_8O7N)'724?86V6 FKA8CVDRXCHX=MV7Z
MI.'$HS_1_PE]84O19PPO"":']W. NNHFYPT"W2Y3-H6[YQHJGYWQ*5F\_$D@
M5[#<?WV7 8C<E6X,F;U4)Y)G:.L#+-^(S/-62S,*>OZ%HZK-%7'Y"M3/ND4Z
M%%2K7CXU\T;0#/%"ABW=>"79/)_ZI:WW0J'W<]=W>LA0_TMRPNCX46=G5Z9M
M"_ FC3-NKJ!T,1GQ<*LSLV!Q96#$2*UTW*0K5P C> 8+3)VKS2Y%E^2*7@14
M./?5).]LG\$;E0V4+?;7&7)]:B@]F3F ),0[21T]SO?:G:/%\T)!077<[)4@
M&R>>5.53KA,91=Y(9JA?B.K.MSYU!W,<;VX=$4"#-5(C&4@+Q=$PQBS<F9O!
M0JY:_MQ1J^^0,"?!(1E.U$J=*"I<]L9-45;JY9%7RU@DY]C51IP!AM'Q8I,C
MU\2-]W#_BWY= UT"A6:LE=,?^24U3QSAC:XST&8"-V(3$F'..C1_& %-Y'AS
M'5I4@YM&77 ;K0Y>74QQN$^1Z>\GDKSLS[*2G!1:9^$][_?T?"@[$9#!&35%
M%=TB?A-2I^.K#-EA3]ZW=_?A&+[-\*-6\.J#S\& P/'!@;L<],>J'>P^<B\^
M EV=A>6C4<8+8.MX UR@T^5[M!\:SUKC$FM!?V<HO#:7=KOJ?;V^]VW2___3
ML?Z=GO6OF)ZE:S3"=+U).3_70';^LMRV3G]V9>G;C/B])WGOWND-5C\(BX]U
M:$MUU8L:^R5-Q8'SDL E.8M5<V]T;7M-5*5G'D^N1]''+PH.LH5]6,<0?X%@
M_MPXPW?MI[A59063T/"7V'H':,(0<O%E>ZN4@O>/C%4?B.-K??W<)[.NZZ6^
M-LJ2="0+^;6Y451<,_B[0H,[F$KFL?2Z)_@M":T%6<[3'E%/^3_-BIN"&2 [
M<FR87">GE)>O6Y6PU;L@*&%&>;C@GF2"PF;=<[_"OD<XU;GP;V<]I;_VL*PQ
MIT''\;3?A]%I;X2ZR?RS"XU%M".R)1M:1U*<'\Z5UV^YEVDK6OW:X%=;Q9"O
M\\I#N$T(P4=X^2X[I/7D\;$2>J7J8YQ5"B:Y$-UA.BR>8L1ZI+%P0U$1$VPX
MV5QP)L!S7UP+=38F7.J4$\W,W@>?8^C>A\=[093NCCNR.F'AFQ=)<%\1OZ;H
M[IQP)=KND=!?\O!80Z5IDN;8P)_L1K6G)[>H%SO?6?D)*H4!@D='*05M-HLS
M#5&1"AG"=P7L^#*=1,H=R5=8M^!E>X6^L;XUI/W1R/;R5!ZXR/,VM^G9>\L%
MXZ&,H)S/V"D!MA1#X:LV#A:JE@X%+==R,IY+Y?F#<)J40]Z,03:59+CF=T2
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MK5W0FC$\[C5)%-K@C0V!=WK>'[798E]#; -(#>"0L(<D4%X?*,],V<MYTAF
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M[N9BPI'?[!5 ;ZBUZ54.\[#N5$J5:QP9*WCK$1R@_5$TL-?0\2;724)EW%C
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MF.1\;)""^NIC89RY&K?XX'2JX#X6#ERN&BMUN#K*=)KE,WO=?8'F"MWZEC:
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M5#:(S=8I4,.T;1>$+RMWVP5=]]D%?7(&*O[@@.%R]JME5K9+-_(W42^@9\-
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M0GY62;*!>3V$.O<_#7C7_P ?0GXD<H3B=]]+^F'"0>YEZ:0[A$<8026WM*Q
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M"W8=ICZ=KCOAKMZT::^1MP'7LC$=W0^\1\=%;#$^]%OF]'DN53UZ!T\..BN
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M@;3UT-++WL$78Q4C1^*\1DH'C9*?D!1B/.JF'MZ*AA1"Z/#X*2I,[1" B#E
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M@3\*P;EZ]2HQ$3$-"0F-P$V&FP+_QS_,5X#\"FXWJ0TNSBW@$CD.+CD.I@T
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M-R G&V T;RS25 :;/5U:"WVAC ':X>&#AEM96I+2%>@;9&$88+5?#P/ =#
MPO.7*QLT(Z3?*J2F36  HK!6#'"P6H !YO(Q +(._'-5S#D4F;[=[.M_B@%"
M6A<PP.G!" ;8'8&@S$![7P+ &$#&+_WB+!8#1$(ILV)MKJW^5VJI7/[:HV+J
MESLIHWA!9!B@/RT/ P1E8X#%S;:U[(E[XA/;Z;_<*?M7\[P6/76VLABVCOM_
MN=?@7]N'D. \UB'U]K?]]79K?V6A3RJ5/V?8;W?^%]P9>'4!QF0?Q#EB7596
MTQ#S<%&04H*3!H^TU_<TQ$MX$4( 6W:JQP#0&]B&$@>O-A!4E611J<_(BN B
MQ#;:Y[_Q&_\,D''^STAZ\?I8CV_!I''MS2?O65B]@#?@$O:M4J%2/\,74J).
MG]9?FHW(7TV5ZIJ4%VEE$JP?C^OS)^LHJ]H-OW$B2L+T1K&D/(W5&E\9M0\<
M=_AL3M9IA=^(M5WPK DCK*&\XP3?>:Y)L'C9E\1WW,&AWJO0<7RC1%1S9-[3
M>U820=VPJ!!D0[O"IL@%T003&^J7^$PIC*(X']6%*M>E@I=FP"L)40LUGK@L
MT_/[XE"!K#K;D%SV7$?A*06:L10-\Q-&!I<[D0QV?3ORA?G=K(> H9;MWDG;
M#=>K&@W>"\]OVB8XDA_2LJRY.I;L:4;;9_KX;)Y\PQNZ9S.K%/"EWHJQ:Q7^
MAOL2-M(XEPBWTG-FU+P$,]O,CI]PQ'89Z$(-<J;M<FU&4[A<7^GEGXA?6+72
M58>$-E;=NN7*KE!+MB@1)%9\3@^IMI@R(?YA;R CL2\+?;17W0B*$O(O\C_W
M08TC&+KP]4?#2/HUY9:JN5_LS2:Q(,-(8GFK:W1MRM*/_#]#[G+FA2?H12O:
MW]/-@=Y@?#_M@Q[;.5>I&!;:?)9DE$?PF#2BT"_A*RUW]ZTOM4$,/J%BQ)'4
M#5'X 95OG<%I!)MF>=$H,XZP-I%JNVA?@=WII9N48NL;*N!$&R1'AT0IM.0#
MH[S*BBIYZD,EJ@*:I9B9P(O-I%=%PYG?\4I@!8V*FOH\//U"\:(12C'WK#W9
MC!X^"I8(YG+D)FI46W':*EE.TT-QUG[M$P@D8$EH]YHC?]K6Q!],_W#DNQOQ
MHY"OTROOE;1*@4VS &@>2GJOY6EDW_O7>K%OO[.+LQZ\@*^;>;1/DKL9OJU6
M(L_<%9I]O4BY 'M-Q[S"$_>ZKR,Y;OMKYZ;I3G;NG+THV!96[<.Z@4M*XQ<L
M!@[Q;%TTKS\.>5,"32+COV-]2::6O9[$<:N)&QET%IM$G83_1=ZO8SWU&REX
M@F4V>PJ>R[:M6[%E6)$G=,J4OU_"I]HTYAQ=G8Z3\BCDVPY1" UM-_,SZLP;
M+ZO676:[G]+WQ=H'U&UK^]E4Q&Z:@5N*S.#&B1,67\+I/OK%:X'WR(V9V)#!
M=1JH,6.S2MW>Z/#<-XSUG7B/'L7S1ZU62;R+:)H8^I3P.5N-(<+#EL-JWNF)
MDXK2<;"Z72F>WK?X?!H\YPX5#N"8T9V[%M$7YE]@=^Q-IQA1KLR[G]]-ET$H
M2\/J=WQ8;(&+S'XPXI4XG"*IX[PMW-9[+;2'HI-A:?<NBNLDJL$^?XUNR&A"
MV7GP'?7XMU>I;>GR8E^I0Y3-]9<8>:N$@S\5U)2\_V$X)DKGM)64[';JT2'K
M-4W/8)O?M:N_T7ZT-1F-.DDF$.A=F:+]VF^9UII1>+2A=&PXO>C=%)9I/W=M
M)X5$4K6R7$YDW D]*)C<O:#N1(/VJD&(K&?N];IB>TL+U\*YG><FIR],;P3S
MA,"CA(ZLI_-_*,2]$2E@1C\R5$88K G_2+5C6&'Q-?(/: ,@B&'SI_DM8OE*
MW+V;T:H2 DZG3+[&08Q5Y[:O#]?XW\"OF%P,N$-D'07J^L-$LI;:!U4\T+&4
MW6=.&&"BJ*FRUOZ;N;*PL&^.M\4UK_.9ZT/=3WGO"][?4B4D?8"S0>;.'1+;
MV<0:HVB5OPLL%]U[)S/#K;<8,IAL45V-1QTZ#7+MU83(5K7"12A"1!7%%46^
M%XTD5WK;5OIXF%4CTL(]G/POA3^XLG,+;^$%PUWIBI=S+""U?0T+S4 .P[K/
M 3]H"8/]H5;(*%!'/21$1_4X5>TIB//6[:5@=ZW3LV&V@6P$7UNC(BO)L1BM
M\5.WCYST$ JR32/=MW8&'PU;$GM2O&ZW'XF;L;1*5'\A&I\4O"<F4$OX_K![
M$VF0NMHZ=\W8I++E2AY1MXJ%AQ6CK%C_@(<9-$)*$9+M:^P<\DGRK5R=XO-*
MMYAO&6[I Y [L23(O+;5A\$D!F,__.VGE1Y.;O''N](SDXJO2A=</&[(WKX5
M;U87.:&KE3B[^K%.R+EK0W]D(3'TBDQHI5 JKAZ<,5FKRE[^#6,W85&ZKF,1
M,C-/SJ5@8DZIWKI.R0A84W-J/ELH0Q)N\5 L:>XQUAQ3797NGXC+INGX\=3Y
M*1,JX:6AE-6QSD>#\MTR_LS=+TUAJ;,H&<3EC_B6+HQ?S=6^GK\CR\-#TPKW
MOLZQOR='TV5B)RO>?]]JK-Z1#[0Y^6#_4QG1]/7[G0QE5XPT_?:R8QKKO7^4
M';ZW1A#$E' DW@I?K34R>WR?K^> 27H/0IDR]G%34=1@S$R'(EIDZ$7>HB2,
M9G+-S7AC[;-1]4VV^]9=RLP45\&M4TQ'W483IALW;CO9XWX7/+Q'"[ZPW#5_
MB3!>J?AD''H*\67A*YC'Q0"905ZUEBZ6\WR$]!\2]=R_TJJEIQB1*=)NB:-P
M9*KZB979:+H5S4U8';E,1^E<[KF1!X@AB-]<I>/V&8\Z=>&<!M^)'2NWVFNJ
MXBU@?U=-=MRFQ9_]1/_4(RI8\TKWEN,32+C$8;*22G2#CO4B'Q\+[1+K0?JW
M1H*6E.4@UN%D[?@9EH97[UB9/?N&O-/JM1C\GW78%5A0*DD-J\V]44J]7:]8
MT>'B.?4=K.,D\^-2C=H#FK>AXLS7\ 73LBI+I6@7Z0U";(8M!,%)+QA!'-#'
MKF(;/B5,7NE8RAY8OYD8A0&TJZ:1P^U."ST^+-7AK WIDNK[^=FTK%[BVX<R
M[T3UR/75KD5H5-ZWERM0;21O20]CNGG--TV_UJEVOZW5.U!:$+E8ZQCIZ^3,
M&NPS*6[E5!IU5PXJMQ<6716HW'9WW$*586#Z^FH/H1ZA2@=_)^-&33NGI<:3
MO@?C[/&X/W#@P)[6!IC,P7-37[\QT<1QG$.3E&%/3((SJS[FT5_(QY_PB_!D
M,Y^:!YU2>&* <WL,D$W7L-6#5(<?VAI0+@6%J2I2&;[VX^#+1,8?Z"'F(@[%
MLU\X><:67:0.JG@?/.:="A<38XG"0<)US"$+?*?<<^20'5H,D+-M_D+VLJLY
M"^)B+!QJNCXXWLJE4$/:*R>N/3=6/XG@ T&ZMO,A4^"+ZU53+W()$^E2FM*7
M/19M.>41(AA@P<$",B RASYWJ/D4H-8 &WVZ-:7UPL!WZ%9SG^P37'");XF]
MSS.TDA,W&G83 PRT^WDT#^@XW5N*]HLNT3Q?(D-%&*0?H=+/>-40$L?]4>#]
MV\80^#YDK9:[;;,K=R]U>!I+N,HOE;3F.HC>+1YX:*9.Z>D9\HYI1K8P<:NG
M=-;GV0)[,N0QBR 0?M[>U<RCQ^$4H;;Z%F*Y,7=(U(@!OC[# (1Y=P2:N16%
M7!@B6UD*\ +E2N?0U^'AX'H;K&;20L*5LS:K010E[(->]2J9(_I$K5+,+SJ]
MNKM8I 7D?B0+&E=>U[+J)F<RNBXVF#H>HJ\3K[H&Y$V;:-GS)7O@O>F.VHXC
M_!A(XFE.4_Y! QEM:>4*I,P>] 1X=K&Z;1LV<4&Z$*(7;K&G^AZ.EB;J'_6U
MJ*.GCW?=2(KWY=_/W5)2*\77U))KES,+:^VGC"8P/9>>?FX/_Q+S:-E):6OU
M%&35KT9O;T?D$9M59\'@8XVT;:.0HR.W >\Z?4@(Z>=.F 8-$S1:K]4I]M46
MF:R/1;YG?T1D]<I\*_#YCQ0'.)'C8[S/#?'CT[DYV\Z"[^]9YW>:^^E.K</A
M<>]YBDLY9+V3(M@?D7V2A<HA(XLFU_V<:EY6QI43>1E\X?*1;DD/0'7.41?-
M7Z@%LBSP_,ATJN@+5J45C8I:]J)FZ(-S)YIW)F. GYQ=Y.8DG=-DUDNAP"Y8
M?8_+[5!X$@.T3"(X3I["=KLQ -U:@.CB%RE_EC4FEK)J>U8E.[:H1\ND;A\7
MRA+BQIDXW>-',XVD8UD+MN^40G_L/]W^]"69=H+89HKI"[65SC"X_&@J6F3C
MZ14.?JG"VE.YCGG!]3[N@2HMQO4TVN'Y(10C%2EA6-+*FR56TDX\V/V$X;RA
M#X%XR1[]T$H>D_OA-DW#SB5+CZ[XWN(2/]D*K!L+]&-_@5#7NS%HXAA*7W\[
M-IG[W:B1W)+4(_)^%D:NV.@ R3RD2X?!^Q!8N3,MNUTKTXUG?<]CE$%]\0F-
M[R8-ZL0JE9,48X1LO6_J/[".]P-NGUP?GE1?F6YF%;"2M);/ RF89V<A#Q2J
MQXJ%ON.V%KB0] [*'G3)=_<XK=)RT/:I^XV!VJ&G#)T7?IVHR1 ._X=T!K6M
M65+E=]RR)<L("[-9$P9PC%T6HOVX]3S8HX/>O S^[MS*A.S4"DH<7Y-AW<,
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M@"YC@$%WPW!X=8 E!HA3&T;#$K!WZ#;GL "K+TB+[U#I*!KAF!>40KHIAC#
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ML2IHK)&X!@D=/E+FY9LWSQ,U-F?$ '$?U+"4L@MRR&]4E;LP=TI;"3U#A6$
M!>JM$21M,RB<\>3GO42'8_4YZQ+?XTTVR7.2-IF]R&Y'N33COE%^[)B.52>4
M7V$'ZP1H_.X_-I;T%&MP!6TM)QPIEZYK&N?X\%#O6NP%^]Q !V*9X]<)\!^;
M6_#V^%!G<E@.60Y!>*+K%4Z39T.VN+REKD><0)%R4E@*+/,&,O\T_8_]+3]=
M*O.GO"_''VS]Y^4&>H<=\#42?"X8WS/FGH7]G AIN3IO<7J(U3NXUG_LXCG;
M)OMAX4=FJ5<V7VG8^&OJ+S8.'DV">IL.F5KRK)KMH'Z_IF* *QPO(*M#9"B2
MA#\VRFQ6@M\'KDF':'8&#YH?_9J*OJ9U"0/TYX"0]!Q_;,"!VT$$S@?\"5-C
M+V<U;OZ:BF).NXQ]FU7 >R)::-[8T@&TS4G&,;4D$Y&B/_R7Q%\\:9:)ZMF5
M^^WF_R]N9A!MWCVE=\8 F^U8#FGMM9W8OV9.MS<;[7=")T6N[#KX]G$RR<V)
M-UJ78UVY,W(VE/(:"3QU(V.BL&1/X>^]#>4W_DGQBT[9'/AUN#2#3#;KWUGS
M^_="J>,B0_2-UE@*@>>JP[;F@837(*F>53TH%0P0[[@(/B?XC@$R4H#Z^?$Q
M$"XRB(VUT+YZ0Q!^2;BDKG,O'15>![IXN8UM8\9C[0"5CN+?%+[84 -;A@8H
M8H OMNB$*K_+?WT&H%XTE\'VI%/87KT:<L;C..78UA"( 5BJL9SDZ1\5AV<F
M80#JLZ#\E784T<B/3?56V+Z@O<71*1DZE%NDLD$2FUDD$0-8O,$ :X\;4])Q
MQ5@0+!,-ZAB &1L*-S^CE6H=-@)^.D09OL8 <^E9,E,XJ&M9$=S-DO(1W.]&
M4(&9ZQ)18Z*Z6JORLH%E% *RTA"ZM59+[D7K!7E2#<>LVE2USY^@HE9Y65_F
MD$9H>@R0E@P^68;+Y3B>F==3RJ1Z)S@!=?.AIF<O^QTFFXRB6EO3JFXK/K,?
M?_W8;B3@<[S+R%!6N91Z*:1%,DL]_R)]F\F$Z]3_V):#T162:#;L J[T+)*<
MX^LYOW=5I'?5>86 =G>L=I:I,*NH:J?&\;0D4$,ZQ_24KW2ED#.K[*^GB8I+
MK-I$)*B2"ORL\=>_*9=Y]#-"^(VK<O)'7K&(<]\V[V^L8=/D^9)7B&T/%9S_
MEI*>V(.C7F%[D5*.TX@-QZ2?C@Z9&#" FWGQ7AD&Z,"6T+CT^K]#S/_&__WX
M1YRH^D]1"PD'[6L$*&. 1Z>P0THS1?=T2M:'3;3(\'<4)%&1G04TH+[G0B@L
M\[GEC%4!C\XA%]>KRHS,::):%Z3IV)G+'W[-8Q2X9E#R.Q+_1Y&X85@CF#XV
MRKA0@T*E28^Q-"-J6\OXL.Z 1V9C=G@)OX"M%R$?*H"KLJ#DG4<KO&OMH$E3
M:G;Q 378'%VU;G&:O-PO+V&>)H??,O)RA,80Q=TO996;][)*$D2^5L@S^FG_
M1XW"*V?!*&^\VWB!_-C7[?@'EMG*J?.AKF@A2G';SW*"!$:?!DAF@R?)GQQP
MI.)K6T6]7,.1.A1G='P:\CB)^R3YV"#@!,;'D[I[YIL0XYG*YST]P]/X??=U
M']O>G7U>U^^4Q.>?2_I)(%U%.1#X6_ 94 Q^/5AL?CE-B%['G$U;$FBIJG3\
M\C2 ,L]L6F3<<C@K;FK@2K-PO]B!C= 2=:,J5I?CA+MYMW?#5BP^"//N\A0[
M32[N^,R'^#5$49&UC9F:\^X=#ONJ%AN[2)$,729 2!G>R+:_ ;[FDCM656#F
M.6K%6%7(K^UV(:VEBS7Q_BS.7N_8#]!66^S*)"/C2[* U82C[Q)?[L"N\EE%
M%'#H0;D,(K>+1DNKKXRUZ9L>9M7ZF9] EIUG+";&7XDFNYJ$26I_9];H'+ M
M>8C5R)KI!78WKOL)]^ZZY=V9]7H;.ZHL#PMC")+>'$99+)(O-.*K5Q+">5O$
MR.NN2_=_!M);&=<7RRV>Y-^1.ITQF<H:+/)S*3G^K-OAX5$7F9P$1\-8E+7'
MA&8X;\,:@^>"O,,9+HT?,FH8EB-X(_._+T\Z> ^I?[W"@"]^2 !=,,T+:R"@
M/N0N\DG,:6CZTM9D4HN#LXP;97WNR<AO; QM+2$\&PU)A8T[A_%_IV3 G6(1
MZ]S<57MH6OCQ(FJCN\>6-9GG@L\[&?*%VO1!LM3CDHE&2-=F(7?D!W^5^W#!
M=F+UT1770C#EPS1:]/@P2F:I3;/)IM;JQWO1LJAGCV72<N+@*<N>,R*0UY.I
M?04%W^_XW:-XMUVR]-1ZWG:]XZK8<MIXL9W-&X\"KBJ*7"U?'I? M_XU2"]>
MGZ1LZBOG0VN'-043>5%2$OM/Z=HSI&7L[X(%VYVXN;/J[MI8OI'KNE7;+86[
M\)XG"C1AETU#7-H<UN21WE>[35O:0+[8%0"6;M7(F?-PV!$WE&ZLG8]U]1]+
MUVU>S.0K4#-%:.QW\^C.?O<R"S\>+1#>CJ\8VLP^J.5HZT>>[9U<!()^)$Y9
M;"31F<JKGW<Y)5;4?'<ELAIXAN)^A2SAKS&[_@B'OW<'9S?Z4\E:&H&9"J-%
M.[MZSWE<?;<W5QGNP".KN/4!OV>EZY9[!]_V1MT$5R)6#=3VG7KR-"1JSMYQ
M)5YGS[E=5.-T;,PHG!SNJ:'D%3RL5YWTY+PLK%5T@*FJR#2F:&]3OJG&I5SN
MF#X#5I_$+D90;2@&[BM"@DP;S_7G0H_"2"!6)R!QWI<QC8BX';ECX57]KPN%
M XD!5!^6D=FLI<E>3G2[XVO1?F]20JRK)DH:22?+>1OT,R;N/TXWJ#(BT*?
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M$L]3'(=@8-7RD#ENT[PLS^'Z66FJ"\2A/2,5-Y.%@  ^VY!GC*S(W91@V_G
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MCLW45:0[A=?6UE8P!AAG2N"F*@E;W-!;"*VTC2CI3P4</JIBISM+LJ<PU%]
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M_Q2]Z;9W1H9A4(3PK.SRR:OXYPM]]RV8''@:=/0?: ^\?OZVLH(^LW]K-OY
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M3^K-'.3:9R$>()^C*V9V.@_SHQ^X:U2<WX=Z'QDECFC5-6&F%&U6%O?MR\(
M]7L(011R%7RT!$4+J[C=[)L;<'LF5D+\Y</X&"^I'2$!";!^P+R3YX)N[L,
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M%_B<^HD\A.4Y1P?>XPAO5+?+'BUTOCIY#[210S]TT_>Q72>#X-FN)CC'Q3@
M=2W5J7FN65]^BU0'#__;-_W3XK,Y*2%J5Z,<)UB3.)=LKY@Z>5R*#E/AO?';
MD0]X218BVACA%<69K+S"90Q38I39!NOH&_F#]I?>B09^Z%"[_%)%\+I(N L
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M%HYGVF_@)O.,1I!'I<GB6FMF?1*A/W._BS];M+CP;=(?(CVE"T'<>$EC7S"
M G#<U6_I[\&3=7GO&5S]+H!UF\SQL.^5PWT'>WEU@7<J$<@R(_CW<7ENYOB(
M]^OK>_#6X5[UQQ-="</X+,E?_N&RQ7/\XV,/'NAQ8]!-U>@K[(4.0<QFJON/
M)?IG6D0VC8ZJ4]\]R+!Y,Q^MV;+ZL(5$-X?UL4/&4LI"L:-@N_(]7&$T8C]/
M+QG.6^2_H%FJZ87<FZWQ+S*D-M,\,8A>UNYJ764>H]?['%CQKO9LXS#/*?G]
M!DE U#+KSEY]YRP47\K<*J"D'RRR$D3#O5)&ZQ!$],58:%U?GU3-2*&]I;,
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M&H"<DNF"+,?B?#77V+='0;T&?]?KQ;P)M>5I9*4;,EYD2;>V[&B9Q;@#UD<
MLH4>Q1R%!D$SL-=!>WDRBT->P@.W94NKT%<J\<"Y93!80BE*_\/)U/] ^\]/
MZM@D^O.$V4/N<CD[[/NL@V:\ (KRT^=_A':\X1O,\+Y> SR0\_U<F$.$[071
M3X2L5T;[1^OK)<$^Q"":O)$$FR*RWJR()!&;GI_YF ORA\  <1)Q K'VV?D!
MCN:.-VL*D+DW3HGU)X/W@OYJ3D;[C,/H2>24922N=!0/W)$-QUY+7C$U@:,R
M)#.<MJOLS4MW-MYLW$1:#7?Z%V7(<RF@U#[[6$WHT-\/0FL\SFJ2NZQ-LVSS
MTO^L590M@NW 9V,*_L5GCZ(=)JS&]VW%[1ATQ#9(OQ6.*QU@1-RV6/?UZP,W
M4TP,T&'5!>4LW=3K2\L2NWJ>BM_.8TA4%EQPM^WQP(8X''2<0]";DZ.G8\^@
M/7N8:_Q:'A>(N:/#4"SK5XJ3)X,L7AYAE'3@MDSE5ER=L_^2Q3$\M-[(WKIM
MMX/=U8:/?L8#1(;Y83=8C3.F_60JKGN<QO'%'9-M\J5ZF,96SS#F#ILTF@B%
MG"7T-N=,"%8N>/GQ/#G5-6T&EJ1CRTPD"AQ5IET,>""(&%2L#B'N/>>][B5M
MV&RX/&\868-("TSC8DGV0G54L Y7%6*7WA:Y$WL /]9;7<^%#IB1',B,P.'3
M4I-[(CNT@E5<8Y<GKH8ZF\R?4V!@%ZD-/O[E(\:E1QM^<5KJV-P#@_+^>DC,
MP"R.H5^G>3)#?C(_O.V+7BBW^/Y +W_QDX]+%,_,-=Y6'+W %-L8=X>?K1$J
MO$IKK*ZYXD7OQYORF16M]>$S4\BL!97(H[%'5D,NNWG.G[:]*NE/9E[;(@G:
M40[C."*28E;J1A0N-DO1[,CXE0P=,;LL(!S7,6$Q(M-6+X5";(FFU/030/4=
M.;XJH_UM'.SERX./-.60^:$74N'AR^I8EXE!5PF#-EN/AYMI5XFH2,Z'C!GL
M!P[V9FBO(=ZL6#!0GW4W$"T/ /KN6]W8R!Y,&L:YREO*ZSEZ:V2PJ"D%W3<$
M(.SG2TK(.N]!$0_<<=*<K?NV])@'>=-;"^?@#<>+\$"F.QZ0O1"%<?9PCM'5
M+*='[>^\Y>/]\D7!N>'R7C8B!0^(M(_C 9)1QV 5.0ZFV?0@^A)J3.Q&LS-_
MD5O,B78\,$Z/ZL[MT!6:F4%)RBA+:4^N.I]]X=+.9JOU2D=#J[JX-GHL^G@I
M5QPI\U"]Q'#%LQ 6]RA;@_D^:&AW?E87K0]?XC<>FB #?1EL:AH'(\5C]D9+
M\8L,G=Y9D87OE21N_@437+G&X;ODN1:8-5!DB8SG[;IR:%V<!.<E7.DC$(Y,
M-=3ZJ56&>N*].0@>_#WQY$]T9P?S$Q]2O(:>GK.:%"-_TBLS1K]+F_O':ICX
M@:+B>1$"$*KS0>LS@VQJ09/>X,C+Z*>LE=&]*<NY2A+/&Q9_)1+2'3E,=S1A
M/]&A+5[<\3G'#G1XAR,A3LKL.UKG(\P0YT&T]A_X ZW-8(,P_L=8M7E,#O(4
M"@)JB*-5Z%>F\+ZO?SB_M@/>T6L_YV! M(=M8\0.>.,#D#?",9RFD8C/8&A%
M).:S+N*-O+3%6_KO" _!84K4U(03C':$>(+:A.GU_:J*A16$'#ZED0^JKP8/
MM-&5!I593 1@??A'M]!(#$%O$+0L# \0SC@5(B:.NUB C%+F#T;I:W) 0PZ5
M&*F^+X.J\T"/QG6 )&V"[LVOY+W-Z,/I*C-0NV^%_M"N#XP9-J*%95G$,+;4
M8$W;.'Y")"?F0ZFJM";(JVM<:V<'0/@ZMOFKQ_U_0R.!H,*P(:MOD#NG\4"'
M_<&!E#]]\2>*$KN#I%\F=:X:+PC,&;KDET#OYWP<A";L$-=^8^R> ^SE+W,.
M?[<3@:\IX@P1>]1+\&WG[_3P$"5Z<.00XYGGB/S1UC1!!/"A5]L-A(ZY>;T%
M#7USUO^0>8&$QP&M<Y L;MUW$\"]"!FG&.O&\;;*TE>!,X*"@0(QWDH*<S10
M-EUD'0M2?U-]KU%V[)T+:>O1+ZQQ:2]%ESM'=8=@LN0R(AD<QVF.UK'0#76!
M0M.>2)D\<U>C+<,V;<XL4>N9D\,Q@>B*.A;[LU*$ 3V(.5W2K0"2^7/S^:$]
M7*<EO'.3IXN8HL9?K,YK>Y(7J:4+Y[3!QRW1[KCGFZU[6RQX@/(ACFEM)F7"
M3TCXTJ*+X(2_THT;C 3O3J[4!7SHY90@(A5OJBP(KBF8'Z=$M;T>7#(?]%FV
MX%GU6HRRHPMQE^#/Y/#4;;<SWN2$C2KG28\\/<7^Y97J%&G+2=%]$T_R(W,0
M5.%S<3P@YFRTCPD&5?;)PI?N,OOMW$YQQN2W:#Q0M]@ZES(5H%\4GI"^&.&/
M=-K.D)W^_.XT:RT%X4>"1/,Y"*D=_.S\S?D>\(&(>&X8!WZSMG:^09]HS:MB
M)?\0:O01#U2.KQ%B=^=C=Q84<=<#R[G0+]^GY'3>D(1TRQQL:17;+A<DZO4W
M'T,%>G5FY_5S+?BXC#E3]NN!NT*I!3'I5KZ;7^GRVG^Z02G&6X%MA>]J /A8
MGE43)+L;G9#5KEBLCE5Q3X982=J0"52&6O[6\5"&.[Z 8 -+0<:#>$_R_!.#
M0R#QUO]+J@&C"P9@ZVQ/1[<F"7$^FKOQY6$H)-9;4V#?\>M!9/PE[0MO4E&&
M!+GZB;B_)XR%'8;$U:V?4@2P&(VU;VV3M<]9FW_*5=C8'0))15(LFS.D?BIQ
M#:$R^#3>>S>X]U<6I$4(JG77>4R06[L"N->F_+FE!TE4_K1_3:*:+AACB=O6
M$M=X/OT$U<R'&$=9?NFS;^BTSBTC-[(QM[A?7C?Y[B"8#Z<JYD5<#SC.OX1$
MFKT"NO)>.')7RBDG"C>!!6-'!YRD&0<.>1F$T!J7?4="+_C4DP[DXCK]_FDH
MLC<\'&LEA((3'R19JK)^52 WX?9SJL)YM(9^]X(9<G$-ODF(8$*X<.%(FC:L
M=*N)?D+J";6?:E$\7.-<NNT!I]:0=S^!9*A:]-RO+%1$_@35@S\6 $IERTH+
MT(J]FU+1/F@P'/TI7[$NNX7T'%V_-@0RT4GXW"GH!_BQA[H3M'D@"SHU_V<#
MQY\#3N-<NQRCI/ 5*CSP:1GV$O;S%W^B*'A @!@/6"?AA@\R!0&1VQ[ZI9ZH
M+'7&; $- $?QYQ_)?&06#Y#C@1E9/)"=68<'C ZX#1HT;&[HOI\]9$_4^3A
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M,Q"(/*(?EQ\R93?VPK0UA#T0^EYSEU;6*O1MZ%R\=]/'7XF1U:4_+5'280E
M3ME_?_?41W-F<3X+#"8"XK$!5Q"U^_)</X6JP$^Q[ 8/Q)\%1C)^L*'C!_M?
M8I 4+0V3B+-W.>JNQJNU>W^)=.(^N2"V+( C6ST-6B0(T0P@%:KN*:\\&-7
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M1#!0$:"772?B:'NM<U%&+M* 2C\J6!VT]S*R=YMXP(LZ,]I@?/%-YNJRV93
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MCU^US='GZ^6!<2YH?^ZUO,Y,.>:&8<Y7#3$=&BFF"G#M?[YR*=;_DI50XTJ
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M):N_.^/B9QD%AJ[2HZ]H1'60XXKWY^I'J,T\DM:WZ7A\+F][0@--$;'\:2P
MN]QDHT7=L.RI9-DLJ$.Q_6ZYM3<"'.P4*7STG=V(TWLIR^M5LU1"Q-8FJU&F
M=T/WV]H$A/DDP\"1\].'':Y#BY]=['*1+//#YBN[:+>.WJKN1H0H@2A=I%E'
MMCGO==IPWHB@[RED=).!8A=6Q3H_BTF=>]IV1OPDZPF_14+I:0\1S['B.IS!
M@G+I3JU5M?:!RJ,GP8L-I!?'<0 4E.PY&7ZPB[P%O:5*X9_%R?VA\',Q%75
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MSZTM-Z/[U8Y;$+5:\_!$T108N[L<6 2P+E%)0-%7[R%S\ZX!;<#EPK$=N=*
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MIIT\/D4)Q47AN(_5RJ60K,]+QD^MQL0HZ)NS968$J)*2HQS)Z2H#NE<6TXT
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M-!-U[2S/,$W_;#J/^]IX\C<EC;^(:-E_#8811Z&<I$Q(YG*SV1+6+KY)R,R
MVO3MW3,-2?Y]GR3$:4857"/'E)"E?Q5\?WZIS<\QK*@#'WE,CJ[ITRRC&2^$
MQD5&TU*R3?ZR9JKP8$(G@NGYB]%[:2R^:/?JKY+?M<(GK@%/#Q*O 5K@RR?%
M[XMYX/592Z:JP(\.#Y4():M?QVK[)WA5'/$3W.#(A.R*0Y\EZ[B31BB;@HR"
MXC\+.^*EWXZI)4_Q.1PCQH4L=<9@G*J%$@V<&@%R(Q1[K@%V">0^05,9V\8C
MVQRB.PJ3M[ +F 5F7[%;>')I83JABT&*#U?O;,"][PVDA_$2@'$I@NWE_]@5
M\-_2';#9 JEH8H(NCMYA5]B]!JAW.H+T(B? W&M\I&X79R&9%NJ[94_X^O(
MQ?QYLL9^MQ9FQ/=L7(HW1:;785I#12-2B8$S'9FG7+Q*Q^D_;R@9IR?ZE?O_
M;2N1U[A&#V)^7H26]NXT)VJDA3B0#U$S_;R@^/G%>B'2/=Z$=UH_+_BZ:?*0
M]@X!7-.NK[XT_;BP<P^14D#L[!/8EIQ:/_]YL75)FI1_/C%+NZFSMRK[\V+D
M)R7Y%3)#[?_CR*)A*'+"%X;BHX\7Z$3HC.I34VPI:X?OV2H_A^BUT]/:DK7G
M4*Z;^?B<8R,KMTYD?WQ=U\2#I'3$O&DX:U9M3MA9AZA5;T=*#CYQ^/N]Y?O/
M9\!QL3\+&P7D\\'C\R3J<H%0N:9&3 *6#H(URM$:I@#P,35X>DH/I0ZG4F1M
M/N2T_E@-N;3I!=OA9H\D!C_68-%I<YZIH91^IRRDZB/;O8>O%>]:D&S&QB14
M3Z$]5EP >HRJ)R1B?%>?7WB#6D>T?V]C_?-<1T=$0Y)+'-\@[AE(3G9$<D\]
MOY1P)A6YN6-\R0::OY(0%R+4Z:N_[QY'<>"1%5HN>#4\/EXAXT#Z/["9<LDN
MJX93D?O+6=K%T4G %+Y15%@2@</VE3M73NZ[TRUQ&8U[6C\?'SDU!M=>Q$4'
MQ)?5*NDR_<U_\52!!%*4"4^?&_)YRC@P*I\2_W+C%Q:KD!,V-T]\H!EGNHLW
M_)J]P)7_.=ZRT53J[I6939ZI=&2@;D!0U)[07S\B.R+GH$3WZ_^$IFV*.K0,
M_2Z3<]/WOET#;&'L# 0:?G1[VG-.BD-S'=7<;;!8P/TCCFHHZ68S1>&'JY_=
MSTS+4Z!FF/[RM.KMKQX&<NI]U_C<]//U(C_Y8JI*6X^C,!WX2PLV][^\(+#D
MG^W^V>Z?[?Z!=F*GRK:)"1?KX^/_763</YO]5S>K)$ZZ;U6UH=PQD/G1X-,J
MNEQ(3=J>>ND>S:\>_(>D;UK%N#E39FW(K$'X?@;+.P"('F?"-'Y#E87ZX:_T
MP[L]M_^N'/D?T*Q2L5VF8H+!8\S@Y2#.:GT+99B5R]A9H;4J5?.O5')1][][
M5D1IPKQ"@T/MLFQ1WFD%\*(C 8!>R#Y(H_\L+6K&Z&_&.RFXB=V->?Y&._9]
M&,&.TF^1R_??4O+]L]T_V_U_W^[X&H!QXQJ 9;F*"<8&S\RA9VE_F$I12H:+
M_RB5JG7Y";S]6BE%MH;J1[6G/V]_Y8^VC(:1CZX!/7K=H%-FB6M 2N'/\NGM
M6N?83IO(+HSF$^#_[IDKI9;LL9$=D]R\"3(]&H_,LO20>2QC1 =2Q=5%PAT1
M+V1X0JP^9WZ]N*&^^=%GJ7"CF1L8(QUY]J[]BZ^3S)6K4:&9!*,2S=@Q>*(G
MTE&,C(% 1N4A@8QR$MWXQIB=&%\?1F.-CJ5%RG*,Q0WRM4+YI]^I@>.R;GE[
MH0+CQ>SF4O(UC'=B"=*P#&:\!YK=RZ>(KP$\MLWR%<'<O#1BE:5!]TI2Y Y<
M(N$1$AK9,MDT_24I<:J^!#+2_^@)#?](=??_[%1%A?'B]#&V_OAM@>>W#/I"
MLLF:'PU $A-*C-L.ML!96K5U">$^T5N\GD1KE?)0M*+BHFDGYS<-SH2.GM>
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MOX? *[Z+OB-5K+K]/*R=K.%^*^:M /:[ =R .X#L$5GUT0]/"WY$(0D(4P3
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M0P8/DM%XX6^%^U2Z8\N]K/@)]3;.5R#,R;2 6+'>VK] A@Q#>=F!5GGL"$D
MD)(KF<!\PO(#SZO":P %T^;\2NEGN01WY2#<3+N^O "@/)V7)Z#E9FTR5N=5
MJBMX]3F:X?Z XEP79DLCZ"4K'/.'!;6?.G>\B]2B?&7F[/C+5/\O.B#J/R54
MZ[_7&5A\5F43]B04>/ J>O'+?*?ASTQ$&:PO;SK"6GB=@*G7 (R'U=< @6#!
M:\!-+839 U!\!SG-%_=>^_YJP1W.-5"F2G%J6QMCD)I(C*K4+*\$$URTLOD"
MVY0"_N :L":"H%)=NKK#CHO  $,+9NG39]I+8]CJX[0@X6;@$Z)Q$(3Z&M 5
M^C?/J%3([*U,<V7.CUX#/@:J70-2NE!D>#$AV<!M0J@Y]$T/M99;8JX!CP;3
M0HUP6@<9-V+^^C/IR <,EDB?1W[(6\WP27,"UU<..":.;,TK3R>O 5LL.>!E
M<93"I?@;"LJ-4925V(K79OZJP\:_HH$]7HA\B,PG3F/P#SM*>VJU1SIZ8/)K
MBD%_2X3AB$BYG_9&C*WX7],\\FNF<P3P)KQ&_^_!MKFZ^:4ZY,0X!;B_?!_'
MT:B*==!P2@MR*((<@=ZMC\(2,.09".^Z!JR@%GM;>7ZO)([Y!WFN;&J"X?>0
MR2^S3'[[+S0"10/K)&W0\"/02YY5YJ0UV<C:1$;NN/12%7@'T/U:RHO1US])
M<H:RJAO45(_J&&J]P%BGI&08$7:O!:F[* %_Q2M3,D6DA)Q<35,,N?Z!NJ<3
MN:?['?05^=VM+>F@YSD5SNQT7&(5?W]85"]?.5#^_SO(_P^NC2]N"@4[,133
M21Z9SDPQ>:U/+1/CS>Y-ZT2VDE=^^_6GUMW$K@',H9<8@E=F-F4?*?>ILW6_
MT_15_CU&%+HGO+[__P]/_SD5_\FV_VMLJVL&".3L<I^/%S-99 ;TWKU'-3 7
M6\=$DRTK4@(KPFP<:WO$/.(&LL3J+EL5>B 1QEISRN.PK>XTTQ5%3YW_;0F7
MD&NWC-,X+0 2*DK_6F,B?83-+/Z<^;W9T7,D#0\MXAKP?C+8>;C#W(JA0U5?
M/\H3(X,LR._UC0OL:BLG8!-Y#$HS&2FZA7]8-9BT?ZVR'K"(W,'F>GDN6V89
MEAS[F6B3;P% EIO\*T87IYU:[SFK#_\_Q>H_=X86:T,LXI_%KN3;)28,L[#V
MUI9[+R8D32-L7*>BX9R"R'GH+1;1V"J_L_+-5)D1,+[7R7"F:["S2M!JH21?
MP7Y;9_V@+X&,ILHT</,:\ "6_ S+G>XER/ER^Y/(8XHHT1.&X16-D[_:@]=$
M+]HY,E.M[-P]N*G4EXL$DM*>+'MD3#G<#.65-"KC*F7][EOO__>'P]5CB"P4
M]#]P0/XQD4%I=M&?JSAQ."/:>N=[#^5QP<X6#PGJ.Q9.WD09ZG."ES/'WW*V
MFOU;+HQ&LTP3GJY/M@=^28SD?=UR\6'6TG<_>B5YX NQ ^L#/)8> 'XW.@W1
M^I2($/#8_MG/W.YT<OD(3-H<)L:5DK*X@Y6J3DQ"VSU0X3LE!R%24$CEUV@D
MO;8@@[?_@MA*EB7LG8B;^]I^I_,UX*\[DFT68[.@R1-IS39@%.L0IA"?EH0N
MU+WA;L;8%(C[ACDK4B1*,?U+O/ ?]1Y87>ZGQ_<_4F+^N;.FJ'QE3_5387%_
M[L+"?#]9A::*\S-=Y<BPVF'*W&[)!%OU!_FO;RO\J/%.3#75X*0GK($N4%W>
M<ES:I/NZ=O?<BL]3Z2&W=:9DK^E0$(_ZIF,9!RU*%@^_I6?M>!0[:B<>7]$:
MI?1!?"$!DH*#B!LK?@F/S*_7:M?!(HM.=TO0QR E:[SP[:507;HG/CLNPYK/
M)\IA?5A@RO'!? ]&7[,FU:!;HTU65V[EW#N$F_6\^9]R^$^U%/*!R.H"*?+$
MJW17T"RI,&7$RHP830U-MLN9.(F,GHZE*94SS]<)SMI^#G0Y34M(N^B#1773
M45KZNRQOI8PH(\>^K16[P#"AY9C^PS/=!N>)<.4F3:-QU PX'DHI?@R-^3R[
MV?&@WX!+N&JPXJ7PM$$W8TN(L%3?7=X;L&)1*&,!FSN.F2_E,'B!'Z-+WP+]
M>^\%FB:A+5,\$[:*O#:KO<7Z_V+OO<.BW)9\X1<14$10 26W"D@&R9D&!4F2
MA2:C! $1D)R3"@@2) B2<PX-DC.2<PZ2H<F9)C;0='_-WC/?/;//WGO.W+ES
MSLR]YX_U//0"5K]OK:I?5:U5(2F'#B4 56)/<USI$U&7IR?1_?>I5&=M2MA^
M[[\SV?\[<.MX-E*D./$FKOQ4C(F+=0:W^V[E[8N=.B5!426:K\O5=R,>5>1/
M:4I_H;-.\-]+7@Y=/H/5'3.&7U,EBV0U2U&7?BEPI7:ZS29(7:"@KY95Q[W'
M Z/-):9)6Y%/1CW[7Q'&QJ !&3'C"^< )5H1!P%JCYKQUS) N#AV#N]"/>,X
MI>;H3B;>DNG^8C/VITADLM'(\J>C]@S'>7,WN>BU$'?)TU=6RV"$C$/A9-E^
M2%<%0;(;0 C\%N5W,&07V?D?1??_2I3(NF37@E "L]["S;%C8Q"#F'&+H\3X
MP;R'3$ZD>1N[ LN#K$=;,1L@HL.)MR*<Q%T["IT'7^6IF!._X66ZHGA'AIC_
MU[FY]FEUA%U<Q(;K0"BK*CYCI@*/XYZL2-\=QI&:XC6 _%%RVB<X*HW<[.WU
M1RP.Y^I=QU:#*?-'5K/QXPD5GX[:#-LU&SH%80N-2)\<WFV%,I;U0B(B.X;X
M1<'&MMMNA_K.J&-A#2F/NS3O?7EB17++J-(G_UV__")>F/S@__YM_,^BCL[0
MTBA2*F_BIWSVG%RFB7MI(4I?J')IWB?1 K^.?R'$?_D'7QD7<N@U(_?%@.=K
M9!L8>U/3D!Z?9SI\/"6#GJGWV6I*KJ]RF@ V57Q2S]"@E/OZAB\M5VK4:_QD
MX_!W0$:A3GMLZ(0]1W'ZK&Y%OA$=0=@M\B\7?'#$Z/"'^!&(JBF[9KG+<0U4
M3RQ%]**LM[>V(K2*P):+U-<V6P ;RK!'^O6WYWD)(RLKRRN3))RG+^R5!;#W
MR$AO>M Q24FQT#S/G*K[\WUDKHL7OO'_[&8+"5]8:$:)"I;=F HM%4H.E)V)
MC(>')<YXX7<7'BPD!EHYD)=I*9-9MG7L<\<0V1R"SF[EYPFH?D@H9X^-7$JS
M&\[?[LV(Y-OFB> Q(^FFO6M*FT-WPBM* NGC]U#29$S]CI3.I08]J:Y5%1G5
M*[["'2W" =*V^1RAHB<Y*;=UX$6Y.<Z%\)T<6UC0X;*$&=,]MOK.5;3FRG2,
MM(C_K5S*P5['BLOV#08MQ9\P,"3*,L"S\]:9!H->IEF&/G*@C/AW<3P/LXM*
M_RW(_O?7,)?@?@CUOPMAR=3=<(I0W)^5_4+W6A ;4;6A!$TF79[43^ KR-7Y
M*8'Z;HI/*+:VX^EMC"+=/7;\\E/KJ;E5C:'OE?O'H+':K2:;CR0/RTPU[K*K
MKGA<7TL-A/?M74ITZL\UW &9NSI#AM3.STVF0AIM$.-J^AR+"4;G\BV0*^1D
M/^Y<) C.^PH:#:=8H8&M<7W\Z-+<&K;GG,1+_CG!-%6YC>]9/.2.R2 ?@]FI
MF$/%N15_Q_V>[1,-Y?]_5EK_'S5,_DFV?Y+MGV3[)]G^2;;_\V3K5]F+1G[=
M_=1P0H &AAPOD[Q^.Q$E^G^B<_;?E*NWHF.-0(V!MY@<T$":=OZHQ;_Y.#ZX
M /Y W E%/B-1D;*/^0^%:KN%?N!1VE(B;*9,T8E! QY\SZX9"A@TOO2PTS>9
M]Z!V\+K3^#W9PLUK3H90L%WBPX@I^7&OFZ6+X%?+'*B&TRNF73[,=[HPF$%N
MP#FT^6*-M5^P2E88\'QT#*))"D!)C]5$F4BQ]I"*=]+-8^G?A%D:G-L95-6I
M?/K\]I,1Z/Z\)P-T4>\GOLB12V+':DM_U%V]YX&,J76+/?_12)S'R+^XE2[Z
MRP_%_G#Z?9[HIO>!C 5!?Q14^)\=A&F-KHRC2,EPN>2I24-3/$2(I\KIP2%N
M7695TA6S5=F]:05FR\KJB\,/B5CG:9M!$ 4#T:"";>::MZ6BST7%9%Q]251T
M_99^&V5:BZ=>'Z$ZDE4;R>@2W_'DD'P;04#45,<!4RQELT>45DZ=5(!J(['1
M .N/>0=JI;6;+K)TX;)TB>GC9=&JRQ^RSQ(]F9VBF=?H253TPSI^/SY/&T4^
M&%(#G=*Z-:OHU"-M3.T9LYZDRFQ"3U8E^F7(<H(F8>]$!M6[!YN6I9G8)8IM
M.9I TNYW(BWRT]5?*.>FO"  < &2LH/+;N5V'DJ&MU4" S$[DIP6BO O"!:6
MO*M2_ZA6F!+OJC32($FI93P4\G11P:0LZ7;?AE(8UKXAW@"-$LS6\]MAH6O]
M9SSI"579G7[FVM,5S%85IMWZ(ZF OD0XI"8(2YP;=UP]\7?N6))&THI=>-W6
MMUQ(H,7P6/EWHT^?K2-70?>74 Q9B_K[N=DIZD^RR0 "@*6[)T^+V2)GXF.6
M4U]K:B!+NW!39>BGV'Q.K:>9G/TQYZ?1CF#'+-_%\UZ?[?=ND+=_D2K5)**0
M2ZVC55E#T"9HP/DAA);JD;114+Q;X';CT&J.TW=!^.6%6<P=87E:F576EF*!
M]D=Q4J2[-"]5I$@:_ZS^T@82*Q4-O$'XOOZ*K:--Q+F/A=/PT0Z1U#A> @'/
M]Y*8)5+[\2NS,UP<MD^'X,T_%JLZ*GQ?[T2N,SEJ^394PU=,QN62A3);W38K
MMUC9V9?O2Q.\766@QI/;HWYR;+%9Q5#Y(V8F\6D_JZ*2_K=YH\DZ2IA5T<#D
MU+H*'T%#?718UP=?,C3@EIC4? 1EAUJPIW43.HT<P-5JJR#BO[2R_U,12"+@
MTE6BNI7B8OSR4UH.W3R^B>/<3?O0<@O5-W?8C4H,HEE^.%XE:B%(O*C+8QXE
M%1"L]VVBVE<197DR9#3(8V%Q;>^YQ4$1BD&D^/)N62.8!-+3I:A0[KK^2UA3
MYN]'X%[GV_*I82GI]:2W8''(:<]LD9"7B!;[_GC)$QL4<%Q(F%5;&;ZQH[5L
M.233&K\J:&CKEK3/C'_VAF=4Z WC/K-2HN)EEE+Z'^.C>AV'8IS&*-O6?32@
MQ>V+![)W HMS>>$KI!>V?9T)6P<3'!J4F!^\*7E$7WE*2W=+T@BZXO6E\#CY
MMZ'(HNZ]KH4%TMSC680RV;Z7&<UV8H)CA-$+)R&/3&*W3ID;30W##OCGN4_'
M/PM;V8K?=R3OPWNEIQ3JT+"MYREC]'+LN*$Z%.]^$LRZ9=YFPB(2FOQ#Y=C^
MZXEI]*><?O#E!A7](7NQC*$HUD%&@\8C=+JRSG/LD*L/P_'F%96L9D=7_N!$
M^K<I.BNO>0M(%1R$'T?NG/X\8TRM-:IE"47X9J<+":W#GD&JA--9)NF74*9F
MU%R*+$70FW#'0@</UQ7[=P.KW;[^3RG"<077%)66];Y1Z \5G),9,G3?<.)D
MB-EA<$FG*XE/E$4*9J^EUAU<HOZW]W_"9S>$/"*KHU)PXFFYGB_@*6T:B$_\
M)AS^ .HG], E:\Q$K8R;@'Q':1;LW8A4RG U<78)MC+?9XM><170=@SEWKA4
M6ZO*D"#$G(;E4^VJEQ,!1!,+P!*I6A3XL]-JRFK@8</=C7;IO>V>M7.&+R[*
M2=)6_GOD8%]GX^_D9,9(#.X9D6%/'9U%Z&?J/=L>,:5A]S(VP<#LC\8_RS 0
M$IC44N4A=WJ9*RH+]1PH_7:H0#'9)$),@=P"!_2S>H&'25<,"'E>-XPKG+^_
M_YW2!W60"" %P=$%KD?.$U\M.M7T")%TK%67W0Q7J'TN&REJFI>1'9:"JRN4
M=[@$P_S):;K10(H'RQ OY=KAC!#L^.V6[XTOPHMESCC;6^,GMM-]4^E?NZM.
M&)+VSK#T0_2D8ZVLC6UA66;[)RR#4J3;B>_^.(]5R=2<]V*++VJS6BO^(9'=
M!1._B2/WH!B9V8+J*N2KV.N+'H80/#@(*G%Z-IZFKL#5Q,;QO+S8G_Z^N'=B
M^@DXH#//X4 SL'XL+6Q3U9_NQ9/+Y @" ]*-N9\HFJI*R'7A4&8JC W2T&B,
M(EU@(!=8GPJ"6,)9-,\URFB2B)/8!Q61-#>*5O?)0$EU-J2[+YEL56MF$E\_
M<A^N>(D1@<K5?W1X\G]VB$K_#='-]<^/_ZO,F-\.HAA+EYI175MHCAY7Q6L:
M"UO1-[WJ16@@U!0-0..2+D#TVM"T)B]<A@@#1! &:]:Y_O:W+;"^N<Z@,[[]
M-O2LW'(H?G&)*JDE1"PS4U7E<\0:3YRC=!92;- O>F&Y,DRFLD[,:.FE+\C>
M4PN\Q[S)1*I.PIRMC@U@>>.PN;=JAZ1/SZG]_/C",/67Y*'E6C>,'V&,<%D(
M[JBJZ5&9G_=%/4)6GH7I<^A)A_)^'45*/Y24>#_@PB@-O^5I= H_O%+E>D9%
M"C*5-7#*688Q_(JH^7^JL']O-,,9D$W@+7JBHX*NO_RY#=02W3%D<)F%6\[]
M7\([<WN.@;S]MY\2!-ZL-:C_1K-Q;1%.1Y1I<:7NP\)8P$5"BD>Y\16W:8%+
M.PF<9- "86>O^)X^.1.G["\R)$S!F%IO?_3DWZ0I,2U>F-@W$(I<:]'5]UP'
M!!YX?4+I>C7ZZ@D(12CKR<9'&B[U/X9?]DZ'3L_Z?/JV_8L];SI]A+1X&,BR
MODA*EEWH'S)E=9E^DO*[ZM6UOUGAOK;9_H8JPZ[5U#5%HIWQX6$&\!<HS^#A
M^.B1F\ZU3ESS*R58"7G3*.Q'=:AKM&45@;,DUTED;I,X*C_&<8D)MM+,O;3C
M?.>XUV2E2"!!3KYV*.XQOX"%B?1G5V!>TTVB'4LH;(;-4.TUE@XQ6@MIY7&<
MCV_=/W-$HH&R!^?M>_.>>&/519%U!2\2.]IJ3^]/M&$P\% Z\H\Q7)OB4=19
M7[&E89QW6*.CRN7#J7.%!]900!RETY \@['#<M%JD;?I)Z;(1,.4#%I6][#'
M:G*-?Y/LQW1TH)XK5(*QE_7C21ZF8I8VUNIR1@,:>L+-T+=4UZ%VM\A77XO9
MC3@NPDD7G[=^BT #&X5Q[:X5QUD!CSAEVJ[A?8G?>^=I*%IANG\&X31X^B%C
M:YUEYTBD5O)T!;.<P[<_=?OL]:\/]A7#9$@C'&I!]9'[ M1XU)WMF^NZVVY@
M;QZ#+2AA^G[VO7O?8NJ>+"Z!HL%[M+K?NF:[(LIWG[J2G*XXO%"1<H=OX/#.
M& 4G=. GARN]4BP$P]B+)IW\4=VW6RKRC?I<KHF=K#8B+>1>S,AFLZ?WR7':
MFG[;/"N-[2MQ<%YEH?-_2=XHT13:?1K;DQIX9M8J11=*73YSJ=B>_!FKDUR1
M 8P3O2&_1,W<^&W4S#<D># D"T97^<[],^OS]HM\9-H!.9)E(J^])T\OUV+%
M:>%!6AQFF=J2(I8^3X;-!T85@["76@T>_$6HV\C^Y4U]_]]6[]B[::%J::!5
MT_ 2TO?E>X[@ U>L4RR]4P]VU_A^8SO#K&Y"]9$4#/-5N_Q9<V$L_:][#3)8
M[ XNRCO@JH])BOE>7Y";?=N6&74U?F,X,ZQ]MW%MPA5Q/+ RUO?6A?3J/H(V
M%L23%W=I5C<4E1;U/5_I1"4]G$G0U-37[4^Q"F2$$AP^^2ZBD(<&7JW=X\_E
M9M0+(S!=%2%J=$"RZ->FP?1+V8\$2BLUR0H\S:_M/J &8YU%K.N1:8N-Y88J
M9JIG=>+VT3SCH.6D"[>5W?#HK^,+9%GKI\,(Z\O?YWN-PSHA2YT7%44?+HS[
M2*@\!J<O@$XD$U_XKYSOSCF(C&,Z,L>Z*6;X^:+11514&OKF$/]]WQ#E#49+
MMO&WRLF2-,UG(T<'O!O5953]^O&"_\+V?<Y3ZJCNO>D%T-L3<%4H7EC8 :CQ
M=:W"E)MIDD22Q%!U_R?7AF/_3[.3@M@29O7*9/-@"-+.!PU@%3ZK_X C/3&D
M@&'['LG3K#7,>HY4"W^V"VK:4_(N3J2E^-I:FLS>UY<NF"EV4!1F7A8CZ:.9
MNJT6^U*)?D_ R>#L_+P7+W*JOJ\W)\HQ9)@+N;MJ1%@8W<)Z%<34;C>-8F"
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M0Z3!+5H<Q80MB9IBO=\+ORR2N3LK2% 2T7$ZLDA^H_V=%T"4PEC(TC)97KS
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M3%D/R8D70K'N!*[W6#W[U9+>8QTF/56 ))/87[[EV+_"*..3B #?O;%]T(O
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M@5$C('WY+,.E#S#]3S+U_^ ?_(-_\ _^P3_X!__@'_P?#A+"Y/\%4$L#!!0
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ME*^6U[?*Q9P-8X;^3(:S$_X\TV_WP0&MB),4R);#!3&<X"(8^'L/^G\#.G'
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M@)O]H3C S 4'K)&;<9H=9DRU@X/=82)>CN5A+%$8<M.3M!9:7M"W'CK]W:,
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M6IDQNY'P>;+$ RA7B:[67Z*O":@03"WD*PXX,EK>S/]MXRB2%@=$R8#._'"
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M>E2KZC&3SXWM&C$=O([["& Q\92AZ2DZ_0B.8C8XNYDNM\:2]^#LJL_I3G_
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MZR9[\A;!]FX5^5G[IFYYF6QUYJ^BV1SLD.K:[)R22UZ+,T61??LBQW)",F7
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MBEW6/*__*Y=M_I:@^C?G!\_ 7S7+\!MQ .9M2?-F& Y@-^'SVG]8+L_Q2-E
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M RA,-ZJJHHSF#!\..[^YUV2?OW2/U9N%[<<!7*F$>*$9RN=N3CJ]WFIQ=/Y
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MCUY.^V^>L2AG3.QNB/DQ+0X8\H#+_<F.__-P 4$?EA?RG1T[!=F*71E=!S.
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M5S"%>6B+;/4L;\H.\D(?OIULNUN)$G2%^$\6K^_):E7^T%8X^.*Z^1*>)AV
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MK>@3HH'HJ/F4XPDT<#_M1;-.6@*^IA>OI;G]O5YXRDTZAZ10GIV*E&S+0?:
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M([N8HVWEVG&!U=LWL=W^;^EU9?]5:)<\7.:\ 0VL1F&&)9D9#43'ST:<0='
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M8;3KXG2(6+;$(..AN<#K W?)W[;:I2!(<+,9J!%^\V92RQE%]+?ENL<SBJW
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MAA2E]FP5985/S!/%(C#L-<C30:]OU^<M"V[W&Z/ _;!Y]MQ,-8(T52#5$&M
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MM1V_N;G&B52U,V5Z:^.*_UXS+04J"V\)JKCE96GDL:SGTF1O,[(SXPKD!C#
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MB$EXZVC*N4<A#=BS2<>7(0N.(.27_4R]U8'/*0,#QUMO!QOEE:PE_16UQS$
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M6=1]=G/-*:+7GJXPCX6=':5G+HC0D\]_7R4)<C.<![E3'+MQUZIWI5\B6<,
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MZ;:)]X?N@5Y[%)K<)7 LP#X\'73+6!$EZM\@3]B 6A>5DT:_G<BQEBA(?EM
M\! G+.S[X*"BTDLQY>&]ZEM4/,J#K+G$>[OZ>!HK_$D-94?"' ZBM 8:<5F
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M6.ZQ&B&P_N*PV;Z.TDE*13%_C6V<78HM7."J7\:3>)C3!%MZ"+D#AV&/&5?
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M-*&/):3?'-NJ;^[ID!B[W<<Y85;R68R\\-Q $U*GACW>7\*DF=C<<D,].26
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M64#@>;7_K>1K&W>'%;/Z8N@-9,R<6TV%7:P4ZZA_0,?C)N-49)K0%<H,^'K
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MM8=]5%&VTX0UM++S=[/C!!(>)2>RM-'ZLM[Z%G^9/M66$K6WJHC2[Z4?%GQ
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M_:\ P:-_-U*>T!C]O<P_EL;1AH=LVI?1.3HJG8;IVH;8^:_2M ]6J)\Z=HT
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M73<U^<SL_PUF:_\E_Y)_R?\":4&_)^9TO ^F_G:/T8Z<>/1AY/4/@'=1T@^
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MHZML &S<Y4S[<;[J'&2:*4E$AI6E8W7<1 U)_MD"57=YC>YL,"WA9G0UF")
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M8]T.4O)/<W?,"#6\C<.V+!O\TBWT$]W(05F+N1$NVM;WD^MW#*<O=.^?S9U
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M#J&RE]RTA!LCH%V^@[T1]3_9+#D?KV[645X; Q"@79V'%5=M26R$CSM-W4[
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MQE!N.<7_N+67=+(A]5?C5AL18B4I#SRFA7A5[>C.<6W>DE ?I6=L,7C[FR>
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M5X:@(I%!<7?Q.2A$%.F:C1Q^FZ$ZS>V8N,65\K)2/@"M5I[5)4YA< <%K'@
MA%#!,_[>SSP 3B[\40ZI=3U]M_,GYC-N7MG@O/:J."'U\BA>PHY+#,M80]!I
M^+/#%I]U6S$A'8YL_-BF.NFG2<_>C8E;IBQ(H;=P/<-2G0DT#4S.WGP K#;M
MM?"MW3%T:&J=+8!<)A0QJ@==AGHUT.[WHS$5\O*^62S8;4B^\._]A&#M7B$%
MP9Z!,MPHH@E^=^Q$$X$? #[MBOOW3. .I'1WJ)Y)^P(%Y]8BIGZ ?U@[VDVL
M?D77C#\1LKU'D@<FB,,,DVEPCLM<VY L#L2BB[) WD]*D4!,)B_$_A@"02Q,
MRU1HC4L]D4&\8(:  GL[X)[?CM(:"'^WB0.G9/\F)'WN.Y<K\]2P2[DIAVM@
M_-STY:A7KZ?4HJC1'4;IHUEN'@!13O_UN/_$?W,A *N%@/MX)W+N+E7,ZB8T
M@Y_;OW6#VV&M2BVHD2DM>&K?=N$E\3-5Q<Y<;"&B<=CE3HI_)Q179V71L-^S
M"+0E.E3"//$#0AL)1V/:M6V:J:6LB:(_5\N@-RCE?(VQ(4S5/WV!LO*-64]?
MM/RI_X@E]! +S[1VJL=S<'O!?Z=@=Z@^M0NCOE:'ENZUT72@M6[2]_*S.=WT
MX2_S+D.YF\''AW\> !ZMDC^:,3P:- R45.LG:X;3WQ]=Z2W*3LK[K.$B]GV?
MZE:((R=\.3,"(M6JU#S=:;D#9YS&H"-/GQM$-0-_TE-/E+>QVDX^QB:T]E^,
M,7D)L5) @#>#JO#@/=,ACV$GJ5HWL0PQAW-VR >U@$PW@ ?9M[6?QL$="]1Z
M "9!-2&Z/S_(I?3C]:8%V4J8Q/0GRL3?92];>Y;\M'S?V,_F\^8:*U8GD=HB
M^?2ZB^+]GVT?I0]Q\,BS)[^=TRP!N&NX:-.S#X %XUNM/Q#D_43U[[/ZJ%N^
MJ/F#2$3*>7OD3?4B6'=1/M@YXU/:JPF4?"ZQU$EV1G*6;:88IXHM7.ZK*0+O
M:"[\,I>"H=V1A9F*X+58\JCW&HQO53+A:"85?L?"STTP;^U\U%O#'JF5(RAI
MBDS+Z*LI=#A\60JE1J:3BA;T$N#NC=O?JO&$F:G%%9L-C(UC"E]?EZ^NLT9
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M:&-#P70\#65"M6&:VW;G]FS^7>:(T6/4_5F_W%/58Q:71U=WVVC)(#W7+HV
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MTJ*.?;FCW:L@#39$RX T^C11"MP?+@NVO/>O];^]8W@ T.0^;B0ZN%.G?XV
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MR9/OR[< XXG-_L'?,R(P4HSBSZ'VQ74;?P"'6:XAZ3+%R2&XANK$?AHC4<#
MUZWJS>R0^R9Q-"5K#\1)^B,70^6ZS#JYL X:(-T+<Q6^%F1*)XG >2+A9X6)
MX3?NE2F;/E6]E".&.OH.J#4TB-X"N&U]PAZ] T& 2$..[FQ)[8EZ/C*CWQ7U
M4FF]5;]350:!2S]K;_:Y#@9FQF5H>\%U$WL%M=6-\<O+3%0LSP/E^BYS[ 8[
M.+[=<*,W8M;HV$&M6MRCUSV+R6Y;,;F8AURS%1S1,_,&48NL&H^]S*\X\52N
MRH8"'I9A$OIO'J-CT55ZK$<\O;&I0"#-Z5M\\3UKHQZC!.4?)PQ2O2T6^@&?
M'*M?A*1<J</:X,U_78/",!&5MI(Y]7:K#O? O >H]P>.BM^_CRTB@^+5I4R\
M1+93D2!B"R.E]?0HIXK@ZTKR#]H[@4-87;M=78C.=J(FU0(94$\.Z<05R^?B
M^@^<L[@P?_<AZ4%P\YX,==[%KYS@Z/"#'2(ZE8J#8MV\,*)!%GI<C:FI]&ID
M@'"5&@?2..*@;HILV)>;_%59UWM!2O/]U%WXEQV[*DQC.<P"2KY!Z5^[4M7P
M6I1D<AB]Z( #ZPISRWF@=^6%YMSM/^K;_:Q+RCZBG M=#91,2DJ&,Q!0'C[Z
MCP%HWY>HP^7ZR:Z<-3 VJY,I7/IKWBT@R'-79PI1V*CEM98>5.XG4;"P(\9?
MMC.K$<4PYT98]5T!(1^"Z/ U:_V_AUXL32H%,%'K]U6U9O;;[J^=+7AY A?8
MM6\!VJ%6-G FA_,$/Q/B3:KM:60G<07U.TSVNK\B\KZK?.21[([WQZ[-*D*Y
MRM+6:*,$>51)J#L"?SO&SIR\;@28ZSHD-N*/,-V2)*U062DH:&X.'IHQ^)2A
M^8A9\Y E"Q?["WN2 2,0[20?ZR=?%Z+^SB!.\\GP0"%6D14G*6,1:1\%Y/#S
MG'SQMF>+?U.?Z#BWRHE&-'J%P#"7\<JT>7;$OD%;("W(@!X@RB2[R7T#;_>U
MO(O,)-^X1F]8,077COO2C]?^F);9/CIFU8:GTWP?\*4(5MD#-K%,<,';'CMG
MEL"='BP:,4PL%(UWYPA4S\A*W!S !&UXD>GF+2BK8/=#H$T9)7[-<LO-S7[Z
MAMN6#'5\[DR+S].:_V8.JVRCN^'8AENXA!D 48AE,_PR4%;^R"E5$? >R8K$
M+MTV=(JI9Y"'YPC($DQP\-O,P#T+G=M"8BWH/0B=FPZ6H#25;YK;E$^:G?(M
MTT1"1V)+G$VHF8(E0R!&*.'B_H96_Z<KOB(]WA4^B<_EOO#<^&@>J"[#_[\D
M0;8]*"A2FL?)#9U11\1&9.?F1I_\,@M',V@1(&GBR+*+F1WGS*?D#*0D!@ !
M.O%7'/%.9)A>([3'O /W:Q=>5\KF,>#E5\H D>T KAF\H#4CU;=CC/@J"8$!
M;D<EQG\BOZ:;/2ZP/Y9YDO#HRKVU@U7%LN@>RWF-+#C5&;;"C6P\_?/J.#?$
MA_J/5^BGMXDI+E\Z/_Z4ZRH*N[&'D1DUM/NR9Z\MJ5^P1/&4LV6H"P67*B-1
M^8>F<+L<XTK#%3\U=%$.[>0![7T@6*(M U_6#GMV)8?2]^$?QN(BZS^T#[,9
MPC_9I_W9DMV)UT72<#2+[]@A9/&42*^86\*Z-C94UVNJI1/)7MT"MM00S94:
M!4;!,GV6),6Z]XI,@L69.SPC>F;.Y&@MQGD^^ =+34H-B+]3H!M"+V"49MH7
M^O1/<\/K5.,T3R/2R:^^-&&S>&H<P/K^5(ICQ*Q$BV$5F H4A<CB )NC0+)7
MYX[60@B&2,%%53MIRN]M6UL-QK]4)@V%J)%@D"RR[Q*X4@+%6?BQSTJ+@4+W
M3R[M/O*<XB[.:@R]D.H(^ ->?L1$.M3.^#+:/9G@':NBH;0]%JZZ(OZ)]&SV
M;BZ>M,07H6&3X^T4 0XR!O2=\*^!)3*]R:S_*'SH[N7S.=6\7%<FOM"Q\>'8
MT"@=.1;G<P:9KIMW(N7%[7$U!OH&_4[WB%DUF!0@5UA=E8P8EU([?=*$@S8Z
M#S\G[CP]JN<2;SFQ<-V&8EWJ7%(PL^4[\['ZB@G>I8@$WIF''X)=LHB1.SX!
MPID-(>H7.:9N_T&:K1\;_R7-0E1WI-GW[)A&:1Q&>]IR3!HBZ5Y>; MA;ATV
MLO7BB3 =YDQ))FVMM;J>/[E@FV.I1W!B1GUE=JR7J:NQ#BH/L#]L0:7>4$SB
M5-^1);L&5'IHW2V P(9L7E_QLRM6SFI"CO8AHB1O_W2P KLWN3).5FAE]YG0
MG(W N?-#&IK?U-O)%BZ0=K6M;T]V#KSA?944.T0>5FM\I-4WTU/*Y,K?L.*%
MDA+^J.SF=/G^<F<D1JEGK^Z+F 4]-)@U7EFJN1KS!Q:@)R]FB=:(0J=EI:#A
MZUL':4OL\<3HN/AJ-.+,[3P%TBL_^2R^8@W"@M;OX2*-],'+-RN0&@Y7= ZA
M<4]T<)08_$YS"[#0:5#];]4P;[SX2C1H/<5NC=6(3HFS2@ ^MJ-BZ*^N>T%,
MLAYY1K";O\4H/M.Y!D(YE@14-IB2Q9/3 4><4I4O*')[VF;7='IC[(9UKQ3*
M7]0,P$73$,%%I$C3E:Q TL_^G$[Q\^,$GZU=JNEJO?C__+X325;77+/"6P[[
M)\/*#B0.A6'DS')-E+C7 HK?Q=+S3?^SI_*[@\7&,S,WR,.X7H%.I+YU\<5A
MM](;9::+G)SS?H]W&[E4;2\M:A-Z)"$_3]54QEGC!%_;)"JZ_,@B::_QO\_6
M]+O::K5O8AAU3?["L]^-4RGW +4RFMET+:64L*[3;Z3SI@7WQ/>I:';SO7?&
MJ92,A9X3\ 49(;C+UV%0;VZ8L57\"T>FQDOIUQ%T)7Z_(_*(]3I"9OZ]]3UM
M[*E6:>&)ZJ5J>TI,=@?BGH(G[S2V -L02_20KMP:954C)^V&Z@\S!A19(]EY
M*;RI\DTEZRQLO0*S\'E;_BQ-7Y+@,\C;BUCB^_;@T8]K.4*-OP-XXW506-45
MA^G]W=#+^[$V0AY$-?R/T"<BFYW_/I1O?V4T.ZN(>CL3.<+K0?''?=XE=.?7
MI?GOOYXTC6%UO6O@B(8?WB:&SZTGA[XUL;\@2@P(1:(*\UHNZ+UB*D]!C-#!
M-JJBQ>M<]0:Z>H*>'&7ID!VL+NQ6CRV!K?E_'<L_Y@M2I?RQVQC_[I!1M[=Z
M8+_$Y4K0[11>[XM+?@?,EC#7>=+ NEQ2Z)T.UJ\3)(JI654DF4,J,J42RL Q
M)%Q%32V-=;$J;M)O\DV"BISSJL6Q.9JEW]:SZ>'^>VVO9*#=>@[ZBD%4E%GM
MA;U8FTVXTY6OU:X:5]4=\:9#K72MH#[:4LLRS[KQY&:-/,C%8#YD-7B/8<E%
MR0ZT[SPR:PQ[',P:S?KHK<+?)C<#5RZ*6!0%!<JKFG\<+9"X!?B'&]\"&'F,
M&,B]S*)KA$Y'>2?UQAWW^,SBE=EB0S:<*9'A"'M&-X@-BM'&0&F&B?7\J7-\
M8<.&)NE6F1%''^*A0A[4TX#.2V?: X>_&W_0I/PHO>MDD[%D%N\S2CNV P\%
MO'#IBTSP]6K$J"\F83B#3BDO"*Z4Z-:3[L)+PH _G[SQLMYVGC#2A0M^""IY
M'1=U>BV9&]4AE-)S\5([[?XM@,+NJ@B8L/2$A=?_O.MLLX&+;O5W5B/< *VV
MBH=\T_RDI(EF<6X_6)<4<]\4^G6 E-K/V8A(JRF-3GE-]TW?,Z=3B",64VR:
M^10(_,K?8>Y3JW'S'!34&P!"C7Z%&*W,+>XF!\]2.[E6R#/FJTA[2,B )4XJ
MAB^M5&\!>:FYUW>T'EV!?4-I%0[;O-2Y!72.WP+0+7+_9=!Q[^)#10O]9G]Q
ME=-##$QSDJ,Q[4A[@2]Y-:N0MV=.)L!,Z 91[[E"X6?%$7826<Y-=\,^>ZY,
M"FIYHVAX>1QTB+!_Y\^R>@L(/RG71&@UMDZ]3UY6R!1@K?[ 2A_L'#)W6J'4
MK\T/;44&;^EG]U7-*Q'VA#-CP[X>.Q/@6-0RYEWX:(U'+1F/[$F3KG628MY/
M\_$>[CEZ##ZWBVELUGF<\*8H1S(KIR3K0L?RNK;X%O#C%>+F%E")F<7Z7R\#
MG/#T5_S?_YL/:1_X$0@?XR=3I3-5,==O&P$$TG=(!<'7%=[;@(!78L6V:3[9
M[<N%PFE'W.-1;+'Y3+\H0AGAY6XW DT&MX!X1E!52W=#@P#5"_%E%?O33=8G
M5Y(^[8_J=?S'4KIDL=1H!<KMY/=]KF</(2H=YEC2B00WO-Y.72ZS'?]/2[02
M&9]MO\Q0/>U,?D17'&8!N#<T!*?9[39,@,\T!E!:%RJA&#[5!(F@Q=3]/QW<
M I#Y,"%#I3X'(VD;I -7CX_;83!=8,I0+#[OW%+"&26H+RF>:WX]BBF,.>[%
M0#356T_LP*?M5%'Z@]4G&F]/'11Y6)3:IJS@Z79$KYZ+C^&YG,K(T28C^.\4
M3W0CLNY!)<(J7Y$F&GU<(G-Y'ENXU1GGL^0=\>]BS<=?PI-=RA"]$DLMM!O
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M10-C^?!*RASOT_LV*I%J2@&4.0(!&@LB6W6:G:9'9RQ-P5QE-@Z;S]"OPAC
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MB:+FEJ'J&P?7;]FW?HX721.GSJF#C_??^>F1)OAIK0TZGLK(VAF\&6JX,/K
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M9K2?08+1C!_8RLXJ;T?,D]8G?(FAK,VUU?03#HGBO80*V]DK;J?(W!/6X5M
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M()EN+6'FG'+$#&EB=GI::'0RNS3%)8/6O_\<])"Y"=I@*':C XJ2!_6)3C3
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M[#+Y6GCL/8#HZ#A]"XP<1[BY1A>710[)M)UIV/6G'YB##(P]SHUBE+$O:9\
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MQFF_ ;:'RQ#9Y4QFZJ?!)<91Z6"*?L&W5PP\DY:I^V66;LWP/F:.E?ZZ/%F
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MSIPGF 0Q2;<VBYVNI,0E/.,14$B^TZO?!Y]IAM*,%;"]H'Z.ZPM+;1VO#6;
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MA$SZT\CVN+BJ:J3+P8?ZE,9QF"\%:%"V^RU$TI[?W#OJ#09NLG#U+UET3I^
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M\.#X;V?\ D/5^B!G/3@EC"^8\L><N<Z8&+6T*O#KR@@ Y0Z[(/?@7555>_@
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M2<+@M/1(R;<4,WX ]M9"W#V')%RT'\M_(.DM8[0R5G]BVSC!XXW$$/3&]0F
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MJV/<[>>"W%)P[F"M'X%%L00,/[(U.>.4SPGY +'\!(@-K2J[/6,1Z=VY<OK
M"^>NPUFP"E+<8[2AKJB:R&U<QQI?)ZQJ4,2JK>-,'@ZQT<391%5(NW%01)Y%
MTA_]AB#H6R.OT_&V%7QILH22-!ZX)GX@LW]!B#_PSWC@\N!"YH_[6R#K1 UR
M&&0&$BTS5+%+MWNM_"&VJPU%@]U[DM(3*@B-:D2PNCQ&W_5M0::C+89@V-Y8
MW%<_!F1X-3OK&B?BH'14<\]3.(R8:^'Q,0&!/HT8*QE94L^$+']LG"]V:I$
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M5K&NJ1^G7]J[A9R\R,<D_]4?WO_!__&/"/XK@;,#^H<O(7_"WE\#?M)< QI
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M[^X5[.3K2,9/'-S^12MFIOJK.-H/:UW,Y*W;#J?A3>%YR.[\Q;FTE M'3Q&
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MK@5)>6N[V^)JG"NVH@I[6^,'S]EU8D[8J%9DJ&8.9:B@Q=ICIV5>6>-OM8R
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MVT(<+>U2IE/0X,[@.Y3*]PPZ $Y/WC&TT-_(.]BJW3$FH]^;)C@GH35FCV=
M5H/8FOT:T$++>84'(U-%WXUM[@@Y.OG8&:UN-Z9(:?&X?[@_AU4O]V]V,_2&
M>-GA34@9'/0YEG5UJ\>?O3Z+%ID<*5ED3 W4"W,'RM'M_6"6VLN.RB()8A$0
MD>!EJ',&JS1> Y9ER;[-J)5!/95FGL'>01IF7F1RJ] ^S?\NI@4LC4D-].4I
M'GW4\/U+BERF4'\'XU;,7*]4$7M!G1(/\AIP#]/1Y_^@?M*.QT -M<YYGFVC
MWK?A.J ;J\EX+T!B$$@F_W=]BKIZCG4+3#JW@[5J&EI"P-#858X$>8OHE>#1
M.]@=<^VYV;6KOV4V4U!XT60Y%@@33: ?+%&Z8W,OU6.3*>#0.=-GK=RFE]+I
M:\+S*$:;7&U*"RXF %.(9-2><^$;RT%I!G1H_Z7T/*;4ZT%;S.SO_*&G-;=4
MN@@%"]SZ)'$,6I70YJK-54GJJ*$?[[R35VGSCI'NA(;WLC_>4MX+ -'OG8)N
M0VT-&WVB#NBGC993XWG[+'=55Y(.WQVFYD#H'U)-"._9FD131_+3-2%X)J^$
M#R/J&IH06''4^RQR%#)H)[FRPGPT\_& !C^YA_CI*6=)KX>PML[BD.I0EP*E
M%O__XA^S?_#_%KB#(*2!+>SG:?%-D/1? U:YK@$AIN77 ,1T]C4 QG(-"*\$
MY[5TU'$S7@/TBKPXL4\.'*_\ZZX!EYAK %:!!763)GY=3-QHL;5K )IJSTW[
M=ZZA3-F+8TV,WOPR]C?D&G".O@9@(O_I.MS3V_F7SZK\]-/6L_]Q#4I8=\7T
M-6!K3_,:T!%W#?AJ4#ZF=!9B<5$N]+]ULW$'1%VGQM:)_[R,]C6 J 5\#<@N
M!UU=@6["V@RNP#)/%;Q;AV#_EW7RKZ@\X-< D#'L-Q9V];#-(1)4QTTP!<E2
M^>=5E/[)(MZ+E# ;?;+2">FD?UPC[I\,<MK,=?7]"\L?H_XQZA^C_C'J'Z/^
M9QK5Q8P0U78>VKYX-FB_?JF46COX5GRA16* 98EJ>DS!Y>7G)XFN*9O?(X,V
MY!0H7U+^5X]3^G\!JD'H6I<+=)R;P7.*M+"PM<CH(?G13TVY460T:4_NKFUY
MWOO]1Q4B_SR96 'WOWP(TQ_\P1_\P1_\P1_\P?^' %W/_3=02P,$%     @
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M45RA8**D9!*YQG9-Y+_[P'\!:"Y?*B(- 1%=!XAIB$ T1/A. $JXSTM$_W(
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MY*D _RS,MOSD9CD>L-@G#+EE#L5$X-2[V_" F14>&+(W7SJ30_:)(PED+)5
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MN_,3&6D@N3V&!ZY=>.-:"(8Z&.NWV_9Q!A&MT#HL1/JT*;*[YRR_XIP*LJ0
MY3UGP2B@!SKOPF0,- 24+J@"$9<B)WMD7<Y\MLG*R[<66^Y]W5,>*WLA^*;#
MQU94F1.\VYC.1K,K$W4FNK3PRK K@W1$7.6U7%^DLOOF37-6^7<PR<$H8,,Z
MF3/L5W)(=]23MX> FZ8_#"5$71?5;%D$MWYBL.DV5.QI](4\:-^'G([E- )E
M&$D:BA[1N>_",RILS22](N^-!U#!>( M@/_7'ACAT_P812ETG^);W:.PA-2B
M;B);KM!>G4X=\ B25.QRLRCZY_2^/_?$IG.^&^*R:A_V!7"A5K(0'&)FT--I
M?KLILG2\O%!X]H?)BNYK\&?!#O0Q_89,[A5HA-#3X#O%=NN1.5F7%8CKA8*<
MXM&UDYQ$B:M/L=)]<YD=(;R@D>)5R/1=G#I')AYX6H '#E_4'%[XMY^I(ON4
M1O# -CT4%YL2)"[/X'\=O1 C2\]07B2'!Z;-?:@C;1[KT"VZ5D^\(^3*U1R4
MF)KC5W"W"0;T-F*N5Y#^S1U('$I^BDF*.7_=XFJSV=(';GM?^3+'%QVBE[N:
M'RHZY;O?@I4:#%6WP)>A,7J#IN]CU4^^][FZ\BB0:M"N ^MR=RX! 8;H'/V&
M\4#&=<-4)W/G&]FWM30NS^609*Q=YL\9KRX0[Z<Z4V_H2?(!?>V,0;EPP70G
MT 7G<A]-$.X=XRSBV3=9I0PX>XH3QN(;I&&Q]H/@M_Z71I\W85UN?UK6E-@W
MT2,C05W# T+I\5];Y)OC%_5VZS#/-[_UGG8&/Y#^2>I^&G7T#>#["Q_.+_@+
M&P:P'(UOHKLLKGI&<M;49.IDS,]+<<5=BUR,902N:HV"V=68>48G!"RLSV^A
M+^HB6MDV:#JHGY0M:C1%<%$,<%(.#%*W*6=!WM4,A)F+H7?3IN.R/]97*\]Q
MO_Z6>.)_U?L2=Y!PW[H<'-2!XQSU%RXUV9PV7>5_R\IU5G:WF&K3+^JL](U(
M\E/RA!"(D@7M^;UASL% 3KBO8\FSNXBRMUU,ZY$+=W2W0418'5"SVC*[W[)J
M],,=NM^,M T:&DQNRS=PF_%9?5)KB7!C[9 %:JY*>,J@&OD5IO'5F_Y6TN2L
M/.O2 PZ'>&"JHP.M^M$A\%JB./Q=_MEM+84;-/H,[9N2#,QXP,6P00?<?J??
M+]=!X[:F>-Y120.)-?>K4=S3$/ZM@3!Y&7D9=-JL&1U+7HZ/I"4CD+GD IN&
M%HBC\$"U>;2CU?+<7?W@JY)M=99W=&-_OJ3LF0W7)1"C8HLJLY'\R)KO"MJI
M A_5.V2M+4!X0$F,Z/!%90^)D-@PMZM*WH>YH,>Z?=P9(:V/L3D8W]]=$^[V
M:;+#T^O\;SBMC?<N\G<9AY PQ<T%:+.R1/SB@VV!W.>I^IE];L*X F)3WWVO
M^&Q8_( Y";HD0Q03%A=5R?0Q.7J =S.AX#O-1#H%Q(V7..[5T@?GSL1F7XE4
M3]]>D57N&X:;ON33+=@GJ%CYN?S,#N]/XLSR.D\>G%,G65AN&&ME9F]4V$^;
MY1K4)E!PZ\809:C]YOXM[A4D3S-XM*/=X5MBG)+D?:-TU#9<J8,BM"9"Y5'P
M:T1YJ3RCOU)$SRFHCX^;I32;S)O\4)I-!@]4NB"V%3E>HA>@\M#I[[F9C/:U
M&_1C39?:+M<?)$02#9PIO(84R&:F-&<NJ4:^[["@J2Y.XA)HZ<Q\7@_*5I-:
MFY08QP-!@^#)U(5]2 ,>*-,\C_6'6/A;('OEUW -DOOB:#D@8&A)^X3V4/L4
M'8H'E$NM_%4QO^J"_*6/UR*U_>XRE7+R$&4RS\X=QV&/0#&KM?ZW\,#UP%=X
MP)P:N5Y3GAHHB0C1=%_6/"1:V)YV84BXM4@L[1[OQ9.Q2 Z@CEJ0QABG\N,6
MO5V_K0:JR=&5L+XE757@.2&,MP@M9L8=:7AFGEUSY/*<;8._L[+:?G3WS1DU
M_V @@%#5"O^FS>!PD]9C=^@)&5/@CBH%2J[OV]IG\'C+S,YXYL$1^.*<C@AC
M$7E.M!Q/EO^^9/V@W3G=9^O5]8$7E8FD?J!0,^>OF=&,&=2MT>ICUHFH>\DA
M2^]O#B;]3H)U;+9%KDF?AN\<?M]2*Q5<J<F8?WZ+6T^DLC'C\O56,6S84J\_
M/RI 0Z,F@;O*\*H)O>-D;/<O/3<MP[L^*RBY==#.<X\4\40)0Q6BY#<KU+[4
M\$1L+*K) L"^6)"Y/5%%RY[7($5UT8<'GGO"@O:,,D&RBC<;T//S9'/S 1(J
M5;?G!H&^^*<EC#B0.1>FJ5,/GDFSY_A;<JIZUK@SUXK$;0UW.K!X"7!MY<3<
M+%_^H%E#:7.J41QRIRF.GO&L*">,HV-KO,:C+7Q>9-QQ?+FG8Z+\2MDO;UTF
MR\TK-&F'Y4%MD-M'RD@&AXK;?<ZP5*LK;DT3)+VJ_E>)ST)<OX@?F@'^0F4(
M0S/TZ$<Y6_7&JEF7TNO^,0%O77PYPAOWPBWH/2&@^1Y;KWTS.Q')/8&#)"IM
M(0Y?CE^^''X'%H:;QM8I%?G]E@73/>YPD61$+C,)="6@YWIS1T<;X"^>ZY T
MORG25\23WN_HR+<3)]8W#<V<9[/* +/S@FHPR3\8,RF:%3T=^31(IL4[$WHC
M^#8MGUV6:R=M%22$G!4>.(%_)YU$G6EW#ZF".YQIE"CLV70W&/DBHXB+(HT
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M.+*[V!C<_2N1&50(U55@*"B#=P7*H7^'OLA[KS]ZG9%<7D-J4FR8[3GP025
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MW39AV4YFWOLO%'O\J:7V+)P)4](A.@CY6Z0LK2_&P2MF?*K3^W/(8-_A"Y>
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M+ZZ$21+]'3RPR794EF  )4=8MS[=N9J4\7Y%#F8Q:/A>@]G@L<T:E;%K:WD
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MUKQ9'\A,N"\736;5P>6[>E^A\J/.@)++ZQ9$]+C[7(U]]_+TU'>'JO[0"N;
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MT'2O\7XC/Z3J>\@)]G:5X/9' )M<^*ZQ1#(5+8Q-5P\[]5MN=?#HW%BE]0]
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M, &(.,%X"V1&57'"S$#1].VBGSJHJ_-%G9 O>E4&!B'X)2GH:E?G-!_^H75
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M5<,?U B'4Q3WGR"9,SW79BWJ IY&=T)9W-=V"Y7T_&M[I7!W:, 0>9W]=;:
MO5*1A"K.+S/E7#8#&6(MVC5AJ9\LV2O/\_6;^YQG]8YR% FM#+$911ZF@;";
MJ;/9L7%W@Z?ZC^7XD5!CGZ(./).0F#MAC#>6@''&,6<7DOP3IJ7ZA +7BQ&H
M=5]/&,6/5-Q/TBM@Z/]-P:!WE#COUZ%,E24#$L\?#>2 T5\P^*3+:+/&UK,?
MZ[JSW)5WY;9DA"0Y[12U/$PAR- @_E5:.GBJBLA[:$-4D^6!BR0MDI&$0O\
M2. \PY)Z:$<*=FT'*WR5OJBGQH?M6O^BM"5]&#H[X:R8/*MWX$V9;-+N4&[[
M)@?QN@$S^WA.S3C[IP=6?FB-TA-TANG"\KP*CX.W+@MO@D[X96G!4<^N^GV8
M2TS1V'AI'G4D0ICB?:%JC\[D%. L9\=;/4Q_+E(O3O 4$BJY1E&("SQ;N3DK
MZ]^(7-PWG\YS?M\EN;-SU_[B\P"NK<OY'^\V/B-C6X+S&B5I+6/O]IVDFG.I
MAXE!*[=::2(P3^,T&*$(&U%G&"9^'T"Z_50>WY*JE,S#DH9'2)Y;:9V+K;P+
M@H2K%#F.ZG5MZ[[EYQ&=*/Y,M)\/TL@-Y!VBM7H<*(\%F1PEM:PYO/IZ:+P0
MA2J2-B!&J?,<B.QYT=2O]NUQO..9)W<=CBJ*,WV^8PB#.B?&W6)167&/)7X0
M+ZTZCH-K[D2SR6YFC!^P8I:W3^9?ZTU&Z4ENP!>2[;9?-;=YLD,KMSOVIC]^
M7KO='-NA%5&KGR=SM]S4A/J^O(GLV]_?8QI)MY:K<10YRJ7S!1_C[MW2?9O:
MO9:V\%ZO(9(8X_H"UC^H$QFRH43L>0OR&-7;$/[XV+BNW"S80,'E\L%*'&J:
MJKI20\^5:'EVH*2+60[5PBI%]/J!107VY8M 56RPTCV3Y*H7NF0QW.6'31Y<
MF1T6A)@,C^+!-U)016W.LT(&V_1Q7.:CT0)3W/ ^6RV'HVA6> '43VR\8"*>
M#Q(II*BD4NOH<5RQB8H[NV0BA,83A6^PH:;##!,+,U[ 'RJ>/7H2N%&NQ(GX
M5(?KL !7V_,_+Z^-;'QS8K*1*E&D^WH.R%WX./=?X SP?W7R16HT";VAK!7N
MT<S?-#_D%\LV8./>PVLJ+37OSA[)45\QJUK;F;W0W01N7M)4&>&@VH*F.LOZ
M^?UZHP*7P$U9KB-)=0Q'HVNP.J$5MX=4,=X^/Y9&Y$IIF/>BI$"MZ(W6:)"N
M&5Y>?\!B/'\BWG;G:8I]J1]O?P9].3Q@;-1'=ZY<\,"O"WSP[,691AP*M2H\
M)$KS%4U%WO>".BY^#6CH0"25UB2TDE9REPKV_?>8(9>]ND''I]FL>XKZEY1]
M!8(5F#M90@!\!D3LK"RKR(T>525TI'#KPQ;\EQ'!^&<?<RGM2L\W?EDY?&5!
M(<R@NO%K-89V*FWA7=BMZ' X<%GX*VM=@8GNA?2> U2)IF6]9&\T]<""(O0!
M7.NO>%[QE</K.&A+4"BU(!6SG9F^WV-](%\.2;*=-&0AC!W8,>.RXR-)'IC'
M?6$R_.'/E%1I?.9\&R3<.2^Y@V0_NER(,U0V9G0K&! 92:(W71:;3E35N0I1
M35>>S(^8#&K 5W76MFUG&VC0N=G>Y6E7^<Q1<J<V/6B*4<M-69U*3Y!/7#DM
MA2!7/$%EB=Y;C]HRP21]M>7QW"NZ&0H%%V:R2M7(ND\_*-< E^4O$S3K*^]M
MB-,Q0A69*4U^2?NN44+R])'P2[$R_'?(I)CHQ2 -E!01$=N5'*?H;Y8!)<9>
MM>,1FX+];12IX#')8]3HB< /8SAV'"(;&@FMTKK!P<TPL_=_.(#6/TF;%C_I
M_?0'(%FV+#P9\0< ^P/(Y#!<*TENL'/=Y9@NRPQ\2);6R,A\?J*6'>W8>7R0
M="5;N^//?(7:Z:TGCXMRL;TX5A^G[X</4^B>5^[EE+C"LCZMW0-M>WBCQ+$H
MAOQ/8GFW6VO++ LJ-Z?RM!-JIB+U&#CM7FYD9DS141<$,D]E.UO3,J(606EA
M>*) <7+'#D&3/*'/%'[H(7# _1$+D&\X8.:+VKO[\,[)&B^'-=XMB4-4?P$'
M:QYG+.W1WA?+:58AYR'DH'!^,6G%=RA7\95NA[BE-I'_$=!Z?!X_=_M'C/.N
M"8W878G^K?T\/79W ^;<L@43$GVK!JQE<\.O?>V%Y#!#19?."W '(]!H#\$[
M6E=DX%EL*(-;7L3C[FV+"8L\!S).+%NP)H$-WY6I:[R!?J[:GM_;B+:L49"A
M<648>O9"'[6HIM5S3+_.QW\;%),MB&;=76[^F;B0()E[)ADZS1@ 5$];H#CO
MBRQ'.C5>EOV@/;.Q3CLL0=_%/ME1<&K?7<[B'\'0?,2Q#I^#O8Q*@$8Z7]Z_
MUGH058D5-V$YU$6[&*=P%1B+]^MHL6I&Z8V5W_G2LFM,F/"==!U#800>GST#
M7E!"E)D18D\D;I>1?DX1Y");H;<ZJ$18.5AZ$U?D?:+HS@3V/8MY:M!^:-*
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M5&SO=YI$G5S-SI8_<O_<IQ!_C_YG2'D6NBHBY:T\/Z9#$X6>/33,N%=\ZO1
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MB4_A< O6'Z/7W%NOH7&O"UVVETGA'"UL'(/(,@'UX4/]>31Q>5R)F;56&(<
MVUW@:]9%8-:1)Q18VM(J*P::J9@2\0%* EBKN">;I!Z4NQFK0*-K^YN\9(7/
MP^>T2X ID%[!H=_[2TL._).;'B1C68$;2_Z<^;PY)K Q%$NS2M95FNAWA?<V
M?*)&V9W$STHH?46R3JHV]YF#F%5DW1;3/CF?2A QO?=*7A!SH !^1K(Y>_7C
MR,%O-(&8D3KW,56>L:>)NWP*/!)7R)I<&>S\PJ,*+[/J<B^AU8$ WD'G]82/
MO7XDX:*JUS$3JRI80^$<L'$W!9X*:L4'[B!AKTSZR;F8X;(-LTVF/3'=37]]
M2ZV7#5ZX$L(TYZ?/[H4CENFUE;Q^[5\0X@M1'^O=BVPJ<@(YKIY,&=8'G2^V
MVJ42R3W:#=&_9EU^*B1X6:4$--?US2'[U&'A?I?6L+G\XPX/\8W,J&^R286K
MUS16 ]\,-AN@OO;8(#<"PFYMWGJ!XO !;SBUR[I#ND167TUN+TNJ)T@AB82_
M"^7.'PF_JX@QH4H9A "GEGQ,AQDW@WS)5PR[%6:=SXNIY1S$JT0<//\ ',W1
M593HW:3JL0F_B:^LV 6I;]G7@X_LB+0VG8CR#+,NDDZ*B#3^BJ:EM4:F$/V!
M;$:D7P5-FA>(ICPBQ$3X!JGIH"*,Z"=2HDF)(9^<E'>_0:7N#WJ$!((F1<5@
MUR!9M=U*-Q.R:N(=6VK!C?8G8Z)F!)>NR17HC/-,Z;CKQ&O2!6=/?C4UD-_R
M&8BX3SREW;D9NU4]_36G,**=;>:_A9U]1AC%_&7V??)9HPE<HM%<,TG@V(')
MLY!M[NT@&#J1U"&S,?>Z<,K,YQJYCBMO^63+LAHE?JJ>NBA5$?$E!#% =VZT
M6K:>_OK'/%;%*TFQ*.T3GY4Z7SUV]4I_EBC/UWP#"D)=P48,->OV3D46<+=L
M?. 'J9G7GGT_^09&FO$$JVBYNH<TISV])A JIW40IQ)6& N]G! YG=G,5T?)
M,5#O=J(_?4RQYVNDJ,G5V &%-54\^PATV;5LN1!CV*YW[)8:R_/0A4KUDKLE
MJB9*5'],UA:JQ@DVPW'=J%*QYJ$?3;DL?[(8\-M;W'H/5DOE.T2\EZ;)XED6
MT-VNKZH8>0XA4$VFNR[Y%'@8W+&XJ\A0+N_7P% N@MBF</:;*>,>V(63TWI+
M!;2K%:MJ\!RK*=('@AAV/+ZF#K\K=W*WU$JX.51\PA>3NC77%#)<,7- IPOC
MS+=;1#-#?F4( F-LL08VFHXM.H G=,71QNP=I99&!.D:V/\9! #1^WB,<N$#
M1<$4HI.4&R0(\6B#11-%"##YQ6[:45$'+*@*7[W[YW<W][<?MJS^ #9*_P#"
MWIK\ >20W$?GW.OZ50)W_P"L)T_^ $B^<U^3B=YT_Z; <'H-PZ*&M>G($GO#
M/OH"-O.N>M_V?&&8!7-Z^W_V%SN++X_981P@$%-'P;[FU]^%O[4].CGV_P.
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MVW,]78P3X@'M:WN9]YJ(WL;>PR"U)5D/L!X)=#0J%C^KU%:)HK K_P-PB/Y
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M6&\C"IC''-\?Q#X4K:WKID7P/T3Z2[$5_:-PWA]I/N5=(].+4W()KT,7\^U
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M(0")(@4]L4GB&YE$%'U\_ 1GU.]M2-Y"208U?YW @QO@3D:5=!UF3GWBJ$]
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MAT82H=,NN;A YI;1P?_G39[M;[*FE!_?TQ8V%[YZ@<LKE:'67AE,?1F8+EI
MG7#0<'G*P^<S!F5!VU5E-U8+Y'HZ+GD!U<_Q.FG1Y:%(7/?A+H;BF8L%,BYR
M-9L4:UGF[<SP^( 31X.]';Z%H2_-!TA_CVD20HZQ&^Y#HZ);?<4L+AW%O3'3
M?D\A!5D)7C06(7IT;Z>0Y.CAX7^4GQ0HVQ^FZ#F85*5[WA0/L#^?.DE"I0LD
MJ(V"-9DA**>QHP=7%<;2HKZ6X(K=J.UJ(W=BJ2BSD$)MD@]>BU;&VRNZX>JH
M@1D7WZ3YRK?:4@C0JH&_^LWP*H!D1-:%4E/8UFYGHCBO%/1Q$-?;WV_T$RA+
M@_9YD!=:(S%)AFF4V&"8?-R[&B/0/BVH9<4GKS)KO066S"IQ_[<NQKFR<S((
MX$_*CF[F/ZY5Q<VS5?Z'O/45MG(=HLIT!* $%KQ<V5$F5"D-XLK+0^NJ0[LN
M9<Z[!E&P+J<:Y;T#VB!;Q_UENU,Z?]FN#&BH6(SF[UKYOVNY$$*84[PU;->3
M28='+X+CC_15_UGLJOEK1X,^ZIO%;Z]$2TN+/6UJN#MZH@??<M](K 6-DU"Q
MB.'O" O#\FH_W7[L$8S2S \&GY<-AU,N!A2:F)_'IO*"I6I)(ZXFPPPLEFBB
M%RE$*.0UBW18WE;5;ISCO!4H=/L; ?#^1H".?T2 7:;_>@30S/:XV^:=VDV4
MG7G7F?>&.FVS"GD6.=1^RONZ"JH6S7LE?=QC5&EB7<&EOK'9_GL>^,P\W<Y#
M[HJ:1T/%^-J?*QKN=KR!O]^:.ZC_18.QQ*KQ]BC*/BN=!,H>(*(S!EL,<(TE
M^.4J).MI>VI&$]V?UY!(H8Y<=G=T U:>]2/W,%200"T><#B>/^ORTH5BCCUH
MTGZF;*R]4[ZV2U%*$99=!*F"&@VCNW@./47AY=LUCYV_42C6/A_%[F5 G[@O
MW$]YE)>!"[!>TA"";[L,+X#V4I$TD1 W]V=DV$*A]91PK!6&&,+I-C9_[C<U
MS$7*=B?_,.+["_2%= OK*PE$(_WFRQT&T0^[,,6WPT1"0/HA7(F27/:5L,J$
M?;4#%%6U9<W.R/V,I_1K&D=AD8LQN#(SZ$0%Q7[_?E0>13TV/N?M;D[6+7>;
MU4?8QH]\6X,]TJ45!*[*)UW)-YQS.<@M8%2)#GC@3F[:B?>(4S\&9;C4M3(\
M%^3R'2C+KAS;/TE!/4:O >*?ORE6O/.E>$(%WKGS^&\Y>80]^UQW/=[0O@ (
MI)Y8E+!> ),YJ2\ OZ(7P/;Q+&XW^?NOZL^#339H9O6)-_NISUBLJ/Y3[U=N
M7@#$DTO?_;..G^>&7P"'1,\4^^9/(A>23=MEU=4WJ-Z\MI24O+_8FUG^*-'$
M DRNJA<JCAY<<Y+-4U(^'R&UXJAC.7 X6<^[S485XA6=368.+A3KM)=*"M8>
MM@=%T%7R?8E@S&F]6 QEVKLL7@!%8G1J<R# RRA+5*+\:$UTU!@6W(H)6+]N
M[+IPJ:-SZL[<)%G,@O-:4.]^V"8(%Y957L\JZ&/SRN+L9=1?O6/\S(IMF;C*
MW,X_D4L]L:+!U?JE_P& X2Q3[A$K.3VB+Z[:&#BDM2S6]7Q/^IS4L@-<G38^
MYJ.C$^A,,<_&#S;94<*PUD1%J@;;73:] R71/C^\:BJ+*F3^?L;08#WM _F^
M_30?%,% 4CFF2RB_Z,ZVTH^!^FN+X(I;EZAH]R2\K!KX_!XS1' \=X7-XL_"
MT$&4QDWV:76A3=-G36P]T37J\#Y$>$3:! =<?[QB"SBM68Z,OY]!6Q#!$/4J
MHJ?C AQZ?>]3&6T^)^(0O6]RW,1;26P8?JU@K<2J.'=ZD I.(<&0JIX-5C[]
ML%9=[2+XB9+M-B9S[]S"OGVA*A<'>-M)/&TV9Y><1?\N'JSI/&71M#BE 7'N
MI/%'A:;,6!&O%YL1:6BR=RP/'BX-\TY((5]RJ=E*_(8*4G_DGU:G7+4'-=7V
MP>6V,7\^26P_>DM&K)PDF([@2 42(XR]4G2>!7F-L:DS]2,A4N<$U31TL/;E
M8,_ZK!C6_5X9:7+]51>[;NJ8:C)91B:$Y""")VB+/][N]3G6F[1FF&=-X75F
M,,9(LV/, 8P<,E%RJ&I75#UI[F%IWKS4AR270&*PUF0_N:]_03%PR'1&O"+>
M&',4%[>(B[NWZ^^"H>6]JZ[T%GYL,,?"ZLIL</HFMK37-$OJ5= O#W5DHA'!
MFU-E#T1Q&*@X22<&4FZENJ'(2=9PAQW_5HBCZ,_.^6RIWF(>=*</6WNR"*I)
M[)KE3H?:>T7--)9#4B8D96@]^J[J!>!)KSMVV?([PM/O/5R6BS1G0D'__)QW
M8\R\JMIS(+7_!8 -%*9K:*QM:I3S+'G;^,@AFSB?.8>Q@[C<D=)RC@8WZ5OF
MHCR6#*5'JQQ83-]/T;NU"_!E_YM3GQT3<[8A21"9FP0@EU=G8&69>"6T641G
M;+-!*LJVZ"\E^3V[#*$[9=5^QT/"A/5Q0RP0:RT'GT8._T.^R@S#<"Y;JU&K
MY2@"C#>RC,:UUX(+$44D=9;;*;C8A,ZCF7(=V=&R= 55!_].&?S_?2W>2F_V
M,._=.1:W(M!(;+MAN.PWIRAIQW,R?F_<(68G8V[+%/8GS+=+OJ+5SUH(IVJT
M#<@0KA%')>?4Z(.F1NFF6@89YF,5T$DA4MK%<D-)W?& 2L+P@[IS/7)HY'>6
MZNEZ+.?F _+D+][EYG'U[!]N*PV-^8X4WPO/M:1;_\"I#?3!#XK.8^>KK%T%
MY%D4FP$Y[GD.PZ(A^JP=T.UK/H;!RZG#E)V_B5_BL=Z#P>/<F.>YNC.+:I[N
M(,6 !LZ?L M-_B:3A7_DA>ZT24>%<TON?\E19TF+1"LYA&'->XJXD'%;L<H\
MB Z_-0<X>3);27P"\7VWH]M^)9<LREM^TLZ'7F1LUN<+G.J9+Y:Y4LJ?)RKK
M75-4QB_B%4M4]0TZ?O8DAN;,+*,E13NKL8#E3?9TH)69DL_;2 (GQIFHX/M=
MZ_9:02D<EEF=8&TS/XV&AGL;"/V\N03R>DM7 ]Z=Q!6DE>_8EN,2;KZ,^.&V
M_-R%9(R$2FC5G"H+X=@ ]$[7*H.Q.+FB?<8G &%XTFNK7=GKX*N<3%KZP@ZM
MD.B B6QEI;8$E>EL]/1(RFC9-=ZRI:#*?B=$<720JMPJO7A<DU?+E9>=#)V3
MRSS&H78!KJ2=L'QAXD8C U9M:D5#F-2!1?)%:=)U7W,?$RNL"#68Q2@R[EUE
MR'+C+:IZV8O71,C/;2[H5[6\:C"QB;A0^(_2]'\&E BK;_]=P/):DVI'CCI3
MQF&8I,/M%V/&Q?<=>?_\4C(B3KAV+]R.JVD)6_2U)A#0@S]L^5--DK$V-DI=
M86TM_9L7I\82C%&2<\!<ESRYD&@[;S7C/QV[]_\<&*I#S_0O@!\FHLR(K"MG
M]63-0EWM&P%4%Y3MDUN+/Y3";V2XA;YRI7R^-+N[.AA9M!+Y27M\KMY)9QU;
MYK&P3_:87Z\>RAYE$J#[ B"GO00;PS32,I2"K\?,$)V_T,3M$%G<Q_BE#VT9
M.+T +/L%3G%/=M=5DR1F9XH-.I+!<-:!1GN&D&\5@&]L@$-ZRX(.W)U_[ J3
M'-ZR'2PTX^$U_P)PQ:!N_?#G %H)Q_ K\M+$W9K$VX ;:._-[C1Q_,K7WOO2
MCS"!+'* ?XX+9^Q+U<11$DY\72\]D+U:RZ2DHFA- /??TL8JM*P!^+=J*^UC
M "?*0T ,.=,R>H],Y-ZIWWJ9J,MEJMNL'SHF,"7A0QXLT]R9=,1+FT3,P8S@
MQZ\XXKYO1(J]KCF&'-&<OV[MQ(L78OS C@/N&^):+3PHA;NBHDJQOL;%^[(F
M>BVBF!OBB[+U"(QF[+G%XF*F^?4>F":)'QDRL>Z!+.@<446FDY!4*&1CUJ^%
M1L/@4KF5RBJBQ&CP;&!>N*8[N$?ND1SV;0(!;Z-QV7]R3N0.IOD#*OSJHK.\
M;-5PS4JWM#EN^."4W82VYOX!(\!+W1ZNX<?Z LB3>I8?> $,3%VHVQ?SP%\
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M$^JYQC^^@?!S]/M=5LX6")YHF,G1V:,$1.P;XN6 NH[W=CT(?OH1'O-CY-+
M,];/EFG6Z'_&#0LY2%$=Z>TM-)59ZVCD%HU1R:"G&[\*3+PBSRDE0V["/Z?
M<K5L "-!D7X+KJ1%-TBO:76-.EZK*&T9F,$J^W*7.S\^SV0C0&9A.R(#K+#8
MOI2'P&.]FS*Z>;6CF]6;NM5E5P?<01,<G]@U-\@:Z&'YH!1N(AO<XX<JT4;Y
M.>9S2[O/"X"(B*J:%\!*YGANP <DV^BG(#]+_: WUBGO/\:KV;29A^E\4[VS
M?1<N&"GM0N+YYKZ6>0)3 GG/H&-X<I-1?$LJ3*2>Z\V\'=7 _/,[4Z=:S+:5
MZ-6F?!*@YX!:.3$[W*1EW]AZ#"FH,GW^F5G3\NGAN3.<)(=]T026&D*N:U0[
MWB!FF;;YF8WW&F ! Z/ ]K.KH!F]Z.]YO/O'[@L!4L_3)MVW0LZS&8?"5, 9
M>.H L/2WN26SX7 @U<&ON#@40L'=3<QBKQ? CR<^Y% N.AN3=^8B0OV1N3E?
M^ 1O3X23B@G"0:9_EE)E&YSD6V25.W1:?]]>77>N_=Z?A+EK9U-G^!K,GV7F
MN->8WWWGA&^W[Q8/YI8E$>EF>CI\O@I375F,-Y2%I^K]S1B0%HKI5::K*;_X
M/86=@0\6EW"7VPVWAL)R^PWH"5(9#!:FV^\C,<BNDO]Z +47HO8V&TPUBOYL
MXE<N3[]:GT;_#O%NS#(-V'[L7.B"YQZX;[L1V&8O?S? '\&X("+T;[\>_A=!
MK,E-(HFN($GWJO:'U[>/Y,DF>-\#*+$CW'ZII14$,.CWTC2Y##JQ&U"!?X^7
M6N, 2HV_BX%='0><=6[#,/)Q<8+][>A+O]-BF Q*7)Q92W3>@82D>J]Z'$;+
M'-"_ZVLIV, 9K*N--O5TMXY50+";*DIM!=:TO@Z!^&$75"\AZP'(Q+WHN/,K
M-[)C<;DTR-2;[/ZM_!-RLIH8!=IQ!M0F+["OC8D3NXX7ZENN0]5&AH5":YJH
M&GQ= <[W286N4]NED2 +)0*(_6JO6IR$^3B%#HI\3P8Y1(7$D.,9:4@#%%Y0
M*-MXY6HYR$\Z4UO*';^F(U6WP'V-S[+LE*^.B-<>,;5-:=D#Y=2^TQ&"3#-=
ME%.[#E@K#ZC8L1Q:*Y![EL-IK=MK<+0ND9R:O/3W@O:W!1&/#);4R"$:!XI-
MK80)W"+*!M&DHT5<.67KA*%-@E\IO@M#J$U<(I!!;L_TL JIUZDI?23(:V2,
ML;-QW#.A)\"Y& [.H@/<ZJRD&RG_?+N(&6[AY(7?,G&,<37)  DTQK):N^1+
M;NH]6MJY$RDQE&%\4W5>DD"-N3D E&X<#Z#"S<P=BX?PRR-S_W)V;MX#0^FQ
M$ _((P#!9"PC/9B)_/IGA>^98=8R2\%Y@5KY2B.[[$C[4-AZMI&,D;-A*K)8
MD8'N0:WA7ZH1:6B&<S>W"^7I0U6,TA+O+/VC)]^)"'?^!NEL=7[P4-6_T-71
M75K]+6'REF6,L]D\;M<BA K@\I Q455,R(/OYF9V73;?W\N]-X8!NCV]6H+M
M>#(MQZ[8I9<F%U^9,JVV3"@)WUR#8L.Y]"6G66PA AK1@PYFW\9.Q/B0EQ91
M17K-4GL_-UH)LD-A;=*S3B9QC1Q%.[P -%)2YR'N88H0 P:<I/<U^,_P; =_
M\)&!*XTAQC/)ZB.3S^6O=8:;9)XW"QV:R:<K<N2QV_[A&<*1J /&3%XAMVR5
MN.9<O)OU&)A3I'\8)Y[8MT"J0P_7&3GEU*&3?G8L)-&[)G=6<"^'0AARZ50G
MACA:Y><6+UK P<GM;W4A_I;=F'8 9H>7*ZBX([K*;:%F" T[BMJQ&E]JIDFM
M0B,AV1;GT-/Y%YNV&;W*6"ZWC.7^@Y>_Q@VO8?C#I:4P8:1T'25]]>+HMS!R
M/<:H/YR]?U"NJ\ _R$E17C]_:(ZR\^D#-KLHWRWY*HWEFM^4>I1N;?Q\4MBV
M@J" 76X:F:C"!8=6XQ&[!W]9E ON4"_F=40MD)-_)J8+I2\('FWDR&+(,F+O
MS7JXWOUC-9A5JCV7,&TCH:=/*JQ+2H-2RA]SY=N>^22LU++3A=?^97DH_$VR
MC=S*4B[K.\Y.D[LN%@+RO(?%2@^!ON.M+G2=)2S!2\&5(('A-7\6@D,DQQP<
MN+%_L4<,LZI6:T.V\:>O6MF_,Q3[=S&RO:\,"I70%?4N*Y6MAR<<&_#?:9%2
M@]]6-JV] #3]1:A$]!:8K\G>'ZNT4)F^E=;;\?9_%^ODP-CG0U XN<-*S#U_
M=$6IC3Z_8H(0SK<R))\[RWW4A27("H)7,.HJ"&]/D$B')XAQQ:!VB76K=A,]
M0>\"V^E? &]+?BY<<3D9R.\=) @F"R6]$N5%7"GGJIA-UAGA/LO?='1A(W(Y
M4-0$J2IQ=8'\=M+ADX(C!4<U])1$+$2YJQ47+X!\XF&X1/51JS/T/4\3MJZ<
M %7_9>>\CZGMR(Y@;+5OY8R@YE:E/]Y_(^\M@^**MG71)I"0("$$=P($AT!P
M:R )%@*-!-<$$MS=W:5Q@C4$"4[C[M9(< ONK@TT-- T+_N>JE?U;KW]SGEU
MZ]3>][T?7]7ZN>98:XSY?7/,,<8>U(3OQI%M%2_'S 2\/R:P>4V'(ZZ*5U8E
M;2<:*.6<)<4XM]-55MI=QG&G79IU8^#]G)'#G1)!3',ONBSA[ ,V;X5S1Q1V
M?F^>L9[ OA? RLZASNYN=8+YO=B"DZ/'IKP'^+NNK^TOLKV=C:21V=(%>=[4
M[>DRB3IML2NT<+VL<SKK^ #$3I(WW<SKF>"$L<(>XV^/\R)U*%+$+RF4E<42
M9R,G>Z=CDJQ_G-_J<./49)8Z#8D!L[E/3^]&5H,A-*2B']*G]X 3'N<?0!KA
M=%!'26E]K5XN1SLB9*NV#FD*KAOI++QX+.V5\%>)87L)?ZCE#-<;OTJ6F@E*
M7"\HJXSMY,MB\C4S?V6I4>&#Q_;MSY!F;CF'/6HSWVLSAMYO<7*.A(F;GJB.
MF]$B7,R'4_B-:P]^\XAD$=CIO>U5<#HF?P 8:AIYS.YK"AKBG 7"&-G[+)ZE
M;,C0^<!3@%L0P"T.W(9A]G #&RQD8,LA'FH53737*'V7<T7>#2Z"&L!W@LJ0
MB0I12I.[M:&D/M?,;M\XGP@&^+N/L>RQOP$@>5$L)O:V*Q1VA7YI&TQ%TN./
MI(#Y:.*#R>2/\2%MT]\"8)/=7SB^9IX:_HIJOKCWE3^,)^7_+(,3R5.2!R"0
MUL?N\WN)S_>.4JDUV, H&B@92GC=P0=K7#8,,E3?D RC98"S1)A-V[YQO@R4
MPXED<AQ\L080-!'>A:KK??6XS^8D+;NHE@F]72B-3%"-;4;X2/Y.72<(144I
MU!V&]]_4D-3+R6#OV&8-P-:LXI'%G)/NY_O?EJN%<[6K_<+,Q;ULN6[G6G46
MWG_Y]KB@&2N4F# WMA-/BVW3"&,!V?"MEZ^\/N_I_(Z)8S-BH0<^ +Q']@O8
MC_UAMU^F3<$4*[POY31DE!_D;TU)0=4AV-PQ^W49W35'APYN%X9V)L0;%+8(
M0P%GG9#G<H?IX[/M3$@G^1!42U][(^9VY/0IUF9TQS+F7()/C,<!B@9.&%=J
M8%&21R>4OBL)2KS92.VE)9ST)LB]:4B5?0!H-U+9Y'5] -^-^3NZ[D9G$L6*
MSEK6,_ C8LIGLIR&SR.1+=VE&1D=G-Z(E05NM)Q ^:%G831BRT/:@LF!IJW9
MM,P8 KA&2!SNT3W?JT3Z2==-?<6\5KCKI^O?39&0\/NDE8IB.NO17VGO<"$[
MH1_2LZ7S5#X"!D7?9EM>?9QZK#0_DW*TM6']#>B^9FZ!X[78@2(8J:SP@_&-
MV*QE&<H_([AR;**-EI+\*3#^F2PE;G4>9&$?L)Z&9UO8R$@RS[]-&G_A[AE?
MJ$O"5)$(.C$; P)F;/CMR.>7C7AB\<2_OW-_-R3%LBCN*W)LB')9IG^_2Z/9
M*Q.S.-)M ZMP,A0K]6:8XZI8LBC'7ZX2>3>)9<\W'M3OF[0LMOZ\PX7USKI^
M5M74-/6"Z@RW"R4/%0PNG5#&(0,N"A0F[[S53OM*;%UNL[K<AA!"6< _8E@Q
M9Z_/Z^SXTI[AL1-<B>VN-E@CR.EP4!+WY1ND,]Q:/FT1SX6<FM6OO:X.D3B3
M,[X$J_QP6/Z23I2I%%[JV\8$N1/YIU(T_C1AY9YR(;7D**'U0QN1C[610I\.
M)[8D0%.55X\JB$NFRT<TS&.M924Q H>SJ+&@;'NK>BYVV[D&W ZK%+^2G?&!
M)"Q#7@EC"!P'U,A7%,.<\[(( I=J,;R\("M^P\/(LOVMX!8<(C<'G-EO9SI#
M%$;46O ?5G]^22M"5F8KRH,XD)5X!J5M12INZ'G,V\PN'/#X:BF\V_(*[9<<
MT^7X&Q'9*[5(-<([-]X.&O,2;;FMVC: &I+!1M.M.CG[*A2V"+TO>Q'T;G:Y
MT>GG=&3(V;O^.8>]6XW:P,'\)\*!Z"M7A#5M4(4DT;&5(E*B3+_11O9@94C\
MG.P:.C5N[.4"53I;#:H%X_;Z]CWS"@5(]!8Z91?F7)$H:4'S4SG]B%A![$/9
MM05O;#1LYCT> $JHZ.RG2->Y3E_*IFD!4CI+7H\&91Y7 %^5CU\QBF/8.4H/
M&DXKONS26'9.4<$#.EG'/@GZ8X(#S&US@Z4_K]E08N824H1,DNM<+Z4M)U62
M+SS!V!3/SBEJQ5R#G67%=+6X?VO/0IN%)_S$EGH&N$U$JHH^5X_A;YOFY+;
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MV0,@#PN\O5FG,6F3W]9HL43'9'IZ!"I0KZQ)5&\\G]J._A;E.??IDV:E'!Z
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MNTX*BDFWS)&ALP35\UVVKU-4B2TAIB--JY@4)DN0G2:["%K6!T"P47>B E:
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MBC+$FLP!,L310Y$ZX3A/%%C\63%#D>4;3NL/ !R!6ORH93EGPML2DUV[SA?
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MFWKI8_V8%^=[JO(CC00FBC5JE]V[WNRA&CO^,5*DOIR'$VF!<4'H?! /57-
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MZ@'5KX9ZO[IE/E2W' M[H<B!H[S$NWB#U7X[HAA)V2CI!KO+J/5V:S\\J0?
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MU+L8RFWD8*TAX.<1XMT%)^YR@)-ID[(E\P4O!(G$L8?MK_H>(/XN2/*EC;>
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M)V>U\4R),!OQQCB?/>)_=27D76P/_;APO>7KJUK4@Y3Q>O+"B=!Y#=E'42G
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M+NQSGS"!?>?%:<:* Q5";X)+R-#X@4Y<V LJ\KA?P:0B>682 2-,U7\^A)_
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MD,BD$?6:VN9)CA]!YL'3TSRQST):ID8XUQ(.M@+O>H5@%=2TL2U_\*)_R-\
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M1;9)^.,J!;K&N")PL0<Z]$$M?FSPW<J@;GKZ=K,?^Y4_XI;%'X^%5O0.^:G
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M9+C?GJ+^IXU64S)AUEGD" ^\7WJ20;$]K"+$4J/##M'4##)EOA":?7R:SM'
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M2T4N-0FZ=-PG+P02BRG@>!*YHS/=&_8YC)EL#-J%!OT;'64W5NFT#"V=>BX
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MK,**B5R&OC2A12*NND@A[ IK;C6[.?<]O*_?[R!8?W\]90@(7,?>D(C)/92
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M_O&T?ATX:_:=6\5(V-@0CP9),JG.2JK:6>;'Y0=2Y]"NS$_O.4IDZ[RZ.8Z
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MO 6=+YKLYWB30]H_+:_R7B6;?18C@5IY,N+4B):--7<^XN@53A^3%\_+_CJ
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MI'O7EP7>RE)QE1.Q8:DA\!VAS\&*'^M(D7Y+G%ZD"/P7F/Y?10^!X &TC.(
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MCK9:F) KE?['?HV9T!@6^F^_4JEU39?),(\+W9+.-]_AI8DZ(7OXATZZ!*#
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MT,IWT6#!JT0<1PUPRDG&CP#2A938;WXKQ&>0B9<DJ/^&!RN0&X\^)FQ;9*?
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MBT(H\*YP<5I@$CS^!QGY):@9Z2/7*=@@TF'X,@MUCP2F'0+2 80"AI%;O@E
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M2A\OZU%T1P8#MAR[JZA OIR?)K/2!)?5!<I,JPJ5_0"G)0 >7)/I23(-HLD
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M]@[8*[%79B>50GG65>('.M47-FL5E2T%6?2(C^EXD:6W(LJ6N:#EH@4WG)I
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MQ I*I1@#$BT9$#4ZSH5B:3?,E>TORLCX_KI@L1Q9^U@G?ZOHS,4/G;#._?
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M--AX[.[1;K*VN*J9ZWY"M04G2;*KH5W0X-4?O/I])"D@N4SHI6Q#6TDA'FL
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M K7:[V\;%%,U(S&XD*_.C/#$6RR7HK?*BJ,:['V281@.Q:P7W(!,MK6J^;J
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M7[-OG+(#*1)]IJO=:#]:0( )D##R<E;5Y;YGMAB9B;:U'4/ZGE%*=]T9OQ7
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MDPJ;,JNK'HGHO7!T;DX8=8(PQKD*XMG-C.&,!&R+8 ]G&P&=O,]EWC5F<&:
MK2"521_>=T+'58)H59556E1E(*(Z+J*//K =IZ_>GN\=23DBJ"K3Q?D/H:@6
MFX )72<"8HB?6:<@R(W#27\U9[P2(3)@9=I<(;A\AD*S;EMV\O("8[X7.EF(
MCLFE&,<O7_SX]*L]1GYR34&Z;Y#WPB%R1W;0G<8S;7.?WL..-9!^;JX:<QXF
MRWO3EO?TA;H[>9-6G".CA1?)3&\N.N_9^P;$X*1);XWO/X6"-^_IA]7.Q/K6
MS3)?#Z4BYADX+Z0I,@%G&WH2DYI; +?$B]WP_>#K J+I\@+S4!E]@BKO"\WX
M:VL)7\^.%65OP=4Q&6G%YG2]+C M;)EP>PSRRH7)P)VI\SUSGWOG##K4ZWZ$
M*#=\NM09!P6(-X)+^Y5QB$@Z<QLC5C6OT@X:U\*TW6-*O;07!34KM,[X@N_'
MS(>&.2('A<YC$51I]VVSI2**8,:X.H[]?O;C^?EA+).+?MNL\*&+JM 1UK;"
M0I\C8:T34!MPPL<;E/6&# -&P]+S\:37DH><%KX>(+:O2/-N%9'XH.*0_Y;8
M3/P,,Z0=E=^.8*[_F,_/SZ<TTZW3+9\N/?/Z6?2+G*HF>A%'+U^>1=^(' ="
M9\/YCY.G*>%S?=#*VD$[V-DKMU[-Q[V2F+$G&*>P#CE3\[G9(_V,%AJV%[:2
M:BM_Z3+!%$U:Y6_BCZ^ZUM=/F7K]Y?E+_IKM7_2?L$.$LYR!X6S);*NX+?D)
MKS%R\IP5FH,>L'B7<$.E5818B-1_W_[XANXG)6"K85TQ,4V[55#!/C_/+:94
M-ZL1]3C0FFG2,5+:%:>;=Z8PF,QMD3P\^UFW'7'&V\W:1"]>B$OM"I(,=NH-
MJ4MI RZNL>YTVY7KU/>#OI]'4]_/W6S1O_OVXO3M>:Q,J=!HK $Y+]9P/RC7
M&JNNEN&_]%?+JJK.(_S1X<Q@9MB27@Z!)89I$M&)*)(RTM+P-=69%?QETV)D
MT"PIN%*AK9F"M-S6Q#H_Z/YXHU_?%9']=-XHN2K.^4 P=Y&;RUN3]YAJGI_\
MH$$>A-.>5 ]]4KMIN *IE!B<6&W&0-!0,HK=,Z9=[D>O*LD=")?$;E\6J=$J
MS7VW.);A<7@Y7A_YJF@R&CJ]3,,T^/96SL3BZE#B "L2IZ!Y"KQ6/1#".ZR@
M?U[#=$I11:YN34N9LW+-:V;DYQ0#IJTC53TG?4N7?8%_(+$^GY.TNO7T+FK!
MDG4+B."LX>Q%,I-7"C+O9;*F+Z;TG"V]LFI.BWS7%87L+N()!"'&R"3C>9(7
MG*"IH@5FHXB Q# %Z[P6.#M#!5UO%U8.[N\@"V+S&]96@ @R!M7 DCSO&G]%
M$<=Z]QAX;T.-K8"F=R]LB,Z@2P5P'Z(<2<S*J@4W7+4H.=[IZ"T7/+6^9ONX
MS(MLB4ZK2YFUT&+6'-T12:JDB>H\?6=:;$D2E@0R>K-VNG-F,.91<EKHZM(W
M-Z]Y7AWBC#/<I#::_"U0-%.9@ RF.MRAQJA(HZ^;X;4(^NI\!=88%G;-!V["
M]]NT"6?/E  !K#*%63")P[NR2M_1?PUVQ90\6X^>L\Y))F6<]CL*C3@)U[CY
MVBHD*@\L*/O1=S*60@;+9LR(8S&E"8N/O!B5;14B0:&"L*5I#6FV(DDELPDG
M0E."?I=\9V?5:OP' 9+C+CY+(!/ILJY*BBO7//Q;BCTICK#X07*TM9'0\K5H
M+QWB;&;C."!U\>7/):N?-[2+JE;.DC+)DJ]X(@<^>FP_^NSGKV34K3;YJ8CA
M._S!A_'QH^!CX6OFHS_Y0/?(QD$D+?;<*A2?*(=\<E]ITC6^)DIZ;6;9DS@_
M;B>]N.RQ/:7F/0_E5(\_4^R0:B([<%82*Z(/-:]B?7\22CK"^"XP/O;J2C$9
M7*4T"VY.@OU9T3;:=(L?+#/;]#NREIN,XHH-JO>ZNO .=LZG8 -4TPSSV\*Y
MI8WN"=<QLKUN[?(_B::[^OGS?MPQG;5[=-;>M&1*FOQ?88V&E#YH"]AKE!Z$
M#9W#^IW1+NI3<%K\-[F%*9FD7#S-J@3M&+/'"ATK?PLTI? ]!OE7V&LZJTFQ
M%XMO1FZ%V>,#^FMW0?:0?J+3;EHNQ@A-FE[1629I9X&+HV8M!-+HX#DA/D6C
M357/\LR2N=)/B%:82'7GRM2#M(MSR]$,PLX;; -WQA[I.3D;I$CBR.X_/QBW
MI-AV]Z#WL6TL?45M%B2ATEJD=T&B%UD"?ZF\Z1/ S3:[N.Y,SLX?'$3#U%7Y
M>QD0C(T@7]6\BR09G*CCNC=C!\[2M&+4<.AVSI2K@+12S>18O$S:Q:[H;0QY
M1>"@,#4F*(M66@>I:G:3_"XZKRW+T:M#?]OH0UO-::5#* )J0WY[5S>VT;^D
M Y+R:TKI6+8UH"$)GU#^,D.^A.5%U">6,/:X; &XW:L1#SVMX.GRL!Z34&0>
M/."D0V^;#OU<0'57HNJ7W+T%GM(YMUUT/G%%LQ)*SN0BR0NTU<1#T1F6/$,L
MWW;FV>)-Q$UV/$0CJ6NKRB_ABZZ1&,#3:D);4M<<HVKZ6IU45O+.2P5Z5:D/
MZFI%SN98:EN]95M%SUDYP\Q) ,_]E6H]>C#;;!28A^];YW@_>C$?JPKGW%L+
MFT&VB!E2+P278W=G],),8\#0X$8]('Y%2I+/R.%>:4!?W@?>5SQ@I55^,9+8
MI,!>66M6298EB&S8G_ NFW2H2D(C\'YFY)J1F+%?0@'Y FOFJ,DY+M9N%FS+
M@OKX_;%;4YEP4L*ZFR\107@H7(\;%<WP72UG*)B_$,V[,E4@,L_SD5PJ#_UQ
M#>66= W<UZ(" H7G1M+:>0L&0&=NJW24;-%W;M!$NP2UG%)J*_-V%L(6/?4;
M*8P5)_->_/C4PZ*UZ7<:.'!MD;/L/! ZKQ63;G%B+[QIM6BDMR$:Z3D95P_F
MN3= YAM1N;=,ET2CJKG5N;B;X?CGI&NK;V=<>.+UTDG]YN!;_OA>D6RJKJ7K
MOS?9MW*OPP/>9/T"@^/7C?FF,6C ;MV<9VY8DFO_&^Y/"W"@&U"02/7E&_M]
M_1!]*NM/57APLO_XP0DF&/^OO[79C@^=/-@_/.E_B/Y1#^]K9S/(1F_?\0-'
MGX+T3+!"WPAB"+\8?]%(T,*34Z$AR</:=HFL?>O7)+.'NV1VQYB+PYUC+@Y'
MASN>A&,N#K?&7(R^IP]L;;@AC_8?GM#Z__ANK_(L*TQOPT-YU^O?[#OX"[HH
M/Z/MQB;]X2CDFB5D+][RT-AHC/Z'/(QW9LTQ@ W79IL>W-26.,1DX6NG/_[P
M//0/1L_SO3NXU^'?_X'I]2-._A\YW-=ZDF_!L?UL$=;68:#_A9F>\,%_$A_\
M>,('_\G ?_(N[XMWN5,6=WB71SN]RZ/)NYR\RX -8Z1!2M@$+1Y>W<L HT+^
MI/B0;M(;8TZ8MA)]_>'P(@:?H%*O<S@%OQK4'_KU 2VRRR=,)G=]OTFPRC8
MO-Q;;_5&C=+DK?[%WL!D,3_:8A[OM)C'D\6<+*:'J&K5^$/U=!,E^6I0EP\
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MI/$(&"B7Z)7!%  =13+5UEIA8SE@6!&>D*,ESW>,UA)F=JFFCR9?)SMPW^S
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MZPE5O567%QT%KRU$28J!T>U18I:UAR$P9H;D79E7U.YTYPB ?T",N,]JG,-
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M0"76(V@0BFBFRT+H:/9Q[2?,QTB_FN][B3CF015AT'FR#>D6T?GFK3+?:P[
M4<68^^CPK AMI]\\OS9I,S$ WR*M:QHJWJ!!P&X]=K@7W[ZZ$8?;>B,!MYHW
MS--A_Z8<%&9OKUVU$&/!Q]7/<#>_U&(%]J]9QBM$8%#<2E.6E[T0PVVQD!@C
M$W!@Q'-@AX-Z>+OFQ,ZZ"?>*N-<G$^YUPKW^89Y6$BD)4]],]8GT'X]G0:D(
M)=+!S1BS\>"0%61;&03!AP:3;1?8.X %'C3"&[>ETR8< !RAP#I?%FES1(N2
M'F!5@QS@,+A#JYGF>>)ER7_;"J0.F;CAK@Y=+'+6E+E;3H*LJSK?,8DM)H(J
M4IC'OU%ZFNX\GB *]:E:FJ4Y>Q4BF9AWKQLF;1Q-P\BL\I^)\=RW9VZU"@TI
M>3N6=^JEMD[F\)BV[U?)BDS2E(D8SDA8Q&G2#)7ML-*:KRM8;%C4<+?@2<VT
M<H2",.&/7EI[]0_4W,0UQGWF][YU6\_=PK0=SK-O:"?EX/HX0BU3-.>J-9QJ
MRUX_*C>?%GTQTRSL&[C# H(H[MTG1(BT,%.J +E.(O4" KP%8#_V%*0:7_W<
M50NI@\DV[0&#E;4T>^[ &% 62W(DQDW<Y>T&CF21O X]4KXN!6%[1]6YVO,,
MH-_,$]![38E%V;A!72S=[O("^649&AXT<0IX[IJDIG5Z+;I31>U;Q"-4M(9>
M\Y*%)3F5T^[7R_]TV^CMYF ;:"@?)?V@_P+OI]#B5EW.8A)^QIEY^I<'PP<&
M;(9M4#48\'?.L>[TLO"AM6"6%5NT0S,\H.B_8("V-?\I7Q+UGY<1(,T$7YF8
MM9 36"O @?=7C3(=.I0_4(\RI#30V8/7QWX;E2)HR7/F;AVV A8N8M[N,#L&
M!_U,EQ=Q!]%CQ33V7)DZ;.) $@!'+ET0, )>?Q6O3W](4@PP3P14I/.)<B-%
MI.4RA*/@)+>=7KH)^]P^A1E>6J AE @N2QTUUU[0\=3?S()_+'R6>!:J&V%(
M*;CK!;^^*BH8:&&S'#Q[!X;1D^T>O.*8\4P7<3+FL(PX&V/ IM0L-!N=G7P)
M>Z<@^!GZ^NNN8.:S&H+MBBZ$=&G4>X232-D;F*TV9H-#F@CS01":LR>/QSRG
MKA.D"6P)=-TE2M"RRG0BWS^C_*G.MI_.WYQGH\<R[J;GNO*_CBO_1LS;=&S?
MKQ7RR=NR>B* 2MNIIYK/-AU,!UE+;SA_OG%+4N+YIJZ7,UI1;/J>U7[K,!"X
M)OY@_"@ER;]Y_BS(6LC91-4FK!?!DE0;3*>1K\V-4 D=+O>=RTM45W,-Q2)P
M=7/QF^_>)!>'/Q0-FL&2++\Y.=$D0\"8%R6>+!0-I<4 <T;0)DH.$+2WS#R!
MX^=IHAX BBNYB)%I$(=+B7;:-5_2@G5^>'ZM8!VP^+H-??8]\W^/?>7K[^U7
M(![&4Z#']!_:-.580JI_OI)P,Z7G4(W%!G #F,RW4G> 2+.P\<BCT#GK)MSE
M#3D@I:,^HYER;*/WY0LU+"L\:""H+VZ+$N>!2:]C)@H\N;PLS2^\*_Z/^RS:
MNN64&$6J5$7UE!M+: [IIZ;O 888FT[;SS![0"/ ?S0%\FW3R>[=@EO@YZ3_
MWNK9BN]1VP+IG4,@#H-05_"_.D]5GX G2'P\7%Y3/NS$3.=;636D#JG[_@B\
MSB9(8)K#SIX[],^Y?H[[EG+=Z%]&7>/$/'.JJX=G:L<& S,+-H:M(8Y@$,8<
M^EX&=N8\N[:&HU]RY%(B<?\RY:?7AML\JV 1T/CL/4<#%'!H'9,4T0 \3(G'
M"!$")@;R@/$FFJ.H5QN)1WWK=OZ+WG)>%K>ZG&0%XDK[XLGYTT>7?_URL,9A
MW#LPHE^L2O=^N+ZQS;=8[?6ETZ?.J$[P):WBLP+3D%]@(PC"TT?7?%P^C\X?
M/7KTU_N]"7J[.&R'(SLAF=,PH46%,W)&\WKTOGV[<63.[50^>?3D\ZO/GSZ]
MN+JXN'QZ^?BO5*Y[?_4DST/!SJR%=%CW:\Y_J>&1;1$.Q8A4- GLF+;.*^KA
M\2V<\ABX:\\Z[F ".'P?O]5#-WS[?00WQ& V8NJ,$$G\>ZR7POS+__Z.._-B
MVIG3SKRG.]/6O;A(PZ!2.;JL!V"/QFU=..GF9_F P$JAK@12_VGLGFQ@Q!]-
MF_,/7RC3YKS_FQ/BX2U$L\(JKXXO53>SES\\US9'<D19UBH+> AUTCD-TD<P
MLM>^%FILN4#6[994$&"Q,6GZ08 ($M'<(0FUDH1QUIB+"MM\Z:9-.FW2$]VD
M(;Q$\3HD+UP2'@*S,$4%D]=VPO\DTC),;L/>ZLO77\?<F&LWF$N+?#(($7->
M$H$44*;;.//PT+K/Q_XNL;ER[RZG73KMTA/=I3O7H$>J>6$XLO[5$3\BM:64
MY9D4]4LXZ<:/S!'Q)^.PPG%LG=99ML8X-5QC)U&J9L6_?7:C67%33)=/G_'N
M59EJZRMCWPR#N9R(;:W4#W?8)Y<O@F!D4=VB+\\B!:9&C&DU,A;(R55SAX.F
M]B8#,1F(4S40#59/)%ZMB K_H._] _ZKP90SU=DD9#80"W4)@D:@M+"-;+FD
M#5C$747Q6TMIV(?49"OGIEAXVI^GNC_%>Y;#S>Q =KNI&+J\+3SFA(,+C1&R
M:VQU?-I!TPXZT1UD2I6A4*D]TN:,PIT$@2OE<RD]N^HU2)B&&F+HCLTUV('#
M*:G P&"3QB/9XA7B.C:F@[;PL<&'FQZ06:$/[Y0<LH&XB#I78Q@@;$OM%H+K
M>JE-KN3I2_N3!@+(_28<KU:S*W;8,L4<LD_XMG'5NMU$1#"A0CL4D)WLRV1?
M)OO2MR_8C4,G-+BYW$X^DLFRF[B_X3%>#F GQ!FO2:U9;%.XV#)O<_;<6\&B
M&(&#U&_X$B]W8+-.W=J_OEO[\ZE;^S=V:T]'Q714_(<?%0Q!IH".2HR:+QE8
MZ5#BY$J&Z5LQPAK4CQ,O<HACC;RZT/MJ/D7DK0JZSO+L=>'?92]BSRP.\56A
MJ=3L#=,Q[X,.XZLW)I5+S$F4SHWWZ@U0<4TRA*4!])YGO^N1-'64W!BLV1O%
MD\%K>OG#\ZEEY'XM@4]G;KX6O+(D:JDWO!><F@)) $&C_TBU($$=#S] P GJ
M^5C7**-0PY3X!-\H]]3VR/@'T_] )@%[WB.VN*ANZ_(6WI+!1\8N_LBG2%PA
M$(_N/^,'@>C4 *\81XWDKQ2LSU)Y%F$W& %<QL#;U)?0F4:$R4(YUP.K+$I,
M2)7)#7#CG7?*KLW4UCT J-XSE<!829M.OR/QD&W_]OL44T8BZG'L;?V^6 CU
M -^/QT2B+YCX("@WQ0VJLM25D?=J9+RSR"9. 4J:'BDJ*C;J.\C+?1OB$^;@
MC20N:? "@X%7A;2^BLC+8]7 E!/KMEY@"[*I3<!+Q?X/'318N*FYXX2,W#5A
MPG ?Y5J58G9:[N9FUN6H:(<KQK16.5'>'*\9PP?9$%JXV*_"FU&/!HX3AE7C
M#F%U);Z:-Y=[= $;8@\W)/5FDA3=V=:G&=C=$DU4:$;!M!^\=-,+F!=HJF"*
M%JYAH"D7Z]!":'4='FVT0C?&^4<,K#Y-.7#^ KW$^+L-. 2DELDM:60R9[HI
M@]'1=$9H9L%V\%((/>NNQ<[Q)2M,R0/$OIO^_9D;B>;W9=+:UAL5-M3C_^9@
MEI/>:VG,HR8U!!)TI;;_"WI(* <^$XZ;DBN=2#%>C<P6@B7H;6"?#'ZD.<^>
M"780N_;/D%5W[*",;7QR)G%7 #R)$F;1ZB"*!"_B?)+6S9M%48%1ANO188=K
M+LB.T["%0(:7%&,HH^;L^,HWSH WF25K=JM#B!%J<2<)U8# .AV+/(4>W]&B
M>*:+XFW8&6]B3C(!$TP!R?U:&)]NBST;F$MR][F3VS0[:_;\(\P3'M'4:[[/
MX%I=A?*$GAN3K4@+%>94.8>8:-O&T4$86]=]M\-V=>UAIB+7JJ!\NHZB1G'#
M_E/D3?#RP_744R6]:G!Y-1$3%*J#DXV.]5Y\>J]I%_=>?UHT!7$<SK)E[0.-
MX3*H/;8L>Y-O47.X3^"[K<$ UTV0MTE0<SP.8G#7F\C7%6JW%"''Z':;0 I/
M:^1Y09<+TT<(EY?X1''UX^?&Y*Z?L@E -_CUUR,8;P,:9Z>VX(4"7LV.W3#E
MH.B!O=F%["55I9@-;IIX.OO^]\2I+%IFK&;Y":&R-F,)#!4T;+H9*3"P,Z7!
M?:Y>%G-76,@.W8W#;KR"R'M5OEBBAEV^12XG3IRV&_@V\C&D V7]U)D:- FR
MB0BT\L1X1 AZA-U1$3+:!=GO,!!VU"31X.-H#DS>^+C"TP2#( F2=#PV"R &
M133 R [T*Z R)F&H*)JL=&O*@,@"R=E:A@!,Q'^8KC&MEAHB%"(.F>S*Z=B5
M_J',- G(36,I8P(1'%;6,XHT\V;I19[!B4 #E>)QC;N@II!NH+##+!!F4)ZG
MDUUR7S%EE\!W4KHXO7P0G>YOK?/L.I1_2D3D4&)RQ!TA.6N,P(;-.?A*=ZE_
MPQJ37G6J8F6FOU<Y@I]E[RKD,D8G0* ';&B,NR%2UDW$)(J^)M^>F7G8\"[5
M=@;'+QH:=!8XU)Z%WCL\!CCXU\PJW 6\F+&OMU%]F@BF%^]V=8$3SXJ@HGCC
MF6A5XG1ZHI OHI?(!I,2%CGQ+>-Y0L1VL.++ Z^@6M=T:F%> KDVE"DG9A)<
M+TD1!A4R'ZOHR!KO#9,1%7RD9_X.\.C)Q-?-DA27?9=4WD2]1S(C"8D/+!Q]
M")Y.\*Z+DF6?QM(T,>Y7=!FV4K+"(KY F_C9Y*0USNM/=$Q( U;.7^/V<Q:-
MW-Y32B1,-ETR"?W-U>L%&F7J,8S'R-W%['G?7_.&&FE8P W;[G>2E8W!'+F<
MC4,=#PISR/G9<"5(&1W1UI;YCJIJ3C6!EQ/;S81N.3%TRPVI25U^H92XPT0R
MYX.YT-LJW)FDL,;\*S@"W-*4-"D%0ASI->H&5TA(G\_!(=EQH*8:O'[;)QV6
ME$KCXH\%$L)[CS(45$U<X]'O\@9%>3!6P5.56@9MHN0\DV=,ZSNIP1A-1\WZ
M#(KDN@628GI(=XL]&U0)7;DSM#LP;>08JJ:P]2.W>%HF@N S08G2',N,:NT?
M'0!BKTV&.LR1B=BYILJX?, NY_D$\9XLVRE;MJLO/I#ZI>I?66R)-T_=]EV]
M4SX@$?G#+A!V?,>V&:'RJ.=BM0\F*A;^R!RQ@92 H"G\.\)E8%VQ)/Y,XN1+
M&J;[7=*V*UK&HS+R<5QBAU')!NN6*.O>M\#<Q@T&&&N6_,??&<LWP<L17OYT
M@I?_^^#ETQGUV\\HK*,Q_.Z+3;&$>;U'I]9_^&GU2I6ZY=@Z@$HR!Q>"@2@+
MF>3N=TV!2?F:$3;,)XTG!$-X"#84!=%N/B E.SF-D]-XBD[CHW&GD5 ";?[.
MJ5=8X5[*J08QXCDB-+AKJ!H7W#KVMF;JHTF-+=%>"9&L[3P,KJ#Q(8D0[]@(
M9BI^TF9K5Z]A%C>2+,-7AJZI <-QX8-Z&RES[EWDM&U<6FP)8&I"1]P2#IQ<
MVK,YA-PPHXRQ[ONM,:U  $5^]AE&]933 ],%?YL1H[YV.L/V+R2C+A=1\2(=
MI#&/'&=+6AJ&0YIM^*(("SFO-0VO<D"D']RBN<2H/>3=X2UU$= 2_A;#<2I(
MR5QLP7=?,!:&E<P[3A7D4>>&8=8A@?D[N]I3ROFK&ZMQ) N"ZVPM347C5JYI
MM$E?3KW'_5-O-CQB&2^@R9EA"KJW!LE&>+X/I:9,WQ>5ZPK.4&F9*BXM[#/0
MM([DG.*&&TV74^RXK!>=](&%A]$=V$M=L;:(:2+Q41&<T4^)1#=6V$JJV2]M
MLUK:X("/25T@N*/CHXIYHI(<?"5G-EW9%]8>% D0V;N6M\?+2-V)F Z,6"V5
M?DXHW:4&R3VRM ,OE^N>,5ZO5TDC7P)M3+1+W/L-N,2XBS%G!QO&V=(=UDM9
M[I' OBA@?N#^C&6.PB9XA663W\G]+0F3F:*I<G9"9DS+U;($0K\/B<U@C9=J
M\YS4H2W7+_7;&C>L\5LX ['%BV<@R4/G2&8BC:9Y:",B=<$$W!.,$IJVN2/<
MUWON.4!;6H'I0$NQ:ZD[B)/HY B<9V_@8"PQ-4\'.N*6%E0L&'L0NQ-''JH@
MJQB19L5J#.A04'%:1IGF]WI4B,F7(TX2T27!.V"\FT%]P%_DOM3,AK5P+IM[
M7R\(+\\7[RJ6\86?\77C"]CDS9:\/9G-:5>?T*Y^:8+S?%YW;>2E[OL?<7\R
M_MCT]!GH'K61,.4U^^S2 "BJ7D,<+RY+;(@,&6.T#RM$'WO%^/Z@6.V7LLT8
MZBR"8.1^LT08! [>T;:E4Y1]#(V5N&O@?%W?AL.?^CV#,1CBJ+#;G/9K;R^;
M21O,E%X70Q/W7G2F<1PO?@I"TFTB^$G0%XRSAFH_TU8\G:WXO NH^IX^^+BH
M4NQ=F.EI+( IBGL)JM)5!4N>;YUKX_%"H/FXU1G EK!G:I[.<'<:LGPYE.FH
M7#%Z);MB)56&0 ^^9OU7CDIP1 @"IH-7,PV(#S,#7_6<#1S0AN/]OMFB:<-M
MO<X)3,U%)HWF]4+2JAENMR0I03$4<#2V\C 8DL1W,&W#$]J&S^IJT4$\7LE^
M&9R##"M$N]WY3L!=@KTT82:"*?N-^0%P3D>A+##[I?%EO=OL/5UG 6L_7V!;
M#>H1AO/W" &#BB27,$6<]"%H*D/6;)M]+_ E&&U#LI#_ZG(1.!QS5@?T@9RB
M2B^NM]7#?Y'OR"/'%"*V+7B<^G(O \!O* AZGK>+C?-'4W6'.PN,(H\0$^B<
M*XDAV07!LU!:XS SX8Q9:!:6HC#(TI' Y.'WP*I]P]][1LQ@1TH'#@B/&J5,
M,[=%0P1OS0>1S:;5+$(ZNX&$T>0A?7:W(8AP*\)\9&8Y *%>X<(CDG;I4*^3
M?1+"\E+K6[E3P+J"I.1I6;&;)F$RB2=D$M,. 9,-A[6[>)>O*8&LCKTK.;R,
M>+L>=THPA\$<V*+ATL%FII9-PS\ZW/?+VG% K90Q2:A/X)*BUC3Y+:9)84]X
M6-LK@L*=SO*=FL=?A<2XT53.WD0/%5<G.H:OJ6EM:AV_7\OB$YHU[[LM-TE1
MQ\ZJ*WMDJYQY%&JY(;_&Q_$;,:5&WXO,D;N#?2CK]1&7BLC[C7(G!YJJ6>H&
MS*(?P&1ZSUX],UQZ@8Q%"Y0S2II^J)WZH$+#B!)P'P-HN6!,(\5Y]AS#-,P;
M$^T-U9ND5>=, KU1&I18U<07<$RS)1].6\>02+H9A-/==@YG GZTA).B8C%T
M7W?-(D5$!THM91W!-J=>[_[;V!@RK,'-8F :YSHFP7#0TH$;?-Y!"?M7*-/(
MVPP\PF8]$S4B^N@K9Q9WB+0/!^Z&UN &5OVB*0@DSPKW/Z&NQC=PQ6NX.R_
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M-ATQ07S_R2"?D$&.0>B-6Q8Y'/^+[+6V1+R 309&\IH58:XN+AYI!>;U"RG
MS'KA11WK"5B[*E7Z%9&3K:"T\>Z!O)"WYM ?(J+#08W*\$"/D(.PPY$7VU2]
MG>!EV*GI2K#>Z%R%1X7-$_M&?>A/U;*;T%B3RY92?E.=B?BFQZ]%'X@ZNT8Z
MEZQ$\CA!)H,28U;T#'ZDX@U8@J4V\U&D&L6RS[,W"M'MF8,X,(++$[\P/!NU
MVG1MR32>,C@V'/VO(-^*R@UM7+R$^/[]>N;>,H;C$RH;,(DYT?B94I(+4II6
MM =26K&.TFNQ!<]D)H7?N-)8EQW0>('@;5()FSK00BK1.L*4:\FZ'0F$\#F$
M3QKO5"='>=6F2=$J\HF'XCI.E&E+HK2G*$?-,MP]J?N\K-4\EW0FC70MKNB]
MQS6];F @M!QB*4[Y0_'AC5[=9,]/QY[KDN4MX8?)G^ 5C:-;0Q'AN,GBY=@:
M] 3Z/51LE@O@'WN"6YZBX3,-)EOC/C&2Y+=+>_.>#=D(31C"K4OZ#G^6V]E#
M9)"RO4HPTK'X@GI,Z3P623H72^F&SS8(%."IAMN:P1(%VV[KO9H498B30R<>
MG8ZQ6"3&CW/4&H2( >\G:N6PR[D/T,B<I4*;(R%%ST-GDH)J+S2$,;?3.#P?
M_1 S;(7F!^@DSBND<1^1_&:N,*4K?G>E:_%1"1#P3'/6KRD%#:_F>_ZK())>
M?\_>""E7]:^@XEJ<F5'T>434C.178M/8C@$I\YYB7,I%EH"0KC,8CO[*9H_D
ME%KL%Z4;*0C0_@AX?UF0:;I<O'@;/V*S>.M#M(L#U"%$I4(^[@7Q'7+2 KSO
MU3NHE2"-L *ZQJQ7Q;;7Z9D=\-Z]OAA<5Y)Y']1!<,?B>'_1SI@EXK+%;8T*
MC>.\/@_\PY0!PVIJT43#(7'&+L)VP'IN-,@&4+LQ3%Z_ 8)"O9S7A!=*Z]F(
M.R$[0,N8_1!-"@SDC99!A#=]E['"(*\U;B%MNQ_./HZ.S39^!Z']R44M3[:0
M8YO<733/"2"," [D24)PGCY0+Z_,5F"X_:,/AF4NM5/+6,45E.4FN1VMZT9-
M!:=UA$R<]Z;.=GM7DY,;:U><0Z&5S7/8[G>.TRMVE5/ CI(SMTJ*,\2X,=!L
MM&0]RS;U'5*HQFE 'BS!GN%RP$3(TF0EK"$($'6>=$W-# \@JKEI$N5DO, )
M-H6PJ;]/L*D)-O4'M?Y;&BC"*]T2&U$P4)'VQ2B=AD-1"HD^L-/*>1-SXVA=
MT3]_X,[7Y[-1!K#HDCW$L!A=N'@NPMW.@@<5B;6^8=:RV? 0")X>IG[1GV"I
M(*,7D48/[,2TDM%OF]QXB!!CY4U%#<K45N<6><=/-7?A9-&1]MF_9NG%=Z,,
M4-'+/TCYU&^.4L(V2;R-X-PU#\>ZG &$'H83=+N7< Q"% >G.M4+!<1,=1'1
M7$F>3+6IU#%7$5QT+%F-1$D-].TGA!&&.IUK*821P%\N9*FHUX>O#ETSL'Z4
MJMDZ%&DI/ R-"S"2?>>D'?:.XW'<, 5\3H$O#QS[% TQEG9!P![0/K0THDBQ
M=/#";ZG[ON'U':8^"4CB_@DZ*VW:$T*O/GY'FAG0F1F;?0T<XXLC3G=T;NAJ
MJE<3H3V\.2(/@"J^+FG>&3YCUG2O<U0NQXG3X 'I*N8DK0^=(D%17*9"%].@
MQ&R +5$![)1\FZGI[G7(!..Z?48*)OSCC70H3WUV]VLE?$)&!:49T=[TP&2X
MW8&Y=TLF H!CI'+$0Z)6K%^9-1^2P@71=YC?TG'+\E/\/"2(KDY-(!/$G*(C
MBH=@6@U[(*?15@WK\^ 5]N8;''9XY4#1=BIOI#?07@8]LX59^_J)\^R?3'2L
M2&?,_F TO@3#"_'F/O-[W[IMG I\92LX+A!)M$?CC0DZ<']@':)9%HG&SUBD
MOHZ_I%0R73,4_.!AZZX9@63 Z5-BA7F]R>X<IQ0P?-W#X1FZNCF=D0P2[X'G
M.86Q \5=>H#AO:QW\/K[__WZZI+Y8_#?EY>?SW $.D'P3B,-ZRWWD^\/7%A>
M?O+.A5QQ\!K0OV*1,@9HTCJ2Y0B[$745/D"M,7AA 2?+2S/ 8T_FY)OB*E.K
M_^;Y,Q:UIQ+,5LKL[#(9:Z-!"2[!#;*A2R\%>/F8 B5"1+8ZPA?<%%M$Q?P,
M7IQ?L@<]XPQ\Z?*E?'9F\% "E!YN 2$4-@5)^J2YC,E/2TM-*QGJRFF&CT+'
MX.8)LCQV2R*"D1 T?,$5JQ4.C"+V1(OYX:QH' ,W"YO:L 0;8HH%:VG-<2B@
MA:>2@$'GL2Q)L;MWH\*GGKR!O=.4;^LEH\YIT@/X75&4XQ/<<8&&8XVQZ_"D
MHZTYBT=:_TJ$(Q,Z%ZIE21!@NSOC6I+GD>PJZ;VDRZ'_53&<9/7'%EA$;HP\
MY&3>3L>\78\OSNJV+AF7+I#/#QR=_8,SFAFS$(<'\($=A,6TL6&)/-)'7L4Z
M#[A/!/@9P^RN\5T>\2.#R_8KVNA3O:Q,#:17+J+R)'EX<0</2@ZR9Y?%+6$N
M>U>S%0=F<>Z#: JAFG0-LCJ$8J):&C84(PC+OG=]Q,HAGU9:9D]*<TJRK712
M"4)L1GSVDI*A)$VDS#Y'RA:>T31C-R#6'K"62J$O>M#A+YT/":!&).U4Y3S
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MC&2@ _/MX, T@H_XBNB5D\SRNBM8T*%FQ=; 26O=':5$C;K-\+3\&$&S\C*
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M'\N:&ZPTXN5C_[-P2+S0F/(:3'<<^XL7MK?8*W*) "$&_X?W@65DXM@(9X)
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MJPBDUTL!7O,".#"N''D"&M_VP-Q\*Y[GD1?5G^G<L')_:-IY@)8WEI2) ]6
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MJ<GUM')#YU&5F!.'"#W@\%U*O+F ;N/E23%TVD]9PSTJ=**/YR_0I5Y7'O/
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MI,OS02<7>N^,]^*=3K9LDUF>Q%]&Q$<[D6/XI"N-8.0MIPCX/4]B\=:O#-6
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M7A3%7=.KN!CPX*Q6XVZ477WMZ#XJKEK_&VT!X<I0G;41;O@4>L 38>BY,5.
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MFG7V1%5+VGYOE;4Z3*!SR2BP+)=-61]Z*=9*[99?1*R($T;<E76ZJU9.8$(
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MD)W7*ME4CM9CNR$+\^PQ;WFC<Q-[&P$\SOQI8JWI/(.GXT(IH:U5VVD-G9W
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M.-(OM,7YP[+3>:E&Y)&^=QHW,8XL:G9TM>I"1[H0X@C 9IFM17 !H)JX!@Y
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M*T>(-2G,D]'ER6-+1O[DNJ0)WFRKI6C>H;BXP'*16CO6XVYL6I2IT!G!0K4
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M#3'=;)^BFNE=<;:Z[-I2=1=0CHG83PWAT8.]>*/C^],F[C_)PL&L&^"XF$7
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MS%!7I<-DF^ )7!SPL6K5&_,M^\ QV79/9A_"T,)UJWIK- &LD[TRH6QFE^W
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M.(O$VA/[<T\OO%3X:%)S1:-#>[3%FU>34JH;-B"^_R-WH[(K=CO0_N>F051
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M<RR;XXENCG4X*:K\I/V35<<>7B2EX,(Q='@'8) 9[W$"'%XKX7G=+YYT;UL
M7+;@L@6?Z!:L;*>,$_DXGLK-7LJQBKK/DHO5!O_8,/2BO W%N!-",B*N]^$S
MVH;+3EMVVM/<:=Q6+ILLHABX#U[I63A#6->5,$VUOLE'N/ 7K:RE_OQ;S*;@
M.MAI@JZ3==RXI)RANHQ*2=OOF,KCMA7L+:/*^R)C4XNMP$Q1UPFL@]%L8;M
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M?Q72R9(*[I/D/;Z'UE&,,%N5$J.)(04WVHA7<3UTM!G@F8VMNO6H<E\A)+&
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MFU\G6GM1;HHYDXF)19RKXF_]G@\0\L$6\[^8_R=G_K\5B_[57RU/A3!INE*
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MWD<+1&^)FA_'MIX CZQRMV>NC%AX?,@ZF5'4G=3&BC"%F,Q(?J<9.G4!9YH
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MLB#S8<O^9O5C(O68^T+. LBIL8 #AD['X'I(K<KG:$+>=@]HEC&CT+^.F7C
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MC;W:-M=>5V*"=2(#=^TK(<-^RVVM"(C9;ZG3Z1D>XG<9'E(R:C1LS=&4U9'
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MS$6OS[<./'(L,#*N)\TU5?Q)=O/%/]8W-"*MXCU(_Z@.Z%FEB>/!QV^JP!N
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M0HGI@S =UN%*]BJ+1]5W>>AQB]#;TL-P.03N:$PF%A_+HZ!95,].&2&C3$5
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M4%KJF'4R-9_&O$7<[15N2ZW(,8Z48H9S+XXWEUK:CCW/@?Y!IY",7XQV'C#
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MNZ,U5_/N9J+:4H5-\I";7@+]1=;VMCS0[/.Y0?-X MB*AU*D3:1Z$ 9XQ*X
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MCT8>?>GP))<N^-1CBK<L!#O1VM?ET B<^@'!6B&ADA41RU5/$?A)F<;DYGD
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M2_K.<-<M)'6+<?\C&/>_%Y0Q-Y<_ L?Y8Q(P_?>4OOF+97B^AR?Z%VC+?Y&
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MIA'NI0!? :$/6,6,QM3TL:58N9^VHQ?8@)?VPL-SYD7V9%2-EC?]!2WN#B
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MKWYZ"<:-XX:7NPH'H+]5;95]@M\A6Q5_A?[TJ5@HP6"+GH7%;>7\\R(O<_2
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MV"&(L,7L9"^T/_)O]% ;_$X-[T!+4NW-*>XN+8(U+2U*_&%X6:\XM+>GW/O
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MH, N]6[25<FG3@F!B_/23M7\M 6SUZ0RCUZ)1V9A,:?0X,&3BS#3Q,1:".4
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M$83LC)1.VBFTT!YZ*VTI_:0DOIA$Z5[X#(]J3-,!IV$K-7EZR'UABD<!6C:
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M&W?/X4D-&/L<B] XRPG"7;6J?,L>E6O-W-TJ6ISO13P)\$IY*0J<W?( F^5
MF^S)I.IO>O:*NUKVU&U]LX:]-VK,2]%[,F<79\[.J*A@PT)8=E_+0]/()HWH
MX]+S2#_<Q'JJF9EZF,JHK8FRM-S-8CI%HEYN:S%.#-Q2IM',7,=MSU0,8 Q:
MHQ6]I7?4F$ QCKU5Q+)M&I\W8%NY:1Q57&B[BA0M\QXL&Q"J2>2+ZOM^2OL>
M0\@Q-_A$<?^*!&F,BI,4[H-3-!\Z7:HU!UMDI.+NJJZVH;S%,QG+K4:26I6B
MV11E-W@TJ#VZBJ91RZKOQ@-?71)GWI_CGDOXA !X_8)\F80IFT@RZK:_ R[
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M$B$!7G:63K)3&.0?W&.78JUE2"V\T[#L9#R$E@?.PA%B(AJ&NCA*U9"23I)
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MM+H8$HZ5X4 2>G+!1B6JSV*O'++*U[R'5XO%D-NB*XE_BOH.<NO^1E5FY+>
MI]B,]77VC&@YX5^X'_;-_)IS4I!DF(!<@DBD%Y4(U?(@G$BE!9HFP]9^KE _
M1R]/VCYI^XO3]N*_>Z<WP&]^!_YXD6?/=R"(41M42)3 /_XZHF#E[/BCGSC6
M?>MI7 B<&#-7ME<K4-7B((.*._F8M4 ^,%R*K]R2MQ>1W$4NXSYZ!L["6X==
M*\_!9_<:UA!]>V;K-N+_UH:LMN/;<EW9[)CE#/8/)&U 5 [P2O<D'4R)4+)5
MOXL1;3F1QPLV/+74-;F9SF9$I#^\?8$L<+I_G#0QK-.AXM&'=JP).'M^LHSL
M-3:U. D/^;LB29!K3\%_#=MGHI#[U?WSGZ?^^62 'D;M_&<7.FD]#)WXQ>L=
MJ$O':>G9:%S;Q9-QD<=_/B>3>@P>_ %\K[P3,_;WDR>0H@<DL(>CY/:'NCTZ
M1W&F(@9(/YZGBS!&5WH+ BR[M/WBJ96X\VH*HS--+MY1RE ,+!8+7-=5^ =[
M)P0V?D7_?9U]BW!:KPOL=<_%O9BU%L;/YIV;T[+GVZ6Y.UV*),VFKCC?&W%:
M;.)M;- C*&S1!@M-+=/&, A1F<496U/[,<7?Z^P?X&7P;>8TSU0?PXRS=P0%
MB-[KB06-,WOBL9MM6  YFFQ<^&"JH][=ZS=.XAUO<2-IA)!V]Y0(_."G6,>(
M$*1M.(#7[()A8B&F9QKN03>62KSG$OH!NLWS&$8;Q*0)"J(X$OWA61CO&;70
MTLF84"V&#OG)ELC1B+:E#J?J?GDLXF8&D6!R4:[-@EXMME-89"\'U]FSYJB
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M]G)E5KO9-,&H[>=26I^-Z5;:$XX-W"Q?*-A)B)(07:@0+3J" I,U :/_&HL
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MO@YN.&)/T"W+N]!=G1$Z'J;RHB?<=@M6&M;TV1UK4NSY$6UL17FUP]@AB]?
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M(0Q,>!2>]L>!=H )ZL,(V%$P26"W8V[00C//,1)0J$13G*M=1".5Z@H<+@C
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M6XEED5=N@R#* J6PX6>V/G,QB;*5(]>1 FB(-Y4MC'?"?'<]!%!E X[*.8:
M$?J@^I0J@X>RJ^U#Y[<<5:E,8^*K*LQ_UOV!2_'L*/]4BL2\9];&!R8B'AT@
M>V;C(6.$4PB*&C HGCF2,G]LY6P!)55'HN,15X[S=)EV0LY#Q+0)M$M8Y>74
M4*S-45F=L'"1 NLRI76"?DR<&EU6&2EP%1:3QI?)X0+?G$=<4.,-LY346/,T
M4 @1RALL9!&MT.[V4[U[F/J%BF_7R7G@+]/S$EH#C[0D![,P6SOP3, GGZ0W
M&M4Q3^]&RL\J!5!HUKS"CWU#_I0TK*H1[V(%%O_S;^$*:_A[);6(8U15#J.(
M:M$L[J78-1X'CT9>9<U-8.5M. F>:84GP;N :A-S<*)J1*99OH[U$! HFYNH
MGUWGI/D-X:.@NU6"F8A^$\DO"6=]EU2C*M '3->*A:2%X!K-:8H&,[H]4N7Z
MYSUPO@">E/4*5:IM)XY3( 2%OR/AQR)A%#AU380,@ .ZLB"=I*SQ8P\%I8-Q
MKIA1N%AS!"RY++-T)I7>MI0E5]?."'F,-K.BCVD,-_TAE%:F!&&*OABD?& 4
M1*Q:$9D*I<6-)/T1K94HB&8XW9?KBE0V/GE-D)J75 ]L3V%.;$C>1#Q*#/0L
M =%AZJXR1@U/Q>SI&V6@5F:I8,/8 V999H!P<%E%"MHC\J!H.BV3Z+^Z]J2R
M'F8JDQ/8DN\E:0(74F!J3\)?\AG7$\U[EM=>:TOD088YJ%S1J^KI&)^P(&=*
M":/X99GC9W#G!5AC&$O#W?V&TJW7Q7=[A_@4?!.^.(] "K&O4=49,\YE5)T?
MD)I_DTZQJ*2 [8TQBLSPP( F*($I!H=7=D'5R53F C_,1*!M/%E,P+1'KUZ&
ME2>P!A!*3E5"-Q(9>[[Z>>V]6(8WK@?G&&-,%BNC"^[EP%N"58#N:><=[Q-3
M%*?&FZ"AB@B3:Y@NM"R !*G6B?" 3Z54811(%;%:W(0L0>Q,(+DF2EF&](:*
MTE8B1S$R 9*)&%,;M-IF!/^>19[PJ<L3?I+0LY-R?^__=5"OE&3MJ689H:*R
M7M99_,ZD%0%D_HO.6!!O<R[@CL40??SX0@%R!]4@$49C]L[:0@,8]U@FN([^
MX,JK,J/4'0PO$>]57=8H90<9+=996&V7+#9><7@,99+,5-64JV*J\O,Y=6I'
MB/83J#Q*;Q5SN%.TD)<\]J,HMAU")):IC0KYC/"V-7:$^G<VHOK&6\P7"D\!
M9$M,C2HS'2O/R]F,ZWA!$0=-0H= S1K\AQ[%.V*13\5!".="-_<LC1>W1$_\
M6ILD$<X%.2)&J*1S''9=Y4V'PS3M#S?M8T90,P*9%U5.PQL[I^&Y8);.E$''
MP"@-2F6#*R*JI[-P29Q*%3%9(MRB=$/B1Y5*>?7A9]\;__*3KW-@0HQ9J7@F
MU=(&G#C+G":=3>!S\;2>(H+\H]<[YH KB$ )1ETM< J"Y4"0">G7W(CH)@P!
M!KK70I1,HF%44*6N=W&TG!*C8[4%NN5T6D<]D0/.PS+UEY_(S[8:L+O-D]!3
M)LK/UY<7N%&=94)]I&:4"&H[4EAO4-R; %#Y06R_!^THVNP%NB4457EVSC&G
M!HA"L')R9RR.?$<R!]YKF>1;Q.1\[^J?OG8^5H$Y6F[-.>=I7 +6$AZ\2[P/
M</M4;;HF"&F\O,#PD%74/3^886,\5"H8F(.I0VC*ODLZ005N D2NQ*3MP<8V
M$_QP[1:J[K0UI#,.[IXW?5_W<D?)G]*$H'K=KC<=V]?](OG;\4LK(B;#94<S
M&.\2$;GN2#[[@9 5?M\_]"9<B#Y2GC6^794]%&_P35M[6'%3#V";M";9^AM)
MS7X_':KF=-S'&+T/()1BI78H![4Z/CO^B=: OX4H].'N =/F)F\^ 3TE*\<'
M.E4<61U"<^G1C#*KT1_^[A:2[-=)0[D?:\1DDB66\*5R(XHEWZ<%/R9-7)[]
M%,1WC3+U"&Y'9YBV4P-ZB)I'PLE#EJ,S.5XP_9 @U((1^\YN*&A?*QXK)>!@
M*L/(!*#(.1<E);OJ6'-?5QX/^_%QY:GJ%TW]*T'(B'F$WXDK'NFOW\!:E>&Y
MZ&E[C/]/; '\7$N[JW(8GPEB@4C\15BI7.E0E?[<I%D<PALHI'1301H@@J5M
MWB>1I*.HJ@']Y^^][O&Q3_GEF1S)3,6G1:Y[7Y#1;S$4;=K7HM3J66K^0<E!
M6KFWL]11CQHGT0B6 <HODZDLO$3J)ASK\^WE-!+J9W ZTVA,9@ML7CM+P;Z)
ME/J<H18&K\6I"&T+9BC9)193@GHD5"LTZJK,I0"@&&;L;9LN@+V!+81>#M +
MO7R1A!E&2CK>A4G#Y'")V3#J X3;2D=2=5KR"\9KN$ K"547VH":)VIH,1NW
M8,LVFRSQTTMYJ92+JHKDB-7GWB^_7ATH3Z3ZF5)$Z1<VL&O]@&/DX:103N0L
MP)PB3-K2OR4P(@C9<82,.K\%]%66*DL+E5&@0H+>NP]O#F0BAI1I@ ;>G-OC
M:>\20L&VG3#S([)#TGAG>&1<<YVGR'LN].P$Q9/EO)NBEF<G).KA>FJA&*OH
M@0GJ7G[)T>D+S%JUOJVT/A E.+I&C0FP<X/(9,JG:$=/P0X,RB7'M2EBLI5'
MHF)NVHB4[!6 A9)8Y.6'JZO>-MZ;GZ^NL.2JDB*4TX["Q;2=FHI0V@5AJNJ'
M]%R\MWI$99IB< 0@,X_F*98H 6E\!FD@Y_A^(&WN-$U#*]$V!6*C VB^1ND,
MW%"=N[^M@)IW@@<>Q^D0.!D<1Q4Q^68/Y(47P4+E=>4KMJ9*5D9CWQB:M7::
MG$I&GA.?L]&X8@X9KX[3IR9+M<ZCT?R-=M62SE4THIIF^JNQKE;8&4Z)=FM2
M.H0JK ?2 ,**A"D7.Q]>R!B]+3HI ]4<4QSGF[:(V V:(XWD8S5ZPP'G:%G:
MQ6IM6*Z2<3BO#,<#J+P;C>7+^$SI'-,ANNG,_BJ]TJ@L>KMXV#$^3">Z1HX$
MU%:]8.F7]F&L&C] _WJ=HTWDV.5ZBAT>]#)5&27W$8CQ]Y1HJ@L%+0=Y6E7&
MD3J%7D%@$/DDFE4[9%^2+J(A )#G'?WN2L4U[6Q7]%Q;LTMT0\TU)8:U"DN^
ME^<BC':HX;2-L3RQAG,M:8+'OV9,#\\%H>H530/?<)5:;8;$R$X*'%9K%/\
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M7B(>D6"7^JWH0E$L/-\_U10;3=4<MWA1M7O3#9Z!<*WI.M3H;160,37#4%T
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MK[V"6]GBM@6V#;NHMM_)[LN>G;JR"S/YQ.^='3FZ='2YH^XB#;L>)]\<';6
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M4J,]4J/O=P<#1T;/QFWI\BU;17[LMKQOI8Z+@#ZY>'.AF^;"VJD2CZQ*W#\
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M;&Q[JA?U5_Q'RUQ@(^5K=C.1(@P X 4^C33=V4#/SC]YWWS;B<PK-Z#R1LZ
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MB,'IZ29(L%YI]GG4.8-_X/8F43 !F3K#F#!]"H^C][]!$=4^*/4IH#1^[WO
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M,)9C,#A%'$>X%7Z.0_"TIKV$L074- BFH)7Y3VJ,TT@$IMB(YSZA6J('2="
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MI%M73+* [/7 #OH:(=A?$:-]2\3>3XJN"/2-^ZTDJ<7F:1)="7R9^!^PK@G
M%Q^A!VB:;"X#T"YH&<>XFD+O;TT2LV-<^X4CWYSKKK3[7J?W5;S+KS$0-;52
M&QW(A>"[@91AS@.]48_ZD,YY#>)]/"KS@%1?T%YI]K$8%1*G0*,"B6L!K&5V
MD_%,ZC#*23'44[FGTRC/C<*EICBSOD7SMO6R>G#]5T+D=-#I?A4S]K>! _[T
MW=7'ASWI.LK?'GLIAO+D^,MSO[[Q*$T@1#[(8YUCJ7/ZSDYQ 7_*!,\$_PCF
MRY@'FC=W_FN[D&2;V<'6#:35#: 2!HQ@A3^[\<'M]8VW='[PX*QSV!_<.2^W
MU_WV8;^GG:,3>WSPZ0[&!S=V7_U=;.OTM%O]TW/;NNV);N?X^%OVU=C),:[K
M>)/;+[@KN7MT0N_4S5)[[K/4KLY__^7RPZ^?O#?_NO1^_-V[NKQ^]_%-,\CU
MN:##DY-U8V6DFZ[FIJOM#QFZ0:5[)EQ__?CK^?MF$.=SN?UF$'&3KLY-C':,
MV#'BVU'A_>6G3]ZO/Y]_X !1S_O]\ORZ%=3=&FQH!E$WZ>H<8W:,V3'FVU&A
M=S @7ORI%13=&@QH!B$WZ>H<,W;,V#'C.TI>#XX<,WZNA-RDJW/,V#%CQXQO
M1X5?/EY?6BX+QYF?(U6[N7_/+[VXZA 04Z%8NC:#VW5&?/+L7]?0Q75K<MV:
MGD>WIJ-3UQ2Q-:V:&DB8KJ>ADY).2C:$&)V4?" $X(9&AXZ\G:ATHK)=M_8\
M:<F)2B<JFRDJG4'II*23DFV[M>=)2TY*.BG93"GI#$HG*IVH;.6M/4]:<J+2
MB4HG*I\M>3\JT]W=1)E&2:6E3QM0/=98F1:E=CX<-^AU3Y: .3$)@#,QEDS<
M!]2Y]I6(;\0B?_V=]]?G@H-/.-6H*6K'$S= 7=_AU!-3[H5,[66D:HXJAND<
M_IW)E<$J>I4<GA8%/2*349H%DE],0B^68Q''"V\(%T2MGVE@!SR<SV00C18>
M_-;+ ;#1" 154GB \=,<QZD$<4EO4)=-+\T\G 8R+:?(JN91(&E RE!2]WV?
MG_+-,_#X7 !<<!NS#)[F3M1Y;6B(F,$/OT13.)!71%/\6#I2TV*XX2NUBE8#
M1M11=]-9WY'CWG6/YU=QAW<UYK]24R$(43]2V_%=]X'>([AO@O)OR*RP,WS%
MQ13;XV_"S\L,$[A'WK#,HT3F.7.]B^N/S$.X(WPQB4 ;GXFL6'ASF81IEE,/
M^R &7@2ZMU?@QA37T?-!X,\ Y'*$+)C:R6NFUO'.<QQ+I3K8IS1J!%DACQA9
MXLK \-*\L$X0IK![_H& QS4[U'-&N,%]P3WM:<82L.P 1TS%,:TZ7  _]<H9
MR +LD ^@PO5@8QWO2O?")_8]%0MDOCC'B9[6BY 8@<_G44YCJDP'?02)X=QF
M+ #\T)X.5>)D+9JT GLUK^(F\52W  );<Q/C)@'&L#8</2^#R>IJG\%&2MR<
ME-U1$Z($W2&A'\ >?E.!G; $FZN+8!+)N=1SS#29X$B'<0D(E&8+,XM!9J!N
MQ#@: @@G3=1@,I#;P#[I\EE BW$F)7_F1GH3,5>D3:@"6@*1+>H#:9G7Z!6>
MXC$40"!Y2>H'/#V) %_T0C0X+F-4A;/#AQ%;:6' =\DJ%.#S#$SM1<=[PX/-
M$!=+H(@,R1 ^9/2*ZNQU',7?PF\,?662/JOA5VDB*!;,<7T+Z;4^-!-1J.A8
MH[I1H4*)ZE64,.$4"(L<-\&BALZ+SP^E3&ZCMH[W24J/71K!ZQ\5=]0NCO<,
M(N]<;Y-_$;ZFCVQZZSS/9>$9T6=>SLW;9D,RSN4-L%[)6X,CG"<)7L.UQ EQ
M'B#:6T!TK]<]^"?Q'0$'SX,LFNGQ?\MPW T;Z+5FB->#C:[ J2HH\\X#FJJ"
MR'V5 LU$:C3A)TO3_T<9CBM)= F2$37QW<U2>JA#NH%O.P+D1Q855#I*1J6:
M$ 3XDQ?P@TI>P\9X]!E.V034RD(:BTE\752H!I8>O#X#8:$'28+E";^7LZ+B
M8_]*(OS;IX+F9;[XR_\,#E__J_.IX_UT?GY%?WO)L][XHT+SC'2[W0(JZR%O
M.%LH3O,RH_F>Q,]S9,O IZ?B,_![C?+TUI^&'-B8'HU N-".,V)K./I4,7K8
MC4!V"?P_!AL79T9$*!MY"B8N9@WR5,9NM1F2NI6$YI786*\6TP,Y[SQQQP/1
M/Z1*1WB\.A( #3@S2'/B![B?+))P:3XK7J 5@ZZL-CLWH--"FE5K5(]1G2:
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M3]!V/(VAS(E=,0V3C;\-^1*G8>U&>1UP'KSB#K3$QF'NQHUF]!#M3U-CZZ2
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M#.G[_+A0?W0TKS_ZQ\VUD)9=K^V8])0A1;TS_[VX":)FYT,;14C_M&O<D17
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M*,7;;CUURRP7L?NC^%H,BNN;X.BK_;2JM^JH*W,M9@0#H ZSYRZH'^R? %@
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MT!)H";2THUKJ6B8+<E?/RUW]VPST3?"/O>#@:CSXY('==CUQM?F3Y#P%6C#
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MGVO[3M5E,316OSL!L!>S4;MUZ&D]</L"52 &.C@HKNU+7UEAY9]-<%)4@,"
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M$=VX;3N+,=-@4L8;-&6\#R%W#?;56%:YSD696X&^=+?]KS]1]N:@N7/]\ZM
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M5B[FWW=7''UMG!GW#M=Y54U]KEH>;E! 5X G;2\37!G%6#D#FIOL0Y/?&OI
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MN;6+]T?,M"T=_N#ZUO,0_L9(M&5U/+V[W0H4M+2]G2<: JWLO%8 N@"ZP$A
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M3AA 3F<AQS-I \/"= >&W6&&E3RBE"8)$@FQ#,MTBF0<:402397(+(_&NHV
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M7^:#8'15C.VENNH%YJLRSCBN1&GJ%8Q=STQ_N[8#&E6>M"[Q2^$;-\S;Y$N
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MUN;:=8ZN3!GD-1($+Z=%2:^>VK,3RI+6X/ELK.NU_UZ0)QH"K>R\5@"Z +K
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M!,".P!/8'4\@%F$62DR0E,35ND882:I"E#(IDSA+$TG:Z1"P>D\@C<$1Z"B
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M#FZ]" G_?</A]N?*'.><?E.6Y>54/L8THR#QWDW+R[KS6UH"</1;K@3)?0F
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M9DVC5[Z0RKH#/RFA  3+D]EG=*K9MNUEU:>@,I[QJ@<TA"?J,![H_D.ET"D
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MS[A03"H)PH6.I!2:?#8%5(!"#?2_.9&R#8:6XVJ8F^S-9M2V+ZL;-TY1MST
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M9Q)]1R81W'GJ'L6@:L?;B+ANL,=O4;4&U5K_5-L_(ZI7K%>+AO^@I7>LK0)
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M57/M@GJ)4_X-R;:O2=F1M?'$T] (P&ZLHOG",]X);WV![QB_)YJ^[Y?8M6$
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M@OZ1!RM ^NI+A%U= N1Z;YIEU[#8.UE%*KF6%2%F#J_V)-[:<F?+5FZE64W
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MW"ME(<<-:Z%;019-E&13?%5-$?[KJ_&X^MJ\6%W2/9+8D^GUW )VD]V^33>
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MU7<_"_MS735[*N43F4>AKYD^V6-GC_WT0L@>.WOLP7MLIS#72EK ,,: <&N
MX%0 +TSP@-0YYM!-CRV=YY!K!ICQ#!#B5/#8F &#2T89]@Q%+__X'IN2[+%[
MZK%S"=81QUS4U6@:!O,O%T16^>E75;O^A$Y[)MK!(+?,/=+O^<[ :RCV<3OP
MTLX2Z$H!C. !>"&,@#** <$DQDIJII3:J*!R C+H.9!6.D P%D Q"@&14%KD
MC'"$/@'P$K*WU5/9\&1_F_WM4POA&.8[^]MA^ULGD2W#AAY@0TM 8/A)(4X
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MJUE=[ZM; 4/]Y8K-5B<[V^QLGUH(QS#?V=D.V]DZ#"&C5 ''=7"VX4<@J=-
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M\9FGI<I2:)PR(YR+Y:AED+=!$&!:(F.LQZ7>H PE6&B'M0,,20U(*0P0Q)6
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M\#X)XD;DFGJ,AJ&E*[_&!D<ML6@UN67N3XO7H]A?(3PASNJ7@/3CV&)?A;"
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MOODN+__$^0'EZ7Z;=AVSF3P&MY31P="J[_KO>'HDI2R9+)ELQK(9R\J2)3.
MH[1<?=N3+>5/5>W=Z&&':3EIJA?6,:</]'N^!^^-AF79_I@[ZVR$"IUV92F8
M ] (#HA1$BA&#+!:"H(%ML9L=-9YBO/ SBO-8DNI+ESXL/- 49X@NKNA5+:V
MPS@6>0B_3T8I@_2:66]R:G<^3GQ$C*"9+STU$#BL/""(,Z!%Z8!E4$-'F?=L
M@TWD28X3MX"$)SY3)*=EQAAY1]?3&>\11,@UQST/^69<D"63S5@V8UE9LF2&
M<J:8R_-ZLJ\\_^UJ5.?RO"%XL)S3.N3Y'KPO&I9=RR>*F]%"KIG1Q'@ +36
ME- #910!B'+GD;76$=V'$\7DD])W]G.BB -<A+F 8.@'(SUJ&-(SD660T@,A
M]%9O<GUB/E"\*T2PPGG%%0>>(0$(4270RD+ &!8!'7BK'._%@>(6C/#D18JE
MR!@C;^CZ.>,]@@BYNJ?G\=Z,"[)DLAG+9BPK2Y;,4 X4<Y%B3_:5\VU7+E(<
M@ ][Q)36N_98[IFPCD$N^^]^W5/O-BQ+F8\HMQ0T2*@,LA!("V4D086QH($
M207TR&,F--Q+_'%:F7^\:9J9LZ]G]6CRN0TAINA?D_ZXB#-V[NQA)Y G$/6W
M]^E 37-O#UQZ5/GX#=&N;H#"Z/LGX^>)E7HFA-XJ6BZ5S">;=T46@F%B"5/
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M,@5M9>8[SS$,:UI>!!<N;)BE=NE5:@=;F2D,]SQ9PK;RB]EX^JZ;H%0LI@J
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MW(&=I ZLL]"U65U,9\$U[Z;P!0!&"?? KVS[%K77,%V%C^EG8,=A8E*0<-[
MC9^)'<+<E:;TVP97@N546EDDO8AI_T@CX[A"F @EC?::"7,(@WMV<3EIKD)X
M$V;OQR[LMK_7MK-OYO:VF9O)^M^?-^W\53/_[P!OLI*232OZYL6UG93K=A*)
MSQG*O79RN(I5P;T3&,I)!2_ASM<[07<JY.9M4IUKC:L:L-25J3ZLNK^89?>7
MRRYM**F0N;R<-1]ATN9A<O5M,Y2'==C9Y/H;ON?)[N[I=8C486"S0M<6<<8
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MZ_Y+,^OR$KZ5Y]3LI%9'S'-&QP""BUGR7I(^=[Y3 /7V1[LI?KT=E^ ,QEE
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MY%3-_MI,Y[Z4WR&,>2AQ^,9BL44 ,M?EG)9ONV9?6<>"R063=YUF'XQ2#T8
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MO0GLEV7<@KBZ\(D;3C;>,.' O)>GN&>.3ZIQM\0G-][_&$3=[8EY7'L;W?A
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M8HYO@W[)VT>"95:\J8T K)A>B8 !'XC+%YAE5OKO*\/^';./*;3")C>.!8;
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M2K!43?/NJNDO!0CPW0I__W]02P,$%     @ \(-F5D4,M;4D#@  G,,  !4
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M5MH4C0(A*Q5EA:)7X50 J$+U50BGG$^9"17:C@JQ#AO,,K .-+@"M>1+P4*
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M-$I&OA^G4<+TZBE;&!\C>NE1S)9D2ICV&26"2K8=IP0S?961Q5=KMXK\;T9
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ML[^>I#OT43H\W2Z\F 4N.7( .@N6PD&8G['*+>?LW,N]\L=[HC\SKNOID[!
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M'C0QS&[-CMT3VGQA0M^D_JX9#_3)JIV_IZ=C3A!?4W6^%0WJSDWO5.=;:S=
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MD/_4T@*FP=CRCF^MLL-$%1!/*Y2KAG;ZS:_Y?YX]BO[^_P%02P,$%     @
M\(-F5H\#B0[!J   5L4' !4   !R;'EB+3(P,C(Q,C,Q7VQA8BYX;6SLO7ES
MXTB2)_K_?HIXM6NO,^U15979<W7M]*Q15S9GE*),HJJVMVQM#"*"(KJ"  <
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M?=@YNZ>(:\Y.N)^'A[N0W_ .Y">B3-RB.'A8/5;J5FYSB#[TB_#9\672R$4
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MMT@.*_^+G^MC5N72D]$RY?C,4YEKO3*<Q);Z$=XC"/1BB6%.,,8N^3D9!L\
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M;27&%Q#M+N&-4RQ+<H,_#]NWRV\7OO^\97,?KZ;4KD-&8CQ6%.Q6/]\F1BI
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M]U5'1-%K;;O-D'P>2'*-=LBGTQEP/LHM9W+Q2MD+Y0I2O"XZ D\FUXOHG#D
MX9QMMMR8H,5U0W7>Z-LL*SB\C;Y2"F<>-8 ZYM>Q)/NYIZ&4""T.Q<P,, 8Y
MSWCZSKG.&!:#Y=1_W_J]<@,E?'=K;GZ(N$S.M7+PR&"T^'15XC26283@1]\!
M1ESJX:/4^^,H=W</%"GJQ[[=;UPA@_(*-0!+U+W9#HI\CL,0.XY:3Y==$*9O
MITL:+4-O6X);4/76F%S-5>9E"X3[JX;)I'75A(&K^?*8OO)AK7_NE6)OG#X\
MEW?S4MTM^?L(O^07X=23-2AE/@@;(_7FATX:ZTEW5FG'J_)W1OC5K]ZVGG1H
MJ@]B;0<?CF2CFY91/IQN;%*S!OD8(D/R&E8$O:K?&]/JK<00T$6V=FZEH\?O
M:W)K@+D. L'UL!FGS+]35;4*M<MW1?@:"T^+3^E3B T0=;E.1]MZ&5I-Z8_I
M=#A,3+*JFQZ.TUY:<PJHV+\.H.YT[BN/4?%=5N_%/@+E&/:&)964591C<)6]
MT6\IS<R?KE;H-J+1P^XI\ES/0902;LPO\;?\A#%3#(L/K"8T.VLB>.U%2X>)
MM/?E+BM,V9-]0)3ZH0Y++YPW >@$\RM]>7?4=QBF\/BN[G8EXE,%7ZD)Q?XZ
M5,ETC7F(^==ER%^%SP\X9@1+;/$:- P5*2J]'"=RH4A=)!<YO>+A/EST>7[8
M(J=[[K-])4Q*55"J@.573\D+?<3B4$VM2FY,/S0(5?XP[%];<<]YU;+30 "-
M/:4A!D[T'=2@U9HTF89/ EP*76U<:17X&K-M #B>"$/@%#;):$IM3)9"_5+%
M#A/CRQGHKV(NUVHN/T#KO-F;:T3D%V!QBKJ:2ETD><_WP;Q 0M2'"F[0TKA$
MV1O](3*9#8-+U-*BIX?D>SW?5R AUGFS5_=36D>6N&[U/$LEKX[I*CATYMP'
MC,GF1/8]1^9@/7<@\=W#WM%'M"4I?;V_'%65U:[,]EK [T4OM:R#5I2A#:+:
MK/ (JY<"4?OU/E9(;M]JZ"Q>&@RN?*U/;&H-_5QR*Q4\W$</,A4NR]@=$C;B
MF'Z3)Y$: K;L+2TZC'(?[<T!(<_ 6GZ([+-#<8.F*M/U'R/YUZBH@?EIM/KM
MA(86UPF-/0O>ZU5+/=@(Z(#0JL>1N:3'4>O#4%+.@:_8.DV$:?4O_^)QO3M<
MKO>EE]1Q--H+7#XQ[UFT& NDXONX#7S9%&JZ7'M4U#;,5Q=<+>!C7W"BWA)A
M:V 5PIYRF.[[G9L"W?X@-G 1$T!#55<)V^MNQZ>=FP6UH1%KDVFOC#@G>< T
M8I(+5AX;>%@D[:P3CY;>2D\Y&]/N6(-P@&L369:W5((MUB;0JX5M9H\L@OD3
M[+ O0>!&HE\'% ]7A2M.)#9HL%8^(&T'KC6AU-ZF1E_@>74#$L/HQ'BVF079
ML/M)YSQ8SY"X""#?)G^I'_Z]K=5;T?&4F]S0\]+<0+FJ0OFS/<(<**\+,)7K
M:2L*.-=^?TP.RLJ<TY_1[+65QGWL\%UT0I@R9N9(+=94/"S;$? #@^U<?I F
MD'S4E<5]1J=8Z$ @$N2PQT.#=@CV^6EM5G,K4(N/[++'^W57UW-'E+S0T6DL
MK9+B_M.IO[?WG3%*GUY%=4K7CGQY()FDD*+G,$C0^\+OKIOB&J::+_?A"J5Q
M'O:82!%-88\5.4#K$^C#I\$/-^SMB%UAWC"#M31X7?)"OTCSN=[_JS<\XETH
M]H<+=J=P7[-)</5BJZT,TI>G>+KD*D.$\ YE30+S'NWCRR:0$R:FF7 T"(]H
MNE]7H89U/*%^T]@3^^E\#TAG<"ON'/;5B6&][:'?:BW/:B.2O>[E;/M%:/QP
MH 0;_@D3_"Q?H4:TDG.,=A[IE>Z2E_:@+&HF6FO<?'1MY*D<)U+JH\ @ CP*
M?J5NH"JCJ&8@_=#0SK6\-,_2TN_3B/61KB =XTD7=G%KPIH*_&>^>#;)G\HR
MMXZF,YQOC"&>%JZN$CJ]Y#\^PUS?TRUTHSD.B*/>NZT=B]*V3TXSOADNG##<
MKT2FEU$4G^NT.9'(D+*#^ &XVK$;;U7<9Z/ZS8%B4/%?BN:?QZ')%A+I-U%
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M+]0XM[)XE(6W6<W7^[5?[IQP'B(TGW!85-1TUGFS(Z#_7RAC_^$'K_X#=:+
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M#YJG8_?36+8/@Q+[71R$^]3#UC,'G%BW9-,<9%_J+;_ ZE29B_CQ^X?O=;/
M2,^#O1R2>G;.3</L@EJV70<)!/8$+8#QZ,EP,W K9"H[WS@JL\1;8D8!V\74
M17")II9["LA"I<[S 471WX3@F**>5(PJ02VZ:2'?T5RD -=VFXW#MRV?CT/9
M,5T=9D=6A3W8K84&<RT(T];A)8V6H;=MV@Y2D,X:@L2@/AJQF"E1CFW;B4PG
ME_HV/9X;%_%VA#@/FRF:KS+-$?;M]*E"XK!E$_(3(MM0==*.RJZ4YL;5HII
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MMMC0QENL;P/$;[5\#9>;\@5L.'IZO\'#6J0V$$M)D'\]):!2ODWP^139M[(
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M)IFEDUBNJTBO1U\I&F^E!M=T7_B/MS Y9-&1[ZMP$V(>Y'OVXX<?AW&I;MC
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M95FF3QICCJ%QJDAO]"CB\$T4*N8).E>>RWNJ/E,.'K!ZX1F@GC&.($GW"%=
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MF */-F9!:PW:R*;"/7Y[%ZV-=-3M0N0F#X%ZP!R47 GH (7;D!.N;5 _KT'
MS1U^].B'P6TLL1X6&+FM O5D%-$55AG45;_Z"S?M^&LNN%JFUZ^)N6W8ZDZ
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MZ#Z,X)U(8DT ^N@]S(2OMN*:+>*K\3P_'N"[@AKD1EGKV@8I%8$&EJ+J>)6
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M*P#B2#0#^1&,T'_O(/SK"L30=?S6<ZD=K;=Y%?\8S1?S#4"4.R+,,A?A>H/
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MO3G(4Y>/>K\W4&R> ]C@$-7ZN=[\,^5#/GR%)*?C.D2E!LHXM!C<P*RO%@M
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M3;JX2.UN0.63[CY![HH46Y2]2TD/HZ^0V"M ,]\/8R+_YL%UB/_\-@_FBP5
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M?SK &T_^#_I3[2\9(!78$:'Z!88_N.'Z4U[AZE/LO(=!N-ZF'[Z$D>N'48+
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MW\^3</O3O_WX_2I?1S_]?U!+ P04    " #P@V96I\[5Y<T]  "$@@( $
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MCYZ?#9^_/!T>/]\DRJU'4<7\_?M@\7TE XY!-PR.SD"*T.#XME<Y>3[@_V_
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M]@PR49R,Z3R[R"6ZX!K2DF\J'G:$#>9NM8_RKC2A]!)GW8?6F5Q5A4U4W#"
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MQ^_Y^F]TJ Z[$C$*[JYF'2%? LVZD100T= J%P;$I7B#R9E(^MK=2%\[--K
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M1;4\)06M^FQU\H[/6O69[#=02P,$%     @ \(-F5AL:ZVE""0  Q%$   \
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MS_UNS_VKZ[18?7;ZQY9R[3L[QE9LUQ 6OA[5]($AF;*ZX;M1E:85+\/FEAD
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MAG3$B&(CSL8L I?FFG32-*>"]!B&U$2FY".,3VI5[R\B8]*C0DP"+LF)5"!
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MB^"T)CL P8@!IAW.NC<AI)(#1CJPU/9R 1*V\M+<84X+6WG!(W?(L9J1.B[
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MS"]6#8L\9TG XMM1U"W1A2*$#:ENBAO*<I4!OVB;#X6A5)%5P)8C!BR%-$<
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MG$#>"#";XKFR-Q&=AGE-_O15IV%?K_\/4$L#!!0    ( /"#9E9X"(N%?@4
M &,O   /    <FQY8BUE>#,R7S(N:'1M[5IK<]HX%/W>7Z%M)YUD!H-M( ^;
MS0PE9#:[W= )=*;[4;9EK*TMN9(HL+]^K^1''I"TTX8V-$P2B*TKZ?K<<^Z5
M9?<2E:6G+U O(3B";]135*7D=/C!:KN]5G$ S:VRO1?P:(FD6J;D]Y<9%E/*
M/(1GBO]&LYP+A9GR<QQ%E$T]=)PO_)=FT+SJHLA"691%A"G/;MI[?LR9LB3]
MCW@.'.?*+P:U%,^]XH2QB'%&TZ4WH1F1Z)+,T17/,*N, ZX4STI[,P5.Z91Y
M*8D5>-#30U0>A#SEPA/3 ._;#?WC'/CSA"IBR1R'Q,L%L>8"Y\6\<T*GB?(8
M%QE.5YV]Z=OK3S.N_+Z@."W^;2")F;0D$33V,W!S3B.5>#%55@C]  +P#;U^
MY1S:?J^EASKMM?*?B9?0%WL7L "''Z>"SUADK6!G'_C?A&? TV@3: X7"0VH
M0FVWZ3X*I,[Q]V(:PCQ$;#.H@^'5Y.+\8M"?7(PNT;OW5^/W_<L)FHR>!FFW
M'V#G&+UOCIN#)AH/!P9DI]VU&Z@_1OVST;O)\&R'^N.C7F%]8A^BT3F:_#%$
MX_[5F_[E<&R-/KP=_H/Z@XEN<6W[JY))I]EMM[^03MQ-E+1-H+ZYBG?!$!PP
M$BK*&9I3E2"5$-1G;(93=$7T,@+Q&%WA-%T&E*,!%W .&_-];?KZU<*UG= ?
M\"S';%D<1OX! H-S\!LYMO47BKDP ^?@#8\087I1@LY(2+* "-1V&A!9UT58
MHIBF)+IV94S"F:"*0EPPB]!P$2:830DXDF542NT'_&K+""N"$B((^'O+M>(R
M:L\:Z *%1"@:+QLHGPDY@X424AQ=2U^O X[\4OG@$XYXKL"KF]:EC68L3&A<
MQ2+ C$AKM$C)$O5# YUF; /:L?+N$#>BGV^OWBQ-*$U=]WC/7TDA$95YBI=>
MG)+%&A[_.Y/ZDJK@&C-+*BR4;]AJ <DRZ058DI0RLI;;US31^CG:^Y7(?@O/
M&DS*-!B6P?3!*<UD#X%\$[NCKNL<'1]V3MSV4>?([>X!</O.017_&X&_[<<V
MX_OR= (:*%-&/(-\ :DERU.MW%K-@GR:44$RZ""U.&29>9SV/H:4(9#3W8\.
M:D%=:[_6?:DJYZ3=\75&J#4%H):?.VT].VVYST%;E,5Z?",8W8+AJB(X:[12
M"0]3 <H#[Z366$,W0^U&T(WH*4&!,@?1R8;I%5.&6:C/PX 1-4/K,@M6L]0(
MC4/)-E/*2I5EI6_>H[RURS$+XM8YV:NV(VHQ?FF-MI%=A_O#6'BQNB[\MIBM
MW4U0.$C)NM2D-V[\@(N("..;WK6Q?6-N 8OY#!1!%R3RBZD<VR2NL@.P-<6Y
M))XD.89XU2G(["(48YO='W! 5+-_IA)NT%.JEE[5OS0"JZA&J]!=M]DY;&NM
M]5HJNL>HV[1U8GO0IOT5-IW#E<G@'W'7_Z007<F:5<_7*]SM=AO5'VBZ8F3)
M-H<R?PZ86H$@^*-G/BU]8KWX/^MU9(C3DFT%"^LQ"_#+4>%B[KL]K-CV(T6P
M7>GO#"CMH;^Q"!-T:.X5VC=TM99*N^AO\\;K$PDI#+(5\=PN-;]9>D\OU*5Z
MRX):@^]V<T"9IQ061;?P6TN+-6'Z633Y<9N"FR-*2[;0GYQA!?=^Z**)WE(2
M$+&..[OUP:Y"[$*Z"^ECA#2C49227S>DFWJ(\V0#^I!&GV7%WA0#=K5Z>[+
M,TSLNY#N0KIE(=W5ZEVMWM";9 DE,3JO'P"-XIB&MPOV#MQO!7?_G:  :PZX
MKB!\\-":"+[U$Y_O>4MR(Z\U?>F9V6,!]XAOX)X\)1SN3%TC\J/ ^"D/4C=*
MBJ2^=\CQE!3%QL(Q) X/IW.\E.8NHM?2+\F?ONBUS,OU_P-02P,$%     @
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MS%AO 27]D!4/3@$K2D!L#.TG5WM[[/(N\;_A77MA@;?8B8.[B;(PHPXB=.%
M$N<JNVDU71#M%C5?*S50MRDKL'/#%>"!B'6O'W%[4[,/I-?J=(W\WES<W@JQ
MQRW$3H;5?O2@>(715.@<L4%#Y-W=][AX=5]=H]+<1+X^@ =*+:TU<!,=;Y_P
M_=\TR*W3PKRR3-9++W>[:^8:DH%ZL!*.\VK.W-!QY@P.\8OR#<ZMX I(ZDZW
MRJBE'A)L!T11I9N;*+G0?..Z+_F7#H?P?1;U<E+9%C6>+FK<:T>\2]>549Q,
MZ?A0(SM\240MZZ?%Y@=(^/4M,(4,S*X]LTD9''C!A3@U1=7B^^7I]1J7=0N
MAM_)<I&(]Z.3+30\#FC8!E(W:F?<+A;_ZOG89(O7?WGU?&:+_/5_ 5!+ 0(4
M Q0    ( /"#9E8^PG]^76$  /J    2              "  0    !I;6<Q
M,30X,#0R,S%?,"YJ<&=02P$"% ,4    " #P@V96)J?XS\7E P#IQ@4 $@
M            @ &-80  :6UG,3$T.# T,C,Q7S$N:G!G4$L! A0#%     @
M\(-F5E>Y8%_V1P$ AC\" !,              ( !@D<$ &EM9S$Q-#@P-#(S
M,5\Q,"YJ<&=02P$"% ,4    " #P@V960[QK1O9@   E8@  $P
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M              "  8.N#0!I;6<Q,30X,#0R,S%?-"YJ<&=02P$"% ,4
M" #P@V9641= B'-K  "J?@  $@              @ $B4 \ :6UG,3$T.# T
M,C,Q7S4N:G!G4$L! A0#%     @ \(-F5E1IK:-78P$ 1,\! !(
M     ( !Q;L/ &EM9S$Q-#@P-#(S,5\V+FIP9U!+ 0(4 Q0    ( /"#9E;B
MN?H[F'<! +G/ @ 2              "  4P?$0!I;6<Q,30X,#0R,S%?-RYJ
M<&=02P$"% ,4    " #P@V96O@B ):BX 0"-R@( $@              @ $4
MEQ( :6UG,3$T.# T,C,Q7S@N:G!G4$L! A0#%     @ \(-F5C[W*W-I P(
MZ78" !(              ( ![$\4 &EM9S$Q-#@P-#(S,5\Y+FIP9U!+ 0(4
M Q0    ( /"#9E;:/R4Y5GP$ *=1,P 1              "  853%@!R;'EB
M+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( /"#9E8R\VC#RA,  )?B   1
M          "  0K0&@!R;'EB+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( /"#
M9E9%#+6U) X  )S#   5              "  0/D&@!R;'EB+3(P,C(Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " #P@V96D"DQ6UHN  #9>0, %0
M    @ %:\AH <FQY8BTR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ \(-F
M5H\#B0[!J   5L4' !4              ( !YR ; ')L>6(M,C R,C$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( /"#9E;ZEW=3L4L  $OE!0 5
M  "  =O)&P!R;'EB+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " #P@V96
MR'N*;SY)  #-U@( $               @ &_%1P <FQY8BUE>#$P7S(T+FAT
M;5!+ 0(4 Q0    ( /"#9E:GSM7ES3T  (2" @ 0              "  2M?
M' !R;'EB+65X,3!?,C4N:'1M4$L! A0#%     @ \(-F5AJ,R_?L P  (TH
M  \              ( !)IT< ')L>6(M97@R,5\Q+FAT;5!+ 0(4 Q0    (
M /"#9E9PK9AIJ (  )H-   /              "  3^A' !R;'EB+65X,C-?
M,2YH=&U02P$"% ,4    " #P@V96&QKK:4()  #$40  #P
M@ $4I!P <FQY8BUE>#,Q7S$N:'1M4$L! A0#%     @ \(-F5J5'1*8K"0
MM%(   \              ( !@ZT< ')L>6(M97@S,5\R+FAT;5!+ 0(4 Q0
M   ( /"#9E82ABK\@@4  &4O   /              "  =NV' !R;'EB+65X
M,S)?,2YH=&U02P$"% ,4    " #P@V96> B+A7X%  !C+P  #P
M    @ &*O!P <FQY8BUE>#,R7S(N:'1M4$L! A0#%     @ \(-F5D!:&:6&
M%@  7)L   X              ( !-<(< ')L>6(M97@T7S0N:'1M4$L%!@
0   = !T - <  .?8'     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
